,trial_id,protocol_or_trial_id,trial_title,therapeutic_area,disease,sponsor,sponsor_type,primary_endpoint,secondary_endpoint,contains_nct,nct_number,drug_id
0,97470,"001-01, 0801-893, 2008_541, MCC 15414, MKV934-002, NCT00753415, TrialTroveID-097470, UPCC 06908, V934-002, V934-002 AM 4","A Phase I Investigation of the Safety, Tolerability and Immunogenicity of V934/V935 hTERT Vaccination in Cancer Patients with Selected Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Adverse Events, Creatinine kinase level, Dose-limiting toxicities, Nausea, Neutropenia, Safety and Tolerability, Serious Adverse Events, Vomiting","Immune Response, Overall response rate, Response rate",True,NCT00753415,41957
1,346259,"2020-0110, 20-286, DRAGON, NCT04291079, SRK-181-001, TrialTroveID-346259","A Phase I, Open-Label, Dose-Escalation, and Dose-Expansion Study to Investigate the Safety, Tolerability, PK, PD, and Efficacy of SRK-181 Alone and in Combination With Anti-PD-(L)1 Antibody Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (DRAGON)",Oncology,"Oncology: Bladder; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Scholar Rock,"Industry, all other pharma","Disease Progression, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Cmax, Elimination half-life, Immune-related response evaluation criteria in solid tumors, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors, Tmax",True,NCT04291079,162422
2,258001,"1409015482, NCT02452346, TrialTroveID-258001, WCMC IST-CTI-MDS",Phase II Clinical Study of the Clinical Efficacy and Safety of Tosedostat in Atients With Myelodysplastic Syndromes (MDS) After Failure of Hypomethylating Agent-Based Therapy,Oncology,Oncology: Myelodysplastic Syndrome,"CTI BioPharma {Cell Therapeutics}, Weill Medical College of Cornell University","Industry, all other pharma, Academic","Overall survival, Safety and Tolerability","Complete response, Duration of overall response, Partial response, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT02452346,31946
3,251516,"15-x017, 201503074, NCI-2015-00425, NCT02352831, TrialTroveID-251516",Phase I/II Study Combining Tosedostat with Capecitabine in Patients with Metastatic Pancreatic Adenocarcinoma,Oncology,Oncology: Pancreas,Washington University School of Medicine,Academic,"Dose-limiting toxicities, Progression-free survival, Progressive disease rate","Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Time to progression",True,NCT02352831,31946
4,213999,"702, EudraCT Number: 2012-000334-19, TrialTroveID-213999",Phase II multicenter study of low dose Cytarabine + Tosedostat for previously untreated older patients with acute myeloid leukemia (AML),Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate","Gene expression profiling, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability, Stable Disease",False,,31946
5,171496,"8265134, NCT01638442, TrialTroveID-171496, TST101","An Open-label, Randomized, Two-way Crossover Trial of the Effect of a High-Fat Meal on the Pharmacokinetics of Oral Tosedostat (CHR 2797) in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,"CTI BioPharma {Cell Therapeutics}, Chroma Therapeutics","Industry, all other pharma, Industry, all other pharma","Adverse Events, Area under the curve score, Cmax, Elimination half-life, Elimination rate, Plasma concentration, Safety and Tolerability, Tmax, Vital signs",Adverse Events,True,NCT01638442,31946
6,171129,"2011-0188, NCI-2018-01817, NCT01636609, TrialTroveID-171129",Phase I/II Study of Cytarabine or 5-Azacitidine Combined With Tosedostat to Evaluate the Safety and Tolerability in Older Patients With Acute Myeloid Leukemia (AML) or High Risk MDS,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Complete response, Disease-free survival, Hematologic Improvement, Maximum tolerated dose, Partial response, Safety and Tolerability",,True,NCT01636609,31946
7,165040,"2566.00, NCI-2012-00274, NCT01567059, TrialTroveID-165040",A Phase II Study of Tosedostat in Combination With Either Cytarabine or Decitabine in Newly Diagnosed AML or High-Risk MDS,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center, CTI BioPharma {Cell Therapeutics}","Government, Academic, Industry, all other pharma","Complete response, Overall survival","Disease-free survival, Overall survival, Safety and Tolerability, Safety and Tolerability, Treatment related mortality",True,NCT01567059,31946
8,158590,"ACTRN12612000848808, AML LI-1, AMLM20, EudraCT Number: 2011-000749-19, ISRCTN40571019, LI-1, SPON934-11, TrialTroveID-158590, UKCRN ID 10357","Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial, , Less Intensive 1 (LI-1) Trial.",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","National Cancer Research Institute, (Other Hospital/Academic/Medical Center), Australasian Leukaemia and Lymphoma Group (ALLG)","Government, Academic, Cooperative Group","Complete response, Duration of overall response, Overall survival, Quality of Life","Overall survival, Quality of Life",False,,31946
9,143647,TrialTroveID-143647,A Phase I/II Study of Tosedostat in Combination with Decitabine for the Treatment of Myelodysplastic Syndrome,Oncology,Oncology: Myelodysplastic Syndrome,CTI BioPharma {Cell Therapeutics},"Industry, all other pharma",,,False,,31946
10,143639,TrialTroveID-143639,A Phase I/II Study of Tosedostat in Combination with Bortezomib For the Treatment of Multiple Myeloma.,Oncology,Oncology: Multiple Myeloma,CTI BioPharma {Cell Therapeutics},"Industry, all other pharma",,,False,,31946
11,143637,"EudraCT Number: 2011-001914-33, HM11/9825, ISRCTN24989786, MREC NÂ°: 11/LO/1362, MUK three, MUK-three, TrialTroveID-143637, UKCRN ID: 11457",A Phase I/IIa Dose Escalation Study of CHR-3996 in Combination With Tosedostat in Subjects With Relapsed Refractory Multiple Myeloma,Oncology,Oncology: Multiple Myeloma,"(Other Cooperative Group), CTI BioPharma {Cell Therapeutics}, University of Leeds, Leeds, UK, (Other government agency), Chroma Therapeutics","Cooperative Group, Industry, all other pharma, Academic, Government, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability, Stable Disease","Overall survival, Progression-free survival, Safety and Tolerability, Treatment compliance",False,,31946
12,143614,TrialTroveID-143614,"A Pivotal, Multinational, Phase II/III, Randomized Controlled Study of Tosedostat in Combination with Vidaza in Acute Myeloid Leukemia (AML) and MDS Patients Who Have Already Relapsed or Proved Refractory to Prior Treatments.",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",CTI BioPharma {Cell Therapeutics},"Industry, all other pharma",Overall survival,,False,,31946
13,133008,"2010-0348, CHR-2797-045, Ext-CHR-2797-038, NCT01180426, TOPAZ, TrialTroveID-133008",The TOPAZ Study: A Long-Term Extension Study in Elderly Subjects With Relapsed/Refractory Acute Myeloid Leukemia to Allow Continued Therapy With Tosedostat,Oncology,"Oncology: Leukemia, Acute Myelogenous","CTI BioPharma {Cell Therapeutics}, Chroma Therapeutics","Industry, all other pharma, Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Complete response, Disease-free survival, Event-free survival, Overall survival, Partial response, Stable Disease, Time to response",True,NCT01180426,31946
14,129896,"EudraCT number: 2009-013094-17, EudraCT number: 2009-014455-68, HO103LEN Hovon, HO103TOS, HOVON 103, HOVON 103 AML, HOVON 103 AML Lenalidomide, HOVON 103 AML Tosedostat, HOVON103AML/SAKK30/Lenalidomide, HOVON103AMLLEN, HOVON103AMLLenalidomide, HOVON103AMLTosedostat, KWF 2009-4591, LN_NN_2010_396, NL29253.078.09, NL30483.078.09, NTR2294, NTR2477, Octopus, SAKK 30/10, TrialTroveID-129896",A Randomized Phase II Multicenter Study To Assess The Tolerability And Efficacy Of The Addition Of New Drugs To Standard Induction Chemotherapy In AML And RAEB > Or = 66 Years And Very Poor Risk AML > Or = 18 Years,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","Dutch-Belgian Cooperative Trial Group for Hematology Oncology (HOVON), Bristol-Myers Squibb/Celgene, Dutch Cancer Society, Swiss Group for Clinical Cancer Research - SAKK","Cooperative Group, Industry, Top 20 Pharma, Not for Profit Funding Entity, Cooperative Group","Dose-limiting toxicities, Neutropenia, Safety and Tolerability, Safety and Tolerability","Disease-free survival, Event-free survival, Gene expression profiling, Minimal Residual Disease, Overall survival",False,,31946
15,66595,"10-002, 16835A, 2009-0187, CHR-2797-038, EudraCT Number: 2008-006799-32, HUM00027102, McG 0927, NCT00780598, OPAL, TrialTroveID-066595","The OPAL Study: A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of Tosedostat (CHR-2797) in Elderly Subjects With Treatment Refractory or Relapsed Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","CTI BioPharma {Cell Therapeutics}, Chroma Therapeutics","Industry, all other pharma, Industry, all other pharma","Complete response, Safety and Tolerability","Complete response, Duration of overall response, Plasma concentration, Safety and Tolerability, Safety and Tolerability",True,NCT00780598,31946
16,66593,"CHR-2797-005, NCT00522938, TrialTroveID-066593","A Phase I-II, Multicenter, Open-Label Trial of Co-Administered CHR-2797 and Erlotinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer.",Oncology,"Oncology: Lung, Non-Small Cell",Chroma Therapeutics,"Industry, all other pharma","Maximum tolerated dose, Overall response rate, Safety and Tolerability","Safety and Tolerability, Safety and Tolerability",True,NCT00522938,31946
17,44699,"CHR-2797-003, EMC 06/173, EudraCT# 2006-002498-35, NCT00737555, TrialTroveID-044699",A Phase Ib Dose-Escalation Study to Evaluate the Safety and Tolerability of the Addition of the Aminopeptidase Inhibitor CHR-2797 to Paclitaxel in Patients With Advanced or Refractory Tumours.,Oncology,Oncology: Unspecified Solid Tumor,Chroma Therapeutics,"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate - duration, Time to progression",True,NCT00737555,31946
18,44697,"06/MRE05/5, CHR-2797-002, EudraCT Number: 2005-004955-36, N0258175368, NCT00689000, TrialTroveID-044697","A Phase I-II Study to Evaluate the Safety, Tolerability and Anti-Disease Activity of the Aminopeptidase Inhibitor, CHR-2797, in Elderly and/or Treatment Refractory patients with Acute Myeloid Leukaemia or Multiple Myeloma.",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",Chroma Therapeutics,"Industry, all other pharma","Complete response, Dose-limiting toxicities, Hemoglobin level, Maximum tolerated dose, Myalgia, Nausea, Partial response, Platelet count, Safety and Tolerability, Stable Disease, Vomiting","Safety and Tolerability, Safety and Tolerability",True,NCT00689000,31946
19,44696,"04/Q1702/71, CHR-2797-001, N0258150005, NCT00692354, TrialTroveID-044696","A Phase I Study to Evaluate the Safety and Tolerability, of the Aminopeptidase Inhibitor, CHR-2797, in Patients With Advanced Tumours.",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Institute of Cancer Research - UK, Chroma Therapeutics","Academic, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",Progressive disease rate,True,NCT00692354,31946
20,378082,"ACTRN12620000707965, TrialTroveID-378082","A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of the recombinant BCG VPM1002 on the Incidence or Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Participants in Australia",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines",Serum Institute of India,"Industry, all other pharma",,"Adverse Events, VRC-prompted Elevated Temperature",False,,35114
21,376649,"20-5413, COBRA, NCT04439045, TrialTroveID-376649","A randomized, double-blind, placebo controlled phase 3 study: Efficacy and safety of Recombinant BCG VPM1002 in reducing SARS-COV-2 infection rate and COVID-19 severity.",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","(Other Cooperative Group), Serum Institute of India, University Health Network, Toronto, Verity Pharmaceuticals","Cooperative Group, Industry, all other pharma, Academic, Industry, all other pharma",,"Adverse Events, Brain Natriuretic Peptide concentration, C reactive protein, Mortality, Stroke",True,NCT04439045,35114
22,376417,"EudraCT Number: 2020-001675-33, NCT04435379, TrialTroveID-376417, VPM1002-DE-3.07CoV","A phase III, randomized, double-blind, placebo-controlled, multicentre, clinical trial to assess the efficacy and safety of VPM1002 in reducing hospital admissions and/or severe respiratory infectious diseases in elderly in the COVID-19 pandemic by modulating the immune system",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","(Other Hospital/Academic/Medical Center), Vakzine Projekt Management (VPM)","Academic, Industry, all other pharma",,VRC-prompted Elevated Temperature,True,NCT04435379,35114
23,374412,"EudraCT Number:2020-001376-15, NCT04387409, TrialTroveID-374412, VPM1002-DE-3.06CoV","A Phase III, Double-blind, Randomized, Placebo-controlled Multicentre Clinical Trial to Assess the Efficacy and Safety of VPM1002 in Reducing Healthcare Professionals' Absenteeism in the SARS-CoV-2 Pandemic by Modulating the Immune System",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines",Vakzine Projekt Management (VPM),"Industry, all other pharma",,VRC-prompted Elevated Temperature,True,NCT04387409,35114
24,373276,"CTRI/2020/04/024749, SII-rBCG/COVID-19/IN-01, TrialTroveID-373276","A Multicenter, Phase III, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy of Recombinant BCG VPM1002 in Reducing Infection Incidence and Disease Severity of SARS-COV-2/COVID-19 Among High-Risk Subjects.",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines",Serum Institute of India,"Industry, all other pharma",,"Adverse Events, Serious Adverse Events",False,,35114
25,372235,"NCT04351685, PACTR202007868402718, priMe, TrialTroveID-372235, VPM1002, VPM1002-MN-3.05TB","A Multicenter, Phase III, Double-blind, Randomized, Active-controlled Study to Evaluate the Efficacy and Safety of VPM1002 in Comparison to BCG in Prevention of Mycobacterium Tuberculosis Infection in Newborn Infants",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"Serum Institute of India, International AIDS Vaccine Initiative, (Other government agency), Vakzine Projekt Management (VPM)","Industry, all other pharma, Not for Profit Funding Entity, Government, Industry, all other pharma",,"Safety and Tolerability, Safety and Tolerability",True,NCT04351685,35114
26,354062,TrialTroveID-354062,A Phase III Study to Evaluate Safety and Efficacy of VPM1002 and MIP(Mycrobacterium Indicus Pranii) in Healthy Household Contacts of Sputum Smear Positive TB cases that are at High Risk of Contracting the Disease to Prevent occurrence of TB among Close Contacts of a TB case,Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,(Other government agency),Government,Safety and Tolerability,,False,,35114
27,300239,TrialTroveID-300239,A Phase III Study to Evaluate VPM1002 on Newborns,Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Serum Institute of India,"Industry, all other pharma",,,False,,35114
28,300152,"CTRI/2017/03/008266, NCT03152903, TrialTroveID-300152, VPM1002-IN-3.01TBR","A Multicenter Phase II/III Double-Blind, Randomized, Placebo Controlled Study To Evaluate The Efficacy And Safety Of VPM1002 In The Prevention Of Tuberculosis (TB) Recurrence In Pulmonary TB Patients After Successful TB Treatment",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Serum Institute of India,"Industry, all other pharma",,"Adverse Events, Reactogenicity, Safety and Tolerability",True,NCT03152903,35114
29,208169,"DRKS00012770, EudraCT Number: 2014-005330-58, NCT02371447, NL58065.000.16, SAKK 06/14, SNCTP000001181, TrialTroveID-208169",A Phase I/II Open Label Clinical Trial Assessing Safety and Efficacy of Intravesical Instillation of VPM1002BC in Patients With Recurrent Non-muscle Invasive Bladder Cancer After Standard BCG Therapy,Oncology,Oncology: Bladder,Swiss Group for Clinical Cancer Research - SAKK,Cooperative Group,"Adverse Events, Dose-limiting toxicities, Recurrence, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Quality of Life, Recurrence, Time to progression",True,NCT02371447,35114
30,193111,"DOH-27-1114-4798, NCT02391415, TrialTroveID-193111, VPM1002-ZA-2.13TB","Phase II Double-blind, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 Compared With BCG in HIV-exposed and HIV-unexposed, BCG-naive Newborn Infants",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Serum Institute of India, Vakzine Projekt Management (VPM)","Cooperative Group, Academic, Industry, all other pharma, Industry, all other pharma",,,True,NCT02391415,35114
31,157607,"DOH-27-0911-3677, NCT01479972, TrialTroveID-157607, VPM1002-ZA-2.12TB","Phase II Open Label, Randomized, Controlled Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in HIV-unexposed, BCG Naive Newborn Infants in South Africa",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Vakzine Projekt Management (VPM)","Cooperative Group, Academic, Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs",Immunogenicity (other timeframe),True,NCT01479972,35114
32,126363,"DOH-27-0210-3083, NCT01113281, TrialTroveID-126363, VPM1002-ZA-1.10TB","Phase Ib Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Volunteers in South Africa.",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Vakzine Projekt Management (VPM)","Cooperative Group, Academic, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs",Immunogenicity (other timeframe),True,NCT01113281,35114
33,101016,"NCT00749034, TrialTroveID-101016, VPM1002-GE-1.01TB","Phase I Open Label, Randomized, Controlled, Dose-Escalation Study to Evaluate Safety and Immunogenicity of VPM1002 in Comparison With BCG in Healthy Male Volunteers Stratified for History of BCG-Vaccination.",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Vakzine Projekt Management (VPM),"Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs",Immunogenicity (other timeframe),True,NCT00749034,35114
34,200584,"CL-2000-II-01, NCI-2014-00486, NCT02034227, Pro00019231, TrialTroveID-200584","An Open-Label, Phase I/Phase II Study to Evaluate the Safety, Tolerability, and Antitumor Activity of the DNA Minor Groove Binding Agent SG2000 in the Treatment of Advanced Chronic Lymphocytic Leukemia and Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic",AstraZeneca {MedImmune}/Spirogen,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Adverse Events, Area under the curve score, Change in oxygen saturation, Cmax, Elimination half-life, Plasma pharmacokinetics, Safety and Tolerability, Vital signs",True,NCT02034227,27148
35,116762,TrialTroveID-116762,"A Phase II Open Label Study of SG2000 for the Treatment of B-cell Chronic Lymphocytic Leukaemia (B-CLL), Multiple Myeloma (MM) and Acute Myeloid Leukemia (AML)",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Multiple Myeloma",AstraZeneca {MedImmune}/Spirogen,"Industry, Top 20 Pharma",,,False,,27148
36,116752,"8489, MCC-16219, MCC-VICC-GYN-1003, Moffitt NCI 8489, NCI 8489, NCI-2011-02519, NCT01199796, NCT01200797, TrialTroveID-116752, VICC GYN 1003, VICCGYN1003","A Phase II Evaluation of SJG-136 in Women With Cisplatin-Refractory or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute","Government, Academic","Complete response, Disease Progression, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT01199796,27148
37,43453,"2005-0607, 6934, MDA-2005-0607, MDACC-2005-0607, NCI-6934, NCT00301769, TrialTroveID-043453",A Phase I Study of SJG-136 in Patients With Advanced Leukemia.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00301769,27148
38,31251,"NCI-6816, NCT00121290, TrialTroveID-031251, VICC-PHI-0453",A Phase I Dose Escalation Study of Daily x 3 Intravenous SJG-136 in Patients With Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, Pfizer, Vanderbilt-Ingram Cancer Center, Cancer Research UK, Ipsen, University College London, AstraZeneca {MedImmune}/Spirogen","Government, Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity, Industry, all other pharma, Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,True,NCT00121290,27148
39,23532,"04-076, MSKCC-04076, NCI-6818, NCT00103220, TrialTroveID-023532",A Phase I Study With SJG-136 (NSC#694501) in Patients With an Advanced Solid Tumor.,Oncology,Oncology: Unspecified Solid Tumor,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",,,True,NCT00103220,27148
40,14377,"N0256147035, N0519147934, TrialTroveID-014377",A Phase I trial of SJG-136 (a minor groove DNA binding drug) given intravenously every 21 days to patients with advanced solid tumours.,Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma","Cancer Research UK, Ipsen, University College London, AstraZeneca {MedImmune}/Spirogen","Not for Profit Funding Entity, Industry, all other pharma, Academic, Industry, Top 20 Pharma",Maximum tolerated dose,,False,,27148
41,175362,"EudraCT Number: 2013-000686-37, NCT02048488, PR-20-5006-C, REFMAL 290 IST, TrialTroveID-175362","A Phase I/IIa Open-Label, Dose Escalation and Cohort Expansion Trial of Oral TSR-011 in Patients With Advanced Solid Tumors and Lymphomas",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",GlaxoSmithKline/Tesaro,"Industry, Top 20 Pharma","Adverse Events, Cmax, Dose-limiting toxicities, Elimination half-life, Elimination rate, Maximum tolerated dose, Overall response rate, Plasma concentration, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Tmax","Area under the curve score, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Progression-free survival, Response rate",True,NCT02048488,70251
42,372752,TrialTroveID-372752,"Double-Blind, Randomized, Placebo-Controlled Phase IIb Study of RUTI Therapeutic Vaccination as Adjuvant of Tuberculosis Chemotherapy in Patients With Drug-Susceptible Tuberculosis (DS-TB) and Multidrug Resistant Tuberculosis (MDR-TB).",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Archivel Farma,"Industry, all other pharma",,,False,,60945
43,372275,"NCT04453488, RUTICOVID19, TrialTroveID-372275","Double-blind, Randomized, Placebo-controlled Clinical Trial to Evaluate the Efficacy of the RUTI Vaccine to Prevent SARS-CoV-2 Infection",Infectious Disease,"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19)",(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Duration of ICU stay",True,NCT04453488,60945
44,303784,"EudraCT Number: 2016-004311-12, NCT03191578, RUTIVAC-1, TrialTroveID-303784","A Randomized, Double-Blind, Placebo-Controlled Phase I Trial to Evaluate the Immunomodulatory Effect of RUTI in Individuals With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Treated With Intravesical Bacillus Calmette-Guerin (BCG)",Oncology,Oncology: Bladder,"(Other Hospital/Academic/Medical Center), Archivel Farma","Academic, Industry, all other pharma",Immune Response,"Adverse Events, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT03191578,60945
45,275097,"201600136, EudraCT Number: 2016-000850-36, NCT02711735, NL56995.000.16, TrialTroveID-275097","Double-Blind, Randomized, Placebo-Controlled Phase IIa Clinical Trial to Investigate the Safety and Immunogenicity of RUTI Therapeutic Vaccination in Patients With Multi-Drug Resistant Tuberculosis After Successful Intensive-phase Treatment",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Hospital/Academic/Medical Center), Groningen University Hospital, Archivel Farma","Academic, Academic, Industry, all other pharma","Adverse Events, C reactive protein, Heart rate, Immunogenicity at 21 days, Immunogenicity at 28 days, Myalgia, Nausea, Safety and Tolerability, Safety and Tolerability, Vital signs",Immunogenicity (other timeframe),True,NCT02711735,60945
46,130790,TrialTroveID-130790,"A phase III, Safety, Efficacy, Non-inferiority, Proof of concept trial of the antituberculous vaccine RUTI based regimen in comparison to six months of Isoniazid treatment in subjects with tuberculosis infection",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Archivel Farma,"Industry, all other pharma",Safety and Tolerability,,False,,60945
47,108541,"NCT01136161, RUTISAPH2, TrialTroveID-108541","Double-Blind, Randomized, Placebo-Controlled Phase II Clinical Trial to Investigate the Safety, Tolerability, and Immunogenicity of the Novel Antituberculous Vaccine RUTI Following One Month of Isoniazid Treatment in Subjects With Latent Tuberculosis Infection",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,Archivel Farma,"Industry, all other pharma","Adverse Events, Cardiac Telemetry, Heart rate corrected QT interval, Heart rate, Immunogenicity (other timeframe), Myalgia, Nausea, Safety and Tolerability, Visual Analog Scale, Vital signs",Immunogenicity (other timeframe),True,NCT01136161,60945
48,102501,"EudraCT Number: 2006-000690-29, FA/MI/01, NCT00546273, TrialTroveID-102501","Double-Blind, Randomized, Placebo-Controlled Phase I Study, to Study the Tolerability and Immunogenicity of RUTI Antituberculosis Vaccine Different Doses (5, 25, 100 and 200mcg of FCMtb) in Healthy Volunteers",Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Hospital/Academic/Medical Center), Archivel Farma","Academic, Industry, all other pharma",Visual Analog Scale for Pain,"Immunogenicity (other timeframe), Immunogenicity at 28 days",True,NCT00546273,60945
49,128528,TrialTroveID-128528,Phase II Study of L19-131I in Patients with Hematological Malignancies.,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma",Philogen,"Industry, all other pharma",Safety and Tolerability,,False,,31272
50,127280,"2009-017072-24, NCT01124812, PH-L19SIPI131-04/09, TrialTroveID-127280","A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With External Beam Radiotherapy (EBRT) and Concurrent Chemotherapy in Patients With Inoperable, Locally-advanced (Stage III) NSCLC",Oncology,"Oncology: Lung, Non-Small Cell",Philogen,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability, Vital signs","Overall response rate, Overall survival",True,NCT01124812,31272
51,124580,"EudraCT Number: 2009-013002-13, NCT01125085, PH-L19SIPI131-01/09, TrialTroveID-124580",A Prospective Non-randomized Study of 131I-L19SIP Radioimmunotherapy (RIT) in Combination With Whole Brain Radiation Therapy (WBRT) in Patients With Multiple Brain Metastases From Solid Tumors,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer",Philogen,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Duration of overall response, Overall survival, Quality of Life",True,NCT01125085,31272
52,74072,"NCT01242943, PH-L19SIPI131-07/07, TrialTroveID-074072",A Phase I/II Dose Finding and Efficacy Study of the Tumour Targeting Human 131I-L19SIP Monoclonal Antibody in Patients with Cancer,Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Prostate","Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, Philogen","Industry, Top 20 Pharma, Industry, all other pharma",Maximum tolerated dose,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01242943,31272
53,67147,"2005-000545-11, INT 05/25, TrialTroveID-067147",Phase I Study of Anti Fibronectin 131I-L19-Small Immunoprotein (SIP).,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal","Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, Southern Europe New Drug Organization, Philogen","Industry, Top 20 Pharma, Not for Profit Funding Entity, Industry, all other pharma",,,False,,31272
54,398569,"CTRI/2021/02/030882, TrialTroveID-398569",Study of Inj. Sepsivac in gram negative sepsis,Infectious Disease,Infectious Disease: Sepsis,(Other Hospital/Academic/Medical Center),Academic,Mortality,"Adverse Events, Days on mechanical ventilation, Duration of hospitalization, Sequential Organ Failure Assessment",False,,39091
55,398027,TrialTroveID-398027,Innate Immune Response Modulation and Resistance to SARS-CoV-2 infection: A Prospective Comparative Cohort Study in High Risk Healthcare Workers,Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","(Other Hospital/Academic/Medical Center), Cadila Pharmaceuticals {Cadila Laboratories}","Academic, Industry, all other pharma",Immunogenicity at 28 days,,False,,39091
56,397010,"01112020001, CTRI/2021/01/030585, TrialTroveID-397010",Study of Inj. Sepsivac in gram negative sepsis,Infectious Disease,Infectious Disease: Sepsis,(Other Hospital/Academic/Medical Center),Academic,Mortality,"Adverse Events, Duration of hospitalization, Sequential Organ Failure Assessment",False,,39091
57,392218,"CTRI/2020/12/029825, TrialTroveID-392218",Study of Inj. Sepsivac in gram negative sepsis,Infectious Disease,Infectious Disease: Sepsis,(Other Hospital/Academic/Medical Center),Academic,Mortality,"Adverse Events, Days on mechanical ventilation, Duration of hospitalization, Sequential Organ Failure Assessment",False,,39091
58,384254,"CTRI/2020/09/027741, TrialTroveID-384254",A Randomized Double Blind Controlled study to assess the dose related effect of Mycobacterium w on clinical course of Corona Virus Disease 2019 (COVID-19),Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","(Other Hospital/Academic/Medical Center), Cadila Pharmaceuticals {Cadila Laboratories}","Academic, Industry, all other pharma",Immunogenicity at 28 days,"Adverse Events, Immunogenicity at 28 days, Serious Adverse Events",False,,39091
59,383844,"CTRI/2020/08/027475, TrialTroveID-383844",Randomized Controlled Trial Of Immunomodulator Mycobacterium w In Mild And Moderate Cases of COVID-19 Pneumonia,Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Infectious Disease: Respiratory Infections; Vaccines (Infectious Disease): Respiratory Vaccines",Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma","Immunogenicity at 28 days, Mortality","Duration of ICU stay, Immunogenicity at 28 days",False,,39091
60,375604,"CTRI/2020/05/025350, TrialTroveID-375604","Observational study to assess safety and efficacy of Inj Sepsivac in patients of COVID-19 at R D Gardi Medical College, Ujjain, India",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines",(Other Hospital/Academic/Medical Center),Academic,Immunogenicity at 28 days,"Duration of hospitalization, Immunogenicity at 28 days, Safety and Tolerability",False,,39091
61,372938,"CRSC20006, CTRI/2020/05/025271, NCT04358809, TrialTroveID-372938","A Randomized, Double-blind, Two Arm, Controlled Clinical Trial to Compare the Efficacy and Safety of Mycobacterium w (Mw) Administered Along With Standard of Care Versus Placebo Administered Along With Standard of Care, in Adult, COVID-19 Positive Patients Hospitalized But Not Critically Ill.",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Industry, all other pharma, Government","Immunogenicity at 21 days, Immunogenicity at 28 days","Adverse Events, Immunogenicity at 21 days, Immunogenicity at 28 days, Leukocyte count, Safety and Tolerability, Serious Adverse Events",True,NCT04358809,39091
62,372399,"CRSC20005, CTRI/2020/05/025277, NCT04353518, TrialTroveID-372399","A Randomized, Double-blind, Two Arm, Placebo Controlled Clinical Trial to Evaluate the Efficacy and Safety of Mycobacterium w in Preventing COVID-19 in Subjects at Risk of Getting Infected With COVID-19",Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Industry, all other pharma, Government",Immunogenicity at 28 days,"Adverse Events, Immunogenicity at 28 days, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT04353518,39091
63,371956,"CRSC20004, CTRI/2020/04/024846, NCT04347174, TrialTroveID-371956",A Clinical Trial to Evaluate the Safety and Efficacy of Mycobacterium W in Critically Ill Patients Suffering From COVID-19 Infection,Infectious Disease; Vaccines (Infectious Disease),"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19); Vaccines (Infectious Disease): Respiratory Vaccines","Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Industry, all other pharma, Government","28-day mortality, Adverse Events, Immunogenicity at 21 days, Immunogenicity at 28 days, Sequential Organ Failure Assessment, Serious Adverse Events","Adverse Events, Duration of hospitalization, Duration of ICU stay, Immunogenicity at 28 days, Mortality, Sequential Organ Failure Assessment, Serious Adverse Events",True,NCT04347174,39091
64,249828,"CTRI/2015/07/005961, MISS, NCT02330432, PGI /0151, Pulm/Mw/002, TrialTroveID-249828","Randomized, Double blind, Two Arm, Comparative Controlled, Prospective Clinical Trial of Mycobacterium w in Combination with Standard Therapy versus Standard Therapy Alone in Sepsis due to Gram Negative Infection, , Mycobacterium w in Patients With Severe Sepsis (MISS)",Infectious Disease,Infectious Disease: Sepsis,"(Other Hospital/Academic/Medical Center), Cadila Pharmaceuticals {Cadila Laboratories}","Academic, Industry, all other pharma","28-day mortality, Mortality","Adverse Events, C reactive protein, Duration of hospitalization, Duration of ICU stay, Sequential Organ Failure Assessment",True,NCT02330432,39091
65,200106,"IP 39, MISS, NCT02025660, TrialTroveID-200106","Does Immune-modulation Improve the Survival in Patients With Severe Sepsis? ""A Proof of the Concept Study""",Infectious Disease,Infectious Disease: Sepsis,(Other Hospital/Academic/Medical Center),Academic,"28-day mortality, Mortality","Duration of hospitalization, Duration of ICU stay, Sequential Organ Failure Assessment",True,NCT02025660,39091
66,149274,TrialTroveID-149274,Efficacy and safety of immunomodulator (Mycobacterium W) as an adjunct therapy in category II pulmonary tuberculosis.,Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,(Other government agency),Government,,,False,,39091
67,149060,"CR-01A/2003-10, NCT00265226, NI-705, TrialTroveID-149060",Efficacy and Safety Study of Immunomodulator (Mycobacterium w) as an Adjunct Therapy in Category-II Pulmonary Tuberculosis Along With Assessment of Immunological Parameters.,Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Industry, all other pharma, Government",Safety and Tolerability,Physician's Global Assessment,True,NCT00265226,39091
68,110662,"70/1192, CTRI/2008/091/000292, TEMP UTRN 024846871-16122008392171, TrialTroveID-110662","Randomized, double bind, two arm, multicentric, comparative controlled,  prospective clinical trial of mycobacterium w in combination with standard therapy versus standard therapy alone in sepsis due to gram(-) ve infections",Infectious Disease; Vaccines (Infectious Disease),Infectious Disease: Sepsis; Vaccines (Infectious Disease): Respiratory Vaccines,"Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Industry, all other pharma, Government","Immunogenicity at 28 days, Mortality","Adverse Events, C reactive protein, Immunogenicity at 28 days",False,,39091
69,107476,"CTRI/2009/091/000055, TEMP UTRN 122338702-09022009472953, TrialTroveID-107476",A comparative study of effectiveness of immunotherapy with intralesional injection of killed Mycobacterium w vaccine and imiquimod cream in clinical resolution and reduction of viral load: A randomized trial,Infectious Disease; Vaccines (Infectious Disease),Infectious Disease: HPV; Vaccines (Infectious Disease): Other Viral Vaccines,"All India Institute of Medical Sciences (AIIMS), (Other government agency)","Academic, Government",,,False,,39091
70,101567,"CR-01C-1/2003-10, NCT00341328, NI-894, TrialTroveID-101567",Efficacy and Safety of Immunomodulator (Mycobacterium w.) as an Adjunct Therapy in Category I Pulmonary Tuberculosis and Along With Assessment of Immunological Parameters.,Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"All India Institute of Medical Sciences (AIIMS), Cadila Pharmaceuticals {Cadila Laboratories}, (Other government agency)","Academic, Industry, all other pharma, Government",Safety and Tolerability,Clinical Global Impression,True,NCT00341328,39091
71,93928,TrialTroveID-093928,Intravenous Cadi-05: Phase I Single Dose Study,Oncology,"Oncology: Bladder; Oncology: CNS, Glioblastoma; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma; Oncology: Testicular",(Other Hospital/Academic/Medical Center),Academic,,,False,,39091
72,92473,"CR-60/9150, CTRI/2007/091/000034, NCT00694915, TEMP UTRN 034051431-1611200742171, TrialTroveID-092473","Open Label, Randomized, Multicentric, Comparative and Controlled Clinical Trial to Compare the Efficacy and Toxicity of Mycobacterium w Intra-Dermal to Intravesical BCG in Patients With Newly Diagnosed Superficial Transitional Cell Carcinoma With High Probability of Recurrence",Oncology,Oncology: Bladder,Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma","Overall response rate, Quality of Life, Recurrence, Response rate, Safety and Tolerability",Quality of Life,True,NCT00694915,39091
73,92466,"CR-80/8230, CTRI/2009/091/000664, NCT00694798, TEMP UTRN 020304144-190820091132171, TrialTroveID-092466","Open Label, Single Arm, Exploratory Phase I Clinical Trial to Evaluate Efficacy and Safety of Mycobacterium W (Mw) in BCG Refractory Superficial Transitional Cell Carcinoma",Oncology,Oncology: Bladder,Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response rate","Complete response, Partial response, Recurrence, Safety and Tolerability",True,NCT00694798,39091
74,90531,"CR-60/7260, CTRI/2007/091/000037, NCT00680940, TEMP UTRN 041218616-0212200747171, TrialTroveID-090531","Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Paclitaxel Plus Cisplatin Versus Paclitaxel and Cisplatin in Advanced Non Small Cell Lung Cancer.",Oncology,"Oncology: Lung, Non-Small Cell",Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma","Overall survival, Quality of Life","Overall response rate, Response rate",True,NCT00680940,39091
75,89998,"1_20061206_118, CR-60/4051, MOSCA-CADI-05, NCT00675727, TrialTroveID-089998","Open Label, Single Arm, Phase I/II Study of CADI-05 in Patients with Advanced Stage III or Stage IV Melanoma.",Oncology,Oncology: Melanoma,Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma",Safety and Tolerability,Immune Response,True,NCT00675727,39091
76,77745,TrialTroveID-077745,Phase II study of Cadi-05 when used along with chemotherapy (Cisplatin plus Etoposide) for advanced stage Non Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma",Safety and Tolerability,,False,,39091
77,75681,"CR-60/1260, CTRI/2007/091/000033, NCT00525408, TEMP UTRN 121716911-1611200741171, TrialTroveID-075681","Open Label, Randomized Multicentric Phase II Clinical Trial of Mycobacterium w in Combination With Docetaxel Versus Docetaxel in Metastatic Hormone Refractory Prostate Cancer",Oncology,Oncology: Prostate,Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma",Overall survival,"PSA progression, Quality of Life",True,NCT00525408,39091
78,72989,TrialTroveID-072989,Improvement in quality of life and symptom control with MYCOBACTERIUM W (CADI-05) in head and neck cancer.,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Quality of Life,,False,,39091
79,54463,TrialTroveID-054463,Poly TLR agonist polyantigenic vaccine (Mycobacterium w) in palliative therapy of head and neck cancer.,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,,,False,,39091
80,48007,TrialTroveID-048007,Poly-TLR agonist polyantigenic vaccine cadi-05 in advanced bladder cancer.,Oncology,Oncology: Bladder,Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma",,,False,,39091
81,48005,TrialTroveID-048005,Poly-TLR agonist polyantigenic vaccine cadi-05 in advanced nonsmall cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Cadila Pharmaceuticals {Cadila Laboratories},"Industry, all other pharma",,,False,,39091
82,30416,TrialTroveID-030416,"Role of immuno-therapy as a adjuvant treatment in advance head & neck cancer, patient receiving chemo radiotherapy.",Oncology,Oncology: Head/Neck,(Other Academic Cancer Center),Academic,,,False,,39091
83,30407,TrialTroveID-030407,Use of immunomodulater mycobacterium w vaccine for palliative treatment in advanced & incurable cancer patients.,Oncology,Oncology: Head/Neck; Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,Quality of Life,,False,,39091
84,286695,"16-299, NCT02905994, TrialTroveID-286695","A Phase I Trial of Volasertib (BI 6727), an Intravenous Polo-Like Kinase Inhibitor, in Combination With ""7+3"" Induction Chemotherapy for Patients With Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous","Boehringer Ingelheim, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall survival, Partial response, Treatment Emergent Adverse Events",True,NCT02905994,42199
85,284876,"1601017105, NCT02875002, TrialTroveID-284876",Phase I Study of Volasertib and Belinostat in Patients With Relapsed and Refractory Aggressive B-cell and T-cell Lymphomas,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Massey Cancer Center, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Yale University","Academic, Academic, Academic","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,True,NCT02875002,42199
86,284228,"NCI-2016-01036, NCT02861040, NU 16H06, STU00203179, TrialTroveID-284228",A Phase I Clinical Trial Evaluating the Combination of Volasertib (BI-6727) With Vincristine Sulfate Liposomal Injections (VSLI) in Adult Patients With Relapsed/Refractory Acute Lymphoblastic Leukemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic","National Institutes of Health/National Cancer Institute, Northwestern University, National Comprehensive Cancer Network","Government, Academic, Cooperative Group","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate","Bioavailability, Complete response, Disease Progression, Minimal Residual Disease, Mortality, Overall response rate - duration, Overall survival, Progression-free survival",True,NCT02861040,42199
87,278021,"NCI-2016-01391, NCT02757248, Pro00060068, TrialTroveID-278021",A Phase I Trial of Volasertib Plus Romidepsin in Patients With Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Boehringer Ingelheim, Duke University Medical Center, National Comprehensive Cancer Network","Industry, Top 20 Pharma, Academic, Cooperative Group",Maximum tolerated dose,Overall response rate,True,NCT02757248,42199
88,275663,"1230.43, EudraCT Number: 2015-004490-32, JapicCTI-163219, NCT02721875, TrialTroveID-275663","An Open Label, Phase I Trial of Intravenous Administration of Volasertib as Monotherapy and in Combination With Azacitidine in Patients With Myelodysplastic Syndrome After Hypomethylating Agents Treatment Failure",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome",Boehringer Ingelheim,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Injection site reactions, Maximum tolerated dose, Nausea, Neutropenia, Vomiting","Cmax, Complete response, Hemoglobin level, Overall response rate, Partial response, Plasma concentration",True,NCT02721875,42199
89,275653,"1230.28, EudraCT Number: 2015-004625-14, NCT02722135, TrialTroveID-275653","Open-label, Dose-escalating Trial to Evaluate the Tolerability, Toxicity, Safety, Pharmacokinetics, Pharmacodynamics and Activity of Volasertib Added to the Standard Intensive Salvage Chemotherapy Regimen With Liposomal Daunorubicine, Fludarabine and Cytarabine (DNX-FLA) Followed by Fludarabine and Cytarabine (FLA) in Children From 3 Months to Less Than 18 Years of Age With Acute Myeloid Leukaemia After Failure of the Front-line Therapy",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Boehringer Ingelheim,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Adverse Events, Area under the curve score, Common Terminology Criteria for Adverse Events, Elimination half-life, Event-free survival, Heart rate corrected QT interval, Overall survival",True,NCT02722135,42199
90,263196,"1230.37, 1230-37, NCT02527174, TrialTroveID-263196, VIAC",A Phase I Study of Volasertib Combined With Standard Induction Chemotherapy for Previously Untreated Patients With Acute Myeloid Leukemia (VIAC),Oncology,"Oncology: Leukemia, Acute Myelogenous",University of Alberta,Academic,"Common Terminology Criteria for Adverse Events, Creatinine kinase level, Dose-limiting toxicities, Maximum tolerated dose, Nausea, Vomiting",Complete response,True,NCT02527174,42199
91,213680,"1230.35, JapicCTI-142625, NCT02201329, TrialTroveID-213680",An Open Label Phase I Trial of Intravenous Volasertib in Combination With Subcutaneous Azacitidine in Japanese Patients With Higher-risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia,Oncology,Oncology: (N/A); Oncology: Myelodysplastic Syndrome,Boehringer Ingelheim,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Neutropenia","Area under the curve score, Cmax, Complete response, Overall response rate, Partial response, Safety and Tolerability, Safety and Tolerability",True,NCT02201329,42199
92,213493,"AMLSG 20-13, EudraCT Number: 2014-000477-39, NCT02198482, TrialTroveID-213493",Dose Finding Safety Run-in Phase Followed by a Randomized Phase II Trial of Intensive Chemotherapy With or Without Volasertib (BI 6727) Administered Prior or After Chemotherapy in Patients With Newly Diagnosed High-Risk Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML),Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,"Complete Response with incomplete blood count recovery, Complete response, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Cumulative Incidence of Relapse, Disease-free survival, Event-free survival, Gastrointestinal symptom severity, Neutropenia, Overall survival, Safety and Tolerability",True,NCT02198482,42199
93,212647,"BI-1230.25, EudraCT Number: 2010-023499-25, NL36814.029.11, POLO-AML 1, TrialTroveID-212647","A phase II/III randomized, open-label study to compare the efficacy and safety of intravenous volasertib in combination with subcutaneous cytarabine versus investigatorâs choice of anti-leukemic treatment in adult patients with relapsed or refractory acute myeloid leukemia with no established treatment options",Oncology,"Oncology: Leukemia, Acute Myelogenous",Boehringer Ingelheim,"Industry, Top 20 Pharma","Complete response, Mortality, Overall survival, Safety and Tolerability","Complete Response with incomplete blood count recovery, Complete response, Disease-free survival, Event-free survival, Quality of Life, Safety and Tolerability",False,,42199
94,198569,"00047619, 1230.30, 1230-0030, EudraCT Number: 2013-001752-36, NCT02003573, TrialTroveID-198569","An Open Label, Phase I, Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Volasertib in Combination With Decitabine in Patients >= 65 Years With Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Boehringer Ingelheim,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Event-free survival, Overall survival",True,NCT02003573,42199
95,196405,"1230.27, BI 1230.27, EudraCT Number: 2013-001291-38, IRAS ID: 143401, NCT01971476, NL45611.078.13, TrialTroveID-196405, UKCRN ID: 15809","Open, Non-Controlled, Dose Escalating Phase I Trial To Evaluate The Pharmacokinetics, Pharmacodynamics, Tolerability And Toxicity Of Volasertib In Paediatric Patients From 2 Years To Less Than 18 Years Of Age With Acute Leukaemia Or Advanced Solid Tumour, For Whom No Effective Treatment Is Known",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Boehringer Ingelheim,"Industry, Top 20 Pharma","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Nausea, Neutropenia, Safety and Tolerability, Uric acid level, Vomiting","Absolute Neutrophil Count, Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Elimination half-life, Event-free survival, Heart rate corrected QT interval, Heart rate, Neutropenia, Overall response rate, Overall survival, Partial response, Platelet count, Progression-free survival, Progressive disease rate, Safety and Tolerability, Stable Disease",True,NCT01971476,42199
96,195189,"1230.33, 548, BI1230.33, EudraCT Number: 2013-001290-24, NCT01957644, RECF2299, TrialTroveID-195189","An Open Label Phase I Dose Escalation Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics and Efficacy of Intravenous Volasertib in Combination with Subcutaneous Azacitidine in Patients with Previously Untreated High-risk Myelodysplastic Syndrome (MDS) or Chronic Myelomonocytic Leukemia (CMML) Ineligible for High-intensity Therapy Test",Oncology,Oncology: (N/A); Oncology: Myelodysplastic Syndrome,Boehringer Ingelheim,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Complete response, Event-free survival, Hemoglobin level, Overall response rate, Overall survival, Partial response, Safety and Tolerability",True,NCT01957644,42199
97,180811,"1230.24, EudraCT Number: 2011-002367-23, NCT01772563, TrialTroveID-180811",An Open-label Fixed Sequence Trial to Investigate the Potential Drug-drug Interaction of Intravenous Volasertib Co-administered With a P-gp and CYP3A4 Inhibitor (Itraconazole p.o.) in Patients With Various Solid Tumours,Oncology,Oncology: Breast; Oncology: Prostate,Boehringer Ingelheim,"Industry, Top 20 Pharma","Cmax, Plasma concentration","Plasma concentration, Safety and Tolerability",True,NCT01772563,42199
98,177221,"1230.14, 2012/1853, 2013-0416, BI 1230.14, CTRI/2014/01/004298, EudraCT Number: 2012-002487-27, JapicCTI-132264, McG 1222, NCT01721876, NL42278.029.13, Po- LMA-2, POLO-AML-2, POLO-LMA, RECF2362, TrialTroveID-177221, VICCHEM1371","A Phase III Randomised, Double-blind, Controlled, Parallel Group Study of Intravenous Volasertib in Combination With Subcutaneous Low-dose Cytarabine vs. Placebo + Low-dose Cytarabine in Patients >or=65 Years With Previously Untreated Acute Myeloid Leukaemia, Who Are Ineligible for Intensive Remission Induction Therapy",Oncology,"Oncology: Leukemia, Acute Myelogenous",Boehringer Ingelheim,"Industry, Top 20 Pharma","Complete Response with incomplete blood count recovery, Complete response, Disease Progression, Event-free survival, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability","Adverse Events, Disease Progression, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Safety and Tolerability",True,NCT01721876,42199
99,172676,"1230.26, JapicCTI-121925, NCT01662505, TrialTroveID-172676","An Open Label, Phase I Trial of Intravenous Once Every 2 Weeks Administration of BI 6727 (Volasertib) in Japanese Patients With Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous",Sanofi/SSP {Boehringer Ingelheim/Nippon Boehringer Ingelheim/SSP},"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Absolute Neutrophil Count, Complete Response with incomplete blood count recovery, Complete response, Neutropenia, Partial response, Platelet count",True,NCT01662505,42199
100,146025,"1230.15, 1230.15/ c01694383-02, JapicCTI-111466, NCT01348347, TrialTroveID-146025",An Open-label Phase I Study of Once Every Three Weeks Intravenous Treatment With BI 6727 in Japanese Patients With Advanced Solid Tumours,Oncology,Oncology: Gastric; Oncology: Unspecified Solid Tumor,Sanofi/SSP {Boehringer Ingelheim/Nippon Boehringer Ingelheim/SSP},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Creatinine kinase level, Dose-limiting toxicities, Liver function, Maximum tolerated dose, Neutropenia","Area under the curve score, Clinical benefit rate, Cmax, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT01348347,42199
101,135293,"1230.20, EudraCT Number: 2010-019437-97, NCT01206816, TrialTroveID-135293",An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBW 2992 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit,Oncology,"Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",Boehringer Ingelheim,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01206816,42199
102,129532,"1230.23, EudraCT Number: 2009-018199-32, NCT01145885, TrialTroveID-129532",BI 6727 Human ADME Trial in Various Solid Tumours,Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell",Boehringer Ingelheim,"Industry, Top 20 Pharma","Area under the curve score, Cmax","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs",True,NCT01145885,42199
103,127033,"1230.18, EudraCT: 2009-015770-35, NCT01121406, RECF1356, TrialTroveID-127033",Phase II Randomized Trial of the Polo-like Kinase 1 Inhibitor BI 6727 Monotherapy Versus InvestigatorÂ´s Choice Chemotherapy in Ovarian Cancer Patients Resistant or Refractory to Platinum-based Cytotoxic Therapy,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Boehringer Ingelheim,"Industry, Top 20 Pharma","Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Area under the curve score, Bloat, CA-125 Response, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Elimination half-life, EORTC Quality of Life Questionnaire, Global health status, Mean residence time, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Tmax, Volume of distribution",True,NCT01121406,42199
104,119412,"1230.7, EudraCT Number: 2008-008304-41, IEO S502/409, NCT01022853, TrialTroveID-119412",An Open Label Phase I Dose Escalation Trial of Intravenous BI 6727 in Combination With Oral BIBF 1120 in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit,Oncology,Oncology: Unspecified Solid Tumor,Boehringer Ingelheim,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01022853,42199
105,114592,"1230.6, EudraCT Number:2008-003926-40, NCT00969761, TrialTroveID-114592",A Phase I Dose Escalation Trial of BI 6727 in Combination With Cisplatin or Carboplatin in Patients With Advanced or Metastatic Solid Tumors,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Boehringer Ingelheim,"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Vital signs",True,NCT00969761,42199
106,114571,"1230.16, NCT00969553, TrialTroveID-114571",A Phase I Single Dose Escalation Study of Two Dosing Schedules of BI 6727 Administered Intravenously in Asian Patients with Various Solid Cancers with Repeated Administration in Patients with Clinical Benefit.,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma",Boehringer Ingelheim,"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate - duration, Overall response rate, Progression-free survival, Vital signs",True,NCT00969553,42199
107,103286,"1230.5, McG 0901, NCT00824408, TrialTroveID-103286",A Randomised Open-label Phase II Trial of BI 6727 Monotherapy and BI 6727 in Combination With Standard Dose Pemetrexed Compared to Pemetrexed Monotherapy in Second Line Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Boehringer Ingelheim,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Duration of overall response, Neutropenia, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Volume of distribution, Vomiting",True,NCT00824408,42199
108,101740,"1230.4, AML BI 1230.4, AML PLK Inhibitor BI 6727, BI 1230.4, DRKS00003750, EudraCT No: 2008-003617-27, LN_AMLINT_2008_293, McG 0943, NCT00804856, RECF1451, TrialTroveID-101740","An Open Phase I/IIa Trial to Investigate the Maximum Tolerated Dose, Safety, Pharmacokinetics, and Efficacy of Intravenous BI 6727 as Monotherapy or in Combination With Subcutaneous Cytarabine in Patients With Acute Myeloid Leukaemia",Oncology,"Oncology: Leukemia, Acute Myelogenous",Boehringer Ingelheim,"Industry, Top 20 Pharma","Complete Response with incomplete blood count recovery, Complete response, Maximum tolerated dose, Overall response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Dose-limiting toxicities, Event-free survival, Heart rate corrected QT interval, Overall survival, Partial response, Safety and Tolerability",True,NCT00804856,42199
109,100858,"09-049, 1230.2, J09122, NCT01023958, NVCI 09-42, TrialTroveID-100858","An Open-label, Single-arm, Phase II Trial of Intravenous BI 6727 in Patients With Locally Advanced, Metastatic or Recurrent Urothelial Cancer of the Bladder, Renal Pelvis, or Ureters After Failure of Prior Chemotherapy",Oncology,Oncology: Bladder; Oncology: Renal,Boehringer Ingelheim,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Disease Progression, Duration of overall response, Elimination half-life, Hemoglobin level, Leukocyte count, Liver function, NCI-CTC scale, Neutropenia, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Tmax, Volume of distribution, Vomiting",True,NCT01023958,42199
110,99563,"1230.1, EudraCT number: 2005-002500-42, NCT02273388, TrialTroveID-099563",An Open Phase I Single Dose Escalation Study of BI 6727 Administered Intravenously in Patients With Advanced Solid Tumours With Repeated Administration in Patients With Clinical Benefit,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Boehringer Ingelheim,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Elimination half-life, Heart rate corrected QT interval, Maximum tolerated dose, Progression-free survival, Safety and Tolerability",True,NCT02273388,42199
111,135105,"11-009, 11-0148, AAAI0725, CTO# 101558, CTRI/2012/07/002821, EMBARC-RF, EN3348-303, EudraCT Number: 2011-003496-11, NCT01200992, NL38103.091.11, TrialTroveID-135105, VICCURO1149","A Phase III, Randomized, Active-Controlled, Open-Label, Multicenter Study to Evaluate the Efficacy and Safety of EN3348 (MCC) as Compared With Mitomycin C in the Intravesical Treatment of Subjects With BCG Recurrent or Refractory Non-Muscle Invasive Bladder Cancer",Oncology,Oncology: Bladder,Endo International {Endo Pharmaceuticals},"Industry, all other pharma","Event-free survival, Recurrence","Adverse Events, Event-free survival, Overall survival, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01200992,15106
112,101113,TrialTroveID-101113,"Phase I/II clinical study of MCC for the treatment of Carcinoma in situ (CIS) high grade bladder cancer, with or without papillary lesions",Oncology,Oncology: Bladder,Liminal BioSciences {ProMetic Life Science {Telesta Therapeutics {Bioniche Life Sciences}}},"Industry, all other pharma",Safety and Tolerability,,False,,15106
113,44157,"20061324, HIS-0611-0602, MDACC 2007-0091, NCT00406068, TrialTroveID-044157, URCC I3806, VICCURO0706","Phase III, Open-Label, Multi-Center Study of the Efficacy and Safety of MCC in the Treatment of Patients With Non-Muscle Invasive (Superficial) Bladder Cancer at High Risk of Progression and Who Are Refractory to BCG.",Oncology,Oncology: Bladder,"Liminal BioSciences {ProMetic Life Science {Telesta Therapeutics {Bioniche Life Sciences}}}, Endo International {Endo Pharmaceuticals}","Industry, all other pharma, Industry, all other pharma","Adverse Events, Disease-free survival, Overall survival, Safety and Tolerability, Time to progression","Adverse Events, Disease-free survival, Overall survival, Safety and Tolerability, Time to progression",True,NCT00406068,15106
114,26361,TrialTroveID-026361,A phase-I study of Intraprostatic injection of mycobacterial cell wall-DNA complex (MCC) in prostate cancer patients.,Oncology,Oncology: Prostate,Liminal BioSciences {ProMetic Life Science {Telesta Therapeutics {Bioniche Life Sciences}}},"Industry, all other pharma",Safety and Tolerability,,False,,15106
115,19498,"EN3348-302, NCT01284205, TrialTroveID-019498","Randomized, Double-blind, Multi-center Study Comparing MCC to BCG as First Line Immunotherapy in Patients with Non-muscle Invasive (Superficial) Bladder Cancer at High Risk of Recurrence or Progression",Oncology,Oncology: Bladder,"Liminal BioSciences {ProMetic Life Science {Telesta Therapeutics {Bioniche Life Sciences}}}, Endo International {Endo Pharmaceuticals}","Industry, all other pharma, Industry, all other pharma","Adverse Events, Disease-free survival, Recurrence","Adverse Events, Disease-free survival, Overall survival, Progression-free survival, Time to progression",True,NCT01284205,15106
116,5663,TrialTroveID-005663,MCC and Carcinoma in Situ of the Bladder.,Oncology,Oncology: Bladder,Liminal BioSciences {ProMetic Life Science {Telesta Therapeutics {Bioniche Life Sciences}}},"Industry, all other pharma",Safety and Tolerability,,False,,15106
117,317261,TrialTroveID-317261,A Phase I/II Study of RX-3117 in Combination with Cisplatin in Subjects with Newly Diagnosed Bladder Cancer,Oncology,Oncology: Bladder,Ocuphire Pharma {Rexahn Pharmaceuticals},"Industry, all other pharma",Maximum tolerated dose,,False,,34773
118,294637,"1707664489, 17-665, NCI-2017-01842, NCT03189914, RX3117-003, TrialTroveID-294637","A Phase I/II Open-Label, Safety, Pharmacokinetic, Pharmacodynamic and Efficacy Study of RX-3117 in Combination With Abraxane in Subjects With Metastatic Pancreatic Cancer",Oncology,Oncology: Pancreas,Ocuphire Pharma {Rexahn Pharmaceuticals},"Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Heart rate, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events, Vital signs","Area under the curve score, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Quality of Life, Time to progression, Time to response, Tmax",True,NCT03189914,34773
119,172343,"16215, 1702242206, 20140254, NCI-2016-01021, NCT02030067, RX-3117-P1-01, TrialTroveID-172343","A Phase I, Open-Label, Dose-Ranging, Safety and Pharmacokinetic Study to Determine the Maximum Tolerated Dose of RX-3117 Administered Orally as a Single-Agent to Subjects With Advanced Malignancies",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Ocuphire Pharma {Rexahn Pharmaceuticals},"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Area under the curve score, Clinical benefit rate, Duration of overall response, Overall response rate, Plasma concentration, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT02030067,34773
120,160384,TrialTroveID-160384,"A Phase I, Exploratory First-in-Human, Safety, Tolerability, Bioavailability Study of RX-3117 For The Treatment of Solid Tumors.",Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Pancreas","Teva, Ocuphire Pharma {Rexahn Pharmaceuticals}","Industry, Top 20 Pharma, Industry, all other pharma",Bioavailability,,False,,34773
121,356803,"031912, NCI-2019-05810, NCT04081688, Pro2019000923, TrialTroveID-356803",A Phase I Trial of Atezolizumab and Varlilumab in Combination With Radiation in Patients With Metastatic Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Progression-free survival, Stable Disease",True,NCT04081688,42439
122,333802,"DERIVe, NCI-2019-05126, NCT03688178, Pro00082570, TrialTroveID-333802, US-1607",DC Migration Study to Evaluate TReg Depletion In GBM Patients With and Without Varlilumab,Oncology,"Oncology: CNS, Glioblastoma","Duke University Medical Center, Celldex Therapeutics {Kolltan}","Academic, Industry, all other pharma","Overall survival, Safety and Tolerability","Disease Progression, Overall survival, Progression-free survival",True,NCT03688178,42439
123,307941,"35676, CRUKD/17/008, EudraCT Number: 2017-000302-37, IRAS ID-223132, ISRCTN15025004, NCT03307746, RHMCAN1278, RiVa, TrialTroveID-307941",A Phase IIa Study of RItuximab and Varlilumab in Relapsed or Refractory B-cell Malignancies,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Cancer Research UK, (Other Hospital/Academic/Medical Center), Celldex Therapeutics {AVANT Immunotherapeutics}, University of Southampton","Not for Profit Funding Entity, Academic, Industry, all other pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Disease Progression, Duration of overall response, Overall survival, Progression-free survival",True,NCT03307746,42439
124,295220,"10089, 19877, DIAL, MC168D, NCI 10089, NCI-2017-00120, NCT03038672, TrialTroveID-295220","A Randomized Phase II Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-Cell Lymphomas, , DIAL (Dual Immunomodulation in Aggressive Lymphoma)",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT03038672,42439
125,287898,"15108, NCI-2017-01369, NCT02924038",Pilot Randomized Neo-adjuvant Evaluation of Agonist Anti-CD27 Monoclonal Antibody Varlilumab on Immunologic Activities of IMA950 Vaccine Plus Poly-ICLC in Patients With WHO Grade II Low-Grade Glioma (LGG),,NA: ClinicalTrials.gov,"Celldex Therapeutics, Nicholas Butowski","ClinicalTrials.gov, ClinicalTrials.gov",Treatment Emergent Adverse Events,,True,NCT02924038,42439
126,253958,"15-288, 15-392, CDX1127-06, NCI-2015-02086, NCT02543645, TrialTroveID-253958","A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal","Celldex Therapeutics {AVANT Immunotherapeutics}, Roche/Genentech","Industry, all other pharma, Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Overall response rate, Safety and Tolerability, Safety and Tolerability","Safety and Tolerability, Safety and Tolerability",True,NCT02543645,42439
127,220315,"17456, NCT02284971, Prostate-04, TrialTroveID-220315",A Pilot Study to Assess the Combination of Stereotactic Body Radiation Therapy and CDX-1127 in Modulating Local and Systemic T-cell Responses Against Prostate Cancer.,Oncology,Oncology: Metastatic Cancer; Oncology: Prostate,Celldex Therapeutics {AVANT Immunotherapeutics {Medarex/Celldex Therapeutics {Alteris Therapeutics}}},"Industry, all other pharma",Adverse Events,,True,NCT02284971,42439
128,210174,"CDX1127-04, NCI-2015-00740, NCT02386111, TrialTroveID-210174",A Phase l/ll Study of Varlilumab in Combination With Sunitinib in Patients With Metastatic Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,Celldex Therapeutics {AVANT Immunotherapeutics},"Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability",,True,NCT02386111,42439
129,209921,"NCT02270372, ONT-10-104, TrialTroveID-209921","A Phase Ib, Study of ONT 10 and Varlilumab in Patients With Advanced Ovarian Cancer or Breast Cancer.",Oncology,Oncology: Breast; Oncology: Ovarian,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}, Celldex Therapeutics {CuraGen}","Industry, all other pharma, Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability",Immune Response,True,NCT02270372,42439
130,208843,"15-048, AAAO7762, CDX1127-02, NCI-2015-00273, NCT02335918, TrialTroveID-208843","A Phase l/ll Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of Anti-CD27 Antibody (Varlilumab) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors",Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal","Bristol-Myers Squibb, Celldex Therapeutics {AVANT Immunotherapeutics}","Industry, Top 20 Pharma, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Overall response rate, Overall survival, Safety and Tolerability, Treatment Emergent Adverse Events","Duration of overall response, Overall survival, Progression-free survival, Progressive disease rate, Time to response",True,NCT02335918,42439
131,204461,TrialTroveID-204461,A Phase I/II study of Varlilumab plus Tafinlar and Mekinist (followed sequentially by a checkpoint inhibitor) for Patients with B-raf mutated Metastatic Melanoma,Oncology,Oncology: Melanoma,Celldex Therapeutics {AVANT Immunotherapeutics},"Industry, all other pharma",Progression-free survival,,False,,42439
132,204458,"CDX1127-03, NCI-2015-01413, NCT02413827, TrialTroveID-204458","A Phase I Safety Pilot/Phase II, Open-label Study of Varlilumab (CDX-1127) in Combination With Ipilimumab and CDX-1401 in Patients With Unresectable Stage III or Stage IV Melanoma",Oncology,Oncology: Melanoma,Celldex Therapeutics {AVANT Immunotherapeutics},"Industry, all other pharma","Adverse Events, Complete response, Dose-limiting toxicities, Overall response rate, Safety and Tolerability, Safety and Tolerability","Safety and Tolerability, Safety and Tolerability",True,NCT02413827,42439
133,150857,"14-0403, CDX1127-01, NCT01460134, OSU-11166, REFMAL 256 IST, TrialTroveID-150857","A Phase I, Open-label, Dose-escalation, Safety and Pharmacokinetic Study of CDX-1127 in Patients With Selected Refractory or Relapsed Hematologic Malignancies or Solid Tumors",Oncology,"Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Celldex Therapeutics {AVANT Immunotherapeutics},"Industry, all other pharma","Adverse Events, Safety and Tolerability, Vital signs",Disease Progression,True,NCT01460134,42439
134,65062,TrialTroveID-065062,"Phase I/II study of Apatone in stage III, IV ovarian cancer",Oncology,Oncology: Ovarian,IC-MedTech,"Industry, all other pharma",,,False,,32384
135,28499,TrialTroveID-028499,A Pilot Study Using Apatone For The Study Of Advanced Prostate Cancer That Failed Standard Therapy.,Oncology,Oncology: Prostate,"(Other Cooperative Group), IC-MedTech","Cooperative Group, Industry, all other pharma",Safety and Tolerability,,False,,32384
136,400342,"NCT04819971, TIS-HER2GC-PERIOPERATIVE-IIT, TrialTroveID-400342","Efficacy and Safety of Perioperative Chemotherapy Combined With Tirelizumab and Trastuzumab in Patients With HER2-positive Resectable Gastric or Gastr-oesophageal Junction Carcinoma (GC/EGJ) -- a Prospective, Single-arm, Phase II Study",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall survival",True,NCT04819971,18411
137,399404,"PerSeUS-BC04, TrialTroveID-399404, UMIN000035235",Nab-Paclitaxel Plus Trastuzumab And Pertuzumab Followed By EC As a  Neoadjuvant Chemotherapy For HER2-Positive Operable Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
138,398640,"BCT 2102, NCT04789096, TrialTroveID-398640, TUGETHER","A Phase II, Two-arm, Non-comparative, Multicentre Study of Tucatinib (ONT-380), Pembrolizumab and Trastuzumab in Patients With Pre-treated Advanced HER2-positive Breast Cancer",Oncology,Oncology: Breast,ANZ Breast Cancer Trials Group,Cooperative Group,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT04789096,18411
139,397646,"DOLPHIN, NCT04769050, TrialTroveID-397646","A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment",Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,Overall response rate,"Overall response rate, Progression-free survival, Progressive disease rate",True,NCT04769050,18411
140,397594,"ChiCTR2100043523, TrialTroveID-397594","Single-Arm, Single-Center Clinical Trial Of Pyrrottinib In Combination With Albumin Paclitaxel, Carboplatin, And Trastuzumab Neoadjuvant Therapy For HER2-Positive Early Or Locally Advanced Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Safety and Tolerability",False,,18411
141,397174,"ATREZZO, ATREZZO / SOLTI 1907, EudraCT Number: 2020-000245-13, NCT04759248, SOLTI-1907, TrialTroveID-397174",A Phase II With 2 Parallel Cohorts Clinical Trial Targeting Estrogen Receptor Negative or PAM50 Non-luminal Disease With Atezolizumab in Combination With Trastuzumab and Vinorelbine in HER2-positive Advanced/Metastatic Breast Cancer - ATREZZO Study,Oncology,Oncology: Breast,"(Other Cooperative Group), Roche","Cooperative Group, Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT04759248,18411
142,396703,"NCT04750122, PekingUPH10B003, TrialTroveID-396703",Neoadjuvant Therapy Study Guided by Drug Screening in Vitro Patient-derived Tumor-like Cell Clusters for HER2 Positive Early Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease Progression, Disease-free survival, Event-free survival, Overall response rate, Partial response, Recurrence",True,NCT04750122,18411
143,396274,"ChiCTR2100043105, TrialTroveID-396274","Pyrotinib, Capecitabine Combined with Trastuzumab among Locally Advanced Her 2 Positive Breast Cancer Who Progress after Receiving the Neoadjuvant Trastuzumab and Pertuzumab Regimens: A Single-arm, Multi-centre Clinical Exploratory Study",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall response rate",False,,18411
144,396236,TrialTroveID-396236,A phase II clinical trial to investigate the efficacy and safety of combined therapy with modified FOLFOX-6 and trastuzumab-pkrb (Herzuma) in patients with HER2-positive recurrent and metastatic bile duct cancer who failed primary chemotherapy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
145,393183,TrialTroveID-393183,21P Neoadjuvant trastuzumab and pertuzumab in real-world data population in two medical institutions in Portugal,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
146,392692,"NCT04680442, PHRI.SCHOLAR-2, SCHOLAR-2","Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial",,NA: ClinicalTrials.gov,Population Health Research Institute,Academic,Safety and Tolerability,"Mortality, New York Heart Association Class",True,NCT04680442,18411
147,391676,TrialTroveID-391676,Differential Effect of Anthracycline and Trastuzumab Cancer Therapeutic Related Vascular Toxicity in Patients With Breast Cancer.,Cardiovascular,Cardiovascular: Coronary Artery Disease,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
148,390343,"69HCL19_0593, NCT04644406, PETRA, TrialTroveID-390343","PETRA: PErtuzumab and Trastuzumab Biosimilars Real Life Association for the First Line Treatment of HER2-positive Metastatic Breast Cancer, an Observational Prospective Multicenter Study",Oncology,Oncology: Breast,Hospices Civils de Lyon,Academic,"Complete response, Partial response, Stable Disease",,True,NCT04644406,18411
149,389918,"2020-006, 2020-A01266-33, NCT04638712, PROTECT-03, TrialTroveID-389918",Impact of (Neo)Adjuvant Therapy Associating Anthracyclines and Taxanes With or Without Trastuzumab on Skeletal Muscle in Breast Cancer Patients,Oncology,Oncology: Breast; Oncology: Supportive Care,University Hospital of Strasbourg,Academic,,"Anorexia measures, Body Mass Index (Cachexia), Functional Assessment of Cancer Therapy-General, Muscle Strength, Quality of Life",True,NCT04638712,18411
150,389843,"NCT04639271, ShandongCHI-16, TrialTroveID-389843","A Single-arm, Open-label Study Of Pyrotinib Combined WithTrastuzumab And Abraxane in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04639271,18411
151,389136,"CTR20201997, ML42058, NCT04661150, TrialTroveID-389136","A Phase II, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) and Trastuzumab in Combination With Capecitabine and Oxaliplatin (Xelox) in Patients With HER2 Positive Locally Advanced Resectable Gastric Cancer of Adenocarcinoma of Gastroesophageal Junction (GEJ)",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Partial response, Recurrence, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Vital signs",True,NCT04661150,18411
152,388890,TrialTroveID-388890,Metformin With Neoadjuvant Chemotherapy in Stage II-III Breast Cancer: A Phase II Clinical Trial,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
153,388259,"NCT04609540, ShandongCHI-14",Pyrotinib Combined With Trastuzumab and Chemotherapy in HER2-positive Metastatic Breast Cancer Patients- a Multicenter Retrospective Study,,NA: ClinicalTrials.gov,Shandong Cancer Hospital and Institute,ClinicalTrials.gov,,Safety and Tolerability,True,NCT04609540,18411
154,387785,"ChiCTR2000039286, TrialTroveID-387785","A Single Arm, Prospective, Multicenter Study Of Pyrroltinib Maleate Combined With Trastuzumab Plus Docetaxel Plus Carboplatin In The Neoadjuvant Treatment Of HER2 Positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Event-free survival, Overall response rate",False,,18411
155,387360,"MCC-20487, ML41590, NCT04588545, TrialTroveID-387360",Phase I/II Study of Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in the Management of HER2+ Breast Leptomeningeal Disease,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"H. Lee Moffitt Cancer Center and Research Institute, Roche/Genentech","Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Overall survival","Complete response, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response rate, Stable Disease",True,NCT04588545,18411
156,387280,"EudraCT Number:  2018-002190-21, MAR-BAS-18-005, NCT04591431, ROME, TrialTroveID-387280",The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy,Oncology,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell",(Other Cooperative Group),Cooperative Group,Overall response rate,"Adverse Events, Circulating Tumor Cells, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Serious Adverse Events, Time to next treatment, Time to treatment failure",True,NCT04591431,18411
157,386663,"CTR20201685, TQB2440-III-01, TrialTroveID-386663","A Phase III  Multi-Center, Randomized Double-Blind, Parallel Control  Clinical Study To Evaluate The Effectiveness And Safety Of TQB2440 Injection/Pazette Combined With Trastuzumab Plus Docetaxel In The Treatment Of Early Or Locally Advanced ER/PR-Negative HER2-Positive Breast Cancer Patients",Oncology,Oncology: Breast,Chia Tai Tianqing Pharmaceutical Group Co./Jiangsu Chiatai Qingjiang Pharmaceutical Co.,"Industry, generic",Complete response,"Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Progressive disease rate, Response rate, Safety and Tolerability",False,,18411
158,386505,"NCI-2021-00125, NCT04579380, SGNTUC-019, TrialTroveID-386505","A Phase II Basket Study of Tucatinib in Combination With Trastuzumab in Subjects With Previously Treated, Locally Advanced Unresectable or Metastatic Solid Tumors Driven by HER2 Alterations",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal",Seagen {Seattle Genetics},"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04579380,18411
159,386370,"ELPIS, EudraCT Number: 2019-005019-18, HCB-ONC001 (ML41519), NCT04578106, TrialTroveID-386370",Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy,Oncology,Oncology: Breast,"Roche, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Complete response, Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Magnetic Resonance Imaging, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT04578106,18411
160,385162,"ChiCTR2000038503, TrialTroveID-385162",Adjuvant Pyrotinib and Trastuzumab for Early or Local Advanced HER2-Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Overall survival, Safety and Tolerability",False,,18411
161,384662,"CRAFT, NCT/DKTK MASTER, NCT04551521, NCT-PMO-1602, TrialTroveID-384662",Continuous ReAssessment With Flexible ExTension in Rare Malignancies - CRAFT: The NCT-PMO-1602 Phase II Trial,Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease",Progression-free survival,False,,18411
162,383502,"ChiCTR2000037827, TrialTroveID-383502","Single Center, Single Arm, Prospective, Open Phase II Trial Of Pyrroltinib Maleate Tablets And Trastuzumab Combined With FOLFOX6 Regimen In The Preoperative Treatment Of HER-2 Positive Colorectal Cancer",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival",False,,18411
163,383266,"ChiCTR2000036919, TrialTroveID-383266",Clinical study on Banxia Xiexin Decoction Combined with palliative chemotherapy in the treatment of HER2 positive advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Safety and Tolerability","Clinical benefit rate, Overall response rate, Quality of Life",False,,18411
164,382356,"ChiCTR2000035874, TrialTroveID-382356",Real-World Evaluation and Translational Research on Trastuzumab Biosimilar,Oncology,Oncology: Breast; Oncology: Gastric,"Fudan University - Shanghai, China",Academic,Safety and Tolerability,Quality of Life,False,,18411
165,381871,"IIT2019-21-Basho-TOPAZ, NCT04512261, TOPAZ, TrialTroveID-381871","TOPAZ: Single Arm, Open Label Phase Ib/II Study of Tucatinib in COmbination With Pembrolizumab And TrastuZumab in Women With HER2-Positive Breast Cancer Brain Metastases",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Cedars-Sinai Medical Center, Merck & Co./Merck Sharp & Dohme (MSD), Seagen","Academic, Industry, Top 20 Pharma, Industry, all other pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04512261,18411
166,381783,"FDZL-PFG, NCT04510064, TrialTroveID-381783",Phase II Clinical Study of PD-1 Antibody Camrelizumab Combined With Modified FLOT Regimen in the Treatment of Unresectable Locally Advanced or Localized Metastatic Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Resection rate,"Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Mortality, Overall response rate, Overall survival, Progression-free survival, Treatment Emergent Adverse Events",True,NCT04510064,18411
167,381775,"20-158, NCT04510285, TrialTroveID-381775",Randomized Phase II Double-Blind Trial Of Adjuvant Pembrolizumab/Trastuzumab Or Trastuzumab In HER2+ Esophagogastric Tumors With Persistent Circulating Tumor DNA Following Curative Resection,Oncology,Oncology: Esophageal; Oncology: Gastric,Memorial Sloan-Kettering Cancer Center,Academic,Circulating Tumor Cells,,True,NCT04510285,18411
168,381626,"CHANGEABLE, NCT04508803, TrialTroveID-381626",Combination of HX008 And Niraparib in GErm-line-mutAted Metastatic Breast Cancer: a mutti-center Phase II Study,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04508803,18411
169,381335,"NCT04500990, TrialTroveID-381335",Magnetic Resonance Imaging (MRI) Diffusion-weighted Imaging (Dwi) None-Gaussian Model Predicting Early Response to Immunotherapy in Digestive System Malignancies: a Prospective Observational Study,Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response","Disease Progression, Overall survival",True,NCT04500990,18411
170,381183,"MOUNTAINEER-02, NCT04499924, SGNTUC-022, TrialTroveID-381183","A Randomized, Double-blind, Placebo-controlled, Active Comparator Phase II/III Study of Tucatinib in Combination With Trastuzumab, Ramucirumab, and Paclitaxel in Subjects With Previously Treated, Locally-advanced Unresectable or Metastatic HER2+ Gastric or Gastroesophageal Junction Adenocarcinoma (GEC)",Oncology,Oncology: Esophageal; Oncology: Gastric,Seagen,"Industry, all other pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT04499924,18411
171,381037,TrialTroveID-381037,Maintenance Trastuzumab in the Setting of Second-line Treatment in HER2 Overexpressing Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Experience of Our Centre,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Safety and Tolerability",,False,,18411
172,380054,"NCT04481932, OBU-BC-II-024, TrialTroveID-380054","Trastuzumab Combined With Pyrotinib and Chemotherapy for Locally Advanced, Inflammatory, or Early HER2-positive Mammary glandsCancer: One Arm, Open, Phase II Clinical Study",Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,Complete response,"Adverse Events, Cardiac Telemetry, Overall survival, Safety and Tolerability, Vital signs",True,NCT04481932,18411
173,376876,"NCI-2020-05784, NCT04430738, SGNTUC-024, TrialTroveID-376876",A Phase Ib/II Dose Escalation and Expansion Study of Tucatinib in Combination With Trastuzumab and Oxaliplatin-based Chemotherapy for HER2+ Gastrointestinal Cancers,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,Seagen {Seattle Genetics},"Industry, all other pharma","Adverse Events, Dose-limiting toxicities","Adverse Events, Cmax, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT04430738,18411
174,376821,TrialTroveID-376821,"Anti-HER2neu Directed Therapy in Advanced Gall Bladder Cancer: A Prospective, Multicenter Experience From India.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival",,False,,18411
175,376806,TrialTroveID-376806,Changing HER2-status of the Primary Gastric Tumor After Neoadjuvant Trastuzumab-based Therapy.,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
176,376296,"NCT04419181, TrialTroveID-376296, UBRS20013",A Feasibility Study of De-escalation of Chemotherapy in Patients With Early-Stage HER2 Positive Breast Cancer,Oncology,Oncology: Breast,University of Rochester,Academic,"Complete response, Disease-free survival","Complete response, Disease-free survival",True,NCT04419181,18411
177,375984,"CTRI/2020/05/025147, TrialTroveID-375984","Comprehensive Genomic Profiling by Next Generation Sequencing (Foundation Medicine) Of Advanced Biliary Tract Cancers (Gallbladder, Cholangiocarcinoma) And Guided Treatment: A Phase II, Prospective, Multicenter Study.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Overall survival, Progression-free survival",False,,18411
178,375026,"EUPAS24812, HEROLD, ML40006, TrialTroveID-375026","A prospective, non-interventional study assessing the diagnostic, therapeutic proceedings and safety of anti-HER2 treatment in elderly patients (=70 years old) with HER2 positive breast cancer in routine clinical practice in Poland - multicenter, observational study (HEROLD)",Oncology,Oncology: Breast,Roche,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events",,False,,18411
179,374925,TrialTroveID-374925,Safety and clinical evaluation of dual inhibition with pertuzumab and trastuzumab in HER-2-positive breast cancer patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
180,374349,"IRIS, NCT04383275, SCHBCC-N030, TrialTroveID-374349","An Open-label,Phase II Study Evaluating the Efficacy and Safety of Trastuzumab Combined With Oral Chemotherapy or Endocrine Therapy in Patients With HER-2 Positive Stage I Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Disease-free survival, Overall survival",True,NCT04383275,18411
181,374092,"IR2019001210, NCT04380012, TrialTroveID-374092",Pyrotinib Maleate With or Without Trastuzumab in the Treatment of HER2-positive Advanced Colorectal Cancer: a Multicenter Clinical Trial,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease",True,NCT04380012,18411
182,373710,"ChiCTR2000032568, TrialTroveID-373710","Real World Study on the Efficacy and Safety of Trastuzumab Combined With Delayed Pertuzumab Application in the Treatment of HER2 Positive Breast Cancer: an Observational, Non-Interventional, Prospective Study",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival",False,,18411
183,373680,"ABCSG_52, ATHENE, EudraCT Number: 2019-002364-27, ML40391, TrialTroveID-373680","An Open-Label, Two-Arm, Randomized, Single-Stage Phase II Study Of Atezolizumab in Combination With Dual HER2 Blockade Plus Epirubicin as Neoadjuvant Therapy For HER2-Positive Early Breast Cancer",Oncology,Oncology: Breast,"Austrian Breast & Colorectal Cancer Study Group, Puma Biotechnology","Cooperative Group, Industry, all other pharma",Complete response,"Overall response rate, Response evaluation criteria in solid tumors",False,,18411
184,371575,"NCT04341181, ProTarget, TrialTroveID-371575",ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor","GlaxoSmithKline, (Other Cooperative Group), Roche, Pfizer","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Stable Disease",,True,NCT04341181,18411
185,371360,"FAVOR, NCT04337658, TrialTroveID-371360","A Phase III, Randomized, Multicenter, Open-Label Study to Compare the Efficacy and Safety of Anti-HER2 Therapy Plus Fulvestrant or Capecitabine in First-line Treatment of Women With HR+, HER2+, Non-visceral Metastases, Stage IV Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT04337658,18411
186,371296,"FACT 1, FACT-1, FB-12, NCI-2020-04537, NCT03412643, NSABP FB-12, TrialTroveID-371296",An Open-Label Phase II Trial to Evaluate the Efficacy and Safety of Neoadjuvant Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel Plus Trastuzumab and Pertuzumab in Early Stage HER2-Negative Breast Cancer Patients Selected With a Test Measuring Live Cell HER2 Signaling Transduction (FACT 1),Oncology,Oncology: Breast,"National Surgical Adjuvant Breast and Bowel Project (NSABP), Roche/Genentech, Celcuity","Cooperative Group, Industry, Top 20 Pharma, Industry, diagnostics or device",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response",True,NCT03412643,18411
187,371178,"NCT04334330, SCBCS025, TrialTroveID-371178","Palbociclib, Trastuzumab, Lapatinib and Fulvestrant Treatment in Patients With Brain Metastasis From ER Positive, HER-2 Positive Breast Cancer: A Multi-center, Prospective Study in China",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04334330,18411
188,370736,"ChiCTR2000031168, TrialTroveID-370736","Clinical Study for Trastuzumab in the Treatment of Resectable HER2-Positive GC, GEJ",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Adverse Events, Overall survival",False,,18411
189,369736,"EudraCT Number: 2020-000849-14, MIMOSA, N19MIM, NCT04307329, NL73029.031.20, TrialTroveID-369736",Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial,Oncology,Oncology: Breast,"AstraZeneca, Netherlands Cancer Institute","Industry, Top 20 Pharma, Government","Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT04307329,18411
190,369419,"ChiCTR2000030618, TrialTroveID-369419","A Prospective, Single-arm, Multicentre Clinical Study of First-line Treatment of Her2-positive Recurrent/Metastatic Breast Cancer with Pyrotinib Maleate Tablet and Trastuzumab plus Albumin-bound Paclitaxel",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival",False,,18411
191,369219,"1503144-7, NCT04296162, ORCHID, TrialTroveID-369219","A Phase II Study to Assess the Effectiveness and Safety of Oral Vinorelbine or Capecitabine Combined With Trastuzumab as Adjuvant Treatment for Patients With Lymph Node Negative, HER-2 Positive and Small Tumor Size Breast Cancer (ORCHID)",Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,Disease-free survival,"Disease-free survival, Overall survival",True,NCT04296162,18411
192,368970,"HERdi PREDICT, NCT04288141, TrialTroveID-368970",HERdi PREDICT: A Pilot Study to Measure the Expression of the HER2-HER3 Dimer in Samples From Patients With HER2 Positive Breast Cancer Receiving HER2 Targeted Therapies,Oncology,Oncology: Breast,"Guys Hospital and Thomas Hospital, London, (Other Hospital/Academic/Medical Center)","Academic, Academic",,Complete response,True,NCT04288141,18411
193,368771,"NCT04281641, PHC-BC, SCHBCC-NO28, TrialTroveID-368771",Gene Expression Assays and 68 Ga-Affibody HER-2 Imaging PET in Predicting Response to Treatment With Trastuzumab and Pertuzumab Before Surgery in Chinese Patients With HER2 Positive Breast Cancer,Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,Complete response,"Complete response, Disease-free survival, Overall survival, Recurrence",True,NCT04281641,18411
194,368557,"19-002190, NCI-2020-00677, NCT04285671, TrialTroveID-368557, UCLA L-08",UCLA L-08: A Phase Ib/II Study of Combined HER Inhibition Adding Necitumumab and Trastuzumab to Osimertinib in Patients With Refractory EGFR-Mutated Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, Jonsson Comprehensive Cancer Center, UCLA, Roche/Genentech","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Lung Cancer, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT04285671,18411
195,368041,"2018-01-054, NCT04276337, TrialTroveID-368041","Genetic Characteristics of HER2 Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Docetaxel, Carboplatin, Trastuzumab and Pertuzumab (TCHP) Regimen",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,True,NCT04276337,18411
196,367524,"20-189, 646320, CompassHER2-pCR, EA1181, NCI-2019-07439, NCT04266249, S20-01382, TrialTroveID-367524",(CompassHER2-pCR): Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, ECOG-ACRIN Cancer Research Group","Government, Cooperative Group","Complete response, Disease-free survival, Recurrence","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT04266249,18411
197,367259,"ChiCTR2000029611, TrialTroveID-367259",Clinical Study For Pyrrotinib Combined with Trastuzumab And Vinorelbine In The Treatment of Advanced HER2 Positive Breast Cancer with Single Arm Phase II,Oncology,Oncology: Breast,"Chinese Academy of Medical Sciences, Jiangsu Hengrui Medicine Co.","Government, Industry, all other pharma",Overall response rate,"Clinical benefit rate, Progression-free survival",False,,18411
198,366966,"EudraCT Number: 2019-001526-94, IPATHER, NCT04253561, SOLTI-1507, TrialTroveID-366966","A Phase Ib Study of Ipatasertib, an AKT Inhibitor, in Combination With Pertuzumab Plus Trastuzumab in Patients With PI3KCA-mutant, HER2-positive Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche","Cooperative Group, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Area under the curve score, Circulating Tumor Cells, Clinical benefit rate, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Immune Response, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT04253561,18411
199,366755,"HER2-RWSNeo, NCT04249440, TrialTroveID-366755",Systemic Therapy Preoperatively Versus Postoperatively in HER2 Positive Early Breast Cancer: a Prospective Nested Case-control Study in Real World,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence",Overall survival,True,NCT04249440,18411
200,366516,"PeRSIA (ML39622), TrialTroveID-366516",Pertuzumab study for HER2-positive non-metastatic breast cancer in the neoadjuvant setting in Australia,Oncology,Oncology: Breast,Roche,"Industry, Top 20 Pharma","Adverse Events, Complete response","Disease-free survival, Overall survival",False,,18411
201,366401,TrialTroveID-366401,Impact of pathologic complete response (pCR) and and biological features of residual tumor (RT) on prognosis after neoadjuvant chemotherapy (NC) in various invasive breast cancer (IBC) subtypes,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
202,366390,TrialTroveID-366390,Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
203,366194,"AMATERAS-BC, JCOG1806, jRCTs031190129, TrialTroveID-366194","JCOG1806: Avoid Mastectomy using Trastuzumab, Pertuzumab and Radiation Study for Breast Cancer (AMATERAS-BC)",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Disease-free survival, Overall survival, Recurrence",False,,18411
204,365785,"NCT04236310, RJBC2001, TrialTroveID-365785","A Study of Neoadjuvant SHR6390 in Combination With Anastrozole, Pyrotinib, and Trastuzumab in Patients With ER-Positive, HER2-Positive Breast Cancer.",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Jiangsu Hengrui Medicine Co.","Academic, Industry, all other pharma",,"Complete response, Disease-free survival, Overall response rate, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04236310,18411
205,365690,TrialTroveID-365690,Validity of omission of axillary lymph node dissection after neoadjuvant chemotherapy for node-positive primary breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Magnetic Resonance Imaging",,False,,18411
206,365684,TrialTroveID-365684,Treatment strategies in male breast cancer: Results of a prospective multicenter study,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
207,365679,TrialTroveID-365679,Characterization of the tumor immune microenvironment (TME) in early stage HR-positive HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
208,365184,"EF-31 / ZL-8301-001, NCT04281576, TrialTroveID-365184","A Phase II, Single Arm, Multi-center, Open-Label Trial to Evaluate the Safety and Efficacy of Treatment With Tumor Treating Fields (TTFields) and Chemotherapy as First-Line Treatment for Subjects With Unresectable Gastroesophageal Junction (GEJ) Adenocarcinoma or Gastric (GC) Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,"Zai Lab, Novocure","Industry, all other pharma, Industry, diagnostics or device","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT04281576,18411
209,364576,"2019-1149, AMC2002, KCT0004391, NCT04309578, TrialTroveID-364576",A Phase II Clinical Study of Trastuzumab in Combination With Capecitabine and Cisplatin (XP) in Patients With Tissue HER2-negative But Serum HER2-positive Advanced Gastric Cancer: XP+Samfenet,Oncology,Oncology: Esophageal; Oncology: Gastric,Asan Medical Center,Academic,"Complete response, Disease Progression, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT04309578,18411
210,364539,"KC18MNDS0777, KCT0004398, TrialTroveID-364539",Implementation of Targeted Therapy During Remission Induction Chemotherapy of De Novo Pediatric Acute Myeloid Leukemia to Improve Rates of Complete Remission,Oncology,"Oncology: Leukemia, Acute Myelogenous","(Other Hospital/Academic/Medical Center), Ministry of Health &  Welfare of the Republic of Korea","Academic, Government",,Complete response,False,,18411
211,364128,"ChiCTR1900028433, TrialTroveID-364128","A Open-Label, Multicenter Clinical Study Of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (PLD) Plus Trastuzumab In HER-2 Positive Breast Cancer",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), CSPC Pharmaceutical Group Co.","Academic, Industry, all other pharma",Overall response rate,"Adverse Events, Clinical benefit rate, Complete response",False,,18411
212,363590,"OMC-BC05 Study, TrialTroveID-363590, UMIN000038715",Phase II Neoadjuvant Trial of Nab-paclitaxel + Pertuzumab + Trastuzumab Followed by Anthracycline Based Regimen in Patients with Operable HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Histological Response, Neuropathy, Overall response rate, Response rate, Safety and Tolerability",False,,18411
213,362029,"CTRI/2019/11/021955, TrialTroveID-362029",Trastuzumab in HER2 Positive Advanced Biliary Tract Cancers - Single Arm Prospective Phase II Clinical Trial,Oncology,Oncology: Liver,Tata Memorial Hospital,Academic,Progression-free survival,"Overall survival, Quality of Life",False,,18411
214,361955,"ChiCTR1900027610, TrialTroveID-361955",An Umbrella Study to Explore Precision Treatment of Colorectal Cancer Based on Molecular Typing,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Clinical benefit rate, Overall survival, Progression-free survival, Serious Adverse Events, Vital signs",False,,18411
215,361596,"2793/19, GASTHER2, NCT04168931, TrialTroveID-361596",Efficacy of Adding Trastuzumab to Standard Chemotherapy in Patients with Advanced HER2-negative Gastric Cancer and HER2 Positive Expression in Circulating Tumor Cell,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Circulating Tumor Cells, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Circulating Tumor Cells, Overall survival, Progression-free survival",True,NCT04168931,18411
216,361567,"ChiCTR1900027482, TrialTroveID-361567","Neoadjuvant Study With Trastuzumab, Pyrotinib and AI in HER2+ / HR+ Breast Cancer Patients Sensitive to Hormonal Therapy Combined With HER2-Targeted Therapy: an Open-Label, Single-Arm, Multicenter, Phase II Trial",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Event-free survival, Overall response rate",False,,18411
217,361544,"MULTOMAB, NL6828, NTR7015, TrialTroveID-361544",Blood Sampling of Oncology Patients treated with Monoclonal Antibodies,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Renal",(Other Hospital/Academic/Medical Center),Academic,,Disease Progression,False,,18411
218,361080,"NCT04158856, SHERO, TrialTroveID-361080","Adjuvant Dual Anti-HER2 Therapy in Patients With Tumors < 8mm, Node-negative, HER2-positive Breast Cancer :a Single-group Arm, Open-label, Prospective, Phase II Study",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Treatment Emergent Adverse Events",True,NCT04158856,18411
219,360882,"LACOG 0615, LATINA breast, MO39485, NCT04158258, TrialTroveID-360882","A Study To Observe Patients Characteristics, Treatment Patterns And Outcomes In Patients With Newly Diagnosed Breast Cancer In Latin America",Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, Latin American Cooperative Oncology Group","Industry, Top 20 Pharma, Cooperative Group",,"Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Progression-free survival, Recurrence, Safety and Tolerability",True,NCT04158258,18411
220,360735,TrialTroveID-360735,A Prospective Observational Study on the Optimal Maintenance Strategy in HER2-positive Advanced Gastric Cancer Treated With Trastuzumab Based Therapy,Oncology,Oncology: Gastric,"Fudan University - Shanghai, China, (Other government agency)","Academic, Government",Overall survival,"Progression-free survival, Safety and Tolerability",False,,18411
221,360586,"BLTN-NeoBC1115, NCT04152057, TrialTroveID-360586","A Single-arm, Exploratory Clinical Study of Pyrotinib Maleate Tablets Combined With Albumin Paclitaxel and Trastuzumab for Her2-positive Early or Locally Advanced Breast Cancer and Its Biomarkers",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Jiangsu Hengrui Medicine Co.","Academic, Industry, all other pharma",Complete response,"Adverse Events, Clinical benefit rate, Complete response, Overall response rate, Response evaluation criteria in solid tumors",True,NCT04152057,18411
222,358776,"8790, NCI-2019-06457, NCT04120246, RG1004302, TrialTroveID-358776",A Phase I Dose Escalation Trial of Alpha-Tocopheryloxyacetic Acid (a-TEA) in Patients With Treatment Refractory HER2+ Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Washington, Veana Therapeutics","Government, Academic, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",,True,NCT04120246,18411
223,358191,"ChiCTR1900026200, ISRCTN72521486, TrialTroveID-358191","Neoadjuvant Chemotherapy with Pyrotinib, Trastuzumab, Docetaxel, and Carboplatin in Combination For Locally Advanced Epidermal Growth Factor Receptor 2-Positve Breast Cancer: A Multicenter, Randomized, Open-label, Parallel-group Controlled Phase III Trial",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Absolute Neutrophil Count, Complete response, Creatinine kinase level, Hemoglobin level, Liver function, Overall response rate, Partial response, Platelet count, Response evaluation criteria in solid tumors, Triglyceride, Urine protein level",False,,18411
224,357641,"2018396H, NCT04094896, TrialTroveID-357641",TCHP (Docetaxel/Carboplatin/Trastuzumab/Pertuzumab) Versus EC -THP(Epirubicin/ Cyclophosphamide Followed by Docetaxe/Trastuzumab/Pertuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer,Oncology,Oncology: Breast,Guangdong General Hospital,Not for Profit Funding Entity,Complete response,,True,NCT04094896,18411
225,357049,"Arise-FJ-B102, NCT04088110, TrialTroveID-357049",Pyrotinib Maleate Combined With Trastuzumab Plus Aromatase Inhibitor in the First-line Treatment of Advanced HER2-positive/HR-positive Breast Cancer Phase II Study,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors",True,NCT04088110,18411
226,355601,"ChiCTR1900025247, TrialTroveID-355601","Phase II Clinical Study for Efficacy and Safety of Interferon Gamma Combined With Docetaxel, Carboplatin and Trastuzumab in Neoadjuvant Treatment of HER-2 Positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Complete response, Disease-free survival, Overall response rate, Overall survival, Response rate",False,,18411
227,353186,TrialTroveID-353186,Nab-pa?litaxel (Nab-P) in Patients with Metastatic Breast Cancer (mBC) with Visceral Crisis (VC): Efficacy and Tolerability,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
228,353029,"jRCT2031180150, JUPITER, TrialTroveID-353029, UMIN000037425",A Phase II Study of Trastuzumab and Pertuzumab Comination Therapy for Her2 Amplified Advanced Solid Tumors,Oncology,Oncology: Bladder; Oncology: Esophageal; Oncology: Liver; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor,"Roche/Chugai Pharmaceutical, (Other Hospital/Academic/Medical Center), (Other government agency)","Industry, Top 20 Pharma, Academic, Government",Overall response rate,"Duration of overall response, Overall response rate, Overall survival, Progression-free survival",False,,18411
229,352992,TrialTroveID-352992,"Neoadjuvant Chemotherapy With Docetaxel, Carboplatin and Biosimilar Trastuzumab In HER2-Positive Early Breast Cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
230,351965,"CSPC-DMS-BC-17, NCT03994107, TrialTroveID-351965","A Single-center, Prospective, Single Arm Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin(PLD)Plus Albumin-Bound Paclitaxel and Trastuzumab in HER-2 Positive Breast Cancer",Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China, CSPC Pharmaceutical Group Co./CSPC Ouyi Pharmaceutical Co.","Academic, Industry, generic",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT03994107,18411
231,349396,"HR-NeoBC-HN003, NCT03947242, TrialTroveID-349396",Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Vinorelbine in Trastuzumab-refractory HER2-Positive Early Stage or Locally Advanced Breast Cancer Patients.,Oncology,Oncology: (N/A); Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Complete response, Disease-free survival, Event-free survival",True,NCT03947242,18411
232,349254,"EudraCT Number: 2018-004247-23, LUMC201811, NL68188.058.18, TrialTroveID-349254",[89Zr]Trastuzumab PET/CT Imaging of HER2 Positive Breast Cancer for Predicting Pathologic Complete Response after Neoadjuvant Chemotherapy; A Multicentre Study,Oncology,Oncology: Breast,Leiden University Medical Center,Academic,,Magnetic Resonance Imaging,False,,18411
233,348669,"CSPC-DMS-BC-11, NCT03933319, TrialTroveID-348669",Phase II Study of Pegylated Liposomal Doxorubicin (PLD) Plus Trastuzumab in HER-2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"Chinese Academy of Medical Sciences, CSPC Pharmaceutical Group Co./CSPC Ouyi Pharmaceutical Co.","Government, Industry, generic","Complete response, Overall response rate, Partial response","Adverse Events, Disease Progression, Progression-free survival",True,NCT03933319,18411
234,348117,"KY20182079-F-1, NCT03925233",Sensitivity Detection and Drug Resistance Mechanism of Breast Cancer Therapeutic Drugs Based on Organ-like Culture,,NA: ClinicalTrials.gov,Xijing Hospital,ClinicalTrials.gov,,,True,NCT03925233,18411
235,347681,"TrialTroveID-347681, UMIN000035869",Phase I and Ii Trial of Combination Therapy Using Nab-Paclitaxel+Pertuzumab+Trastuzumab for Her2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Time to treatment failure,"Overall response rate, Response rate",False,,18411
236,347155,"NCT03907800, NeoPATH, RJBC1801, TrialTroveID-347155",Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease-free survival, Overall response rate, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03907800,18411
237,346940,"ChiCTR1900022293, TrialTroveID-346940",A Multi-center Prospective Randomized Controlled Trial for Neoadjuvant Chemotherapy with Pyrotinib plus Trastuzumab for HER2-positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall response rate, Overall survival",,False,,18411
238,345409,TrialTroveID-345409,Myocardial Dysfunction During Trastuzumab Therapy: A Randomized Single-Center Study.,Cardiovascular,Cardiovascular: Congestive Heart Failure,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,,False,,18411
239,344298,"ChiCTR1900021473, TrialTroveID-344298",The Clinical Study Of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (PLD) Plus Docetaxel And Trastuzumab In HER-2 Positive Breast Cancer,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), CSPC Pharmaceutical Group Co./CSPC Ouyi Pharmaceutical Co.","Academic, Industry, generic",Complete response,"Adverse Events, Disease-free survival, Overall survival",False,,18411
240,343804,"495573096, NCT03847818, TrialTroveID-343804","A Prospective, Open-label, Multicenter Phase II Study of Neoadjuvant Pyrotinib Plus Trastuzumab and Chemotherapy in Women With HER2 Positive Early Stage or Locally Advanced Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Event-free survival, Overall response rate",True,NCT03847818,18411
241,343674,"EudraCT Number: 2018-003506-11, IFCT-1703, IFCT-1703 R2D2, NCT03845270, R2D2 trial, RECF3930, TrialTroveID-343674",Phase II Trial of Trastuzumab in Combination With Pertuzumab in Pretreated Patients With Non-small Cell Lung Cancer (NSCLC) Harboring a Her2 Mutation and Receiving Docetaxel,Oncology,"Oncology: Lung, Non-Small Cell",(Other Cooperative Group),Cooperative Group,"Complete response, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT03845270,18411
242,343645,"18-621, NCT03846583, TrialTroveID-343645",Phase Ib Trial of Tucatinib in Combination With Abemaciclib and Trastuzumab for Patients With HER2-Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"Eli Lilly, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Treatment Emergent Adverse Events",True,NCT03846583,18411
243,343593,"NCT03843749, PTHMC, TrialTroveID-343593","Pyrotinib in Combination With Trastuzumab in Treatment-Refractory, HER2-Positive Metastatic Colorectal Cancer.",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors",,True,NCT03843749,18411
244,341828,"ChiCTR1900021068, TrialTroveID-341828","A Randomized, Open Label, Multicenter, Phase II Study For Comparing Docetaxel + Carboplatin + Trastuzumab Versus Docetaxel + Trastuzumab Sequential Epirubicin + Cyclophosphamide + Trastuzumab In The Neoadjuvant Therapy of Patient With Early or Locally Advanced HER2 Positive Mammary Glands Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
245,341265,"2018-03 TRAIN-3, ARCH 2018-01, BOOG2018-01, EudraCT number: 2018-003275-35, NCT03820063, NL66887.031.18, NL66887.038.18, TRAIN-3, TrialTroveID-341265",Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study,Oncology,Oncology: Breast,"(Other Cooperative Group), Netherlands Cancer Institute, Roche {F. Hoffmann-La Roche}","Cooperative Group, Government, Industry, Top 20 Pharma","Disease Progression, Event-free survival, Progression-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Event-free survival, Magnetic Resonance Imaging, Neuropathy, Overall survival, Quality of Life, Safety and Tolerability",True,NCT03820063,18411
246,340609,TrialTroveID-340609,Efficacy of Short-course Adjuvant Trastuzumab in Early Stage Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,18411
247,339964,"ChiCTR1800020449, TrialTroveID-339964","A Prospective, Multicenter Clinical Study for Pyrotinib Combined With Herceptin Plus Paclitaxel Combined With Cisplatin in the Preoperative Treatment of Her2-positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Event-free survival, Overall response rate",False,,18411
248,339882,"4-2018-0765, NCT03913234, TrialTroveID-339882","Phase IB & II Study of Ribociclib With Trastuzumab Plus Letrozole in Postmenopausal HR+, HER2+ Advanced Breast Cancer Patients",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",True,NCT03913234,18411
249,339830,TrialTroveID-339830,"Randomized, Placebo-Controlled Trial Comparing The Efficacy Of abemaciclib + Trastuzumab With Doxorubicin Plus Placebo In Women With Locally Advanced or Metastatic Breast Cancer Compared With Standardized Chemotherapy + Trastuzumab, Manifold, 3 Groups, Open Test",Oncology,Oncology: Breast,Eli Lilly,"Industry, Top 20 Pharma",,,False,,18411
250,339407,"HCRN GI17-319, NCI-2018-03813, NCT03783936, TrialTroveID-339407","A Single Arm, Multi-center Phase II Trial of mFOLFOX6 + Trastuzumab + Avelumab in First-line, Metastatic, HER2-amplified Gastric and Esophageal Adenocarcinomas",Oncology,Oncology: Esophageal; Oncology: Gastric,"Hoosier Cancer Research Network {Hoosier Oncology Group}, Merck KGaA/EMD Serono {EMD Pharmaceuticals}, University of North Carolina","Cooperative Group, Industry, all other pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Immune-related response evaluation criteria in solid tumors, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03783936,18411
251,339209,"ChiCTR1800020175, TrialTroveID-339209","A Prospective Randomized Controlled Trial for Neoadjuvant Chemotherapy With Docetaxel, Lobaplatin Plus Trastuzumab (Tlh) for HER2-positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall survival","Complete response, Disease-free survival, Overall survival, Partial response, Stable Disease",False,,18411
252,338403,"DLY201812, NCT03768375, TrialTroveID-338403","A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors",,True,NCT03768375,18411
253,338332,"KCT0003638, KSWOG 1018, NCT03766607, TrialTroveID-338332",A Multi-center Phase II Study of Trastuzumab Biosimilar (SB3) in Combination With Ramucirumab and Paclitaxel in HER2 Positive Metastatic Gastric Cancer Patients,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT03766607,18411
254,337204,TrialTroveID-337204,Cyclin D1 Differential Activation and its Prognostic Impact Among Advanced Breast Cancer Patients Treated with Trastuzumab,Oncology,Oncology: Breast,Hellenic Oncology Research Group,Cooperative Group,,,False,,18411
255,336798,"17-00890, NCI-2019-03074, NCT03742986, S17-00890, TrialTroveID-336798",Phase II Trial of Nivolumab With Chemotherapy as Neoadjuvant Treatment in Inflammatory Breast Cancer (IBC),Oncology,Oncology: Breast,NYU Langone Health,Academic,Complete response,"Complete response, Gene expression profiling, Safety and Tolerability, Safety and Tolerability",True,NCT03742986,18411
256,336672,"KOEB2, TrialTroveID-336672, UMIN000034477",Efficacy and Safety of Eribulin in Combination with Trastuzumab and Pertuzumab for HER2-Positive Advanced Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Overall survival, Progression-free survival",False,,18411
257,336639,"7889, NCT03738553, RG3013002",Multiparametric MRI for Assessing Breast Cancer Response to Anti-HER2 Therapy,,NA: ClinicalTrials.gov,University of Washington,Academic,,,True,NCT03738553,18411
258,336557,"EudraCT Number: 2012-002347-23, MA1213, POSIRI, TrialTroveID-336557",Phase II Study of Irinotecan Weekly in Combination with Trastuzumab in Patients with Locally Advanced or Metastatic HER2-Positive Breast Cancer and Increased Cancer Cell Copy Number of TOP1,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Clinical benefit rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Overall survival, Progression-free survival",False,,18411
259,336362,"HR-NeoBC-HN002, NCT03735966, TrialTroveID-336362","Neoadjuvant Study of Pyrotinib in Combination With Trastuzumab Plus Docetaxel and Carboplatin in Patients With HER2 Positive Early Stage or Locally Advanced Breast Cancer : a Single-arm,Ahead , Open-label Study.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Event-free survival, Overall response rate",True,NCT03735966,18411
260,336081,"NCT03728829, TrialTroveID-336081",An Observational Phase II Trial of Targeted Next Generation Sequencing Analysis for the Efficacy of Trastuzumab Neoadjuvant Chemotherapy in Patients With HER2 Positive Breast Cancer,Oncology,Oncology: Breast,"(Other Industry Sponsor), (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic",,"Adverse Events, Complete response, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03728829,18411
261,335855,TrialTroveID-335855,Multicenter Clinical Trial of Ramucirumab in Combination with Trastuzumab and Weekly Paclitaxel in the Treatment of Patients with HER2-positive Recurrent / Metastatic Gastric Cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
262,335485,"TrialTroveID-335485, UMIN000034475",Assessment Of Safety On Trastuzumab With Varied Dilution Solution Volume In HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,Infusion-related reactions,False,,18411
263,335353,"18-394, DAPHNe, NCI-2018-02827, NCT03716180, TrialTroveID-335353",DAPHNe: De-escalation to Adjuvant Antibodies Post-pCR to Neoadjuvant THP (Paclitaxel/Trastuzumab/Pertuzumab)-a Pilot Study in HER2-positive Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}, Breast Cancer Research Foundation","Cooperative Group, Academic, Not for Profit Funding Entity, Not for Profit Funding Entity",Complete response,"Complete response, Event-free survival, Overall survival",True,NCT03716180,18411
264,334490,"NCT03705429, REaCT-Low Risk HER-2, TrialTroveID-334490",A Multi-Centre Randomized Study Comparing Two Standard of Care Adjuvant Chemotherapy Regimens for Lower Risk HER-2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Activities of Daily Living, Adverse Events, FACIT-Fatigue, Neuropathy, Neutropenia, Quality of Life, Quality-adjusted life year",True,NCT03705429,18411
265,333612,"CTRI/2018/09/015755, TrialTroveID-333612",Pilot Study to Evaluate the Biodistribution and Dosimetry of 177Lu â Trastuzumab in HER2 Receptor Positive Metastatic Breast Carcinoma and its Toxicity and Efficacy Profile.,Oncology,Oncology: Breast,Tata Memorial Hospital,Academic,,"Common Terminology Criteria for Adverse Events, Safety and Tolerability",False,,18411
266,333589,"Ni-HIGH study, TrialTroveID-333589, UMIN000034222",A Phase Ib Study of Nivolumab Plus Trastuzumab with S-1/Capecitabine Plus Oxaliplatin for HER2 Positive Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"Ono Pharmaceutical, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs","Circulating Tumor Cells, Clinical benefit rate, Microbiome, Overall response rate, Overall survival, Progression-free survival",False,,18411
267,332615,TrialTroveID-332615,Efficacy Analysis of S-1/Oxaliplatin(SOX)/Trastuzumab Therapy for HER2-positive Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors, Safety and Tolerability",,False,,18411
268,330023,"18 SEIN 08, NCT03619044, REVER, TrialTroveID-330023",The Use of FES-PET Imaging as a Tool to Detect a Possible Reversion of Estrogen Receptor (ER)-a Status in Patients With Metastatic Breast Cancer HER2 + and ERa Neg Treated With Trastuzumab + Pertuzumab + Taxane.,Oncology,Oncology: Breast,Institut Claudius Regaud,Academic,,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT03619044,18411
269,328198,"DAUHIRB-18-121, HERZUMA-GC, NCT03588533, TrialTroveID-328198","Safety and Efficacy Evaluation of Capecitabine, Cisplatin, and Herzuma Combination Chemotherapy for the First Line Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma Patients.",Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Celltrion","Academic, Industry, all other pharma",Adverse Events,"Adverse Events, Complete response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03588533,18411
270,328062,"2018-0450, BILHER, BTC-HER2, KCT0003158, NCT03613168, TrialTroveID-328062",A Pilot Study of Trastuzumab in Combination With Gemcitabine and Cisplatin Combination in Patients With HER2 Positive Advanced Biliary Cancer,Oncology,Oncology: Liver,Asan Medical Center,Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Disease Progression, Overall survival, Progression-free survival",True,NCT03613168,18411
271,327434,"ChiCTR1800016882, TrialTroveID-327434","Esophageal Artery Perfusion Chemotherapy Combined with Apatinib in the Treatment of Advanced Esophageal Carcinoma with Failure of Radiochemotherapy: A Prospective, Exploratory, Open, Single-center, One-arm Clinical Trial",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Overall survival",,False,,18411
272,325412,"NCC201804007, NCT03544047, TrialTroveID-325412",Clinical Study on Drug Sensitivity Verification or Prediction of Therapy for Breast Cancer by Patient-Derived Organoid Model,Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Complete response, Disease-free survival, Resection rate",True,NCT03544047,18411
273,324718,"ChiCTR1800016222, TrialTroveID-324718",The Clinical Study of PLD Plus Trastuzumab and Paclitaxel as Neoadjuvant Therapy for HER2 Positive Breast Cancer,Oncology,Oncology: Breast,Chinese Academy of Medical Sciences,Government,,"Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability",False,,18411
274,324260,TrialTroveID-324260,"Treatment prediction by subset analysis of tumor infiltrating lymphocytes (TILs) in combination therapy with trastuzumab, pertuzumab, and docetaxel for advanced HER2-positive breast cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
275,324104,"NCT03521245, OB0012018",Molecular Pathway Activation Markers Predicting Efficacy of Trastuzumab Therapy for HER2-positive Breast Cancer,,NA: ClinicalTrials.gov,"Oncobox Ltd., Russia, Republican Oncological Dispensary of Karelia Republic, Russia, OmicsWay Corp., Vitamed LLC, Russia","ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT03521245,18411
276,323550,"NCT02305043, TrialTroveID-323550, VARIANT NIS, VARIANZ",Identification of Biomarkers for Prediction of Response or Resistance Against Target Therapy in Adenocarcinoma of the Stomach or Gastroesophageal Junction. A Non-interventional Study,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Complete response, Overall response rate, Partial response","Disease Progression, Overall survival",True,NCT02305043,18411
277,323120,"ChiCTR1800015814, TrialTroveID-323120",A Multi-Center Phase II Clinical Trial of HER2 Positive Metastatic Breast Cancer Treated by Lapatinib Trastuzumab Combined With Single-Drug Chemotherapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Response rate, Safety and Tolerability",False,,18411
278,322721,"19-387, NCI-2019-05084, NCT03501979, TBCRC 049, TBCRC049, TrialTroveID-322721, UAB 1794, UAB1794",A Phase II Non-randomized Study to Assess the Safety and Efficacy of the Combination of Tucatinib and Trastuzumab and Capecitabine for Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Seagen {Seattle Genetics/Cascadian Therapeutics {Oncothyreon {Biomira}}}, University of Alabama, Birmingham, Johns Hopkins University, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic, Academic, Academic",Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, MD Anderson Symptom Inventory, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03501979,18411
279,322532,"TrialTroveID-322532, UMIN000032153",A Phase II Neoadjuvant Trial of Sequential Nab-Paclitaxel Followed By 5-Fluorouracil/Epirubicine/Cyclophosphamide (FEC) In Operable Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Complete response, Safety and Tolerability",False,,18411
280,320683,"ACTRN12617001325392, BCT 1703, DIAmOND, DIAMOND, TrialTroveID-320683","BCT 1703 (Diamond): An Investigator-initiated, Non-randomised, Phase II Study of Combination Ctla-4 and Pd-l1 Blockade in Advanced Her2-positive Breast Cancers Who Have Progressed on Prior Trastuzumab-based Therapy., , DIAmOND: Double Immune ActivatiON in her2-positive Disease",Oncology,Oncology: Breast,ANZ Breast Cancer Trials Group,Cooperative Group,Response evaluation criteria in solid tumors,"Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to treatment failure",False,,18411
281,320008,"NCI-2018-01377, NCT03457896, NSABP FC-11, TrialTroveID-320008","A Phase II Study Evaluating the Combination of Neratinib Plus Trastuzumab or Neratinib Plus Cetuximab in Patients With ""Quadruple Wild-Type"" (KRAS/NRAS/BRAF/PIK3CA Wild-Type) Metastatic Colorectal Cancer Based on HER2 Status: Amplified, Non-Amplified (Wild-Type) or Mutated",Oncology,Oncology: Colorectal,"National Surgical Adjuvant Breast and Bowel Project (NSABP), Puma Biotechnology","Cooperative Group, Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT03457896,18411
282,319260,"EudraCT Number: 2013-002684-25, MYETT, SICOG13 / 01, TrialTroveID-319260",Phase II Study of Liposomal Doxorubicin in Combination with Trastuzumab Plus Cyclophosphamide Followed by Docetaxel plus Trastuzumab as Primary Systemic Therapy for Patients with Locally Advanced Breast Cancer with Her2 Overexpression or Amplification.,Oncology,Oncology: Breast,Southern Italy Cooperative Oncology Group,Cooperative Group,Complete response,"Overall response rate, Response rate",False,,18411
283,318838,"EudraCT Number: 2011-000490-30, METTEN, METTEN-01, TrialTroveID-318838","Phase II Randomised, Open-Label, Multicentric Clinical Trial Of Neoadjuvant Treatment Comprising Chemotherapy And Trastuzumab With Or Without Metformin, In Women With HER2/Erbb2 Positive Primary Breast Cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Safety and Tolerability, Safety and Tolerability",False,,18411
284,318765,TrialTroveID-318765,Association between BRCA1 and BRCA2 mutations and survival in breast cancer patients according to molecular subtype,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,18411
285,318762,TrialTroveID-318762,Clinical observation of lapatinib versus continued use of trastuzumab for trastuzumab-resistant HER2-positive advanced breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,18411
286,318608,"MC1689, NCI-2018-00149, NCT03432741, TrialTroveID-318608",Pilot Safety and Feasibility Study of an In Vivo Sensitivity Screen Using a Direct Tumor Microinjection Technique and FDG-PET,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response rate",True,NCT03432741,18411
287,317559,"17-546, NCI-2018-00401, NCT03417544, TrialTroveID-317559",A Phase II Study of Atezolizumab in Combination With Pertuzumab Plus High-dose Trastuzumab for the Treatment of Central Nervous System Metastases in Patients With Her2-positive Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Roche/Genentech,"Industry, Top 20 Pharma",Overall response rate,"Clinical benefit rate, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Duration of overall response, EQ-5D, MD Anderson Symptom Inventory, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03417544,18411
288,317214,"AIO-STO-0217, AIO-STO-0217 - INTEGA, CA209-99R, EudraCT Number: 2017-000624-10, INTEGA, KNH000638, NCT03409848, TrialTroveID-317214",Ipilimumab or FOLFOX in Combination With Nivolumab and Trastuzumab in Previously Untreated HER2 Positive Locally Advanced or Metastatic EsophagoGastric Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"Bristol-Myers Squibb, Arbeitsgemeinschaft fur Internistische Onkologie","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Ability to swallow, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Global health status, Immune Response, Overall response rate, Progression-free survival, Quality of Life, Reflux, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT03409848,18411
289,316289,"TrialTroveID-316289, UMIN000009437",Docetaxel And Trastuzumab Therapy Or Maximal Androgen Blockade For Patients With Recurrent And/Or Metastatic Salivary Grand Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability, Stable Disease",False,,18411
290,316027,"TIRUMPH TR, TrialTroveID-316027, UMIN000030505","TR Study of ""Multicenter Phase II Study to Evaluate Efficacy and Safety of Combination Therapy with Trastuzumab and Pertuzumab in Patients with HER2-Positive Metastatic Colorectal Cancer""",Oncology,Oncology: Colorectal,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}",Academic,,,False,,18411
291,315879,"365, NCT03390608","Prognosis, Prognostic Factors and Predictive Factors in Centimeter or Subcentimeter Node-negative Breast Cancer",,NA: ClinicalTrials.gov,"Swedish Breast Cancer Group, Karolinska Institutet, The Swedish Society of Medicine, The Swedish Breast Cancer Association (BRO)","Cooperative Group, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT03390608,18411
292,314403,"NCT03367676, RJBC1712, SOBER, TrialTroveID-314403","12 Weeks Adjuvant Docetaxel Plus Trastuzumab in Patients With Tumors < or = 1cm, Node-negative, HER2-positive Breast Cancer (SOBER): A Single-group Arm, Open-label, Prospective, Phase II Study",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Treatment Emergent Adverse Events",True,NCT03367676,18411
293,314389,"Alien Crafe 0005, ChiCTR1800014815, NCT03368131, TrialTroveID-314389","A Prospective Study of Concurrent Neoadjuvant Chemoradiotherapy Plus Trastuzumab for Siewert II, III of HER-2 Positive Adenocarcinoma at Gastroesophageal Junction",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Appetite, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Nausea, Overall response rate, Overall survival, Partial response, Quality of Life, Recurrence, Stable Disease, Vomiting",True,NCT03368131,18411
294,314378,"F2017000 (UAB 17112), NCI-2020-07859, NCT03368729, TrialTroveID-314378",A Phase Ib/II Study of the PARP Inhibitor Niraparib in Combination With Trastuzumab in Patients With Metastatic HER2+ Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), University of Alabama, Birmingham, Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}, (Other Hospital/Academic/Medical Center), GlaxoSmithKline/Tesaro","Cooperative Group, Academic, Not for Profit Funding Entity, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Nausea, Overall response rate, Response evaluation criteria in solid tumors, Vomiting","Adverse Events, Area under the curve score, Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03368729,18411
295,314160,"17438, CGIC17126, NCI-2016-01422, NCT03365882, S1613, SWOG S1613, SWOG-S1613, TrialTroveID-314160","S1613, A Randomized Phase II Study of Trastuzumab and Pertuzumab (TP) Compared to Cetuximab and Irinotecan (CETIRI) in Advanced/Metastatic Colorectal Cancer (mCRC) With HER-2 Amplification",Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03365882,18411
296,312855,"NCT03349177, ShandongCHI-02, TrialTroveID-312855","Pathological Complete Response Rate in Locally Advanced Breast Cancer With Neoadjuvant Fluorourcil/Epirubicin/Cyclophosphamide, Epirubicin/Cyclophosphamide Followed by Docetaxel, or Docetaxel/Cyclophosphamide as Neoadjuvant Chemotherapy",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Complete response,True,NCT03349177,18411
297,312327,"17-1585, GCO 17-1585, NCI-2018-03595, NCT03329378, TrialTroveID-312327",A Phase II Randomized Trial Evaluating Neoadjuvant Dose-Dense Doxorubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab/Pertuzumab (AC THP) and Docetaxel/Carboplatin/Trastuzumab/Pertuzumab (TCHP) For Early Her2Neu Positive Breast Cancer,Oncology,Oncology: Breast,Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Academic,Complete response,"Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Overall survival",True,NCT03329378,18411
298,310517,"17-0919, GCO 17-0919, NCI-2018-00678, NCT03304080, TrialTroveID-310517","A Multicenter, Phase I/II Trial of Anastrozole, Palbociclib, Trastuzumab and Pertuzumab in HeR-positive, Her2-positive Metastatic Breast Cancer",Oncology,Oncology: Breast,"Herbert Irving Comprehensive Cancer Center at Columbia University, Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}, Weill Medical College of Cornell University, NYU Langone Health","Academic, Academic, Academic, Academic","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Neutropenia, Partial response, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Maximum tolerated dose, Progression-free survival, Serum estradiol level",True,NCT03304080,18411
299,310274,"Ml25232 Study, TrialTroveID-310274",Clinical Outcomes Of Delayed Start Of Trastuzumab Treatment In Patients With Early Breast Cancer: Ml25232 Study,Oncology,Oncology: Breast,Roche,"Industry, Top 20 Pharma","Disease-free survival, Overall survival","Adverse Events, Treatment compliance",False,,18411
300,308954,"PASSION trial, TrialTroveID-308954, UMIN000028065",Predictive Value of Genetic Analysis for Pathological Complete Response to Preoperative Treatment in HER2-Positive HR-Negative Early Breast Cancer,Oncology,Oncology: Breast,(Other government agency),Government,,,False,,18411
301,308538,"KY20162048-1, NCT03273595, TrialTroveID-308538","A Prospective, Open-label,Multicentre,Real-word Study of Lapatinib Plus Chemotherapy Versus Trastuzumab Plus Chemotherapy as Neoadjuvant Therapy for Women With HER2-positive and p95HER2-positive,PI3K Mutation,or PTEN Loss Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT03273595,18411
302,308442,"EudraCT Number: 2016-005157-21, NCT03272477, PH002-TP-II, TP-II, TrialTroveID-308442, WSG-TP-II","A Prospective, Randomized, Multicenter, Open-label Comparison of Pre-surgical Combination of Trastuzumab and Pertuzumab With Concurrent Taxane Chemotherapy or Endocrine Therapy Given for Twelve Weeks With a Quality of Life Assessment of Trastuzumab, Pertuzumab in Combination With Standard (Neo)Adjuvant Treatment in Patients With Operable HER2+/HR+ Breast Cancer",Oncology,Oncology: Breast,"Roche, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Complete response,"Appetite, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, EQ-5D, Overall survival, Quality of Life, Safety and Tolerability, Vomiting",True,NCT03272477,18411
303,306887,"EPOC1602, TrialTroveID-306887, TRIUMPH study, UMIN000027887",Multicenter Phase II Study To Evaluate Efficacy and Safety of Combination Therapy with Trastuzumab and Pertuzumab in Patients with HER2-Positive Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",Overall response rate,"Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Time to treatment failure",False,,18411
304,306776,"BINC-B, NCT03242551, Shenzhen BC-001, TrialTroveID-306776",The Role of Multimodal Imaging and Circulating Biomarkers in Predicting the Response of Neoadjuvant Chemotherapy for Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease-free survival, Overall response rate, Overall survival, Partial response, Recurrence, Response rate",True,NCT03242551,18411
305,306486,"HETIAN64, NCT03239015, TrialTroveID-306486",Efficacy and Safety of Targeted Precision Therapy in Refractory Tumor With Druggable Molecular Event,Oncology,"Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT03239015,18411
306,304975,"(JBCRG-M06/EMERALD), EMERALD, JBCRG-M06, JBCRG-M06 (EMERALD), jRCTs021180027, NCT03264547, TrialTroveID-304975, UMIN000027938",A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD),Oncology,Oncology: Breast,"(Other Cooperative Group), Eisai","Cooperative Group, Industry, all other pharma",Progression-free survival,"Circulating Tumor Cells, Duration of overall response, Metastasis-free survival, Neuropathy, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Safety and Tolerability, Time to treatment failure, Treatment Emergent Adverse Events",True,NCT03264547,18411
307,304196,"201700454, InvestiCAT, NCT03199300",Investigating Cardiovascular Adverse Events Related to Cancer Treatment: a Study of Extreme Toxicity Using Induced Pluripotent Stem Cells,,NA: ClinicalTrials.gov,University Medical Center Groningen,ClinicalTrials.gov,,,True,NCT03199300,18411
308,303570,"CGOG2006, NCT03185988, TrialTroveID-303570","Multicenter, Phase II Study of Chemotherapy in Combination With Trastuzumab in Patients of Pretreated, HER2 Positive, Relapse or Metastatic Carcinoma of Digestive System",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall response rate, Response rate","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease, Time to progression, Time to response, Treatment Emergent Adverse Events",True,NCT03185988,18411
309,303383,TrialTroveID-303383,Characteristics of HER2 3+ Metastatic Breast Cancer Patients With Long-term Benefit of Trastuzumab,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
310,303049,"MC1633, NCI-2017-00944, NCT03179904, TrialTroveID-303049","Phase II Trial to Evaluate the Efficacy of the FASN Inhibitor, TVB-2640, in Combination With Paclitaxel and Trastuzumab in Patients With HER2+ Metastatic Breast Cancer Resistant to Trastuzumab and Taxane-Based Therapy",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Complete response, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to response",True,NCT03179904,18411
311,302686,"H4621g, MotHER, NCT00833963, TrialTroveID-302686","An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma",,,True,NCT00833963,18411
312,301427,"TrialTroveID-301427, UMIN000018165",Phase II Study of Trastuzumab and Docetaxel Therapy for HER2-Positive Recurrent/Metastatic Salivary Gland Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
313,301167,"EudraCT Number: 2016-000435-41, GOIRC-01-2016, ImmunHER, IMMUN-HER, NCT03144947, TrialTroveID-301167","Phase II, Open Label, Randomized, Biomarker Study of Immune-mediated Mechanism of Action of Neoadjuvant Subcutaneous (SC) Trastuzumab in Patients With Operable or Locally Advanced/Inflammatory HER2-positive Breast Cancer (ImmunHER)",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Mipharm","Academic, Industry, all other pharma",Immune Response,"Area under the curve score, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Functional Assessment of Cancer Therapy-Breast, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability, Time to clinical response",True,NCT03144947,18411
314,300796,"20170308, NCT03140553, TrialTroveID-300796",TCH (Docetaxel/Carboplatin/Trastuzumab) Versus EC -TH(Epirubicin/Cyclophosphamide Followed by Docetaxe/Trastuzumab) as Neoadjuvant Treatment for HER2-Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,True,NCT03140553,18411
315,299330,"MCC-18936, NCI-2017-00923, NCT03112590, TrialTroveID-299330","A Phase I-II Study of Interferon-gamma Plus Weekly Paclitaxel, Trastuzumab and Pertuzumab in Patients With HER-2 Positive Breast Cancer",Oncology,Oncology: Breast,"H. Lee Moffitt Cancer Center and Research Institute, Horizon Therapeutics {Horizon Pharma}","Academic, Industry, all other pharma","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Complete response, Immune Response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03112590,18411
316,298748,"2016-0537, NCI-2017-00813, NCT03101748, TrialTroveID-298748","A Phase 1b Study of Neratinib, Pertuzumab and Trastuzumab With Taxol (3HT) in Primary Metastatic and Locally Advanced Breast Cancer, and Phase II Study of 3HT Followed by AC in HER2 + Primary IBC, and Neratinib With Taxol (NT) Followed by AC in HR+ /HER2- Primary IBC",Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Puma Biotechnology","Academic, Government, Industry, all other pharma","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate","Adverse Events, Circulating Tumor Cells, Complete response, Overall survival, Progression-free survival",True,NCT03101748,18411
317,296315,"TrialTroveID-296315, UMIN000020852",An Observational Study of Nab-Paclitaxel-induced Peripheral Neuropathy,Oncology,Oncology: Breast; Oncology: Supportive Care,(Other Hospital/Academic/Medical Center),Academic,Neuropathy,Neuropathy,False,,18411
318,295391,"ACTRN12606000523505, CAN-NCIC-MA20, CDR0000067938, MA.20, MA20, NCCTG-CAN-NCIC-MA20, NCT00005957, NSABP-CAN-NCIC-MA20, RTOG-CAN-NCIC-MA20, SWOG-CAN-NCIC-MA20, TrialTroveID-295391, TROG-CAN-NCIC-MA20",A Phase III Study of Regional Radiation Therapy in Early Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, North Central Cancer Treatment Group (NCCTG), Radiation Therapy Oncology Group (RTOG), Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Government",Overall survival,"Disease-free survival, Quality of Life",True,NCT00005957,18411
319,294386,"NCT03024450, TrialTroveID-294386, ZS-ON-08",Efficacy and Prognostic Factors of Trastuzumab Based Therapy in HER2 Positive Advanced Gastric Cancer: a Single Center Prospective Observational Study,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,True,NCT03024450,18411
320,293390,"2014-FXY-077, ChiCTR-1800015415, NCT03006614, PERS, TrialTroveID-293390","Using PERS(PErsonalized Regimen Selection) Genetic Model Assistant Decision-making System of Neoadjuvant Chemotherapy for Breast Cancer Multicentric, Prospective, Randomized Controlled Phase III Clinical Study",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease Progression, Recurrence, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03006614,18411
321,291733,TrialTroveID-291733,Pertuzumab And Trastuzumab In Combination With Weekly Paclitaxel Delivers High PCR Rates With Favourable Toxicity Profile In Neo-Adjuvant Treatment Of Her-2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability, Safety and Tolerability",,False,,18411
322,291603,TrialTroveID-291603,Prospective Evaluation of the Predictive Value of Biomarkers with Complete Pathologic Response using Neoadjuvant Chemotherapy plus Trastuzumab + Pertuzumab in HER2 (+) Breast Cancer Patients with Invasive Tumors,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall survival",,False,,18411
323,290019,TrialTroveID-290019,Molecular characterization of HER2-positive (HER2+) metastatic gastric and gastro-esophageal junction cancer patients (mGC): Identification of resistance mechanisms to trastuzumab-based therapy (TTZ),Oncology,Oncology: Esophageal; Oncology: Gastric,"Memorial Sloan-Kettering Cancer Center, (Other Hospital/Academic/Medical Center)","Academic, Academic",,,False,,18411
324,289323,"ChiCTR-OOC-16009575, TrialTroveID-289323",Molecular Characteristics of Refractory Gastric Adenocarcinoma highly sensitive to Trastuzumab: A study based on Phosphorylated Proteomics,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,Overall survival,False,,18411
325,289214,"HER2 Retry Study, KSCC1604, TrialTroveID-289214, UMIN000024492",Multicenter Observational Study On HER2 Status In HER2-Positive Advanced Or Recurrent Gastric Cancer Refractory To Trastuzumab KSCC1604 (HER2 Retry Study),Oncology,Oncology: Gastric,"Roche/Chugai Pharmaceutical, Kyushu Thoracic Oncology Group","Industry, Top 20 Pharma, Cooperative Group",,,False,,18411
326,289187,"JPRN-UMIN000024477, TrialTroveID-289187, UMIN000024477",Phase II Trial of Pertuzumab And Trastuzumab In Combination With S-1 For Patients With HER2-Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
327,288656,"LC2014A04, NCT02934828, TrialTroveID-288656",A Randomized Study of Preoperative Chemotherapy or Postoperative Chemotherapy for Early Triple Negative or Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Operable Breast Cancer,Oncology,Oncology: Breast,Chinese Academy of Medical Sciences,Government,Disease-free survival,,True,NCT02934828,18411
328,287082,"ML21201, NCT02424682, TrialTroveID-287082",Safety of Herceptin in Metastatic Breast Cancer,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Serious Adverse Events",Serious Adverse Events,True,NCT02424682,18411
329,286809,"NCT02907021, SCHOLAR, SCHOLAR-2016, TrialTroveID-286809",A Phase I Clinical Study to Examine the Safety of Continued Treatment With Trastuzumab for Individuals With Overt Left Ventricular Dysfunction,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Safety and Tolerability",,True,NCT02907021,18411
330,283915,"API/2011/21, NCT02855775, TrialTroveID-283915",Study of the Relative Impact of the Neonatal Fc Receptor (FcRn) and the Therapeutic History on Monoclonal Antibodies Elimination. Proof of the Concept on Patients Treated by Bevacizumab or Trastuzumab in Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,True,NCT02855775,18411
331,283109,"NCT02843126, TrialTroveID-283109",A Phase I/II Study to Evaluate Safety and Efficacy of Trastuzumab Plus Natural Killer(NK) Immunotherapy To Recurrent Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,"Overall survival, Progression-free survival",True,NCT02843126,18411
332,283094,"EudraCT Number: 2016-000080-16, NCT02909751, NeoToc, TrialTroveID-283094",Tocotrienol in Combination With Neoadjuvant Chemotherapy for Women With Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Circulating Tumor Cells, Complete response",True,NCT02909751,18411
333,282116,"16079, NCI-2016-00570, NCT02827877, TrialTroveID-282116",Use of 64Cu-DOTA-Trastuzumab PET Imaging and Molecular Markers for Prediction of Response to Trastuzumab and Pertuzumab-Based Neoadjuvant Therapy,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic",Complete response,Complete response,True,NCT02827877,18411
334,282090,"ML23001, NCT01480674","A Retrospective Study to Characterize Patients With HER2-positive Metastatic or Locally Advanced Breast Cancer, Treated by Herceptin?? as 1st Line-therapy and Without Progression for at Least 3 Years Followed by a 1-year Prospective Study for Patients Still Alive",,NA: ClinicalTrials.gov,Hoffmann-La Roche,ClinicalTrials.gov,,"Adverse Events, Serious Adverse Events",True,NCT01480674,18411
335,282052,"Bisgrove, NCT00530192, SCRI-CA-001, TrialTroveID-282052",A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00530192,18411
336,281789,"ChiCTR-IOR-16008729, DLY201507, NCT02836847, TrialTroveID-281789","A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02836847,18411
337,280871,"NCT02805829, TrialTroveID-280871, XYFY2016-KL014-01",Combination Trastuzumab With Expanded NK Cells for Treating HER2-positive Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability, Safety and Tolerability",Recurrence,True,NCT02805829,18411
338,279998,"BrUOG 308, NCT02789657, TrialTroveID-279998",Efficacy of Carboplatin and Paclitaxel With Trastuzumab and Pertuzumab (wPCbTP) and Switching to an Anthracycline-based Regimen (AC) in Non-responding Patients in Clinical Stage I-III HER2-positive Breast Cancer,Oncology,Oncology: Breast,"Rhode Island Hospital, (Other Hospital/Academic/Medical Center), Women and Infants Hospital of Rhode Island","Academic, Academic, Academic","Common Terminology Criteria for Adverse Events, Complete response, Neuropathy, Neutropenia, Vomiting",,True,NCT02789657,18411
339,279978,TrialTroveID-279978,"Neoadjuvant Metformin along with Systemic Therapy Increase Pathological Complete Responses in Breast Cancer: Results of a Cross-sectional Study, Hospital Mexico, Costa Rica",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",Complete response,,False,,18411
340,279086,"14-1076, NCT02774421",Pilot Study of the Effect of Trastuzumab and GM-CSF on Children With Recurrent Ependymoma,,NA: ClinicalTrials.gov,"Children's Hospital Colorado, University of Colorado, Denver","ClinicalTrials.gov, ClinicalTrials.gov",Maximum tolerated dose,,True,NCT02774421,18411
341,277701,"DRUP, EudraCT Number: 2015-004398-33, M15DRU, NCT02925234, NL54757.031.16, TrialTroveID-277701","A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Roche, Pfizer, Bayer AG/Bayer Pharmaceuticals, Eisai, Netherlands Cancer Institute, Boehringer Ingelheim, Ipsen, Merck & Co./Merck Sharp & Dohme (MSD), Clovis Oncology, Johnson & Johnson/Janssen Biotech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma, Government, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Serious Adverse Events, Stable Disease","Overall survival, Progression-free survival",True,NCT02925234,18411
342,277512,"TrialTroveID-277512, UMIN000021554","A Feasibility Study Of Combination With Oral Fluoropyrimidine, Oxaliplatin And Trastuzumab For HER2-Positive Advanced Or Recurrent Gastric Cancer",Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,18411
343,276691,"15952, NCT02735798, TrialTroveID-276691","A Pilot Study of 64-Cu Labeled Brain PET/MRI for MM-302, a Novel HER2 Targeting Agent, in Advanced HER2+ Cancer With Brain Metastases",Oncology,Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,"University of California, San Francisco",Academic,,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT02735798,18411
344,276390,"ML27940, NCT02731313",Evaluation of Human HER-2 Status in Gastric and Gastro-Oesophageal Junction Cancer.,,NA: ClinicalTrials.gov,Hoffmann-La Roche,ClinicalTrials.gov,,,True,NCT02731313,18411
345,276000,"CH-GI-071, MATCH, NCT02725424, TrialTroveID-276000","A Randomized, Multicenter, Controlled Phase II Study to Compare Preoperative Chemotherapy Versus Chemoradiotherapy in Locally Advanced Gastric/Gastroesophageal Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,Chinese Academy of Medical Sciences,Government,"Complete response, Overall response rate, Response rate","Adverse Events, Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Resection rate",True,NCT02725424,18411
346,275970,"15-301, NCI-2016-00548, NCT02726399, TrialTroveID-275970","Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,Memorial Sloan-Kettering Cancer Center,Academic,"Disease Progression, Progression-free survival","Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",True,NCT02726399,18411
347,275562,"SBCCSG-36, TrialTroveID-275562, UMIN000021585",A Phase II Study Of Eribulin In Combination With Trastuzumab And Pertuzumab As First-Line Therapy For Metastatic HER2-Positive Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,18411
348,275027,"13.0037, ML28257, NCI-2014-00984, NCT01615068, SystHERs, TrialTroveID-275027, USON 13098",An Observational Cohort Study Of Treatment Patterns And Outcomes In Patients With HER2 Positive (Her2+) Metastatic Breast Cancer (SystHERs Registry (Systemic Therapies for HER2+ Metastatic Breast Cancer Study)).,Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma",,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Time to treatment failure",True,NCT01615068,18411
349,274589,"TrialTroveID-274589, UMIN000021209",A Phase II Trial Of Tri-Week Cycle TS-1+L-OHP+Trastuzumab Combination Therapy For HER2 Positive Advanced Or Recurrent Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Time to treatment failure",False,,18411
350,273941,"20170529, NCI-2017-00510, NCT02693535, Pro00014171, TAPUR, TrialTroveID-273941",Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","AstraZeneca, Bristol-Myers Squibb, Eli Lilly, (Other Cooperative Group), Pfizer, Bayer AG/Bayer Pharmaceuticals, Merck & Co./Merck Sharp & Dohme (MSD), Roche/Genentech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT02693535,18411
351,273714,"ML30001, MZ2016006, MZ2016006_NEOADAPT, NCT02689921, NEOADAPT, TrialTroveID-273714",A Phase II Study of NEOADjuvant Aromatase Inhibitor and Pertuzumab/Trastuzumab (NEOADAPT),Oncology,Oncology: Breast,Midwestern Regional Medical Center,Academic,Complete response,"Cardiac Telemetry, Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT02689921,18411
352,273231,TrialTroveID-273231,"A Phase I Trial of Trastuzumab, Anti-HER2 Monoclonal Antibody, in Patients with Metastatic Breast Cancer",Oncology,Oncology: Breast,Stragen Pharma,"Industry, generic",,,False,,18411
353,272101,"15-02, EudraCT Number: 2015-003687-36, ICORG 15-02, ICORG1502, NCT02705859, Panther, TrialTroveID-272101",Phase Ib/II Clinical Trial of Copanlisib in Combination With Trastuzumab in Pretreated Recurrent or Metastatic HER2-positive Breast Cancer,Oncology,Oncology: Breast,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,"Clinical benefit rate, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Congestive heart failure, Disease Progression, Duration of overall response, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to treatment failure",True,NCT02705859,18411
354,271517,"NCT02656589, SSC201512, TrialTroveID-271517",A Perspective Study of the Predictive Value of microRNA in Patients With HER2 Positive Advanced Stage Breast Cancer Who Were Treated With Herceptin,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall survival, Progression-free survival",,True,NCT02656589,18411
355,271400,"318-15, NCI-2015-01879, NCT02654119, TrialTroveID-271400","A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With Trastuzumab in Stage I-II HER2/Neu Positive Breast Cancer Patients",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Nebraska Medical Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Neuropathy, Neutropenia",,True,NCT02654119,18411
356,270951,TrialTroveID-270951,A phase I dose-escalation study of a biosimilar trastuzumab in Chinese metastasis breast cancer patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
357,270518,TrialTroveID-270518,"Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability",Complete response,False,,18411
358,270346,"2015-08-008, NCT02638428, TrialTroveID-270346",Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Unspecified Solid Tumor","(Other Hospital/Academic/Medical Center), Ministry of Health &  Welfare of the Republic of Korea","Academic, Government","Disease Progression, Event-free survival, Treatment related mortality","Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events",True,NCT02638428,18411
359,269482,"2015/8463, 912008, EudraCT Number: 2015-002816-34, NCT02624973, PETREMAC, TrialTroveID-269482",Personalized Treatment of High-risk Mammary Cancer - the PETREMAC Trial,Oncology,Oncology: Breast,"AstraZeneca, Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",,"Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Treatment Emergent Adverse Events",True,NCT02624973,18411
360,269420,TrialTroveID-269420,A Prospective Study on TIMP-4 Expression Correlates with Disease Progression among HER2-positive Breast Cancers,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
361,269383,TrialTroveID-269383,A Clinical Study on Prediction of Treatment Responses to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
362,269370,TrialTroveID-269370,Evaluation of single nucleotide polymorphisms (SNPs) as predictive factors of progression (PFS) and metastatic (MFS) free survival in adjuvant breast cancer (BC),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Metastasis-free survival, Overall survival, Progression-free survival",,False,,18411
363,269248,TrialTroveID-269248,"Neoadjuvant chemotherapy with docetaxel, carboplatin and weekly trastuzumab (TCH) is active in HER2-positive early breast cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
364,269247,TrialTroveID-269247,Targeting HER2 in Heavily Petreated HER2-negative Metastatic Breast Cancer Patients Presenting with Elevated Serum Levels of The HER2 Extracellular Domain and/or HER2 Overexpressing Circulating Tumor Cells,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Circulating Tumor Cells, C-terminal telopeptide measurements, Overall survival, Response evaluation criteria in solid tumors",,False,,18411
365,269240,TrialTroveID-269240,"A Prospective, Non-randomized Study on Assessing Benefits of Performing Extensive Nodal Dissection in Primary or Recurrent Aggressive Form of Breast Cancer",Oncology,Oncology: Breast,"(Other Academic Cancer Center), (Other Hospital/Academic/Medical Center)","Academic, Academic","Adverse Events, Disease-free survival, Overall survival",,False,,18411
366,267504,"NCT02598310, OMC BC-04, OMC-BC04, TrialTroveID-267504, UMIN000019616",Phase II Study of Neoadjuvant Nab-paclitaxel (PTX) and Trastuzumab for ER Negative and HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Histological Response, Overall response rate, Response rate, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02598310,18411
367,267500,"NCI-2016-00827, NCT02598427, Pro00061309, TrialTroveID-267500",Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Duke University Medical Center,Academic,"Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Circulating Tumor Cells, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Response rate, Stable Disease",True,NCT02598427,18411
368,267485,TrialTroveID-267485,Depth of response is a significant predictor for long-term outcome in advanced gastric cancer patients treated with trastuzumab,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,18411
369,267331,"Myl-Her 1002, NCT02594761, TrialTroveID-267331","Pharmacokinetic Study Comparing Hercules, EU-approved Herceptin and US-Licensed Herceptin Administered as a Single Intravenous Infusion to Healthy Male Volunteers",Oncology,Oncology: Unspecified Cancer,Viatris {Mylan/Mylan Pharmaceuticals},"Industry, generic","Area under the curve score, Cmax, Plasma concentration","Adverse Events, C reactive protein, Cardiac Telemetry, Elimination half-life, Safety and Tolerability, Tmax, Treatment Emergent Adverse Events",True,NCT02594761,18411
370,267207,"149517, NCT02593708, TrialTroveID-267207","Phase I Study to Evaluate the Safety of Neratinib in Combination With Paclitaxel, Trastuzumab and Pertuzumab in Women and Men With Advanced or Metastatic HER2+ Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,"University of California, San Francisco",Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose","Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT02593708,18411
371,266712,TrialTroveID-266712,Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
372,266271,"AIO/CAO-V/CAOGI, DRKS00012347, EudraCT Number: 2014-002665-30, FLOT5, NCT02578368, RENAISSANCE, RENAISSANCE (AIO-FLOT5), Renaissance / FLOT5, S575, TrialTroveID-266271",Effect of Chemotherapy Alone vs. Chemotherapy Followed by Surgical Resection on Survival and Quality of Life in Patients With Limited-metastatic Adenocarcinoma of the Stomach or Esophagogastric Junction - A Phase III Trial of Arbeitsgemeinschaft Internistische Onkologie/Chirurgische Arbeitsgemeinschaft Onkologie/Chirurgische Arbeitsgemeinschaft fÃ¼r Den Oberen Gastrointestinaltrakt (AIO/CAO-V/CAOGI),Oncology,Oncology: Esophageal; Oncology: Gastric,"Arbeitsgemeinschaft fur Internistische Onkologie, (Other Hospital/Academic/Medical Center), German Research Foundation","Cooperative Group, Academic, Academic","Overall survival, Quality of Life","Common Terminology Criteria for Adverse Events, Disease Progression, Mortality, Overall survival, Progression-free survival, Quality of Life, Recurrence, Treatment Emergent Adverse Events",True,NCT02578368,18411
373,265834,"15-312, NCT02571530, TrialTroveID-265834",Phase 1 Trial of Super-selective Intra-arterial Cerebral Infusion of Trastuzumab After Blood-Brain Barrier Disruption for the Treatment of Cerebral Metastases of HER2/Neu Positive Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale","Overall survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT02571530,18411
374,263858,"15-351, 1594GCC, 16-6001, 18369, 20150973, ML29366, NCI-2015-01825, NCT02536339, PATRICIA, TrialTroveID-263858","An Open-Label, Single-Arm, Phase II Study of Pertuzumab With High-Dose Trastuzumab for the Treatment of Central Nervous System Progression Post-Radiotherapy in Patients With HER2-Positive Metastatic Breast Cancer (PATRICIA)",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Roche/Genentech,"Industry, Top 20 Pharma","Clinical benefit rate, Disease Progression, Overall response rate","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, MD Anderson Symptom Inventory, Overall response rate - duration, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events",True,NCT02536339,18411
375,263437,"EudraCT Number: 2014-001984-11, FM-14-B01, NA-PHER2, NCT02530424, TrialTroveID-263437","Neo-Adjuvant Treatment With the CDK4,6 Inhibitor Palbociclib in HER2-positive and ER-positive Breast Cancer: Effect on Ki67 and Apoptosis Before, During and After Treatment",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Complete response, Overall response rate, Safety and Tolerability, Safety and Tolerability",True,NCT02530424,18411
376,262799,"TrialTroveID-262799, UMIN000018294",Feasibility study of a short Trastuzumab infusion in patients with breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Body Mass Index, Common Terminology Criteria for Adverse Events",False,,18411
377,262283,"BJ307-Neo02, NCT02510781, TrialTroveID-262283",A Study on Neoadjuvant Therapy for Her-2 Positive Breast Cancer and the Prognosis Detecting Circulating Tumor Cells,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Event-free survival, Overall response rate, Overall survival, Safety and Tolerability",True,NCT02510781,18411
378,260653,"BOLD-1, EudraCT Number: 2015-002323-25, FBCG-01-2015, NCT02625441, TrialTroveID-260653","A Randomized Phase III Study Comparing Trastuzumab, Pertuzumab Plus Docetaxel (TPD) Followed by 3 Cycles of Chemotherapy to the Current Standard Regimen as the Treatments of Early Breast Cancer",Oncology,Oncology: Breast,"Helsinki University, Finnish Breast Cancer Group","Academic, Cooperative Group","Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, EQ-5D, Overall survival, Quality of Life, Recurrence",True,NCT02625441,18411
379,259339,TrialTroveID-259339,Risk factors for the occurrence and irreversibility of cardiotoxicity caused by trastuzumab therapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
380,259162,"19069, BR3044, CRUK/12/046, EudraCT Number: 2013-004307-39, ISRCTN15094808, RG_13-090, ROSCO, TrialTroveID-259162, UKCRN ID: 19069","Response to Optimal Selection of neo-adjuvant Chemotherapy in Operable breast cancer: A randomised phase III, stratified biomarker trial of neoÂ­adjuvant 5-Fluorouracil, Epirubicin and Cyclophosphamide vs Docetaxel and Cyclophosphamide chemotherapy",Oncology,Oncology: Breast,"Cancer Research UK, Bristol-Myers Squibb/Celgene, (Other Hospital/Academic/Medical Center)","Not for Profit Funding Entity, Industry, Top 20 Pharma, Academic","Complete response, Resection rate","Adverse Events, Complete response, Disease-free survival, EQ-5D, Functional Assessment of Cancer Therapy-Breast, Magnetic Resonance Imaging, Overall survival, Partial response, Quality of Life, Recurrence, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,18411
381,258747,"15-7002, 16-750, 20150671, AAAP9159, CTSU/EAY131, EAY131, ECOG-ACRIN EAY131, MATCH, NCI-2015-00054, NCI-MATCH, NCT02465060, TrialTroveID-258747",Molecular Analysis for Therapy Choice (MATCH).,Oncology,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Roche/Genentech, ECOG-ACRIN Cancer Research Group","Government, Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT02465060,18411
382,258390,"KSCC 1501B, TrialTroveID-258390, UMIN000017552",A phase II clinical trial (KSCC/HGCSG/CCOG/PerSeUS1501B) examining oxaliplatin + S-1 + trastuzumab for treatment of HER2-positive advanced/recurrent gastric cancer previously untreated with chemotherapy,Oncology,Oncology: Gastric,"Yakult Honsha, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Adverse Events, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Neuropathy, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
383,258365,"HUM00084633, NCT02455882, TrialTroveID-258365",Tissue Procurement Protocol for Patients Undergoing Treatment for Early-Stage Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,True,NCT02455882,18411
384,258093,TrialTroveID-258093,Intraoperative radiotherapy as a boost after neoadjuvant chemotherapy: DFS after a median follow-up of 4 years.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
385,257760,"CHERNAC, IRAS ID: 173435, MO15/085, NCT02449824, TrialTroveID-257760, UKCRN ID 19641",Characterising Early Response to Neoadjuvant Chemotherapy With Quantitative Breast MRI,Oncology,Oncology: Breast,"University of Leeds, Leeds, UK",Academic,,Complete response,True,NCT02449824,18411
386,257603,"HIGHSOX, jRCTs051180196, TrialTroveID-257603, UMIN000017602",A phase II study of Trastuzumab with S-1 plus Oxaliplatin for HER2 positive advanced gastric cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
387,257501,"CTRI/2015/05/005766, ML29282, NCT02445586, TrialTroveID-257501","A Phase IV, Multicenter, Open-Label, Single-Arm Study of Pertuzumab (in Combination With Trastuzumab and Docetaxel) in First Line Treatment of Indian Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Congestive heart failure, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02445586,18411
388,257374,"ML20397, NCT02443467, TrialTroveID-257374",A Study to Determine the Safety and Tolerability of Herceptin as an Adjuvant Therapy of Early Breast Cancer,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Serious Adverse Events",,True,NCT02443467,18411
389,257064,"2015-1888, NCI-2015-02066, NCT02436993, TrialTroveID-257064, UCI 14-67",A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin + Paclitaxel With Pertuzumab + Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting,Oncology,Oncology: Breast,"University of California Medical Center, Irvine",Academic,"Complete response, Magnetic Resonance Imaging, Medication adherence, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response",True,NCT02436993,18411
390,255888,"TrialTroveID-255888, UMIN000017182",Phase II clinical trial of S-1/L-OHP+Trastuzumab for HER2 positive gastric cancer,Oncology,Oncology: Gastric,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Overall survival,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
391,255808,"CTRI/2015/05/005789, ML28714, NCT02419742, TrialTroveID-255808","An Indian Multicentric Open Label Prospective Phase IV Study to Evaluate Safety and Efficacy of Trastuzumab in Her2 Positive, Node Positive or High Risk Node Negative Breast Cancer as Part of a Treatment Regimen Consisting of Doxorubicin, Cyclophosphamide, With Either Docetaxel or Paclitaxel (AC-TH) or Docetaxel and Carboplatin (TCH)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Safety and Tolerability","Disease Progression, Disease-free survival, Overall survival, Recurrence",True,NCT02419742,18411
392,255149,"AS.T.R.O.BC01-13, AS.TRO BC01-13, EudraCT Number: 2013-002662-40, NCT02411344, PERELISA, PER-ELISA, TrialTroveID-255149",PERtuzumab-trastuzumab Plus lEetrozoLe In Endocrine Sensitive Breast Cancer: a Phase II neoAdjuvant Study,Oncology,Oncology: Breast,"(Other Cooperative Group), (Other Academic Cancer Center)","Cooperative Group, Academic",Complete response,"Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02411344,18411
393,255108,"JCOG1301, JCOG1301C, jRCTs031180006, TrialTroveID-255108, Trigger Study, UMIN000016920",A Randomized Phase II Study Of Systemic Chemotherapy With And Without Trastuzumab Followed By Surgery In HER2 Positive Advanced Gastric Or Esophagogastric Junction Adenocarcinoma With Extensive Lymph Node Metastasis (JCOG1301:Trigger Study),Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Metastatic Cancer,"Japan Clinical Oncology Group, Japanese Ministry of Health, Labour and Welfare","Cooperative Group, Government",Overall survival,"Adverse Events, Complete response, Overall response rate, Progression-free survival, Response rate",False,,18411
394,254617,"EudraCT Number: 2012-005352-41, TACT-2C-TRIAL, TrialTroveID-254617","A phase II randomized, open-label study evaluating the addition of trastuzumab to (nabTM)-paclitaxel as first line treatment in primary HER2 negative metastatic breast cancer patients with HER2 positive Circulating Tumor Cells (CTCs).",Oncology,Oncology: Breast,"Bristol-Myers Squibb/Celgene, (Other Hospital/Academic/Medical Center), (Other government agency)","Industry, Top 20 Pharma, Academic, Government",,"Circulating Tumor Cells, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,18411
395,253444,"EudraCT Number: 2014-002602-20, IRST 174.09 metHEReMYTA, IRST174.09, met-HEReMYTA, NCT02488564, TrialTroveID-253444",Clinical and Translational Phase II Study of Liposomal Doxorubicin Plus Docetaxel and Trastuzumab With Metformin as Primary Systemic Therapy for Operable and Locally Advanced Recombinant Human ErbB-2 (HER2) Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02488564,18411
396,253398,"1145332, NCT02379585, STEFNE, TrialTroveID-253398",A Pilot Study of Short-term Fasting on Neoadjuvant Chemotherapy in Patients With Newly Diagnosed Breast Cancer (STEFNE Study),Oncology,Oncology: Breast,Midwestern Regional Medical Center,Academic,"Complete response, Overall response rate, Response rate","Clinical Global Impression, Complete response, NCI-CTC scale, Overall response rate, Response rate",True,NCT02379585,18411
397,253346,"Alien-Craft 0002, NCT02380131, TrialTroveID-253346",Phase IV Multi-Institutional Randomized Trial of Capecitabine Plus Oxaliplatin With Herceptin in Patients with Potentially Resectable HER-2 Positive Gastric Cancer with Liver Metastasis,Oncology,Oncology: Gastric; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, NCI-CTC scale, Overall response rate, Overall survival",True,NCT02380131,18411
398,253307,"Caremore-Trastuzumab, Erasmus MC, EudraCT Number: 2014-004432-18, MEC-2014-589, NL51298.078.14, NTR5115, TrialTroveID-253307",Activity Of Trastuzumab Based Chemotherapy In Metastatic Breast Patients With HER2-Negative Primary Tumor But HER2 Positive Circulating Tumor Cells (Caremore-Trastuzumab),Oncology,Oncology: Breast,"(Other Industry Sponsor), (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Overall survival, Progression-free survival","Circulating Tumor Cells, Progression-free survival",False,,18411
399,253273,TrialTroveID-253273,Phase II trial of trastuzumab followed by weekly paclitaxel/carboplatin as first-line treatment for patients with metastatic breast cancer.,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Response rate",,False,,18411
400,253184,"NCT02376413, sysubcr001, TrialTroveID-253184",Prospective Non-randomized Evaluation of Oncoplastic Breast-conserving Surgery in Non-metastatic Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,Disease-free survival,True,NCT02376413,18411
401,252554,"NCI-2014-02574, NCT02366819, TrialTroveID-252554",PERIOP-FOLFIRINOX: A Pilot Trial of Perioperative Genotype-guided Irinotecan Dosing of gFOLFIRINOX for Locally Advanced Gastroesophageal Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Resection rate","Circulating Tumor Cells, Complete response, Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Recurrence, Response rate",True,NCT02366819,18411
402,252003,"BCIRG 102, TrialTroveID-252003","Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, University of California Los Angeles","Industry, Top 20 Pharma, Academic","Overall response rate, Safety and Tolerability","Duration of overall response, Overall survival, Time to progression",False,,18411
403,251026,"CHEVENDO, Detect V, DETECT V, DETECT V/CHEVENDO, DRKS00008184, DV, D-V, EudraCT Number: 2014-002249-22, NCT02344472, TrialTroveID-251026","DETECT V / CHEVENDO A Multicenter, Randomized Phase III Study to Compare Chemo- Versus Endocrine Therapy in Combination With Dual HER2-targeted Therapy of Herceptin (Trastuzumab) and Perjeta (Pertuzumab) Plus KisqaliÂ® (Ribociclib) in Patients With HER2 Positive and Hormone-receptor Positive Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Roche, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Neuropathy, Neutropenia, Quality of Life, Safety and Tolerability","Circulating Tumor Cells, Clinical benefit rate, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT02344472,18411
404,251024,"NCT02345772, NeoHTTP, TrialTroveID-251024, WIRB 20140462","Neoadjuvant Hormonal Therapy Combined With Chemoimmunotherapy (Taxotere, Trastuzumab and Pertuzumab) in Patients With HER2-positive and ER-Positive Breast Cancer (NeoHTTP Study)",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Overall response rate, Response rate",True,NCT02345772,18411
405,250443,"EudraCT Mumber: 2013-001800-13, GEP13, GEP13-NEOTOP, NCT02339532, NeoTOP, TrialTroveID-250443, UC-0101/1306","Neoadjuvant Phase II Trial Combining [3 FEC 100 Followed by 3 Docetaxel Associated With Trastuzumab Plus Pertuzumab] or [6 Docetaxel, Carboplatin Associated With Trastuzumab Plus Pertuzumab] According to TOP2A Status in Patients With T1c Operable, HER2-positive Breast Cancer",Oncology,Oncology: Breast,Federation Nationale des Centres de Lutte contre le Cancer,Cooperative Group,Complete response,"Complete response, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT02339532,18411
406,250322,"NCT02336984, TrialTroveID-250322, UPCC 03114",A Phase I/II Trial of HER-2/Neu Pulsed DC1 Vaccine Combined With Trastuzumab for Patients With DCIS,Oncology,Oncology: Breast,H. Lee Moffitt Cancer Center and Research Institute,Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale",,True,NCT02336984,18411
407,249826,TrialTroveID-249826,"Association of Baseline Pro-Inflammatory (IL-6, CRP) and Coagulation (D-dimer) Markers with Baseline Functional Status in Women with Breast Cancer (BC) undergoing Chemotherapy.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,C reactive protein,,False,,18411
408,249756,"JCOG 1017, JCOG1017, JCOG1017 PRIM-BC, jRCTs031180151, PRIM-BC, TrialTroveID-249756, UMIN000005586","A Randomized Controlled Trial Comparing Primary Tumor Resection Plus Systemic Therapy with Systemic Therapy Alone in Metastatic Breast Cancer (JCOG1017, PRIM-BC)",Oncology,Oncology: Breast,"Japan Clinical Oncology Group, (Other government agency)","Cooperative Group, Government",Overall survival,"Adverse Events, Disease-free survival, Serious Adverse Events",False,,18411
409,248826,"NCT02318901, PembroMab, TrialTroveID-248826",A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Unspecified Solid Tumor,Midwestern Regional Medical Center,Academic,,"Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Treatment Emergent Adverse Events",True,NCT02318901,18411
410,244221,"1004006704, NCT01427244",A Phase II Evaluation of Trastuzumab In Patients With HER2 Positive Persistent Or Recurrent Vulvar Paget's Disease,,NA: ClinicalTrials.gov,"Yale University, Genentech, Inc.","Academic, ClinicalTrials.gov",,Safety and Tolerability,True,NCT01427244,18411
411,232095,"Herceptin, NCT02062983, TrialTroveID-232095",Early Predictor of Herceptin Cardio Toxicity in Breast Cancer Patients,Oncology,Oncology: Breast,(Other government agency),Government,"Brain Natriuretic Peptide concentration, Magnetic Resonance Imaging",Brain Natriuretic Peptide concentration,True,NCT02062983,18411
412,230859,"ML 28685, NCI-2017-02454, NCT01904903, SAFE-HEaRt, TrialTroveID-230859",SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function,Oncology,Oncology: Breast,"Washington Hospital Center, (Other Hospital/Academic/Medical Center), Roche/Genentech","Academic, Academic, Industry, Top 20 Pharma","Cardiac Telemetry, Myocardial infarction (safety), Myocardial infarction, Safety and Tolerability",,True,NCT01904903,18411
413,230776,"MEC 09-4-075, NCT01894711",Real-world Use and (Cost)-Effectiveness of Adjuvant Trastuzumab in Early Breast Cancer,,NA: ClinicalTrials.gov,Maastricht University Medical Center,ClinicalTrials.gov,,,True,NCT01894711,18411
414,224392,"CDR0000067558, MSKCC-99097, NCI-T98-0083, NCT00005033",Phase II Study of Recombinant Humanized Monoclonal Antibody Against HER2 for the Treatment of Recurrent Osteosarcoma,,NA: ClinicalTrials.gov,"Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",,,True,NCT00005033,18411
415,222148,"CRO-18-2006, NCT02307227, TrialTroveID-222148",Antitumor Immune Responses in Breast Cancer Patients Treated With Neoadjuvant Chemotherapy: a Phase II Study With Trastuzumab and Concomitant Weekly Paclitaxel in Patients With HER2+ Tumors or Epirubicin + Taxotere in HER2- Tumors.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Complete response, Immune Response","Adverse Events, Immune Response, NCI-CTC scale, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT02307227,18411
416,221544,"012/048 / IMO / BC / 806, TrialTroveID-221544",Biomarkers and endurance response to neoadjuvant treatment with Herceptin and chemotherapy in patients with Locally Advanced Breast Cancer HER2 positive,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
417,220542,"LB1985106, NCT02288754, TrialTroveID-220542","Detection of Tumor DNA in Blood Samples FromFrom Patients With Late Stage Cancer and ""Healthy Controls""",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(Other Industry Sponsor),"Industry, all other pharma",,,True,NCT02288754,18411
418,218769,TrialTroveID-218769,Phase I dose escalation and cohort expansion study of the safety of intrathecal trastuzumab in HER2 positive parenchymal brain metastatic breast cancer: Trial protocol,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Safety and Tolerability, Safety and Tolerability",,False,,18411
419,218753,TrialTroveID-218753,Study Comparing Trastuzumab Plus Vinorelbine with Trastuzumab Plus Capecitabine in Heavily Pretreated HER-2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
420,218726,TrialTroveID-218726,Optimizing Adherence to Adjuvant Trastuzumab Therapy: A Prospective Controlled Clinical Trial of Monitoring Cardiotoxicity.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
421,218601,"14-ROC-5, EudraCT Number: 2014-001017-61, IRAS ID: 162679, MO29112, MO29112 (MODUL), MODUL, NCT02291289, NL50698.100.14, REec-2015-1969, TrialTroveID-218601, UKCRN ID: 17493",A Multi-centre Randomised Clinical Trial of Biomarker-driven Maintenance Treatment for First-line Metastatic Colorectal Cancer (MODUL),Oncology,Oncology: Colorectal,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT02291289,18411
422,218514,"14-359, NCI-2014-02365, NCT02260531, TrialTroveID-218514",A Phase II Study of Cabozantinib Alone or in Combination With Trastuzumab in Breast Cancer Patients With Brain Metastases,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Roche/Genentech {Genentech}, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Exelixis","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Functional Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02260531,18411
423,217944,"14-124, NCI-2015-00078, NCT02252887, TrialTroveID-217944","Phase II Study of Gemcitabine, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer After Prior Trastuzumab/Pertuzumab- or Pertuzumab-Based Therapy",Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, (Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}, Roche/Genentech","Academic, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Disease Progression, NCI-CTC scale, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02252887,18411
424,217756,"CGOG20130101005, NCT02250209, TrialTroveID-217756",Trastuzumab Plus XELOX for HER2-positive Stage III Gastric Cancer After D2 Gastrectomy:Prospective Observational Study.,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence","Adverse Events, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT02250209,18411
425,217749,"1814, EudraCT number: 2011-006259-12, TrialTroveID-217749",Phase II study on prospective evaluating the quantification of total choline by magnetic resonance spectroscopy (MRS) in breast tumours as an early predictive marker of neoadjuvant chemotherapy response in early breast cancer patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Magnetic Resonance Imaging, Partial response, Response evaluation criteria in solid tumors","Apparent diffusion coefficient, Complete response, Magnetic Resonance Imaging",False,,18411
426,217130,"TrialTroveID-217130, UMIN000013378","The Phase I Clinical Study about the Combined Therapy, High Purity Natural Killer (Nk) Cell Therapy and IgG1 Antibody to Inoperable Advance and Recurrence Digestive Cancer",Oncology,Oncology: Colorectal; Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Takara Bio","Academic, Industry, all other pharma","Adverse Events, Safety and Tolerability",,False,,18411
427,216708,"EudraCT Number: 2013-005044-29, GIM12-TYPHER, NCT02238509, TrialTroveID-216708, TYPHER","A Randomised, Multicentre, Open-label Phase II Trial Investigating Activity of Chemotherapy and Lapatinib and Trastuzumab in Patients With HER2-positive Metastatic Breast Cancer (MBC) Refractory to Anti HER2 Therapies",Oncology,Oncology: Breast,Consorzio Oncotech,Cooperative Group,"Clinical benefit rate, Complete response, Partial response, Stable Disease","Adverse Events, Disease Progression, Functional Assessment of Cancer Therapy-Breast, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02238509,18411
428,215731,"13011, ML29212, NCT02229149, TrialTroveID-215731","Randomized Phase II Trial of Chemotherapy of Physician's Choice Plus Trastuzumab Versus Chemotherapy of Physician's Choice Plus Trastuzumab Plus Pertuzumab In Women With Pretreated, HER2-Overexpressing Metastatic Breast Cancer (MBC)",Oncology,Oncology: Breast,"US Oncology Research, Roche/Genentech","Cooperative Group, Industry, Top 20 Pharma","Progression-free survival, Time to progression","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT02229149,18411
429,215593,"EudraCT Number: 2014-002238-29, NCT02226757, NL49479.029.14, TrialTroveID-215593",Paclitaxel-trastuzumab in EGFR-mutated NSCLC Patients After Progression on TKI-treatment; a Pilot-study,Oncology,"Oncology: Lung, Non-Small Cell","Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Overall survival, Progression-free survival",True,NCT02226757,18411
430,214524,"HERAKLES, KCT0001583, ML28601, NCT02214004, TrialTroveID-214524",A Phase II Trial of Preoperative HER2 Targeting and Endocrine Therapy in Postmenopausal Women With HER2 and HR Positive Breast Cancer,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Asan Medical Center","Academic, Academic",Complete response,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Gene expression profiling, Overall response rate, Partial response, Response rate, Safety and Tolerability, Stable Disease, Vital signs",True,NCT02214004,18411
431,214444,"NCI-2014-02415, NCT02213289, PANGEA-IMBBP, platform, TrialTroveID-214444",PANGEA-IMBBP: Personalized Antibodies for Gastro-Esophageal Adenocarcinoma - A 1st Pilot Metastatic Trial of Biologics Beyond Progression,Oncology,Oncology: Esophageal; Oncology: Gastric,"Amgen, National Institutes of Health, University of Chicago Medical Center, AbbVie","Industry, Top 20 Pharma, Government, Academic, Industry, Top 20 Pharma","Overall survival, Safety and Tolerability","Adverse Events, Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT02213289,18411
432,214435,"117165, CLAP016A2206, DB in 3L MBC, EGF117165, EudraCT Number: 2014-001220-30, NCT02213042, PER-071-14, RBR-58ghgp, REec-2014-1065, TrialTroveID-214435, U1111-1175-5621","An Open-Label, Phase II, Study to Evaluate Biomarkers Associated with Response to Subsequent Therapies in Subjects with HER2-Positive Metastatic Breast Cancer Receiving Treatment with Trastuzumab in Combination with Lapatinib or Chemotherapy (EGF117165)",Oncology,Oncology: Breast,"GlaxoSmithKline, Novartis","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Clinical benefit rate, Complete response, Disease Progression, Functional Assessment of Cancer Therapy-Breast, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT02213042,18411
433,213929,"1203-GITCG, EORTC-1203, EORTC-1203-GITCG, EudraCT Number: 2014-000722-38, INNOVATION, IRAS ID: 177557, MO28922, NCT02205047, NL51319.031.15, TrialTroveID-213929","Integration of Trastuzumab, With or Without Pertuzumab, Into Perioperative chemotherapy of HER-2 Positive Stomach Cancer: The INNOVATION-TRIAL",Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), EORTC Gastrointestinal Tract Cancer Group, Roche {F. Hoffmann-La Roche}","Cooperative Group, Cooperative Group, Industry, Top 20 Pharma","Complete response, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall survival, Progression-free survival, Resection rate",True,NCT02205047,18411
434,212846,TrialTroveID-212846,Phase II Study of S-1 in Combination with Trastuzumab for HER2-positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Clinical benefit rate, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,18411
435,212597,"ESCAPE, ML28839, NCT02194166, TrialTroveID-212597, UmbHER1","An Open-Label, Randomized, Cross-Over, Multicenter, Phase IIIb Study, to Assess Patients' Tolerability of Trastuzumab Administrated Subcutaneously (SC) Either Via a Single Use Injection Device (SID) or Via Vial for Manual Administration (SC Vial) in Patients With HER2-Positive Early Breast Cancer (eBC)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Visual Analog Scale,"Adverse Events, Disease Progression, Disease-free survival, Overall survival, Safety and Tolerability",True,NCT02194166,18411
436,211253,"14-057, NCI-2014-01362, NCT02167854, TrialTroveID-211253","A Phase I, Open-Label Study Evaluating the Safety and Tolerability of LJM716, BYL719 and Trastuzumab in Patients With Metastatic HER2+ Breast Cancer.",Oncology,Oncology: Breast,"Novartis, Memorial Sloan-Kettering Cancer Center, MorphoSys","Industry, Top 20 Pharma, Academic, Industry, all other pharma",Maximum tolerated dose,"Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02167854,18411
437,210707,"DRKS00003078, EudraCT Number: 2006-006088-22, GASTRIPEC, Gastripec I, Gastripec-I, NCT02158988, TrialTroveID-210707",Prospective Multicenter Phase III Trial Using CRS With / Without HIPEC After Preoperative Chemotherapy in Patients With Peritoneal Carcinomatosis of Gastric Cancer Incl. Adenocarcinoma of the Esophagogastric Junction,Oncology,Oncology: (N/A); Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Quality of Life, Safety and Tolerability",True,NCT02158988,18411
438,210420,"Recover HER2, TrialTroveID-210420, UMIN000014189",Reinduction with lapatinib followed by retreatment with trastuzumab-based therapy after disease progression multi-HER2 targeted therapies in HER2-positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,,False,,18411
439,210398,"20140259-01H, NCT02156648, OTT 14-01, OTT14-01, TrialTroveID-210398",A Feasibility Study for Women Receiving Adjuvant or Neo-adjuvant Anthracycline Chemotherapy with or without Radiation for HER2-neu Positive Invasive Ductal Carcinoma,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,Adverse Events,True,NCT02156648,18411
440,210119,"2014-0119, NCI-2014-01615, NCT02152943, TrialTroveID-210119","Combination Treatment With Everolimus, Letrozole and Trastuzumab in Hormone Receptor and HER2/Neu-positive Patients With Advanced Metastatic Breast Cancer and Other Solid Tumors: Evaluating Synergy and Overcoming Resistance",Oncology,Oncology: Breast; Oncology: Cervical; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,"Novartis, MD Anderson Cancer Center, University of Texas","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Stable Disease",,True,NCT02152943,18411
441,209955,"SONG-02, TrialTroveID-209955, UMIN000014107","A Phase II Study Of Eribulin In Combination With Pertuzumab And Trastuzumab For Advanced Or Recurrent Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer, , SONG-02",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Progression-free survival,"Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability",False,,18411
442,209455,TrialTroveID-209455,A pilot study of dose-dense (biweekly) carboplatin plus paclitaxel with or without trastuzumab as neoadjuvant treatment for breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
443,209316,"EudraCT Number: 2013-001363-23, MetAction, NCT02142036, N-of-1 Trial, TrialTroveID-209316","N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy , , MetAction: Actionable targets in cancer metastasis",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","(Other Hospital/Academic/Medical Center), Norwegian Research Council","Academic, Government",Progression-free survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02142036,18411
444,209234,TrialTroveID-209234,Neoadjuvant chemotherapy with nonpegylated liposome-encapsulated doxorubicin (NPLD) plus cyclophosphamide followed by trastuzumab plus nabpaclitaxel for HER2-positive breast cancer (BC),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
445,209186,TrialTroveID-209186,Predictive value of  circulating tumor cells (CTCs) biomarkers status in patients with metastatic breast cancer (MBC) receiving anti-HER2 therapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Circulating Tumor Cells,,False,,18411
446,209131,TrialTroveID-209131,Dual anti-HER2 therapy (lapatinib and trastuzumab) plus capecitabine is a very effective and well-tolerated regimen (CLT) in metastatic HER2-positive breast cancer patients.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
447,208961,"14.01.0062, 17656, 280513, MCC # 17656, MCC 17656, MCC17656, MCC-17656, ML28939, NCI-2014-01935, NCT02139358, TrialTroveID-208961",Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer,Oncology,Oncology: Breast,"H. Lee Moffitt Cancer Center and Research Institute, Roche/Genentech","Academic, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate",True,NCT02139358,18411
448,208515,TrialTroveID-208515,Prediction of reversibility of cardiotoxicity caused by immunotherapy with trastuzumab,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
449,208413,"BERENICE, EudraCT Number: 2014-000156-28, H00005611, IRAS ID: 154256, NCI-2014-02129, NCT02132949, TrialTroveID-208413, UKCRN ID: 16379, WO29217, WO29217-V2","A Multicenter, Multinational, Phase II Study to Evaluate Pertuzumab in Combination with Trastuzumab and Standard Neoadjuvant Anthracycline-based Chemotherapy in Patients with HER2-Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer",Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, Roche/Genentech","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,"Adverse Events, Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Event-free survival, New York Heart Association Class, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT02132949,18411
450,208244,"TrialTroveID-208244, UMIN000013886",A Phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with trastuzumab for HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall survival",False,,18411
451,208240,"CCOG1402, EXPRESS-GC study, TrialTroveID-208240, UMIN000013840",The feasibility study of modified XP (+ trastuzumab) for the patients who underwent gastrectomy for Stage IV gastric cancer: EXPRESS-GC study,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,,,False,,18411
452,208065,"(GeparOcto-GBG 84), DRKS00007322, EudraCT Number: 2014-000619-14, GBG 84, GBG84, GeparOcto, NCT02125344, TrialTroveID-208065","A Randomized Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)",Metabolic/Endocrinology; Oncology,Metabolic/Endocrinology: Anemia; Oncology: Breast; Oncology: Supportive Care,"Amgen, Teva, Roche {F. Hoffmann-La Roche}, German Breast Group, Vifor Pharma Group {Galenica/Vifor Pharma}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Industry, all other pharma","Complete response, Hemoglobin level","Complete response, Disease-free survival, Follicle Stimulating Hormone level, Functional Assessment of Cancer Therapy-Anemia, Hemoglobin level, Hemoglobin levels, Leutinizing hormone, Magnetic Resonance Imaging, Metastasis-free survival, Overall response rate, Overall survival, Quality of Life, Recurrence, Resection rate, Response rate, Safety and Tolerability, Serum estradiol level, Treatment compliance",True,NCT02125344,18411
453,207545,"2014.257, AMCMEDONC 2013-377, EudraCT Number: 2013-004111-42, NCT02120911, NL46460.018.13, TRAP, TrialTroveID-207545","Feasibility Study of Chemoradiation, TRAstuzumab and Pertuzumab in Resectable HER2+Esophageal Carcinoma: the TRAP Study",Oncology,Oncology: Esophageal; Oncology: Gastric,"Universiteit van Amsterdam, Academic Medical Center Amsterdam, Roche {F. Hoffmann-La Roche}","Academic, Academic, Industry, Top 20 Pharma",,"Complete response, Overall survival, Resection rate, Safety and Tolerability",True,NCT02120911,18411
454,206440,"TrialTroveID-206440, UMIN000006590",Capecitabine / Cisplatin / Trastuzumab for previously untreated HER2 positive advanced gastric cancer.-Phase II study,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Response rate, Safety and Tolerability",False,,18411
455,206212,"NCT02102438, NP 477, TrialTroveID-206212",Neoadjuvant or Adjuvant Chemotherapy Without Anthracyclines for Elderly Patients Diagnosed With HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Disease-free survival,"Overall survival, Safety and Tolerability",True,NCT02102438,18411
456,206144,"TrialTroveID-206144, UMIN000013607","Observational study of Pertuzumab,Trastuzumab and taxane combination therapy for patient with pretreated HER2-positive advanced or recurrent breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Overall response rate, Response rate, Safety and Tolerability",False,,18411
457,205493,"TrialTroveID-205493, UMIN000013513",Phase II Clinical Trial of Primary Systemic Therapy for Primary Breast cancer Sequential regimen of Nab-Paclitaxel followed by EC for HER2 Negative Breast Cancer and Concurrent Regimen of Docetaxel/Carboplatin/Herceptin for HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Histological Response, Overall survival",False,,18411
458,205033,"1403013519, 19-115, 2014-0459, 9593, AAAN9701, HIC# 1403013519, J1480, ML28897, ML28897/PRO 02, ML28897/PRO 02 My Pathway, ML28897PRO/02, My Pathway, MY PATHWAY, MyPathway, NCI-2014-01811, NCT02091141, PRO 02, PRO 02/ML28897, PRO-02, TrialTroveID-205033, Version 2, VICCMD16103","My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Roche/Genentech,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT02091141,18411
459,204331,"SBP04, SBP-04, TrialTroveID-204331, UMIN000009296",Combination Therapy of Eribulin with Trastuzumab for HER2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
460,203982,"HOG-GC 01, TrialTroveID-203982, UMIN000006603",A phase II study of S-1/Cisplatin/Trastuzumab for human epidermal growth factor receptor 2 (HER2)-positive advanced and/or recurrent gastric cancer,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Overall survival, Safety and Tolerability",False,,18411
461,203969,TrialTroveID-203969,A Phase II Clinical Trial of TPIV110 Vaccine (Her2neu Vaccine Conjugate) in Combination with Trastuzumab in Women with HER2 Positive (NER2/neu) Breast Cancer,Oncology,Oncology: Breast,"Mayo Clinic, US Department of Defense, Marker Therapeutics {TapImmune {GeneMax}}","Academic, Government, Industry, all other pharma",,,False,,18411
462,203881,"TrialTroveID-203881, UMIN000006591",Capecitabine/Cisplatin/Trastuzumab for previously untreated HER2 positive advanced gastric cancer. -Phase II study,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Cooperative Group),Cooperative Group,Progression-free survival,"Overall response rate, Response rate, Safety and Tolerability",False,,18411
463,203695,"TrialTroveID-203695, UMIN000013263",A phase II study of neoadjuvant chemotherapy in docetaxel plus cyclophosphamide plus trastuzumab with operable HER2 positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Overall response rate, Safety and Tolerability",False,,18411
464,203068,"201307037, 20130737, NCI-2014-00374, NCT02065609, TrialTroveID-203068",Assessment of HER2 Receptors in Breast Carcinoma by Positron Emission Tomography (PET) Using 89 Zr-Trastuzumab,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Washington University School of Medicine","Government, Academic","Adverse Events, Safety and Tolerability, Safety and Tolerability",,True,NCT02065609,18411
465,202561,"20120608, NCT02059876, TrialTroveID-202561",A Pilot Study of Dose-dense (Biweekly) Carboplatin Plus Paclitaxel With or Without Trastuzumab as Neoadjuvant Treatment for Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,True,NCT02059876,18411
466,200971,TrialTroveID-200971,A pilot study of low-dose capecitabine plus trastuzumab as first-line treatment for patients older than 75 years with HER2-positive advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
467,200533,"TrialTroveID-200533, UMIN000012798",The Safety and Efficacy Trial of Nab-Paclitaxel and Trastuzumab as Neoadjuvant Chemotherapy for HER2-Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall survival",False,,18411
468,200369,"2013/00566, MC01/21/13, NCT02030561, TrialTroveID-200369","Phase I/II Study of Expanded, Activated Autologous Natural Killer Cell Infusions With Trastuzumab for Patients With HER2+ Breast and Gastric Cancer",Oncology,Oncology: Breast; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Disease Progression, Heart rate, Liver function, NCI-CTC scale, Overall response rate - duration",,True,NCT02030561,18411
469,200350,"LORHA, TrialTroveID-200350","LORHA: Efficacy and safety of 1st-line trastuzumab based treatment, administered for at least 3 years, in patients with HER2-positive metastatic or locally advanced breast cancer â Final results",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
470,200326,TrialTroveID-200326,Postmastectomy radiation improves loco-regional control for patients with advanced breast cancer treated with neoadjuvant chemotherapy,Oncology,Oncology: Breast,Aichi Cancer Center,Academic,,,False,,18411
471,200192,TrialTroveID-200192,"A phase II trial of myocet, cyclophosphamide + or - trastuzumab followed by weekly paclitaxel + or - trastuzumab as primary systemic therapy in operable and locally advanced breast cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Response rate",False,,18411
472,200126,"NCI-2014-02015, NCT02066532, TrialTroveID-200126",Phase I/II Trial of Ruxolitinib in Combination With Trastuzumab in Metastatic HER2 Positive Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Herbert Irving Comprehensive Cancer Center at Columbia University, Incyte Corporation","Government, Academic, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Phosphate level, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, C reactive protein, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02066532,18411
473,200055,"BEAUTY, MC1137, NCT02022202, TrialTroveID-200055",Breast Cancer Genome Guided Therapy Study (BEAUTY),Oncology,Oncology: Breast,Mayo Clinic,Academic,Complete response,Complete response,True,NCT02022202,18411
474,199983,"TrialTroveID-199983, UMIN000007113",Evaluation of efficacy and safety of combination therapy with trastuzumab and eribulin for HER2-positive inoperableness or metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Overall survival, Progression-free survival, Time to treatment failure",False,,18411
475,198890,"HER2-CLHERC-A/HOT1303-A, HER2-CLHERC-B/HOT1303-B, TrialTroveID-198890, UMIN000012551, UMIN000012552","A Phase II, Open-Label Single-Arm Study to Evaluate the Efficacy and Safety of Trastuzumab (Herceptin) in Patients With HER2 Overexpression/Amplification/Mutation-Positive, Pretreated, Non-Small Cell Lung Cancer (HER2-CLHERC-B/HOT1303-B)",Oncology,"Oncology: Lung, Non-Small Cell","(Other Cooperative Group), Japanese Ministry of Health, Labour and Welfare","Cooperative Group, Government","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,18411
476,198765,"ML28670, NCT02004769, TrialTroveID-198765",Phase II Study of Trastuzumab in Combination With Chemotherapy (Docetaxel Plus Capecitabine) For First Line Treatment of Her2-Positive Advanced Gastric or Gastro-Esophageal Junction Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic","Disease Progression, Progression-free survival","Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02004769,18411
477,198662,TrialTroveID-198662,Study of Circulating Myeloid Derived Suppressor Cells (MDSC) in Patients with Breast Cancer Undergoing Neo-Adjuvant Chemotherapy.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
478,198398,"1303GCC, GCC 1303, HP-00054959, NCT02000596, TrialTroveID-198398",Phase II Study of Trastuzumab and Pertuzumab Alone and in Combination With Hormonal Therapy or Chemotherapy in Women Aged 60 and Over With HER2/Neu Overexpressed Locally Advanced and/or Metastatic Breast Carcinoma,Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT02000596,18411
479,198296,"EudraCT Number: 2013-000138-37, NL42799.031.13, NTR4250, PERISCOPE, TrialTroveID-198296",Treatment of PeriItoneal dissemination in Stomach Cancer patients with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy,Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Metastatic Cancer,"Netherlands Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic","NCI-CTC scale, Safety and Tolerability","Maximum tolerated dose, Mortality, Overall survival, Recurrence",False,,18411
480,198231,"CYBORG-002, TrialTroveID-198231, UMIN000012452",Phase II Trial of Pertuzumab plus Trastuzumab plus Docetaxel for HER2-Positive Metastatic Breast Cancer that Progressed During Prior Trastuzumab Therapy,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
481,198219,"H.E.R.O.S. Study, ML21975, NCT01991340, TrialTroveID-198219",H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability","Congestive heart failure, New York Heart Association Class",True,NCT01991340,18411
482,198130,"JPRN-UMIN000012444, TrialTroveID-198130, UMIN000012444",Observational Study of Pertuzumab in Combination with Trastuzumab and Docetaxel in Patients with Metastatic HER2-Positive Breast Cancer that have the History of Trastuzumab Treatment,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
483,197442,"N-SOG 10, TrialTroveID-197442, UMIN000012350",Phase II Study of Eribulin with Trasutuzumab for Pretreated Locally Advanced / Metastatic HER2-positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Progression-free survival, Safety and Tolerability",False,,18411
484,197430,"BNGO/01, BNGO/01 THOR, EudraCT Number: 2012-000598-22, NCT01985893, THOR, TrialTroveID-197430","Randomized, Open-label Phase II Study to Compare the Safety and Efficacy of Lapatinib Plus Trastuzumab or Lapatinib Plus Capecitabine in Trastuzumab-resistant HER2-overexpressing Metastatic Breast Cancer",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival","Clinical benefit rate, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01985893,18411
485,196890,"BfArM-No.:4038232, DRKS00003301, EudraCT Number: 2011-005655-13, TrialTroveID-196890, TRY",A Phase II Study To Evaluate Safety And Efficacy of Combined Trastuzumab And AUY922 In Advanced Non-Small-Cell Lung Cancer (NSCLC) With HER2 Overexpression or Amplification or Mutation,Oncology,"Oncology: Lung, Non-Small Cell","University of Cologne Germany, German Research Foundation, (Other government agency)","Academic, Academic, Government","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate",False,,18411
486,196870,"KBC-SG 1201, TrialTroveID-196870, UMIN000012256","Phase II Study of Neoadjuvant Chemotherapy with Docetaxel, Carboplatin, and Trastuzumab for Operable Her2-positive Breast Cancer Patients.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,,False,,18411
487,196596,"TrialTroveID-196596, UMIN000012208",A Phase II Trial of Pertuzumab and Trastuzumab in Combination with Capecitabine in Patients with Metastatic Breast Cancer who Received Prior Trastuzumab Combination Chemotherapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
488,196354,"ACTRN12612000777897, IMPaCT, TrialTroveID-196354","The IMPaCT Trial: Individualised Molecular Pancreatic Cancer Therapy. A Pilot, Randomized, Open label Phase II Trial Assessing First Line Treatment With Gemcitabine or Personalized Treatment Based on Tumour Molecular Signatures in Patients With Metastatic Pancreatic Cancer",Oncology,Oncology: Pancreas,"(Other Cooperative Group), (Other Academic Cancer Center), Australasian Gastrointestinal Trials Group, National Health and Medical Research Council  (NHMRC)","Cooperative Group, Academic, Cooperative Group, Government",Safety and Tolerability,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",False,,18411
489,195634,"041318, 2013-CT0184, 20140740, BO28407, BO28407 Kaitlin, BRTKAITLIN, CT653, CTBE2014000270, EudraCT Number: 2012-004902-82, F14005, IRAS ID 120959, JapicCTI-142421, Kaitlin, NCI-2014-00853, NCRN-2639, NCT01966471, PER-027-14, PHRR140603-000202, REec-2014-0715, TrialTroveID-195634, TX4229, UKCRN ID: 15506, UW13051, UW13051-KAITLIN Trial","A Randomized, Multicenter, Open-label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer",Oncology,Oncology: Breast,"Roche/Chugai Pharmaceutical, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease-free survival, Recurrence","Adverse Events, Appetite, Cardiac Telemetry, Disease-free survival, EORTC Quality of Life Questionnaire, Global health status, Overall survival, Quality of Life, Recurrence, Safety and Tolerability",True,NCT01966471,18411
490,195428,"jRCTs061180096, TrialTroveID-195428, UMIN000012042","Phase II Study of S-1, Docetaxel, Cisplatin and Trastuzumab Combination Chemotherapy (DCS-T) in Patients with HER2-Positive Unresectable Metastatic Gastric Cancer",Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate",,False,,18411
491,195323,"CASE 14112, CASE 14112-04-13-14C, CASE14112, NCI-2013-01422, NCT01959490, TrialTroveID-195323",Next Generation Sequencing to Evaluate Breast Cancer Subtypes and Genomic Predictors of Response to Therapy in the Preoperative Setting for Stage II-III Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic",Complete response,"Cardiac Telemetry, Complete response",True,NCT01959490,18411
492,195226,"TrialTroveID-195226, UMIN000012018","Combination Therapy of Eribulin, Trastuzumab and Pertuzumab for the Treatment of Patients with Previously Treated Advanced HER2-Positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
493,195194,"SBCCSG-33, TrialTroveID-195194, UMIN000012030",A Phase II Study of Pertuzumab+Trastuzumab+Capecitabine in Patients with Taxans and Trastuzumab Refractory for Advanced or Recurrent Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
494,195120,"EudraCT Number: 2013-000551-41, IMPACT, IMPACT MBC, IMPACT_Breast_6.3, IMPACT-MBC, NCT01957332, NL43582.042.13, TrialTroveID-195120","Towards Patient Tailored Cancer Treatment Supported by Molecular Imaging IMPACT: IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer., , IMaging PAtients for Cancer Drug selecTion - Metastatic Breast Cancer (IMPACT-MBC)",Oncology,Oncology: Breast,"University Medical Center Nijmegen, Vrije Universiteit Medical Center, Amsterdam, Netherlands, Groningen University Hospital","Academic, Academic, Academic",,"Circulating Tumor Cells, Progression-free survival, Quality of Life",True,NCT01957332,18411
495,195039,"FIT, FIT08/2013, NCT01954836, TrialTroveID-195039",Short-Term Fasting During Chemotherapy in Patients With Gynecological Cancer- a Randomized Controlled Cross-over Trial,Oncology,Oncology: Breast; Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,"Functional Assessment of Cancer Therapy-Ovarian Cancer, Quality of Life",Likert scale,True,NCT01954836,18411
496,194434,"NCT01950182, SYSUCC-002, TrialTroveID-194434","A Multicentre, Randomized Study of Trastuzumab Combined With Chemotherapy or Endocrine Therapy as the First Line Treatment for Patients With Metastatic Luminal B2 Breast Cancer Subtype",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,True,NCT01950182,18411
497,194374,"TrialTroveID-194374, UMIN000011863",Phase I/II study of Paclitaxel+Trastuzumab therapy in second line treatment for advanced or recurrent gastric cancer with HER2 positive.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Overall response rate, Overall survival, Progression-free survival",False,,18411
498,193683,TrialTroveID-193683,A study of beta-blocker therapy on left ventricular responses to three different cardiotoxic regimens in cancer patients,Cardiovascular,Cardiovascular: Congestive Heart Failure,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
499,193472,"2014-0363, 9198, NA_00080994, NCI-2014-00245, NCI-2014-01543, NCT01937117, TBCRC 026, TBCRC 026/UAB 1367, TBCRC026, TrialTroveID-193472, VICCBRE1358",A Phase II Clinical Trial Assessing the Correlation of Early Changes in Standardized Uptake Value (SUV) on Positron Emission Tomography (PET) with Pathological Complete Response (pCR) to Pertuzumab and Trastuzumab in Patients with Primary Operable HER2-Positive Breast Cancer,Oncology,Oncology: Breast,Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center},Academic,Complete response,"Complete response, Gene expression profiling",True,NCT01937117,18411
500,193423,"TrialTroveID-193423, UMIN000011672",Phase I/ II trial with Abraxane and Trastuzumab for Advanced/Recurrent HER2-positive Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,Safety and Tolerability,False,,18411
501,193084,"1505594326, CIR00000810, CRMS-57980, IUSCC-J13104, J13104, J13104, J-13104, J13104 (IU study), NCI-2013-02402, NCT01928589, PBI 3.0, TrialTroveID-193084, TX5321",Randomized Phase II Study of Partial Breast Irradiation and Sequential vs. Concurrent Chemotherapy in Women with Early Stage Breast Cancer (PBI 3.0).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Quality of Life, Recurrence",True,NCT01928589,18411
502,193038,"1P50CA138293, 7587, Breast SPORE, NCI-2013-01668, NCT01931709, RG1712020, SPORE Project 3 (7587), TrialTroveID-193038",Quantitative Dynamic PET and MRI and Breast Cancer Therapy.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Washington University","Government, Academic",Complete response,"Complete response, Magnetic Resonance Imaging, Overall survival, Recurrence",True,NCT01931709,18411
503,192831,"KGCG-01, TrialTroveID-192831, UMIN000011595",Phase II Study Of Combination Chemotherapy With SPT In Patient With HER2(+) Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
504,192620,"201309035, NCI-2013-01783, NCT01928290, TrialTroveID-192620","Phase II Study of FOLFIRINOX Chemotherapy for Treatment of Advanced Gastric, Gastro-esophageal Junction, and Esophageal Tumors",Oncology,Oncology: Esophageal; Oncology: Gastric,Washington University School of Medicine,Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01928290,18411
505,192529,"EudraCT Number: 2013-001023-39, LISAH, ML28786, NCT01928615, TrialTroveID-192529","An Open Label, Randomised Phase II Study Assessing Quality of Life Associated With Subcutaneous Trastuzumab Injected Into the Thigh or Upper Arm in Patients With HER2-positive Early Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Quality of Life, Safety and Tolerability, Visual Analog Scale","Area under the curve score, Cmax, Disease-free survival, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax",True,NCT01928615,18411
506,192517,"BELIS, EudraCT Number: 2013-000123-13, ML28794, NCT01926886, TrialTroveID-192517, UmbHER1, Umbrella_BELIS",A Single Arm Multi-center Study Investigating the at Home Administration of Trastuzumab Subcutaneous Vial for the Treatment of Patients with HER2-positive Early Breast Cancer,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Congestive heart failure, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Disease-free survival, MD Anderson Symptom Inventory, Safety and Tolerability, Vital signs",True,NCT01926886,18411
507,192321,"HP-00056720, NCT01924351, TrialTroveID-192321",A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer with Brain Metastasis,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,University of Maryland School of Medicine,Academic,,Adverse Events,True,NCT01924351,18411
508,192080,"BCSMANC, BCSMANC001, NCT01917578, TrialTroveID-192080",Phase III Trial of Breast Cancer Shrinkage Modes After Neoadjuvant Chemotherapy With Whole-mount Serial Sections and Three-dimensional Pathological and MRI Reconstruction,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,Magnetic Resonance Imaging,True,NCT01917578,18411
509,192013,"2012-03 TRAIN-2, BOOG2013-03, EudraCT Number: 2013-001863-21, M13TRT, NCT01996267, NL44736.031.13, TRAIN-2, TRAIN-2 Study, TrialTroveID-192013",Optimizing Neoadjuvant Systemic Treatment for HER2 Positive Breast Cancer - the TRAIN-2 Study,Oncology,Oncology: Breast,"(Other Cooperative Group), Netherlands Cancer Institute, Roche {F. Hoffmann-La Roche}","Cooperative Group, Government, Industry, Top 20 Pharma",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Event-free survival, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT01996267,18411
510,191983,"TrialTroveID-191983, UMIN000011445",Phase II Clinical Trial of Surgical Intervention Following Chemotherapy for Synchronous and Metachronous Liver Metastasis from Gastric Cancer,Oncology,Oncology: Gastric; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Overall survival, Resection rate, Safety and Tolerability",False,,18411
511,191264,"13-163, 688097, 707389, NCI-2013-01826, NCT01912963, TrialTroveID-191264","A Phase II Study of Eribulin Mesylate in Combination with Trastuzumab and Pertuzumab in Women with Metastatic, Unresectable Locally Advanced, or Locally Recurrent Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer",Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Eisai, Roche/Genentech","Academic, Industry, all other pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Circulating Tumor Cells, Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT01912963,18411
512,190590,"13-02-079, NCI-2013-01194, NCT01897441, TrialTroveID-190590",Prospective Tissue Collection in Breast Cancer Patients Receiving Preoperative Systemic Therapy.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Albert Einstein Medical College","Government, Academic",,,True,NCT01897441,18411
513,189633,"EudraCT Number: 2012-003679-21, NCT01891357, Neo-Predict, Neo-PREDICT-HER2, TrialTroveID-189633, WSG Neo-Predict, WSG-AM07, WSG-AM07 (Neo-PREDICT-HER2)","A Multicenter Site, Open Label, Phase II Trial to Validate Predictive Markers for the Response Evaluation of a Combined Chemo-immunotherapy in Patients With HER2-positive Early Breast Cancer",Oncology,Oncology: Breast,"GlaxoSmithKline, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Complete response,"Complete response, Cost effectiveness, Event-free survival, Overall survival",True,NCT01891357,18411
514,189282,"TrialTroveID-189282, UMIN000011049",Safety Study of q3w S-1 in Combination with q3w Trastuzumab for HER2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Overall response rate, Progression-free survival, Response rate",False,,18411
515,188836,"SBCCSG-31, TrialTroveID-188836, UMIN000011020",Phase II study of the combination of Eribulin and Trastuzumab Evaluating Efficacy and Safety in Patients with advanced/recurrent HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
516,188831,"TrialTroveID-188831, UMIN000011023, WJOG7412B, WJOG7412B/Tra-Ana study","A Phase II Study of Neo-adjuvant Combination Therapy of Trastuzumab and Anastrozole for Hormone Receptor-Positive, HER2-Positive Postmenopausal Breast Cancer (WJOG7412B)",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,"Disease-free survival, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
517,188697,"ML25168, NCT01880385, TrialTroveID-188697","Efficacy & Safety of Bevacizumab as Neoadjuvant Treatment in Patients With Locally Advanced Inflammatory Breast Cancer, a Pilot Study.",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01880385,18411
518,188549,"TrialTroveID-188549, UMIN000010845",Phase II trial with abraxane and trastuzumab for advanced/recurrent HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
519,188535,"TrialTroveID-188535, UMIN000010844",Phase II trial with eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
520,188436,"13-1826, 13-401, 2015-0168, CLAP016AUS33T, LAP200136, LCCC 1214, LCCC1214, ML28342, NCI-2014-00972, NCI-2014-01407, NCT01875666, TrialTroveID-188436","Defining the HER2 Positive (+) Breast Cancer Kinome Response to Trastuzumab, Pertuzumab, Combination Trastuzumab +Pertuzumab, or Combination Trastuzumab + Lapatinib",Oncology,Oncology: Breast,"GlaxoSmithKline, Novartis, UNC Lineberger Comprehensive Cancer Center, Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}, Roche/Genentech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity, Industry, Top 20 Pharma",,"Adverse Events, Safety and Tolerability",True,NCT01875666,18411
521,188333,"ChangHER-SC, EudraCT Number: 2012-004928-38, GEICAM/2012-07, NCT01875367, TrialTroveID-188333",Phase III Trial to Evaluate PatientÂ´s Preference of Subcutaneous Trastuzumab vs Intravenous (IV) Administration in HER2 Positive Advanced Breast Cancer Who Have Received IV Trastuzumab at Least 4 Months and Without Disease Progression,Oncology,Oncology: Breast,Spanish Breast Cancer Research Group,Cooperative Group,,"Safety and Tolerability, Safety and Tolerability",True,NCT01875367,18411
522,188235,"1B-12-10, NCI-2013-01086, NCT01873833, TrialTroveID-188235",Phase II Trial of Metronomic Capecitabine and Cyclophosphamide With Lapatinib and Ttrastuzumab in Patients With HER2 Positive Metastatic Breast Cancer Who Have Progressed on a Previous Trastuzumab-Based Regimen,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, USC/Norris Comprehensive Cancer Center and Hospital","Government, Academic",Progression-free survival,"Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT01873833,18411
523,188199,"jRCTs021180015, T-CORE1203, TrialTroveID-188199, UMIN000010869",Phase II Trial Of Trastuzumab Plus Docetaxel For Previous Trastuzumab Treated Unresectable Or Recurrent HER2 Positive Gastric Cancer (T-CORE1203),Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,Overall response rate,"Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
524,187355,TrialTroveID-187355,Left atrium in women with positive human epidermal growth factor type 2 receptor (HER-2) treated with trastuzumab in adjuvant setting,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
525,187294,TrialTroveID-187294,PI3K pathway as a major determinant of resistance to HER2-targeted therapy in advanced gastric cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
526,186732,"KSCOG-BC06, TrialTroveID-186732, UMIN000010761",Prospective study of Eribulin plus Trastuzumab in patients with HER-2 positive metastatic breast cancer (KSCOG-BC06).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate, Safety and Tolerability",,False,,18411
527,186731,TrialTroveID-186731,Study of lapatinib (T) in combination with trastuzumab (T) in women heavily pretreated with HER2-positive metastatic breast cancer (MBC),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
528,186678,"EudraCT Number: 2013-001036-22, NCT01973660, PAMELA, PAMELA SOLTI 1114, REec-2013-0524, SOLTI-1114, TrialTroveID-186678",PAMELA: PAM50 HER2-enriched Phenotype as a Predictor of Early Response to Neoadjuvant Lapatinib Plus Trastuzumab in Stage I to IIIA HER2-positive Breast Cancer,Oncology,Oncology: Breast,"GlaxoSmithKline, Novartis, (Other Cooperative Group), Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}, Breast Cancer Research Foundation","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Not for Profit Funding Entity, Not for Profit Funding Entity",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Neuropathy, Neutropenia, New York Heart Association Class, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01973660,18411
529,186623,"ML21589, TrialTroveID-186623",Efficacy of trastuzumab re-therapy in routine treatment of HER2-positive breast cancer patients who relapsed after completed (neo-) adjuvant anti-HER2 therapy.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
530,186539,"1305012136, ML28772, NCI-2015-02018, NCT01855828, TrialTroveID-186539","Single Arm, Neoadjuvant, Phase II Trial of Pertuzumab and Trastuzumab Administered Concomitantly With Weekly Paclitaxel and FEC for Clinical Stage I-II HER2-Positive Breast Cancer",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Yale University","Industry, Top 20 Pharma, Academic",Complete response,"Congestive heart failure, NCI-CTC scale, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01855828,18411
531,186194,"NCT01850628, NSABP DP-1, TrialTroveID-186194",NSABP Biospecimen Discovery Project,Oncology,Oncology: Breast,"National Surgical Adjuvant Breast and Bowel Project (NSABP), Washington University School of Medicine, Breast Cancer Research Foundation","Cooperative Group, Academic, Not for Profit Funding Entity",,,True,NCT01850628,18411
532,185553,"TrialTroveID-185553, UMIN000010579",Phase II study of neoadjuvant tri-weekly Nab-paclitaxel and Trastuzumab followed by FEC (5-FU/epirubicin/cyclophosphamide) in patients for HER2 positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Overall response rate,False,,18411
533,185443,"2012/1909, 2012-A01364-39, HERBIN, NCT01834950, TrialTroveID-185443",Identification of Early Markers of Response and Resistance to Trastuzumab in Patients With Localized Human Epidermal Growth Factor Receptor-2(HER-2)-Positive Breast Cancer Candidates for Breast Conserving Surgery,Oncology,Oncology: Breast,"Institut Gustave Roussy, (Other government agency)","Academic, Government","Overall response rate, Response evaluation criteria in solid tumors, Response rate",Complete response,True,NCT01834950,18411
534,185275,"EVIDENCE, ML28934, NCT01839500, TrialTroveID-185275","A Non-Interventional, Registry Study for Chinese Gastric Cancer Patients With HER2 Status: Clinical and Pathological Characteristics, Treatment Patterns and Clinical Outcomes (EVIDENCE)",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Disease Progression, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Partial response, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Time to treatment failure","Adverse Events, Serious Adverse Events",True,NCT01839500,18411
535,184910,"EudraCT Number: 2012-003789-41, Her2.4, Her2.5, NCT01832051, NL41707.042.12, TrialTroveID-184910",HER2-PET as a Diagnostic Tool in Breast Cancer Patients With a Clinical Dilemma,Oncology,Oncology: Breast,Groningen University Hospital,Academic,,Circulating Tumor Cells,True,NCT01832051,18411
536,184657,"ALCC12.01, NCT01830244, Neonab, TrialTroveID-184657",Tailored Neoadjuvant Epirubicin and Cyclophosphamide (EC) and Nanoparticle Albumin Bound (Nab) Paclitaxel for Newly Diagnosed Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, NCI-CTC scale, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT01830244,18411
537,184528,"KSCOG-BC07, TrialTroveID-184528, UMIN000010504",Phase II study of neoadjuvant chemotherapy with the FEC followed by weekly nab-Paclitaxel(nanoparticle albumin-bound paclitaxel) for the operable breast cancer (KSCOG-BC07),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Safety and Tolerability",False,,18411
538,184287,"2013-03 PERNETTA, EudraCT Number: 2012-002556-17, NCT01835236, NL46227.029.13, PERNETTA, RECF2233, SAKK 22/10, SAKK 22/10 / UNICANCER UC-0140/1207, SAKK22/10/UC-0140/1207, TrialTroveID-184287, UNICANCER UC-0140/1207","A Randomized Phase II Trial of Pertuzumab in Combination With Trastuzumab With or Without Chemotherapy, Both Followed by T-DM1 in Case of Progression, in Patients With HER2-positive Metastatic Breast Cancer",Oncology,Oncology: Breast,"(Other Cooperative Group), Federation Nationale des Centres de Lutte contre le Cancer, Swiss Group for Clinical Cancer Research - SAKK","Cooperative Group, Cooperative Group, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01835236,18411
539,183919,TrialTroveID-183919,Asymptomatic Echocardiographic Changes of Cardiac Structure and Function as a Trastuzumab Induced Cardiotoxcity in Patients with Breast Cancer; single center experience.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
540,183134,"KBOG-1204, TrialTroveID-183134, UMIN000010227","Multicenter Phase II Trial of Neoadjuvant Chemotherapy with Trastuzumab, Docetaxel, and Carboplatin For HER2-Positive Operable Breast Cancer: KBOG-1204 Trial",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,"Adverse Events, Disease-free survival, Overall response rate, Overall survival",False,,18411
541,183130,"EudraCT Number: 2012-003442-32, MetaSPHer ML28589, ML28589, NCT01810393, PrefHer, TrialTroveID-183130","An Open-Label, Randomized, Multicenter Phase III Study in Patients With HER2-Positive Metastatic Breast Cancer Responding to First Line Treatment With Intravenous Trastuzumab for at Least 3 Years and Investigating Patient Preference for Subcutaneous Trastuzumab",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",,"Adverse Events, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01810393,18411
542,182381,"12-497, ML28193, NCI-2013-01110, NCT01796197, TrialTroveID-182381",Phase II Trial of Paclitaxel Combined With Trastuzumab and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer,Oncology,Oncology: Breast,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Academic,"Complete response, Parathyroid hormone level","Circulating Tumor Cells, Complete response, Congestive heart failure, Disease-free survival, Overall survival, Time to treatment failure",True,NCT01796197,18411
543,181718,"NCT01785420, TMH Project-982, TrialTroveID-181718",A Phase III Double Blind Randomized Placebo Controlled Study of Trastuzumab as Short Duration Preoperative Therapy in Patients with HER2-neu Positive Operable Breast Cancer,Oncology,Oncology: Breast,Tata Memorial Hospital,Academic,Disease-free survival,"Circulating Tumor Cells, Overall survival, Safety and Tolerability",True,NCT01785420,18411
544,181482,"GBCCSG-02, TrialTroveID-181482, UMIN000009973",Phase I Study of Nanoparticle albumin-bound paclitaxel and Cyclophosphamide combination chemotherapy for Patients with Metastatic Breast Cancer(GBCCSG-02),Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Maximum tolerated dose,"Overall response rate, Response rate, Safety and Tolerability",False,,18411
545,181371,"ADAPT HER2+/HR-, EudraCT Number: 2011-001462-17, NCT01817452, TrialTroveID-181371, WSG-ADAPT-HER2+/HR-, WSG-AM06 / ADAPT HER2+/HR-","A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Combination of Trastuzumab and Pertuzumab With or Without Concurrent Taxane Chemotherapy Given for Twelve Weeks in Patients With Operable HER2+/HR- Breast Cancer Within the ADAPT Protocol",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma",Complete response,,True,NCT01817452,18411
546,181262,"TrialTroveID-181262, UMIN000009865",Clinical trial of TS-1 + CDDP + Trastuzumab-3 weekly cycle in HER2-positive advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
547,181149,"C-1214, TrialTroveID-181149, UMIN000009890, UMIN000028594",Phase II clinical trial of the combination of eribulin and trastuzumab for advanced/recurrent HER2-positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
548,181074,"12-X356, 201309084, NCI-2012-03110, NCT01779050, TrialTroveID-181074",A Phase II Randomized Trial Evaluating the Effect of Trastuzumab on Disease Free Survival in Early Stage HER2-Negative Breast Cancer Patients With ERBB2 Expressing Bone Marrow Disseminated Tumor Cells,Oncology,Oncology: Breast,Washington University School of Medicine,Academic,"Disease-free survival, Overall survival, Recurrence",Safety and Tolerability,True,NCT01779050,18411
549,180777,TrialTroveID-180777,A clinical study on early clinical experience of trastuzumab plus capecitabine/cisplatin (HXP) therapy for patients with unresectable advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
550,180724,"NCT01771549, TrialTroveID-180724",Pilot Study of the Kinetics of High Sensitivity Troponin and Brain Natriuretic Peptide in Breast Cancer Chemotherapy With Adriamycin and Trastuzumab,Oncology,Oncology: Breast,Mayo Clinic,Academic,,,True,NCT01771549,18411
551,180640,"EudraCT Number: 2012-002646-20, IC 2012-04, NCT01771458, RECF1848, SHIVA, TrialTroveID-180640",A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer,Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(Other Cooperative Group),Cooperative Group,"Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01771458,18411
552,180579,"HELENA, ML28750, ML28750 HELENA, NCT01777958, NIS HELENA ML28750, TrialTroveID-180579","Noninterventional Study - Advanced HER2-positive Breast Cancer (Metastatic or Locally Recurrent, Inoperable): First-Line Treatment With PERJETA After Adjuvant Herceptin Therapy (HELENA)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Functional Assessment of Cancer Therapy-Breast, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01777958,18411
553,180278,TrialTroveID-180278,Concurrent Loco-Regional Radiotherapy and Trastuzumab in Early-Stage Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
554,180274,"ML20315, TrialTroveID-180274",Hormone Receptor Status and Endocrine Therapy in a Prospective Observation Study on Trastuzumab (Herceptin) in the Adjuvant Treatment of Breast Cancer,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Disease-free survival,,False,,18411
555,179895,TrialTroveID-179895,High Antitumoral Activity of Neoadjuvant Chemotherapy (NCT) with Weekly Paclitaxel + Capecitabine and Trastuzumab in Patients with Locally Advanced HER2+ Breast Cancer (HER2+ LABC).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Safety and Tolerability",,False,,18411
556,179329,"264-12, 264-12-FB, NCI-2012-01372, NCT01750073, TrialTroveID-179329",A Phase II Study Of Neoadjuvant Chemotherapy With And Without Trastuzumab In Patients With Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Nebraska Medical Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Gene expression profiling, Serious Adverse Events","Complete response, Gene expression profiling, Overall survival, Progression-free survival",True,NCT01750073,18411
557,179229,"004-IRCC-10IIS-12, EudraCT Number: 2012-002128-33, HERACLES, HERACLES A, HERACLES B, NCT03225937, TrialTroveID-179229","Open-Label, Phase II Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in Patients with HER2-positive Metastatic Colorectal Cancer: , , the HERACLES Trial (HER2 Amplification for Colorectal Cancer Enhanced Stratification)",Oncology,Oncology: Colorectal,(Other Cooperative Group),Cooperative Group,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability",True,NCT03225937,18411
558,179216,"KGCSG1201, TrialTroveID-179216, UMIN000009565",Pilot study of S-1/Paclitaxel/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Overall response rate, Overall survival, Response rate",False,,18411
559,178838,"ML25574, NCT01748773, TOXAG [ML25574], TOXAG Study, TrialTroveID-178838","Safety and Tolerability of Oxaliplatin-Capecitabine-Trastuzumab Combination and Chemoradiotherapy in Operated Patients With HER-2 Positive Gastric or Gastroesophageal Junction Adenocarcinoma: Phase II Study, TOXAG [ML25574], , TOXAG: Trastuzumab, Oxaliplatin, and Xeloda for Adjuvant Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Disease-free survival, Overall survival, Response evaluation criteria in solid tumors",True,NCT01748773,18411
560,178183,"IEO S040/200, TrialTroveID-178183",Randomized phase III Herceptin alone followed by Herceptin plus chemotherapy to the initial combination of Herceptin and chemotherapy in patients with breast cancer HER-2 positive,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
561,178182,"EudraCT Number: 2007-006025-27, IEO S380/607, TrialTroveID-178182","A phase II study of metronomic oral chemotherapy with cyclophosphamide plus capecitabine combined with bevacizumab and erlotinib (BEXE), plus trastuzumab in HER2/neu positive tumors (BEXET), in advanced breast cancer",Oncology,Oncology: Breast,European Institute of Oncology,Government,"Overall response rate, Stable Disease","Overall survival, Stable Disease, Time to progression",False,,18411
562,177942,"105932, 109681, 119638, 12147, NCI-2012-02371, NCT01730833, TrialTroveID-177942","Phase II Prospective Open Label Study of Pertuzumab, Trastuzumab, and Nab-Paclitaxel in Patients With HER-2 Positive Advanced Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic","Complete response, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Vital signs",True,NCT01730833,18411
563,177443,"CTRIAL-IE (ICORG) 10-16, ICORG 10-16, NCT01726322, TrialTroveID-177443",A Study to Determine Alteration of Hormone Levels in Premenopausal Patients Receiving Adjuvant or Neo-adjuvant Chemotherapy for Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,,Quality of Life,True,NCT01726322,18411
564,177416,"T-ACT study, TrialTroveID-177416, UMIN000009297, WJOG7112G","Randomized phase II study comparing trastuzumab plus weekly paclitaxel with weekly paclitaxel alone for patients with HER2-positive advanced gastric or gastro-esophageal junction cancer refractory to trastuzumab combined with fluoropyrimidine and platinum., , T-ACT study: Trial to Assess the Concept of using Trastuzumab beyond progression",Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), West Japan Thoracic Oncology Group","Cooperative Group, Cooperative Group",Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Safety and Tolerability, Time to treatment failure",False,,18411
565,177216,"NCT01805908, OCOG-2011-PETRA, PETRA, TrialTroveID-177216",Imaging with 111In-Pertuzumab to Predict Response to Trastuzumab in HER2 Positive Metastatic or Locally Advanced Breast Cancer Breast Cancer,Oncology,Oncology: Breast,Ontario Clinical Oncology Group,Cooperative Group,"Adverse Events, Safety and Tolerability","Elimination half-life, Response evaluation criteria in solid tumors",True,NCT01805908,18411
566,176342,TrialTroveID-176342,Effect of Targeted Therapy on Circulating Tumor Cells in Patients with Metastatic Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Circulating Tumor Cells,,False,,18411
567,176007,"MSKCC IRB#12-129, NCI-2012-01759, NCT01705340, TrialTroveID-176007",A Phase I Study of MK-2206 in Combination With Trastuzumab and Lapatinib in HER2-Positive Breast and Gastric Cancer,Oncology,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Duration of overall response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01705340,18411
568,175990,"HERPLET, TrialTroveID-175990, UMIN000009108","A Phase II Neoadjuvant Trial of Concurrent Trastuzumab, Paclitaxel and Endocrine Therapy in Women with HER2-Positive and Hormone Receptor-Positive Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Complete response, Disease-free survival",False,,18411
569,175814,"ASTER study, TrialTroveID-175814",Neoadjuvant Chemotherapy in operable Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate",,False,,18411
570,175802,TrialTroveID-175802,Trastuzumab-Induced Early Cardiac Dysfunction Assessed by Speckle Tracking Echocardiography: Correlation with Chronic Inflammation and Oxidative Stress Markers,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
571,175584,TrialTroveID-175584,New immunohistochemical markers predictive of response to neoadjuvant chemotherapy plus trastuzumab in Her2-positive locally advanced breast cancer : A single centre experience,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
572,174923,"KBCSG03, TrialTroveID-174923, UMIN000008983",Assessment of Safety on Trastuzumab With Varied Dilution Solution Volume in HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Maximum tolerated dose, Safety and Tolerability",Infusion-related reactions,False,,18411
573,174760,"9020, ACE-001, NCI-2012-01970, NCT01688609, TrialTroveID-174760","Phase II Study of Lapatinib and Trastuzumab Followed by Concurrent Lapatinib, Trastuzumab, and Paclitaxel Followed by Surgery for Primary HER2-positive (HER2+) Breast Cancer",Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,Complete response,"Circulating Tumor Cells, Complete response, Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT01688609,18411
574,174734,"DECT, TrialTroveID-174734",Phase II Trial of Primary Systemic Therapy (PST) with Docetaxel (D) Followed By High-Dose Epirubicin in Combination with Cyclophosphamide (Ec) Plus Concurrent Trastuzumab (T) for Stage II-III Her-2 Positive Breast Cancer Patients (Pts).,Oncology,Oncology: Breast,"Regina Elena National Cancer Institute, Rome, Italy",Academic,Complete response,"Disease-free survival, Safety and Tolerability",False,,18411
575,173400,"EudraCT Number: 2012-001201-24, NCT01669239, Opti-HER, Opti-HER HEART, OptiHerHEART, OPTIHER-HEART, SOLTI 1002 / OPTIHER HEART, SOLTI Opti-HER HEART, SOLTI-1002, TrialTroveID-173400","OptiHER-Heart: A Prospective, Multicenter, Single-arm, Phase II Study to Evaluate the Safety of Neoadjuvant Liposomal Doxorubicin (Myocet Plus Paclitaxel, Trastuzumab, and Pertuzumab in Patients With HER2-positive Breast Cancer",Oncology,Oncology: Breast,"(Other Cooperative Group), Teva, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Congestive heart failure, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Neutropenia, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT01669239,18411
576,172574,"HERBIS-5, OGSG1203, TrialTroveID-172574, UMIN000008626",Phase II trial of Trastuzumab + CPT-11 therapy for HER2-positive advanced gastric cancer patients with prior chemotherapy,Oncology,Oncology: Esophageal; Oncology: Gastric,Osaka Gastrointestinal Cancer Chemotherapy Study Group,Cooperative Group,"Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to treatment failure",False,,18411
577,172514,"TrialTroveID-172514, UMIN000008623",Exploratory study of Paclitaxel+Trastuzumab therapy for advanced or recurrent gastric cancer with HER2 positive,Oncology,Oncology: Gastric,(Other Academic Cancer Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Circulating Tumor Cells, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression, Time to treatment failure",False,,18411
578,172496,"KSCOG-BC02, TrialTroveID-172496, UMIN000008647",Prospective Study of TS-1 / CPT-11 Plus Trastuzumab in Patients with HER-2 Positive Metastatic Breast Cancer (KSCOG-BC02),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,18411
579,172417,"TrialTroveID-172417, UMIN000008622",Exploratory Study of Xeloda + CDDP(XP) + Trastuzumab Therapy for Advanced Gastric Cancer With HER2  Positive CTCs,Oncology,Oncology: Colorectal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival","Circulating Tumor Cells, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
580,171392,"TrialTroveID-171392, UMIN000008465",Phase II Study of Neoadjuvant Chemotherapy with the Nab Paclitaxel And Trastuzumab Followed by FEC for the HER2-positive Resectable Primary Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,"Adverse Events, Overall response rate",False,,18411
581,170833,"TrialTroveID-170833, T-SPACE, UMIN000008389, WJOG7212G","Phase II study of Trastuzumab in combination with TS-1 and Cisplatin for patients with Human Epidermal Growth Factor Receptor type-2 (HER-2)-positive Advanced Gastric Cancer, , ""Trastuzumab, TS-1 plus Platinum ACtivity Evaluation"" T-SPACE study",Oncology,Oncology: Esophageal; Oncology: Gastric,"West Japan Thoracic Oncology Group, Taiho Pharmaceutical","Cooperative Group, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
582,170404,"ABX-1201, NCT01625429, TrialTroveID-170404","A Single-center, Prospective, Phase II Study of Albumin-bound Paclitaxel (Nab-paclitaxel) and Carboplatin With or Without Trastuzumab (Herceptin) as Neoadjuvant Therapy in Locally Advanced Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Complete response, Disease-free survival, Overall response rate, Overall survival, Partial response, Recurrence, Safety and Tolerability",True,NCT01625429,18411
583,170308,"TrialTroveID-170308, UMIN000008292",A phase II Study of Irinotecan + Trastuzumab Therapy as a Second-line Chemotherapy for Unresectable Advanced or Recurrent Gastric Cancer with HER2 Overexpression,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Response rate",False,,18411
584,170155,"TrialTroveID-170155, UMIN000008254",A randomized phase II study investigating an optimal dosing regimen of TS-1 plus CDDP plus Trastuzumab combination therapy for HER2-positive unresectable and/or recurrent gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,18411
585,169927,"STAR, TrialTroveID-169927, UMIN000008220",A Phase II Study of Combination Chemotherapy with TS-1 and Trastuzumab for Patients with HER2 Positive Advanced or Recurrent Gastric Cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Time to treatment failure",False,,18411
586,168501,TrialTroveID-168501,18F-fluorodeoxyglucose (FDG) positron emission tomography (PET) as early imaging biomarker of axillary sentinel lymph node (SLN) status in locally advanced node-positive breast cancer (NPBC) patients (pts) receiving neoadjuvant chemotherapy (NACT),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
587,168041,TrialTroveID-168041,Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy.,Oncology,Oncology: Breast,New York University,Academic,,,False,,18411
588,167990,TrialTroveID-167990,"Expression of PTEN, Akt, MAPK, p53, p95 for predicting trastuzumab resistance in breast cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
589,167907,TrialTroveID-167907,Elevated pretreatment serum activin A and progression-free and overall survival in trastuzumab-treated metastatic breast cancer.,Oncology,Oncology: Breast,"Bristol-Myers Squibb/Celgene, Acceleron Pharma","Industry, Top 20 Pharma, Industry, all other pharma",Overall survival,,False,,18411
590,167421,"HERBIS-1B, OGSG 1202, TrialTroveID-167421, UMIN000007941",Phase ll trial of TS-1 + CDDP + Trastuzumab (SPT) - 3 Weekly Schedule in HER2-Positive Advanced Gastric Cancer Without Measurable Metastatic Lesion,Oncology,Oncology: Esophageal; Oncology: Gastric,Osaka Gastrointestinal Cancer Chemotherapy Study Group,Cooperative Group,Overall survival,"Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
591,166123,TrialTroveID-166123,Short-term therapeutic effect of neoadjuvant chemotherapy with herceptin and docetaxel in patients with localized advanced breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
592,165655,"TrialTroveID-165655, UMIN000007689",Stability of Capecitabine + CDDP + Trastuzumab Therapy for HER2-positive Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Clinical benefit rate, Overall response rate, Progression-free survival, Response rate",False,,18411
593,165588,"HGCSG 1201, HGCSG 1201/OGSG1205, TrialTroveID-165588, UMIN000007636",Phase II Study Of Trastuzumab With Irinotecan In HER2-Positive Metastatic Or Advanced Gastric Cancer Patients Previously Treated With Trastuzumab And Failed,Oncology,Oncology: Gastric,Hokkaido Gastrointestinal Cancer Study Group,Cooperative Group,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
594,165503,"TrialTroveID-165503, UMIN000007600","Phase I/II study of Chemotherapy with Nab-paclitaxel, Carboplatin and Trastuzumab in HER2-positive Locally Advanced Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Maximum tolerated dose, Overall response rate, Response rate",,False,,18411
595,165477,"TrialTroveID-165477, UMIN000007648","A phase II study of neoadjuvant epirubicin/cyclophosphamide (EC) followed by weekly nanoparticle albumin-bound paclitaxel with or without trastuzumab for node-positive breast cancer , , EC-wnabPTX as NAC PII",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Overall survival,False,,18411
596,165384,"IJBMNZrT003, NCT01420146, TrialTroveID-165384",Pilot Imaging Study With 89Zr-Trastuzumab in HER2-positive Metastatic Breast Cancer Patients : Correlation With FDG-PET/CT and Anatomopathological Results,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,True,NCT01420146,18411
597,165092,"SHERLOCK2, TrialTroveID-165092, UMIN000006442, UMIN000006445",Observational study of Serum HER2 in HER2 negative advanced gastric cancer treated with capecitabine plus cisplatin (XP),Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,18411
598,164927,"CTR20130952, EudraCT Number: 2011-005334-20, IRAS ID-97442, JXSL1200006, McG 1307, MO28047, NCRN354, NCT01572038, NL39727.060.12, PER-069-12, PERUSE, RECF2044, TrialTroveID-164927, UKCRN 11574","A Multicenter, Open-Label, Single-Arm Study of Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2-Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Congestive heart failure, Heart failure event, Neutropenia, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to response",True,NCT01572038,18411
599,164816,"201100543, CTBE2012000054, EudraCT Number: 2011-005437-39, IJBMNTDM1, MO27955, NCT01565200, NL39546.042.12, TrialTroveID-164816, ZEPHIR",Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients with Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma",Response evaluation criteria in solid tumors,"Gene expression profiling, Response evaluation criteria in solid tumors",True,NCT01565200,18411
600,164392,"Nature study, TrialTroveID-164392, UMIN000006547",Phase II Study of Q3w Nab-Paclitaxel In Combination With Q3w Trastuzumab For HER2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
601,164354,"201206025, NCT01557764, TrialTroveID-164354",A Phase II Study of Lapatinib in Combination With Trastuzumab in Metastatic HER2 Non-amplified But HER2 Mutant Breast Cancer,Oncology,Oncology: Breast,Washington University School of Medicine,Academic,"Clinical benefit rate, Response evaluation criteria in solid tumors","Disease-free survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01557764,18411
602,164139,"TrialTroveID-164139, UMIN000006403",A phase II study of paclitaxel plus trastuzumab in patients with pretreated recurrent or metastatic gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Overall survival, Progression-free survival",False,,18411
603,164135,"SBCCSG-22, TrialTroveID-164135, UMIN000006085",A Feasibility Study of Sequential Anthracycline-based Regimen and Nab-Paclitaxel / Trastuzumab Followed by Trastuzumab as Postoperative Adjuvant Chemotherapy For Her 2 Positive Breast Cancer (SBCCSG-22),Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,,"Disease-free survival, Overall survival, Safety and Tolerability",False,,18411
604,163863,"TrialTroveID-163863, UMIN000006458",A Phase II Study Of Capecitabine Plus Cisplatin (Plus/Minus Trastuzumab) For Previously Untreated Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,Safety and Tolerability,False,,18411
605,163415,TrialTroveID-163415,"A phase II study of neoadjuvant chemotherapy with docetaxel, cisplatin and trastuzumab for T2 breast cancers.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,18411
606,163328,"TrialTroveID-163328, UMIN000007436",Phase I/II multicenter clinical trial of S-1/CDDP/Trastuzumab combination chemotherapy for HER2-positive Stage IV advanced gastric cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
607,162915,"JACCRO GC-06, JPRN-UMIN000007368, TrialTroveID-162915, UMIN000007368",Phase II study of TS-1+Trastuzumab in HER2-positive advanced gastric cancer patients more than 65 years old,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), Taiho Pharmaceutical","Cooperative Group, Industry, all other pharma","Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
608,162796,"R12-076, TrialTroveID-162796, UMIN000007353",A phase II neoadjuvant trial of concurrent trastuzumab and aromatase inhibitor in postmenopausal women with HER2-positive and hormone receptor-positive breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Complete response, Disease-free survival",False,,18411
609,162425,"KSCC 1105, KSCC1105, TrialTroveID-162425, UMIN000007246",Observation study of Trastuzumab for HER2 Positive Advanced or Recurrent Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Adverse Events, Infusion-related reactions, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Time to treatment failure",,False,,18411
610,162082,"TrialTroveID-162082, UMIN000006710",Assessment on safety of intravenously administered trastuzumab with 100 ml saline solution in HER2 positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Infusion-related reactions,"Adverse Events, Infusion-related reactions",False,,18411
611,161392,"TRI-ABC FEC trial, TrialTroveID-161392, UMIN000007180","A phase II neoadjuvant trial of sequential tri-weekly nanoparticle albumin-bound paclitaxel (Abraxane)/cyclophosphamide, with trastuzumab in HER2-positive patients, followed by 5-fluorouracil/epirubicin/cyclophosphamide (FEC) in operable breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease-free survival, Safety and Tolerability",False,,18411
612,161294,TrialTroveID-161294,Clinical Study of Different Regimens of Chemotherapies for Elderly Patients with Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Disease Progression,,False,,18411
613,160851,"TrialTroveID-160851, UMIN000007074",Ki67 Index Guided Selection of Preoperative Chemotherapy for HER2 Positive Breast Cancer - A Randomized Phase II Trial,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Complete response,"Disease-free survival, Overall response rate, Overall survival",False,,18411
614,160305,TrialTroveID-160305,A clinical study on the therapeutic effect of taxol (TAX) combined with Herceptin or epirubicin against breast cancer positive for Her-2/neu.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,CA-125 Response,,False,,18411
615,159782,TrialTroveID-159782,Adjuvant Trastuzumab Treatment without Adjuvant Chemotherapy in Early Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
616,159769,TrialTroveID-159769,N-Terminal Pro-Brain B-Type Natriuretic Peptide (nt-pro-BNP) before and during Treatment with Trastuzumab Allows Early Detection of Cardiotoxicity in Breast Cancer Patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
617,159712,"EudraCT Number: 2011-001231-23, FUPOCAN-01-11, HerXO, NCT01503983, TrialTroveID-159712","Phase II Study to Assess the Efficacy and Safety of Trastuzumab in Combination With Xelox as First-line Treatment of Patients With Advanced or Metastatic Gastric Cancer or Gastro-esophageal Junction, (HER2)-Positive.",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Overall response rate, Overall survival, Response rate","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Time to response",True,NCT01503983,18411
618,159666,"Agendia MINT I, MINT, MINT I, NCI-2015-01391, NCT01501487, P0334, TrialTroveID-159666",MINT I Multi- Institutional Neo-adjuvant Therapy MammaPrint Project I,Oncology,Oncology: Breast,"(Other Industry Sponsor), University of South Florida, (Other Hospital/Academic/Medical Center), University of Miami School of Medicine, University of Oklahoma","Industry, all other pharma, Academic, Academic, Academic, Academic",Complete response,Gene expression profiling,True,NCT01501487,18411
619,159663,"Cabot, CABOT, TrialTroveID-159663",Cardiac Biomarkers on Trastuzumab (Cabot Trial): Determining the Cardiac Biomarker Profile in Breast Cancer Patients Receiving Adjuvant Trastuzumab Therapy,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,N-Terminal Pro-Brain Natriuetic Peptide concentration,,False,,18411
620,159654,TrialTroveID-159654,Complete Pathological Response of Ductal Carcinoma In Situ after Treatment with Neoadjuvant Herceptin.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
621,159638,TrialTroveID-159638,Early Detection of Cardiotoxicity by Advanced Cardiac Imaging and a Novel Biomarker in Breast Cancer Patients Undergoing Chemotherapy.,Oncology,Oncology: Breast,University of Connecticut Health Center,Academic,"Brain Natriuretic Peptide concentration, Complete response",New York Heart Association Class,False,,18411
622,159300,"ADAPT, ADAPT Umbrella, EudraCT Number: 2011-001462-17, NCT01781338, TrialTroveID-159300, WSG-AM06",Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Recurrence,Overall survival,True,NCT01781338,18411
623,159149,TrialTroveID-159149,A clinical study on the efficacy and toxicity of trastuzumab combined vinorelbine in patients with HER2 overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
624,158782,"HERBIS-1, OGSG1101, T-CORE 1101, TrialTroveID-158782, UMIN000005739",Phase ll Trial of TS-1 + CDDP + Trastuzumab (SPT)-3 Weekly Schedule in HER2-Positive Advanced Gastric Cancer.,Oncology,Oncology: Esophageal; Oncology: Gastric,"Taiho Pharmaceutical, Osaka Gastrointestinal Cancer Chemotherapy Study Group","Industry, all other pharma, Cooperative Group","Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
625,158668,"TrialTroveID-158668, UMIN000006159",Phase II Trial of Trastuzumab in Combination with Abraxane for Patients with HER2-Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Progression-free survival,"Overall response rate, Response rate, Safety and Tolerability",False,,18411
626,158527,TrialTroveID-158527,Result of Phase II clinical trial of herceptin in advanced Chinese breast cancer patients,Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,,,False,,18411
627,158358,"TrialTroveID-158358, UMIN000006838",Multicenter Phase II tiral of Combination Therapy Using Abraxane and Trastuzumab +/-Pertuzumab For HER2-Positive Locally Advanced or Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
628,158349,"TrialTroveID-158349, UMIN000006757",S-1/trastuzumab for elderly HER2 positive advanced gastric cancer-Pilot study,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,,"Overall response rate, Overall survival, Progression-free survival",False,,18411
629,158151,"TrialTroveID-158151, UMIN000006115",A Phase II Study of Trastuzumab and TS-1 for HER2-Positive Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Response rate",False,,18411
630,157972,"TrialTroveID-157972, UMIN000005984","Feasibility Study of Combination Docetaxel, Cisplatin, and S-1 as Neoadjuvant Chemotherapy for Advanced Gastric Cancer",Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
631,157881,"TrialTroveID-157881, UMIN000005975",Feasibility study of S-1/Docetaxel plus trastuzumab in fluoropirimidine and platinum agents- refractory HER-2 positive advanced gastric cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,18411
632,157865,"TrialTroveID-157865, UMIN000005998",A Phase II study of capecitabine plus cisplatin (plus trastuzumab) for previously untreated advanced gastric cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Safety and Tolerability",False,,18411
633,157516,"TrialTroveID-157516, UMIN000005792",Trastuzumab in combination with S-1/CDDP of HER2-positive advanced gastric cancer: a phase II trial.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,18411
634,157141,"TrialTroveID-157141, UMIN000005603","Feasibility study of S-1, docetaxel, cisplatin and trastuzumab combination chemotherapy (DCS-T) in patients with HER2-positive unresectable metastatic gastric cancer",Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,,,False,,18411
635,157038,"CBEZ235B2203, EudraCT Number: 2011-003602-25, NCT01471847, NL38732.042.11, TrialTroveID-157038",A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab,Oncology,Oncology: Breast,Novartis,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale, Progression-free survival","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT01471847,18411
636,156967,"AIO-STO-0310, EudraCT Number: 2011-001507-13, HerFLOT, NCT01472029, TrialTroveID-156967","Multicenter, Explorative Phase II Study of Perioperative 5-FU, Leucovorin, Docetaxel, and Oxaliplatin (FLOT) in Combination With Trastuzumab in Patients With HER2-positive, Locally Advanced, Resectable Adenocarcinoma of the Gastroesophageal Junction or Stomach (HerFLOT)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Arbeitsgemeinschaft fur Internistische Onkologie, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma",Complete response,"Complete response, Disease Progression, Disease-free survival, Mortality, Overall survival, Resection rate, Safety and Tolerability, Safety and Tolerability",True,NCT01472029,18411
637,156916,"JFMC45-1102, TrialTroveID-156916, UMIN000006223","Phase II study of trastuzumab and paclitaxel in patients with HER2 positive (IHC 3+, IHC 2+ and FISH +) previously treated advanced or recurrent gastric cancer",Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
638,156648,"S1302, TrialTroveID-156648",A Phase II Study of Trastuzumab and mFOLFOX6 as First Line Therapy of HER2-Positive Advanced Gastric or Gastroesophageal Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,Southwest Oncology Group,Cooperative Group,,,False,,18411
639,156596,"TrialTroveID-156596, UMIN000006058",Phase II trial of S-1 based therapy + or - Trastuzumab combination therapy for unresectable gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,18411
640,156567,"GCSPH, TrialTroveID-156567, UMIN000005876",Combination treatment with TS-1+CDDP+Trastuzumab for unresectable HER 2 positive gastric cancer (A Phase II Study),Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Overall survival, Progression-free survival",False,,18411
641,156376,TrialTroveID-156376,Effect of Herceptin combined with Taxol on patients with Her-2/neu overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
642,156184,"SBP-01, TrialTroveID-156184, UMIN000005881",Phase II Study of Gemcitabine and Trastuzumab in Patients With Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Overall response rate,"Adverse Events, Overall survival, Progression-free survival",False,,18411
643,156072,TrialTroveID-156072,Primary safety analysis of trastuzumab after adjuvant chemotherapy in 30 Chinese Her2-positive early breast cancer patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
644,155992,"""TREAT CTC"" Trial, BIG 1-12, CTBE2013000250, DRKS00005208, EORTC 10093, EORTC90091-10093, EORTC-90091-10093, EORTC-90091-10093-NOCI-BCG, EudraCT Number: 2009-017485-23, IRAS ID: 124625, NCT01548677, TREAT CTC (BIG 1-12), TREAT-CTC, TrialTroveID-155992, UKCRN ID 16547","Trastuzumab in HER2-negative Early Breast Cancer as Adjuvant Treatment for Circulating Tumor Cells (CTC) (""TREAT CTC"" Trial)",Oncology,Oncology: Breast,"(Other Cooperative Group), Johnson & Johnson/Janssen R&D {Johnson & Johnson/J&JPRD}, EORTC Breast Cancer Group, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma",Circulating Tumor Cells,"Disease Progression, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability",True,NCT01548677,18411
645,155316,TrialTroveID-155316,Changes of Left Ventricular Function Assessed by 2D and Doppler Echocardiography in Patients Receiving trastuzumab Therapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,,False,,18411
646,155201,"2011-0650, NCI-2011-03450, NCT01454804, TrialTroveID-155201",Phase I Study of Pazopanib in Combination With Lapatinib or Trastuzumab in Subjects With Solid Tumors,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,"MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Magnetic Resonance Imaging, Maximum tolerated dose, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",,True,NCT01454804,18411
647,154627,TrialTroveID-154627,Phase I/II Study of XL184 in Combination with Trastuzumab in Patients with HER2/neu Amplified Metastatic Breast Cancer Patients,Oncology,Oncology: Breast,Southwest Oncology Group,Cooperative Group,,,False,,18411
648,154572,"BO27798, BO27798B, CTR20140021, EudraCT Number: 2011-001526-19, HELOISE, NCI-2012-01186, NCT01450696, S498, TrialTroveID-154572","A Randomized, Open Label, Multicenter Phase IIIb Study Comparing Two Trastuzumab Dosing Regimens, Each in Combination With Cisplatin/Capecitabine Chemotherapy, as First-Line Therapy in Patients With HER2-Positive Metastatic Gastric or Gastro-Esophageal Junction Adenocarcinoma Who Have Not Received Prior Treatment for Metastatic Disease",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Overall survival,"Cmin, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01450696,18411
649,154234,"TrialTroveID-154234, UMIN000005548",Neoadjuvant Chemotherapy for HER2-positive Stage IV advanced gastric cancer with S-1/Cisplatin/Trastuzumab,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability","Overall survival, Progression-free survival",False,,18411
650,154186,"CTRIAL-IE (ICORG) 10-05, EudraCT number: 2010-020966-34, ICORG 10-05, ICORG10-05, NCT01485926, TCHL Phase II, TrialTroveID-154186","A Phase II Neo-adjuvant Study Assessing TCH (Docetaxel, Carboplatin and Trastuzumab) and TCHL (Docetaxel, Carboplatin, Trastuzumab and Lapatinib) in HER-2 Positive Breast Cancer Patients.",Oncology,Oncology: Breast,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,Complete response,"Adverse Events, Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability",True,NCT01485926,18411
651,154138,"DRKS00010753, EudraCT Number: 2009-013331-37, GALADON, NCT01690325, TrialTroveID-154138, WSG-AM05",Molecular Imaging for Response Assessment of Bevacizumab + Docetaxel as Neoadjuvant Chemotherapy in Primary Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging","Disease-free survival, Magnetic Resonance Imaging, Overall survival",True,NCT01690325,18411
652,153969,TrialTroveID-153969,Bcl2 Expression Predicts Clinical Outcome of Combined Targeted Therapies of HER2+/ER+ and the Potential Benefit of Anthracycline-based Chemotherapy of HER2+ Breast Cancer (BC),Oncology,Oncology: Breast,University of Nottingham,Academic,,,False,,18411
653,153957,TrialTroveID-153957,Efficacy and toxicity of trastuzumab combined with docetaxel for Her-2/neu overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
654,153765,TrialTroveID-153765,Gemcitabine Based Combination Regimens for Treatment of Refractory Advanced Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
655,153723,"BREAST IMMUN, ET11-059, NCT01440413, RCB-2011-A00657-34, RECF1869, TrialTroveID-153723",Study of the Response to a Neoadjuvant Chemotherapy Based on the Antitumor Immune Response in Localized Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Tumor control rate","Overall survival, Progression-free survival, Retinal thickness",True,NCT01440413,18411
656,153621,TrialTroveID-153621,Randomized phase II study of weekly docetaxel plus trastuzumab versus weekly paclitaxel plus trastuzumab in patients with previously untreated advanced nonsmall cell lung carcinoma.,Oncology,"Oncology: Lung, Non-Small Cell",Roche/Genentech {Genentech},"Industry, Top 20 Pharma",,,False,,18411
657,153535,TrialTroveID-153535,Phase II Study of Vinorelbine Plus Trastuzumab in HER-2 Overexpressing Metastatic Breast Cancer Pretreated With Anthracyclines and Taxanes,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Time to progression",False,,18411
658,153191,"2010-A01463-36, MRTOX, NCT01436604, RECF1736, TrialTroveID-153191",Early Detection of Cardiac Toxicity of Trastuzumab (Herceptin) in Patients Treated for Breast Carcinoma: Value of Magnetic Resonance Imaging.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Magnetic Resonance Imaging,Magnetic Resonance Imaging,True,NCT01436604,18411
659,152907,"2010-0842, 8871, NCI 8871, NCI-2011-03222, NCI-8871, NCT01434303, TrialTroveID-152907","Phase I and Phase II Trastuzumab Cohort Study of Entinostat, Lapatinib and Trastuzumab in Patients With HER2-Positive Metastatic Breast Cancer in Whom Trastuzumab Has Failed",Oncology,Oncology: Breast,"GlaxoSmithKline, Novartis, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Government","Dose-limiting toxicities, Maximum tolerated dose","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events",True,NCT01434303,18411
660,152829,"NCT01432223, OMC-BC01, TrialTroveID-152829, UMIN000006288",Phase II Study of Primary Chemotherapy With Anthracycline-based Regimen Followed by Nab-paclitaxel and Trastuzumab in Patients With HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Complete response, Disease-free survival, Overall response rate - duration, Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT01432223,18411
661,152436,"ML27770, NCT01428414, TrialTroveID-152436","Multicenter, Randomized, Open-label Phase II Study to Compare the Efficacy and Safety of Trastuzumab and Paclitaxel Based Regimen Plus Carboplatin or Epirubicin as Neoadjuvant Therapy in HER2-positive Breast Cancer Patients",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Safety and Tolerability","Adverse Events, Disease-free survival, NCI-CTC scale, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01428414,18411
662,152411,"TrialTroveID-152411, UMIN000005210",Neoadjuvant trastuzumab and nab-paclitaxel for HER2 positive breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Disease-free survival, Overall response rate",False,,18411
663,152394,TrialTroveID-152394,Calpain-1 expression is associated with relapse-free survival in breast cancer patients treated with trastuzumab following adjuvant chemotherapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
664,151962,"NCT01423695, TrialTroveID-151962, WISP_RO78",Weekly Application of Trastuzumab and Paclitaxel in the Treatment of HER2-overexpressing Metastatic Breast Cancer,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Progression-free survival,,True,NCT01423695,18411
665,151455,"KBC-SG 1101, TrialTroveID-151455, UMIN000004764",Phase II trial of TS-1 plus Trastuzumab in patients with metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate, Safety and Tolerability","Overall survival, Time to progression, Time to treatment failure",False,,18411
666,151275,"NCT01413828, PUMCH- Breast-AH, TrialTroveID-151275",Safety and Efficacy Evaluation of Trastuzumab Administered Concurrently or Sequentially to Anthracycline-containing Adjuvant Regimen for Breast Cancer,Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,Safety and Tolerability,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence",True,NCT01413828,18411
667,150551,"EudraCT Number: 2011-003031-55, HER-ception, NCT01400438, RECF1472, TrialTroveID-150551","Experience of the Patient Treated With Trastuzumab (Herceptin) as Adjuvant for Breast Cancer: Fatigue and Quality of Life During and Waning of Treatment, Psychosocial Aspects (Environment, Work)",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,FACIT-Fatigue,Quality of Life,True,NCT01400438,18411
668,150354,"EudraCT Number: 2010-024099-25, ML29123, MO22982, NCT01401166, NCT02658461, PrefHer, PrefHer Study, TrialTroveID-150354","A Randomized, Multi-Center Cross-Over Study to Evaluate Patient Preference and Health Care Professional (HCP) Satisfaction With Subcutaneous (SC) Administration of Trastuzumab in HER2-Positive Early Breast Cancer (EBC)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",,"Anti-drug antibodies, Disease-free survival, Event-free survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT01401166,18411
669,150060,"AMC1102, NCT01396707, TrialTroveID-150060",A Phase II Study of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) in Patients With Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"Roche {F. Hoffmann-La Roche}, Asan Medical Center","Industry, Top 20 Pharma, Academic",Overall response rate,"Duration of overall response, Overall survival, Progression-free survival, Time to progression",True,NCT01396707,18411
670,149920,TrialTroveID-149920,Trastuzumab clears HER2/neu-positive isolated tumor cells from bone marrow in primary breast cancer patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
671,149349,"EudraCT Number: 2009-014863-37, MA 0919, MA0919, NCT01387373, TrialTroveID-149349",Intra-hepatic Chemotherapy with Oxaliplatin Every Second Week in Combination with Systemic Capecitabine in Patient with Non-resectable Liver Metastases from Breast Cancer. A Phase II Trial,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Herlev and Gentofte Hospital {Herlev Hospital},Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",Time to progression,True,NCT01387373,18411
672,149256,"EudraCT Number: 2009-014821-17, MA 0918, MA0918, NCT01387295, TrialTroveID-149256",Intra-hepatic Chemotherapy With Oxaliplatin Every Second Week in Combination With Systemic Capecitabine in Patient With Non-resectable Liver Metastases From Breast Cancer A Phase II Trial in Patients With Limited Extrahepatic Disease,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Herlev and Gentofte Hospital {Herlev Hospital},Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",Progression-free survival,True,NCT01387295,18411
673,148279,"09/501/M, Eudract Number: 2009-017218-63, HIT, NCT01373710, RECF1519, TrialTroveID-148279",Phase I-II Study of Safety and Efficacy of Intrathecal Trastuzumab Administration in Metastatic HER2 Positive Breast Cancer Patients Developing Carcinomatous Meningitis,Oncology,Oncology: Breast,"Institut Gustave Roussy, (Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival","Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Quality of Life",True,NCT01373710,18411
674,147662,"2010/1049, ABCSG 32, ABCSG32, ABCSG-32, EudraCT Number: 2010-023324-25, ML22765, NCT01367028, TrialTroveID-147662",Multicentre Randomized Phase II Study of Neoadjuvant Trastuzumab Plus Docetaxel With and Without Bevacizumab and Trastuzumab Plus Docetaxel Plus Non-pegylated Liposome-encapsulated Doxorubicin (NPLD) With and Without Bevacizumab in HER2-positive Early Breast Cancer,Oncology,Oncology: Breast,"Austrian Breast & Colorectal Cancer Study Group, Teva {Cephalon}, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma",,"Adverse Events, Complete response, Overall response rate, Safety and Tolerability",True,NCT01367028,18411
675,147641,"00032751, 1012007786, 13-0210, ANF1101, HIC 1012007786, NCI-2013-00894, NCT01367002, OCT11-0083S, TrialTroveID-147641, YALE-001",Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma,Oncology,Oncology: Endometrial,"Yale University, Roche/Genentech","Academic, Industry, Top 20 Pharma",Progression-free survival,"CA-125 Response, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Safety and Tolerability",True,NCT01367002,18411
676,147560,TrialTroveID-147560,"The predictive role of midtreatment changes in survivin, GSTP1, and topoisomerase 2 alpha expressions for pathologic complete response to neoadjuvant chemotherapy in patients with locally advanced breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
677,147512,"CGOG1001, NCT01364493, TrialTroveID-147512","An Open-label, Single Arm Study to Evaluate the Efficacy and Safety of Trastuzumab in Combination With Capecitabine and Oxaliplatin (XELOX) as a First-line Chemotherapy for Inoperable, Locally Advanced or Recurrent and/or Metastatic Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Overall survival, Progression-free survival",True,NCT01364493,18411
678,147457,"bHERt-2, EudraCT Number: 2010-021191-29, ML25432, NCT01363986, TrialTroveID-147457","A Multicenter, Open Label Study to Assess the Effect of Trastuzumab + Whole Brain Radiotherapy (WBRT) on Brain Metastases From HER-2 Positive Breast Cancer. (bHERt-2)",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01363986,18411
679,147235,TrialTroveID-147235,Mutations of the catalytic domain of PI3 kinase and correlation with clinical outcome in trastuzumab-treated metastatic breast cancer (MBC).,Oncology,Oncology: Breast,Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation},Not for Profit Funding Entity,,,False,,18411
680,147224,TrialTroveID-147224,IGF1R and phosphorylated IGF1R in HER2-positive breast cancer.,Oncology,Oncology: Breast,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,,,False,,18411
681,147223,TrialTroveID-147223,Detection of early cardiac effects through strain rate imaging in patients undergoing breast cancer treatment with trastuzumab.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
682,147180,TrialTroveID-147180,Prognostic and predictive value of HER2 extracellular domain in patients with early and metastatic breast cancer treated with trastuzumab and lapatinib: Correlation with clinicopathological parameters and response,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
683,147156,TrialTroveID-147156,Immunologic profiling and clinical outcome in HER2+ breast cancer patients treated in a neoadjuvant phase II study: A step forward to understand trastuzumab activity.,Oncology,Oncology: Breast,"National Cancer Institute, Aviano, Italy",Government,,,False,,18411
684,147127,TrialTroveID-147127,Fc gamma-receptor IIa polymorphism and cardiotoxicity in patients with breast cancer treated with adjuvant trastuzumab,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
685,147092,"B-DOCT, EudraCT Number: 2010-022699-30, M10B-DOCT, NCT01359397, NL33964.031.10, TrialTroveID-147092","Phase II Study of Docetaxel, Oxaliplatin, Capecitabine With Bevacizumab and Trastuzumab in Case of Human Epidermal Growth Factor Receptor 2 (HER2)-Positivity in Patients With Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT Study)",Oncology,Oncology: Esophageal; Oncology: Gastric,Netherlands Cancer Institute,Government,Progression-free survival,"Complete response, Duration of overall response, NCI-CTC scale, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01359397,18411
686,146264,TrialTroveID-146264,A phase II study on metastatic breast cancer patients treated with weekly vinorelbine with or without trastuzumab according to HER2 expression: changing the natural history of HER2-positive disease.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Duration of overall response, Overall response rate - duration, Overall survival, Time to progression",False,,18411
687,145716,"DASH, TrialTroveID-145716, UMIN000005366",A phase II study of trastuzumab added to docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Safety and Tolerability, Time to treatment failure",False,,18411
688,145112,"ML22958, NCT01332981, Post-HERMINE Study, TrialTroveID-145112",Overall Survival Estimation After a 7 Year Follow-up in Metastatic Breast Cancer Patients Treated by Herceptin as 1st Line Therapy (Post-HERMINE Study),Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Overall survival,"Disease Progression, Overall survival, Progression-free survival, Time to progression",True,NCT01332981,18411
689,144845,"NCT01329640, TraQ-Me 01, TrialTroveID-144845",Phase II Feasibility Study of Weekly Paclitaxel Plus Weekly Trastuzumab Followed by Weekly Doxorubicin Plus Daily Oral Cyclophosphamide Plus Weekly Trastuzumab for Locally Advanced HER2-Positive Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), University of Sao Paulo","Cooperative Group, Academic",,"Complete response, Disease Progression, Magnetic Resonance Imaging, Overall survival, Progression-free survival",True,NCT01329640,18411
690,144824,"CCAM 11-01, CCAM-11-01, NAC CCAM 11-01, NACprotocol, NCT01330212, NCT01641406, TrialTroveID-144824",Phase II Study of PET Guided Neoadjuvant Chemotherapy (NAC) and Oncotype Guided Hormonal Therapy of Breast Cancer: CCAM 11-01.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,"Complete response, Overall response rate, Response rate",Complete response,True,NCT01330212,18411
691,144325,"13-159, H4320//NU 10C03, MSKCC 12-123, NCI-2011-00110, NCT01325207, NU 10C03, STU00040150-MOD0003, TrialTroveID-144325",Phase I/II Dose Escalation Trial to Assess Safety of Intrathecal Trastuzumab for the Treatment of Leptomeningeal Metastases in HER2 Positive Breast Cancer,Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Metastatic Cancer",Northwestern University,Academic,"Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability","Circulating Tumor Cells, Disease Progression, Magnetic Resonance Imaging",True,NCT01325207,18411
692,144193,"ACTRN12611000153910, TrialTroveID-144193, U1111-1119-2755",Early Cardiac Changes During Anthracycline and/or Trastuzumab Therapy in Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,Complete response,False,,18411
693,144110,"AVANTHER, EudraCT Number: 2009-011405-16, NCT01321775, TrialTroveID-144110","Bevacizumab and Trastuzumab with Paclitaxel on Women with Her2+ Breast Cancer Weekly Paclitaxel Followed, After Surgery, by Encapsuled Liposomal Doxorubicin, Cyclophosphamide and Trastuzumab as Adjuvant Treatment After Surgery on Women with Her2+ Breast Cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01321775,18411
694,143603,"AB23/01/XX, TrialTroveID-143603",A Phase II Study of Taxol plus Carboplatin Combination Chemotherapy with or without Herceptin as Primary Treatment for Patients with advanced Bladder Cancer and HER2 Overexpression,Oncology,Oncology: Bladder,Association of Urogenital Oncology (AUO),Cooperative Group,,,False,,18411
695,143197,"000500561, LCCC 1025, LCCC1025, NCT01305941, TrialTroveID-143197, VICCBRE1304",A Phase II Study Evaluating The Efficacy And Tolerability Of Everolimus (RAD001) In Combination With Trastuzumab And Vinorelbine In The Treatment Of Progressive HER2-Positive Breast Cancer Brain Metastases,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Novartis, (Other Cooperative Group), UNC Lineberger Comprehensive Cancer Center, National Institutes of Health","Industry, Top 20 Pharma, Cooperative Group, Academic, Government","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Functional Assessment of Cancer Therapy-Breast, Functional Assessment of Cancer Therapy-General, Instrumental Activities of Daily Living, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01305941,18411
696,142625,TrialTroveID-142625,Study of three-weekly docetaxel and weekly trastuzumab treatment in HER 2-overexpressing metastatic breast cancer patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,"Adverse Events, Time to progression",False,,18411
697,142325,"10.05, EudraCT Number:2010-021016-41, Her-TEX, NCT01295086, TrialTroveID-142325","Dose Determination of Taxotere, Eloxatin and Xeloda (TEX)in Combination with Herceptin as First-line Treatment for Patients with HER2 Positive Non-resectable Oesophagus, Cardia or Gastric Cancer (ECV)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Rigshospitalet, (Other Hospital/Academic/Medical Center), Aarhus University Hospital, Odense University Hospital","Academic, Academic, Academic, Academic","Maximum tolerated dose, Safety and Tolerability","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT01295086,18411
698,142075,"ML25288, NCT01301729, TrialTroveID-142075","A Multicenter, Single arm, Open-Label Phase IV study to investigate the Effect of First-Line Herceptin (Trastuzumab) in Combination With a Taxane in Patients With Metastatic Breast Cancer Who Relapsed After Receiving (neo)adjuvant Herceptin for HER2-Positive Early Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT01301729,18411
699,141678,"ML21833, NCT01290718, TrialTroveID-141678",Study of Trastuzumab Combined With Capecitabine on HER2-positive Metastatic Breast Cancer Patients Pretreated With Trastuzumab and Taxanes or HER2- Positive Breast Cancer Patients Relapsed From (Neo)Adjuvant Therapy of Trastuzumab and Taxanes.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Response evaluation criteria in solid tumors,"Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT01290718,18411
700,141588,"JBCRG-C02, TrialTroveID-141588, UMIN000002738",Cohort Study Evaluating Efficacy of Trastuzumab Retreatment in Recurrent Breast Cancer Patients Who Previously Received Trastuzumab Adjuvant Therapy,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Progression-free survival,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
701,141575,"JBCRG C-01, JBCRG-C01, TrialTroveID-141575, UMIN000002737",Cohort study evaluating (neo) adjuvant trastuzumab for HER2 positive breast cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Disease-free survival,"Overall survival, Safety and Tolerability",False,,18411
702,141268,"CRLOT/01, EudraCT Number: 2010-018324-13, TrialTroveID-141268","Phase II Randomized, Open Label Study To Evaluate Safety,Tolerability And Efficacy Of Trastuzumab In Combination With Vinorelbine In Patients With HER2 Positive Metastatic Breast Cancer Patients With Cardiovascular Disease",Oncology,Oncology: Breast,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,Adverse Events,"Adverse Events, Overall survival, Progression-free survival, Time to progression",False,,18411
703,141210,"EudraCT Number: 2009-016453-17, IEO S504/509, IEURONC_ II_2009_008, TrialTroveID-141210",Phase II study of preoperative treatment of inflammatory breast cancer with bevacizumab in combination with weekly carboplatin and paclitaxel + or - trastuzumab and metronomic cyclophosphamide and endocrine therapy.,Oncology,Oncology: Breast,European Institute of Oncology,Government,"Complete response, Overall response rate, Response evaluation criteria in solid tumors",Safety and Tolerability,False,,18411
704,140902,"062-12, 48CIRBHFH, B-47, CTSU/NSABP B-47, CTSUNSABPBREB-47-M, ICORG 11-24, NASBP-B-47, NCG 195511, NCI-2011-02572, NCT01275677, NSABP B47, NSABP B-47, NSABP-B47, NSABP-B-47-CIRB, NSB47, TrialTroveID-140902",A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women With Node- Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.,Oncology,Oncology: Breast,"National Surgical Adjuvant Breast and Bowel Project (NSABP), National Institutes of Health/National Cancer Institute, Roche/Genentech, NRG Oncology","Cooperative Group, Government, Industry, Top 20 Pharma, Cooperative Group","Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence",True,NCT01275677,18411
705,140844,"10-142, NCT01276041, TrialTroveID-140844","Paclitaxel, Trastuzumab, and Pertuzumab in the Treatment of Metastatic HER2-Positive Breast Cancer.",Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, University of Pennsylvania, Roche/Genentech","Academic, Academic, Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Brain Natriuretic Peptide concentration, Complete response, Magnetic Resonance Imaging, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT01276041,18411
706,140733,"00033468, 10112, 2156, COH-10112, I 256014, NCI-2011-00116, NCT01273610, TrialTroveID-140733",Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Age 60 or Older With HER2 Positive Locally Advanced or Metastatic Breast Cancer,Oncology,Oncology: Breast,"GlaxoSmithKline, Novartis, City of Hope Comprehensive Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Congestive heart failure, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Nausea, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Vomiting",True,NCT01273610,18411
707,140389,"TrialTroveID-140389, UMIN000002660",A Prospective Study On Prediction Of Sensitivity To Trastuzumab Using Gene Expression Of Peripheral Blood Mononuclear Cells.,Oncology,Oncology: Breast,(Other government agency),Government,"Overall response rate, Response rate",,False,,18411
708,140252,"10354, EudraCT Number: 2010-021600-24, NCT01340430, NEOHER-021, TrialTroveID-140252",Neoadjuvant Therapy With FEC Followed by Weekly Paclitaxel and Concurrent Trastuzumab in Her2 Positive Non Operable Breast Cancer. Phase II Study,Oncology,Oncology: Breast,Istituto Nazionale per la Ricerca sul Cancro,Academic,Complete response,"Disease-free survival, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT01340430,18411
709,140015,TrialTroveID-140015,Role of ABCB1 Polymorphisms as Predictive Markers in Patients with HER-2 FISH Positive Metastatic Breast Cancer Who Were Treated with Taxane Plus Trastuzumab First Line Chemotherapy.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
710,139970,"GBCCSG-01, TrialTroveID-139970, UMIN000001408",A Phase II Study of Trastuzumab plus S-1 in Patients with Advanced or Recurrent HER2 positive Breast Cancer.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
711,139384,"CTRI/2011/10/002087, ML25477, NCT01260194, TrialTroveID-139384","An Open-label, Multicentre Phase IV Study of Trastuzumab in Combination With the Standard Therapy (as Per Routine Clinical Practice) as First-line Therapy in Patients With HER2 Positive Metastatic Gastric Cancer.",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease",True,NCT01260194,18411
712,139216,TrialTroveID-139216,A Phase II Preoperative Trial of Concurrent Trastuzumab and Paclitaxel without Anthracycline in HER2-Positive Operable Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
713,138154,"13603094, EudraCT Number: 2010-021618-42, NCT01242449, OVINTRA, TrialTroveID-138154",A Phase II Investigation of Oral Vinorelbine in Combination With Trastuzumab for 1st and 2nd Line Treatment of Women With Metastatic HER2 Positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01242449,18411
714,137379,TrialTroveID-137379,Efficacy and Safety Assessment of Neoadjuvant Paclitaxel and Trastuzumab in Chinese Women with Her-2 Positive Operable Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Overall response rate,False,,18411
715,137368,TrialTroveID-137368,Our Experience in the Use of Trastuzumab in Patients with Advanced Stomach Cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
716,137145,TrialTroveID-137145,"Low Expression Level Of Nucleostemin (GNL3), Stimulator of Cancer Stem Cell Feather, is A Promising Biomarker to Predict Pathologic Complete Response (PCR) In Neoadjuvant Treatment With Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
717,137074,TrialTroveID-137074,Elevated Serum Levels of the Her2 Extracellular Domain (Ecd) in Primary Breast Cancer (Pbc) with Her2 Overexpression Predict Early Failure of  Adjuvant Trastuzumab,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
718,136876,"NCC0906, NCT01228045, NCT01736410, S1/CDDP/Her, TrialTroveID-136876",A Study of Trastuzumab in Combination with TS-ONE and Cisplatin in First-line Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Academic Cancer Center), (Other Hospital/Academic/Medical Center)","Academic, Academic","Overall response rate, Response rate","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",True,NCT01228045,18411
719,136816,"21-47, TrialTroveID-136816, UMIN000002651",A Phase II Trial of Lapatinib and Trastuzumab in Patients with Heavily Pretreated Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}",Academic,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,18411
720,136467,TrialTroveID-136467,Capecitabine-Based Therapy For Patients With Brain Metastases From Breast Cancer.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
721,136428,TrialTroveID-136428,Phase I study of S-1 plus trastuzumab combination therapy in human epidermal-growth Receptor 2-positive metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Clinical benefit rate, Overall response rate",False,,18411
722,136409,TrialTroveID-136409,Bevacizumab/ Trastuzumab-Combination Induces Rapid Tumor Control and Long-Lasting Remission in Patients with Metastatic Her2-Positive Breast Cancer and High Tumor Burden,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
723,136342,"497, HERMES, ML22834, NCT01220934, TrialTroveID-136342",Clinical Practice Surveillance of the Use of Herceptin in Patients With HER2-positive Advanced Adenocarcinoma of the Stomach or Gastro-esophageal Junction (GEJ) (HERMES),Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Quality of Life, Safety and Tolerability",True,NCT01220934,18411
724,136125,"SOLTI 0901, TrialTroveID-136125","Phase II, Open-Label, Randomized Study of the Efficacy and Safety of Lapatinib in Combination with Cyclophosphamide (C), Epirubicin (E) and 5-fluorouracil (F) Followed by Docetaxel (D) and Lapatinib Compared with FEC Followed by D and Trastuzumab, as Systemic Neoadjuvant Therapy for Patients with Previously Untreated ErbB2+ve Stage I -IIIa Breast Cancer.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Safety and Tolerability,,False,,18411
725,135432,TrialTroveID-135432,"Phase I Study of the Combination of an Anti-HER3 Antibody (AMG 888) plus Anti-IGF-1R Antibody (AMG 479) plus Trastuzumab in Patients with Advanced, HER2 Positive, Trastuzumab-Resistant Solid Tumors.",Oncology,Oncology: Unspecified Solid Tumor,Southwest Oncology Group,Cooperative Group,,,False,,18411
726,135287,"EudraCT Number: 2008-007951-29, NCT01206881, PO5903, TrialTroveID-135287",A Phase II Study of Neoadjuvant Treatment With Pegylated Liposomal Doxorubicin (Caelyx) and Cyclophosphamide + or - Trastuzumab Followed by Docetaxel in Patients With Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,"Rigshospitalet, Aarhus University Hospital, Herlev and Gentofte Hospital {Herlev Hospital}, Odense University Hospital","Academic, Academic, Academic, Academic",Overall response rate,"Complete response, Overall response rate, Response rate",True,NCT01206881,18411
727,134617,"1010RTOG, 11-163, 11368, 12-094, 13290, AAAJ5404, CDR0000683717, CTSU/RTOG 1010, NCI-2011-02601, NCT01196390, R1010, RTOG 1010, RTOG-1010, RTOG1010/11-702, TrialTroveID-134617",A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of Her2-Overexpressing Esophageal Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"Radiation Therapy Oncology Group (RTOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group",Disease-free survival,"Ability to swallow, Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EQ-5D, Overall survival, Quality of Life, Resection rate",True,NCT01196390,18411
728,133989,"09-457, DFCI 09-457, NCT01191697, TrialTroveID-133989","Phase II Trial of CAPOX, Bevacizumab and Trastuzumab for Patients With HER2-Positive Metastatic Esophagogastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Massachusetts General Hospital, Brigham and Womens Hospital, Roche/Genentech","Academic, Academic, Academic, Industry, Top 20 Pharma","Overall response rate, Response rate",Duration of overall response,True,NCT01191697,18411
729,133608,"HERODOT, ML25235, NCT01187381, TrialTroveID-133608","Multicenter, Single-Arm, Observational Study of Mean Duration of Trastuzumab (Herceptin) Treatment in Patients With HER2-Positive Early or Metastatic Breast Cancer in Romanian Population",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",,"Disease Progression, Progression-free survival",True,NCT01187381,18411
730,133451,"10-207, H4913s, NCT01185509, TrialTroveID-133451","A Phase II, Single Arm, Open Label Study to Evaluate the Efficacy and Safety of Trastuzumab and Vinorelbine in Advanced Breast Cancer Patients With HER2 Negative Primary Tumors and HER2 Positive Circulating Tumor Cells",Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Womens Hospital, Roche/Genentech","Academic, Academic, Academic, Academic, Industry, Top 20 Pharma","Circulating Tumor Cells, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT01185509,18411
731,132058,"EudraCT Number: 2009-016875-30, GATE 1, NCT01204372, RECF1370, TrialTroveID-132058, VA 2009/40","Phase II Trial Evaluating the Combination of Gemcitabine, Trastuzumab and Erlotinib as First-line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma",Oncology,Oncology: Pancreas,"(Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma","Clinical benefit rate, Magnetic Resonance Imaging, Response evaluation criteria in solid tumors","Magnetic Resonance Imaging, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01204372,18411
732,131843,"ML22700, NCT01170143, TrialTroveID-131843","A Randomized Study to Investigate the Efficacy and Safety of qw or q3w Trastuzumab, Paclitaxel and Carboplatin in Patients With IIB-IIIB HER2 Positive Breast Cancer",Oncology,Oncology: Breast,"Fudan University - Shanghai, China, Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma","Complete response, Recurrence",,True,NCT01170143,18411
733,130650,TrialTroveID-130650,Liposome-encapsulated doxorubicin plus paclitaxel and trastuzumab as neoadjuvant chemotherapy for operable and locally advanced breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
734,130649,TrialTroveID-130649,Use of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,18411
735,127758,"EudraCT Number: 2009-017848-14, ML25189, NCT01130337, NEOHX, TrialTroveID-127758","An Open-label, Multi-center Study to Evaluate the Disease Free Survival Rate of a Perioperative Combination of Capecitabine (Xeloda), Trastuzumab (Herceptin) and Oxaliplatin (XELOX- Trastuzumab) in Patients With Resectable Gastric or Gasro-esophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Disease-free survival,"Complete response, Overall response rate, Overall survival, Partial response, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01130337,18411
736,127702,"COG-AOST0121, NCT00023998, TrialTroveID-127702",A Groupwide Phase II Study of Trastuzumab (Herceptin) in Metastatic Osteosarcoma Patients With Tumors That Overexpress HER2,Oncology,Oncology: Osteosarcoma,"National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group",,,True,NCT00023998,18411
737,127197,"EudraCT Number: 2008-001369-27, PACLIDOX 07, TrialTroveID-127197","Phase II study of liposomal doxorubicin, paclitaxel and trastuzumab therapy for locally advanced operable breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Overall response rate,False,,18411
738,125932,"371-09, NCI-2010-00608, NCT01106898, TrialTroveID-125932","A Phase II Study of Adjuvant Therapy Using a Regimen of Cyclophosphamide, Paclitaxel With or Without Trastuzumab in Stage I-II Breast Cancer Patients",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, UNMC Eppley Cancer Center at the University of Nebraska Medical Center","Government, Academic","Disease-free survival, Recurrence",,True,NCT01106898,18411
739,125899,"(N-SAS BC) 07, NCT01104935, N-SAS BC 07, N-SAS BC07/RESPECT, RESPECT, TrialTroveID-125899, UMIN000002349, UMIN000028476","Evaluation of Trastuzumab without Chemotherapy as a Postoperative Adjuvant Therapy in HER2 Positive Elderly Breast Cancer Patients: Randomized Controlled Trial , , National Surgical Adjuvant Study of Breast Cancer 07 (N-SAS BC 07)",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Disease-free survival, Functional Assessment of Cancer Therapy-General, Recurrence","Absolute Neutrophil Count, Adverse Events, Cost effectiveness, Creatinine kinase level, Disease-free survival, EQ-5D, Functional Assessment of Cancer Therapy-General, Instrumental Activities of Daily Living, Neuropathy, Overall survival, Platelet count, Quality of Life, Recurrence, Safety and Tolerability",True,NCT01104935,18411
740,123950,"EudraCT Number: 2009-012048-18, IEO S479/209, S479/209, TrialTroveID-123950","Phase II Study of Epirubicin, Cisplatin and 5 - Fluorouracil Continuous Infusion (ECF) Followed by Weekly Paclitaxel in Combination with Metronomic Cyclophosphamide + or - Trastuzumab as Preoperative Treatment in Locally Advanced Breast Carcinoma ER and PgR Negative",Oncology,Oncology: Breast,European Institute of Oncology,Government,Resection rate,"Complete response, Overall response rate",False,,18411
741,121640,"2905, EudraCT Number: 2009-017083-16, GOIM2905, TrialTroveID-121640",A Phase II Study of Metronomic Oral Chemotherapy with Cyclophosphamide plus Capecitabine in combination with Herceptin to treat HER2 positive Advanced Breast Cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Stable Disease","Clinical benefit rate, Overall survival, Progression-free survival, Time to progression",False,,18411
742,121385,"BRE 166 IIT, NCT01048099, SCRI BRE 166, TrialTroveID-121385",Use of the PRO Onc Assay to Assess HER2 Overexpression and Activation in Patients With Metastatic Breast Cancer Whose Tumors Are HER2-Negative by Standard FISH Testing,Oncology,Oncology: Breast,"Prometheus Biosciences {Precision IBD/Prometheus Laboratories {Nestle Health Science/Prometheus Laboratories}}, Roche/Genentech","Industry, all other pharma, Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors",Circulating Tumor Cells,True,NCT01048099,18411
743,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,18411
744,120406,"EudraCT Number: 2006-006010-15, IEO S329/606, TrialTroveID-120406","Preoperative Therapy with Pegylated Liposomal Doxorubicin, Cisplatin and Infusional Fluoruracil + Trastuzumab (+ or -Endocrine Therapy) in Locally Advanced HER2 Positive Breast Cancer.",Oncology,Oncology: Breast,European Institute of Oncology,Government,"Complete response, Overall response rate","Complete response, Disease-free survival, Overall survival, Safety and Tolerability",False,,18411
745,118331,TrialTroveID-118331,Amplification of the chromosome 17 q22 amplicon containing TOP2A gene is correlated with better survival in HER2 amplified/hormone receptors negative breast cancers,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
746,118300,TrialTroveID-118300,"Phase II study of liposome-encapsulated doxorubicin plus cyclophosphamide, followed by sequential trastuzumab (T) plus docetaxel as primary systemic therapy (PST) for breast cancer patients with HER2 overexpression or amplification",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Response rate",False,,18411
747,118285,TrialTroveID-118285,A pilot study of primary systemic therapy with weekly trastuzumab and paclitaxel followed by epirubicin/cyclophophamide and sequential trastuzumab monotherapy for HER2-positive advanced breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
748,118250,TrialTroveID-118250,Late phase capecitabine plus docetaxel for metastatic breast cancer patients,Oncology,Oncology: Breast,Shizuoka Cancer Center,Academic,,,False,,18411
749,116694,TrialTroveID-116694,Evaluating the prognostic role of serum extracellular domain (ECD) of HER-2/neu (s-HER2) in patients (PTS) with metastatic (M) breast cancer (BC): results of an observational study.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,18411
750,116216,TrialTroveID-116216,Triple combination of 3weekly trastuzumab (T) plus oral vinorelbine (VNR) and capecitabine (CAP) as first-line treatment in HER2-positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
751,115817,"JBCRG-10, JBCRG-10TR, TrialTroveID-115817, UMIN000002365",A phase II randomized study of neoadjuvant chemotherapy including trastuzumab + cyclophosphamide + docetaxel in patients with operable HER2 positive breast cancer (JBCRG 10),Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,"Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,18411
752,114857,"0905-982, CDR0000653173, GENENTECH-JHOC-J0947, J0947, JHOC-J0947, NA_00024527, NCI-2010-02004, NCT00971737, TrialTroveID-114857, US-0982","A Randomized, Open-Label Comparative Study of Combination Therapy With Cyclophosphamide and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine With or Without Trastuzumab for the Treatment of Metastatic Breast Cancer That Does NOT Over-express HER-2/Neu",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Roche/Genentech","Government, Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Immune Response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",Gene expression profiling,True,NCT00971737,18411
753,114649,"CADY, EU-20948, ICORG-08-01, NCT00968682, TrialTroveID-114649",Detection of Cardiac Dysfunction in Patients Treated With Trastuzumab for HER-2 Positive Breast Cancer. The CADY Study,Oncology,Oncology: Breast,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,,,True,NCT00968682,18411
754,114194,"EudraCT Number: 2008-007495-20, ML22056, NCT00964704, TrialTroveID-114194","A Single Arm, Open-label Study to Evaluate the Efficacy on Tumor Response and the Safety of Bevacizumab and Trastuzumab Combination and Sequential Capecitabine in Patients With HER2 +ve Locally Recurrent or Metastatic Breast Cancer After Early Relapse to Adjuvant Trastuzumab-containing Therapy.",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00964704,18411
755,113116,"CASE-4108, CASE4108-CC685, NCT00949247, TrialTroveID-113116","Docetaxel, Carboplatin, Trastuzumab and Bevacizumab (TCH+B) For Early-Stage HER-2/Neu(+) Breast Cancer and Bone Marrow Micrometastases",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"National Institutes of Health/National Cancer Institute, Case Western Reserve University","Government, Academic",Complete response,,True,NCT00949247,18411
756,113101,TrialTroveID-113101,"Radiosensitization of Chemotherapy-Refractory, Locally Advanced or Locally Recurrent Breast Cancer with Trastuzumab: A Phase II Trial.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Complete response,False,,18411
757,113038,"09-034, BO22227, BO22227 (HannaH), EudraCT Number: 2008-007326-19, HANNAH, NCT00950300, RECF1171, RO0452317, TrialTroveID-113038","A Phase III, Randomized Open-label Study to Compare the Pharmacokinetics, Efficacy and Safety of Subcutaneous (SC) Trastuzumab With Intravenous (IV) Trastuzumab Administered in Women With HER2-positive Early Breast Cancer (EBC)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Complete response,"Anti-drug antibodies, Area under the curve score, Cmax, Complete response, Event-free survival, Overall response rate, Overall survival, Partial response, Progressive disease rate, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Tmax",True,NCT00950300,18411
758,112838,TrialTroveID-112838,Evaluating the Use of Cardiac Biomarkers for Early Detection of Chemotherapy Induced Cardiotoxicity: A Pilot Study in a Minority Population.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Brain Natriuretic Peptide concentration,,False,,18411
759,112015,"0S-08-9, HS-09-00010, NCI-2010-00357, NCT00936364, TrialTroveID-112015",Short-Term Fasting Prior To Platinum-based Chemotherapy: Feasibility and Impact on Toxicity,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",University of Southern California,Academic,,Common Terminology Criteria for Adverse Events,True,NCT00936364,18411
760,110965,"20082223, GO01305, H4613g, Her-Q-Les, HERQLES, NCT00927589, TrialTroveID-110965, VICCPHI0910","A Phase Ib, Single-arm, Open-label Clinical Trial to Evaluate Corrected QT Interval and Drug-drug Interaction of Trastuzumab on Carboplatin in the Presence of Docetaxel in Patients With Metastatic Cancer.",Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Roche/Genentech","Government, Industry, Top 20 Pharma",,"Adverse Events, Serious Adverse Events",True,NCT00927589,18411
761,110748,TrialTroveID-110748,Trastuzumab Plus Capecitabine and Docetaxel as First-Line Therapy for Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Time to progression,,False,,18411
762,110731,"CLCC-THERAPY, EudraCT Number: 2008-003988-39, INCA-THERAPY, NCT00923299, RECF0910, THERAPY, TrialTroveID-110731, VA-2008/34",Phase I-II Study Evaluating Combined Treatment of Cetuximab and Trastuzumab in Metastatic Pancreatic Cancer Patients Progressing After Gemcitabine Based Chemotherapy,Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00923299,18411
763,110613,"2006-003390-27, CSET 1364, EudraCT 2006-003390-27, NCT01613482, RECF0442, TrialTroveID-110613, TSARINE, TSARINE 0602, TSARINE-0602",Interest of the Prophylactic Cerebral Radiotherapy in the Metastatic Breast Cancer Expressing HER2/NEU Treated by Trastuzumab,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Federation Nationale des Centres de Lutte contre le Cancer, (Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Cooperative Group, Academic, Industry, Top 20 Pharma",Magnetic Resonance Imaging,"EORTC Quality of Life Questionnaire, Mini Mental State Examination, Overall survival, Progression-free survival, Quality of Life",True,NCT01613482,18411
764,110436,"ASL1205/001, EudraCT Number: 2006-000413-37, HOT trial, HOT-ASL 1205/001, TrialTroveID-110436","Combination of Trastuzumab, Oxaliplatin, and Docetaxel as First-Line Treatment in HER2-positive Metastatic Breast Cancer Patients",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Quality of Life, Time to progression",False,,18411
765,110421,TrialTroveID-110421,"Adjuvant paclitaxel, capecitabine, and trastuzumab for HER-positive breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,18411
766,110420,TrialTroveID-110420,Comparison of Serum HER-2/neu Between Trastuzumab-Based Regimen and Anthyracycline-Based Regimen During Neoadjuvant Chemotherapy in Advanced Primary Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Partial response",,False,,18411
767,110211,"EudraCT Number: 2006-000392-15, ML18743, TrialTroveID-110211",Neoadjuvant Trastuzumab in a Sequential Nonanthracycline-Based Regimen for Patients with Stage II-III Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,Safety and Tolerability,False,,18411
768,110000,"NCT00912340, NU EM11B03, TrialTroveID-110000, WCI1524-08, WCI1524-08-HRMBC",Randomized Phase II Trial of Trastuzumab or Everolimus in Hormone-refractory Metastatic Breast Cancer,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Roche/Genentech","Academic, Industry, Top 20 Pharma","Overall response rate, Response rate","Clinical benefit rate, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00912340,18411
769,108866,TrialTroveID-108866,Epirubicin and cyclophosphamide (EC) followed by weekly paclitaxel with/without trastuzumab as primary systemic therapy in locally advanced breast cancer: Phase II study.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
770,108846,TrialTroveID-108846,Pathologic complete response (pCR) in HER2 positive breast cancer to sequential FEC 100-docetaxel (D) plus trastuzumab (T) neoadjuvant chemotherapy (NCT).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
771,108804,TrialTroveID-108804,"Phase II study of neoadjuvant treatment with docetaxel, capecitabine, and trastuzumab in HER-2-positive locally advanced or inflammatory breast cancer: TXH trial",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Response rate",False,,18411
772,108796,TrialTroveID-108796,Effect of Primary Polychemotherapy after Sentinel Lymph Node Biopsy on The Necessity for Lymphadenectomy in Stage II Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
773,108699,"15925B, CDR0000509417, J0524, JHOC-J0524, JHOC-SKCCC-J0524, NCT00899548, SKCCC-J0524, TrialTroveID-108699",DNA Methylation in Serum as a Predictive Marker of Progression and Survival Following Systemic Therapy in Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Government, Academic",,"Circulating Tumor Cells, Time to progression",True,NCT00899548,18411
774,108523,"06-163, MSKCC-06163, NCT00897702, TrialTroveID-108523",Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",Disease Progression,Disease Progression,True,NCT00897702,18411
775,108521,"CLCC-IC-2006-04, IC 2006-04, INCA-RECF0474, NCT00898014, RECF0474, TrialTroveID-108521",Study Evaluating the Prognostic and Predictive Value of Response to First-Line Chemotherapy by  Detection of Circulating Tumor Cells (CTC) in Patients with Metastatic Breast Cancer.,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Johnson & Johnson/Janssen Diagnostics {Veridex {Immunicon}}","Academic, Industry, Top 20 Pharma","Circulating Tumor Cells, Overall survival, Progression-free survival","Circulating Tumor Cells, Progression-free survival",True,NCT00898014,18411
776,107806,"GETNA 3, Getner 3, RECF0376, TrialTroveID-107806","Phase I, multicenter, open label study assessing the tolerance of chemotherapy consisting of the combination of weekly trastuzumab and chemotherapy every 3 weeks for 4 cycles FEC100-dexrazoxane followed by 4 cycles of docetaxel 100 intended for patients with breast cancer, metastatic or inflammatory overexpressing HER2 (FISH positive).",Oncology,Oncology: Breast,"Novartis, Pfizer, Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability",Complete response,False,,18411
777,107578,"EudraCT Number: 2008-004013-94, IRAS ID: 32499, MO22004, MO2204B, NCRN158, NCT00885755, SHERsig Study, TrialTroveID-107578, UKCRN 8331",A Prospective Study to Evaluate Alterations in Molecular Biomarkers in HER2 Neu Positive Metastatic Breast Cancer Together With Assessment of Trastuzumab Use Beyond Progression After Initial Response to Trastuzumab-taxane Based Treatment,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00885755,18411
778,107171,TrialTroveID-107171,Elevated pretreatment serum TIMP-1 level predicts reduced PFS and overall survival in trastuzumab-treated metastatic breast cancer patients.,Oncology,Oncology: Breast,"(Other Industry Sponsor), Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}","Industry, all other pharma, Not for Profit Funding Entity","Overall survival, Progression-free survival",,False,,18411
779,106381,"CATS, NCT00858039, TrialTroveID-106381, X08-0296",Prediction of Cardiotoxicity Using Serum N-Terminal Pro-B-Type Natriuretic Peptide in Breast Cancer Patients Receiving Adjuvant Trastuzumab,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,New York Heart Association Class,,True,NCT00858039,18411
780,106364,TrialTroveID-106364,"Cardiotoxicity of adjuvant trastuzumab in early stage, HER2-positive, breast cancer patients treated with prior adjuvant anthracyline-based chemotherapy.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
781,104888,"0810-953, J0885, JHOC-J0885, JHOC-NA_00021048, NA_00021048, NCT00847171, TrialTroveID-104888, US-0953","A Safety and Bioactivity Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for the Treatment of Patients With High Risk/ Metastatic HER-2/Neu- Overexpressing Breast Cancer With No Evidence of Disease",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Government, Academic","Common Terminology Criteria for Adverse Events, Immune Response, Safety and Tolerability","Progression-free survival, Time to progression",True,NCT00847171,18411
782,104742,"KBC-SG 0802, KBC-SG0802, TrialTroveID-104742, UMIN000001583","Feasibility study of adjuvant chemotherapy consisting of FEC (fluorouracil, epirubicin and cyclophosphamide) followed by DH (docetaxel+herceptin) for patients with HER2 positive breast cancer.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,,Safety and Tolerability,False,,18411
783,104481,"20080331, 20080331 - HERLAP, EudraCT No: 2008-001916-18, HERLAP, NCT00842998, TrialTroveID-104481","A Phase II, Randomized Trial With Single Agent Trastuzumab or Lapatinib in Patients With Metastatic HER2-Overexpressing Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Duration of overall response, Time to progression",True,NCT00842998,18411
784,103177,"BRE 139, BRE 139 IIT, NCT00821886, SCRI BRE 139, TrialTroveID-103177",Phase II Study of Neoadjuvant Ixabepilone/Carboplatin/Trastuzumab in HER2-Positive Locally Advanced Breast Cancer,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT00821886,18411
785,103109,"N083E, NCCTG-N083E, NCI-2009-00671, NCT00820872, TrialTroveID-103109",Phase II Safety Study of Docetaxel and Carboplatin in Combination With Trastuzumab and Lapatinib in Early Breast Cancer.,Oncology,Oncology: Breast,"GlaxoSmithKline, North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Breast Cancer Research Foundation, Alliance for Clinical Trials in Oncology","Industry, Top 20 Pharma, Cooperative Group, Government, Not for Profit Funding Entity, Cooperative Group","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability",True,NCT00820872,18411
786,102252,"EudraCT Number: 2008-003283-20, HAX, MO21926, NCT00811135, RECF1069, TrialTroveID-102252","A Single Arm Open-label, Phase II Study of Bevacizumab in Combination With Trastuzumab and Capecitabine as First-line Treatment of Patients With HER2-positive Locally Recurrent or Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Time to progression",True,NCT00811135,18411
787,102171,"IIT_H446Us, NCT00810017, TrialTroveID-102171",Phase II Clinical Study Combining Trastuzumab with Etoposide in Treatment of HER2-Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Washington Hospital Center","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Overall response rate, Treatment Emergent Adverse Events","Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Stable Disease, Time to progression",True,NCT00810017,18411
788,102133,TrialTroveID-102133,Immunoglobulin G fragment C gamma receptor (FcGR) polymorphisms and efficacy of single-agent trastuzumab in patients treated with metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate",,False,,18411
789,102018,"JO17360, TrialTroveID-102018",Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Overall survival, Progression-free survival, Progressive disease rate","Adverse Events, Overall response rate, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
790,101363,"BP22023, BP22023/A, NCT00800436, TrialTroveID-101363","An Open-Label, Two-Part, Multi-Centre, Trastuzumab Dose-Finding Study in Healthy Male Volunteers and HER2 Positive Female Patients",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Area under the curve score,"Cmax, Elimination half-life, Tmax",True,NCT00800436,18411
791,101228,"102,624, 20110724, CASE-10107, CASE-10107-CC443, H4234s, NCT00796978, TrialTroveID-101228",Safety and Efficacy of Single Agent Adjuvant Trastuzumab (Herceptin) in Older Women With Early-Stage and Locally Advanced Breast Cancer: A Phase II Trial,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Roche/Genentech","Government, Industry, Top 20 Pharma",Congestive heart failure,"Disease-free survival, Overall survival, Quality of Life",True,NCT00796978,18411
792,100995,"09-109, CASE 4107-CC385, CASE4107, CASE-4107, NCT00795678, TrialTroveID-100995",Clinical Study to Assess Entry of Chemotherapeutic Agents Into Brain Metastases in Women With Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, US Department of Defense","Academic, Government, Government",Hemoglobin level,,True,NCT00795678,18411
793,98732,"08-307, 0974/B-43, 09F.20, 101312, B-43, B-43, CTSU/NSABP B-43, CTSUBRENB-43-M, NCI-2009-00702, NCT00769379, NSABP B-43, NSABP B-43 (RTOG 0974 Endorsed), NSABPB43, NSABP-B43, NSABP-B-43, NSABP-B-43-CC, RTOG 0974, RTOG/NSABP B-43, STU 032012-023, SU-03172009-2001, TrialTroveID-098732",A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently With Radiation Therapy and Radiation Therapy Alone for Women With HER2-Positive Ductal Carcinoma In Situ Resected by Lumpectomy,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Surgical Adjuvant Breast and Bowel Project (NSABP), National Institutes of Health/National Cancer Institute, NRG Oncology","Industry, Top 20 Pharma, Cooperative Group, Government, Cooperative Group",Recurrence,"Disease-free survival, Overall survival, Recurrence",True,NCT00769379,18411
794,98728,"146708, C40601, CALGB (Alliance) 40601, CALGB 40601, CALGB 40601 (Alliance), CALGB-40601, CTSU/CALGB-40601, MSKCC 10-076, NCI-2009-01073, NCT00770809, TrialTroveID-098728",Randomized Phase III Trial of Paclitaxel +Trastuzumab + Lapatinib Versus Paclitaxel + Trastuzumab As Neoadjuvant Treatment Of HER2-Positive Primary Breast Cancer,Oncology,Oncology: Breast,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall response rate, Overall survival, Partial response, Recurrence, Response evaluation criteria in solid tumors, Response rate",True,NCT00770809,18411
795,98646,"EudraCT Number:2008-000987-18, M08TRA, NCT00768859, TRAIN, TrialTroveID-098646",Trastuzumab in a Neo-adjuvant Regimen for HER2+ Breast Cancer - the TRAIN Study,Oncology,Oncology: Breast,Netherlands Cancer Institute,Government,Complete response,"Complete response, Event-free survival, Gene expression profiling, Overall survival",True,NCT00768859,18411
796,98368,TrialTroveID-098368,Oral vinorelbine in metastatic breast cancer - The Vienna experience,Oncology,Oncology: Breast,Medical University of Vienna,Academic,Time to progression,"Clinical benefit rate, Overall survival",False,,18411
797,97835,"EudraCT Number: 2007-003709-29, MO20509, NCT00758134, ONC-2007-001, TrialTroveID-097835","Prospective Phase II Trial Evaluating Efficacy of Trastuzumab Therapy in HER2 FISH Positive and/or HER2 Mutation Positive, Pretreated, Non-Small Cell Lung Cancer Patients (MO20509)",Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma","Overall response rate, Response rate","Overall survival, Safety and Tolerability, Time to progression",True,NCT00758134,18411
798,97104,"2008-03 HAT, 3483, BOOG 2008-03, C2009-4398, CKTO 2009-4398, Eudract Number: 2008-003834-12, HAT, KWF 2009-4398, M08HAT METC, NL23763.031.08, NTR 3483, NTR1349, PTC09.0140, PTC09.0140/M08HAT, TrialTroveID-097104","A randomized phase II study of concomitant trastuzumab, bevacizumab with paclitaxel versus trastuzumab and bevacizumab followed by the combination of trastuzumab, bevacizumab and paclitaxel at progression as first-line treatment of patients with metastatic breast cancer with HER2-neu overexpression",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma","Overall survival, Progression-free survival","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Stable Disease",False,,18411
799,96231,"NCT00740532, ONC/OSS-01/2007, TrialTroveID-096231",Observational Study Assessing Molecular Features Predicting Response/Resistance to Trastuzumab in Metastatic Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,Time to progression,True,NCT00740532,18411
800,95073,"HUM00016828, NCT00726180, TrialTroveID-095073, UMCC 2007.130","Evaluation of the Use of Trastuzumab to Induce Increased ER Expression in ER-Negative/Low, Her-2/Neu Positive Breast Cancer.",Oncology,Oncology: Breast,University of Michigan Comprehensive Cancer Center,Academic,"Overall response rate, Response rate",,True,NCT00726180,18411
801,94914,"BRD04/2-T, CHU Nantes#BRD04/2-T, NCT00724360, RECF0820, TrialTroveID-094914",A Phase II Trial Evaluating the Safety and the Efficacy of Trastuzumab in Relapsed/Refractory HER2 Positive B-Acute Lymphoblastic Leukemia Patients.,Oncology,"Oncology: Leukemia, Acute Lymphocytic",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response rate","Cytogenetic response, Disease-free survival, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT00724360,18411
802,94242,"BEVERLY 2, EudraCT Number: 2008-000783-16, ML21531, NCT00717405, RECF0829, RLI_ML21531, TrialTroveID-094242",An Open Label Study to Assess the Rate of Pathological Complete Response in Patients With Primary Inflammatory HER2-positive Breast Cancer Treated With Avastin + Herceptin Based Chemotherapy,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Complete response,"Common Terminology Criteria for Adverse Events, Disease-free survival, Overall response rate, Overall survival, Recurrence, Safety and Tolerability",True,NCT00717405,18411
803,93990,"PMDA 18-3806, TrialTroveID-093990, UMIN000000651",Randomized Phase II Study of Neoadjuvant Chemotherapy and Trastuzumab (Herceptin) for Operable Breast Cancer with Overexpression of HER2,Oncology,Oncology: Breast,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Japanese Ministry of Health, Labour and Welfare","Academic, Government","Complete response, Disease-free survival, Overall survival","Adverse Events, Complete response, Disease-free survival, Safety and Tolerability",False,,18411
804,93943,"GOG #0181-B, GOG 181B, GOG-0181B, GOG-0181-B, NCT00006089, TrialTroveID-093943, WSU #G-2243","A Phase II Evaluation of Trastuzumab (MoAb HER2) in Patients With Advanced, Recurrent or Persistent Endometrial Carcinoma With or Without Prior Chemotherapy.",Oncology,Oncology: Endometrial,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Overall response rate - duration,"Overall survival, Progression-free survival",True,NCT00006089,18411
805,93684,"10228, EudraCT Number: 2007-006060-29, FARM6N78KN, GIM7-DOT Study, TrialTroveID-093684",Efficacy and Toxicity of Trastuzumab at the Maintaining Dose of 1 mg/kg/week vs Standard Dose of 2 mg/kg/week in Association with Chemotherapy in the Treatment of HER-2 Positive Metastatic Breast Cancer. Phase III Multicenter Study.,Oncology,Oncology: Breast,"Istituto Nazionale per la Ricerca sul Cancro, (Other government agency)","Academic, Government",Progression-free survival,"Overall response rate, Overall survival, Response rate",False,,18411
806,93667,"BRTTRA1Y, TrialTroveID-093667",Pilot study into Trastuzumab pharmacokinetics in women completing one year of adjuvant therapy.,Oncology,Oncology: Breast,British Columbia Cancer Agency,Government,Elimination half-life,,False,,18411
807,93657,"BRTTRA4W, TrialTroveID-093657",Pilot Pharmacokinetics Study of Trastuzumab Trough Levels with a Four Weekly or Longer Administration Schedule in Metastatic Breast Cancer.,Oncology,Oncology: Breast,British Columbia Cancer Agency,Government,,,False,,18411
808,93359,TrialTroveID-093359,Use of total HER2 and HER2 homodimer levels to predict response to trastuzumab.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Recurrence,,False,,18411
809,92658,"EudraCT Number: 2005-005669-12, TrialTroveID-092658","A dose-finding study of PTK787/ZK222584 (PTK/ZK) in combination with weekly vinorelbine (V) and trastuzumab (T) as treatment of patients with metastatic breast cancer (MBC) overexpressing HER-2/neu, previously treated with at least one line of chemotherapy (CT).",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,Safety and Tolerability,False,,18411
810,92577,TrialTroveID-092577,Trastuzumab plus gemcitabine and cisplatin chemotherapy for HER2/neu-overexpressing breast cancer with visceral metastasis.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
811,90988,TrialTroveID-090988,Nail changes induced by weekly paclitaxel as a surrogate marker for response assessment in patients with metastatic breast cancer,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,18411
812,90742,TrialTroveID-090742,HER2 guided neoadjuvant treatment of advanced breast cancer: Clinico-biological correlations.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
813,90695,"J0805, J-0805, NA_00015271, NCT00681993, PBI 2.0, TrialTroveID-090695",A Feasibility Trial of Partial Breast Irradiation With Various Concurrent Chemotherapy Regimens (PBIC),Oncology,Oncology: Breast,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Breast Cancer Research Foundation","Academic, Not for Profit Funding Entity",Common Terminology Criteria for Adverse Events,"Clinical benefit rate, Recurrence",True,NCT00681993,18411
814,90640,TrialTroveID-090640,Patterns of relapse during adjuvant trastuzumab therapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
815,90438,"Cardiotox_001, NCT00679874, TrialTroveID-090438",Characterization of the Cardiotoxic Effects of Chemotherapies With Anthracyclines and Trastuzumab for Breast Cancer by Contrast-Enhanced Cardiovascular Magnetic Resonance Imaging (CMR).,Oncology,Oncology: Breast,University of Calgary,Academic,,,True,NCT00679874,18411
816,90066,"2005/35, CALACASS-2005/35, CALACASS-PHRC 2005 Herceptine, INCA-RECF0618, NCT00896376, Nice CLCC # 2005/35 PHRC 2005 Herceptin, Nice Test No. 2, RECF0618, TrialTroveID-090066",Prospective Multicenter Study of Genetic Factors Predictive of the Pharmacodynamics of Trastuzumab in Patients With Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,,True,NCT00896376,18411
817,89688,"07-214, NCT00670982, TrialTroveID-089688","Phase II Study of Bevacizumab in Combination with Vinorelbine and Trastuzumab for HER2-Positive, Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, (Other Hospital/Academic/Medical Center), Brigham and Womens Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic, Academic, Academic","Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00670982,18411
818,89000,TrialTroveID-089000,A Phase III Trial of Herceptin in Patients with HER2-Positive Breast Cancer,Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma",,,False,,18411
819,87922,"NCT00657345, TrialTroveID-087922, UM200801",IRS Proteins and Trastuzumab Resistance.,Oncology,Oncology: Breast,University of Massachusetts Medical Center,Academic,,,True,NCT00657345,18411
820,86170,"EudraCT Number: 2007-005021-30, FARM5P8YFC, NCT00637325, TOP, TrialTroveID-086170",TOP Trial. A Randomised Phase III Clinical Trial of Trastuzumab (Herceptin) Optimization in Patients With Locally Advanced and/or Metastatic Breast Cancer Overexpressing HER2 After a First Line Chemotherapy Plus Trastuzumab.,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Overall survival, Progression-free survival","Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00637325,18411
821,85109,"AOUMODENA-SHORT-HER, EU-20825, EudraCT Number: 2007-004326-25, FARM62MC97, NCT00629278, Short-HER, SHORT-HER, Shorther 2007-004326-25, TrialTroveID-085109",SHORT-HER: Multicentric Randomised Phase III Trial of 2 Different Adjuvant Chemotherapy Regimens Plus 3 Vs 12 Months of Trastuzumab In Her2 Positive Breast Cancer Patients.,Oncology,Oncology: Breast,Azienda Ospedaliera San Sebastiano,Academic,"Disease-free survival, Overall survival","Common Terminology Criteria for Adverse Events, Cumulative Incidence of Relapse",True,NCT00629278,18411
822,84377,"2007-6084, 20990234, HS#2007-6084, NCI-2010-00155, NCT00618657, TrialTroveID-084377, UCI 07-61, UCI-07-61","A Phase II Study of Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-) in the Neoadjuvant Setting",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, National Institutes of Health, University of California Medical Center, Irvine","Government, Government, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Progression-free survival, Response rate","Area under the curve score, Complete response, Magnetic Resonance Imaging, NCI-CTC scale",True,NCT00618657,18411
823,84329,"11135, 211B, BrUOG 211B, BrUOG BR-211B, BrUOG-BR-211B, HIC 0705002672, NCT00617942, TrialTroveID-084329",BrUOG-BR-211B q3week Carboplatin With Weekly Abraxane and Trastuzumab As Neoadjuvant Therapy in Resectable and Unresectable HER2+ (Stage IIa-IIIb) Breast Cancer,Oncology,Oncology: Breast,"Brown University Oncology Group, Yale University","Cooperative Group, Academic","Complete response, Minimal Residual Disease, Overall response rate, Response rate",,True,NCT00617942,18411
824,83970,"CT/04.23, NCT00615602, TrialTroveID-083970",A Multicenter Randomized Phase III Study Comparing 6 Versus 12 Months of Trastuzumab in Combination With Dose Dense Docetaxel Following FE75C as Adjuvant Treatment of Women With Axillary Lymph Node Positive Breast Cancer Overexpressing HER2,Oncology,Oncology: Breast,"Hellenic Oncology Research Group, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Disease-free survival,"Overall survival, Quality of Life, Recurrence",True,NCT00615602,18411
825,82785,"GOG-160, MCC-11333, TrialTroveID-082785","Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group",Oncology,Oncology: (N/A); Oncology: Ovarian,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Overall response rate,Progression-free survival,False,,18411
826,82299,"09-157, BIG 1-010 SOLD, CRUKE/10/033, CTBE2012000095, EudraCT number: 2007-002016-26, FBCSG-01-2007, NCT00593697, SOLD, TrialTroveID-082299, UKCRN ID: 9751","A Randomized Phase III Study Comparing Trastuzumab Plus Docetaxel (HT) Followed by 5-FU, Epirubicin, and Cyclophosphamide (FEC) to the Same Regimen Followed by Single-agent Trastuzumab as Adjuvant Treatments for Early Breast Cancer, , The Synergism Or Long Duration (SOLD) Study",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis}, Helsinki University, Finnish Breast Cancer Group, (Other government agency)","Industry, Top 20 Pharma, Academic, Cooperative Group, Government","Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Congestive heart failure, Disease-free survival, Myocardial infarction (safety), Myocardial infarction, Overall survival, Quality of Life, Recurrence, Safety and Tolerability",True,NCT00593697,18411
827,81622,TrialTroveID-081622,HER-2 positive inflammatory breast cancer: high pathological response rate with trastuzumab-based neoadjuvant therapy.,Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas",Academic,Complete response,,False,,18411
828,81199,TrialTroveID-081199,The initial response of circulating epithelial tumor cells to primary systemic chemotherapy in breast cancer is highly predictive for final tumor reduction and outcome.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
829,80952,TrialTroveID-080952,Significance of Akt activation and compartmentalization for prediction of outcome in Her-2 positive breast cancer patients treated with trastuzumab.,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Czech Republic Ministry of Health","Academic, Government",,,False,,18411
830,80912,"Mamma-HER2, TrialTroveID-080912",Safety and tolerability of sequential treatment with Epirubicin followed by Taxol and Herceptin in patients with metastatic breast cancer and HER2 overexpression,Oncology,Oncology: Breast,Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie Group,Cooperative Group,Adverse Events,,False,,18411
831,80897,TrialTroveID-080897,A phase II study of trastuzumab and paclitaxel either as first or second line chemotherapy in patients with HER2 positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
832,80785,TrialTroveID-080785,Increased b1 integrin expression is a predictor of trastuzumab resistance in HER-2 overexpressing metastatic breast cancer patients.,Oncology,Oncology: Breast,University of Alberta,Academic,,,False,,18411
833,78595,"BCCA BRTTRA46, TrialTroveID-078595",A Pilot Pharmacokinetic Study of Four and Six weekly cycles of Trastuzumab for metastatic breast cancer.,Oncology,Oncology: Breast,British Columbia Cancer Agency,Government,,,False,,18411
834,78026,"2006-0638, NCI-2012-01552, NCT00543504, TrialTroveID-078026","A Phase I Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib.",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00543504,18411
835,77620,"00007235, 07-199, 077538, 201102387, APT, BRE 143 IST, DFCI-07-199, J07135, MSKCC-08-017, NCT00542451, SIEG002547HE, TrialTroveID-077620",A Phase II Trial of Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2-Positive Breast Cancer,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Womens Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic",Disease-free survival,"Congestive heart failure, Disease-free survival, Overall survival, Recurrence",True,NCT00542451,18411
836,76857,"GORG-001, NCT00535509, RAC #2061-048, TrialTroveID-076857",Phase II Trial of Neoadjuvant[FEC100]/Cisplatin-Docetaxel + or - Trastuzumab in Women With Over Expressed or Amplified Her2/Neu With Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability","Disease-free survival, Overall survival",True,NCT00535509,18411
837,76732,"INCAN/CC/095/06, MEX-INC-INCAN-CC-09506, NCT00533936, TrialTroveID-076732",Adjuvant Trastuzumab vs Observation in Locally Advanced Breast Cancer Treated with Neoadjuvant Trastuzumab.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,"Complete response, Disease-free survival","Overall survival, Safety and Tolerability",True,NCT00533936,18411
838,75218,"M77004, TrialTroveID-075218",Pharmacokinetic Study of Herceptin (H) and Doxorubicin (A) plus Paclitaxel (T) followed by weekly Paclitaxel (AT+/-H?TH) in Women with Metastatic Breast Cancer and HER2 Overexpression.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Complete response, Overall response rate, Partial response, Response rate, Safety and Tolerability, Time to progression, Vital signs",,False,,18411
839,74738,TrialTroveID-074738,"Phase III Multinational, Multi-centric, Open, Controlled, Randomized Parallel Group Study of Gemcitabine Versus Herceptin + Gemcitabine with Metastatic or Locally Advanced Pancreatic Carcinoma.",Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
840,74084,"ACOSOG Z1041, ACOSOGZ1041, ACOSOG-Z1041, ACOSOG-Z1041 A1, Alliance, CTSU Z1041, MUSC 101161, NCI-2009-00341, NCT00513292, TrialTroveID-074084, Z1041",A Randomized Phase III Trial Comparing a Neoadjuvant Regimen of FEC-75 Followed by Paclitaxel Plus Trastuzumab With a Neoadjuvant Regimen of Paclitaxel Plus Trastuzumab Followed by FEC-75 Plus Trastuzumab in Patients With HER-2 Positive Operable Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group",Complete response,"Complete response, Disease-free survival, Overall response rate, Overall survival, Recurrence",True,NCT00513292,18411
841,72422,"KCSG-BR07-01, NCCCTS-06-235, NCT00532857, TrialTroveID-072422","Phase II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Trastuzumab in Patients With HER2 Positive Operable Breast Cancer",Oncology,Oncology: Breast,"National Cancer Center - Goyang, Korea",Government,"Complete response, Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability","Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability",True,NCT00532857,18411
842,71926,TrialTroveID-071926,HER2-positive breast cancer cells percentage and progression to trastuzumab treatment in metastatic patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall survival, Time to progression",,False,,18411
843,71872,TrialTroveID-071872,Phase II of trastuzumab and cisplatin in patients with advanced gastric cancer (AGC) with HER2/neu overexpression/amplification.,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
844,71855,TrialTroveID-071855,HER2 expression and HER2:HER2 dimerization identifies subpopulations of metastatic breast cancer patients with different probabilities of long-term survival following trastuzumab treatment and with different requirements for concomitant chemotherapy.,Oncology,Oncology: Breast,(Other Industry Sponsor),"Industry, all other pharma","Overall survival, Time to progression",,False,,18411
845,71577,TrialTroveID-071577,Combined neoadjuvant weekly paclitaxel and trastuzumab for HER2-overexpressing breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Overall survival,False,,18411
846,71566,TrialTroveID-071566,Trastuzumab (T) plus capecitabine (C) in heavily pretreated patients (pts) with advanced breast cancer (ABC).,Oncology,Oncology: Breast,Austrian Breast & Colorectal Cancer Study Group,Cooperative Group,Time to progression,,False,,18411
847,71561,TrialTroveID-071561,Correlation between natural killer cells function and response to trastuzumab in metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
848,71560,TrialTroveID-071560,"Phase II study of docetaxel, carboplatin and trastuzumab (THC) in patients with locally advanced breast cancer in neo-adjuvant setting.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Circulating Tumor Cells,,False,,18411
849,71478,"P 02649, TrialTroveID-071478",Phase II study of combination of Caelyx (Pegliposomales doxorubicin) and Herceptin (Trastuzumab) in the first - and second-line treatment of metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Disease-free survival,False,,18411
850,71229,"HERCEPT â NAVEL, RECF0418, TrialTroveID-071229",Efficacy and Safety of Trastuzumab Plus Vinorelbine as Second-line Treatment for Women with HER2-positive Metastatic Breast Cancer Beyond Disease Progression,Oncology,Oncology: Breast,"Federation Nationale des Centres de Lutte contre le Cancer, Pierre Fabre, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, all other pharma, Industry, Top 20 Pharma",Overall response rate,"Overall survival, Time to progression, Time to treatment failure",False,,18411
851,71179,TrialTroveID-071179,Phase II trial of vinorelbine (V) days 1+8 every 3 weeks and trastuzumab (T) weekly as first-line chemotherapy for HER2+ metastatic breast cancer (MBC).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Time to progression",False,,18411
852,71168,TrialTroveID-071168,"EGFR, MAPK, and Akt status by immunohistochemistry (IHC) are not correlated with clinical outcome in HER2-positive (HER2+) metastatic breast cancer (MBC) patients (pts) treated with trastuzumab (T) with or without chemotherapy (CT).",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
853,71070,TrialTroveID-071070,Dose Scheduling and Pharmacokinetic (PK) Study of Trastuzumab in Patients (pts) with HER2/neu Overexpressing Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
854,71018,TrialTroveID-071018,Cardiotoxicity of weekly trastuzumab (T) plus epirubicin (E) and paclitaxel (P) for HER2-posit ive locally advanced (LA) and/or metastatic (M) breast cancer (BC): A feasibility phase II study.,Oncology,Oncology: Breast,"Regina Elena National Cancer Institute, Rome, Italy",Academic,,,False,,18411
855,71010,TrialTroveID-071010,Effect of Early Detection of Occult Brain Metastases in HER2-Positive Breast Cancer Patients on Survival.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall survival",,False,,18411
856,70971,TrialTroveID-070971,Results of trastuzumab targeted therapy in metastatic breast cancer (MBC): The Sultanate of Oman experience 2002-2006.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response rate",,False,,18411
857,70591,TrialTroveID-070591,Assessment of pathological complete response (pCR) to neoadjuvant dose-dense chemotherapy in HER2+ patients with locally advanced breast cancer (LABC) treated with trastuzumab (T) compared with HER2+ and HER2- patients treated without trastuzumab.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
858,70540,TrialTroveID-070540,A phase II combination trial of bevacizumab and anti-HER2 therapy in breast cancer,Oncology,Oncology: Breast,Memorial Sloan-Kettering Cancer Center,Academic,,,False,,18411
859,70043,"2006-0851, 3G-07-5, 7756, MDA-2006-0851, NCI 7756, NCI-2009-00217, NCT00478140, NSC 688097, P30CA016672, TrialTroveID-070043",A Phase II Study Trastuzumab (NSC 688097) in Her2/Neu Positive Cancer of the Gallbladder or Biliary Tract (NCI 7756),Oncology,Oncology: Liver,National Institutes of Health/National Cancer Institute,Government,"Complete response, Disease Progression, Overall response rate - duration, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT00478140,18411
860,69436,"2611, EudraCT Number: 2007-003156-11, GOIM 2611, TrialTroveID-069436","Docetaxel, Gemcitabine and Herceptin in Advanced Breast Cancer. A GOIM Phase II Study.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Clinical benefit rate, Duration of overall response, Overall survival, Time to progression",False,,18411
861,69322,"2606 B, EudraCT Number: 2006-007089-12, GOIM 2606 B, TrialTroveID-069322",Pegylated Liposomal Doxorubicin Hydrochloride and Trastuzumab in the First Line Treatment of Metastatic HER2 Positive Breast Carcinoma in Elderly Women,Oncology,Oncology: Breast,Southern Italy Cooperative Oncology Group,Cooperative Group,,"Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Time to progression",False,,18411
862,68144,"CINJ 040704, FP-NSABP FB-5, HSR-07-0801, NCT00464646, NSABP FB-5, TrialTroveID-068144",A Phase II Clinical Trial of Epirubicin Plus Cyclophosphamide Followed by Docetaxel Plus Trastuzumab and Bevacizumab Given as Neoadjuvant Therapy for HER2-Positive Locally Advanced Breast Cancer or Given as Adjuvant Therapy for HER2-Positive Pathologic Stage III Breast Cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Surgical Adjuvant Breast and Bowel Project (NSABP)","Industry, Top 20 Pharma, Cooperative Group","Complete response, Congestive heart failure, New York Heart Association Class","Complete response, Disease-free survival, Overall survival, Recurrence",True,NCT00464646,18411
863,66988,"RPCI 50905, TrialTroveID-066988, UTCIH3074s","A Multicenter, Open-Label, Single Arm Phase II Trial Investigating the Efficacy and Tolerability of Vinorelbine, Carboplatin and Trastuzumab for the First-Line Treatment of Metastatic Breast Cancer in Women with HER2+ Disease.",Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma",,,False,,18411
864,66822,"CT/03.08, NCT00453635, TrialTroveID-066822","A Multicenter Randomized Phase II Study of First Line Treatment With Sequential Administration of Docetaxel, Carboplatin and Herceptin Versus the Administration of Vinorelbine and Herceptin Combination in HER-2 Positive Patients With Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Hellenic Oncology Research Group, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Time to progression,Overall survival,True,NCT00453635,18411
865,65950,TrialTroveID-065950,"A Phase I/II study of KOS-862 (epothilone D), administered intravenously weekly for 3 weeks every 4 weeks in combination with weekly Herceptin in patients with HER-2 overexpressing locally advanced or metastatic solid tumours.",Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,"Bristol-Myers Squibb {Kosan Biosciences}, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,,False,,18411
866,65939,"EudraCT Number: 2004-000748-26, PM0259CA215B0, TrialTroveID-065939","An international multicentre phase II trial of oral vinorelbine in combination with Xeloda, and Herceptin as first line therapy in women with previously untreated HER2 positive metastatic breast cancer.",Oncology,Oncology: Breast,"Pierre Fabre, Roche {F. Hoffmann-La Roche}","Industry, all other pharma, Industry, Top 20 Pharma",Overall response rate,"Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,18411
867,65416,"BIH-99-12, BIH-W-99-0053-FB, NCI-V00-1610, NCT00006123, TrialTroveID-065416",Autotransplantation and Her 2 Neu Antibody Immunotherapy in Advanced Breast Cancer.,Oncology,Oncology: Breast,Beth Israel Deaconess Medical Center,Academic,"Disease-free survival, Minimal Residual Disease, Safety and Tolerability, Time to progression",,True,NCT00006123,18411
868,65306,"CT/03.09, NCT00440622, TrialTroveID-065306",A Multicenter Randomized Phase III Study of Gemcitabine Plus Herceptin Combination Versus the Capecitabine Plus Herceptin Combination in Pretreated Patients With HER-2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Hellenic Oncology Research Group, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Time to progression,Overall survival,True,NCT00440622,18411
869,65158,TrialTroveID-065158,"Phase 2 Trial of Neoadjuvant Chemotherapy with 5-Fluorouracil, Epirubicin and Cyclophosphamide (FEC100) followed by Docetaxel and Carboplatin and Herceptin (tch) for her-2 Overexpressing Locally Advanced Breast Cancer.",Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,,False,,18411
870,64499,"06/303/98, 07/MRE08/35, EU-20857, EudraCT Number: 2006-007018-39, HTA 06/303/98, ISRCTN52968807, MREC 07/MRE08/35, MREC-PERSEPHONE, N0051199166, NCT00712140, PERSEPHONE, TrialTroveID-064499, UKCRN Study ID 4078, WMS-PERSEPHONE",Persephone: Duration of Trastuzumab With Chemotherapy in Women With Early Stage Breast Cancer: Six Months Versus Twelve,Oncology,Oncology: Breast,"National Health Service (NHS) - UK, (Other Hospital/Academic/Medical Center), University of Cambridge","Government, Academic, Academic","Disease-free survival, Overall survival","Cost effectiveness, Health economic assessment, Overall survival, Quality of Life, Quality-adjusted life year",True,NCT00712140,18411
871,64390,"CETRA, EudraCT number: 2006-003993-85, NCT00434031, TrialTroveID-064390","Neoadjuvant Therapy With Trastuzumab and Docetaxel Followed by Trastuzumab, Caelyx (Liposomal Doxorubicin) and Cyclophosphamide in Operable or Locally Advanced Her-2 Positive Breast Cancer.",Oncology,Oncology: Breast,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,"Complete response, Overall response rate, Response rate",,True,NCT00434031,18411
872,64208,TrialTroveID-064208,"Phase II study of Liposomal doxorubicin (Myocet), Docetaxel (taxotere) and Trastuzumab (Herceptin) as first line therapy in patients with metastatic breast cancer",Oncology,Oncology: Breast,"Perrigo Company {Elan}}, Sanofi {Sanofi-Aventis}","Industry, all other pharma, Industry, Top 20 Pharma",Progression-free survival,,False,,18411
873,64153,"EudraCT Number: 2006-003994-28, NCT00431704, TrialTroveID-064153, VinCAT","Vinorelbine, Carboplatin and Trastuzumab in Advanced Her-2 Positive Breast Cancer, a Phase II Study",Oncology,Oncology: Breast,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,"Overall response rate, Safety and Tolerability","Overall survival, Time to progression",True,NCT00431704,18411
874,63909,"0413, HERNATA, NCT00430001, TrialTroveID-063909",A Randomised Phase III Study of Trastuzumab-Docetaxel vs Trastuzumab-Vinorelbine as First Line Therapy for Patients With Metastatic HER2 Positive Breast Cancer.,Oncology,Oncology: Breast,"Danish Breast Cancer Cooperative Group, Pierre Fabre, Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Cooperative Group, Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease-free survival, Time to progression","Duration of overall response, Overall response rate, Overall survival, Response rate, Time to response, Time to treatment failure",True,NCT00430001,18411
875,63836,"CT/01.60, NCT00429247, TrialTroveID-063836",A Pilot Randomized Phase II Study of Adjuvant Administration of Trastuzumab (HERCEPTIN) Versus Observation After the Completion of Adjuvant Chemotherapy and Radiotherapy in Patients With Stage I-III Breast Cancer Who Have Detectable Disseminated and/or Circulating Tumor Cells (DTCs and/or CTCs) in the Bone Marrow or/and the Peripheral Blood Before or/and After the Completion of Adjuvant Treatment.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall response rate - duration","Circulating Tumor Cells, Elimination rate",True,NCT00429247,18411
876,63740,"08-053, NCI-2011-03219, NCT00428922, OSU-06027, TrialTroveID-063740","Phase II Trial of Trastuzumab (Herceptin), Bevacizumab, and Docetaxel (Taxotere) Trial in Stage IV Metastatic Breast Cancer (MBC) Patients.",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, (Other Academic Cancer Center), University of Pittsburgh","Industry, Top 20 Pharma, Academic, Academic","Progression-free survival, Safety and Tolerability","Circulating Tumor Cells, Clinical benefit rate, Complete response, Magnetic Resonance Imaging, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00428922,18411
877,63520,"98-286, DFCI-98286, NCI-G99-1628, NCT00004163, TrialTroveID-063520",Phase II Study of Trastuzumab (Herceptin) in Patients With Advanced or Metastatic Salivary Gland Cancer,Oncology,Oncology: Head/Neck,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Government, Academic","Overall response rate, Response rate",Time to progression,True,NCT00004163,18411
878,63454,"H3754s, IRB 06-05-104, NCT00427427, TrialTroveID-063454",A Phase II Trial of Delayed Adjuvant Herceptin in Patients With HER-2 Positive Breast Cancer.,Oncology,Oncology: Breast,University of California Los Angeles,Academic,,Overall survival,True,NCT00427427,18411
879,63233,TrialTroveID-063233,PTEN and phospho-MAP kinase are independent predictors of response only in metastatic breast cancer patients treated with trastuzumab plus chemotherapy as first-line option.,Oncology,Oncology: Breast,(Other government agency),Government,,,False,,18411
880,63114,"ISRCTN10059974, Remagus 0002, REMAGUS 02, REMAGUS02, REMAGUS-02, TrialTroveID-063114",A Randomised Phase II Study of Cytotoxic Chemotherapy or Cytotoxic Chemotherapy Combined with Celecoxib or Trastuzumab as Primary Chemotherapy for Patients with High Risk Localised Breast Cancer Not Amenable to Breast Conserving Therapy,Oncology,Oncology: Breast,"Pfizer, Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}, (Other government agency)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government","Complete response, Overall response rate, Response rate","Overall response rate, Safety and Tolerability",False,,18411
881,62709,"CALGB-9661, CLB-9661, NCT00002994, TrialTroveID-062709",A Pilot Study of Low-Dose Interleukin-2 Plus Recombinant Human Anti-HER2 Monoclonal Antibody in Solid Tumors.,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian","Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",,,True,NCT00002994,18411
882,62474,TrialTroveID-062474,Trastuzumab and oral vinorelbine ( endocrine therapy) as primary therapy in patients (pts) with HER-2/neu positive breast cancer.,Oncology,Oncology: Breast,European Institute of Oncology,Government,Complete response,,False,,18411
883,61881,TrialTroveID-061881,Serum HER2/nue extra-cellualar domain level predicts clinical response in the patients treated with sequential trastuzumab monotherapy and combination with chemotherapy.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
884,61779,"M77022, TrialTroveID-061779",Trastuzumab (Ro 45-2317) in combination with epirubicin and docetaxel as first-line chemotherapy in metastatic breast cancer patients.,Oncology,Oncology: Breast,Roche,"Industry, Top 20 Pharma",Safety and Tolerability,"Duration of overall response, Overall response rate, Response rate, Time to progression",False,,18411
885,61737,"Expanded access programme, M77998, N0123137530, N0157067059, TrialTroveID-061737",Expanded access program: Treatment with Herceptin (trastuzumab) in patients with metastatic breast cancer  who overexpress HER2.,Oncology,Oncology: Breast,Roche,"Industry, Top 20 Pharma","Overall response rate, Response rate, Safety and Tolerability",,False,,18411
886,61721,"M77502, TrialTroveID-061721",An open-label pilot Phase II trial of Herceptin (trastuzumab) (humanized anti-HER2 antibody) administered as monotherapy in patients with HER2-overexpressing metastatic or locally advanced Transitional Cell Carcinoma of the Bladder (TCC).,Oncology,Oncology: Bladder,Roche,"Industry, Top 20 Pharma","Adverse Events, Overall response rate, Overall survival, Safety and Tolerability, Time to progression, Time to response",,False,,18411
887,61690,"F0430, H2757n, IBR-05-174, NCT00105456, registHER, TrialTroveID-061690",registHER: An Observational Cohort Study of Patients With HER2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Time to progression, Time to treatment failure","Adverse Events, Duration of overall response, Overall survival, Safety and Tolerability, Time to progression",True,NCT00105456,18411
888,61642,"0605001396, HIC 0605001396, NCT00411788, TrialTroveID-061642","A Phase II Study of Rapamycin (Rapamune, Sirolimus) and Trastuzumab (Herceptin) for Patients With HER-2 Receptor Positive Metastatic Breast Cancer",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Yale University","Industry, Top 20 Pharma, Academic","Complete response, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00411788,18411
889,60461,"L_9116, NCT00403988, TrialTroveID-060461",A Clinical Phase II Study of Vinorelbine and Oxaliplatin (Vinox) With or Without Trastuzumab (Herceptin) in Advanced Breast Carcinoma.,Oncology,Oncology: Breast,"Roche, Pierre Fabre, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Response rate, Time to progression",,True,NCT00403988,18411
890,59859,"EU-20655, EUDRACT-2006-001591, IJB-HER2-NEU-CE-1384, NCT00398437, TrialTroveID-059859",Role of Gadolinium Enhanced Brain Magnetic Resonance in the Follow Up of Metastatic Breast Cancer Patients Overexpressing HER2 Neu. A Randomized Prospective Study,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Magnetic Resonance Imaging,"Magnetic Resonance Imaging, Overall survival",True,NCT00398437,18411
891,59806,"EU-20634, EUDRACT-2005-000967-24, HEDON, Herceptin-Docetaxel-Neoadjuvant, KRDI-TUM-HED-324-PAE-0090-I, NCT00398489, TrialTroveID-059806","Evaluation of Response Rate to Pre-Operative Docetaxel + Herceptin Study Part A and Docetaxel Study Part B in Locally Advanced Breast Cancer Patients, Stratified by HER2-Status Trial - PHASE II [(Herceptin Docetaxel Neoadjuvant) HEDON].",Oncology,Oncology: Breast,Technische Universitaet Muenchen,Academic,"Adverse Events, Complete response","Complete response, Disease-free survival",True,NCT00398489,18411
892,59737,"SBCCSG 08, TrialTroveID-059737, UMIN000000513",Prospecitve study of radiotherapy without surgery after Adriamycin/cyclophosphamide (AC) followed by weekly paclitaxel and trastuzumab for inflammatory breast cancer with HER2 over expression.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Time to progression,"Complete response, Overall response rate, Overall survival, Response rate",False,,18411
893,59655,"SBCCSG 02, TrialTroveID-059655",Phase II clinical trial of Trastuzumab and Paclitaxel combined use medical therapy for the advanced recurrent breast cancer.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall survival, Recurrence, Safety and Tolerability, Time to progression",,False,,18411
894,59648,"2188, NCT00397501, OHSU-2188, OHSU-SOL-06015, SOL-06015, SOL-06015-L, TrialTroveID-059648","A Phase I/II Pilot Study of Patients With Brain Metastasis Secondary to Breast Cancer Treated With Methotrexate and Carboplatin in Conjunction With Blood-Brain Barrier Disruption, With Concurrent Trastuzumab in HER-2 Positive Patients.",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"National Institutes of Health/National Cancer Institute, OHSU Cancer Institute","Government, Academic","Overall survival, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",True,NCT00397501,18411
895,59607,"0605-778, GENENTECH-H3755s, J05118, JHMIRB RPN001801, JHOC-00001801, JHOC-0605-778, JHOC-GT0606190101, JHOC-J05118, NCT00397371, NCT00399529, RAC 0605-778, TrialTroveID-059607","A Feasibility Study of Combination Therapy With Trastuzumab, Cyclophosphamide, and an Allogeneic GM-CSF-secreting Breast Tumor Vaccine for HER-2/Neu-Overexpressing Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, (Other Cooperative Group), Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, US Department of Defense, American Cancer Society, Cancer Treatment Research Foundation (CTRF)","Industry, Top 20 Pharma, Cooperative Group, Academic, Government, Not for Profit Funding Entity, Not for Profit Funding Entity","Adverse Events, Complete response, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Gene expression profiling, Immune Response",True,NCT00397371,18411
896,59591,"C000000447, TrialTroveID-059591",A Phase I/II Study of Vinorelbine plus Trastuzumab in Patients with Advanced/Recurrent Breast Cancer Previously Treated with Anthracyclines and Taxanes.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,18411
897,59518,"EudraCT Number: 2006-000703-42, ML18742, NCT00448279, RLI_ML18742, THOR, TrialTroveID-059518","A Randomized, Open-label Study to Compare Progression-free Survival in Patients With HER2 Positive Metastatic Breast Cancer Who Continue or Discontinue Herceptin in Combination With 2nd Line Chemotherapy, Having Progressed on 1st Line Chemotherapy in Combination With Herceptin",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00448279,18411
898,58874,"EudraCT Number: 2006-002860-25, ML19944, NCT00444587, PANDORA, RLI_ML19944, TrialTroveID-058874","A Multicenter Phase II Trial of Trastuzumab (Herceptin) Continuation in Combination With 2nd-line Chemotherapies After Progression on a 1st-line Chemotherapy Combined With Trastuzumab in Patients With HER2 Positive Metastatic Breast Cancer (Treatment Beyond Progression, TBP)",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Disease Progression, Magnetic Resonance Imaging, Response evaluation criteria in solid tumors, Time to progression","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Complete response, Creatinine kinase level, Disease Progression, Eosinophil levels, Hemoglobin level, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Platelet count, Potassium level, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to treatment failure",True,NCT00444587,18411
899,58632,"NCT00392392, SCRI BRE 83, TrialTroveID-058632",Phase II Study of Preoperative Bevacizumab and Trastuzumab Administered With ABI-007 and Carboplatin in HER2 Overexpressing Breast Cancer,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Complete response, Overall response rate, Response rate",,True,NCT00392392,18411
900,58260,"OTT 02-08, TrialTroveID-058260","Cisplatin, Docetaxel and Trastuzumab for Her-2 Positive Inoperable or Metastatic Gastric Carcinoma (OTT 02-08).",Oncology,Oncology: Esophageal; Oncology: Gastric,Ottawa Regional Cancer Center,Academic,,,False,,18411
901,58140,TrialTroveID-058140,Trastuzumab Plus Intravenous or Oral Vinorelbine in Chemonaive Patients with Her-2 Overexpressing Metastatic Breast Cancer: Final Results of An Extended Phase II Trial.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
902,58134,"06-AB-1021-ESMO, TrialTroveID-058134","Serum Her2 extracellular domain (ECD) levels, pAkt and pMAPK expressions as potential markers for response to trastuzumab (T) based therapy in metastatic breast cancer (MBC) patients (pts). A Turkish Oncology Group Study.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,,,False,,18411
903,58130,TrialTroveID-058130,Trastuzumab in Combination with Metronomic Cyclophosphamide And Methotrexate in Patients With Her-2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
904,58121,"JapicCTI-R130310, TrialTroveID-058121","Multicenter Phase I/II Study of Efficacy, Safety,And Pharmacokinetics of Vinorelbine And trastuzumab As First-Line Therapy For Her2- Overexpressing Metastatic Breast Cancer.",Oncology,Oncology: Breast,Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma",Safety and Tolerability,,False,,18411
905,58087,TrialTroveID-058087,Weekly Paclitaxel and Trastuzumab as First-Line Chemotherapy in Patients with Her-2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
906,58077,TrialTroveID-058077,Trastuzumab Influence on CD4+CD25+T-Lymphocytes Quantity in Breast Cancer patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
907,58066,TrialTroveID-058066,High Pathologic Complete Response After Primary Chemotherapy in Patients Treated With Weekly Paclitaxel Followed by FEC Chemotherapy with Simultaneous Trastuzumab in HER-2 positive Operable Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,18411
908,58060,TrialTroveID-058060,Prognostic and Therapeutic Relevance of Disseminated Tumor Cells in The Bone Marrow in Adjuvant Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
909,57319,"EudraCT Number: 2006-000070-67, INCA-PHARE, INCA-RECF0146, NCT00381901, PHARE, TrialTroveID-057319","Protocol of Herceptin Adjuvant With Reduced Exposure, a Randomised Comparison of 6 Months vs 12 Months in All Women Receiving Adjuvant Herceptin [PHARE].",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence, Time to progression","Disease-free survival, Metastasis-free survival, Overall survival, Time to progression",True,NCT00381901,18411
910,57018,"ACCOG-HER-PCI, Anglo Celtic VII Trial, B132, EU-20822, HER-PCI, ISRCTN64624715, MREC NÂ° 06/S0703/103, MREC/06/S0703/108, N0035197773, N0232196534, NCT00639366, TrialTroveID-057018, UKCRN 2186",Prospective Randomised Clinical Trial Testing the Role of Prophylactic Cranial Radiotherapy in Patients Treated with Trastuzumab (Herceptin) for Metastatic Breast Cancer.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Cancer Research UK, Anglo Celtic Cooperative Oncology Group, National Health Service (NHS) - UK","Not for Profit Funding Entity, Cooperative Group, Government",,Quality of Life,True,NCT00639366,18411
911,56893,"NCT00379015, TrialTroveID-056893, TUSM-BRI-BC04-01",Neoadjuvant Epirubicin/Cyclophosphamide Followed by Docetaxel Combined with Trastuzumab for the Patients with HER-Positive Advanced Breast Cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall response rate, Overall survival, Recurrence",True,NCT00379015,18411
912,55205,"CETRA, CETRA 01, NCT00367250, TrialTroveID-055205",Phase I Study Investigating the Combined Immunotherapy With Trastuzumab and Cetuximab in Patients With Metastatic Breast Cancer With High and Moderate HER2 Expression.,Oncology,Oncology: Breast,Medical University of Vienna,Academic,,"Safety and Tolerability, Safety and Tolerability",True,NCT00367250,18411
913,55015,TrialTroveID-055015,Biweekly Docetaxel and Weekly Trastuzumab Treatment in HER 2-Overexpressing Metastatic Breast Cancer Patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate, Safety and Tolerability, Time to progression",,False,,18411
914,54812,"6213, NCT00362973, TrialTroveID-054812, UWCC-06-0445-H/D, UWCC-UW-6213",Early Assessment of Response to Targeted Breast Cancer Therapy.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center, University of Washington/Seattle Cancer Care Alliance","Government, Academic, Academic",,,True,NCT00362973,18411
915,53283,"05-0648, 201101961, NCT00353483, TrialTroveID-053283","Effect of Neoadjuvant or Adjuvant Systemic Therapy on Breast Cancers, Bone Marrow Cancer Cells, and Circulating Cancer Cells",Oncology,Oncology: Breast,Washington University School of Medicine,Academic,Recurrence,,True,NCT00353483,18411
916,53088,"BIG 3-06 HELTH, HELTH, TrialTroveID-053088","A randomized, open label, pharmacodynamic and efficacy study of letrozole alone and letrozole in combination with trastuzumab in the neoadjuvant treatment of postmenopausal women with breast cancer. , , HELTH: Herceptin and Letrozole Trial in HER2+ ER+ Breast Cancer.",Oncology,Oncology: Breast,Novartis,"Industry, Top 20 Pharma",,,False,,18411
917,52935,"MDACC-2004-0701, NCT00496808, TrialTroveID-052935",Neoadjuvant Herceptin for Ductal Carcinoma In Situ of the Breast,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government",Apoptotic index,Resection rate,True,NCT00496808,18411
918,52923,"000161, 00-C-0161, NCI-00-C-0161, NCT00005926, TrialTroveID-052923","A Phase II Trial of Gemcitabine, Herceptin, and Radiation for Regionally Confined Adenocarcinoma of the Pancreas",Oncology,Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,"Quality of Life, Time to progression",,True,NCT00005926,18411
919,52646,TrialTroveID-052646,"Phase II trial of trastuzumab, paclitaxel and cisplatin in metastatic or recurrent head and neck squamous cell carcinoma (HNSCC): Response by tumor EGFR and HER2/neu status.",Oncology,Oncology: Head/Neck,"Bristol-Myers Squibb, Roche/Genentech {Genentech}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Response rate","Overall survival, Progression-free survival",False,,18411
920,52574,TrialTroveID-052574,Correlation between HER2/neu overexpression/amplification and clinicopathologic parameters in advanced gastric cancer (AGC) patients: A prospective study.,Oncology,Oncology: Esophageal; Oncology: Gastric,Roche,"Industry, Top 20 Pharma",,,False,,18411
921,52559,TrialTroveID-052559,Immunoglobulin G fragment C receptor polymorphisms and response to trastuzumab-based treatment in patients with HER-2/neu-positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
922,52555,TrialTroveID-052555,Mutations of HER2 gene in HER2-positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
923,52549,TrialTroveID-052549,Brain metastases in HER2-overexpressing metastatic breast cancer: Comparative analysis of trastuzumab levels in serum and cerebrospinal fluid.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Ludwig Maximilians University of Munich,Academic,,,False,,18411
924,52530,TrialTroveID-052530,Predictors of brain relapse in HER-2 positive metastatic breast cancer (MBC) patients (pts).,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Ligand Pharmaceuticals","Academic, Industry, all other pharma",,,False,,18411
925,52493,TrialTroveID-052493,Circulating regulatory T cells in advanced breast cancer patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
926,52479,TrialTroveID-052479,"Paclitaxel (P), pegylated liposomal doxorubicin (PLD) and trastuzumab as 1st-line chemotherapy (chemo) in HER2/neu-positive (+) metastatic breast cancer (MBC).",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
927,52472,TrialTroveID-052472,Clinical significance of brain metastases occurrence in HER2 overexpressing metastatic breast cancer patients treated with trastuzumab.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",,,False,,18411
928,52455,"7232, B9E-US-S321, TrialTroveID-052455",Phase II study of gemcitabine (Gem) + docetaxel (D) in combination with trastuzumab (T) in patients (pts) with HER2-overexpressing metastatic breast cancer (MBC).,Oncology,Oncology: Breast,Eli Lilly,"Industry, Top 20 Pharma",Overall response rate,"Overall survival, Time to progression",False,,18411
929,52433,TrialTroveID-052433,Trastuzumab-containing therapies: Activity beyond disease progression in M.B.C.--A pivotal experience.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Response rate, Time to progression",,False,,18411
930,52426,TrialTroveID-052426,Long term cardiac tolerability of trastuzumab in HER-2-overexpressing metastatic breast cancer (MBC).,Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas",Academic,Safety and Tolerability,,False,,18411
931,52419,TrialTroveID-052419,Changes in circulating endothelial cells (CEL) in patients receiving trastuzumab for metastatic breast cancer predict response to treatment.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
932,52380,TrialTroveID-052380,"Concurrent administration of weekly trastuzumab and adjuvant breast radiotherapy increases skin, esophageal, and cardiac acute toxicities in the neoadjuvant setting",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
933,52328,TrialTroveID-052328,Cost-effective treatment with half year of trastuzumab and chemotherapy as adjuvant treatment for overexpression of Her2/neu breast cancer patients: Two institutional experiences in Taiwan.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
934,52008,"JCCC 05-05-075, NCT00433407, TrialTroveID-052008, UCLA-0505075-01",A Study to Assess HER2-Specific T Cell Responses in Patients Receiving Trastuzumab for Solid Tumor Treatment.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate","Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute","Academic, Government",,,True,NCT00433407,18411
935,51702,TrialTroveID-051702,Trastuzumab prolonged administration: Safety and toxicity profile in heavily pre-treated patients.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
936,51271,TrialTroveID-051271,Prospective analysis of mRNA expression signatures as Prediction of response to neoadjuvant chemotherapy in breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Gene expression profiling,,False,,18411
937,50964,TrialTroveID-050964,Open labeled phase II observation study of gemcitabine plus cisplatin plus trastuzumab (GCT) in metastatic breast cancer patients with prior anthracyclines and taxanes exposures:,Oncology,Oncology: Breast,"Uludag University, Bursa, Turkey",Academic,,,False,,18411
938,50734,TrialTroveID-050734,"Weekly carboplatin and nab-paclitaxel plus trastuzumab, or plus or minus bevacizumab: Clinical response in patients with breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
939,50679,TrialTroveID-050679,Randomized phase II trial of two different schedules of carboplatin (C) and paclitaxel (P) + trastuzumab (T) as first line treatment for metastatic breast cancer (MBC).,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,18411
940,50626,TrialTroveID-050626,Reverting Estrogen-Receptor-Negative Phenotype in HER-2-Overexpressing Advanced Breast Cancer Patients Exposed to Trastuzumab Plus Chemotherapy.,Oncology,Oncology: Breast,European Institute of Oncology,Government,,,False,,18411
941,49473,TrialTroveID-049473,A Phase I Study of Herceptin/CCI-779 in HER2-Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Government, Academic","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,False,,18411
942,48739,"MAMMA-2-2004, NCT00433095, TrialTroveID-048739",A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer,Oncology,Oncology: Breast,"Arbeitsgemeinschaft fur Internistische Onkologie, Pierre Fabre, Ludwig Maximilians University of Munich","Cooperative Group, Industry, all other pharma, Academic","Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00433095,18411
943,48703,TrialTroveID-048703,Oral vinorelbine alone or in combination with trastuzumab in advanced breast cancer: Results from a pilot trial.,Oncology,Oncology: Breast,Medical University of Vienna,Academic,,,False,,18411
944,48080,"M77050, TrialTroveID-048080",A Study to Evaluate the Effect of Administration of Herceptin in Combination with Cisplatin-Epirubicin-Paclitaxel (PET) on Tumor Response in Metastatic Breast Cancer Patients.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall response rate, Response rate","Adverse Events, Cardiac Telemetry, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,18411
945,48001,"C000000265, KMBOG-0402, PST0402, TrialTroveID-048001","Sequential chemotherapy with FEC (fluorouracil, epirubicin and cyclophosphamide) and P+H (weekly Paclitaxel+Trastuzumab) as primary systemic therapy for operable breast cancer with HER2 positive disease-a phase 2 study.",Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Complete response,"Adverse Events, Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability, Treatment compliance",False,,18411
946,47994,"Beyond PD study, C000000264, TrialTroveID-047994",Second-line Trastuzumab/Docetaxel combination therapy in patients with HER2-positive metastatic breast cancer (MBC)- a phase II study.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,18411
947,47986,"C000000263, Her-mono study, H-mono study, TrialTroveID-047986",First-line Trastuzumab monotherapy in Patients with HER2-positive Metastatic Breast Cancer (MBC)- A Phase II Study.,Oncology,Oncology: Breast,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,18411
948,47378,"ACTRN12606000191594, ANZ 0502, ANZ 0502 NeoGem, NeoGem, TrialTroveID-47378",A Phase II Trial Evaluating the Efficacy and Safety of Four Cycles of  Epirubicin and Cyclophosphamide (EC) Followed by Four Cycles of Docetaxel with Gemcitabine (DG) + or - Herceptin as Neoadjuvant Chemotherapy for Women with Large Operable or Locally Advanced Breast Carcinoma.,Oncology,Oncology: Breast,"Eli Lilly, Roche, ANZ Breast Cancer Trials Group, Sanofi {Sanofi-Aventis}, National Health and Medical Research Council  (NHMRC)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Government","Complete response, Resection rate","Nausea, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Vomiting",False,,18411
949,47361,"C000000165, TrialTroveID-047361",Study of Docetaxel and trastuzumab as preoperative chemotherapy for advanced-stage breast cancer with HER2 over expression.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,"Complete response, Magnetic Resonance Imaging, Overall response rate, Safety and Tolerability",Overall survival,False,,18411
950,45562,"02103, BRTDCECF, Neo-adjuvant Trial I, TrialTroveID-045562, US Oncology Study 02-103, USO 02103, USOR 02103","Phase II Trial of 5-Fluorouracil, Epirubicin, Cyclophosphamide (FEC100) for 4 cycles followed by Docetaxel with Capecitabine (wTX) with Herceptin (in HER2-positive patients only) administered as preoperative therapy for patients with locally advanced breast cancer. Stages II and III.",Oncology,Oncology: Breast,"Pfizer, US Oncology Research, Roche {F. Hoffmann-La Roche}, Predictive Oncology {Precision Therapeutics}/Helomics {Helomics {Precision Therapeutics}}","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, diagnostics or device",Complete response,"Complete response, Gene expression profiling, Safety and Tolerability",False,,18411
951,45068,"05015, 09147, CHNMC-05015, NCT00295893, NCT01231386, TrialTroveID-045068","Randomized Phase II Study of Docetaxel, Adriamycin, and Cytoxan (TAC) Versus Adriamycin/Cytoxan, Followed by Abraxane/Carboplatin (ACAC) +/- Trastuzumab as Neoadjuvant Therapy for Patients With Stage II-III Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic",Complete response,"Neuropathy, Quality of Life, Recurrence",True,NCT00295893,18411
952,42419,TrialTroveID-042419,High efficacy of gemcitabine and cisplatin plus trastuzumab in patients with HER2-overexpressing metastatic breast cancer: a phase II study,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
953,41898,"ACORN ALSSNBC0401, NCT00270894, TrialTroveID-041898",Pilot Trial of Sequential Dose-Dense Neoadjuvant Chemotherapy Plus Herceptin in HER2 Positive Stage II-III Breast Cancer Patients,Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events","Cardiac Telemetry, Complete response, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT00270894,18411
954,41841,TrialTroveID-041841,A multicenter Phase II study of Epirubicin with low-dose Herceptin as a first line treatment in HER2 overexpressing metastatic breast cancer (MBC),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
955,41734,"JapicCTI-050021, JapicCTI-R110129, TrialTroveID-041734",Post marketing study of Herceptin in patients with HER2-overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Disease Progression, Overall survival, Safety and Tolerability, Time to progression",,False,,18411
956,41480,"GET(N)A-1, GETN[A]1, GETN[A]-1, GETNA 1, TrialTroveID-041480","Pathological complete response with neoadjuvant docetaxel, carboplatin and trastuzumab in HER2-positive, locally advanced breast cancer on behalf of the GETN(A) Group.",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Roche","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Complete response,"Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,18411
957,41282,"M77024, M77024 HERA, TrialTroveID-041282",An open label randomised phase 2 study of trastuzumab (Herceptin) given with weekly paclitaxel (Taxol) versus weekly paclitaxel as single agent in first-line therapy for patients with HER-2/neu overexpressing advanced breast cancer (ABC).,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall response rate, Time to progression","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",False,,18411
958,41196,"LCCC 0418, NCT00266110, TrialTroveID-041196, UNC-LCCC-0418",Phase II Trial Evaluating the Toxicity and Efficacy of a Multiepitope Dendritic Cell Vaccine Given With Trastuzumab and Vinorelbine Ditartrate for the Treatment of Women With Metastatic Breast Cancer That Express HLA-A0201 and Whose Tumors Overexpress HER-2/NEU,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Government, Academic","Complete response, Partial response, Response evaluation criteria in solid tumors",,True,NCT00266110,18411
959,41028,"NCT00795899, TECHNO, TrialTroveID-041028","Preoperative Therapy With Epirubicin/Cyclophosphamide Followed by Paclitaxel/Trastuzumab and Postoperative Therapy With Trastuzumab in Patients With HER-2 Over Expressed Breast Cancer. , , Taxol-Epirubicin-Cyclophosphamid-Herceptin Neoadjuvant (TECHNO).",Oncology,Oncology: Breast,"Arbeitsgemeinschaft Gynakologische Onkologie, (Other Hospital/Academic/Medical Center), German Breast Group","Cooperative Group, Academic, Cooperative Group","Complete response, Safety and Tolerability","Disease-free survival, Overall response rate, Overall survival, Quality of Life",True,NCT00795899,18411
960,40950,"FBCG 00-01, FinHer, HYKS Institute Project Number 2161, ISRCTN76560285, TrialTroveID-040950","Comparison of vinorelbine vs docetaxel, and trastuzumab vs no trastuzumab as adjuvant treatments of early breast cancer.",Oncology,Oncology: Breast,Finnish Breast Cancer Group,Cooperative Group,Disease-free survival,"Quality of Life, Safety and Tolerability",False,,18411
961,40308,TrialTroveID-040308,Phase II study of biochemotherapy in metastatic breast cancer (MBC),Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Response rate, Time to progression",,False,,18411
962,39720,TrialTroveID-039720,"Multicenter Study of Weekly Trastuzumab, Paclitaxel and Carboplatin Followed by a Week of Rest Every 28 Days in Patients with Her-2+ Metastatic Breast Cancer (MBC).",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Overall survival, Time to progression",False,,18411
963,39654,"2005-4550, NCT00254592, TrialTroveID-039654, UCI 05-38",Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Nab-paclitaxel Plus or Minus Trastuzumab and Plus or Minus Bevacizumab in Treatment of Large or Inflammatory Breast Cancer-a Phase II Study,Oncology,Oncology: Breast,"University of California Medical Center, Irvine",Academic,Overall response rate,,True,NCT00254592,18411
964,39001,"L017, Myocet 008, Myocet 008 (L017), NCT00250874, TrialTroveID-039001","Phase I-II Study of Liposomal Doxorubicin (Myocet), Docetaxel and Trastuzumab as First-Line Treatment of Patients With HER-2/Neu Positive Metastatic Breast Cancer",Oncology,Oncology: Breast,Teva {Cephalon/Zeneus Pharma {Medeus Pharma}},"Industry, Top 20 Pharma",Overall response rate,"Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00250874,18411
965,37675,"EU-20527, NCT00238290, SAKK-23/03, SWS-SAKK-23/03, TrialTroveID-037675","Trastuzumab Monotherapy Followed By the Combination of Trastuzumab and Letrozole in Post-Menopausal Women With ER-Positive, HER-2 Positive Advanced Breast Cancer Resistant to a Nonsteroidal Aromatase Inhibitor: A Multicenter Two-Step Phase II Trial.",Oncology,Oncology: Breast,Swiss Group for Clinical Cancer Research - SAKK,Cooperative Group,"Clinical benefit rate, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT00238290,18411
966,37556,"04126, 04-126, MSKCC-04-126, NCT00591851, TrialTroveID-037556",Phase II Study of Dose-Dense Doxurubicin and Cyclophosphamide (AC) Followed By Paclitaxel With Trastuzumab in HER2/ NEU-Amplified Breast Cancer: Feasibility,Oncology,Oncology: Breast,"Amgen, Roche/Genentech {Genentech}, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Congestive heart failure, Safety and Tolerability","Overall survival, Recurrence",True,NCT00591851,18411
967,36756,"05-363, 101108, 20081055, CTSU R0524, H-25192, HUM00005459, NCI-2009-00730, NCT00238420, R0524, RTOG 0524, RTOG05-24, RTOG-0524, TrialTroveID-036756",A Phase I/II Trial of a Combination of Paclitaxel and Trastuzumab With Daily Irradiation or Paclitaxel Alone With Daily Irradiation Following Transurethral Surgery for Non-Cystectomy Candidates With Muscle-Invasive Bladder Cancer,Oncology,Oncology: Bladder,"Radiation Therapy Oncology Group (RTOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Common Terminology Criteria for Adverse Events, Neutropenia","Complete response, Disease-free survival, Overall survival",True,NCT00238420,18411
968,36377,"NCT00201760, OSU-0342, TrialTroveID-036377",A Randomized Phase II Study of Gemcitabine/ Trastuzumab and Gemcitabine/ Cisplatin/ Trastuzumab in Patients with Metastatic Breast Cancer,Oncology,Oncology: Breast,Eli Lilly,"Industry, Top 20 Pharma",Disease Progression,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response rate",True,NCT00201760,18411
969,36028,"03-8731-B, 03-8731-B 01, 6278, 74297157, FHCRC-6278, NCT00194779, TrialTroveID-036028, UWCC-03-8731-B-02, UWCC-UW-6278","A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic","Complete response, Overall response rate, Resection rate, Response rate","Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT00194779,18411
970,35933,"Herceptin-proteasome inhibitor, NCT00199212, TrialTroveID-035933","A Phase I, Open Label, Dose-Escalating Study of the Proteasome Inhibitor PS-341 in Combination With Two Schedules of Herceptin, in Patients With Advanced Breast Cancer That Overexpresses HER-2.",Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Maximum tolerated dose,"Overall response rate, Response rate",True,NCT00199212,18411
971,35929,"05042, CHNMC-05042, NCT00182793, TrialTroveID-035929","Phase II Study of Tandem Cycle Dose-Intense Chemotherapy of Melphalan and Carboplatin, Thiotepa and Cyclophosphamide (STMP V) +or- Trastuzumab Followed by Helical Tomotherapy or Local Regional Radiation Therapy for Stage IV Metastatic and Stage IIIB/C Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic","Disease Progression, Disease-free survival, Overall survival, Recurrence",,True,NCT00182793,18411
972,34898,"CFEM345C2403, eLEcTRA, NCT00171847, TrialTroveID-034898",Study of the Efficacy and Safety of Letrozole Combined With Trastuzumab in Patients with Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Novartis, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Safety and Tolerability, Time to progression","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Time to treatment failure",True,NCT00171847,18411
973,34818,"ML17599, NCT02013765, TrialTroveID-034818",An Open-Label Pilot Study of the Effect of Second-Line Treatment with Herceptin Monotherapy on Time to Disease Progression in Patients with Metastatic Urothelial Cancer and HER2 Overexpression.,Oncology,Oncology: Bladder; Oncology: Renal,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Progression-free survival,"Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02013765,18411
974,34812,"ML17600, NCT02006667, TrialTroveID-034812","An Open-Label pilot Study Evaluating the Effect of a Combination Regimen of Herceptin, Cisplatin, and Gemcitabine on Time to Disease Progression in Patients with Metastatic Urothelial Cancer",Oncology,Oncology: Bladder; Oncology: Renal,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Progression-free survival,"Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT02006667,18411
975,34747,"AIO-PK0204, ISRCTN70474205, ML17743, PA-7524, TrialTroveID-034747, UKF000577",An Open-Label Study of Herceptin and Xeloda on Progression-Free Survival in Treatment-Naive Patients with HER2-Positive Advanced or Metastatic Pancreatic Cancer.,Oncology,Oncology: Pancreas,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall survival, Progression-free survival","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate, Time to progression",False,,18411
976,34338,"FA711B0150, ML17263, NCT02005484, TrialTroveID-034338",An Open-label Pilot Study of Herceptin Monotherapy on Objective Treatment Response in Patients With Metastatic or Locally Advanced Gastric Cancer Who Had Disease Progression During Platinum-based or 5-fluoropyrimidine-based Chemotherapy,Oncology,Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT02005484,18411
977,34268,"7302, B9E-US-S324, B9E-US-S324(b), BRE 63, H3036S, Lilly-7302, NCT00191776, NCT00193076, SC BRE 63, SCRI BRE 63, TrialTroveID-034268","A Phase II Trial of Combination Gemcitabine, Carboplatin With or Without Trastuzumab in Patients With Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Eli Lilly, Roche/Genentech {Genentech}, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Overall response rate,"Overall survival, Time to progression",True,NCT00191776,18411
978,33869,"00-273, NCT00148681, TrialTroveID-033869","Preoperative Herceptin and Navelbine in Early Stage, HER-2 Positive Breast Cancer.",Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Womens Hospital","Academic, Academic, Academic, Academic",,Safety and Tolerability,True,NCT00148681,18411
979,33864,"03311, 03-311, DFCI 03-311, HIC 0602001073, NCT00148668, TrialTroveID-033864","A Randomized Phase II Study of Preoperative Herceptin/Navelbine Versus Taxotere/Carboplatin/ Herceptin in Early Stage, HER-2 Positive Breast Cancer.",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Yale University, Brigham and Womens Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic, Academic, Academic",Complete response,,True,NCT00148668,18411
980,33829,"H1880n, NCT00146042, TrialTroveID-033829, UMCC 9901",Phase II Study of Tailored-Dose Docetaxel + Trastuzumab in Her-2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, University of Michigan Comprehensive Cancer Center","Industry, Top 20 Pharma, Academic",,"Overall response rate, Response rate, Safety and Tolerability, Time to progression",True,NCT00146042,18411
981,33756,"CC#037517, NCT00145821, NCT00303992, TrialTroveID-033756, UCSF-037517, UCSF-H6961-24269-02A",Weekly Trastuzumab (Herceptin) and Irinotecan in Patients with HER-2 Positive Advanced Breast Cancer: A Phase II Trial,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of California, San Francisco","Government, Academic","Complete response, Overall response rate, Stable Disease","Duration of overall response, Time to progression",True,NCT00145821,18411
982,33300,"441350-RI-78322, NCT00138125, TORI-B-04, TrialTroveID-033300, UCLA-0502057-01","Phase II Randomized Trial of Faslodex and Herceptin, Alone and Combined, in the First - Line Treatment of Hormone Receptor-Positive, HER-2/Neu-Overexpressing Metastatic Breast Cancer",Oncology,Oncology: Breast,"AstraZeneca, Roche/Genentech {Genentech}, University of California Los Angeles, Translational Oncology Research International","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Cooperative Group","Overall response rate, Progression-free survival","Duration of overall response, Overall response rate, Overall survival, Safety and Tolerability, Time to progression",True,NCT00138125,18411
983,33077,"98-222, NCT00136539, TrialTroveID-033077",Neoadjuvant Therapy with Herceptin and Taxol for Stage II/III Breast Cancer,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bayer AG, Massachusetts General Hospital, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Academic, Industry, Top 20 Pharma, Academic, Academic",,Safety and Tolerability,True,NCT00136539,18411
984,32863,"713-798-7814, H-10379, NCT00133796, TrialTroveID-032863",A Phase II Study of the Effects of Herceptin in Patients with Locally Advanced HER-2/NEU Overexpressing Breast Cancer,Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma",,,True,NCT00133796,18411
985,32430,"EudraCT Number: 2005-000405-56, GEICAM 2004-06, GEICAM/2004-06, NCT00130507, TrialTroveID-032430","Randomized Trial to Assess the Benefit of Adding Trastuzumab to Capecitabine and Vinorelbine as Second Line for HER2positive Breast Cancer Patients With Locally Advanced or Metastatic Disease, Previously Treated With Trastuzumab and Taxanes",Oncology,Oncology: Breast,"Spanish Breast Cancer Research Group, Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Time to progression",True,NCT00130507,18411
986,32339,"GEICAM 2003/03, GEICAM 2003-03, NCT00129896, TrialTroveID-032339",Open-Label Phase I-II Clinical Trial to Evaluate Treatment With Myocet/Taxotere/Herceptin as Primary Chemotherapy Treatment for HER2neu Positive Breast Cancer Patients,Oncology,Oncology: Breast,"Amgen, Spanish Breast Cancer Research Group, Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}, Teva {Cephalon/Zeneus Pharma {Medeus Pharma}}","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Complete response,"Adverse Events, Overall response rate, Safety and Tolerability",True,NCT00129896,18411
987,32197,"05100620, 06-019, 100921, GSE22358, ML 18530, ML18530, NCT00127933, RLI-ML18530, TrialTroveID-032197, Xena, XeNA","An Open-Label Study of Xeloda Plus Taxotere on Treatment Response in Patients with HER2-Neu-Negative, and the Addition of Herceptin for HER2-Neu-Positive Breast Cancer.",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Complete response,"Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Gene expression profiling, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Recurrence, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00127933,18411
988,31742,"HUM00001175, NCT00126607, S0431, SWOG-S0431, TrialTroveID-031742",Phase II Study of Trastuzumab (NSC-688097) in Advanced High Grade Salivary Gland Carcinoma,Oncology,Oncology: Head/Neck,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall survival, Partial response",,True,NCT00126607,18411
989,31735,"INT 03/02 NOAH, ISRCTN86043495, MO16432, NCT01998906, NOAH, NOAH/MO16432, TrialTroveID-031735","A Randomized, Open-Label Study of The Effect of Paclitaxel, Doxorubicin, And Cyclophosphamide, Methotrexate, 5-Fluorouracil Neoadjuvant Chemotherapy, with And without Herceptin, onTumor Response in Women with Her2-Positive Breast Cancer. , , NeOAdjuvant Herceptin (NOAH)",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, (Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma","Event-free survival, Recurrence","Complete response, Event-free survival, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01998906,18411
990,31722,"BO15943, EudraCT Number: 2007-000348-28, NCT02721641, TrialTroveID-031722","A Single Arm, Multi-Center, International, Continuation Trial of Recombinant Humanized Antibody Herceptin (Trastuzumab) in Patients With HER2-Overexpressing Tumors",Oncology,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Disease Progression, Safety and Tolerability","Safety and Tolerability, Serious Adverse Events",True,NCT02721641,18411
991,31690,"EudraCT Number: 2004-000752-17, FA711B0134, NCT00475670, PDO_WO17299, RHEA, TrialTroveID-031690, WO17299, WO17299 (RHEA)",An Open-label Study of the Effect of First-line Herceptin Alone or in Combination With a Taxane on Tumor Response and Disease Progression in Patients With Metastatic Breast Cancer Who Relapsed After Receiving Adjuvant Herceptin for HER2-positive Early Breast Cancer.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to treatment failure",True,NCT00475670,18411
992,31558,"CB.0901, CHAT, MO16419, MREC/01/1/87, N0143108958, NCT01038466, NCT02748213, TrialTroveID-031558","A Randomized, Open-Label Study of the Effect of the Combination of Herceptin and Taxotere, With and Without Xeloda, on Survival in Patients With Advanced and/or Metastatic Breast Cancer With Overexpressed HER2",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01038466,18411
993,31521,"BO18255, EudraCT Number: 2005-000387-39, JapicCTI-050189, JP19959, NCT01041404, ToGA, TrialTroveID-031521","A Randomized, Open-label Study of the Effect of First-line Herceptin in Combination with a Fluoropyrimidine and Cisplatin Versus Chemotherapy Alone on Overall Survival in Patients with HER2-positive Advanced Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,"Roche/Chugai Pharmaceutical, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall survival,"Ability to swallow, Appetite, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Numeric Rating Scale, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Reflux, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Visual Analog Scale",True,NCT01041404,18411
994,30710,"0220045191, CINJ-040412, CINJ-5191, CINJ-NJ1104, CINJOG 040412, CSMC Protocol #: 2005-10, NCT00118053, TrialTroveID-030710","A Phase II Trial of Taxotere, Carboplatin and Herceptin in Locally Advanced or Inflammatory Breast Cancer",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, National Institutes of Health/National Cancer Institute, Cancer Institute of New Jersey","Industry, Top 20 Pharma, Government, Academic","Overall response rate, Response rate","Complete response, Disease-free survival",True,NCT00118053,18411
995,28655,"NCT00189579, TC-Herceptin1, TCHERCEPTIN1, TrialTroveID-028655","A Phase II Study Designed to Evaluate the Safety and Efficacy of the Addition of Herceptin to a Carboplatin-Paclitaxel Regimen in Early Relapse Patients (< 6 Months) with Ovarian Cancer, Overexpressing HER2, Previously Treated with Carboplatin-Paclitaxel",Oncology,Oncology: Ovarian,"(Other Cooperative Group), Roche","Cooperative Group, Industry, Top 20 Pharma","Progression-free survival, Time to response",,True,NCT00189579,18411
996,28627,TrialTroveID-028627,A study of safety and effectiveness of primary systemic therapy with docetaxel and trastuzumab in HER-2 positive breast cancer in adjuvant setting.,Oncology,Oncology: Breast,University of Rochester,Academic,Safety and Tolerability,,False,,18411
997,28623,"2004-3517, NCT00256243, TrialTroveID-028623, UCI 03-70",A Pilot Study of Neoadjuvant Biweekly Doxorubicin and Cyclophosphamide With GMCSF Followed by Weekly Carboplatin/Paclitaxel With Plus and Minus Transtuzumab (TC + or - H) in the Treatment of Breast Cancer,Oncology,Oncology: Breast,"University of California Medical Center, Irvine",Academic,Overall response rate,"Complete response, Overall response rate, Response rate",True,NCT00256243,18411
998,28616,"BrUOG BR-95, TrialTroveID-028616",A Study of Neoadjuvant q4week Carboplatin and Weekly Paclitaxel Plus Trastuzumab in Resectable and Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Brown University Oncology Group, Roche/Genentech","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma",Complete response,,False,,18411
999,28613,"JBCSG-003, TrialTroveID-028613",Multicenter phase II study of trastuzumab and capecitabine as first- or second-line treatment in HER2 over-expressing metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
1000,28582,"AFSSAPS-030322, CVH-CT 02, CVH-CT02, CVH-CT-02, NCT01828736, TrialTroveID-028582",Multicenter Randomized Phase II Trial of Gemcitabine - Platinum With or Without Trastuzumab in Advanced or Metastatic Urothelial Carcinoma With HER2 Overexpression,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT01828736,18411
1001,28579,TrialTroveID-028579,A German multicentre phase II study of safety and efficacy of trastuzumab plus capecitabine in pre-treated metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
1002,28571,TrialTroveID-028571,A pilot study of HER2/neu status between primary breast cancer and metastatic sites developed during trastuzumab-based therapy in patients with metastatic breast cancer,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,18411
1003,28547,TrialTroveID-028547,A multicenter phase II trial of trastuzumab and vinorelbine as first and second line therapy for patients with HER2-positive metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",Time to progression,False,,18411
1004,28541,"B9E-MC-X339, BRE 44, H2371n, NCT00193063, SCRI BRE 44, TrialTroveID-028541",Phase II trial of gemcitabine plus trastuzumab in minimally pretreated HER2 overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,"Eli Lilly, Roche/Genentech {Genentech}, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT00193063,18411
1005,28524,TrialTroveID-028524,A Pilot Clinical Trial of Autologous Tumor-stimulated T Lymphocyte and Herceptin on the Immunotherapy of Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
1006,27773,TrialTroveID-027773,Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response",Progression-free survival,False,,18411
1007,26559,"NCT00107393, TrialTroveID-026559, TUGSM-UHA-BC03-01",Phase II Study of Trastuzumab (Herceptin) and Capecitabine (Xeloda) in Women With Taxanes and Anthracyclines Refractory Metastatic Breast Cancer and HER2 Over-Expression.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Overall survival,"Clinical benefit rate, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",True,NCT00107393,18411
1008,26035,"BRE03-61, HOG BRE03-61, IU-0311-28, NCT00216073, TrialTroveID-026035","A Phase II Trial of Capecitabine, Oxaliplatin and Trastuzumab (CAPOX-T) in Patients with Previously Treated HER-2 Positive Metastatic Breast Cancer : Hoosier Oncology Group BRE03-61",Oncology,Oncology: Breast,"Walther Cancer Institute, Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Not for Profit Funding Entity, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall response rate,Time to progression,True,NCT00216073,18411
1009,25026,TrialTroveID-025026,Biodistribution and pharmacokinetics of radiolabeled trastuzumab in HER2-positive metastatic breast cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,18411
1010,25013,"HUM00001451, NCT00104949, OSHU-1853, S0346, SOL-05110-C, SWOG-S0346, TrialTroveID-025013",Phase II Study of Trastuzumab (NSC-688097) in Treatment of Locally Advanced or Metastatic Synovial Sarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Overall response rate, Partial response, Response rate","Overall survival, Progression-free survival",True,NCT00104949,18411
1011,24605,TrialTroveID-024605,Neoadjuvant Trastuzumab Induces Apoptosis in Primary Breast Cancers,Oncology,Oncology: Breast,"Yale Comprehensive Cancer Center, Baylor College of Medicine","Academic, Academic",,,False,,18411
1012,24131,"HERVIN, NCT00401427, TrialTroveID-024131",A Single-Centre Phase 2 Study of Vinorelbine Plus 3-Weekly Trastuzumab in Metastatic Breast Cancer Overexpressing Her-2.,Oncology,Oncology: Breast,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Time to progression",True,NCT00401427,18411
1013,24119,TrialTroveID-024119,Trastuzumab in combination with i.v. vinorelbine in advanced breast cancer patients with HER2 overexpression,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,18411
1014,23346,"NCT00103233, SWOG-S0347, TrialTroveID-023346",A Randomized Study of Weekly Vinorelbine (NavelbineÂ®) Alone or in Combination With Trastuzumab (HerceptinÂ®) (NSC-688097) for Patients With HER-2-Positive Metastatic Breast Cancer Whose Tumors Have Progressed After Taxane + Trastuzumab Combination Therapy - Phase III,Oncology,Oncology: Breast,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Circulating Tumor Cells, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to treatment failure",,True,NCT00103233,18411
1015,22581,"MO16982, TrialTroveID-022581",A PK-Loading Study of q3w Herceptin (Trastuzumab) Monotherapy in Women With HER2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability","Overall response rate, Response rate, Time to progression",False,,18411
1016,22149,TrialTroveID-022149,Phase II Feasibility and Pharmacokinetic Study of Concurrent Administration of Trastuzumab and High-Dose Chemotherapy in Advanced HER2+ Breast Cancer,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,18411
1017,21492,TrialTroveID-021492,"Study of docetaxel (T) and trastuzumab (H) combination, administered every 21 days, in patients (p) with metastatic breast cancer (MBC) and HER-2 over-expression.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,18411
1018,21452,TrialTroveID-021452,A Phase II trial of Herceptin plus Xeloda in patients with previously untreated HER2-positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Progression-free survival,,False,,18411
1019,21436,"MREC/00/1/87, N0063096733, N0258161803, TrialTroveID-021436, WO16229","A multicenter, open-label, single arm phase II study of safety and efficacy of a three-weekly regimen of Herceptin monotherapy in patients with HER2-overexpressing/amplification in metastatic breast cancer.",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall response rate, Response rate","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Stable Disease, Time to progression",False,,18411
1020,21346,"TAX-HER, TAXHER01, TAXHER-S01, TrialTroveID-021346",Final pathological complete response (pCr) of neoadjuvant (NA) trastuzumab (T) and docetaxel (D) chemotherapy (CT) in HER-2 positive (3+) localized breast cancer without possible primary conserving surgery.,Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Roche","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Complete response,"Disease-free survival, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",False,,18411
1021,20261,"H2251n, NCT00097487, TrialTroveID-020261","Clinical Outcomes in Patients with HER2 Gene-Amplified Metastatic Breast Cancer Treated with First Line Herceptin in Combination with a Taxane: A Phase IV, Prospective, Community Based Study",Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma",,,True,NCT00097487,18411
1022,15310,"IRB 2448-04, N0337, NCCTG-N0337, NCT00093808, TrialTroveID-015310",Phase II Study of Capecitabine in Combination With Vinorelbine and Trastuzumab for the First- or Second-LineTreatment of HER2+ Metastatic Breast Cancer.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Complete response, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00093808,18411
1023,15078,TrialTroveID-015078,Pilot study of the mechanism of action of preoperative trastuzumab in patients with primary operable breast tumors overexpressing HER2,Oncology,Oncology: Breast,European Institute of Oncology,Government,,,False,,18411
1024,13809,"BOOG-2002-02, HERTAX, ISRCTN13770586, TrialTroveID-013809","Open label, comparative, randomized, multicenter, study of trastuzumab given with docetaxel versus sequential single agent therapy with trastuzumab followed by docetaxel as first-line treatment for Her2neu+++ metastatic breast cancer patients.",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}, Sanofi {Sanofi-Aventis}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Progression-free survival,"Overall response rate, Overall survival, Response rate",False,,18411
1025,13527,TrialTroveID-013527,Phase II Clinical Trial of the Combination of Weekly Taxotere and Herceptin in HER-2 Expressing Metastatic Breast Cancer.,Oncology,Oncology: Breast,Tufts Medical Center {Tufts-New England Medical Center},Academic,"Duration of overall response, Overall response rate, Safety and Tolerability, Time to progression",,False,,18411
1026,13338,"TrialTroveID-013338, VCC GI 9931, VCC-GI-9931","A phase I/II trial of Herceptin, Paclitaxel, Cisplatin and radiation followed by maintenance Herceptin for adenocarcinomas of the esophagus",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Maximum tolerated dose",,False,,18411
1027,12697,"L016, TrialTroveID-012697","Multi-center, Phase II, Open Label Study, of Liposome Encapsulated Doxorubicin in Combination with Trastuzumab and Docetaxel as First Line Chemotherapy in Metastatic Breast Cancer Patients.",Oncology,Oncology: Breast,"Istituto Nazionale per la Ricerca sul Cancro, Perrigo Company {Elan}}, Teva {Cephalon}","Academic, Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Quality of Life, Safety and Tolerability",,False,,18411
1028,12007,"CECOG BC.1.3.003, CECOG/BC.1.3.003, HERCOG1, TrialTroveID-012007","A multicenter, randomised comparison of upfront trastuzumab followed by a weekly combination therapy of trastuzumab, carboplatin and paclitaxel after progression vs. upfront weekly combination therapy of trastuzumab, carboplatin and paclitaxel in women with HER2-positive metastatic breast cancer.",Oncology,Oncology: Breast,Central European Cooperative Oncology Group,Cooperative Group,Time to progression,"Duration of overall response, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression",False,,18411
1029,11986,"HERCULES, M77 003E, M77003, M77003/HL80MBC, TrialTroveID-011986",Cardiac safety of recombinant humnaized anti-p185 HER2 monoclonal antibody trastuzumab (Herceptin) in combination with epirubicin/cyclophosphamide as first line therapy in antracycline-naive patients with HER2/neu overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Safety and Tolerability,"Overall response rate, Time to progression",False,,18411
1030,10779,TrialTroveID-010779,Trastuzumab and vinorelbine combination in the treatment of Her2 positive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,"Overall response rate, Response rate, Time to progression",,False,,18411
1031,10778,TrialTroveID-010778,Three-weekly (q3w) trastuzumab (H) plus chemotherapy in HER2-positive recurrent breast cancer (RBC).,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Safety and Tolerability,,False,,18411
1032,10775,TrialTroveID-010775,"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin versus trastuzumab and paclitaxel in women with HER-2 overexpressing metastatic breast cancer.",Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, Roche","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall response rate,"Duration of overall response, Overall survival, Progression-free survival",False,,18411
1033,10770,"03-05-051 B, TrialTroveID-010770","Phase II trial to study the efficacy and toxicity of combined docetaxel, carboplatin, with or without trastuzumab administered weekly in patients with HER-2/neu +/- metastatic breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate, Safety and Tolerability, Time to progression",,False,,18411
1034,10769,TrialTroveID-010769,Phase II trial of trastuzumab and paclitaxel or docetaxel administered every 3 weeks to patients receiving a first treatment for HER2+ metastatic breast cancer.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Safety and Tolerability,,False,,18411
1035,10690,TrialTroveID-010690,"Phase II, prospective, open-label, multicenter  study of  vinorelbine (N) and trastuzumab (H) as first line therapy in patients with HER2-positive metastatic breast cancer.",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",,False,,18411
1036,10681,TrialTroveID-010681,"Gemcitabine, vinorelbine and trastuzumab combination (GemVinT) as second-third line therapy for HER-2 overexpressing metastatic breast cancer (MBC).",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,18411
1037,10679,TrialTroveID-010679,"Gemcitabine, paclitaxel plus trastuzumab (GTH) in HER2 ECD-positive metastatic breast cancer.",Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,"Overall response rate, Response rate",,False,,18411
1038,10667,TrialTroveID-010667,Final results of a phase II study of weekly trastuzumab and vinorelbine in chemonaive patients with HER2-overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,18411
1039,10664,TrialTroveID-010664,"A large multinational, prospective phase II trial of vinorelbine and trastuzumab as first line therapy for HER2-positive metastatic breast cancer patients.",Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",Overall response rate,"Duration of overall response, Overall survival, Progression-free survival, Time to treatment failure",False,,18411
1040,10589,TrialTroveID-010589,"A multicenter phase II study of docetaxel, gemcitabine and trastuzumab administration as first-line treatment in patients with advanced breast cancer (ABC) overexpressing HER-2.",Oncology,Oncology: Breast,Hellenic Oncology Research Group,Cooperative Group,,,False,,18411
1041,9326,"CALGB 39810, CLB-39810, NCT00004883, TrialTroveID-009326","A Phase II Trial of Trastuzumab (Herceptin) for Advanced Stage (IIIB, IV), HER2 Overexpressing, Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",,,True,NCT00004883,18411
1042,9208,"CALGB-90101, NCI-T99-0108, NCT00004856, TrialTroveID-009208, UCSF-99535","A Phase II Trial of Trastuzumab (Herceptin; NSC #688097, IND #6667) in Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma",Oncology,Oncology: Bladder; Oncology: Renal,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Government","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease-free survival, NCI-CTC scale, Overall survival",True,NCT00004856,18411
1043,8966,TrialTroveID-008966,Multicenter phase II study of trastuzumab (herceptin; H) and vinorelbine (navelbine; N) as first-line therapy for HER2 overexpressing metastatic breast cancer (HER2+ MBC).,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, GlaxoSmithKline","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,,False,,18411
1044,8781,"GENENTECH-NYU-9901, NCI-G00-1905, NCT00009997, NYU-9901, TrialTroveID-008781",Herceptin and Paclitaxel in Locally Advanced Breast Cancer With Her-2 Overexpression,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, New York University","Industry, Top 20 Pharma, Government, Academic",Safety and Tolerability,,True,NCT00009997,18411
1045,8774,"DMS-9904, NCI-G01-1932, NCT00014430, TrialTroveID-008774",Phase I Clinical Trial Of Vinorelbine (Navelbine) And Trastuzumab (Herceptin) In Patients with Carcinoma Of The Breast Or Non-Small Cell Lung Cancer And HER-2/NEU Overexpression,Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, Dartmouth-Hitchcock Norris Cotton Cancer Center, GlaxoSmithKline {Glaxo Wellcome}","Government, Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Overall response rate",,True,NCT00014430,18411
1046,8698,"NCI-62, NCT00005842, SACI-IDD-99-26, TrialTroveID-008698, UTHSC-IDD-99-26",Phase I Study of R115777 and Trastuzumab (Herceptin) in Patients With Advanced or Metastatic Adenocarcinoma,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, University of Texas","Government, Academic",Maximum tolerated dose,,True,NCT00005842,18411
1047,8615,TrialTroveID-008615,Cardiac safety of trastuzumab in combination with epirubicin and cyclophosphamide in women with metastatic breast cancer; results of a phase I trial.,Oncology,Oncology: Breast,Ludwig Maximillian Universitaet Womens Hospital,Academic,Safety and Tolerability,,False,,18411
1048,6138,"C015, NCT00043394, TrialTroveID-006138","Phase I/II Open Label, Multi-Center Dose-Escalation Study of s.c. CpG 7909 plus Herceptin in Patients with Metastatic Breast Cancer",Oncology,Oncology: Breast,Pfizer {Coley Pharmaceutical Group},"Industry, Top 20 Pharma",,,True,NCT00043394,18411
1049,3365,"M77001, MREC 99/0/73, N0236106495, TrialTroveID-003365","A Multicenter, Randomized Comparative Study on the Efficacy and Safety of Herceptin (Trastuzumab) Plus Docetaxel (Taxotere) Versus Docetaxel Alone as First Line Treatment in Patients with HER2-Positive Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Overall response rate, Response rate","Overall survival, Progression-free survival, Time to progression, Time to treatment failure",False,,18411
1050,2881,"E-2598, ECOG-2598, ECOG-E2598T1, NCT00003881, NCT00896909, TrialTroveID-002881","Phase II Pilot Trial of Carboplatin, Paclitaxel, and Herceptin in HER2/Neu (+) Advanced NSCLC",Oncology,"Oncology: Lung, Non-Small Cell","Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute, ECOG-ACRIN Cancer Research Group","Cooperative Group, Government, Cooperative Group",Time to progression,,True,NCT00003881,18411
1051,2846,"NCI-V96-0947, TrialTroveID-002846, UCLA-HSPC-9510492",Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Jonsson Comprehensive Cancer Center, UCLA","Industry, Top 20 Pharma, Academic","Duration of overall response, Overall response rate, Quality of Life, Safety and Tolerability, Time to progression",,False,,18411
1052,2806,"LCCC 9925, LCCC9925, NCI-G00-1835, NCT00006109, NCT00943410, TrialTroveID-002806, UNC-9925, UNC-LCCC9925",Phase II Trial of Herceptin Concurrent With External Beam Radiation Following Neoadjuvant Chemotherapy for the Treatment of HER2 Over-Expressing Breast Cancer,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Industry, Top 20 Pharma, Government, Academic",,"Complete response, Overall response rate, Recurrence, Response rate",True,NCT00006109,18411
1053,2800,"MSKCC-98028, NCI-G98-1473, NCT00003539, TrialTroveID-002800",Phase II Study of Weekly 1-Hour Paclitaxel (Taxol) Plus Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in the Treatment of Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government",Safety and Tolerability,,True,NCT00003539,18411
1054,2762,"E2198, E-2198, ECOG-2198, NCT00003992, TrialTroveID-002762",Phase II Randomized Pilot Study of Paclitaxel Plus Trastuzumab (Herceptin) Followed By Adjuvant Chemotherapy in Women With Node Positive Stage II or IIIA Breast Cancer With HER2 Overexpression,Oncology,Oncology: Breast,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Safety and Tolerability,,True,NCT00003992,18411
1055,2567,"99-11-084, AVENTIS-GIA-11156, CDR0000321924, GENENTECH-H2269s, NCT00068341, TrialTroveID-002567",Neoadjuvant Treatment and Molecular Characterization of Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Roche/Genentech {Genentech}, Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Government","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Stable Disease","Complete response, Magnetic Resonance Imaging",True,NCT00068341,18411
1056,2207,"NCI-T98-0078, NCT00003995, PCI-98-056, TrialTroveID-002207","Phase II and Pharmacokinetic Study of CPT-11 and Trastuzumab (RhuMab HER2, Herceptin) in Advanced Colo-Rectal Cancer With p185 HER 2 Overexpression",Oncology,Oncology: Colorectal,"Roche/Genentech {Genentech}, Pfizer {Pharmacia}, National Institutes of Health/National Cancer Institute, University of Pittsburgh","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government, Academic","Overall response rate, Overall survival, Safety and Tolerability, Time to progression",,True,NCT00003995,18411
1057,2201,"99-C-0121, NCI-99-C-0121, NCI-T98-0087, NCT00019812, TrialTroveID-002201",Phase II Study of Trastuzumab (Herceptin) and Paclitaxel in Patients With HER2-Overexpressing Metastatic Breast Cancer,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,,,True,NCT00019812,18411
1058,1422,"EU-20236, FNCLCC-PACS 04, FNCLCC-PACS04, FRE-FNCLCC-PACS-04/0005, NCT00054587, PACS 04, PACS04, TrialTroveID-001422, UCBG 2-04, UNICANCER PACS04","Randomized And Multicentric Opened Phase III Study Evaluating The Concomitant Administration Of Docetaxel 75MG/M2 and Epirubicine 75MG/M2 Versus FEC 100 In Non Metastatic With Positive Lymphatic Nodes Breast Cancer Subjects, And The Sequential Addition Of Herceptin In (HER2+++) And (HER2++ And FISH+) Subjects.",Oncology,Oncology: Breast,Federation Nationale des Centres de Lutte contre le Cancer,Cooperative Group,"Disease-free survival, Progression-free survival, Safety and Tolerability","Overall survival, Quality of Life, Safety and Tolerability",True,NCT00054587,18411
1059,1398,"ACTRN12607000011482, ANZ 0101, B.R.E.A.S.T.: BIG 01-01, BIG 1-01, BIG 1-01 HERA, BIG 1-01/BO 16348, BIG-01-01, BIG01-01/BO16348B, BO16348, CAN-NCIC-MA24, EORTC-10011, EU-20216, EudraCT Number: 2005-002385-11, HERA, IBCSG-28-02, ISRCTN82811952, JapicCTI-050188, JapicCTI-R160883, MA24, MREC01/1/68, N0258107389, N0265110588, NCRN-725, NCT00045032, NCTR446, ROCHE-B016348B, ROCHE-B016348C, ROCHE-B016348E, TrialTroveID-001398, UKCRN ID: 725","A Randomized Three-Arm, Multicenter Comparison of 1 Year and 2 Years of Herceptin Versus No Herceptin in Women With HER2-Positive Primary Breast Cancer Who Have Completed Adjuvant Chemotherapy, , HERceptin Adjuvant (HERA) study.",Oncology,Oncology: Breast,"Breast International Group, Canadian Cancer Trials Group {NCIC Clinical Trials Group}, International Breast Cancer Study Group, Roche/Chugai Pharmaceutical, EORTC Breast Cancer Group, Roche {F. Hoffmann-La Roche}","Cooperative Group, Cooperative Group, Cooperative Group, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma","Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability","Chest discomfort, Congestive heart failure, Disease-free survival, Myocardial infarction (safety), Myocardial infarction, New York Heart Association Class, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT00045032,18411
1060,1267,"E1100, E-1100, ECOG1100, ECOG-1100, NCT00024154, TrialTroveID-001267","A Phase I/II Trial of Herceptin and ZD1839 (Iressa, NSC #715055, IND#61187) in Patients With Metastatic Breast Cancer That Overexpresses HER2/Neu (erbB-2)",Oncology,Oncology: Breast,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Time to progression,,True,NCT00024154,18411
1061,1256,"2582, NCT00041067, S0215, SWOG-S0215, TrialTroveID-001256, UMCC 2003.092, URCC C 3102","Docetaxel (NSC-628503) And Vinorelbine (NSC-608210) Plus Filgrastim (NSC-614629) With Weekly Trastuzumab (NSC-688097) For HER-2 Positive, Stage IV Breast Cancer.",Oncology,Oncology: Breast,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",,"Adverse Events, Complete response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT00041067,18411
1062,1136,"DM99-244, TrialTroveID-001136","A Phase II, Multicenter, Single-Arm Study Of Herceptin (Trastuzumab) In Subjects With Her2-Overexpressing Colorectal Cancer Who Have Not Received Prior Cytotoxic Chemotherapy For Metastatic Disease.",Oncology,Oncology: Colorectal,Roche/Genentech {Genentech},"Industry, Top 20 Pharma",,,False,,18411
1063,1119,"007516, TrialTroveID-001119",Phase II Trial of Weekly Docetaxel (Taxotere) Plus Capecitabine (Xeloda) and Trastuzumab (Herceptin) for Patients with HER2/neu Expressing Stage IV Breast Cancer.,Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Roche/Genentech {Genentech}, Roche, UCSF Comprehensive Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Overall response rate,"Duration of overall response, Quality of Life, Safety and Tolerability, Time to progression, Time to treatment failure",False,,18411
1064,1104,"TrialTroveID-001104, UPCI 01-013",A Phase II Study of Neoadjuvant Taxotere/Navelbine plus Herceptin followed by Adjuvant Adriamycin and Cytoxan in Women with HER-2 Overexpressing Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,University of Pittsburgh Cancer Institute,Academic,Complete response,"Overall response rate, Safety and Tolerability",False,,18411
1065,1095,"1144-05-6R5, NCT00134680, TrialTroveID-001095",Phase II Trial of the Combination of Letrozole 2.5 mg Daily and Trastuzumab 2 mg/Kg Weekly in ErbB2 Positive and Estrogen Receptor and/or Progesterone Receptor Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Novartis, Duke University Medical Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Complete response, Partial response","Duration of overall response, Safety and Tolerability, Time to progression",True,NCT00134680,18411
1066,892,"BG-IDBBC EORTC10995, BO16228, ECSG-EORTC 10995, EORTC 10995, EORTC-10995, EORTC-10995-16999, EORTC-16999, IDBBC-EORTC-10995, N0394123372, NCT00036868, TrialTroveID-000892",A Randomized Phase II Study Of CMF Alone And In Combination With Anti c-erbB2 Antibody (Herceptin) In Women With c-erbB2 Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"EORTC European Organisation for Research and Treatment of Cancer, National Institutes of Health/National Cancer Institute, Roche {F. Hoffmann-La Roche}","Cooperative Group, Government, Industry, Top 20 Pharma","Cardiac Telemetry, Congestive heart failure, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Duration of overall response, Response evaluation criteria in solid tumors, Time to progression",True,NCT00036868,18411
1067,890,"BCIRG 101, BCIRG-101-102, TrialTroveID-000890",Open label Multicentre phase II pilot studies with Herceptin in combination with docetaxel and platinum salts (Cis or Carboplatin) (TCH) as therapy for advanced breast cancer in women with tumors over-expressing the HER2-neu proto-oncogene,Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Breast Cancer International Research Group, University of California Los Angeles, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Cooperative Group, Academic, Industry, Top 20 Pharma","Overall response rate, Safety and Tolerability","Duration of overall response, Overall survival, Time to progression",False,,18411
1068,866,"MSKCC-00078, NCI-G00-1869, NCT00006381, TrialTroveID-000866",Phase II Study of Celecoxib in HER-2/Neu Overexpressing Metastatic Breast Cancer Patients Who Have Failed Recombinant Humanized Anti-p 185HER Monoclonal Antibody Trastuzumab (HERCEPTIN),Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",,Safety and Tolerability,True,NCT00006381,18411
1069,855,"ID99-146, NCT00038402, TrialTroveID-000855",Evaluation of the Addition of Herceptin to Standard Chemotherapy in the Neoadjuvant Setting for Operable Breast Cancer.,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, Pfizer {Pharmacia}, MD Anderson Cancer Center, University of Texas","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Complete response,,True,NCT00038402,18411
1070,725,"MSKCC-98085, NCI-G99-1493, NCT00003740, TrialTroveID-000725",Phase II Study of Herceptin (Recombinant Humanized Anti-p185HER2 Monoclonal Antibody) for the Treatment of Androgen Independent Prostate Cancer,Oncology,Oncology: Prostate,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",,,True,NCT00003740,18411
1071,679,"99118, CHNMC-PHII-19, NCI-T98-0090, NCT00005857, T98-0090, TrialTroveID-000679",Randomized Phase II Trial of Herceptin (NSC 688097) and Weekly Docetaxel (NSC 628503) in Androgen-Independent (Horomone Refractory) Adenocarcinoma of the Prostate (CaP),Oncology,Oncology: Prostate,"Sanofi {Sanofi-Aventis {Aventis}}, Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government, Academic",,,True,NCT00005857,18411
1072,373,"FHCRC-1338.00, GENENTECH-FHCRC-1338.00, NCI-G99-1557, NCT00004013, TrialTroveID-000373",Treatment of Refractory Stage IV Metastatic Breast Cancer With Weekly Paclitaxel or Weekly Paclitaxel and Herceptin Following Autologous/Syngeneic Stem Cell Transplant.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Industry, Top 20 Pharma, Government, Academic",Overall survival,,True,NCT00004013,18411
1073,369,"GENENTECH-H1994g, MSKCC-99118, NCI-G00-1769, NCT00005635, TrialTroveID-000369",Phase II Randomized Study of Subcutaneous Trastuzumab (Herceptin) Plus Paclitaxel in Women With HER2 Overexpressing Metastatic Breast Cancer,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government","Safety and Tolerability, Safety and Tolerability",,True,NCT00005635,18411
1074,283,"150002/9840, C9840, CALGB 150002, CALGB 9840, CALGB-150002/9840, CALGB-9840, CLB-9840, NCT00003440, TrialTroveID-000283",A Phase III Study of Paclitaxel Via Weekly One Hour Infusion Versus Standard Three Hour Infusion Every Three Weeks in the Treatment of Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute, Cancer Trials Support Unit - CTSU/NCI","Cooperative Group, Government, Cooperative Group","Overall response rate, Response rate",Time to progression,True,NCT00003440,18411
1075,274,"LCCC 9818, LCCC9818, NCI-G00-1836, NCT00006110, NCT01000883, TrialTroveID-000274, UNC-9818, UNC-LCCC-9819","A Nonrandomized Phase II Study of Multimodality Therapy for Stage IIB, IIIA/B, or Initially Presenting Stage IV Breast Cancer With Four Cycles of AC Followed by 12 Weeks of Single Agent Paciltaxel With or Without Herceptin Followed by Local Therapy Followed by Weekly Herceptin or No Additional Therapy",Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government, Academic",,"Complete response, Disease-free survival, Magnetic Resonance Imaging, Partial response, Response evaluation criteria in solid tumors",True,NCT00006110,18411
1076,267,"EU-99028, NCT00004935, SAKK 22/99, SWS-SAKK-22/99, TrialTroveID-000267, ZOOM SAKK 22/99",Randomized Phase III Trial of Herceptin Followed by Chemotherapy Plus Herceptin Versus the Combination of Herceptin and Chemotherapy as Palliative Treatment in Patients With HER2- Overexpressing Advanced/Metastatic Breast Cancer,Oncology,Oncology: Breast,Swiss Group for Clinical Cancer Research - SAKK,Cooperative Group,Time to progression,"Adverse Events, Overall response rate, Overall survival, Response rate, Time to treatment failure",True,NCT00004935,18411
1077,265,"01-03-064, E-3198, ECOG-3198, NCT00004888, TrialTroveID-000265",A Safety and Efficacy Study of Doxil and Taxotere +/- Herceptin in Advanced Breast Cancer,Oncology,Oncology: Breast,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Congestive heart failure, Safety and Tolerability","Brain Natriuretic Peptide concentration, Congestive heart failure, N-Terminal Pro-Brain Natriuetic Peptide concentration, Overall response rate, Overall survival, Progression-free survival, Time to treatment failure",True,NCT00004888,18411
1078,261,"20000348, B-31, NCT00004067, NCT01424865, NRG Oncology/NSABP B-31, NSABP B31, NSABP B-31, NSABP-B-31, NSABP-B31-ICSC-A, TrialTroveID-000261",A Randomized Trial Comparing the Safety and Efficacy of Adriamycin and Cyclophosphamide Followed by Taxol (AC-T) to That of Adriamycin and Cyclophosphamide Followed by Taxol Plus Herceptin (AC-T+H) in Node-Positive Breast Cancer Patients Who Have Tumors That Overexpress HER2,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, National Surgical Adjuvant Breast and Bowel Project (NSABP), National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Cooperative Group, Government","Disease-free survival, Recurrence",,True,NCT00004067,18411
1079,234,"CLB-89902, NCT00006015, TrialTroveID-000234","Phase II Study Evaluating the Combination of 5-Fluorouracil, Leucovorin, Oxaliplatin, and Herceptin in the Treatment of Patients With Metastatic Colorectal Cancer Who Have Progressed After 5-FU and/or Irinotecan-Containing Therapy",Oncology,Oncology: Colorectal,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Response rate, Time to progression",,True,NCT00006015,18411
1080,197,"CCUM-9955, NCI-198, NCT00005831, NCT00151034, TrialTroveID-000197, UMCC 9955, UPCI 01-029, WSU-C-2078","Phase II Evaluation of Trastuzumab (Herceptin), Paclitaxel, Carboplatin, and Gemcitabine in the Treatment of Advanced Urothelial Cancer",Oncology,Oncology: Bladder; Oncology: Renal,"Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, University of Michigan Comprehensive Cancer Center","Industry, Top 20 Pharma, Government, Academic",,Time to progression,True,NCT00005831,18411
1081,189,"DM99-315, HSC-01-178, PCRN 2001-0055, TrialTroveID-000189",Randomized Study of Weekly Vinorelbine plus Trastuzumab for Patients with HER2-positive Breast Cancer Who Have Failed Previous Taxane/Trastuzumab Combination Therapy,Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas",Academic,,,False,,18411
1082,179,"NCCTG 98-32-52, NCCTG-983252, NCT00003612, TrialTroveID-000179","Phase II Study of Paclitaxel, Carboplatin, and Trastuzumab (Herceptin) as First-Line Chemotherapy in Women With Overexpressed HER-2, Metastatic Breast Cancer",Oncology,Oncology: Breast,"Bristol-Myers Squibb, Roche/Genentech {Genentech}, North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Government, Cooperative Group","Overall response rate, Response rate",Time to progression,True,NCT00003612,18411
1083,169,"ACTRN12607000032459, ANZBCTG 0102, BCIRG 007, BCIRG 07, BCIRG-007, GENENTECH-UCLA-0109024, NCI-G02-2116, NCT00047255, ROCHE-UCLA-0109024, TrialTroveID-000169, UCLA-0109024, WO16437","A Multicenter Phase III Randomized Trial Comparing Docetaxel (Taxotere) and Trastuzumab (Herceptin) With Docetaxel (Taxotere), Carboplatin and Trastuzumab (Herceptin) as First Line Chemotherapy for Patients With Advanced Breast Cancer Containing the HER2 Gene Amplification",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, (Other Cooperative Group), Breast Cancer International Research Group, Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group, Academic, Government, Industry, Top 20 Pharma","Disease Progression, Time to progression","Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Response rate, Stable Disease, Time to progression",True,NCT00047255,18411
1084,145,"9343, C49909, CALGB-49909, CAN-NCIC-MA.28, CAN-NCIC-MA28, ECOG-N9831, GUMC-00224, H01-053, MA.28, N9831, NCCTG N9831, NCCTG-N9831, NCCTG-N9831D-NCCTG-ICSC, NCCTG-N9831-ICSC, NCI-2012-01849, NCIC-MA.28, NCT00005970, NCT00898898, NCT01562288, SWOG-N9831, TrialTroveID-000145",Phase III Trial of Doxorubicin and Cyclophosphamide (AC) Followed by Weekly Paclitaxel With or Without Trastuzumab as Adjuvant Treatment for Women With HER-2 Over-Expressing or Amplified Node Positive or High-Risk Node Negative Breast Cancer,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Cancer and Leukemia Group B (CALGB), Eastern Cooperative Oncology Group (ECOG), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, North Central Cancer Treatment Group (NCCTG), Southwest Oncology Group, National Institutes of Health/National Cancer Institute, National Cancer Institute of Canada, Breast Cancer Research Foundation","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Government, Government, Not for Profit Funding Entity","Adverse Events, Disease-free survival, Overall survival","Adverse Events, Brain Natriuretic Peptide concentration, Disease-free survival, Overall survival, Recurrence",True,NCT00005970,18411
1085,144,"CALGB 49808, CLB-49808, NCI-2012-02380, NCT00016276, TrialTroveID-000144",A 2X2X2 Factorial Randomized Phase III Trial Of Multimodality Therapy Comparing 4 Cycles Of Doxorubicin And Cyclophosphamide With Or Without Dexrazoxane (AC+/-Z) Followed By 12 Weeks Of Weekly Paclitaxel With Or Without Trastuzumab (T+/-H) Followed By Local Therapy Followed By 40 Weeks Of Weekly Trastuzumab Or None In Women With HER-2+ Stage IV Breast Cancer.,Oncology,Oncology: Breast,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute, Cancer Trials Support Unit - CTSU/NCI","Cooperative Group, Government, Cooperative Group","Complete response, Disease-free survival, NCI-CTC scale","Overall survival, Recurrence",True,NCT00016276,18411
1086,133,"20010537, AVENTIS-TAX-GMA-302, BCIRG 006, BCIRG-006, EudraCT Number: 2008-005127-29, HKUCTR-79, MREC01/2/17, N0063143032, N0170111131, NCI-G01-1978, NCT00021255, NCT00768092, TAX GMA 302, TAX_GMA_302, TrialTroveID-000133, UAB-0106, UAB-F010326012, UCLA-0102006, UCLA-010200601","Multicenter Phase III Randomized Trial Comparing Doxorubicin And Cyclophosphamide Followed By Docetaxel (AC-T) With Doxorubicin And Cyclophosphamide Followed By Docetaxel And Tastuzumab (AC-TH) And With Docetaxel, Platinum Salt And Trastuzumab (TCH) In The Treatment Of Node Positive And High Risk Node Negative Adjuvant Patients With Operable Breast Cancer Containing The HER2NEU Alteration.",Oncology,Oncology: Breast,"Sanofi {Sanofi-Aventis {Aventis}}, Roche/Genentech {Genentech}, Breast Cancer International Research Group, Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Academic, Government",Disease-free survival,"Disease-free survival, Overall survival, Quality of Life, Safety and Tolerability",True,NCT00021255,18411
1087,121,"BO16216, CWRU-030118, GENENTECH-H2223g, NCT00022672, ROCHE-1100, ROCHE-B016216F, ROCHE-BO16216, TAnDEM, TrialTroveID-000121","A Randomized, Open-label Study of the Effect of Herceptin Plus Arimidex Compared With Arimidex Alone on Progression-free Survival in Patients With HER2-positive and Hormone-receptor Positive Metastatic Breast Cancer.",Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall survival, Partial response, Response rate, Safety and Tolerability, Stable Disease, Time to response",True,NCT00022672,18411
1088,83,"MDA-DM-99015, NCI-4450, NCT00016367, TrialTroveID-000083","Phase II Multidose, Single Arm, Multicenter Clinical Trial of Cisplatin and Gemcitabine in Combination With Recombinant Humanized Anti-p185HER2 Monoclonal Antibody (Herceptin) in Patients Who Have Untreated p185HER2 Overexpressing Advanced Local Stage (Stage IIIb Pleural Effusion Only) and Metastatic (Stage IV) Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Roche/Genentech {Genentech}, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government",Safety and Tolerability,,True,NCT00016367,18411
1089,60,"99-095, BRUOG-PA-77, NCI-T98-0067, NCT00003797, TrialTroveID-000060",Herceptin (NSC #688097) and Gemcitabine for Metastatic Pancreatic Cancers That Overexpress HER-2/NEU,Oncology,Oncology: Pancreas,"National Institutes of Health/National Cancer Institute, Brown University Oncology Group","Government, Cooperative Group","Overall response rate, Response rate",,True,NCT00003797,18411
1090,363730,"2020-0231, CMN-001-1, NCT04203901, TrialTroveID-363730",A Phase IIb Randomized Trial of Autologous Dendritic Cell Immunotherapy (CMN-001) Plus Standard Treatment of Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,SCM Lifescience/CoImmune {Argos Therapeutics},"Industry, all other pharma",Overall survival,"Adverse Events, Immune-related response evaluation criteria in solid tumors, Progression-free survival, Treatment Emergent Adverse Events",True,NCT04203901,27041
1091,282655,TrialTroveID-282655,A Phase II Study of AGS-003 in Combination with Other Therapies in Patients with Pediatric Glioblastoma.,Oncology,"Oncology: CNS, Glioblastoma",SCM Lifescience/CoImmune {Argos Therapeutics},"Industry, all other pharma",,,False,,27041
1092,271921,"AGS-003-024, NCT02662634, TrialTroveID-271921",A Safety and Feasibility Study of AGS-003-LNG for the Treatment of Stage 3 Non Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Resection rate, Response evaluation criteria in solid tumors",True,NCT02662634,27041
1093,254259,"1405-1317, Pst10000, TrialTroveID-254259, US-1317",AGS-003 in Combination with Standard Treatment for Colorectal Cancer Patient Pst10000,Oncology,Oncology: Colorectal,"Roswell Park Cancer Institute, SCM Lifescience/CoImmune {Argos Therapeutics}","Academic, Industry, all other pharma",,,False,,27041
1094,200283,"MC1452, NCI-2016-01517, NCT02944357, TrialTroveID-200283",Pilot Study of Gemcitabine and Cisplatin Plus AGS-003-BLD in Patients With Muscle-Invasive Bladder Cancer Undergoing Neoadjuvant Cisplatin-Based Chemotherapy,Oncology,Oncology: Bladder,"National Institutes of Health/National Cancer Institute, Mayo Clinic, SCM Lifescience/CoImmune {Argos Therapeutics}","Government, Academic, Industry, all other pharma",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall survival",True,NCT02944357,27041
1095,200274,"1405-1309, AGS-003-012, I 250113, NCI-2014-01254, NCT02170389, TrialTroveID-200274",Neoadjuvant AGS-003 Immunotherapy in Patients With Localized Kidney Cancer and pT2,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute, SCM Lifescience/CoImmune {Argos Therapeutics}","Government, Academic, Industry, all other pharma",,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT02170389,27041
1096,200266,TrialTroveID-200266,A Phase II Open Label Study of AGS-003 in Patients with Metastatic Renal Cell Carcinoma and Non-Clear Cell Histology,Oncology,Oncology: Renal,SCM Lifescience/CoImmune {Argos Therapeutics},"Industry, all other pharma",Safety and Tolerability,,False,,27041
1097,158083,"2011IS144, AGS-003-005, NCI-2011-03808, NCT01482949, TrialTroveID-158083",A Rollover Phase II Study Testing the Biologic Activity and Safety of AGS-003 in Renal Cell Carcinoma Subjects with Prolonged Response or Stable Disease and Ongoing AGS-003 Treatment in Protocol AGS-003-004 or AGS-003-006,Oncology,Oncology: Renal,SCM Lifescience/CoImmune {Argos Therapeutics},"Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Injection site reactions, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT01482949,27041
1098,135594,"1260GCC, 127017, 2012-0885, 20121579, ADAPT, AGS-003-007, ARGOS AGS 003-007, EudraCT Number: 2012-000871-17, F13015, NCRN544, NCT01582672, TrialTroveID-135594, UKCRN ID 13943",An International Phase III Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT),Oncology,Oncology: Renal,SCM Lifescience/CoImmune {Argos Therapeutics},"Industry, all other pharma",Overall survival,"Adverse Events, Clinical benefit rate, Duration of overall response, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT01582672,27041
1099,78786,"2008IS073, 4K-08-4, AGS-003-006, NCT00678119, TrialTroveID-078786",A Phase II Study Testing the Safety and Activity of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Advanced Stage Renal Cell Carcinoma in Combination With Sunitinib,Oncology,Oncology: Renal,"Pfizer, SCM Lifescience/CoImmune {Argos Therapeutics}","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Response evaluation criteria in solid tumors","Complete response, Immune Response, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT00678119,27041
1100,65460,"9912-367, DUMC-1862-99-10, DUMC-DORIS-99124, DUMC-GCRC-839, NCI-G00-1787, NCT00005816, TrialTroveID-065460",Active Immunotherapy of Metastatic Renal Cell Carcinoma Using Autologous Dendritic Cells Transfected With Autologous Total Tumor RNA.,Oncology,Oncology: Renal,Duke Comprehensive Cancer Center,Academic,"Immune Response, Maximum tolerated dose, Overall survival",,True,NCT00005816,27041
1101,42490,"0712-887, AGS-003-004, ARGOS-003-004, Bukowski-8077, Drabkin-05-0167, Figlin-05-03-099-01, Logan-0506-05, NCT00272649, NCT00309829, TrialTroveID-042490, UCLA-0503099-01, White-04-05-01A",A Phase I/IIa Study Testing the Biologic Activity and Safety of AGS-003 as an Immunotherapeutic in Subjects With Newly Diagnosed Stage IV Renal Cell Carcinoma,Oncology,Oncology: Renal,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, SCM Lifescience/CoImmune {Argos Therapeutics}","Academic, Government, Industry, all other pharma","Immune Response, Progressive disease rate, Response evaluation criteria in solid tumors","Immune Response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00272649,27041
1102,31721,"ARGOS-ERLANGEN-DERMA-DC-07, DERMA-ER-DC 07, ERLANGEN-DERMA-ER-DC-07, EU-20513, NCT00126685, Study ID: 406, TrialTroveID-031721","Vaccination of Stage IV Cutaneous Melanoma Patients With Mature, Autologous Monocyte-Derived Dendritic Cells Transfected With Unselected Autologous Amplified Tumor-RNA.",Oncology,Oncology: Melanoma,"Dermatologische Klinik MIT Poliklinik-Universitaetsklinikum Erlangen, SCM Lifescience/CoImmune {Argos Therapeutics}","Academic, Industry, all other pharma","Overall response rate, Overall survival, Safety and Tolerability, Time to progression",,True,NCT00126685,27041
1103,12001,"003, MB-002-003, NCT00087984, TrialTroveID-012001","A Phase I/II Study To Examine The Safety, Feasibility, Immunological Response, And Measures Of Clinical Antitumor Activity After Administering Unselected, Autologous, Amplified Tumor Total RNA-Transfected, Dendritic Cell Vaccine (MB-002) To Patients With Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,"Kyowa Kirin/Kyowa Kirin Pharmaceutical Development {Kyowa Hakko Kirin/Kyowa Hakko Kirin Pharma {Kyowa Hakko/Kirin Pharma}}, SCM Lifescience/CoImmune {Argos Therapeutics {Merix Bioscience}}","Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall response rate, Safety and Tolerability",,True,NCT00087984,27041
1104,7793,"9912-367, M01RR00030, NCRR-M01RR00030-0153, NCT00006431, TrialTroveID-007793",Active immunotherapy of metastatic renal cell carcinoma using autologous dendritic cells transfected with autologous total tumor RNA.,Oncology,Oncology: Renal,"National Center for Research Resources, Duke University Medical Center, SCM Lifescience/CoImmune {Argos Therapeutics {Merix Bioscience}}","Government, Academic, Industry, all other pharma","Dose-limiting toxicities, Immune Response, Overall survival",,True,NCT00006431,27041
1105,363020,"CTR20192459, CXSL1900051, NCT04190823, RC98-C001, TrialTroveID-363020","A Phase I Study to Evaluate the Safety,Tolerability and Pharmacokinetics of RC98 For Injection in Subjects With Advanced Malignant Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,RemeGen,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Clinical benefit rate, Complete response, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04190823,174888
1106,399226,"516-009, NCT04800614","An Open-label, Randomized, Three-period, Crossover Study of the Effect of Food on the Pharmacokinetics of a Single Oral Dose of Sitravatinib in Healthy Adult Subjects",,NA: ClinicalTrials.gov,Mirati Therapeutics Inc.,ClinicalTrials.gov,"Area under the curve score, Cmax",Adverse Events,True,NCT04800614,66950
1107,397858,"516-012, NCT04772612","A Phase 1, Multicenter, Open-Label Study to Evaluate the Effect of Mild, Moderate, and Severe Hepatic Impairment on the Single-Dose Pharmacokinetics of Sitravatinib",,NA: ClinicalTrials.gov,Mirati Therapeutics Inc.,ClinicalTrials.gov,"Area under the curve score, Cmax, Drug clearance, Elimination half-life, Tmax",Adverse Events,True,NCT04772612,66950
1108,395794,"BGB-900-2001-IIT, NCT04734262, TrialTroveID-395794","A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib and Tislelizumab in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,"Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Serious Adverse Events, Stable Disease",True,NCT04734262,66950
1109,395235,"BTC-BGB, H-2005-156-1126, KCT0005512, NCT04727996, TrialTroveID-395235",Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Clinical benefit rate,"Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability",True,NCT04727996,66950
1110,382310,"2020-0264, 516-008, NCT04518046, TrialTroveID-382310, TX252463",A Phase I/Ib Study of Sitravatinib in Combination With Nivolumab and Ipilimumab in Patients With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma or Other Solid Malignancies,Oncology,Oncology: Renal; Oncology: Unspecified Solid Tumor,Mirati Therapeutics {MethylGene},"Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability","Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT04518046,66950
1111,379441,"BGB-Sitravatinib-101, NCT04472650, TrialTroveID-379441","A Phase I, Open-label, Single-dose, Randomized Crossover Study to Evaluate the Relative Bioavailability of Two Different Capsule Formulations of Sitravatinib in Healthy Subjects",Oncology,Oncology: Unspecified Solid Tumor,BeiGene,"Industry, all other pharma","Area under the curve score, Cmax, Drug clearance, Elimination half-life, Tmax, Volume of distribution","Adverse Events, Serious Adverse Events",True,NCT04472650,66950
1112,365664,"516-007, EudraCT Number: 2019-003898-26, TrialTroveID-365664","A Phase I, Open-label, Single-dose Study to Assess the Mass Balance, Route of Elimination, and Metabolic Profile of [14C] Labeled MGCD516 Malate Salt in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,Mirati Therapeutics {MethylGene},"Industry, all other pharma","Area under the curve score, Cmax, Drug clearance, Elimination half-life, Elimination rate, Tmax","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Vital signs",False,,66950
1113,359020,"H-43432, NCT04123704, TrialTroveID-359020","A Phase II Study of Sitravatinib in Metastatic, Pre-treated, Triple Negative Breast Cancer",Oncology,Oncology: Breast,"Mirati Therapeutics {MethylGene}, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Disease Progression, Response evaluation criteria in solid tumors, Time to progression",True,NCT04123704,66950
1114,339970,"BGB-900-104, CTR20182149, CTR20182363, NCT03941873, TrialTroveID-339970","A Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJC",Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,"(Other Industry Sponsor), BeiGene/BeiGene (Beijing) Co., BeiGene","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Drug clearance, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax",True,NCT03941873,66950
1115,336742,"19018, 516-005, EudraCT Number: 2019-001043-41, NCI-2019-02881, NCT03906071, NL73350.031.20, SAPPHIRE, TrialTroveID-336742",A Randomized Phase III Study of Sitravatinib in Combination With Nivolumab Versus Docetaxel in Patients With Advanced Non-Squamous Non-Small Cell Lung Cancer With Disease Progression On or After Platinum-Based Chemotherapy and Checkpoint Inhibitor Therapy SAPPHIRE,Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, Mirati Therapeutics {MethylGene}","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Overall survival","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, EQ-5D-5L, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03906071,66950
1116,333424,"2018-0296, 516-002, NCI-2019-02945, NCT03680521, TrialTroveID-333424",A Phase II Study of Sitravatinib in Combination With Nivolumab in Patients Undergoing Nephrectomy for Locally-Advanced Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,Mirati Therapeutics {MethylGene},"Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Safety and Tolerability, Safety and Tolerability",True,NCT03680521,66950
1117,330727,"BGB-900-103, CTR20181404, CTR20181947, NCT03666143, TrialTroveID-330727","A Phase Ib Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal","(Other Industry Sponsor), BeiGene/BeiGene (Beijing) Co., BeiGene","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Drug clearance, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT03666143,66950
1118,329114,"18033, 516-003, NCI-2018-01733, NCT03606174, TrialTroveID-329114",A Phase II Study of Sitravatinib in Combination With Nivolumab in Patients With Advanced or Metastatic Urothelial Carcinoma,Oncology,Oncology: (N/A); Oncology: Bladder,Mirati Therapeutics {MethylGene},"Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Dose-limiting toxicities, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Safety and Tolerability, Stable Disease",True,NCT03606174,66950
1119,327256,"NCT03575598, SNOW, SNOW-001, TrialTroveID-327256",Sitravatinib (MGCD516) and Nivolumab in Oral Cavity Cancer Window Opportunity Study (SNOW),Oncology,Oncology: Head/Neck,"University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Mirati Therapeutics {MethylGene}","Academic, Industry, all other pharma",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03575598,66950
1120,293941,"2016-0332, NCI-2017-00324, NCT03015740, TrialTroveID-293941",Phase I/II Trial of MGCD516 Combined With Nivolumab in Patients With Advanced Clear Cell Renal Cell Cancer That Progressed on Prior VEGF-Targeted Therapy,Oncology,Oncology: Renal,"(Other Cooperative Group), MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Mirati Therapeutics {MethylGene}","Cooperative Group, Academic, Government, Industry, all other pharma","Adverse Events, Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Immune Response, Overall response rate, Overall survival, Progression-free survival, Quality of Life, SF-12",True,NCT03015740,66950
1121,291661,"17-090, AAAQ8661, NCI-2017-00187, NCT02978859, TrialTroveID-291661","A Phase II Trial of Sitravatinib (MGCD516), a Multi-receptor Tyrosine Kinase Inhibitor, in Advanced Liposarcoma and Other Soft Tissue Sarcomas",Oncology,Oncology: Soft Tissue Sarcoma,"Mirati Therapeutics {MethylGene}, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic",Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02978859,66950
1122,290116,"17039, 17414, MRTX-500, NCI-2016-01892, NCT02954991, OSU-17075, TrialTroveID-290116, UW16131, VICCTHO16139","A Parallel Phase II Study of Glesatinib, Sitravatinib or Mocetinostat in Combination With Nivolumab in Advanced or Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Mirati Therapeutics {MethylGene},"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability",True,NCT02954991,66950
1123,207251,"EudraCT Number: 2014-000814-73, IRAS ID: 151280, ISRCTN38344105, MREC NÂ°: 14/SC/1346, National Lung Matrix trial, NCT02664935, RG_14-072, TrialTroveID-207251, UKCRN ID: 17746","National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, (Other Academic Cancer Center), Pfizer, Cancer Research UK, Mirati Therapeutics {MethylGene}, (Other Hospital/Academic/Medical Center), University of Cambridge","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity, Industry, all other pharma, Academic, Academic","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Time to progression",True,NCT02664935,66950
1124,197300,"14-308, 14-308, 16071502, 2014-1005, 20150094, 516-001, 76853, MC# 16-16, NCI-2014-01866, NCT02219711, Study 516-001, TrialTroveID-197300, UMCC 2015.040, USOR Number: 17038, UW15054",A Phase I/Ib Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor","Taiho Pharmaceutical, Mirati Therapeutics {MethylGene}","Industry, all other pharma, Industry, all other pharma","Adverse Events, Area under the curve score, Cmax, Plasma concentration, Safety and Tolerability, Safety and Tolerability","Circulating Tumor Cells, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT02219711,66950
1125,81394,TrialTroveID-081394,"A Two Stage, Uncontrolled, Phase I Intra-Prostatic Drug Distribution and Light Dose Escalation Study to Assess the Prostatic Localization, Safety, Tolerability, and Preliminary Efficacy of Interstitial Photodynamic Therapy with SL052 in Subjects with Localized Prostate Cancer",Oncology,Oncology: Prostate,Quest Pharmatech {Altachem Pharma},"Industry, all other pharma","Adverse Events, Magnetic Resonance Imaging, Plasma concentration, Safety and Tolerability, Safety and Tolerability",,False,,29412
1126,348124,"CTR20191229, SYHA1803201901, TrialTroveID-348124","To Evaluate the Safety, Tolerability, Pharmacokinetic Characteristics of SYHA1803 in Patients with Advanced Malignant Solid Tumors, and to Increase the Dose-phase, Open Phase I Clinical Trial",Oncology,Oncology: Bladder; Oncology: Liver,CSPC Pharmaceutical Group Co./CSPC ZhongQi Pharmaceutical Technology Co.,"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Drug clearance, Overall response rate, Phosphate level, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,165816
1127,255265,"A-046, NCT02413502, TrialTroveID-255265",Collection and Storage of Biological Samples Obtained by Leukapheresis for the Future Study of Immune Responses After BCG Vaccination in BCG-naive Healthy Adults in the US (A-046),Vaccines (Infectious Disease),Vaccines (Infectious Disease): Respiratory Vaccines,"(Other Cooperative Group), University of Rochester","Cooperative Group, Academic",Immunogenicity (other timeframe),,True,NCT02413502,65393
1128,210347,TrialTroveID-210347,A Tolerability and Efficacy Study on Sequential BCG/Electromotive Drug Administration (EMDA) Mitomycin C (MMC) as the Standard Intravesical Regimen in High Risk Non Muscle Invasive Bladder Cancer (NMIBC),Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,,,False,,65393
1129,208245,"FinnBladder 4, FinnBladder IV, TrialTroveID-208245",Weekly mitomycin C followed by monthly bacillus Calmette-Guerin or alternating monthly interferon-alpha 2B and bacillus Calmette-Guerin for prophylaxis of recurrent papillary superficial bladder carcinoma,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,"Recurrence, Time to progression",Mortality,False,,65393
1130,202034,TrialTroveID-202034,"Bacillus Calmette-Guerin is superior to a combination of Epirubicin and Interferon-a2b in the Intravesical treatment of patients with Stage T1 Urinary Bladder Cancer. A Prospective, Randomized, Nordic Study",Oncology,Oncology: Bladder,Nordic Urothelial Cancer Group,Cooperative Group,Disease-free survival,"Adverse Events, Overall survival",False,,65393
1131,189079,"69HCL16_0186, AB37/10, DRKS00005651, EAU-RF 2008-01, EAURF2008-01, EudraCT Number: 2010-019181-91, LSID000069, NIMBUS, NL3829, NL49845.091.14, NTR4011, TrialTroveID-189079",Treatment of High Grade Non-Muscle Invasive Urothelial Carcinoma of the Bladder by Standard Number and Dose of Intravesical BCG Instillations Versus Reduced Number of Intravesical Instillations with Standard Dose of BCG.,Oncology,Oncology: Bladder,(Other Cooperative Group),Cooperative Group,Recurrence,"Recurrence, Safety and Tolerability",False,,65393
1132,157205,TrialTroveID-157205,A Clinical Study on the Tolerance and Efficacy of Intravesical Bacille Calmette Guerin (BCG) Treatment in Non Muscle-Invasive Bladder Cancer after Renal Transplantation.,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,,,False,,65393
1133,142575,TrialTroveID-142575,Efficacy of immediate post-TUR mitomycin-C (MMC) instillation in high-risk non-muscle-invasive bladder cancer treated with bacillus Calmette-Guerin (BCG).,Oncology,Oncology: Bladder,Korea Cancer Center Hospital,Academic,Recurrence,,False,,65393
1134,84870,TrialTroveID-084870,A prospective study on the effects of intravesical chemo immunotherapy with gemcitabine and bacillus Calmette-GuÃ©rin for prophylaxis of recurrence of superficial bladder cancer.,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,"Recurrence, Safety and Tolerability",,False,,65393
1135,66385,TrialTroveID-066385,A clinical study on the relevance of urinary interferon-gamma in the prognosis of superficial bladder cancer treated with BCG immunotherapy.,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,,,False,,65393
1136,66243,TrialTroveID-066243,"A prospective, randomized, comparative study of high dose intravesical epirubicin versus BCG for prophylaxis in intermediate risk superficial bladder tumors.",Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Recurrence,,False,,65393
1137,447,"EU-98075, NCT00003779, SWS-SAKK-06/98, TrialTroveID-000447",A Prospective Randomized Trial for the Comparison of Two BCG Strains (Bacille Calmette-Guerin) in the Prophylaxis of Papillary Bladder Tumors Stage Ta and T1 and Treatment of Carcinoma in Situ.,Oncology,Oncology: Bladder,Swiss Institute for Applied Cancer Research,Government,"Disease-free survival, Overall response rate - duration, Overall survival, Quality of Life, Time to progression",,True,NCT00003779,65393
1138,394026,"CAIRE, EudraCT Number: 2019-003303-35, IB2019-04, NCT04705818, TrialTroveID-394026",Combining Epigenetic And Immune Therapy to Beat Cancer. CAIRE Study,Oncology,Oncology: Colorectal; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,"AstraZeneca, (Other Hospital/Academic/Medical Center), Epizyme","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04705818,68807
1139,389047,"202011174, NCI-2020-13896, NCT04624113, TrialTroveID-389047","Tazemetostat and Pembrolizumab in Patients With Pembrolizumab- or Nivolumab-Resistant, Recurrent or Metastatic Head and Neck Squamous-Cell Carcinoma: A Phase I-II Trial",Oncology,Oncology: Head/Neck,"Washington University School of Medicine, Epizyme","Academic, Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT04624113,68807
1140,387294,"EPZ-6438-007-2019, EZH-1401, NCT04590820, NCT04762160, TrialTroveID-387294","A Phase II Open-Label, Multicenter Trial of Oral Tazemetostat in Combination With Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Hospital/Academic/Medical Center), Epizyme","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT04590820,68807
1141,383660,"EZH-108, MC# 20-19, NCT04537715, TrialTroveID-383660","A Phase I, Open-label Multi-dose Two-part Study to Characterize the Effects of a Strong CYP3A4 Inhibitor and a Strong CYP3A4 Inducer on the Steady-State Pharmacokinetics of Tazemetostat (EPZ-6438) in Subjects With Advanced Malignancies",Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Epizyme,"Industry, all other pharma","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Diastolic blood pressure, Elimination half-life, Elimination rate, Heart rate, Overall response rate, Plasma concentration, PR interval, Tmax, Treatment Emergent Adverse Events",True,NCT04537715,68807
1142,366328,"EZH-1201, NCI-2020-04929, NCT04241835, TrialTroveID-366328","A Phase I, Open-label Multi-dose Pharmacokinetic and Safety Study of Oral Tazemetostat in Subjects With Moderate and Severe Hepatic Impairment With Advanced Malignancies",Oncology,Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor,Epizyme,"Industry, all other pharma","Area under the curve score, Cmax, Elimination half-life, Elimination rate, Plasma concentration, Tmax","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Diastolic blood pressure, Heart rate, Overall response rate, PR interval, Treatment Emergent Adverse Events",True,NCT04241835,68807
1143,366045,"EZH-801, NCT04225429, TrialTroveID-366045",Tazemetostat Expanded Access Program for Adults With Epithelioid Sarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"(Other Hospital/Academic/Medical Center), Epizyme","Academic, Industry, all other pharma",,,True,NCT04225429,68807
1144,354048,"EudraCT Number: 2019-003648-55, EZH-301, NCI-2020-00071, NCT04204941, Study 301, TrialTroveID-354048","A Phase Ib/III Global, Randomized, Double-blind, Placebo-Controlled Trial of Tazemetostat in Combination With Doxorubicin as Frontline Therapy for Advanced Epithelioid Sarcoma",Oncology,Oncology: Soft Tissue Sarcoma,Epizyme,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Cmax, Disease Progression, Drug clearance, Duration of overall response, Global health status, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04204941,68807
1145,345401,"EZH-701, NCT03874455, TrialTroveID-345401",Tazemetostat Expanded Access Program for Adults With Solid Tumors,Oncology,Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,Epizyme,"Industry, all other pharma",,,True,NCT03874455,68807
1146,344566,"CRUK/17/016, EudraCT Number: 2018-001843-29, ISRCTN68270067, TASTER, TASTER (TArgeting STEm cell Resistance), TASTER2018, TrialTroveID-344566",An Umbrella Adaptive Randomised Multiâarm Screening Phase II Trial for Patients with IInd/IIIrd Generation TKI Resistant Chronic Myeloid Leukaemia,Oncology,"Oncology: Leukemia, Chronic Myelogenous","Cancer Research UK, (Other Hospital/Academic/Medical Center), University of Glasgow","Not for Profit Funding Entity, Academic, Academic",,"Common Terminology Criteria for Adverse Events, Complete response, Cytogenetic response, Disease Progression, Disease-free survival, Event-free survival, Platelet count, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability",False,,68807
1147,344176,"10183, ETCTN 10183, NCI-2019-01035, NCT03854474, TrialTroveID-344176",A Pilot Study of Tazemetostat and MK-3475 (Pembrolizumab) in Advanced Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response rate, Safety and Tolerability, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Tumor control rate",True,NCT03854474,68807
1148,341043,TrialTroveID-341043,"A Clinical Study To Evaluate Tazemetostat in Combination With PARP Inhibitors for the Treatment of Platinum Resistant Small-Cell Lung Cancer, Triple-Negative Breast Cancer and Ovarian Cancer",Oncology,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian",Epizyme,"Industry, all other pharma",,,False,,68807
1149,341041,"EudraCT Number: 2019-003649-14, EZH-1101, NCI-2020-02345, NCT04179864, TrialTroveID-341041",A Phase Ib/II Open-Label Study Evaluating Tazemetostat in Combination With Enzalutamide or Abiraterone/Prednisone in Chemotherapy Naive Subjects With Metastatic Castration-Resistant Prostate Cancer,Oncology,Oncology: Neuroendocrine; Oncology: Prostate,Epizyme,"Industry, all other pharma","Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Brief Pain Inventory, Circulating Tumor Cells, Clinical benefit rate, EQ-5D-5L, Functional Assessment of Cancer Therapy-Prostate, Overall response rate, PSA progression, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to skeletal-related event, Treatment Emergent Adverse Events, Visual Analog Scale",True,NCT04179864,68807
1150,321338,"2020-0272, EudraCT Number: 2019-003333-42, EZH-302, NCT04224493, TrialTroveID-321338","A Phase 1b/3 Double-blind, Randomized, Active-controlled, 3-stage, Biomarker Adaptive Study of Tazemetostat or Placebo in Combination With Lenalidomide Plus Rituximab in Subjects With Relapsed/Refractory Follicular Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Epizyme,"Industry, all other pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Cmax, Complete response-duration, Disease Progression, Duration of overall response, EQ-5D-5L, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04224493,68807
1151,319924,"E7438-J081-206, JapicCTI-183918, NCT03456726, Study 206, TrialTroveID-319924",A Phase II Study of Tazemetostat in Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma With EZH2 Gene Mutation,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Eisai,"Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response","Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Progression-free survival, Safety and Tolerability, Time to response",True,NCT03456726,68807
1152,312431,"17-626, 2000021570, BO39610, EudraCT Number: 2017-001267-21, MORPHEUS, MORPHEUS BO39610, Morpheus cancer, Morpheus Lung, Morpheus-Lung, MORPHEUS-NSCLC, NCI-2018-00183, NCT03337698, TrialTroveID-312431","A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)",Oncology,"Oncology: Lung, Non-Small Cell","Gilead Sciences/Immunomedics, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03337698,68807
1153,305309,"10130, NCI-2017-01231, NCT03217253, PJC-025, TrialTroveID-305309",A Phase I Study of Single Agent Tazemetostat in Subjects With Advanced Solid Tumors and B-Cell Lymphomas With Hepatic Dysfunction,Oncology,"Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Duration of overall response, Plasma concentration, Response evaluation criteria in solid tumors",True,NCT03217253,68807
1154,305021,"APEC1621 C, APEC1621C, MATCH, NCI-2017-01245, NCT03213665, Pediatric MATCH, TrialTroveID-305021",NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice)- Phase II Subprotocol of Tazemetostat in Patients With Tumors Harboring Alterations in EZH2 or Members of the SWI/SNF Complex,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors",Progression-free survival,True,NCT03213665,68807
1155,301676,"17-729, 2017-0625, 20170841, APEC1621SC, COGAPEC1621, COGAPEC1621SC, N 55017 SC, NCI-2017-01251, NCI-COG Pediatric MATCH, NCT03155620, Pediatric MATCH, TrialTroveID-301676",NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol,Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Drug clearance, Overall response rate, Progression-free survival, Recurrence, Response rate",True,NCT03155620,68807
1156,294621,"1612098443, 19324, AAAR1139, EZH-105, NCI-2017-00281, NCT03028103, TrialTroveID-294621","An Open-Label, Multicenter, Two-Part, Phase I Study to Characterize the Effects of a Moderate CYP3A Inhibitor on the Pharmacokinetics of Tazemetostat (EPZ-6438) (Part A), the Effects of Tazemetostat on the Pharmacokinetics of CYP2C8 and CYP2C19 Substrates, and the Effect of Increased Gastric pH on the Pharmacokinetics of Tazemetostat (Part B) in Subjects With B-cell Lymphoma or Advanced Solid Tumors",Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Epizyme,"Industry, all other pharma","Area under the curve score, Cmax","Area under the curve score, Cmax, Elimination half-life, Overall survival, Safety and Tolerability, Tmax, Treatment Emergent Adverse Events",True,NCT03028103,68807
1157,293704,"EZH-103, NCT03010982, TrialTroveID-293704","An Open-Label, Multi-Center, Two-Part, Phase 1 Study to Characterize the Pharmacokinetics of an Intravenous Micro-Dose of [14C]-Tazemetostat (EPZ 6438) and the Absorption, Distribution, Metabolism and Elimination of an Oral [14C]-Labeled Dose of Tazemetostat in Subjects With B-Cell Lymphomas or Advanced Solid Tumors",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Epizyme,"Industry, all other pharma",Area under the curve score,"Area under the curve score, Bioavailability, Cmax, Elimination half-life, Plasma concentration, Safety and Tolerability, Tmax",True,NCT03010982,68807
1158,293574,"E7438-J081-106, JapicCTI-173486, NCT03009344, TrialTroveID-293574",A Phase I Study of Tazemetostat in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Eisai,"Industry, all other pharma","Dose-limiting toxicities, Treatment compliance","Adverse Events, Area under the curve score, Cmax, Complete response, Disease Progression, Overall response rate, Partial response, Plasma concentration, Serious Adverse Events, Tmax",True,NCT03009344,68807
1159,290597,"14182, 19-193, GY014 (DT1718), NCI-2017-02147, NCT03348631, NRG GY014, NRG-GY014, NRG-GY-014, TrialTroveID-290597","A Phase II Study of Tazemetostat (EPZ-6438) in Recurrent or Persistent Endometrioid or Clear Cell Carcinoma of the Ovary, and Recurrent or Persistent Endometrioid Endometrial Adenocarcinoma",Oncology,Oncology: Endometrial; Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, NRG Oncology","Government, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03348631,68807
1160,284987,"1706515486, AAAR3232, EudraCT Number:2015-004984-35, EZH - 105, EZH-501, IRAS ID 209172, NCI-2017-01533, NCT02875548, TrialTroveID-284987, TRuST",Tazemetostat Rollover Study (TRuST): An Open-Label Rollover Study.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Epizyme,"Industry, all other pharma","Adverse Events, Disease Progression, Overall response rate, Safety and Tolerability, Safety and Tolerability","Disease Progression, Overall response rate - duration, Overall survival, Progression-free survival, Time to treatment failure",True,NCT02875548,68807
1161,270946,"16-1034, 16177, 16-471, EudraCT Number: 2016-001139-10, EZH-203, IRAS ID: 204761, NCI-2016-01485, NCT02860286, TrialTroveID-270946",A Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With Relapsed or Refractory Malignant Mesothelioma With BAP1 Loss of Function,Oncology,Oncology: Mesothelioma,Epizyme,"Industry, all other pharma","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Elimination half-life, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Tmax, Treatment Emergent Adverse Events","Adverse Events, Clinical benefit rate, Cmax, Complete response, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tmax, Treatment Emergent Adverse Events, Volume of distribution",True,NCT02860286,68807
1162,265246,"Epi-RCHOP, EudraCT Number: 2016-001499-31, EZH-104, Lysa Study, NCT02889523, TrialTroveID-265246",A Phase Ib-II Study of Tazemetostat (EPZ-6438) in Newly Diagnosed Diffuse Large B Cell Lymphoma (DLBCL) or High Risk Follicular Lymphoma (FL) Patients Treated by R-CHOP,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","The Lymphoma Academic Research Organisation {Groupe d Etudes des Lymphomes de L Adulte}, Epizyme","Cooperative Group, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Adverse Events, Dose-limiting toxicities, Duration of overall response, Event-free survival, Overall response rate, Overall survival, Progression-free survival, Response rate, Serious Adverse Events",True,NCT02889523,68807
1163,221660,"15-467, 16-065, CSET 2398, EudraCT Number: 2015-002468-18, EZH-102, IRAS ID 190625, IRAS ID-190625, NCI-2015-02224, NCT02601937, NL57333.078.16, SC-4007, TrialTroveID-221660",A Phase I Study of the EZH2 Inhibitor Tazemetostat in Pediatric Subjects With Relapsed or Refractory INI1-Negative Tumors or Synovial Sarcoma,Oncology,Oncology: (N/A); Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer,Epizyme,"Industry, all other pharma","Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Safety and Tolerability, Treatment Emergent Adverse Events","Adverse Events, Cmax, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Safety and Tolerability, Tmax, Treatment Emergent Adverse Events, Volume of distribution",True,NCT02601937,68807
1164,214214,"14-220, 14231, 173396, 2017-0195, 9162, DRKS00007129, EudraCT Number: 2014-001812-21, GO29383, NCI-2014-02375, NCT02220842, TrialTroveID-214214",A Phase Ib Study of the Safety and Pharmacology of Atezolizumab Administered With Obinutuzumab in Patients With Relapsed/Refractory Follicular Lymphoma or Atezolizumab Administered With Obinutuzumab or Tazemetostat in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Roche {F. Hoffmann-La Roche}, Epizyme","Industry, Top 20 Pharma, Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival",True,NCT02220842,68807
1165,208860,"15-328, 15-512, 17-517, 194473, 2015-0774, 201601074, 201601074, EudraCT Number: 2015-002469-41, EZH-202, IRAS ID: 191084, NCI-2015-02047, NCT02601950, TrialTroveID-208860","A Phase II, Multicenter Study of the EZH2 Inhibitor Tazemetostat in Adult Subjects With INI1-Negative Tumors or Relapsed/Refractory Synovial Sarcoma",Oncology,"Oncology: (N/A); Oncology: CNS, Other; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Epizyme,"Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease","Adverse Events, Clinical benefit rate, Cmax, Complete response, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Tmax, Treatment Emergent Adverse Events, Volume of distribution",True,NCT02601950,68807
1166,187556,"154916, 16-1002, 17041, 2016-0438, CSET 1976, CT736, E7438-G000-101, EudraCT Number: 2012-004083-21, IRAS ID: 154916, NCI-2017-00030, NCT01897571, RECF3018, SHS_492378 PAGJ CEPZ 17068, TrialTroveID-187556","An Open-Label, Multicenter, Phase I/II Study of Tazemetostat (EZH2 Histone Methyl Transferase [HMT] Inhibitor) as a Single Agent in Subjects With Advanced Solid Tumors or With B-cell Lymphomas and Tazemetostat in Combination With Prednisolone in Subjects With Diffuse Large B Cell Lymphoma",Oncology,"Oncology: (N/A); Oncology: Lymphoma, Non-Hodgkin's; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Epizyme","Government, Industry, all other pharma","Complete response, Maximum tolerated dose, Overall response rate, Partial response, Progressive disease rate, Safety and Tolerability","Area under the curve score, Bioavailability, Cmax, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT01897571,68807
1167,183517,TrialTroveID-183517,Phase I study of S-288310 in patients with resected non-muscle invasive bladder cancer after transurethral resection of the bladder tumor,Oncology,Oncology: Bladder,Shionogi,"Industry, all other pharma",Safety and Tolerability,,False,,40907
1168,120897,"JapicCTI-090980, TrialTroveID-120897",Phase I/II Study of S-288310 (Peptide Cancer Vaccine) for Patients with Bladder Cancer Progression,Oncology,Oncology: Bladder,"Shionogi, OncoTherapy Science","Industry, all other pharma, Industry, all other pharma",Safety and Tolerability,,False,,40907
1169,224907,"CDR0000269644, CHLA-NANT-N2002-01, NANT N2002-01, NCI-2012-03166, NCT00053950, P01CA081403",A Phase I Study of High-dose Pyrazoloacridine (PZA) (NSC 366140) Supported With Autologous Hematopoietic Stem Cell Rescue in Children With Recurrent or Resistant Neuroblastoma (IND # 36325),,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,"Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale","Area under the curve score, Cmax, Tmax",True,NCT00053950,14966
1170,53225,"NCI-T94-0001H, NCT00002656, TrialTroveID-053225, WSU-C-1087-93",Phase II Study of Pyrazoloacridine for Advanced Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","Barbara Ann Karmanos Cancer Institute, National Institutes of Health/National Cancer Institute","Academic, Government",,,True,NCT00002656,14966
1171,9124,"JHOC-98111005, JHOC-JH9875, JHOC-T96-0116, NCI-T96-0116, NCT00003802, TrialTroveID-009124",Phase II Study of Pyrazoloacridine in Patients with Metastatic Cutaneous or Ocular Melanoma,Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Government, Academic",,,True,NCT00003802,14966
1172,8880,"NCI-T96-0120, NCT00003041, OSU-9712, T96-0120, TrialTroveID-008880",Phase II Study of Pyrazoloacridine in Women With Refractory Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Richard J. Solove Research Institute, Arthur G. James Cancer Hospital","Government, Academic, Academic",,,True,NCT00003041,14966
1173,6071,"JHOC-NABTT-9804, NABTT-9804, NCT00006355, TrialTroveID-006071","Phase I/II Study of Pyrazoloacridine and Radiotherapy in Adults With Newly Diagnosed, Supratentorial Glioblastoma Multiforme.",Oncology,"Oncology: CNS, Glioblastoma","National Institutes of Health/National Cancer Institute, Adult Brain Tumor Consortium {New Approaches to Brain Tumor Therapy}","Government, Cooperative Group","Disease-free survival, Maximum tolerated dose, Overall response rate, Response rate",,True,NCT00006355,14966
1174,4431,"NCI-T96-0122, TrialTroveID-004431, UCCRC-8625","Phase II Study of Pyrazoloacridine for Patients with Recurrent, Locally Advanced, or Metastatic Adenocarcinoma of the Liver (Hepatoma), Bile Duct, or Gallbladder (Cholangiocarcinoma)",Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Overall response rate, Response rate, Time to progression",,False,,14966
1175,4430,"MDA-DM-98107, NCI-T98-0031, NCT00003714, TrialTroveID-004430",Phase II Study of Pyrazoloacridine in Previously Untreated Patients With Unresectable Primary or Metastatic Hepatocellular Carcinoma,Oncology,Oncology: Liver,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Overall response rate, Response rate",,True,NCT00003714,14966
1176,4324,"NCCTG-987254, NCT00005976, TrialTroveID-004324",Phase II Study of Pyrazoloacridine Plus Carboplatin in Patients With Recurrent Glioma,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability, Time to progression",,True,NCT00005976,14966
1177,2803,"NCI-T94-0003H, NCT00002585, TrialTroveID-002803, WSU-C-1148-93",Phase II Study of Pyrazoloacridine in Women with Metastatic Breast Cancer,Oncology,Oncology: Breast,"Barbara Ann Karmanos Cancer Institute, National Institutes of Health/National Cancer Institute","Academic, Government",Overall response rate - duration,,True,NCT00002585,14966
1178,327614,"ACTRN12618001074280, NCT03600467, START, The START Trial, TrialTroveID-327614","A Single-arm, Open-label, Signal-seeking, Phase IIa Trial of the Activity of Seviteronel in Patients With Androgen Receptor (AR)-Positive GBM",Oncology,"Oncology: Bladder; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","(Other Hospital/Academic/Medical Center), Innocrin Pharmaceuticals","Academic, Industry, all other pharma","Disease Progression, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Mortality, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03600467,42255
1179,257499,"15-464, 18492, 18545, 20151131, C14-146, Clinical Trial 18492, INO-VT-464-CL-003, NCI-2015-01076, NCT02445976, Pharm INO-VT-464-CL-003, Study 003, TrialTroveID-257499, VMT-VT-464-CL-003",A Phase II Open-label Study to Evaluate the Efficacy and Safety of Seviteronel in Subjects With Castration-Resistant Prostate Cancer Progressing on Enzalutamide or Abiraterone,Oncology,Oncology: Prostate,"(Other Cooperative Group), Innocrin Pharmaceuticals","Cooperative Group, Industry, all other pharma","Disease Progression, Magnetic Resonance Imaging, PSA progression, Response evaluation criteria in solid tumors",,True,NCT02445976,42255
1180,255492,"15-289, 15-471, 18213, BRE 274 - INO-VT-464-CL-006, CLARITY-01, INO-VT-464-CL-006, NCI-2016-00216, NCT02580448, Study 006, TrialTroveID-255492","A Phase I/II Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer, , CYP17 Lyase and Androgen Receptor Inhibitor Treatment with Seviteronel (CLARITY)",Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, Innocrin Pharmaceuticals","Academic, Industry, all other pharma","Adverse Events, Clinical benefit rate, Complete response, Partial response, Stable Disease","Circulating Tumor Cells, Clinical benefit rate, Overall response rate, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02580448,42255
1181,252058,"15-464, INO-VT-464-CL-004, NCI-2015-00285, NCT02361086, Study 004, TrialTroveID-252058, VMT-VT-464-CL-004","A Phase I/II Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients with Castration-Resistant Prostate Cancer",Oncology,Oncology: Prostate,Innocrin Pharmaceuticals,"Industry, all other pharma","Adverse Events, Progressive disease rate, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs","Area under the curve score, Cmax, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors, Tmax",True,NCT02361086,42255
1182,207423,"140090, 14-C-0090, INO-VT-464-CL-002, NCT02117531, NCT02130700, NIH 14-c-0090, Study 002, TrialTroveID-207423, VMT-VT-464-CL-002","A Phase II Open-Label Study to Evaluate the Efficacy and Safety of VT-464 in Patients With Metastatic Castration Resistant Prostate Cancer Who Have Previously Been Treated With Enzalutamide, Androgen Receptor Positive Triple-Negative Breast Cancer Patients, and Men With ER Positive Breast Cancer",Oncology,Oncology: Breast; Oncology: Prostate,"National Institutes of Health/National Cancer Institute, Innocrin Pharmaceuticals","Government, Industry, all other pharma","Clinical benefit rate, Complete response, Partial response, Progression-free survival, PSA progression, Stable Disease","Adverse Events, Overall response rate, Overall survival, Progression-free survival, PSA progression, Response rate, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02117531,42255
1183,157944,"00048629, 11/LO/1563, 17863, 2011-0381, 2011DR1184, EKSG 11/070, EudraCT Number: 2011-004103-20, i2002, INO-VT-464-CL-001, IRAS ID 87168, NCI-2014-00229, NCT02012920, Study 001, TrialTroveID-157944, UW13067, VMT-VT-464-CL-001","A Phase I/II Open-Label Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Seviteronel in Subjects With Castration-Resistant Prostate Cancer",Oncology,Oncology: Prostate,"Mycovia Pharmaceuticals {Viamet}, Innocrin Pharmaceuticals","Industry, all other pharma, Industry, all other pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Magnetic Resonance Imaging, Maximum tolerated dose, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression","Adrenocorticotropin level, Circulating Tumor Cells, Cmax, Cortisol level, Elimination half-life, Overall response rate, Plasma concentration, Progressive disease rate, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT02012920,42255
1184,288035,"16-246, NCI-2016-02023, NCT02925533, TrialTroveID-288035",A Phase IB Study of B-701 in Combination With Pembrolizumab in Relapsed or Refractory Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract,Oncology,Oncology: Bladder; Oncology: Renal,"Merck & Co./Merck Sharp & Dohme (MSD), Rainier Therapeutics {BioClin Therapeutics}","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs",,True,NCT02925533,84962
1185,262856,"2017-0580, B-701-U22, Bioclin B-70-U22, EC-52623, EudraCT Number: 2017-001292-23, FIERCE-22, NCI-2017-00749, NCT03123055, NL63144.041.17, TrialTroveID-262856, U22","A Multi-Center, Open-Label Phase Ib/II Study of a Novel FGFR3 Inhibitor (B-701) Combined With Pembrolizumab in Subjects With Locally Advanced or Metastatic Urothelial Carcinoma Who Have Progressed Following Platinum-based Chemotherapy",Oncology,Oncology: Bladder; Oncology: Renal,Rainier Therapeutics {BioClin Therapeutics},"Industry, all other pharma","Adverse Events, Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Clinical benefit rate, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Gene expression profiling, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT03123055,84962
1186,221201,"15-201, 18-116, avslutad_B-701-U21, B-701-U21, EudraCT Number: 2017-001319-36, FIERCE 21, FIERCE-21, FIERCE-21(B-701-U21), NCI-2015-00701, NCT02401542, slut_B-701-U21, TrialTroveID-221201","A Dose Escalation, Expansion Study of Vofatamab (B-701) Alone, Plus Docetaxel, or Versus Docetaxel in Subjects with Locally Advanced or Metastatic Urothelial Cell Carcinoma Who Have Relapsed After, or Are Refractory to Standard Therapy",Oncology,Oncology: Bladder; Oncology: Renal,Rainier Therapeutics {BioClin Therapeutics},"Industry, all other pharma","Adverse Events, Area under the curve score, Cmax, Complete response, Disease Progression, Elimination half-life, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Vital signs","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Patient-Reported Outcomes Measurement Information System, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT02401542,84962
1187,221200,TrialTroveID-221200,A phase I study of B-701 in patients with relapsed/refractory t(4;14)-positive multiple myeloma,Oncology,Oncology: Multiple Myeloma,Rainier Therapeutics {BioClin Therapeutics},"Industry, all other pharma",,,False,,84962
1188,221199,TrialTroveID-221199,A Phase I Study of B-701 in Patients With Advanced Solid Tumors Including Metastatic Bladder Cancer and Locally Advanced or Metastatic Urothelial Cell Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,Rainier Therapeutics {BioClin Therapeutics},"Industry, all other pharma",,,False,,84962
1189,268192,"EudraCT Number: 2014-002497-37, IOV-SCLC-1-2014 TIMES, IOV-SCLC-1-2014-TIMES, NCT02608411, TIMES, TrialTroveID-268192","TIvantinib as Maintenance Treatment in Extended Small-cell Lung Cancer (TIMES). Phase II Clinical Trial, Single Arm, Two Stage",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Academic Cancer Center),Academic,"Disease Progression, Progression-free survival","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall survival, Partial response, Progression-free survival, Quality of Life, Stable Disease",True,NCT02608411,29921
1190,210051,"0C-14-1, ARQ197-A-U160, NCI-2014-01712, NCT02150733, TrialTroveID-210051","A Phase I, Open-Label Study assessing the Impact of Hepatic Impairment on the Pharmacokinetics of Tivantinib in Subjects with Advanced Solid Tumors",Oncology,Oncology: Liver; Oncology: Prostate,Daiichi Sankyo,"Industry, all other pharma","Area under the curve score, Cmax, Drug clearance, Plasma pharmacokinetics, Volume of distribution","Area under the curve score, Cmax, Plasma pharmacokinetics, Tmax",True,NCT02150733,29921
1191,201622,"NCT02049060, ONC-2011-001, TrialTroveID-201622",Phase I-Ib Study of the Combination of Tivantinib Plus Pemetrexed and Carboplatin as First-line Therapy in Patients With Advanced or Metastatic Cancer Suitable for a Carboplatin and Pemetrexed Regimen as Part of Their Specific Therapy,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma",(Other Hospital/Academic/Medical Center),Academic,"Area under the curve score, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Area under the curve score, Dose-limiting toxicities, Duration of overall response, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02049060,29921
1192,200312,"ARQ 197-009, ARQ197-009, JapicCTI-142401, JET-HCC, NCT02029157, TrialTroveID-200312","A Phase III Randomized Double-blind, Placebo-controlled Trial of ARQ 197 in Subjects With c-MET Diagnostic-high Inoperable Hepatocellular Carcinoma (HCC) Treated With One Prior Sorafenib Therapy, , JET-HCC: Japanese Evaluation of Tivantinib in Hepato Cellular Carcinoma",Oncology,Oncology: Liver,Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma",Progression-free survival,Overall survival,True,NCT02029157,29921
1193,189796,"EudraCT Number: 2012-005578-79, NCT01892527, ONC-2012-001, RESOUND, TrialTroveID-189796",A Single-Arm Phase II Study of Tivantinib (ARQ 197) Plus Cetuximab in EGFR Inhibitor-Resistant MET High Subjects With Locally Advanced or Metastatic Colorectal Cancer With Wild-Type KRAS,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival","Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01892527,29921
1194,187036,"12-2158, 18M-13-1 PhII-128, NCI 9267, NCI#9267, NCI-2013-00937, NCT01861301, PHII-128, PSHCI-13-081, TrialTroveID-187036, UC12-2158",A Phase II Study of ARQ 197 in Patients With Previously-Treated Malignant Mesothelioma,Oncology,Oncology: Mesothelioma,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT01861301,29921
1195,179040,"9153, NCI-2012-02765, NCT01749384, TrialTroveID-179040, UPCI 12-085",Phase I Study of Tivantinib Plus Bevacizumab,Oncology,Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors",True,NCT01749384,29921
1196,177382,"2012CG108, AAAK6757, ADVL1111, COG ADVL1111, COG-ADVL1111, NCI-2012-02163, NCT01725191, SOL-12143-C, TrialTroveID-177382","A Phase I Study of the c-Met Inhibitor, Tivantinib (ARQ 197) in Children With Relapsed or Refractory Solid Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose",Response evaluation criteria in solid tumors,True,NCT01725191,29921
1197,175452,"ARQ197-A-U159, NCT01699061, TrialTroveID-175452","A phase I single blind, single -sequence study assessing the effect of tivantinib on the QTc interval in cancer subjects",Oncology,Oncology: Unspecified Solid Tumor,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Cardiac Telemetry, Heart rate corrected QT interval","Cardiac Telemetry, Heart rate corrected QT interval, Heart rate, Overall response rate, Plasma concentration, Plasma pharmacokinetics",True,NCT01699061,29921
1198,175312,"12-1359, 12-577, 1259GCC, 13-030, 2012-131, 478834, 7H-12-4, 9165, N01CM00071, NCI 9165 / UC 12-1359, NCI UC12N01, NCI-2012-01640, NCT01696955, P2C 9165, TrialTroveID-175312",A Randomized Phase II Trial of ARQ 197 (Tivantinib)/Cetuximab Versus Cetuximab in Patients With Recurrent/Metastatic Head and Neck Cancer,Oncology,Oncology: Head/Neck,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT01696955,29921
1199,172292,"ARQ 197-008, JapicCTI-121905, NCT01656265, TrialTroveID-172292",Phase I Study of ARQ 197 in Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Elimination half-life, Response evaluation criteria in solid tumors, Volume of distribution",True,NCT01656265,29921
1200,172276,"0C-12-2, 12089, 9152, NCI #9152, NCI-2012-01220, NCT01654965, PHI-68, TrialTroveID-172276",A Phase I Study of ARQ 197 in Combination With IV Topotecan in Advanced Solid Tumors With an Expansion Cohort in Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events","Area under the curve score, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01654965,29921
1201,170402,"905854-02-06, CO 11914, NCI 9145, NCI-2012-00949, NCI-2012-00974, NCT01625156, TrialTroveID-170402",A Phase I Study of ARQ 197 in Combination With Temsirolimus in Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale","Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale, Overall response rate, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT01625156,29921
1202,169200,"NCT01611857, SCRI GI 157, TrialTroveID-169200","A Phase I/II Trial of the c-Met Inhibitor, Tivantinib, in Combination With FOLFOX for the Treatment of Patients With Advanced Solid Tumors (Phase I) and Previously Untreated Metastatic Adenocarcinoma of the Distal Esophagus, Gastroesophageal (GE) Junction, or Stomach (Phase II)",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,Daiichi Sankyo,"Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01611857,29921
1203,169155,"1300000300, 13017, 13-216, 13630, 2012-1317, 20122073, 2013IS025, ARQ197-A-U303, EudraCT Number: 2012-003308-10, METIV-HCC, NCT01755767, NL43348.018.13, ORPHA327497, TrialTroveID-169155, UCI-13-06","A Phase III, Randomized, Double-Blind Study of Tivantinib (ARQ 197) in Subjects With MET Diagnostic-High Inoperable Hepatocellular Carcinoma Treated With One Prior Systemic Therapy",Oncology,Oncology: Liver,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Overall survival,"Clinical benefit rate, Disease Progression, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Progression-free survival, Progressive disease rate, Time to progression",True,NCT01755767,29921
1204,166090,"23-4882, ARQ 197-007, JapicCTI-121808, NCT01580735, TrialTroveID-166090","A Phase II, Multicenter, Open-label, Single-arm Study of ARQ 197 Plus Erlotinib in Patient With Locally Advanced or Metastatic EGFR Mutation-positive Non-small-cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma",Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01580735,29921
1205,164824,TrialTroveID-164824,"A Randomized, Crossover, Phase 1 Study To Evaluate The Effect Of A Strong CYP3A4 Inhibitor On Tivantinib (Arq 197) Pharmacokinetics In Healthy Subjects.",Oncology,Oncology: Unspecified Cancer,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Area under the curve score, Cmax, Tmax",,False,,29921
1206,164817,TrialTroveID-164817,"Absorption, Distribution, Metabolism, And Excretion Of 14c-Labeled Tivantinib (Arq 197) In Healthy Male Subjects.",Oncology,Oncology: Unspecified Cancer,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Adverse Events,,False,,29921
1207,164813,TrialTroveID-164813,"A Randomized, Open-Label, Phase 1 Study To Evaluate The Effect Of Food On Tivantinib (Arq 197) Pharmacokinetics",Oncology,Oncology: Unspecified Cancer,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Area under the curve score, Cmax, Elimination half-life, Tmax",,False,,29921
1208,163351,"12-017, 8985, DFCI-12-017, NCI-2012-00722, NCT01542996, NCT01575522, TrialTroveID-163351",A Phase II Study of ARQ 197 in Metastatic Triple-Negative Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Government, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors",True,NCT01542996,29921
1209,161156,"208411, 8986, CO12800, NCI-2012-00237, NCT01519414, OSU 11132, OSU11132, OSU-11132, TrialTroveID-161156","A Randomized, Double-Blind, Placebo-Controlled Phase II Study of ARQ 197 (Tivantinib) in Men With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer.",Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, National Institutes of Health","Government, Government","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Bone resorption rate, Bone specific alkaline phosphatase, Common Terminology Criteria for Adverse Events, N-terminal telopeptide measurements, Overall response rate, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT01519414,29921
1210,161042,"00032884, ARQ197-A-U158, NCT01517399, TrialTroveID-161042","A Phase I, Open-Label, Single-Sequence Crossover Study Assessing the Effect of Tivantinib (ARQ 197) on the Pharmacokinetics of Omeprazole/S-Warfarin/Caffeine/Midazolam and Digoxin in Cancer Subjects",Oncology,Oncology: (N/A); Oncology: Prostate; Oncology: Unspecified Solid Tumor,Daiichi Sankyo,"Industry, all other pharma",Area under the curve score,"Cmax, Drug clearance, Tmax, Volume of distribution",True,NCT01517399,29921
1211,156533,"120009, 12-C-0009, NCI-12-C-0009, NCT01468922, TrialTroveID-156533","Phase Ib Study of the Combination of Pazopanib, an Oral VEGFR Inhibitor, and ARQ 197 (Tivantinib), an Oral MET Inhibitor, in Patients With Refractory Advanced Solid Tumors.",Oncology,Oncology: Gastric; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,National Institutes of Health/National Cancer Institute,Government,"Safety and Tolerability, Safety and Tolerability",,True,NCT01468922,29921
1212,154383,"2011-0197, 8984, MDA-2011-0197, NCI-2011-03470, NCT01447914, TrialTroveID-154383","A Phase II Study of the c-Met Inhibitor ARQ 197 in Patients With Relapsed, or Relapsed and Refractory Multiple Myeloma",Oncology,Oncology: Multiple Myeloma,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Stable Disease","Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Gene expression profiling, MD Anderson Symptom Inventory, Overall response rate - duration, Partial response, Progression-free survival, Quality of Life, Time to next treatment",True,NCT01447914,29921
1213,150041,"101574, 2011-468, ARQ 197-218, J1144, NCT01395758, STU 042011-044, TrialTroveID-150041",A Phase II Randomized Open-label Study of Erlotinib Plus ARQ 197 Versus Single Agent Chemotherapy in Previously Treated KRAS Mutation Positive Subjects With Locally Advanced or Metastatic Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Merck & Co. {ArQule},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01395758,29921
1214,148504,"ARQ197-006, ATTENTION, JapicCTI-111523, NCT01377376, TrialTroveID-148504","A Phase III, Randomized, Double-Blinded, Placebo-Controlled Study of ARQ 197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer With Wild-type Epidermal Growth Factor Receptor, , Asian Trial of Tivantinib plus Erlotinib vs Erlotinib for NSCLS without EGFR Mutation (ATTENTION)",Oncology,"Oncology: Lung, Non-Small Cell",Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma",Overall survival,"Adverse Events, Clinical benefit rate, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01377376,29921
1215,138959,"ARQ 197-005, JapicCTI-101355, NCT01251796, TrialTroveID-138959",A Phase I Study of ARQ 197 in Combination With Erlotinib in CYP2C19 Poor Metabolizer Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability","Overall response rate, Plasma concentration, Response rate",True,NCT01251796,29921
1216,132864,"0C-11-2, 14-196, 20100674, ARQ 197-299, ARQ197-299, EudraCT Number: 2010-020151-31, MISC 40 IST, NCI-2012-00129, NCT01178411, STU 032014-047, TrialTroveID-132864, VICCPHI1185",An Extension Protocol for Subjects Who Were Previously Enrolled in Other Tivantinib (ARQ 197) Protocols,Oncology,"Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Solid Tumor",Merck & Co. {ArQule},"Industry, Top 20 Pharma",Safety and Tolerability,"Safety and Tolerability, Safety and Tolerability",True,NCT01178411,29921
1217,132327,"20101784, 2010IS058, AAAI0754, ARQ 197-A-U302, ARQ197-A-U302, DFCI: 10-381, EudraCT Number: 2010-022365-10, HCI 44685, IRAS ID 73482, LUN 212 IST, MARQUEE, McG 1032, NCT01244191, NL35273.018.11, PER-025-11, TrialTroveID-132327, USO 10-090","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of ARQ197 Plus Erlotinib Versus Placebo Plus Erlotinib in Previously Treated Subjects With Locally Advanced or Metastatic, Non-Squamous, Non-Small-Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell","Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Overall survival,"Disease Progression, EQ-5D, Functional Assessment of Cancer Therapy-Lung Cancer, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01244191,29921
1218,130134,"ARQ 197-004, JapicCTI-101168, NCT01152645, TrialTroveID-130134",Phase II Study of ARQ 197 Monotherapy for Previously Treated Advanced/Recurrent Gastric Cancer.,Oncology,Oncology: Gastric,"Merck & Co. {ArQule}, Kyowa Kirin {Kyowa Hakko Kirin}","Industry, Top 20 Pharma, Industry, all other pharma",Clinical benefit rate,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT01152645,29921
1219,129820,"ARQ197-A-U157, NCT01149720, REFMAL 204, TrialTroveID-129820","An Open-Label, Phase I, Randomized, Two-Treatment, Two-Period, Two-Way Crossover, Relative Bioavailability Study of A Capsule and a Tablet Formulation of ARQ 197 In Subjects with Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Bioavailability, Cmax","Cmax, Cmin, Drug clearance, Tmax, Volume of distribution",True,NCT01149720,29921
1220,123099,"ARQ 197-003, ARQ 197-003/005, JapicCTI-101042, NCT01069757, TrialTroveID-123099",A Phase I Study of ARQ 197 in Combination With Erlotinib in Patients With Advanced/Recurrent Non-Small-Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Kyowa Kirin {Kyowa Hakko Kirin},"Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability",Plasma concentration,True,NCT01069757,29921
1221,122329,"ARQ 197-A-U252, EudraCT Number:2009-016025-34, GI 138, MDACC 2009-0990, NCT01075048, RECF1665, TrialTroveID-122329","A Randomized, Placebo-Controlled, Phase I/II Study Of ARQ 197 in Combination With Irinotecan and Cetuximab in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Who Have Received Front-Line Systemic Therapy",Oncology,Oncology: Colorectal,Daiichi Sankyo,"Industry, all other pharma","Progression-free survival, Safety and Tolerability, Safety and Tolerability","Functional Assessment of Cancer Therapy-Colorectal Cancer, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability",True,NCT01075048,29921
1222,121882,"4T-09-1, ARQ197-A-U251, CSET 1614, EudraCT Number: 2009-015400-26, NCT01055067, TrialTroveID-121882",Multicenter Phase II Trial of ARQ 197 for Subjects With Relapsed or Refractory Germ Cell Tumors,Oncology,Oncology: (N/A); Oncology: Testicular,Daiichi Sankyo,"Industry, all other pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT01055067,29921
1223,118572,"CGUK12075, NCI-2012-01641, NCT01688973, S1002, S1107, SS1107, SWOG 1107, SWOG-S1107, TrialTroveID-118572",Parallel (Randomized) Phase II Evaluation of ARQ 197 and ARQ 197 in Combination with Erlotinib in Papillary Renal Cell Carcinoma,Oncology,Oncology: Renal,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01688973,29921
1224,116555,"ARQ 197-215, ARQ197-215, EudraCT Number: 2008-007155-27, NCT00988741, TrialTroveID-116555",A Randomized Controlled Phase II Trial of ARQ 197 in Patients With Unresectable Hepatocellular Carcinoma (HCC) Who Have Failed One Prior Systemic Therapy.,Oncology,Oncology: Liver,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Time to progression","Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00988741,29921
1225,106889,"2009-0139, ARQ 197-117, GI 145, NCT00874042, REFMAL 178, TrialTroveID-106889",A Phase I Dose Escalation Study of ARQ 197 Administered in Combination With Gemcitabine in Adult Patients With Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Merck & Co. {ArQule},"Industry, Top 20 Pharma","Disease Progression, Maximum tolerated dose, Safety and Tolerability",Disease Progression,True,NCT00874042,29921
1226,103497,"ARQ 197-116, NCT00827177, RPCI 50009, TrialTroveID-103497, VICCPHI0912",A Phase I Dose Escalation Study of ARQ 197 in Combination With Sorafenib in Adult Patients With Advanced Solid Tumors,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Renal","Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability",,True,NCT00827177,29921
1227,101589,"ARQ 197-114, NCT00802555, TrialTroveID-101589",A Phase 1b Safety Study of ARQ 197 in Cirrhotic Patients With Hepatocellular Carcinoma (HCC).,Oncology,Oncology: Liver,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Safety and Tolerability,"Clinical benefit rate, Overall response rate, Time to progression",True,NCT00802555,29921
1228,93532,"ARQ 197-206, EudraCT Number: 2007-004622-25, McG 0808, NCT01070290, TrialTroveID-093532",A Randomized Phase II Study of ARQ 197 Versus Investigator's Choice of Second-Line Chemotherapy in Patients With Locally Advanced or Metastatic Gastric Cancer Who Have Progressive Neoplastic Disease Following Treatment With One Prior Chemotherapy Regimen,Oncology,Oncology: Gastric,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Progression-free survival,"Overall response rate, Overall survival, Safety and Tolerability",True,NCT01070290,29921
1229,88002,"ARQ 197-113, NCT00658554, TrialTroveID-088002",Bioequivalence Study of ARQ 197 Amorphous and Crystalline Polymorphs A and B in Normal Healthy Volunteers.,Oncology,Oncology: Unspecified Cancer,Merck & Co. {ArQule},"Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT00658554,29921
1230,87158,"ARQ 197-112, NCT00651638, TrialTroveID-087158",A Study of ARQ 197 in Healthy Volunteers to Assess the Pharmacokinetic (PK) Profile in Extensive and Poor Metabolizers as Defined by Cytochrome P450 2C19 (CYP 2C19) Genotype,Oncology,Oncology: Unspecified Cancer,Merck & Co. {ArQule},"Industry, Top 20 Pharma",Safety and Tolerability,Safety and Tolerability,True,NCT00651638,29921
1231,86365,TrialTroveID-086365,A Phase II study of ARQ 197 in hormone-refractory prostate cancer.,Oncology,Oncology: Prostate,"Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",,,False,,29921
1232,83788,"ARQ 197-111, NCT00612703, TrialTroveID-083788",A Phase I Dose Escalation Study of ARQ 197 Administered in Combination With Erlotinib in Adult Patients With Advanced Solid Tumors,Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Cancer",Merck & Co. {ArQule},"Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00612703,29921
1233,83405,"ARQ 197-209, EudraCT Number: 2007-004634-17, NCT00777309, TrialTroveID-083405",A Randomized Phase II Study of Erlotinib Plus ARQ 197 Versus Erlotinib Plus Placebo in Previously Treated Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell","Merck & Co. {ArQule}, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00777309,29921
1234,83404,"ARQ 197-0701, NCT00609921, TrialTroveID-083404",A Phase l Dose Escalation Study of ARQ 197 in Adult Patients With Advanced/Recurrent Solid Tumors.,Oncology,"Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell","Merck & Co. {ArQule}, Kyowa Kirin {Kyowa Hakko Kirin {Kyowa Hakko}}","Industry, Top 20 Pharma, Industry, all other pharma",Safety and Tolerability,,True,NCT00609921,29921
1235,78753,"08081, 20080825, ARQ 197-204, DFCI 07-329, EudraCT Number: 2009-011669-10, MiT trial, NCT00557609, TrialTroveID-078753",A Phase II Study of ARQ 197 in Patients With Microphthalmia Transcription Factor Associated Tumors,Oncology,Oncology: Renal; Oncology: Soft Tissue Sarcoma,Merck & Co. {ArQule},"Industry, Top 20 Pharma",Overall response rate,"Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00557609,29921
1236,63240,"ARQ 197-103, NCT00612209, TrialTroveID-063240",A Phase I Dose Escalation Study of ARQ 197 Given Twice Daily Continuously in Adult Patients with Advanced Solid Tumors.,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Merck & Co. {ArQule},"Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00612209,29921
1237,63237,"ARQ 197 - 205, EudraCT Number: 2007-002727-32, NCT00558207, TrialTroveID-063237",A Randomized Phase II Study of ARQ 197 Versus Gemcitabine in Treatment-NaÃ¯ve Patients With Unresectable Locally Advanced or Metastatic Pancreatic Adenocarcinoma,Oncology,Oncology: Pancreas,Merck & Co. {ArQule},"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Safety and Tolerability",True,NCT00558207,29921
1238,43676,"ARQ 197-101, MCMRC IRB# 06-21, NCT00302172, TrialTroveID-043676",A Phase 1 Dose Escalation Study of ARQ 197 in Adult Patients with Metastatic Solid Tumors.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Merck & Co. {ArQule},"Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability",,True,NCT00302172,29921
1239,372101,"ARTACUS, HCC-20-011, NCI-2020-03018, NCT04349436, RPL-003-19, TrialTroveID-372101","An Open-Label, Multicenter, Phase 1B Study of RP1 in Organ Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma (CSCC)",Oncology,"Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Replimune,"Industry, all other pharma","Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease-free survival, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Stable Disease",True,NCT04349436,117677
1240,364484,TrialTroveID-364484,A Phase II Study of RP1 Monotherapy in Patients with Cutaneous Squamous Cell Carcinoma (CSCC),Oncology,"Oncology: Skin, Squamous Cell Carcinoma (cSCC)",Replimune,"Industry, all other pharma",Safety and Tolerability,,False,,117677
1241,364479,TrialTroveID-364479,A Clinical Study of RP1 in Combination with an Anti-PD-1 Therapy in Anti-PD-1 Refractory Melanoma Patients,Oncology,Oncology: Melanoma,Replimune,"Industry, all other pharma",,,False,,117677
1242,354916,"126555, 20562, CERPASS, EudraCT Number:2018-003964-30, NCI-2019-06779, NCT04050436, RPL-002-18, S19-00585, TrialTroveID-354916, UCI-20-116","A Randomized, Controlled, Open-Label, Phase II Study of Cemiplimab as a Single Agent and in Combination With RP1 in Patients With Advanced Cutaneous Squamous Cell Carcinoma",Oncology,"Oncology: Skin, Squamous Cell Carcinoma (cSCC)","Regeneron, Replimune","Industry, all other pharma, Industry, all other pharma","Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04050436,117677
1243,314671,"20180802, EudraCT Number: 2016-004548-12, IGNYTE, IRAS ID 225425, NCI-2019-01331, NCT03767348, REPL-001-16, RPL-001-16, TrialTroveID-314671","An Open-Label, Multicenter, Phase I/II Study of RP1 as a Single Agent and in Combination with PD1 Blockade in Patients with Solid Tumors",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Skin, Basal Cell Carcinoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","Bristol-Myers Squibb, Replimune","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Immune-related response evaluation criteria in solid tumors, Maximum tolerated dose, Overall response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival",True,NCT03767348,117677
1244,386996,"B8011011, EudraCT Number: 2020-002829-28, NCT04585815, TrialTroveID-386996",A Phase Ib/II Open Label Umbrella Study of Sasanlimab Combined With Anti-Cancer Therapies Targeting Multiple Molecular Mechanisms in Participants With Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Anti-drug antibodies, Area under the curve score, Cmax, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to response, Tmax, Treatment Emergent Adverse Events",True,NCT04585815,118222
1245,362375,"B8011007, B8011007 53135, CTR20202513, EudraCT Number: 2019-003818-14, JapicCTI-205182, NCT04181788, NMRR-20-259-53135, TrialTroveID-362375","A Phase Ib/II Open-Label Study to Evaluate Pharmacokinetics, Safety, Efficacy, and Pharmacodynamics of PF-06801591 (PD-1 Inhibitor) in Participants With Advanced Malignancies",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Dose-limiting toxicities","Anti-drug antibodies, Area under the curve score, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Treatment Emergent Adverse Events",True,NCT04181788,118222
1246,361693,"19-2761, 2019-0905, 20-345, C3861001, GUCY2C, JapicCTI-205241, NCI-2019-08095, NCT04171141, TrialTroveID-361693","A Phase I Dose Escalation And Expansion Study Evaluating The Safety, Tolerability, Pharmacokinetics, Pharmacodynamics And Anti Tumor Activity Of PF-07062119 In Patients With Advanced Gastrointestinal Tumors",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Overall response rate","Anti-drug antibodies, Area under the curve score, Cmax, Cmin, Drug clearance, Duration of overall response, Elimination half-life, Neutralizing antibody response, Overall response rate, Progression-free survival, Tmax",True,NCT04171141,118222
1247,361353,"B8011006, CREST, CTR20202139, EudraCT Number: 2019-003375-19, jRCT2071200044, NCI-2020-05161, NCT04165317, TrialTroveID-361353","A Phase III, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an Anti-PD-1 Antibody, in Combination With Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants With High-Risk, BCG Naive Non-Muscle Invasive Bladder Cancer",Oncology,Oncology: Bladder,Pfizer,"Industry, Top 20 Pharma",Event-free survival,"Adverse Events, Appetite, Common Terminology Criteria for Adverse Events, Complete response-duration, Complete response, EORTC Quality of Life Questionnaire, Global health status, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT04165317,118222
1248,268856,"15-325, 16-C-0079, 20151318, B7791001, i2190, NCI-2016-00393, NCT02616185, PrCa VBIR, PRCA VBIR FIP STUDY, TrialTroveID-268856","A Phase I Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (VBIR) For Prostate Cancer (PF-06753512)",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Treatment Emergent Adverse Events","Anti-drug antibodies, Cmax, Immune Response, Neutralizing antibody response, Tmax",True,NCT02616185,118222
1249,265910,"B8011001, EudraCT Number: 2016-003314-27, ILUN17111, NCI-2016-00704, NCT02573259, REFMAL 431, TrialTroveID-265910","A Phase I, Open-label, Dose Escalation and Expansion Study Of Pf-06801591 In Patients with Locally Advanced or Metastatic Melanoma, Squamous Cell Head And Neck Cancer, Ovarian Cancer, Sarcoma, Non-small Cell Lung Cancer, Urothelial Carcinoma or Other Solid Tumors.",Oncology,"Oncology: Bladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Anti-drug antibodies, Cmax, Disease Progression - duration, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Neutralizing antibody response, Occupancy, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Time to progression, Time to response",True,NCT02573259,118222
1250,391135,"2020-05-175, NCT04656002, TrialTroveID-391135","As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase IIa Clinical Trial to Biomarkers",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,Clinical benefit rate,True,NCT04656002,88408
1251,377006,"MK3475 B37, MP-VAC-205, NCT04515979, TrialTroveID-377006","A Phase II, Open-label, Multicenter Study to Assess the Efficacy and Safety of Vactosertib in Combination With Pembrolizumab as a First-line Treatment for Subjects With PD-L1 Positive Advanced Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",MedPacto,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors",,True,NCT04515979,88408
1252,367215,"2019-10-054, KCT0004983, NCT04258072, TrialTroveID-367215",Phase Ib Study of Vactosertib (TEW-7197) in Combination With Nal-IRI/FL in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine/Nab-Paclitaxel,Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Safety and Tolerability","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04258072,88408
1253,357933,"19-06020285, NCT04103645, TrialTroveID-357933","A 2-tiered, Phase 2, Rule-based, Intra-patient Dose Escalation Study to Investigate Safety and Feasibility of Vactosertib (TEW-7197) in the Treatment of Anemic Patients With Philadelphia Chromosome-negative MPNs (Ph-neg MPNs)",Oncology,Oncology: Myeloproliferative Neoplasms,Weill Medical College of Cornell University,Academic,"Adverse Events, Hemoglobin level, Safety and Tolerability, Spleen Volume Reduction",Histological Response,True,NCT04103645,88408
1254,355697,"ION-03, MP-VAC-202 (ION-03), NCI-2020-05654, NCT04064190, TrialTroveID-355697",A Phase 2 Study of TGF-Ã Inhibition (Vactosertib) With Anti-PD-L1 (Durvalumab) in Patients With Advanced or Recurrent Urothelial Carcinoma Failing to Achieve Response With Checkpoint Inhibition,Oncology,Oncology: Bladder; Oncology: Renal,"AstraZeneca, MedPacto","Industry, Top 20 Pharma, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Immune Response, Overall response rate - time, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Treatment Emergent Adverse Events",True,NCT04064190,88408
1255,340794,"4-2018-0807, KCT0003449, NCT03802084, TrialTroveID-340794","A Phase Ib/IIa, Open-label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Imatinib in Patients With Advanced Desmoid Tumor (Aggressive Fibromatosis)",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Maximum tolerated dose, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03802084,88408
1256,334052,TrialTroveID-334052,"To Evaluate the Safety and Tolerability of TEW-7197 in Patients with Advanced Hepatocellular Carcinoma and to Investigate Preliminary Efficacy in Multicenter, Open-label, Phase I / II Clinical Trials",Oncology,Oncology: Liver,Elevar Therapeutics {LSK BioPharma {LSK BioPartners}},"Industry, all other pharma",Safety and Tolerability,,False,,88408
1257,333279,"MP-VAC-105, NCT03704675, TrialTroveID-333279","Clinical Trial for the Safety, Tolerability, and Pharmacokinetics of TEW-7197 Under Fed or Fasting in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,MedPacto,"Industry, all other pharma","Area under the curve score, Cmax",,True,NCT03704675,88408
1258,333190,"MP-GC-01, NCT03698825, TrialTroveID-333190","An Open-label, Multicenter Phase Ib/IIa Study of TEW-7197 (Vactosertib) Plus Weekly Paclitaxel as Second-line Treatment for Metastatic Gastric Adenocarcinoma",Oncology,Oncology: Gastric,MedPacto,"Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Creatinine kinase level, Overall response rate, Overall survival, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03698825,88408
1259,330604,"Mk3475 Keynote 900, MP-VAC-204, NCT03724851, TrialTroveID-330604","A Phase Ib/IIa Study to Assess the Safety, Tolerability, PK, and Antitumor Activity of Vactosertib in Combination With Pembrolizumab in Patients With Metastatic Colorectal or Gastric Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric,"Merck & Co./Merck Sharp & Dohme (MSD), MedPacto","Industry, Top 20 Pharma, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Plasma concentration, Response rate, Safety and Tolerability",True,NCT03724851,88408
1260,328950,"MP-VAC-203, NCT03732274, TrialTroveID-328950","Phase Ib/IIa, Open Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics, and Antitumor Activity of Vactosertib in Combination With Durvalumab in Patients With Advanced Non Small Cell Lung Cancer Who Progressed Following Platinum-based Chemotherapy",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, MedPacto","Industry, Top 20 Pharma, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03732274,88408
1261,325046,"2017-10-150, KCT0003710, MP-PDAC-01, NCT03666832, TrialTroveID-325046","Multi-center, Open-label, Phase Ib Clinical Trial to Evaluate the Safety, Tolerability, and Exploratory Efficacy of TEW-7197 in Combination With FOLFOX in Patients With Metastatic Pancreatic Ductal Adenocarcinoma Who Have Failed First-Line Gemcitabine and Nab-Paclitaxel",Oncology,Oncology: Pancreas,"(Other Hospital/Academic/Medical Center), MedPacto","Academic, Industry, all other pharma","Progression-free survival, Progressive disease rate",Overall survival,True,NCT03666832,88408
1262,301018,"CASE1A17, NCI-2018-00543, NCT03143985, TrialTroveID-301018",A Phase Ib Trial of Vactosertib in Combination With Pomalidomide (POM) in Relapsed or Relapsed and Refractory Multiple Myeloma (RRMM),Oncology,Oncology: Multiple Myeloma,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response, Duration of overall response, Maximum tolerated dose, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT03143985,88408
1263,297142,"1779GCCC, 19430, 2017-7767, MP-MDS-01, NCI-2018-00774, NCT03074006, TrialTroveID-297142",Phase I/II Study of Vactosertib (TEW-7197) Monotherapy in Patients With Low or Intermediate Myelodysplastic Syndromes,Oncology,Oncology: Myelodysplastic Syndrome,MedPacto,"Industry, all other pharma","Hematologic Improvement, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Adverse Events, Cytogenetic response, Hematologic Improvement, Overall response rate, Quality of Life, Time to progression, Vital signs",True,NCT03074006,88408
1264,210655,"00053834, MP-001, NCT02160106, TrialTroveID-210655",First-in-Human Dose-Escalation Study of Vactosertib (TEW-7197) Monotherapy in Subjects With Advanced Stage Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma","(Other government agency), MedPacto","Government, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose","Dose-limiting toxicities, Treatment Emergent Adverse Events",True,NCT02160106,88408
1265,195691,TrialTroveID-195691,"Tolerability, safety and pharmacokinetics of ridaforolimus in combination with bicalutamide in patients with asymptomatic, metastatic castration-resistant prostate cancer (CRPC)",Oncology,Oncology: Prostate,Merck & Co.,"Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,28941
1266,187622,TrialTroveID-187622,"A Single Dose Open Label, Randomized, 4-period, Partially Fixed-Sequence, Crossover,  Biocomparison Study To Assess Two Pediatric Formulations Of Ridaforolimus (RIDA) To The Provisional Market Formulation In Healthy Subjects",Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,Merck & Co.,"Industry, Top 20 Pharma",,,False,,28941
1267,152700,"12082, 12-C-0138, 8669-056, EudraCT Number: 2011-000729-55, IRAS ID: 87572, Merck 8669-056, MK-8669-056, NCI-12-C-0138, NCRN339, NCT01431534, TrialTroveID-152700, UCSF 12082, UKCRN 11168",A Phase I Study of Ridaforolimus in Pediatric Patients with Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Lymphoma, Hodgkin's; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Area under the curve score, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Gene expression profiling, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT01431534,28941
1268,148917,"MK-8669-059, NCT01380184, TrialTroveID-148917",A Study to Assess the Pharmacokinetics of Ridaforolimus in Chinese Patients,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma",Merck & Co.,"Industry, Top 20 Pharma",Adverse Events,"Area under the curve score, Cmax, Elimination half-life, Tmax",True,NCT01380184,28941
1269,142314,"IDD 10-09, NCT01296659, TrialTroveID-142314",Phase Ib Study of Oral Ridaforolimus in Combination With Standard Chemotherapy for Patients With Advanced Unresectable Soft Tissue Sarcoma.,Oncology,Oncology: Soft Tissue Sarcoma,"Merck & Co., Cancer Therapy & Research Center San Antonio, Texas","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT01296659,28941
1270,142243,"11991, 17028, 2010-0857, 8669-049, CSET 1720, EudraCT number: 2010-020800-31, MDACC# 2010-0857, MK-8669-049, MK-8669-049 AM1, NCT01295632, RECF1669, TrialTroveID-142243, UCI 12-27",Phase I Parallel Protocol of MK-8669 (Ridaforolimus) + MK-2206 and MK-8669 (Ridaforolimus) + MK-0752 Doublets (MK-MK) in Patients With Advanced Cancer,Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate",Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response","Area under the curve score, Plasma concentration",True,NCT01295632,28941
1271,141752,"MK-8669-P005, TrialTroveID-141752","An Open-label, Randomized, 3-Period Crossover study on the Effect of Food on the Pharmacokinetics of Ridaforolimus (AP23573; MK-8669) in Healthy Young Male Subjects.",Oncology,Oncology: Unspecified Cancer,Merck & Co.,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,28941
1272,141751,"MK-8669-P045, TrialTroveID-141751","An open label, randomized, 2-period, fixed-sequence study on the effect of multiple doses of both rifampin and ketoconazole on the single dose pharmacokinetics of ridaforolimus.",Oncology,Oncology: Unspecified Cancer,Merck & Co.,"Industry, Top 20 Pharma",,,False,,28941
1273,139087,"MCC-16472, NCT01256268, TrialTroveID-139087","Phase I A/B Study of Combination Carboplatin, Paclitaxel and Ridaforolimus in Patients With Solid, Endometrial, and Ovarian Cancers",Oncology,Oncology: (N/A); Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Mesothelioma; Oncology: Ovarian,"H. Lee Moffitt Cancer Center and Research Institute, Merck & Co./Merck Sharp & Dohme (MSD)","Academic, Industry, Top 20 Pharma","Duration of overall response, Maximum tolerated dose, Overall response rate, Response rate, Stable Disease","Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01256268,28941
1274,138191,"0646-027, MCC#16483, MK-0646-027, MK-0646-027 AM2, NCT01243762, TrialTroveID-138191","Phase I Parallel Arm Study of MK-0646 (Dalotuzumab) + MK-2206, Dalotuzumab + MK-0752, and Dalotuzumab + MK-8669 (Ridaforolimus) Doublets (MK-MK Doublets) in Patients With Advanced Cancer",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Fallopian Tube; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Merck & Co.,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Heart rate corrected QT interval, Infusion-related reactions, Nausea, Neutropenia, Vomiting","Complete response, Disease Progression, Magnetic Resonance Imaging, Maximum tolerated dose, Partial response, Recurrence, Response evaluation criteria in solid tumors",True,NCT01243762,28941
1275,137405,"10759, 2010IS055, 8669-041, EudraCT Number:2010-019867-13, IEO S571/109, MK-8669-041, MK-8669-041 AM3, MK8669-041-00, MK-8669-P041, NCT01234857, NRO EC INS: 089-10, TrialTroveID-137405, USON 10002","A Two-Part Adaptive, Randomized Trial of Ridaforolimus in Combination With Dalotuzumab Compared to Exemestane or Compared to Ridaforolimus or Dalotuzumab Monotherapy in Estrogen Receptor Positive Breast Cancer Patients",Oncology,Oncology: Breast,Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01234857,28941
1276,136505,"16424, 8669-050, MK-8669-050, NCT01220570, TrialTroveID-136505",A Clinical Trial to Qualify the Growth Factor Signature (GFS) as an Intermediate Biomarker of Response for Development of PI3K-Pathway Inhibitors in Patients With Breast Cancer,Oncology,Oncology: Breast,Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma",,,True,NCT01220570,28941
1277,135611,"BrUOG-Phase 1-233, MK-8669-P051, NCT01212627, TrialTroveID-135611","BrUOG- Phase 1-233: A Phase I Study of Ridaforolimus With Cetuximab for Patients With Advanced Head and Neck Cancer, Non-Small Cell Lung Cancer and Colon Cancer",Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell","Roger Williams Medical Center, Rhode Island Hospital, (Other Hospital/Academic/Medical Center)","Academic, Academic, Academic","Dose-limiting toxicities, Maximum tolerated dose","Dose-limiting toxicities, Maximum tolerated dose",True,NCT01212627,28941
1278,131787,"09-034, FCCC IRB 09-034, IND 109130, MK-8669-P052, NCI-2010-01907, NCT01169532, TrialTroveID-131787",A Phase I Study of Ridaforolimus and Vorinostat in Patients With Advanced Solid Tumors or Lymphoma (IND 109130),Oncology,"Oncology: (N/A); Oncology: Esophageal; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Renal","National Institutes of Health/National Cancer Institute, Fox Chase Cancer Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Lipid Profile, Maximum tolerated dose, Nausea, Safety and Tolerability, Vomiting","Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT01169532,28941
1279,123783,"2009_706, MK8669-046, NCT01043887, TrialTroveID-123783",A Single Dose Study to Investigate the Pharmacokinetics of Ridaforolimus in Patients With Hepatic Insufficiency,Oncology,Oncology: Soft Tissue Sarcoma,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,Cmax,True,NCT01043887,28941
1280,123152,"2010_511, MK8669-044, MK-8669-044, MK-8669-044 AM1, NCT01071304, TrialTroveID-123152",A Study to Evaluate the Effect of Multiple Doses of Ridaforolimus (AP23573; MK-8669) on the Single Dose Pharmacokinetics of Midazolam.,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor",Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Cmax, Elimination half-life, Tmax",,True,NCT01071304,28941
1281,118454,"2009_688, 8669-030, MK8669-030, MK-8669-030, NCT01010672, No-1002, TrialTroveID-118454",A Phase II Study of MK8669 When Administered as Maintenance Therapy to Patients With Metastatic Bone or Soft-tissue Sarcomas,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",,True,NCT01010672,28941
1282,106851,"2009_569, 8669-037, MK8669-037, NCT00874731, TrialTroveID-106851",A Clinical Trial to Assess the Effect of Ridaforolimus (AP23573; MK-8669) on QTc Interval in Patients,Oncology,Oncology: Unspecified Cancer,Merck & Co.,"Industry, Top 20 Pharma",,Adverse Events,True,NCT00874731,28941
1283,105924,"EN 8, EN.8, EN8, TrialTroveID-105924",A Phase III Study of Standard Therapy versus Ridaforolimus in Women with Recurrent or Metastatic Endometrial Cancer Who Have Previously Received Chemotherapy,Oncology,Oncology: Endometrial,Canadian Cancer Trials Group {NCIC Clinical Trials Group},Cooperative Group,Overall survival,"Duration of overall response, Overall response rate, Progression-free survival, Quality of Life, Response rate",False,,28941
1284,104049,"8669-038, AP23573-08-901, MK-8669-038, MK-8669-P038, NCT00836927, TrialTroveID-104049","An Extension Trial of Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, for Patients With Advanced Cancer",Oncology,Oncology: Unspecified Cancer,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability","Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Recurrence, Response evaluation criteria in solid tumors",True,NCT00836927,28941
1285,102999,"09-047, 09-0498, 2008_599, 8669-021, EudraCT Number: 2008-005942-22, MERCK 2008_599, MK8669-021, MK-8669-021 AM1, NCT00818675, TrialTroveID-102999",A Randomized Discontinuation Phase II Trial of Ridaforolimus in Non-Small Cell Lung Cancer (NSCLC) Patients With KRAS Mutations,Oncology,"Oncology: Lung, Non-Small Cell","Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progression-free survival, Stable Disease","Cardiac Telemetry, EQ-5D, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT00818675,28941
1286,99800,"AP23573-08-111, MK-8669-P010, NCT00781846, TrialTroveID-099800","A Phase I Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination With Bevacizumab for Patients With Advanced Cancers.",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","Merck & Co., Takeda {Ariad}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,"Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00781846,28941
1287,97367,"ARIAD-CAN-NCIC-IND192, CAN-NCIC-IND192, I192, IND.192, MK-8669-P039, NCIC IND 192, NCT00770185, TrialTroveID-097367",A Phase II Study of Deforolimus in Patients With Metastatic And/Or Locally Advanced Recurrent Endometrial Cancer,Oncology,Oncology: Endometrial,"Merck & Co., Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Takeda {Ariad}","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Time to progression",Overall response rate - duration,True,NCT00770185,28941
1288,95459,"2008_538, MK8669-004, NCT00730379, REFMAL 139, RM 139, TrialTroveID-095459",A Phase I Study of Ridaforolimus (MK8669) and MK0646 in Patients With Advanced Cancer,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer","Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Maximum tolerated dose",,True,NCT00730379,28941
1289,95035,"08-1294, 2008_572, 8669-002, DRKS00009671, EudraCT Number: 2008-000422-39, MK8669-002, MK8669-002-00, MK-8669-P002, NCRN102, NCT00777959, TrialTroveID-095035, UKCRN: 7368","A Phase II Randomized, Placebo Controlled Clinical Trial to Study the Efficacy and Safety of Bicalutamide with or without Deforolimus (Ridaforolimus) in Men With Asymptomatic, Metastatic Castrate-resistant Prostate Cancer",Oncology,Oncology: Prostate,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, PSA progression, Safety and Tolerability, Vital signs","Area under the curve score, Cmax, Overall response rate, Progression-free survival, PSA progression, Response rate, Tmax",True,NCT00777959,28941
1290,95026,"007-01, 8669-007, AP23573-07-205, AP23573-07-205(8669-007), CTRI/2009/091/000160, EudraCT Number: 2008-000634-53, GYN 22, McG 0907, MK-8669-P007, NCT00739830, TrialTroveID-095026",A Randomized Phase II Trial of Ridaforolimus (AP23573; MK-8669) Compared to Progestin or Chemotherapy in Female Adult Patients With Advanced Endometrial Carcinoma,Oncology,Oncology: Endometrial,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Progression-free survival,"Disease Progression, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00739830,28941
1291,94970,"2008-001971-30r, AP23573-08-207, BRE 151, MK-8669-P009, NCT00736970, RECF1030, TrialTroveID-094970","A Phase II Trial of Oral Deforolimus (AP23573; MK-8669), an mTOR Inhibitor, in Combination with Trastuzumab for Patients with HER2-Positive Trastuzumab-Refractory Metastatic Breast Cancer.",Oncology,Oncology: Breast,"Merck & Co., Takeda {Ariad}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT00736970,28941
1292,93845,"AP23573, AP23573-04-203, EudraCT Number: 2004-005094-29, MK-8669, MK-8669-P019, NCT00122343, TrialTroveID-093845","A Phase II Study of AP23573, an mTOR Inhibitor, in Female Adult Patients With Recurrent or Persistent Endometrial Cancer.",Oncology,Oncology: Endometrial,"Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Clinical benefit rate, Overall response rate, Partial response, Response rate, Stable Disease","Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00122343,28941
1293,92235,"2008_011, MK8669-003, NCT00694083, TrialTroveID-092235",A Phase I Study of MK8669 in Patients With Metastatic or Locally Advanced Solid Tumors,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma",Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma",,,True,NCT00694083,28941
1294,64962,"8669-028, AP23573-07-110, MDACC-2008-0052, MSKCC-08-110, NCT00704054, SUN08-01, TrialTroveID-064962","A Multi-Center Phase I Study of Intravenous Deforolimus (AP23573, MK-8669) Administered QDX5 Every Other Week in Pediatric Patients With Advanced Solid Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma","(Other Cooperative Group), Memorial Sloan-Kettering Cancer Center, H. Lee Moffitt Cancer Center and Research Institute, Takeda {Ariad}, (Other Hospital/Academic/Medical Center), University of Colorado, Merck & Co./Merck Sharp & Dohme (MSD)","Cooperative Group, Academic, Academic, Industry, Top 20 Pharma, Academic, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Maximum tolerated dose, Safety and Tolerability",True,NCT00704054,28941
1295,44538,"08-0343, 2008IS067, 8669-011, ACTRN12608000214336, AP23573-07-302, CTRI/2008/091/000008, EudraCT Number: 2007-003462-18, GCC0770, MK-8669-P011, NCT00538239, PARIAD002 /08-009, RECF0776, SUCCEED, TrialTroveID-044538, VICCSAR0854",A Pivotal Trial to Determine the Efficacy and Safety of AP23573 When Administered as Maintenance Therapy to Patients With Metastatic Soft-Tissue or Bone Sarcomas,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"EORTC Soft Tissue and Bone Sarcoma Group, Takeda {Ariad}, Merck & Co./Merck Sharp & Dohme (MSD), Sarcoma Alliance for Research through Collaboration","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group","Progression-free survival, Recurrence","Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT00538239,28941
1296,44356,"2005-046, AP23573-05-107, MK-8669-P015, NCT00288431, TrialTroveID-044356, WSU# 2005-046","A Phase IB, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination with Doxorubicin.",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,Takeda {Ariad},"Industry, Top 20 Pharma",Maximum tolerated dose,Maximum tolerated dose,True,NCT00288431,28941
1297,27980,"AP23573-04-204, IRB 6712, MK-8669-P017, NCT00110188, Pro00006712, TrialTroveID-027980",A Phase II Study of the Efficacy and Safety of AP23573 in Patients With Taxane-Resistant Androgen-Independent Prostate Cancer (AIPC).,Oncology,Oncology: Prostate,Takeda {Ariad},"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT00110188,28941
1298,27955,"62383, AP23573-05-106, MK-8669-P016, NCT00112372, TrialTroveID-027955","A Phase I/IIa, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability and Maximum Tolerated Dose of AP23573 when Administered Orally in Patients with Refractory or Advanced Malignancies.",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Merck & Co., Takeda {Ariad}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00112372,28941
1299,27708,"AP23573.104, STUDIO INT 05/15, TrialTroveID-027708",A phase lb pharmacokinetic and pharmacodynamic study to define the optimal dose for combining the mTOR inhibitor AP23573 with paclitaxel (PTX).,Oncology,"Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma","Takeda {Ariad}, Southern Europe New Drug Organization","Industry, Top 20 Pharma, Not for Profit Funding Entity",,,False,,28941
1300,27707,"AP23573.105, MK-8669-P012, Studio INT 05/16, TrialTroveID-027707",A phase lb pharmacokinetic and pharmacodynamic study to define the optimal dose for combining the mTOR inhibitor AP23573 with capecitabine.,Oncology,"Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Takeda {Ariad}, Southern Europe New Drug Organization","Industry, Top 20 Pharma, Not for Profit Funding Entity",,,False,,28941
1301,26231,"11S-04-1, 8669-018, AP23573-04-202, EudraCT 2004-002231-92, MK-8669-P018, NCT00093080, TrialTroveID-026231","A Phase II Study of AP23573, An mTOR Inhibitor, in Patients With Advanced Sarcoma",Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"Merck & Co., Takeda {Ariad}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Clinical benefit rate, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00093080,28941
1302,19866,"04104, 1196, AP23573-04-103, CCF IRB 6976, MDACC-2005-0093, MK-8669-P023, NCT00087451, TrialTroveID-019866",A Phase I Sequential Ascending Dose Trial of AP23573 in Patients with Progressive or Recurrent Malignant Glioma,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma",Takeda {Ariad},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Progression-free survival, Quality of Life",True,NCT00087451,28941
1303,10889,"04118, 2004-0362, AP23573-04-201, MK-8669-P024, NCT00086125, TrialTroveID-010889","A Phase II Study of AP23573, an mTOR Inhibitor, in Patients with Relapsed or Refractory Hematologic Malignancies.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",Takeda {Ariad},"Industry, Top 20 Pharma","Overall response rate, Response rate","Duration of overall response, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00086125,28941
1304,9273,"AP23573-02-101, MK-8669-P001, NCT00060632, TrialTroveID-009273","A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of AP23573, an mTOR Inhibitor, in Patients with Refractory or Advanced Malignancies",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Takeda {Ariad},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,True,NCT00060632,28941
1305,6718,"AP23573-02-102, MK-8669-P013, NCT00060645, TrialTroveID-006718","A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Daily x 5 Administration of AP23573, an mTOR Inhibitor, in Patients with Refractory or Advanced Malignancies.",Oncology,"Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer",Takeda {Ariad},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,True,NCT00060645,28941
1306,336851,"H-43405 VISTA, NCT03740256, TrialTroveID-336851, VISTA",A First in Human Phase I Trial of Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR T Cells in Patients With Advanced HER2 Positive Solid Tumors,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","Baylor College of Medicine, (Other Hospital/Academic/Medical Center), Tessa Therapeutics {FF CanVac}","Academic, Academic, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT03740256,112603
1307,399353,"ACROPOLI, ACROPOLI (SOLTI-1904), NCT04802876, TrialTroveID-399353",Efficacy of Spartalizumab Across Multiple Cancer-types in Patients With PD1-high mRNA Expressing Tumors Defined by a Single and Pre-specified Cutoff,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Cancer","Novartis, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to response, Treatment Emergent Adverse Events",True,NCT04802876,86442
1308,395911,"EudraCT Number: 2020-004497-21, GASPAR, NCT04736485, TrialTroveID-395911","Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT): A Phase II Study (GASPAR)",Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute","Academic, Government",Complete response,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Mortality, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04736485,86442
1309,393679,"CJDQ443A12101, EudraCT Number: 2020-004129-22, jRCT2031200379, NCI-2021-01594, NCT04699188, TrialTroveID-393679","A Phase Ib/II Open-label, Multi-center Dose Escalation Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation",Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs",True,NCT04699188,86442
1310,386649,"NCT04581343, PanCAN-SR1, TrialTroveID-386649",A Phase IB Study to Determine the Safety and Tolerability and Confirm the Dose of Canakinumab and Spartalizumab in Combination With Nab-paclitaxel and Gemcitabine for Patients With Metastatic Pancreatic Cancer,Oncology,Oncology: Pancreas,"Novartis, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Dose-limiting toxicities,"Anti-drug antibodies, C reactive protein, Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to response",True,NCT04581343,86442
1311,384209,"20-258, NCT04544111, TrialTroveID-384209",Phase II Study of PDR001 in Combination With MAPK Pathway Inhibitors in Patients With Radioiodine-Refractory Thyroid Cancer,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,Memorial Sloan-Kettering Cancer Center,Academic,"Overall response rate, Response evaluation criteria in solid tumors",,True,NCT04544111,86442
1312,374787,"CNIS793B12201, EudraCT Number: 2020-000349-14, JapicCTI-205420, NCT04390763, TrialTroveID-374787","A Phase II, Open Label, Randomized, Parallel Arm Study of NIS793 (With and Without Spartalizumab) in Combination With SOC Chemotherapy Gemcitabine/Nab-paclitaxel, and Gemcitabine/Nab-paclitaxel Alone in First-line Metastatic Pancreatic Ductal Adenocarcinoma (mPDAC)",Oncology,Oncology: Pancreas,Novartis,"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Dose-limiting toxicities, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs","Adverse Events, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to progression, Vital signs",True,NCT04390763,86442
1313,370480,"CINC280J12201, EudraCT Number: 2019-003097-11, INC280J12201, JapicCTI-205439, NCI-2021-01896, NCT04323436, TrialTroveID-370480","A Double-blind, Placebo Controlled, Randomized, Phase II Study Evaluating the Efficacy and Safety of Capmatinib and Spartalizumab vs Capmatinib and Placebo as 1st Line Treatment for Advanced NSCLC Patients With MET exon14 Skipping Mutations",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to response, Tmax",True,NCT04323436,86442
1314,369959,"2019-0906, ALTER-PATH NeoDT, NCI-2020-00941, NCT04310397, TrialTroveID-369959",Altering Adjuvant Therapy Based on Pathologic Response to Neoadjuvant Dabrafenib and Trametinib (ALTER-PATH NeoDT),Oncology,Oncology: Melanoma,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Complete response, Disease-free survival, Recurrence","Adverse Events, Complete response, Disease-free survival, Metastasis-free survival, Overall survival, Recurrence, Resection rate, Safety and Tolerability",True,NCT04310397,86442
1315,368991,"CADPT01C12101, NCI-2020-05789, NCT04294160, TrialTroveID-368991","A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Drug Combinations in Adult Patients With Advanced or Metastatic BRAF V600 Colorectal Cancer",Oncology,Oncology: Colorectal,Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Vital signs","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Tmax",True,NCT04294160,86442
1316,368435,"CMBG453D12101, EudraCT Number: 2019-003738-18, NCI-2020-08195, NCT04283526, TrialTroveID-368435","A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Combinations in Adult Patients With Myelofibrosis",Oncology,Oncology: Myeloproliferative Neoplasms,Novartis,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Safety and Tolerability, Serious Adverse Events, Vital signs","Absolute Neutrophil Count, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Hemoglobin level, Partial response, Platelet count, Progression-free survival, Progressive disease rate, Spleen Volume Reduction, Stable Disease, Time to progression, Tmax",True,NCT04283526,86442
1317,364511,"201907017MIPD, CPDR001A0TW01T, NCT04213404, RISE-HN, TrialTroveID-364511","Ribociclib and Spartalizumab for Head and Neck Squamous Cell Carcinoma, A Phase I Study With Expansion Cohort (RISE-HN)",Oncology,Oncology: Head/Neck,"Novartis, National Taiwan University Hospital","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival",True,NCT04213404,86442
1318,363008,"NCI-2018-01793, NCT04191421, TrialTroveID-363008, Winship4463-18",A Phase Ib/II Trial of Siltuximab and Spartalizumab in Metastatic Pancreatic Cancer,Oncology,Oncology: Pancreas,"Novartis, Jazz Pharmaceuticals {Jazz Pharmaceuticals/EUSA Pharma {Cytogen}}, Emory University Hospital - Atlanta","Industry, Top 20 Pharma, Industry, all other pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Complete response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04191421,86442
1319,355470,"CPDR001X2X01B, CTR20210043, NCI-2020-04603, NCT04058756, TrialTroveID-355470","An Open-label, Multi-center Rollover Protocol for Continued Characterization of Safety and Tolerability for Subjects Who Have Participated in a Novartis-sponsored Spartalizumab Study as Single Agent or in Combination With Other Study Treatments",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events",,True,NCT04058756,86442
1320,353760,"AAAS2814, NCI-2020-01069, NCT04028245, SPARC-1, TrialTroveID-353760",A Pilot Study of Neoadjuvant Combination Spartalizumab and Canakinumab Prior to Radical Nephrectomy in Patients With Localized Clear Cell Renal Cell Carcinoma (SPARC-1 Trial),Oncology,Oncology: Renal,"Novartis, Columbia University Medical Center","Industry, Top 20 Pharma, Academic",Safety and Tolerability,"Immune Response, Overall response rate, Response evaluation criteria in solid tumors",True,NCT04028245,86442
1321,351289,"201904832, NCT03982134, TrialTroveID-351289",Phase Ib Study to Assess Safety and Tolerability of PDR001 in Combination With Panobinostat in Metastatic Melanoma and Non-small Cell Lung Cancer After Failure of Prior Anti PD1 or PD-L1 Therapy,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Melanoma","Novartis, University of Iowa","Industry, Top 20 Pharma, Academic","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03982134,86442
1322,349298,"4-2018-1171, KCT0004933, NCT03945227, PASTURE, TrialTroveID-349298",A Phase II Clinical Trial for Evaluating Efficacy and Safety of PDR001 in Concurrent Plus Consolidation Versus Consolidation Only in Addition to Standard Chemoradiotherapy in Unresectable Stage III NSCLC Patients (PASTURE),Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03945227,86442
1323,346263,"19-244, CDKY709A12101C, NCT03891953, TrialTroveID-346263","A Phase I/Ib, Open-label, Multi-center, Study of DKY709 as a Single Agent and in Combination With PDR001 in Patients With Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Area under the curve score, Cmax, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Progression-free survival, Time to progression, Tmax",True,NCT03891953,86442
1324,339490,"4-2018-0938, KCT0003631, KM-12, MCS110PDR001, NCT03785496, TrialTroveID-339490",Phase II Study of PDR001 in Combination With MCS110 in Patients With Squamous Cell Carcinoma of the Esophagus.,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Immune-related response evaluation criteria in solid tumors, Overall response rate, Recurrence, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Immune-related response evaluation criteria in solid tumors, Magnetic Resonance Imaging, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT03785496,86442
1325,336814,"19-120, BRE 330, BRE036, CADPT01A12101C, EudraCT Number: 2018-002244-82, JapicCTI-194628, NCI-2019-02809, NCT03742349, NL68735.031.19, TrialTroveID-336814","A Phase Ib, Multicenter, Open-label Dose Escalation and Expansion Platform Study of Select Immunotherapy Combinations in Adult Patients With Triple-negative Breast Cancer",Oncology,Oncology: Breast,Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Anti-drug antibodies, Area under the curve score, Cmax, Immune-related response evaluation criteria in solid tumors, Overall response rate, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Tmax",True,NCT03742349,86442
1326,333945,"H-1710-062-893, KCT0003237, NCT03694977, TrialTroveID-333945",Biomarker Study of PDR001 in Combination With MCS110 in Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT03694977,86442
1327,332781,"18-144, NCI-2018-02374, NCT03668431, TrialTroveID-332781",A Phase II Study of Dabrafenib and Trametinib in Combination With PDR001 in Patients With BRAFV600E Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"(Other Industry Sponsor), Novartis, Massachusetts General Hospital","Industry, all other pharma, Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03668431,86442
1328,331664,"2018-0610, KCT0002975, NCT03693326, PDR001 study, STARTER_PDR001, TrialTroveID-331664","An Open-Label, Multicenter, Phase II Study of PDR001 in Patients with Non-Small Cell Lung Cancer Harboring KRAS/NRAS Mutation or Without Actionable Genetic Abnormalities, Detected Using NGS Platform",Oncology,"Oncology: Lung, Non-Small Cell",Asan Medical Center,Academic,"Complete response, Overall response rate, Overall survival, Partial response","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT03693326,86442
1329,329379,"2018-0859, AMC1802, GIST PDR001, KCT0003086, NCT03609424, TrialTroveID-329379","A Phase Ib/II Study Of PDR001 Plus Imatinib For Metastatic Or Unresectable GIST With Prior Failure Of Imatinib, Sunitinib And Regorafenib",Oncology,Oncology: GIST,"Novartis, Asan Medical Center","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Stable Disease","Clinical benefit rate, Disease Progression, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT03609424,86442
1330,325444,"CINC280D2201, EudraCT Number: 2018-001420-19, JapicCTI-194614, NCI-2019-01029, NCT03647488, NL67932.091.18, TrialTroveID-325444","A Phase II Multicenter Randomized Two-arm Study of Capmatinib (INC280, an oral MET inhibitor) and Spartalizumab (PDR001, a PD-1 inhibitor) Combination Therapy vs Docetaxel in Pretreated Adult Patients With EGFR Wild-type ALK Rearrangement Negative Advanced/Metastatic Non-small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma","Adverse Events, Overall survival, Safety and Tolerability, Safety and Tolerability, Vital signs","Adverse Events, Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to response, Tmax",True,NCT03647488,86442
1331,321663,"18-625, 2018-00902, CPDR001J2201, CSET 2762, EudraCT Number: 2018-000610-38, NCI-2018-01379, NCT03484923, NL65729.031.18, PLATforM, S18-00341, SNCTP000003159, TrialTroveID-321663","A Randomized, Open-label, Phase II Open Platform Study Evaluating the Efficacy and Safety of Novel Spartalizumab (PDR001) Combinations in Previously Treated Unresectable or Metastatic Melanoma",Oncology,Oncology: Melanoma,Novartis,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Anti-drug antibodies, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03484923,86442
1332,314163,"NCI-2018-00157, NCT03365791, TrialTroveID-314163, TX8855",Modular Phase II Study to Link Combination Immune-therapy to Patients With Advanced Solid and Hematologic Malignancies. Module 9: PDR001 Plus LAG525 for Patients With Advanced Solid and Hematologic Malignancies.,Oncology,"Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Hematological Cancer",Novartis,"Industry, Top 20 Pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events, Time to response, Vital signs",True,NCT03365791,86442
1333,310446,"2017-0821, CLHC165X2101, IEO 717, JapicCTI-183904, NCI-2018-00068, NCT03301896, TrialTroveID-310446","A Phase I/Ib, Open-label, Multi-center Dose-escalation and Dose-expansion Study of the Safety and Tolerability of Intra-tumorally Administered LHC165 Single Agent and in Combination With PDR001 in Patients With Advanced Malignancies",Oncology,Oncology: Head/Neck; Oncology: Melanoma; Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Serious Adverse Events, Vital signs","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Tmax",True,NCT03301896,86442
1334,310048,"17-285, NCI-2017-02349, NCT03294694, TrialTroveID-310048",A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Combination With the PD-1 Inhibitor PDR001 in Patients With Metastatic Hormone Receptor-positive Breast Cancer and Metastatic Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian,"Novartis, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Microbiome, Overall response rate, Partial response, Response evaluation criteria in solid tumors",True,NCT03294694,86442
1335,304736,"19228, CNIR178X2201, EudraCT Number: 2017-000241-49, J1791, NCI-2017-02241, NCT03207867, NL62490.056.17, TrialTroveID-304736","A Phase II, Multi-center, Open Label Study of NIR178 in Combination With PDR001 in Patients With Selected Advanced Solid Tumors and Non-Hodgkin Lymphoma",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",Novartis,"Industry, Top 20 Pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT03207867,86442
1336,302858,"CPDR001I2101, CRC-101, ElevatION, ElevatION CRC101, EudraCT Number: 2017-000520-96, IRAS ID: 228700, MOH_2017-09-06_000786, NCT03176264, TrialTroveID-302858",ElevatION: CRC-101: A Phase Ib Study of PDR001 in Combination With Bevacizumab and mFOLFOX6 as First Line Therapy in Patients With Metastatic MSS Colorectal Cancer,Oncology,Oncology: Colorectal,Novartis,"Industry, Top 20 Pharma","Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03176264,86442
1337,299348,"CPDR001X2106, CR1716NS, NCI-2018-00833, NCT03111992, TrialTroveID-299348","Phase I/Ib, Multi-center, Open-label, Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Relapsed and/or Refractory Multiple Myeloma",Oncology,Oncology: Multiple Myeloma,Novartis,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Treatment Emergent Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Elimination half-life, Overall response rate, Progression-free survival, Tmax",True,NCT03111992,86442
1338,297714,"CPDR001I2102, CR1721NS, EudraCT Number: 2017-000466-30, MOH_2017-07-02_000507, NCT03081494, NL61135.058.17, TrialTroveID-297714",Phase Ib Study of PDR001 in Combination With Regorafenib in Adult Patients With Previously Treated Metastatic Microsatellite Stable (MSS) Colorectal Cancer,Oncology,Oncology: Colorectal,Novartis,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Dose-limiting toxicities","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs",True,NCT03081494,86442
1339,296667,"17-293, 2017-0256, CPDR001X2105, EudraCT Number: 2016-005060-33, IRAS ID-224410, NCI-2017-02439, NCT03066648, NL61755.029.17, TrialTroveID-296667","Phase Ib, Multi-arm, Open-label Study of PDR001 and/or MBG453 in Combination With Decitabine in Patients With Acute Myeloid Leukemia or High Risk Myelodysplastic Syndrome.",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Progression-free survival, Time to progression, Tmax",True,NCT03066648,86442
1340,296608,"17-1021, CPDR001C2101, CRO-2017-18, ELEVATION 101, ElevatION:NSCLC-101, EudraCT Number: 2016-002815-17, JapicCTI-184238, NCI-2017-01064, NCT03064854, NL60666.031.17, TrialTroveID-296608","Phase Ib, Multicenter, Open Label Study of PDR001 in Combination With Platinum-doublet Chemotherapy in PD-L1 Unselected, Metastatic NSCLC Patients (ElevatION:NSCLC-101 Trial)",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma","Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT03064854,86442
1341,292118,"CPDR001G2101, EudraCT Number: 2016-004131-20, JapicCTI-173589, NCI-2017-01376, NCT02988440, SNCTP000002321, TrialTroveID-292118",A Phase Ib Study of PDR001 in Combination With Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,Novartis,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Serious Adverse Events, Vital signs","Area under the curve score, Cmax, Disease Progression, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors, Tmax",True,NCT02988440,86442
1342,290878,"052592, 19474, 2017-0134, 2017-0173, COMBI-1, COMBI-i, COMBI-I -CPDR001F2301, CPDR001F2301, CSET 2513, EudraCT Number: 2016-002794-35, GYFKK/66/2017, IRAS ID: 219950, JapicCTI-173660, NCI-2017-00814, NCT02967692, NL59819.028.16, OGYÃI/33605-5/2017, PDR001F2301, S17-00325, SNCTP000002080, TrialTroveID-290878, UCI-17-09","A Randomized, Double-blind, Placebo-controlled, Phase III Study Comparing the Combination of PDR001, Dabrafenib and Trametinib Versus Placebo, Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma",Oncology,Oncology: Melanoma,Novartis,"Industry, Top 20 Pharma","Disease Progression, Dose-limiting toxicities, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Global health status, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02967692,86442
1343,290113,"16415, CPDR001E2201, ElevatION:NET-201, EudraCT Number: 2016-002522-36, i2395, IRAS ID: 212451, JapicCTI-173569, NCI-2017-00420, NCT02955069, RECF3368, slut_PDR001, SNCTP000002181, TrialTroveID-290113","An Open Label Phase II Study to Evaluate the Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC), That Have Progressed on Prior Treatment.",Oncology,Oncology: Neuroendocrine,Novartis,"Industry, Top 20 Pharma","Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Appetite, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Global health status, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT02955069,86442
1344,289503,"BASEC2019-01157, CNIS793X2101, EudraCT Number: 2016-003044-36, JapicCTI-173749, NCI-2018-02440, NCT02947165, TrialTroveID-289503","A Phase I/Ib, Open-label, Multi-center Dose Escalation Study of NIS793 in Combination With PDR001 in Adult Patients With Advanced Malignancies",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma",Adverse Events,"Area under the curve score, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT02947165,86442
1345,285976,"16-423, 20162431, 94144, CPDR001X2102, CTMS# 16-0058, EudraCT Number: 2016-000654-35, IRAS ID: 209571, J16108, NCI-2016-01890, NCT02890069, NL57900.041.16, TrialTroveID-285976, UW16037","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With LCL161, Everolimus (RAD001) or Panobinostat (LBH589)",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Renal",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs","Area under the curve score, Cardiac Telemetry, Cmax, Cmin, Disease Progression, Immune Response, Overall response rate, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT02890069,86442
1346,285688,"16-479, 2016-0382, CPDR001X2103, EudraCT Number: 2016-000633-49, NCI-2018-00202, NCT02900664, REFMAL 466, TrialTroveID-285688","Phase Ib, Open-label, Multi-center Study to Characterize the Safety, Tolerability and Pharmacodynamics (PD) of PDR001 in Combination With CJM112, EGF816, Ilaris (Canakinumab) or Mekinist (Trametinib)",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs","Adverse Events, Cardiac Telemetry, Disease Progression, Overall response rate, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax, Vital signs",True,NCT02900664,86442
1347,282222,"2016-0657, 20-369, CBLZ945X2101, CTMS# 16-0071, EudraCT Number: 2015-005806-12, JapicCTI-183903, NCI-2016-01505, NCT02829723, SNCTP000003182, TrialTroveID-282222","A Phase I/II, Open-label, Multi-center Study of the Safety and Efficacy of BLZ945 as Single Agent and in Combination With PDR001 in Adults Patients With Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT02829723,86442
1348,280420,"16-491, 2016-01872, 2016-0394, ACT012, CMCS110Z2102, EudraCT Number: 2016-000210-29, JapicCTI-173724, NCI-2016-01142, NCT02807844, TrialTroveID-280420","A Phase Ib/II, Open Label, Multicenter Study Of MCS110 In Combination With PDR001 In Patients With Advanced Malignancies",Oncology,Oncology: Breast; Oncology: Endometrial; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT02807844,86442
1349,276827,"16-1447, 16-306, CGWN323X2101, EudraCT Number: 2015-004206-42, IRAS ID: 201239, JapicCTI-183922, MOH_2017-01-05_000036, NCI-2016-00997, NCT02740270, TrialTroveID-276827","A Phase I/Ib Open-label, Multi-center, Dose Escalation Study of GWN323 (Anti-GITR) as a Single Agent and in Combination With PDR001 (Anti-PD-1) in Patients With Advanced Solid Tumors and Lymphomas",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02740270,86442
1350,272828,"CPDR001X1101, JapicCTI-163149, NCT02678260, TrialTroveID-272828",A Phase-I Study of PDR001 Administered to Japanese Patients With Advanced Malignancies,Oncology,Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Ovarian,Novartis,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Area under the curve score, Clinical benefit rate, Cmax, Elimination half-life, Overall response rate - duration, Overall response rate, Tmax",True,NCT02678260,86442
1351,268216,"16-225, 18-108, 2015-0913, CLXH254X2101, EudraCT Number: 2015-003421-33, JapicCTI-163224, NCI-2015-02280, NCT02607813, NL55506.078.15, Nov RAFi (CLXH254X2101), REec-2016-2132, SNCTP000002708, TrialTroveID-268216",A Phase I Dose Finding Study of Oral LXH254 in Adult Patients With Advanced Solid Tumors Harboring MAPK Pathway Alterations,Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response rate, Tmax",True,NCT02607813,86442
1352,268196,"16-214, 2015-0637, CMBG453X2101, CT864, EudraCT Number: 2015-002354-12, J15195, JapicCTI-163357, NCI-2015-02091, NCT02608268, NL55479.058.15, SNCTP000002894, TrialTroveID-268196",Phase I-Ib/II Open-label Multi-center Study of the Safety and Efficacy of MBG453 as Single Agent and in Combination With PDR001 in Adult Patients With Advanced Malignancies,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Area under the curve score, Cmax, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Tmax, Vital signs, Volume of distribution",True,NCT02608268,86442
1353,268151,"CPDR001X2201, CTR20170837, EudraCT Number: 2015-000454-38, NCI-2017-00609, NCT02605967, RECF3102, s16-01993, TrialTroveID-268151","A Phase II, Open-label, Randomized Controlled Study of PDR001 in Patients With Moderately Differentiated/Undifferentiated Locally Advanced Recurrent or Metastatic Nasopharyngeal Carcinoma Who Progressed on Standard Treatment",Oncology,Oncology: Head/Neck,Novartis,"Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cmax, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to progression, Tmax, Vital signs",True,NCT02605967,86442
1354,258664,"15-185, 2015-0263, 82831, CLAG525X2101C, CTMS# 15-2054, EudraCT Number: 2015-000449-21, JapicCTI-163304, NCI-2015-00966, NCT02460224, TrialTroveID-258664","A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies",Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Renal; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax, Vital signs",True,NCT02460224,86442
1355,254737,"18321, AdenONCO, MC18321, NCI-2015-01728, NCT02403193, PBFCC07, TrialTroveID-254737",Phase I/Ib Trial of Single Agent PBF-509 and in Combination With PDR001 for Patients With Advanced NSCLC,Oncology,"Oncology: Lung, Non-Small Cell","Novartis, H. Lee Moffitt Cancer Center and Research Institute, Palobiofarma","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability","Accumulation index, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Tmax, Volume of distribution",True,NCT02403193,86442
1356,254661,"15-157, 2015-0075, 3388, 7805 / p, 82223, CPDR001X2101, CSET 2267, EudraCT Number: 2014-003929-17, J1541, LBCTR2019060201, NCI-2015-00577, NCT02404441, NL52948.058.15, RECF2966, REFMAL 393, TrialTroveID-254661",Open Label Multicenter Phase I/II Study of the Safety and Efficacy of PDR001 Administered to Patients With Advanced Malignancies,Oncology,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Novartis,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax, Vital signs",True,NCT02404441,86442
1357,370358,"2019-1166, JTX-2011-R01, NCI-2020-03403, NCT04319224, TrialTroveID-370358","An Open-label, Multi-center, Rollover Study in Subjects With Advanced Solid Tumor Malignancies After Participation in a Vopratelimab (JTX-2011) Clinical Study",Oncology,Oncology: Unspecified Solid Tumor,Jounce Therapeutics,"Industry, all other pharma","Adverse Events, Serious Adverse Events",Progression-free survival,True,NCT04319224,80892
1358,365203,"EudraCT Number: 2019-004953-96, JTX-4014-202, NCT04549025, SELECT, TrialTroveID-365203","Phase II Study of PD-1 Inhibitor JTX-4014 Alone and in Combination with Vopratelimab, an Icos Agonist, in Biomarker-selected Subjects with Metastatic NSCLC after One Prior Platinum-containing Regimen",Oncology,"Oncology: Lung, Non-Small Cell",Jounce Therapeutics,"Industry, all other pharma",,"Clinical benefit rate, Duration of overall response, Neutralizing antibody response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04549025,80892
1359,351687,"19-365, 2019-0489, EMERGE, JTX-2011-201, NCI-2019-04198, NCT03989362, TrialTroveID-351687",Phase II Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) Vopratelimab (JTX -2011) and a CTLA-4 Inhibitor in PD-1/PD-L1 Inhibitor Experienced Adult Subjects With Non-small Cell Lung Cancer or Urothelial Cancer,Oncology,"Oncology: Bladder; Oncology: Lung, Non-Small Cell",Jounce Therapeutics,"Industry, all other pharma",Overall response rate,"Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Duration of overall response, Neutralizing antibody response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Volume of distribution",True,NCT03989362,80892
1360,277953,"1606017922, 16-501, 16-966, 2016-0386, 201608036, 20162312, ICONIC, JTX-2011-101, NCI-2016-01652, NCT02904226, TrialTroveID-277953","Phase I/II Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination With Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects With Advanced and/or Refractory Solid Tumor Malignancies",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Jounce Therapeutics,"Industry, all other pharma","Adverse Events, Anti-drug antibodies, Complete response, Dose-limiting toxicities, Duration of overall response, Maximum tolerated dose, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Mean residence time, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Tmax, Volume of distribution",True,NCT02904226,80892
1361,398742,"21-x066, NCT04791839, TrialTroveID-398742",A Pilot Study to Evaluate the Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Washington University School of Medicine, Arcus Biosciences","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events",True,NCT04791839,141448
1362,395920,"ARC-10, NCT04736173, TrialTroveID-395920","A Phase III Study to Evaluate Zimberelimab (AB122) Monotherapy Compared to Standard Chemotherapy or Zimberelimab Combined With AB154 in Front-Line, PD-L1-Positive, Locally Advanced or Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Arcus Biosciences,"Industry, all other pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Response evaluation criteria in solid tumors",True,NCT04736173,141448
1363,391362,"ARC-9, NCT04660812, TrialTroveID-391362","A Phase Ib/II, Open-Label, Randomized Platform Study Evaluating The Efficacy and Safety of Etrumadenant (AB928) Based Treatment Combinations in Patients With Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,Arcus Biosciences,"Industry, all other pharma","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",,True,NCT04660812,141448
1364,391120,"2000028799, NCT04656535, TrialTroveID-391120",A Multi-Center Phase 0/I Trial of Anti-TIGIT Antibody AB154 in Combination With Anti-PD-1 Antibody AB122 for Recurrent Glioblastoma.,Oncology,"Oncology: CNS, Glioblastoma","Yale University, Arcus Biosciences","Academic, Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",Immune Response,True,NCT04656535,141448
1365,368501,"ARC-6, NCI-2020-04162, NCT04381832, S19-01947, TrialTroveID-368501","A Phase Ib/II, Open-Label, Randomized Platform Study Evaluating the Efficacy and Safety of AB928-Based Treatment Combinations in Patients With Metastatic Castrate Resistant Prostate Cancer",Oncology,Oncology: Prostate,Arcus Biosciences,"Industry, all other pharma","Adverse Events, Overall response rate, Partial response, Serious Adverse Events","Anti-drug antibodies, Disease Progression, Overall response rate, Plasma concentration, PSA progression, Response evaluation criteria in solid tumors",True,NCT04381832,141448
1366,367313,"AB154CSP0002, AB154CSP0002 (ARC-7), ARC-7, NCI-2020-04927, NCT04262856, TrialTroveID-367313","A Phase II Study to Evaluate the Safety and Efficacy of AB122 Monotherapy, AB154 in Combination With AB122, and AB154 in Combination With AB122 and AB928 in Front-Line, Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Arcus Biosciences,"Industry, all other pharma","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors",True,NCT04262856,141448
1367,350686,"ChiCTR1900023529, CTR20190394, NCT03972722, TrialTroveID-350686, YH-S001-05","An Open, Multi-center, Single-arm Phase II Clinical Study to Evaluate the Efficacy and Safety of Recombinant Fully Human Anti-PD-1 Monoclonal Antibody (GLS-010 Injection) in Patients With Recurrent or Metastatic Cervical Cancer",Oncology,Oncology: Cervical,"(Other Hospital/Academic/Medical Center), Harbin Gloria Pharmaceuticals Co., Wuxi Apptec {Wuxi PharmaTech}, Harbin Gloria Pharmaceuticals Co./Guangzhou Gloria Biotechnology Co.","Academic, Industry, all other pharma, Miscellaneous, Industry, all other pharma",Overall response rate,"Adverse Events, Clinical benefit rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03972722,141448
1368,349025,"AB122CSP0002, NCI-2019-06713, NCT04087018, TrialTroveID-349025",A Phase Ib Study to Evaluate the Safety and Clinical Activity of AB122 in Biomarker-Selected Participants With Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Arcus Biosciences, Strata Oncology","Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Time to response, Treatment Emergent Adverse Events",True,NCT04087018,141448
1369,337640,"15121, 20-070, 2019-1098, AAAS7260, AB680CSP0002, ARC-8, NCI-2019-08489, NCT04104672, TrialTroveID-337640",A Phase I Study to Evaluate the Safety and Tolerability of AB680 Combination Therapy in Participants With Gastrointestinal Malignancies.,Oncology,Oncology: Pancreas,Arcus Biosciences,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events","Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT04104672,141448
1370,330954,"ChiCTR1800018042, CTR20181224, NCT03655483, TrialTroveID-330954, YH-S001-04","A Single-arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of GLS-010 Injection in the Treatment of Recurrent or Refractory Classical Hodgkin's Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's","(Other Hospital/Academic/Medical Center), Harbin Gloria Pharmaceuticals Co., Wuxi Apptec {Wuxi PharmaTech}, Harbin Gloria Pharmaceuticals Co./Guangzhou Gloria Biotechnology Co.","Academic, Industry, all other pharma, Miscellaneous, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate","Adverse Events, Clinical benefit rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03655483,141448
1371,330440,"AB928-005, AB928CSP0005, NCT03629756, Study 005, TrialTroveID-330440",A Phase I Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Advanced Malignancies,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Arcus Biosciences,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities","Anti-drug antibodies, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Occupancy, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT03629756,141448
1372,322848,"18-234, AB928-004, AB928CSP0004, ARC-4 study, KCT0004139, NCI-2020-00875, NCT03846310, Study 004, TrialTroveID-322848",A Phase I/Ib Study to Evaluate the Safety and Tolerability of Immunotherapy Combinations in Participants With Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Renal",Arcus Biosciences,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities","Anti-drug antibodies, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Occupancy, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03846310,141448
1373,312704,"ACTRN12617001641381, TrialTroveID-312704",A Phase I Study to Evaluate the Safety and Tolerability of AB122 in Subjects with Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal",Arcus Biosciences,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Vital signs","Area under the curve score, Clinical benefit rate, Duration of overall response, Occupancy, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Tmax",False,,141448
1374,306949,"CTR20170692, TrialTroveID-306949, YH-S001-02",Phase I Clinical Study Of GLS-010 Injection In The Treatment Of Patients With Advanced Solid Tumors,Oncology,Oncology: Breast; Oncology: Liver; Oncology: Unspecified Solid Tumor,"WuXi MedImmune Biopharmaceutical Co. (MedImmune and WuXi AppTec joint venture), Harbin Gloria Pharmaceuticals Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events, Vital signs","Dose-limiting toxicities, Maximum tolerated dose, Occupancy, Safety and Tolerability",False,,141448
1375,304931,"2019-0074, AB154CSP0001, NCT03628677, TrialTroveID-304931",A Phase I Study to Evaluate the Safety and Tolerability of AB154 Monotherapy and Combination Therapy in Participants With Advanced Malignancies,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal",Arcus Biosciences,"Industry, all other pharma","Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events","Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Occupancy, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT03628677,141448
1376,303429,"ChiCTR1800014425, CTR20170433, NCT03713905, TrialTroveID-303429, YH-S001-01","A Phase I Study to Investigate the Safety, Tolerability, Pharmacokinetics and Antitumor Activities of the Recombinant Human Anti-PD-1 Monoclonal Antibody for Subjects With Advanced Solid Tumors",Oncology,"Oncology: Anal; Oncology: Bladder; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Penile; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","WuXi MedImmune Biopharmaceutical Co. (MedImmune and WuXi AppTec joint venture), Harbin Gloria Pharmaceuticals Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Dose-limiting toxicities, Elimination half-life, Maximum tolerated dose, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT03713905,141448
1377,397825,"TrialTroveID-397825, VB N-02",A Phase Ib Study of VB10.NEO in Combination with Atezolizumab in Patients with Locally Advanced and Metastatic Tumors,Oncology,Oncology: Unspecified Cancer,Vaccibody,"Industry, all other pharma",,,False,,122127
1378,306593,"DIRECT-01, EudraCT Number: 2017-002474-39, NCT03548467, TrialTroveID-306593, VB N-01, VB10.NEO DIRECT, VBN-01","An Open Labelled First Human Dose Phase I/IIa Study to Evaluate Safety, Feasibility, Efficacy of Multiple Dosing With Individualised VB10.NEO and Bempegaldesleukin (NKTR-214) Immunotherapy in Patients With Locally Advanced or Metastatic Melanoma, Non-small Cell Lung Cancer (NSCLC), Clear Renal Cell Carcinoma, Urothelial Cancer or Squamous Cell Carcinoma of Head and Neck, Who Did Not Reach Complete Responses With Current Standard of Care Immune Checkpoint Blockade",Oncology,"Oncology: Bladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal","Nektar Therapeutics, Vaccibody","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Vital signs","Duration of overall response, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Progression-free survival",True,NCT03548467,122127
1379,330779,"18-311, 201812049, DFCI-18-311, NCI-2018-02767, NCT03636503, TrialTroveID-330779",A Multi-Cohort Phase Ib Clinical Trial of Rituximab in Combination With Immunotherapy in Untreated and Previously Treated Follicular Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic",Complete response,"Adverse Events, Microbiome, Minimal Residual Disease, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Stable Disease, Time to next treatment",True,NCT03636503,69520
1380,319160,"17428, NCI-2018-00098, NCT03440567, TrialTroveID-319160",A Phase I Study of Avelumab Plus Utomilumab-Based Combination Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Phosphate level, Safety and Tolerability, Safety and Tolerability","Complete response, Disease Progression, Duration of overall response, Minimal Residual Disease, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival",True,NCT03440567,69520
1381,317486,"17-455, 19-063, 2018-0486, AVIATOR, NCI-2018-01455, NCT03414658, TBCRC 045, TBCRC045, TrialTroveID-317486, UPCC 03119","A Randomized, Phase II Study Comparing Trastuzumab and Vinorelbine in Combination With Avelumab or Avelumab and Utomilumab (41BB/CD137 Agonist), in Patients With HER2-positive Metastatic Breast Cancer Who Have Progressed on Prior Trastuzumab and Pertuzumab",Oncology,Oncology: Breast,"Pfizer, Johns Hopkins University, Breast Cancer Research Foundation","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tumor control rate",True,NCT03414658,69520
1382,316939,"18-509, 19725, AAAS0322, KTE-C19-111, NCI-2018-02988, NCT03704298, TrialTroveID-316939, ZUMA-11",A Phase I/II Multi-center Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination With Utomilumab in Subjects With Relapsed/Refractory Large B-Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Pfizer, Gilead Sciences/Kite Pharma","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Complete response, Dose-limiting toxicities, Safety and Tolerability","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability",True,NCT03704298,69520
1383,314062,"BRS0070, NCI-2016-01881, NCT03364348, TrialTroveID-314062",A Phase IB Dose Escalation Trial of Human Anti 4 1BB Agonistic Antibody Utomilumab (PF 05082566) in Combination With Ado Trastuzumab Emtansine or Trastuzumab in Patients With HER2 Postive Advanced Breast Cancer,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Maximum tolerated dose, Treatment Emergent Adverse Events","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate - time, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT03364348,69520
1384,311458,"2016-0400, NCI-2018-01034, NCT03318900, TrialTroveID-311458",Phase I/Ib Study of Adoptive Cellular Therapy Using Autologous IL-21-Primed CD8+ Tumor Antigen-Specific T Cells in Combination With Utomilumab (PF-05082566) in Patients With Platinum Resistant Ovarian Cancer,Oncology,Oncology: Ovarian,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Tumor control rate","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT03318900,69520
1385,309891,"2017-0180, NCI-2018-01036, NCT03290937, TrialTroveID-309891","Phase I Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer",Oncology,Oncology: Colorectal,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Immune-related response evaluation criteria in solid tumors, Maximum tolerated dose, Overall response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT03290937,69520
1386,307533,"2017-0145, NCI-2018-01093, NCT03258008, TrialTroveID-307533",Phase II Trial of Utomilumab and ISA101b Vaccination in Patients With HPV-16-Positive Incurable Oropharyngeal Cancer,Infectious Disease; Oncology; Vaccines (Infectious Disease),Infectious Disease: HPV; Oncology: Head/Neck; Vaccines (Infectious Disease): Other Viral Vaccines,"MD Anderson Cancer Center, University of Texas, Pfizer, ISA Pharmaceuticals","Academic, Industry, Top 20 Pharma, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT03258008,69520
1387,264804,"16-1028, 16-163, 2015-0848, 20151522, B9991004, Clinical Trial 18558, EudraCT Number: 2015-002552-27, IRAS ID: 184651, JapicCTI-163218, JAVELIN MEDLEY, NCI-2015-02263, NCT02554812, NL55255.031.16, RECF2773, s16-02110, TrialTroveID-264804, UMCC 2017.064, VICCMD1636","A Phase Ib/II Open-label Study To Evaluate Safety, Clinical Activity, Pharmacokinetics And Pharmacodynamics Of Avelumab (msb0010718c) In Combination With Other Cancer Immunotherapies In Patients With Advanced Malignancies",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",Pfizer,"Industry, Top 20 Pharma","Dose-limiting toxicities, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT02554812,69520
1388,222649,"0C-14-11, 151-17/0C-14-11, 16-414, 2014-0996, 20150061, B0601002, Clinical Trial 18758, CSET 2425, EudraCT Number: 2014-004107-75, JapicCTI-163253, NCI-2015-00761, NCT02315066, NL51911.031.15, OX40, TrialTroveID-222649","A Phase I, Open-label, Dose Escalation Study Of PF-04518600 As A Single Agent And In Combination With PF-05082566 In Patients With Selected Locally Advanced Or Metastatic Cancers",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Cervical; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Cmax, Disease Progression - duration, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT02315066,69520
1389,217902,"15-667, 2015-0161, B1641004, NCI-2015-01217, NCT02444793, PFIZ1Y15, TrialTroveID-217902",A Phase Ib Study Of PF-05082566 In Combination with Mogamulizumab (KW-0761) In Patients with Advanced Solid Tumors,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian","Pfizer, Kyowa Kirin {Kyowa Hakko Kirin}","Industry, Top 20 Pharma, Industry, all other pharma","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Infusion-related reactions, Nausea, Neutropenia, Vomiting","Adverse Events, Anti-drug antibodies, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Disease Progression, Duration of overall response, Hemoglobin level, Leukocyte count, Liver function, Neutralizing antibody response, Overall response rate, Partial response, Phosphate level, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Serious Adverse Events, Time to response, Tmax, Treatment Emergent Adverse Events, Uric acid level, Vital signs",True,NCT02444793,69520
1390,202119,"20141293, B1641003, B1641003/KEYNOTE-0036, KEYNOTE-0036, NCT02179918, TrialTroveID-202119",A Phase Ib Study Of The 4-1bb Agonist Pf-05082566 In Combination With The Pd-1 Inhibitor Mk-3475 In Patients With Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","Pfizer, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Liver function, Maximum tolerated dose, Nausea, Neutropenia, Vomiting","Absolute Neutrophil Count, Anti-drug antibodies, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Disease Progression, Elimination half-life, Hemoglobin level, Liver function, Overall response rate, Partial response, Phosphate level, Platelet count, Progressive disease rate, Response evaluation criteria in solid tumors, Serious Adverse Events, Seroconversion, Stable Disease, Tmax, Treatment compliance, Treatment Emergent Adverse Events, Uric acid level, Vital signs, Volume of distribution",True,NCT02179918,69520
1391,143124,"11-085, 201109213, 2011-160, 20150061, 2015-1127, B1641001, EudraCT Number: 2011-002799-17, JapicCTI-152893, LYMNHL0092, MSKCC 11-085, NCI-2012-00880, NCT01307267, TrialTroveID-143124, UW10051","A Phase I Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-hodgkin's Lymphoma (NHL)",Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Nausea, Neutropenia, Vomiting","Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Duration of overall response, Elimination rate, Heart rate corrected QT interval, Heart rate, Hemoglobin level, Leukocyte count, Liver function, Mean residence time, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to response, Tmax, Treatment Emergent Adverse Events, Vital signs, Volume of distribution",True,NCT01307267,69520
1392,398466,"EudraCT Number: 2020-003681-40, TrialTroveID-398466, WO42633","A Phase Iii, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Efficacy And Safety Of Adjuvant Atezolizumab Or Placebo And Trastuzumab Emtansine For Her2-Positive Breast Cancer At High Risk Of Recurrence Following Preoperative Therapy.",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Disease-free survival,"Adverse Events, Anti-drug antibodies, Disease-free survival, EORTC Quality of Life Questionnaire, Global health status, Immune Response, Overall survival, Quality of Life, Safety and Tolerability",False,,24737
1393,397646,"DOLPHIN, NCT04769050, TrialTroveID-397646","A Phase II, Single-center, Dynamic Observational Study With PET of 68Ga-HER2-affibody in Anti-HER2 Treatment",Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,Overall response rate,"Overall response rate, Progression-free survival, Progressive disease rate",True,NCT04769050,24737
1394,395652,"MedOPP293, NCT04733118, PHERGAIN-2, TrialTroveID-395652",Chemotherapy-Free pCR-Guided Strategy With Subcutaneous Trastuzumab-Pertuzumab and T-DM1 in HER2-Positive Early Breast Cancer (PHERGAIN-2),Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, MedSIR","Industry, Top 20 Pharma, Miscellaneous","Global health status, Quality of Life, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Event-free survival, Global health status, Magnetic Resonance Imaging, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Serious Adverse Events",True,NCT04733118,24737
1395,392692,"NCT04680442, PHRI.SCHOLAR-2, SCHOLAR-2","Safety of Continuing HER-2 Directed Therapy in Overt Left Ventricular Dysfunction: A Randomized, Controlled Trial",,NA: ClinicalTrials.gov,Population Health Research Institute,Academic,Safety and Tolerability,"Mortality, New York Heart Association Class",True,NCT04680442,24737
1396,388792,"20-432, NCT04620187, TrialTroveID-388792",A Phase II Study of Adjuvant Ado-trastuzumab Emtansine (T-DM1) in HER2-positive Salivary Gland Carcinomas,Oncology,Oncology: Head/Neck,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Roche/Genentech","Academic, Industry, Top 20 Pharma","Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival",True,NCT04620187,24737
1397,387321,"BO41932, EudraCT Number: 2020-001847-16, NCT04589845, TAPISTRY, TrialTroveID-387321",Tumor-Agnostic Precision Immunooncology and Somatic Targeting Rational for You (TAPISTRY) Phase II Platform Trial,Oncology,Oncology: Unspecified Solid Tumor,Roche,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Appetite, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Immune Response, Nausea, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vomiting",True,NCT04589845,24737
1398,387280,"EudraCT Number:  2018-002190-21, MAR-BAS-18-005, NCT04591431, ROME, TrialTroveID-387280",The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy,Oncology,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell",(Other Cooperative Group),Cooperative Group,Overall response rate,"Adverse Events, Circulating Tumor Cells, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Serious Adverse Events, Time to next treatment, Time to treatment failure",True,NCT04591431,24737
1399,386370,"ELPIS, EudraCT Number: 2019-005019-18, HCB-ONC001 (ML41519), NCT04578106, TrialTroveID-386370",Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy,Oncology,Oncology: Breast,"Roche, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Complete response, Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Magnetic Resonance Imaging, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT04578106,24737
1400,378807,"A011801, COMPASS HER2 RD, CompassHER2 RD, NCI-2020-03770, NCT04457596, TrialTroveID-378807","The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer) CompassHER2 Residual Disease (RD), a Double-Blinded, Phase III Randomized Trial of T-DM1 Compared With T-DM1 and Tucatinib",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology, Seagen","Government, Cooperative Group, Industry, all other pharma","Disease-free survival, Recurrence","Disease-free survival, Metastasis-free survival, Overall survival, Quality of Life, Recurrence",True,NCT04457596,24737
1401,377490,"(EAY131) subprotocol Q, EAY131-Q, NCI-2020-02979, NCT04439110, TrialTroveID-377490",MATCH Treatment Subprotocol Q: Ado-trastuzumab Emtansine in Patients With Tumors With HER2 Amplification (Except Breast and Gastric/Gastro-Esophageal Junction (GEJ) Adenocarcinomas),Oncology,"Oncology: (N/A); Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04439110,24737
1402,376296,"NCT04419181, TrialTroveID-376296, UBRS20013",A Feasibility Study of De-escalation of Chemotherapy in Patients With Early-Stage HER2 Positive Breast Cancer,Oncology,Oncology: Breast,University of Rochester,Academic,"Complete response, Disease-free survival","Complete response, Disease-free survival",True,NCT04419181,24737
1403,372248,"ACCRU-BR-1801, NCI-2020-02218, NCT04351230, TrialTroveID-372248","Phase II Trial of Abemaciclib and T-DM1 in Women and Men With HER2-Positive Advanced or Metastatic Breast Cancer Who Progressed on Treatment With a Taxane, Trastuzumab and Pertuzumab",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic",Progression-free survival,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04351230,24737
1404,371575,"NCT04341181, ProTarget, TrialTroveID-371575",ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor","GlaxoSmithKline, (Other Cooperative Group), Roche, Pfizer","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Stable Disease",,True,NCT04341181,24737
1405,369484,"(ELPIS Trial), ELPIS, EudraCT Number: 2019-004559-35, NCT04301375, TrialTroveID-369484",Omission of Surgery and Sentinel Lymph Node Dissection in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti- HER2-based Neoadjuvant Therapy (ELPIS Trial),Oncology,Oncology: Breast,"Hospital Clinic, Barcelona, Spain, (Other Hospital/Academic/Medical Center)","Academic, Academic","Complete response, Disease-free survival, Overall survival, Recurrence","Complete response, Disease-free survival, Overall survival, Recurrence",True,NCT04301375,24737
1406,369272,"CO41863, EudraCT Number: 2019-004200-35, NCI-2020-04142, NCT04298918, TrialTroveID-369272, VICKI","A Phase lb/ll, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Venetoclax in Combination With Trastuzumab Emtansine in Patients With Previously Treated HER2-Positive Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Safety and Tolerability",True,NCT04298918,24737
1407,365485,"EudraCT Number: 2019-001316-38, GCP, INDIGO, NCT04644432, PACTIUS, TrialTroveID-365485, UR1909",A Phase II Study of an Individualized Treatment Strategy for Patients With Metastatic Non-clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,Herlev and Gentofte Hospital {Herlev Hospital},Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors, Time to treatment failure","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall survival, Partial response, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT04644432,24737
1408,363429,"MC1835, NCI-2019-08038, NCT04197687, TrialTroveID-363429, W81XWH-18-1-0564",Phase II Trial to Evaluate Immune-Related Biomarkers for Pathological Response in Stage II-III HER2-Positive Breast Cancer Receiving Neoadjuvant Chemotherapy With Subsequent Randomization to Multi-Epitope HER2 Vaccine vs. Placebo in Patients With Residual Disease Post-Neoadjuvant Chemotherapy,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Disease-free survival, Recurrence, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Complete response, Immune Response, Overall survival, Recurrence",True,NCT04197687,24737
1409,360882,"LACOG 0615, LATINA breast, MO39485, NCT04158258, TrialTroveID-360882","A Study To Observe Patients Characteristics, Treatment Patterns And Outcomes In Patients With Newly Diagnosed Breast Cancer In Latin America",Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, Latin American Cooperative Oncology Group","Industry, Top 20 Pharma, Cooperative Group",,"Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Progression-free survival, Recurrence, Safety and Tolerability",True,NCT04158258,24737
1410,357844,"ACTRN12619001265167p, CTC0141-addendum 8, MoST Addendum 8, TrialTroveID-357844, U1111-1182-6652","Single Arm, Open Label, Signal Seeking, Phase IIa Trial Of The Activity Of Trastuzumab Emtansine (T-DM1) In Patients With Tumours Harbouring HER2 Amplifications Or Mutations",Oncology,Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Brief Pain Inventory, Disease Progression, EORTC Quality of Life Questionnaire, Magnetic Resonance Imaging, Partial response, Quality of Life, Time to progression","Adverse Events, Brief Pain Inventory, Common Terminology Criteria for Adverse Events, Disease Progression, EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",False,,24737
1411,354472,"CTRIAL-IE 17-13, NCT04042051, Panthera, TrialTroveID-354472","Phase Ib Clinical Trial of Copanlisib in Combination With Trastuzumab Emtansine (T-DM1) in Pretreated Unresectable Locally Advanced or Metastatic HER2-positive Breast Cancer ""Panthera""",Oncology,Oncology: Breast,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,"Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to treatment failure",True,NCT04042051,24737
1412,342438,"JapicCTI-194620, PRECISION, TrialTroveID-342438, UMIN000035622",A Multicenter Phase II Study Of Trastuzumab Emtansine For Non-Small Cell Lung Cancer Positive For HER2 Exon 20 Insertion Mutation.,Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Overall response rate, Response rate","Adverse Events, Duration of overall response, Overall survival, Progression-free survival",False,,24737
1413,341265,"2018-03 TRAIN-3, ARCH 2018-01, BOOG2018-01, EudraCT number: 2018-003275-35, NCT03820063, NL66887.031.18, NL66887.038.18, TRAIN-3, TrialTroveID-341265",Image-guided De-escalation of Neo-adjuvant Chemotherapy in HER2-positive Breast Cancer: the TRAIN-3 Study,Oncology,Oncology: Breast,"(Other Cooperative Group), Netherlands Cancer Institute, Roche {F. Hoffmann-La Roche}","Cooperative Group, Government, Industry, Top 20 Pharma","Disease Progression, Event-free survival, Progression-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Event-free survival, Magnetic Resonance Imaging, Neuropathy, Overall survival, Quality of Life, Safety and Tolerability",True,NCT03820063,24737
1414,339511,"EudraCT Number: 2018-002885-38, M18TEO, NCT03784599, NL66662.031.18, TRAEMOS, TrialTroveID-339511",Trastuzumab-emtansine and Osimertinib Combination Treatment to Target HER2 Bypass Track Resistance in EGFR Mutation Positive NSCLC,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Roche, Netherlands Cancer Institute","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT03784599,24737
1415,331963,"TrialTroveID-331963, UMIN000018630",The Feasibility Study of Pharmacokinetics and Immune Response of T-DM1 in Metastatic/Recurrent HER2-Positive Breast Cancer,Oncology,Oncology: Breast,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, (Other government agency)","Academic, Government",Immune Response,,False,,24737
1416,317538,"HERB TEA, JCOG1607, TrialTroveID-317538, UMIN000030783","A Phase III Study Comparing T-DM1 with Pertuzumab, Trastuzumab and Docetaxel in Elderly Patients with Advanced Stage HER2 Positive Breast Cancer (JCOG1607, HERB TEA study)",Oncology,Oncology: Breast,"Japan Clinical Oncology Group, National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}","Cooperative Group, Academic",Overall survival,"Activities of Daily Living, Adverse Events, Instrumental Activities of Daily Living, Overall response rate, Progression-free survival, Serious Adverse Events",False,,24737
1417,304471,"EudraCT Number: 2016-004398-41, IJB-BC-TDM1BM-2016, KIARA, NCT03203616, TrialTroveID-304471","Multicenter, Non-randomised, Open-label, Single Agent Phase II Study to Determine the Clinical Benefit of Trastuzumab Emtansine (T-DM1) in HER2-positive Metastatic Breast Cancer Patients With Brain Metastasis",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT03203616,24737
1418,302686,"H4621g, MotHER, NCT00833963, TrialTroveID-302686","An Observational Study of Pregnancy and Pregnancy Outcomes in Women With Breast Cancer Treated With Herceptin, Perjeta in Combination With Herceptin, or Kadcyla During Pregnancy or Within 7 Months Prior to Conception",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma",,,True,NCT00833963,24737
1419,299263,"BP29920, CTR20170125, NCT03153163, TrialTroveID-299263",A Phase I Study of Pharmacokinetics and Safety of Trastuzumab Emtansine in Chinese Patients With Logically Advanced Inoperable or Metastatic HER2-Positive Breast Cancer Who Have Received Prior Trastuzumab Based Therapy,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Area under the curve score, Cmax, Cmin, Elimination half-life, Safety and Tolerability, Volume of distribution","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT03153163,24737
1420,297926,"BO29919, CTR20170095, NCT03084939, TrialTroveID-297926","A Randomized, Multicenter, Phase III Open-Label Study of the Efficacy and Safety of Trastuzumab Emtansine Versus Lapatinib Plus Capecitabine in Chinese Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Disease Progression, Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Magnetic Resonance Imaging, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03084939,24737
1421,294839,"16-492, DFCI 16-492, NCI-2017-00402, NCT03032107, TrialTroveID-294839",A Phase Ib Study Of Pembrolizumab In Combination With Trastuzumab-DM1 In Metastatic HER2-Positive Breast Cancer,Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Merck & Co./Merck Sharp & Dohme (MSD)","Academic, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03032107,24737
1422,287599,"CHAMELEON, EudraCT Number: 2015-001377-40, KAMELEON, MO29694, NCT02999672, NL58278.042.16, TrialTroveID-287599","Phase II, Exploratory, Multicenter, Non Randomized, Single Agent Cohort Study To Determine Best Tumor Response With Trastuzumab Emtansine In Her2 Overexpressing Solid Tumors",Oncology,Oncology: Bladder; Oncology: Liver; Oncology: Pancreas,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Congestive heart failure, Disease Progression, Immune Response, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT02999672,24737
1423,283143,"EudraCT Number: 2015-004189-27, IRAS ID: 208246, KATE2, NCI-2016-01660, NCT02924883, PD3-01, S15-01511, TrialTroveID-283143, WO30085","A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in Combination With Atezolizumab or Atezolizumab-Placebo in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab and Taxane Based Therapy",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cmax, Complement levels, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02924883,24737
1424,275994,"NATURE, NCT02725541, Pro00013875, TrialTroveID-275994",Trial of Neoadjuvant Trastuzumab Emtansine in Patients With HER2-Equivocal Breast Cancer,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Roche/Genentech","Academic, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Treatment Emergent Adverse Events",True,NCT02725541,24737
1425,271796,"011-IRCC-10IIS-15, EudraCT Number: 2015-003275-30, HERACLES-RESCUE, NCT03418558, RESCUE, TrialTroveID-271796","Open-label, Phase II Study of Trastuzumab Emtansine in Patients With HER2-positive Metastatic Colorectal Cancer Progressing After Trastuzumab and Lapatinib: HERACLES RESCUE. (HER2 Amplification for Colo-rectaL Cancer Enhanced Stratification - REchallenge With her2 Selective Cytotoxic Uptake of Emtansine)",Oncology,Oncology: Colorectal,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival",True,NCT03418558,24737
1426,271617,"20151055, NCT02658084, TrialTroveID-271617",A Phase I/II Study to Evaluate the Safety and Efficacy of Vinorelbine With Trastuzumab Emtansine in Pre-Treated HER2-Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"Sylvester Cancer Center, University of Miami, Roche/Genentech","Academic, Industry, Top 20 Pharma","Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events","Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02658084,24737
1427,268447,"CTRI/2015/10/006258, ML29662, NCT02658734, TDM4370g/BO21977, TrialTroveID-268447","A Multicenter, Open-Label, Single-Arm, Phase IV Study of Trastuzumab Emtansine in Indian Patients With HER2-Positive Unresectable Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Treatment With Trastuzumab and a Taxane",Oncology,Oncology: Breast,"Roche {F. Hoffmann-La Roche}, Tata Memorial Hospital","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Congestive heart failure, Safety and Tolerability","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Complete response, Congestive heart failure, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT02658734,24737
1428,265364,"EudraCT Number:  2014-001056-28, Medopp038, NCT02562378, THELMA, TrialTroveID-265364",Phase I Multicenter Clinical Trial Evaluating the Combination of Trastuzumab Emtansine (T-DM1) and Non-pegylated Liposomal Doxorubicin in HER2-positive Metastatic Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Roche","Cooperative Group, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Area under the curve score, Brain Natriuretic Peptide concentration, Clinical benefit rate, Cmax, Complete response, Elimination half-life, Overall response rate, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT02562378,24737
1429,262741,"MARIA15-01, TrialTroveID-262741, UMIN000018383",A Phase Ib Study of Trastuzumab emtansine Plus S-1 or Capecitabine in Patients With Previously Trastuzumab Treated Metastatic Breast Cancer,Oncology,Oncology: Breast,"Roche/Chugai Pharmaceutical, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Dose-limiting toxicities,"Adverse Events, Overall response rate, Response rate",False,,24737
1430,258747,"15-7002, 16-750, 20150671, AAAP9159, CTSU/EAY131, EAY131, ECOG-ACRIN EAY131, MATCH, NCI-2015-00054, NCI-MATCH, NCT02465060, TrialTroveID-258747",Molecular Analysis for Therapy Choice (MATCH).,Oncology,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Roche/Genentech, ECOG-ACRIN Cancer Research Group","Government, Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT02465060,24737
1431,258506,"HER2-CS-2 Study, TrialTroveID-258506, UMIN000017709","A Study of Trastuzumab Emtansine in Patients With HER2-Positive, Recurrent Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to response",False,,24737
1432,257380,"EudraCT Number: 2014-005341-44, ICT, TrialTroveID-257380",Molecular-Biological Tumor Profiling for Drug Treatment Selection in Patients with Advanced and Refractory Carcinoma,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,24737
1433,256389,"15-335, NCI-2016-00262, NCT02675829, TrialTroveID-256389",A Phase II Trial of Ado-Trastuzumab Emtansine for Patients With HER2 Amplified or Mutant Cancers,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Unspecified Solid Tumor","Roche/Genentech {Genentech}, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival",True,NCT02675829,24737
1434,255420,"15-019, 18-124, 19-256, ATOP, NCI-2015-00468, NCI-2018-02318, NCT02414646, NCT03587740, P30CA015083, RU011301I, TrialTroveID-255420",ATOP Trial: Adjuvant Ado-Trastuzumab Emtansine (T-DM1) for Older Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Disease-free survival, Overall survival, Recurrence","Adverse Events, Disease-free survival, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Quality of Life, Recurrence",True,NCT02414646,24737
1435,249435,"14-409, NCI-2015-00454, NCT02326974, TrialTroveID-249435",The Impact of HER2 Heterogeneity on the Treatment of Early-stage HER2-positive Breast Cancer: a Phase II Study of T-DM1 in Combination with Pertuzumab in the Preoperative Setting.,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Overall response rate, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT02326974,24737
1436,248826,"NCT02318901, PembroMab, TrialTroveID-248826",A Phase Ib/II Study of Pembrolizumab and Monoclonal Antibody Therapy in Patients With Advanced Cancer (PembroMab,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Unspecified Solid Tumor,Midwestern Regional Medical Center,Academic,,"Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Treatment Emergent Adverse Events",True,NCT02318901,24737
1437,243494,"32007, end_PREDIX HERE 2, EudraCT Number: 2014-000808-10, NCT02568839, PREDIX HER2, PREDIXHER2, TrialTroveID-243494",PREDIX HER2 - Neoadjuvant Response-guided Treatment of HER2 Positive Breast Cancer. Part of a Platform of Translational Phase II Trials Based on Molecular Subtypes,Oncology,Oncology: Breast,Karolinska Hospital and Institutet,Academic,Overall response rate,"Cardiac Telemetry, Disease-free survival, Magnetic Resonance Imaging, Overall response rate, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02568839,24737
1438,230859,"ML 28685, NCI-2017-02454, NCT01904903, SAFE-HEaRt, TrialTroveID-230859",SAFE-HEaRt: A Pilot Study Assessing the Cardiac SAFEty of HER2 Targeted Therapy in Patients With HER2 Positive Breast Cancer and Reduced Left Ventricular Function,Oncology,Oncology: Breast,"Washington Hospital Center, (Other Hospital/Academic/Medical Center), Roche/Genentech","Academic, Academic, Industry, Top 20 Pharma","Cardiac Telemetry, Myocardial infarction (safety), Myocardial infarction, Safety and Tolerability",,True,NCT01904903,24737
1439,222691,"14/0274, DARWIN II, DARWIN2, DARWINII, Eudract Number: 2014-005456-25, IRAS ID: 191232, NCT02314481, TrialTroveID-222691",Deciphering Antitumour Response and Resistance With INtratumour Heterogeneity - DARWINII,Oncology,"Oncology: Lung, Non-Small Cell","University College London, Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma",Progression-free survival,"Circulating Tumor Cells, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Recurrence",True,NCT02314481,24737
1440,222026,"ML29629, NCT02305641, TrialTroveID-222026",Post-Marketing Surveillance of Kadcyla in Breast Cancer,Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events","Complete response, Partial response, Progressive disease rate, Stable Disease",True,NCT02305641,24737
1441,219756,"20142268, BO29389, EudraCT Number: 2014-001237-83, NCI-2014-02389, NCT02289833, REec-2014-1206, TrialTroveID-219756","A Phase II, Multicenter, Single-Arm Study of Trastuzumab Emtansine in Patients with HER2 IHC-Positive,  Locally Advanced or Metastatic Non-Small Cell Lung Cancer who Have Received At Least One Prior Chemotherapy Regimen",Oncology,"Oncology: Lung, Non-Small Cell",Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Volume of distribution",True,NCT02289833,24737
1442,219577,"EudraCT Number: 2014-000793-19, REec-2014-1182, SOLTI-1203, TrialTroveID-219577","A Phase II, Randomized Study of T DM1 Versus T DM1 Plus Short Induction with Docetaxel in First Line Treatment for Locally Advanced or Metastatic HER2+ Breast Cancer.",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",False,,24737
1443,218087,TrialTroveID-218087,Activity of T-DM1 in HER2-positive Breast Cancer Brain Metastases.,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,24737
1444,215663,"108543, 114291, 117437, 14099, NCI-2014-01812, NCT02226276, TrialTroveID-215663",A Pilot Study of 64Cu-DOTA-trastuzumab Positron Emission Tomography in Treatment of Advanced HER2 Positive Breast Cancer With the Antibody Drug Conjugate Ado-trastuzumab Emtansine,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic",,,True,NCT02226276,24737
1445,215196,"TrialTroveID-215196, UMIN000014750",The effect of trastuzumab emtansine (T-DM1) to the platelets for HER2-positive advanced breast cancer patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,Platelet function,False,,24737
1446,214050,"JBCRG-20, JPRN-UMIN000014649, Neo-peaks study, TrialTroveID-214050, UMIN000014649","A Randomized, Multicenter, Phase II Trial Comparing Neo-Adjuvant Therapy Using Pertuzumab And Trastuzumab Emtansine Based On The Dual HER2 Blockade In Patients With Operable HER2-Positive Primary Breast Cancer(Neo-Peaks Study)",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche/Chugai Pharmaceutical","Cooperative Group, Industry, Top 20 Pharma",Complete response,"Adverse Events, Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,24737
1447,209350,"2014-CT0201, NCT02144012, NMRR-14-244-20044, PHRR150227-000910, TrialTroveID-209350, YO28405, YO28405 20044","A Randomized, Multicenter, Open-label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine versus the Combination of Trastuzumab plus Docetaxel as First-line Treatment of Patients with HER2-Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Activities of Daily Living, Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Anti-drug antibodies, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Magnetic Resonance Imaging, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02144012,24737
1448,208571,"BIRTH, NCT02135159, TrialTroveID-208571, VA2012/38",A Phase I Study to Evaluate the Feasibility of Different Sequences of Combined Trastuzumab Emtansine (T-DM1) and Whole-brain Radiotherapy in Patients With Brain Metastases From HER2-positive Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,"Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors",True,NCT02135159,24737
1449,205117,"JapicCTI-132395, JapicCTI-R171019, KARIN, TrialTroveID-205117",Clinical Phase II Study of Trastuzumab emtansine (Genetical Recombination) (T-DM1) in Patients with inoperable or Recurrent HER2-positive Breast Cancer,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Infusion-related reactions, Liver function, Safety and Tolerability","Adverse Events, Vital signs",False,,24737
1450,204342,"DTM1301, TrialTroveID-204342","A phase II evaluation of trastuzumab-DM1 (T-DM1), a HER2 antibody-drug conjugate, in patients with persistent or recurrent HER2- positive endometrial carcinoma",Oncology,Oncology: Endometrial,NRG Oncology,Cooperative Group,,,False,,24737
1451,203684,"NCT02073916, Pro00009544, STELA, TrialTroveID-203684",Phase Ib Trial of Trastuzumab Emtansine in Combination with Lapatinib Plus Abraxane in Metastatic Her 2 neu Over-Expressed Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Maximum tolerated dose, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Plasma pharmacokinetics, Response evaluation criteria in solid tumors",True,NCT02073916,24737
1452,203471,"A311233-2014, NCT02070094, RSW - 233 - 14, TrialTroveID-203471",A Phase I/II Study of Ado-Trastuzumab Emtansine(T-DM1) + ABT-737 in Treating Patients With HER2(+) Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center), Breast Cancer Research Foundation","Government, Academic, Not for Profit Funding Entity","Dose-limiting toxicities, Maximum tolerated dose",Progression-free survival,True,NCT02070094,24737
1453,197247,TrialTroveID-197247,A Study of Kadcyla in Patients with HER2-Positive Inoperable or Recurrent Breast Cancer.,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma",,,False,,24737
1454,196665,"CirCe TDM-1, IC 2013-03, NCT01975142, TrialTroveID-196665",Validity of HER2-amplified Circulating Tumor Cells to Select Metastatic Breast Cancer Considered HER2-negative for Trastuzumab-emtansine (T-DM1) Treatment,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma","Circulating Tumor Cells, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Circulating Tumor Cells, Clinical benefit rate, Disease Progression, Progression-free survival, Stable Disease",True,NCT01975142,24737
1455,195634,"041318, 2013-CT0184, 20140740, BO28407, BO28407 Kaitlin, BRTKAITLIN, CT653, CTBE2014000270, EudraCT Number: 2012-004902-82, F14005, IRAS ID 120959, JapicCTI-142421, Kaitlin, NCI-2014-00853, NCRN-2639, NCT01966471, PER-027-14, PHRR140603-000202, REec-2014-0715, TrialTroveID-195634, TX4229, UKCRN ID: 15506, UW13051, UW13051-KAITLIN Trial","A Randomized, Multicenter, Open-label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients with Operable HER 2 Positive Primary Breast Cancer",Oncology,Oncology: Breast,"Roche/Chugai Pharmaceutical, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease-free survival, Recurrence","Adverse Events, Appetite, Cardiac Telemetry, Disease-free survival, EORTC Quality of Life Questionnaire, Global health status, Overall survival, Quality of Life, Recurrence, Safety and Tolerability",True,NCT01966471,24737
1456,192321,"HP-00056720, NCT01924351, TrialTroveID-192321",A Phase II Study of Stereotactic Radiosurgery Plus HER-2 Directed Therapy in HER2-positive Breast Cancer with Brain Metastasis,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,University of Maryland School of Medicine,Academic,,Adverse Events,True,NCT01924351,24737
1457,188507,"S1311, S1506, TrialTroveID-188507",Phase II Study of Trastuzumab Emtansine (T-DM1) Plus Pertuzumab With or Without Paclitaxel in Her2+ Metastatic Breast Cancer (MBC),Oncology,Oncology: Breast,Southwest Oncology Group,Cooperative Group,,,False,,24737
1458,186443,"00048638, 13-048, 137522, 14-221, 2013-0957, ATEMPT Trial, DFCI 13-048, ML28160, NCI-2013-01818, NCT01853748, OSU-13150, TBCRC 033, TrialTroveID-186443",A Randomized Phase II Study of Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination With Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial),Oncology,Oncology: Breast,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Academic,"Disease-free survival, Neutropenia, Serious Adverse Events","Adverse Events, Disease-free survival, Functional Assessment of Cancer Therapy-Breast, Overall survival, Quality of Life, Rotterdam Symptom Checklist, Work Productivity and Activity Impairment Questionnaire",True,NCT01853748,24737
1459,183712,"7900, CC-7900, NCI-2013-00552, NCT01816035, TrialTroveID-183712",Thrombokinetic Studies of Ado-trastuzumab Emtansine,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic",Platelet function,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate - duration, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT01816035,24737
1460,181365,"ADAPT HER2+/HR+, ADAPT-TP, EudraCT Number: 2011-001462-17, NCT01745965, TrialTroveID-181365, WSG-ADAPT HER2+/HR+, WSG-AM06, WSG-AM06/ADAPT HER2+/HR+","A Prospective, Randomized Multicenter, Open-label Comparison of Preoperative Trastuzumab Emtansine (T-DM1) With or Without Standard Endocrine Therapy vs. Trastuzumab With Standard Endocrine Therapy Given for Twelve Weeks in Patients With Operable HER2+/HR+ Breast Cancer Within the ADAPT Protocol",Oncology,Oncology: Breast,"(Other Cooperative Group), Roche {F. Hoffmann-La Roche}","Cooperative Group, Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging","Disease-free survival, Event-free survival, Metastasis-free survival, Overall survival, Quality of Life, Safety and Tolerability",True,NCT01745965,24737
1461,179229,"004-IRCC-10IIS-12, EudraCT Number: 2012-002128-33, HERACLES, HERACLES A, HERACLES B, NCT03225937, TrialTroveID-179229","Open-Label, Phase II Study of Trastuzumab in Combination with Lapatinib or Pertuzumab in Combination with Trastuzumab in Patients with HER2-positive Metastatic Colorectal Cancer: , , the HERACLES Trial (HER2 Amplification for Colorectal Cancer Enhanced Stratification)",Oncology,Oncology: Colorectal,(Other Cooperative Group),Cooperative Group,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability",True,NCT03225937,24737
1462,175473,"CTR20150630, EudraCT Number: 2012-001628-37, IRAS ID: 109645, KAMILLA, McG 1302, MO28231, NCRN463, NCT01702571, NL42030.031.12, PER-130-12, RECF1930, T-DM1 Trial, TrialTroveID-175473, UKCRN: 12866","A Two-cohort, Open-label, Multicenter Study of Trastuzumab Emtansine (T-DM1) in HER2-positive Locally Advanced or Metastatic Breast Cancer Patients Who Have Received Prior Anti-HER2 and chemotherapy-based Treatment.",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to response",True,NCT01702571,24737
1463,175431,"EudraCT Number: 2012-001547-46, MO28230, MO28230 TRAX-HER2, NCT01702558, PER-082-14, TRAXHER2, TrialTroveID-175431","Phase I Study of the Combination of Trastuzumab Emtansine (T-DM1) and Capecitabine in HER2-Positive Metastatic Breast Cancer and HER2-Positive Locally Advanced/Metastatic Gastric Cancer Patients, Followed by a Randomized, Open-Label Phase II Study of Trastuzumab Emtansine and Capecitabine Versus Trastuzumab Emtansine Alone in HER2-Positive Metastatic Breast Cancer",Oncology,Oncology: Breast; Oncology: Gastric,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Absolute Neutrophil Count, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Neutropenia, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Cmax, Duration of overall response, Elimination half-life, Maximum tolerated dose, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Time to treatment failure",True,NCT01702558,24737
1464,171353,"1209010816, 2012-1062, 2012-CT00042, BO27952, BO27952 12390, CTR20140446, DFCI ID: 12-344, EudraCT Number: 2012-000660-22, Gatsby, GITGATSBY, IRAS ID: 99751, JapicCTI-121926, NCRN369, NCT01641939, NMRR-12-419-12390, PHRR130705-000090, TrialTroveID-171353, UKCRN: 12204","A Randomized, Multicenter, Adaptive Phase II/III Study To Evaluate The Efficacy And Safety Of Trastuzumab Emtansine (T-DM1) Versus Taxane (Docetaxel Or Paclitaxel) In Patients With Previously Treated Locally Advanced Or Metastatic HER2-Positive Gastric Cancer, Including Adenocarcinoma Of The Gastroesophageal Junction",Oncology,Oncology: Esophageal; Oncology: Gastric,"Roche/Chugai Pharmaceutical, Roche {F. Hoffmann-La Roche}, Roche/Genentech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Abdominal pain, Ability to swallow, Adverse Events, Appetite, Area under the curve score, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Elimination half-life, EORTC Quality of Life Questionnaire, EQ-5D-3L, EQ-5D, Nausea, Overall response rate - duration, Overall response rate, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Reflux, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Visual Analog Scale, Volume of distribution, Vomiting","Abdominal pain, Ability to swallow, Adverse Events, Appetite, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Elimination half-life, EORTC Quality of Life Questionnaire, Nausea, Neuropathy, Overall response rate - duration, Overall response rate, Partial response, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Reflux, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Volume of distribution, Vomiting",True,NCT01641939,24737
1465,169381,"2014-0688, 20140740, BO28408, BO28408/TRIO021, CTBE2014000273, EudraCT Number: 2012-004879-38, KRISTINE, NCT02131064, REec-2014-1258, TrialTroveID-169381, TRIO 021","A Randomized, Multicenter, Open-Label, Two-Arm, Phase III Neoadjuvant Study Evaluating Trastuzumab Emtansine Plus Pertuzumab Compared With Chemotherapy Plus Trastuzumab And Pertuzumab For Patients With HER2-Positive Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Complete response,"Adverse Events, Anti-drug antibodies, Appetite, Cmax, Cmin, Disease Progression, Disease-free survival, EORTC Quality of Life Questionnaire, Event-free survival, Global health status, Nausea, Neuropathy, Neutropenia, Overall survival, Quality of Life, Recurrence, Time to progression, Vomiting",True,NCT02131064,24737
1466,169379,"041303, 20140812-1032, AAAL5409, B-50-I, BO27938, BRE148, CTR20150276, DRKS00004950, EudraCT Number: 2012-002018-37, GBG 77, ICORG 13-05, KATHERINE, NCI-2013-01660, NCRN384, NCT01772472, NSABP B-50-I, ON/4220, PER-010-13, TrialTroveID-169379, UKCRN ID 13395","A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients with HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy",Oncology,Oncology: Breast,"National Surgical Adjuvant Breast and Bowel Project (NSABP), ImmunoGen, Roche {F. Hoffmann-La Roche}, German Breast Group","Cooperative Group, Industry, all other pharma, Industry, Top 20 Pharma, Cooperative Group","Disease-free survival, Recurrence","Adverse Events, Anti-drug antibodies, Appetite, Area under the curve score, Common Terminology Criteria for Adverse Events, Disease-free survival, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01772472,24737
1467,164816,"201100543, CTBE2012000054, EudraCT Number: 2011-005437-39, IJBMNTDM1, MO27955, NCT01565200, NL39546.042.12, TrialTroveID-164816, ZEPHIR",Phase II Prospective Imaging Study Evaluating the Utility of Pre-treatment zr89 Labelled Trastuzumab PET/CT and an Early FDG-PET/CT Response to Identify Patients with Advanced HER2+ BC Unlikely to Benefit From a Novel antiHER2 Therapy: TDM1,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Academic, Industry, Top 20 Pharma",Response evaluation criteria in solid tumors,"Gene expression profiling, Response evaluation criteria in solid tumors",True,NCT01565200,24737
1468,160786,"BO25499, BRE 199, EudraCT Number: 2011-004591-10, NCT01513083, SOL-11149-P, TrialTroveID-160786","A Phase I, Open Label, Parallel Group, Pharmacokinetic Study of Trastuzumab Emtansine in Patients With HER2-Positive Metastatic Breast Cancer and Normal or Reduced Hepatic Function",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma",Area under the curve score,"Adverse Events, Safety and Tolerability",True,NCT01513083,24737
1469,159616,"JO22591, TrialTroveID-159616",Phase I Study of Single Agent Trastuzumab Emtansine in Japanese Patients with Human Epidermal Growth Factor Receptor2 (HER2)-Positive Metastatic Breast Cancer (JO22591).,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,False,,24737
1470,159300,"ADAPT, ADAPT Umbrella, EudraCT Number: 2011-001462-17, NCT01781338, TrialTroveID-159300, WSG-AM06",Adjuvant Dynamic marker- Adjusted Personalized Therapy trial optimizing risk assessment and therapy response prediction in early breast cancer,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Recurrence,Overall survival,True,NCT01781338,24737
1471,145806,"20110690, 2011IS033, BO25734, BO25734/TDM4997g, CTRI/2012/07/002804, DFCI 11-309, EudraCT Number: 2011-000509-29, IRAS ID: 86989, IRAS ID: 86989, NCRN318, NCT01419197, TDM4997g, TDM4997g/BO25734, TH3RESA, THERESA, TrialTroveID-145806, UKCRN 10832, VICCBRE1161","A Phase III Randomized, Multicenter, Two Arm, Open-label Trial to Evaluate the Efficacy of Trastuzumab Emtansine Compared With Treatment of Physician's Choice in Patients With HER2-positive Metastatic Breast Cancer Who Have Received at Least Two Prior Regimens of HER2 Directed Therapy, , TH3RESA - TDM1 in 3rd line HER2+ breast cancer",Oncology,Oncology: Breast,"ImmunoGen, Roche {F. Hoffmann-La Roche}, Roche/Genentech","Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01419197,24737
1472,136920,"JapicCTI-101277, JapicCTI-R160841, JO22997 study, TrialTroveID-136920",Phase II clinical study of RG3502 in HER2 positive patients with locally advanced/recurrent or metastatic breast cancer.,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,24737
1473,135646,"JapicCTI-101234, TrialTroveID-135646",Phase I Clinical Study of RG3502 in Combination With RG1273 in Patients With Advanced or Recurrent HER2-Positive Breast Cancer,Oncology,Oncology: Breast,Roche/Chugai Pharmaceutical,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability","Response evaluation criteria in solid tumors, Safety and Tolerability",False,,24737
1474,134587,"BO22857, BO22857 / TDM4874g, EudraCT 2010-019752-50, NCT01196052, RECF1420, TDM4874g, TrialTroveID-134587","A Multicenter, Multinational Phase II Study to Assess the Clinical Safety and Feasibility of Trastuzumab Emtansine Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage HER2-positive Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Congestive heart failure, New York Heart Association Class, Safety and Tolerability, Serious Adverse Events","Adverse Events, Complete response, Disease-free survival, Recurrence, Safety and Tolerability",True,NCT01196052,24737
1475,126971,"BRE 176 IST, NCT01120561, TDM4884g, TrialTroveID-126971","An Expanded Access, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2- Positive Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT01120561,24737
1476,121995,"062010-151, 101472, 2010-0768, 20100979, 2010IS046, B/TDM4788g B-ROW, BO22589, BO22589 6521, BO22589 TDM4788g B/B-ROW, BO22589/TDM4788g, BO22589B / TDM4788G, BO22589B/ TDM4788g B-EU, EudraCT Number: 2009-017905-13, IRAS ID: 42673, JapicCTI-111487, MARIANNE, NCRN150, NCT01120184, NMRR-10-700-6521, RECF1404, TrialTroveID-121995, UKCRN 8093, VICCBRE1030","A Randomized, 3 Arm, Multicenter, Phase III Study to Evaluate the Efficacy and the Safety of T-DM1 Combined With Pertuzumab or T-DM1 Combined With Pertuzumab-Placebo (Blinded for Pertuzumab), Versus the Combination of Trastuzumab Plus Taxane, as First Line Treatment in HER2 Positive Progressive or Recurrent Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,"Roche/Chugai Pharmaceutical, ImmunoGen, Roche/Genentech","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Disease Progression, IRF assessment, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Activities of Daily Living, Adverse Events, Cmin, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Functional Assessment of Cancer Therapy-Colorectal Cancer, IRF assessment, Myalgia, Nausea, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Rotterdam Symptom Checklist, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression, Time to treatment failure, Work Productivity and Activity Impairment Questionnaire",True,NCT01120184,24737
1477,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,24737
1478,113082,"09-093, 2009-104, GO01355, NCT00951665, TDM4652g, TrialTroveID-113082","A Phase Ib-IIa, Open-label, Dose-Escalation Study of the Safety, Tolerability and Pharmacokinetics of Trastuzumab Emtansine, Paclitaxel and Pertuzumab Administered Intravenously to Patients With Her2-positive, Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Elimination half-life, Maximum tolerated dose, Neutropenia, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Volume of distribution","Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00951665,24737
1479,112654,"2009-071, NCT00943670, TDM4688g, TrialTroveID-112654","A Phase II, Open-Label Study to Evaluate Corrected QT Interval Effects of Trastuzumab-MCC-DM1 (T-DM1) in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer and to Evaluate the Safety and Tolerability of Combined T-DM1 and Pertuzumab in Patients With Early Disease Progression While Receiving T-DM1 Alone.",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma","Cardiac Telemetry, Heart rate corrected QT interval","Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Heart rate corrected QT interval, Heart rate, Overall response rate - duration, Overall response rate, Partial response, PR interval, Progression-free survival, QRS duration, Response evaluation criteria in solid tumors, Stable Disease, Volume of distribution",True,NCT00943670,24737
1480,111986,"09/H0606/69, BP22572, EudraCT No: 2009-010000-28, NCT00934856, RECF1133, TrialTroveID-111986","An Open-label, Multi-center Study of the Safety and Tolerability of the Combination of Trastuzumab-MCC-DM1 (T-DM1) With Docetaxel, and Potentially Pertuzumab, for Treatment for Patients With Advanced Breast Cancer",Oncology,Oncology: Breast,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Complete response, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Time to treatment failure",True,NCT00934856,24737
1481,108523,"06-163, MSKCC-06163, NCT00897702, TrialTroveID-108523",Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",Disease Progression,Disease Progression,True,NCT00897702,24737
1482,99801,"09-0114, 09-096, 2014-CT0213, BO25430, BRE 155 IST, CTR20180854, EudraCT Number: 2010-021067-32, IRAS ID: 77750, JapicCTI-163168, NCI-2009-01154, NCT00781612, PER-075-11, PHRR150810-001060, SNCTP000002893, TDM4529g, TDM4529g / BO25430, TrialTroveID-099801, UW10039","An Open-Label, Multicenter Extension Study of Trastuzumab Emtansine Administered as a Single Agent or in Combination With Other Anti-Cancer Therapies in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd-Sponsored Trastuzumab Emtansine Study",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Roche/Chugai Pharmaceutical, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Disease Progression, Safety and Tolerability, Serious Adverse Events","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors",True,NCT00781612,24737
1483,99167,"BO22495, BRE 159, EudraCT: 2008-008276-14, McG 0938, NCT00875979, RECF1127, TDM4373g, TrialTroveID-099167","A Phase Ib/II, Open-label Study of the Safety, Tolerability, and Efficacy of Trastuzumab Emtansine (Trastuzumab-MCC-DM1, T-DM1) in Combination With Pertuzumab Administered Intravenously to Patients With Human Epidermal Growth Factor Receptor-2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer Who Have Previously Received Trastuzumab",Oncology,Oncology: Breast,Roche/Genentech,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Disease Progression, Duration of overall response, Overall response rate - duration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT00875979,24737
1484,99021,"00015169, 09-0549, 20090291, BO21977, BO21977 - TDM4370g, BRE 157 IST, CTRI/2011/07/001865, DRKS00003643, EMILIA, EudraCT Number: 2008-005713-22, IRAS ID: 15684, McG 0916, NCRN097, NCT00829166, RECF1128, TDM4370g, TDM4370g / Bo21977, TDM4370g/BO21977, TrialTroveID-099021, UKCRN ID: 7211","A Randomized, Multicenter, Phase III Open-label Study of the Efficacy and Safety of Trastuzumab MCC-DM1 vs. Capecitabine + Lapatinib in Patients With HER2-Positive Locally Advanced or Metastatic Breast Cancer Who Have Received Prior Trastuzumab-Based Therapy",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, ImmunoGen, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Complete response, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to treatment failure",True,NCT00829166,24737
1485,90383,"BO21976, EudraCT Number: 2008-002819-40, NCT00679341, TDM4450g, TrialTroveID-090383","A Randomized, Multicenter, Phase II Study of the Efficacy and Safety of Trastuzumab-Mcc-DM1 vs. Trastuzumab (Herceptin) and Docetaxel (Taxotere) in Patients With Metastatic HER2-Positive Breast Cancer Who Have Not Received Prior Chemotherapy for Metastatic Disease",Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Complete response, Disease Progression, Functional Assessment of Cancer Therapy-Breast, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00679341,24737
1486,90362,"08-119, 2008-057, BRE 147, NCT00679211, TDM4374g, TrialTroveID-090362, VICCBRE0857","A Phase II, Single-Arm, Open-Label Study of Trastuzumab-Mcc-DM1 Administered Intravenously to Patients with HER2-Positive Metastatic Breast Cancer",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, ImmunoGen","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT00679211,24737
1487,70699,"BRE 130, NCT00509769, TDM4258g, TrialTroveID-070699, US Oncology 07-067, USON 07067","A Phase II, Single-Arm, Open-Label Study of Trastuzumab-MCC-DM1 Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Progressed While Receiving HER2-Directed Therapy",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, ImmunoGen","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Complete response, Disease Progression, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00509769,24737
1488,70516,TrialTroveID-070516,Phase I Study Of Trastuzumab-DM1 In Patients Who Have Progressed After Herceptin With HER2 Positive Metastatic Breast Cancer,Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,False,,24737
1489,44108,"06046, MSKCC-06-049, NCT00932373, REFMAL 93, TDM3569g, TrialTroveID-044108","A Phase I, Open-Label, Dose-Escalation Study of the Safety and Pharmacokinetics of Trastuzumab-MCC-DM1 (PRO132365) Administered Intravenously to Patients With HER2-Positive Metastatic Breast Cancer Who Have Previously Received a Trastuzumab-Containing Regimen",Oncology,Oncology: Breast,Roche/Genentech {Genentech},"Industry, Top 20 Pharma","Absolute Neutrophil Count, Adverse Events, Cmax, Dose-limiting toxicities, Elimination half-life, Liver function, Maximum tolerated dose, Neutropenia, Plasma concentration, Safety and Tolerability, Serious Adverse Events","Anti-drug antibodies, Complete response, Disease Progression, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00932373,24737
1490,290690,"ACT14884, EudraCT Number: 2016-001962-27, MC# 16-36, NCT02984683, NL58637.068.16, TrialTroveID-290690, U1111-1182-7044",Open-label Phase II Study Evaluating Efficacy and Safety of SAR566658 Treatment in Patients With CA6 Positive Metastatic Triple Negative Breast Cancer,Oncology,Oncology: Breast,Sanofi {Sanofi-Aventis},"Industry, Top 20 Pharma","Overall response rate, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT02984683,30703
1491,130540,"EudraCT Number: 2011-003891-35, NCT01156870, RECF2162, SANOFI#TED10499#U1111-1116-4129, TED10499, TrialTroveID-130540, U1111-1116-4129","Dose Escalation, Safety and Pharmacokinetic, First in Man Study, of SAR566658 Administered as a Single Agent by Intravenous Infusion in Adult Patients With CA6-Positive and Refractory Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas",Sanofi {Sanofi-Aventis},"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Anti-drug antibodies, Overall response rate, Response rate, Safety and Tolerability, Vital signs",True,NCT01156870,30703
1492,400649,"000144-C, 10000144, NCT04826341",A Phase I/II Study of Sacituzumab Govitecan Plus Berzosertib in Small Cell Lung Cancer and Homologous Recombination-Deficient Cancers Resistant to PARP Inhibitors,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,Maximum tolerated dose,"Safety and Tolerability, Safety and Tolerability",True,NCT04826341,39522
1493,395154,"20-614, NCT04724018, TrialTroveID-395154",Sacituzumab Govitecan Plus Enfortumab Vedotin for Metastatic Urothelial Carcinoma Progressing on Platinum-based Chemotherapy and PD1/L1 Inhibitors: the Double Antibody Drug Conjugate (DAD) Phase I Trial,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Gilead Sciences/Immunomedics","Academic, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Treatment Emergent Adverse Events","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT04724018,39522
1494,390624,"NCI-2020-07706, NCT04647916, S2007, TrialTroveID-390624",A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients With HER2-Negative Breast Cancer and Brain Metastases,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute, Gilead Sciences/Immunomedics","Cooperative Group, Government, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT04647916,39522
1495,390157,"Asian Study, CTR20210096, EVER-132-002, NCT04639986, TrialTroveID-390157",A Phase III Asian Study of Sacituzumab Govitecan (IMMU-132) Versus Treatment of Physician's Choice (TPC) in Subjects With HR+/ HER2- Metastatic Breast Cancer (MBC) Who Have Failed at Least 2 Prior Chemotherapy Regimens,Oncology,Oncology: Breast,"BSP Pharma, Medidata Solutions, Everest Medicines","Industry, all other pharma, Miscellaneous, Industry, all other pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progressive disease rate",True,NCT04639986,39522
1496,388713,"Immu-132-15, NCT04617522, TrialTroveID-388713","A Phase I, Open-Label, Dose-Escalation Study to Determine an Appropriate Starting Dose of Sacituzumab Govitecan in Subjects With Advanced or Metastatic Solid Tumor and Moderate Liver Impairment",Oncology,Oncology: Unspecified Solid Tumor,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Area under the curve score, Cmax",,True,NCT04617522,39522
1497,385105,"CTMS# 20-0102, HSC20200576X, NCT04559230, TrialTroveID-385105","A Phase II, Multicenter, Prospective Study of Sacituzumab Govitecan in Recurrent Glioblastoma",Oncology,"Oncology: CNS, Glioblastoma",University of Texas Health Science Center at San Antonio,Academic,Progression-free survival,,True,NCT04559230,39522
1498,383225,"IMMU-132-13, NCT04527991, TrialTroveID-383225, TROPiCS-04",A Randomized Open-Label Phase III Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Subjects With Metastatic or Locally Advanced Unresectable Urothelial Cancer (TROPiCS-04),Oncology,Oncology: Bladder,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-3L, EQ-5D-5L, Global health status, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT04527991,39522
1499,375321,"20-153, NCT04448886, TrialTroveID-375321",Saci-IO HR+: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in Hormone Receptor-positive (HR+) / HER2- Metastatic Breast Cancer (MBC),Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Gilead Sciences/Immunomedics, Merck & Co./Merck Sharp & Dohme (MSD)","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Treatment Emergent Adverse Events",True,NCT04448886,39522
1500,375320,"20-166, NCI-2020-06546, NCT04468061, Saci-IO TNBC, TrialTroveID-375320",Saci-IO TNBC: Randomized Phase II Study of Sacituzumab Govitecan With or Without Pembrolizumab in PD-L1-negative Metastatic Triple Negative Breast Cancer (TNBC),Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Gilead Sciences/Immunomedics, Merck & Co./Merck Sharp & Dohme (MSD)","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Abdominal pain, Adverse Events, Appetite, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Microbiome, Nausea, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Treatment Emergent Adverse Events, Vomiting",True,NCT04468061,39522
1501,372737,"CTR20200914, EVER-132-001, NCT04454437, TrialTroveID-372737","A Phase IIb, Single Arm, Multicenter Trial of Sacituzumab Govitecan in Chinese Patients With Metastatic Triple-negative Breast Cancer Who Received at Least Two Prior Treatments",Oncology,Oncology: Breast,"Medidata Solutions, Everest Medicines","Miscellaneous, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT04454437,39522
1502,370443,"NCT04320693, TrialtroveID-370443",Expanded Access for IMMU-132,Oncology,Oncology: Breast,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma",,,True,NCT04320693,39522
1503,370359,"20-185, EudraCT Number: 2019-004868-22, IMMU-132-14, NCT04319198, TrialTroveID-370359",Open-label Rollover Study to Evaluate Long-Term Safety in Subjects With Metastatic Solid Tumors That Are Benefiting From Continuation of Therapy With Sacituzumab Govitecan,Oncology,Oncology: Unspecified Solid Tumor,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events",,True,NCT04319198,39522
1504,365430,"19-578, NCT04230109, NeoSTAR, TrialTroveID-365430",A Phase II Study of Response-guided Neoadjuvant Sacituzumab Govitecan (IMMU-132) in Patients With Localized Triple-Negative Breast Cancer (NeoSTAR),Oncology,Oncology: Breast,"Gilead Sciences/Immunomedics, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic",Complete response,"Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04230109,39522
1505,361776,"CO40115, MORPHEUS, TrialTroveID-361776",A Phase IB/II Study of Sacituzumab Govitecan in Combination with Atezolizumab in Patients with Newly-diagnosed Metastatic Triple-negative Breast Cancer (mTNBC).,Oncology,Oncology: Breast,"Roche, Gilead Sciences/Immunomedics","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,False,,39522
1506,361678,"EudraCT Number: 2019-004100-35, GBG102 - SASCIA, GBG102-SASCIA, NCT04595565, SASCIA, TrialTroveID-361678","Phase III Postneoadjuvant Study Evaluating Sacituzumab Govitecan, an Antibody Drug Conjugate in Primary HER2-negative Breast Cancer Patients With High Relapse Risk After Standard Neoadjuvant Treatment - SASCIA",Oncology,Oncology: Breast,"Gilead Sciences/Immunomedics, German Breast Group","Industry, Top 20 Pharma, Cooperative Group","Disease-free survival, Overall survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, EQ-5D-5L, EQ-5D, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Treatment compliance, Visual Analog Scale",True,NCT04595565,39522
1507,354401,"19-239, NCI-2019-07939, NCT04039230, TrialTroveID-354401",Phase I/II Study to Evaluate Safety and Anti-Tumor Activity of Antibody-Drug Conjugate Sacituzumab Govitecan in Combination With the Poly (Adenosine Diphosphate [ADP]-Ribose) Polymerase (PARP) Inhibitor Talazoparib in Patients With Metastatic Triple-Negative Breast Cancer,Oncology,Oncology: Breast,"Pfizer, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Progression-free survival","Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT04039230,39522
1508,352053,"CTMS# 19-0069, HSC20190378H, NCT03995706, TrialTroveID-352053","A Phase 0, Investigator Initiated Study to Determine the Bioavailability of Sacituzumab Govitecan in Breast Brain Metastasis and Glioblastoma",Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Metastatic Cancer","Gilead Sciences/Immunomedics, University of Texas Health Science Center at San Antonio","Industry, Top 20 Pharma, Academic",,,True,NCT03995706,39522
1509,350447,"Immu-132-11, NCI-2019-05251, NCT03964727, TrialTroveID-350447, Tropics-03",A Phase II Open Label Study of Sacituzumab Govitecan (IMMU-132) in Subjects With Metastatic Solid Tumors,Oncology,"Oncology: Endometrial; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors","Area under the curve score, Cmax, Elimination half-life, Overall response rate, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT03964727,39522
1510,346812,"041919, 122694, 19-000737, 19-225, 19-365, EudraCT Number: 2018-004201-33, IMMU 132-09, IMMU-132-09, IRAS ID:260202, NCI-2019-03005, NCT03901339, NL70250.068.19, S18-01628, TrialTroveID-346812, TROPICS-02, TROPICS-02 IMMU-132-09",Phase III Study of Sacituzumab Govitecan vs Physician's Choice in Subjects With Hormonal Receptor-Positive Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer Who Have Failed at Least 2 Prior Chemotherapy Regimens.,Oncology,Oncology: Breast,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Abdominal pain, Adverse Events, Appetite, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Nausea, Overall response rate - duration, Overall response rate, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vomiting",True,NCT03901339,39522
1511,344936,"EudraCT Number: 2017-004634-28, IRAS ID-247918, MORPHEUS mUC, MORPHEUS-mUC, NCI-2019-06211, NCT03869190, TrialTroveID-344936, WO39613","A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating the Efficacy and Safety of Multiple Immunotherapy-Based Treatments and Combinations in Patients With Urothelial Carcinoma (MORPHEUS-UC)",Oncology,Oncology: Bladder; Oncology: Renal,"GlaxoSmithKline, Seagen {Seattle Genetics}, Gilead Sciences/Immunomedics, Gilead Sciences, Ono Pharmaceutical, Roche {F. Hoffmann-La Roche}, Astellas Pharma","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Disease-free survival, Duration of overall response, Event-free survival, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03869190,39522
1512,337351,TrialTroveID-337351,A Phase I/II Study of Imfinzi in Combination with Sacituzumab Govitecan in Patients with Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Gilead Sciences/Immunomedics, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,39522
1513,329272,TrialTroveID-329272,A Phase II Study to Evaluate Sacituzumab Govitecan as a Single Agent in Patients with Persistent or Recurrent Cervical Cancer,Oncology,Oncology: Cervical,"Gilead Sciences/Immunomedics, Yale University","Industry, Top 20 Pharma, Academic",,,False,,39522
1514,329271,"2000026850, NCI-2020-02513, NCT04251416, TrialTroveID-329271","A Phase II Evaluation of Sacituzumab Govitecan (IMMU-132), an Anti-Trop-2-SN-38 Antibody-drug Conjugate, in Patients With Persistent or Recurrent Endometrial Carcinoma",Oncology,Oncology: Endometrial,"Gilead Sciences/Immunomedics, Yale University","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events",True,NCT04251416,39522
1515,328731,TrialTroveID-328731,A Randomized Phase I/II Study of Imfinzi In Combination With Sacituzumab Govitecan In Frontline Treatment Of Patients With Urothelial Cancer,Oncology,Oncology: Bladder; Oncology: Renal,"Gilead Sciences/Immunomedics, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,False,,39522
1516,328730,TrialTroveID-328730,A Randomized Phase I/II Study of Imfinzi In Combination With Sacituzumab Govitecan In Previously-Untreated Patients with Triple-negative Breast Cancer,Oncology,Oncology: Breast,"Gilead Sciences/Immunomedics, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,False,,39522
1517,325564,"19-168, CO-338-098, NCI-2019-04655, NCT03992131, SEASTAR, SEASTAR-A, SEASTAR-B, TrialTroveID-325564","SEASTAR: A Phase Ib/II, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor",Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor,"Gilead Sciences/Immunomedics, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Area under the curve score, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Elimination rate, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Tmax, Volume of distribution",True,NCT03992131,39522
1518,325557,"19988, EudraCt Number: 2018-001167-23, IMMU-132-06, IMMU-132-06 - TROPHY U-01, NCI-2018-03421, NCT03547973, RG1003350, TrialTroveID-325557, TROPHY U-01, TROPHY-u-01","Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy.",Oncology,Oncology: Bladder; Oncology: Renal,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03547973,39522
1519,317148,"18-533, 2018-1779, A534260, NCI-2018-02551, NCT03725761, SMPH\MEDICINE\HEM-ONC, TrialTroveID-317148, UW18043",A Study to Evaluate the Safety and Efficacy of IMMU-132 (Sacituzumab Govitecan) in Patients With Metastatic Castration-Resistant Prostate Cancer Who Have Progressed on Second Generation AR-Directed Therapy,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, Gilead Sciences/Immunomedics, University of Wisconsin","Government, Industry, Top 20 Pharma, Academic","Overall response rate, PSA progression, Response rate","Circulating Tumor Cells, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT03725761,39522
1520,312431,"17-626, 2000021570, BO39610, EudraCT Number: 2017-001267-21, MORPHEUS, MORPHEUS BO39610, Morpheus cancer, Morpheus Lung, Morpheus-Lung, MORPHEUS-NSCLC, NCI-2018-00183, NCT03337698, TrialTroveID-312431","A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Non-Small Cell Lung Cancer (Morpheus-Lung)",Oncology,"Oncology: Lung, Non-Small Cell","Gilead Sciences/Immunomedics, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03337698,39522
1521,305958,"19632, CO40115, EudraCT Number: 2017-002038-21, IRAS ID: 237296, MORPHEUS, Morpheus-TNBC, NCI-2018-00650, NCT03424005, S17-01241, TrialTroveID-305958","A Phase Ib/II, Open-Label, Multicenter, Randomized Umbrella Study Evaluating The Efficacy And Safety Of Multiple Immunotherapy-Based Treatment Combinations In Patients With Metastatic Triple-Negative Breast Cancer (Morpheus-TNBC)",Oncology,Oncology: Breast,"Merck & Co., Seagen {Seattle Genetics}, Gilead Sciences/Immunomedics, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Disease Progression, Immune Response, Overall response rate, Safety and Tolerability, Vital signs","Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03424005,39522
1522,266013,"16023, 17-1501, 17-23, 17-495, 18-064, 20180280, ASCENT, BRE 298 - IMMU-132-05, C-311, C-311, COMIRB 17-1501, EudraCT Number: 2017-003019-21, IEO 735, IMMU-132-05, NCI-2017-01806, NCT02574455, PRMS 17-133, Study #16023, TrialTroveID-266013, USO 16023, USON16023, USOncology 16023, USOR 16023",Phase III Study of Sacituzumab Govitecan (IMMU-132) in Refractory/Relapsed Triple-Negative Breast Cancer.,Oncology,Oncology: Breast,"Seagen {Seattle Genetics}, Gilead Sciences/Immunomedics","Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02574455,39522
1523,210740,"IMMU-132-02, NCT02161679, TrialTroveID-210740",Randomized Phase II Study of IMMU-132 alone or in Combination with Carboplatin in Patients with Relapsed/Refractory Triple-Negative Breast Cancer,Oncology,Oncology: Breast,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma","Progression-free survival, Safety and Tolerability",,True,NCT02161679,39522
1524,192654,TrialTroveID-192654,A Phase I/II Proof-Of-Concept Study of IMMU-132 in Patients with Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Gilead Sciences/Immunomedics,"Industry, Top 20 Pharma",,,False,,39522
1525,170570,"13-541, AAAP0469, IMMU-132-01, IM-T-IMMU-132-01, NCI-2014-00136, NCT01631552, TrialTroveID-170570",A Phase I/II Study of IMMU-132 (hRS7-SN38 Antibody Drug Conjugate) in Patients with Epithelial Cancers,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid","Seagen {Seattle Genetics}, Gilead Sciences/Immunomedics","Industry, all other pharma, Industry, Top 20 Pharma","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease","Magnetic Resonance Imaging, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT01631552,39522
1526,388933,"eFT508-0011, KICKSTART Trial, NCT04622007, TrialTroveID-388933","A Randomized, Double-Blind, Placebo-Controlled Trial of Tomivosertib in Combination With Anti-PD-(L)1 Therapy in Subjects With Non-Small Cell Lung Cancer as First Line Therapy or When Progressing on Single-Agent First-Line Anti PD (L)1 Therapy",Oncology,"Oncology: Lung, Non-Small Cell",eFFECTOR Therapeutics,"Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04622007,84977
1527,361853,"NCT04261218, TrialTroveID-361853, TRIO036","A Trial to Assess the Safety, Pharmacodynamic Effects, Pharmacokinetics and Efficacy of the MNK Inhibitor Tomivosertib (eFT508) in Combination With Paclitaxel, Following a Run-in Period of Tomivosertib Monotherapy, in Patients With Advanced Breast Cancer",Oncology,Oncology: Breast,"(Other Cooperative Group), McGill University Health Centre, eFFECTOR Therapeutics","Cooperative Group, Academic, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Progressive disease rate, Response rate, Safety and Tolerability, Serious Adverse Events","Clinical benefit rate, Complete response, Overall response rate, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04261218,84977
1528,334733,TrialTroveID-334733,A Phase II Study of eFT508 in Combination with Pembrolizumab in Patients with Metastatic Triple Negative Breast Cancer,Oncology,Oncology: Breast,"Merck & Co., eFFECTOR Therapeutics","Industry, Top 20 Pharma, Industry, all other pharma","Clinical benefit rate, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",,False,,84977
1529,333841,"eFT508-0009, J1883, NCT03690141, RG1003920, TrialTroveID-333841",A Phase II Non-randomized Open-label Study Examining the Effect of Tomivosertib (eFT508) in Patients With Advanced Castrate-resistant Prostate Cancer (CRPC),Oncology,Oncology: Prostate,eFFECTOR Therapeutics,"Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate","Progression-free survival, PSA progression",True,NCT03690141,84977
1530,322682,"eFT508-0010, NCI-2018-01876, NCT03616834, TrialTroveID-322682, TX213567, TX9313",Tomivosertib (eFT-508) in Combination With PD-1/PD-L1 Inhibitor Therapy: A Study of Subjects Administered Anti-PD-1/Anti-PD-L1 Therapy That Are Experiencing Insufficient Response to Checkpoint Inhibitor Alone.,Oncology,"Oncology: Bladder; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal; Oncology: Unspecified Cancer",eFFECTOR Therapeutics,"Industry, all other pharma","Adverse Events, Complete response, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03616834,84977
1531,311441,"17336, eFT508-0008, NCI-2017-02271, NCT03318562, TrialTroveID-311441",A Pharmacodynamic Study of Oral eFT508 in Subjects With Advanced Triple Negative Breast Cancer and Hepatocellular Carcinoma,Oncology,Oncology: Breast; Oncology: Liver,eFFECTOR Therapeutics,"Industry, all other pharma",,"Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Treatment Emergent Adverse Events",True,NCT03318562,84977
1532,304241,"2017-0529, eFT508-0006, NCT03258398, REFMAL 515, TrialTroveID-304241","A Phase II, Open-Label, Randomized, Non-Comparative Study With Preliminary Dose Finding to Evaluate eFT508 Monotherapy or eFT508 in Combination With Avelumab in Subjects With Microsatellite Stable Relapsed or Refractory Colorectal Cancer",Oncology,Oncology: Colorectal,"Merck KGaA, Pfizer, eFFECTOR Therapeutics","Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma","Dose-limiting toxicities, Overall response rate, Partial response",,True,NCT03258398,84977
1533,288721,"20170102, eFT508-0002, ILYM17002, NCI-2017-00209, NCT02937675, TrialTroveID-288721",A Phase I-II Dose-Escalation and Cohort-Expansion Study of Oral Tomivosertib (eFT-508) in Subjects With Hematological Malignancies,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",eFFECTOR Therapeutics,"Industry, all other pharma","Maximum tolerated dose, Overall response rate","Progressive disease rate, Safety and Tolerability",True,NCT02937675,84977
1534,268071,"2016-0345, eFT508-0001, NCI-2016-00971, NCT02605083, TrialTroveID-268071",A Phase I-II Dose Escalation and Cohort-Expansion Study of Oral eFT508 in Subjects With Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",eFFECTOR Therapeutics,"Industry, all other pharma","Maximum tolerated dose, Overall response rate","Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02605083,84977
1535,400241,TrialTroveID-400241,A Clinical Study of Trilaciclib in Patients with 2L or 3L Non-small cell lung cancer,Oncology,"Oncology: Lung, Non-Small Cell",G1 Therapeutics,"Industry, all other pharma",,,False,,78716
1536,395352,TrialTroveID-395352,A Clinical Study of Trilaciclib Injection in Patients with Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"G1 Therapeutics, Simcere Pharmaceutical Group {Jiangsu Simcere Pharmaceutical Co.}","Industry, all other pharma, Industry, all other pharma",,,False,,78716
1537,394629,TrialTroveID-394629,A Phase II Clinical Study of  Trilaciclib in Combination with an Anti-PD-L1 in Patients with First-Line Locally Advanced or Metastatic Bladder Cancer Bladder Cancer,Oncology,Oncology: Bladder,G1 Therapeutics,"Industry, all other pharma",,,False,,78716
1538,381385,"G1T28-501, NCT04504513, TrialTroveID-381385",Expanded Access Program: Trilaciclib for Chemotherapy-induced Myelosuppression in Patients Receiving Chemotherapy for Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",G1 Therapeutics,"Industry, all other pharma",,,True,NCT04504513,78716
1539,365052,TrialTroveID-365052,A Registrational Study of Trilaciclib in Additional Tumor Types and in Combination with Different Chemotherapy Regimens,Oncology,Oncology: Unspecified Cancer,G1 Therapeutics,"Industry, all other pharma",,,False,,78716
1540,358310,"EudraCT Number: 2020-004930-39, G1T28-208, NCT04799249, PRESERVE 2, TrialTroveID-358310","Phase III randomized, double-blind, Clinical Study of Trilaciclib  in combination with a chemotherapy regimen of GC in Metastatic Triple-Negative Breast Cancer",Oncology,Oncology: Breast,G1 Therapeutics,"Industry, all other pharma",Overall survival,"Neutropenia, Progression-free survival, Quality of Life",True,NCT04799249,78716
1541,358308,"EudraCT Number: 2019-003826-25, G1T28-207, NCT04607668, PRESERVE1, TrialTroveID-358308","PRESERVE 1: A Phase III Randomized, Double-blind Trial of Trilaciclib Versus Placebo in Patients Receiving FOLFOXIRI/Bevacizumab for Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,G1 Therapeutics,"Industry, all other pharma","Neutropenia, Severe neutropenia","Adverse Events, Cardiac Telemetry, Disease Progression, FACIT-Fatigue, Hemoglobin level, Neutropenia, Overall response rate - duration, Overall response rate, Overall survival, Platelet count, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Severe neutropenia, Vital signs",True,NCT04607668,78716
1542,293421,"20170516, EudraCT Number: 2017-000358-20, G1T28-05, NCI-2017-02073, NCT03041311, TrialTroveID-293421","Phase II Study of Carboplatin, Etoposide, and Atezolizumab With or Without Trilaciclib in Patients With Untreated Extensive Stage Small Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",G1 Therapeutics,"Industry, all other pharma","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT03041311,78716
1543,291665,"Clinical Trial 18977, EudraCT Number: 2016-004466-26, G1T28-04, NCI-2017-01278, NCT02978716, TrialTroveID-291665","Phase II Study of the Safety, Efficacy, and Pharmacokinetics of G1T28 in Patients With Metastatic Triple Negative Breast Cancer Receiving Gemcitabine and Carboplatin Chemotherapy",Oncology,Oncology: Breast,G1 Therapeutics,"Industry, all other pharma","Adverse Events, Neutropenia, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Duration of overall response, Elimination half-life, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Volume of distribution",True,NCT02978716,78716
1544,261448,"15021002, EudraCT Number: 2016-001583-11, F15167, G1T28-02, IRAS ID: 208844, LUN 303, NCI-2015-01360, NCT02499770, PH 278815, TrialTroveID-261448, USOR Number: 15068",Phase Ib/IIa Safety and Pharmacokinetic Study of G1T28 in Patients With Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Etoposide and Carboplatin,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",G1 Therapeutics,"Industry, all other pharma","Adverse Events, Cardiac Telemetry, Dose-limiting toxicities, Infusion-related reactions, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment compliance, Treatment Emergent Adverse Events, Vital signs","Hematocrit level, Hemoglobin level, Overall survival, Platelet count, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02499770,78716
1545,258283,"2015-0545, EudraCT Number: 2016-004611-13, G1T28-03, NCI-2015-01365, NCT02514447, TrialTroveID-258283, USOR 15-001",Phase I/IIa Safety and Pharmacokinetic Study of G1T28 in Patients With Previously Treated Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Topotecan Chemotherapy,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",G1 Therapeutics,"Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Severe neutropenia, Treatment Emergent Adverse Events","Hematocrit level, Hemoglobin level, Overall survival, Platelet count, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02514447,78716
1546,216595,"G1T28-1-01, NCT02243150, TrialTroveID-216595","First-In-Human Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of G1T28-1 in Healthy Male and Female Subjects",Oncology,"Oncology: Breast; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",G1 Therapeutics,"Industry, all other pharma","Adverse Events, Vital signs","Area under the curve score, Cmax, Elimination half-life, Plasma concentration, Tmax, Volume of distribution",True,NCT02243150,78716
1547,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,78716
1548,395072,"KI / 0419-3, TrialTroveID-395072","Open Randomized Crossover Comparative Study Of Pharmacokinetics And Bioequivalence Of Drugs Sunitinib, Capsules 50 Mg (JSC"" Rafarma "" Russia) And SutentÂ®, Capsules 50 Mg (Pfizer Inc., USA) With The Participation Of Healthy Volunteers""",Oncology,Oncology: Unspecified Cancer,Byondis {Synthon},"Industry, all other pharma",,,False,,27584
1549,391928,"A6181234, NCT04669366, RENCOMP3",Treatment Patterns With Targeted Therapies in Metastatic Renal Cell Carcinoma (mRCC) in Sweden - A Retrospective Analysis of Data From National Registries,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,,True,NCT04669366,27584
1550,391403,"1-10-72-277-19, NCT04659343, TrialTroveID-391403",Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Rigshospitalet, (Other Hospital/Academic/Medical Center), Herlev and Gentofte Hospital {Herlev Hospital}, Odense University Hospital","Academic, Academic, Academic, Academic","Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",,True,NCT04659343,27584
1551,373339,"ChariteU-ECRC-TSS2, EA1/044/15, NCT04368546",Effect of Sunitinib Treatment on Tissue Sodium Accumulation in Patients With Renal Cancer: a Pilot Study,,NA: ClinicalTrials.gov,"Charite University, Berlin, Germany, German Heart Institute","ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT04368546,27584
1552,371575,"NCT04341181, ProTarget, TrialTroveID-371575",ProTarget - A Danish Nationwide Clinical Trial on Targeted Cancer Treatment Based on Genomic Profiling,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor","GlaxoSmithKline, (Other Cooperative Group), Roche, Pfizer","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Stable Disease",,True,NCT04341181,27584
1553,368730,TrialTroveID-368730,Individualized Dosing Schedule Of Sunitinib Switched Through Plasma Concentration Monitoring In Patients With Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability",,False,,27584
1554,362009,"A6181233, NCT04175262",Clinical Effectiveness of Second-Line Sunitinib Following Immune-oncologic (IO) Therapy in Patients With Metastatic Renal Cell Carcinoma in the International Metastatic Renal Cell Carcinoma Database (IMDC),,NA: ClinicalTrials.gov,"Pfizer, IMDC group, Analysis Group","Industry, Top 20 Pharma, ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT04175262,27584
1555,358489,"A6181231, NCT04115189",A Retrospective Medical Record Review of First-Line Sunitinib Administration Schedules and Outcomes Among Patients With Metastatic Renal Cell Carcinoma in Latin America,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,,True,NCT04115189,27584
1556,356437,"A6181229, NCT04076787",The Effect of Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitors (TKI) on Clinical Outcomes Among Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received First-Line Sunitinib in the International mRCC Database Consortium (IMDC) Based on Prognostic Risk Score,,NA: ClinicalTrials.gov,"Pfizer, International Metastatic Renal Cell Carcinoma Database Consortium (IMDC), Analysis Group","Industry, Top 20 Pharma, ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT04076787,27584
1557,355975,"CSPAC-26, NCT04066322, TrialTroveID-355975",Resection of Metastatic Pancreatic Neuroendocrine Tumors After Induction System Treatment: Real World Study,Oncology,Oncology: Metastatic Cancer; Oncology: Neuroendocrine,"Fudan University - Shanghai, China",Academic,Progression-free survival,"Gastric emptying rate, Mortality, Overall survival, Progression-free survival",True,NCT04066322,27584
1558,354097,"NCT04033991, X9001180",A Real World Retrospective Database Study of Patients Diagnosed With Metastatic and/or Advanced Renal Cell Carcinoma and Treated With Sunitinib and/or Axitinib in a Specialist United Kingdom Oncology Centre,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT04033991,27584
1559,353053,TrialTroveID-353053,Clinical outcomes of sunitinib (Su) for patients (pts) with desmoid tumors (DT),Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Response evaluation criteria in solid tumors",False,,27584
1560,352309,"12-058, NCT01603004, TrialTroveID-352309",A Pilot Study to Identify Potential Molecular Predictors of Response to Novel Therapies in Metastatic Pancreatic Neuroendocrine Tumors,Oncology,Oncology: Neuroendocrine,Memorial Sloan-Kettering Cancer Center,Academic,"Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors","Magnetic Resonance Imaging, Overall survival, Response evaluation criteria in solid tumors",True,NCT01603004,27584
1561,347258,"EudraCT Number: 2017-000364-15, NCT03909724, NL60716.029.18, NL8081, SUNRISE-CRC, TrialTroveID-347258",A Randomized Phase II Study of Pulsatile High-dose Sunitinib Versus TAS-102 in Patients With Metastatic Colorectal Carcinoma (mCRC),Oncology,Oncology: Colorectal,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Cost effectiveness, EORTC Quality of Life Questionnaire, EQ-5D, Overall survival, Quality of Life, Quality-adjusted life year, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT03909724,27584
1562,346956,"NCT03905889, PSCI-18-055, TrialTroveID-346956",Targeting PIM1 and CDK4/6 Kinases in Renal Cell Carcinoma (PICKRCC): A Phase Ib Study of Abemaciclib (Verzenio) in Combination With Sunitinib in Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Eli Lilly, Penn State Cancer Institute at Milton S. Hershey Medical Center","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Heart rate corrected QT interval, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression, Time to response",True,NCT03905889,27584
1563,346867,"CTR20182541, QL-SNTN-001, TrialTroveID-346867",Bioequivalence Study of Sunitinib Malate Capsules in Humans,Oncology,Oncology: Unspecified Cancer,Qilu Pharmaceutical Co./Qilu Pharmaceutical (Hainan) Co.,"Industry, generic","Cmax, Safety and Tolerability","Adverse Events, Cardiac Telemetry, Elimination half-life, Safety and Tolerability, Serious Adverse Events, Tmax, Vital signs",False,,27584
1564,346828,"18-2740.cc, NCI-2019-06119, NCT03900793, TrialTroveID-346828",A Phase I/Ib Study of Losartan in Combination With Sunitinib in the Treatment of Pediatric and Adult Patients With Relapsed or Refractory Osteosarcoma,Oncology,Oncology: Osteosarcoma,"National Institutes of Health/National Cancer Institute, University of Colorado","Government, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Clinical benefit rate, Complete response, Immune-related response evaluation criteria in solid tumors, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03900793,27584
1565,345470,"NCI-2020-02743, NCT03878524, SMMART, STUDY00015588, TrialTroveID-345470",Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial,Oncology,"Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Pancreas; Oncology: Prostate","(Other Cooperative Group), National Institutes of Health/National Cancer Institute, OHSU Cancer Institute, Oregon Health and Science University","Cooperative Group, Government, Academic, Academic",,"Activities of Daily Living, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Quality of Life",True,NCT03878524,27584
1566,344209,"EudraCT Number: 2018-003954-26, METC2018-1538, NL67818.078.18, NL7514, STAR22, TrialTroveID-344209",CYP3A4*22 Genotype-Guided Dosing of TKIs in Cancer Patients: A New Way of Personalized Therapy. Based On CYP3A4 * 22 Genotype Dosing of Tyrosine-Kinase Inhibitors In Patients With Cancer: A New Way of Personalized Therapy.,Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,Common Terminology Criteria for Adverse Events,False,,27584
1567,343661,"2017/181/HP, BERS_207, BIOSUNTOX, NCT03846128, TrialTroveID-343661",Impact of Sunitinib Bioavailability on Toxicity and Treatment Efficacy in Patients Treated for Metastatic Renal Cancer,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Plasma concentration,,True,NCT03846128,27584
1568,342847,"EudraCT Number: 2012-003936-21, SULA-P Study, TD-212-2308, TrialTroveID-342847","A Prospective Multicentric, Proof of Concept Study to Evaluate the Value of 18-FDG-PET-Scan on Tumour Response in Patients with a Progressive Pancreatic Endocrine Tumour Receiving a Combination Therapy of Lanreotide Autogel 120 MG Every 28 Days and Sunitinib 37.5 MG Daily",Oncology,Oncology: Neuroendocrine,"Ipsen, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Magnetic Resonance Imaging, Response evaluation criteria in solid tumors, Time to progression","Magnetic Resonance Imaging, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,27584
1569,337197,"TrialTroveID-337197, UMIN000029861",Association Between CTC and Tumor Shrinkage by TKI Treatment on RCC Patients,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1570,334003,"NCT03696186, STAMP, TrialTroveID-334003",Selective Treatment According to Molecular Subtype of Prostate Cancer,Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall response rate, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03696186,27584
1571,331095,"180137, 18-C-0137, NCI-2018-01929, NCT03641326, P162920, TrialTroveID-331095",Phase II Clinical Trial of Sunitinib in Sarcomas of the Central Nervous System,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,Overall response rate,"Adverse Events, Magnetic Resonance Imaging, MD Anderson Symptom Inventory, Overall survival, Progression-free survival, Quality of Life",True,NCT03641326,27584
1572,328385,"NCT03592199, NP 1096/17, SuAx, TrialTroveID-328385",Biomarker Study of Patients With Metastatic Clear Cell Renal Carcinoma (ccRCC) Undergoing Sequential Therapy With First Line Sunitinib and Second Line Axitinib,Oncology,Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Treatment Emergent Adverse Events",True,NCT03592199,27584
1573,328123,"ChiCTR1800017136, TrialTroveID-328123",A Phase-II Study of Stereotactic Body Radiotherapy and Sunitinib for Patients With New Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Quality of Life",False,,27584
1574,323979,"NCT03519542, SOGANG, SOG-ANG-2013-01",Muticentric and Prospective Epidemiological Study to Identify Prognosis and Predictive Biomarkers of Response to Angiogenic Drugs Approved in First Line of Treatment for Advanced or Metastatic Renal Cell Carcinoma,,NA: ClinicalTrials.gov,Spanish Oncology Genito-Urinary Group,ClinicalTrials.gov,,,True,NCT03519542,27584
1575,320283,"NCI-2018-00192, NCT03463460, OSU-17234, P30CA016058","A Multicenter, Phase II Trial of Pembrolizumab and Sunitinib in Refractory Advanced Thymic Carcinoma",,NA: ClinicalTrials.gov,"National Cancer Institute (NCI), Dwight Owen","ClinicalTrials.gov, ClinicalTrials.gov",,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT03463460,27584
1576,319499,"INT 165-16, NCT03449173, STYLE",Phase II Trial of Sunitinib in Patients With Type B3 Thymoma or Thymic Carcinoma in Second and Further Lines (Style Trial),,NA: ClinicalTrials.gov,"Fondazione IRCCS Istituto Nazionale dei Tumori, Milano",ClinicalTrials.gov,,"Adverse Events, Safety and Tolerability",True,NCT03449173,27584
1577,319341,"001, EudraCT Number: 2014-001956-52, NCT03456401, TOKIO, Tokio Study, TrialTroveID-319341",Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study),Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival, Progressive disease rate","Adverse Events, EORTC Quality of Life Questionnaire, NCI-CTC scale, Overall survival, Quality of Life, Safety and Tolerability",True,NCT03456401,27584
1578,311732,"NCT03323710, ProSun, PS-001, TrialTroveID-311732",A Phase II Study of Propranolol Plus Sunitinib in First-line Treatment of Metastatic Renal Cell Carcinoma (ProSun Study),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT03323710,27584
1579,310184,"CA209-9DL, CAPTUR, ESR-17-12831, ML39800, NCT03297606, PM1, TrialTroveID-310184, WI233446",Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR): A Phase II Basket Trial,Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Solid Tumor","AstraZeneca, Bristol-Myers Squibb, Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Pfizer, Boehringer Ingelheim, Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability",True,NCT03297606,27584
1580,308643,"NCT03275558, NST-4-G, TrialTroveID-308643","Phase I Clinical Trial of Nasal Spray in Treating Patients With Recurrent Glioblastoma, Gliosarcoma, Glioma",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma",(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Nausea, Neutropenia, Overall survival, Vomiting",True,NCT03275558,27584
1581,304949,TrialTroveID-304949,Prognostic Role Of Circulating Tumor Cells-Ctcs In Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate",False,,27584
1582,303827,"TrialTroveID-303827, UMIN000027619, UroPRO","Effect of systemic chemotherapy, hormonal therapy and immunotherapy on onclogical outcomes and patient reported outcomes in urological cancers (UroPRO study)",Oncology,Oncology: Bladder; Oncology: Prostate; Oncology: Renal; Oncology: Testicular,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1583,303616,"MMP-Rein-IPC 2015-029, NCT03185039, TrialTroveID-303616",Study of the Predictive Impact of MMP2 and MMP9 Levels for Patients With Metastatic Kidney Cancer Treated With Anti-angiogenic Agents Compared to Patients Not Treated With Antiangiogenic (Localized Kidney Cancer and Oligometastatic),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors",,True,NCT03185039,27584
1584,302506,"2016-12-058, NCT03170180",Exploratory Study of Drug Sensitivity Prediction Software (IRCR-DReSS) With Patient-derived Tumor Cells of Metastatic Gastric Cancer,,NA: ClinicalTrials.gov,Samsung Medical Center,ClinicalTrials.gov,,,True,NCT03170180,27584
1585,302066,"EudraCT Number: 2016-004040-10, GEIS 52, GEIS-52, ImmunoSarc, NCT03277924, TrialTroveID-302066",Phase I-II Trial of Sunitinib Plus Nivolumab After Standard Treatment in Advanced Soft Tissue and Bone Sarcomas,Oncology,Oncology: (N/A); Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Immune Response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03277924,27584
1586,300809,"A6181223, NCT03140176, OPTIMISE, TrialTroveID-300809",Real-world Clinical Patterns Of Care And Outcomes Among Patients In Africa Middle East (Afme) With Metastatic Renal Cell Carcinoma (MRCC) Receiving Sunitinib As First Line Therapy.(OPTIMISE),Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Time to treatment failure","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03140176,27584
1587,299057,"ASSET, NCT03109015, Pro00072588",Alternative Schedule Sunitinib in Metastatic Renal Cell Carcinoma: Cardiopulmonary Exercise Testing,,NA: ClinicalTrials.gov,Duke University,ClinicalTrials.gov,,"6-minute walk test, FACIT-Fatigue, Timed Up and Go test",True,NCT03109015,27584
1588,296677,"EudraCT Number: 2016-004011-12, INMUNOSUN, INMUNOSUN-SOGUG, NCT03066427, SOGUG-2016-A- IEC(REN)-10, TrialTroveID-296677",Phase II Study to Evaluate Efficacy and Safety of Sunitinib Therapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Have Progressed to First-line Immunotherapy Treatment (INMUNOSUN Study),Oncology,Oncology: Renal,"Pfizer, Spanish Oncology GenitoUrinary Group","Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT03066427,27584
1589,295026,"GU15-223, HCRN GU15-223, NCT03035630, SUAVE, TrialTroveID-295026",Randomized Phase II Trial Comparing Sequential First-line Sunitinib and Second-line Avelumab vs First-line Avelumab and Second-line Sunitinib for Metastatic Renal Cell Carcinoma: SUAVE Trial. Hoosier Cancer Research Network GU15-223,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Overall response rate, Overall survival, Progression-free survival",True,NCT03035630,27584
1590,294893,"A G.I.O.N, EudraCT Number: 2012-000473-23, RETRY, TrialTroveID-294893",Phase II Study Of Sunitinib As Rechallenge Third-Line Therapy In Metastatic Renal Cancer,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival","Overall response rate, Overall survival, Progression-free survival",False,,27584
1591,293185,"TrialTroveID-293185, UMIN000025209",Efficacy of Presurgical Targeting Therapy on Tumor Shrinkage in Patients With Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,"Overall survival, Treatment Emergent Adverse Events",False,,27584
1592,292187,"ACTRN12616001639415, ISE TAD 14-7, TrialTroveID-292187, WI200619",Improving Sunitinib Efficacy And Tolerability In Patients With Metastatic Clear Cell Carcinoma Of The Kidney By Using A 14/7 Day Schedule And Toxicity-Adjusted Dosing,Oncology,Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Common Terminology Criteria for Adverse Events, FACIT-Fatigue, Overall survival, Quality of Life",False,,27584
1593,291422,"2016.221, BRF47-2016, EudraCT Number: 2016-001797-15, NCT03025893, NL57648.029.16, NTR6308, STELLAR, TrialTroveID-291422","A Phase II/III Study Of High-Dose, Intermittent Sunitinib In Patients With Recurrent Glioblastoma Multiforme: the STELLAR Study",Oncology,"Oncology: CNS, Glioblastoma","Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Magnetic Resonance Imaging, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Magnetic Resonance Imaging, NCI-CTC scale, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability",True,NCT03025893,27584
1594,290932,"12-138 METC ErasmusMC, EudraCT Number: 2012-000425-45, NL3378, NTR3526, TrialTroveID-290932",Effects of Morning versus Evening Dosing on the Pharmacokinetics and Pharmacodynamics of Sunitinib (Sutent).,Oncology,Oncology: GIST; Oncology: Neuroendocrine; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1595,289958,TrialTroveID-289958,Sunitinib (2 Weeks On/1 Week Off Schedule) In Metastatic Renal Cell Cancer Patients. Progression Free And Overall Survival.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Progression-free survival, Time to progression",,False,,27584
1596,289557,"16088, NCI-2016-01068, NCT02944617",Assessment of the Role of Bifidobacterium-Containing Food Supplement Activia??? and Bacteriomic Profiling and Other Biomarkers Associated With Vascular Endothelial Growth Factor Tyrosine Kinase Inhibitor (VEGF-TKI)-Induced Diarrhea in Patients With Metastatic Renal Cell Carcinoma (mRCC),,NA: ClinicalTrials.gov,"City of Hope Medical Center, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",,Common Terminology Criteria for Adverse Events,True,NCT02944617,27584
1597,287821,"CT/08.22, EudraCT Number: 2008-005033-29, TrialTroveID-287821",A Phase II Study of Sunitinib in Patients with Advanced Harmone Resistant and Chemotherapy Resistant Prostate Cancer.,Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Safety and Tolerability, Time to progression",False,,27584
1598,287567,"2141-102, CASA, NCT02919371, TrialTroveID-287567",Phase I/II Combined Alternating Sunitinib and Bevacizumab (AvastinÂ®) in Advanced Renal Cell Carcinoma (CASA),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Progression-free survival, Response rate","Common Terminology Criteria for Adverse Events, Overall survival",True,NCT02919371,27584
1599,283387,"35RC14_9896, NCT02848768, RTKI",Validation of a Predictive Nomogram of Response or Resistance to Targeted Therapies in Metastatic Clear Cell Renal Cell Carcinoma,,NA: ClinicalTrials.gov,Rennes University Hospital,ClinicalTrials.gov,,,True,NCT02848768,27584
1600,282664,"ChiCTR-OPC-16008840, TrialTroveID-282664","The Relationship and Mechanism of SNPs, AEs and PK in Chinese Renal Cell Carcinoma Patients Treated With Sunitinib",Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1601,282052,"Bisgrove, NCT00530192, SCRI-CA-001, TrialTroveID-282052",A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00530192,27584
1602,280065,"2016/00327, BR01/01/16, NCT02790580, TrialTroveID-280065",Dose-Dense Doxorubicin/Cyclophosphamide With Intermittent Low-Dose Sunitinib as Neoadjuvant or First-Line Palliative Treatment of Newly Diagnosed HER2 Negative Breast Cancer Patients With Measurable Primary Breast Tumor,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Complete response, Progression-free survival",True,NCT02790580,27584
1603,279928,"160121, 16-C-0121, COXEN, NCI-16-C-0121, NCI-2016-00966, NCI-2018-03327, NCT02788201, P152399, TrialTroveID-279928",A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,,"Adverse Events, Circulating Tumor Cells, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT02788201,27584
1604,279227,"NCI-2016-00083, NCT02779283, TrialTroveID-279227",A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, OHSU Cancer Institute","Government, Academic",,"Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Minimal Residual Disease, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT02779283,27584
1605,278386,TrialTroveID-278386,A Pilot Study Of Sunitinib As First-line Therapy For Metastatic Renal Cell Carcinoma On a 2 Weeks On/1 Week Off Intermittent Dosing Schedule,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival",False,,27584
1606,278259,"201605026, CCTG: REC.3/S1500, NCI-2015-01707, NCT02761057, PAPMET, PCRC_S1500, REC3, S1500, STUDY00016085, SWOG S1500, TrialTroveID-278259","A Randomized, Phase II Efficacy Assessment of Multiple MET Kinase Inhibitors (Cabozantinib [NSC #761968], Crizotinib [NSC #749005], Savolitinib [NSC #785348], and Sunitinib [NSC #736511]) in Metastatic Papillary Renal Carcinoma (PAPMET)",Oncology,Oncology: Renal,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}, (Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, University of Queensland","Cooperative Group, Academic, Government, Academic","Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT02761057,27584
1607,277701,"DRUP, EudraCT Number: 2015-004398-33, M15DRU, NCT02925234, NL54757.031.16, TrialTroveID-277701","A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Roche, Pfizer, Bayer AG/Bayer Pharmaceuticals, Eisai, Netherlands Cancer Institute, Boehringer Ingelheim, Ipsen, Merck & Co./Merck Sharp & Dohme (MSD), Clovis Oncology, Johnson & Johnson/Janssen Biotech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma, Government, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Serious Adverse Events, Stable Disease","Overall survival, Progression-free survival",True,NCT02925234,27584
1608,275205,"EudraCT Number: 2015-005774-37, GETNE-2016-01, NCT02713763, RESUNET, TrialTroveID-275205",Phase II Study to Evaluate Efficacy of Rechallenge With Sunitinib in Patients With Metastatic Pancreatic Neuroendocrine Tumor (pNETs) Well Differentiated GI/II Advanced or Metastatic Who Previously Failed to Sunitinib.,Oncology,Oncology: Neuroendocrine,"(Other Cooperative Group), Pfizer","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Complete response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT02713763,27584
1609,273941,"20170529, NCI-2017-00510, NCT02693535, Pro00014171, TAPUR, TrialTroveID-273941",Targeted Agent and Profiling Utilization Registry (TAPUR) Study,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","AstraZeneca, Bristol-Myers Squibb, Eli Lilly, (Other Cooperative Group), Pfizer, Bayer AG/Bayer Pharmaceuticals, Merck & Co./Merck Sharp & Dohme (MSD), Roche/Genentech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT02693535,27584
1610,273791,"2016-02-098, NCT02691793, TrialTroveID-273791","Study to Evaluate the Safety and Efficacy of Sunitinib, in Subject With Refractory Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Safety and Tolerability, Time to progression",True,NCT02691793,27584
1611,273590,"[2016]015, NCT02688491, TrialTroveID-273590","A Multi-site, Open, Perspective Study of Prognostic Value and Benefit From Adjuvant Targeted Therapy of Stage III Clear Cell Renal Cell Carcinoma Based on a CpG-methylation-based Assay",Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,Overall survival,True,NCT02688491,27584
1612,273568,"EudraCT Number: 2015-002575-16, NCT02689167, P/2015/254, SURF, TrialTroveID-273568","Open Label, Randomised Multi-centre Phase II Study to Assess the Efficacy and Tolerability of Sunitinib by Dose Administration Regimen (Dose Modification or Dose Interruptions) in Patients With Advanced or Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",,"Body Mass Index, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to response, Treatment Emergent Adverse Events",True,NCT02689167,27584
1613,271185,TrialTroveID-271185,Impact of dose reduction on survival in patients starting sunitinib (SU) or pazopanib (PA) as first-line for metastatic renal cell carcinoma (mRCC).,Oncology,Oncology: Renal,"European Institute of Oncology, (Other Hospital/Academic/Medical Center)","Government, Academic",,"Overall survival, Progression-free survival",False,,27584
1614,270834,"ACTRN12616001187437, MatchMel, MIA2015/174, MIA-M-15-01, NCT02645149, TrialTroveID-270834",Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,Oncology,Oncology: Melanoma,"(Other Cooperative Group), National Health and Medical Research Council  (NHMRC)","Cooperative Group, Government",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02645149,27584
1615,269557,"2014-10-002A, NCT02626754, TrialTroveID-269557",A Prospective Study on Sunitinib as First Line Therapy for Advanced/Metastatic Renal Cell Carcinoma in Asian Population,Oncology,Oncology: Renal,Taipei Veterans General Hospital,Academic,"Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Overall response rate, Progression-free survival, Quality of Life, Response rate",True,NCT02626754,27584
1616,269281,"KOSMIC, NCT02623127, SNUBH-15-01","A Phase II, Non-comparative, Open Label, Multi-center Study of Sunitinib in Patients With Metastatic or Recurrent Thymic Carcinoma",,NA: ClinicalTrials.gov,"Seoul National University Hospital, SMG-SNU Boramae Medical Center","ClinicalTrials.gov, ClinicalTrials.gov",,"Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02623127,27584
1617,268856,"15-325, 16-C-0079, 20151318, B7791001, i2190, NCI-2016-00393, NCT02616185, PrCa VBIR, PRCA VBIR FIP STUDY, TrialTroveID-268856","A Phase I Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (VBIR) For Prostate Cancer (PF-06753512)",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Treatment Emergent Adverse Events","Anti-drug antibodies, Cmax, Immune Response, Neutralizing antibody response, Tmax",True,NCT02616185,27584
1618,267024,TrialTroveID-267024,Early Tumor Shrinkage Under Treatment With First-Line Tyrosine Kinase Inhibitors As A Surrogate Endpoint of Overall Survival In Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,27584
1619,265222,"GU-14-102, HSC-14-0665, NCT02560012, TrialTroveID-265222",Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations,Oncology,Oncology: Renal,University of Texas- Houston Medical School,Academic,"Disease Progression, Progression-free survival",,True,NCT02560012,27584
1620,264987,"14 URO 06, NCT02555748, RECF2848, SUP-R, TrialTroveID-264987",Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Hospital/Academic/Medical Center), Institut Claudius Regaud","Academic, Academic","Adverse Events, Plasma concentration, Progression-free survival","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, NCI-CTC scale, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02555748,27584
1621,264619,"9226, NCI-2015-01299, NCT02551718, RG1015012, TrialTroveID-264619",Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic",,"Complete response, Overall response rate - duration, Overall survival",True,NCT02551718,27584
1622,264436,"chictr-onc-11001681, TrialTroveID-264436",Targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,27584
1623,264095,"2015/91, EudraCT Number: 2014-004830-25, KIT, TrialTroveID-264095",Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Circulating Tumor Cells, Quality of Life",False,,27584
1624,258914,"2015-000194-12, NCT02446795, QUASAR, QUASAR - 2014-001",Isoquercetin as an Adjunct Therapy in Patients With Kidney Cancer Receiving First-line Sunitinib: a Phase I/II Trial,,NA: ClinicalTrials.gov,"Consorzio Oncotech, Quercis Pharma {Quercegen Pharmaceuticals}, Clinical Research Technology S.r.l.","Cooperative Group, Industry, all other pharma, ClinicalTrials.gov",Maximum tolerated dose,"Adverse Events, Cardiac Telemetry, Doppler ultrasound, Functional Assessment of Cancer Therapy-General, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment compliance, Vital signs",True,NCT02446795,27584
1625,258747,"15-7002, 16-750, 20150671, AAAP9159, CTSU/EAY131, EAY131, ECOG-ACRIN EAY131, MATCH, NCI-2015-00054, NCI-MATCH, NCT02465060, TrialTroveID-258747",Molecular Analysis for Therapy Choice (MATCH).,Oncology,"Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Roche/Genentech, ECOG-ACRIN Cancer Research Group","Government, Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT02465060,27584
1626,258208,TrialTroveID-258208,A Clinical Study on Clinical Outcome of Single Nucleotide Polymorphisms on Pharmacokinetic Genes in Japanese Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Progression-free survival",,False,,27584
1627,257904,TrialTroveID-257904,The efficacy and safety analysis of sunitinib plus temozolomide therapy in patients with metastatic mucosal melanoma.,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Safety and Tolerability","Overall survival, Progression-free survival",False,,27584
1628,257849,"2014-10-076, NCT02450123, TrialTroveID-257849","Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Time to progression",True,NCT02450123,27584
1629,257380,"EudraCT Number: 2014-005341-44, ICT, TrialTroveID-257380",Molecular-Biological Tumor Profiling for Drug Treatment Selection in Patients with Advanced and Refractory Carcinoma,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,27584
1630,257180,"McG 1132, NCT02928575, TrialTroveID-257180","A Phase II Trial of Concurrent Sunitinib, Temozolomide and Radiation Therapy Followed by Adjuvant Temozolomide for Newly Diagnosed Glioblastoma Patients With an Unmethylated MGMT Gene Promoter",Oncology,"Oncology: CNS, Glioblastoma","Pfizer, McGill University Health Centre, Canadian Cancer Society","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity","Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT02928575,27584
1631,256007,"EudraCT Number: 2014-004072-30, GETNE-1408, NCT02402062, SUNEVO (GETNE-1408), SUNINET, TrialTroveID-256007",A Phase II Study to Assess the Activity and Safety of TH-302 in Combination With Sunitinib in Treatment-naive Patients With Well- and Moderately-differentiated Metastatic Pancreatic Neuroendocrine Tumours (pNET),Oncology,Oncology: Neuroendocrine,"(Other Cooperative Group), Pfizer, Molecular Templates {Threshold Pharmaceuticals}","Cooperative Group, Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Cardiac Telemetry, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT02402062,27584
1632,255948,"EVD-003, NCT02380625, TrialtroveID-255948",An Adaptive Randomized Trial Comparing Multiple Treatments for Ebola Virus (EBOV) Infected Children and Adults,Infectious Disease,Infectious Disease: Ebola,"Duke University Medical Center, University of North Carolina, (Other Hospital/Academic/Medical Center), Bill & Melinda Gates Foundation","Academic, Academic, Academic, Not for Profit Funding Entity",,Adverse Events,True,NCT02380625,27584
1633,254668,"EudraCT Number: 2014-005534-55, gencinib-artificial, GenCInibs-Suni, LOCAL/2014/LM-01bis, NCT02404584, TrialTroveID-254668",The Pharmacokinetic Variability of Sunitinib in Patients With Metastatic Renal Cancer: Searching for Pharmacogenetic Determinants,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Plasma concentration,"Common Terminology Criteria for Adverse Events, Plasma concentration",True,NCT02404584,27584
1634,254537,"703131-1, NCT02400385, TrialTroveID-254537",A Phase II Trial of Sunitinib and Nivolumab for KIT-mutated Advanced Melanoma,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Leukocyte count, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02400385,27584
1635,254340,"BCH-RCC-150212, NCT02398552, TrialTroveID-254340",A Randomized Phase II Trial of Sunitinib Four-weeks on/Two-weeks Off Versus Two-weeks on/One-week Off as First Line Therapy in Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Adverse Events, Complete response, Partial response",True,NCT02398552,27584
1636,253438,TrialTroveID-253438,Thyroid and Gonadal Dysfunction in Patients with Metastatic Carcinoma Trated with Tyrosine Kinase Inhibitors,Oncology,Oncology: GIST; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Doppler ultrasound, Follicle Stimulating Hormone level, Leutinizing hormone",,False,,27584
1637,247314,"2006-0877, NCT00569725",A Treatment Protocol for Patients Continuing From SU011248 Protocols,,NA: ClinicalTrials.gov,"Pfizer, M.D. Anderson Cancer Center","Industry, Top 20 Pharma, ClinicalTrials.gov",Safety and Tolerability,,True,NCT00569725,27584
1638,243208,"150040, 15-C-0040, 339636, NCI-2015-00091, NCI-2019-00383, NCT02315625, P141605, TrialTroveID-243208",A Phase II Trial of Mutation-Targeted Therapy With Sunitinib or Everolimus in Patients With Advanced Low-or Intermediate Grade Neuroendocrine Tumors of the Gastrointestinal Tract and Pancreas With or Without Cytoreductive Surgery,Oncology,Oncology: Neuroendocrine,National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Progression-free survival, Resection rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Vital signs",True,NCT02315625,27584
1639,242935,"A6181193, NCT01121562",A Phase II Study Of Sunitinib In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Neuroendocrine Tumors,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,Plasma concentration,True,NCT01121562,27584
1640,242263,"A6181189, NCT01033981",Cost Effectiveness Of Sunitinib Vs IFN-Alfa Or Bevacizumab + IFN-Alfa As First-Line Treatment In MRCC In Central America And The Caribbean,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,"Cost effectiveness, Quality of Life, Quality-adjusted life year",True,NCT01033981,27584
1641,241867,"NCT00981890, UHN REB 09-0115-C",A Phase I Study of Stereotactic Radiosurgery Concurrent With Sunitinib in Patients With Brain Metastases,,NA: ClinicalTrials.gov,"University Health Network, Toronto",Academic,"Maximum tolerated dose, Safety and Tolerability",,True,NCT00981890,27584
1642,241854,"NCT00980213, R09045",Evaluation of the Cost and Effectiveness in the First-line Treatment of Advanced Renal Cell Cancer With Sunitinib Compared to Interferon-alfa in Finland.,,NA: ClinicalTrials.gov,"Oulu University Hospital, Pirkko-Liisa Kellokumpu-Lehtinen, University of Turku","ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov",,Quality of Life,True,NCT00980213,27584
1643,240777,"2011/271, EudraCT number: 2011-003163-29, NCT00843037, NL37777.042.11, SNIPP, SNIPP study, TrialTroveID-240777",A Investigator Initiated Phase II Study Of Sunitinib In Patients With Recurrent Paraganglioma/Pheochromocytoma,Oncology,Oncology: Neuroendocrine,"Pfizer, Groningen University Hospital, University Health Network, Toronto","Industry, Top 20 Pharma, Academic, Academic","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Time to progression",True,NCT00843037,27584
1644,240398,"NCT00796861, PSHCI25224",Phase II Pilot Efficacy Trial of Sunitinib for Refractory Malignant Ascites,,NA: ClinicalTrials.gov,Milton S. Hershey Medical Center,ClinicalTrials.gov,,,True,NCT00796861,27584
1645,239390,"080129, 08-EI-0129, NCT00673816, VHL3",Pilot Study of Sunitinib Malate for Advanced Ocular Disease of Von Hippel-Lindau Syndrome,,NA: ClinicalTrials.gov,National Eye Institute (NEI),ClinicalTrials.gov,BCVA,Retinal thickness,True,NCT00673816,27584
1646,238664,"07-135, NCT00589784",Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma,,NA: ClinicalTrials.gov,"Pfizer, University of Virginia, University of Pittsburgh, Dana-Farber Cancer Institute, Memorial Sloan Kettering Cancer Center","Industry, Top 20 Pharma, Academic, Academic, ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT00589784,27584
1647,238113,"7831, CASE 1706 - AMC 049, CASE 1706 / AMC 049, CDR0000561751, NCI-2009-00229, NCT00521092, P30AI036219, U01CA062502",Phase II Study of Sunitinib (SU11248) in Patients With Kaposi's Sarcoma in East Africa,,NA: ClinicalTrials.gov,"National Cancer Institute (NCI), National Institute of Allergy and Infectious Diseases (NIAID)","ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT00521092,27584
1648,237540,"NCT00453895, SIRAC, SIRAC-1",Sunitinib in Refractory Adrenocortical-Carcinoma Patients Progressing After Cytotoxic Chemotherapy,,NA: ClinicalTrials.gov,"Pfizer, University of Wuerzburg","Industry, Top 20 Pharma, ClinicalTrials.gov",,,True,NCT00453895,27584
1649,237358,"GA6181079, MCC-14888, NCT00434109",Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization for Metastatic Gastrointestinal Neuroendocrine Tumors,,NA: ClinicalTrials.gov,"Pfizer, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic",,,True,NCT00434109,27584
1650,237301,"A6181111, NCT00428597","A Phase III Randomized, Double-Blind Study Of Sunitinib (SU011248, SUTENT) Versus Placebo In Patients With Progressive Advanced/Metastatic Well-Differentiated Pancreatic Islet Cell Tumors",,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,"Appetite, EORTC Quality of Life Questionnaire, Nausea, Quality of Life, Vomiting",True,NCT00428597,27584
1651,236917,"IND.184, NCI-2014-00648, NCIC CTG IND.184, NCIC-184, NCT00389974","A Phase II Study of Sunitinib (SU11248; NSC 736511) an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Unresectable, Locally Advanced or Metastatic Cervical Carcinoma",,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,,True,NCT00389974,27584
1652,236895,"2006-0208, 7700, CDR0000504056, N01CM62202, NCI-2009-00207, NCT00387426",A Phase II Study of Sunitinib Malate in Idiopathic Myelofibrosis,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,,True,NCT00387426,27584
1653,236372,"2005-0463, NCT00330564",A Phase 2 Study of SU011248 (Sunitinib Malate) in Von Hippel-Lindau Syndrome,,NA: ClinicalTrials.gov,"Pfizer, M.D. Anderson Cancer Center","Industry, Top 20 Pharma, ClinicalTrials.gov",Safety and Tolerability,,True,NCT00330564,27584
1654,233855,"A6181215, NCT02282059, TrialTroveID-233855","A Multi-center, Prospective, Non-interventional (ni) Study Of The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors",Oncology,Oncology: Neuroendocrine,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Serious Adverse Events, Treatment Emergent Adverse Events","Overall survival, Progression-free survival",True,NCT02282059,27584
1655,233713,"A6181214, NCT02264665, OPALINE, TrialTroveID-233713","An Observational Study Real-World  Of The Systemic Treatment Of Well Differentiated, Unresectable Or Metastatic, Progressive Pancreatic Neuroendocrine Tumors (Pnet): A Study Of Morbidity And Mortality At 2 Years",Oncology,Oncology: Neuroendocrine,"Novartis, Pfizer","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Treatment Emergent Adverse Events",,True,NCT02264665,27584
1656,231676,"GIHSYSU04, GITIC, NCT02013089, TrialTroveID-231676",A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Clinical benefit rate, Overall response rate, Response rate",True,NCT02013089,27584
1657,229670,"CASE8811, NCI-2012-00988, NCT01740154",Exploration of the Neuromuscular Mechanisms Associated With Sunitinib Related Fatigue,,NA: ClinicalTrials.gov,"Case Comprehensive Cancer Center, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",Motor Evoked Potential,,True,NCT01740154,27584
1658,229609,"D12-01, EudraCT Number: 2012-001098-94, NCT01731925, SUNLAND, SUNLAND D12-01, TrialTroveID-229609",A Randomized Phase II Double-blind Trial of Sunitinib Versus Placebo in Combination with Lanreotide in Patients with Progressive Advanced/Metastatic Midgut Carcinoid Tumors,Oncology,Oncology: Neuroendocrine,"GERCOR, Pfizer, Ipsen","Cooperative Group, Industry, Top 20 Pharma, Industry, all other pharma","Progression-free survival, Progressive disease rate","Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - time, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT01731925,27584
1659,228819,"120118, 12-C-0118, NCT01621568",A Phase II Study of Sunitinib in Patients With Advanced Relapsed or Refractory Thymoma or Thymic Carcinoma With at Least One Prior Line of Platinum-Based Systemic Chemotherapy,,NA: ClinicalTrials.gov,"Indiana University School of Medicine, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",,"Safety and Tolerability, Safety and Tolerability",True,NCT01621568,27584
1660,228061,"A6181202, CTR20140783, CTRI/2014/03/004480, EudraCT Number: 2011-004363-74, NCI-2014-00456, NCT01525550, NL39081.042.12, TrialTroveID-228061","A Single-arm Open-label International Multi-center Study Of The Efficacy And Safety Of Sunitinib Malate (su011248, Sutent (Registered)) In Patients With Progressive Advanced Metastatic Well-differentiated Unresectable Pancreatic Neuroendocrine Tumors",Oncology,Oncology: Neuroendocrine,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Appetite, Area under the curve score, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Diastolic blood pressure, Disease Progression, Drug clearance, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Heart rate corrected QT interval, Heart rate, Hemoglobin level, Leukocyte count, Liver function, Nausea, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Partial response, Phosphate level, Plasma concentration, Platelet count, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to progression, Time to response, Treatment Emergent Adverse Events, Urine protein level, Vital signs, Vomiting",True,NCT01525550,27584
1661,227870,"IUCRO-0279, NCT01502228",PET/CT Assessment of Tumor Perfusion in Patients With Renal Cell Carcinoma,,NA: ClinicalTrials.gov,Indiana University,ClinicalTrials.gov,,,True,NCT01502228,27584
1662,226819,"2010-024621-20, FIRSTMAPPP, IGR2010/1715, MSI/A110356-31, NCT01371201",First International Randomized Study in Malignant Progressive Pheochromocytoma and Paraganglioma (PPGL),,NA: ClinicalTrials.gov,"ENSAT-CANCER European Network for the Study of Adrenal Tumours, Gustave Roussy, Cancer Campus, Grand Paris, National Cancer Institute, France","ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov",,"Adverse Events, Visual Analog Scale",True,NCT01371201,27584
1663,225650,"2007-005628-34, NCT01215578, NET, P070145",A Multicenter Phase II Open Study Coupled With a Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Poorly-differentiated Advanced/Inoperable NEURO-Endocrine Tumors.,,NA: ClinicalTrials.gov,Assistance Publique - H??pitaux de Paris,ClinicalTrials.gov,,,True,NCT01215578,27584
1664,225306,"NCT01168440, VHLSUT, VHLSUT09","A Single-arm, Phase II Study of Sunitinib in Patients With Von Hippel-Lindau (VHL) Disease",,NA: ClinicalTrials.gov,Association Pour La Recherche des Th??rapeutiques Innovantes en Canc??rologie,ClinicalTrials.gov,,"Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01168440,27584
1665,224926,"NCT00056693, RTKC-0511-015",A Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Advanced Unresectable Neuroendocrine Tumor,,NA: ClinicalTrials.gov,Pfizer,"Industry, Top 20 Pharma",,"Adverse Events, Safety and Tolerability",True,NCT00056693,27584
1666,221484,"C-IV-001, DRKS00005220, EudraCT Number: 2012-001415-23, EuroTARGET, EuT-PK/PD, NL48521.058.14, TrialTroveID-221484",A Single Arm Pharmacokinetic/Pharmacodynamic Study of Sunitinib and Pazopanib in Patients with Metastasized Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Progression-free survival, Progressive disease rate, Treatment compliance",Treatment compliance,False,,27584
1667,216902,"2013.465, NCT02239952, TrialTroveID-216902",Pilot Study on the Determination of Tumor Concentrations of Protein Kinase Inhibitors in Patients With Newly Diagnosed High-grade Glioma,Oncology,"Oncology: CNS, Glioblastoma","Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,,True,NCT02239952,27584
1668,215264,"TrialTroveID-215264, UMIN000014685","A Prospective Study Comparing The Pharmacokinetics, Efficacy, And Side Effects Of Sunitinib In Patients With Advanced Renal Cell Carcinoma",Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1669,214218,"DRKS00006193, MORE, NCT02208128, S-539/2013, TrialTroveID-214218",Molecular Determinants for Therapy Response on Renal Cell Carcinoma,Oncology,Oncology: Renal,University of Heidelberg,Academic,"Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",,True,NCT02208128,27584
1670,213981,"EudraCT Number: 2011-006085-40, METASUN, NCT02570789, TrialTroveID-213981, UCL-ONCO 2012-09/MetaSun",A proof of concept study to evaluate the use of metabonomics and lipidomics in predicting toxicity and  efficacy of anti-VEGF therapy in patients with metastatic clear cell renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Response evaluation criteria in solid tumors",Overall survival,True,NCT02570789,27584
1671,212724,"A4061078, ADONIS, CTBE2015000286, IRAS ID: 149302, NCT02184416, TrialTroveID-212724",Axitinib In Advanced / Metastatic Renal Cell Carcinoma - A Non-interventional Study Of Real World Treatment Outcomes In Patients Receiving 2nd Line Axitinib After 1st Line Sunitinib (ADONIS),Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Progression-free survival, Time to treatment failure","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, SF-36",True,NCT02184416,27584
1672,211374,TrialTroveID-211374,"Relationships between Pharmacokinetics of Antiangiogenic Drugs, Large Arteries Properties and Cancer Progression",Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1673,210966,"14-149, NCI-2014-02033, NCT02164240, ONC-2013-024, SURE, TrialTroveID-210966, WI186553","A Non-randomized, Open-label Phase Ib Study of SUnitinib Alternating With REgorafenib in Patients With Metastatic and/or Unresectable Gastrointestinal Stromal Tumors (GIST) Progressing After Prior Therapy With Tyrosine Kinase Inhibitors",Oncology,Oncology: GIST,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Bayer AG/Bayer Pharmaceuticals","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Complete response, Drug clearance, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT02164240,27584
1674,210734,TrialTroveID-210734,Phase I Trial of Sunitinib Malate plus Interferon-alpha for Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability",Adverse Events,False,,27584
1675,210257,TrialTroveID-210257,Tyrosine-kinase inhibitors (TKI) in metastatic kidney cancer (mKC) treatment.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1676,209450,"SuniG II, TrialTroveID-209450",A Phase Ib study on treatment with Sunitinib Malate (Sutent) for patients with recurrent CNS glioma,Oncology,"Oncology: CNS, Glioblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1677,209316,"EudraCT Number: 2013-001363-23, MetAction, NCT02142036, N-of-1 Trial, TrialTroveID-209316","N-of-1 Trial of Actionable Target Identification in Metastatic Cancer for Palliative Systemic Therapy , , MetAction: Actionable targets in cancer metastasis",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","(Other Hospital/Academic/Medical Center), Norwegian Research Council","Academic, Government",Progression-free survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02142036,27584
1678,204792,"CTP NK 2012, DRKS00006375, NCT02086734, TrialTroveID-204792",Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients with Metastasized Renal Cell Carcinoma,Oncology,Oncology: Renal,Ludwig Maximilians University of Munich,Academic,Overall survival,Response evaluation criteria in solid tumors,True,NCT02086734,27584
1679,203786,"CRIZENT, H-33624, NCT02074878, TrialTroveID-203786",A Phase Ib Study of Crizotinib (XALKORI) and Sunitinib (SUTENT) in Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability",True,NCT02074878,27584
1680,203653,"2012/109, 2012/109 METC VUmc, NCT02071719, NTR3710, TrialTroveID-203653",Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients.,Oncology,Oncology: Renal,"(Other Industry Sponsor), Vanderbilt University Medical Center","Industry, all other pharma, Academic","Disease Progression, Progression-free survival",Progression-free survival,True,NCT02071719,27584
1681,203290,"13P.377, 2013-047, 2437, NCI-2014-00338, NCT02068586, TrialTroveID-203290",A Randomized Phase ll Study of Adjuvant Sunitinib or Valproic Acid in High-Risk Patients With Uveal Melanoma.,Oncology,Oncology: Melanoma,"Pfizer, Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA","Industry, Top 20 Pharma, Academic",Overall survival,"Disease-free survival, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT02068586,27584
1682,202660,"14-350, 2013-0944, MDACC-2013-0944, NCI-2014-01171, NCI-2014-01908, NCT02060370, TrialTroveID-202660",A Phase II Study of Alternative Sunitinib Scheduling in Patients With Metastatic Renal Cell Carcinoma (mRCC),Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events","Adverse Events, Common Terminology Criteria for Adverse Events, Functional Assessment of Cancer Therapy-General, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",True,NCT02060370,27584
1683,202419,"2013/75, EudraCT Number: 2012-005756-41, NCT02058901, NL43122.029.13, NTR4167, SUNRISE, TrialTroveID-202419","A Phase I Study of High-dose, Intermittent Sunitinib in Patients with Solid Tumors.",Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Vanderbilt University Medical Center,Academic,"Adverse Events, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Elimination half-life, Maximum tolerated dose, Plasma concentration, Time to progression, Volume of distribution",True,NCT02058901,27584
1684,201843,TrialTroveID-201843,Circulating tumor cell kinetics in metastatic RCC (mRCC) patients treated with sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Circulating Tumor Cells,,False,,27584
1685,201545,TrialTroveID-201545,A prospective multicenter phase II study of sunitinib in patients with advanced aggressive fibromatosis.,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,27584
1686,199694,"GUTSUNI, NCT02019576, OZM-053, OZM-053 GU, TrialTroveID-199694","A Phase II, Multi-Centre Study, of Stereotactic Radiotherapy for Oligo-Progression in Metastatic Renal Cell Cancer Patients Receiving 1st Line Sunitinib Therapy",Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"Pfizer, Toronto Sunnybrook Regional Cancer Centre","Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Vital signs",True,NCT02019576,27584
1687,198510,"KIME-01, NCT02001493, TrialTroveID-198510",Observational Prospective Study to Analyze a Metabolomic Profile and to Explore it as Prognostic Factor in Patients with Renal Cell Carcinoma (mRCC),Oncology,Oncology: Renal,Cambridge University Hospitals NHS Foundation Trust,Academic,"Metabolomic profile, Progression-free survival","Metabolomic profile, Overall survival, Progression-free survival, Time to progression",True,NCT02001493,27584
1688,196745,"13/LO/1182, 13SM0754, NCT01977586, TrialTroveID-196745",Pilot Study to Evaluate the Feasibility of Functional MRI in Metastatic Renal Cell Carcinoma (mRCC) With Test--retest Repeatability and Early Response Assessment,Oncology,Oncology: Renal,Imperial College,Academic,Magnetic Resonance Imaging,"Magnetic Resonance Imaging, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01977586,27584
1689,193424,"A6181209, APERCU, NCT01934452, NRA6180080, TrialTroveID-193424",Prospective Observational Analysis Of CR With Sunitinib Treatment In mRCC Patients (APERCU),Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Complete response,Complete response,True,NCT01934452,27584
1690,193194,"TrialTroveID-193194, UMIN000011649",Safety and Efficacy of Sunitinib Given in Schedule Modification in Patients with Advanced Renal Cell Carcinoma (RCC),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Quality of Life",False,,27584
1691,188631,TrialTroveID-188631,Association of drug exposure with clinical response and toxicities in metastatic renal cell carcinoma patients (mRCC) receiving an alternative dosing (AD) regimen of sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1692,188401,"ChiCTR-TRC-13004016, TrialTroveID-188401",Clinical and prognostic implications of delta-like ligand 4 and hypoxia-inducible factors in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib as first-line therapy.,Oncology,Oncology: Renal,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Overall survival, Progression-free survival","Overall response rate, Overall survival, Safety and Tolerability",False,,27584
1693,188388,TrialTroveID-188388,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with brain metastases (BM) from renal cell cancer (RCC).,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Academic Cancer Center),Academic,"Overall response rate, Overall survival, Partial response, Progression-free survival",,False,,27584
1694,188250,TrialTroveID-188250,Clinical efficacy of sunitinib as post-operative adjuvant therapy in patients with high-risk renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1695,186859,"2012/259, 2012/259 METC VUmc, EudraCT Number:2012-002891-15, NCT02071641, NTR3711, OND1355282, SURE, TrialTroveID-186859",Phase II study of sunitinib rechallenge in patients with metastatic renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02071641,27584
1696,186222,TrialTroveID-186222,A clinical study on the prognostic impact of C-reactive protein kinetics for advanced renal cell carcinoma treated with sunitinib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"C reactive protein, Clinical benefit rate, Overall survival, Progression-free survival",,False,,27584
1697,186213,TrialTroveID-186213,A clinical study on neutrophil-to-lymphocyte ratio as a surrogate marker of prognosis in patients with metastatic clear cell renal cell carcinoma receiving sunitinib as first-line therapy,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,27584
1698,186147,"NCT01850147, SU-2013-041, TrialTroveID-186147",Study of Efficacy and Safety of Sequential Low-dose Sunitinib With Chemotherapy in Advanced Non-small Cell Lung Cancer After Failure of Conventional Regimen,Oncology,"Oncology: Lung, Non-Small Cell",Chinese Academy of Medical Sciences,Government,Progression-free survival,"Clinical benefit rate, Overall survival, Safety and Tolerability",True,NCT01850147,27584
1699,185658,TrialTroveID-185658,A prospective observational study to validate the influence of genetic polymorphisms in sunitinib treated metastatic renal carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1700,184526,"13-086, NCI-2013-01116, NCT01829217, TrialTroveID-184526",A Phase II Trial of Sunitinib in Never-smokers With Lung Adenocarcinoma: Identification of Oncogenic Alterations Underlying Sunitinib Sensitivity,Oncology,"Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Government, Academic","Disease Progression, Overall response rate, Partial response",,True,NCT01829217,27584
1701,184316,"CT99076, NCT01824615, TGOG-101, TrialTroveID-184316",Evaluation of the Efficacy of Sunitinib in Patients With Recurrent Ovarian Clear Cell Carcinoma,Oncology,Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,"CA-125 Response, Complete response, Overall response rate, Partial response, Progressive disease rate, Response rate, Stable Disease",,True,NCT01824615,27584
1702,183438,TrialTroveID-183438,A clinical study on tumor growth rates before and after the withdrawal of molecular targeted agents in patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Growth velocity, Progressive disease rate",,False,,27584
1703,183437,TrialTroveID-183437,A Clinical Study to Evaluate the Association of Pharmacokinetics of Sunitinib with Treatment Outcome and Adverse Events in Advanced Renal Cell Carcinoma Patients,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,,False,,27584
1704,182821,"2013/00170, BR01/08/13, NCT01803503, TrialTroveID-182821","Phase II Randomized Study of Docetaxel With or Without Low-dose, Short Course Sunitinib in the Treatment of Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate",(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Complete response, Overall response rate, Partial response, Stable Disease","Disease Progression, Progression-free survival",True,NCT01803503,27584
1705,180006,"2012/76, EudraCT Number: 2011-005309-57, NCT01758575, TrialTroveID-180006",Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities,Oncology,Oncology: Unspecified Solid Tumor,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,,True,NCT01758575,27584
1706,179749,"TrialTroveID-179749, UMIN000009622",Prospective multicenter trial on the identification of novel biomarkers for Sunitinib therapy in the treatment of Japanese patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,C reactive protein,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,27584
1707,179717,"NCT01743300, P07.111, TrialTroveID-179717","The Influence of Genotype/Phenotype, Grapefruit Juice and Orange Juice on the Pharmacokinetics of Sunitinib (Sutent, SU011248) in Patient With Imatinib Resistant Gastrointestinal Stromal Cell Tumor (GIST) or Metastatic Renal Cell Carcinoma",Oncology,Oncology: GIST; Oncology: Renal,Leiden University Medical Center,Academic,Area under the curve score,,True,NCT01743300,27584
1708,177835,"BERAT, BERAT C-II-008, C-II-008, C-II-008 / BERAT, DRKS00005606, EudraCT Number: 2011-005939-78, NCT01731158, TrialTroveID-177835","A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)",Oncology,Oncology: Renal,Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,"Circulating Tumor Cells, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01731158,27584
1709,176941,"CSET 1705, D09-2-CK SUN, EudraCT Number: 2011-000073-30, GERCOR # D09 # SUN-2-CK, GERCOR D09-2 SUN-CK, NCT01718327, RECF1789, SUN-CK, SUN-CK D09-2, TrialTroveID-176941",A Phase II Open-label Single Arm Study of Sunitinib in Patients With Advanced Cholangiocarcinoma,Oncology,Oncology: Liver,"GERCOR, Pfizer","Cooperative Group, Industry, Top 20 Pharma","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Stable Disease, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01718327,27584
1710,176373,"CRESTO, HGWH008, NCT01711268, TrialTroveID-176373",Correlating Renal Cell Cancer Treatment Efficacy With Sunitinib Therapeutic Levels and Outcomes,Oncology,Oncology: Renal,(Other government agency),Government,Time to treatment failure,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01711268,27584
1711,175323,TrialTroveID-175323,Early Assessment of Response With Perfusion-CT in Patient With Metastatic Renal Cell Carcinoma Treated With Sunitinib,Oncology,Oncology: Renal,"Hospital Clinic, Barcelona, Spain",Academic,,,False,,27584
1712,175313,TrialTroveID-175313,Sunitinib Therapy in Advanced Alveolar Soft Part Sarcomas,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1713,175297,"CCR3164, EudraCT Number: 2008-008676-13, IRAS ID: 9477, SUN-CYCL, TrialTroveID-175297",A Phase II Study Of Sunitinib And Low Dose Metronomic Cyclophosphamide In Advanced Renal Cell Cancer,Oncology,Oncology: Renal,Royal Marsden NHS Trust,Government,"Maximum tolerated dose, Overall response rate, Partial response, Response rate","Circulating Tumor Cells, Overall survival",False,,27584
1714,174820,"3066K1-4407, B1771009, DRKS00004015, NCT00700258, STAR-TOR, TrialTroveID-174820","STAR-TOR- Registry for the Evaluation of the Safety, Tolerability and Efficacy of Temsirolimus (Torisel), Sunitinib (Sutent) and Axitinib (Inlyta) for the Treatment of Subjects with Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl) and Gastro-intestinal Stroma Tumor (Gist).",Oncology,"Oncology: GIST; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Renal",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",Safety and Tolerability,True,NCT00700258,27584
1715,171181,"2011/128, NCT01636908, OND1355289, TrialTroveID-171181",Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.,Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,,True,NCT01636908,27584
1716,169923,TrialTroveID-169923,The level of FSHR expression in the primary kidney tumors to predict the response to subsequent antiangiogenic therapy with sunitinib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1717,169853,TrialTroveID-169853,Development and validation of prognostic models in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib: A Greek-French collaboration.,Oncology,Oncology: Renal,Hellenic Oncology Research Group,Cooperative Group,,,False,,27584
1718,169751,TrialTroveID-169751,Hypertension and cardiotoxicity in metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1719,169746,TrialTroveID-169746,The effect of continuing therapy for more than one course and CRP level on PFS and OS in the general practice of sunitinib therapy in Japanese patients with metastatic renal cancer.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1720,169720,"7195, CA180-392, NCI-2012-01084, NCT01620216, TrialTroveID-169720","A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","Bristol-Myers Squibb, National Institutes of Health/National Cancer Institute, OHSU Cancer Institute, Oregon Health and Science University","Industry, Top 20 Pharma, Government, Academic, Academic",,"Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival",True,NCT01620216,27584
1721,169693,TrialTroveID-169693,Phase II trial of sunitinib malate and lomustine in patients with temozolomide refractory recurrent low-grade and anaplastic gliomas.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",Pfizer,"Industry, Top 20 Pharma","Overall response rate, Safety and Tolerability","Overall survival, Progression-free survival, Safety and Tolerability",False,,27584
1722,168511,TrialTroveID-168511,Adjuvant sunitinib in high-risk patients with uveal melanoma: A pilot study.,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall survival",Safety and Tolerability,False,,27584
1723,168175,TrialTroveID-168175,A Clinical Study of C-reactive Protein as a Marker of Treatment Response and Predictor of Prognosis in Chinese Metastatic Renal Cell Carcinoma Patients Treated With Sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"C reactive protein, Progression-free survival",,False,,27584
1724,167672,"EudraCT Number: 2005-004502-82, IRAS ID 10880, NeoSun, NEO-SUN, SUN1972, TrialTroveID-167672",A Phase II Study of Neoadjuvant Sunitinib in Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"National Health Service (NHS) - UK, University of Cambridge, Addenbrookes Hospital, UK","Government, Academic, Academic",Overall response rate,"Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Mortality, Overall response rate - duration, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to progression, Wound healing",False,,27584
1725,163711,"2010-023739-41, KS-ONCOFARMA-01, NCT01548170, TrialTroveID-163711","A Phase I, Pilot, Dose Finding Clinical Trial to Assess the Interaction Between Sunitinib and Ketoconazole to Reduce the Dose and Cost of Sunitinib for National Health System",Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,"Cmax, Plasma concentration","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Plasma concentration, Tmax",True,NCT01548170,27584
1726,162297,"KCRB-003, NCT00891475, TrialTroveID-162297",Evaluation plasma levels of bFGF and VEGF-A in metastatic renal cell carcinoma patients treated with sunitinib.,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,Progression-free survival,,True,NCT00891475,27584
1727,161855,TrialTroveID-161855,Metastatic renal cell carcinoma (mRCC) in elderly patients: Can a personalized approach be an effective therapeutic option?,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,"Overall survival, Safety and Tolerability",False,,27584
1728,161847,TrialTroveID-161847,A new modified sunitinib schedule for metastatic renal cell cancer (mRCC): A pilot study.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,"Disease Progression, Progression-free survival",False,,27584
1729,161663,TrialTroveID-161663,Modulation of Immune Cell Subpopulations in Renal Cell Carcinoma Patients by Sunitinib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1730,161539,TrialTroveID-161539,Efficacy and safety of sunitinib in the treatment of metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall response rate, Overall survival",,False,,27584
1731,161350,TrialTroveID-161350,Clinical efficacy and tolerance of sunitinib in the treatment of advanced renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1732,160949,"D1011, DMS 1011, M13-004, NCI-2011-03505, NCT01517243, TrialTroveID-160949",Alternating Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma: A Phase II Study of Alternating Sunitinib and Temsirolimus.,Oncology,Oncology: Renal,Dartmouth-Hitchcock Medical Center,Academic,Time to progression,"Complete response, Overall response rate, Partial response, Stable Disease",True,NCT01517243,27584
1733,159846,"CC-IRB 6489, SI11, TrialTroveID-159846",DCE-MRI and FDG PET with Kinetic Analysis to Monitor Breast Cancer Response to Neoadjuvant Sunitinib and Metronomic Chemotherapy (CC-IRB #6489). A Companion Trial to a Phase II Study Evaluating the Safety and Efficacy of Sunitinib Malate in Combination with Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide plus GCSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer (CC-IRB #6488),Oncology,Oncology: Breast,"Fred Hutchinson Cancer Research Center, University of Washington/Seattle Cancer Care Alliance","Academic, Academic",,,False,,27584
1734,159398,"NCT01499121, OCT1223, OZM-042, TrialTroveID-159398","A Phase II, Multi-Centre, Study of the Efficacy and Safety of Sunitinib Given on an Individualized Schedule as First-Line Therapy for Metastatic Renal Cell Cancer",Oncology,Oncology: Renal,"Pfizer, Toronto Sunnybrook Regional Cancer Centre","Industry, Top 20 Pharma, Academic","Disease Progression, Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Disease Progression, Functional Assessment of Cancer Therapy-General, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Vital signs",True,NCT01499121,27584
1735,159238,"EudraCT Number: 2007-002864-87, GISG 03, GISG-03, NCT01498835, SUNRASE, TrialTroveID-159238",Phase I Trial of Concurrent Sunitinib and Radiation Therapy as Preoperative Treatment for Locally Advanced or Recurrent Soft Tissue Sarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"University of Heidelberg, German Research Foundation","Academic, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities","Complete response, Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT01498835,27584
1736,158541,TrialTroveID-158541,Response Rates and Adverse Effects of Continuous Once-daily Sunitinib in Patients with Advanced Renal Cell Carcinoma: A Single-center Study in Turkey.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,27584
1737,155949,"CSTI571BDE78T, DRKS00005168, EudraCT Number: 2011-002544-27, NCT01462994, TrialTroveID-155949","Prospective, Explorative Trial for the Detection of Circulating Cell-free Tumor DNA in the Plasma of Patients With Gastrointestinal Stromal Tumors (GIST)Harboring Activating Mutations of CKIT or PDGFRA Pre/Post Surgery or Pre/Under Treatment With a Tyrosine Kinase Inhibitor or Progressive Disease Irrespective of Current or Planned Treatment. An Open-label, Non-randomized, Multicenter Phase IIIb Clinical Trial",Oncology,Oncology: GIST,Technische Universitaet Muenchen,Academic,,Circulating Tumor Cells,True,NCT01462994,27584
1738,155869,"12-361, 2012CG034, 213512, AAAJ6052, ACNS1021, CIRB-ACNS1021, COG-ACNS1021, EudraCT Number: 2018-004520-10, NCI-2011-03536, NCT01462695, PSHCI-12-040, STU 032012-026, TrialTroveID-155869","A Phase II Study of Sunitinib (NSC# 736511, IND# 74019) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response","Overall response rate, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT01462695,27584
1739,153819,TrialTroveID-153819,Treatment of Metastatic Renal Cancer with High-dose Interleukin-2 After Targeted Therapy Can Be Given Safely and Can Produce High Rates of Response Including Complete Remissions,Oncology,Oncology: Renal,Christie Hospital N.H.S. Trust,Academic,Complete response,,False,,27584
1740,153746,TrialTroveID-153746,ABCB-1 and VEGFR-3 Single Nucleotide Polymorphisms (SNPs) and Outcome on Sunitinib (SUN) Treatment in Metastatic Clear Cell Renal Cell Carcinoma (RCC),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1741,150434,"NCT01402089, SG 327/10, TrialTroveID-150434",Cytochrom p450 3A4 and 1A2 Phenotyping for the Individualization of Treatment With Sunitinib or Erlotinib in Cancer Patients,Oncology,"Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Renal",(Other Hospital/Academic/Medical Center),Academic,"Area under the curve score, Drug clearance, Plasma concentration",,True,NCT01402089,27584
1742,149983,"12-106, 12-226, 20120071, A6181196, CTRI/2015/03/005609, EudraCT Number: 2011-002008-33, IRAS ID 113727, NCI-2014-00205, NCRN 227, NCT01396148, TrialTroveID-149983, UKCRN ID 11768",A Phase I/II Study Of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor,Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma","Area under the curve score, Bioavailability, Cmax, Drug clearance, Plasma concentration, Tmax","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Creatinine kinase level, Diastolic blood pressure, Disease Progression, Duration of overall response, Hematocrit level, Hemoglobin level, Leukocyte count, Liver function, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Plasma concentration, Platelet count, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events, Uric acid level, Vital signs",True,NCT01396148,27584
1743,149680,"110200, 11-C-0200, 12-044, 12-095, 2011-0634, CTEP8875, NCI 8875, NCI#8875, NCI-11-C-0200, NCI-2013-01496, NCT01391962, P11836, PHL-092, TrialTroveID-149680","A Phase II Trial In Which Patients with Metastatic Alveolar Soft Part Sarcoma Are Randomized to Either Sunitinib or Cediranib Monotherapy, With Cross-Over at Disease Progression",Oncology,Oncology: Soft Tissue Sarcoma,"AstraZeneca, National Institutes of Health/National Cancer Institute, Pfizer","Industry, Top 20 Pharma, Government, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors",Progression-free survival,True,NCT01391962,27584
1744,147916,"812935, CREST, NCT01370109, TrialTroveID-147916, UPCC 34810, UW13032",The Cardiovascular Effects of Sunitinib Therapy: Off Target Changes in Cardiac Metabolism and Ventricular Vascular Mechanics (CREST),Oncology,Oncology: Renal,Abramson Cancer Center at  University of Pennsylvania Medical Center,Academic,,Adverse Events,True,NCT01370109,27584
1745,147674,TrialTroveID-147674,"All cases post-marketing study (PMS) of sunitinib in 1,027 Japanese patients with renal cell carcinoma (RCC) or gastrointestinal stromal tumor (GIST).",Oncology,Oncology: GIST; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,27584
1746,147375,TrialTroveID-147375,Pharmacogenetic determinants of sunitinib-induced toxicity in Korean patients with metastatic renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1747,147341,TrialTroveID-147341,Impact of sarcopenia (Sp) on early dose-limiting toxicity (DLT) and acute vascular toxicity in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib (SUT).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Dose-limiting toxicities,"Area under the curve score, Progression-free survival",False,,27584
1748,147310,"9920, DIRECTS, MREC NÂ° 10/H0801/64, TrialTroveID-147310, UKCRN ID: 9920",Quantitative diffusion-weighted (DW) MR imaging of microcapillary perfusion and tissue diffusivity as biomarkers of response of renal cell carcinoma (RCC) to treatment with sunitinib,Oncology,Oncology: Renal,"Royal Marsden NHS Trust, Cancer Research UK","Government, Not for Profit Funding Entity",,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors",False,,27584
1749,146944,TrialTroveID-146944,"Efficacy and safety of single-agent sunitinib in treating patients with advanced hepatocelluar carcinoma after sorafenib failure: A prospective, open-label, phase II study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,27584
1750,146682,TrialTroveID-146682,A pilot study of sunitinib in Chinese patients with heavily pretreated metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Safety and Tolerability",,False,,27584
1751,145623,"EudraCT Number: 2011-001098-16, HTA - 09/91/21, IRAS ID: 75784, ISRCTN06473203, MO10/9353, MREC NÂ°: 11/NW/0246, STAR, TrialTroveID-145623, UKCRN 10674","A Randomised Multi Stage, Phase II/III Trial of Sunitinib Comparing Temporary Cessation With Allowing Continuation, At The Time Of Maximal Radiological Response, In The First-line Treatment Of Locally Advanced And/Or Metastatic Renal Cancer, , Sunitinib comparing Temporary cessation with Allowing continuation in the first-line treatment of locally advanced/metastatic Renal cell carcinoma (STAR)",Oncology,Oncology: Renal,"University of Leeds, Leeds, UK, (Other government agency)","Academic, Government","Cost effectiveness, Disease Progression, Overall survival, Quality of Life, Quality-adjusted life year","Common Terminology Criteria for Adverse Events, Cost effectiveness, EQ-5D, Functional Assessment of Cancer Therapy-General, Progression-free survival, Quality of Life",False,,27584
1752,145311,TrialTroveID-145311,Phase II trial of sequential administration of sunitinib followed by axitinib compared to axitinib followed by sunitinib in 1st line treatment of advanced kidney cancer,Oncology,Oncology: Renal,Spanish Oncology GenitoUrinary Group,Cooperative Group,Progression-free survival,,False,,27584
1753,144321,TrialTroveID-144321,A Clinical Study on the Response to Targeted Therapy Between the Primary Tumor and Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1754,144112,TrialTroveID-144112,A Clinical Study on Expression of Molecular Markers in Radical Nephrectomy Specimens in Sunitinib Treated Patients with Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1755,144107,TrialTroveID-144107,A prospective study on TSH as a prognostic biomarker of sunitinib efficacy in metastatic renal cell carcinoma patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1756,143406,TrialTroveID-143406,Initial Experience of Neoadjuvant Therapy With Sunitinib for Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,"Asahikawa Medical College, Asahikawa, Japan",Academic,,,False,,27584
1757,143405,"NCT01309633, NP01/27/10, TrialTroveID-143405",Phase II Open-label Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Systemic Therapy for Locally Advanced or Metastatic Nasopharyngeal Carcinoma (NPC),Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Overall response rate, Partial response, Progression-free survival",True,NCT01309633,27584
1758,143325,"EudraCT Number: 2010-021551-11, NCT01308034, RECF1648, RT - SUTENT, RT-SU, TrialTroveID-143325",Phase I Study of Continuous Dosing of Sunitinib in Non GIST Sarcomas With Concomitant Radiotherapy,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"French Health Ministry, (Other Hospital/Academic/Medical Center)","Government, Academic","Dose-limiting toxicities, Maximum tolerated dose","Clinical benefit rate, Magnetic Resonance Imaging, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01308034,27584
1759,143177,"110096, 11-C-0096, CUSTOM, NCI-11-C-0096, NCT01306045, TrialTroveID-143177","Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies.",Oncology,"Oncology: (N/A); Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell",National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival",True,NCT01306045,27584
1760,143106,TrialTroveID-143106,Safety and Efficacy of Sunitinib Therapy in Japanese Patients With GIST: A Prospective Study in a Single Institution.,Oncology,Oncology: GIST,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1761,142534,TrialTroveID-142534,Anti-VEGF drugs combined with gemcitabine-based chemotherapy in treatment of metastatic collecting duct carcinoma,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,,,False,,27584
1762,141504,"2010-021454-20, M10PKS, NCT01286896, NKI-AvL M10PKS, TrialTroveID-141504",Use of Individual PK-guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors.,Oncology,Oncology: Colorectal; Oncology: GIST; Oncology: Melanoma; Oncology: Renal,"Pfizer, Netherlands Cancer Institute","Industry, Top 20 Pharma, Government","Adverse Events, Disease Progression, Safety and Tolerability, Safety and Tolerability","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01286896,27584
1763,140999,"SUNCAP, TrialTroveID-140999",SUNCAP: A Phase II Study with Sunitinib and Capecitabine in Patients with Metastatic Colorectal Cancer (MCRC) Refractory to Previous Treatment with 5FU/irinotecan/oxaliplatin.,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,27584
1764,140837,"009-0348, TrialTroveID-140837, UMIN000001994",Phase II Randomized Comparative Study of Sequential Alternating Therapy with Interferon and Molecular-Targeted Drug for Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,Progression-free survival,,False,,27584
1765,139581,"CROSS-J-RCC, NCT01481870, TrialTroveID-139581, UMIN000003040",Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall survival, Progression-free survival",True,NCT01481870,27584
1766,139022,"2010-0070, NCI-2011-00267, NCT01254864, TrialTroveID-139022",Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies,Oncology,Oncology: Prostate,"Bristol-Myers Squibb, MD Anderson Cancer Center, University of Texas, Pfizer, Johnson & Johnson/Janssen Pharmaceuticals {Janssen Pharmaceutica}","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progression-free survival, Safety and Tolerability","Progression-free survival, Safety and Tolerability, Time to treatment failure",True,NCT01254864,27584
1767,138642,"NCT01227213, SUMAVA, TrialTroveID-138642",The Vascular and Metabolic Effects of Sunitinib in Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Hospital/Academic/Medical Center), Dutch Cancer Society","Academic, Not for Profit Funding Entity",,,True,NCT01227213,27584
1768,138359,"8477, CO09904, CO-09904, J10129, NCI 8477, NCT01243359, TrialTroveID-138359, WCCC-CO-09904",Phase I Pharmacodynamic Trial of Sequential Sunitinib With Bevacizumab in Patients With Renal Cell Carcinoma and Other Advanced Solid Malignancies,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Renal","National Institutes of Health/National Cancer Institute, University of Wisconsin Comprehensive Cancer Center","Government, Academic","Overall response rate, Safety and Tolerability, Safety and Tolerability",,True,NCT01243359,27584
1769,138168,"ACTRN12610000897066, PMCC Protocol No 10/56, PREDICT SU, TrialTroveID-138168",The utility of genomics and functional imaging to predict Sunitinib pharmacokinetics and pharmacodynamics: The PREDICT SU Study.,Oncology,Oncology: GIST; Oncology: Renal,"National Health and Medical Research Council  (NHMRC), Peter MacCallum Cancer Centre, Australia","Government, Academic","Overall response rate, Overall survival, Progression-free survival","Elimination half-life, Progression-free survival, Progressive disease rate",False,,27584
1770,137740,TrialTroveID-137740,Antitumor Activity of Sunitinib Malate (SM) in Solitary Fibrous Tumors (SFT),Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1771,137491,"2008-09-031, NCT01238055, TrialTroveID-137491",Randomized Phase II Trial of Sunitinib and Docetaxel in Advanced Gastric Cancer Patients Who Had Prior Chemotherapy With Fluoropyrimidine and Platinum,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT01238055,27584
1772,137353,"8440, CRUK/09/017, EudraCT Number: 2008-008794-55, IRAS ID 42866, ISRCTN75033520, MEL032, MREC NÂ° 10/H0904/15, NCT01551459, RDD299, SUAVE, TrialTroveID-137353, UKCRN ID 8440",A Randomised Phase II Study of Sunitinib Versus Dacarbazine in the Treatment of Patients With Metastatic Uveal Melanoma,Oncology,Oncology: Melanoma,"(Other Academic Cancer Center), Pfizer, Cancer Research UK, National Health Service (NHS) - UK","Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity, Government","Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",True,NCT01551459,27584
1773,136989,"I206, IND 206, IND.206 MS, NCT01396408, TrialTroveID-136989",A Phase II Study of Sunitinib or Temsirolimus in Patients with Advanced Rare Tumours,Oncology,"Oncology: (N/A); Oncology: Endometrial; Oncology: Leukemia, Acute Lymphocytic; Oncology: Liver; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Canadian Cancer Trials Group {NCIC Clinical Trials Group},Cooperative Group,"Complete response, Duration of overall response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT01396408,27584
1774,136955,TrialTroveID-136955,Activity Of Sunitinib In Advanced Soft Tissue Sarcoma And Its Correlation With Potential Predictive  Biomarkers,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors",,False,,27584
1775,136460,"AN 20/04, BfArM-No.: 4036290, DRKS00003518, EudraCT Number: 2008-007609-36, NCT01216371, SMAT, SMAT - AN 20/04, SMAT-AN of 20.4 AUO, TrialTroveID-136460",Prospective randomized multicenter phase II study on resection of pulmonary metastases in clear cell renal cell carcinoma with or without adjuvant sunitinib therapy over 1 year (SMAT - AN 20/04 AUO),Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"(Other Hospital/Academic/Medical Center), Association of Urogenital Oncology (AUO)","Academic, Cooperative Group","Disease-free survival, Overall survival","Mortality, Overall survival, Quality of Life",True,NCT01216371,27584
1776,136261,TrialTroveID-136261,Activity of Sunitinib Malate in Non-Clear Cell Kidney Cancer Patients: A Single Institution Experience,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1777,136235,"NCT01219751, TrialTroveID-136235, UOSG_AMC_0801",Phase II Trial Of Sunitinib in Advanced Non-Clear Cell Type Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Hospital/Academic/Medical Center), Asan Medical Center","Academic, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT01219751,27584
1778,136061,"EudraCT Number: 2007-002828-15, NCT01216657, S 379, S379 SUMA, TrialTroveID-136061","An Open-label, Uncontrolled Phase II Trial of Single Agent Sunitinib (SU 11248) for Patients With Chemo-refractory Metastatic Melanoma.",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,"Disease Progression - duration, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT01216657,27584
1779,136003,"Eudract No: 2008-003423-23, NCT01215565, P070134, RECF1442, TrialTroveID-136003",A Multicenter National Phase II Open Study Coupled With Translational Assessment of Biomarkers Predictive of Response to Sunitinib in Patients With Advanced/Inoperable Fibrolamellar Hepatocellular Carcinoma.,Oncology,Oncology: Liver,Assistance Publique - Hopitaux de Paris,Academic,"Overall response rate, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival",True,NCT01215565,27584
1780,135489,"NCT01210053, TrialTroveID-135489, Yang-001",This Phase II Trial is Studying Sunitinib to See How Well it Works When Given as Maintenance Therapy in Treating Patients With Stage III or Stage IV Non-small Cell Lung Cancer Which is Previously Treated With Combination Chemotherapy.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate",True,NCT01210053,27584
1781,134158,"2010/124, ABR-32011, EudraCT Number: 2010-019982-27, NCT01190241, NL2353, NTR2460, TrialTroveID-134158, TSAP","Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study",Oncology,Oncology: Unspecified Solid Tumor,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Clinical benefit rate, Overall response rate, Partial response, Stable Disease",Progression-free survival,True,NCT01190241,27584
1782,132657,"BR01/09/10, NCT01176799, TrialTroveID-132657","Phase II Randomized Study of Doxorubicin and Cyclophosphamide With or Without Intermittent Sunitinib in the First-line Treatment of Locally Advanced or Metastatic Breast Cancer Patients With Measurable Primary Breast Tumor. , , Phase Ib/II randomized, open-label study of doxorubicin and cyclophosphamide with or without low-dose, short-course sunitinib in the pre-operative treatment of breast cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate, Partial response, Progression-free survival",True,NCT01176799,27584
1783,132271,TrialTroveID-132271,Sunitinib in treatment of advanced non-small cell lung cancer after failure of multiregimens of chemotherapy and EGFR-TKI.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1784,131361,TrialTroveID-131361,Phase II study of bortezomib and sunitinib in thyroid neoplasms.,Oncology,Oncology: Thyroid,Winship Cancer Institute of Emory University,Academic,,,False,,27584
1785,131304,"EU-21050, EudraCT Number: 2009-017064-16, FFCD 0905-PRODIGE 16, FFCD0905, FFCD-0905, FFCD-PRODIGE-16, NCT01164202, PRODIGE 16, PRODIGE16, RECF1320, SATURNE, TrialTroveID-131304","A Double-Blind, Randomized, Phase II/III Study Comparing the Use of Chemoembolization Combined With Sunitinib Against Chemoembolization Combined With a Placebo in Patients With Hepatocellular Carcinoma (SATURNE)",Oncology,Oncology: Liver,"(Other Cooperative Group), Pfizer, Federation Francophone de Cancerologie Digestive","Cooperative Group, Industry, Top 20 Pharma, Miscellaneous",Overall survival,"Disease-free survival, Overall survival, Quality of Life, Safety and Tolerability, Tumor control rate",True,NCT01164202,27584
1786,130687,"CASE8809, NCI-2010-01391, NCT01158222, TrialTroveID-130687",A Phase II Study of Intermittent Sunitinib in Previously Untreated Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,Case Western Reserve University,Academic,Disease Progression,"Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Progression-free survival, Response rate",True,NCT01158222,27584
1787,129534,TrialTroveID-129534,Phase II study of sunitinib and irinotecan in patients with recurrent high-grade glioma (HGG).,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",(Other Cooperative Group),Cooperative Group,Time to progression,,False,,27584
1788,129414,TrialTroveID-129414,Association of ABCG2 polymorphisms with exposure and toxicity of sunitinib in a patient with renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1789,129294,TrialTroveID-129294,Plasma angiopoietin-2 (ANG2) as an angiogenic biomarker in renal cell carcinoma (RCC).,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
1790,129287,TrialTroveID-129287,Liver Functional Reserve and Survival after Sunitinib Therapy in Cirrhotic Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1791,129248,TrialTroveID-129248,Sunitinib for unselected Korean patients with advanced renal cell carcinoma: A comparable efficacy with different toxicity profiles.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1792,129227,TrialTroveID-129227,TKI Therapy-related Proteomic Patterns in Serum from Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Bayer AG, Pfizer {Wyeth}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progressive disease rate, Response evaluation criteria in solid tumors",,False,,27584
1793,129206,TrialTroveID-129206,Incidence and clinical significance of sunitinib-induced cardiotoxicity in metastatic renal cancer.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1794,129171,TrialTroveID-129171,Sunitinib malate in advanced hepatocellular carcinoma: Results of a phase II study.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",,False,,27584
1795,129064,"OCT1205, OCT125, TrialTroveID-129064",Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",,False,,27584
1796,128904,"EudraCT Number: 2006-006491-38, N06SUN, TrialTroveID-128904","A Phase II, Prospective, Single Arm Study On Presurgical Sunitinib In Metastatic Clear Cell Renal Cancer (mRCC): Surgical Safety And Effect On The Primary Tumour.",Oncology,Oncology: Renal,"Pfizer, Netherlands Cancer Institute","Industry, Top 20 Pharma, Government","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Magnetic Resonance Imaging, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,27584
1797,128570,TrialTroveID-128570,A Clinical study on Fiducial-free frameless real-time image guided single-fraction radiosurgery using the Cyberknife effectively controls spinal and cerebral metastases from renal cell carcinoma under systemic angiogenic therapy.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1798,128550,TrialTroveID-128550,Pharmacogenetic pathway analysis to identify factors for survival in metastatic renal cell cancer patients treated with sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,Overall survival,False,,27584
1799,127113,"2009-0037, NCT01122615, TrialTroveID-127113",Phase I Trial of Sunitinib Plus Temsirolimus in Patients With Metastatic Renal Cell Cancer.,Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Overall response rate, Response rate",True,NCT01122615,27584
1800,126961,"CASE 3808-CC530, CASE3808, CC530, NCI-2010-01137, NCT01118351, TrialTroveID-126961","Phase II Single Arm, Open Label, Single Institution Study of Continuous Sunitinib (Sutent) in Patients With High-Risk (BCG-Refractory) Superficial Transitional Cell Carcinoma (TCC) of the Bladder",Oncology,Oncology: Bladder,"Pfizer, Case Western Reserve University","Industry, Top 20 Pharma, Academic",Complete response,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease-free survival, Immune Response, Overall survival, Progression-free survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT01118351,27584
1801,126037,"00020714, 10-282-A, 2010-071, 201105396, 20714, ASPEN, CC00006, CRAD001L2402T, CRUKE/10/015, DUKE 2810, EudraCT Number: 2010-019966-95, GU 85, MREC NÂ° 10/S0703/58, NCT01108445, Pro00020714, REN019, TrialTroveID-126037, UKCRN ID 9718, VICCURO1032",A Randomized Phase II Study of Afinitor (RAD001) vs. Sutent (Sunitinib) in Patients With Metastatic Non-Clear Cell Renal Cell Carcinoma (ASPEN),Oncology,Oncology: Renal,"Novartis, Pfizer, Duke University Medical Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT01108445,27584
1802,125626,"EudraCT Number: 2008-006728-73, GENOM-008, NCT01100177, TrialTroveID-125626",An Open Label Non- Randomized Multicentric Phase II Study of Sunitinib Before and During Radiotherapy in Newly Diagnosed Biopsy-only Glioblastoma Patients,Oncology,"Oncology: CNS, Glioblastoma",(Other Cooperative Group),Cooperative Group,Overall response rate,"Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01100177,27584
1803,125418,TrialTroveID-125418,Sunitinib in pretreated advanced non-small-cell lung carcinoma: a primary result from Asian population.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response","Overall survival, Progression-free survival",False,,27584
1804,125327,"30073-23103, CRUK/10/050, EORTC-30073, EORTC-30073-GUCG, EU-21022, KWF 2010-4887, McG 1022, MREC NÂ° 11/WA/0093, NCRN  10561, NCT01099423, NL29931.031.09, PFIZER-EORTC-30073, SURTIME, Surtime â EORTC 30073, TrialTroveID-125327, UKCRN ID 10561",Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Cooperative Group), Pfizer, Cancer Research UK, Institute of Cancer Research - UK, National Cancer Research Institute, EORTC Genito-Urinary Cancers Group, (Other Hospital/Academic/Medical Center), Canadian Uro-Oncology Group","Cooperative Group, Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic, Government, Cooperative Group, Academic, Cooperative Group","Disease Progression, Progression-free survival","Adverse Events, Overall survival",True,NCT01099423,27584
1805,125213,"CLEARSUN, EudraCT Number: 2008-005438-57, HGWH0008, NCT01098903, NL24812.018.08, TrialTroveID-125213","Predictive Value of Drug Elimination Gene Polymorphisms on Clearance and Dose Adjustment of Sunitinib (Sutent, SU11248) in Patients With Cancer",Oncology,Oncology: GIST; Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center), Universiteit van Amsterdam, Academic Medical Center Amsterdam, (Other government agency)","Industry, Top 20 Pharma, Academic, Academic, Academic, Government",,,True,NCT01098903,27584
1806,124550,"09-259-A, 8313, NCI-2011-01455, NCT01122888, TrialTroveID-124550, UCCRC-09-259-A",Pilot Biomarker Study of the Integrin AlphavBeta3 Antagonist Cilengitide (EMD121974) in Combination With Sunitinib,Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma",National Institutes of Health/National Cancer Institute,Government,,"Common Terminology Criteria for Adverse Events, C-terminal telopeptide measurements, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT01122888,27584
1807,123888,"2009-02-025, CTRI/2010/091/000433, NCT01082809, TEMP UTRN 023347243-2704201020563461, TrialTroveID-123888","Phase II Study of Sunitinib as Second-line Treatment in Advanced Biliary Tract Carcinoma: Multicenter, Multinational Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT01082809,27584
1808,123703,TrialTroveID-123703,New Onset Hypothyroidism and Macrocytosis as Surrogate Markers for the Efficacy of Sunitinib in the Treatment of Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1809,123671,TrialTroveID-123671,Prospective evaluation of FDG-PET/CT in patients with advanced RCC treated with antiangiogenic therapies.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1810,123662,TrialTroveID-123662,Activity of sunitinib as third-line treatment of metastatic renal cell carcinoma (mRCC).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",,False,,27584
1811,123652,TrialTroveID-123652,Biomarkers predicting major response to sunitinib in metastatic renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1812,123647,"SUT-REN-07, TrialTroveID-123647",Identification of genetic markers of sunitinib efficacy and toxicity in first-line treatment of renal clear cell carcinoma: A prospective multicenter study.,Oncology,Oncology: Renal,"Pfizer, Spanish Oncology GenitoUrinary Group","Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Response rate",,False,,27584
1813,123339,"EudraCT Number: 2008-007677-21, ONCOAT200801, TrialTroveID-123339",Phase II Multicenter Study of Sequential Treatment with Sunitinib and Interleukin-2 in Patients with Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1814,123289,"A6181118, NCT01073644, TrialTroveID-123289",Post Marketing Surveillance On The Safety And Tolerability Of Sunitinib Malate (Sutent) For Filipino Patients,Oncology,Oncology: GIST; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs",Response evaluation criteria in solid tumors,True,NCT01073644,27584
1815,123130,"NCCCTS-08-369, NCT01070706, TrialTroveID-123130","Phase Ib/II Study of Primary Chemotherapy With Paclitaxel, Gemcitabine, and Sunitinib in Patients With HER2-negative Stage II/III Breast Cancer",Oncology,Oncology: Breast,"Pfizer, Kolmar Korea/HK inno.N {CJ HealthCare {CJ Cheiljedang/CJ HealthCare {CJ Cheiljedang}}}","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Maximum tolerated dose, Safety and Tolerability","Complete response, Disease-free survival, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01070706,27584
1816,123008,"09-07-068, NCT01070186, TrialTroveID-123008","Phase II, Open Label, Single Center Study of Sunitinib in Subjects With High Risk Renal Cell Carcinoma",Oncology,Oncology: Renal,"Pfizer, University of California Los Angeles","Industry, Top 20 Pharma, Academic",Recurrence,Safety and Tolerability,True,NCT01070186,27584
1817,122924,"NCT01069770, Sutent-IIR, TrialTroveID-122924",Neoadjuvant Sunitinib Therapy in Patients With Metastatic Clear Cell Type Renal Cell Carcinoma: a Prospective Study.,Oncology,Oncology: Renal,"(Other Cooperative Group), Pfizer","Cooperative Group, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Resection rate, Time to progression",True,NCT01069770,27584
1818,122641,"ABCSG 34, ABCSG-34, EudraCT Number: 2009-009874-28, GA6182EI, Study 34, TrialTroveID-122641","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Trial of Neoadjuvant Chemotherapy + or - Sunitinib Before Surgery for the Treatment of Patients with Operable Breast Cancer.",Oncology,Oncology: Breast,Austrian Breast & Colorectal Cancer Study Group,Cooperative Group,"Complete response, Overall response rate, Response rate","Overall response rate, Response rate, Safety and Tolerability",False,,27584
1819,122324,"AU792, NCT01058044, RCB 2009-A00244-53, RECF1281, TrialTroveID-122324",A Pilot Study of Adherence to Oral Anticancer Treatment Using Electronic Monitoring System,Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,True,NCT01058044,27584
1820,121776,"F090910001, NCT01054911, TrialTroveID-121776, UAB 0855",Pilot Trial of Neoadjuvant Sunitinib in Patients With Bulky GIST,Oncology,Oncology: GIST,"Pfizer, University of Alabama at Birmingham Comprehensive Cancer Center","Industry, Top 20 Pharma, Academic",,"Apparent diffusion coefficient, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT01054911,27584
1821,120973,"HUM00030127, NCT01042795, TrialTroveID-120973",Phase II Trial of Adjuvant Sutent for Patients With High Risk Urothelial Carcinoma After Neoadjuvant Chemotherapy and Cystectomy,Oncology,Oncology: Bladder,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Disease-free survival,,True,NCT01042795,27584
1822,120345,"EudraCT Number: 2009-010672-16, NCT01034878, ONC-2008-004, Protocol number: 736, TrialTroveID-120345",Phase II Study of Sunitinib in Metastatic Renal Cancer With Non-clear Cell Histology,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Safety and Tolerability",True,NCT01034878,27584
1823,119644,"EudraCT Number: 2006-004511-21, MREC-07/Q0603/58, NCT01024205, OCTG-SuMR, PFIZER-OCTG-SuMR, RC-2007-01, REDA-4911, TrialTroveID-119644",Upfront Sunitinib (SU011248) Therapy Followed by Surgery in Patients With Metastatic Renal Cancer: A Pilot Phase II Study [SuMR],Oncology,Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",,"Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT01024205,27584
1824,119372,"TrialTroveID-119372, UMIN000001995",Randomized Parallel Group Phase II Clinical Study of Sorafenib/Interferon Combination Therapy and Sunitinib Monotherapy for Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,Progression-free survival,,False,,27584
1825,119280,"2009-02-SUN-Case, AIO-STO 0209, EudraCT Number: 2009-014336-38, NCT01020630, SUN-CASE, TrialTroveID-119280","A Randomized, Placebo-controlled Phase II Trial Investigating SUNITINIB Versus Placebo in Patients With Chemorefractory Advanced Adenocarcinoma of the Stomach or Lower Esophagus Treated With Chemotherapy FOLFIRI",Oncology,Oncology: Esophageal; Oncology: Gastric,University of Mainz,Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tumor control rate",True,NCT01020630,27584
1826,119269,"CRC-01-08-03, NCT01019798, TrialTroveID-119269","Phase II Study of Salvage Therapy With Sunitinib, Docetaxel and Platinum on Metastatic or Unresectable Non Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Pfizer, (Other Hospital/Academic/Medical Center), TTY Biopharm","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Disease Progression, NCI-CTC scale, Safety and Tolerability, Serious Adverse Events, Time to progression, Urine protein level, Wound healing",True,NCT01019798,27584
1827,119118,"CASE 1380-CC603, CASE1308, NCT00910039, PFIZER-CASE-1308, SUNDANCE, TrialTroveID-119118",Phase II Trial of Sunitinib as Maintenance Therapy After Stereotactic Radiosurgery in Patients With 1-3 Newly Diagnosed Brain Metastases.,Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal","(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Overall survival, Progression-free survival","Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00910039,27584
1828,118790,"00028 / 24942, NCT01014065, SUPER, TrialTroveID-118790",A Prospective Study of Acute Cardiovascular Effects of First-line Sunitinib in Metastatic Renal Cell Carcinoma Patients,Oncology,Oncology: Renal,"(Other Cooperative Group), Alberta Health Services Research and Innovation Fund","Cooperative Group, Government",,,True,NCT01014065,27584
1829,118252,"TrialTroveID-118252, VCC 0703",Sunitinib Malate and Metronomic Cyclophosphamide/Methotrexate (CM) for Patients Who Do Not Achieve a Pathologic Complete Response After Neoadjuvant Chemotherapy: A Toxicity Assessment,Oncology,Oncology: Breast,"Pfizer, (Other Hospital/Academic/Medical Center), Breast Cancer Research Foundation","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity",Safety and Tolerability,Disease-free survival,False,,27584
1830,117831,"2006-0685, 48315, NCI-2012-01645, NCT00912912, TrialTroveID-117831",Phase II Study of Sunitinib Malate in Refractory Germ Cell Tumors,Oncology,Oncology: Testicular,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival",True,NCT00912912,27584
1831,117608,"07-004, MSKCC-07004, NCT00453310, TrialTroveID-117608",A Phase II Study of Sunitinib in Patients With Refractory or Relapsed Germ Cell Tumors,Oncology,Oncology: Testicular,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate - time, Safety and Tolerability",True,NCT00453310,27584
1832,117372,"CUOG-TE 05/OZM-007, EudraCT 2006-004667-61, GUTSUN, NCT00371553, SUITE, SUITE - CUOG-TE 05, Testis protocol Version 003, TrialTroveID-117372",Prospective Open-Labeled Non Randomised Phase-II Study of SU011248 (Sunitinib) in Male Patients With Relapsed or Cisplatin-Refractory Germ Cell Cancer - A CUOG / GTCSG Cooperative Phase II Study,Oncology,Oncology: Testicular,"(Other Cooperative Group), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Pfizer, British Columbia Cancer Agency, (Other Hospital/Academic/Medical Center), Canadian Uro-Oncology Group","Cooperative Group, Cooperative Group, Industry, Top 20 Pharma, Government, Academic, Cooperative Group","Overall response rate, Response rate","Disease Progression - duration, Overall response rate - duration, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00371553,27584
1833,116951,TrialTroveID-116951,Do circulating tumor cells (CTCs) correlate with response to first-line sunitinib in metastatic renal carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Circulating Tumor Cells,,False,,27584
1834,116659,TrialTroveID-116659,Activity of sunitinib in advanced malignant melanoma and its correlation with potential predictive biomarkers,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,27584
1835,116265,TrialTroveID-116265,"Clinical, biochemical (PSA) and radiographic benefit with sunitinib as a single agent in metastatic chemoresistant and hormone-refractory prostate cancer (HRPC) patients",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate",,False,,27584
1836,115833,"CESAR C-II-006, C-II-006, EudraCT 2009-010143-13, NCT00979966, TrialTroveID-115833",Prospective Randomized Phase-II Trial With Temsirolimus Versus Sunitinib in Previously Untreated Patients With Advanced or Metastatic Non-Clear Cell Renal Carcinoma,Oncology,Oncology: Renal,Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,"Progression-free survival, Response evaluation criteria in solid tumors, Time to progression","Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00979966,27584
1837,115746,"00024190, GOG-0254, GOG-254, NCI-2011-03811, NCT00979992, STU 032011-087, TrialTroveID-115746",A Phase II Evaluation of SU11248 (Sunitinib Malate) (NSC #736511) in the Treatment of Persistent or Recurrent Clear Cell Ovarian Carcinoma,Oncology,Oncology: Ovarian,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00979992,27584
1838,114529,"SOGUG 07-02, SOGUG07-02, TrialTroveID-114529","A Dose Escalating Phase I Study of Combined Gemcitabine, Capecitabine and Sunitinib in Patients with Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,Spanish Oncology GenitoUrinary Group,Cooperative Group,"Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability",,False,,27584
1839,114419,"EU-20945, EudraCT Number: 2008-000814-65, NCT00967603, PACT-12, SRSI-PACT-12, TrialTroveID-114419",Maintenance Therapy with Sunitinib or Observation in Metastatic Pancreatic Cancer: a Phase II Randomized Trial,Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate, Safety and Tolerability, Time to response",True,NCT00967603,27584
1840,112568,"2008/20, CALACASS-SUVEGIL-8, EudraCT Number: 2008-004137-21, INCA-RECF0943, INCA-SUVEGIL-8, NCT00943839, PACA, RECF0943, SUVEGIL 8, TrialTroveID-112568",Effects of Sunitinib in the Expression of VEGF and of Interleukin 6 and CXCL7 - CXCL5 Cytokins : Explanation of Anti-angiogenic Effects.,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,Response evaluation criteria in solid tumors,"Disease-free survival, Duration of overall response, Overall survival, Plasma concentration, Progression-free survival, Time to progression",True,NCT00943839,27584
1841,112139,"EU-20918, EUDRACT-2008-005959-19, FFCD 08-01, FFCD 0801 SUREME, FFCD-0801, NCT00936832, SUREMET, SUREMETS, TrialTroveID-112139",Front-line Combination Therapy of Sunitinib Malate Plus Chemotherapy With Leucovorin/5-Fluorouracil and Irinotecan (FOLFIRI) for Rectal Cancer Patients With Synchronous Non-Resectable Metastases: A Phase II Non Controlled Study. (SUREMETS),Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,Fondation Francaise de Cancerologie Digestive,Miscellaneous,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Resection rate, Time to progression",True,NCT00936832,27584
1842,112125,"GA61822D, NCT00961571, TrialTroveID-112125","A Single-Center, Phase II Trial of Sunitinib and Capecitabine in First Line Treatment of Patients With Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,"Pfizer, Lombardi Cancer Center at Georgetown University Medical Center","Industry, Top 20 Pharma, Academic",Progression-free survival,"Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00961571,27584
1843,112012,"AP-HP PREINSUT, EudraCT Number: 2007-003054-28, NCT00930345, P070104, PREINSUT, RECF0990, S-PREDICT, TrialTroveID-112012","A Study of Biological, Pathological and Imagery Markers in the First-Line Treatment of Metastatic Clear-Cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy",Oncology,Oncology: Renal,"(Other Academic Cancer Center), Pfizer, Assistance Publique - Hopitaux de Paris","Academic, Industry, Top 20 Pharma, Academic","Circulating Tumor Cells, Doppler ultrasound, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Complete response, Doppler ultrasound, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT00930345,27584
1844,111501,"EudraCT Number: 2008-002105-39, ICO-SUT-EXE-08, NCT00931450, PFIZER-ICO-SUT-EXE-08, SUT-EXE-08, TrialTroveID-111501","Pilot / Phase II Randomised, Double Blind, Placebo Controlled Multicenter Study With Biomarker Evaluation of Neoadjuvant Exemestane in Combination With Sunitinib in Post-menopausal Women With Hormone- Sensitive, Her-2 Negative Primary Breast Cancer.",Oncology,Oncology: Breast,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Partial response,"Complete response, Safety and Tolerability",True,NCT00931450,27584
1845,111363,TrialTroveID-111363,Decreased toxicity schedule of sunitinib in renal cell cancer: 2 weeks on/1 week off.,Oncology,"Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Renal",(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1846,111323,"CARMENA, CRUK/10/031, CSET 1496, ISRCTN 19562321, MREC N 10/S07/03/66, NCT00930033, P_070144, P070144, P070144 CARMENA, RECF1194, TrialTroveID-111323, UKCRN ID 9849",Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With  Metastatic Renal Cell Carcinoma Treated With Sunitinib,Oncology,Oncology: Renal,"Pfizer, Cancer Research UK, (Other Hospital/Academic/Medical Center), Assistance Publique - Hopitaux de Paris","Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic, Academic",Overall survival,"Complete response, Medication adherence, Mortality, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT00930033,27584
1847,111114,"EudraCT Number: 2006-005188-25, NL14454.078.06, TrialTroveID-111114",Phase I Safety and Pharmacokinetic (PK) Study of Sunitinib (S) in Combination with Ifosfamide (I) in Patients (pts) with Advanced Solid Tumors (STs).,Oncology,"Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Soft Tissue Sarcoma",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose",,False,,27584
1848,110416,TrialTroveID-110416,Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1849,110383,TrialTroveID-110383,Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR).,Oncology,Oncology: GIST; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1850,110355,TrialTroveID-110355,Addition of bevacizumab or sunitinib to biweekly cetuximab and irinotecan as salvage therapy in patients with metastatic colorectal cancer after failure to CetIri.,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,27584
1851,110279,"809442, NCI-2009-01414, NCT00915993, NCT01026337, TrialTroveID-110279, UPCC 03809, UPCC-03809",An Imaging and Histopathologic Study to Predict Response to Sunitinib Therapy in Patients With Metastatic or Locally Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Pfizer, Abramson Cancer Center at  University of Pennsylvania Medical Center","Government, Industry, Top 20 Pharma, Academic","Magnetic Resonance Imaging, Progression-free survival",Response evaluation criteria in solid tumors,True,NCT00915993,27584
1852,110042,TrialTroveID-110042,An open-label phase II trial to assess to efficacy of sunitinib as an antieffusion agent in patients with malignant peritoneal and/or pleural effusions.,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1853,109776,TrialTroveID-109776,Identification of Baseline Predictive Markers of Sunitinib Activity Using a Human Cytokine Antibody Array in Patients with Metastatic Renal Cell Carcinoma (MRCC).,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
1854,109699,TrialTroveID-109699,Pharmacogenetic Pathway Analysis for Determination of Sunitinib-Induced Toxicity,Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1855,109531,TrialTroveID-109531,The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1856,109192,TrialTroveID-109192,Modulation of regulatory T cells and myeloid-derived suppressor cells by sorafenib and sunitinib in renal cell carcinoma patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1857,109051,"16051B, 8079, GCO #: 00-0248 8079 01 RO, NCI-2009-00279, NCT00906360, TrialTroveID-109051, UCCRC-16051B","A Phase I Trial of Concurrent Chemoradiation/Chemoreirradiation With Cetuximab (ERBITUX), Sunitinib, and Accelerated Radiation in Patients With Locally Advanced/High-Risk/Recurrent Poor Prognosis Head and Neck Cancer.",Oncology,Oncology: Head/Neck,"National Institutes of Health/National Cancer Institute, Pfizer","Government, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Clinical benefit rate, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Recurrence, Response evaluation criteria in solid tumors, Time to progression",True,NCT00906360,27584
1858,108944,"EXTENT, H 24786 / EXTENT, H-24786, NCT00905021, TrialTroveID-108944",EXTENT: Exemestane (AROMASIN) in Combination With Sunitinib (SUTENT) in Hormone Receptor Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Pfizer, Baylor College of Medicine","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Time to progression","Circulating Tumor Cells, Clinical benefit rate, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT00905021,27584
1859,108097,"AMC061, AMC-061, NCI-2012-02208, NCT00890747, TrialTroveID-108097",A Phase I/Pharmacokinetic Study of Sunitinib in Patients With Cancer Who Also Have HIV and Are on HAART Therapy.,Infectious Disease; Oncology,"Infectious Disease: HIV; Oncology: Colorectal; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Renal; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Pfizer, AIDS Associated Malignancies Clinical Trials Consortium","Government, Industry, Top 20 Pharma, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Treatment Emergent Adverse Events","Leukocyte count, Response evaluation criteria in solid tumors",True,NCT00890747,27584
1860,107943,"NCT00890110, RCC-vac-sut-1, TrialTroveID-107943",Phase I/II Study of Vaccination With DNP Modified Autologous Renal Cell Carcinoma in Combination With Sunitinib in Stage IV RCC,Oncology,Oncology: Renal,Hadassah Medical Organization,Academic,Immune Response,"Progression-free survival, Safety and Tolerability",True,NCT00890110,27584
1861,107696,"BRE 122, BRE 122 IIT, NCT00887575, SCRI BRE 122, TrialTroveID-107696",Phase I/II Trial of Neoadjuvant Sunitinib Administered With Weekly Paclitaxel/Carboplatin in Patients With Locally Advanced Triple-Negative Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Pfizer","Cooperative Group, Academic, Industry, Top 20 Pharma","Complete response, Maximum tolerated dose","Adverse Events, Disease-free survival, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00887575,27584
1862,107112,"HS#:2008-6187, NCT00879619, TrialTroveID-107112, UCI 07-64","A Pilot Phase I/II Study to Evaluate the Effects of Taxotere/Prednisone Plus Sunitinib in Chemotherapy-NaÃ¯ve, Hormone Refractory Prostate Cancer Patients With Biochemical Relapse.",Oncology,Oncology: Prostate,"Chao Family Comprehensive Cancer Center, Sanofi {Sanofi-Aventis}","Academic, Industry, Top 20 Pharma","Overall response rate, PSA progression, Response rate","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00879619,27584
1863,106870,"A6181185, NCT00873210, TrialTroveID-106870",Non-Interventional Study In Patients with Advanced and/or Metastatic Renal Cell Carcinoma (mRCC) Treated with Sutent,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Quality of Life, Safety and Tolerability",Safety and Tolerability,True,NCT00873210,27584
1864,106358,TrialTroveID-106358,Use of Tyrosine Kinase inhibitors (TKi) in hemodialytic metastatic renal cell carcinoma patients,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,"Safety and Tolerability, Safety and Tolerability",,False,,27584
1865,106347,TrialTroveID-106347,Phase II multicentric study of sunitinib in metastatic renal cell carcinoma (MRCC) with a poor prognosis refractory to immunotherapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",Progression-free survival,False,,27584
1866,106344,TrialTroveID-106344,Effectivity of radiation therapy in combination with Multi-Kinase inhibition based on Sorafenib or Sunitinib in progressive metastatic renal cancer,Oncology,Oncology: Renal,Ludwig Maximilians University of Munich,Academic,Response evaluation criteria in solid tumors,,False,,27584
1867,106300,"06-307, NCT00864864, TrialTroveID-106300",Pilot Study of Sunitinib Tumor Levels in Patients Not on Enzyme-Inducing Anti-Epileptic Drugs Undergoing Debulking Surgery for Recurrent Glioblastoma,Oncology,"Oncology: CNS, Glioblastoma","Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Massachusetts General Hospital, Brigham and Womens Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic",,Overall survival,True,NCT00864864,27584
1868,106101,"06-135, GA6181UU, NCT00864721, TrialTroveID-106101, USO 06-135",Phase II Trial of Sunitinib Malate in Previously Untreated NSCLC Patients Over the Age of 70,Oncology,"Oncology: Lung, Non-Small Cell","Pfizer, US Oncology Research","Industry, Top 20 Pharma, Cooperative Group","Clinical benefit rate, Complete response, Magnetic Resonance Imaging, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00864721,27584
1869,105796,"AAAC2308, NCT00859456, TrialTroveID-105796","A Phase II, Open-Label, Non-Randomized Trial of Sunitinib in Certain Subtypes of Soft Tissue Sarcomas.",Oncology,Oncology: Soft Tissue Sarcoma,Columbia University Medical Center,Academic,"Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00859456,27584
1870,105729,"07-11-052, NCT00859326, NCT01005472, P05513-GA6181FZ, PFIZER-GA6181FZ, SPRI-P05513, TrialTroveID-105729, UCLA-0711052",A Phase I/II Study of Daily Oral Dosing With Temozolomide and Sunitinib Malate for 6 Weeks of an 8-Week Cycle in Patients With Metastatic and Unresectable Locally-Advanced Malignant Melanoma.,Oncology,Oncology: Melanoma,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute","Academic, Government","Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00859326,27584
1871,105719,"ARTiST, ARTiST version 1.0, EudraCT Number: 2008-006161-84, IRAS ID: 4333, ISRCTN11277575, TrialTroveID-105719",ARTiST - Aromasin Randomised Trial +/- Sutent as neoadjuvant Therapy for post-menopausal women with breast cancer,Oncology,Oncology: Breast,"Pfizer, National Health Service (NHS) - UK","Industry, Top 20 Pharma, Government",Safety and Tolerability,"Complete response, Gene expression profiling, Overall response rate, Overall survival, Response rate",False,,27584
1872,105307,TrialTroveID-105307,Predictive value of baseline circulating vascular endothelial growth factor (VEGF) and neutrophil gelatinase-associated lipocalin (NGAL) in advanced renal cell cancer (aRCC) patients (pts) receiving sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1873,105293,"0220080220, 080708, CINJ-080708, NCT00853125, SPECIAL, TrialTroveID-105293",Phase II Study of Sunitinib Plus Extended Courses of Irradiated Allogeneic Lymphocytes for Patients With Renal Cell Carcinoma (SPECIAL Trial),Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00853125,27584
1874,105258,TrialTroveID-105258,Association between acute severe renal toxicity (ASRT) and survival in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving sunitinib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,27584
1875,105137,TrialTroveID-105137,Prospective Comparison of Sorafenib and Sunitinib for Second-line Treatment of Cytokine-Refractory Kidney Cancer Patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,27584
1876,105074,"08-159, NCT00847015, TrialTroveID-105074","Phase II Study of Gemcitabine, Cisplatin, and Sunitinib (GC-S) as Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer.",Oncology,Oncology: Bladder,"Memorial Sloan-Kettering Cancer Center, Pfizer","Academic, Industry, Top 20 Pharma",Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Recurrence, Response rate, Safety and Tolerability, Time to progression",True,NCT00847015,27584
1877,105059,TrialTroveID-105059,Effectivity of simultaneous radiation therapy and multi-kinase inhibition with sunitinib in progressive metastatic renal cell cancer.,Oncology,Oncology: Renal,Ludwig Maximilians University of Munich,Academic,,,False,,27584
1878,104078,"A6181181, CTRI/2009/091/000348, NCT00836745, TEMP UTRN 045521085-080620097981180, TrialTroveID-104078",A Non-Interventional Study Of Indian Patients with Advanced Renal Cell Cancer Receiving Therapy with Sutent.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors",True,NCT00836745,27584
1879,103995,"EudraCT Number: 2008-005519-17, NCT00831857, NL24452.042.08, Renimage, TrialTroveID-103995",89Zr-Bevacizumab PET Imaging in Patients with Renal Cell Carcinoma Treated with Sunitinib or Bevacizumab Plus Interferon; a Pilot Study,Oncology,Oncology: Renal,"Roche {F. Hoffmann-La Roche}, Groningen University Hospital, Roche/Genentech","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma",,Response evaluation criteria in solid tumors,True,NCT00831857,27584
1880,103491,TrialTroveID-103491,Addition of Sunitinib to Biweekly Cetuximab and Irinotecan as Salvage Therapy in Patients with Metastatic Colorectal Cancer After Failure to CetIri,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1881,103369,"077539, NCT00824538, TrialTroveID-103369",Pilot Study to Evaluate the Effect of Sunitinib on Occult Tumor Cells in the Bone Marrow of Patients With High Risk Early Stage Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Pfizer, University of California, San Francisco","Government, Industry, Top 20 Pharma, Academic",,"Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival",True,NCT00824538,27584
1882,103112,"06040, NCT00821327, TrialTroveID-103112, US0 06-040, USOR06040, WS356467","Phase II Trial of Gemcitabine, Cisplatin, and Sunitinib in Patients with Advanced/Metastatic Urothelial Carcinoma.",Oncology,Oncology: Bladder; Oncology: Renal,"Pfizer, US Oncology Research","Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Partial response","Disease Progression, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT00821327,27584
1883,102857,"AGOC O1, NCT00818350, TrialTroveID-102857",Phase II Study of Sunitinib in Metastatic and Pretreated Urothelial Cancer.,Oncology,Oncology: Bladder; Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT00818350,27584
1884,102454,"07URO02, EUDRACT-2008-000948-13, ICREGAUD-07URO02, ICREGAUD-Metastases Cerebrales, INCA-RECF0821, NCT00814021, PFIZER-ICREGAUD-07URO02, RECF0821, TrialTroveID-102454","Phase II Study, Multicenter, Open-label, Evaluating Efficacy of Treatment With Sutent (Sunitinib) in Patients With Previously Untreated or Recurrent Brain Metastases Originating From Renal Cancer",Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"Pfizer, Institut Claudius Regaud","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate, Progression-free survival, Time to progression",True,NCT00814021,27584
1885,102438,"0220080281, 0220090238, 8342, CINJ 050801, CINJ-050909, CTEP #8342, NCI-2012-03112, NCT00813423, TrialTroveID-102438",Autophagic Modulation With Anti-Angiogenic Therapy in Patients With Advanced Malignancies: A Phase I Trial of Sunitinib and Hydroxychloroquine,Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Circulating Tumor Cells, Plasma concentration",True,NCT00813423,27584
1886,102428,"41213, EudraCT Number: 2008-006214-26, GU07-123, HOG GU07-123, NCT00859339, TrialTroveID-102428","A Phase II Trial of Neoadjuvant Cisplatin, Gemcitabine and Sunitinib Malate Followed by Radical Cystectomy for Transitional Cell Carcinoma (TCC) of the Bladder: Hoosier Oncology Group GU07-123",Oncology,Oncology: Bladder,Pfizer,"Industry, Top 20 Pharma",Complete response,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00859339,27584
1887,102265,"20080376, BMS-SCCC-2008001, EPROST-20080376, IRB#20080376, NCT00884676, SCCC 2008001, SCCC- 2008001, TrialTroveID-102265",A Phase I Trial of Weekly and Every Three Weeks Ixabepilone and Sunitinib in Solid Tumor Patients.,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma,"Bristol-Myers Squibb, Pfizer, Sylvester Cancer Center, University of Miami","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability","Complete response, Partial response, Safety and Tolerability, Stable Disease",True,NCT00884676,27584
1888,101892,"CESAR, C-II-005, C-II-005 /2008-001515-37, EudraCT Number: 2008-001515-37, NCT00806663, TrialTroveID-101892","A Prospective Angiogenic Imaging Study with DCE-MRI and DCE-USI in Patients with Colorectal Cancer and Liver Metastases Receiving Sunitinib in Addition to 5-FU, Folinic Acid and Irinotecan (FOLFIRI) as 1st Line Therapy",Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"Pfizer, Central European Society for Anticancer Drug Research","Industry, Top 20 Pharma, Not for Profit Funding Entity",,"Safety and Tolerability, Time to progression",True,NCT00806663,27584
1889,101178,"10217, 145508, EudraCT Number: 2007-002962-37, I 145508, J0705, NA_00008675, NCI-2009-01694, NCT01061411, NL30412.029.10, TrialTroveID-101178","Phase I Study of Dalteparin, A Low Molecular Weight Heparin (LMWH), in Combination With Sunitinib (SU11248), an Oral, Selective Multi-targeted Tyrosine Kinase Inhibitor, as First Line Treatment, in Patients With Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Pfizer, Roswell Park Cancer Institute, Vrije Universiteit Medical Center, Amsterdam, Netherlands","Government, Industry, Top 20 Pharma, Academic, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Complete response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT01061411,27584
1890,100991,"EudraCT Number: 2007-003705-27, MK URO 4, NCT00795171, TrialTroveID-100991","A Phase IIa Randomized, Controlled Biomarker Study Evaluating the Anti-Angiogenic Activity of Sunitinib in Hormone Refractory Prostate Cancer Patients Treated by Docetaxel",Oncology,Oncology: Prostate,Medical University of Vienna,Academic,Maximum tolerated dose,"Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00795171,27584
1891,100980,"NCT00794950, Sutent, Sutent V5, TrialTroveID-100980",A Phase II Study of Intravesical Bacillus Calmette-Guerin Followed by Sunitinib for the Treatment of High Risk Non-muscle Invasive Lower Urinary Tract Urothelial Carcinoma.,Oncology,Oncology: Bladder,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival",True,NCT00794950,27584
1892,100899,"A6181177, CTR20132952, NCT00793871, TrialTroveID-100899","A Single-arm, Open-label, Multi-center, Phase Iv, Efficacy And Safety Study Of Sunitinib Malate In The Treatment Of Chinese Patients With Gastrointestinal Stromal Tumor After Disease Progression On Or Intolerance To Imatinib Mesylate",Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Complete response, Creatinine kinase level, Disease Progression, Eosinophil levels, Heart rate, Hemoglobin level, Leukocyte count, Liver function, Overall response rate - time, Overall response rate, Overall survival, Partial response, Phosphate level, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to response, Uric acid level, Urine protein level, Vital signs",True,NCT00793871,27584
1893,100734,"CRH 06/374/M, EudraCT Number: 2008-001004-22, FRE CRH-VESSU, FRE-CRH-06/374/M, INCA-RECF0845, NCT00792025, PFIZER-FRE-CRH-06/374/M, RECF0845, TrialTroveID-100734, VESSU",A Multicentre Phase II Trial to Determine the Efficacy of the Anti-Tyrosine Kinase Sunitinib (Sutent) as Second Line Therapy in Patients With Transitional Cell Carcinoma (TCC) of the Urothelium Which Failed or Progressed After First Line Chemotherapy for Advanced or Metastatic Disease,Oncology,Oncology: Bladder; Oncology: Renal,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Doppler ultrasound, Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to response",True,NCT00792025,27584
1894,100708,TrialTroveID-100708,Cardiac Toxicity of Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Medical University of Vienna,Academic,,,False,,27584
1895,100388,"07218, NCT00788060, Pro00000548, TrialTroveID-100388","A Single Arm, Phase Ib Study of RAD001 and Sunitinib in Patients with Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Novartis, Pfizer, Duke University Medical Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00788060,27584
1896,100376,"6553, CapSul, IR-6553, NCI-2010-00605, NCT00787787, TrialTroveID-100376, UWCC-6553",The CapSul Trial: A Phase II Study of Sunitinib and Capecitabine for the Treatment of Unresectable or Metastatic Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center, University of Washington","Government, Academic, Academic","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT00787787,27584
1897,100092,"AMLSG 10/07, AMLSG 10-07, AMLSG10-07, AMLSG-SU11248, EudraCT Number: 2007-007553-31, NCT00783653, TrialTroveID-100092",Phase I/II Clinical Study of SU11248 (Sutent) Combined With Standard Chemotherapy With Cytosine Arabinoside and Daunorubicin in Patients With FLT3 Mutated AML Over 60 Years of Age,Oncology,"Oncology: Leukemia, Acute Myelogenous","(Other Hospital/Academic/Medical Center), German AML Study Group","Academic, Cooperative Group",Safety and Tolerability,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Safety and Tolerability",True,NCT00783653,27584
1898,99452,"EudraCT Number: 2008-004813-90, NCT00777478, ONCO 2008-03, sutent-capiri, TrialTroveID-099452, UMCN 2008-03, UMCNONCO20083",A Phase I Dose Escalation Study with Sunitinib (Sutent) in Combination with Capecitabine and Irinotecan (Capiri) in Previously Treated Patients with Advanced Colorectal Cancer.,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00777478,27584
1899,98535,"08-056, NCT00768144, TrialTroveID-098535","A Phase II Trial of Sunitinib in Recurrent and Refractory Ovarian, Fallopian Tube and Peritoneal Carcinoma",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Womens Hospital","Academic, Academic, Academic, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00768144,27584
1900,98187,TrialTroveID-098187,24-hour Arterial Blood Pressure Monitoring in Patients with Renal Cell Carcinoma Treated with Sunitinib Results in Control of Hypertension without Dose Reduction in the Majority of Patients,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1901,98147,TrialTroveID-098147,Expanded-Access Program (EAP) of Sunitinib in Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,27584
1902,97467,"ACTRN12608000474358, ASSG01, ASSG01-08 SUNXRT, NCT00753727, SUNXRT, TrialTroveID-097467","A Phase IB/II Study of Sunitinib in Combination With Neoadjuvant Radiation in Patients With Resectable Soft-tissue Sarcoma , , Sunitinib and Radiation in Patients With Resectable Soft-Tissue Sarcoma (SUNXRT)",Oncology,Oncology: Soft Tissue Sarcoma,"(Other Cooperative Group), Pfizer, Peter MacCallum Cancer Centre, Australia","Cooperative Group, Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00753727,27584
1903,97069,"NCT00748358, P070404, PROSUT, TrialTroveID-097069",An Open Label Phase II Study of Oral Treatment With Sunitinib (SUTENT) in Patients Suffering From Hormone Refractory Prostate Cancer After Progression With Docetaxel Based Regimen.,Oncology,Oncology: Prostate,"Pfizer, Assistance Publique - Hopitaux de Paris","Industry, Top 20 Pharma, Academic","Bone formation rate, Bone resorption rate, Creatinine kinase level, Disease Progression, Parathyroid hormone level, Phosphate level, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00748358,27584
1904,96914,"101219, CTO# 101219, MUSC-101219, NCT00747305, TrialTroveID-096914",Biomarkers of Tumor Angiogenesis and Response to Sunitinib Maleate in Renal Cell Carcinoma,Oncology,Oncology: Renal,Medical University of South Carolina,Academic,Time to progression,,True,NCT00747305,27584
1905,95830,"00010747, 10747, 39674, J0910, NCT00734851, Pro00010747, TrialTroveID-095830",Multimodality Therapy for Recurrent High Risk Prostate Cancer: A Phase II Study.,Oncology,Oncology: Prostate,"Pfizer, (Other Hospital/Academic/Medical Center), Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Overall survival, Progression-free survival, PSA progression, Safety and Tolerability","Disease-free survival, Expanded Prostate Cancer Index Composite, Metastasis-free survival, Overall survival, Progression-free survival, PSA progression, Quality of Life, Recurrence, Safety and Tolerability, Urinary incontinence",True,NCT00734851,27584
1906,95635,"A6181165, JapicCTI-080633, JapicCTI-R130313, NCT00732992, TrialTroveID-095635",Phase I Study of Sunitinib (SU011248) in Combination with Pemetrexed in Patients with Advanced Solid Malignancies in Japan,Oncology,"Oncology: (N/A); Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Cmax, Complete response, Elimination half-life, Elimination rate, Overall response rate, Partial response, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT00732992,27584
1907,95607,"09072008-13772, 520, DRKS00003884, EudraCT Number: 2008-005011-18, NCT00732914, RCC SWITCH study, SWITCH, TrialTroveID-095607",A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Cooperative Group), Bayer AG","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Brain Natriuretic Peptide concentration, Clinical benefit rate, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00732914,27584
1908,95499,"GI06-112, HOG GI06-112, NCT00730353, TrialTroveID-095499",A Phase II Study of Sunitinib Malate (Sutent) With Paclitaxel (Taxol) in Patients With Advanced Esophageal Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"Hoosier Cancer Research Network {Hoosier Oncology Group}, Pfizer","Cooperative Group, Industry, Top 20 Pharma","Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT00730353,27584
1909,95191,"HCI 21897, NCT00694096, TrialTroveID-095191",Sunitinib for Metastatic Renal Cell Cancer With Imaging Biomarker Assessments for the Early Prediction of Tumor Response,Oncology,Oncology: Renal,"University of Utah, National Comprehensive Cancer Network","Academic, Cooperative Group","Partial response, Progressive disease rate, Stable Disease",Overall survival,True,NCT00694096,27584
1910,94836,"P-I-007, TrialTroveID-094836",PK/PD modeling of Sunitinib in healthy volunteers,Oncology,Oncology: Unspecified Cancer,Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,,,False,,27584
1911,94545,"3549, NCT00720148, TrialTroveID-094545, X05226",Phase IB Dose Escalation Study of Bortezomib (VELCADE) Administered Weekly for 4 Weeks and Sunitinib (SU-011248) Administered Daily for 4 Weeks Followed by a 14 Day Rest in Patients With Refractory Solid Tumors,Oncology,Oncology: Head/Neck; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,"Pfizer, Takeda/Takeda Oncology {Millennium}, Winship Cancer Institute of Emory University","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,True,NCT00720148,27584
1912,94203,"NCT00717587, PFIZER-807184, TrialTroveID-094203, UPCC 10807, UPCC-10807",A Histopathologic and Imaging Study of Renal Cell Carcinoma Vasculature in the Setting of Sunitinib Therapy Prior to Cytoreductive Nephrectomy,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Pfizer, University of Pennsylvania","Government, Industry, Top 20 Pharma, Academic",Progression-free survival,Response evaluation criteria in solid tumors,True,NCT00717587,27584
1913,94199,"A6181176, NCT00716625, TrialTroveID-094199",Special Investigation For RCC Of Sutent (Regulatory Post Marketing Commitment Plan),Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events","Adverse Events, Common Terminology Criteria for Adverse Events, Muscle related side effect, NCI-CTC scale, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00716625,27584
1914,94189,"A6181175, NCT00716820, TrialTroveID-094189",Outcome Survey Of Specific Use Of 12.5 Mg Sutent Capsule Against Gastrointestinal Stromal Tumor: Implementation Guidelines.,Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events","Adverse Events, Common Terminology Criteria for Adverse Events, Muscle related side effect, NCI-CTC scale, Overall response rate, Response evaluation criteria in solid tumors, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00716820,27584
1915,94135,"2007-0511, NCI-2012-01678, NCT00715442, TrialTroveID-094135",Phase II Non-Randomized Pre-Surgical Study Evaluating Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC) Who Are Eligible for Cytoreductive Nephrectomy,Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma","Disease Progression, Time to progression","Complete response, Duration of overall response, Overall response rate, Overall survival, Response rate",True,NCT00715442,27584
1916,93958,"07204 PHII-89, 15579A, 7713, NCI-2009-00210, NCT00478426, PHL.062, PHL-062, PMH-PHL-062, TrialTroveID-093958, UOC 15579A",A Phase II Study of Sunitinib Malate in Recurrent or Metastatic Endometrial Carcinoma,Oncology,Oncology: Endometrial; Oncology: Soft Tissue Sarcoma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00478426,27584
1917,93368,"080168, 08-C-0168, NCI-08-C-0168, NCI-P07336, NCT00713388, NCT00923117, TrialTroveID-093368",A Phase II Trial of Sunitinib in the Treatment of Recurrent Malignant Gliomas,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,Progression-free survival,"Adverse Events, Quality of Life",True,NCT00713388,27584
1918,93156,"A6181132, NCT00706706, TrialTroveID-093156","A Single-Arm, Open-Label, Multi-Center, Phase IV, Safety and Efficacy Study of Sunitinib Malate as First-Line Systemic Therapy In Chinese Patients with Metastatic Renal Cell Carcinoma (Post Approval Commitment Study)",Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Progression-free survival, Progressive disease rate","Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT00706706,27584
1919,92716,"37818, NCI-2011-03148, NCT00702884, OSU 07121, OSU-07121, OSU-2008C0028, TrialTroveID-092716",A Mechanistic Radiographic and Biologic Phase II Single Agent Study of Sunitinib Malate in Relapsed/ Refractory Esophageal and Gastroesophageal Cancers,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Complete response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00702884,27584
1920,92675,"A6181170, A6181170 1602, EudraCT Number: 2007-006637-14, GI 121, GITSUNSOR, JapicCTI-090678, JapicCTI-R130315, NCRN046, NCT00699374, Nexavar SPC/A6181170, NMRR-08-447-1602, PFIZER # A6181170, RECF0886, SUN 1170, TrialTroveID-092675, UKCRN ID 5083","A Multinational, Randomized, Open-Label, Phase III Study Of Sunitinib Malate Versus Sorafenib In Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,Pfizer,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, EQ-5D, Progression-free survival, Progressive disease rate, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00699374,27584
1921,92363,"08-282, 2008CG102, 30704, CALGB 30704, CALGB-30704, NCI-2009-00471, NCT00698815, TrialTroveID-092363",A Randomized Phase II Study to Assess the Efficacy of Pemetrexed or Sunitinib (NSC # 736511) or Pemetrexed Plus Sunitinib in the Second-Line Treatment of Advanced Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00698815,27584
1922,92296,"38567, LUN 156, LUN 156 SCRI IIT, NCT00695292, SCRI LUN 156, TrialTroveID-092296","Phase II Study of Irinotecan, Carboplatin, and Sunitinib in the First Line Treatment of Extensive-Stage Small Cell Lung Cancer.",Oncology,"Oncology: Lung, Small Cell","Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Pfizer","Academic, Industry, Top 20 Pharma",Overall survival,"Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00695292,27584
1923,92238,TrialTroveID-092238,Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1924,92043,"(NCI 8076), 8076, NCI-2009-00277, NCT00691730, PHL-064, PMH-PHL-064, TrialTroveID-092043",The Role of VEGF-A Signaling in Maintenance of the Glomerular Filtration Barrier and Blood Pressure,Oncology,Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, University Health Network, Toronto","Government, Academic",Urine protein level,,True,NCT00691730,27584
1925,91938,TrialTroveID-091938,Response to sunitinib malate (SM) in alveolar soft part sarcoma (ASPS).,Oncology,Oncology: Soft Tissue Sarcoma,(Other Cooperative Group),Cooperative Group,,,False,,27584
1926,91584,"Eudract 2007-001561-15, TrialTroveID-091584",A phase II trial of sunitinib in patients with recurrent high-grade glioma.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,,"Overall survival, Progression-free survival",False,,27584
1927,91509,TrialTroveID-091509,Detection of cis-mutations in the activation loop of the KIT gene in sunitinib-resistant gastrointestinal stromal tumors.,Oncology,Oncology: GIST,(Other Cooperative Group),Cooperative Group,,,False,,27584
1928,91470,TrialTroveID-091470,Evaluation of thyroid dysfunction as a candidate surrogate marker for efficacy of sunitinib in patients (pts) with advanced renal cell cancer (RCC).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,27584
1929,91461,TrialTroveID-091461,Immune cell changes in the peripheral blood of metastatic renal cell carcinoma (mRCC) patients (pts) treated with sunitinib or temsirolimus.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1930,91440,TrialTroveID-091440,Potential non-synonymous single nucleotide polymorphisms (nsSNPs) associated with toxicity in metastatic clear cell renal cell carcinoma (MCCRCC) patients (pts) treated with sunitinib,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
1931,91036,"A6181171, NCT00684645, TrialTroveID-091036",Non-Interventional Study In Patients With Advanced And/Or Metastatic Renal Cell Carcinoma (mRCC) Treated With SUTENT.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression, Treatment Emergent Adverse Events",True,NCT00684645,27584
1932,90581,TrialTroveID-090581,High-resolution electrocardiography (HRECG) in detection of preclinical cardiotoxicity of sunitinib and sorafenib in renal cell carcinoma (RCC) patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1933,89985,"00007396, 2008-0069, DUMC-8725, NCT00672594, TrialTroveID-089985",Investigator-Initiated Pilot Study of Sunitinib Malate in Patients With Newly Diagnosed Prostate Cancer Prior to Prostatectomy,Oncology,Oncology: Prostate,"Pfizer, Duke University Medical Center","Industry, Top 20 Pharma, Academic",,"Adverse Events, Common Terminology Criteria for Adverse Events, Plasma concentration, Safety and Tolerability",True,NCT00672594,27584
1934,89726,"CESAR C-II-004, C-II-004, C-II-004 / 2007-005022-71, EudraCT Number: 2007-005022-71, NCT00673504, TrialTroveID-089726",Prospective Randomized Phase II Trial With Gemcitabine Plus Sunitinib Versus Gemcitabine Alone in First-line Therapy of Metastatic or Locally Advanced Pancreatic Cancer,Oncology,Oncology: Pancreas,Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,"Progression-free survival, Time to progression","Adverse Events, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT00673504,27584
1935,89620,"42568, N0747, NCCTG-N0747, NCI-2011-01920, NCT00891878, TrialTroveID-089620",A Randomized Phase II Trial of Sunitinib Plus Capecitabine Versus Capecitabine Alone (With the Potential for Crossover) for Elderly and/or Poor Performance Status Patients With Metastatic Adenocarcinoma of the Esophagus or Gastroesophageal Junction.,Oncology,Oncology: Esophageal; Oncology: Gastric,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to treatment failure","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Response rate, Time to progression, Time to treatment failure",True,NCT00891878,27584
1936,89158,"C9325/A9347, CRUK 07/044, EU-21013, EudraCT Number: 2007-007591-42, ISRCTN54607216, MREC NÂ° 08/S0703/123, NCT01089088, SPON 416-07, SPON416-07(WCTU011), SUCCINCT, TrialTroveID-089158, UKCRN ID 4561, WCTU011, WCTU-SPON-416-07, WCTU-SUCCINCT",A Phase II Single-Arm Trial to Evaluate Cisplatin and Gemcitabine Chemotherapy in Combination With Sunitinib for First-Line Treatment of Patients With Advanced Transitional Carcinoma of the Urothelium,Oncology,Oncology: Bladder; Oncology: Renal,"(Other Academic Cancer Center), Cancer Research UK, National Health Service (NHS) - UK, (Other Hospital/Academic/Medical Center)","Academic, Not for Profit Funding Entity, Government, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events",True,NCT01089088,27584
1937,89123,"A6181151, JapicCTI-080542, JapicCTI-R120262, NCT00668863, TrialTroveID-089123","A Phase II Study of Sunitinib In Combination With Irinotecan, l-Leucovorin, And 5-Fluorouracil In Patients With Unresectable or Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,Pfizer,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Concentration at steady state, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, Elimination rate, Mean residence time, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Tmax, Treatment Emergent Adverse Events, Volume of distribution",True,NCT00668863,27584
1938,89051,"IIT Sutent, NCT00668811, TrialTroveID-089051, WCI-2007-214",Sutent Adjunctive Treatment of Differentiated Thyroid Cancer.,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,"Pfizer, Washington Hospital Center","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Response rate",True,NCT00668811,27584
1939,88578,TrialTroveID-088578,Sunitinib mediates reversal of myeloid derived suppressor cell accumulation in renal cell carcinoma patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Resection rate,,False,,27584
1940,88575,"NCT00663559, SOGUG/0107, TrialTroveID-088575",Study Phase II to Determinate the Efficacy of Sunitinib in Patients With Renal Cells Carcinoma Metastasic or Locally Avanced in Patients Not Candidates to Curative Previous Nefrectomy,Oncology,Oncology: Renal,Spanish Oncology GenitoUrinary Group,Cooperative Group,Progression-free survival,Duration of overall response,True,NCT00663559,27584
1941,88475,"A6181163, JapicCTI-080592, JapicCTI-R100117, NCT00662025, TrialTroveID-088475",A Phase II Study Of Sunitinib Malate In Combination With Capecitabine In Patients With Advanced or Metastatic Breast Cancer,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Cmax, Complete response, Disease Progression, Elimination half-life, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Tmax",True,NCT00662025,27584
1942,87872,"0802-15, 0802-15/1011003564, 36384, IUCRO-0215, NCT00656669, TrialTroveID-087872",An Exploratory Study of the Biological and Clinical Activity of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer.,Oncology,Oncology: Breast,"Pfizer, Indiana University School of Medicine, Breast Cancer Research Foundation","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity",,"Adverse Events, Complete response, Safety and Tolerability",True,NCT00656669,27584
1943,87796,TrialTroveID-087796,Angiogenesis markers in sunitinib-treated clear-cell renal carcinoma patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
1944,85586,"GA6181DN, NCT00631618, TrialTroveID-085586",A Phase II Trial of Sutent in Metastatic Melanoma Patients With KIT Aberrations.,Oncology,Oncology: Melanoma,"Pfizer, University of California, San Francisco, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic, Academic","Overall response rate, Response rate",Safety and Tolerability,True,NCT00631618,27584
1945,85480,"08-098, 2008-0746, A6181120, EudraCT Number: 2008-002158-40, McG 0831, NCRN049, NCT00676650, RECF0885, Study 510, SUN 1120, TrialTroveID-085480, UKCRN ID 5634, VICC URO 0851","A Multicenter, Randomized, Double-Blind, Phase III Study Of Sunitinib Plus Prednisone Versus Prednisone In Patients With Progressive Metastatic Castration-Resistant Prostate Cancer After Failure Of A Docetaxel-Based Chemotherapy Regimen",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma",Overall survival,"Appetite, Complete response, Disease Progression, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-General, Functional Assessment of Cancer Therapy-Prostate, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00676650,27584
1946,85247,"J0858, MDACC 2006-0684, NCI-2010-01524, NCT00631527, TrialTroveID-085247","Sunitinib, Hormonal Ablation and External Beam Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer",Oncology,Oncology: Prostate,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose",Quality of Life,True,NCT00631527,27584
1947,85213,"A6181148, JapicCTI-070501, JapicCTI-R120263, NCT00631410, TrialTroveID-085213","Phase I Study of Sunitinib In Combination with Oxaliplatin, L-Leucovorin, and 5-Fluorouracil in Patients with Metastatic Colorectal Cancer.",Oncology,Oncology: Colorectal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Complete response, Duration of overall response, Overall response rate, Partial response, Plasma concentration, Plasma pharmacokinetics, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00631410,27584
1948,84853,"EUDRACT-2007-005977-67, GICR-GIR-1, GIM-GIR-1, GIR-1, NCT00626509, TrialTroveID-084853",Sunitinib Either Before or After Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,"(Other Cooperative Group), Consorzio Oncotech","Cooperative Group, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease","Duration of overall response, Overall survival, Time to progression",True,NCT00626509,27584
1949,84231,TrialTroveID-084231,The role of adding gemcitabine at time of sunitinib resistance in patients with metastatic renal cell cancer,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,,False,,27584
1950,84122,"EUDRACT-2005-005115-16, HDM-SU-011248, NCT01118039, PFIZER-HDM-SU-011248, TrialTroveID-084122",A Phase II Study Assessing SU-011248 in Previously Untreated Patients With Advanced Urothelial Cancer Ineligible for Cisplatin-Based Chemotherapy,Oncology,Oncology: Bladder; Oncology: Renal,"Pfizer, Spanish Oncology GenitoUrinary Group, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Cooperative Group, Academic","NCI-CTC scale, Overall response rate, Safety and Tolerability, Time to progression","EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Time to progression, Time to treatment failure",True,NCT01118039,27584
1951,84010,"NCCCTS-07-285, NCT00620347, TrialTroveID-084010",A Phase II Study of Sunitinib as a Second-line Treatment for Patients With Recurrent Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Small Cell","Pfizer, National Cancer Center - Goyang, Korea","Industry, Top 20 Pharma, Government","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, NCI-CTC scale, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00620347,27584
1952,83751,"EudraCT Number: 2006-005751-16, NCT00617253, NN028-1642, TrialTroveID-083751","An Open Label, Dose Escalation Safety and Tolerability Trial of the Combination of s.c. Recombinant Human IL-21 (rIL-21) and Sunitinib (Phase I) Followed by an Open Label Stratified Randomized 2-arm Trial of rIL-21 Plus Sunitinib Versus Sunitinib Alone (Phase IIa) in Subjects With Stage IV Renal Cell Carcinoma",Oncology,Oncology: Renal,Novo Nordisk,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability","Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00617253,27584
1953,83681,"00000931, NCT00611728, Pro00000931, TrialTroveID-083681",A Phase I Study of SU011248 Plus Irinotecan in the Treatment of Patients With Malignant Glioma.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other","Pfizer, Duke University Medical Center","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00611728,27584
1954,83615,"A6181104, A6181104-1145, EudraCT Number: 2007-002987-84, JapicCTI-080673, NCT00609622, TrialTroveID-083615","A Randomized, Phase IIB Study Of Sunitinib Plus Oxaliplatin, 5-Fluorouracil And Leucovorin (FOLFOX) Versus Bevacizumab Plus FOLFOX As First-Line Treatment In Patients With Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Progression-free survival, Progressive disease rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Colorectal Cancer, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00609622,27584
1955,83159,"14916, 2005-1136, MCC-14916, NCT00606008, TrialTroveID-083159, USFIRB#105192",A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma Multiforme.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other","Pfizer, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival","Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate, Stable Disease",True,NCT00606008,27584
1956,83073,"I 95206, NCT00849186, RPCI 95206, RPCI-I-95206, TrialTroveID-083073",A Pilot Study of Neoadjuvant SUNITINIB MALATE (Sunitinib) in Patients With Renal Cell Carcinoma Undergoing Nephrectomy.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Pfizer, Roswell Park Cancer Institute","Government, Industry, Top 20 Pharma, Academic",Safety and Tolerability,"Overall response rate, Progression-free survival, Response rate",True,NCT00849186,27584
1957,82890,TrialTroveID-082890,A Study in Patients with Metastatic Papillary RCC (PRCC) and Chromophobe RCC (ChRCC) Who Received Either Sunitinib or Sorafenib As Their Initial TKI Treatment,Oncology,Oncology: Renal,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Academic,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",,False,,27584
1958,82696,"05112, 2006-0012, NCT00599313, TrialTroveID-082696",Phase II Trial of Sunitinib Malate for the Therapy of Progressive Metastatic Androgen Independent Prostate Cancer (AIPC) Following Docetaxel-Based Chemotherapy,Oncology,Oncology: Prostate,"Pfizer, US Oncology Research","Industry, Top 20 Pharma, Cooperative Group","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Overall response rate, Overall survival, Partial response, PSA progression, Quality of Life",True,NCT00599313,27584
1959,81842,"00014547, 08-193, 101272, 251625, 30607, 30607CALGB, C30607, CALGB 30607, CALGB30607, CALGB-30607, CTSU CALGB-30607, CTSUTHOC30607-M, NCI-2009-00469, NCT00693992, NCT01647087, ONI10209, TrialTroveID-081842, UPCI 11-104","Randomized, Phase III, Double-Blind Placebo-Controlled Trial of Sunitinib (NSC #736511, IND #74019) as Maintenance Therapy in Non-Progressing Patients Following an Initial Four Cycles of Platinum-Based Combination Chemotherapy in Advanced, Stage IIIB / IV Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Disease Progression, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT00693992,27584
1960,81706,"15328B, NCT00583063, TrialTroveID-081706",A Pharmacokinetic Interaction Study of Rapamycin (Sirolimus) and SU11248 (Sunitinib) in Patients With Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Pfizer, University of Chicago Cancer Research Center","Industry, Top 20 Pharma, Academic",,,True,NCT00583063,27584
1961,81448,"NCT00578526, SPRUCE, SPRUCE02, SPRUCE-02, TrialTroveID-081448","A Randomized, Placebo-controlled Phase II Study to Compare the Efficacy and Safety of SU011248 Versus Placebo in Patients With Advanced Urothelial Transitional Cell Carcinoma Who Have Failed or Are Intolerant to Cisplatin-based Chemotherapy.",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"(Other Cooperative Group), Pfizer","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Duration of overall response, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability",True,NCT00578526,27584
1962,81420,"06-145, 33305, DFCI : 06-145, NCT00577382, TrialTroveID-081420, VICCMEL0759",A Phase II Study of SU011248 in Patients With Metastatic Mucosal or Acral/Lentiginous Melanoma,Oncology,Oncology: Melanoma,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT00577382,27584
1963,80905,"NCT00570882, RESTORE trial, TrialTroveID-080905, UOSG_AMC_0701","A Randomized Phase II Trial Of Sunitinib Administered Daily For 4 Weeks, Followed By 2-Week Rest Vs. 2-Week On And 1-Week Off In Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,Asan Medical Center,Academic,Progression-free survival,"Adverse Events, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT00570882,27584
1964,80889,"42232, H 20924, H-20924, NCT00570908, TrialTroveID-080889","A Phase II Trial of Capecitabine Concomitantly With Whole Brain Radiotherapy (WBRT) Followed by Capecitabine and Sunitinib for Central Nervous System, (CNS) Metastases in Breast Cancer.",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Pfizer, Baylor College of Medicine","Industry, Top 20 Pharma, Academic",Progression-free survival,"Overall response rate, Overall survival",True,NCT00570908,27584
1965,80176,"ACC-Siu 2006, NCT00886132, TrialTroveID-080176",A Phase II Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands,Oncology,Oncology: Head/Neck,"University Health Network, Toronto",Academic,"Complete response, Overall response rate","Disease Progression - duration, Overall response rate - duration, Overall survival",True,NCT00886132,27584
1966,79519,"07-202, DF/HCC 07-202, NCT00556205, TrialTroveID-079519","Phase II, Randomized Trial of Bevacizumab with or without Sunitinib in Sunitinib-Refractory Patients with Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Pfizer, Beth Israel Deaconess Medical Center, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic, Academic",Time to progression,"Disease Progression, Overall response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00556205,27584
1967,79501,"07-212, DF/HCC 07-212, NCT00556049, TrialTroveID-079501","Phase II, Single Arm Trial of Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-Risk Patients with Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00556049,27584
1968,79441,"07-0562, 07-0562 / 201101709, 201101709, NCT00555256, TrialTroveID-079441",A Phase I Study of SUNITINIB and Rapamycin in Advanced Non-Small Cell Lung Cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell","Pfizer, Washington University School of Medicine","Industry, Top 20 Pharma, Academic",Dose-limiting toxicities,"Overall response rate, Overall survival, Response rate",True,NCT00555256,27584
1969,79382,"A6181128, NCT00555672, TrialTroveID-079382",A Phase I Study Of Sunitinib Malate In Combination With Cisplatin And 5-Fluorouracil In Patients With Advanced Gastric Cancer.,Oncology,Oncology: Esophageal; Oncology: Gastric,Pfizer,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Area under the curve score, Cmax, Complete response, Duration of overall response, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT00555672,27584
1970,79361,"A6181126, NCT00555620, TrialTroveID-079361",A Phase I Study of Sunitinib Malate In Combination With Cisplatin/Capecitabine or Oxaliplatin/Capecitabine In Patients With Advanced Gastric Cancer.,Oncology,Oncology: Esophageal; Oncology: Gastric,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Nausea, Neutropenia, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Vomiting","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Maximum tolerated dose, Overall response rate, Partial response, Plasma concentration, Plasma pharmacokinetics, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT00555620,27584
1971,79234,"A6181127, JapicCTI-070500, NCT00553696, TrialTroveID-079234",A Phase I Study Of Sunitinib In Combination With S-1 And Cisplatin In Patients With Advanced Or Metastatic Gastric Cancer.,Oncology,Oncology: Esophageal; Oncology: Gastric,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Cmax, Complete response, Duration of overall response, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Tmax",True,NCT00553696,27584
1972,78633,"NCT00550810, SMART, SMART/TBCC-0707001, TBCC-0707001, TrialTroveID-078633",A Phase II Study of SU011248 for Maintenance Therapy in Hormone Refractory Prostate Cancer After First Line Chemotherapy.,Oncology,Oncology: Prostate,"Pfizer, Alberta Health Services Research and Innovation Fund","Industry, Top 20 Pharma, Government","Disease Progression, Progression-free survival","Disease Progression, Overall response rate, PSA progression, Response rate",True,NCT00550810,27584
1973,78450,TrialTroveID-078450,A phase 1b/2 study of CVX-045 in combination with sunitinib.,Oncology,Oncology: Colorectal,"Pfizer, Pfizer {Pfizer/CovX}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,,False,,27584
1974,78181,"S0724, TrialTroveID-078181","A Randomized Phase II Trial of VEGF, AKT, mTOR Combination Targeted Therapy (CTT) with Sunitinib, Bevacizumab, Perifosine, and Temsirolimus in Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,Southwest Oncology Group,Cooperative Group,,,False,,27584
1975,78026,"2006-0638, NCI-2012-01552, NCT00543504, TrialTroveID-078026","A Phase I Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib.",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00543504,27584
1976,77921,TrialTroveID-077921,Safety profile of single-agent sunitinib malate from the French Temporary Authorization for Use program (Cohort ATU) in metastatic renal cell carcinoma (MRCC) after failure of treatment with cytokines and gastrointestinal stromal tumor (GIST) patients.,Oncology,Oncology: GIST; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,27584
1977,77781,"AGO 2.11, AGO-OVAR 2.11, EudraCT Number: 2007-003089-16, NCT00543049, TrialTroveID-077781","Phase II Trial in Platinum-Refractory Ovarian Cancer: A Randomized Multicenter Trial with SU11248 to Evaluate Dosage, Tolerability, Toxicity and Effectiveness of a Multitargeted Receptor Tyrosine Kinase Inhibitor Monotherapy.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AGO-Study Group Ovarian Cancer, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","CA-125 Response, Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - duration, Overall survival, Stable Disease, Time to progression, Wound healing",True,NCT00543049,27584
1978,77770,"CDR0000569863, EU-20761, EUDRACT: 2006-003339-62, FNCLCC SUPAP GEP 03/0603, FNCLCC-GEP 03/0603, FRE-FNCLCC-GEP-03/0603, FRE-FNCLCC-GEP-03-0603, GETUG â GEP 03/SUPAP, NCT00541008, PFIZER-FRE-FNCLCC-GEP-03/0603, PFIZER-FRE-FNCLCC-GEP-03-0603, RECF0460, SUPAP, SUPAP PG 03, TrialTroveID-077770",Phase II of Sunitinib (SUTENT) in First Line for Patients with Locally Advanced or Metastatic Papillary Renal Cell Carcinoma - SUPAP.,Oncology,Oncology: Renal,"Federation Nationale des Centres de Lutte contre le Cancer, Pfizer","Cooperative Group, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression, Time to response",True,NCT00541008,27584
1979,77080,"97807, IRB 97807, NCT00537056, RENAL0013, TrialTroveID-077080",Evaluating Sunitinib Therapy in Renal Cell Carcinoma Using F-18 FDG PET/CT and DCE MRI.,Oncology,Oncology: Renal,"Stanford University Medical Center, National Comprehensive Cancer Network","Academic, Cooperative Group","Area under the curve score, Magnetic Resonance Imaging, Partial response, PEFR, Progression-free survival, Stable Disease","Adverse Events, Area under the curve score, Liver function, Magnetic Resonance Imaging, PEFR",True,NCT00537056,27584
1980,77059,"2005-195, ISRCTN03334163, TrialTroveID-077059",A phase II study of Sutent (SU11248) as second line treatment in pleural mesothelioma after first line treatment with a platinum and antimetabolite.,Oncology,Oncology: Mesothelioma,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Change in FVC, NCI-CTC scale, Overall response rate, Overall survival, Percent change in FEV1, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Time to treatment failure",False,,27584
1981,76848,"EudraCT Number: 2007-002142-37, NCT00535379, SURGE 01-07, SURGE01-07, TrialTroveID-076848","SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-arm Phase II Clinical Trial Including Ranslational Research Studies.",Oncology,"Oncology: CNS, Glioblastoma","Pfizer, Innsbruck Medical University","Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival, Time to progression","Adverse Events, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT00535379,27584
1982,76653,"057519, NCI-2011-01275, NCT00616122, TrialTroveID-076653, UCSF-057519",Phase I/II Study of SU11248 (Sutent) in Combination With Metronomic Dosing of Cyclophosphamide and Methotrexate in Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Pfizer, University of California, San Francisco","Government, Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Neutropenia, Progression-free survival, Time to progression","Circulating Tumor Cells, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",True,NCT00616122,27584
1983,76631,"2006-0921, NCT00532064, TrialTroveID-076631",Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers,Oncology,Oncology: Unspecified Cancer,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government",Brain Natriuretic Peptide concentration,MD Anderson Symptom Inventory,True,NCT00532064,27584
1984,76502,"NCT00531544, RAC#2061 043, TrialTroveID-076502",A SU011248 Expanded Access Protocol for Metastatic RCC Patients Who Are Ineligible for Participation in Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,True,NCT00531544,27584
1985,76259,"2007-103, HUM00012046, HUM12046, NCT00616109, TrialTroveID-076259, UMCC 2007.034, UMCC2007-034","Phase II Trial of Sunitinib (Sutent, SU11248) Maintenance Therapy After Induction Platinum-Based Chemotherapy in Patients With Extensive-Stage Small Cell Lung Cancer.",Oncology,"Oncology: Lung, Small Cell","Pfizer, University of Michigan Comprehensive Cancer Center","Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival","Adverse Events, Complete response, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT00616109,27584
1986,76062,"A6181084, COMIRB 06-0351, NCT00528619, PRMC 06-51, TrialTroveID-076062","Phase I Study of SU011248 in Combination with Pemetrexed, Pemetrexed/Cisplatin and Pemetrexed/ Carboplatin In Patients with Advanced Solid Malignancies.",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,"Disease Progression, Plasma pharmacokinetics, Response evaluation criteria in solid tumors",True,NCT00528619,27584
1987,75930,"CASE24806, CASE-24806 CC-242, CASE-24806-CC242, GA6180CV, NCT00526656, PFIZER-GA6180CV, TrialTroveID-075930","Phase II Single Arm, Open Label, Single Institution Study of Neoadjuvant Sunitinib (SUTENT) in Patients With Muscle-Invasive Locally Advanced Transitional Cell Carcinoma of the Bladder",Oncology,Oncology: Bladder,"National Institutes of Health/National Cancer Institute, Pfizer, Cleveland Clinic Taussig Cancer Center","Government, Industry, Top 20 Pharma, Academic","Complete response, Safety and Tolerability, Safety and Tolerability","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT00526656,27584
1988,75714,TrialTroveID-075714,Phase 3 study of Sutent and standard of care versus standard of care in first line metastatic non-small cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma",,,False,,27584
1989,75635,"69605, I 69605, NCT00524186, RPCI-I-69605, TrialTroveID-075635","Phase I Study of Sunitinib With FOLFIRI (Irinotecan, 5-Fluorouracil and Leucovorin) for Advanced Gastroesophageal Cancers",Oncology,Oncology: Esophageal; Oncology: Gastric,"Pfizer, Roswell Park Cancer Institute","Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT00524186,27584
1990,75631,"29400, 82706, I 82706, NCT00524316, RPCI-I-82706, TrialTroveID-075631, UGIH09035",A Phase II Study of sunitinib malate (Sutent) and Chemoembolization in Patients With Unresectable Hepatocellular Cancer.,Oncology,Oncology: Liver,Roswell Park Cancer Institute,Academic,"Overall response rate, Progression-free survival, Response rate","Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00524316,27584
1991,75418,"0806-0132, NCT00522249, RCC-06-101, TrialTroveID-075418","A Study of Pegylated Alfa Interferon, Sunitinib and Tarceva in Patients With Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Merck & Co. {Schering-Plough}, Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Overall response rate, Time to progression",Overall survival,True,NCT00522249,27584
1992,75354,"NPC019, TrialTroveID-075354",Phase II Study Of SU011248 In Patients With Recurrent Or Metastatic Nasopharyngeal Carcinoma.,Oncology,Oncology: Head/Neck,"Chinese University, Hong Kong",Academic,"Clinical benefit rate, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability",,False,,27584
1993,75268,"LUD2007-004, NCT00520533, TrialTroveID-075268","A Pilot Study of the Safety, Efficacy, and Effects on Functional Imaging of the Combination of cG250 and Sunitinib in Patients With Advanced Renal Cell Carcinoma",Oncology,Oncology: Renal,"Pfizer, Ludwig Institute for Cancer Research, Heidelberg Pharma {WILEX}","Industry, Top 20 Pharma, Not for Profit Funding Entity, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability",Response evaluation criteria in solid tumors,True,NCT00520533,27584
1994,75203,"6494, NCI-2011-01305, NCT00519896, PFIZER-UWCC-6494, TrialTroveID-075203, UWCC- 07-6030-H/B, UWCC-6494, UWCC-UW 6494",Phase II Study of Sunitinib in Iodine Refractory Differentiated Thyroid Cancer and Metastic Medullary Carcinoma of Thyroid With Functional Imaging Correlation,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, Pfizer, Fred Hutchinson Cancer Research Center, University of Washington","Government, Industry, Top 20 Pharma, Academic, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Duration of overall response, NCI-CTC scale, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",True,NCT00519896,27584
1995,74635,"7702, MC058F, MCCRC-MC058F, MYE001, NCT00514137, TrialTroveID-074635",A Phase II Trial of Sunitinib (SU11248) in Multiple Myeloma.,Oncology,Oncology: Multiple Myeloma,"National Institutes of Health/National Cancer Institute, Pfizer","Government, Industry, Top 20 Pharma","Complete response, Partial response","Common Terminology Criteria for Adverse Events, Duration of overall response, Event-free survival, Progression-free survival, Time to progression",True,NCT00514137,27584
1996,74505,"6488, FHCRC-6488, NCI-2010-00607, NCT00513695, NCT00831584, TrialTroveID-074505, UWCC-07-6437-H/A, UWCC-6488, UWCC-UW-6488",A Phase II Study Evaluating the Safety and Efficacy of Sunitinib Maleate in Combination With Weekly Paclitaxel Followed by Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF as Neoadjuvant Chemotherapy for Locally Advanced or Inflammatory Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Pfizer, University of Washington","Government, Industry, Top 20 Pharma, Academic",Complete response,"Adverse Events, Complete response, Disease-free survival, Overall survival, Time to progression",True,NCT00513695,27584
1997,74207,"2006-023, 9277-06, NCT00510640, RECF0800, THYSU, TrialTroveID-074207","Phase II of Sunitinib (Sutent) in Patients With Locally Advanced or Metastatic Anaplastic, Differentiated or Medullar Thyroid Cancer.",Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00510640,27584
1998,74026,"CMO 2006/232, NCT00509704, TrialTroveID-074026",Pilot Study on the Influence of Sutent on Tumor Vascularization and Necrosis in Patients With Renal Cell Carcinoma.,Oncology,Oncology: Renal,"Novo Nordisk, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",,,True,NCT00509704,27584
1999,73034,"7898, CO 06902, CO06902, H-2007-0039, NCI-2009-00245, NCT00499135, TrialTroveID-073034, WCCC-CO-06902",Pharmacodynamic Study of Sunitinib Malate in Patients With Renal Cell Cancer and Other Advanced Solid Malignancies,Oncology,"Oncology: Bladder; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Pfizer, University of Wisconsin Comprehensive Cancer Center","Government, Industry, Top 20 Pharma, Academic",Overall response rate,"Area under the curve score, Cmax, Tmax",True,NCT00499135,27584
2000,73020,"06060, 7745, MSKCC 07-153, NCT00499473, OSU-06060, OSU-IRB-2006C0098, PHL-065, TrialTroveID-073020",A Pharmacokinetic and Phase II Study of Sunitinib Malate in Recurrent Malignant Gliomas.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Pfizer, Richard J. Solove Research Institute, Arthur G. James Cancer Hospital","Government, Industry, Top 20 Pharma, Academic, Academic","Dose-limiting toxicities, Maximum tolerated dose, Plasma concentration, Progression-free survival, Safety and Tolerability","Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00499473,27584
2001,72667,"MCC-14733, NCT00495625, Pfizer #2005-0880, TrialTroveID-072667",Phase II Open-Label Study of Sunitinib Malate (SUO11248) in Adult Subjects With Metastatic and/or Surgically Unresectable Hepatocellular Cancers,Oncology,Oncology: Liver,"Pfizer, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic","Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Overall survival, Serious Adverse Events, Time to progression",True,NCT00495625,27584
2002,72617,"MCC-14743, NCT00496223, TrialTroveID-072617",A Phase I/II Study of Sunitinib and Dacarbazine in Patients With Metastatic Melanoma.,Oncology,Oncology: Melanoma,"Pfizer, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic","Overall response rate, Progression-free survival, Safety and Tolerability",Overall survival,True,NCT00496223,27584
2003,72501,"2007-0170, 27763, NCT00495872, TrialTroveID-072501",A Multi-Arm Complete Phase I Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor,Oncology,Oncology: Ovarian; Oncology: Unspecified Solid Tumor,"MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00495872,27584
2004,72359,"GI0621, IND exemption -77631, NCT00495001, NCT00573404, TrialTroveID-072359, VICC GI 0621, VICCGI0621, VICC-GI-0621, VICCPHI0621, VU GCRC 1642, VU-VICC-GI-0621",A Phase I Study of Imatinib Mesylate and SU011248 for Patients with Gastrointestinal Stromal Tumors.,Oncology,Oncology: GIST,"National Institutes of Health/National Cancer Institute, Vanderbilt-Ingram Cancer Center","Government, Academic",Maximum tolerated dose,"Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors",True,NCT00495001,27584
2005,71670,TrialTroveID-071670,Circulating endothelial cells and progenitor cells in metastatic renal cell cancer: Predictive value during anti-angiogenic therapy?,Oncology,Oncology: Renal,Institut Gustave Roussy,Academic,Disease-free survival,,False,,27584
2006,71584,"06-04, NCT00489944, POHA-0604, TrialTroveID-071584","A Phase II Pilot Trial of Sutent, Tamoxifen, and Cisplatin in Patients With High-Risk Ocular Melanoma.",Oncology,Oncology: Melanoma,(Other Cooperative Group),Cooperative Group,"Disease-free survival, Overall survival",,True,NCT00489944,27584
2007,71329,TrialTroveID-071329,Relation between lactate dehydrogenase (LDH) during two first cycles in patients with metastatic renal cell carcinoma (mRCC) treated with sunitinib (SU).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
2008,71276,TrialTroveID-071276,Side effects of sunitinib malate (SM) treatment for patients with metastatic renal cell carcinoma (mRCC).,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
2009,71208,"A6181051, TrialTroveID-071208",A Phase I Dose Escalation Study of Sunitinib in Combination with Gemcitabine + Cisplatin for Advanced Non-Small Cell Lung Cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma",Maximum tolerated dose,Plasma pharmacokinetics,False,,27584
2010,71002,TrialTroveID-071002,Evaluation of VEGF targeted therapy efficacy in mRCC after sorafenib failure or intolerance.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",,False,,27584
2011,70812,TrialTroveID-070812,Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.,Oncology,Oncology: Renal,University of Minnesota,Academic,,,False,,27584
2012,70475,TrialTroveID-070475,"Insulin-like growth factor (IGF)-II in gastrointestinal stromal tumors (GIST): expression, secretion, and clinical relevance.",Oncology,Oncology: GIST,(Other Hospital/Academic/Medical Center),Academic,,,False,,27584
2013,70348,"07-0017-C, 31645, NCT00480935, Sutent_Trial_(KC)_01, TrialTroveID-070348","A Phase II, Single Arm, Prospective Study of Neoadjuvant Sutent for Patients With Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Pfizer, University Health Network, Toronto","Industry, Top 20 Pharma, Academic","Overall response rate, Response rate","Gene expression profiling, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00480935,27584
2014,69810,"07-054, MSKCC-07054, NCT00474994, PFIZER-MSKCC-07054, TrialTroveID-069810","A Multicenter Phase II Study of Continuous Dosing of Sunitinib (Sutent, SU11248) in Non-GIST Sarcomas.",Oncology,Oncology: (N/A); Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Academic, Government, Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Complete response, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT00474994,27584
2015,69341,"GOIM 2607, TrialTroveID-069341",Capecitabine plus Sunitinib Versus Sunitinib in Treatment of Metastatic Renal Carcinoma; A Randomized Study of Phase II.,Oncology,Oncology: Renal,Southern Italy Cooperative Oncology Group,Cooperative Group,"Complete response, Overall response rate, Partial response","FACIT-Fatigue, Quality of Life, Response evaluation criteria in solid tumors",False,,27584
2016,69159,"A6181068, A6181068/1027, NCT00471276, TrialTroveID-069159",A Phase II Study of Sunitinib Malate Single Agent For The Treatment of Women with Advanced Breast Cancer,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Appetite, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Likert scale, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT00471276,27584
2017,68637,"GOIM 2703, TrialTroveID-068637",A Randomized Phase II Study of Gemcitabine and Cisplatin plus or minus Sutent in the Treatment of Advanced Pancreatic Carcinoma.,Oncology,Oncology: Pancreas,Southern Italy Cooperative Oncology Group,Cooperative Group,,,False,,27584
2018,68446,"07-C-0134, NCI-07-C-0134, NCT00482911, TrialTroveID-068446","A Phase II Study of Combination Oral CC-5013 Lenalidomide (Revlimid), Oral Sunitinib (Sutent) and Low Dose Oral Metronomic Cyclophosphamide for the Treatment of Stage IV Ocular Melanoma.",Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, National Institutes of Health","Government, Government","Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",Progression-free survival,True,NCT00482911,27584
2019,68319,"CAN-NCIC-MA29, MA. 29, MA29, NCT00482755, PFIZER-CAN-NCIC-MA29, TrialTroveID-068319",A Feasibility Study of Pre-Operative Sunitinib (SU11248) With Multiple Pharmacodynamic Endpoints in Patients With T1c-T3 Operable Carcinoma of the Breast.,Oncology,Oncology: Breast,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Pfizer","Cooperative Group, Industry, Top 20 Pharma",,"Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00482755,27584
2020,68226,TrialTroveID-068226,A phase I mass-balance study to evaluate the metabolism and excretion of [14C]-sunitinib (SU11248) in healthy male subjects.,Oncology,Oncology: Unspecified Cancer,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
2021,68197,"2006-0437, NCT00465179, TrialTroveID-068197",Phase II Trial of Sunitinib Malate (Sutent) Therapy in Patients With Advanced Non-Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Opioid-related death, Overall survival, Safety and Tolerability",True,NCT00465179,27584
2022,67979,"06-0906, GCO # 06-0906, GCO 06-0906, MSH 06-0906, NCT00463060, TrialTroveID-067979",Phase I/II Study of Stereotactic Radiation Therapy and Concurrent and Adjuvant Sutent (SU11248) as Treatment for Oligometastatic Disease,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Pfizer, Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine}","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival",Quality of Life,True,NCT00463060,27584
2023,67968,"07U.68, TrialTroveID-067968",An open-label uncontrolled single institution pilot study using sunitinib malate as therapy in patients with stage IV uveal melanoma.,Oncology,Oncology: Melanoma,"Pfizer, Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA","Industry, Top 20 Pharma, Academic",Safety and Tolerability,"Disease Progression - duration, Overall survival, Progression-free survival",False,,27584
2024,67917,"07-009, MSKCC-07009, NCT00462982, TrialTroveID-067917",A Phase II Study of SU11248 (Sunitinib) in Patients With Renal Cell Carcinoma and Melanoma Metastatic to the Brain.,Oncology,Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government","Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Response rate",Progression-free survival,True,NCT00462982,27584
2025,67903,"7731, CASE3206, NCT00462553, TrialTroveID-067903",A Phase I Study of Sunitinib Malate and Standard Infusion Gemcitabine in Solid Tumors,Oncology,Oncology: Breast; Oncology: Liver; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid,"(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, National Institutes of Health","Academic, Government, Government","Disease Progression, Maximum tolerated dose","Disease Progression, Overall response rate, Overall survival, Response rate",True,NCT00462553,27584
2026,67761,"CASE17806, CASE-17806, CASE-17806-CC209, NCT00459979, TrialTroveID-067761",A Phase II Study of Sunitinib Malate in Patients With Renal Cell Carcinoma and Unresectable Primary Tumors.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Case Western Reserve University","Government, Academic",,"Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00459979,27584
2027,67739,"07-019, MSKCC-07019, NCT00459875, TrialTroveID-067739",Phase II Study of Sunitinib in Patients With Metastatic Papillary Renal Cell Carcinoma.,Oncology,Oncology: Renal,Memorial Sloan-Kettering Cancer Center,Academic,"Complete response, Overall response rate, Partial response","Duration of overall response, Safety and Tolerability",True,NCT00459875,27584
2028,67555,"A6181115, NCT00460798, SUNIKA, TrialTroveID-067555",SUNIKA - A Non-Interventional Study With SUTENT In The First Line Treatment Of Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Appetite, Complete response, EORTC Quality of Life Questionnaire, Global health status, Nausea, Overall response rate, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease, Time to progression, Vomiting",Adverse Events,True,NCT00460798,27584
2029,67200,"A6181087, CER-0708-008, EudraCT Number: 2007-001915-52, LUN033, NCRN017, NCT00457392, NL17998.068.07, SUN1087, TrialTroveID-067200, UKCRN ID:3354","A Multicenter, Randomized, Double-Blind, Controlled Phase III, Efficacy And Safety Study Of Sunitinib (SU011248) In Patients With Advanced/Metastatic Non-Small Cell Lung Cancer Treated With Erlotinib",Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Complete response, Disease Progression, Duration of overall response, EQ-5D, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00457392,27584
2030,67190,"A6181122, CTRI/2011/091/000025, EudraCT Number: 2007-000325-21, NCT00457691, PROVCTRI/2008/091/000025, SUN 1122, TrialTroveID-067190, VGHKS96-CT2-40","A Multicenter, Randomised, Double-Blind, Phase III Study of Sunitinib in Metastatic Colorectal Cancer Patients Receiving Irinotecan, 5-Fluorouracil And Leucovorin (FOLFIRI) as First Line Treatment",Oncology,Oncology: Colorectal,Pfizer,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Appetite, Complete response, Disease Progression, Duration of overall response, EQ-5D, Gastrointestinal symptoms, MD Anderson Symptom Inventory, Nausea, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Somnolence, Visual Analog Scale, Vomiting",True,NCT00457691,27584
2031,66802,"2008CG076, 30504, CALGB 30504, CALGB 30504 (Alliance), CALGB 30504-05, CALGB-30504, DUKE-00014547, MSKCC-07-106, NCI-2009-00465, NCT00453154, RPCI-106107, TrialTroveID-066802",Combination Chemotherapy With or Without Maintenance Sunitinib Malate (IND 74019; NSC 736511) For Untreated Extensive Stage Small Cell Lung Cancer: A Phase IB/Randomized Phase II Study,Oncology,"Oncology: Lung, Small Cell","National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Dose-limiting toxicities, Maximum tolerated dose, Neutropenia, Progression-free survival","Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00453154,27584
2032,66555,"00009042, 2006-0951, A6181078, CO04X02, EudraCT Number: 2005-005335-94, MREC 05/MRE03/8, N0258166354, NCT00443534, TrialTroveID-066555, UMCC 2003.080",A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol.,Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Cancer",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Serious Adverse Events","Adverse Events, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Time to progression",True,NCT00443534,27584
2033,66496,"7718, NCT00451048, PHL-063, PMH-PHL-063, TrialTroveID-066496",A Phase II Study of Sunitinib Malate (Sutent; SU11248) in Patients With Intermediate-2 or High-Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia.,Oncology,Oncology: Myelodysplastic Syndrome,National Institutes of Health/National Cancer Institute,Government,"Complete response, Hematologic Improvement, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Time to progression",True,NCT00451048,27584
2034,66379,"A6181045, JapicCTI-070386, JapicCTI-R080030, NCT00457743, TrialTroveID-066379",A Phase I/II Study of Sunitinib Malate (SU011248) In The Treatment of Patients with Malignant Gastrointestinal Stromal Tumor (GIST) Previously Treated by Imatinib Mesylate.,Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Clinical benefit rate, Cmax, Dose-limiting toxicities, EQ-5D, FACIT-Fatigue, Maximum tolerated dose, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Time to treatment failure, Tmax","Clinical benefit rate, EQ-5D, FACIT-Fatigue, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Response rate, Time to progression, Time to response, Time to treatment failure",True,NCT00457743,27584
2035,65862,"A6181146, NCT00444795, TrialTroveID-065862",Post Marketing Surveillance Study To Observe Safety And Efficacy Of Sutent,Oncology,Oncology: GIST; Oncology: Neuroendocrine; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Serious Adverse Events","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00444795,27584
2036,64896,"06C.549, 2006-30, NCT00437372, TrialTroveID-064896","A Phase IB, Open-Label, Safety Study of the Combination of Sunitinib and Radiation for the Treatment of Patients With Cancer",Oncology,"Oncology: Bladder; Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Prostate; Oncology: Testicular","Pfizer, Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA","Industry, Top 20 Pharma, Academic","NCI-CTC scale, Safety and Tolerability",,True,NCT00437372,27584
2037,64592,"A6181099, AFSSAPS: A70003-31, BRE 120, EHMC Protocol # E-07-302, Eudract: 2006-004624-36, H07-100, IND # 62,382, McG 0709, NCT00435409, SUN 1099, TrialTroveID-064592","A Randomized, Phase lll Study of Sunitinib In Combination with Capecitabine Compared with Capecitabine In Patients with Previously Treated Breast Cancer",Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Appetite, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Hot flashes, Nausea, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vomiting",True,NCT00435409,27584
2038,64504,"07-007, 0C-04-3, AVF4057g, GCC 0708, HUM00012383, NCT00434356, SABRE-B, TrialTroveID-064504, UMCC 2007.038","A Multicenter, Phase II, Randomized, Controlled Trial Evaluating the Efficacy and Safety of Sunitinib in Combination With Bevacizumab and Paclitaxel in Previously Untreated Patients With Metastatic Breast Cancer",Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Pfizer","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Disease Progression,"Adverse Events, Serious Adverse Events",True,NCT00434356,27584
2039,64460,"AVF3996g, NCT00434226, SABRE-L, TrialTroveID-064460","A Randomized, Controlled, Open-Label, Multicenter, Phase II Study of the Safety and Efficacy of Sunitinib in Combination With Bevacizumab, Carboplatin, and Paclitaxel in Previously Untreated Patients With Advanced Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Roche/Genentech {Genentech}, Pfizer","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Disease Progression,"Adverse Events, Serious Adverse Events",True,NCT00434226,27584
2040,64275,"A6181114, DRKS00004013, EudraCT Number: 2006-006538-16, McG 0801, NCT00428220, NL17630.042.07, SUTENT Breast Extension, TrialTroveID-064275",An Open-Label Sunitinib Malate (SU011248) Continuation Protocol For Patients Who Have Completed A Prior Sunitinib Study And Are Judged By The Investigator To Have The Potential To Benefit From Sunitinib Treatment,Oncology,Oncology: Breast; Oncology: GIST; Oncology: Pancreas; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Treatment Emergent Adverse Events","Adverse Events, Duration of overall response, Overall response rate - duration, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT00428220,27584
2041,63974,"CRC 05160, NCT00430261, TrialTroveID-063974",Phase II Trial of Sunitinib in Bronchoalevolar Carcinoma or Never-Smokers With Any Lung Adenocarcinoma.,Oncology,"Oncology: Lung, Non-Small Cell","Pfizer, Swedish Cancer Institute","Industry, Top 20 Pharma, Academic",Progression-free survival,,True,NCT00430261,27584
2042,63396,"07-15, 4K-07-4, NCT00425386, OHSU-2683, OHSU-SOL-06051-LM, SOL-9-LM, TrialTroveID-063396",A Dose Escalation Phase l/II Study of Sunitinib Plus Erlotinib in Advanced Renal Carcinoma.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Pfizer, Astellas Pharma {OSI Pharmaceuticals}, OHSU Cancer Institute","Government, Industry, Top 20 Pharma, Industry, all other pharma, Academic","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response, Progression-free survival, Stable Disease","Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00425386,27584
2043,62919,"08061, EORTC 08061, EORTC E08061, EORTC-08061, EORTC-08061-LCG, EU-20910, EUDRACT-2006-002485-19, NCT00953459, NL21019.029.09, TrialTroveID-062919, UKCRN ID 7149","Phase II Study of Sunitinib (SU011248) in Patients With Small Cell Lung Cancer Who Are Either Chemo-naive (Extensive Disease) or Have a ""Sensitive"" Relapse",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",EORTC Lung Cancer Group,Cooperative Group,"Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00953459,27584
2044,62907,"EU-20750, EudraCT Number: 2007-003977-22, NCT00514228, SAKK 77/06, SAKK 77/06 and SASL 23, SASL 23, SWS-SAKK-77/06, TrialTroveID-062907",Continuous Sunitinib Treatment in Patients With Unresectable Hepatocellular Carcinoma A Multicenter Phase II Trial.,Oncology,Oncology: Liver,"Pfizer, Swiss Group for Clinical Cancer Research - SAKK, (Other government agency)","Industry, Top 20 Pharma, Cooperative Group, Government",Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00514228,27584
2045,62456,"2007016, A6181108, McG 0703, NCT00417885, TrialTroveID-062456",Phase I/II Open-Label Trial of Sutent (Sunitinib Malate) And Aromasin(Exemestane) in the First-Line Treatment of Hormone Receptor-Positive Metastatic Breast Cancer.,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Progression-free survival, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00417885,27584
2046,61559,"EudraCT Number: 2006-000476-33, GC-SU-2006, KKS 2005-015, NCT00411151, TrialTroveID-061559","An Open-Label, Multicenter Phase II Trial of Sunitinib for Patients with Chemo-Refractory Metastatic Gastric Cancer.",Oncology,Oncology: Esophageal; Oncology: Gastric,"Pfizer, University of Mainz","Industry, Top 20 Pharma, Academic","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT00411151,27584
2047,61146,"2006/29MAI/116, EudraCT: 2006-001780-30, GORTEC 2006-01, GORTEC 2006-01 SUTENT, IIR Study A6181004, NCT00408252, RECF0450, TrialTroveID-061146",A Phase II Study of SU011248 in Patients with Recurrent And/Or Metastatic Squamous Head And Neck Carcinoma.,Oncology,Oncology: Head/Neck,"(Other Cooperative Group), Pfizer, (Other Hospital/Academic/Medical Center)","Cooperative Group, Industry, Top 20 Pharma, Academic","Clinical benefit rate, Overall response rate, Response evaluation criteria in solid tumors","Disease Progression, Gene expression profiling, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00408252,27584
2048,60310,"0510000723, HIC 0510000723, NCT00402415, TrialTroveID-060310",A Phase I Trial of the Combination of Sirolimus and SU11248 (Sutent) in Patients With Advanced Solid Tumors That Are Non-Curable With Standard Therapy.,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Pfizer, Yale University","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,Response evaluation criteria in solid tumors,True,NCT00402415,27584
2049,60027,"105022, GA618075, MCC-14902, NCT00400569, TrialTroveID-060027",Phase II Open-Label Study of Sunitinib Malate (SU011248) in Adult Patients with Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma.,Oncology,Oncology: Soft Tissue Sarcoma,"Pfizer, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT00400569,27584
2050,59976,"06-0407-C, ASSET, NCT00400114, TrialTroveID-059976","Adjuvant Sutent Following Chemotherapy, Radiation and Surgery For Esophageal Cancer, A Phase II Trial (ASSET)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Pfizer, University Health Network, Toronto","Industry, Top 20 Pharma, Academic","Overall survival, Time to progression, Time to treatment failure","Time to progression, Time to treatment failure",True,NCT00400114,27584
2051,59848,"N0683, NCCTG-N0683, NCI-2012-01830, NCT00398112, TrialTroveID-059848",A Phase II Study of Sunitinib Malate for Treatment of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL),Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Duration of overall response, Hemoglobin level, Overall response rate, Overall survival, Partial response, Response rate, Time to progression","Complete response, Duration of overall response, Progression-free survival",True,NCT00398112,27584
2052,59777,"07-015, 07-037, CALGB 80603, CALGB-80603, IRB- 090 - 07, NCT00397787, TrialTroveID-059777","A Phase II Study of Sunitinib Malate (SU11248, NSC #736511, IND #74,019) in Patients With Previously Treated Pancreatic Adenocarcinoma With Measurable Metastatic Disease Following Progression on Front-Line Gemcitabine-Based Therapy",Oncology,Oncology: Pancreas,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute, Pfizer","Cooperative Group, Government, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00397787,27584
2053,59616,"06-081, MSKCC-06081, NCT00397488, TrialTroveID-059616",Phase II Study of Sunitinib in Metastatic Transitional Cell Carcinoma of the Urothelium,Oncology,Oncology: Bladder; Oncology: Renal,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Disease Progression, Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Plasma concentration, Safety and Tolerability, Time to progression",True,NCT00397488,27584
2054,58767,"A6181064, A6181064 2006-004693-27, CER-0607-045, EudraCT Number: 2006-004693-27, NCT00393939, RECF0529, SUN 1064, SUN1064, TrialTroveID-058767",A Randomized Phase III Study of Docetaxel In Combination With Sunitinib Versus Docetaxel In The First-Line Treatment Of Advanced Breast Cancer Patients,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma",Progression-free survival,"Appetite, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Nausea, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Visual Analog Scale, Vomiting",True,NCT00393939,27584
2055,58684,"CAN-NCIC-IND.183, CAN-NCIC-IND183, I183, IND 183, IND.183, IND183, NCIC IND.183, NCIC-183, NCT00392444, TrialTroveID-058684",A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients with Advanced Malignant Pleural Mesothelioma.,Oncology,Oncology: Mesothelioma,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",,True,NCT00392444,27584
2056,58655,TrialTroveID-058655,Pharmacokinetics of Sunitinib Malate (Su11248) in patients with Hepatic Impairment.,Oncology,Oncology: GIST; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
2057,58097,"14718B, 22752, H-22935, HUM00003485, NCT00393796, NCT01225848, TrialTroveID-058097, UMCC 2005.145, UPCC 14809",Randomized Blinded Phase II Trial of Maintenance SU011248 Versus Placebo Post Chemotherapy Patients With Advanced Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,"Pfizer, University of Michigan Comprehensive Cancer Center, Abramson Cancer Center at  University of Pennsylvania Medical Center","Industry, Top 20 Pharma, Academic, Academic",Stable Disease,"Disease Progression, Overall response rate, Safety and Tolerability, Stable Disease",True,NCT00393796,27584
2058,58043,"06-286, 07-C-0220, 11-C-0002, 2007CG010, AAAC2898, ADVL0612, COG-ADVL0612, EudraCT: 2012-000690-23, HUM00009268, NCI-07-C-0220, NCI-07-C-0220, NCT00387920, OHSU 3361, SOL-07008, SOL-07008-C, TrialTroveID-058043","A Phase I Study of Sunitinib (SU11248), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Children With Refractory Solid Tumors.",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Pfizer, Childrenâs Oncology Group","Government, Industry, Top 20 Pharma, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose",Magnetic Resonance Imaging,True,NCT00387920,27584
2059,57037,"06-03-129, 39451, NCT00790595, Pfizer2005-0958, TrialTroveID-057037","Phase I, Open Label, Single Center, Multiple Dose, Dose Escalation Clinical Study of SU011248 in Subjects With High Risk Prostate Cancer Who Have Elected to Undergo Radical Prostatectomy.",Oncology,Oncology: Prostate,"Pfizer, University of California Los Angeles","Industry, Top 20 Pharma, Academic",Safety and Tolerability,PSA progression,True,NCT00790595,27584
2060,56890,"231-C, GOG 0231-C, GOG 231C, GOG-0231C, MSKCC 07-005, NCT00378911, TrialTroveID-056890","A Phase II Evaluation of Sunitinib Malate (Sutent, SU11248, NCI-Supplied Agent , NSC # 736511, IND #74019) in the Treatment of Recurrent or Persistent Leiomyosarcoma of the Uterus.",Oncology,Oncology: Soft Tissue Sarcoma,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival","Overall survival, Progression-free survival",True,NCT00378911,27584
2061,56440,"31489, A6181109, A6181109 2550, CTR20132932, DRKS00004000, EudraCT Number: 2006-004024-37, INT 53/07, NCI-2010-00311, NCT00375674, NMRR-08-1309-2550, PFIZER A6181109, RECF0560, STAR, S-TRAC, S-TRAC TRIAL, SUN 1109, TrialTroveID-056440",Sunitinib Treatment Of Renal Adjuvant Cancer (S-trac): A Randomized Double-blind Phase III Study Of Adjuvant Sunitinib Vs. Placebo In Subjects At High Risk Of Recurrent Rcc,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Disease-free survival, Recurrence","Adverse Events, Appetite, Common Terminology Criteria for Adverse Events, Disease-free survival, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Likert scale, Overall survival, Quality of Life, Safety and Tolerability, Treatment Emergent Adverse Events, Visual Analog Scale",True,NCT00375674,27584
2062,56143,"A3671025, A3671025-1002, CINJ 050610, IRB 0420060105, NCT00372853, TrialTroveID-056143","A Phase I Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00372853,27584
2063,56138,"A6181107, EudraCT No: 2006-001267-33, NCT00373113, PFIZER # A6181107, RECF0533, SUN 1107, TrialTroveID-056138","Phase III Randomized, Multi Center Study Of Sunitinib Malate (SU 011248) Or Capecitabine In Subjects With Advanced Breast Cancer Who Failed Both A Taxane And An Anthracycline Chemotherapy Regimen Or Failed With A Taxane And For Whom Further Anthracycline Therapy Is Not Indicated",Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma",Progression-free survival,"Clinical benefit rate, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Hot flashes, Overall response rate - time, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Time to response",True,NCT00373113,27584
2064,56120,"07-0116, 10172, A6181092, EudraCT: 2006-004451-38, MSKCC-07-010, NCT00372775, Pfizer # A6181092, RECF0801, TrialTroveID-056120",A Phase II Efficacy And Safety Study Of SU011248 In Patients With Non-Small Cell Lung Cancer And Brain Metastases,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate","Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to neurological progression, Time to progression",True,NCT00372775,27584
2065,56117,"A6181113, EudraCT Number: 2006-001151-35, NCT00372424, TrialTroveID-056117",An Explorative Study of The tolerability of SU011248 In Combination with Docetaxel and Trastuzumab as First-Line Treatment In Patients with Breast Cancer Over-Expressing HER-2,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Adverse Events, Cmax, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT00372424,27584
2066,56105,"07-153, A6181112, EudraCT Number: 2006-004309-24, MGH-07153, NCT00372567, OHSU001 /08-011, SUN 1112, TrialTroveID-056105","A Phase IIIb, Randomized, Active Controlled Open-Label Study Of Sunitinib (Sutent) 37.5 Mg Daily Vs Imatinib Mesylate 800 mg Daily In The Treatment Of Patients with Gastrointestinal Stromal Tumors (GIST) Who Have Had Progressive Disease While On 400 mg Daily Of Imatinib.",Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma",Progression-free survival,"Complete response, Duration of overall response, EQ-5D, Overall response rate - time, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Time to response, Time to treatment failure, Visual Analog Scale",True,NCT00372567,27584
2067,55130,TrialTroveID-055130,T regulatory cells (Treg) in patients with metastatic renal cell carcinoma (mRCC) decrease during sunitinib treatment: Correlations with clinical responses and T helper 1/T helper 2 (Th1/Th2) bias.,Oncology,Oncology: Renal,The Cleveland Clinic Foundation,Academic,,,False,,27584
2068,54394,"7738, GCC0658, LOI 7738, NCI-2009-00214, NCI-7738, NCT00387335, PHL-061, TrialTroveID-054394, UCCRC-14701A, UCIRB 14701A, UMCC 2006.081",Phase II Study of Sunitinib Malate in Head and Neck Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,"National Institutes of Health/National Cancer Institute, Pfizer","Government, Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival, Time to progression",True,NCT00387335,27584
2069,54388,"14696A, 2007-0526, 7735, B.06.023, B.06.023 (EFF), GCC0659, HUM00007665, LOI 7735, LOI 7735, NCI-2009-00213, NCI-7735, NCT00381641, TrialTroveID-054388, UC14696A, UCCRC-14696A, UCCRC-NCI-7735, UCIRB 14696A, UMCC 2006.080, UOC 14696A","Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancer",Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT00381641,27584
2070,53837,"7537, CASE5Y05, CASE-5Y05, CASE-5Y05-CC008, NCI-2009-00185, NCI-7537, NCT00357318, TrialTroveID-053837",A Phase I Study of Bevacizumab in Combination With SU11248,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, Pfizer, Case Western Reserve University","Government, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Disease Progression, Overall response rate, Overall survival, Time to progression",True,NCT00357318,27584
2071,53335,"CAN-NCIC-IND.182, CAN-NCIC-IND182, I182, IND182, NCI-2009-00692, NCIC-182, NCT00392496, TrialTroveID-053335","A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019), an Oral Multi-Targeted Tyrosine Kinase Inhibitor, in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma.",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Canadian Cancer Trials Group {NCIC Clinical Trials Group}, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Partial response, Response rate",Overall survival,True,NCT00392496,27584
2072,52995,"05439, 05-439, NCT00361244, TrialTroveID-052995",A Phase I/II Study of SU011248 (Sutent) in Combination With Irinotecan and Cetuximab as a Second Line Regimen for Patients With Stage IV Colorectal Cancer,Oncology,Oncology: Colorectal,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic","Maximum tolerated dose, Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival, Time to progression",True,NCT00361244,27584
2073,52862,"IUCRO-0115, TrialTroveID-052862",A pilot study of physiologic imaging in breast cancer patients treated with SU011248.,Oncology,Oncology: Breast,Indiana University Cancer Center,Academic,,,False,,27584
2074,51688,"A6181060, TrialTroveID-051688",A Phase I study of SU-011248 in combination with irinotecan in patients with advanced solid malignancies,Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell","Pfizer, Vrije Universiteit Medical Center, Amsterdam, Netherlands","Industry, Top 20 Pharma, Academic","Adverse Events, Maximum tolerated dose, Overall response rate, Response rate","Plasma pharmacokinetics, Safety and Tolerability, Safety and Tolerability",False,,27584
2075,51625,"A6181110, NCT00338884, TrialTroveID-051625",A Phase II Efficacy And Safety Study Of Sunitinib Malate (SU011248) Administered In A Continuous Daily Regimen In Patients With Advanced (First-Line) Renal Cell Cancer.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Duration of overall response, FACIT-Fatigue, Likert scale, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression",True,NCT00338884,27584
2076,51559,"1B-08-4, A6181094, A6181094-1113, EudraCT Number: 2007-002969-12, IRB 06-233, NCT00373256, SMMC 07-018, SOL-06102-P, SUN 1094, TrialTroveID-051559, UPMC 06-083, US Oncology 07-036, USON 07036",A Phase lll Study of SU011248 in Combination with Paclitaxel Versus Bevacizumab with Paclitaxel in the First-Line Advanced Disease Setting in Patients having Breast Cancer.,Oncology,Oncology: Breast,"Pfizer, US Oncology Research","Industry, Top 20 Pharma, Cooperative Group",Progression-free survival,"Appetite, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Hot flashes, Nausea, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Visual Analog Scale, Vomiting",True,NCT00373256,27584
2077,51149,TrialTroveID-051149,Sunitinib treatment of pediatric metastatic GIST after failure of imatinib.,Oncology,Oncology: GIST,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic","Overall response rate, Overall survival, Time to progression",,False,,27584
2078,50016,"2005-0903, NCI-2012-01364, NCT00329043, TrialTroveID-050016",A Phase II Neoadjuvant Trial of Sunitinib Malate (SU011248) Plus Hormonal Ablation for Patients Who Have High Risk Localized Prostate Cancer and Will Undergo Prostatectomy,Oncology,Oncology: Prostate,"MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Industry, Top 20 Pharma",Complete response,"PSA progression, Safety and Tolerability",True,NCT00329043,27584
2079,49315,"06-016, MSKCC-06-016, NCT00421512, TrialTroveID-049315",A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients.,Oncology,Oncology: Renal,"Roche/Genentech {Genentech}, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00421512,27584
2080,49248,"A6181005, TrialTroveID-049248",A Phase l Study to Evaluate the Effect of SU011248 on QTc Interval in Subjects with Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Pfizer,"Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,27584
2081,49181,"A6181048, NCT00599924, TrialTroveID-049181, VICCPHI0526","Phase I Study of SU011248 in Combination With Oxaliplatin, Leucovorin, and 5-Fluorouracil in Patients With Advanced Solid Malignancies.",Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Cmax, Cmin, Drug clearance, Elimination half-life, Magnetic Resonance Imaging, Overall response rate, Plasma concentration, Tmax",True,NCT00599924,27584
2082,48270,"20050170, 2005-0794, 20052072, MDACC-2005-0794, NCT00861419, TrialTroveID-048270","An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors.",Oncology,Oncology: Head/Neck; Oncology: Renal,"Amgen, Pfizer, Takeda","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00861419,27584
2083,47497,TrialTroveID-047497,A Phase I Study Evaluating Administration of Oral Su11248 (Sunitinib Malate) Using a Loading and Maintenance Dose on a 2/1 Schedule in Patients with Advanced Solid Tumors.,Oncology,Oncology: Thyroid; Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Pfizer","Government, Industry, Top 20 Pharma",Safety and Tolerability,,False,,27584
2084,47234,"CAN-NCIC-IND185, I185, IND 185, IND185, NCIC CTG IND 185, NCIC IND185, NCIC-185, NCT00388037, TrialTroveID-047234","A Phase II Study of Sunitinib (SU11248; NSC 736511; IND 74019) in Patients With Recurrent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","CA-125 Response, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",,True,NCT00388037,27584
2085,46320,"NCT00304200, TrialTroveID-046320","Temodar and Sutent as Therapy for Patients With Malignant Melanoma, a Phase I/II Study.",Oncology,Oncology: Melanoma,"Merck & Co. {Schering-Plough}, Pfizer, Northern California Melanoma Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival",True,NCT00304200,27584
2086,46099,"A6181100, EudraCT Number: 2006-000224-13, INT 06/17, NCT00291577, TrialTroveID-046099",Exploratory Evaluation of a Sequential Administration of Docetaxel and SU011248 In Women with Advanced Breast Cancer Evaluation,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Elimination half-life, Plasma concentration, Safety and Tolerability, Tmax","Complete response, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT00291577,27584
2087,45532,"05142, NCT00299741, TrialTroveID-045532, W81XWH-05-1-0439",A Phase II Study of SU011248 in Men With Advanced Prostate Cancer,Oncology,Oncology: Prostate,"Massachusetts General Hospital, US Department of Defense","Academic, Government","Disease Progression, Overall response rate, PSA progression, Response rate","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00299741,27584
2088,44992,"04-385, A6181041, NCT00615446, TrialTroveID-044992",A Phase I Study Of SU011248 And Gemcitabine In Patients With Advanced Solid Tumors,Oncology,Oncology: Pancreas; Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",CA-125 Response,True,NCT00615446,27584
2089,44600,"2005-0476, CO 05507, CO05507, H-2007-0063, NCT00581789, TrialTroveID-044600, UWCC-CO5507",Phase I Study of Erlotinib and Sunitinib in Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Roche/Genentech {Genentech}, Pfizer, University of Wisconsin","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability","Overall response rate, Response rate",True,NCT00581789,27584
2090,44332,"A6181049, EudraCT Number: 2005-000526-23, N0258171428, TrialTroveID-044332","A Phase I Study of SU011248 in Combination with FOLFIRI (Irinotecan, 5-FU and Leucovorin) in Patients with Metastatic Colorectal Cancer.",Oncology,Oncology: Colorectal,Pfizer,"Industry, Top 20 Pharma","Maximum tolerated dose, Overall response rate, Safety and Tolerability, Safety and Tolerability",Plasma pharmacokinetics,False,,27584
2091,44311,"2006-0414, 2980, A6181050, CO05905, NCT00511849, TrialTroveID-044311, Z-2761",Phase I Study of SU011248 In Combination with Paclitaxel/Carboplatin in Patients with Advanced Solid Malignancies.,Oncology,"Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability",Plasma pharmacokinetics,True,NCT00511849,27584
2092,43126,"04004, 04-07-02-07, 1030, 2004EX003, 2761, A6181030, Colombia IRB 192, EudraCT Number: 2004-001093-11, NCT00798889, Pharm 0518P, RTKC-0511-017, RTKC-05-11-017, TrialTroveID-043126, VICCPHI0515",A Treatment Protocol For Patients Continuing From A Prior SU011248 Protocol,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Renal",Pfizer,"Industry, Top 20 Pharma",Overall response rate,"Overall survival, Progression-free survival, Time to progression",True,NCT00798889,27584
2093,41828,"EudraCT 2005-004587-23, NCT00270413, SUCON, TrialTroveID-041828, UZL/MBC SUBE0501",A Belgian Multicenter Phase II Randomized Trial in her2 Negative Metastatic Breast Cancer Evaluating Consolidation Antiangiogenic Therapy With SU11248 After Response to Taxane Chemotherapy Induction,Oncology,Oncology: Breast,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Safety and Tolerability, Safety and Tolerability",True,NCT00270413,27584
2094,41513,"05049, A6181065, A6181065-1025, CO05810, MSKCC 05-124, NCT00267748, PPFIZER017, PPFIZER017/05-049, Renal EFFECT, SUN 1065, TrialTroveID-041513",A Randomized Phase I/II Study of the Efficacy and Safety of Sunitinib Malate Schedule 4/2 vs. Sunitinib Malate Continuous Dosing as First-Line Therapy for Metastatic Renal Cell Cancer (Renal EFFECT Trial).,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Time to progression,"Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Hemoglobin level, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00267748,27584
2095,41072,"2005-0796, A6181058, EudraCT Number: 2005-006022-29, NCT00265317, SUN 1058, TrialTroveID-041072, UAB 0557","Randomized, Double-Blind, Phase II Study Of Erlotinib With Or Without SU011248 In The Treatment Of Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Safety and Tolerability, Safety and Tolerability","Ability to swallow, Absolute Neutrophil Count, Appetite, Area under the curve score, Cmax, Complete response, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, EORTC Quality of Life Questionnaire, Global health status, Hemoglobin level, Nausea, Neuropathy, Neutropenia, Overall response rate, Overall survival, Partial response, Plasma concentration, Plasma pharmacokinetics, Platelet count, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Tmax, Vomiting",True,NCT00265317,27584
2096,41057,"12848, 97243, ASSURE, CALGB-E2805, CAN-NCIC-E2805, CTSU E2805, CTSU/E2805, E2805, ECOG 2805, ECOG-ACRIN 2805, ECOG-ACRIN E2805, ECOGE2805, ECOG-E2805, ECOGUROE2805, HCI 19793, NCI-2009-00534, NCT00326898, REC2, SU-07232007-560, SWOG-E2805, TrialTroveID-041057",ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma,Oncology,Oncology: Renal,"Cancer and Leukemia Group B (CALGB), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Southwest Oncology Group, National Institutes of Health/National Cancer Institute, Pfizer, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group","Cooperative Group, Cooperative Group, Cooperative Group, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Disease-free survival, FACIT-Fatigue, Overall survival, Recurrence","Common Terminology Criteria for Adverse Events, Congestive heart failure, Disease-free survival, FACIT-Fatigue, Overall survival, Patient-Reported Outcomes Measurement Information System, Quality of Life, Recurrence, Safety and Tolerability",True,NCT00326898,27584
2097,40639,TrialTroveID-040639,Tumor Perfusion as Assessed by (Oxygen-15)-Water PET Imaging during Treatment with Sunitinib Malate (SU11248) in Patients with Advanced Malignancies.,Oncology,"Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Renal",Pfizer,"Industry, Top 20 Pharma",,,False,,27584
2098,40550,TrialTroveID-040550,"Food Effect on he Pharmacokinetics of Sunitinib Malate (SU11248), a Multi-targeted Receptor Tyrosine Kinase Inhibitor, in Healthy Subjects.",Oncology,Oncology: (N/A); Oncology: Unspecified Solid Tumor,Pfizer,"Industry, Top 20 Pharma",Bioavailability,,False,,27584
2099,39637,"A6181072, JapicCTI-060206, NCT00254540, TrialTroveID-039637",Phase II Study of Single-Agent SU011248 In The Treatment of Patients with Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - time, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to response, Visual Analog Scale",True,NCT00254540,27584
2100,38603,"05348, 05-348, NCT00361309, TrialTroveID-038603",A Phase II Study of SU011248 in Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"Pfizer, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, Brigham and Womens Hospital","Industry, Top 20 Pharma, Academic, Academic, Academic, Academic",Progression-free survival,"Adverse Events, Duration of overall response, Overall response rate, Overall survival, Response rate",True,NCT00361309,27584
2101,38583,TrialTroveID-038583,"Phase I trial of SU011248, a novel tyrosine kinase inhibitor in advanced solid tumors.",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid","Pfizer {Pharmacia}, Pfizer {Sugen}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,27584
2102,38408,"A6181077, EudraCT Number: 2005-003774-15, H07-046, HCI 20851, IEO S281/605, IUCC-0511-01, MDBCCC-05-31, NCT00246571, RECF0541, SUN 1077, TrialTroveID-038408, UPMC 05-114","A Randomized Phase ll Study of SU011248 versus Standard-of-Care for Patients with Previously Treated, Advanced, Triple Receptor Negative (ER, PR, HER2) Breast Cancer",Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Appetite, Circulating Tumor Cells, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Hot flashes, Nausea, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Vomiting",True,NCT00246571,27584
2103,38136,"A6181067, EudraCT No: 2005-003773-25, NCT00243503, Pfizer A6181067, RECF0539, TrialTroveID-038136",A Phase II Efficacy And Safety Study Of SU011248 In Combination With Trastuzumab As Treatment For Metastatic Disease In Patients With Breast Cancer.,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, EORTC Quality of Life Questionnaire, Hot flashes, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00243503,27584
2104,36900,"A6181054, EudraCT Number: 2005-000524-16, GAT005, JapicCTI-060303, JapicCTI-R130314, NCT00226811, TrialTroveID-036900",An Open Label International Multi-Center Phase II Activity And Safety Study Of SU011248 In Patients With Advanced / Metastatic Gastric Cancer Progressing Or Recurring After One Prior Chemotherapy.,Oncology,Oncology: Esophageal; Oncology: Gastric,Pfizer,"Industry, Top 20 Pharma","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00226811,27584
2105,34792,"0509-13, A6181073, NCT00174434, TrialTroveID-034792",A Phase I Study of Paclitaxel In Combination with SU011248 For Patients with Breast Cancer As First-Line Treatment In the Advanced Disease Setting.,Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,"Plasma pharmacokinetics, Progression-free survival",True,NCT00174434,27584
2106,33121,"A6181047, A618-1047, EudraCT Number: 2005-001303-19, NCT00137449, TrialTroveID-033121",A Phase II Efficacy and Safety Study of SU011248 Administered in a Continuous Daily Regimen in Patients with Advanced Gastrointestinal Stromal Tumor.,Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma","Clinical benefit rate, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression - duration, EQ-5D, FACIT-Fatigue, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Visual Analog Scale",True,NCT00137449,27584
2107,33120,"07078, 2005-0297, A6181043, GU 29, MISC 26, NCT00137436, TrialTroveID-033120",A Phase I/II Safety And Pharmacokinetic Study Of SU011248 In Combination With Docetaxel (Taxotere) And Prednisone In Patients With Metastatic Hormone Refractory Prostate Cancer (HRPC).,Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Overall response rate, PSA progression, Response rate, Safety and Tolerability, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Overall response rate, PSA progression, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00137436,27584
2108,33117,"A6181061, A618-1061, EudraCT Number: 2005-001270-27, NCT00137423, TrialTroveID-033117",A Phase ll Efficacy And Safety Study of SU011248 Administered In A Continuous Daily Regimen In Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma",Overall response rate,"Adverse Events, EQ-5D, FACIT-Fatigue, Overall response rate - duration, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression, Visual Analog Scale",True,NCT00137423,27584
2109,32453,"05-090, 2005EX005, A6181037, A6181037 2541, EudraCT Number: 2005-002097-30, GUT11248, HCI 14159, HKUCTR-193, MCC#14615, MREC-05/MRE06/56, N0258171439, N0678168340, NCT00130897, NMRR-08-1264-2541, Pfizer A6181037, TrialTroveID-032453",A SU011248 Expanded Access Protocol For Systemic Therapy Of Patients With Metastatic Renal Cell Carcinoma Who Are Ineligible For Participation In Other SU011248 Protocols But May Derive Benefit From Treatment With SU011248,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00130897,27584
2110,30213,"3604P, A6181044, NCT00618124, TrialTroveID-030213, UNM-3604P",A Phase 1 Safety And Pharmacokinetic Study Of SU011248 And Capecitabine In Patients With Advanced Solid Tumors.,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid,Pfizer,"Industry, Top 20 Pharma","Disease Progression, Maximum tolerated dose",Disease Progression,True,NCT00618124,27584
2111,29696,"04-108, 05032, A6181038, NCT00113529, PPFIZER014, PPFIZER014/05-032, TrialTroveID-029696",A Phase I/II Safety And Pharmacokinetic Study Of SU011248 In Combination With Gefitinib (Iressa) In Patients With Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Complete response, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Time to progression, Time to response",True,NCT00113529,27584
2112,29695,"A6181057, IRB# 21248, NCT00113516, TrialTroveID-029695",Phase II Study Of SU011248 as Consolidation Therapy in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma","Overall response rate, Overall survival, Safety and Tolerability","Appetite, Chest discomfort, Complete response, Concentration at steady state, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Nausea, Neuropathy, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Vomiting",True,NCT00113516,27584
2113,29443,TrialTroveID-029443,Effect of rifampin on the pharmacokinetics of SU11248 in healthy volunteers.,Oncology,Oncology: Unspecified Cancer,Pfizer,"Industry, Top 20 Pharma",,,False,,27584
2114,23103,TrialTroveID-023103,An Innovative Phase I Clinical Study Demonstrates Inhibition of FLT3 Phosphorylation by SU11248 in Acute Myeloid Leukemia Patients,Oncology,"Oncology: Leukemia, Acute Myelogenous","Pfizer {Pharmacia}, Pfizer {Sugen}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,Safety and Tolerability,False,,27584
2115,23000,TrialTroveID-023000,A phase 1 study of SU11248 in the treatment of patients with refractory or resistant acute myeloid leukemia (AML) or not amenable to conventional therapy for the disease.,Oncology,"Oncology: Leukemia, Acute Myelogenous","Pfizer {Pharmacia}, Pfizer {Sugen}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,27584
2116,21371,"A6181035, CO04901, NCT00712504, PA-7075, TrialTroveID-021371, UAB 0484, VICC PHI 0436",A Phase I Safety and Pharmacokinetic Study of SU011248 in Combination with Docetaxel in Patients with Advanced Solid Tumors,Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Renal",Pfizer,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Response evaluation criteria in solid tumors",True,NCT00712504,27584
2117,20615,"2004EX001, 2837, A6181036, A6181199, CRO-06-2005, EudraCT Number: 2004-001860-27, HKUCTR-195, N0258156416, NCT00094029, NCT01459757, Pfizer A6181036, TrialTroveID-020615",A Treatment Protocol For Patients With Gastrointestinal Stromal Tumor Who Are Ineligible For Participation In Other SU011248 Protocols And Are Refractory To Or Intolerant Of Imatinib Mesylate,Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,"Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00094029,27584
2118,14934,"A6181040, EudraCT Number: 2004-001467-22, J0493, NCT00092001, TrialTroveID-014934, UPCI-04-138",A Phase II Efficacy And Safety Study Of SU011248 In Patients With Metastatic Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma",Overall response rate,"Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00092001,27584
2119,13258,"A6181039, COH 04100, DUMC 05079, NCT00089648, TrialTroveID-013258, UCSF 04522, VICCURO0468",Phase ll Study of SU011248 in the Treatment of Patients with Bevacizumab-Refractory Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Cmin, Duration of overall response, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00089648,27584
2120,9978,"RTKC-0511-013, TrialTroveID-009978","A Phase I/II Study of SU011248 in the Treatment of Patients with Malignant Gastrointestinal Stromal Tumor (GIST) who Are Intolerant of, or with Disease Progressing on, Imatinib Mesylate (Gleevec).",Oncology,Oncology: GIST,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,Plasma concentration,False,,27584
2121,9630,"04/MRE06/51, 245-04, A6181034, EudraCT Number: 2004-001149-14, F0427, HCI 12824 Pfizer / A6181034, HIC 27061, MSKCC-04077, N0258156375, NCT00083889, NCT00098657, Pfizer A6181034, TrialTroveID-009630, UCLA-0406015-01, UNM 245-04","A Phase III, Randomized Study of SU011248 versus Interferon-alfa as First-Line Systemic Therapy for Patients with Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","EQ-5D, Functional Assessment of Cancer Therapy-General, Progression-free survival, Visual Analog Scale","Cost effectiveness, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-General, Overall response rate, Overall survival, Plasma concentration, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression, Visual Analog Scale",True,NCT00083889,27584
2122,9192,"A6181018-1001, NCT00054886, PPHARMA015, RTKC-0511-014, TrialTroveID-009192",Phase II Study Of Single-Agent SU011248 In The Second-Line Treatment Of Patients With Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall response rate - time, Overall response rate, Overall survival, Plasma concentration, Safety and Tolerability, Time to response, Time to treatment failure",True,NCT00054886,27584
2123,8543,"04063, A6181006, DUMC-04063, MSKCC-04001, NCT00077974, NCT00082849, PFIZER-A6181006, PPFIZER007, TrialTroveID-008543",A Pivotal Study Of SU011248 In The Treatment Of Patients With Cytokine-Refractory Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00077974,27584
2124,7134,"0310-28, A6181002, A6181002P, NCT00078000, NCT00095615, PFIZER-A6181002, PFIZER-PHA-RTKC-0511, TrialTroveID-007134, UCLA-0402087-01, UCSF-037514",Phase II Study Of The Efficacy And Safety Of SU011248 In Patients With Anthracycline- And Taxane-Refractory Or Intolerant Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall survival, Plasma concentration, Safety and Tolerability",True,NCT00078000,27584
2125,7129,"A6181003, MSKCC-03143, NCT00077987, NCT00082771, PFIZER-A6181003, PFIZER-PHA-RTKC-0511, TrialTroveID-007129, USC-3C-03-18","A Phase II Study Of SU011248 In Patients With Metastatic Colorectal Cancer Who Have Previously Failed Treatment With Irinotecan, Oxaliplatin, And Fluoropyrimidine, With And Without Bevacizumab.",Oncology,Oncology: Colorectal,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Safety and Tolerability, Time to progression",True,NCT00077987,27584
2126,5906,TrialTroveID-005906,A Phase I study of SU11248 in patients with malignant tumors refractory to conventional therapies,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Pfizer {Pharmacia}, Pfizer {Sugen}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,False,,27584
2127,5905,TrialTroveID-005905,Pharmacokinetic and pharmacodynamic evaluation of SU11248 in a Phase I clinical trial of patients with imatinib-resistant gastrointestinal stromal tumor (GIST),Oncology,Oncology: GIST,Pfizer {Pharmacia},"Industry, Top 20 Pharma",Progressive disease rate,,False,,27584
2128,5699,"A6181004, MREC/3/3/097, MSKCC-04028, N0258140975, NCT00075218, NCT00085618, PFIZER-A6181004, TrialTroveID-005699, UCLA-0311021-01","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study Of SU011248 In The Treatment Of Patients With Imatinib Mesylate (Gleevec Tm, Glivec)-Resistant Or Intolerant Malignant Gastrointestinal Stromal Tumor.",Oncology,Oncology: GIST,"Jonsson Comprehensive Cancer Center, UCLA, Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Academic, Government, Industry, Top 20 Pharma","Response evaluation criteria in solid tumors, Time to progression","Duration of overall response, EQ-5D, McGill Pain Questionnaire, Overall response rate - time, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Time to response, Visual Analog Scale",True,NCT00075218,27584
2129,295045,"NCT03035006, TLC388A1008, TLCTLC388A1008, TrialTroveID-295045","A Phase I/II, Dose-escalation Study of Lipotecan Based Concurrent Chemoradiotherapy in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis",Oncology,Oncology: Liver,Taiwan Liposome Company,"Industry, all other pharma","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response-duration, Disease Progression, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT03035006,17077
2130,272896,"TLC388F1009, TrialTroveID-272896","A Phase I/II, Dose Escalation Trial, in Patients with Locally Advanced Rectal Cancer That Can be Surgically Resected, The Study uses LipotecanÂ® Combined with Capecitabine Concurrent Chemoradiation Therapy (CCRT) as a Preoperative Adjuvant Treatment",Oncology,Oncology: Colorectal,Taiwan Liposome Company,"Industry, all other pharma","Complete response, Maximum tolerated dose, Resection rate",Resection rate,False,,17077
2131,258967,"NCT02457273, T1Z14, TCOGT1Z14, TrialTroveID-258967","An Open-Label, Single-Arm, Two-Stage, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Poorly Differentiated Neuroendocrine Carcinomas",Oncology,Oncology: Neuroendocrine,"Taipei Veterans General Hospital, (Other Hospital/Academic/Medical Center), Kaohsiung Medical University Hospital, National Health Research Institutes, Taiwan, National Taiwan University Hospital","Academic, Academic, Academic, Government, Academic",Overall response rate,"Adverse Events, Clinical benefit rate, NCI-CTC scale, Overall survival, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02457273,17077
2132,183486,"NCT01831973, TLC388.3, TrialTroveID-183486","An Open-Label, Single-Arm, Multi-center Phase II Study to Evaluate the Efficacy and Safety of TLC388 in  Patients With Advanced/Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,Taiwan Liposome Company,"Industry, all other pharma",,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01831973,17077
2133,183483,"CTR20150149, NCT02267213, TLC388.4, TrialTroveID-183483","An Open-Label, Single-Arm, Two-Stage, Multi-Centre Phase II Study to Evaluate the Efficacy and Safety of TLC388 as Second-line Treatment in Subjects With Advanced Hepatocellular Carcinoma.",Oncology,Oncology: Liver,"Alcami {AAIPharma Services Corp. / Cambridge Major Laboratories, Inc. {aaiPharma}}, Taiwan Liposome Company","Miscellaneous, Industry, all other pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response rate, Stable Disease","Adverse Events, Area under the curve score, Cmax, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Safety and Tolerability, Time to progression, Tmax, Vital signs",True,NCT02267213,17077
2134,152091,"NCT01425996, TLC388.2, TrialTroveID-152091","A Phase I/II, Dose-escalation Study of Lipotecan Plus Radiotherapy in Locally Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,Taiwan Liposome Company,"Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate","Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT01425996,17077
2135,92942,"DFCI ID: 08-197, NCT00747474, TLC388 HCI, TLC388-101, TrialTroveID-092942","A Phase I Open-Label, Sequential Dose Escalation Study Investigating the Safety, Tolerability, and Pharmacokinetics of Intravenous Lipotecan (TLC388 HCl for Injection) when Administered to Patients with Advanced Solid Tumors",Oncology,Oncology: Anal; Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Vaginal,Taiwan Liposome Company,"Industry, all other pharma","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Elimination half-life, Maximum tolerated dose, Plasma concentration, Tmax","Complete response, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00747474,17077
2136,327722,"18-521, 19-702, 20190524, 2020-0073, AAAS2224, ACNS1721, NCI-2018-01361, NCT03581292, TrialTroveID-327722","A Phase II Study of Veliparib (ABT-888) and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients With Newly Diagnosed High-Grade Glioma (HGG) Without H3 K27M or BRAFV600E Mutations",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",National Institutes of Health/National Cancer Institute,Government,"Event-free survival, Overall response rate","Overall response rate, Overall survival",True,NCT03581292,35813
2137,316708,"EudraCT Number: 2018-000313-20, M15-536, NCT03400306, TrialTroveID-316708","A Phase I, Single-Dose, Open-Label, Randomized Cross-Over Study Evaluating the Bioavailability and Food Effect of Veliparib Tablets Followed by an Extension in Subjects With Ovarian Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,AbbVie,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Elimination half-life, Elimination rate, Plasma concentration, Tmax",,True,NCT03400306,35813
2138,309663,"10147, 171/ NCI 10147, 9L-18-13, ETCTN10147, NCI 10147, NCI-2017-01715, NCT03289910, TrialTroveID-309663",A Phase II Randomized Study of Topotecan/Carboplatin With or Without Veliparib in Advanced Myeloproliferative Disorders and Chronic Myelomonocytic Leukemia (CMML),Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",National Institutes of Health/National Cancer Institute,Government,Complete response,"Common Terminology Criteria for Adverse Events, Disease-free survival, Minimal Residual Disease, Overall survival, Plasma concentration",True,NCT03289910,35813
2139,305855,"C-II-011, NCT03227016, TrialTroveID-305855",Phase I/II Study in Patients With Small Cell Lung Cancer (SCLC) of Veliparib in Combination With Topotecan,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,"Adverse Events, Dose-limiting toxicities",,True,NCT03227016,35813
2140,299919,"C16-468, NCT03123211, TrialTroveID-299919",Expanded Access to Veliparib,Oncology,Oncology: Breast,AbbVie,"Industry, Top 20 Pharma",,,True,NCT03123211,35813
2141,296406,"NCI-2016-02018, NCT03061188, NU 16MH03, NU 16MH03 23786, STU00204250, TrialTroveID-296406",Phase I/Ib Study of Nivolumab and Veliparib in Patients With Advanced Solid Tumors and Lymphoma With and Without Alterations in Selected DNA Repair Genes,Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor","Bristol-Myers Squibb, National Institutes of Health/National Cancer Institute, Northwestern University, AbbVie","Industry, Top 20 Pharma, Government, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03061188,35813
2142,295484,"201600942, NCT03044795, REPAIR, TrialTroveID-295484",Phase II Study With PARP Inhibitor Veliparib (ABT-888) in Patients With Increased Risk of Homologous Recombination Deficiency to Determine the Value of an (Ex-vivo) RAD51 Assay as a Biomarker,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Cancer","Dutch Cancer Society, Groningen University Hospital, AbbVie","Not for Profit Funding Entity, Academic, Industry, Top 20 Pharma",,,True,NCT03044795,35813
2143,294825,"CTMS#16-0133, NCT03032614, TrialTroveID-294825","Phase II Clinical Trial on the Combination of Carboplatin, Eribulin and Veliparib in Stage IV Cancer Patients With Homologous Recombination Deficiency",Oncology,Oncology: Breast; Oncology: Ovarian,University of Texas Health Science Center at San Antonio,Academic,"Adverse Events, NCI-CTC scale, Response evaluation criteria in solid tumors, Serious Adverse Events",,True,NCT03032614,35813
2144,291965,"9763, NCT02985658, RG1716061, TrialTroveID-291965",Expanded Access Protocol With ABT-888 (Veliparib) in Patients With Metastatic BRCA-Mutation Associated or Triple Negative Breast Cancer,Oncology,Oncology: Breast,"University of Washington, AbbVie","Academic, Industry, Top 20 Pharma",,,True,NCT02985658,35813
2145,289232,"EudraCT Number: 2016-001658-16, M15-534, NCI-2017-00503, NCT02944396, TrialTroveID-289232, TX151362","A Phase I Dose-Escalation and Phase II Randomized, Open-Label Study of Nivolumab and Veliparib in Combination With Platinum Doublet Chemotherapy in Subjects With Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",AbbVie,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Anti-drug antibodies, Area under the curve score, Cmax, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT02944396,35813
2146,284920,TrialTroveID-284920,A Phase I study of the PARP inhibitor Veliparib in Combination with Temozolomide in Acute Myeloid Leukemia.,Oncology,"Oncology: Leukemia, Acute Myelogenous","Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, The Cleveland Clinic Foundation, Mayo Clinic, (Other Hospital/Academic/Medical Center)","Academic, Academic, Academic, Academic",,,False,,35813
2147,283096,"EudraCT Number: 2016-000171-24, GCTSK004, NCT02860819, TrialTroveID-283096","Phase II Study of Gemcitabine, Carboplatin and VELIPARIB (ABT-888) in Refractory Testicular Germ Cell Cancer",Oncology,Oncology: Testicular,National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Favorable Response Rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression, Treatment Emergent Adverse Events",True,NCT02860819,35813
2148,282325,"NCI-2016-01044, NCT02831179, TrialTroveID-282325, VICC GI 14134",A Phase 1 Study of Veliparib (ABT-888) in Combination With Capecitabine and Temozolomide in Advanced Well-Differentiated Neuroendocrine Tumors,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, Vanderbilt-Ingram Cancer Center","Government, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Complete response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT02831179,35813
2149,279586,"16-2009, 18-730, CTSU/NRG-GI002, NCI-2016-00222, NCT02921256, NRG GI002, NRG-GI002, s17-00197, TrialTroveID-279586",A Phase II Clinical Trial Platform of Sensitization Utilizing Total Neoadjuvant Therapy (TNT) in Rectal Cancer,Oncology,Oncology: Colorectal,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Disease-free survival, Overall survival, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Treatment compliance",True,NCT02921256,35813
2150,275899,"160087, 16-C-0087, 17-016, 9771, NCI-2016-00355, NCT02723864, P141582, TrialTroveID-275899","Phase I Study of Veliparib (ABT-888), an Oral PARP Inhibitor, and VX-970, an ATR Inhibitor, in Combination With Cisplatin in Patients With Refractory Solid Tumors",Oncology,"Oncology: Breast; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Maximum tolerated dose, Safety and Tolerability","Dose-limiting toxicities, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT02723864,35813
2151,273116,"NCI R21-CA135572, NCI U01-CA062487, TrialTroveID-273116","Phase I safety, pharmacokinetic and pharmacodynamic study of the poly (ADP-ribose) polymerase inhibitor veliparib with irinotecan in patients with advanced tumors.",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,35813
2152,272879,"ACTRN12615000407594, COGNO 14/01, CTC 0131, NC111, TrialTroveID-272879, U1111-1167-6365, VERTU","A Randomised Phase II Study Of Veliparib and Radiotherapy With Adjuvant Temozolomide and Veliparib Versus Standard Radiotherapy and Temozolomide Followed By Temozolomide in Patients With Newly Diagnosed Glioblastoma with Unmethylated O (6)-methylguanine-DNA methyltransferase, , VEliparib, Radiotherapy and Temozolomide trial in Unmethylated MGMT Glioblastoma - VERTU",Oncology,"Oncology: CNS, Glioblastoma","(Other Cooperative Group), (Other Academic Cancer Center)","Cooperative Group, Academic","Overall survival, Progression-free survival","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Mini Mental State Examination, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression, Treatment compliance",False,,35813
2153,269901,"17-C-0012, 9914, NCI-2015-02125, NCT02631733, TrialTroveID-269901",A Phase I Study of a Combination of MM-398 and Veliparib in Solid Tumors,Oncology,Oncology: Ovarian; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02631733,35813
2154,260512,"M14-488, NCT02483104, TrialTroveID-260512",A Phase I Study of Veliparib in Combination With Carboplatin And Weekly Paclitaxel in Japanese Subjects With Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,AbbVie,"Industry, Top 20 Pharma",Dose-limiting toxicities,"Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Plasma concentration, Response evaluation criteria in solid tumors, Tmax",True,NCT02483104,35813
2155,259565,"15-004488, 15-1070, 15-18433, 201505502, 20150649, EudraCT Number: 2014-005070-11, GOG3005, GOG-3005, M13-694, M13-694/GOG 3005, NCI-2015-01623, NCT02470585, TrialTroveID-259565, VELIA, VELIA/GOG-3005","A Phase III Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Gynecologic Oncology Group (GOG), Australian and New Zealand Gynaecological Oncology Group, AbbVie","Cooperative Group, Cooperative Group, Industry, Top 20 Pharma","Disease Progression, Mortality, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT02470585,35813
2156,226146,"GOG0076HH, GOG-0076HH, NCI-2011-02661, NCT01281852, TrialTroveID-226146","A Limited Access Phase I Trial of Paclitaxel, Cisplatin and CTEP Supplied Agent ABT-888 (Veliparib) (NSC#737664) in the Treatment of Advanced, Persistent, or Recurrent Carcinoma of the Cervix",Oncology,Oncology: Cervical,"National Institutes of Health/National Cancer Institute, NRG Oncology","Government, Cooperative Group","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Safety and Tolerability","Overall survival, Progression-free survival",True,NCT01281852,35813
2157,226015,"GOG0127W, GOG-0127W, GOG-0127W_2010-12-14, NCI-2011-02659, NCT01266447, TrialTroveID-226015","A Phase II Evaluation of ABT-888 (NCI Supplied Agent: ABT-888, NSC #737664), Topotecan (NSC # 609699) and Filgrastim or Pegfilgrastim in the Treatment of Persistent or Recurrent Squamous or Non-squamous Cell Carcinoma of the Cervix",Oncology,Oncology: Cervical,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Nausea, Neutropenia, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Vomiting","Complete response, Disease Progression, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Serum estradiol level",True,NCT01266447,35813
2158,222063,"15/36, CT734, EudraCT Number: 2014-002866-65, IRAS ID: 161809, M14-217, NCT02305758, REec-2015-1323, TrialTroveID-222063","Randomized, Blinded, Multicenter, Phase ll Study Comparing Veliparib Plus FOLFIRI + or - Bevacizumab Versus Placebo Plus FOLFIRI + or - Bevacizumab in Previously Untreated Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,AbbVie,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02305758,35813
2159,220659,"00056953, 2014-0998, DRUG M14-361, E2511, EudraCT Number: 2014-001764-35, M14-361, NCI-2015-00490, NCT02289690, NL50299.042.14, RECF3356, TrialTroveID-220659",A Phase I Dose Escalation and Phase II Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naive Extensive Stage Disease Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",AbbVie,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT02289690,35813
2160,218882,"14.1010, 201408128, EudraCT Number: 2014-002565-30, IRAS ID 162696, M14-359, NCI-2014-02249, NCT02264990, NL50469.060.14, REec-2015-1330, STU 082014-070, TrialTroveID-218882, VELA","A Randomized, Open Label, Multicenter, Phase llI Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Investigators Choice of Standard Chemotherapy in Subjects Receiving First Cytotoxic Chemotherapy for Metastatic or Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) Who Are Current or Former Smokers.",Oncology,"Oncology: Lung, Non-Small Cell",AbbVie,"Industry, Top 20 Pharma",Overall survival,"Disease Progression, Duration of overall response, EQ-5D-5L, Mortality, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02264990,35813
2161,218464,"C15-050TRAVEL, EudraCT Number: 2014-003785-24, TrialTroveID-218464",Treatment of Pancreatic Adenocarcinoma With the Combination of Carboplatin and Veliparib,Oncology,Oncology: Pancreas,"(Other Hospital/Academic/Medical Center), AbbVie","Academic, Industry, Top 20 Pharma",Disease Progression,,False,,35813
2162,214238,"M14-489, NCT02210663, TrialTroveID-214238",A Phase I Study of Single Agent Veliparib in Japanese Subjects With Advanced Solid Tumors,Oncology,Oncology: Breast; Oncology: Ovarian,AbbVie,"Industry, Top 20 Pharma",Dose-limiting toxicities,"Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Plasma concentration, Response evaluation criteria in solid tumors, Tmax",True,NCT02210663,35813
2163,210637,"000504723, F131219003, F131219003 (UAB 1372), NCI-2014-02253, NCI-2015-00265, NCT02158507, TrialTroveID-210637, UAB1372","An Open Label, Pilot Study of Veliparib (ABT-888) and Lapatinib (Tykerb) in Patients With Metastatic, Triple Negative (ER, PR, and HER-2 Negative) Breast Cancer",Oncology,Oncology: Breast,"GlaxoSmithKline, (Other Cooperative Group), University of Alabama, Birmingham, AbbVie","Industry, Top 20 Pharma, Cooperative Group, Academic, Industry, Top 20 Pharma","Nausea, NCI-CTC scale, Neutropenia, Safety and Tolerability","Circulating Tumor Cells, Complete response, Disease Progression, Gene expression profiling, Overall response rate, Partial response, Plasma concentration, Progression-free survival",True,NCT02158507,35813
2164,210155,"20150030, A071102, A071102-CIRB, ALLIANCE A071102, ALLIANCEA071102-NO, CALGB-A071102, CBRT-15027, Clinical Trial 18308, CTSU/A071102, NCI-2014-00616, NCT02152982, STU 032015-081, TrialTroveID-210155",A Phase II/III Randomized Trial of Veliparib or Placebo in Combination With Adjuvant Temozolomide in Newly Diagnosed Glioblastoma With MGMT Promoter Hypermethylation,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, AbbVie, Alliance for Clinical Trials in Oncology","Government, Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Area under the curve score, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response rate, Time to progression, Treatment Emergent Adverse Events",True,NCT02152982,35813
2165,208552,"16-2008, 95172 (S1416), N 32716, NCI-2015-01912, NCT02595905, PCRC_S1416, S1416, S1416-CIRB, SWOG 1416, SWOG S1416, TrialTroveID-208552","Phase II Randomized Placebo-Controlled Trial of Cisplatin With or Without ABT-888 (Veliparib) in Metastatic Triple-Negative Breast Cancer and/or BRCA Mutation-Associated Breast Cancer, With or Without Brain Metastases",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT02595905,35813
2166,208474,"NCI-2015-02248, NCT02890355, S1513, SWOG S1513, TrialTroveID-208474",Randomized Phase II Study of 2nd Line FOLFIRI versus Modified FOLFIRI with PARP Inhibitor ABT-888 (Veliparib) (NSC-737664) in Metastatic Pancreatic Cancer,Oncology,Oncology: Pancreas,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Stable Disease",True,NCT02890355,35813
2167,206581,"14.0258, 14-ABV-1, Abbvie-089 Lung, EudraCT Number: 2013-005020-42, F14167, IRAS ID 150889, M11089, M11-089, NCI-2014-01448, NCRN - 2974, NCRN - 2974 VESTA, NCT02106546, NL47784.060.14, PSHCI-14-030, REec-2014-1041, S-20140059, STU 052014-074, TrialTroveID-206581, UKCRN ID: 16393, USO 13232, VESTA (M11-089)","Randomized, Double-Blind, Multicenter, Phase III Study Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Advanced or Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",AbbVie,"Industry, Top 20 Pharma",Overall survival,"Disease Progression, Duration of overall response, EQ-5D-5L, Mortality, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02106546,35813
2168,205254,TrialTroveID-205254,"A Clinical Study on Impact of Renal Impairment, CYP2D6 Deficiency, and OCT2 Inhibitor on Veliparib Pharmacokinetics",Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,35813
2169,204623,"OVM1307, TrialTroveID-204623","Phase II Randomized, Placebo-Controlled Trial of Veliparib and Standard Chemotherapy in Patients with Newly Diagnosed Advanced High Grade Serous Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer but without Identified Deleterious Germ Line BCA Gene Mutations",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,NRG Oncology,Cooperative Group,,,False,,35813
2170,200570,"EudraCT Number: 2013-003137-16, M14-144, NCT02033551, NL46475.042.13, TrialTroveID-200570",An Extension Study to Evaluate the Safety of Veliparib as Single Agent Therapy or in Combination With Chemotherapy in Subjects With Solid Tumors,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",AbbVie,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT02033551,35813
2171,200505,"041312, 1311863574, 1379GCC, 69027, AAAP5501, AbbVie M14-011, Abbvie M14-011 (BRIGHTNESS), BRIGHTNESS, CT665, EudraCT Number: 2013-002377-21, IRAS ID: 149700, M14-011, M14-011ABBVIE, MCC-17830, MP-20-2016-2404, NCI-2014-00367, NCT02032277, NL48946.029.14, NSABP B-56, NSABP-B-56-I, OSU-15152, RECF2384, REec-2014-1159, TrialTroveID-200505, USO 12152, UW14040","A Randomized, Placebo-Controlled, Double-Blind, Phase III Study Evaluating Safety and Efficacy of the Addition of Veliparib Plus Carboplatin Versus the Addition of Carboplatin to Standard Neoadjuvant Chemotherapy Versus Standard Neoadjuvant Chemotherapy in Subjects With Early Stage Triple Negative Breast Cancer (TNBC)",Oncology,Oncology: Breast,"(Other Cooperative Group), Grupo Espanol de investigacion del Cancer de Mama, National Surgical Adjuvant Breast and Bowel Project (NSABP), Austrian Breast & Colorectal Cancer Study Group, Spanish Breast Cancer Research Group, US Oncology Research, German Breast Group, AbbVie, Alliance for Clinical Trials in Oncology","Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Cooperative Group, Industry, Top 20 Pharma, Cooperative Group","Complete response, Safety and Tolerability","EORTC Quality of Life Questionnaire, Event-free survival, Neuropathy, Overall response rate, Overall survival, Quality of Life, Recurrence, Response rate",True,NCT02032277,35813
2172,199021,"EudraCT Number: 2013-002028-18, M12-020, NCT02009631, NL46329.042.13, TrialTroveID-199021","A Randomized, Placebo-Controlled Crossover Study to Evaluate the Effect of Veliparib (ABT-888) on Cardiac Repolarization in Subjects With Relapsed or Refractory Solid Tumors",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",AbbVie,"Industry, Top 20 Pharma",,"Adverse Events, Area under the curve score, Cmax, Heart rate, Plasma concentration, Tmax, Vital signs",True,NCT02009631,35813
2173,191048,"CSMC IIT VelGemRad, IIS-ABT888-0002, IIT2012-06-TULI-VELGEMRAD, NCT01908478, TrialTroveID-191048, VelGemRad","A Phase I Study of Veliparib (ABT-888) in Combination With Gemcitabine and Intensity Modulated Radiation Therapy in Patients With Locally Advanced, Unresectable Pancreatic Cancer",Oncology,Oncology: Pancreas,"Cedars-Sinai Medical Center, AbbVie","Academic, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01908478,35813
2174,186426,"051207, 20121952, M13-695, NCT01853306, TrialTroveID-186426","A Phase I Study to Evaluate the Safety, Pharmacokinetics and Oral Bioavailability of Veliparib Extended Release Formulations in Subjects With Solid Tumors",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian,AbbVie,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Bioavailability, Cmax, Elimination rate, Heart rate, Maximum tolerated dose, Safety and Tolerability, Tmax, Vital signs","Adverse Events, Safety and Tolerability",True,NCT01853306,35813
2175,184482,"130105, 13-C-0105, 9149, MPACT, M-PACT, NCI-13-C-0105, NCI-2013-01588, NCI-MPACT, NCT01827384, P121047, TrialTroveID-184482",Molecular Profiling-Based Assignment of Cancer Therapy for Patients with Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Progression-free survival, Response rate",Progression-free survival,True,NCT01827384,35813
2176,183877,"12G.376, 2012001, 2012-47, 2997, NCI-2013-00594, NCT01818063, TrialTroveID-183877","An Adaptive, Randomized Phase II Trial To Determine Pathologic Complete Response With The Addition Of Carboplatin With And Without Veliparib To Standard Chemotherapy In The Neoadjuvant Treatment Of Triple-Negative Breast Cancer",Oncology,Oncology: Breast,"Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}, Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA","Not for Profit Funding Entity, Academic",Complete response,"Circulating Tumor Cells, Complete response, Disease-free survival, Overall response rate, Partial response, Progressive disease rate, Stable Disease",True,NCT01818063,35813
2177,179215,"9182, J1326, MC1114, NCI-2012-02767, NCT01749397, TrialTroveID-179215","A Phase I Trial of the Combination of the PARP Inhibitor ABT-888 With Intraperitoneal Floxuridine (FUDR) in Epithelial Ovarian, Primary Peritoneal and Fallopian Tube Cancers",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Neutropenia, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression, Time to treatment failure",True,NCT01749397,35813
2178,176401,"A091101, CALGB A091101, NCI-2012-02009, NCT01711541, TrialTroveID-176401",Carboplatin-Paclitaxel Induction Chemotherapy and ABT-888 (Veliparib) - a Phase I/Randomized Phase II Study in Patients With Locoregionally Advanced Squamous Cell Carcinoma of the Head and Neck.,Oncology,Oncology: Head/Neck,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability","Disease-free survival, Overall survival, Progression-free survival",True,NCT01711541,35813
2179,174901,"EudraCT Number: 2012-001661-32, NCT01690598, TrialTroveID-174901, VeTo",Veliparib (ABT888) and Topotecan (Hycamtin) for Patients With Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer With Negative or Unknown BRCA Status,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AbbVie {Abbott}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","CA-125 Response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT01690598,35813
2180,172435,"13-051, 20120399, 2N-12-4, ABBT1512, ACTRN12612001245886, EudraCT Number: 2011-003618-18, M10-897, NCT01657799, PABBOTT009/12-035, STU 052012-050, TrialTroveID-172435, UPCC: 27312","A Randomized, Double-Blind, Phase II, Dose-Ranging Study to Evaluate the Safety and Efficacy of Veliparib and Whole Brain Radiation Therapy Versus Placebo and Whole Brain Radiation Therapy in Subjects With Brain Metastases From Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",AbbVie {Abbott},"Industry, Top 20 Pharma","Overall survival, Safety and Tolerability","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Quality of Life, Response rate, Safety and Tolerability, Stable Disease",True,NCT01657799,35813
2181,171478,"051206, 17105 ECOG-ACRIN E2511, 20130909, CDR0000736704, E2511, ECOG E2511, ECOG-ACRIN E2511, ECOG-E2511, NCI-2012-01985, NCT01642251, PSHCI-12-097, STU 102012-035, TrialTroveID-171478",Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination With Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine","National Institutes of Health/National Cancer Institute, ECOG-ACRIN Cancer Research Group","Government, Cooperative Group","Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Progression-free survival, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Neuropathy, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",True,NCT01642251,35813
2182,170773,"12-021, 2012-0216, 201311115, 9026, J11165, MSKCC1512, NCI#9026, NCI-2012-01130, NCI9026, NCT01638546, TrialTroveID-170773","A Multi-Center, Randomized, Double-Blind Phase II Study Comparing ABT-888, a PARP Inhibitor, Versus Placebo With Temozolomide in Patients With Relapsed Sensitive or Refractory Small Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",National Institutes of Health/National Cancer Institute,Government,Progression-free survival,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01638546,35813
2183,169972,"JapicCTI-121838, M12-629, NCT01617928, TrialTroveID-169972",Phase I Study of Veliparib (ABT-888) in Combination With Carboplatin/Paclitaxel in Japanese Subjects With Solid Tumors,Oncology,"Oncology: Lung, Non-Small Cell",AbbVie {Abbott},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax, Vital signs",True,NCT01617928,35813
2184,169641,"J11155, NCT01618357, TrialTroveID-169641",Pre-Operative PARPi and Irradiation (POPI) in Women With an Incomplete Response to Neo-Adjuvant Chemotherapy for Breast Cancer,Oncology,Oncology: Breast,Indiana University School of Medicine,Academic,"Maximum tolerated dose, Safety and Tolerability","Adverse Events, Overall response rate, Response rate",True,NCT01618357,35813
2185,166853,"CO12203, CT542, M12-950, M12-950 14544, NCT01589419, TrialTroveID-166853, VICCGI1214",An Open-Label Phase Ib Study of the Safety and Tolerability of Veliparib in Combination With Capecitabine and Radiation in Subjects With Locally Advanced Rectal Cancer (LARC),Oncology,Oncology: Colorectal,AbbVie {Abbott},"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Safety and Tolerability, Safety and Tolerability",True,NCT01589419,35813
2186,166595,"8993, CDR0000732189, CTEP # 8993, HUM00078659, IRB#12-045, MSKCC-12-045, MSKCC12045-PT1, NCI-2012-00864, NCT01585805, PHL-089 / NCI 8993, TrialTroveID-166595","A Randomized Phase II Study of Gemcitabine, Cisplatin +/- Veliparib in Patients With Pancreas Adenocarcinoma and a Known BRCA/ PALB2 Mutation (Part I) and a Phase II Single Arm Study of Single-Agent Veliparib in Previously Treated Pancreas Adenocarcinoma (Part II)",Oncology,Oncology: Pancreas,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, AbbVie","Cooperative Group, Government, Academic, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT01585805,35813
2187,165716,"081209, 12-0109, 12-0109, 12284, 2012-1038, 7847, 9012, CDR0000730114, J12103, N01CM00071, NCI 9012, NCI/CTEP 9012, NCI-2012-01149, NCI-2012-01919, NCI9012, NCT01576172, PHII-123, TrialTroveID-165716, UCCRC-IL057, UMCC 2012.022",A Randomized Gene Fusion Stratified Phase 2 Trial of Abiraterone With or Without ABT-888 for Patients With Metastatic Castration-Resistant Prostate Cancer,Oncology,Oncology: Prostate,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response rate","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01576172,35813
2188,164458,"12-0302, 14.0258, 2011-162, EudraCT Number: 2011-003427-36, M10-898, NCT01560104, PABBOTT008, TrialTroveID-164458","Randomized, Double-Blind, Multicenter, Phase II Trial Comparing Veliparib Plus Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Previously Untreated Metastatic or Advanced Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",AbbVie {Abbott},"Industry, Top 20 Pharma","Disease Progression, Mortality, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Neuropathy, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01560104,35813
2189,160027,"00035751, 12-176, 12-C-0213, C9073, NCI-12-C-0213, NCI-2012-00082, NCT01507324, NCT01514201, P12978, PBTC-033, PBTC33, TrialTroveID-160027","A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children With Newly Diagnosed Diffuse Pontine Gliomas (DIPG)",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, National Institutes of Health, Pediatric Brain Tumor Consortium","Government, Government, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Nausea, Neutropenia, Overall survival, Plasma pharmacokinetics, Progression-free survival, Response rate, Safety and Tolerability, Vomiting","Apparent diffusion coefficient, Cmax, Disease Progression, Drug clearance, Elimination half-life, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Recurrence, Response rate, Volume of distribution",True,NCT01507324,35813
2190,160004,"00032731, 12-122, 201110186, BROCADE, CT517, CTBE2013000192, DFCI 12-084, EudraCT Number: 2011-002913-12, HCI 52056, J11110, M12-895, MCC 16909, McG 1211, MSKCC 12-122, MUSC 101675, NCT01506609, NL43591.078.13, REec-2013-0357, STU 092011-060, TrialTroveID-160004","A Randomized, Phase II Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer",Oncology,Oncology: Breast,AbbVie {Abbott},"Industry, Top 20 Pharma","Disease Progression, Mortality, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, EORTC Quality of Life Questionnaire, Neuropathy, Overall response rate, Overall survival, Quality of Life, Stable Disease",True,NCT01506609,35813
2191,158919,"E24055, MM11-01, NCT01495351, TrialTroveID-158919",Phase I Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma,Oncology,Oncology: Multiple Myeloma,"(Other Academic Cancer Center), AbbVie {Abbott}, Alberta Health Services Research and Innovation Fund","Academic, Industry, Top 20 Pharma, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",Gene expression profiling,True,NCT01495351,35813
2192,157243,"2012-0399, MDACC 2012-0399, MSKCC 12-215, NCT01477489, TBCRC 024, TBCRC24-A, TrialTroveID-157243, UMCC 2011.087",A Phase I Study of Veliparib Administered Concurrently With Chest Wall and Nodal Radiation Therapy in Patients With Inflammatory or Loco-regionally Recurrent Breast Cancer,Oncology,Oncology: Breast,"University of Michigan Comprehensive Cancer Center, Johns Hopkins University, Breast Cancer Research Foundation","Academic, Academic, Not for Profit Funding Entity",Maximum tolerated dose,"Disease-free survival, Overall survival",True,NCT01477489,35813
2193,157055,"EudraCT Number: 2011-002099-18, NCT01472783, S-20110097, TrialTroveID-157055, Veli-BRCA",Veliparib (ABT888) Monotherapy for Patients With BRCA Germline Mutation and Platinum-Resistant or Partially Platinum-Sensitive Relapse of Epithelial Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AbbVie {Abbott}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01472783,35813
2194,155653,"11-0697, G9927, GOG 9927, GOG-9927, MSKCC 12-197, NCI-2011-01977, NCT01459380, TrialTroveID-155653, U10CA027469","A Phase I Trial of Pegylated Liposomal Doxorubicin (PLD), Carboplatin, and NCI Supplied Veliparib (ABT-888), and NCI Supplied Bevacizumab in Recurrent Platinum Sensitive Ovarian, Primary Peritoneal and Fallopian Tube Cancer",Oncology,Oncology: (N/A); Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, NRG Oncology","Government, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Overall response rate, Partial response, Progression-free survival",True,NCT01459380,35813
2195,152944,"11-144, 8484, DFCI-11-144, NCI 8484, NCI-2011-03458, NCT01434316, TrialTroveID-152944",Phase I Trial of ABT-888 and SCH727965 in Patients With Advanced Solid Tumors,Oncology,Oncology: Breast; Oncology: Prostate; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Elimination half-life, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT01434316,35813
2196,151507,"N1141, TrialTroveID-151507","Randomized Phase II Trial of Gemcitabine and Cisplatin Alone, with Cixutumumab, or with Veliparib in Patients with Cholangiocarcinoma or Gallbladder Carcinoma not Amenable to Local or Curative Therapy",Oncology,Oncology: Liver,"North Central Cancer Treatment Group (NCCTG), Southwest Oncology Group","Cooperative Group, Cooperative Group",Progression-free survival,"Duration of overall response, Overall response rate, Overall survival, Response rate, Time to progression",False,,35813
2197,147570,"051404, 110215, 11-118, 11-C-0215, 1B-10-5, 2011-082, 8808, CO11902, J1137, MSKCC 11-118, NCI-2011-02500, NCI8808, NCT01366144, NCT01419548, PHI-65, TrialTroveID-147570, UPCI 10-115, UPCI-10-115",An Early Phase I Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Abbott","Government, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT01366144,35813
2198,147432,"15-031, 8811, AFT-07, CHNMC-PHII-111, EudraCT Number: 2016-001659-32, HSC20130133H, M14-360, NCI 8811, NCI-2011-02592, NCI-2015-00710, NCT01386385, NCT02412371, PHII-111, S1206, S1206 (8811), SWOG 1206, SWOG S1206, SWOGS1206, SWOG-S1206, TrialTroveID-147432","A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)",Oncology,"Oncology: Lung, Non-Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute, AbbVie","Cooperative Group, Government, Industry, Top 20 Pharma","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT01386385,35813
2199,147124,"2009-608, LCCC 2009-608, NCI-2013-00656, NCT01489865, TrialTroveID-147124",A Phase I/II Study of ABT-888 in Combination With 5-fluorouracil and Oxaliplatin (Modified FOLFOX-6) in Patients With Metastatic Pancreatic Cancer,Oncology,Oncology: Pancreas,"AbbVie {Abbott}, Lombardi Cancer Center at Georgetown University Medical Center","Industry, Top 20 Pharma, Academic","Adverse Events, Dose-limiting toxicities, Overall response rate","Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01489865,35813
2200,146287,"11-01501, 11-02-068, 8853, AECM-11-02-068, NCI#8853, NCI-2011-02590, NCI8853, NCT01351909, P8853, P8853_A18PAMDREVW01, TrialTroveID-146287",Phase I Trial of Low-Dose Cyclophosphamide in Combination With Veliparib (ABT-888) in HER2/Neu-Negative Metastatic Breast Cancer,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival","Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT01351909,35813
2201,144408,"10-174, 8818, MSKCC-10174, NCI-2011-02583, NCT01326702, TrialTroveID-144408","A Phase Ib/IIa Study of ABT-888 in Combination With Bendamustine + or - Rituximab in Lymphoma, Multiple Myeloma and Solid Tumors",Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Complete response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT01326702,35813
2202,143991,"DTM1106, TrialTroveID-143991","A Randomized, Placebo Controlled Phase II Study of the Safety and Efficacy of Veliparib (ABT-888), Administered in Combination With Pegylated Liposomal Doxorubicin (PLD) Versus PLD and Placebo in Platinum resistant Recurrent Ovarian, Fallopian Tube, and Primary Peritoneal Cancer Patients",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Gynecologic Oncology Group (GOG),Cooperative Group,Safety and Tolerability,,False,,35813
2203,143620,"12-103, CDR0000726699, DTM1113, GOG-0280, NCI-2012-00684, NCT01540565, S12-02446, TrialTroveID-143620","A Phase II Evaluation of the Poly (ADP-Ribose) Polymerase (PARP)-1 and -2 Inhibitor Veliparib (ABT-888) (NSC#737664) in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Patients Who Carry a Germline BRCA1 or BRCA2 Mutation",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01540565,35813
2204,142837,"0S-11-4 PhII-118, 110080, 11-C-0080, 2011-0466, 8788, CTEP #8788, NCT01306032, P2C 8788, TrialTroveID-142837","Phase II Randomized Trial of ABT-888 in Combination With Metronomic Oral Cyclophosphamide in Refractory BRCA-Positive Ovarian, Primary Peritoneal, Ovarian High-Grade Serous Carcinoma, Fallopian Tube Cancer, or Triple-Negative Breast Cancer",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression","Adverse Events, Circulating Tumor Cells, Gene expression profiling",True,NCT01306032,35813
2205,141334,"8632, NCI 8632, NCI-2011-02576, NCT01282333, PCI-10-037, PSHCI-11-024, TrialTroveID-141334, UPCI-10-037","Phase I Study of Veliparib (ABT-888) in Combination With Cisplatin Plus Gemcitabine in Advanced Biliary, Pancreatic, Urothelial, and Non-small Cell Lung Cancer",Oncology,"Oncology: Bladder; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Renal",National Institutes of Health/National Cancer Institute,Government,Common Terminology Criteria for Adverse Events,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Plasma pharmacokinetics, Response evaluation criteria in solid tumors",True,NCT01282333,35813
2206,141207,"09-084, 8620, BELANINCI7967, NCI-2011-02490, NCT01281150, PCI-09-084, PSHCI-11-014, TrialTroveID-141207",A Phase I Study of ABT-888 (Veliparib) in Combination With Weekly Carboplatin and Paclitaxel in Advanced Solid Tumors,Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate","(Other Cooperative Group), National Institutes of Health/National Cancer Institute, AbbVie {Abbott}","Cooperative Group, Government, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT01281150,35813
2207,139795,"1172GCC, 8813, J1097, NA_00043143, NCI 8813, NCI-2011-00382, NCI-2012-02913, NCT01264432, TrialTroveID-139795","A Phase I Study of Veliparib (ABT-888) in Combination With Low-Dose Fractionated Whole Abdominal Radiation Therapy (LDFWAR) in Patients With Advanced Solid Malignancies With Peritoneal Carcinomatosis With Two Additional Dose Levels in Patients With Epithelial Ovarian, Fallopian or Primary Peritoneal Cancers and Intra-abdominal Disease",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Metastatic Cancer; Oncology: Ovarian; Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",True,NCT01264432,35813
2208,138944,"8609, CDR0000688990, NCI 8609, NCI-2011-02552, NCT01251874, OSU-10080, TrialTroveID-138944",A Phase I Dose-Escalation Study of ABT-888 (Veliparib) in Combination With Carboplatin in HER2 Negative Metastatic Breast Cancer,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Neutropenia, Safety and Tolerability, Safety and Tolerability","Circulating Tumor Cells, Partial response, Response evaluation criteria in solid tumors",True,NCT01251874,35813
2209,137347,"8604, CO10903, NCI-2011-02543, NCT01233505, TrialTroveID-137347, WCCC-CO-10903",A Phase I Study of ABT-888 in Combination with Oxaliplatin and Capecitabine in Advanced Solid Tumors,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Common Terminology Criteria for Adverse Events, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01233505,35813
2210,136994,"00054924, 041403, 14117, 14-ABV-2, 17835, 201405137, 2014-0619, 32185, ACC #15-12, BROCADE 3, BROCADE III, BROCADE M12-914, BROCADE3, Brocade-3 M12-914, CRUK 13041, CT707, end_M12-914 BRoCAde, EudraCT Number: 2014-000345-70, H00005984, IRAS ID: 52549, J1441, M12-914, MCC-17835, MCG 1428, NCI-2014-01442, NCT02163694, NL48835.078.14, REec-2014-1104, S1416, SWOG 1416, TrialTroveID-136994","A Phase III Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer.",Oncology,Oncology: Breast,AbbVie,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT02163694,35813
2211,134666,"M11-846, NCT01199224, TrialTroveID-134666","A Phase I, Single-Dose, Randomized, Group Sequential Cross-Over Study Evaluating the Bioavailability and Food Effect of Three Formulations of Veliparib on Pharmacokinetics in Subjects With Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,AbbVie {Abbott},"Industry, Top 20 Pharma","Area under the curve score, Bioavailability, Cmax, Plasma concentration, Tmax","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT01199224,35813
2212,134222,"EXT-M11-846, M12-273, NCT01193140, TrialTroveID-134222",An Extension Study to Evaluate the Safety of Veliparib in Combination With Temozolomide in Subjects With Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,AbbVie {Abbott},"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs","Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT01193140,35813
2213,133122,"2009-268, NCT01205828, TrialTroveID-133122",Phase II Study of ABT-888 and Temozolomide in Patients With Advanced Hepatocellular Carcinoma (HCC) Progressing Following Sorafenib Treatment or Intolerant to Sorafenib,Oncology,Oncology: Liver,"AbbVie {Abbott}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival",True,NCT01205828,35813
2214,130139,"09-012, 8324, NCI 8324, NCI-2011-01473, NCT01154426, PSHCI-10-021, TrialTroveID-130139, UPCI 09-012",Phase I Study of ABT-888 in Combination With Gemcitabine in Patients With Advanced Malignancies,Oncology,Oncology: Breast; Oncology: Prostate,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Partial response, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT01154426,35813
2215,129935,"07211-V00, 1B-10-5, 2010-0224, 8264, CHNMC-PHII-96, NCI 8264, NCI-2011-01379, NCT01149083, PHII-96, PSHCI-10-028, TrialTroveID-129935",Phase II Trial of Single Agent ABT-888 With Post-Progression Therapy of ABT-888 in Combination With Carboplatin in Patients With Stage IV BRCA-Associated Breast Cancer,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT01149083,35813
2216,129464,"00-0248, 00-0248-08475, 10-01206, 8475, AAAF2754, AECM-000248, NCI# 8475, NCI-2012-03161, NCT01145430, TrialTroveID-129464","Phase I Study of ABT-888, PARP Inhibitor, and Pegylated Liposomal Doxorubicin (PLD) in Recurrent Gynecologic Cancer and Breast Cancer",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT01145430,35813
2217,128866,"8456, GCC 0940, GCC0940, GCC-0940, J1051, JHUJ1051, JHUJ1051, NCI-2011-01457, NCT01139970, TrialTroveID-128866, UCCRC-0940, UMCC-0940",A Phase I Study of the PARP Inhibitor ABT-888 in Combination With Temozolomide in Acute Leukemias,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous",National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Maximum tolerated dose, Overall response rate, Percentage of Responders, Response rate",True,NCT01139970,35813
2218,127210,"00021574, 0C-09-8, 2010-025, GCRC 1350, HS-10-00117, M10-977, NCT01123876, TrialTroveID-127210, VICCPHI09105","A Phase I Open-Label, Dose-Escalation Study of Veliparib in Combination With Bimonthly FOLFIRI in Subjects With Advanced Solid Tumors",Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,AbbVie {Abbott},"Industry, Top 20 Pharma",Maximum tolerated dose,"Safety and Tolerability, Safety and Tolerability",True,NCT01123876,35813
2219,125774,"7161, NCI-2010-00356, NCT01104259, TrialTroveID-125774",Phase I Study of ABT-888 in Combination with Cisplatin and Vinorelbine for Patients with Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic","Dose-limiting toxicities, Maximum tolerated dose","Area under the curve score, Bioavailability, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Drug clearance, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Tmax, Volume of distribution",True,NCT01104259,35813
2220,125605,"10-057, EudraCT Number: 2009-015082-31, M10-757, MDACC: 2010-0230, NCT01113957, OSU-09129, TrialTroveID-125605",A Phase ll Randomized Clinical Trial of ABT-888 in Combination With Temozolomide Versus Pegylated Liposomal Doxorubicin Alone in Subjects with Recurrent High Grade Serous Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,AbbVie {Abbott},"Industry, Top 20 Pharma","CA-125 Response, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Time to progression","Cardiac Telemetry, Duration of overall response, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression, Vital signs",True,NCT01113957,35813
2221,124110,"J09151, M11-070, MSKCC 10-082, NCT01085422, SOL-09171-P, TrialTroveID-124110, UMCC 2009.114","A Pilot Study Combining ABT-888, an Oral PARP Inhibitor, With Temozolomide in Patients with Metastatic Castration Resistant Prostate Cancer who Have Failed Up to Two Non-hormonal Systemic Therapies",Oncology,Oncology: Prostate,"(Other Cooperative Group), AbbVie {Abbott}","Cooperative Group, Industry, Top 20 Pharma","Overall response rate, PSA progression, Response rate","Adverse Events, Cardiac Telemetry, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Vital signs",True,NCT01085422,35813
2222,122422,"09-154, 09158, 09-267-B, 20091988, BELANINCI7967, M10-758, NCT01063816, PSHCI-10-028, TrialTroveID-122422, UW09039",A Phase I Study of ABT-888 in Combination With Carboplatin and Gemcitabine in Subjects With Advanced Solid Tumors,Oncology,"Oncology: Breast; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma",AbbVie {Abbott},"Industry, Top 20 Pharma",Maximum tolerated dose,"Adverse Events, Area under the curve score, Safety and Tolerability, Vital signs",True,NCT01063816,35813
2223,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,35813
2224,119763,"031006, 12-C-0004, AAAJ7909, CHRMS M13-114, CTO: 101482, NCI-12-C-0004, NCT01026493, PSHCI-11-012, R0929, RTOG 0929, RTOG0929, RTOG-0929, TrialTroveID-119763",A Randomized Phase I/II Study of ABT-888 in Combination with Temozolomide in Recurrent (Temozolomide Resistant) Glioblastoma,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma","Radiation Therapy Oncology Group (RTOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Dose-limiting toxicities, Maximum tolerated dose, Nausea, Neutropenia, Overall survival, Progression-free survival, Vomiting","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Safety and Tolerability",True,NCT01026493,35813
2225,119072,"2010-022, 8472, NCI-2012-01473, NCT01017640, OSU-09100, TrialTroveID-119072",ABT-888 as Monotherapy and in Combination With Mitomycin C in Patients With Solid Tumors With Deficiency in Homologous Recombination Repair,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate",National Institutes of Health/National Cancer Institute,Government,Safety and Tolerability,,True,NCT01017640,35813
2226,118985,"2009-170, NCT01051596, TrialTroveID-118985","A Phase II Study of ABT-888, an Inhibitor of Poly(ADP-ribose) Polymerase (PARP) in Combination With Temozolomide in Patients With Heavily Pretreated, Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,"AbbVie {Abbott}, Georgetown University Medical Center","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Time to progression, Vital signs",True,NCT01051596,35813
2227,118701,"09-000742, 104564 (8329), 8329, MAYO-MC0861, MC0861, NCI-2011-00312, NCT01012817, TrialTroveID-118701","A Phase I/II Trial of ABT-888, an Inhibitor of Poly(ADP-Ribose) Polymerase (PARP), and Topotecan (TPT) in Patients With Solid Tumors (Phase I) and Relapsed Ovarian Cancer or Primary Peritoneal Cancer (Phase II) After Prior Platinum Containing First-Line Chemotherapy",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Mayo Clinic Cancer Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Time to treatment failure",True,NCT01012817,35813
2228,118399,"09-261, NCT01009788, TrialTroveID-118399",A Phase II Study of ABT-888 and Temozolomide for Metastatic Breast Cancer and an Expansion Cohort in BRCA1/2 Mutation Carriers.,Oncology,Oncology: Breast,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, AbbVie {Abbott}, Beth Israel Deaconess Medical Center, Massachusetts General Hospital","Academic, Industry, Top 20 Pharma, Academic, Academic","Complete response, Overall response rate, Safety and Tolerability","Clinical benefit rate, Complete response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01009788,35813
2229,116615,"09-106, 10-14864, 10-323-B, 12-401, 14864, 200912727, 9923, CC853, G9923, GOG 9923, GOG9923, GOG-9923, NCG 259814, NCI-2011-03730, NCT00989651, NRG-GOG-9923, TrialTroveID-116615","A Phase I Study of Intravenous Carboplatin/Paclitaxel or Intravenous and Intraperitoneal Paclitaxel/Cisplatin in Combination With Continuous or Intermittent/ CTEP-Supplied Agent ABT-888 (NSC 737664) and CTEP-Supplied Agent Bevacizumab (NSC 704865) in Newly Diagnosed Patients With Previously Untreated Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Oncology,Oncology: (N/A); Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute, AbbVie {Abbott}, NRG Oncology","Cooperative Group, Government, Industry, Top 20 Pharma, Cooperative Group","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall survival, Progression-free survival","Common Terminology Criteria for Adverse Events, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT00989651,35813
2230,112958,"00018926, 090243, 09-C-0243, NCI-09-C-0243, NCI-2012-03177, NCT00946335, NCT00994071, PBTC 027, PBTC-027, TrialTroveID-112958, U01CA081457","A Phase I Study of ABT-888, an Oral Inhibitor of Poly (ADP-Ribose) Polymerase and Temozolomide in Children With Recurrent/Refractory CNS Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",National Institutes of Health/National Cancer Institute,Government,"Area under the curve score, Drug clearance, Elimination half-life, Elimination rate, Maximum tolerated dose, Plasma concentration, Plasma pharmacokinetics",,True,NCT00946335,35813
2231,108104,"(226023) CCRC: PHI-63, 050810, 08-121, 08240, 0S-09-1, 1309 Phl-63, 8282, CINJ-050810, NCI-2011-01472, NCI-8282, NCT00892736, PHI-63, PSHCI-09-006, TrialTroveID-108104, UPCI 08-121","A Phase I Study of Chronically-Dosed, Single-Agent ABT-888 in Patients With Either BRCA 1/2 -Mutated Cancer; Platinum-Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer; or Basal-Like Breast Cancer",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, AbbVie {Abbott}","Cooperative Group, Government, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Common Terminology Criteria for Adverse Events, Complete response, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT00892736,35813
2232,102243,"090048, 09-C-0048, 0C-08-4, 8275, NCI# 8275, NCI-09-C-0048, NCT00810966, NCT01445522, P8437, PHI-62, PSHCI-09-009, TrialTroveID-102243",A Phase I Study of ABT-888 in Combination with Metronomic Cyclophosphamide in Adults With Refractory Solid Tumors and Lymphomas,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma",National Institutes of Health/National Cancer Institute,Government,"Maximum tolerated dose, Safety and Tolerability",,True,NCT00810966,35813
2233,101726,"09-0505, 201102395, Bio 09-0587-11, EudraCT Number: 2008-004941-27, M10-440, McG 0911, MDACC 2009-0452, NCRN058, NCT00804908, TrialTroveID-101726, UKCRN 6519, VICCMEL0890","A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Evaluating the Efficacy of ABT-888 in Combination With Temozolomide Versus Temozolomide Alone in Subjects With Metastatic Melanoma",Oncology,Oncology: Melanoma,AbbVie {Abbott},"Industry, Top 20 Pharma","Disease Progression, Mortality, Progression-free survival, Progressive disease rate","Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00804908,35813
2234,96225,"050803, 7998, CDR0000600234, CINJ#050803, CINJ-050803, NCI-2009-00262, NCT00740805, TrialTroveID-096225",A Phase I Study of ABT-888 in Combination With Cyclophosphamide in Solid Tumors or Non-Hodgkin Lymphoma,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Prostate; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Area under the curve score, Circulating Tumor Cells",True,NCT00740805,35813
2235,86823,"J07126, J-07126, M10-128, NCT00649207, PABBOTT002, RO07324, TrialTroveID-086823","A Phase I Study Evaluating the Safety, Tolerability and Pharmacokinetics of ABT-888 in Combination With Whole Brain Radiation Therapy in Subjects With Brain Metastases",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Metastatic Cancer; Oncology: Renal",AbbVie {Abbott},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00649207,35813
2236,81663,"7968, J0783, JHOC-J0783, NCI-2009-00259, NCT00588991, TrialTroveID-081663",A Phase I Study of ABT-888 in Combination With Topotecan Plus Carboplatin for High-Risk Myeloproliferative Disorders and AML Out of Myeloproliferative Disorders,Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Maximum tolerated dose","Area under the curve score, Cmax",True,NCT00588991,35813
2237,81312,"0782GCC, 08-121, 1410014852, 2007-014, 7977, GCC0782, HIC 1410014852, HIC1410014852, HP-40036, NCI 7977, NCI-2009-01057, NCT00576654, TrialTroveID-081312, WSU-2007-014","A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) Plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients With Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Vital signs","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00576654,35813
2238,79617,"0801, ABBOTT-M10-190, ABTC08-01, ABTC-0801, NABTT0801, NABTT-0801, NCT00770471, TrialTroveID-079617",A Phase I/II Trial of Temozolomide and ABT-888 in Subjects with Newly Diagnosed Glioblastoma Multiforme,Oncology,"Oncology: CNS, Glioblastoma","National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, AbbVie {Abbott}","Government, Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Overall survival","Maximum tolerated dose, Overall survival, Safety and Tolerability",True,NCT00770471,35813
2239,76894,"07-015, 0C-07-7, 7967, BELANINCI7967, COH  07242, NCI-2009-00258, NCI-7967, NCT00535119, PCI-07-015, PHI-61, TrialTroveID-076894, UPCI-07-015",A Phase I Study of ABT-888 in Combination With Carboplatin and Paclitaxel in Advanced Solid Malignancies,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal","(Other Cooperative Group), National Institutes of Health/National Cancer Institute, AbbVie {Abbott}","Cooperative Group, Government, Industry, Top 20 Pharma",Common Terminology Criteria for Adverse Events,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT00535119,35813
2240,74906,"070203, 07-C-0203, 7981, NCI-07-C-0203, NCT00553189, NCT01445353, P7241, TrialTroveID-074906",A Phase I Study of ABT-888 in Combination With Topotecan Hydrochloride in Adults With Refractory Solid Tumors and Lymphomas,Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",National Institutes of Health/National Cancer Institute,Government,"Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00553189,35813
2241,67556,"06-005817, M06-862, NCT00526617, TrialTroveID-067556",A Phase I Study of ABT-888 in Combination with Temozolomide (TMZ) in Subjects with Non-Hematologic Malignancies (NHM) and Metastatic Melanoma (MM).,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian,AbbVie {Abbott},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00526617,35813
2242,58028,"060172, 06-C-0172, NCI-06-C-0172, NCI-P6890, NCT00347633, NCT00387608, TrialTroveID-058028","A Phase 0 Pharmacokinetic, Pharmacodynamic Study of ABT-888, an Inhibitor of Poly (ADP-Ribose) Polymerase (PARP), in Refractory Solid Tumors and Lymphoid Malignancies",Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's",National Institutes of Health/National Cancer Institute,Government,,Safety and Tolerability,True,NCT00347633,35813
2243,377749,"CTR20200738, HR-SHR-1309-PK-01, TrialTroveID-377749",Comparative Study on Pharmacokinetics and Safety of SHR-1309 Injection and Perjeta,Oncology,Oncology: Unspecified Cancer,"Jiangsu Hengrui Medicine Co./Shanghai Hengrui Pharmaceutical Co. {Shanghai Hengrui Pharmaceutical Co. (Jiangsu Hengrui Medicine, Hong Kong Science & Tech. joint venture)}","Industry, all other pharma","Area under the curve score, Cmax","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Neutralizing antibody response, Vital signs",False,,166799
2244,39834,"CELMED-CR-TSC-001, CR-TSC-001, HS-05-00118, NCT00248404, NCT00255736, OC-05-3, TrialTroveID-039834, UCLA-0504019-01",A Phase I/II Study of NB1011 Administered Intravenously by Continuous Infusion in an Every Second Week Regimen With Open-Label Continuation in Cancers That Overexpress the Enzyme Thymidylate Synthase,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian","Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Kiadis Pharma {Celmed Biosciences}","Academic, Government, Industry, all other pharma","Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability",,True,NCT00248404,22895
2245,9198,"NB-1011-1001, NCI-V01-1689, NCT00031616, TrialTroveID-009198",Phase I/II Study of NB1011 in Patients With Fluoropyrimidine-Resistant Metastatic or Recurrent Colorectal Cancer,Oncology,Oncology: Colorectal,NewBiotics,"Natural products, OTC, cosmetics","Maximum tolerated dose, Safety and Tolerability",,True,NCT00031616,22895
2246,345038,TrialTroveID-345038,A Phase Ib Study to evaluate TLD 1433 for the Treatment of Cancer,Oncology,Oncology: Unspecified Cancer,Theralase,"Industry, diagnostics or device",,,False,,112319
2247,318383,"ACT-NMIBC, NCT03945162, Study II, TLD-1433 Bladder Cancer PDT, TLD-1433-2, TrialTroveID-318383","A Phase II Clinical Study of Intravesical Photodynamic Therapy in Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (""NMIBC"") Or Patients Who Are Intolerant to BCG Therapy (""Study"").",Oncology,Oncology: Bladder,"University Health Network, Toronto, Theralase","Academic, Industry, diagnostics or device","Complete response, Recurrence","Adverse Events, Safety and Tolerability",True,NCT03945162,112319
2248,254859,"NCT03053635, Study, TLD1433, TLD1433 Bladder Cancer PDT, TrialTroveID-254859",A Phase Ib Trial of Intravesical Photodynamic Therapy in Patients With Non-muscle Invasive Bladder Cancer at High Risk of Progression Who Are Refractory to Bacillus Calmette-Guerin Therapy and Who Are Medically Unfit for/Refuse Cystectomy,Oncology,Oncology: Bladder,"University Health Network, Toronto, Theralase","Academic, Industry, diagnostics or device","Adverse Events, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Disease-free survival, Overall survival, Recurrence",True,NCT03053635,112319
2249,384514,TrialTroveID-384514,A Phase I Clinical Study of TARA-002 to Assess the Safety and Tolerability of TARA-002 in Patients with Non-Muscle Invasive Bladder Cancer,Oncology,Oncology: Bladder,Protara Therapeutics {ArTara Therapeutics {Proteon Therapeutics}},"Industry, all other pharma","Safety and Tolerability, Safety and Tolerability",,False,,168401
2250,392465,"CATCH-R, CO-338-111, NCT04676334, TrialTroveID-392465",CATCH-R: A Rollover Study to Provide Continued Access to Clinical Therapy With Rucaparib,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Prostate,Clovis Oncology,"Industry, all other pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events",,True,NCT04676334,35280
2251,389046,"20-358, NCT04624178, TrialTroveID-389046",Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"Bristol-Myers Squibb, Memorial Sloan-Kettering Cancer Center, Clovis Oncology","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival",True,NCT04624178,35280
2252,383988,"GEICO 87-R, NCT04539327",Analysis of the Clinical Experience With Rucaparib in the Rucaparib Access Program (RAP) in Spain - A GEICO Study,,NA: ClinicalTrials.gov,"Grupo Espa??ol de Investigaci??n en C??ncer de Ovario, Clovis Oncology, Inc.","ClinicalTrials.gov, ClinicalTrials.gov","Adverse Events, Safety and Tolerability",,True,NCT04539327,35280
2253,378455,"A031902, CASPAR, NCI-2020-02360, NCT04455750, TrialTroveID-378455",CASPAR - A Phase III Trial of Enzalutamide and Rucaparib as a Novel Therapy in First-Line Metastatic Castration-Resistant Prostate Cancer.,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Disease Progression, Functional Assessment of Cancer Therapy-Prostate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability","Adverse Events, Brief Pain Inventory, Complete response, Disease Progression, Duration of overall response, EQ-5D-5L, Functional Assessment of Cancer Therapy-Prostate, NCI-CTC scale, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, PSA progression, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT04455750,35280
2254,366969,"BrUOG 360, NCT04253262, TrialTroveID-366969",A Phase Ib/II Study of Copanlisib Combined With Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer,Oncology,Oncology: Prostate,"Brown University Oncology Group, Bayer AG, Rhode Island Hospital, (Other Hospital/Academic/Medical Center), Clovis Oncology","Cooperative Group, Industry, Top 20 Pharma, Academic, Academic, Industry, all other pharma","Maximum tolerated dose, Overall response rate",,True,NCT04253262,35280
2255,365291,"ENGOT-ov59/NOGGO/MAMOC, MAMOC, NCT04227522, NOGGO ov42, NOGGO Ov-42/MAMOC, TrialTroveID-365291",Rucaparib Maintenance After Bevacizumab Maintenance Following Carboplatin Based First Line Chemotherapy in Ovarian Cancer Patients,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"(Other Cooperative Group), (Other Academic Cancer Center), Clovis Oncology","Cooperative Group, Academic, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Global health status, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Safety and Tolerability, Serious Adverse Events, SF-12, SF-36, Treatment Emergent Adverse Events",True,NCT04227522,35280
2256,364178,"200013, 20-C-0013, NCI-2019-08959, NCT04209595, TrialTroveID-364178",Phase I/II Trial of PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers.,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Clinical benefit rate, Disease Progression, Maximum tolerated dose, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT04209595,35280
2257,362194,"2019IS147, CO-338-107, NCI-2019-08649, NCT04179396, RAMP, TrialTroveID-362194","A Phase Ib, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With Metastatic Castration Resistant Prostate Cancer",Oncology,Oncology: Prostate,Clovis Oncology,"Industry, all other pharma","Adverse Events, Cmin, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Overall response rate, Response evaluation criteria in solid tumors",True,NCT04179396,35280
2258,361833,"19-756, 20619, AAAS6974, CO-338-100, LODESTAR, NCI-2019-08226, NCT04171700, TrialTroveID-361833","A Phase II Multicenter, Open-label Study of Rucaparib as Treatment for Solid Tumors Associated With Deleterious Mutations in Homologous Recombination Repair Genes",Oncology,Oncology: Bladder; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT04171700,35280
2259,351941,"IIT-2018-RucaRamNivo, NCI-2020-01661, NCT03995017, RiME, TrialTroveID-351941",A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME),Oncology,Oncology: Esophageal; Oncology: Gastric,"Bristol-Myers Squibb, University of Kansas, Clovis Oncology","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events",True,NCT03995017,35280
2260,350055,"49346 MCC-18-LUN-107-CLO, MCC-18-LUN-107-PMC, NCI-2019-03335, NCT03958045, TrialTroveID-350055",Phase II Study of Combination Rucaparib With Nivolumab in Platinum-Sensitive Small Cell Lung Carcinoma Patients as Maintenance After Induction Therapy With Platinum Doublet,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",University of Kentucky,Academic,"Complete response, Progression-free survival","Clinical benefit rate, Complete response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03958045,35280
2261,349933,"CO-338-095, NCT03954366, TrialTroveID-349933","A Phase I, Open-label, Drug-drug-interaction Study to Determine the Effect of Rucaparib on the Pharmacokinetics of Oral Rosuvastatin (Arm A) and Oral Contraceptives (Ethinylestradiol and Levonorgestrel) (Arm B) in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Area under the curve score, Cmax","Adverse Events, Cmax, Cmin, Drug clearance, Elimination half-life, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Volume of distribution",True,NCT03954366,35280
2262,347304,"1903397220, 30388, NCI-2019-02454, NCT03911453, TrialTroveID-347304",Window of Opportunity Trial to Evaluate Change in PD-L1 Expression in Triple Negative Breast Tumors in Response to the PARP Inhibitor Rucaparib,Oncology,Oncology: Breast,University of Arizona,Academic,,Circulating Tumor Cells,True,NCT03911453,35280
2263,343673,"LUNG-MAP Sub-Study, NCI-2018-02129, NCT03845296, S1900A, SWOG S1900A, TrialTroveID-343673",A Phase II Study of Rucaparib in Patients With Genomic LOH High and/or Deleterious BRCA1/2 Mutation Stage IV or Recurrent Non-Small Cell Lung Cancer (LUNG-MAP Sub-Study),Oncology,"Oncology: Lung, Non-Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Circulating Tumor Cells, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03845296,35280
2264,343499,"BO40933, NCT03840200, TrialTroveID-343499","A Phase Ib, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Ipatasertib in Combination With Rucaparib in Patients With Advanced Breast, Ovarian, or Prostate Cancer",Oncology,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate,Roche {F. Hoffmann-La Roche},"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Disease Progression, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03840200,35280
2265,342097,"ARIES, CO-338-097, NCT03824704, TrialTroveID-342097","A Phase II, Open-label Study to Evaluate Rucaparib in Combination With Nivolumab in Patients With Selected Solid Tumors (ARIES)",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Bristol-Myers Squibb, Clovis Oncology, Roche/Foundation Medicine","Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03824704,35280
2266,337892,"2018/2727, ARIANES, ARIANES study, EudraCT Number: 2018-001744-62, NCT04276376, RECF3851, TrialTroveID-337892","A Multicenter, Open Label, Phase II Basket Trial Exploring the Efficacy And Safety of The Combination of Rucaparib (PARP Inhibitor) And Atezolizumab (Anti-PD-L1 Antibody) In Patients With DNA Repair-Deficient or Platinum-Sensitive Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",Institut Gustave Roussy,Academic,"Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT04276376,35280
2267,333969,"EndoBARR, IIT-BRADLEY-ENDOBARR, NCI-2020-07164, NCT03694262, PRO, TrialTroveID-333969","An Open Label, Non-Randomized Multisite Phase II Trial Combining Bevacizumab, Atezolizumab and Rucaparib for the Treatment of Previously Treated Recurrent and Progressive Endometrial Carcinoma",Oncology,Oncology: Endometrial; Oncology: Soft Tissue Sarcoma,"Medical College of Wisconsin Cancer Center, Roche/Genentech, Clovis Oncology","Academic, Industry, Top 20 Pharma, Industry, all other pharma",Overall response rate,"Cardiac Telemetry, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Microbiome, Overall survival, Progression-free survival, Treatment Emergent Adverse Events",True,NCT03694262,35280
2268,331770,"0627, EudraCT Number: 2017-003353-41, IRAS ID: 217815, ISRCTN39816629, MiST, NCT03654833, TrialTroveID-331770",Mesothelioma Stratified Therapy (MiST): A Stratified Multi-arm Phase IIa Clinical Trial to Enable Accelerated Evaluation of Targeted Therapies for Relapsed Malignant Mesothelioma,Oncology,Oncology: Mesothelioma,"Eli Lilly, (Other Cooperative Group), Roche, Christie Hospital N.H.S. Trust, University Hospitals of Leicester, (Other Hospital/Academic/Medical Center), Merck & Co./Merck Sharp & Dohme (MSD), Clovis Oncology, BerGenBio","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Academic, Academic, Academic, Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Clinical benefit rate, Complete response, Disease Progression, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Microbiome, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03654833,35280
2269,330995,"BilT-02, HUM00142974, NCI-2019-01859, NCT03639935, TrialTroveID-330995, UMCC 2018.044",Phase II Multi-Center Study of PARP Inhibitor Rucaparib in Combination With Anti-PD-1 Antibody Nivolumab in Patients With Advanced or Metastatic Biliary Tract Cancer Following Platinum Therapy,Oncology,Oncology: Liver,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, University of Michigan Comprehensive Cancer Center, Vanderbilt University Medical Center","Academic, Academic, Academic",Progression-free survival,"Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability",True,NCT03639935,35280
2270,330845,TrialTroveID-330845,"A Phase II, Open-label, Multi-cohort Study Evaluating the Combination of Rubraca and Opdivo in Patients with Relapsed, BRCA Wild-type Ovarian Cancer and in Patients with Locally Advanced or Metastatic Bladder Carcinoma.",Oncology,Oncology: Bladder; Oncology: Ovarian,"Bristol-Myers Squibb, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma",,,False,,35280
2271,329718,"18-0567, 18-0567.cc, NCI-2018-02063, NCT03617679, TrialTroveID-329718","A Phase II, Randomized, Double-Blind Study of the Use of Rucaparib vs. Placebo Maintenance Therapy in Metastatic and Recurrent Endometrial Cancer",Oncology,Oncology: Endometrial,"National Institutes of Health/National Cancer Institute, University of Colorado, Clovis Oncology","Government, Academic, Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03617679,35280
2272,327105,"NCI-2018-01747, NCT03572478, TrialTroveID-327105",A Phase Ib/IIa Study of Rucaparib (PARP Inhibitor) Combined With Nivolumab in Metastatic Castrate - Resistant Prostate Cancer and Advanced/Recurrent Endometrial Cancer,Oncology,Oncology: Endometrial; Oncology: Prostate,"Bristol-Myers Squibb, University of Chicago Medical Center, Clovis Oncology","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Dose-limiting toxicities, Infiltrate thickness","CA-125 Response, Infiltrate thickness, Overall response rate, Progression-free survival, Response rate, Time to progression",True,NCT03572478,35280
2273,326279,"2018.033, HUM00142973, NCI-2019-01067, NCT03559049, TrialTroveID-326279, UMCC 2018.033","A Phase I/II Multi-site Study of Rucaparib and Pembrolizumab Maintenance Therapy in Stage IV Non-Squamous Non-Small Cell Lung Cancer After Initial Therapy With Carboplatin, Pemetrexed, and Pembrolizumab",Oncology,"Oncology: Lung, Non-Small Cell","University of Michigan Comprehensive Cancer Center, Merck & Co./Merck Sharp & Dohme (MSD), Clovis Oncology","Academic, Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Partial response, Progression-free survival, Stable Disease","Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT03559049,35280
2274,325980,"2018C0042, NCI-2018-00438, NCT03552471, OSU-18007, TrialTroveID-325980","Phase I Study of Mirvetuximab Soravtansine (IMGN853) and Rucaparib for Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer",Oncology,Oncology: (N/A); Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian,"ImmunoGen, Ohio State University, Clovis Oncology","Industry, all other pharma, Academic, Industry, all other pharma",Dose-limiting toxicities,"Cmax, Common Terminology Criteria for Adverse Events, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT03552471,35280
2275,325564,"19-168, CO-338-098, NCI-2019-04655, NCT03992131, SEASTAR, SEASTAR-A, SEASTAR-B, TrialTroveID-325564","SEASTAR: A Phase Ib/II, Open-label, Parallel Arm Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of Oral Rucaparib in Combination With Other Anticancer Agents in Patients With a Solid Tumor",Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor,"Gilead Sciences/Immunomedics, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Area under the curve score, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Elimination rate, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Tmax, Volume of distribution",True,NCT03992131,35280
2276,325321,"18-002, NCI-2018-01207, NCT03542175, TrialTroveID-325321",A Phase I Study of Rucaparib Administered Concurrently With Postoperative Radiotherapy in Patients With Triple Negative Breast Cancer With an Incomplete Pathologic Response Following Neoadjuvant Chemotherapy,Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, Clovis Oncology","Academic, Industry, all other pharma",Maximum tolerated dose,"Quality of Life, Radiation Therapy Oncology Group Scale",True,NCT03542175,35280
2277,324854,"HCI111833, NCI-2018-01754, NCT03533946, ROAR, TrialTroveID-324854","A Phase II Study of Rucaparib Monotherapy in Nonmetastatic, Hormone-Sensitive Prostate Cancer Demonstrating ""BRCAness"" Genotype (ROAR)",Oncology,Oncology: Prostate,"University of Utah, Clovis Oncology","Academic, Industry, all other pharma",PSA progression,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, PSA progression, Safety and Tolerability",True,NCT03533946,35280
2278,324110,"CO-338-078, NCT03521037, TrialTroveID-324110","A Phase I, Open-Label, Parallel Group Study to Determine the Pharmacokinetics, Safety and Tolerability of Rucaparib in Patients With an Advanced Solid Tumor and Either Moderate Hepatic Impairment or Normal Hepatic Function",Oncology,Oncology: Liver; Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Cmax, Plasma concentration","Adverse Events, Cmax, Drug clearance, Elimination half-life, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Volume of distribution",True,NCT03521037,35280
2279,322648,"CO-338-081, NCT03499444, RUCA-J, TrialTroveID-322648","A Phase I, Open-label, Safety and Pharmacokinetic Study of Rucaparib in Japanese Patients With a Previously-treated Solid Tumor",Oncology,Oncology: Breast; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Area under the curve score, Cmax, Disease Progression, Dose-limiting toxicities, Plasma concentration, Response evaluation criteria in solid tumors",True,NCT03499444,35280
2280,321178,"Clovis-001, NCI-2019-00334, NCT03476798, OU-SCC-Clovis-001, TrialTroveID-321178",A Phase II Trial of Bevacizumab and Rucaparib in Recurrent Carcinoma of The Cervix or Endometrium,Oncology,Oncology: Cervical; Oncology: Endometrial,"University of Oklahoma, Clovis Oncology","Academic, Industry, all other pharma",,"Circulating Tumor Cells, Overall response rate, Overall survival, Progression-free survival",True,NCT03476798,35280
2281,320114,"CeNturIOn, CeNturIOn-2016, EudraCT Number: 2017-004780-13, ISRCTN10490346, TrialTroveID-320114","An Open-Label, Randomised, Phase I/II Trial Of Rucaparib Combined With Nivolumab + or - Ipilimumab To Augment Response In Homologous Repair Deficient Patients With Relapsed Ovarian, Primary Peritoneal And Fallopian Tube Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Bristol-Myers Squibb, National Health Service (NHS) - UK, (Other Hospital/Academic/Medical Center), University of Glasgow, Clovis Oncology","Industry, Top 20 Pharma, Government, Academic, Academic, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","CA-125 Response, Disease Progression, Duration of overall response, EQ-5D-5L, EQ-5D, Health economic assessment, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",False,,35280
2282,319129,"9841, NCI-2018-00016, NCT03442556, PLATI-PARP, RG1717043, TrialTroveID-319129",PLATI-PARP: A Phase II Study of Induction Docetaxel and Carboplatin Followed by Maintenance Rucaparib in Treatment of Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Overall response rate - duration, Overall response rate, Partial response, PSA progression, Response evaluation criteria in solid tumors",True,NCT03442556,35280
2283,317354,"CRMS-68145, J17187, NCI-2018-01989, NCT03413995, TrialTroveID-317354, TRIUMPH",Phase II Trial of Rucaparib in Patients With Metastatic Hormone-Sensitive Prostate Cancer Harboring Germline DNA Repair Gene Mutations (TRIUMPH),Oncology,Oncology: Prostate,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Clovis Oncology","Academic, Industry, all other pharma","Overall response rate, Response rate","Common Terminology Criteria for Adverse Events, Overall response rate, Partial response, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03413995,35280
2284,316299,"ENGOT-cx7, ENGOT-Cx7 / MaRuC, ENGOT-CX7 / NSGO / MaRuC, ENGOT-Cx7-NSGO/MaRuC, EudraCT Number: 2018-003756-20, MaRuC, NCT03795272, TrialTroveID-316299",A Randomized Double-blind Placebo-controlled Phase II Trial of Rucaparib Maintenance Therapy for Patients With Locally Advanced Cervical Cancer.,Oncology,Oncology: Cervical,"(Other Cooperative Group), Nordic Society for Gynaecologic Oncology, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Institute of Cancer Research - UK, (Other Hospital/Academic/Medical Center), Clovis Oncology","Cooperative Group, Not for Profit Funding Entity, Academic, Academic, Academic, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Disease Progression, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment compliance",True,NCT03795272,35280
2285,312559,"109848 (ATLAS; CO-338-085), 1824GCCC, 18-297, 20180915, ATLAS, CO-338-085, EudraCT Number: 2017-004166-10, NCI-2018-01112, NCT03397394, RWF_CO-338-085, TrialTroveID-312559","A Phase II, Open-label Study of Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma.",Oncology,Oncology: Bladder; Oncology: Renal,"Clovis Oncology, Roche/Foundation Medicine","Industry, all other pharma, Industry, Top 20 Pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Cardiac Telemetry, Circulating Tumor Cells, Clinical benefit rate, Cmin, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment compliance, Treatment Emergent Adverse Events, Vital signs",True,NCT03397394,35280
2286,312203,"115141, ACCRU-GI-1603, NCI-2017-01976, NCT03337087, TrialTroveID-312203","Phase I Study of Irinotecan Liposome (Nal-IRI), Fluorouracil, Leucovorin and Rucaparib in the Treatment of Select Gastrointestinal Metastatic Malignancies Followed by a Phase Ib of First and Second Line Treatment of Both Unselected and Selected ( for BRCA 1/2 and PALB2 Mutations) Patients With Metastatic Adenocarcinoma of the Pancreas Then Followed by a Phase II Study of First Line Treatment of Selected Patients With Metastatic Adenocarcinoma of the Pancreas With Genomic Markers (Signature) of Homologous Recombination Deficiency (HRD)",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Clinical benefit rate, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03337087,35280
2287,311271,"169521, 17-22565, CC# 169521, NCI-2017-02294, NCT03318445, TrialTroveID-311271",Combination Therapy of Rucaparib and Irinotecan in Cancers With Mutations in DNA Repair,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Prostate; Oncology: Testicular,"University of California, San Francisco, Clovis Oncology","Academic, Industry, all other pharma","Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",Overall response rate - duration,True,NCT03318445,35280
2288,306275,TrialTroveID-306275,"A Pivotal, Multi Arm Phase III Study to Evaluate Rubraca + Opdivo, Rubraca, Opdivo and Chemotherapy as First-line Maintenance Treatment in Patients with Stage IV or Recurrent locally Advanced Inoperable Triple-Negative Breast Cancer Associated with a Homologous Recombination Deficiency",Oncology,Oncology: Breast,Bristol-Myers Squibb,"Industry, Top 20 Pharma",,,False,,35280
2289,306273,"17182, 18-481, 215102, ARIEL5, ATHENA, C-354, CO-338-087, ENGOT, ENGOT-ov45, ENGOT-ov45/NCRI/ATHENA, EudraCT Number: 2017-004557-17, GOG3020, GOG-3020, IRAS ID 240011, JapicCTI-194668, NCI-2018-01248, NCT03522246, TrialTroveID-306273","ATHENA A Multicenter, Randomized, Double-Blind, Placebo- Controlled Phase 3 Study in Ovarian Cancer Patients Evaluating Rucaparib and Nivolumab as Maintenance Treatment Following Response to Front-Line Platinum-Based Chemotherapy",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Bristol-Myers Squibb, (Other Cooperative Group), Gynecologic Oncology Group (GOG), Clovis Oncology, Roche/Foundation Medicine","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group, Industry, all other pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs",True,NCT03522246,35280
2290,300793,"NCI-2017-00846, NCT03140670, TrialTroveID-300793, UPCC 05217","A Phase II, Open Label Study of Rucaparib in Patients With Advanced Pancreatic Cancer and a Known Deleterious Germline or Somatic BRCA or PALB2 Mutation",Oncology,Oncology: Pancreas,"Abramson Cancer Center at  University of Pennsylvania Medical Center, Clovis Oncology","Academic, Industry, all other pharma","Adverse Events, Overall survival, Phosphate level, Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03140670,35280
2291,292086,"AME, CO-338-045, EudraCT Number: 2015-004394-32, NCT02986100, TrialTroveID-292086","An Open-Label, Non-Randomized, Phase I Study to Assess the Absorption, Metabolism, and Excretion Following a Single Oral Dose of [14C]-Rucaparib in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Area under the curve score, Cmax, Drug clearance, Elimination half-life, Tmax, Volume of distribution, Vomiting","Adverse Events, Disease Progression, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02986100,35280
2292,288630,"16-1087, 16-2449, 16445, 201610146, 20162429, CA018003, CA018-003, EudraCT Number: 2016-002807-24, FRACTION CA018-003, FRACTIONGastric Cancer, FRACTION-Gastric Cancer, FRACTION-GC, NCI-2017-00025, NCT02935634, NL59770.018.17, RWF_CA018-003, TrialTroveID-288630, U1111-1184-8857","A Phase II, Fast Real-time Assessment of Combination Therapies in Immuno-ONcology Study in Participants With Advanced Gastric Cancer (FRACTION-Gastric Cancer)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Bristol-Myers Squibb, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Serious Adverse Events","Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT02935634,35280
2293,286951,"ATLANTIS, ATLANTIS_2015, CRUK/12868, EudraCT Number: 2015-003249-25, IRAS ID: 186191, ISRCTN25859465, TrialTroveID-286951",An Adaptive Multi-Arm Phase II Trial of Maintenance Targeted Therapy after Chemotherapy in Metastatic Urothelial Cancer,Oncology,Oncology: Bladder; Oncology: Renal,"Cancer Research UK, Exelixis, (Other Hospital/Academic/Medical Center), University of Glasgow","Not for Profit Funding Entity, Industry, all other pharma, Academic, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",False,,35280
2294,284575,"081704, 17-200, Clinical Trial 18986, CO-338-052, EudraCT Number: 2016-003162-13, FVCTS-2017-25439, GU 142, IGUP17014, IRAS ID: 219516, NCI-2017-01109, NCT02952534, P 36616, S16-01935, TrialTroveID-284575, TRITON2, USO 16237","TRITON2: A Multicenter, Open-label Phase II Study of Rucaparib in Patients With Metastatic Castration-resistant Prostate Cancer Associated With Homologous Recombination Deficiency.",Oncology,Oncology: Prostate,"(Other Industry Sponsor), Clovis Oncology","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Adverse Events, Brief Pain Inventory, Circulating Tumor Cells, Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, EQ-5D, Heart rate, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT02952534,35280
2295,284176,"INT 148-17, MITO 25, MITO25, MITO-25, NCT03462212, TrialTroveID-284176","A Randomized, Molecular Driven Phase II Trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib, Selected According to HRD Status, in Patients With Advanced (Stage III B-C-IV) Ovarian, Primary Peritoneal and Fallopian Tube Cancer Preceded by a Phase I Dose Escalation Study on Rucaparib-Bevacizumab Combination",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Clovis Oncology, Roche/Foundation Medicine","Cooperative Group, Academic, Industry, all other pharma, Industry, Top 20 Pharma","Maximum tolerated dose, Progression-free survival, Recurrence","Adverse Events, Area under the curve score, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Disease Progression, EQ-5D, NCI-CTC scale, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT03462212,35280
2296,278695,"ET00100869, EudraCT Number: 2016-002610-47, IRAS ID 215913, NCT03101280, RECF3515, TrialTroveID-278695, WO39409",A Phase IB Combination Study of Rucaparib (CO-338) and Atezolizumab (MPDL3280A) in Participants With Advanced Gynecologic Cancers and Triple-Negative Breast Cancer,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian,"Roche/Genentech, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities","Anti-drug antibodies, Area under the curve score, CA-125 Response, Cmax, Cmin, Complete response, Disease Progression, Drug clearance, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT03101280,35280
2297,277701,"DRUP, EudraCT Number: 2015-004398-33, M15DRU, NCT02925234, NL54757.031.16, TrialTroveID-277701","A Dutch National Study on behalf of the Center for Personalized Cancer Treatment (CPCT) to Facilitate Patient Access to Commercially Available, Targeted Anti-cancer Drugs to determine the Potential Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Colorectal; Oncology: Endometrial; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, Novartis, Roche, Pfizer, Bayer AG/Bayer Pharmaceuticals, Eisai, Netherlands Cancer Institute, Boehringer Ingelheim, Ipsen, Merck & Co./Merck Sharp & Dohme (MSD), Clovis Oncology, Johnson & Johnson/Janssen Biotech","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma, Government, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma, Industry, Top 20 Pharma","Overall response rate, Serious Adverse Events, Stable Disease","Overall survival, Progression-free survival",True,NCT02925234,35280
2298,276817,"CO-338-044, DDI, NCT02740712, TrialTroveID-276817","A Phase I, Open-label, Multiple-probe Drug-drug Interaction Study to Determine the Effect of Rucaparib on Pharmacokinetics of Caffeine, S-Warfarin, Omeprazole, Midazolam, and Digoxin in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Clovis Oncology,"Industry, all other pharma","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Cmax, Disease Progression, Drug clearance, Elimination half-life, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax, Volume of distribution",True,NCT02740712,35280
2299,271804,"3804, EudraCT Number: 2014-002169-30, IRAS ID-154429, NCT02678182, PLATFORM, TrialTroveID-271804",Planning Treatment for Oesophago-gastric Cancer: a Randomised Maintenance Therapy Trial,Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, Royal Marsden NHS Trust, AstraZeneca {MedImmune}, Clovis Oncology","Industry, Top 20 Pharma, Government, Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events",True,NCT02678182,35280
2300,271589,"106289, 1612038226, 20162178, ARIEL4, CO-338-043, EudraCT Number: 2016-000816-14, i2254, IRAS ID 206855, NCI-2016-01669, NCT02855944, TrialTroveID-271589, UCI-16-69","ARIEL4 (Assessment of Rucaparib In Ovarian CancEr Trial): A Phase III Multicenter, Randomized Study of Rucaparib Versus Chemotherapy in Patients With Relapsed, BRCA Mutant, High Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"(Other Industry Sponsor), Clovis Oncology","Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Disease Progression, EORTC Quality of Life Questionnaire, Heart rate, Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02855944,35280
2301,271547,"16238, 1723GCCC, 18-146, 18-300, 20171185, 2018IS040, CO-338-063, CSET 2620, EudraCT Number: 2016-003163-20, GU 146, IGUP17020, IRAS ID: 222298, NCI-2017-01110, NCT02975934, S16-02260, STAR Trial, TrialTroveID-271547, TRITON 3_CO-338-063, TRITON3","TRITON3: A Multicenter, Randomized, Open Label Phase III Study of Rucaparib Versus Physician's Choice of Therapy for Patients With Metastatic Castration Resistant Prostate Cancer Associated With Homologous Recombination Deficiency",Oncology,Oncology: Prostate,"(Other Industry Sponsor), Clovis Oncology","Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Brief Pain Inventory, Cardiac Telemetry, Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, EQ-5D-5L, EQ-5D, Functional Assessment of Cancer Therapy-Prostate, Overall response rate - duration, Overall response rate, Overall survival, Partial response, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT02975934,35280
2302,263096,"CRUK/12/034, EudraCT Number: 2014-003319-12, ICR-CTSU-2014-10046, IRAS ID: 154300, ISRCTN92154110, MREC NÂ° 14/LO/2181, RIO, TrialTroveID-263096, UKCRN ID: 18804",Window Study Of The PARP Inhibitor Rucaparib In Patients With Primary Triple Negative Or BRCA1/2 Related Breast Cancer (RIO),Oncology,Oncology: Breast,"(Other Cooperative Group), Royal Marsden NHS Trust, Cancer Research UK, Institute of Cancer Research - UK, (Other government agency), Clovis Oncology","Cooperative Group, Government, Not for Profit Funding Entity, Academic, Government, Industry, all other pharma",,"Circulating Tumor Cells, Safety and Tolerability, Safety and Tolerability",False,,35280
2303,261913,"EudraCT number: 2015-000580-14, GMP 06 RUBY, GMP 06- RUBY, NCT02505048, RECF2816, RUBY, TrialTroveID-261913, UC 0105-1501 _RUBY, UC-0105/1501","A Single Arm, Open-label, Phase II Study to Assess the Efficacy of Rucaparib in Metastatic Breast Cancer Patients With a BRCAness Genomic Signature",Oncology,Oncology: Breast,"(Other Cooperative Group), Clovis Oncology","Cooperative Group, Industry, all other pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT02505048,35280
2304,201000,"2014-0151, CO-338-023, NCT02042378, RUCAPANC, TrialTroveID-201000","A Phase II, Open-Label Study of Rucaparib in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation, , Rucaparib in Pancreatic Cancer (RUCAPANC)",Oncology,Oncology: Pancreas,Clovis Oncology,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Cmin, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02042378,35280
2305,184602,"14-067, 2013-0208, ARIEL3, CO-338-014, CTBE2015000293, EudraCT Number: 2013-000518-39, IRAS ID: 140185, NCI-2014-00430, NCRN-2746/ARIEL 3, NCT01968213, REec-2014-0803, TrialTroveID-184602, UKCRN ID 15840",Phase III Study of Rucaparib as Switch Maintenance After Platinum in Relapsed High Grade Serous and Endometrioid Ovarian Cancer (ARIEL3).,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"(Other Industry Sponsor), Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}, Clovis Oncology","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Disease Progression, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01968213,35280
2306,184598,"13-255, 13-496, 2013-0207, 20150508, ARIEL2, ARIEL-2, CO-338-017, EudraCT Number: 2013-000517-20, GOTARIEL2, IRAS ID: 132240, J1395, NCRN - 2434, NCT01891344, REec-2014-0807, TrialTroveID-184598, UKCRN ID: 15303","A Phase II, Open-Label Study of Rucaparib in Patients with Platinum-Sensitive, Relapsed, High-Grade Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (ARIEL2).",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Clovis Oncology, Roche/Foundation Medicine, Myriad Genetics","Industry, all other pharma, Industry, Top 20 Pharma, Industry, all other pharma","CA-125 Response, Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Circulating Tumor Cells, Cmin, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01891344,35280
2307,149555,"12-048, CO-338, CO-338-010, EudraCT Number: 2011-004250-26, IRAS ID 95258, NCRN365, NCT01482715, REFMAL 259 IST, Study 10, TrialTroveID-149555","A Phase I/II, Open-Label, Safety, Pharmacokinetic, and Preliminary Efficacy Study of Oral Rucaparib in Patients With gBRCA Mutation Ovarian Cancer or Other Solid Tumor",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","(Other Industry Sponsor), Clovis Oncology","Industry, all other pharma, Industry, all other pharma","Adverse Events, Area under the curve score, CA-125 Response, Cmax, Dose-limiting toxicities, Elimination half-life, Elimination rate, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax, Volume of distribution","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01482715,35280
2308,123304,"1011003554, 47300, BRE09-146, HOG BRE09-146, NCT01074970, TrialTroveID-123304","PARP Inhibition After Preoperative Chemotherapy in Patients With Triple Negative Breast Cancer or ER/PR +, HER2 Negative With Known BRCA1/2 Mutations: Hoosier Oncology Group BRE09-146",Oncology,Oncology: Breast,"Hoosier Cancer Research Network {Hoosier Oncology Group}, Pfizer, Clovis Oncology","Cooperative Group, Industry, Top 20 Pharma, Industry, all other pharma",Disease-free survival,"Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability",True,NCT01074970,35280
2309,118370,"09/H0907/83, A4991014, CO-338-1014, EudraCT Number: 2009-013879-22, NCRN135, NCT01009190, RECF1166, SA136, TrialTroveID-118370, UKCRN ID 7737","A Parallel Arms Phase l Safety, Pharmacokinetic And Pharmacodynamic Study Of The Intravenous Poly (ADP-Ribose) Polymerase (PARP) Inhibitor PF-01367338 (AG-014699) In Combination With Several Chemotherapeutic Regimens In Adult Patients With Advanced Solid Tumor",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Ovarian","Pfizer, Clovis Oncology","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Bioavailability, Cmax, Elimination half-life, Heart rate corrected QT interval, Plasma concentration, Tmax",True,NCT01009190,35280
2310,79020,"CRUKD/08/042, CRUK-PARP/BRCA, CRUK-PH2/052, CRUK-PH2-052, EU-20842, EudraCT Number: 2006-002348-27, MREC NÂ°07/H0907/103, N0503198086, NCT00664781, PH2/052, TrialTroveID-079020, UKCRN 4034","A Cancer Research UK Phase II Proof of Principle Trial of the Activity of the PARP-1 Inhibitor, AG-014699, in Known Carriers of a BRCA 1 or BRCA 2 Mutation With Locally Advanced or Metastatic Breast or Advanced Ovarian Cancer",Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Fallopian Tube; Oncology: Ovarian,Cancer Research UK,Not for Profit Funding Entity,"Adverse Events, Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Disease Progression, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Time to progression",True,NCT00664781,35280
2311,67173,"A4991010, NCT00457470, TrialTroveID-067173","A Phase 2, Multi-Stage, Multi-Center Trial Exploring The Safety And Efficacy Of AG-014699 In Subjects With Diffuse Diabetic Macular Edema (DME) Involving The Center Of The Retina.",Metabolic/Endocrinology; Ophthalmology,Metabolic/Endocrinology: Diabetic Complications; Ophthalmology: Diabetic Retinopathy,Pfizer,"Industry, Top 20 Pharma","Retinal thickness, Retinal Thickness","Retinal thickness, Retinal Thickness, Visual acuity",True,NCT00457470,35280
2312,38049,TrialTroveID-038049,"A Phase II, Open-Label, Single Arm, Non-Randomized Study of AG014699 in Combination with Temozolomide in Melanoma Patients.",Oncology,Oncology: Melanoma,"Pfizer, Cancer Research UK","Industry, Top 20 Pharma, Not for Profit Funding Entity","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Progression-free survival, Safety and Tolerability",False,,35280
2313,14383,TrialTroveID-014383,"Phase I Study of the Novel Poly(ADP-ribose)polymerase (PARP) Inhibitor, AG014699, in Combination with Temozolomide in Patients with Advanced Solid Tumors",Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Melanoma; Oncology: Prostate; Oncology: Soft Tissue Sarcoma,"Cancer Research UK, Pfizer {Agouron}","Not for Profit Funding Entity, Industry, Top 20 Pharma",Safety and Tolerability,Safety and Tolerability,False,,35280
2314,274045,TrialTroveID-274045,A Study to Evaluate Zoptrex in Patients with Endometrial Cancer,Oncology,Oncology: Endometrial,Sinopharm A-Think Pharmaceutical Co.,"Industry, all other pharma",,,False,,26678
2315,139443,"20111036, AEZS 108-049, AEZS-108-049, EudraCT Number: 2012-000134-19, NCT01698281, TrialTroveID-139443","A Randomized Phase II Trial Of AEZS-108 In Chemotherapy Refractory Triple Negative, LHRH-Positive Metastatic Breast Cancer",Oncology,Oncology: Breast,Aeterna Zentaris,"Industry, all other pharma","Disease Progression, Progression-free survival","Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01698281,26678
2316,139440,TrialTroveID-139440,A Proof of Concept Study of AEZS-108 in Patients with Pancreatic Cancer,Oncology,Oncology: Pancreas,Aeterna Zentaris,"Industry, all other pharma",,,False,,26678
2317,139432,"1309GCC, 13-520, AEZS -108-050, EudraCT Number: 2012-005546-38, NCT01767155, NL45515.018.13, REec-2013-0599, STU 022013-038, Study AEZS-108-050, TrialTroveID-139432, UCI-13-40, ZoptEC","Randomized Controlled Study Comparing AEZS-108 with Doxorubicin as Second Line Therapy for Locally Advanced, Recurrent or Metastatic Endometrial Cancer., , ZoptEC - Zoptarelin doxorubicin in Endometrial Cancer",Oncology,Oncology: Endometrial,Aeterna Zentaris,"Industry, all other pharma",Overall survival,"Adverse Events, Clinical benefit rate, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01767155,26678
2318,132447,"4P-09-9, NCI-2009-01418, NCT01240629, TrialTroveID-132447",A Phase I/II Trial of AN-152 [AEZS-108) in Castration- and Taxane-Resistant Prostate Cancer,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, University of Southern California, Aeterna Zentaris","Government, Academic, Industry, all other pharma","Dose-limiting toxicities, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Circulating Tumor Cells, Disease Progression, Overall response rate, Overall survival, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT01240629,26678
2319,126915,"20091095, AEZS-108-046, EProst # 20091095, NCT01234519, TrialTroveID-126915",A Phase I/II Trial of AEZS-108 in Locally Advanced Unresectable or Metastatic Luteinizing Hormone-releasing Hormone(LHRH) Positive Urothelial Carcinoma Patients Who Failed Platinum Based Chemotherapy,Oncology,Oncology: Bladder,"Aeterna Zentaris, Sylvester Cancer Center, University of Miami, University of Miami School of Medicine","Industry, all other pharma, Academic, Academic","Common Terminology Criteria for Adverse Events, Maximum tolerated dose","Circulating Tumor Cells, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01234519,26678
2320,70896,"AEZS-10, AEZS-108-040, AGO GYN 5, AGO-GYN 5, AGO-GYN5, AGO-GYN-5, EudraCT Number: 2007-002663-26, NCT00569257, TrialTroveID-070896","Antitumoral Activity and Safety of AEZS-108 (AN-152), a LHRH Agonist Linked Doxorubicin, in Women with LHRH Receptor Positive Gynecological Tumors.",Oncology,Oncology: Endometrial; Oncology: Ovarian,"Aeterna Zentaris, AGO-Study Group Ovarian Cancer","Industry, all other pharma, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall survival, Safety and Tolerability, Time to progression",True,NCT00569257,26678
2321,22784,TrialTroveID-022784,"Phase I dose-ranging study of anti-cancer agent AEZS-108 in ovarian, endometrial or breast cancer.",Oncology,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian,Aeterna Zentaris,"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,False,,26678
2322,400170,"EudraCT Number: 2020-003440-92, INFINITY, NCT04817826, TrialTroveID-400170","TremelImumab aNd Durvalumab Combination For the Non-operatIve Management (NOM) of Microsatellite InstabiliTY (MSI)-High Resectable Gastric or Gastroesophageal Junction Cancer: The Multicentre, Single-arm, Multi-cohort, Phase II INFINITY Study.",Oncology,Oncology: Esophageal; Oncology: Gastric,Gruppo Oncologico Nord-Ovest (G.O.N.O.),Cooperative Group,"Circulating Tumor Cells, Complete response","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, EORTC Quality of Life Questionnaire, EQ-5D, Metastasis-free survival, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04817826,31975
2323,389247,"AAAT0800, NCT04625699, TrialTroveID-389247",A Feasibility Study of Durvalumab + Tremelimumab in Resected Non Small Cell Lung Cancer (NSCLC) Patients With Detectable Circulating Tumor DNA After Adjuvant Treatment,Oncology,"Oncology: Lung, Non-Small Cell",Columbia University Medical Center,Academic,"Circulating Tumor Cells, Resection rate","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Safety and Tolerability",True,NCT04625699,31975
2324,388077,"20187, NCI-2020-06932, NCT04605731, TrialTroveID-388077",A Phase Ib Study of Durvalumab (Medi4736) and Tremelimumab Following Radioembolization in Patients With Unresectable Locally Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04605731,31975
2325,387017,"ACTRN12620000918921, CTC0141 Addendum 7, MoST addendum 7, TrialTroveID-387017, U1111-1182-6652","Single Arm, Open Label, Signal Seeking, Phase IIa Trial Of The Activity Of Tremelimumab In Patients With Advanced Rare Or Neglected Cancers",Oncology,Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, EORTC Quality of Life Questionnaire, Magnetic Resonance Imaging, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",False,,31975
2326,382543,"AIO-HEP-0319/ass, EudraCT Number: 2019-004597-26, IMMUWIN, NCT04522544, TrialTroveID-382543",A Phase II Study of Immunotherapy With Durvalumab (MEDI4736) and Tremelimumab in Combination With Either Y-90 SIRT or TACE for Intermediate Stage HCC With Pick-the-winner Design,Oncology,Oncology: Liver,"AstraZeneca, (Other Academic Cancer Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, EORTC Quality of Life Questionnaire, Liver function, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events",True,NCT04522544,31975
2327,376884,"19-29403, 194522, NCI-2020-03671, NCT04430452, TrialTroveID-376884",Phase II Trial of Palliative Hypofractionated Radiotherapy Followed by Durvalumab (MEDI4736) With/Without Tremelimumab for Advanced Hepatocellular Carcinoma After Progression on Prior PD-1 Inhibition,Oncology,Oncology: Liver,AstraZeneca,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04430452,31975
2328,375006,"19-000459, NCI-2020-01095, NCT04395079, TrialTroveID-375006",Brachytherapy With Durvalumab (MEDI4736) and Tremelimumab in Subjects With Platinum-Resistant or Refractory and Recurrent or Metastatic Gynecological Malignancies,Oncology,Oncology: Cervical; Oncology: Endometrial; Oncology: Ovarian,"AstraZeneca, Jonsson Comprehensive Cancer Center, UCLA","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04395079,31975
2329,368679,"N17DTL, NCT04287894, TrialTroveID-368679","A Phase Ib, Open-label, Single-center Study to Assess the Safety of Cancer-immunotherapy Induction With Tremelimumab and Durvalumab Prior to Chemoradiotherapy and/or Resection in the Treatment of Locally Advanced NSCLC.",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Netherlands Cancer Institute","Industry, Top 20 Pharma, Government","Retinal thickness, Safety and Tolerability","Clinical benefit rate, Disease-free survival, Overall survival",True,NCT04287894,31975
2330,367918,"2011-000139-10, NCT04274816, TrialTroveID-367918",Releasing the Brakes on CD8+ T Cells in the Melanoma Sentinel Lymph Node by Pre-operative Local Administration of Low-dose Anti-CTLA-4 (Tremelimumab),Oncology,Oncology: Melanoma,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Adverse Events, Common Terminology Criteria for Adverse Events",,True,NCT04274816,31975
2331,365855,"EudraCT Number: 2018-004778-81, IMMUWHY, IMMUWHY AIO-HEP-0119 / ass, NCT04238637, TrialTroveID-365855","Phase II Study of Immunotherapy With Durvalumab (MEDI4736) or Durvalumab and Tremelimumab, Both Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC)",Oncology,Oncology: Liver,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04238637,31975
2332,361729,"GUIDE2REPAIR, NCT04169841, TrialTroveID-361729",Precision Medicine Phase II Study Evaluating the Efficacy of a Double Immunotherapy by Durvalumab and Tremelimumab Combined with Olaparib in Patients with Solid Cancers and Carriers of Homologous Recombination Repair Genes Mutation in Response or Stable After Olaparib Treatment.,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Endometrial; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal","AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Progression-free survival, Safety and Tolerability",,True,NCT04169841,31975
2333,360783,"EudraCT Number:2018-002852-34, MIMIPAC, NCT04156087, TrialTroveID-360783, UZ S61508",Progression-free Survival After Minimally Invasive Surgical Microwave Ablation Plus Durvalumab (MEDI4736) and Tremelimumab for Unresectable Non-metastatic Locally Advanced Pancreatic Cancer: MIMIPAC Trial,Oncology,Oncology: Pancreas,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Common Terminology Criteria for Adverse Events, Duration of hospitalization, Length of hospital stay, Overall survival, Safety and Tolerability",True,NCT04156087,31975
2334,358151,"C7535/A27717, MITRE, NCT04107168, TrialTroveID-358151",An Observational Study To Evaluate The Microbiome As A Biomarker Of Efficacy And Toxicity In Cancer Patients Receiving Immune Checkpoint Inhibitor Therapy,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal","(Other Hospital/Academic/Medical Center), Microbiotica","Academic, Industry, all other pharma","Microbiome, Progression-free survival","Adverse Events, Body Mass Index, Common Terminology Criteria for Adverse Events, Disease-free survival, Microbiome, Overall response rate, Overall survival, Progression-free survival",True,NCT04107168,31975
2335,356295,"NCT04073160, Pro00102352, TrialTroveID-356295, TRIO Bladder","TRIO Bladder: A Phase Ib Study of Durvalumab (MEDI 4736) Plus Tremelimumab Followed by Concurrent Durvalumab Plus Bladder Radiation, Based on Molecular Subtypes in Muscle-Invasive Bladder Cancer",Oncology,Oncology: Bladder,"AstraZeneca, Duke University Medical Center","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Complete response, Disease-free survival, Overall survival",True,NCT04073160,31975
2336,354208,"20-015, 2020-0224, HSR200350, NCI-2019-04829, NCT04034927, NRG-GY021, TrialTroveID-354208",A Phase II Randomized Trial of Olaparib Versus Olaparib Plus Tremelimumab in Platinum-Sensitive Recurrent Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, NRG Oncology","Government, Cooperative Group","Adverse Events, Dose-limiting toxicities, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04034927,31975
2337,351002,"EudraCT Number: 2017-001664-37, MILES 5, MILES5, MILES-5, NCT03975114, TrialTroveID-351002",A Randomized Phase II Study Comparing Immunotherapy With Chemotherapy in the Treatment of Elderly Patients With Advanced NSCLC (MILES-5),Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic, Academic","Mortality, Overall survival, Progressive disease rate, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Immune-related response evaluation criteria in solid tumors, Instrumental Activities of Daily Living, Overall response rate, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT03975114,31975
2338,348910,"190094, 19-C-0094, NCI-2019-03113, NCT03937830, TrialTroveID-348910","A Phase II Study of Combined Treatment of Durvalumab, Bevacizuamab, Tremelimumab and Transarterial Chemoembolization (TACE) in Subjects With Hepatocellular Carcinoma (HCC)or Biliary Tract Carcinoma (BTC)",Oncology,Oncology: Liver,National Institutes of Health/National Cancer Institute,Government,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03937830,31975
2339,347924,"MCC-19942, NCI-2019-02885, NCT03923270, TrialTroveID-347924",Sequential Maintenance With Thoracic Radiotherapy and Durvalumab (MEDI4736) Monotherapy or Durvalumab (MEDI 4736) Combinations (Tremelimumab or Olaparib) in Patients With Extensive Stage-Small Cell Lung Cancer After First Line Platinum Based Chemotherapy,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","AstraZeneca, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Academic","Adverse Events, Progression-free survival, Safety and Tolerability, Serious Adverse Events","Overall survival, Progression-free survival",True,NCT03923270,31975
2340,347871,"2018/2798, EudraCT Number: 2018-003115-21, IGR 2798, MATILDA, NCT03982173, TrialTroveID-347871",A Phase II Whole Exome Secquencing-based Basket Trial for Combination Therapy With Durvalumab (Anti-PDL1) (MEDI4736) and Tremelimumab (Anti-CTLA4) in Patients With Metastatic Solid Tumors,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Prostate; Oncology: Unspecified Solid Tumor,Institut Gustave Roussy,Academic,"Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT03982173,31975
2341,347699,"DURIGAST, EudraCT Number: 2018-002014-13, FFCD 1707, NCT03959293, PRODIGE 59 - DURIGAST, PRODIGE59- (FFCD1707) -DURIGAST, TrialTroveID-347699",A Randomized Phase II Study Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression",True,NCT03959293,31975
2342,347316,"48051, IDMCC-18-MULTI-25-PMC, NCI-2019-00665, NCT03911557, TrialTroveID-347316",Phase II Investigation of MEDI4736 (Durvalumab) and Tremelimumab Combination in Somatically Hypermutated Recurrent Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,University of Kentucky,Academic,Time to progression,"Duration of overall response, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability, Time to progression",True,NCT03911557,31975
2343,347016,"C-II-012, EudraCT Number: 2017-003780-35, Re-Check, TrialTroveID-347016","Randomized Phase II, Open-label Efficacy and Safety Study of Second-line Platinum-based Chemotherapy Followed by Durvalumab (MEDI4736) Plus Tremelimumab Versus Platinum-based Chemotherapy Alone in Patients With NSCLC and First-line Checkpoint-inhibitor Therapy",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Central European Society for Anticancer Drug Research","Industry, Top 20 Pharma, Not for Profit Funding Entity","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival",False,,31975
2344,346696,"4-2019-0083, ESR-17-13142, KCT0003742, KGOG 3046, KGOG 3046/TRU-D, KGOG3046, NCT03899610, TrialTroveID-346696, TRU-D",A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D),Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AstraZeneca, (Other Cooperative Group), National Cancer Center - Goyang, Korea, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Cooperative Group, Government, Academic","Overall survival, Progression-free survival","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03899610,31975
2345,345102,"EudraCT Number: 2018-004148-53, ICRA, M18ICR, M18ICR/ESR-18-13667, NCT03871036, NL67737.031.18, TrialTroveID-345102","ICRA (Improve Checkpoint-blockade Response in Advanced Urothelial Cancer), an Adaptive Clinical Study to Determine Efficacy of Combining Weekly Paclitaxel With Tremelimumab +/- Durvalumab (MEDI4736)",Oncology,Oncology: Bladder; Oncology: Renal,"AstraZeneca, Netherlands Cancer Institute","Industry, Top 20 Pharma, Government","Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT03871036,31975
2346,343419,"141756, 19-116, D419EC00001, EudraCT Number: 2018-003118-42, NCI-2019-01529, NCT03837899, NL67429.041.19, TrialTroveID-343419","Phase I/II, Open-Label Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of Durvalumab Monotherapy or in Combination With Tremelimumab in Pediatric Patients With Advanced Solid Tumors and Hematological Malignancies",Oncology,"Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Vital signs","Area under the curve score, Cmax, Cmin",True,NCT03837899,31975
2347,340767,"18-0710, 18-0710.cc, ESR-17-13132, NCI-2019-03866, NCT03802747, TrialTroveID-340767",Phase I Study of Dual Immune Checkpoint Blockade (Anti-PD-L1 (Durvalumab) (MEDI4736) and Anti-CTLA4 (Tremelimumab) Plus Yttrium-90 (Y-90) Radioembolization & Stereotactic Body Radiation Therapy (SBRT) in Refractory Metastatic MSS (Microsatellite Stable) Colorectal Cancer With Liver Metastases,Oncology,Oncology: Colorectal,"AstraZeneca, University of Colorado","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, NCI-CTC scale, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Complete response, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT03802747,31975
2348,339403,"DUTRELASCO, DUTRELASCO trial, ESR-16-12192, EudraCT Number: 2017-000577-36, NCT03784066, S60379, TrialTroveID-339403","Durvalumab (MEDI4736) Plus Tremelimumab in Resectable, Locally Advanced Squamous Cell Carcinoma of the Oral Cavity: a Window of Opportunity Study",Oncology,Oncology: Head/Neck,"AstraZeneca, EORTC European Organisation for Research and Treatment of Cancer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Cooperative Group, Academic",,"Clinical benefit rate, Immune Response, Magnetic Resonance Imaging, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to treatment failure",True,NCT03784066,31975
2349,337604,"DUTHY, EudraCT Number- 2018-001066-42, GETNE-T1812, NCT03753919, TrialTroveID-337604","A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial",Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,(Other Cooperative Group),Cooperative Group,"Complete response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events",True,NCT03753919,31975
2350,337407,"2017-0803, AMC1803, KCT0004533, NCT03751761, TrialTroveID-337407","Durvalumab(MEDI4736)/Tremelimumab Plus Paclitaxel in Patients With Metastatic Gastric Cancer After Failure of First-line Chemotherapy, Phase Ib/II",Oncology,Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Asan Medical Center","Academic, Academic","Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Duration of overall response, Overall survival, Progression-free survival, Progressive disease rate",True,NCT03751761,31975
2351,336591,"39187, EudraCT Number: 2017-003589-28, ISRCTN89314418, OBERON, TrialTroveID-336591","Phase I/Ib trial of durvalumab (MEDI4736), tremelimumab + cetuximab in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (OBERON)",Oncology,Oncology: Head/Neck,"AstraZeneca, Christie Hospital N.H.S. Trust","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability",,False,,31975
2352,335200,"ACTRN12618001742268, ALTG 16/009, CTC 0209, ILLUMINATE, NCT03994393, TrialTroveID-335200",A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab With Chemotherapy in Metastatic EGFR Mutant Non-squamous Non-small Cell Lung Cancer (NSCLC) Following Progression on EGFR Tyrosine Kinase Inhibitors (TKIs),Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, (Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Cooperative Group, Academic","Adverse Events, Clinical benefit rate, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT03994393,31975
2353,334431,"(IMMUNO-BIL), IMMUNO-BIL D18-1 PRODIGE 57, NCT03704480, TrialTroveID-334431",Durvalumab Plus Tremelimumab Combination Immunotherapy With or Without Weekly Paclitaxel in Patients With Advanced Biliary Tract Carcinoma (BTC) After Failure of Platinum-based Chemotherapy: a Randomized Non-comparative Two-arm Phase II Study,Oncology,Oncology: Liver,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT03704480,31975
2354,334375,"19-069, ADRIATIC, CTR20190131, CTRI/2019/01/017034, D933QC00001, EudraCT Number: 2018-000867-10, JapicCTI-184165, NCI-2019-01390, NCT03703297, NL67090.029.18, TrialTroveID-334375","A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","(Other Industry Sponsor), AstraZeneca {MedImmune}","Industry, all other pharma, Industry, Top 20 Pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Complement levels, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03703297,31975
2355,334278,"1810-035-977, 2018-10-009, 4-2018-0749, AMBITION, ESR-17-12678, KCT0003283, KGOG3045, NCT03699449, TrialTroveID-334278",An Umbrella Study of Biomarker-driven Targeted Therapy In Patients With Platinum-resistant Recurrent Ovarian Cancer (AMBITION),Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Duration of overall response, Progression-free survival",True,NCT03699449,31975
2356,333942," , 19-094, 207871, INDUCE2, NCI-2019-00926, NCT03693612, S18-01740, TrialTroveID-333942","A Phase I/II, Open-label, Two Part Study of GSK3359609 in Combination With Tremelimumab in Participants With Selected, Advanced Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal","GlaxoSmithKline, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Change in oxygen saturation, Creatinine kinase level, Diastolic blood pressure, Dose-limiting toxicities, Eosinophil levels, Hematocrit level, Hemoglobin level, Liver function, NCI-CTC scale, Overall survival, Platelet count, Serious Adverse Events","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Change in oxygen saturation, Clinical benefit rate, Cmax, Cmin, Complete response, Creatinine kinase level, Disease Progression, Duration of overall response, Eosinophil levels, Hematocrit level, Hemoglobin level, Overall response rate, Partial response, Plasma concentration, Platelet count, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease, Time to response",True,NCT03693612,31975
2357,333794,"EudraCT Number: 2017-003159-44, IMMUNOPRESERVE, NCT03702179, SOGUG-2017-A-IEC(VEJ)-1, TrialTroveID-333794",Phase II Trial of Durvalumab (Medi4736) Plus Tremelimumab With Concurrent Radiotherapy in Patients With Localized Muscle Invasive Bladder Cancer Treated With a Selective Bladder Preservation Approach.,Oncology,Oncology: Bladder,"AstraZeneca, Spanish Oncology GenitoUrinary Group","Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03702179,31975
2358,333493,"(NILE), CTR20190596, D933SC00001, EudraCT Number: 2018-001883-48, JapicCTI-184160, NCI-2019-02117, NCT03682068, NILE, PHRR190110-001981, TrialTroveID-333493, UAB1883","A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line Durvalumab in Combination With Standard of Care Chemotherapy and Durvalumab in Combination With Tremelimumab and Standard of Care Chemotherapy Versus Standard of Care Chemotherapy Alone in Patients With Unresectable Locally Advanced or Metastatic Urothelial Cancer.",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"AstraZeneca {MedImmune}, Catalent","Industry, Top 20 Pharma, Miscellaneous","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03682068,31975
2359,330907,"CRMS-69872, J18118, NCI-2018-03653, NCT03638141, TrialTroveID-330907",The Effect of CTLA-4/PD-L1 Blockade Following Drug-eluting Bead Transarterial Chemoembolization (DEB-TACE) in Patients With Intermediate Stage of HCC Using Durvalumab (MEDI4736) and Tremelimumab,Oncology,Oncology: Liver,"AstraZeneca, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT03638141,31975
2360,329880,"17-001204, NCI-2018-01214, NCT03618134, TrialTroveID-329880",Phase Ib/II Trial of Stereotactic Body Radiotherapy (SBRT) in Combination With Immunotherapy Prior to Transoral Robotic Surgery (TORS) for Human Papillomavirus Positive (HPV+) Squamous Cell Carcinoma of the Head and Neck (SCCHN),Oncology,Oncology: Head/Neck,"AstraZeneca, Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Immune Response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Quality of Life, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tumor control rate",True,NCT03618134,31975
2361,329818,"CCCC-H&N-IRT-1, DURTRERAD, DURTRE-RAD, EudraCT Number: 2016-003175-22, NCT03624231, TrialTroveID-329818",Ph II Trial to Assess Feasibility+Efficacy of Treatment w Durva+Treme+Radiation and Treatment w Durva+Radiation as First-line Therapy for Patients w Non-resectable Locally Advanced HPV-HNSCC- a Comparision With a Historical Control Group,Oncology,Oncology: Head/Neck,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Metastasis-free survival, Progression-free survival","Common Terminology Criteria for Adverse Events, Disease Progression, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03624231,31975
2362,329392,"4-2016-0912, KCSG BR17-04, KCT0003319, MUTATION1, NCT03608865, TrialTroveID-329392","Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Hormone Receptor-positive, Hypermutated Metastatic Breast Cancer Identified by Whole Exome Sequencing",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03608865,31975
2363,328909,"18-x172, 202003083, NCI-2020-02875, NCT03598816, PIVOT-RCC, TrialTroveID-328909",A Randomized Phase II PIVOT-RCC (PolyImmune {Durvalumab (MEDI4736) and Tremelimumab} & Vaccine Orchestrated Treatment for Patients With Advanced/Metastatic Renal Cell Carcinoma) Trial,Oncology,Oncology: Renal,"Washington University School of Medicine, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT03598816,31975
2364,328838,"17-001894, NCI-2018-01415, NCT03601455, TrialTroveID-328838","Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibitor (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Locally Advanced, or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy",Oncology,Oncology: Bladder,"AstraZeneca, Jonsson Comprehensive Cancer Center, UCLA","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Additional Treatment Necessary, Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Tumor control rate",True,NCT03601455,31975
2365,326316,"18-1027, GU17-294, HCRN GU17-294, NCI-2018-02260, NCT03557918, TrialTroveID-326316",Phase II Trial of Tremelimumab in Patients With Metastatic Urothelial Cancer Previously Treated With PD-1/PD-L1 Blockade,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03557918,31975
2366,324557,"LCCC1725, NCI-2018-01130, NCT03529422, Pro00089876, TrialTroveID-324557",A Phase II Study of Durvalumab (MEDI 4736) With Radiotherapy for the Adjuvant Treatment of Intermediate Risk Head and Neck Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,"AstraZeneca, UNC Lineberger Comprehensive Cancer Center","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Disease-free survival, Dose-limiting toxicities, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Disease Progression, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability",True,NCT03529422,31975
2367,324073,"9881, NCI-2018-00540, NCT03522584, RG1717067, TrialTroveID-324073","Durvalumab (MEDI4736), Tremelimumab and Palliative Hypofractionated Image Guided Radiation Therapy (HIGRT) in Patients With Recurrent/Metastatic Squamous Cell Carcinomas of the Head and Neck Previously Treated With Immune Checkpoint Inhibitors",Oncology,Oncology: Head/Neck,"AstraZeneca, National Institutes of Health/National Cancer Institute, University of Washington","Industry, Top 20 Pharma, Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT03522584,31975
2368,323888,"EudraCT Number: 2017-001857-14, MOVIE, NCT03518606, RECF3886, TrialTroveID-323888, UC-0101/1709",A Phase I/II Basket Trial Evaluating A Combination Of Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy In Patients With Advanced Solid Tumour,Oncology,Oncology: Breast; Oncology: Cervical; Oncology: Head/Neck; Oncology: Prostate; Oncology: Unspecified Solid Tumor,"AstraZeneca, (Other Cooperative Group), National Institutes of Health/National Cancer Institute, Pierre Fabre","Industry, Top 20 Pharma, Cooperative Group, Government, Industry, all other pharma","Clinical benefit rate, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT03518606,31975
2369,323253,"1805527255, CLOVER, D933BC00001, JapicCTI-183987, NCI-2018-01579, NCT03509012, TrialTroveID-323253",A Phase I Multicenter Study of Immunotherapy in Combination With Chemoradiation in Patients With Advanced Solid Tumors (CLOVER),Oncology,"Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Disease-free survival, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03509012,31975
2370,321544,"17-517, NCI-2018-01193, NCT03482102, TrialTroveID-321544",A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab and Radiation Therapy in Hepatocellular Carcinoma and Biliary Tract Cancer,Oncology,Oncology: Liver,"AstraZeneca, Massachusetts General Hospital","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Complete response, Disease Progression, Immune-related response evaluation criteria in solid tumors, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease, Time to progression, Treatment Emergent Adverse Events",True,NCT03482102,31975
2371,320864,"DUTRENEO, DUTRENEO MEDI4736, EudraCT Number: 2017-002246-68, NCT03472274, TrialTroveID-320864","The DUTRENEO Trial: A Prospective Study to Individualize the Approach With DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients., , DUrvalumab (MEDI4736) and TREmelimumab in NEOadjuvant Bladder Cancer Patients (DUTRENEO)",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Complete response,"Adverse Events, Cardiac Telemetry, Complete response, Disease-free survival, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03472274,31975
2372,320683,"ACTRN12617001325392, BCT 1703, DIAmOND, DIAMOND, TrialTroveID-320683","BCT 1703 (Diamond): An Investigator-initiated, Non-randomised, Phase II Study of Combination Ctla-4 and Pd-l1 Blockade in Advanced Her2-positive Breast Cancers Who Have Progressed on Prior Trastuzumab-based Therapy., , DIAmOND: Double Immune ActivatiON in her2-positive Disease",Oncology,Oncology: Breast,ANZ Breast Cancer Trials Group,Cooperative Group,Response evaluation criteria in solid tumors,"Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to treatment failure",False,,31975
2373,320534,"AIO-HEP-0117, AIO-HEP-0117 IMMUCHEC, EudraCT Number: 2017-001538-25, IMMUCHEC, NCT03473574, TrialTroveID-320534",A Randomized Phase II Trial Of Durvalumab And Tremelimumab With Gemcitabine Or Gemcitabine And Cisplatin Compared To Gemcitabine And Cisplatin In Treatment-NaÃ¯ve Patients With Cholangio- And Gallbladder Carcinoma (IMMUCHEC),Oncology,Oncology: Liver,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT03473574,31975
2374,319688,"2017-0548, NCI-2018-00627, NCT03452332, TrialTroveID-319688","Phase I Multi-Center Study of Hypofractionated Radiotherapy in Combination With Durvalumab and Tremelimumab in Patients With Recurrent/Metastatic Advanced Cervical, Vaginal, or Vulvar Cancer",Oncology,Oncology: Cervical; Oncology: Vaginal; Oncology: Vulvar,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Disease Progression, Duration of overall response, Immune Response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to next treatment",True,NCT03452332,31975
2375,319586,"2017-09-026, NCT03450967, TrialTroveID-319586",A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab Combined With Proton Therapy for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",,True,NCT03450967,31975
2376,318540,"kbcrnb001, NCT03430466, TrialTroveID-318540, UMIN000026050","Phase II Study to Assess Efficacy, Safety & Immunological Biomarker of Anti PD-L1 Antibody + Anti CTLA-4 Antibody in Combination With Hormone Therapy in Patients With Hormone Receptor Positive HER2-negative Recurrent or Metastatic Breast Cancer",Oncology,Oncology: Breast,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response rate","Clinical benefit rate, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Progression-free survival, Response rate",True,NCT03430466,31975
2377,318523,"17-511, NCI-2018-00313, NCT03430895, TrialTroveID-318523","A Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab in Metastatic, Non-transitional Cell Carcinoma of the Urothelial Tract",Oncology,Oncology: Bladder; Oncology: Neuroendocrine; Oncology: Renal,"AstraZeneca, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Gene expression profiling, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT03430895,31975
2378,318232,"0480, CheckRad-CD8, EudraCT NUMBER: 2017-003226-33, NCT03426657, TrialTroveID-318232","First-line Treatment of Locally Advanced HNSCC with Double Checkpoint Blockade and Radiotherapy Dependent on Intratumoral CD8+ T Cell Infiltration (CheckRad-CD8, EudraCT NUMBER: 2017-003226-33)",Oncology,Oncology: Head/Neck,"AstraZeneca, University of Erlangen-Nuremberg","Industry, Top 20 Pharma, Academic",Dose-limiting toxicities,"Magnetic Resonance Imaging, Overall survival, Progression-free survival",True,NCT03426657,31975
2379,317917,"ACTRN12618000109202, iPRIME, TrialTroveID-317917, U1111-1207-7229","A Phase II Study of Durvalumab and Tremelimumab in Combination With Neoadjuvant Carboplatin and Paclitaxel in Newly Diagnosed Women with Advanced High Grade Serous Ovarian, Fallopian Tube and Peritoneal Cancers âiPRIMEâ.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Australian and New Zealand Gynaecological Oncology Group,Cooperative Group,Complete response,"Common Terminology Criteria for Adverse Events, Disease Progression, Functional Assessment of Cancer Therapy-Ovarian Cancer, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,31975
2380,317244,"1740-HNCG, CCTG HN.9, EORTC-1740-HNCG, EudraCT Number: 2019-000308-13, HN9, NCT03410615, TrialTroveID-317244",Randomized Phase II Study of Cisplatin Plus Radiotherapy Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Durvalumab Versus Durvalumab Plus Radiotherapy Followed by Adjuvant Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer (LA-OSCC),Oncology,Oncology: Head/Neck,"AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group","Event-free survival, Recurrence","Ability to swallow, Adverse Events, Clinical benefit rate, Cost effectiveness, EQ-5D-5L, Event-free survival, Functional Assessment of Cancer Therapy-Head & Neck Cancer, Immune-related response evaluation criteria in solid tumors, Likert scale, Metastasis-free survival, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Quality of Life, Recurrence, Safety and Tolerability",True,NCT03410615,31975
2381,315487,"(CCTG) IND.234 / PC-BETS - Master Protocol, CCGT 1234B, CCTG I234B, CCTG IND234, I234, IND.234, IND234, NCT03385655, PC-BETS Study, TrialTroveID-315487",Prostate Cancer Biomarker Enrichment and Treatment Selection (PC-BETS) Study,Oncology,Oncology: Prostate,"(Other Cooperative Group), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, (Other Hospital/Academic/Medical Center), Canadian Cancer Society","Cooperative Group, Cooperative Group, Academic, Academic, Not for Profit Funding Entity","Clinical benefit rate, Overall response rate, Stable Disease","Adverse Events, Overall response rate, Overall survival, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors",True,NCT03385655,31975
2382,315138,"ESR-16-12571, MCC-19356, NCI-2019-05649, NCT03381183, TrialTroveID-315138","A Phase Ib Trial of the IRX-2 Regimen and Durvalumab (MEDI4736), in Patients with Incurable Head and Neck Squamous Cell Carcinoma.",Oncology,Oncology: Head/Neck,"AstraZeneca, H. Lee Moffitt Cancer Center and Research Institute, Brooklyn ImmunoTherapeutics {IRX Therapeutics}","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03381183,31975
2383,314968,"NCT03377400, SMC 2017-06-138, TrialTroveID-314968",Phase II Trial of Durvalumab (MEDI4736 )/Tremelimumab Combined With Definitive Concurrent Chemo-radiotherapy for Inoperable Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival",,True,NCT03377400,31975
2384,311961,"ESR1612461, EudraCT Number: 2017-002797-39, NTR6553, TrialTroveID-311961",A Phase Ib Open Label Study of Safety and Tolerability in Patients Treated With Stereotactic Radiotherapy (To The Primary Tumor) Combined With Durvalumab (Medi4736) and tremelimumab in Patients with Stage IV Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Adverse Events, Immune Response, Overall response rate, Overall survival, Progression-free survival, Response rate",False,,31975
2385,311434,"EORTC-1643, EudraCT Number: 2017-001827-39, NCT03319316, SOLUTION, TrialTroveID-311434",Randomized Phase II Study of Durvalumab and Tremelimumab Combination Versus Standard of Care Following First-line Platinum Based Chemotherapy in Two Cohorts of Patients With Non Squamous and Squamous Non-small-cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell",EORTC European Organisation for Research and Treatment of Cancer,Cooperative Group,"Disease Progression, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03319316,31975
2386,311294,"AIO_STS-0415, AIO-STS-0415, AIO-STS-0415 MEDISARC, EudraCT Number: 2016-004750-15, MEDISARC, NCT03317457, TrialTroveID-311294",A Randomized Phase II Study of Durvalumab (MEDI4736) and Tremelimumab Compared to Doxorubicin in Patients With Advanced or Metastatic Soft Tissue Sarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"AstraZeneca, Arbeitsgemeinschaft fur Internistische Onkologie","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03317457,31975
2387,310227,"17-1067, 18-306, 18-434, CC#174532, CSET 2642, CTR20180607, CTRI/2018/01/011353, D419CC00002, D419CC00002 (HIMALAYA), Dayyani, EudraCT Number: 2016-005126-11, HIMALAYA, J1891, JapicCTI-183849, NCI-2018-01057, NCT03298451, TrialTroveID-310227, UCI 17-97","A Randomized, Open-label, Multi-center Phase III Study of Durvalumab and Tremelimumab as First-line Treatment in Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,"AstraZeneca, AstraZeneca {MedImmune}, Boehringer Ingelheim","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Overall survival","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT03298451,31975
2388,309856,"13Y-MC-E011, KCSG HN15-16, KCSG-TRIUMPH, NCT03292250, NCT03356587, TrialTroveID-309856, TRIUMPH Trial","Public-interest Multicenter Umbrella Trial Based on Genetic Analysis in Korean Head and Neck Cancer and Esophageal Cancer Patient - Part 1 (HNSCC)], , A Biomarker-driven, Open Label, Single Arm, Multicentre Phase II Study of Abemaciclib in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Who Failed to Platinum-based Therapy",Oncology,Oncology: Esophageal; Oncology: Head/Neck,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Clinical benefit rate, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Duration of overall response, Functional Assessment of Cancer Therapy-Head & Neck Cancer, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Time to progression",True,NCT03292250,31975
2389,309692,"17/LO/1875, 20363/0380/001-0001, 34496, EudraCT Number: 2017-002329-39, IRAS ID: 219487, ISRCTN53348826, MRC RE06, NCT03288532, RAMPART, RE06, TrialTroveID-309692","An International Investigator-Led Phase III Multi Arm Multi Stage Multi-centre Randomised Controlled Platform Trial of Adjuvant Therapy in Patients With Resected Primary Renal Cell Carcinoma (RCC) at High or Intermediate Risk of Relapse, , Renal Adjuvant MultiPle Arm Randomised Trial (RAMPART)",Oncology,Oncology: Renal,"AstraZeneca, (Other Cooperative Group), Cancer Research UK, University College London","Industry, Top 20 Pharma, Cooperative Group, Not for Profit Funding Entity, Academic","Disease-free survival, Mortality, Overall survival, Recurrence","Adverse Events, Metastasis-free survival, Quality of Life",True,NCT03288532,31975
2390,309204,"ESR-16-12361, NCT03283605, TrialTroveID-309204",Phase I/II Of Durvalumab (MEDI4736) + Tremelimumab + Stereotactic Body Radiotherapy For Metastatic Head And Neck Carcinoma,Oncology,Oncology: Head/Neck,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events","Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Recurrence, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events, Stable Disease",True,NCT03283605,31975
2391,308896,"17-382, NCI-2018-00221, NCT03277482, TrialTroveID-308896","A Phase I Study of Durvalumab, Tremelimumab and Radiotherapy in Recurrent Gynecologic Cancer",Oncology,Oncology: (N/A); Oncology: Cervical; Oncology: Endometrial; Oncology: Fallopian Tube; Oncology: Ovarian; Oncology: Vaginal; Oncology: Vulvar,"AstraZeneca, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT03277482,31975
2392,308641,"2017-0665, A533300, NCI-2017-01952, NCT03275597, SMPH\HUMAN ONCOLOGY\HUMAN ONCO, TrialTroveID-308641, UW17003",Comprehensive Stereotactic Body Radiotherapy (SBRT) to All Sites of Oligometastatic Non-small Cell Lung Cancer (NSCLC) Combined With Durvalumab (MEDI4736) and Tremelimumab Dual Immune Checkpoint Inhibition.,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer","AstraZeneca, University of Wisconsin","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Circulating Tumor Cells, Disease Progression, Immune Response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03275597,31975
2393,308094,"ENGOT OV30, ENGOT-OV30 / NSGO, ENGOT-OV30/NSGO, EudraCT Number: 2017-002805-36, NCT03267589, NSGO-OV-UMB1, TrialTroveID-308094",NSGO-OV-UMB1; ENGOT-OV30 / NSGO: A Phase II Umbrella Trial in Patients With Relapsed Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"(Other Cooperative Group), Nordic Society for Gynaecologic Oncology, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Nord-Ostdeutsche Gesellschaft fur Gynakologische Onkologie Group, Japanese Gynecologic Oncology, Australian and New Zealand Gynaecological Oncology Group","Cooperative Group, Not for Profit Funding Entity, Academic, Cooperative Group, Cooperative Group, Cooperative Group","Clinical benefit rate, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03267589,31975
2394,307118,"CSET 2573, GINECO-OV127b, INeOV, NCT03249142, TrialTroveID-307118","A Multicentre Feasibility Randomized Study of Anti-PD-L1 Durvalumab (MEDI4736) With or Without Anti-CTLA-4 Tremelimumab in Patients With Ovarian, Fallopian Tube or Primary Peritoneal Adenocarcinoma, Treated With a First-line Neo-adjuvant Strategy",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events","Adverse Events, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03249142,31975
2395,306403,"CRMS-66593, J1772, NCI-2018-03088, NCT03237377, TrialTroveID-306403",Neoadjuvant Immunoradiation for Stage III Resectable Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Industry, Top 20 Pharma, Academic, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Resection rate, Safety and Tolerability, Safety and Tolerability","Adverse Events, Circulating Tumor Cells, Complete response, Disease-free survival, Duration of overall response, Mortality, Overall survival, Partial response, Progressive disease rate, Recurrence, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events, Tumor control rate",True,NCT03237377,31975
2396,306239,"2017-001988, BASEC ID: 2017-01240, NCT03234153, NITIMIB, NITIMIB-Trial, SNCTP000002663, TrialTroveID-306239",Neoadjuvant Immunotherapy With Durvalumab in Combination With Tremelimumab in Patients With Muscle-invasive Bladder Cancer Ineligible for Cisplatin-based Chemotherapy,Oncology,Oncology: Bladder,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Adverse Events, Disease-free survival, Overall survival",True,NCT03234153,31975
2397,305055,"2016/2454, ABBIMUNE, EudraCT Number: 2016-003293-40, NCT03212469, TrialTroveID-305055","A Phase I/II Study Evaluating the Safety and Clinical Activity of Anti-PDL1 (Durvalumab [MEDI4736]) + Anti CTLA-4 (Tremelimumab) Antibodies Administrated in Combination With Stereotactic Body Radiotherapy (SBRT) in Patients With Metastatic Squamous Cell Carcinoma of Head and Neck, Lung, Oesophageus, Cervix, Vagina,Vuvla or Anus",Oncology,"Oncology: Anal; Oncology: Cervical; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Vaginal; Oncology: Vulvar",Institut Gustave Roussy,Academic,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities",,True,NCT03212469,31975
2398,304496,"MEDETREME, MEDITREME, MEDI-TREME-COLON, NCT03202758, RECF3376, TrialTroveID-304496","Phase Ib/II Trial Evaluating the Safety, Tolerability and Immunological Activity of Durvalumab (MEDI4736) (Anti-PD-L1) Plus Tremelimumab (Anti-CTLA-4) Combined With FOLFOX in Patients With Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Progression-free survival, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",True,NCT03202758,31975
2399,302184,"729, CTR20180636, D419MC00004, EudraCT Number: 2017-000920-81, IRAS ID: 228153, JapicCTI-173673, NCI-2017-02015, NCT03164616, PER-025-17, POSEIDON, TrialTroveID-302184","A Phase III, Randomized, Multi-Center, Open-Label, Comparative Global Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination with Platinum-Based Chemotherapy for First-Line Treatment in Patients with Metastatic Non Small-Cell Lung Cancer (NSCLC) (POSEIDON)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT03164616,31975
2400,301783,"17-160, NCI-2017-01093, NCT03158064, TrialTroveID-301783","A Single-arm, Phase II Study of Durvalumab (MEDI4736) and Tremelimumab for Relapsed/Refractory Germ Cell Tumors",Oncology,Oncology: Ovarian; Oncology: Testicular,"AstraZeneca, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Academic","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03158064,31975
2401,301482,"16529, NCT03150836, TrialTroveID-301482","Multi-Institutional Phase II Study of Radiation Therapy and Anti-PD-L1 Checkpoint Inhibition (Durvalumab) With or Without Anti-CTLA-4 Inhibition (Tremelimumab) in Patients With Unresectable, Muscle-Invasive or Metastatic Urothelial Bladder Cancer That Are Ineligible or Refusing Chemotherapy",Oncology,Oncology: Bladder,AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT03150836,31975
2402,301173,"2016-0805, CIAO, NCI-2018-01199, NCT03144778, TrialTroveID-301173",Checkpoint Inhibitors Assessment in Oropharynx Carcinoma (CIAO),Oncology,Oncology: Head/Neck,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, MD Anderson Symptom Inventory, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events",True,NCT03144778,31975
2403,300282,"2016-0902, NCI-2018-01189, NCT03132467, TrialTroveID-300282","A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast Cancer",Oncology,Oncology: Breast,"AstraZeneca, MD Anderson Cancer Center, University of Texas","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability",Complete response,True,NCT03132467,31975
2404,300187,"AAAQ8535, NCI-2017-01896, NCT03130764, TrialTroveID-300187",Identification of Tumor Neoantigens During Immune Checkpoint Blockade in Resectable Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell",Columbia University Medical Center,Academic,,"Disease-free survival, Overall survival, Recurrence, Safety and Tolerability",True,NCT03130764,31975
2405,299794,"17-108, NCI-2017-00745, NCT03122496, TrialTroveID-299794",A Pilot Study of Durvalumab (MEDI4736) With Tremelimumab in Combination With Image Guided Stereotactic Body Radiotherapy (SBRT) in the Treatment of Metastatic Anaplastic Thyroid Cancer,Oncology,Oncology: Thyroid,"AstraZeneca, Memorial Sloan-Kettering Cancer Center","Industry, Top 20 Pharma, Academic","Overall survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Treatment Emergent Adverse Events, Tumor control rate",True,NCT03122496,31975
2406,299793,"17-139, NCI-2017-00742, NCT03122509, TrialTroveID-299793",Phase II Study to Assess the Efficacy of Durvalumab (MEDI4736) and Tremelimumab Plus Radiotherapy or Ablation in Patients With Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"Memorial Sloan-Kettering Cancer Center, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT03122509,31975
2407,298761,"1560-GITCG, 2018-00571, EORTC ILOC, EudraCT Number: 2017-001375-22, ILOC, NCT03101475, NL64627.031.18, SNCTP000003184, TrialTroveID-298761",Phase II of Immunotherapy Plus Local Tumor Ablation (RFA or Stereotactic Radiotherapy) in Patients With Colorectal Cancer Liver Metastases,Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"EORTC European Organisation for Research and Treatment of Cancer, Netherlands Cancer Institute","Cooperative Group, Government","Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Immune Response, Immune-related response evaluation criteria in solid tumors, NCI-CTC scale, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT03101475,31975
2408,298412,"DUNE, ESR 15-11561-61-DUNE, ESR-15-11561-61/DUNE, EudraCT Number: 2016-002858-20, GETNE1601, NCT03095274, TrialTroveID-298412",A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Advanced Neuroendocrine Neoplasms of Gastroenteropancreatic or Lung Origin (the DUNE Trial),Oncology,Oncology: Neuroendocrine,(Other Cooperative Group),Cooperative Group,"Clinical benefit rate, Complete response, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Common Terminology Criteria for Adverse Events, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT03095274,31975
2409,298168,"D6840C00001, NCI-2018-00666, NCT03089645, TrialTroveID-298168","A Phase I First Time in Human Study to Evaluate the Safety, Pharmacokinetics and Immunogenicity of MEDI5083 Alone or in Combination With Durvalumab, Tremelimumab, and/or Docetaxel in Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Anti-drug antibodies, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03089645,31975
2410,297945,"AAAQ8257, NCI-2017-01393, NCT03085849, TrialTroveID-297945",A Phase I Study Evaluating the Safety and Efficacy of SGI-110 Followed by Combined Durvalumab Plus Tremelimumab in Subjects With Extensive-stage Small Cell Lung Cancer (ES-SCLC),Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Treatment Emergent Adverse Events","Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Treatment Emergent Adverse Events",True,NCT03085849,31975
2411,297928,"AstraZeneca D4191C00068, CSET 2599, D4191C00068, EudraCT Number: 2016-005068-33, IRAS ID: 224051, NCT03084471, NL61095.091.17, SNCTP000002304, STRONG, TrialTroveID-297928","An Open-Label, Multi-Centre, Safety Study of Fixed-Dose Durvalumab + Tremelimumab Combination Therapy or Durvalumab Monotherapy in Advanced Solid Malignancies.",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal; Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT03084471,31975
2412,297288,"16-549, NCI-2017-00758, NCT03075527, TrialTroveID-297288",A Phase II Study of Durvalumab in Combination With Tremelimumab in Malignant Pleural Mesothelioma,Oncology,Oncology: Mesothelioma,"AstraZeneca, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03075527,31975
2413,296306,"Lung-MAP, Lung-Map Non-Match Sub Study, Lung-Map Sub-Study, NCI-2016-01597, NCT03373760, S1400F, SWOG1400F, TrialTroveID-296306",A Phase II Study of MEDI4736 (Durvalumab) Plus Tremelimumab as Therapy for Patients With Previously Treated Anti-PD-1/PD-L1 Resistant Stage IV Squamous Cell Lung Cancer (Lung-Map Non-Match Sub-Study),Oncology,"Oncology: Lung, Non-Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03373760,31975
2414,296064,"ACTRN12617001468314, ALTG 15/004, ALTG 15/004 BR.34, ALTG BR.34, BR.34, BR.34 ALTG 15/004, BR34, BR-34, CCTG BR.34, CCTG BR-34, CTC 0155, NCT03057106, SSA/17/QPCH/426, TrialTroveID-296064",A Randomized Trial of Durvalumab and Tremelimumab Â± Platinum-Based Chemotherapy in Patients With Metastatic (Stage IV) Squamous or Non-Squamous Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), (Other Hospital/Academic/Medical Center), National Health and Medical Research Council  (NHMRC)","Industry, Top 20 Pharma, Cooperative Group, Academic, Academic, Government",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Cost effectiveness, Disease Progression, EORTC Quality of Life Questionnaire, EQ-5D, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT03057106,31975
2415,295649,"BTC-1st MEDITREME, H-1609-120-795, KCT0004505, NCT03046862, TrialTroveID-295649",Biomarker-oriented Study of Durvalumab(MEDI4736)/Tremelimumab in Combination With Gemcitabine/Cisplatin in Chemotherapy-naÃ¯ve Biliary Tract Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03046862,31975
2416,295403,"CASPIAN, CTR20180090, D419QC00001, EudraCT Number: 2016-001203-23, JapicCTI-173635, NCI-2017-00703, NCT03043872, NL59719.031.17, STADIUM IV, TrialTroveID-295403","A Phase III, Randomized, Multicenter,Open-Label, Comparative Study to Determine the Efficacy of Durvalumab or Durvalumab and Tremelimumab in Combination With Platinum-Based Chemotherapy for the First-Line Treatment in Patients With Extensive Disease Small-Cell Lung Cancer (SCLC) (CASPIAN)",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","AstraZeneca, AstraZeneca {MedImmune}, Boehringer Ingelheim","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT03043872,31975
2417,294652,"2016-0093, NCI-2018-01240, NCT03026062, TrialTroveID-294652",Randomized Phase II Trial of Durvalumab (MEDI4736) and Tremelimumab Administered in Combination Versus Sequentially in Recurrent Platinum-Resistant Epithelial Ovarian Cancer.,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AstraZeneca, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government","Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT03026062,31975
2418,294301,"NCT03022500, PSC, TrialTroveID-294301",Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT03022500,31975
2419,293635,"ESR-15-11514, FC-9, NCI-2017-01134, NCT03007407, NSABP FC-9, Study HIC#: 2000021242, TrialTroveID-293635",A Phase II Study of the Dual Immune Checkpoint Blockade With Durvalumab (MEDI4736) Plus Tremelimumab Following Palliative Hypofractionated Radiation in Patients With Microsatellite Stable (MSS) Metastatic Colorectal Cancer Progressing on Chemotherapy,Oncology,Oncology: Colorectal,National Surgical Adjuvant Breast and Bowel Project (NSABP),Cooperative Group,"Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03007407,31975
2420,293350,"16423, NCI-2016-02001, NCT03005002, TrialTroveID-293350",A Pilot Feasibility Study of Durvalumab (MEDI4736) and Tremelimumab Following Radioembolization in Patients With Metastatic Microsatellite Stable (MSS) Colorectal Cancer to the Liver,Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03005002,31975
2421,292880,"BIG 16-01, BIG-106, EudraCT Number: 2016-000764-42, NCT02997995, RECF3323, TrialTroveID-292880, UC-0140/1606, UC-0140/1606 - ULTIM, UCBG-105, ULTIMATE",A Phase II Trial Testing Durvalumab Combined With Endocrine Therapy in Patients With ER+/Her2- Breast Cancer Eligible for Neoadjuvant Endocrine Therapy And Who Present CD8+ T Cell Infiltration After 4-6 Weeks Exposure to Immune-Attractant,Oncology,Oncology: Breast,"Breast International Group, Federation Nationale des Centres de Lutte contre le Cancer","Cooperative Group, Cooperative Group",Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Safety and Tolerability",True,NCT02997995,31975
2422,291676,"CTR20160926, D419AC00006, NCT02978482, TrialTroveID-291676","A Phase I/II Open-label, Multi-center Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of Durvalumab (MEDI4736) in Combination With Tremelimumab in Chinese Patients With Advanced Malignancies",Oncology,Oncology: Head/Neck; Oncology: Unspecified Solid Tumor,"AstraZeneca, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Overall response rate, Plasma concentration, Safety and Tolerability, Vital signs","Anti-drug antibodies, Complete response, Neutralizing antibody response, Overall survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02978482,31975
2423,290563,"16-1405, NCI-2016-01758, NCT02962063, TrialTroveID-290563",Phase Ib/II Study of Induction Chemotherapy and Durvalumab (MEDI4736) and Tremelimumab With Chemoradiation for Esophageal and Gastroesophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Industry Sponsor), AstraZeneca, Memorial Sloan-Kettering Cancer Center, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Industry, Top 20 Pharma, Academic, Academic","Complete response, NCI-CTC scale, Neutropenia, Safety and Tolerability","Complete response, Overall survival, Progression-free survival",True,NCT02962063,31975
2424,289903,"I 288216, NCI-2016-01598, NCT02953457, TrialTroveID-289903","A Phase I/II Evaluation of Olaparib in Combination With Durvalumab (Medi4736) and Tremelimumab in the Treatment of Recurrent Platinum Sensitive or Resistant or Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer in Patients Who Carry a BRCA1 or BRCA2 Mutation",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"AstraZeneca, Roswell Park Cancer Institute","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall survival, Progression-free survival, Safety and Tolerability","Immune Response, Immune-related response evaluation criteria in solid tumors, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02953457,31975
2425,288930,"APACHE, EudraCT number: 2016-001688-35, INT123-16, NCT03081923, TrialTroveID-288930","APACHE: An open label, randomized, phase 2 study of the anti-programmed death-ligand 1 (PD-L1) durvalumab (D, MEDI4736), alone or in combination with tremelimumab (T), in patients (pts) with advanced germ cell tumors (GCT)",Oncology,Oncology: Testicular,"AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT03081923,31975
2426,288841,"BALTIC, D419QC00002, EudraCT Number: 2016-001202-42, NCT02937818, TrialTroveID-288841","A Phase II, Open-Label, Multi-Arm Study to Determine the Preliminary Efficacy of Novel Combinations of Treatment in Patients With Platinum Refractory Extensive-Stage Small-Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",AstraZeneca,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Area under the curve score, Circulating Tumor Cells, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT02937818,31975
2427,288816,"ESR-15-11633, NCT02938793, TrialTroveID-288816",A Phase II Study of Durvalumab (MEDI4736) (Anti-PD-L1 Antibody) in Combination With Tremelimumab (Anti-CTLA-4 Antibody) in Subjects With Advanced Rare Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"AstraZeneca, AstraZeneca {MedImmune}, Prisma Health/Prisma Health-Upstate","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",,True,NCT02938793,31975
2428,285858,"10021, 17-719, ETCTN 10021, NCI10021, NCI-2016-01325, NCT02888743, PRO00085875, TrialTroveID-285858",A Phase II Study of MEDI4736 (Durvalumab) and Tremelimumab Alone or in Combination With High or Low-Dose Radiation in Metastatic Colorectal and NSCLC,Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Treatment compliance",True,NCT02888743,31975
2429,285786,"ACTRN12616001019493, MoST addendum 2, MOST Substudy, TrialTroveID-285786, U1111-1182-6652","Single Arm, Open Label, Signal Seeking, Phase IIa Trial Of The Activity Of Durvalumab (medi4736) In Combination With Tremelimumab In Patients With Advanced Rare Or Neglected Cancers",Oncology,Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government","Brief Pain Inventory, EORTC Quality of Life Questionnaire, Overall response rate, Partial response, Quality of Life, Response rate, Time to progression","Adverse Events, EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",False,,31975
2430,285149,"I228, IND.228, NCT02879162, TrialTroveID-285149",A Phase II Study of Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours,Oncology,Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma,"AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Overall response rate - duration, Progression-free survival, Stable Disease, Time to progression",True,NCT02879162,31975
2431,285145,"CCTG PA.7, NCT02879318, PA.7, PA7, TrialTroveID-285145","A Randomized Phase II Trial of Gemcitabine and Nab-Paclitaxel vs Gemcitabine, Nab-Paclitaxel, Durvalumab and Tremelimumab as 1st Line Therapy in Metastatic Pancreatic Adenocarcinoma.",Oncology,Oncology: Pancreas,"AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02879318,31975
2432,284614,"CCTG CO.26, CO.26, CO26, NCT02870920, TrialTroveID-284614",A Phase II Randomized Study of Durvalumab and Tremelimumab and Best Supportive Care vs Best Supportive Care Alone in Patients with Advanced Colorectal Adenocarcinoma Refractory to Standard Therapies,Oncology,Oncology: Colorectal,"AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02870920,31975
2433,284539,"14-01317, NCI-2016-01446, NCT02868632, NYU S14-01317, S14-01317, TrialTroveID-284539",A Phase I Study of Immune Checkpoint Inhibition (Anti-CTLA4 and/or Anti-PD-L1) in Combination With Radiation Therapy in Patients With Unresectable and Non-metastatic Pancreatic Cancer,Oncology,Oncology: Pancreas,"AstraZeneca, New York University","Industry, Top 20 Pharma, Academic","Overall survival, Safety and Tolerability","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT02868632,31975
2434,281839,"160135, 16-C-0135, NCI-16-C-0135, NCI-2016-01061, NCT02821754, TrialTroveID-281839",A Pilot Study of Combined Immune Checkpoint Inhibition in Combination With Ablative Therapies in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC),Oncology,Oncology: Liver,National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Progression-free survival","Adverse Events, Safety and Tolerability",True,NCT02821754,31975
2435,281625,"010580QM, CALYPSO, EudraCT Number:2015-002042-31, NCT02819596, TrialTroveID-281625",MEDI4736 Combinations in Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"AstraZeneca, (Other Hospital/Academic/Medical Center), Hutchison MediPharma","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Disease Progression, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors","Area under the curve score, Cmax, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Tmax",True,NCT02819596,31975
2436,281436,"2015-1071, NCI-2016-01178, NCT02815995, TrialTroveID-281436",A Phase II Multi-Arm Study to Test the Efficacy of Immunotherapeutic Agents in Multiple Sarcoma Subtypes,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"MD Anderson Cancer Center, University of Texas, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Complete response, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT02815995,31975
2437,281290,"2016-0033, NCI-2016-01147, NCT02812420, TrialTroveID-281290","A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab) Plus Anti-CTLA-4 (Tremelimumab) in Patients With Muscle-Invasive, High-Risk Urothelial Carcinoma Who Are Ineligible for Cisplatin-based Neoadjuvant Chemotherapy",Oncology,Oncology: Bladder,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Adverse Events, Safety and Tolerability, Safety and Tolerability",Complete response,True,NCT02812420,31975
2438,280243,"NCI-2016-00665, NCT02794883, NU 15C03, STU00202283, TrialTroveID-280243","A Phase II, Open Label, Clinical Trial Of Pre-Surgical and Adjuvant Treatment of Recurrent Malignant Glioma With Tremelimumab and Durvalumab (MEDI4736) Alone and in Combination to Determine Immunologic Changes From Treatment",Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma","AstraZeneca, National Institutes of Health/National Cancer Institute, Northwestern University, AstraZeneca {MedImmune}","Industry, Top 20 Pharma, Government, Academic, Industry, Top 20 Pharma",,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Magnetic Resonance Imaging, Overall survival, Safety and Tolerability, Time to progression",True,NCT02794883,31975
2439,277749,"2015-0828, NCI-2016-00772, NCT02754856, TrialTroveID-277749",Pilot Study Assessing the Safety and Tolerability of the Neoadjuvant Use of Tremelimumab (Anti-CTLA-4) Plus Durvalumab (MEDI4736) (Anti-PD-L1) in the Treatment of Resectable Colorectal Cancer Liver Metastases,Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Adverse Events, Safety and Tolerability",Disease-free survival,True,NCT02754856,31975
2440,276527,"EudraCT Number: 2015-005298-19, IRAS ID 194443, LUD2015-005, NCT02735239, OCTO-079, TrialTroveID-276527",Phase I/II Study of Anti-PD-L1 in Combination With Chemo (Radio) Therapy for Oesophageal Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, University of Oxford, Ludwig Institute for Cancer Research","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT02735239,31975
2441,275363,"16-1329, LUD2014-010, NCI-2017-00885, NCT02716805, TrialTroveID-275363","A Phase I Study To Assess Safety And Tolerability Of Tremelimumab And Durvalumab, Administered With High Dose Chemotherapy And Autologous Stem Cell Transplant (HDT/ASCT)",Oncology,Oncology: Multiple Myeloma,"AstraZeneca {MedImmune}, Ludwig Institute for Cancer Research, Multiple Myeloma Research Foundation","Industry, Top 20 Pharma, Not for Profit Funding Entity, Not for Profit Funding Entity","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Immune Response, Minimal Residual Disease, Mortality, Overall response rate, Overall survival, Progression-free survival, Stable Disease",True,NCT02716805,31975
2442,274460,"ESR-14-10531, NCI-2016-00026, NCT02701400, TrialTroveID-274460, Winship3112-15",A Randomized Study of Tremelimumab Plus Durvalumab Combination With or Without Radiation in Relapsed Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","AstraZeneca, Winship Cancer Institute of Emory University","Industry, Top 20 Pharma, Academic","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Response rate",True,NCT02701400,31975
2443,271611,"D419SC00001, JapicCTI-173766, NCT02658214, TrialTroveID-271611",A Phase Ib Study to Evaluate the Safety and Tolerability of Durvalumab and Tremelimumab in Combination With First-Line Chemotherapy in Patients With Advanced Solid Tumors.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",,True,NCT02658214,31975
2444,270785,"LUD2014-011, NCI-2017-01766, NCT02643303, TrialTroveID-270785","A Phase I/II Study of In Situ Vaccination With Tremelimumab and IV Durvalumab (MEDI4736) Plus the Toll-like Receptor Agonist PolyICLC in Subjects With Advanced, Measurable, Biopsy-accessible Cancers",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Head/Neck; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Cancer","(Other Academic Cancer Center), AstraZeneca {MedImmune}, Ludwig Institute for Cancer Research","Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity","Immune-related response evaluation criteria in solid tumors, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT02643303,31975
2445,270431,"823532, NCI-2015-02268, NCT02639026, TrialTroveID-270431, UPCC 23915","Phase I Trial Of Hypofractionated Radiotherapy In Combination With MEDI4736 And Tremelimumab For Patients With Metastatic Melanoma And Lung, Breast And Pancreatic Cancers",Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",Abramson Cancer Center at  University of Pennsylvania Medical Center,Academic,"Adverse Events, Safety and Tolerability","Overall survival, Progression-free survival",True,NCT02639026,31975
2446,269574,"2013-0539, NCI-2016-00008, NCT02626130, TrialTroveID-269574",A Pilot Study of Tremelimumab With or Without Tissue Cryoablation in Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"AstraZeneca, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Academic, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events","Leukocyte count, Overall response rate, Progression-free survival, Response rate",True,NCT02626130,31975
2447,268856,"15-325, 16-C-0079, 20151318, B7791001, i2190, NCI-2016-00393, NCT02616185, PrCa VBIR, PRCA VBIR FIP STUDY, TrialTroveID-268856","A Phase I Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (VBIR) For Prostate Cancer (PF-06753512)",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Treatment Emergent Adverse Events","Anti-drug antibodies, Cmax, Immune Response, Neutralizing antibody response, Tmax",True,NCT02616185,31975
2448,266997,"051515, D1345C00003, EudraCT Number: 2016-003780-19, i2409, NCI-2016-00915, NCT02586987, SELECT-4, TrialTroveID-266997","A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, BCVA, Cardiac Telemetry, Disease Progression, Ophthalmic examination, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02586987,31975
2449,266882,"EudraCT Number: 2015-001995-23, NCT02588131, NIBIT-MESO-1, TrialTroveID-266882","A Single Arm, Phase II Clinical Study of Tremelimumab Combined With the Anti-PD-L1 MEDI4736 Monoclonal Antibody in Unresectable Malignant Mesothelioma Subjects: The NIBIT-MESO-1",Oncology,Oncology: Mesothelioma,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Partial response","Adverse Events, Clinical benefit rate, Complete response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT02588131,31975
2450,265826,"19479, INST 1419, NCI-2016-00434, NCT02571725, TrialTroveID-265826","A Phase I-II Study of the Combination of Olaparib and Tremelimumab, in BRCA1 and BRCA2 Mutation Carriers With Recurrent Ovarian Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,University of New Mexico Cancer Research and Treatment Center,Academic,"Complete response, Nausea, Overall response rate, Partial response, Safety and Tolerability, Vomiting","Adverse Events, Leukocyte count, Overall survival, Progression-free survival",True,NCT02571725,31975
2451,265448,"15-038, NCI-2015-01787, NCT02563925, TrialTroveID-265448",A Pilot Study of Brain Irradiation and Tremelimumab in Metastatic Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Memorial Sloan-Kettering Cancer Center, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02563925,31975
2452,263912,"D4190C00030, ESR-14-10694, NCI-2015-01445, NCT02536794, NU 15B01, STU00200984, TrialTroveID-263912",A Single Arm Phase II Study Evaluating the Efficacy and Safety of MEDI4736 in Combination With Tremelimumab in Patients With Metastatic Her2 Negative Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, Northwestern University, AstraZeneca {MedImmune}","Cooperative Group, Government, Academic, Industry, Top 20 Pharma","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT02536794,31975
2453,263884,"(CCTG) IND.226, I226, IND.226, NCT02537418, TrialTroveID-263884",A Phase IB Study of Durvalumab (MEDI4736) With or Without Tremelimumab in Patients With Advanced Incurable Solid Malignancies Given With or Without Standard Chemotherapy Regimens,Oncology,"Oncology: Bladder; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","AstraZeneca, (Other Cooperative Group), Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Safety and Tolerability, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events",True,NCT02537418,31975
2454,263873,"CTR20170046, CTRI/2016/08/007204, D419AC00003, D419AC00003 28619, EudraCT Number: 2015-002197-21, HKUCTR-2138, IRAS ID: 187687, JapicCTI-163211, NCT02542293, NEPTUNE, NMRR-15-2173-28619, PER-071-15, TrialTroveID-263873","A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy Versus Standard of Care Platinum-Based Chemotherapy in First-Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma",Overall survival,"Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02542293,31975
2455,263328,"2015-0667, D4884C00001, EudraCT Number: 2015-002934-32, NCI-2015-01763, NCT02527434, NL54780.031.15, Tremelimumab_CTLA4_Basket, TrialTroveID-263328","A Phase II, Multi-Center, Open-Label Study of Tremelimumab Monotherapy in Patients With Advanced Solid Tumors",Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Pancreas,AstraZeneca,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Overall response rate, Safety and Tolerability","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02527434,31975
2456,262600,"2015-0755, AB 51/15, CTR20170135, D419BC00001, D419BC00001/DANUBE, DANUBE, DRKS00011224, EudraCT Number: 2015-001633-24, GUTDANUBE, IRAS ID: 186328, JapicCTI-163154, NCI-2015-02054, NCT02516241, NL54581.029.15, TrialTroveID-262600, UKCRN ID: 19884","A Phase III, Randomized, Open-Label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 (Durvalumab) Monotherapy and MEDI4736 (Durvalumab) in Combination With Tremelimumab Versus Standard of Care Chemotherapy in Patients With Unresectable Stage IV Urothelial Cancer",Oncology,Oncology: Bladder; Oncology: Renal,"(Other Industry Sponsor), AstraZeneca {MedImmune}","Industry, all other pharma, Industry, Top 20 Pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Progression-free survival, Safety and Tolerability",True,NCT02516241,31975
2457,260684,"CRMS-62040, J15113, NCI-2016-01835, NCT02485990, TrialTroveID-260684","An Open Label Dose Escalation/Expansion Study of Tremelimumab Alone or Combined With Olaparib for Recurrent or Persistent EOC (Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma)",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Progressive disease rate, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Gene expression profiling, Immune-related response evaluation criteria in solid tumors, Leukocyte count, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02485990,31975
2458,258229,"15656, 18359, 2015-CT0317, AAAP9838, D419AC00001, DRKS00009527, EudraCT Number: 2015-001279-39, JapicCTI-153067, MYSTIC, NCI-2015-02030, NCT02453282, NL53710.031.15, PHRR160112-001142, TrialTroveID-258229","A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 in Combination With Tremelimumab Therapy or MEDI4736 Monotherapy Versus Standard of Care Platinum-Based Chemotherapy in First Line Treatment of Patients With Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC) (MYSTIC)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02453282,31975
2459,256370,"15-1082, 16-629, EudraCT Number: 2015-002971-12, IMCgp100-201, IRAS ID-190915, NCI-2016-00475, NCT02535078, TrialTroveID-256370","A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab Compared to IMCgp100 Alone in Patients With Advanced Melanoma",Oncology,Oncology: Melanoma,"AstraZeneca {MedImmune}, Immunocore","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Disease Progression, Duration of overall response, Elimination half-life, Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Tmax, Vital signs",True,NCT02535078,31975
2460,250124,"14-530, 15-537, 20151030, 2016-CT0333, CTBE2016000336, CTRI/2016/08/007169, D419LC00001, D419LC00001 (Kestrel), DRKS00010227, EudraCT Number: 2015-003589-10, H-ST 16/13, IRAS ID: 194511, J1591, JapicCTI-153107, KESTREL, NCI-2015-02221, NCT02551159, OSU-15210, PHRR160503-001220, RD12/0036/0006, REec-2016-2079, TrialTroveID-250124, U1111-1163-5391","A Phase III Randomized, Open-label, Multi-center, Global Study of MEDI4736 Alone or in Combination With Tremelimumab Versus Standard of Care in the Treatment of First-line Recurrent or Metastatic Squamous Cell Head and Neck Cancer Patients",Oncology,Oncology: Head/Neck,AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Ability to swallow, Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Circulating Tumor Cells, Cmax, Diastolic blood pressure, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Mortality, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Vital signs",True,NCT02551159,31975
2461,250115,TrialTroveID-250115,Phase I Trial of PD-L1 + tremelimumab+ radiation in patients with solid tumours.,Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma",,,False,,31975
2462,241216,"NCT00897312, VICC MEL0651, VU-VICC-060614, VU-VICC-MEL-0651",Title: Evaluation of Systemic IDO Levels After Various Immunotherapeutics,,NA: ClinicalTrials.gov,"Vanderbilt-Ingram Cancer Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",,,True,NCT00897312,31975
2463,222389,"150027, 15-C-0027, NCI-2015-00101, NCI-2019-00384, NCT02311361, TrialTroveID-222389",A Pilot Study of Immune Checkpoint Inhibition (Durvalumab With or Without Tremelimumab) in Combination With Radiation Therapy in Patients With Unresectable Pancreatic Cancer,Oncology,Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Safety and Tolerability","Disease Progression, Overall response rate, Overall survival, Plasma pharmacokinetics, Progression-free survival",True,NCT02311361,31975
2464,219727,TrialTroveID-219727,A Phase I study of MEDI4736 (PD-L1) in Combination with Tremelimumab in Patients with Haematological Cancer,Oncology,Oncology: Unspecified Hematological Cancer,AstraZeneca,"Industry, Top 20 Pharma",,,False,,31975
2465,219640,"00060939, 14340, 14-530, 15201, 18060, 7H-14-3, ACC #08-17, CANC - 3928 - CONDOR, CONDOR, D4193C00003, D4193C00003 25789, EudraCT Number: 2014-003717-29, HN1504, IRAS ID 164909, NCI-2015-00612, NCT02319044, NMRR-15-819-25789, REec-2015-1670, TrialTroveID-219640","A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Oncology,Oncology: Head/Neck,AstraZeneca,"Industry, Top 20 Pharma","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability","Ability to swallow, Adverse Events, Appetite, Change in oxygen saturation, Clinical benefit rate, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Vital signs",True,NCT02319044,31975
2466,214049,"D4193C00002, EAGLE, EudraCT Number: 2014-003863-40, JapicCTI-153025, NCI-2015-01842, NCT02369874, PER-043-15, S16-00095, TrialTroveID-214049","A Phase III Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Therapy in Patients with Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Oncology,Oncology: Head/Neck,AstraZeneca,"Industry, Top 20 Pharma","Overall survival, Progression-free survival","Ability to swallow, Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression",True,NCT02369874,31975
2467,213910,"D4981C00001, NCT02205333, RWF_D4981C00001, TrialTroveID-213910","A Phase Ib/II, Open-label Study to Evaluate the Safety and Tolerability of MEDI6469 in Combination with Immune Therapeutic Agents or Therapeutic Monoclonal Antibodies in Subjects with Selected Advanced Solid Tumors or Aggressive B-cell Lymphomas",Oncology,"Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's",AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Adverse Events, C reactive protein, Cardiac Telemetry, Creatinine kinase level, Dose-limiting toxicities, Hematocrit level, Hemoglobin level, Infusion-related reactions, Maximum tolerated dose, Platelet count, PR interval, QRS duration, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Triglyceride, Uric acid level, Vital signs","Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Elimination half-life, Hamilton Rating Scale for Anxiety, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02205333,31975
2468,213831,"0761-012, 14-269, 17986, 2014-0763, Clinical Trial 17986, MSKCC:14-269, NCI-2014-02570, NCT02301130, TrialTroveID-213831",Phase I Study of Mogamulizumab (KW-0761) in Combination With MEDI4736 (Durvalumab) and Mogamulizumab in Combination With Tremelimumab in Subjects With Advanced Solid Tumors,Oncology,"Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","AstraZeneca, Kyowa Kirin {Kyowa Hakko Kirin}","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Immune-related response evaluation criteria in solid tumors, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02301130,31975
2469,212196,"201408131, 2014-0872, D4191C00011, NCT02179671, TrialTroveID-212196","A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma",Complete response,"Adverse Events, Clinical benefit rate, Overall response rate, Safety and Tolerability, Safety and Tolerability",True,NCT02179671,31975
2470,211681,"ARCTIC, D4191C00004, D4191C00004 - ARCTIC, EudraCT Number: 2014-000338-46, IRAS ID: 154166, JapicCTI-152828, NCI-2015-00428, NCT02352948, NL49408.056.15, REec-2014-1197, TrialTroveID-211681","A Phase III, Open Label, Randomised, Multi-centre, International Study of MEDI4736, Given as Monotherapy or in Combination With Tremelimumab Determined by PD-L1 Expression Versus Standard of Care in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV) Who Have Received at Least Two Prior Systemic Treatment Regimens Including One Platinum Based Chemotherapy Regimen and Do Not Have Known EGFR TK Activating Mutations or ALK Rearrangements (ARCTIC).",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Appetite, Chest discomfort, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT02352948,31975
2471,209243,"D4880C00010, JapicCTI-142553, NCT02141347, TrialTroveID-209243","A Ph I Open-Label Multicentre Study to Assess Safety, Tolerability, PK and Anti-tumor Activity of Tremelimumab /Tremelimumab With MEDI4736 in Japanese With Advanced Solid Malignancies or Tremelimumab in Japanese With Malignant Mesothelioma",Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability",,True,NCT02141347,31975
2472,203663,"13-613, 2014-03-01, NCI-2014-01561, NCT02141542, TrialTroveID-203663",Phase I Clinical Trial Of Tremelimumab Plus MEDI3617 In Patients With Unresectable Stage III Or Stage IV Melanoma,Oncology,Oncology: Melanoma,AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival",True,NCT02141542,31975
2473,201208,"2013/2028, EudraCT Number: 2013-003015-21, GEFTREM, IGR 2028, NCT02040064, RECF2283, TrialTroveID-201208","Phase I, Open-label, Safety, Tolerability and Preliminary Efficacy Study of Tremelimumab in Combination With Gefitinib in EGFR Mutant NSCLC Patients",Oncology,"Oncology: Lung, Non-Small Cell","Federation Nationale des Centres de Lutte contre le Cancer, Institut Gustave Roussy, AstraZeneca {MedImmune}","Cooperative Group, Academic, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02040064,31975
2474,198766,"00057165, 14.1077, 1407538042, 14203, 15-17857, 17908, AAAO0305, BRC6, C-163, CTSU S1400, ECOG-ACRIN S1400, Lung-MAP, Master Lung-1, NCG 260614, NCI-2014-00627, NCI-CIRB-SWOG-S1400, NCT02154490, S1400, S1400A, S1400B, S1400C, S1400D, S1400E, S1400F, S1400G, S1400I, S1400K, SWOG S1400, SWOG1400, SWOGS1400, TrialTroveID-198766",A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map).,Oncology,"Oncology: Lung, Non-Small Cell","(Other Industry Sponsor), Amgen, Bristol-Myers Squibb, Southwest Oncology Group, National Institutes of Health/National Cancer Institute, Pfizer, AstraZeneca {MedImmune}, Roche/Genentech","Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT02154490,31975
2475,198376,"1310012856, 13-197, 14-554, 17608, 20131955, D4190C00006, EudraCT Number: 2015-003715-38, IRAS ID: 199892, NCI-2013-02416, NCT02000947, REec-2016-2335, STUDY 006, TrialTroveID-198376",A Phase Ib Open-label Study to Evaluate the Safety and Tolerability of MEDI4736 in Combination with Tremelimumab in Subjects with Advanced Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vital signs","Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Duration of overall response, Elimination half-life, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT02000947,31975
2476,196694,"13-198, 13-378, 2014-1052, Basket study, CANC 5659, D4190C00010, Eudract number: 2015-005518-31, I 243813, IRAS ID-201803, LUD2013-003, NCI-2014-02609, NCI-2017-00138, NCT01975831, NCT02261220, NL57363.031.16, S14-01594, STUDY 10, TrialTroveID-196694","A Phase I Study to Evaluate the Safety and Tolerability of Anti-PD-L1, MEDI4736, in Combination with Tremelimumab in Subjects with Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal","(Other Academic Cancer Center), AstraZeneca {MedImmune}, Ludwig Institute for Cancer Research","Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01975831,31975
2477,186430,"130120, 13-C-0120, NCI-2013-01557, NCI-2019-00447, NCT01853618, P121113, TrialTroveID-186430","A Pilot Study of Tremelimumab - A Monoclonal Antibody Against CTLA-4 in Combination With Trans-Arterial Catheter Chemoembolization (TACE), Radiofrequency Ablation (RFA), or Cryoablation in Subjects With Hepatocellular Carcinoma (HCC) or Biliary Tract Carcinomas (BTC)",Oncology,Oncology: Liver,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT01853618,31975
2478,185612,"13-092, 14-ATL-7, 17367, 2013-0081, D4880C00003, DETERMINE, DRKS00005210, EudraCT Number: 2012-003524-21, IRAS ID: 131970, J1376, KCT0000961, NCRN - 2509, NCT01843374, NL44425.060.13, RECF2422, STU 062013-033, TrialTroveID-185612, U1111-1143-4798, UKCRN ID  15407","A Phase IIb, Randomized, Double-blind Study Comparing Tremelimumab to Placebo in Second- or Third-line Treatment of Subjects With Unresectable Pleural or Peritoneal Malignant Mesothelioma",Oncology,Oncology: Mesothelioma,AstraZeneca {MedImmune},"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Anti-drug antibodies, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression",True,NCT01843374,31975
2479,172271,"EudraCT Number: 2012-002762-12, MESOT-TREM-2012, NCT01655888, TrialTroveID-172271","A Second-line, Single Arm, Phase II Clinical Study with Tremelimumab, a Fully Human Anti-ctla-4 Monoclonal antibody, as Monotherapy in Patients with Unresectable Malignant Mesothelioma. , The MESOT-TREM-2012",Oncology,Oncology: Mesothelioma,"AstraZeneca {MedImmune}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Immune Response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT01655888,31975
2480,145068,"GA3671RD IIR#1, NCT01334099, TrialTroveID-145068","Phase I Study of Local Radiation and CP-675,206 Administration in Patients With Inoperable Locally Recurrent or Metastatic Breast Cancer",Oncology,Oncology: Breast,"University Health Network, Toronto",Academic,"Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability","Immune Response, Response evaluation criteria in solid tumors",True,NCT01334099,31975
2481,125961,"EudraCT Number: 2008-005171-95, MESOT-TREM-200, MESOT-TREM-2008, NCT01649024, TrialTroveID-125961","A Second-line, Single Arm, Phase II Clinical Study With Tremelimumab, a Fully Human Anti-CTLA-4 Monoclonal Antibody as Monotherapy in Patients With Unresectable Malignant Mesothelioma",Oncology,Oncology: Mesothelioma,"(Other Cooperative Group), Pfizer, (Other Hospital/Academic/Medical Center)","Cooperative Group, Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Immune Response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT01649024,31975
2482,125733,"NCI-2010-00507, NCT01103635, TrialTroveID-125733, UPCC 05609","A Phase I Dose-Escalation Trial To Evaluate Safety, Tolerability And Immune Pharmacodynamics Of Combined Administration Of Tremelimumab (Blocking Anti-CTLA-4 Antibody) And CP-870,893 (Agonist Anti-CD40 Antibody) In Patients With Metastatic Melanoma",Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, Abramson Cancer Center at  University of Pennsylvania Medical Center","Government, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Immune Response, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival",True,NCT01103635,31975
2483,121015,TrialTroveID-121015,"A Phase III Study of Tremelimumab in Patients with Unresectable, Stage IV Melanoma.",Oncology,Oncology: Melanoma,Debiopharm,"Industry, all other pharma",,,False,,31975
2484,120388,"McG 1016, NCT01034787, TBCC 905001, TrialTroveID-120388",Open Label Phase II Study of AntiCTLA4 in Patients With Unresectable or Metastatic Uveal Melanoma,Oncology,Oncology: Melanoma,Alberta Cancer Board,Government,Progression-free survival,"Adverse Events, Complete response-duration, Overall response rate - duration, Overall response rate, Overall survival",True,NCT01034787,31975
2485,118435,"CT-2007-01, EudraCT Number: 2008-001177-15, NCT01008358, TrialTroveID-118435","Phase II Trial of Anti-CTLA-4 Human Monoclonal Antibody CP-675,206 in Patients with Advanced Hepatocellular Carcinoma",Infectious Disease; Oncology,Infectious Disease: HCV; Oncology: Liver,"Pfizer, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors","Immune Response, Liver function, Overall survival, Progression-free survival",True,NCT01008358,31975
2486,107264,"A534260, CO08807, H-2008-0227, NCI-2011-03676, NCT00880854, SMPH/MEDICINE/MEDICINE*H, TrialTroveID-107264","Phase I Dose-escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) for Patients With BCG-resistant Localized Transitional Cell Carcinoma of the Bladder.",Oncology,Oncology: Bladder,"Pfizer, University of Wisconsin","Industry, Top 20 Pharma, Academic",Safety and Tolerability,"Complete response, Disease-free survival, Immune Response, Maximum tolerated dose",True,NCT00880854,31975
2487,107122,TrialTroveID-107122,A Phase II Study of CP-675206 in Patients with Pancreatic Cancer,Oncology,Oncology: Pancreas,Pfizer,"Industry, Top 20 Pharma",,,False,,31975
2488,92646,"A534260, CO07808, MPH/MEDICINE/MEDICINE*H, NCI-2011-00713, NCT00702923, TrialTroveID-092646","Phase I Dose Escalation Trial of CP-675,206 (Tremelimumab, Anti-CTLA-4 Monoclonal Antibody) in Combination With Short Term Androgen Deprivation in Patients With Stage D0 Prostate Cancer",Oncology,Oncology: Prostate,"Pfizer, University of Wisconsin","Industry, Top 20 Pharma, Academic","Immune Response, Safety and Tolerability","Immune Response, Maximum tolerated dose, PSA progression, Recurrence",True,NCT00702923,31975
2489,81751,"A3671022, NCT00585000, TrialTroveID-081751","A Phase I, open label, single arm study to establish the safety of administering CP 675,206 as a one hour infusion in patients with surgically incurable stage III or stage IV Melanoma",Oncology,Oncology: Melanoma,"Pfizer, Takeda/Takeda Oncology {Millennium}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability","Duration of overall response, Immune Response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00585000,31975
2490,81736,"A3671028, MEL 17, NCT00584493, Pfizer A3671028, TrialTroveID-081736","Treatment Use Study of CP-675,206 for Advanced Melanoma",Oncology,Oncology: Melanoma,Pfizer,"Industry, Top 20 Pharma",,,True,NCT00584493,31975
2491,81409,"05-125, NCT00610857, TrialTroveID-081409, UPCI-05-125",Safety and Efficacy of Combination Biotherapy with High-Dose Interferon Alfa-2b and Anti-CTLA4 Monoclonal Antibody for Recurrent Inoperable Stage III or Stage IV Melanoma,Oncology,Oncology: Melanoma,"Pfizer, University of Pittsburgh Cancer Institute","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Disease Progression, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00610857,31975
2492,80469,"A3671018, Pfizer 1018 Melanoma Study, PFIZER MELANOMA A3671018, TrialTroveID-080469",Phase I study of tremelimumab (CP-675 206) plus PF-3512676 (CPG 7909) in patients with melanoma or advanced solid tumours,Oncology,Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,31975
2493,79444,"A3671016, NCT00556023, TrialTroveID-079444","A Phase I Dose Escalation Trial Of CP-675,206 In Combination With Gemcitabine In Patients With Chemotherapy Naive Metastatic Pancreatic Cancer",Oncology,Oncology: Pancreas,Pfizer,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Immune Response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00556023,31975
2494,77616,"S0721, TrialTroveID-077616",Stereotactic Radiosurgery Followed by Intravenous CP675206 Treatment for Patients with Extracranial Metastatic Melanoma and < or = 5 Brain Metastases: A Phase II Trial.,Oncology,Oncology: Melanoma; Oncology: Metastatic Cancer,Southwest Oncology Group,Cooperative Group,,,False,,31975
2495,71629,"A3671029, NCT00488995, TrialTroveID-071629","A phase 2 study to evaluate the safety, tolerability, virologic and immunologic effect of single-dose CP-675,206 in patients infected with Human Immunodeficiency Virus.",Infectious Disease,Infectious Disease: HIV,Pfizer,"Industry, Top 20 Pharma",CD4+ cell count,,True,NCT00488995,31975
2496,69230,"06-06-093-01, 11-0002360, CDR0000543416, NCT00471887, PFIZER-UCLA-0606093-01, TrialTroveID-069230, UCLA-0606093-01","A Phase II, Open-Label, Single Arm Clinical Trial to Study the Mechanism of Action of CP-675,206 in Patients with In-Transit and Metastatic Melanoma Amenable to Repeated Outpatient Tumor Biopsies",Oncology,Oncology: Melanoma,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma",,"Common Terminology Criteria for Adverse Events, Gene expression profiling, Immune Response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00471887,31975
2497,59344,"A3671011, NCT00431275, TrialTroveID-059344, UPCC 01606","An Open Label, Randomized Clinical Comparability Study of the Current Liquid and Commercial Liquid Formulations of Ticilimumab.",Oncology,Oncology: Melanoma,Pfizer,"Industry, Top 20 Pharma","Area under the curve score, Cmax","Adverse Events, Safety and Tolerability",True,NCT00431275,31975
2498,59334,"06_DOG03_107, EudraCT Number: 2005-005660-86, N0063185345, TrialTroveID-059334","A phase II, open label, single arm study to evaluate Ticilimumab in advanced gastric/oesophageal adenocarcinoma.",Oncology,Oncology: Esophageal; Oncology: Gastric,"Pfizer, Christie Hospital N.H.S. Trust, National Health Service (NHS) - UK","Industry, Top 20 Pharma, Academic, Government","Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Immune Response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability",False,,31975
2499,56812,"1011003658, 106646, 2006-0818, 62370, A3671024, D4881C00024, D4881C00024 (A3671024), EudraCT Number: 2008-000989-23, HUM00010506, MCC-15014, NCT00378482, TrialTroveID-056812, TX1002, UMCC 2006.132","A Rollover Protocol For Patients Who Received Tremelimumab (CP-675,206 ) In Other Protocols",Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor",AstraZeneca {MedImmune},"Industry, Top 20 Pharma","Adverse Events, Complete response, Safety and Tolerability, Serious Adverse Events","Safety and Tolerability, Safety and Tolerability",True,NCT00378482,31975
2500,56143,"A3671025, A3671025-1002, CINJ 050610, IRB 0420060105, NCT00372853, TrialTroveID-056143","A Phase I Dose Escalation Trial To Evaluate The Safety And Tolerability Of CP-675,206 Administered In Combination With SU011248 To Patients With Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,Pfizer,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00372853,31975
2501,52251,"2969, A3671006, TrialTroveID-052251, UPMC 06-030","A Phase I, Open Label, Non-Randomized, Dose Escalation Study To Evaluate the Safety of CP-675,206 in Combination with Exemestane in Second Line Treatment For Post-Menopausal Women with Metastatic or Locally Advanced Breast Cancer.",Oncology,Oncology: Breast,Pfizer,"Industry, Top 20 Pharma",Safety and Tolerability,"Immune Response, Response evaluation criteria in solid tumors",False,,31975
2502,49599,"ORPHA81511, PMDS19, TrialTroveID-049599","A Single Center, Phase I/II Clinical Trial to Study the Safety of Treatment with CP-675,206 or Ticilimumab (antiCTLA-4) in Patients with Low Risk Myelodysplastic Syndrome",Oncology,Oncology: Myelodysplastic Syndrome,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,31975
2503,48406,"A3671014, EudraCT Number: 2006-001270-24, MSKCC-06-050, NCT00313794, TrialTroveID-048406","Phase ll, Single Arm Study Of Ticilimumab In Patients With Refractory Metastatic Adenocarcinoma Of The Colon Or Rectum.",Oncology,Oncology: Colorectal,"AstraZeneca, Pfizer","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Immune Response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00313794,31975
2504,47480,"05-LUN-78-PI, A3671015, EudraCT Number: 2006-000568-95, NCT00312975, PPFIZER020/06-008, SUSPECT, TrialTroveID-047480","Phase II Randomized, Non-Comparative Study of CP-675,206 or Best Supportive Care Immediately Following First-Line, Platinum-Based Therapy in Patients with Stage IIIB (with Effusion) or Stage IV Non-Small Cell Lung Cancer That Has Responded or Remained Stable.",Oncology,"Oncology: Lung, Non-Small Cell",Pfizer,"Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Stable Disease","Anti-drug antibodies, Immune Response, Overall response rate, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT00312975,31975
2505,40638,TrialTroveID-040638,Potential Determinants of Clinical Efficacy of Ticilimumab in Melanoma.,Oncology,Oncology: Melanoma,Pfizer,"Industry, Top 20 Pharma","Clinical benefit rate, Safety and Tolerability",,False,,31975
2506,40110,"05/MRE03/79, 05-MEL-02-PI, A3671009, EudraCT Number: 2005-002827-15, FA771B0115, HCI 15809, HCI 15809 Pfizer / A3671009, N0258179476, NCT00257205, Pfizer A3671009-1150, SCC 06-0231, TrialTroveID-040110","A Phase III, Open Label, Randomized, Comparative Study Of CP-675,206 And Either Dacarbazine Or Temozolomide In Patients With Advanced Melanoma.",Oncology,Oncology: Melanoma,Pfizer,"Industry, Top 20 Pharma",Overall survival,"Anti-drug antibodies, Duration of overall response, Overall response rate, Progression-free survival, Safety and Tolerability",True,NCT00257205,31975
2507,39641,"185-06, A3671008, CRC 0597, EudraCT Number: 2005-002826-70, HUM00002021, INT 06/06, MREC-05/S0501/114, N0258171431, NCT00254579, RECF0691, TrialTroveID-039641, UCLA-0606093-01, UMCC 2005.110, VICC MEL 0553, VICCMEL0553","A Phase II, Open Label, Single Arm Study To Evaluate The Efficacy, Safety, Tolerability And Pharmacokinetics Of CP-675,206 In Patients With Advanced Refractory And/Or Relapsed Melanoma.",Oncology,Oncology: Melanoma,AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT00254579,31975
2508,14299,"62394, NCT00090896, PFIZER-NRA3670003, TrialTroveID-014299, UCLA-0312023","A Phase I, Open Label, Study To Evaluate The Safety And Immune Function Effects Of CP-675,206 In Combination with MART-1 Peptide-Pulsed Dendritic Cells In Patients with Advanced Melanoma",Oncology,Oncology: Melanoma,"Jonsson Comprehensive Cancer Center, UCLA, Pfizer","Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Clinical benefit rate, Immune Response, Safety and Tolerability",True,NCT00090896,31975
2509,11323,"A3671002, ID03-0090, NCT00086489, NCT00093340, PFIZER-A3671002, TrialTroveID-011323, UCLA-0301059, VICC MEL 0428","Phase 1 Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immune Function Effects, and Efficacy of Multiple Doses of CP-675,206 in Patients With Advanced Melanoma, and Phase 2, Open Label, Randomized Study to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of 2 Regimens of CP-675,206 in Patients With Advanced Melanoma.",Oncology,Oncology: Melanoma,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Pfizer","Academic, Government, Industry, Top 20 Pharma","Immune Response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Duration of overall response, Immune Response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT00086489,31975
2510,6588,"A3671001, TrialTroveID-006588","A Phase I, Open Label, Non-Randomized Dose Escalation Study To Evaluate The Safety, Tolerability, Pharmacokinetics And Immune Function Effects Of CP-675,206 In Subjects With Solid Tumor Malignancies",Oncology,Oncology: Colorectal; Oncology: Melanoma; Oncology: Renal,"Jonsson Comprehensive Cancer Center, UCLA, MD Anderson Cancer Center, University of Texas, Pfizer","Academic, Academic, Industry, Top 20 Pharma",Safety and Tolerability,,False,,31975
2511,5734,"A3671004, NCT00075192, TrialTroveID-005734","A Phase 1, Open Label, Non-Randomized, Dose Escalation Study to Evaluate the Safety of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and a Phase 2, Open Label, Randomized Study to Evaluate the Efficacy of CP-675,206 in Combination With Neoadjuvant Androgen Ablation and Androgen Ablation Alone in Patients With High Risk Prostate Cancer.",Oncology,Oncology: Prostate,Pfizer,"Industry, Top 20 Pharma","Complete response, Safety and Tolerability","Anti-drug antibodies, Immune Response, Safety and Tolerability",True,NCT00075192,31975
2512,279928,"160121, 16-C-0121, COXEN, NCI-16-C-0121, NCI-2016-00966, NCI-2018-03327, NCT02788201, P152399, TrialTroveID-279928",A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,,"Adverse Events, Circulating Tumor Cells, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT02788201,17979
2513,223990,"CDR0000078421, EU-93002, GER-GMALL-ALL-05/93, NCT00002531",MULTICENTRE TRIAL OF INTENSIFIED THERAPY FOR ADULT ALL (O5/93),,NA: ClinicalTrials.gov,Johann Wolfgang Goethe University Hospitals,ClinicalTrials.gov,,,True,NCT00002531,17979
2514,195316,"hnslblzlzx2011-6, NCT01960192, TrialTroveID-195316",The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival","Overall response rate, Overall survival, Response rate",True,NCT01960192,17979
2515,175492,"ALLR18, NCI-2012-00587, NCT01700946, TrialTroveID-175492",A Phase II Study of Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), St. Jude Children's Research Hospital","Cooperative Group, Academic","Event-free survival, Overall survival",Minimal Residual Disease,True,NCT01700946,17979
2516,168663,TrialTroveID-168663,Teniposide Based Chemotherpy For Non-Hodgkin's Lymphoma In Central Nervous System,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2517,166872,TrialTroveID-166872,Comparison of regimen VOF and VCF in treatment of advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival",,False,,17979
2518,164378,TrialTroveID-164378,Sequential treatment of VmP regimen and whole brain radiotherapy for small cell lung cancer patients with brain metastases,Oncology,"Oncology: Lung, Small Cell; Oncology: Metastatic Cancer",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2519,163374,TrialTroveID-163374,A clinical effect of nimustine and teniposide combination chemotherapy in patients with malignant gliomas.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2520,161760,TrialTroveID-161760,Combined whole brain radiotherapy with teniposide for brain metastasis from lung cancer: phase I clinical study,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2521,158239,TrialTroveID-158239,Palliative irradiation combined with chemotherapy for lung cancer with brain metastasis.,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2522,102874,"ALL PETHEMA LAL-AR-03, ALL-AR-03, AR-03, LAL-AR/2003, LN_PETHEM_2005_123, NCT00853008, PETHEMA ALL-AR-03, PETHEMA LAL AR-03, TrialTroveID-102874",Treatment of High Risk Adult Acute Lymphoblatic Leukemia.,Oncology,"Oncology: Leukemia, Acute Lymphocytic",(Other Cooperative Group),Cooperative Group,Minimal Residual Disease,,True,NCT00853008,17979
2523,84867,"ALL GMALL 07/2003, GMALL 07/03, GMALL 07/2003, GMALL01, LN_GMALLE_2003_4, NCT00198991, TrialTroveID-084867",German Multicenter Study for Treatment Optimisation in Acute Lymphoblastic Leukemia in Adults and Adolescents Above 15 Years (Amend 3) (GMALL 07/2003),Oncology,"Oncology: Leukemia, Acute Lymphocytic","(Other Cooperative Group), Johann Wolfgang Goethe Universitat, (Other Hospital/Academic/Medical Center), (Other government agency), Medac GmbH {Medac Pharma}","Cooperative Group, Academic, Academic, Government, Industry, all other pharma","Complete response, Disease-free survival, Minimal Residual Disease","Minimal Residual Disease, Treatment compliance",True,NCT00198991,17979
2524,84787,"LAL-Ph-2000, NCT00526305, TrialTroveID-084787",LAL-Ph-2000: Treatment of Acute Lymphoblastic Leukemia Chromosome Philadelphia Positive.,Oncology,"Oncology: Leukemia, Acute Lymphocytic",(Other Cooperative Group),Cooperative Group,"Disease-free survival, Overall response rate, Overall survival, Response rate",,True,NCT00526305,17979
2525,84624,"385, COALL 07-03, CoALL0703, COALL-07-03, EU-205104, GER-COALL-07-03, NCT00343369, ORPHA181076, Study 385, TrialTroveID-084624",Multicenter Study for the Treatment of Children with Acute Lymphoblastic Leukemia.,Oncology,"Oncology: Leukemia, Acute Lymphocytic",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall survival",,True,NCT00343369,17979
2526,62592,TrialTroveID-062592,Durable Event-Free and Overall Survival (EFS/OS) in Mantle Cell Lymphoma (MCL) without Rituximab: Long-Term Follow-Up of a Phase II Trial with Intensive Chemotherapy (CTAP/VMAC) Followed by Autologous Hematopoietic Stem Cell Transplant (aHSCT).,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Northwestern University,Academic,Overall survival,,False,,17979
2527,61923,TrialTroveID-061923,Treatment of Primary Central Nervous System Lymphoma with a Combination of Intraventricular Administration of Rituximab and Systemic Chemotherapy.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,,,False,,17979
2528,60946,TrialTroveID-060946,The Effect of Rituximab in Combination with MEVP Chemotherapy and rhG-CSF in Old Patients of Refractory and Terminal Non-Hodgkins Lymphoma.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,17979
2529,56972,"Amend 1, GMALL T-LBL 1/2004, GMALL04, LN_GMALLE_2004_50, NCT00199017, TrialTroveID-056972",Multicenter Trial for Treatment Optimization in T-Lymphoblastic Lymphoma in Adults and Adolescents Older Than 15 Years (GMALL T-LBL 1/2004) (Amend 1),Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Johann Wolfgang Goethe Universitat,Academic,"Complete response, Disease-free survival, Minimal Residual Disease, Overall survival, Recurrence",Treatment compliance,True,NCT00199017,17979
2530,42909,TrialTroveID-042909,Treatment of Hematological Malignancies in Central Nervous System with Idarubicin and Teniposide Containing Regimens.,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2531,35173,"ALLR17, NCT00186875, TrialTroveID-035173",A Study of Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",St. Jude Children's Research Hospital,Academic,"Complete response, Overall response rate, Overall survival, Response rate","Gene expression profiling, Minimal Residual Disease",True,NCT00186875,17979
2532,32906,TrialTroveID-032906,Clinical and pharmacological study of CPT-11 and VM-26/VP-16 for patients with recurrent malignant primary brain tumors.,Oncology,"Oncology: CNS, Glioblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,17979
2533,22151,"NCI-T84-0274D, TrialTroveID-022151, UCCRC-3985",Phase III Combination Chemotherapy with High-Dose ARA-C/VM-26 in Adults with Refractory Acute Lymphoblastic Leukemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate - duration",,False,,17979
2534,11767,TrialTroveID-011767,A pilot study of concurrent chemotherapy (teniposide and carboplatin) combined with whole brain radiotherapy in non-small cell lung cancer patients with brain metastases.,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",(Other Academic Cancer Center),Academic,,,False,,17979
2535,9188,"NCI-G00-1711, NCT00004916, NU-98H2, TrialTroveID-009188","Phase I/II Study of Mesna, Ifosfamide, Teniposide and Weekly Taxol (MITTen) in Relapsed Lymphoma.",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University","Government, Academic","Overall response rate, Response rate, Time to progression",,True,NCT00004916,17979
2536,1074,"EORTC-20962, NCT00003061, TrialTroveID-001074",Phase II Study of Methotrexate and Cytarabine in Combination with Radiation Therapy for Patients with Non-AIDS Related Primary Central Nervous System Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","EORTC European Organisation for Research and Treatment of Cancer, Dutch Cancer Foundation","Cooperative Group, Government","Overall response rate, Response rate, Safety and Tolerability",,True,NCT00003061,17979
2537,526,"NCI-G99-1659, NCT00004231, NU-96H3, TrialTroveID-000526",Phase II Study of Multimodality Therapy in Mantle Cell Lymphoma.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University","Government, Academic",,,True,NCT00004231,17979
2538,306482,"17-217, NCI-2017-01707, NCT03239145, TrialTroveID-306482",Phase Ib Study to Test the Safety and Potential Synergy of Pembrolizumab (Anti-PD-1) and AMG386 (Angiopoietin-2 (Ang-2) in Patients With Advanced Solid Tumor,Oncology,Oncology: Colorectal; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor,"Amgen, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Immune Response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT03239145,31518
2539,197770,"20101151, NCT01992341, TrialTroveID-197770","An Open-Label, Pharmacokinetic Drug-Drug Interaction (DDI) Study of AMG 386 in Combination With Paclitaxel in Adult Subjects With Advanced Solid Tumors",Oncology,Oncology: Bladder; Oncology: Ovarian,Amgen,"Industry, Top 20 Pharma",,"Cardiac Telemetry, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT01992341,31518
2540,190941,"13-1502.cc, NCI-2013-01348, NCT01907308, TrialTroveID-190941",A Phase II Single-arm Study of AMG 386 in Combination With Docetaxel for Advanced Urothelial Carcinoma After Failure of a Platinum-containing Regimen,Oncology,Oncology: Bladder; Oncology: Renal,"Amgen, University of Colorado","Industry, Top 20 Pharma, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate",Overall survival,True,NCT01907308,31518
2541,173059,"20101128, CT533, EudraCT Number: 2011-001111-31, NCT01666977, REec-2013-0432, TrialTroveID-173059",A Phase Ib/II Trial of AMG 386 in Combination with Pemetrexed and Carboplatin as First Line Treatment of Metastatic Non-Squamous Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Amgen,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Progression-free survival","Adverse Events, Area under the curve score, Cmax, Cmin, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Lung Cancer, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01666977,31518
2542,172968,"N01CM00038, NCI#9048, NCI-2012-01289, NCT01664182, P9048_A12PAMDREVW01, PHII-122, PSHCI-13-071, TrialTroveID-172968","A Randomized Phase II Study of AMG 386 with or without Continued Anti-Vascular Endothelial Growth Factor (VEGF) Therapy in Patients with Renal Cell Carcinoma who have Progressed on Bevacizumab, Pazopanib, Sorafenib, or Sunitinib",Oncology,Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival",True,NCT01664182,31518
2543,170201,"12-128, A091103, Alliance A091103, CALGB A091103, CALGB-A091103, CTSU A091103, NCI-2012-01978, NCT01623869, TrialTroveID-170201",Phase II Study of the Angiopoietin-1 and -2 Peptibody AMG 386 for the Treatment of Angiosarcoma,Oncology,Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Overall response rate, Overall survival, Progression-free survival",True,NCT01623869,31518
2544,168828,"4562, AAAK1800, NCI-2012-01969, NCT01609790, NRG/RTOG 1122, RTOG 1122, RTOG-1122, S13-00759, STU 042013-026, TrialTroveID-168828",Phase II Double-Blinded Placebo-Controlled Study of Bevacizumab With or Without AMG 386 in Patients With Recurrent Glioblastoma or Gliosarcoma,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, NRG Oncology","Government, Cooperative Group","Adverse Events, Disease Progression, Dose-limiting toxicities, Magnetic Resonance Imaging, Progression-free survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate",True,NCT01609790,31518
2545,164284,"I 186010, NCI-2011-02979, NCT01555268, TrialTroveID-164284","A Phase Ib Study of the Safety, Feasibility, and Pharmacokinetics of AMG 386 Alone and in Combination With Low Dose Cytarabine in Acute Myeloid Leukemia (AML) Patients",Oncology,"Oncology: Leukemia, Acute Myelogenous","Amgen, National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute","Industry, Top 20 Pharma, Government, Academic","Adverse Events, Cmax, Common Terminology Criteria for Adverse Events, Leukocyte count, Progressive disease rate, Safety and Tolerability",,True,NCT01555268,31518
2546,163943,"081503, 120079, 12-C-0079, CTEP9068, NCI/CTEP #9068, NCI-12-C-0079, NCT01553188, TrialTroveID-163943",A Phase II Multicenter Study of AMG 386 and Abiraterone in Metastatic Castration Resistant Prostate Cancer,Oncology,Oncology: Prostate,National Institutes of Health/National Cancer Institute,Government,"Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Magnetic Resonance Imaging, Maximum tolerated dose, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT01553188,31518
2547,163687,"9041, NCI-2012-02848, NCT01548482, PJC-008, PJC-008 (NCI 9041), TrialTroveID-163687","A Phase I Trial of AMG 386 and Temsirolimus in Advanced Solid Tumors with an Expansion Cohort in Uterine Cancer, Renal Cell Carcinoma and Carcinoid Tumors",Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, University Health Network, Toronto","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Overall response rate, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT01548482,31518
2548,162931,"2012CG048, AAAJ7106, ADV1115, ADVL1115, COG-ADVL1115, NCI-2012-00252, NCT01538095, PADVL1115_A05PAMDREVW01, TrialTroveID-162931","A Phase I Study of AMG 386, an Angiopoietin Neutralizing Peptibody, in Children With Relapsed or Refractory Solid Tumors, Including CNS Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Head/Neck; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Drug clearance, Magnetic Resonance Imaging, Maximum tolerated dose","Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT01538095,31518
2549,153699,"20101129, BGOG-ov7, CTBE2013000178, DRKS00004829, ENGOT - ov2/Trinova-3, EudraCT Number: 2011-001112-53, GOG 3001, GOG3001, JapicCTI-121823, NCT01493505, NL38125.058.11, TrialTroveID-153699, TRINOVA-3, TRINOVA-3 20101129/ENGOT-ov2, TRINOVA-3/ENGOT-ov2/GOG-3001","A Phase III Randomized, Double-blind, Placebo-controlled, Multicenter Study of AMG 386 with Paclitaxel and Carboplatin as First-line Treatment of Subjects with FIGO Stage III-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Amgen, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01493505,31518
2550,144902,"11-0251, 20090277, AMGN1Y11, F11164, NCT01331941, TrialTroveID-144902",An Open-label Pharmacokinetic Study of AMG 386 in Advanced Cancer Subjects With Normal and Impaired Renal Function,Oncology,Oncology: Unspecified Solid Tumor,Amgen,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Cmin, Tmax","Adverse Events, Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Vital signs",True,NCT01331941,31518
2551,144132,"OVM1101, TrialTroveID-144132","Phase III randomized study of carboplatin plus pegylated liposomal doxorubicin with and without AMG 386 versus carboplatin plus eribulin with and without AMG 386 for platinum-sensitive recurrent ovarian carcinoma, fallopian tube carcinoma, and peritoneal carcinoma.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Gynecologic Oncology Group (GOG),Cooperative Group,,,False,,31518
2552,143997,"DTM1111, TrialTroveID-143997",Phase II evaluation of AMG 386 combined with gemcitabine in the treatment persistent or recurrent leiomyosarcoma of the uterus,Oncology,Oncology: Soft Tissue Sarcoma,Gynecologic Oncology Group (GOG),Cooperative Group,,,False,,31518
2553,143479,"DTM1112, TrialTroveID-143479","Phase II trial of AMG 386 in Patients with Recurrent Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer in Second or Third Remission",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Gynecologic Oncology Group (GOG),Cooperative Group,,,False,,31518
2554,141790,"12-185, 13-16660, NCT01290263, Pro00021773, TrialTroveID-141790",Phase I/II Study of Amgen 386 With and Without Bevacizumab for Recurrent Glioblastoma,Oncology,"Oncology: CNS, Glioblastoma","Amgen, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic","Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Neutropenia, Partial response, Progression-free survival, Progressive disease rate, Stable Disease, Urine protein level","Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Safety and Tolerability, Stable Disease",True,NCT01290263,31518
2555,140900,"20060517, 201101064MA, BGOG-ov6, CTBE2013000179, DRKS00007748, ENGOT-ov 6, ENGOT-ov-6, EudraCT Number: 2009-017946-30, IRAS ID: 67980, NCT01281254, TrialTroveID-140900, TRINOVA-2, UKCRN ID 9283","A Phase III, Randomized, Double-Blind Trial of Pegylated Liposomal Doxorubicin (PLD) Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer , , TRINOVA-2: Trebananib in Ovarian Cancer-2",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Amgen,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Cmax, Cmin, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Response rate",True,NCT01281254,31518
2556,138672,"03501, NCT01249521, TrialTroveID-138672, Vengeance study",Open Label Phase II Study Evaluating the Combination of Bevacizumab and AMG386 Without Chemotherapy as First Line Treatment of Advanced Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Partial response, Stable Disease","Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT01249521,31518
2557,137664,"20090155, AMG20090155, NCT01253681, TrialTroveID-137664","A Phase Ib Open-Label, Multi-Center Study of AMG 386 in Combination With Paclitaxel and Carboplatin in Subjects With High-Risk Stage I and Stages II-IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Amgen,"Industry, Top 20 Pharma",Dose-limiting toxicities,"Adverse Events, Area under the curve score, Cmax, Cmin, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival",True,NCT01253681,31518
2558,135481,"DTM0910, GOG-0229L, GOG-229L, NCI-2011-02655, NCT01210222, TrialTroveID-135481","A Phase II Trial of AMG 386, a Selective Angiopoietin 1/2 Neutralizing Peptibody, in Patients With Persistent/Recurrent Carcinoma of the Endometrium",Oncology,Oncology: Endometrial,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Event-free survival, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01210222,31518
2559,122328,"20060212, JapicCTI-101161, NCT02525536, TrialTroveID-122328, U1111-1170-0395","A Phase I, Open-Label, Dose Escalation Study Evaluating the Safety, Tolerability and Pharmacokinetics of AMG 386 in Adult Japanese Patients with Advanced Solid Tumors",Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Gastric; Oncology: GIST; Oncology: Pancreas,"Amgen, Takeda","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Elimination half-life, Infusion-related reactions, Liver function, Mean residence time, Safety and Tolerability, Serious Adverse Events, Tmax, Treatment Emergent Adverse Events, Vital signs, Volume of distribution","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT02525536,31518
2560,121253,"10-349, 20090508, 20090508 7171, CSET 1708, CTRI/2011/11/002163, EudraCT Number: 2010-019821-32, GCC 1120, GYNOPF0008, IRAS ID: 100203, JapicCTI-101314, NCRN390, NCRN390 TRINOVA 1, NCT01204749, NMRR-10-799-7171, SU-01182011-7378, TrialTroveID-121253, TRINOVA 1, TRINOVA-1, UKCRN ID 11893","A Phase III, Randomized, Double-Blind Trial of Weekly Paclitaxel Plus AMG 386 or Placebo in Women With Recurrent Partially Platinum Sensitive or Resistant Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancers",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Amgen, Takeda {Takeda Bio Development Center}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, CA-125 Response, Cmax, Cmin, Duration of overall response, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",True,NCT01204749,31518
2561,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,31518
2562,106668,"20080580, AMGEN 20080580, EudraCT Number: 2008-006212-38, NCT00872014, RECF1155, TrialTroveID-106668",Phase II Open-label Multi-Center Study to Evaluate the Efficacy and Safety of AMG 386 and Sorafenib as First Line Therapy for Subjects With Advanced or Inoperable Hepatocellular Carcinoma,Oncology,Oncology: Liver,Amgen,"Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression","Adverse Events, Clinical benefit rate, Liver function, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00872014,31518
2563,105250,"09-105, 101334, 20080579, CTO#101334, EudraCT Number: 2008-006210-14, NCT00853372, NCT00953446, RECF1103, TrialTroveID-105250","Phase II Open-Label, Multi-Center Study to Evaluate the Safety and Efficacy of Sunitinib Malate in Combination With AMG 386 as First Line or Second Line Therapy for Subjects With Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,Amgen,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Neutralizing antibody response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT00853372,31518
2564,101914,"20062042, 20081765, AAAE3550, Amgen 20062042, F0915, NCT00807859, RECF1195, TrialTroveID-101914",An Open-Label Study of AMG 386 in Combination With Either Paclitaxel and Trastuzumab or Capecitabine and Lapatinib in Subjects With HER2-positive Locally Recurrent or Metastatic Breast Cancer,Oncology,Oncology: Breast,Amgen,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities","Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival",True,NCT00807859,31518
2565,99714,TrialTroveID-099714,Phase II Study of AMG 386 in Patients with HER + Breast cancer,Oncology,Oncology: Breast,Amgen,"Industry, Top 20 Pharma",,,False,,31518
2566,98765,"20070182, 20081876, 2653, AMG386 182, MCC# 15707, NCT00770536, PAMGEN018, TrialTroveID-098765",A Phase Ib Study of AMG 386 in Combination With Either Pegylated Liposomal Doxorubicin or Topotecan in Subjects With Advanced Recurrent Epithelial Ovarian Cancer,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Amgen,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities","Adverse Events, Area under the curve score, CA-125 Response, Cmax, Cmin, Dose-limiting toxicities, Duration of overall response, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00770536,31518
2567,97447,"20070307, EudraCT Number: 2008-003258-14, NCT00752570, TrialTroveID-097447","A Phase II, Randomized, Double Blind, Placebo Controlled Study of AMG 386 in Combination With FOLFIRI in Subjects With Previously Treated Metastatic Colorectal Carcinoma",Oncology,Oncology: Colorectal,Amgen,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Adverse Events, Area under the curve score, Cmax, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response",True,NCT00752570,31518
2568,81726,"20060439, 20071618, Amgen-20060439, EudraCT Number: 2007-003573-50, NCT00583674, NL20002.096.07, RECF0530, TrialTroveID-081726","A Randomized, Double Blind, Multi-Center, Phase II Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Cisplatin & Capecitabine (CX) in Combination with AMG 386 or Placebo in Subjects with Metastatic Gastric, Gastroesophageal Junction, or Distal Esophageal Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,Amgen,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to response",True,NCT00583674,31518
2569,74211,"20060341, EudraCT Number: 2007-003384-51, NCT00511459, NL19244.068.07, RECF0731, TrialTroveID-074211","A Randomized, 4-Arm, Placebo-Controlled Phase II Trial of AMG 386 in Combination with Bevacizumab and Paclitaxel or AMG 386 Plus Paclitaxel as First-Line Therapy in Subjects with HER2-Negative, Metastatic or Locally Recurrent Breast Cancer.",Oncology,Oncology: Breast,Amgen,"Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to response",True,NCT00511459,31518
2570,70243,"07-0833-04, 20060342, BIO07105, GYN 0727, HSC 07105, NCT00479817, TrialTroveID-070243","A Randomized, Double-Blind, Placebo Controlled, Phase II Trial of Paclitaxel in Combination With AMG 386 in Subjects With Advanced Recurrent Epithelial Ovarian or Primary Peritoneal Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Amgen,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, CA-125 Response, Cmax, Cmin, Disease Progression, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to response",True,NCT00479817,31518
2571,68917,"20060159, DFCI ID: 07-257, EudraCT Number: 2007-000147-98, HCC 101117, MCC 14987, MDACC 2007-0248, NCT00467025, RECF0694, TrialTroveID-068917","A Randomized, Double Blinded, Multi-Center Phase ll Study to Estimate the Efficacy and Evaluate the Safety and Tolerability of Sorafenib in Combination With AMG 386 or Placebo In Subjects With Metastatic Clear Cell Carcinoma of the Kidney",Oncology,Oncology: Renal,Amgen,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, EQ-5D, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00467025,31518
2572,51716,"2005-033, AMGEN-20050191, TrialTroveID-051716","A Phase Ib, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG-386 in combination with FOLFOX-4 (oxaliplatin, fluorouracil, and leucovorin) , carboplatin/paclitaxel and docetaxel in subjects with advanced solid tumors.",Oncology,Oncology: Bladder; Oncology: Pancreas,Amgen,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,31518
2573,48270,"20050170, 2005-0794, 20052072, MDACC-2005-0794, NCT00861419, TrialTroveID-048270","An Open-Label, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of AMG 386 With AMG 706, AMG 386 With Bevacizumab, AMG 386 With Sorafenib, and AMG 386 With Sunitinib in Adult Patients With Advanced Solid Tumors.",Oncology,Oncology: Head/Neck; Oncology: Renal,"Amgen, Pfizer, Takeda","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00861419,31518
2574,23544,"20040169, 2004-0855, MDA-2004-0855, NCT00102830, TrialTroveID-023544","A Phase 1 Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of AMG 386 in Adult Patients With Advanced Solid Tumors.",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Amgen,"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs","Magnetic Resonance Imaging, Maximum tolerated dose, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT00102830,31518
2575,393604,"HGCSG1903, jRCTs011200010, TrialTroveID-393604",Phase II Trail of Docetaxel and Ramucirumab Combination Therapy as Second-line Treatment in Patients with Metastatic or Advanced Gastric Cancer (HGCSG1903),Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2576,391366,"ACCRU-GI-1810, NCI-2020-11436, NCT04660760, TrialTroveID-391366","Ramucirumab Plus Trifluridine/Tipiracil (TAS-102) for Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Adenocarcinoma: An Investigator-Initiated, Randomized Non-Inferiority Phase II Study",Oncology,Oncology: Esophageal; Oncology: Gastric,"National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center)","Government, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Quality of Life, Safety and Tolerability",True,NCT04660760,40407
2577,391135,"2020-05-175, NCT04656002, TrialTroveID-391135","As a Second-line Treatment for Metastatic Gastric Adenocarcinoma Patients, the Safety and Effective of Vactosertib Administration in Combination With Paclitaxel+Ramucirumab is Evaluated, and a Phase IIa Clinical Trial to Biomarkers",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,Clinical benefit rate,True,NCT04656002,40407
2578,389514,"2020-03-115, KCT0005753, NCT04632459, SMC2020-03-115, TrialTroveID-389514",Phase II Study of Pembrolizumab Plus Ramucirumab in Metastatic Gastric or GEJ Adenocarcinoma as Salvage Treatment,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival",True,NCT04632459,40407
2579,384925,"17800, I4T-MC-JVDU, NCT04557384, TrialTroveID-384925","A Phase I, Nonrandomized, Open-Label Investigation of Subcutaneous Ramucirumab Administration in Participants With Advanced Solid Tumors",Oncology,Oncology: Gastric; Oncology: Liver; Oncology: Unspecified Solid Tumor,"Eli Lilly, 1ST Biotherapeutics, Inc.","Industry, Top 20 Pharma, ClinicalTrials.gov","Area under the curve score, Cmax",Injection site reactions,True,NCT04557384,40407
2580,382179,"EudraCT Number: 2020-001075-32, NCT04517747, RE-ExPEL, TrialTroveID-382179","A Pilot Study of Ramucirumab Beyond Progression Plus TAS-102 in Patients With Advanced or Metastatic Adenocarcinoma of the Stomach or the Gastroesophageal Junction, After Treatment Failure on a Ramucirumab Based Therapy",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Neutropenia, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT04517747,40407
2581,381037,TrialTroveID-381037,Maintenance Trastuzumab in the Setting of Second-line Treatment in HER2 Overexpressing Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma: Experience of Our Centre,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival, Safety and Tolerability",,False,,40407
2582,380899,TrialTroveID-380899,Ramucirumab after lenvatinib failure for patients with advanced hepatocellular carcinoma: initial experience,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,40407
2583,380833,"17748, I4T-MC-JVDT, NCT04495478, TrialTroveID-380833",A Single-Dose Study in Healthy Participants to Characterize Ramucirumab Pharmacokinetics and Investigate Injection Site Reactions Following an Intravenous Infusion or Subcutaneous Administration of Ramucirumab,Oncology,Oncology: Unspecified Cancer,Eli Lilly,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cmax, Injection site reactions, Serious Adverse Events",,True,NCT04495478,40407
2584,371928,"CIBI308E302, CTR20202468, NCT04675983, ORIENT-106, TrialTroveID-371928","A Randomized, Multicenter, Phase III Study to Evaluate the Efficacy and Safety of Sintilimab Combined With Ramucirumab as Compared to Chemotherapy for the First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (ORIENT-106)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, Innovent Biologics (Suzhou) Co.","Industry, Top 20 Pharma, Industry, all other pharma","Overall survival, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT04675983,40407
2585,371584,"NCI-2020-01134, NCT04340882, STUDY00000030, TaxRamPem, TrialTroveID-371584, WINSHIP4950-20","A Phase II Study of Docetaxel, Ramucirumab, and Pembrolizumab for Patients With Metastatic or Recurrent Non-Small Cell Lung Cancer Who Progressed on Platinum-Doublet and PD-1/PD-L1 Blockade",Oncology,"Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, Winship Cancer Institute of Emory University, Merck & Co./Merck Sharp & Dohme (MSD)","Government, Academic, Industry, Top 20 Pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04340882,40407
2586,370885,"05519, 833759, NCI-2020-13703, NCT04332367, TrialTroveID-370885, UPCC 05519","Phase II, Single-Arm Study Of Carboplatin, Weekly Taxane, And Ramucirumab In Advanced Non-Squamous Non-Small Cell Lung Cancer (NSCLC) After Progressive Disease On Maintenance Pemetrexed And/Or Pembrolizumab",Oncology,"Oncology: Lung, Non-Small Cell",Abramson Cancer Center at  University of Pennsylvania Medical Center,Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT04332367,40407
2587,367624,"ECOG-ACRIN LUNG-MAP, LUNG-MAP, NCI-2020-00171, NCT04267913, S1900D, TrialTroveID-367624","A Randomized Phase II Study of TAK228 (MLN0128, Sapanisertib) Plus Docetaxel Versus Standard of Care in Patients With Previously - Treated NFE2L2 or KEAP1-Positive Stage IV or Recurrent Squamous Cell Lung Cancer (ECOG-ACRIN LUNG-MAP Sub-Study)",Oncology,"Oncology: Lung, Non-Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Progression-free survival,"Circulating Tumor Cells, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04267913,40407
2588,367569,"DRUN study, jRCT1051190091, TrialTroveID-367569",Phase II Study of Docetaxel and Ramucirumab as Second-Line Treatment for Patients with Advanced Non-Small Cell Lung Cancer who received an Immune Checkpoint Inhibitor plus Platinum Chemotherapy as First-Line Therapy,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2589,366783,"GI-SCREEN CRC-Ukit, TrialTroveID-366783, UMIN000028616",The multicenter study to examine angiogenesis-related factors in advanced colorectal cancer,Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",,,False,,40407
2590,366393,"jRCTs051190071, OGSG1901, TrialTroveID-366393",A Phase II Trial of Ramucirumab plus Irinotecan for Patients with Early Relapced Gastric Cancer after Adjuvant Docetaxel plus S1 Therapy for Stage III (OGSG1901),Oncology,Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Clinical benefit rate, Overall response rate, Progression-free survival, Response rate, Safety and Tolerability, Time to treatment failure",False,,40407
2591,366390,TrialTroveID-366390,Mismatch repair-deficient or other molecular subtypes and efficacy of chemotherapy for advanced gastric cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,40407
2592,366374,"jRCTs041190077, SCORPION, TrialTroveID-366374",Phase II Study of Docetaxel Plus Ramucirumab after Treatment of Platinum Based Chemotherapy Combined with Immune Check point Inhibitors in Patients with Non-small Cell Lung Cancer  (SCORPION study),Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly,"Industry, Top 20 Pharma",Overall response rate,"Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2593,366175,"jRCT1041190083, Post Lenva RAM, TrialTroveID-366175",Phase II Study of Ramucirumab for the Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Time to progression, Time to treatment failure, Tumor control rate",False,,40407
2594,364912,"CTR20191906, TrialTroveID-364912, ZDTQ-2019-LMLDK","A Single-center, Randomized, Double-blind, Single-dose, Parallel Phase I Clinical Study Comparing the Pharmacokinetics and Safety of Ramucirumab Injection with Cyramza in Healthy Men",Oncology,Oncology: Unspecified Cancer,Chia Tai Tianqing Pharmaceutical Group Co./Nanjing Shunxin Pharmaceutical Co.,"Industry, all other pharma","Area under the curve score, Cmax, Tmax","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Neutralizing antibody response, Safety and Tolerability, Vital signs",False,,40407
2595,363982,"NCI-2019-04213, NCT04205968, S1922, U10CA180888",Randomized Phase II Selection Study of Ramucirumab and Paclitaxel Versus FOLFIRI in Refractory Small Bowel Adenocarcinoma,,NA: ClinicalTrials.gov,"Southwest Oncology Group, National Cancer Institute (NCI)","Cooperative Group, ClinicalTrials.gov",,Adverse Events,True,NCT04205968,40407
2596,363923,"jRCTs071190013, PLEURAM study, TrialTroveID-363923",Phase II Trial of Ramucirumab and Docetaxel for Previously Treated Nsclc Patients With Malignant Pleural Effusion (PLEURAM study),Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly,"Industry, Top 20 Pharma",,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,40407
2597,363911,"C2018-305, JACCRO CC-16, jRCTs061180002, TrialTroveID-363911",A Phase II Study of Second-line Combination Therapy with FOLFIRI plus Ramucirumab in Patients with RAS Wild-type Unresectable Advanced/recurrent Colorectal Cancer (JACCRO CC-16) (JACCRO CC-16),Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,40407
2598,362853,"jRCT2051190027, RELAY-Brain, TrialTroveID-362853",Single-arm Phase I Study of Erlotinib or Osmeltinib plus Ramcilmab in Patients with Untreated EGFR Gene Mutation-Positive Non-Small Cell Lung Cancer with Brain Metastases,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Overall response rate, Response rate",False,,40407
2599,362254,"2000022801, NCT04179110, TrialTroveID-362254",A Phase II Trial of Pembrolizumab and Ramucirumab in Patients With Progressive Transitional Cell Carcinoma After Treatment With an Immune Checkpoint Inhibitor,Oncology,Oncology: Bladder; Oncology: Renal,Yale University,Academic,"Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival, Progressive disease rate",True,NCT04179110,40407
2600,360734,"RamSelGa, russco25072017, TrialTroveID-360734",Ramucirumab in the Treatment of Refractory Metastatic Gastric Cancer: Results From the RamSelGa trial,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Progression-free survival, Safety and Tolerability",False,,40407
2601,360732,TrialTroveID-360732,Clinical Experience: Ramucirumab with FOLFIRI/XELIRI as a Second-line for Patients With Metastatic Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2602,358769,"2019C0145, NCI-2019-05348, NCT04120454, OSU-19132, TrialTroveID-358769",An Investigator-Sponsored Phase II Single Arm Trial of Ramucirumab and Pembrolizumab in Patients With EGFR Mutant Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, Ohio State University","Government, Academic","Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Tumor control rate",True,NCT04120454,40407
2603,357774,"Balast study, TrialTroveID-357774, UMIN000037867",An Observational Cohort Study on the Nutrition Status of Patients With Advanced Gastric Cancer Who Receive Combination Chemotherapy With Ramucirumab and a Taxane,Oncology,Oncology: Gastric,"Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2604,356630,"17305, CAMPFIRE, EudraCT Number: 2018-004242-42, J1S-MC-JV01, JapicCTI-205247, JV01, NCI-2020-01459, NCT04145349, NL69237.041.20, TrialTroveID-356630","A Randomized, Open-Label Phase I/II Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with Relapsed, Recurrent, or Refractory Desmoplastic Small Round Cell Tumor",Oncology,Oncology: Soft Tissue Sarcoma,Eli Lilly,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT04145349,40407
2605,354371,"EAST ENERGY, EPOC1710, JapicCTI-194889, NCT04040361, TrialTroveID-354371",Efficacy and Safety of Neoadjuvant Therapy of Pembrolizumab Combined With Ramucirumab for PD-L1 Positive Stage IB-IIIA Lung Cancer: An Open-label Single-arm Phase II Study,Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Complete response, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Resection rate, Response evaluation criteria in solid tumors, Response rate",True,NCT04040361,40407
2606,351941,"IIT-2018-RucaRamNivo, NCI-2020-01661, NCT03995017, RiME, TrialTroveID-351941",A Phase I/II Trial of Rucaparib in Combination With Ramucirumab With or Without Nivolumab in Previously Treated Patients With Advanced Gastric and Esophageal Adenocarcinoma (RiME),Oncology,Oncology: Esophageal; Oncology: Gastric,"Bristol-Myers Squibb, University of Kansas, Clovis Oncology","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events",True,NCT03995017,40407
2607,351705,"17306, CAMPFIRE, EudraCT Number: 2018-004243-23, J1S-MC-JV02, J1S-MS-JV02, JapicCTI-205246, JV02, NCI-2020-01458, NCT04145700, NL69238.041.19, TrialTroveID-351705","A Randomized, Open-Label Phase II Study Evaluating Ramucirumab in Pediatric Patients and Young Adults with relapsed, Recurrent, or Refractory Synovial Sarcoma.",Oncology,Oncology: Soft Tissue Sarcoma,Eli Lilly,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT04145700,40407
2608,350847,"NCI-2019-00703, NCT03971474, S1800A, TrialTroveID-350847",A Phase II Randomized Study of Ramucirumab Plus MK3475 (Pembrolizumab) Versus Standard of Care for Patients Previously Treated With Immunotherapy for Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-MAP Non-Matched Sub-Study),Oncology,"Oncology: Lung, Non-Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Overall survival,"Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Response rate, Stable Disease",True,NCT03971474,40407
2609,346881,"NCT03904108, SBU-RAMUCIRUMAB-NSCLC, TrialTroveID-346881",Phase-II Trial of Platinum-Based Chemotherapy Plus Ramucirumab in Patients With Advanced NSCLC Who Have Progressed on First Line Anti-PD-1 Immunotherapy,Oncology,"Oncology: Lung, Non-Small Cell",Stony Brook University Hospital,Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Serious Adverse Events","Circulating Tumor Cells, Eosinophil levels",True,NCT03904108,40407
2610,345299,"AIO-STO-0218, EudraCT Number: 2018-002938-20, NCT03966118, RAP, RAP-Trial, TrialTroveID-345299",Avelumab + Paclitaxel/ Ramucirumab as Second Line Treatment in Gastro-esophageal Adenocarcinoma: a Phase II Trial of the AIO (The RAP-Trial),Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Circulating Tumor Cells, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs",True,NCT03966118,40407
2611,342848,"AIO-NET-0117, AIO-NET-0117/ass, DRKS00014689, EudraCT Number: 2017-001207-68, KKSH140, RamuNet, TrialTroveID-342848",A Multicenter Single-arm Pilot Study of Ramucirumab in Combination with Dacarbazine in Patients with Progressive Well-differentiated Metastatic Pancreatic Neuroendocrine Tumors.,Oncology,Oncology: Neuroendocrine,"Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Response evaluation criteria in solid tumors","EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life",False,,40407
2612,338332,"KCT0003638, KSWOG 1018, NCT03766607, TrialTroveID-338332",A Multi-center Phase II Study of Trastuzumab Biosimilar (SB3) in Combination With Ramucirumab and Paclitaxel in HER2 Positive Metastatic Gastric Cancer Patients,Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT03766607,40407
2613,337383,"JACCRO CC-16AR, TrialTroveID-337383, UMIN000034885","A Biomarker Research of ""A Phase II Study of Second-Line Combination Therapy With FOLFIRI Plus Ramucirumab in Patients With RAS Wild-type Unresectable Advanced/Recurrent Colorectal Cancer """,Oncology,Oncology: Colorectal,"Eli Lilly, (Other Cooperative Group), University of Southern California, USC/Norris Comprehensive Cancer Center and Hospital","Industry, Top 20 Pharma, Cooperative Group, Academic, Academic",Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,40407
2614,335855,TrialTroveID-335855,Multicenter Clinical Trial of Ramucirumab in Combination with Trastuzumab and Weekly Paclitaxel in the Treatment of Patients with HER2-positive Recurrent / Metastatic Gastric Cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,40407
2615,335427,"JapicCTI-184146, TORG 1833, TORG1833, TrialTroveID-335427",Randomized Phase II Study of Osimeltinib + Ramucirumab and Osimertinib as Initial Chemotherapy for EGFR Gene Mutation Positive Non-squamous Non-small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,40407
2616,335196,"TrialTroveID-335196, UMIN000019075",Feasibility Study Of Ramucirumab Plus Irinotecan In Patients With Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Clinical benefit rate, Overall response rate, Progression-free survival, Response rate, Time to treatment failure",False,,40407
2617,334941,"NCI-2017-02254, NCT03694002, S1701, U10CA180888","A Randomized Phase II Trial of Carboplatin-Paclitaxel With or Without Ramucirumab in Patients With Unresectable Locally Advanced, Recurrent, or Metastatic Thymic Carcinoma",,NA: ClinicalTrials.gov,"Southwest Oncology Group, National Cancer Institute (NCI)","Cooperative Group, ClinicalTrials.gov",,Adverse Events,True,NCT03694002,40407
2618,333978,"EudraCT Number: 2017-004792-30, HE3/16, HE316, NCT03745430, RACING, TrialTroveID-333978",Phase Ib-II Study of Ramucirumab Combined With Standard Nab-paclitaxel and Gemcitabine As First-line Treatment in Patients With Advanced Pancreatic Adenocarcinoma,Oncology,Oncology: Pancreas,"Eli Lilly, Bristol-Myers Squibb/Celgene, Hellenic Oncology Research Group","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT03745430,40407
2619,333924,"201810163, NCI-2018-02494, NCT03689855, RamAtezo-1, TrialTroveID-333924",Ramucirumab and Atezolizumab After Progression on Any Immune Checkpoint Blocker in NSCLC (RamAtezo-1),Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, Washington University School of Medicine","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Serious Adverse Events, Stable Disease",True,NCT03689855,40407
2620,333697,"MCC-19477, NCI-2018-03261, NCT03686488, TrialTroveID-333697","A Phase II Study of TAS 102 in Combination With Ramucirumab in Advanced, Refractory Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,H. Lee Moffitt Cancer Center and Research Institute,Academic,Overall survival,"Adverse Events, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT03686488,40407
2621,331619,"201809094, NCI-2018-02080, NCT03650764, TrialTroveID-331619",A Prospective Phase I and II Trial of Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,Washington University School of Medicine,Academic,"Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response rate, Safety and Tolerability","Adverse Events, Appetite, Common Terminology Criteria for Adverse Events, Disease Progression - duration, Duration of overall response, EORTC Quality of Life Questionnaire, Functional Assessment of Cancer Therapy-General, Functional Assessment of Cancer Therapy-Head & Neck Cancer, Global health status, Nausea, Overall response rate - duration, Overall survival, Progression-free survival, Quality of Life, Stable Disease, Vomiting",True,NCT03650764,40407
2622,330716,"AIO-STO-0216, AIO-STO-0216/ass, EudraCT Number: 2016-003850-33, NCT03762564, RAMOS, TrialTroveID-330716","A Randomized, Multicenter Open Label Phase II Trial Of Paclitaxel + Ramucirumab Versus Paclitaxel Alone In Patients With Squamous-Cell Carcinoma Of The Esophagus, Refractory Or Intolerant To Combination Therapy With Fluoropyrimidine And Platinum-Based Drugs â The RAMOS Study",Oncology,Oncology: Esophageal,"Eli Lilly, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Tumor control rate",True,NCT03762564,40407
2623,327570,"EudraCT Number: 2017-001683-37, NCT03760822, PRODIGE 55 - SOCRATE, PRODIGE 55 - SOCRATES, PRODIGE55, SOCRATE, TrialTroveID-327570",Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel In Elderly Advanced Gastric Or Gastroesophageal Junction Cancer Patients,Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, Federation Francophone de Cancerologie Digestive","Industry, Top 20 Pharma, Miscellaneous","EORTC Quality of Life Questionnaire, Overall survival, Quality of Life","Disease Progression, EORTC Quality of Life Questionnaire, Global health status, Instrumental Activities of Daily Living, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT03760822,40407
2624,326506,"EudraCT Number: 2016-001132-36, GOIRC-03-2016, NCT03560973, RAMES, TrialTroveID-326506","A Double-blind, Placebo Controlled, Randomized Multicenter Phase II Study Evaluating Gemcitabine With or Without Ramucirumab as II Line Treatment for Advanced Malignant Pleural Mesothelioma",Oncology,Oncology: Mesothelioma,Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) {Italian Oncology Group for Cancer Research},Cooperative Group,"Overall survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT03560973,40407
2625,325137,"CIRCLE, TrialTroveID-325137, UMIN000032671","Phase Ib Study Of Combination Therapy With Cisplatin, Irinotecan, And Ramucirumab For Extensive-Disease Small-Cell Lung Cancer.",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","Eli Lilly, Shizuoka Cancer Center","Industry, Top 20 Pharma, Academic",Dose-limiting toxicities,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate",False,,40407
2626,324384,"20-1034, NCI-2020-10364, NCT03527108, TH-189, TrialTroveID-324384","A Phase II Study of Nivolumab Plus Ramucirumab in Patients With Recurrent, Advanced, Metastatic Non-Small Cell Lung Carcinoma",Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, Eli Lilly, Fox Chase Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Clinical benefit rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03527108,40407
2627,324115,"AIO-KRK-0316 / ass, EudraCT Number: 2017-004162-99, NCT03520946, RAMTAS, TrialTroveID-324115",A Phase IIb Study of RAMucirumab in Combination With TAS102 vs. TAS102 Monotherapy in Chemotherapy Refractory Metastatic Colorectal Cancer Patients,Oncology,Oncology: Colorectal,"(Other Industry Sponsor), Eli Lilly, University Clinic Frankfurt","Industry, all other pharma, Industry, Top 20 Pharma, Academic",Overall survival,"Clinical benefit rate, EQ-5D-5L, Neutropenia, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT03520946,40407
2628,322831,"19694, HCRN-LUN15-299, Hoosier Cancer Research Network LUN15-299, LUN15-299, NCT03502746, TrialTroveID-322831",Phase II Study of Nivolumab and Ramucirumab for Patients With Previously-Treated Mesothelioma:Hoosier Cancer Research Network LUN15-299,Oncology,Oncology: Mesothelioma,"Bristol-Myers Squibb, Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall survival, Progression-free survival",True,NCT03502746,40407
2629,319143,"TrialTroveID-319143, UMIN000031285",A phase II Study of Weekly Nab-Paclitaxel plus Ramucirumab in patients with Previously Treated Advanced Gastric Cancer,Oncology,Oncology: Gastric,Yamaguchi University School of Medicine,Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,40407
2630,318752,TrialTroveID-318752,Efficacy and Tolerability of Ramucirumab Monotherapy or in Combination with Paclitaxel in Gastric Cancer Patients from the Expanded Access Program Cohort by the Korean Cancer Study Group (KCSG),Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Progression-free survival",,False,,40407
2631,317094,"HSR 1701, HSR1701, TrialTroveID-317094, UMIN000030603",Phase II Trial Of Docetaxel Plus Ramucirumab Combination Therapy In Patients With Advanced EGFR Gene Mutation Positive Advanced Stage Non-Squamous Cell Non small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Safety and Tolerability","Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,40407
2632,316167,"TrialTroveID-316167, UMIN000030614",Phase I / II Study to Confirm Tolerability of Nab-Paclitaxel (Nab-PTX) + Ramucirumab Combination Therapy in Second-Line Treatment for Unresectable Advanced / Recurrent Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,40407
2633,315854,"DOC+RAM+PEG-G-CSF in elderly NSCLC, DRAGON, jRCTs051180232, TrialTroveID-315854, UMIN000030598, WJOG9416L",Docetaxel Plus Ramucirumab With Pegylated Granulocyte-Colony Stimulating Factor Support For Elderly Patients With Advanced Non-Small Cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Study: DRAGON Study(WJOG9416L),Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, West Japan Thoracic Oncology Group","Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Response rate","Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2634,315295,"HGCSG 1603, HGCSG1603, jRCTs011180029, TrialTroveID-315295, UMIN000030372",Phase II Study of Ramucirumab and Irinotecan Combination Therapy as Second-line Treatment in Patients with Metastatic or Advanced Gastric Cancer,Oncology,Oncology: Gastric,"Eli Lilly, Hokkaido Gastrointestinal Cancer Study Group","Industry, Top 20 Pharma, Cooperative Group","Overall survival, Progression-free survival","Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,40407
2635,314566,"LY3009806-IIT-01, TrialTroveID-314566, UMIN000030142, UMIN000030164, UMIN000035642","A Phase Ib study of osimertinib with ramucirumab in EGFR mutated, T790M positive patients who had progressed EGFR-TKIs. (LY3009806-IIT-01)",Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,40407
2636,310813,"TrialTroveID-310813, UMIN000029318",Safety evaluation of a short-term infusion of ramucirumab for GI tract cancer patients,Oncology,Oncology: Colorectal; Oncology: Gastric,Aichi Cancer Center,Academic,,Adverse Events,False,,40407
2637,307960,"jRCTs051180238, RAINCLOUD, RAINCLOUD-TR, TrialTroveID-307960, UMIN000028677, UMIN000028678",Phase II Study of FOLFIRI + Ramucirumab with Early Recurrent Colorectal Cancer Refractory to Adjuvant Chemotherapy With Oxaliplatin / Fluoropyrimidine (RAINCLOUD),Oncology,Oncology: Colorectal,"Eli Lilly, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Progression-free survival,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to treatment failure",False,,40407
2638,307181,"EudraCT Number: 2017-000456-26, NCT03251612, TICC1, TrialTroveID-307181, Tumorspheres Colrec, Tumorspheres_Colrec",Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"EQ-5D-5L, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",True,NCT03251612,40407
2639,306209,"N-DOCC-F-C-1701, TrialTroveID-306209, UMIN000028170",A multicenter phase II study of S-1 and CPT-11 plus ramucirumab (IRIS+Rmab) as second-line chemotherapy for patients with oxaliplatin-refractory metastatic colorectal cancer in Japan (N-DOCC-F-C-1701),Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Nausea, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Vomiting",False,,40407
2640,306126,"jRCTs071180066, KSCC1701, TrialTroveID-306126, UMIN000028309",A Multicenter Phase II Study of S-1+Ramucirumab as First line Treatment in Elderly Patients with Advanced/Recurrent Gastric Cancer (KSCC1701),Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,40407
2641,304322,"TrialTroveID-304322, UMIN000027223",A Phase II Study of Docetaxel Plus Ramcirumab With Pegfilgrastim in Treated Patients With Advanced Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response rate",False,,40407
2642,302334,TrialTroveID-302334,Regulatory-T Cells (Tregs) in Tumor Infiltrating Lymphocytes from Patients with Advanced Gastric Cancer after Chemotherapy Containing Ramucirumab,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,,False,,40407
2643,301308,"TrialTroveID-301308, UMIN000025972",Phase II Study of Ramucirumab plus Docetaxel plus Pegfilgrastim in Patients with Stage IV Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2644,300784,"20019, 201704082, NCI-2017-00700, NCT03141034, TrialTroveID-300784",Ramucirumab Plus Irinotecan in Patients With Previously Treated Advanced Gastric or Gastro-Esophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, Washington University School of Medicine","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT03141034,40407
2645,300461,"jRCTs041180074, TrialTroveID-300461, UMIN000025659","A Multicenter, Single-arm, Phase II Study of Ramucirumab Plus FOLFIRI with 150 mg/m^2 Irinotecan, Standard Nippon Dose, as the Second-line Treatment for Japanese Patients with Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,"Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Time to treatment failure",False,,40407
2646,298604,"jRCTs041180166, TrialTroveID-298604, UMIN000026527, WJOG9216G",Randomized Phase II Study Of FOLFIRI Plus Ramucirumab Versus  FOLFOXIRI Plus Ramucirumab As First-Line Treatment In Patients  With Metastatic Colorectal Cancer(WJOG9216G),Oncology,Oncology: Colorectal,"Eli Lilly, West Japan Thoracic Oncology Group","Industry, Top 20 Pharma, Cooperative Group",Overall response rate,"Overall survival, Progression-free survival, Resection rate, Safety and Tolerability",False,,40407
2647,295999,"TrialTroveID-295999, UMIN000025947","Phase I/II multicenter trial of paclitaxel, ramucirumab and nivolumab for metastatic gastric cancer patients who progressed on chemotherapy with fluoropyrimidine plus platinum",Oncology,Oncology: Esophageal; Oncology: Gastric,"Ono Pharmaceutical, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Dose-limiting toxicities, Progression-free survival","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2648,295672,TrialTroveID-295672,Plasma Biomarker Analysis of Ramucirumab in Japanese Patients with Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Academic Cancer Center),Academic,Progression-free survival,,False,,40407
2649,293606,"10017760, 10066, 17450, 18-708, 2000021407, NCI 10066, NCI-2016-02049, NCT03008278, PHII-162, TrialTroveID-293606",A Phase I/II Study of Olaparib in Combination With Ramucirumab in Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma (10017760),Oncology,Oncology: Esophageal; Oncology: Gastric,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall survival, Progression-free survival, Stable Disease",True,NCT03008278,40407
2650,292960,"NCCH-1611, NCT02999295, NivoRam, TrialTroveID-292960, UMIN000025560","A Multicenter, Phase I/II Study of Ramucirumab Plus Nivolumab as Second-line Therapy in Participants With Gastric or GEJ Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Industry Sponsor), Ono Pharmaceutical, (Other Hospital/Academic/Medical Center), National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}","Industry, all other pharma, Industry, all other pharma, Academic, Academic","Dose-limiting toxicities, Overall survival, Progression-free survival","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune Response, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT02999295,40407
2651,292193,"TrialTroveID-292193, UMIN000023515",A Combination Therapy Of Ramucirumab And Paclitaxel As Second-Line Treatment For Elderly Gastric Cancer Patients: A Exploratory Phase II Research,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,40407
2652,291430,"jRCTs071180048, RAMNITA, TrialTroveID-291430, UMIN000024551",Phase II Study Of The Efficacy And Safety Of Ramucirumab Plus Docetaxel For Recurrent NSCLC Patients With Brain Metastasis,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer","Eli Lilly, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,40407
2653,290715,"AIO-STO-0415, EudraCT Number: 2015-005171-24, NCT03081143, RAMIRIS, TrialTroveID-290715","Ramucirumab plus Irinotecan / Leucovorin / 5-FU versus Ramucirumab plus Paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy - The Phase II/III RAMIRIS Study.",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Tumor control rate",True,NCT03081143,40407
2654,290020,"RAMoss, TrialTroveID-290020",Safety and efficacy profile of ramucirumab alone or combined with paclitaxel in metastatic gastric cancer (MGC): A real-life overview of compassionate-use named patients (pts) (RAMoss study),Oncology,Oncology: Gastric,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), (Other Hospital/Academic/Medical Center)","Academic, Academic",Safety and Tolerability,"Overall response rate, Overall survival, Progression-free survival",False,,40407
2655,288665,"ARMANI, EudraCT Number: 2016-001783-12, INT 103-16, NCT02934464, TrialTroveID-288665",Assessment of Ramucirumab Plus Paclitaxel as Switch MANteInance Versus Continuation of First-line Chemotherapy in Patients With Advanced HER-2 Negative Gastric or Gastroesophageal Junction Cancers: the ARMANI Phase III Trial,Oncology,Oncology: Esophageal; Oncology: Gastric,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,"Disease Progression, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to treatment failure",True,NCT02934464,40407
2656,286373,"15244, 2017-CT0392, CTR20160574, I4T-CR-JVCR, I4T-CR-JVCR 32795, NCI-2016-00243, NCT02898077, NMRR-16-2205-32795, PHRR170523-001547, RAINBOW-ASIA, TrialTroveID-286373","A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Phase III Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine.",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma",Overall survival,"Complete response, Disease Progression, EORTC Quality of Life Questionnaire, EQ-5D-3L, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression",True,NCT02898077,40407
2657,283371,"TrialTroveID-283371, UMIN000023277",Phase Ib Study Of FOLFOXIRI Plus Ramucirumab As First-Line Treatment In Patients With Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Shizuoka Cancer Center","Academic, Academic",Dose-limiting toxicities,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,40407
2658,283231,"TrialTroveID-283231, UMIN000022956",A Phase II study of Ramucirumab Beyond Disease Progression in Combination with Irinotecan After Failure of Weekly Paclitaxel Plus Ramucirumab in Advanced Gastric Cancer Patients Previously Treated with Fluoropyrimidine and Platinum,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability",False,,40407
2659,283152,"JCOG1603INT, jRCTs051180187, RINDBeRG trial, TrialTroveID-283152, UMIN000023065",A Phase III Trial of Ramucirumab plus Irinotecan in Third or More Line Beyond Progression after Ramucirumab for Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"Eli Lilly, Osaka Gastrointestinal Cancer Chemotherapy Study Group","Industry, Top 20 Pharma, Cooperative Group",Overall survival,"Adverse Events, Clinical benefit rate, Overall response rate, Progression-free survival, Response rate, Time to treatment failure",False,,40407
2660,282986,"TrialTroveID-282986, UMIN000022221",Feasibility Study for 2nd Line Combination Chemotherapy of Nab-paclitaxel with Ramucirumab for Inoperable Advanced Recurrent Gastric Cancer.,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Response rate",False,,40407
2661,282315,"16404, EudraCT Number: 2016-001317-25, I4T-MC-JVDN, NCT02831491, TrialTroveID-282315","A Single-Arm, Phase II Study of Ramucirumab in Combination With Weekly Docetaxel in Patients With Stage IV Non-Small Cell Lung Cancer Following Disease Progression After Prior Platinum-Based Chemotherapy",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly,"Industry, Top 20 Pharma","Neutropenia, Safety and Tolerability","Cmin, Neutropenia, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02831491,40407
2662,280319,"16-072, NCI-2016-00941, NCT02795858, TrialTroveID-280319","A Phase II Study of Ramucirumab With Somatostatin Analog Therapy in Patients With Advanced, Progressive Carcinoid Tumors",Oncology,Oncology: Neuroendocrine,"Eli Lilly, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Industry, Top 20 Pharma, Academic",Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT02795858,40407
2663,280208,"Ramuciru-AC, TrialTroveID-280208, UMIN000021330",The Efficiency of Ramucirumab Therapy for Advanced Gastric Cancer after Chemotherapy,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response rate",,False,,40407
2664,280010,"16357, 16-876, EudraCT Number: 2015-005296-25, I4T-MC-JVDL, JVDL, NCI-2017-01259, NCT02789345, TrialTroveID-280010","An Open-Label, Multicenter, Phase I Study With Expansion Cohorts of Ramucirumab or Necitumumab in Combination With Osimertinib in Patients With Advanced T790M-Positive EGFR-Mutant Non-Small Cell Lung Cancer After Progression on First-Line EGFR TKI Therapy",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Eli Lilly","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT02789345,40407
2665,279942,"TrialTroveID-279942, UMIN000021949",A Phase I Trial of Biweekly Nab-Paclitaxel Plus Ramucirumab in Patients with Previously Treated Advanced Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Adverse Events, Clinical benefit rate, Overall response rate, Safety and Tolerability",False,,40407
2666,278522,"jRCTs021180016, T-CORE1501, TrialTroveID-278522, UMIN000021728",Phase II study of ramucirumab plus paclitaxel therapy for elderly patients with non-resectable or metastatic gastric cancer (T-CORE1501),Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Safety and Tolerability, Time to treatment failure",False,,40407
2667,277117,"16165, 2016-0473, EudraCT Number: 2015-004381-28, I4T-MC-JVDK, IRAS ID: 206123, JVDK, NCI-2017-00003, NCT02745769, TrialTroveID-277117","An Open-Label, Phase Ia/Ib Study of Ramucirumab in Combination With Other Targeted Agents in Advanced Cancers",Oncology,"Oncology: Colorectal; Oncology: Lymphoma, Non-Hodgkin's",Eli Lilly,"Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Cmin, Complete response, Immune Response, Overall response rate, Partial response, Progression-free survival",True,NCT02745769,40407
2668,276202,"15-169, NCI-2016-01641, NCT02730247, TrialTroveID-276202, UPCI 15-169",A Phase II Clinical Trial of the Safety and Efficacy of the Addition of Ramucirumab to Nab-paclitaxel in Previously Treated Patients With Advanced Non-small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell",University of Pittsburgh Cancer Institute,Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Complete response, EQ-5D-5L, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02730247,40407
2669,275970,"15-301, NCI-2016-00548, NCT02726399, TrialTroveID-275970","Phase II Study of Ramucirumab With Trastuzumab, Fluoropyrimidine, and Platinum in Patients With Metastatic HER2-Positive Gastroesophageal Junction and Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,Memorial Sloan-Kettering Cancer Center,Academic,"Disease Progression, Progression-free survival","Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",True,NCT02726399,40407
2670,275101,"16-1016, 16329, 16-LIL-2, 47R/2015, EudraCT Number: 2015-004699-31, GI-234, I3O-MC-JSBF, IRAS ID: 200426, JSBF, NCI-2016-01171, NCT02711553, REec-2016-2349, TrialTroveID-275101","Randomized, Double-Blind, Phase II Study of Ramucirumab or Merestinib or Placebo Plus Cisplatin and Gemcitabine as First-Line Treatment in Patients With Advanced or Metastatic Biliary Tract Cancer",Oncology,Oncology: Liver; Oncology: Pancreas,Eli Lilly,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Cmin, Complete response, Disease Progression, EQ-5D-5L, Functional Assessment of Cancer Therapy-General, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Partial response, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT02711553,40407
2671,274069,"JapicCTI-153088, TrialTroveID-274069",A Phase II Study Of ABI-007 In Combination With Ramucirumab In Patients With Unresectable/Recurrent Gastric Cancer Refractory To Prior Chemotherapy Containing Fluoropyrimidines,Oncology,Oncology: Esophageal; Oncology: Gastric,Taiho Pharmaceutical,"Industry, all other pharma",Overall response rate,"Adverse Events, Clinical benefit rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,40407
2672,271940,"EudraCT Number: 2015-003118-26, NCT02661971, RAMSES, RAMSES/FLOT7, TrialTroveID-271940",Perioperative Ramucirumab in Combination With FLOT Versus FLOT Alone for resectable esophagogastric Adenocarcinoma - RAMSES - a Phase II/III Trial of the AIO,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall survival","Adverse Events, Complete response, Disease Progression, Mortality, Overall response rate, Overall survival, Progression-free survival, Recurrence, Resection rate, Response rate, Safety and Tolerability",True,NCT02661971,40407
2673,271877,"TrialTroveID-271877, UMIN000020579","An Open Label, Non-Randomized Phase I/II Study Of Ramucirumab In Combination With Nab-Paclitaxel As Second-Line Therapy In Patients With Advanced Gastric Cancer",Oncology,Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Dose-limiting toxicities, Overall response rate",,False,,40407
2674,270834,"ACTRN12616001187437, MatchMel, MIA2015/174, MIA-M-15-01, NCT02645149, TrialTroveID-270834",Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,Oncology,Oncology: Melanoma,"(Other Cooperative Group), National Health and Medical Research Council  (NHMRC)","Cooperative Group, Government",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02645149,40407
2675,269629,"2015-11-110, KCT0003440, NCT02628951, TrialTroveID-269629",Phase II Ramucirumab/Paclitaxel as Second-line Treatment in Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma With Integrative Genomic Analysis,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall response rate, Response rate",True,NCT02628951,40407
2676,266525,"16.1195, GI14-198, HCRN GI14-198, HCRN_GI14-198, NCI-2016-00206, NCT02581215, TrialTroveID-266525, TX7486, Winship3142-16","Phase II Randomized, Double-Blind Study of mFOLFIRINOX Plus Ramucirumab Versus mFOLFIRINOX Plus Placebo in Advanced Pancreatic Cancer Patients: Hoosier Cancer Research Network GI14-198",Oncology,Oncology: Pancreas,"Eli Lilly, Hoosier Cancer Research Network {Hoosier Oncology Group}","Industry, Top 20 Pharma, Cooperative Group","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",True,NCT02581215,40407
2677,265435,"15542, AAAQ5801, ADVL1416, COG-ADVL1416, I4T-MC-JVDA, JVDA, NCI-2015-00744, NCT02564198, PHO-LILLY-CROOP-ADVL1416, TrialTroveID-265435","A Phase I Study Of Ramucirumab, a Human Monoclonal Antibody Against the Vascular Endothelial Growth Factor-2 (VEGFR-2) Receptor in Children With Refractory Solid Tumors, Including CNS Tumors",Oncology,"Oncology: CNS, Other; Oncology: Unspecified Solid Tumor","Eli Lilly, Childrenâs Oncology Group","Industry, Top 20 Pharma, Cooperative Group","Cmin, Maximum tolerated dose","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Stable Disease",True,NCT02564198,40407
2678,264094,"G-IRIRAM study, TrialTroveID-264094, UMIN000018606",Phase I study of Ramucirumab and Irinotecan For Metastatic Gastric Cancer Previously Treated With Fluoropyrimidine With/Without Platinum and Taxane.,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,40407
2679,263989,"15461, I4T-JE-JVCW, JapicCTI-153053, JVCW, NCT02539225, RAINSTORM, TrialTroveID-263989","A Randomized, Double-Blind, Placebo-Controlled Phase II Study of S-1 and Oxaliplatin With or Without Ramucirumab as First-line Therapy Followed by Paclitaxel With Ramucirumab as Second-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Clinical benefit rate, Cmin, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT02539225,40407
2680,262816,"2015-0393, NCI-2015-01442, NCT02520141, TrialTroveID-262816","A Phase II Study of Ramucirumab for Advanced, Pre-treated Biliary Cancers",Oncology,Oncology: Liver,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Disease Progression, Progression-free survival","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Gene expression profiling, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Stable Disease",True,NCT02520141,40407
2681,262466,"15541, 15-545, EudraCT Number: 2014-005067-32, I4T-MC-JVCZ, JVCZ (S571), NCI-2016-00243, NCT02514551, TrialTroveID-262466","Randomized Phase II Trial Evaluating Alternative Ramucirumab Doses in Combination With Paclitaxel in Second-Line Metastatic or Locally Advanced, Unresectable Gastric or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Clinical benefit rate, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Clinical benefit rate, Cmin, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events, Vital signs",True,NCT02514551,40407
2682,257277,"15608, 2015-0256, EudraCT Number: 2014-003791-23, I4T-MC-JVDB, IRAS ID: 176779, JVBD Lilly, NCI-2015-01087, NCT02443883, TrialTroveID-257277",Randomized Phase II Trial Evaluating Pharmacokinetics and Safety of Four Ramucirumab Dosing Regimens in Second-Line Gastric or Gastroesophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Cmin, Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT02443883,40407
2683,256998,"15-287, 15755, 784, CTR20170561, EudraCT Number: 2014-005068-13, I4T-MC-JVDE, IRAS ID: 179483, JapicCTI-152971, JVDE, NCI-2016-00158, NCT02435433, REACH-2, TrialTroveID-256998, U1111-1165-1891, UW15-396","Randomized, Double-Blind, Placebo-Controlled, Phase III Study of Ramucirumab and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma and Elevated Baseline Alpha-Fetoprotein (AFP) Following First-Line Therapy With Sorafenib",Oncology,Oncology: Liver,Eli Lilly,"Industry, Top 20 Pharma","Overall survival, Safety and Tolerability","Anti-drug antibodies, Cmax, Cmin, Complete response, EQ-5D-5L, Infusion-related reactions, Nausea, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT02435433,40407
2684,255401,"15679, 20150398, 20150428, DRKS00008825, EudraCT Number: 2014-003655-66, GUTJVDC, I4t-MC-JVDC, I4T-MC-JVDC, IRAS ID:  176881, JapicCTI-153032, JVDC Study, NCI-2015-02085, NCT02426125, NL52931.028.15, RANGE, REec-2015-1516, TrialTroveID-255401","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Ramucirumab Plus Docetaxel Versus Placebo Plus Docetaxel in Patients with Locally Advanced or Unresectable or Metastatic Urothelial Carcinoma who Progressed on or After Platinum-Based Therapy",Oncology,Oncology: Bladder; Oncology: Renal,Eli Lilly,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT02426125,40407
2685,255146,"136971, 15540, 257134, EudraCT Number: 2014-004824-22, H00007990, I4T-MC-JVCY, IMC-1121B, IRAS ID: 172859, JapicCTI-152939, JVCY, NCI-2016-00365, NCT02411448, RECF2948, REec-2015-1504, RELAY, RELAY Study, RELAY+, TrialTroveID-255146","A Multicenter, Randomized, Double-Blind Study of Erlotinib in Combination with Ramucirumab or Placebo in Previously Untreated Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Adverse Events, Appetite, Circulating Tumor Cells, Clinical benefit rate, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, EQ-5D-5L, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Visual Analog Scale",True,NCT02411448,40407
2686,251921,"15532, I4T-JE-JVCX, JapicCTI-152816, NCT02359058, TrialTroveID-251921",Phase Ib Study of Ramucirumab in Combination with Fluoropyrimidines and Platinum-Based Agents in Japanese Patients with Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Cmax, Cmin, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02359058,40407
2687,250370,"1507016120, 15787, 20151222, EudraCT Number: 2015-001473-40, I4T-MC-JVDF, IRAS ID 183773, JVDF, KEYNOTE -098, KEYNOTE-098, MULTI 04, NCI-2015-01802, NCT02443324, TrialTroveID-250370","An Open-Label, Multicenter, Phase I Study of Ramucirumab Plus Pembrolizumab in Patients With Locally Advanced and Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Non-Small Cell Lung Cancer, Transitional Cell Carcinoma of the Urothelium, or Biliary Tract Cancer",Oncology,"Oncology: Bladder; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Renal","Eli Lilly, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease, Time to response",True,NCT02443324,40407
2688,248786,"i2134, NCT02317991, SCRI GI 201, TrialTroveID-248786",Phase II Study of Nab-Paclitaxel and Ramucirumab for the Second-line Treatment of Patients With Metastatic Gastroesophageal Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,Bristol-Myers Squibb/Celgene,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT02317991,40407
2689,222571,"15-1002, 15372, EudraCT Number: 2014-002240-40, GITRAINFAL, I4T-MC-JVCU, IRAS ID: 171812, JapicCTI-152827, JVCU, NCI-2015-00221, NCT02314117, NL51761.028.14, RAINFALL, REec-2015-1513, TrialTroveID-222571","A Randomized, Double-Blind, Placebo-Controlled Phase III Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Anti-drug antibodies, Clinical benefit rate, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Visual Analog Scale",True,NCT02314117,40407
2690,222118,"15263, I4T-FR-JVCS, NCT02307812, TrialTroveID-222118",Ramucirumab Use in Combination With Paclitaxel in Gastric or Gastroesophageal Junction Adenocarcinoma; Temporary Authorization for Use (ATU) in France,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma",,,True,NCT02307812,40407
2691,203293,"15233, I4T-CR-JVCQ, NCT02069041, TrialTroveID-203293",Phase Ib Study of 5-FU/FA and Oxaliplatin (FOLFOX4) Plus Ramucirumab (LY3009806) in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,Eli Lilly,"Industry, Top 20 Pharma",Serious Adverse Events,"Area under the curve score, Cmax, Disease Progression, Overall response rate",True,NCT02069041,40407
2692,203106,"14945, I4T-MC-JVCP, NCT02065765, TrialTroveID-203106",An International Single-Arm Protocol to Provide Expanded Access to Ramucirumab for the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression After Prior Fluoropyrimidine and/or Platinum-Containing Chemotherapy,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma",Disease Progression,,True,NCT02065765,40407
2693,197186,"15045, Cyramza, I4T-JE-JVCL, JapicCTI-132341, NCT01983878, TrialTroveID-197186",A Phase II Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Clinical benefit rate, Cmax, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT01983878,40407
2694,175765,"14658, I4T-JE-JVCG, JapicCTI-122032, JVCG, NCT01703091, TrialTroveID-175765","A Randomized, Double-Blind, Phase II Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly,"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Appetite, Clinical benefit rate, Complete response, EQ-5D, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease, Visual Analog Scale",True,NCT01703091,40407
2695,174260,"14139, CTR20132703, I4T-CR-JVBU, NCT01682135, TrialTroveID-174260",Phase I Study of Ramucirumab in Patients with Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cmax, Cmin, Safety and Tolerability, Serious Adverse Events","Complete response, Disease Progression - duration, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT01682135,40407
2696,170783,"14433, CP12-1033, I4T-IE-JVCB, IMCL4Y12, NCT01634555, TrialTroveID-170783",A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Irinotecan and Its Metabolite SN-38 When Coadministered With Folinic Acid and 5 Fluorouracil in Patients With Advanced Malignant Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Eli Lilly {ImClone},"Industry, Top 20 Pharma",Cmax,Cmax,True,NCT01634555,40407
2697,164981,"14434, CP13-0713, I4T-IE-JVCC, NCT01567163, TrialTroveID-164981",A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Docetaxel in Patients With Advanced Malignant Solid Tumors,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Prostate",Eli Lilly {ImClone},"Industry, Top 20 Pharma",Cmax,Cmax,True,NCT01567163,40407
2698,160966,"051204, 14432, CP12-1032, I4T-IE-JVCA, NCT01515306, TrialTroveID-160966",A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Eli Lilly {ImClone},"Industry, Top 20 Pharma",Cmax,Cmax,True,NCT01515306,40407
2699,141494,"14223, 14T-IE-JVBY, CP12-1029, JapicCTI-111425, NCT01286818, TrialTroveID-141494","A Phase Ib Study of Irinotecan, Levofolinate, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab (IMC-1121B) Drug Product in Japanese Subjects With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine",Oncology,Oncology: Colorectal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Infusion-related reactions, Neutropenia, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Urine protein level","Area under the curve score, Cmax, Complete response, Elimination half-life, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Volume of distribution",True,NCT01286818,40407
2700,141311,"10522, 13943, 20101692, 4B-11-1, CP20-0902, I4Y-IE-JCDC, IML CP20-0902, NCT01282463, TrialTroveID-141311, USO 09-217","An Open-Label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Docetaxel in Combination with Ramucirumab (IMC-1121B) Drug Product or IMC-18F1 or without Investigational Therapy as Second-line Therapy in Patients with Locally Advanced or Metastatic Transitional Cell Carcinoma of the Bladder, Urethra, Ureter, or Renal Pelvis Following Disease Progression on First-line Platinum-based Therapy",Oncology,Oncology: Bladder; Oncology: Renal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Complete response, Duration of overall response, Neutralizing antibody response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events",True,NCT01282463,40407
2701,139137,"14200, CP12-1028, I4T-IE-JVBX, NCT01256567, TrialTroveID-139137",A Phase Ib Study of Docetaxel in Combination With Ramucirumab (IMC-1121B) Drug Product in Patients With Locally Advanced or Metastatic Breast Cancer,Oncology,Oncology: Breast,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Heart rate corrected QT interval, Neutropenia, Partial thromboplastin time, Prothrombin ratio, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Area under the curve score, Cmax, Elimination half-life, Volume of distribution",True,NCT01256567,40407
2702,138925,"14204, CP12-1026, I4T-IE-JVBW, NCT01253525, TrialTroveID-138925",A Phase Ib Study of Weekly Paclitaxel With Ramucirumab (IMC-1121B) Drug Product in Patients With Advanced Gastric Adenocarcinomas.,Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Neutropenia, Partial thromboplastin time, Prothrombin ratio, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Cmax, Elimination half-life, Volume of distribution",True,NCT01253525,40407
2703,138406,"14057, 2011.098.C, 201102269, 7575, GCC 1127, GI 152, I4T-MC-JVBT, MUSC 101560, NCT01246960, TrialTroveID-138406","Randomized, Placebo-Controlled, Double-Blind Phase II Study of mFOLFOX6 Chemotherapy Plus Ramucirumab Drug Product (IMC-1121B) Versus mFOLFOX6 Plus Placebo for Advanced Adenocarcinoma of the Esophagus, Gastroesophageal Junction or Stomach",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly,"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",True,NCT01246960,40407
2704,137384,"05005388, 13944, 1B-10-11, BRE 183, CP20-0903, I4Y-IE-JCDD, IMCL CP20-0903, NCT01234402, STU 032011-167, TrialTroveID-137384","An Open-Label, Multicenter, Randomized Phase II Study Evaluating the Safety and Efficacy of Ramucirumab (IMC-1121B) Drug Product or Icrucumab (IMC-18F1) in Combination With Capecitabine or Capecitabine Monotherapy, in Unresectable, Locally Advanced or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",Oncology,Oncology: Breast,Eli Lilly,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Circulating Tumor Cells, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Volume of distribution",True,NCT01234402,40407
2705,133347,"13856, 13856I4T-MC-JVBB, 201011820, 20101327, CP12-0920, CTRI/2011/07/001900, EudraCT Number: 2010-021037-32, I4T-MC-JVBB, I4T-MC-JVBB(e), I4T-MD-JVBB, IMCL CP12-0920, J10112, JapicCTI-111571, JVBB, Lilly I4T-MC-JVBB, NCT01183780, NL34026.096.10, RAISE, RECF1553, TrialTroveID-133347, USON 10101, Veeda V10-009","A Randomized, Double-blind, Multicenter Phase III Study of Irinotecan, Folinic Acid, and 5-Fluorouracil (FOLFIRI) Plus Ramucirumab or Placebo in Patients With Metastatic Colorectal Carcinoma Progressive During or Following First-Line Combination Therapy With Bevacizumab, Oxaliplatin, and a Fluoropyrimidine",Oncology,Oncology: Colorectal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Vital signs","Anti-drug antibodies, Cmax, Cmin, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01183780,40407
2706,131903,"13894, 14-IE-JVBE, CP12-0922, EudraCT Number: 2010-020426-18, I4T-IE-JVBE, IMCL CP12-0922, IMCLCP12-0922, ImClone#13894#14-IE-JVBE#RAINBOW, IRAS ID: 60241, JapicCTI-111456, NCT01170663, RAINBOW, RECF1625, TrialTroveID-131903, UW10036","A Randomized, Multicenter, Double-Blind, Placebo-Controlled Phase III Study of Weekly Paclitaxel With or Without Ramucirumab (IMC-1121B) Drug Product in Patients With Metastatic Gastric Adenocarcinoma, Refractory to or Progressive After First-Line Therapy With Platinum and Fluoropyrimidine",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Overall survival, Safety and Tolerability, Vital signs","Adverse Events, Anti-drug antibodies, Appetite, Cmax, Cmin, Complete response, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Nausea, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression, Vomiting",True,NCT01170663,40407
2707,130980,"13916, 14T-IE-JVBL, CP12-0917, EudraCT Number: 2009-016784-11, IMC-CP12-0917, IMCLCP12-0917, NCRN172, NCT01160744, SMMC 10-009, TrialTroveID-130980, UKCRN ID 11199, USO 09179, USON 09-179","An Open-label, Multicenter, Randomized, Phase II Study of a Recombinant Human Anti-VEGFR-2 Monoclonal Antibody, 1121B in Combination with Platinum-based Chemotherapy Versus Platinum-based Chemotherapy Alone as First-line Treatment of Patients with Recurrent or Advanced Non-small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Magnetic Resonance Imaging, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT01160744,40407
2708,128824,"13895, 20101238, CP12-0919, DRKS00003671, EudraCT Number: 2010-019318-26, HCC027, HIC 1108008910, I4T-IE-JVBF, IMCL CP12-0919, IMCL CP12-0919 8248, IMCL_CP12-0919, IMCL_CP12-0919_(I4T-IE-JVBF), ImClone IMCL CP12-0919, JapicCTI-101318, NCT01140347, NL37954.018.11, NMRR-11-34-8248, REACH, REACH (IMCL CP12-0919), RECF1479, TrialTroveID-128824, Yale9507671","A Multicenter, Randomized, Double-Blind, Phase III Study of Ramucirumab (IMC-1121B) Drug Product  and Best Supportive Care (BSC) Versus Placebo and BSC as Second-Line Treatment in Patients With Hepatocellular Carcinoma Following First-Line Therapy With Sorafenib (REACH)",Oncology,Oncology: Liver,"Eli Lilly {ImClone}, Menarini Group/Stemline Therapeutics","Industry, Top 20 Pharma, Industry, all other pharma","Body Mass Index, Disease Progression, Overall survival","Adverse Events, Anti-drug antibodies, Cmax, Complete response, EQ-5D, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to progression, Vital signs",True,NCT01140347,40407
2709,126319,"13942, CP20-0801, GI 141, I4Y-IE-JCDB, IMCL CP20 GI, IMCL CP20-0801, McG 1008, NCT01111604, TrialTroveID-126319, VICCGI0999","An Open-label, Multicenter, Randomized Phase 2 Study Evaluating the Safety and Efficacy of 5 FU/FA and Oxaliplatin (Modified FOLFOX 6) in Combination With Ramucirumab or IMC-18F1 or Without Investigational Therapy as Second Line Therapy in Patients With Metastatic Colorectal Cancer Following Disease Progression on First Line Irinotecan-based Therapy",Oncology,Oncology: Colorectal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events",True,NCT01111604,40407
2710,123837,"11-00394, CTSU/E7208, E7208, ECOG 7208, ECOG E7208, ECOG-E7208, NCI-2011-02018, NCT01079780, TrialTroveID-123837","A Randomized Phase II Study of Irinotecan and Cetuximab With or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy",Oncology,Oncology: Colorectal,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute, ECOG-ACRIN Cancer Research Group","Cooperative Group, Government, Cooperative Group",Progression-free survival,"Complete response, Overall response rate, Overall survival, Partial response, Response rate, Stable Disease",True,NCT01079780,40407
2711,119974,"14392, 14T-IE-JVCD, 16924, 201201085, BRE 191, CP12-1134, IMCL CP2020-0903, NCT01427933, TrialTroveID-119974, USO 11-158","An Open-Label, Multicenter, Randomized, Phase II Study Evaluating the Efficacy and Safety of Ramucirumab (IMC-1121B) Drug Product in Combination With Eribulin Versus Eribulin Monotherapy in Unresectable, Locally-Recurrent or Metastatic Breast Cancer Patients Previously Treated With Anthracycline and Taxane Therapy",Oncology,Oncology: Breast,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Circulating Tumor Cells, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01427933,40407
2712,119973,TrialTroveID-119973,A Phase II Study of Ramucirumab in Patients with Colorectal Cancer,Oncology,Oncology: Colorectal,Eli Lilly {ImClone},"Industry, Top 20 Pharma",,,False,,40407
2713,119969,TrialTroveID-119969,A Phase II Study of Ramucirumab in Patients with Bladder Cancer.,Oncology,Oncology: Bladder,Eli Lilly {ImClone},"Industry, Top 20 Pharma",,,False,,40407
2714,119968,"13852, 15-lil-1, CP12-1027, CTRI/2011/08/001942, EudraCT Number: 2010-021297-11, I4T-MC-JVBA, IMCL CP12-1027, IRAS ID: 59951, NCRN169, NCT01168973, NL33924.028.10, RECF1552, REVEL, TrialTroveID-119968, UKCRN 8908, USO 10061","A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non-Small Cell Lung Cancer Following Disease Progression After One Prior Platinum-Based Therapy",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Overall survival","Adverse Events, Anti-drug antibodies, Appetite, Clinical benefit rate, Cmax, Cmin, Complete response, EQ-5D, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events, Visual Analog Scale",True,NCT01168973,40407
2715,119127,"13915, CP12-0712, I4T-IE-JVBK, IMCL CP12-0712, LS-P-IMCL CP12-0712, NCT01017731, PIMCLON009, TrialTroveID-119127",A Study to Evaluate the Relationship Between Ramucirumab (IMC-1121B) Therapy and Corrected QT (QTc) Interval Changes in Patients With Advanced Cancer.,Oncology,Oncology: Unspecified Solid Tumor,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Cardiac Telemetry, Heart rate corrected QT interval, Heart rate, Overall response rate, Safety and Tolerability, Safety and Tolerability","Adverse Events, Area under the curve score, Cmax, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT01017731,40407
2716,118032,"13898, CP12-0816, I4T-IE-JVBI, NCT01005355, TrialTroveID-118032",Phase I Study of IMC-1121B in Patients With Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Elimination half-life, Serious Adverse Events, Volume of distribution",,True,NCT01005355,40407
2717,108380,"ABTC 09-01, ABTC-0901, I5B-IE-JGDE, IMC (0901), IMCL-CP-19-0801, N0901, NABTT 0901, NCT00895180, TrialTroveID-108380","An Open Label, Phase II Study Evaluating the Safety and Efficacy of IMC-3G3 or IMC-1121B in Patients With Recurrent Glioblastoma Multiforme",Oncology,"Oncology: CNS, Glioblastoma","National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Eli Lilly {ImClone}","Government, Academic, Industry, Top 20 Pharma","Overall survival, Progression-free survival, Progressive disease rate","Adverse Events, Apparent diffusion coefficient, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00895180,40407
2718,90797,"00007984, 13924, 2008-0433, 20080767, CP18-0601, CRC 08060, GU 60, HIC0801003428, I4T-IE-JVBS, IMCL CP18-0601, ImClone CP18-0601, NCT00683475, RPCI 136408, TrialTroveID-090797, UPMC08-069","A Phase II, Multicenter, Randomized Study of IMC-A12 or IMC-1121B Plus Mitoxantrone and Prednisone in Metastatic Androgen-Independent Prostate Cancer (AIPC) Following Disease Progression on Docetaxel-Based Chemotherapy",Oncology,Oncology: Prostate,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00683475,40407
2719,79087,"13893, 2009-0231, BB IND 11856, CAAE 0037.1.083.000-10, CP12-0715, CTRI/2010/091/001245, EudraCT Number: 2008-005964-15, I4T-IE-JVBD, IMCL CP12-0715, IMCL CP12-0715 2610, IMCLCP12-0715 (I4T-IE-JVBD), IMCLONE  CP12-0715, NCT00917384, NMRR-08-1634-2610, RBR-5f6qjg, REGARD, TrialTroveID-079087","A Phase III, Randomized, Double-Blinded Study of IMC-1121B and Best Supportive Care (BSC) Versus Placebo and BSC in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First-Line Platinum- or Fluoropyrimidine-Containing Combination Therapy",Oncology,Oncology: Esophageal; Oncology: Gastric,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Overall survival","Adverse Events, Anti-drug antibodies, Appetite, Cmax, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Nausea, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Vomiting",True,NCT00917384,40407
2720,75995,"13892, ANZ 0802, CP12-0606, EudraCT Number: 2008-001727-65, GEICAM/2008-02, I4T-IE-JVBC, ICP12-0606, ICP12-0606 / TRIO-012, IMCL CP12-0606/TRIO-012, NCT00703326, ROSE, ROSE/TRIO-12, TRI0-012, TrialTroveID-075995, TRIO-012, TRIO-CIRG 012","A Multicenter, Multinational, Randomized, Double-Blind, Phase III Study of IMC-1121B Plus Docetaxel Versus Placebo Plus Docetaxel in Previously Untreated Patients with HER2-Negative, Unresectable, Locally-Recurrent or Metastatic Breast Cancer , , ROSE (Ramucirumab Overall Survival Evaluation)",Oncology,Oncology: Breast,"Breast Cancer International Research Group, Eli Lilly {ImClone}","Cooperative Group, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Complete response-duration, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Infusion-related reactions, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to progression",True,NCT00703326,40407
2721,75993,"13897, CP12-0709, EudraCT Number: 2008-004936-19, I4T-IE-JVBH, IMCL CP12-0709, NCT00862784, TrialTroveID-075993","An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of IMC-1121B in Combination With 5-FU/FA and Oxaliplatin (Modified FOLFOX-6) as First-line Therapy in Patients With Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Overall response rate, Overall survival, Partial response, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Volume of distribution",True,NCT00862784,40407
2722,75992,"13922, 2007-106, CP12-0710, DFCI 07-333, I4T-IE-JVBQ, NCT00627042, TrialTroveID-075992","An Open Label, Multicenter, Phase II Study Evaluating the Safety and Efficacy of IMC-1121B as First Line Monotherapy in Patients With Unresectable Hepatocellular Cancer.",Oncology,Oncology: Liver,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Time to progression, Treatment Emergent Adverse Events",True,NCT00627042,40407
2723,75991,"08653, 13914, CP12-0708, CRC 08064, EudraCT Number: 2007-006715-22, I4T-IE-JVBJ, NCT00735696, TrialTroveID-075991","A Phase II, Open-Label Study of IMC-1121B in Combination With Paclitaxel and Carboplatin as First-Line Therapy in Patients With Stage IIIB/IV Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cmax, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00735696,40407
2724,75990,"13923, CP12-0711, CRC 08041, dfci 08-077, EudraCT Number: 2007-006717-17, I4T-IE-JVBR, MDACC 2008-0289, NCT00721162, TrialTroveID-075990","A Phase II, Non-randomized, Open-label, Multicenter Study of IMC-1121B in the Treatment of Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00721162,40407
2725,75989,"2007-0019, 20071087, CP12-0604, EudraCT Number: 2007-006713-16, I-07-020, MDACC 2007-0019, MSKCC 07-136, NCT00533702, RPCI 114007, TrialTroveID-075989","Phase II Randomized, Open-Label Study of IMC-1121B with or without Dacarbazine in Patients with Metastatic Malignant Melanoma",Oncology,Oncology: Melanoma,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT00533702,40407
2726,74767,"13921, 14T-IE-JVBP, 15525B, CP12-0605, DF/HCC 08-068, FERGU018 (CP12-0605), IMC CP12-0605, NCT00515697, PIMCLON007, PIMCLON007/07-037, RPCI 132008, TrialTroveID-074767",Phase II Single Arm Study of IMC-1121B in Patients With Metastatic Renal Cell Carcinoma With Disease Progression on or Intolerance to Tyrosine Kinase Inhibitor Therapy.,Oncology,Oncology: Renal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Cmax, Cmin, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT00515697,40407
2727,66228,"CP12-0402, I4T-IE-JVBN, IRB 07005, NCT00786383, PIMCLON006, TrialTroveID-066228",Phase I Study of Every Other Week Anti-Vascular Endothelial Growth Factor Receptor 2 (VEGFR-2) Monoclonal Antibody IMC-1121B in Patients with Advanced Solid Tumors Who Have Not Responded to Standard Therapy.,Oncology,Oncology: Colorectal; Oncology: Liver; Oncology: Ovarian; Oncology: Renal,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability","Area under the curve score, Cmax, Cmin, Elimination half-life, Safety and Tolerability, Volume of distribution",True,NCT00786383,40407
2728,22089,"302, CP12-0401, I4T-IE-JVBM, NCT00793975, PIMCLON003, TrialTroveID-022089",Phase I Study Of Weekly Anti-Vascular Endothelial Growth Factor Receptor 2(Vegfr-2) Monoclonal Antibody Imc-1121b In Patients With Advanced Solid Tumors Who Have Not Responded To Standard Therapy,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,Eli Lilly {ImClone},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Progressive disease rate, Safety and Tolerability",True,NCT00793975,40407
2729,99923,"HZ2-08-01, IPOP, NCT00782587, TrialTroveID-099923",Phase I Safety and Tolerability Study of Immediate Post-Operative Intravesical Instillation of Chemophase (Recombinant Human Hyaluronidase in Combination with Mitomycin) in Patients with Non-Muscle-Invasive Bladder Cancer.,Oncology,Oncology: Bladder,Halozyme Therapeutics,"Industry, all other pharma","Safety and Tolerability, Safety and Tolerability",,True,NCT00782587,37652
2730,48328,"HZ2-05-01, NCT00318643, TrialTroveID-048328","A Phase I-IIa, Multicenter, Open-Label, Multiple Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination With Mitomycin in Patients With Non-Muscular-Invasive Bladder Cancer.",Oncology,Oncology: Bladder,Halozyme Therapeutics,"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",True,NCT00318643,37652
2731,30495,TrialTroveID-030495,"A Phase I, Open-Label, Single Dose, Safety, Tolerability and Pharmacokinetic Study of Recombinant Human Hyaluronidase (Chemophase) in Combination with Mitomycin in Patients with Non-Muscular-Invasive Bladder Cancer.",Oncology,Oncology: Bladder,Halozyme Therapeutics,"Industry, all other pharma","Recurrence, Safety and Tolerability",,False,,37652
2732,314203,TrialTroveID-314203,A Phase III Study of S-588410 in Patients with Bladder Cancer,Oncology,Oncology: Bladder,Shionogi,"Industry, all other pharma",,,False,,81323
2733,284727,"TrialTroveID-284727, UMIN000023324",Exploratory Study To Determine S-588410-Induced Tumor Infiltrating Lymphocytes And Changes In The Tumor Microenvironment In Esophageal Cancer Patients,Oncology,Oncology: Esophageal,Shionogi,"Industry, all other pharma",,,False,,81323
2734,254858,"IMS2643, NCT02410369, TrialTroveID-254858, UMIN000016979",Phase II Study Of S-588410 As Maintenance Monotherapy After Adjuvant Chemotherapy In Patients With Completely Resected Non-Small- Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Shionogi, (Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Industry, all other pharma, Academic, Government",Disease-free survival,"Adverse Events, Disease-free survival, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT02410369,81323
2735,252753,"TrialTroveID-252753, UMIN000016954","A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Phase III Study of S-588410 as Adjuvant Therapy After Curative Resection in Patients with Esophageal Cancer",Oncology,Oncology: Esophageal,Shionogi,"Industry, all other pharma",Disease-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Quality of Life",False,,81323
2736,184935,"1408P1921, EudraCT Number: 2013-005274-22, IRAS ID: 152581, SHIONOGI BLADDER 1408P192, TrialTroveID-184935, UKCRN ID: 19903, UMIN000013656","A Multicenter, Open-label, Phase 2 Study of S-588410 as Maintenance Monotherapy after First-line Platinum-containing, Chemotherapy in Patients with Advanced And/Or Metastatic Bladder Cancer.",Oncology,Oncology: Bladder,Shionogi,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Clinical benefit rate, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Global health status, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Visual Analog Scale",False,,81323
2737,334512,TrialTroveID-334512,A Study to Evaluate the Safety and Efficacy of Sapacitabine Either as Single Agent or in Combination with an Approved Drugs in Patients with Hematological Malignancies,Oncology,Oncology: Unspecified Hematological Cancer,"MD Anderson Cancer Center, University of Texas, Cyclacel","Academic, Industry, all other pharma",Safety and Tolerability,,False,,3976
2738,333949,TrialTroveID-333949,"A Phase III Study of Sapacitabine in BRCA +ve Ovarian, Pancreatic cancer patients",Oncology,Oncology: Ovarian; Oncology: Pancreas,Cyclacel,"Industry, all other pharma",,,False,,3976
2739,331085,"18-223, NCI-2018-02398, NCT03641755, TrialTroveID-331085",A Phase Ib/II Study of Olaparib With Sapacitabine in BRCA Mutant Breast Cancer,Oncology,Oncology: Breast,"AstraZeneca, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Cyclacel","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events","Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03641755,3976
2740,272783,TrialTroveID-272783,"A Phase I/II, Safety and Tolerability Study of Sapacitabine in Combination with Other Agents in Patients with Myelodysplastic Syndrome",Oncology,Oncology: Myelodysplastic Syndrome,Cyclacel,"Industry, all other pharma","Safety and Tolerability, Safety and Tolerability",,False,,3976
2741,210040,TrialTroveID-210040,"A Phase IIb Randomized, Controlled (RCT) Lead-in Stage Study of a regimen of Sapacitabine in Patients with Intermediate-2 or High-risk MDS who have failed Prior Hypomethylating Agent Therapy.",Oncology,Oncology: Myelodysplastic Syndrome,Cyclacel,"Industry, all other pharma",Overall survival,,False,,3976
2742,158590,"ACTRN12612000848808, AML LI-1, AMLM20, EudraCT Number: 2011-000749-19, ISRCTN40571019, LI-1, SPON934-11, TrialTroveID-158590, UKCRN ID 10357","Leukaemia Lymphoma Research and NCRI Working Group Pick a Winner Programme (LI-1) Trial, , Less Intensive 1 (LI-1) Trial.",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","National Cancer Research Institute, (Other Hospital/Academic/Medical Center), Australasian Leukaemia and Lymphoma Group (ALLG)","Government, Academic, Cooperative Group","Complete response, Duration of overall response, Overall survival, Quality of Life","Overall survival, Quality of Life",False,,3976
2743,138937,"2010-0516, NCI-2011-00119, NCT01253460, TrialTroveID-138937","A Phase II Clinical Trial of Sapacitabine, Cyclophosphamide, and Rituximab (SCR) for Relapsed Patients With Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma (CLL/SLL) and Deletion 11q22-23 by FISH",Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Cyclacel","Academic, Government, Industry, all other pharma",Overall response rate,"Disease-free survival, Duration of overall response, Overall survival, Safety and Tolerability, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT01253460,3976
2744,135524,"2009-1002, CYC682-11, CYC682-11(A1), NCI-2011-01175, NCT01211457, TrialTroveID-135524",A Phase I/II Combination Study of Sapacitabine in Acute Myeloid Leukemia or Myelodysplastic Syndromes,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, Cyclacel","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response, Safety and Tolerability","Complete response, Hematologic Improvement, Overall response rate - duration, Overall survival, Partial response, Platelet count",True,NCT01211457,3976
2745,108731,"08-271, CYC682-07, DFCI-08-271, NCI-2009-00963, NCT00999401, TrialTroveID-108731",A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors.,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Cyclacel,"Industry, all other pharma",Maximum tolerated dose,"Overall response rate, Response rate",True,NCT00999401,3976
2746,104158,"00027827, 12-034, 2010-0727, CYC682-12, EudraCT Number: 2013-003586-34, IRAS ID: 145125, NCRN - 2956, NCT01303796, PSHCI-09-098, REec-2014-0888, SEAMLESS, TrialTroveID-104158, UKCRN ID: 16820",A Phase III Randomized Study of Oral Sapacitabine in Elderly Patients with Newly Diagnosed Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous",Cyclacel,"Industry, all other pharma",Overall survival,"Complete response, Hematologic Improvement, Overall response rate, Partial response, Platelet count, Response rate, Safety and Tolerability, Stable Disease",True,NCT01303796,3976
2747,97490,"CYC682-08, NCT00885963, PSHCI-08-082, TrialTroveID-097490",A Phase II Study of Oral Sapacitabine in Patients With Previously Treated Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Cyclacel,"Industry, all other pharma","Complete response, Partial response, Stable Disease","Disease Progression - duration, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00885963,3976
2748,71823,"03408, 16139B, 2007-0727, 9L-08-4, CYC682-06, CYC682-06-05, HEMAML0009, MDACC 2007-0727, NCI-2010-00412, NCT00590187, RPCI 120407, SU-04082008-1082, TrialTroveID-071823, VICCHEM0813","A Randomized Phase II Study of Oral Sapacitabine in Elderly Patients With Acute Myeloid Leukemia Previously Untreated or in First Relapse, or Previously Treated Myelodysplastic Syndromes",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Cyclacel,"Industry, all other pharma","Complete response, Overall survival","Complete response, Overall response rate - duration, Overall response rate, Overall survival, Safety and Tolerability",True,NCT00590187,3976
2749,68432,"2006-1019, CYC682-06-05, e8530, LYMNHL0052, NCT00475995, NCT00476554, SU-12212007-952, TrialTroveID-068432",A Randomized Phase II Study of Oral Sapacitabine in Patients With Advanced Cutaneous T-Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","MD Anderson Cancer Center, University of Texas, Cyclacel","Academic, Industry, all other pharma","Overall response rate, Response rate","Overall response rate - duration, Time to progression, Time to response",True,NCT00475995,3976
2750,48257,"CYC682-05-04, MDACC-2005-0768, NCT00380653, TrialTroveID-048257",A Phase I Pharmacologic Study of Oral Sapacitabine in Patients with Advanced Leukemias or Myelodysplastic Syndromes,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome",Cyclacel,"Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability",Plasma concentration,True,NCT00380653,3976
2751,14336,"CYC682-03-03, FCCC-IRB-04011, PA-6947, PCYCLAC001, TrialTroveID-014336","An Open-Label, Phase Ib Study of CYC682 in Patients with Refractory Solid Tumors or Lymphomas (IND#53,748).",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Ovarian",Cyclacel,"Industry, all other pharma","Maximum tolerated dose, Overall response rate, Safety and Tolerability",,False,,3976
2752,370068,"NCI-2020-05223, NCT04312282, ODO-TE-S101, TrialTroveID-370068","An Open-Label Study of the Effect of Tesetaxel on the QTc Interval and the Effect of Food, Itraconazole, and Rifampin on Tesetaxel Pharmacokinetics in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Odonate Therapeutics,"Industry, all other pharma","Area under the curve score, Cmax, Plasma concentration","Area under the curve score, Cmax, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT04312282,26278
2753,346930,"19009, 19-170, CONTESSA TRIO, EudraCT Number: 2018-004715-41, NCI-2019-05490, NCT03952325, ODONATE ODO-TE-B202 (CONTESSA TRIO), ODONATE ODO-TE-B301 (CONTESSA TRIO OLDER ADULTS), ODO-TE-B202, TrialTroveID-346930, USO 19009","A Multicenter, Phase II Study of Tesetaxel Plus 3 Different PD-(L)1 Inhibitors in Patients With Metastatic TNBC and Tesetaxel Monotherapy in Elderly Patients With HER2 Negative MBC",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,Odonate Therapeutics,"Industry, all other pharma","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT03952325,26278
2754,344432,"19-221, 20-152, CONTESSA 2, EudraCT Number: 2018-003896-37, NCI-2019-03936, NCT03858972, ODO-TE-B201, TrialTroveID-344432","Multinational, Multicenter, Phase II Study of Tesetaxel Plus a Reduced Dose of Capecitabine in Patients With HER2 Negative, Hormone Receptor Positive, Locally Advanced or Metastatic Breast Cancer Who Have Not Previously Received a Taxane",Oncology,Oncology: Breast,Odonate Therapeutics,"Industry, all other pharma",Overall response rate,"Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Neutropenia, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT03858972,26278
2755,311802,"17009, 18-172, 18-547, 20180085, CONTESSA, CONTESSA ODO-TE-B301, EudraCT Number: 2017-002961-23, NCI-2018-00273, NCT03326674, ODO-TE-B301, TrialTroveID-311802","A Multinational, Multicenter, Randomized, Phase III Study of Tesetaxel Plus a Reduced Dose of Capecitabine Versus Capecitabine Alone in Patients With HER2 Negative, HR Positive, Locally Advanced or Metastatic Breast Cancer Previously Treated With a Taxane",Oncology,Oncology: Breast,Odonate Therapeutics,"Industry, all other pharma","Disease Progression, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT03326674,26278
2756,169713,TrialTroveID-169713,A Phase III Trial of Tesetaxel as Initial Chemotherapy for Women with Metastatic and Advanced Breast Cancer.,Oncology,Oncology: Breast,Genta,"Industry, all other pharma",Progression-free survival,,False,,26278
2757,168076,"NCT01609127, TOB206, TrialTroveID-168076","A Randomized, Phase II Study of Tesetaxel Once Every 3 Weeks Versus Tesetaxel Once Weekly for 3 Weeks Versus Capecitabine Twice Daily for 14 Days as First-line Therapy for Subjects With Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Genta,"Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Disease Progression, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT01609127,26278
2758,165557,"EudraCT Number: 2010-022164-12, MDACC 2011-0544, NCI-2012-00660,, NCT01573468, S501, TESEGAST, TOG301, TrialTroveID-165557","A Randomized, Double-blind Study of Capecitabine Plus Tesetaxel Versus Capecitabine Plus Placebo as Second-line Therapy in Subjects With Gastric Cancer",Oncology,Oncology: Esophageal; Oncology: Gastric,Genta,"Industry, all other pharma",Overall survival,"Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT01573468,26278
2759,146987,TrialTroveID-146987,A Phase IIb Confirmatory Trial of Tesetaxel for Breast Cancer,Oncology,Oncology: Breast,Genta,"Industry, all other pharma",,,False,,26278
2760,145913,TrialTroveID-145913,"A Dose-Ranging, Pharmacokinetic Study of Tesetaxel plus Capecitabine for the Treatment of Gastric Cancer",Oncology,Oncology: Gastric,Genta,"Industry, all other pharma",,,False,,26278
2761,145879,"NCT01348009, TOPK105, TrialTroveID-145879",A Phase I-II Study of Tesetaxel Plus Capecitabine and Cisplatin in Subjects With Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,Genta,"Industry, all other pharma","Overall survival, Progression-free survival","Adverse Events, Clinical benefit rate, Dose-limiting toxicities, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT01348009,26278
2762,145235,"NCT01337310, TOPK106, TrialTroveID-145235",A Phase I Study of Tesetaxel Administered Once Every 21 Days to Japanese Subjects with Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Genta,"Industry, all other pharma","Adverse Events, Maximum tolerated dose","Adverse Events, Dose-limiting toxicities, Overall response rate, Response rate",True,NCT01337310,26278
2763,143678,"NCT01315431, TOST107, TOST107/107XT, TOST107/TOST107XT, TOST107XT, TrialTroveID-143678",A Phase I Study of Tesetaxel Administered in Combination With Capecitabine to Subjects With Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid",Genta,"Industry, all other pharma",Adverse Events,,True,NCT01315431,26278
2764,136384,"10-197, NCI-2017-02185, NCT01221870, TOB203, TOB203/TOB203XT, TOB203XT, TrialTroveID-136384",A Phase II Study of Tesetaxel as First-line Therapy for Subjects With Metastatic Breast Cancer,Oncology,Oncology: Breast,Genta,"Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Response rate, Stable Disease, Time to progression",True,NCT01221870,26278
2765,135253,"10-135, 10C.386, NCT01215877, TOBL204, TrialTroveID-135253",A Phase II Study of Tesetaxel in Subjects Previously Treated With Chemotherapy for Metastatic Transitional Cell Carcinoma of the Urothelium,Oncology,Oncology: Bladder; Oncology: Renal,Genta,"Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01215877,26278
2766,132110,"NCT01170975, TOPK103, TrialTroveID-132110","An Open-label, Single-dose, Randomized, Crossover Study to Determine the Effects of Food on the Pharmacokinetics of Tesetaxel 10 mg Capsule in Solid Tumor Cancer Subjects.",Oncology,Oncology: Unspecified Solid Tumor,Genta,"Industry, all other pharma","Area under the curve score, Cmax, Drug clearance, Elimination half-life, Tmax","Adverse Events, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT01170975,26278
2767,118758,TrialTroveID-118758,"A Phase I Dose Ranging, Pharmacokinetic Study of Tesetaxel for the Treatment of Cancer.",Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Prostate; Oncology: Renal,Genta,"Industry, all other pharma",Safety and Tolerability,,False,,26278
2768,118757,"2009-0995, DRUG TOG201, NCT01095120, TOG201, TrialTroveID-118757",A Phase II Study of Tesetaxel Administered at a Flat Dose Once Every 21 Days as Second-line Therapy to Subjects With Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,Genta,"Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Partial response, Response rate, Safety and Tolerability, Stable Disease",True,NCT01095120,26278
2769,118754,"11-012, NCT01296243, PCCTC LOI # c10-071, TOP205, TrialTroveID-118754","A Phase II Study of Single-agent Tesetaxel in Chemotherapy-naive Patients Who Have Progressive, Castration-resistant Prostate Cancer",Oncology,Oncology: Prostate,"Genta, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic",Progression-free survival,"Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, PSA progression, Response evaluation criteria in solid tumors, Response rate",True,NCT01296243,26278
2770,118749,"2009-0624, NCI-2011-00557, NCT01064713, NCT01092585, TOM202, TrialTroveID-118749",A Phase II Study of Tesetaxel as Second-line Therapy for Subjects With Advanced Melanoma and Normal Serum LDH,Oncology,Oncology: Melanoma,"MD Anderson Cancer Center, University of Texas, Genta","Academic, Industry, all other pharma","Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Partial response, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01064713,26278
2771,104348,TrialTroveID-104348,"A Phase III Multinational, Randomized, Double-Blind, Placebo-Controlled Study of Tesetaxel in Patients with Advanced Gastric Cancer whose Disease has Progressed after Receiving First-Line Chemotherapy",Oncology,Oncology: Gastric,Genta,"Industry, all other pharma",Overall survival,,False,,26278
2772,103129,TrialTroveID-103129,"Pharmacokinetics (PK) and safety of tesetaxel, an orally administered taxane, in a study examining a range of doses including the active phase II dose.",Oncology,Oncology: GIST; Oncology: Head/Neck,Genta,"Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability",,False,,26278
2773,59111,"04/MRE02/35, M0044151952, TrialTroveID-059111",Phase IIa study of DJ-927 administered orally once every 3 weeks as second line therapy to subjects with locally advanced or metastatic breast carcinoma after failure of an anthracycline non taxane regimen,Oncology,Oncology: Breast,Daiichi Sankyo {Daiichi Pharmaceutical},"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Duration of overall response, Time to treatment failure",False,,26278
2774,53757,TrialTroveID-053757,A phase II study of DJ-927 as second-line therapy in patients with advanced gastric cancer  who have failed a 5-FU non taxane based regimen.,Oncology,Oncology: Esophageal; Oncology: Gastric,Daiichi Sankyo {Daiichi Pharmaceutical},"Industry, all other pharma",Overall response rate,,False,,26278
2775,27156,TrialTroveID-027156,"Phase I and Pharmacokinetics (PK) of DJ-927, an oral taxane, in patients with advanced cancers.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Daiichi Sankyo {Daiichi Pharmaceutical},"Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose",,False,,26278
2776,24089,"927E-PRT007, EudraCT Number: 2004-000696-34, TrialTroveID-024089",A Phase II Study of DJ-927 Administered Orally Once Every Three Weeks as Second Line Therapy to Subjects with Locally Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) After Failure of a Platinum-based Non-taxane Regimen.,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo {Daiichi Pharmaceutical},"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression","Duration of overall response, Overall survival, Time to treatment failure",False,,26278
2777,7825,"DAIICHI-927A-PRT004, MDA-2003-0749, NCT00080834, TrialTroveID-007825",Phase II Study of DJ-927 as Second-Line Treatment in Patients With Progressive Locally Advanced or Metastatic Colorectal Adenocarcinoma.,Oncology,Oncology: Colorectal,Daiichi Sankyo {Daiichi Pharmaceutical},"Industry, all other pharma",Overall response rate,"Duration of overall response, Overall survival",True,NCT00080834,26278
2778,5405,"DAIICHI-927A-PRT006, NCT00077077, TrialTroveID-005405, WSU-085503MP4F",A Phase I Study Of The Combination Of Oral DJ-927 And Capecitabine In Patients With Advanced Solid Tumors,Oncology,Oncology: Liver; Oncology: Unspecified Solid Tumor,"Daiichi Sankyo {Daiichi Pharmaceutical}, Johnson & Johnson/Janssen Biotech {{Centocor Ortho Biotech {J&J/Centocor}}","Industry, all other pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose",Safety and Tolerability,True,NCT00077077,26278
2779,294132,"CASA404A2401, EudraCT Number: 2009-016834-28, TrialTroveID-294132","An Open-Label, Multi-Center, Continued Access Trial Of Investigational Drug ASA404 For Patients In Previous ASA404 Clinical Trials",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Vital signs",,False,,26604
2780,142651,"CASA404A2113, NCT01299415, TrialTroveID-142651","A Multi-center, Open-label, Drug-drug Interaction Study to Assess the Effects of Fluvoxamine on the Pharmacokinetics of ASA404 in Adult Patients With Solid Tumor Malignancies.",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,"Adverse Events, Safety and Tolerability",True,NCT01299415,26604
2781,142580,"CASA404A2108, NCT01299701, TrialTroveID-142580","An Open-label Single Center Study to Characterize the Absorption, Distribution, Metabolism, and Excretion (ADME) of ASA404 after a Single Intravenous Infusion of 3000 mg [14C]ASA404 in Patients with Advanced Solid Tumor Malignancies",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT01299701,26604
2782,141909,"CASA404A2111, NCT01290380, TrialTroveID-141909","An Open-label, Multi-center Study to Evaluate the Effects of ASA404 Alone and in Combination With Taxane-based Chemotherapy on the Pharmacokinetics of Simvastatin, Caffeine, Omeprazole, and Diclofenac in Patients With Advanced Solid Tumor Malignancies.",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,"Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs",True,NCT01290380,26604
2783,139781,"20091958, CASA404A2109, EudraCT 2009-017159-88, NCT01278758, TrialTroveID-139781","A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of Intravenous ASA404 in Adult Advanced Cancer Patients With Impaired Renal Function and With Normal Renal Function",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,"Area under the curve score, Cmax, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT01278758,26604
2784,136820,"CASA404A2112, EudraCT 2009-011142-26, NCT01240642, TrialTroveID-136820","A Multi-center, Open-label, Dose-escalation Study in Patients with Advanced Cancer to Determine the Effect of the ASA404 Infusion Rate and Co-administration With the Paclitaxel Plus Carboplatin Regimen or Docetaxel on the Pharmacokinetics of Free and Total ASA404",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,"Area under the curve score, Cmax, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT01240642,26604
2785,130599,"CASA404A1102, NCT01285453, TrialTroveID-130599","A Safety, Tolerability Study of Intravenous ASA404 Administered in Combination with Docetaxel in Japanese Patients with Advanced or Recurrent Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Novartis,"Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT01285453,26604
2786,123126,"GU09-144, NCT01071928, TrialTroveID-123126",A Phase II Trial of Docetaxel Plus ASA404 as Second-Line Therapy in Patients With Advanced Urothelial Carcinoma: Hoosier Oncology Group GU09-144,Oncology,Oncology: Bladder; Oncology: Renal,"Novartis, Hoosier Cancer Research Network {Hoosier Oncology Group}","Industry, Top 20 Pharma, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors","NCI-CTC scale, Progression-free survival, Safety and Tolerability",True,NCT01071928,26604
2787,122991,TrialTroveID-122991,A Phase II Investigator Initiated Study of ASA404 in Combination with Taxane-Based Regimens in Patients with Bladder Cancer.,Oncology,Oncology: Bladder,Novartis,"Industry, Top 20 Pharma",,,False,,26604
2788,121277,"EU-21001, EUDRACT-2009-016960-34, NCT01057342, NOVARTIS-CASA404ACCH01T, SAKK 15/08, SWS-SAKK-15/08, TrialTroveID-121277",Carboplatin and Paclitaxel Plus ASA404 as First Line Chemotherapy for Extensive-Stage Small-Cell Lung Cancer (ES-SCLC): A Phase II Trial,Oncology,"Oncology: Lung, Small Cell","Novartis, Swiss Group for Clinical Cancer Research - SAKK","Industry, Top 20 Pharma, Cooperative Group","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01057342,26604
2789,120193,"H53469-35218, NCT01031212, TrialTroveID-120193, UCSF-09997",A Phase I Study of ASA 404 in Combination With Carboplatin/Paclitaxel/Cetuximab in Patients With Refractory Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Novartis, University of California, San Francisco","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Adverse Events, Response evaluation criteria in solid tumors",True,NCT01031212,26604
2790,118000,"CASA404A2105, EudraCT 2009-016471-30, MEC/08/10/122, NCT01278849, TrialTroveID-118000","A Multi-center, Open-label, Dose-escalation Study to Assess the Pharmacokinetics of ASA404 in Adult Cancer Patients With Impaired Hepatic Function and With Normal Hepatic Function",Oncology,Oncology: Unspecified Solid Tumor,"Novartis, Cancer Trials New Zealand","Industry, Top 20 Pharma, Not for Profit Funding Entity",,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability",True,NCT01278849,26604
2791,106731,"NCT00863733, PHI/050, TrialTroveID-106731","Phase I Trial of 5,6 Dimethylxanthenone - 4 - Acetic Acid (DMXAA) in Solid Tumors",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma","(Other Cooperative Group), Cancer Research UK","Cooperative Group, Not for Profit Funding Entity",Maximum tolerated dose,,True,NCT00863733,26604
2792,104429,TrialTroveID-104429,A Phase IB/II Study of ASA404 in Combination with Taxanes in Patients Receiving First-Line Treatment for HER-2 Negative Metastatic Breast Cancer.,Oncology,Oncology: Breast,Novartis,"Industry, Top 20 Pharma",,,False,,26604
2793,89010,"CASA404A1101, NCT00674102, TrialTroveID-089010","An Open-Label, Phase I Trial of Intravenous ASA404 Administered in Combination With Paclitaxel and Carboplatin in Japanese Patients With NSCLC.",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00674102,26604
2794,65758,"ATTRACT-2, CASA404A2302, EUDRACT number: 2008-002309-38, JapicCTI-090975, LUN0032, NCT00738387, NL26510.091.09, RECF1005, SU-05192009-2598, TrialTroveID-065758, USOR08094","A Phase III, Randomized, Double-Blind, Placebo-Controlled Multi-Center Study of ASA404 in Combination With Docetaxel in Second-Line Treatment of Patients With Locally Advanced or Metastatic (Stage IIIb/IV) Non-Small Cell Lung Cancer (NSCLC). , , Anti-vascular Targeted Therapy: attract-2",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma",Overall survival,"Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response",True,NCT00738387,26604
2795,50644,TrialTroveID-050644,Phase II Single-Arm Open-label Extension Study Of AS1404 In Patients With Non-small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","Novartis, Antisoma","Industry, Top 20 Pharma, Industry, all other pharma","Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease",,False,,26604
2796,50639,"ASA404A2301, ATTRACT-1, CASA404A2301, EudraCT Number: 2007-006072-11, JapicCTI-090741, LUN 182, MEC/08/02/018, NCT00662597, NL22600.060.08, TrialTroveID-050639","A Phase III, Randomized, Double blind, Placebo Controlled Multi-Center Study of ASA404 in Combination with Paclitaxel and Carboplatin as First-Line Treatment for Locally Advanced or Metastatic (Stage IIIB/IV) Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",Novartis,"Industry, Top 20 Pharma","Disease Progression, Overall survival","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00662597,26604
2797,30310,"DART, NCT00856336, TrialTroveID-030310","5,6-Dimethylxanthenone-4-Acetic Acid (DMXAA) in the Treatment of Refractory Tumors: A Phase I Multicentre Doubleblind Randomized Six-Way Intrapatient Dose-Ranging Crossover Safety Study.",Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: GIST; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal,Antisoma,"Industry, all other pharma",Heart rate corrected QT interval,"Adverse Events, Heart rate corrected QT interval, Magnetic Resonance Imaging, Plasma concentration, Safety and Tolerability",True,NCT00856336,26604
2798,29391,"AS1404-202, EudraCT Number:2004-004375-11, TrialTroveID-029391","An Open Label, Randomized, Phase II Study Of AS1404 In Combination With Carboplatin and Paclitaxel In Patients With Platinum-Sensitive Recurrent Ovarian Epithelial Cancer.",Oncology,Oncology: (N/A); Oncology: Ovarian,"Novartis, Antisoma","Industry, Top 20 Pharma, Industry, all other pharma","Duration of overall response, Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression","Safety and Tolerability, Safety and Tolerability",False,,26604
2799,28656,"AS1404-201, NCT00832494, TrialTroveID-028656","An Open Label, Randomized, Phase I/II Study of DMXAA in Combination with Carboplatin and Paclitaxel in Patients with Locally Advanced and Metastatic Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Antisoma,"Industry, all other pharma","Duration of overall response, Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",,True,NCT00832494,26604
2800,28651,"95954, ANTISOMA-AS1404-203, AS1404-203, J0505, NCT00111618, NCT00119275, PROS0014, SU-07232007-380, TrialTroveID-028651, WIRB-20050432","An Open Label, Randomized, Phase II Study of AS1404 in Combination With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer",Oncology,Oncology: Prostate,"Novartis, Antisoma","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Complete response, Disease Progression - duration, Duration of overall response, Overall response rate, Partial response, PSA progression, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",,True,NCT00111618,26604
2801,6610,"CRC-PHASE-I/II-PH1/048, EU-98065, NCT00003697, TrialTroveID-006610",Phase I Study of Dimethylxanthenone Acetic Acid in Patients With Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,"Cancer Research UK {Cancer Research Campaign}, Antisoma","Not for Profit Funding Entity, Industry, all other pharma","Magnetic Resonance Imaging, Maximum tolerated dose",,True,NCT00003697,26604
2802,387684,"10411, NCI-2020-08011, NCT04595747, TrialTroveID-387684",Phase II Study of Rogaratinib (BAY 1163877) in the Treatment of Patients With Sarcoma Harboring Alterations in Fibroblast Growth Factor Receptor (FGFR) 1-4 and SDH-Deficient Gastrointestinal Stromal Tumor (GIST),Oncology,Oncology: GIST; Oncology: Soft Tissue Sarcoma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT04595747,84727
2803,380172,"EudraCT Number: 2020-000055-12, NCT04483505, ROGABREAST, TrialTroveID-380172","Rogaratinib, Palbociclib and Fulvestrant in Advanced Hormone Receptor Positive, FGFR1/2/3-positive Breast Cancer: Phase I Clinical Trial Plus an Expansion Cohort",Oncology,Oncology: Breast,"(Other Cooperative Group), Pfizer, Bayer AG","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Treatment Emergent Adverse Events","Overall response rate, Phosphate level, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT04483505,84727
2804,359191,"20252, EudraCT number: 2019-000808-15, NCT04125693, TrialTroveID-359191",A Roll-over Study to Provide Continued Treatment With Rogaratinib in Participants Who Were Enrolled in Rogaratinib Studies,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Soft Tissue Sarcoma",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events",,True,NCT04125693,84727
2805,356542,"31973, KCT0004314, NCC2019-0196, NCT04077255, TrialTroveID-356542",Anti-EGFR Antibody (GC-1118) or FGFR Inhibitor (Rogaratinib) in Combination With Weekly Paclitaxel as a Second-line Therapy for Gastric and Gastroesophageal Junction Adenocarcinomas With Amplifications,Oncology,Oncology: Esophageal; Oncology: Gastric,"(Other Cooperative Group), National Cancer Center - Goyang, Korea, Bayer AG, GC Pharma {Green Cross Corp.}","Cooperative Group, Government, Industry, Top 20 Pharma, Industry, all other pharma","Magnetic Resonance Imaging, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Serious Adverse Events",True,NCT04077255,84727
2806,354504,"(BLASST)-3, 19-205, NCT04040725, TrialTroveID-354504",Phase II Clinical Trial of Rogaratinib for High Risk Non-Muscle Invasive Bladder Cancer (NMIBC) Unresponsive to Bacillus Calmette-Guerin (BCG) With FGFR1 or FGFR3 Gene Overexpression: The Bladder Cancer Signal Seeking Trial (BLASST)-3,Oncology,Oncology: Bladder,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Bayer AG","Academic, Industry, Top 20 Pharma",Complete response,Duration of overall response,True,NCT04040725,84727
2807,338057,"2018-02355, NCT03762122, SAKK 19/18, SNCTP000003239, TrialTroveID-338057","Fibroblast Growth Factor Receptor (FGFR) Inhibitor Rogaratinib in Patients With Advanced Pretreated Squamous-cell Non-small Cell Lung Cancer (SQCLC) Overexpressing FGFR mRNA. A Multicenter, Single Arm Phase II Trial",Oncology,"Oncology: Lung, Non-Small Cell",Swiss Group for Clinical Cancer Research - SAKK,Cooperative Group,Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03762122,84727
2808,337306,"19177, CTR20180877, NCT03788603, TrialTroveID-337306","An Open Label, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Rogaratinib (BAY1163877) in Chinese Patients With FGFR-positive Refractory, Locally Advanced, or Metastatic Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,"(Other Industry Sponsor), Bayer AG/Bayer Pharmaceuticals","Industry, all other pharma, Industry, Top 20 Pharma","Area under the curve score, Cmax, Safety and Tolerability, Treatment Emergent Adverse Events","Complete response, Overall response rate, Partial response, Phosphate level, Response rate",True,NCT03788603,84727
2809,323911,"18-395, 19774, EudraCT Number: 2018-000419-26, NCI-2018-01492, NCT03517956, ROCOCO, TrialTroveID-323911","A Multicenter Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Maximum Tolerated Dose (MTD) and/or Recommended Phase II Dose (RP2D) of the Combination of Rogaratinib and Copanlisib in Patients With FGFR-positive, Locally Advanced or Metastatic Solid Tumors.",Oncology,Oncology: Bladder; Oncology: Renal; Oncology: Unspecified Solid Tumor,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival",True,NCT03517956,84727
2810,321680,"18084, EudraCT Number: 2017-002777-19, NCT03484585, TrialTroveID-321680","Single Center, Open-label, Non-randomized, Non-placebo-controlled Study to Investigate the Metabolism, Excretion Pattern, Mass Balance, Safety, Tolerability and Pharmacokinetics After Single Administration of 200 mg [14C]Rogaratinib (Oral Solution) in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,Bayer AG,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Vomiting",,True,NCT03484585,84727
2811,320919,"18-394, 19131, BAY1163877, BAY1163877/19131, BAYER19131, EudraCT Number: 2017-001483-38, FORT-2, JapicCTI-184050, NCI-2018-01233, NCT03473756, TrialTroveID-320919","An International, Multicenter, Phase Ib/II Study of Rogaratinib (BAY1163877) in Combination With Atezolizumab as First-line Treatment in Cisplatin-ineligible Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs",True,NCT03473756,84727
2812,317242,"17403, BAY 1163877 / 17403, BAY 1163877/17403, CTR20180876, EudraCT Number: 2016-004340-11, FORT-1, FORT-1 17403, JapicCTI-183990, NCI-2018-01376, NCT03410693, NL62741.031.17, Pro00019585, S17-00371, SNCTP000002885, TrialTroveID-317242","A Randomized, Open Label, Multicenter Phase II/III Study to Evaluate the Efficacy and Safety of Rogaratinib (BAY1163877) Compared to Chemotherapy in Patients With FGFR-positive Locally Advanced or Metastatic Urothelial Carcinoma Who Have Received Prior Platinum-containing Chemotherapy",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, CordenPharma, Bayer AG/Bayer China","Industry, Top 20 Pharma, Miscellaneous, Industry, all other pharma","Complete response, Overall response rate, Overall survival, Partial response","Adverse Events, Area under the curve score, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03410693,84727
2813,298084,"1559-HNCG, EORTC HN1559, EORTC-1559-HNCG, EORTC-HNCG-1559, EudraCT Number: 2017-000086-74, IRAS ID 236404, NCT03088059, RECF3462, TrialTroveID-298084, UPSTREAM",A Pilot Study of Personalized Biomarker-based Treatment Strategy or Immunotherapy in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck,Oncology,Oncology: Head/Neck,EORTC European Organisation for Research and Treatment of Cancer,Cooperative Group,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT03088059,84727
2814,267126,"16958, JapicCTI-153070, NCT02592785, TrialTroveID-267126","An Open Label, Phase I Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of BAY 1163877 in Japanese Subjects With Refractory, Locally Advanced or Metastatic Solid Tumors",Oncology,Oncology: Bladder; Oncology: Head/Neck; Oncology: Unspecified Solid Tumor,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Phosphate level, Response evaluation criteria in solid tumors",True,NCT02592785,84727
2815,196724,"16443, BAY 1163877/16443, BAY 16443, DRKS00010345, EKSG 13/105, EudraCT Number: 2013-002155-15, IRAS ID: 178348, NCI-2017-00618, NCT01976741, TrialTroveID-196724","An Open Label, Non-randomized, Phase I Dose Escalation Study to Characterize Safety, Tolerability, Pharmacokinetics and Maximum Tolerated Dose of BAY1163877 in Subjects with Refractory, Locally Advanced or Metastatic Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Gastric; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Maximum tolerated dose, Plasma concentration","Bioavailability, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT01976741,84727
2816,378188,TrialTroveID-378188,A Study of UGN-302 in Patients with High-grade Upper Tract Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,UroGen Pharma,"Industry, all other pharma",,,False,,176212
2817,204765,TrialTroveID-204765,MMP-1 and pro-MMP-10 as potential urinary pharmacodynamic biomarkers of FGFR3-targeted therapy in patients with bladder cancer,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,,,False,,74379
2818,400589,"JCCG MB19, jRCTs051200021, TrialTroveID-400589",Phase II Study To Evaluate The Efficacy And Safety Of The Introduction Of High-Dose Chemotherapy Comprising Thiotepa And Melphalan To Conventional Chemoradiotherapy Depending On New Risk Classification For Medulloblastoma (JCCG MB19),Oncology,"Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response rate",False,,57462
2819,396142,TrialTroveID-396142,Encouraging Results of Haploidentical Transplantation in Older Patents Using the Two-Step T Cell Tolerization Platform â Results of a Prospective Trial,Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2820,395463,TrialTroveID-395463,Total Marrow Irradiation for Second Allogeneic Haematopoietic Stem Cell Transplantation in Patients with Advanced Acute Leukemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2821,392763,"ACNS2021, NCI-2020-13175, NCT04684368, U10CA180886",A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor,,NA: ClinicalTrials.gov,Children's Oncology Group,ClinicalTrials.gov,,,True,NCT04684368,57462
2822,383175,"2020-0496, NCI-2020-05879, NCT04530487, TrialTroveID-383175",A Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric and Adolescent-Young Adults Patients With High Risk Solid Tumors,Oncology,"Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","MD Anderson Cancer Center, University of Texas",Academic,Transplant related mortality,"Cumulative Incidence of Relapse, Overall survival, Progression-free survival",True,NCT04530487,57462
2823,382899,"ISRCTN54428419, SZCHXYK2020001, SZTM2020, TrialTroveID-382899","Combined haematopoietic stem cell transplantation with haploidentical graft and cord blood for paediatric patients with thalassemia major: a single centre, prospective study (SZTM2020)",Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Event-free survival,Transplant related mortality,False,,57462
2824,382556,"2020-0495, NCI-2020-05878, NCT04521946, TrialTroveID-382556",A Pilot Study of Allogeneic Hematopoietic Cell Transplantation for Patients With High Grade Central Nervous System Malignancies,Oncology,"Oncology: CNS, Medulloblastoma","MD Anderson Cancer Center, University of Texas",Academic,Transplant related mortality,"Cumulative Incidence of Relapse, Overall survival, Progression-free survival",True,NCT04521946,57462
2825,372840,"NCT04362293, SCDHCT, TrialTroveID-372840",Reduced Intensity Related Donor Peripheral Blood Derived Hematopoietic Progenitor Cell Transplantation for Patients With Severe Sickle Cell Disease,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,St. Jude Children's Research Hospital,Academic,,Quality of Life,True,NCT04362293,57462
2826,368969,TrialTroveID-368969,Haploidentical HCT with CTLA4Ig-Based T Cell Costimulation Blockade Along with Post Transplant Cy for Thalassemia Major (TM) and Sickle Cell Disease (SCD) Results in Improved Disease-Free Survival without GVHD,Autoimmune/Inflammation; Metabolic/Endocrinology,Autoimmune/Inflammation: Transplantation/GVHD; Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2827,368466,"2019-KOE-001, NCT04282174, TrialTroveID-368466",A Phase II Trial of CD34+ Enriched Transplants From HLA-Compatible Related or Unrelated Donors for Treatment of Patients With Hematologic Malignancies,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: Transplantation/GVHD; Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Incidence of aGVHD, Incidence of cGVHD, Mortality, Patient survival, Transplant related mortality","Mortality, Patient survival",True,NCT04282174,57462
2828,368184,TrialTroveID-368184,Outcomes of Acute Myelogenous Leukemia Patients Undergoing Haploidentical Hematopoietic Cell Transplantation with Post-Transplant Cyclophosphamide: Impact of Total Body Irradiation Versus Chemotherapy-Based Myeloablative Conditioning,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Mortality, Overall survival",,False,,57462
2829,366363,"2019/2894, EudraCT Number: 2019-001068-31, HR-NBL2, IGR 2894, NCT04221035, RECF2205, TrialTroveID-366363",High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN),Oncology,Oncology: Neuroblastoma,Institut Gustave Roussy,Academic,Event-free survival,,True,NCT04221035,57462
2830,365641,"NF-14-TM -CT, TrialTroveID-365641",Complementary Transplantation Improved Results of Both Peripheral Blood Stem Cells and Unrelated Cord Blood Transplants in Thalassemia: A Multi-Center Study from China,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2831,365042,TrialTroveID-365042,HLA-Haploidentical Hematopoietic Cell Transplantation after TCR-?Ã and CD45RA+ Depletion Following Reduced Intensity Conditioning in Adults and Children with Hematological Malignancies- Two-Year Follow-up of Multicenter Study in Singapore.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,"Donor Specific Antibodies (DSA), Overall survival",,False,,57462
2832,364755,"COSI, NCT04217278, RG_17-234, TrialTroveID-364755",An International Randomised Clinical Trial of Therapeutic Interventions With the Potential to Improve Outcome in Adults With Acute Myeloid Leukaemia and High Risk Myelodysplasia Undergoing Allogeneic Stem Cell Transplantation,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, EQ-5D, Minimal Residual Disease, Mortality, Quality of Life, Serious Adverse Events",True,NCT04217278,57462
2833,364368,TrialTroveID-364368,MATRix Regimen for Newly Diagnosed Primary Diffuse B-cell Lymphoma of the Central Nervous System.,Oncology,"Oncology: (N/A); Oncology: Lymphoma, Non-Hodgkin's",(Other Cooperative Group),Cooperative Group,"Complete response, Partial response, Progression-free survival, Safety and Tolerability",,False,,57462
2834,362407,TrialTroveID-362407,No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Compared to Conventional CBT.,Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Absolute Neutrophil Count,"Disease-free survival, Mortality, Overall survival",False,,57462
2835,360594,"BMT339, NCI-2020-07240, NCT04151706, TrialTroveID-360594",CD34 Selected Allogeneic Hematopoietic Cell Transplantation With Myeloablative Conditioning and CD8+ Memory T Cell Infusion For Patients With Myelodysplastic Syndrome and Acute Leukemia,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: (N/A); Autoimmune/Inflammation: Transplantation/GVHD; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Stanford University Medical Center,Academic,"Disease-free survival, GRFS","Allograft rejection, Disease-free survival, Incidence of aGVHD, Incidence of cGVHD, Mortality, Overall survival, Recurrence, Systemic steroids",True,NCT04151706,57462
2836,358914,"ASTRAL, ASTRAL / GLA-aNHL-R1, NCT04121507, TrialTroveID-358914",A Prospective Phase II Clinical Study to Assess the Efficacy and Toxicity of High-dose Chemotherapy Followed by Allogeneic Stem Cell Transplantation as Treatment of Primary Progressive and Relapsed Aggressive Non-Hodgkin Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Complete response, Event-free survival, Incidence of New Infection, Mortality, Overall response rate, Overall survival, Partial response, Progressive disease rate, Safety and Tolerability, Serious Adverse Events, Treatment related mortality",True,NCT04121507,57462
2837,356956,"10304, NCI-2019-05729, NCT04083170, RG1004070, TrialTroveID-356956",Infusion of Off-the-Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells to Facilitate the Engraftment of a Single CCR532 Homozygous or Heterozygous Cord Blood Unit in Patients With HIV and Hematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Unspecified Hematological Cancer","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center, National Institutes of Health/National Heart, Lung, and Blood Institute","Government, Academic, Government",,"Absolute Neutrophil Count, Common Terminology Criteria for Adverse Events, Immune Response, Mortality, Overall survival, Platelet count, Safety and Tolerability",True,NCT04083170,57462
2838,355992,"DNR: 2017/8, NCT04067180, TrialTroveID-355992",Randomized Clinical Study of Haplo-Identical Donors Versus Unrelated Donors in Hematopoietic Stem Cell Transplant Patients With Acute Myeloid Leukemia,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: Transplantation/GVHD; Oncology: Leukemia, Acute Myelogenous","University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Karolinska Hospital and Institutet, Medical University of Vienna, Department of Hematology, University Hospital, Uppsala, Sweden, Helsinki University","Academic, Academic, Academic, Academic, Academic","Disease-free survival, GRFS, Incidence of aGVHD, Incidence of cGVHD","Disease-free survival, Incidence of aGVHD, Incidence of cGVHD, Overall survival, Patient survival",True,NCT04067180,57462
2839,353951,TrialTroveID-353951,"Assessment of  efficacy and safety of regimens R-MPV/TBC for patients with Primary CNS Lymphoma, .",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability",,False,,57462
2840,352283,"NCPHOI-2018-08, NCT04000698, TrialTroveID-352283",A Phase I-II Pilot Clinical Trial of Safety and Efficacy of Personalized Targeted Preparative Regimen With Allogeneic TcRaÃ/CD19-depleted Hematopoietic Stem Cell Transplantation and Posttransplant Donor T- Cells Infusion in Children With Chemoresistant Acute Leukemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Common Terminology Criteria for Adverse Events, Complete response, Minimal Residual Disease, Overall response rate, Transplant related mortality","Event-free survival, Overall survival",True,NCT04000698,57462
2841,351212,"9621, NCI-2019-03243, NCT03980769, P01HL122173, P30CA015704, RG1005072","Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa",,NA: ClinicalTrials.gov,"Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI), National Heart, Lung, and Blood Institute (NHLBI), National Institutes of Health (NIH)","Academic, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov",,Transplant related mortality,True,NCT03980769,57462
2842,350745,"9749, NCI-2019-03188, NCT03970096, RG1005364, TrialTroveID-350745",A Phase II Randomized Controlled Trial Comparing Four GVHD-Reduction Strategies for Allogeneic Peripheral Blood Transplantation (PBSCT) for Patients With Acute Leukemia: Selective Depletion of CD45RA+ Naive T Cells (TND) vs. CD34+-Selected Pan T Cell Depletion (CD34+) vs. Post-Transplantation Cyclophosphamide (PTCy) vs. Tacrolimus and Methotrexate (TacMTX) PBSCT.,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: Transplantation/GVHD; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Disease-free survival, GRFS, Incidence of aGVHD, Incidence of cGVHD","Absolute Neutrophil Count, Allograft rejection, Disease-free survival, Incidence of aGVHD, Incidence of cGVHD, Mortality, Overall survival, Patient survival, Recurrence, Systemic steroids, Tumor control rate",True,NCT03970096,57462
2843,346912,"NCT03902665, TrialTroveID-346912, UBA17",Up-front Hematopoietic Stem Cell Transplantation in Patients With Acute Myeloid Leukemia Aged 65-75,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,Complete response,Disease-free survival,True,NCT03902665,57462
2844,345879,"18-2534, GCO 14-0451, GCO 14-0451-2, NCI-2019-00600, NCT03885947, TrialTroveID-345879",Phase I Study of Valproic Acid Expanded Cord Blood Stem Cells as an Allogeneic Donor Source for Adults With Hematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",Icahn School of Medicine at Mount Sinai {Mount Sinai School of Medicine},Academic,"Infusion-related reactions, Safety and Tolerability","Disease-free survival, Overall survival, Transplant related mortality",True,NCT03885947,57462
2845,343894,"HAP2HCT, NCI-2019-00338, NCT03849651, TrialTroveID-343894","TCRaÃ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use of Blinatumomab, in Naive T-cell Depleted Haploidentical Donor Hematopoietc Cell Transplantation for Hematologic Malignancies",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Unspecified Hematological Cancer",St. Jude Children's Research Hospital,Academic,Event-free survival,"Adverse Events, Cumulative Incidence of Relapse, Event-free survival, Overall survival, Recurrence, Safety and Tolerability, Transplant related mortality",True,NCT03849651,57462
2846,339317,"9880, NCI-2018-01752, NCT03779854, RG1003345, TrialTroveID-339317",Multi-Center Phase II Randomized Controlled Trial of Naive T Cell Depletion for Prevention of Chronic Graft-Versus-Host Disease in Children and Young Adults,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Allograft rejection, Disease-free survival, Systemic steroids","Disease-free survival, Incidence of aGVHD, Incidence of cGVHD, Mortality, Patient survival, Systemic steroids",True,NCT03779854,57462
2847,331809,"NCT03653338, STUDY19050050, TrialTroveID-331809","T-Cell Depleted, Alternative Donor Transplant in Pediatric and Adult Patients With Severe Sickle Cell Disease (SCD) and Other Transfusion-Dependent Anemias",Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,University of Pittsburgh,Academic,Treatment related mortality,"Acute chest syndrome occurances, Platelet count, Quality of Life",True,NCT03653338,57462
2848,330591,TrialTroveID-330591,Busulfan Fludarabine (Bu-Flu) Compared to Thiotepa Busulfan Fludarabine (TBF) for Allogeneic Transplants in Acute Myeloid Leukemia (AML) or Refractory Anemia with Excess Blasts (RAEB) In Remission,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2849,330425,"NCT03630211, PRO18050360, TrialTroveID-330425",Autologous Stem Cell Transplantation With CD34-Selected Peripheral Blood Stem Cells (PBSC) in Patients With Treatment Resistant Systemic Sclerosis (SSc),Autoimmune/Inflammation,Autoimmune/Inflammation: Scleroderma,University of Pittsburgh,Academic,"Cardiac Telemetry, Change in oxygen saturation, Congestive heart failure, DLCO, Event-free survival, Need for dialysis, Safety and Tolerability, Supplemental oxygen, Treatment related mortality","Cardiac Telemetry, Change in FVC, Creatinine kinase level, DLCO, Magnetic Resonance Imaging, modified Rodnan skin score, Pulmonary function test, Quality of Life, Reticulocyte count, SF-36",True,NCT03630211,57462
2850,329592,"18-224, NCI-2018-01805, NCT03615105, TrialTroveID-329592",Allogeneic Hematopoietic Cell Transplantation Using alpha/beta+ T-lymphocyte Depleted Grafts From HLA Mismatched Donors,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,Memorial Sloan-Kettering Cancer Center,Academic,Incidence of aGVHD,,True,NCT03615105,57462
2851,329591,"17-596, NCT03615144","A Phase II Trial of Alpha Beta T-cell and CD19 B-cell Depleted Peripheral Blood Stem Cell Transplantation Using the CliniMACS System for Patients With Non-Malignant Hematologic Disorders From Matched or Mismatched, Related or Unrelated Donors",,NA: ClinicalTrials.gov,Memorial Sloan Kettering Cancer Center,ClinicalTrials.gov,,,True,NCT03615144,57462
2852,328669,"NCT03597594, SCIDBMT",Haplocompatible Transplant Using TCR??/?? Depletion Followed by CD45RA-Depleted Donor Lymphocyte Infusions for Severe Combined Immunodeficiency (SCID),,NA: ClinicalTrials.gov,St. Jude Children's Research Hospital,Academic,,,True,NCT03597594,57462
2853,324861,TrialTroveID-324861,TBF Conditioning Regimen For Allogeneic Transplant In High Risk Acute Lymphoblastic Leukemia: Results Of Rome Transplant Network,Oncology,"Oncology: Leukemia, Acute Lymphocytic","Regina Elena National Cancer Institute, Rome, Italy, (Other Hospital/Academic/Medical Center)","Academic, Academic","Disease-free survival, Overall survival, Transplant related mortality",,False,,57462
2854,324185,TrialTroveID-324185,BCNU-EAM Vs Non-BCNU Alternative Alkylator -EAM Conditioning Regimens For Autologous Stem Cell Transplantation In Lymphoma Patients,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Transplant related mortality,,False,,57462
2855,323986,TrialTroveID-323986,LOW-TOXICITY/HIGH-EFFICACY HLA HAPLOIDENTICAL TRANSPLANTATION FOR ELDERLY/UNFIT PATIENTS WITH ACUTE LEUKEMIA,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","(Other Hospital/Academic/Medical Center), University of Perugia","Academic, Academic",Transplant related mortality,,False,,57462
2856,323443,"AWD05935, NCT03513328, OCR17838, PEDS024, TrialTroveID-323443","PEDS024, Phase I/II Feasibility Study of Busulfan Fludarabine and Thiotepa Conditioning Regimen for Allogeneic Hematopoietic Stem-Cell Transplantation (HSCT) for Children With Non-Malignant Disorders",Metabolic/Endocrinology,Metabolic/Endocrinology: Alpha-mannosidosis; Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,University of Florida - Gainesville,Academic,,"Disease-free survival, Transplant related mortality",True,NCT03513328,57462
2857,323354,"EndRAD Trial, NCI-2019-02525, NCI-20-C-0042, NCT03509961, OCR18817, PBMTC ONC1701, PBMTC ONC1701 EndRAD, PHO-PBMTC-ENDRAD, TrialTroveID-323354",A Phase II Pilot Trial to Estimate Survival After a Non-total Body Irradiation (TBI) Based Conditioning Regimen in Patients Diagnosed With Acute Lymphoblastic Leukemia (ALL) Who Are Pre-allogeneic Hematopoietic Cell Transplantation (HCT) Next-generation-sequence (NGS) Minimal Residual Disease (MRD) Negative,Oncology,"Oncology: Leukemia, Acute Lymphocytic",(Other Hospital/Academic/Medical Center),Academic,Event-free survival,"Event-free survival, Minimal Residual Disease, Overall survival",True,NCT03509961,57462
2858,322745,"NCT03500731, PRO17110400",Lung Transplant in Tandem With Bone Marrow Transplant for Combined Lung and Bone Marrow Failure,,NA: ClinicalTrials.gov,Paul Szabolcs,ClinicalTrials.gov,,,True,NCT03500731,57462
2859,321908,TrialTroveID-321908,"Low Toxicity and Efficacy of High-dose Chemotherapy TEAM (Thiotepa, Etoposide, Aracytine, Melphalan) Followed by Autologous Peripheral Blood Stem Cell Transplantation in Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2860,321141,TrialTroveID-321141,"Thiotepa-Based Autologous Hematopoietic Stem Cell Transplantation (ASCT) For CNS Or Non-CNS Lymphoma: First Results Of A Prospective, Multicenter, Non-Interventional Study",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2861,319629,TrialTroveID-319629,Stable Pulmonary Function after Myeloimmunosupressive Conditioning (MIC) and Familial Haploidentical (FHI) Transplantation Utilizing CD34+ Enrichment and PBMC (CD3) Add Back in Children and Young Adults with High Risk (HR) Sickle Cell Disease (SCD),Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,(Other Hospital/Academic/Medical Center),Academic,"Acute chest syndrome occurances, Pulmonary function test, Stroke, Vaso-occlusive crisis rate",,False,,57462
2862,318693,"EudraCT Number: 2017-004423-78, NCT03434704, SIR-POSA, TrialTroveID-318693",A Phase II Trial of Allogeneic Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Antifungal Prophylaxis with Posaconazole,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, GRFS, Incidence of cGVHD, Patient survival",,True,NCT03434704,57462
2863,318261,TrialTroveID-318261,Comparable Outcome of CD3+-/CD19+ Depleted Haploidentical with Matched Sibling Donor Hematopoietic Stem Cell Transplantation for Advanced Stage Sickle Cell Disease: Result of a Pilot Study,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2864,317998,TrialTroveID-317998,Hematopoietic Stem Cell Transplantation from Full Matched Alternative Donor Has Same Results As Those from Matched Sibling for Patients with Beta-Thalassemia Major -a Large-Cohort Multicenter Study from China,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2865,316551,"9910, NCI-2017-02205, NCT03399773, RG9218003, TrialTroveID-316551",Pilot Study: Infusion of Off the Shelf Ex Vivo Expanded Cryopreserved Progenitor Cells (NLA101) in the Setting of Single Cord Blood Transplantation for Patients With Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center, National Institutes of Health/National Heart, Lung, and Blood Institute, Nohla Therapeutics","Government, Academic, Government, Industry, all other pharma",,"Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Mortality, Platelet count, Safety and Tolerability",True,NCT03399773,57462
2866,314340,"2017LS101, MT2017-30, NCI-2018-00356, NCT03367546, TrialTroveID-314340",Haploidentical Donor T-cell Replete Allogeneic Hematopoietic Cell Transplant Following Reducing Intensity Conditioning for Patients With Selected High Risk Non-Malignant Disease,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,University of Minnesota Cancer Center,Academic,Safety and Tolerability,,True,NCT03367546,57462
2867,312708,"MOH_2017-11-19_001961, NCT03346096, Sheba - 17 - 4053 - AN - CTIL, TEAM, TrialTroveID-312708","TEAM (Thiotepa, Etoposide, Cytosar, Melphalan ) in Preparation for Autologous Hematopoietic Stem-Cell Transplantation in Patients With Non-Hodgkin's and Hodgkin's Lymphoma.",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Sheba Medical Center,Academic,"Overall response rate, Response rate",,True,NCT03346096,57462
2868,312552,"CASE10Z17, NCI-2018-01003, NCT03342196, TrialTroveID-312552",A Phase II Study of Thiotepa Added to Fludarabine and Melphalan as the Preparative Regime for Alternative Donor Transplantation,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",Case Western Reserve University,Academic,Disease-free survival,"Absolute Neutrophil Count, Overall survival, Platelet count, Treatment related mortality",True,NCT03342196,57462
2869,309807,"00011932, DRKS00011932, EudraCT Number: 2016-001628-72, MARTA, P001317, TrialTroveID-309807",Age-adjusted High-Dose Chemotherapy and Autologous Stem Cell Transplant in Elderly and Fit Primary CNS Lymphoma Patients,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",University of Freiburg,Academic,"Disease Progression, Progression-free survival","Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Mini Mental State Examination, Mortality, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,57462
2870,306673,"DREPHAPLO, NCT03240731, TrialTroveID-306673",Bone Marrow Transplantation HLA Haploidentical After a Reduced Intensity Conditioning and Prevention of GvHD Based on Post-transplant Cyclophosphamide Administration in Patients With Severe Sickle Cell Disease,Autoimmune/Inflammation; Metabolic/Endocrinology,Autoimmune/Inflammation: Transplantation/GVHD; Metabolic/Endocrinology: Sickle Cell Disease,"(Other Hospital/Academic/Medical Center), Esteve/Riemser/Keocyt, Association Clinique ThÃ©rapeutique Infantile du val de Marne","Academic, Industry, generic, Cooperative Group","Hemoglobin level, Patient survival","DLCO, Hemoglobin level, Magnetic Resonance Imaging, Patient survival, Urine albumin level",True,NCT03240731,57462
2871,302283,"2015/2294, EudraCT Number: 2015-003130-27, NCT03165292, TrialtroveID-302283, VERITAS",An International Multicenter Phase II Randomised Trial Evaluating and Comparing Two Intensification Treatment Strategies for Metastatic Neuroblastoma Patients With a Poor Response to Induction Chemotherapy,Oncology,Oncology: Neuroblastoma,"(Other Cooperative Group), Institut Gustave Roussy, (Other government agency)","Cooperative Group, Academic, Government",Event-free survival,,True,NCT03165292,57462
2872,301218,TrialTroveID-301218,Donor-specific anti-HLA antibodies and primary graft failure risk in mismatched hematopoietic stem cell transplantation,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,Donor Specific Antibodies (DSA),,False,,57462
2873,300761,TrialTroveID-300761,"Post-Transplant Cyclophosphamide (PT-CY) Regimen, Following Unmanipulated Haploidentical Bone Marrow Transplantation post Myeloablative conditioning",Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2874,300671,"2008-07-002, NCT00793845",Tandem High-dose Chemotherapy and Autologous Stem Cell Rescue in Patients With High-risk Neuroblastoma,,NA: ClinicalTrials.gov,Samsung Medical Center,ClinicalTrials.gov,Event-free survival,,True,NCT00793845,57462
2875,300227,"201611172, FAM BMT, NCT03128996, TrialTroveID-300227",A Phase I/II Trial of Reduced Intensity Conditioning and Familial HLA-Mismatched Bone Marrow Transplantation in Children With Non-Malignant Disorders,Autoimmune/Inflammation; Metabolic/Endocrinology,Autoimmune/Inflammation: Transplantation/GVHD; Metabolic/Endocrinology: Sickle Cell Disease,Washington University School of Medicine,Academic,Event-free survival,"Cardiac Telemetry, Cmax, Incidence of aGVHD, Incidence of cGVHD, Pulmonary function test, Quality of Life",True,NCT03128996,57462
2876,299765,TrialTroveID-299765,Recipient CMV Seropositivity & Viremia Is Associated with the Development of Cord Blood (CB) Derived CD8+ Effectors & Effector Memory Cells in Adults Undergoing CB Transplantation (CBT),Infectious Disease,Infectious Disease: Cytomegalovirus Infection (CMV),Memorial Sloan-Kettering Cancer Center,Academic,Degree of viremia,,False,,57462
2877,299764,TrialTroveID-299764,"Incidence, Severity, Day 100 Treatment Efficacy and Therapy Toxicity of Cytomegalovirus (CMV) Infections with Early Pre-Emptive Therapy in Adult Cord Blood (CB) Transplant Recipients",Infectious Disease,Infectious Disease: Cytomegalovirus Infection (CMV),Memorial Sloan-Kettering Cancer Center,Academic,Degree of viremia,,False,,57462
2878,296394,"2011-10-020, NCT03061656",High-dose 131I-MIBG Treatment Incorporated Into Tandem High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With High-risk Neuroblastoma,,NA: ClinicalTrials.gov,"Samsung Medical Center, Ministry of Health, Republic of Korea","ClinicalTrials.gov, ClinicalTrials.gov",Event-free survival,"Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events",True,NCT03061656,57462
2879,295030,"2016-A00862-49, NCT03035422, SET-HAPLO, TrialTroveID-295030",Sequential Chemotherapy Prior to Reduced Intensity Conditioning: Interventional Study in Haploidentical Hematopoietic Stem Cells Transplantation for Patients With Refractory Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Complete response, Disease-free survival, Mortality",True,NCT03035422,57462
2880,285265,"16-1237, NCT02880293",Partially HLA-Mismatched Related Donor Hematopoietic Stem Cell Transplantation Using Killer Immunoglobulin Receptor and Human Leukocyte Antigen Based Donor Selection,,NA: ClinicalTrials.gov,Memorial Sloan Kettering Cancer Center,ClinicalTrials.gov,,,True,NCT02880293,57462
2881,284991,"17-475, 17-708, 2018-0840, HeadStart4, NCH-15004, NCI-2016-01993, NCT02875314, PHO-SHIH-NWC-HEADSTART4, Pro00089045, TrialTroveID-284991, VICCPED1751",HeadStart4: Newly Diagnosed Children (<10 y/o) With Medulloblastoma and Other CNS Embryonal Tumors Clinical and Molecular Risk-Tailored Intensive and Compressed Induction Chemotherapy Followed by Consolidation With Randomization to Either Single Cycle or to Three Tandem Cycles of Marrow-Ablative Chemotherapy With Autologous Hematopoietic Progenitor Cell Rescue,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Neuroblastoma",(Other Hospital/Academic/Medical Center),Academic,"Duration of hospitalization, Event-free survival, Overall survival","Complete response, Cortisol level, Event-free survival, Gene expression profiling, Insulin-like growth factor-binding protein-3 level, Overall survival, Progression-free survival, Quality of Life",True,NCT02875314,57462
2882,284615,"IC 2009-04 RB SFCE 09, NCT02870907",Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated,,NA: ClinicalTrials.gov,Institut Curie,Cooperative Group,,Magnetic Resonance Imaging,True,NCT02870907,57462
2883,284220,"2016-0137, NCI-2017-00614, NCT02861417, TrialTroveID-284220",Timed Sequential Busulfan and Post Transplant Cyclophosphamide for Allogeneic Transplantation,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","MD Anderson Cancer Center, University of Texas",Academic,"Mortality, Safety and Tolerability","Adverse Events, Disease-free survival, Mortality, Overall survival, Progression-free survival, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT02861417,57462
2884,281146,"EudraCT number: 2013-001226-25, HD-TNBC-TRIAL, TrialTroveID-281146","A Phase II Randomized, Open-Label Neo-Adjuvant Study Of Standard Chemotherapy Regimen Compared To High Dose Chemotherapy Regimen With Autologous Stem Cell Transplantation In Patients With Triple Negative Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,57462
2885,279928,"160121, 16-C-0121, COXEN, NCI-16-C-0121, NCI-2016-00966, NCI-2018-03327, NCT02788201, P152399, TrialTroveID-279928",A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,,"Adverse Events, Circulating Tumor Cells, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT02788201,57462
2886,279518,"2015-07-115, NCT02784015, TrialTroveID-279518",Response-based Treatment for Children With Unresectable Localized Soft Tissue Sarcomas,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,Event-free survival,Adverse Events,True,NCT02784015,57462
2887,279516,"2013-07-146, NCT02784054",Reduced-dose Radiotherapy Following High-dose Chemotherapy and Autologous Stem Cell Transplantation in Patients With Central Nervous System Non-germinomatous Germ Cell Tumors,,NA: ClinicalTrials.gov,Samsung Medical Center,ClinicalTrials.gov,Event-free survival,Adverse Events,True,NCT02784054,57462
2888,278001,"NCT02757885, TRANSFORM, TrialTroveID-278001",Transplantation Using Reduced Intensity Approach for Patients With Sickle Cell Disease From Mismatched Family Donors of Bone Marrow,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,Emory University Hospital - Atlanta,Academic,Event-free survival,"Change in oxygen saturation, Platelet count, Stroke, Weight gain",True,NCT02757885,57462
2889,277399,TrialTroveID-277399,Results of tandem high-dose chemotherapy and autologous stem cell transplantation using thiotepa in children with high-risk medulloblastoma,Oncology,"Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2890,277183,TrialTroveID-277183,"Sequential Chemotherapy Combining Thiotepa, Etoposide and Cyclophosphamide Followed by Reduced-Intensity Conditioning in T-Cell Replete HLA-Haploidentical Hematopoietic Stem Cell Transplantation for the Treatment of Refractory Hematological Malignancies",Oncology,"Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2891,276964,TrialTroveID-276964,Immune recovery after transplantation of TCR alpha beta depleted allografts from haploidentical donors in adult patients,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2892,276788,TrialTroveID-276788,A study of Progression-Free Survival (PFS) in Adult Double Unit Cord Blood (dCB) Transplant Recipients with High Risk Disease after a Novel Intermediate Intensity Conditioning Regimen,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",Memorial Sloan-Kettering Cancer Center,Academic,Progression-free survival,,False,,57462
2893,276146,TrialTroveID-276146,Allogeneic Haematopoietic Stem Cell Transplantation for Beta Thalassaemia Major in Pakistan.,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,57462
2894,273945,"DRKS00008900, EudraCT Number: 2015-002305-11, MARiTA, TrialTroveID-273945",Pilot Study For a Phase II Trial To Evaluate High-Dose Chemotherapy And Autologous Stem Cell Transplant In Primary CNS Lymphoma Patients > 65 years MARiTA,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Complete response, Overall survival, Progression-free survival",False,,57462
2895,271768,"HaploOnly, NCT02660281, TrialTroveID-271768, UBMT 15056",Haploidentical Donor Hematopoietic Stem Cell Transplantation,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Unspecified Solid Tumor",University of Rochester,Academic,Platelet count,"Disease-free survival, Recurrence",True,NCT02660281,57462
2896,271294,"2014-3856, NCT02653196, TrialTroveID-271294",A Multi-Institutional Pilot Study of Allogeneic Hematopoietic Stem Cell Transplantation for Patients With Malignant Neuro-Epithelial and Other Solid Tumors,Oncology,"Oncology: CNS, Other; Oncology: Unspecified Solid Tumor","(Other Hospital/Academic/Medical Center), Montefiore Medical Center","Academic, Academic",Progression-free survival,"Drug clearance, Minimal Residual Disease, Overall survival, Transplant related mortality",True,NCT02653196,57462
2897,269558,"NCT02626715, PRO14100126, STUDY19030327, TrialTroveID-269558",A Phase II Study of Myeloablative and Reduced-Intensity Conditioning Regimens for Children and Young Adults With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",University of Pittsburgh,Academic,"Event-free survival, Safety and Tolerability","Absolute Neutrophil Count, Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Platelet count, Treatment related mortality",True,NCT02626715,57462
2898,268058,"2015LS108, MT2015-25, NCT02605421, TrialTroveID-268058",Tandem Myeloablative Consolidation Therapy and Autologous Stem Cell Rescue for High-Risk Neuroblastoma,Oncology,Oncology: Neuroblastoma,University of Minnesota Cancer Center,Academic,Progression-free survival,"Absolute Neutrophil Count, Overall survival",True,NCT02605421,57462
2899,263627,"DRKS00005503, EudraCT Number: 2012-000620-17, IELSG 43, IELSG43, MATRix, MATRix / IELSG43, NCT02531841, TrialTroveID-263627",High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), (Other Hospital/Academic/Medical Center), (Other government agency)","Cooperative Group, Academic, Government","Disease Progression, Progression-free survival, Progressive disease rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Mini Mental State Examination, Overall response rate - duration, Overall survival, Progressive disease rate, Quality of Life, Safety and Tolerability",True,NCT02531841,57462
2900,262054,"NCT02507479, SHEBA-13-0874-AN-CTIL, TrialTroveID-262054","Phase II Trial of Fludarabine Combined With Intravenous Thiotepa and Allogeneic Hematopoietic Stem-cell Transplantation in Patients With Lymphatic Malignancies Including Multiple Myeloma, Non Hodgkin's, Hodgkin Lymphoma and CLL",Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma",Sheba Medical Center,Academic,"Disease-free survival, Recurrence","Recurrence, Treatment related mortality",True,NCT02507479,57462
2901,262040,"2015-0290, A536700, NCI-2015-01163, NCT02508038, Protocol Version 9/13/2018, SMPH\PEDIATRICS\PEDIATRICS, UW13090",TCR-????+ and CD19+ Depleted KIR/KIR Ligand-mismatched Haploidentical Hematopoietic Stem Cell Transplant and Zoledronate for Pediatric Relapsed/Refractory Hematologic Malignancies and High Risk Solid Tumors,,NA: ClinicalTrials.gov,"University of Wisconsin, Madison",ClinicalTrials.gov,,,True,NCT02508038,57462
2902,261885,"NCT02504190, TEAM, TrialTroveID-261885",Non-interventional Study Evaluating Efficacy and Tolerance on TEAM Conditioning (Thiotepa/Etoposide/Aracytin/Melphalan) Followed by Autologous Haematopoietic Stem Cells Transplantation in Patients With Lymphoma,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Cooperative Group),Cooperative Group,Progression-free survival,"Gastrointestinal symptom severity, Overall survival, Transplant related mortality",True,NCT02504190,57462
2903,254434,"20150301, NCT02399189, TrialTroveID-254434",MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Event-free survival, Overall response rate, Overall survival, Quality of Life",True,NCT02399189,57462
2904,253902,TrialTroveID-253902,Haploidentical hematopoietic stem cell transplantation using a reduced-intensity conditioning regimen which consist rituximab and mesencymal stem cell infusion in children; preliminary results,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2905,253826,"FEAM vs TEAM, TrialTroveID-253826",Comparison of two conditioning regimen for autologous stem-cell transplantation for lymphoma. FEAM vs TEAM,Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2906,253762,TrialTroveID-253762,"Two chemotherapy-based conditioning regimens compared to TBI-based conditioning secure consistent engraftment of T-cell depleted allogeneic HSCT, similarly low incidences of GVHD and favorable rates of disease-free survival (DFS).",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",Memorial Sloan-Kettering Cancer Center,Academic,"Disease-free survival, Overall survival, Transplant related mortality",,False,,57462
2907,253761,TrialTroveID-253761,Prospective study of T-cell -replete Haploidentical matched hematopoietic stem cell transplantation (HSCT) for patients with high risk hematological malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2908,253698,TrialTroveID-253698,Haploidentical T-cell Replete Hematopoietic Transplantation conditioned with Thiotepa-fludarabine-busulfan (TBF) and followed by Rraft versus Host Disease Prophylaxis including High-Dose Cyclophosphamide and Tacrolimus: Results from 4 Spanish Centers.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,"Mortality, Overall survival, Progression-free survival",,False,,57462
2909,253654,TrialTroveID-253654,Intravenous busulfan in combination with thiotepa and fludarabine (TBF) as preparative regimen for patients with lymphoma submitted to allogeneic stem cell transplantation (HCT),Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,57462
2910,253653,TrialTroveID-253653,Therapeutic drug monitoring (TDM) of iv busulfan (Bu) in adults undergoing allogeneic hematopoietic stem-cell transplantation (allo-HSCT) to better control the targeted exposure after a 3-day Bu-based myeloablative conditioning (MAC),Oncology,Oncology: Unspecified Hematological Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2911,253611,TrialTroveID-253611,TEPADINA (thiotepa) plus Busulfan i.v as conditioning regimen before Autologous Stem Cells Transplantation (ASCT) in patients with acute myeloid Leukemia (AML),Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2912,253599,TrialTroveID-253599,Haploidentical Stem Cell Transplantation after Depletion of T Cells Expressing the aÃ Chain of the T-Cell Receptor (TCR) and CD19+ B cells for Adults with Hematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Tumor control rate,,False,,57462
2913,253593,"KSBMT200809, NCT02385955, TrialTroveID-253593",Prospective Multicenter Phase II Study of Myeloablative Double Unit Umbilical Cord Blood Transplantation in Adult Patients With Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Overall survival,"Mortality, Progression-free survival, Serious Adverse Events",True,NCT02385955,57462
2914,253559,"NCT02386332, TPH, TrialTroveID-253559",A Randomized Multicenter Study Comparing Unrelated Umbilical-cord Blood Transplant Versus Human Leukocyte Antigen (HLA)-Haploidentical Related Hematopoietic Stem Cell Transplant for Adult Patients With Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,True,NCT02386332,57462
2915,251165,"17668, EudraCT Number: 2014-000227-24, IRAS ID 148036, ISRCTN12857473, MREC N: 14/LO/1568, RG_13-320, TIER, TrialTroveID-251165, UK NCRI TAP, UKCRN ID: 17668","A Phase I/II Study of Thiotepa, Ifosphamide, Etoposide and Rituximab for the Treatment of Relapsed or Refractory Primary Central Nervous System Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Complete response, Maximum tolerated dose, Overall response rate, Partial response","Common Terminology Criteria for Adverse Events, Complete response, Event-free survival, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival",False,,57462
2916,250514,"NCT02339753, SNUCH_carboplatinPK, TrialTroveID-250514",Pharmacokinetic Study of Carboplatin in Pediatric Hematopoietic Stem Cell Transplantation,Oncology,Oncology: Neuroblastoma; Oncology: Unspecified Solid Tumor,(Other Cooperative Group),Cooperative Group,Area under the curve score,Adverse Events,True,NCT02339753,57462
2917,249969,"EudraCT Number: 2014-002109-39, NCT02333838, P130916, P130916 TBF-CORD, TBF-Cord, TrialTroveID-249969",Reduced Toxicity Conditioning Prior to Unrelated Cord Cell Transplantation for High Risk Myeloid Malignancies,Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Quality of Life,True,NCT02333838,57462
2918,249479,"2017-01575, CRUK/14/044, EudraCT Number: 2014-003031-19, IELSG 42, IELSG42, IELSG-42, IRAS ID: 174392, NCT02329080, NL54212.078.16, SNCTP000002407, TrialTroveID-249479","An International Phase II Trial Assessing Tolerability and Efficacy of Sequential Methotrexate-Aracytin-based Combination and R-ICE Combination, Followed by HD Chemotherapy Supported by ASCT, in Patients With Systemic B-cell Lymphoma With CNS Involvement at Diagnosis or Relapse (MARIETTA Regimen)",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Cancer Research UK, International Extranodal Lymphoma Study Group, University of Southampton","Not for Profit Funding Entity, Cooperative Group, Academic",Progression-free survival,"Adverse Events, Complete response, Overall response rate - duration, Overall survival, Safety and Tolerability",True,NCT02329080,57462
2919,249263,"13-010495, 13BT051, AB-CliniMACs, BT13BT051, NCI-2019-08127, NCT02323867, TrialTroveID-249263",Unrelated And Patially Matched Related Donor Peripheral Stem Cell Transplantation With Alpha/Beta T Cell And B Cell Depletion For Patients With Hematologic Malignancies.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",Children's Hospital of Philadelphia,Academic,"Absolute Neutrophil Count, Disease-free survival, Treatment related mortality",,True,NCT02323867,57462
2920,249204,TrialTroveID-249204,A Clinical Study on Outcomes of Combined Transplants of Cord Blood Plus Peripheral Blood from an HLA Matched Sibling in Thalassemia Patients,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2921,245064,"HAPNK1, NCI-2013-00609, NCT01807611, TrialTroveID-245064",Haploidentical Donor Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation With a TLI Based Conditioning Regimen in Patients With Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","(Other Cooperative Group), St. Jude Children's Research Hospital","Cooperative Group, Academic",,"Adverse Events, Common Terminology Criteria for Adverse Events, Event-free survival, Minimal Residual Disease, Overall survival, Recurrence, Transplant related mortality",True,NCT01807611,57462
2922,243415,TrialTroveID-243415,A Clinical Study on Assessing Risk factors for haemorrhagic cystitis in beta thalassemic patients undergoing allogeneic haematopoietic stem cell transplant,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2923,243361,TrialTroveID-243361,"A Clinical Study on Conditioning With Treosulfan, Fludarabine, Thiotepa And Anti-thymocyte Globulin (ATG) For Matched Family Donor Transplantation In Children With Sickle Cell Anemia",Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2924,243350,TrialTroveID-243350,A Clincal study on Haploidentical Stem Cell Transplantation With CD3+/19+ Depleted Peripheral Blood Stem Cell (PBSC) For Advanced Stage Sickle Cell Disease,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2925,243319,TrialTroveID-243319,Increased incidence of acute graft-versus-host disease in children with thalassemia following HLA-identical sibling bone marrow transplants with high CD3 and CD34 cell doses,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2926,241793,"2006-0075, NCT00972101",Infusion of Expanded Cord Blood T Cells Following Cord Blood Transplantation,,NA: ClinicalTrials.gov,M.D. Anderson Cancer Center,ClinicalTrials.gov,Maximum tolerated dose,,True,NCT00972101,57462
2927,240448,"AAAC3457, CHNY-06-533, NCT00801931",Double Umbilical Cord Blood Transplantation for Patients With Malignant and Non-Malignant Disorders,,NA: ClinicalTrials.gov,Columbia University,ClinicalTrials.gov,Disease-free survival,,True,NCT00801931,57462
2928,240336,"385/2005, NCT00790413",High-dose MIBG With Subsequent Transplantation of Haploidentical Stem Cells in Children With Therapy Resistant Neuroblastoma,,NA: ClinicalTrials.gov,Lund University Hospital,ClinicalTrials.gov,,,True,NCT00790413,57462
2929,239207,"09-0058, ACNS0333, CDR0000592812, COG-ACNS0333, NCI-2009-00337, NCT00653068, U10CA098543","Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation",,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",Event-free survival,,True,NCT00653068,57462
2930,238483,"08-524, ANBL0532, CDR0000576571, COG-ANBL0532, NCI-2009-01065, NCT00567567, U10CA098543, U10CA180886",Phase III Randomized Trial of Single vs. Tandem Myeloablative Consolidation Therapy for High-Risk Neuroblastoma,,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",Event-free survival,"Cmax, Event-free survival",True,NCT00567567,57462
2931,238384,"ARET0321, CDR0000573987, COG-ARET0321, NCI-2009-00421, NCT00554788, U10CA098543, U10CA180886",A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma,,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",Event-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT00554788,57462
2932,236214,"CCLG-9405, CCLG-CNS-1995-01, CDR0000454503, EU-20575, NCT00313521",Continuous Infusion Thiotepa in High Grade Astrocytic Tumors of Childhood and Adolescence A UKCCSG Phase II Study Involving the Brain Tumour and New Agent Groups,,NA: ClinicalTrials.gov,Children's Cancer and Leukaemia Group,ClinicalTrials.gov,,,True,NCT00313521,57462
2933,232925,"2013LS104, MT2013-31, NCT02171104, TrialtroveID-232925","MT2013-31: Allogeneic Hematopoietic Cell Transplantation for Inherited Metabolic Disorders and Severe Osteopetrosis Following Conditioning With Busulfan (Therapeutic Drug Monitoring), Fludarabine +/- ATG",Metabolic/Endocrinology,Metabolic/Endocrinology: Alpha-mannosidosis; Metabolic/Endocrinology: Aspartylglucosaminuria; Metabolic/Endocrinology: Krabbe Disease,University of Minnesota Cancer Center,Academic,,Transplant related mortality,True,NCT02171104,57462
2934,224858,"ACNS0122, CDR0000257664, COG-ACNS0122, NCT00047320",A Phase II Study To Assess The Ability Of Neoadjuvant Chemotherapy Plus/Minus Second Look Surgery To Eliminate All Measurable Disease Prior To Radiotherapy For NGGCT,,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",,Event-free survival,True,NCT00047320,57462
2935,224818,"00-065, MSKCC-00065, NCI-G02-2083, NCT00040872, P30CA008748",N8: Dose-Intensive Chemotherapy Plus Biologics in the Treatment of Neuroblastoma,,NA: ClinicalTrials.gov,"Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",,,True,NCT00040872,57462
2936,224665,"CDR0000068950, CHLA-NYU-0007H, NCI-G01-2019, NCT00025324",Clinical Correlative Studies In Primary Central Nervous System Germ Cell Tumors: The Third International CNS Germ Cell Tumor Study Group Protocol,,NA: ClinicalTrials.gov,"Children's Hospital Los Angeles, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov","Event-free survival, Quality of Life",,True,NCT00025324,57462
2937,224607,"ANBL00P1, CDR0000068681, COG-ANBL00P1, NCT00017368",A Pilot Study Of Tandem High Dose Chemotherapy With Stem Cell Rescue Following Induction Therapy In Children With High Risk Neuroblastoma,,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",Transplant related mortality,Event-free survival,True,NCT00017368,57462
2938,224083,"97-077, CDR0000065833, NCI-G97-1335, NCT00003101",A Phase II Trial of Intensive Chemotherapy and Autotransplantation for Patients With Newly Diagnosed Anaplastic Oligodendroglioma,,NA: ClinicalTrials.gov,"Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",,,True,NCT00003101,57462
2939,224081,"1205.00, CDR0000065777, NCI-G97-1331, NCT00003081","A Phase I Trial of Busulfan, Thiotepa and Melphalan Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Transplantation and Followed by Total Marrow (Skeletal) Irradiation (TMI) in Patients With High-Risk Ewing's Sarcoma, PNET or Rhabdomyosarcoma",,NA: ClinicalTrials.gov,"Fred Hutchinson Cancer Research Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov","Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00003081,57462
2940,224021,"CDR0000064509, NCI-2012-01528, NCT00002704, POG-9412",TREATMENT OF ISOLATED CNS RELAPSE OF ACUTE LYMPHOBLASTIC LEUKEMIA -- A PEDIATRIC ONCOLOGY GROUP-WIDE PHASE II STUDY,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,Safety and Tolerability,,True,NCT00002704,57462
2941,223992,"93-045, CDR0000078464, NCI-H93-0293, NCT00002534",A RANDOMIZED TRIAL OF UNMODIFIED VERSUS T-CELL DEPLETED ALLOGENEIC HLA-IDENTICAL BONE MARROW TRANSPLANTATION FOR THE TREATMENT OF ACUTE LEUKEMIAS,,NA: ClinicalTrials.gov,"Memorial Sloan-Kettering Cancer Center, National Cancer Institute (NCI)","Academic, ClinicalTrials.gov",Disease-free survival,,True,NCT00002534,57462
2942,223967,"90-013, CDR0000076672, NCI-V90-0104, NCT00002471, NYU-97-9","Phase II Trial of Intensive, Short-Course Combination Chemotherapy in the Treatment of Newly Diagnosed Patients With Poor-Risk Nonlymphoblastic Lymphoma and Acute B-Lymphoblastic Leukemia and in Patients With Recurrent Non-Hodgkin's Lymphoma",,NA: ClinicalTrials.gov,Memorial Sloan-Kettering Cancer Center,Academic,,,True,NCT00002471,57462
2943,219804,"NF-08-TM, NF-08-TM-HSCT, TrialTroveID-219804",A Novel Conditioning Regimen Improves Outcomes In SS-thalassemia Major Patients Using Unrelated Donor Peripheral Blood Stem Cell Transplantation,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,Transplant related mortality,,False,,57462
2944,219781,TrialTroveID-219781,Pretreatment doses of antithymocyte globubin-fresenius for allogeneic hematopoietic stem cell transplantation for beta-thalassemia major,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2945,219726,"201110144, NCT00920972, TrialTroveID-219726",A Study of Hematopoietic Stem Cell Transplantation (HSCT) in Non-Malignant Disease Using a Reduced-Intensity Preparatory Regime,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,Washington University School of Medicine,Academic,,"Disease-free survival, Event-free survival, Quality of Life",True,NCT00920972,57462
2946,219501,"NCT01850108, TrialTroveID-219501, VGC2, VICCBMT12108, VICCNC BMT 12108",A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients With Sickle Cell Disease and Other Hemoglobinopathies,Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,Vanderbilt-Ingram Cancer Center,Academic,"Event-free survival, Transplant related mortality","Platelet count, Serious Adverse Events",True,NCT01850108,57462
2947,219251,"2005-3-4222, NCT00579124, TrialTroveID-219251",CHP 834 Unrelated and Partially Matched Related Donor Peripheral Stem Cell Transportation with the CliniMACs Device for T and B Cell Depletion,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,Children's Hospital of Philadelphia,Academic,"Incidence of aGVHD, Treatment related mortality",,True,NCT00579124,57462
2948,218411,"NCI-2014-01925, NCT02259348, REFNK1, TrialTroveID-218411",CD45A-Depleted Haploidentical Hematopoietic Progenitor Cell and Natural Killer Cell Transplantation for Hematologic Malignancies Relapsed or Refractory Despite Prior Transplantation,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",St. Jude Children's Research Hospital,Academic,,"Cumulative Incidence of Relapse, Event-free survival, Overall survival, Transplant related mortality",True,NCT02259348,57462
2949,215204,"2684.00, NCI-2014-01301, NCT02220985, RG9214012, TrialTroveID-215204",A Phase II Study Evaluating Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts From HLA-Matched Related and Unrelated Donors for Prevention of GVHD,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: Transplantation/GVHD; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Absolute Neutrophil Count, Incidence of aGVHD, Minimal Residual Disease, Phosphate level, Systemic steroids","Mortality, Patient survival, Platelet count, Transplant related mortality",True,NCT02220985,57462
2950,214458,"DRKS00005126, EudraCT Number: 2012-005414-18, TFT 2 Tx, TFT 2Tx, TFT-2Tx, TrialTroveID-214458, ZKS000783",Thiotepa- Fludarabine- Treosulfan (TFT) Conditioning for 2nd Allogeneic PBSCT from a Different Unrelated Donor in Patients with AML Relapsing from Prior Allogeneic HCT,Oncology,"Oncology: Leukemia, Acute Myelogenous",University of Freiburg,Academic,"Disease-free survival, Mortality, Overall survival","Adverse Events, Disease-free survival, Mortality, Overall survival, Safety and Tolerability",False,,57462
2951,213789,"20110280, NCT01005576, TCRN-NMD 0901, TrialTroveID-213789, URTH",A Pilot Trial of Unrelated Donor Hematopoietic Cell Transplantation for Children With Severe Thalassemia Using a Reduced Intensity Conditioning Regimen (The URTH Trial),Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,"(Other Cooperative Group), Washington University School of Medicine","Cooperative Group, Academic",Event-free survival,,True,NCT01005576,57462
2952,207965,"HSCT+RIC, NCT01962415, PRO13100018, RIC for HSCT in NMD, RIC HSCT NMD, TrialTroveID-207965","A Phase II Study of Reduced Intensity Conditioning in Pediatric Patients and Young Adults < or = 55 Years of Age With Non-Malignant Disorders Undergoing Umbilical Cord Blood, Bone Marrow, or Peripheral Blood Stem Cell Transplantation, , HSCT+RIC",Metabolic/Endocrinology,Metabolic/Endocrinology: Alpha-mannosidosis; Metabolic/Endocrinology: Gaucher Disease; Metabolic/Endocrinology: Krabbe Disease; Metabolic/Endocrinology: Sickle Cell Disease; Metabolic/Endocrinology: Thalassemia,University of Pittsburgh,Academic,"Opportunistic infection, Treatment related mortality",Adverse Events,True,NCT01962415,57462
2953,206837,"CML SCT I-BFM Study, CML-SCT, CML-SCT -IBFM Study, EudraCT Number: 2008-000569-50, IBFM-CML-SCT, NCT02707393, TrialTroveID-206837","Allogeneic Stem Cell Transplantation for Children and Adolescents With CML: Conditioning Regimen, Donor Selection, Supportive Care and Diagnostic Procedures",Oncology,"Oncology: Leukemia, Chronic Myelogenous","(Other Academic Cancer Center), The International BFM Study Group","Academic, Cooperative Group","Disease-free survival, Event-free survival, Overall survival, Transplant related mortality","Disease-free survival, Event-free survival, Overall survival, Transplant related mortality",True,NCT02707393,57462
2954,202874,"AAAK8060, NCI-2014-00137, NCT02061800, TrialTroveID-202874",CD34+ Stem Cell Selection for Patients Receiving a Matched or Partially Matched Family or Unrelated Adult Donor Allogeneic Stem Cell Transplant for Malignant Disease,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,Columbia University Medical Center,Academic,"Event-free survival, Incidence of aGVHD","Allograft rejection, Incidence of aGVHD, Incidence of cGVHD",True,NCT02061800,57462
2955,202258,TrialTroveID-202258,Long Term Outcomes of Autologous Hematopoietic Cell Transplant (AHCT) Following Thiotepa-Based High-Dose Therapy (HDT) in Patients with Non-Hodgkin Lymphoma (NHL),Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2956,202194,"CMH 13H11, CMH SCT 0813, NCI-2015-00141, NCT02053545, SCT 0813, SCT 0813 Haplo, TrialTroveID-202194",Haplo-identical Stem Cell Transplantation (SCT) for High-Risk Hematologic Malignancies With Post-Transplant In-Vivo T-cell Depletion,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Mortality,"Event-free survival, Overall survival",True,NCT02053545,57462
2957,201726,"EudraCT Number: 2012-005580-27, NCT02049580, ONC-2011-005, TrialTroveID-201726","Multi-center, Phase II Study to Assess the Safety and Efficacy of Haploidentical Bone Marrow Transplantation Using Reduced Intensity Conditioning(RIC)Regimen and Post-transplant Cyclophosphamide,in Patients with Poor Prognosis Lymphomas",Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Cumulative Incidence of Relapse, Treatment related mortality",True,NCT02049580,57462
2958,200073,"2012/1908, CSET2012/1908, EudraCT number: 2012-004842-14, HR MB-5, NCT02025881, RECF2420, TrialTroveID-200073",Phase I/II Study of Sequential High-dose Chemotherapy With Stem Cell Support in Children Younger Than 5 Years of Age With High-risk Medulloblastoma,Oncology,"Oncology: CNS, Medulloblastoma",Institut Gustave Roussy,Academic,"Complete response, Dose-limiting toxicities, Event-free survival, Maximum tolerated dose","Complete response, Maximum tolerated dose, Overall survival, Partial response",True,NCT02025881,57462
2959,199613,TrialTroveID-199613,Haploidentical Transplantation For Patients With Advanced Hematologic Malignancies With Melphalan-Based Conditioning,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","MD Anderson Cancer Center, University of Texas",Academic,,,False,,57462
2960,198128,TrialTroveID-198128,Bam Regimen Followed By High-Dose Therapy and Autologous Stem Cell Transplantation As First-Line Treatment Of Primary Central Nervous System Lymphoma: A Multicenter Study From Spanish Group GEL-TAMO,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Cooperative Group),Cooperative Group,"Overall survival, Progression-free survival",,False,,57462
2961,194509,"624, ACTRN12616001394437, ALL SCT ped FORUM, ALL SCTped 2012 FORUM, ALL SCTPED 2012 FORUM, ALL SCTped FORUM 2012, ALL-SCT-ped-FORUM, EudraCT Number: 2012-003032-22, NCT01949129, NL45280.078.13, TrialTroveID-194509","Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia , , ALL SCTped FORUM (For Omitting Radiation Under Majority age)",Oncology,"Oncology: Leukemia, Acute Lymphocytic","(Other Cooperative Group), (Other Academic Cancer Center), European Bone Marrow Transplantation Group, Swiss Pediatric Oncology Group, Assistance Publique - Hopitaux de Paris, (Other government agency), The International BFM Study Group","Cooperative Group, Academic, Cooperative Group, Cooperative Group, Academic, Government, Cooperative Group","Adverse Events, Cumulative Incidence of Relapse, Disease Progression, Event-free survival, Overall survival, Treatment related mortality","Cumulative Incidence of Relapse, Disease Progression, Event-free survival, Overall survival, Treatment related mortality",True,NCT01949129,57462
2962,186900,"2660, 2660.00, NCI-2013-00958, NCT01858740, TrialTroveID-186900",A Phase II Study of Selective Depletion of CD45RA+ T Cells From Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD in Children,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",Platelet count,"Incidence of aGVHD, Incidence of cGVHD, Mortality, Patient survival, Systemic steroids, Transplant related mortality",True,NCT01858740,57462
2963,184995,TrialTroveID-184995,Haploidentical unmanipulated bone marrow transplantation and post-transplantation cyclophosphamide for patient with high risk of acute non-lymphoid leukaemia,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2964,184893,TrialTroveID-184893,Thiotepa/Melphalan as Conditioning Regimen For Multiple Myeloma Patients Not Achieving Complete Remission After the Reinfusion of Autologous HSC. Preliminary Data From a Multicentre Study,Oncology,Oncology: Multiple Myeloma,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Complete response, Disease Progression, Mortality, Overall response rate, Overall survival, Platelet count, Progression-free survival, Treatment related mortality","Complete response, Overall response rate, Overall survival, Progression-free survival",False,,57462
2965,184871,TrialTroveID-184871,Thiotepa and melphalan as a new conditioning regimen for autologous transplantation in multiple myeloma,Oncology,Oncology: Multiple Myeloma,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,57462
2966,183717,TrialTroveID-183717,Reduced-dose craniospinal radiotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation in patients with high-risk medulloblastoma,Oncology,"Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2967,181690,"EudraCT Number: 2012-005378-73, NCT01786018, TBF2012, TrialTroveID-181690","Allogeneic Transplantation After a Conditioning with Thiotepa, Busulfan and Fludarabin for the Treatment of Refractory/Early Relapsed Aggressive B-cell Non Hodgkin Lymphomas: A Phase II Multi-Center Trial",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,Overall survival,True,NCT01786018,57462
2968,180715,TrialTroveID-180715,A Clinical Study on Long Term Outcomes of Pediatric Patients with Sickle Cell Disease Who Underwent a Reduced Intensity T Cell Depleted Haploidentical Transplantation,Autoimmune/Inflammation; Metabolic/Endocrinology,Autoimmune/Inflammation: Transplantation/GVHD; Metabolic/Endocrinology: Sickle Cell Disease,St. Jude Children's Research Hospital,Academic,,,False,,57462
2969,180657,TrialTroveID-180657,A single center study on autologous transplantation as consolidation therapy for primary and secondary CNS- lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2970,180144,"12D.501, 2012-67, NCI-2012-02762, NCT01760655, TrialTroveID-180144",A Two Step Approach to Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA",Academic,Disease-free survival,"Mortality, NCI-CTC scale, Overall survival",True,NCT01760655,57462
2971,177963,TrialTroveID-177963,"Phase II Trial of Clofarabine in Combination with Topotecan, Vinorelbine, and Thiotepa (TVTC) in Pediatric Patients with Refractory or Relapsed Acute Leukemia",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous",Memorial Sloan-Kettering Cancer Center,Academic,"Complete response, Overall response rate",,False,,57462
2972,177465,"EudraCT Number: 2010-022052-23, GITMO - MF2010, GITMO MF2010, NCT01814475, ProtocolCodeGITMO-MF2010, TrialTroveID-177465","Prospective, Phase II Randomized Study to Compare Busulfan-fludarabine Reduced-intensity Conditioning (RIC) with Thiotepa-fludarabine RIC Regimen Prior to Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Myelofibrosis",Oncology,Oncology: Myeloproliferative Neoplasms,Gruppo Italiano Trapianto Midollo Osseo,Cooperative Group,"Disease Progression, Progression-free survival","Complete response, Histological Response, Mortality, Overall survival, Safety and Tolerability",True,NCT01814475,57462
2973,174567,"12-153, NCI-2012-01707, NCT01682226, TrialTroveID-174567",Myeloablative Unrelated Donor Cord Blood Transplantation With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cells for Patients With High Risk Hematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",Memorial Sloan-Kettering Cancer Center,Academic,Absolute Neutrophil Count,"Disease-free survival, Overall survival, Transplant related mortality",True,NCT01682226,57462
2974,171717,"EudraCT Number: 2012-000838-19, N12OLG, NCT01646034, NL39700.031.12, OLIGO study, TrialTroveID-171717",High-dose Alkylating Chemotherapy in Oligo-metastatic Breast Cancer Harboring Homologous Recombination Deficiency,Oncology,Oncology: Breast,Netherlands Cancer Institute,Government,"Event-free survival, Recurrence","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Event-free survival, Overall survival, Quality of Life, Recurrence, Time to progression",True,NCT01646034,57462
2975,169219,"EudraCT Number: 2011-004729-29, GELTAMO-O-CRT-2011, NCT01613300, O-CRT, TrialTroveID-169219",Ofatumumab as Part of the Reduced Intensity Conditioning Regimen (RIC) for Patients With High Risk B Non Hodgkin's Lymphoma Undergoing Allogeneic Hematopoietic Cell Transplantation.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Cooperative Group),Cooperative Group,"Complete response, Overall response rate, Partial response, Response rate","Disease-free survival, Event-free survival, Leukocyte count, Mortality, Overall survival, Progression-free survival, Safety and Tolerability, Transplant related mortality",True,NCT01613300,57462
2976,166960,TrialTroveID-166960,"Sequential chemotherapy, high-dose thiotepa, circulating progenitor cell rescue, and radiotherapy for childhood high-grade glioma.",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,57462
2977,165644,TrialTroveID-165644,Observation on hyperthermia combined with intravesical thiotepa instillation for prevention recurrence of superficial bladder carcinoma after operation,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Recurrence,,False,,57462
2978,164737,TrialTroveID-164737,Results of high-dose chemotherapy with autologous haematopoietic stem cell transplantation in the treatment of paediatric brain tumours,Oncology,"Oncology: (N/A); Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2979,164726,"BCNHL, EudraCT Number: 2007-003657-87, TrialTroveID-164726",Reduced Intensity Conditioning with High-Dose Rituximab Followed by Allogeneic Transplantation of Hematopoietic Cells for the Treatment of Relapsed/Refractory B-Cell Non Hodgkinâs Lymphomas,Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",Gruppo Italiano Trapianto Midollo Osseo,Cooperative Group,Progression-free survival,"Complete response, Mortality, Overall survival",False,,57462
2980,164369,"ISRCTN52623943, TrialTroveID-164369",High dose chemotherapy and autologous stem cell transplantation as adjuvant therapy for primary breast cancer patients with four or more lymph nodes involved: long-term results of an international randomised trial.,Oncology,Oncology: Breast,"Amgen, Pfizer, Cancer Research UK","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Not for Profit Funding Entity","Disease-free survival, Event-free survival, Overall survival",,False,,57462
2981,160637,"00062558, 12262, 12-440, 16-388, 17868, 62842, C51101, CALGB-51101, CLYM-13045, CTSU/CALGB 51101, DFCI ID: 12-440, NCI-2012-00110, NCT01511562, RWF_C51101, TrialTroveID-160637",A Randomized Phase II Trial of Myeloablative Versus  Non-Myeloablative Consolidation Chemotherapy for Newly  Diagnosed Primary CNS B-cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group",Progression-free survival,"Apparent diffusion coefficient, Common Terminology Criteria for Adverse Events, Complement levels, Event-free survival, Gene expression profiling, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Quality of Life, Treatment Emergent Adverse Events",True,NCT01511562,57462
2982,159884,"1107M02641, 2011OC057, MT2011-09C, NCI-2013-02265, NCT01505569, TrialTroveID-159884",Alkylator-Intense Conditioning Followed by Autologous Transplantation for Patients With High Risk or Relapsed Solid or CNS Tumors,Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Neuroblastoma; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor",University of Minnesota,Academic,Overall survival,"Disease-free survival, Treatment related mortality",True,NCT01505569,57462
2983,159331,TrialTroveID-159331,Outcome of Unrelated Donor Bone Marrow Transplantation for Thalassemia Major Patients,Metabolic/Endocrinology,Metabolic/Endocrinology: Thalassemia,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",,,False,,57462
2984,158944,TrialTroveID-158944,A Novel Treatment Protocol Successfully Prevented Graft Rejection and Improved Disease-Free Survival in Class 3 Children with Thalassemia,Autoimmune/Inflammation; Metabolic/Endocrinology,Autoimmune/Inflammation: Transplantation/GVHD; Metabolic/Endocrinology: Thalassemia,(Other Hospital/Academic/Medical Center),Academic,"Allograft rejection, Disease-free survival",,False,,57462
2985,158825,TrialTroveID-158825,A Clinical Study on the Efficacy of Flu/ivBu/TT Conditioning Regimen in Refractory or Relapsed Acute Non-lymphocytic Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation.,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2986,155725,"HaploSCD, IND 14359, NCT01461837, NYMC526, NYMC-526, NYMC526-4090, TrialTroveID-155725","Familial Haploidentical T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease (IND 14359), , HaploSCD- Haplo T-Cell Depleted Transplantation in High-Risk Sickle Cell Disease",Metabolic/Endocrinology,Metabolic/Endocrinology: Sickle Cell Disease,"Washington University School of Medicine, University of California Los Angeles, FDA Office of Orphan Products Development, Otsuka Pharmaceutical/Otsuka Pharmaceutical Development & Commercialization {Otsuka/Otsuka Maryland Research Institute}, Cincinnati Children's Hospital Medical Center, University of California, San Francisco, (Other Hospital/Academic/Medical Center), Tufts University, Tufts Medical Center {Tufts-New England Medical Center}, Miltenyi Biomedicine","Academic, Academic, Government, Industry, all other pharma, Academic, Academic, Academic, Academic, Academic, Industry, all other pharma",,Quality of Life,True,NCT01461837,57462
2987,155046,TrialTroveID-155046,Phase I Study of Tandem High-Dose Chemotherapy with Autologous Peripheral Blood Stem Cell Rescue for Children with Recurrent Brain Tumors: A Pediatric Blood and Marrow Transplant Consortium Study.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,,False,,57462
2988,153709,"EudraCT Number: 2007-000586-38, Thio-MS, THIO-SM, TrialTroveID-153709",Immunosuppression thiotepa with High Dose Cyclophosphamide and Followed by Autologous Stem Cell Transplantation in Multiple Sclerosis,CNS,CNS: Multiple Sclerosis,(Other Cooperative Group),Cooperative Group,"Common Terminology Criteria for Adverse Events, Expanded Disability Status Scale, Magnetic Resonance Imaging, MS Lesions, Relapse Rate, Safety and Tolerability","Beck Depression Inventory, Brain atrophy, Magnetic Resonance Imaging, MS Function Composite, MS Lesions, Quality of Life",False,,57462
2989,151974,"ALL SCT I-BFM, ALLSCT06BFMi, ALL-SCT-BFMi, EudraCT Number: 2005-005106-23, NCT01423500, TrialTroveID-151974",Allogeneic Stem Cell Transplantation in Children and Adolescents With Acute Lymphoblastic Leukaemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic","(Other Cooperative Group), (Other Academic Cancer Center)","Cooperative Group, Academic","Event-free survival, Overall survival","Event-free survival, Mortality",True,NCT01423500,57462
2990,149948,"CTX+TSPA+CBP, NCT01395056, TrialTroveID-149948",Study of Chemotherapy Combined With Adoptive Cellular Therapy With Dendritic and Cytokine-induced Killer Cells in Triple Negative Breast Cancer Patients,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Overall survival, Stable Disease",True,NCT01395056,57462
2991,148668,TrialTroveID-148668,Successful autologous hematopoietic stem cell (AHSC) mobilization with salvage etoposide (VP16)-ifosfamide-platinum (VIP) followed by high-dose chemotherapy (HDC) and AHSC transplantation (AHSCT) in relapsed malignancies,Oncology,"Oncology: (N/A); Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2992,145741,"NCT01342237, SNUCH-SCT-1102, TrialTroveID-145741",Tandem High Dose Chemotherapy and Autologous Stem Cell Rescue for High Risk Pediatric Brain Tumors,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,"Event-free survival, Overall survival","Overall survival, Treatment related mortality",True,NCT01342237,57462
2993,144461,TrialTroveID-144461,First clinical results with alpha-beta+ T-cell depleted haplo-identical stem cells in children,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2994,144410,TrialTroveID-144410,Treosulfan/fludarabine/thiotepa conditioning for patients with advanced malignant haematologic lymphoproliferative diseases.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,57462
2995,141732,TrialTroveID-141732,"High Dose Cyclophosphamide, Thiotepa & Etoposide Followed by Autologous Hematopoietic Stem Cell Transplantation (Intermediate & High Grade).",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2996,138127,TrialTroveID-138127,Clinical Relevance of the Dose of Cytarabine In the Treatment of Primary CNS Lymphomas with Methotrexate-Cytarabine Chemotherapy Combination,Oncology,"Oncology: CNS, Other; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
2997,134710,"GEP, NCT01198301, TrialTroveID-134710",Gene Expression Profiling of Metastatic Breast Cancer Predict the Therapeutic Response to Chemotherapy,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,"Disease Progression, Overall survival, Time to progression",True,NCT01198301,57462
2998,127645,"ET2008-044, EudraCT Number: 2009-009899-12, NCT00978471, OSII-TTP, RECF1009, TrialTroveID-127645",Efficacy and Tolerance Adjuvant High-Dose Thiotepa with Peripheral Stem Cell Rescue Associated With Conventional Chemotherapy in Children and Adults With Relapsed Osteosarcoma,Oncology,Oncology: Osteosarcoma,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Histological Response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Histological Response, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00978471,57462
2999,127133,"10-050, NCI-2010-01240, NCT01119066, TrialTroveID-127133","A Phase II Trial of Transplants From HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic Malignancies and Other Lethal Hematologic Disorders",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",Memorial Sloan-Kettering Cancer Center,Academic,"Disease-free survival, Mortality, Transplant related mortality",Mortality,True,NCT01119066,57462
3000,124193,"KSPNO-S-053, TrialTroveID-124193",High-dose chemotherapy and autologous haematopoietic stem cell transplantation for children with relapsed medulloblastoma: the results of the prospective multicentre study KSPNO-S-053,Oncology,"Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3001,124134,TrialTroveID-124134,Allogeneic Stem Cell Transplantation With a Thiotepa-Based Conditioning Regimen for Poor Prognosis Haematological Patients: A Single-Centre Experience,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3002,121955,"AVLZ 2009-4593, EudraCT Number: 2009-015238-31, KWF 2009-4593, M09TNM, NCT01057069, Neo-TN, NL29425.031.09, TrialTroveID-121955",Randomized Phase II/III Study of Individualized Neoadjuvant Chemotherapy in ' Triple Negative' Breast Tumors,Oncology,Oncology: Breast,Netherlands Cancer Institute,Government,Complete response,"Disease-free survival, Overall survival",True,NCT01057069,57462
3003,121596,"AAAB3095, CHNY-02-516, IRB# AAAB3095, NCT01050439, TrialTroveID-121596",Unrelated Donor Stem Cell Transplant for Patients With Malignant and Non-Malignant Disorders,Metabolic/Endocrinology; Oncology,"Metabolic/Endocrinology: Alpha-mannosidosis; Metabolic/Endocrinology: Aspartylglucosaminuria; Metabolic/Endocrinology: Gaucher Disease; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",Columbia University Medical Center,Academic,Safety and Tolerability,"Event-free survival, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01050439,57462
3004,119828,"ChiCTR-TRC-09000573, TrialTroveID-119828",Comparative Study of High-Dose versus Standard-dose Chemotherapy with Docetaxel and Thiotepa regimen for Metastatic Breast Cancer,Oncology,Oncology: Breast,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival",False,,57462
3005,119706,"BUS2009/1, EudraCT Number: 2009-012437-30, NCT01025778, TrialTroveID-119706",Clofarabine Based Remission Induction Followed by Haploidentical Stem Cell Transplantation in Children With Refractory Hematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Event-free survival, Overall survival","Overall response rate, Quality of Life, Response rate, Safety and Tolerability",True,NCT01025778,57462
3006,118615,"000643, 356, 4036295, 453, CRUK/10/023, DRKS00003763, EudraCT Number: 2009-012432-32, IELSG 32, IELSG32, ISRCTN49014661, MREC NÂ° 11/LO/0420, NCT01011920, RHMCAN0743, TrialTroveID-118615, UKCRN ID 10139","Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Cancer Research UK, International Extranodal Lymphoma Study Group, University of Freiburg, University of Southampton","Not for Profit Funding Entity, Cooperative Group, Academic, Academic","Complete response, Overall response rate, Progression-free survival, Response rate","Overall survival, Safety and Tolerability",True,NCT01011920,57462
3007,117674,"2006LS032, MT2005-21, NCI-2010-01700, NCT00432094, TrialTroveID-117674, UMN-0608M90586, UMN-2006LS032, UMN-MT2005-21",Autologous Peripheral Blood Stem Cell Transplant for Germ Cell Tumors.,Oncology,Oncology: (N/A); Oncology: Ovarian; Oncology: Testicular,University of Minnesota Cancer Center,Academic,Overall survival,"Absolute Neutrophil Count, Disease-free survival, Overall survival, Progression-free survival",True,NCT00432094,57462
3008,117512,"AOM04128, NCT00231582, P031101, TAXIF II, TrialTroveID-117512",Sequential High-Dose Chemotherapy Combining Two Mobilization and Cyto-Reductive Treatments Followed by Three High-Dose Chemotherapy Regimens Supported by Autologous Stem Cell Transplantation,Oncology,Oncology: Testicular,"Amgen, Baxter International, Assistance Publique - Hopitaux de Paris, (Other government agency)","Industry, Top 20 Pharma, Industry, all other pharma, Academic, Government",,,True,NCT00231582,57462
3009,117019,"MMES-99, TrialTroveID-117019",Experience In High-Dose Chemotherapy With Peripheral Stem Cell Rescue And Biotherapy For Young Adults With High-Risk Ewing/Pnet Sarcoma.,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3010,114452,"NCT00966498, PBSCT for ST, TrialTroveID-114452",Peripheral Blood Stem Cell Transplantation in Children with High-Risk or Recurrent Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Emory University Hospital - Atlanta,Academic,,,True,NCT00966498,57462
3011,111971,"CSET 1329, EudraCT: 2008-000368-18, HR 5 PNET, IGR 1329, NCT00936156, PNET HR+ 5, RECF1136, RIG # 5 # HR + PNET CSET 1329, RMI 1329, TrialTroveID-111971",Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years.,Oncology,"Oncology: CNS, Medulloblastoma","Amgen, Merck & Co. {Schering-Plough}, (Other Cooperative Group), Federation Nationale des Centres de Lutte contre le Cancer, Institut Gustave Roussy","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Cooperative Group, Academic",Progression-free survival,"Complete response, Disease-free survival, Overall survival, Resection rate",True,NCT00936156,57462
3012,111388,TrialTroveID-111388,Clinical significance of prophylactic intrathecal chemotherapy in the treatment of glioblastoma multiforme,Oncology,"Oncology: CNS, Glioblastoma",(Other Academic Cancer Center),Academic,"Overall survival, Progression-free survival",,False,,57462
3013,110074,"07CC12, EudraCT - 2007-001657-26, KCH-BMT-07-1.0, NCT00916045, REC - 07/H0808/193, TrialTroveID-110074",Pilot Study of Unrelated Cord Blood Transplantation in Patients With Poor Risk Haematological Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,Treatment related mortality,"Disease Progression, Disease-free survival, Overall survival, Quality of Life",True,NCT00916045,57462
3014,110049,"0903004832, CDR0000644201, FHCRC-2222.00, NCI-2010-00713, NCT00914940, RG2810004, TrialTroveID-110049","A Multi-Center, Phase II Study of Selective Depletion of CD45RA+ T Cells from Allogeneic Peripheral Blood Stem Cell Grafts for the Prevention of GVHD",Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Common Terminology Criteria for Adverse Events, Incidence of aGVHD","Incidence of cGVHD, Transplant related mortality",True,NCT00914940,57462
3015,106646,TrialTroveID-106646,"TEAM (Thiotepa, Etoposide, Cytarabine, Melphalan) as Conditioning Regimen for Lymphoma Treatment with Autologous Haematopoietic Stem Cell Transplantation.",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3016,106574,"CRH 07/422/H, EudraCT Number: 2007-005378-30, NCT00863460, PRECIS, PRECIS 01, RECF0760, TrialTroveID-106574","Prospective, Multicentric, Randomized Phase II Study, Evaluating the Role of Cranial Radiotherapy or Intensive Chemotherapy With Hematopoietic Stem Cell Rescue After Conventional Chemotherapy for Primary Central Nervous System in Young Patients (< 60 y)",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Amgen, (Other Cooperative Group), French Health Ministry, Pierre Fabre, (Other Hospital/Academic/Medical Center), Roche {F. Hoffmann-La Roche}","Industry, Top 20 Pharma, Cooperative Group, Government, Industry, all other pharma, Academic, Industry, Top 20 Pharma",Progression-free survival,"Event-free survival, Overall response rate, Overall survival, Response rate",True,NCT00863460,57462
3017,106558,TrialTroveID-106558,Kinetics of CD3+ T-cell engraftment correlates with development of acute GvHD and relapse in patients treated with reduced-intensity conditioning allogeneic stem cell transplantation.,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3018,105519,"2008-0363, NCI-2012-01630, NCT00857389, TrialTroveID-105519",Thiotepa-Clofarabine-Busulfan with Allogeneic Stem Cell Transplant for High Risk Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas",Academic,"Disease-free survival, Overall survival, Safety and Tolerability",Overall survival,True,NCT00857389,57462
3019,105245,"CKTO 2005-15, METc 2004/110, NCT00851110, TrialTroveID-105245",A Prospective Randomized Feasibility and Phase II Adjuvant Breast Cancer Study of the Netherlands Working Party for Autotransplantation in Solid Tumors,Oncology,Oncology: Breast,Groningen University Hospital,Academic,,Quality of Life,True,NCT00851110,57462
3020,104724,TrialTroveID-104724,"Fludarabine, Melphalan And Thiotepa Conditioning For Unrelated Donor Cord Blood Transplantation.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas",Academic,,,False,,57462
3021,102840,TrialTroveID-102840,Reduced Intensity Conditioning with Thiotepa and Fludarabine for Allogeneic Transplantation: Evidence for Low Toxicity and Long-Lasting Disease Control in MDS with Low/Intermediate-1 IPSS Score and in AML from MDS in Complete Remission,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3022,97127,"BfArM-4030755, DK 2008.17, DKG 05-05, DKS 2006.01, EC-105/05, E-HIT-REZ-2005, EudraCT Number: 2005-002618-40, HIT-REZ-2005, NCT00749723, P-HIT-REZ-2005, TrialTroveID-097127, UKF000477",Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other",University of Bonn,Academic,"Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Recurrence, Response rate, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Recurrence, Time to progression",True,NCT00749723,57462
3023,91785,"7049, NCT00692939, TrialTroveID-091785",Autologous Stem Cell Transplantation with CD34 Selected Peripheral Blood Stem Cells (PBSC) in Pediatric and Young Adult Patients with Severe Crohn's Disease,Autoimmune/Inflammation,Autoimmune/Inflammation: Crohn's Disease,"University of Pittsburgh, Miltenyi Biomedicine","Academic, Industry, all other pharma","CDAI, Crohn's Disease Activity Index, Pediatric Crohn's Disease Activity Index",Platelet count,True,NCT00692939,57462
3024,91389,"EudraCT No: 2006-006516-30, NCT01148173, NHL-ZNS-1, NHL-ZNS-Rezidiv, TrialTroveID-091389",Combined Systemic and Intrathecal Chemotherapy Followed by High-dose Chemotherapy and Autologous Stem Cell Transplantation for CNS Relapse of Aggressive Lymphomas.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Hospital/Academic/Medical Center), Mundipharma International","Academic, Industry, all other pharma",Time to treatment failure,"Complete response, Overall survival",True,NCT01148173,57462
3025,90620,TrialTroveID-090620,High-dose chemotherapy and autologous hematopoietic stem cell transplant for women with breast cancer and 10 or more involved axillary lymph nodes: Long-term follow-up.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3026,86777,"DRKS00003748, EudraCT: 2005-000615-99, Freiburg ZNS-NHL Study, NCT00647049, TrialTroveID-086777, ZNS-00465",Freiburg ZNS-NHL Study: Therapy for Patients With Primary Non-Hodgkin Lymphoma of the CNS - Sequential High Dosage Chemotherapy With Autologous Peripheral Blood Stem Cell transplantation.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Hospital/Academic/Medical Center), University of Freiburg","Academic, Academic",Complete response,"Adverse Events, Duration of overall response, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT00647049,57462
3027,86381,TrialTroveID-086381,An Efficacy and Safety Study of an Immunesuppressive Regimen Based on Thiotepa and Cyclophosphamide in the treatment of Refractory or Replapsed MS,CNS,CNS: Multiple Sclerosis,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Safety and Tolerability",,False,,57462
3028,85780,"B-ALL-BFM, B-NHL BFM 04, B-NHL FOM 04, CTGR 476, DRKS00009436, EudraCT Number: 2005-002345-39, GÃ¶teborg University, ID 476, StudienID: 476, TrialTroveID-085780, UKF000178",Multi-center observation study for the treatment of children and adolescents  with mature B-cell Non- Hodgkin's lymphoma or B ALL,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), (Other Hospital/Academic/Medical Center), The International BFM Study Group","Cooperative Group, Academic, Cooperative Group","Disease Progression, Event-free survival",,False,,57462
3029,83608,"3990, NCT00607984, TrialTroveID-083608",High Dose Thiotepa and Melphalan With Autologous Hematopoietic Stem Cell Transplant in Children and Adolescents With Solid Tumors,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver",(Other Hospital/Academic/Medical Center),Academic,,,True,NCT00607984,57462
3030,82843,TrialTroveID-082843,"A fludarabine, thiotepa reduced toxicity conditioning regimen designed specifically for allogeneic second haematopoietic cell transplantation after failure of previous autologous or allogeneic transplantation.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3031,82429,TrialTroveID-082429,Low Transplant Related Toxicity and Mortality after Transplantation of CD3/CD19 Depleted Haploidentical Stem Cells with Reduced Intensity Conditioning in Children.,Oncology,"Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Soft Tissue Sarcoma",(Other Hospital/Academic/Medical Center),Academic,Mortality,,False,,57462
3032,81843,"NCT00584428, OU 9206, TrialTroveID-081843",High Dose Chemotherapy with Autologous Bone Marrow Transplantation in the Treatment of Metastatic Breast Cancer.,Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), University of Oklahoma","Academic, Academic",,,True,NCT00584428,57462
3033,80513,TrialTroveID-080513,Results of Haploidentical Stem Cell Transplantation after a Conditioning Regimen without Total Body Irradiation in Elderly Patients with Advanced Myeloid and Lymphoid Malignancies.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3034,76937,"I 72806, NCI-2011-00131, NCT00536601, RPCI-I-72806, TrialTroveID-076937, TX75544",Autologous Blood and Marrow Transplantation for Hematologic Malignancies and Selected Solid Tumors,Oncology,"Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Neuroblastoma; Oncology: Testicular; Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute","Government, Academic","Disease Progression, Progression-free survival","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00536601,57462
3035,74219,"JCOG 9208, JCOG9208, TrialTroveID-074219",Randomized Phase III Study of High-Dose Chemotherapy (HDC) with Autologous Stem Cell Support as Consolidation in High-Risk Postoperative Breast Cancer.,Oncology,Oncology: Breast,"Japan Clinical Oncology Group, Japanese Ministry of Health, Labour and Welfare","Cooperative Group, Government",Disease-free survival,"Overall survival, Safety and Tolerability",False,,57462
3036,70877,TrialTroveID-070877,Randomized clinical trial comparing standard-dose to high-dose myeloablative chemotherapy in the adjuvant treatment of breast cancer with more than three positive nodes (LN+).,Oncology,Oncology: Breast,"Pfizer {Pharmacia}, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group",Progression-free survival,,False,,57462
3037,66199,"N06IAA, NCT00448266, TrialTroveID-066199",Randomized Phase II/III Study of Intensified Alkylating Agent Chemotherapy With Peripheral Blood Progenitor Cell Support in the Preoperative Chemotherapy of Breast Tumors That Are Deficient for Homologous Recombination.,Oncology,Oncology: Breast,Netherlands Cancer Institute,Government,Complete response,"Disease-free survival, Overall survival",True,NCT00448266,57462
3038,65800,"CHMC-6006, FHCRC-1244.00, NCI-G98-1373, NCT00003194, TrialTroveID-065800",A Phase I Study of Thiotepa in Combination With Carboplatin and Topotecan With Peripheral Blood Progenitor Cell Support for the Treatment of Children With Recurrent or Refractory Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Seattle Children's Hospital","Government, Academic",Maximum tolerated dose,,True,NCT00003194,57462
3039,65651,"05.10.115, 05-0804, 07-148, 12853, 2007-0028, H12853, NCT00528437, NYU 05-40 H12853, NYU 05-40 PBMTC ONC-032P, ONC032, ONC-032P, PBMTC ONC-032, PBMTC ONC-032P, RPCI-63705, STU 032011-114, TrialTroveID-065651, VICCPED0617","NYU 05-40 PBMTC ONC-032P:High Dose Temozolomide,Thiotepa and Carboplatin With Autologous Stem Cell Rescue (ASCR) Followed by Continuation Therapy With 13-cis-retinoic Acid in Patients With Recurrent/Refractory Malignant Brain Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other","(Other Cooperative Group), New York University, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic, Academic","Event-free survival, Minimal Residual Disease, Overall survival, Progression-free survival","Event-free survival, Minimal Residual Disease, Overall survival, Plasma pharmacokinetics",True,NCT00528437,57462
3040,64915,"NCI-G00-1689, NCT00004900, NU-HAC98B2, TrialTroveID-064915",A Phase II Pilot Study of Sequential High Dose Chemotherapy and CD 34+ Selected Stem Cell Support Without Conventional-Dose Induction Chemotherapy for Women With Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University","Government, Academic","Duration of overall response, Overall response rate, Response rate",,True,NCT00004900,57462
3041,63867,"2006-0280, MDACC 2006-0280, NCT00429182, TrialTroveID-063867",Phase II Study of Purging of Circulating Tumor Cells (CTCs) From Metastatic Breast Cancer Patients.,Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas",Academic,"Circulating Tumor Cells, Progression-free survival","Circulating Tumor Cells, Disease Progression, Overall survival, Progression-free survival",True,NCT00429182,57462
3042,63816,TrialTroveID-063816,Mismatched Family Member Donor Transplantation for Patients with Refractory Hematologic Malignancies: A Prospective Clinical Trial.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome",St. Jude Children's Research Hospital,Academic,Safety and Tolerability,,False,,57462
3043,63034,"FHCRC-1343.00, NCI-H99-0032, NCT00003899, TrialTroveID-063034",Phase I Study of Melphalan and Thiotepa with Bone Marrow or Stem Cell Rescue in Patients with Responsive or Refractory Solid Tumors.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Maximum tolerated dose, Overall response rate, Overall survival, Response rate",,True,NCT00003899,57462
3044,62526,TrialTroveID-062526,Intensive Chemotherapy Followed by Hematopoietic Stem Cell Rescue for Refractory or Recurrent Primary Central Nervous System (PCNSL) or Intra Ocular Lymphoma (IOL). A  Multicentric Phase II Study.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Cooperative Group),Cooperative Group,,,False,,57462
3045,62027,TrialTroveID-062027,"A Phase II, Single Center, Pilot Study for High-Dose Chemotherapy and Autologous Stem-Cell Transplantation with Whole-Brain Radiation restricted to residual disease in Patients < or = 65 Years of Age with Primary CNS Lymphoma.",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",University of Freiburg,Academic,,,False,,57462
3046,58867,"Head Start II, Head-Start II, TrialTroveID-058867",Induction Chemotherapy Intensified With High-Dose Methotrexate for Young Children With Newly Diagnosed High-Risk Disseminated Medulloblastoma,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,57462
3047,58188,"CHAM-05-07-178, CHLA-2004-020, CHLA-HEAD-START-III, CHLA-HSIII, CHLA-NANT-04.020, CHLA-NANT-2004-020, CHLA-NANT-HEAD-START-III, CHLA-NANT-HSIII, HEAD START III, MDACC-2006-0110, NCT00392886, RCCC0609-12, TrialTroveID-058188, UMN-MT2004-06","Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III].",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma",Children's Hospital Los Angeles,Academic,"Event-free survival, Mortality, Overall survival, Recurrence","Event-free survival, Overall survival, Time to progression",True,NCT00392886,57462
3048,56471,TrialTroveID-056471,Randomized trial of single compared with tandem high-dose chemotherapy followed by autologous stem-cell transplantation in patients with chemotherapy-sensitive metastatic breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Partial response",False,,57462
3049,55778,"AOH94041, IRB Number: 94041, PBT-3, RRC7493, TrialTroveID-055778",Phase II Trial of High Dose Chemotherapy with Peripheral Stem Cell Infusion in Women with Locally Advanced Breast Cancer.,Oncology,Oncology: Breast,"(Other Cooperative Group), Fox Chase Cancer Center","Cooperative Group, Academic","Complete response, Overall survival",,False,,57462
3050,54377,TrialTroveID-054377,High dose chemotherapy with autologous stem cell rescue (ASCR) for recurrent medulloblastoma.,Oncology,"Oncology: CNS, Medulloblastoma",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3051,53580,"EudraCT:2005-000805-68, GITMO-1, GLOBAL, NCT00354120, TrialTroveID-053580",Randomized Study for Comparison of Reduced Intensity Conditioning Protocols Containing Either Thymoglobuline or Alemtuzumab in Patients Undergoing Allogeneic Transplant From Voluntary Unrelated Donors,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",Gruppo Italiano Trapianto Midollo Osseo,Cooperative Group,"Disease-free survival, Event-free survival, Overall survival, Safety and Tolerability",,True,NCT00354120,57462
3052,53292,"960032, 96-C-0032, NCI-96-C-0032F, NCI-96-C-0032H, NCI-MB-381, NCT00001498, TrialTroveID-053292","A Pilot Trial of Sequential Chemotherapy With Antimetabolite Induction, High-Dose Alkylating Agent Consolidation With Peripheral Blood Progenitor Cell Support, and Intensification With Paclitaxel and Doxorubicin for Patients With High-Risk Breast Cancer.",Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,,,True,NCT00001498,57462
3053,52808,"NKI 2005-3418, TrialTroveID-052808",Impact of polymorphisms in the CYP2B6 gene on the pharmacokinetics of cyclophosphamide and thiotepa.,Oncology,Oncology: Unspecified Solid Tumor,Netherlands Cancer Institute,Government,,,False,,57462
3054,52475,TrialTroveID-052475,High dose chemotherapy with autologous stem cell rescue as a part of combined modality therapy in stage IIIB inflammatory breast cancer.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3055,51244,TrialTroveID-051244,Randomized trial of high-dose chemotherapy with autologous haematopoietic stem cell support vs. standard-dose chemotherapy in breast cancer patients with 10 or more positive lymph nodes: Overall survival after 6 years of follow up.,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Event-free survival, Overall survival",,False,,57462
3056,48444,"AIEOP-EICNHL-ALCL-RELAPSE, ALCL-Relapse, BFM-EICNHL-ALCL-RELAPSE, BSPHO-EICNHL-ALCL-RELAPSE, CCLG-NHL-2006-01, DCOG-EICNHL-ALCL-RELAPSE, DRKS00003770, EICNHL-ALCL-RELAPSE, EU-205118, EU-20618, EudraCT Number: 2005-003321-57, MREC NÂ°: 05/MRE04/54, N0519171281, NCT00317408, NHL 2005 XX, NOPHO-EICNHL-ALCL-RELAPSE, PPLLSG-EICNHL-ALCL-RELAPSE, SFCE-EICNHL-ALCL-RELAPSE, SHOP-EICNHL-ALCL-RELAPSE, TrialTroveID-048444, UKCCSG-EICNHL-ALCL-RELAPSE, UKCRN 2248",Treatment Protocol for Relapsed Anaplastic Large Cell Lymphoma of Childhood and Adolescence,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), University Hospitals of Leicester NHS Trust, The International BFM Study Group","Cooperative Group, Academic, Cooperative Group","Event-free survival, Phosphate level","Overall survival, Treatment related mortality",True,NCT00317408,57462
3057,46332,"EU-205105, GPOH-HIT-2000, HIT-2000, HIT-SKKâ2000BIS4, NCT00303810, TrialTroveID-046332",Multicenter Therapy Optimizing Study for Treatment of Children and Adolescents With Intracranial Medulloblastoma / PNET and Ependymoma,Oncology,"Oncology: (N/A); Oncology: CNS, Medulloblastoma",(Other Cooperative Group),Cooperative Group,,,True,NCT00303810,57462
3058,45450,"E203/2004, HaploStudie, HSZ-001, IRB Project Nr. 21/2004, LN_EZIEXP_2004_234, NCT00202917, SZT Haplo-SZT CD3/CD19, TrialTroveID-045450",Multicenter Phase I/II Study of Haploidentical Hematopoietic Cell Transplantation With CD3/CD19 Depleted Grafts in Patients With Treatment Refractory Hematologic Malignancies,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",(Other Academic Cancer Center),Academic,Mortality,,True,NCT00202917,57462
3059,45315,TrialTroveID-045315,High Dose Chemotherapy and Autologous Stem Cell Transplantation in Multiple Myeloma: Comparison of Four Preparative Regimens.,Oncology,Oncology: Multiple Myeloma,(Other Hospital/Academic/Medical Center),Academic,"Event-free survival, Overall survival",,False,,57462
3060,43167,TrialTroveID-043167,Reduced-Intensity Conditioning (RIC) Followed by Allogeneic Stem Cell Transplantation (SCT) for Relapsed Lymphomas: Impact of Pre-Transplantation Factors on Long-Term Outcome,Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",Gruppo Italiano Trapianto Midollo Osseo,Cooperative Group,,,False,,57462
3061,43166,TrialTroveID-043166,Reduced-Intensity Conditioning Followed by Allogeneic Stem Cell Transplantation (allo-SCT) Is an Effective Salvage Treatment for Peripheral T-Cell Non-Hodgkin's Lymphoma (PTCL).,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3062,42805,"OSHO-53, TrialTroveID-042805","Primary CNS lymphoma treated with HD-methotrexate, HD-busulfan/thiotepa, autologous stem cell transplantation and response-adapted whole-brain radiotherapy.",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",East German Hematology and Oncology Group (OSHO),Cooperative Group,Safety and Tolerability,,False,,57462
3063,42508,TrialTroveID-042508,Primary CNS Lymphoma - High-Dose-Chemotherapy with Autologous PBSCT and Hyperfractionated Radiotherapy as First-Line-Therapy - a Multicenter Phase II Study,Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Supportive Care",(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,57462
3064,41924,"ACCOG1, MREC/03/10/43, N0519152542, TrialTroveID-041924","Conventional Adjuvant Chemotherapy Versus Single-Cycle, Autograft-Supported, High-Dose, Late-Intensifcation Chemotherapy in High-Risk Breast Cancer Patients: A Randomized Trial.",Oncology,Oncology: Breast,Anglo Celtic Cooperative Oncology Group,Cooperative Group,Overall survival,,False,,57462
3065,40807,"AM01, TrialTroveID-040807, WSG-01, WSG-AM01, WSG-AM-01",Comparison of rapidly cycled tandem high-dose chemotherapy plus peripheral-blood stem-cell support versus dose-dense conventional chemotherapy for adjuvant treatment of high-risk breast cancer: results of a multicentre phase III trial.,Oncology,Oncology: Breast,(Other Cooperative Group),Cooperative Group,Event-free survival,Overall survival,False,,57462
3066,39376,TrialTroveID-039376,High-dose chemotherapy with autologous stem-cell rescue in children with high-risk medulloblastoma/primitive neuroectodermal tumors.,Oncology,"Oncology: CNS, Medulloblastoma",(Other Academic Cancer Center),Academic,,,False,,57462
3067,38103,"01070, 01-070, CA23766, CA33049, MSKCC-01-070, NCT00587054, TrialTroveID-038103","Phase II Trial of Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Treatment of Adult Patients (>18 Years) With Lymphohematopoietic Disorders",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",Overall survival,,True,NCT00587054,57462
3068,38022,"05-059, MSKCC-05059, MSKCC-05-059, NCT00357396, TrialTroveID-038022","A Phase II Trial of a Chemotherapy Based Regimen of Intravenous Busulfan (Busulfex), Melphalan and Thiotepa as Myeloablative Regimen Followed by a T- Cell Depleted Allogeneic Hematopoietic Stem Cell Transplant From and HLA-Compatible Donor in the Treatment of High Risk Ewing's Sarcoma Family Tumors",Oncology,Oncology: Soft Tissue Sarcoma,Memorial Sloan-Kettering Cancer Center,Academic,"Disease-free survival, Minimal Residual Disease, Mortality, Overall survival",,True,NCT00357396,57462
3069,37784,"HEM-04083-L, NCT00238433, OHSU-HEM-04083-L, OHSU-IRB-248, TrialTroveID-037784","A Phase II Study to Evaluate the Safety and Efficacy of IV Busulfan, Melphalan, and Thiotepa (BuMelTT) Followed By Autologous PBSC Infusion for Patients With Hodgkin's Disease and Non-Hodgkin's Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, OHSU Cancer Institute","Government, Academic","Adverse Events, Disease-free survival",,True,NCT00238433,57462
3070,35303,"HR PNET, IGR # 791 # PNET HR, NCT00180791, PNET HR, PNET-HR-2002, RECF0194, TrialTroveID-035303","Treatment Protocol for High-Risk PNET Brain Tumors in Children with Surgery, Sequential Chemotherapy, Conventional and High-Dose with Peripheral Blood Stem Cell Transplantation and Radiation Therapy",Oncology,"Oncology: CNS, Medulloblastoma","Federation Nationale des Centres de Lutte contre le Cancer, Institut Gustave Roussy","Cooperative Group, Academic","Event-free survival, Overall response rate, Response rate","Event-free survival, Overall response rate, Overall survival, Response rate",True,NCT00180791,57462
3071,33679,"1996-0195, NCT00141765, TrialTroveID-033679, UMCC 9626",Myeloablative Chemotherapy with Stem Cell Rescue for Rare Poor-Prognosis Cancers,Oncology,"Oncology: CNS, Other; Oncology: Head/Neck; Oncology: Liver; Oncology: Renal; Oncology: Soft Tissue Sarcoma",University of Michigan Comprehensive Cancer Center,Academic,"Disease-free survival, Progression-free survival",,True,NCT00141765,57462
3072,32954,TrialTroveID-032954,"Final results of a multicenter phase II trial of high-dose methotrexate, cytarabine, thiotepa, and idarubicin  followed by whole-brain irradiation for primary CNS lymphomas.",Oncology,"Oncology: CNS, Other; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Complete response,"Overall response rate - duration, Overall survival",False,,57462
3073,30480,TrialTroveID-030480,High-dose therapy with autologous stem cell rescue in patients with breast cancer at high risk for relapse,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,57462
3074,29218,"1629.00, FHCRC-1629.00, NCT00112567, TrialTroveID-029218","A Phase I/II Study of Total Body Irradiation, Thiotepa, and Fludarabine as Conditioning for Haploidentical CD34+ Purified Peripheral Blood Stem Cell Transplants.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome","National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",Safety and Tolerability,,True,NCT00112567,57462
3075,25032,"HIC 25971, NCI-6765, NCT00104975, TrialTroveID-025032, YALE-25971",Reduced Intensity Conditioning Regimen for Haplo-identical Family Donor Stem Cell Transplants for Hematologic Malignancies with Delayed add-back of Non-alloreactive T Cells.,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","National Institutes of Health/National Cancer Institute, Yale Comprehensive Cancer Center","Government, Academic",Safety and Tolerability,,True,NCT00104975,57462
3076,23663,"MUDSCT, NCT00152139, TrialTroveID-023663",Hematopoietic Stem Cell Transplantation for Patients with Hematologic Malignancies: A Comparison of T-Cell Depleted Peripheral Blood Stem Cells with Unmanipulated Bone Marrow (Phase III Controlled Trial),Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,St. Jude Children's Research Hospital,Academic,Incidence of aGVHD,"Disease-free survival, Incidence of cGVHD, Mortality, Patient survival",True,NCT00152139,57462
3077,23638,TrialTroveID-023638,Use of intensive antibiotic prophylaxis and a chemotherapy only T-cell depleted preparative regimen (prep reg) as a pilot study in haploidentical (haplo) transplant (tp) for treatment of patients with advanced leukemia.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous","MD Anderson Cancer Center, University of Texas",Academic,,,False,,57462
3078,21318,"SBG-9401, TrialTroveID-021318","Tailored fluorouracil, epirubicin, and cyclophosphamide compared with marrow-supported high-dose chemotherapy as adjuvant treatment for high-risk breast cancer: a randomised trial. Scandinavian Breast Group 9401 study.",Oncology,Oncology: Breast,Scandinavian Breast Group,Cooperative Group,Disease-free survival,"Overall survival, Safety and Tolerability",False,,57462
3079,20619,TrialTroveID-020619,Molecular Remission Can Be Attained in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Follicular Lymphomas after Reduced Intensity Conditioning (RIC) and Allogeneic Stem Cell Transplantation (allo-SCT),Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Non-Hodgkin's",University of Torino,Academic,,,False,,57462
3080,20563,TrialTroveID-020563,Early Myeloablative Allogeneic Stem Cell Transplantation during High-Dose Cytarabine-Induced Cytopenia in Patients with Refractory or Relapsed Myeloid Leukemias.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",(Other Hospital/Academic/Medical Center),Academic,,,False,,57462
3081,20233,TrialTroveID-020233,"High Dose Thiotepa, Busulfan, Cyclophosphamide (TBC) and Autologous Hematopoietic Stem Cell Transplantation (ASCT) without Whole Brain Radiotherapy (WBRT) for Primary Central Nervous System Lymphoma (PCNSL).",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",University of Calgary,Academic,,,False,,57462
3082,16043,"ID03-0095, TrialTroveID-016043",Phase III Randomized Study of High-Dose Chemotherapy With Autologous Hematopoietic Stem Cell Transplantation for Patients With Metastatic Breast Cancer in Complete Response by Standard Treatment,Oncology,Oncology: Breast,"MD Anderson Cancer Center, University of Texas",Academic,"Complete response, Safety and Tolerability",,False,,57462
3083,14062,TrialTroveID-014062,Safety and outcome after fludarabine-thiotepa-TBI conditioning for allogeneic transplantation: a prospective study of 30 patients with hematologic malignancies.,Oncology,Oncology: Unspecified Hematological Cancer,University of Illinois at Chicago Health Sciences Center,Academic,,,False,,57462
3084,13822,"CAMP 006, IRB-7982, TrialTroveID-013822",Study of tandem high dose chemotherapy and autologous blood stem cell transplantation for poor risk lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Academic Cancer Center),Academic,"Maximum tolerated dose, Phosphate level",,False,,57462
3085,11579,TrialTroveID-011579,Intensive chemotherapy with autologous bone marrow transplantation in patients with locally advanced breast cancer: 12-years follow-up.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Disease-free survival,,False,,57462
3086,11155,TrialTroveID-011155,IGEV Regimen and High Dose Chemotherapy (HDT) Consolidation with Peripheral Blood Stem Cell (PBSC) Support for Refractory-Relapsed Hodgkins Disease,Oncology,"Oncology: Lymphoma, Hodgkin's",Centro di Riferimento Oncologico - Aviano,Academic,"Complete response, Overall survival, Progression-free survival",,False,,57462
3087,10689,TrialTroveID-010689,High dose chemotherapy (HDCT) and hematopoietic stem cell transplantation (HPSCT) with subsequent immunotherapy in metastatic breast cancer (MBC): Final results of a phase I study.,Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,,,False,,57462
3088,10662,"IBDIS, IBDIS-I, TrialTroveID-010662","Effect of tandem high-dose chemotherapy (HDC) on long-term complete remissions (LTCR) in metastatic breast cancer (MBC), compared to conventional dose (CDC) in patients (pts) who were not selected on the basis of response to prior C: Mature results of the IBDIS-I.",Oncology,Oncology: Breast,(Other Academic Cancer Center),Academic,Progression-free survival,,False,,57462
3089,9225,"FHCRC-1204.00, NCI-H97-0007, NCT00003146, TrialTroveID-009225","Phase II Study of Busulfan, Melphalan, and Thiotepa Followed by Autologous or Syngeneic Marrow or Peripheral Blood Stem Cell Transplantation in Patients with Multiple Myeloma",Oncology,Oncology: Multiple Myeloma,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",,,True,NCT00003146,57462
3090,9114,"DM98-283, MDA-DM-98283, NCI-G00-1742, NCT00005092, TrialTroveID-009114",A Phase I Study of Photochemically Treated Donor T-Cell Supplements in HLA Haplotype Mismatched Hematopoietic Stem Cell Transplantation,Autoimmune/Inflammation,Autoimmune/Inflammation: Transplantation/GVHD,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00005092,57462
3091,9058,"FHCRC-1144.00, NCI-G97-1329, NCT00003080, TrialTroveID-009058",A Phase I Trial of Sequential High Dose Chemotherapy Regimens Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With Persistent Stage III/IV Ovarian Cancer,Oncology,Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",Maximum tolerated dose,,True,NCT00003080,57462
3092,9051,"FHCRC-1181.00, NCI-G97-1229, NCT00002977, TrialTroveID-009051",A Phase I Trial of Melphalan and Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell (PBSC) Rescue in Patients With a Complete Response Following Standard Therapy for Stage III/IV Epithelial Ovarian Cancer.,Oncology,Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Complete response, Maximum tolerated dose",,True,NCT00002977,57462
3093,8833,"98-0405, 98-502, 99703, CCG-99703, COG-99703, MSKCC-98-097, NCT00003141, P98 11-85, TrialTroveID-008833",Phase I Pilot Study of Intensive Chemotherapy and Peripheral Blood Stem Cell Rescue in Infants With Malignant Brain or Spinal Cord Tumors.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Event-free survival, Maximum tolerated dose, Overall survival",,True,NCT00003141,57462
3094,5662,"ACNS0231, COG-ACNS0231, NCT00078988, TrialTroveID-005662",A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group",Event-free survival,Overall survival,True,NCT00078988,57462
3095,4393,"MSKCC-89173A4, NCI-V90-0008, NYU-97-5, TrialTroveID-004393",Phase II Study of Intensive Chemotherapy with Thiotepa/Etoposide/Carboplatin and Autologous Stem Cell Reconstitution for Recurrent or Progressive Malignant Brain Tumors.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other",Memorial Sloan-Kettering Cancer Center,Academic,"Overall response rate, Overall survival, Response rate",,False,,57462
3096,4377,"CCG-99702, COG-99702, NCT00003846, TrialTroveID-004377",Treatment of High Risk Central Nervous System Embryonal Tumors With Conventional Radiotherapy and Intensive Consolidation Chemotherapy With Peripheral Blood Progenitor Cell (PBSC) Support.,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Event-free survival, Maximum tolerated dose, Safety and Tolerability",,True,NCT00003846,57462
3097,4370,"MSKCC-94101, NCI-V94-0594, NCT00002619, NYU-97-8, TrialTroveID-004370","A Trial Of Intensive Chemotherapy And Autologous Stem Cell Reconstitution For Patients Between Six And Sixty Years Of Age, With Non-Progressive Glioblastoma Multiforme Or Diffuse Intrinsic Brainstem Tumors, Following Initial Local-Field Irradiation",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma",Kaplan Cancer Center,Academic,"Overall survival, Recurrence, Time to progression",,True,NCT00002619,57462
3098,3816,"CPMC-CAMP-013, CPMC-IRB-8017, NCI-G00-1883, NCT00008008, TrialTroveID-003816, VT1569","CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy.",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Herbert Irving Comprehensive Cancer Center at Columbia University","Government, Academic","Overall response rate - duration, Overall response rate, Overall survival, Response rate",,True,NCT00008008,57462
3099,3815,"CCLG-CNS-2000-01, CNS 2000 01, EU-20105, MREC 99/9/63, MREC-99/8/63, N0045125249, N0129073756, N0206066183, N0220110994, N0544074149, NCT00025077, PNET-CNS 2000 01, Recurrent PNET, TrialTroveID-003815, UKCCSG-CNS-2000-01, UKCRN-1142",Treatment Of Recurrent Central Nervous System Primitive Neuroectodermal Tumors (PNETs) In Children And Adolescents A Strategy Including The Use Of High Dose Thiotepa And High Dose Carboplatin.,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other","(Other Cooperative Group), National Health Service (NHS) - UK, University Hospitals of Leicester NHS Trust","Cooperative Group, Government, Academic",Event-free survival,,True,NCT00025077,57462
3100,3473,"030209, 03-H-0209, NCT00062725, NCT00066417, NHLBI-03-H-0209, TrialTroveID-003473",Pilot Study Of T-Cell-Depleted Peripheral Blood Stem Cell Transplantation From Partially Matched Related Donors For Patients With High-Risk Leukemia.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","National Institutes of Health/National Heart, Lung, and Blood Institute",Government,"Disease-free survival, Overall survival, Transplant related mortality",,True,NCT00062725,57462
3101,2779,"NCI-V93-0240, TrialTroveID-002779, UAB-4105","Phase II Study of Cyclophosphamide/Thiotepa with Autologous Bone Marrow Rescue as Intensification Therapy Following Low-Dose, Doxorubicin-Based, Adjuvant Chemotherapy for Stage III Breast Cancer at High Risk of Recurrence",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Alabama at Birmingham Comprehensive Cancer Center","Government, Academic","Disease-free survival, Overall survival, Recurrence",,False,,57462
3102,2778,"MCC-11072, MCC-IRB-3898, NCI-G00-1760, NCT00005798, TrialTroveID-002778","Phase II Study of Cyclophosphamide, Thiotepa, and Carboplatin Followed by Autologous Hematopoietic Stem Cell Transplantation in Women With Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute","Government, Academic","Complete response, Disease-free survival, Safety and Tolerability",,True,NCT00005798,57462
3103,2777,"FHCRC-955.01, NCI-H95-0704, TrialTroveID-002777",Phase II Study of Busulfan/Melphalan/Thiotepa Followed by Autologous or Syngeneic Peripheral Blood Stem Cell Rescue for High-Risk Primary Breast Cancer.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",,,False,,57462
3104,2776,"J-9737, JHOC-97101004, NCI-G98-1404, TrialTroveID-002776","Phase II Study of Busulfan, Cyclophosphamide, Thiotepa, and Allogeneic Bone Marrow Transplantation in Women with Metastatic Breast Cancer.",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Government, Academic",,,False,,57462
3105,2758,"NCI-G99-1640, NCT00004172, NU-92B3T, TrialTroveID-002758","Phase II Pilot Study of Autologous Peripheral Blood Stem Cell (APBSC) Mobilization with High Dose Cyclophosphamide and Filgrastim (G-CSF) vs G-CSF Alone Followed By High Dose Carboplatin, Ifosfamide, and Thiotepa Followed By APBSC Transplantation and Consolidation Radiotherapy in Patients with Previously Treated Advanced Breast Cancer.",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University","Government, Academic",Disease-free survival,,True,NCT00004172,57462
3106,2751,"CLB-9496, E2190, E2190/Int0121, E2190/Intergroup 0121, ECOG 2190, ECOG 2190/Intergroup 0121, EST-2190, INT-0121, SWOG-9061, TrialTroveID-002751",NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Study of Adjuvant CAF (Cyclophosphamide/Doxorubicin/Fluorouracil) vs Adjuvant CAF Followed by Intensification with High-Dose Cyclophosphamide/Thiotepa plus Autologous Stem Cell Rescue in Women with Stage II/III Breast Cancer At High Risk of Recurrence.,Oncology,Oncology: Breast,"Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Cooperative Group, Government","Disease-free survival, Overall survival, Recurrence",,False,,57462
3107,2748,"ALZA-UARIZ-HSC-9728, NCI-V97-1329, NCT00003068, TrialTroveID-002748, UARIZ-HSC-9728","Phase II Dose Escalation Study of High Dose Mitoxantrone, Thiotepa, and Cyclophosphamide Plus Autologous Blood Cell Rescue and Amifostine (Ethyol) Cytoprotection in Patients with Primary, Locally Advanced, or Stage IV Breast Cancer",Oncology,Oncology: Breast; Oncology: Supportive Care,"Johnson & Johnson/ALZA, University of Arizona","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Overall survival, Quality of Life, Recurrence",,True,NCT00003068,57462
3108,2270,"NCI-V91-0151, SLUMC-6209, TrialTroveID-002270",Phase II Study of High-Dose MVT (DHAD/VP-16/TSPA) with Autologous Bone Marrow Transplantation and/or Peripheral Blood Stem Cell Rescue in Patients with Multiple Myeloma,Oncology,Oncology: Multiple Myeloma,St. Louis University School of Medicine,Academic,"Overall survival, Progression-free survival",,False,,57462
3109,2186,"Anglo-Celtic I, EU-95048, ISRCTN62673495, NCT00002755, SCTN-BR9405, TrialTroveID-002186",Prospective Randomised Evaluation Of High-Intensity Chemotherapy With Peripheral Blood Progenitor Support In Patients With High Risk Breast Cancer.,Oncology,Oncology: Breast,"Amgen, Scottish Cancer Therapy Network, Anglo Celtic Cooperative Oncology Group","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group",,,True,NCT00002755,57462
3110,2175,"E-PBT01, NCCTG-913201, NCI-T90-0180D, PBT-1, SWOG-9412, TrialTroveID-002175",NCI HIGH PRIORITY CLINICAL TRIAL --- Phase III Randomized Comparison of Conventional CMF Maintenance vs High-Dose Combination Chemotherapy plus Autologous Bone Marrow and Peripheral Stem Cell Rescue in Women with Metastatic Breast Cancer Responding to Conventional Induction Chemotherapy,Oncology,Oncology: Breast,National Institutes of Health/National Cancer Institute,Government,,,False,,57462
3111,2142,"970523, MDA-DM-95029, NCI-G96-0995, TrialTroveID-002142",Phase II Pilot Study of Allogeneic Transplantation of Bone Marrow Enriched for Graft Facilitating Cells in Patients With High Risk Hematologic Malignancies.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome",National Institutes of Health/National Cancer Institute,Government,,,False,,57462
3112,2132,"NCT00060255, RPCI-DS-9115, TrialTroveID-002132",Autologous Blood and Marrow Transplantation for Hematologic Malignancy and Selected Solid Tumors,Oncology,"Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Testicular","National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute","Government, Academic","Disease-free survival, Mortality, Overall response rate, Overall survival, Response rate",,True,NCT00060255,57462
3113,1225,"JHOC-NABTT-2109, NABTT-2109, NCT00045539, TrialTroveID-001225",Phase II Study of Methotrexate and Thiotepa in Patients With Newly Diagnosed Primary CNS Lymphoma.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",National Institutes of Health/National Cancer Institute,Government,"Overall survival, Progression-free survival",,True,NCT00045539,57462
3114,1224,"MSKCC-01105, NCI-H01-0083, NCT00028730, TrialTroveID-001224","Phase II Trial of T-Cell Depleted Hematopoietic Stem Cell Transplants (SBA-E-BM) From HLA Compatible Related or Unrelated Donors After a Myeloablative Preparative Regimen of Hyperfractionated TBI, Thiotepa and Cyclophosphamide (TBI/Thio/cy) for Treatment of Patients Less Than or Equal to 18 Years With Lymphohematopoietic Disorders.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Myelodysplastic Syndrome","Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government","Disease-free survival, Mortality",,True,NCT00028730,57462
3115,1214,"MSKCC-97089A3, NCI-G97-1366, NCT00003173, NYU-97-7, TrialTroveID-001214",Phase II Study of High Dose Thiotepa With Autologous Stem Cell Rescue in Patients With Refractory Malignancies,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular","Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",,,True,NCT00003173,57462
3116,946,"EU-99004, FRE-FNCLCC-GETUG-04, GETUG - 04, NCT00003852, TAXIF, TrialTroveID-000946",Phase II Study of Intensive Chemotherapy With Autologous Peripheral Blood Stem Cell Support in Patients With Cisplatin Resistant Germ Cell Tumors.,Oncology,Oncology: Liver; Oncology: Ovarian; Oncology: Testicular,Federation Nationale des Centres de Lutte contre le Cancer,Cooperative Group,,"Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00003852,57462
3117,901,"FHCRC-1316.00, NCI-G99-1552, NCT00003972, PSOC-1604, TrialTroveID-000901","A Phase III Study of High-Dose Chemotherapy Using Busulfan, Melphalan and Thiotepa Versus Cyclophosphamide,Thiotepa, Carboplatin Followed by Autologous Stem Cell Transplantation in Patients With High-Risk Primary Stage II or III (Non-Inflammatory) Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic","Disease-free survival, Mortality",,True,NCT00003972,57462
3118,658,"FHCRC-1454.00, NCI-G00-1843, TrialTroveID-000658",Phase II Randomized Study of Docetaxel and Estramustine Versus High-Dose Busulfan and Thiotepa With Autologous Peripheral Blood Stem Cell Transplantation in Patients With Hormone-Refractory Metastatic Prostate Cancer,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",,,False,,57462
3119,572,"MSKCC-92148, NCI-V93-0214, NCT00002515, TrialTroveID-000572","Phase II Study of Myeloablative Chemotherapy With Thiotepa, Carboplatin, and Topotecan Followed By Bone Marrow or Peripheral Blood Stem Cell Rescue in Patients With Rare, Poor Prognosis Cancers",Oncology,"Oncology: CNS, Other; Oncology: Liver; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma",Memorial Sloan-Kettering Cancer Center,Academic,Disease-free survival,,True,NCT00002515,57462
3120,534,"CAMP 004A, CPMC-CAMP-004A, CPMC-IRB-8445, NCI-G00-1881, NCT00007982, TrialTroveID-000534, VT1582",CAMP 004A - Phase II Study Of Intensive Chemotherapy (BET) For Selected Categories of Malignant Central Nervous System Tumor.,Oncology,"Oncology: CNS, Medulloblastoma; Oncology: CNS, Other","National Institutes of Health/National Cancer Institute, Herbert Irving Comprehensive Cancer Center at Columbia University","Government, Academic","Overall response rate, Overall survival, Quality of Life, Response rate",,True,NCT00007982,57462
3121,375,"NCI-V95-0721, NCT00002680, TrialTroveID-000375, YALE-HIC-7372","Phase II Study of Sequential High-Dose Cyclophosphamide, Melphalan, and Thiotepa Plus Peripheral Blood Stem Cell Rescue in Patients With Chemotherapy-Sensitive, Metastatic Breast Cancer",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Yale Comprehensive Cancer Center","Government, Academic",Overall response rate,,True,NCT00002680,57462
3122,263,"FHCRC-1229.00, NCI-2010-00728, NCI-G98-1399, NCT00003199, PSOC 1605, PSOC-1605, TrialTroveID-000263","A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF",Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Fred Hutchinson Cancer Research Center","Government, Academic",Event-free survival,Overall survival,True,NCT00003199,57462
3123,262,"98096, CHNMC-IRB-98096, CHNMC-PHII-18, NCI-H99-0038, NCT00004092, PHII-18, TrialTroveID-000262","Randomized Phase II Study of Adriamycin/Cytoxan/Taxol (ACT) vs. Cytoxan, Thiotepa, Carboplatin (STAMP V) in Patients With High-Risk Primary Breast Cancer",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"National Institutes of Health/National Cancer Institute, City of Hope Comprehensive Cancer Center","Government, Academic","Disease-free survival, Overall survival, Recurrence",Overall survival,True,NCT00004092,57462
3124,185,"EU-96032, FRE-FNCLCC-PEGASE03, NCT00002870, Pegase 03, TrialTroveID-000185","A Randomized, Multi-Centre Phase III Trial to Evaluate the Role of Intensified Therapy with Autologous Transplantation of  Hematopoietic Stem Cells in Advanced or Metastatic Breast Cancer Responding to Induction Chemotherapy.",Oncology,Oncology: Breast,Federation Nationale des Centres de Lutte contre le Cancer,Cooperative Group,"Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",,True,NCT00002870,57462
3125,177,"ANGLO-CELTIC II - Part B, BR9810, EU-98054, NCT00003680, SCTN-BR9810, TrialTroveID-000177","A Randomised Comparative Trial of Highly Intensive Chemotherapy With Stem Cell Support vs. Relatively Intensive Chemotherapy (CMF 8 Cycles) in Breast Cancer Patients Node Positive Surgery, Having Received Primary Medical Therapy With an Anthracycline Regimen",Oncology,Oncology: Breast,"Scottish Cancer Therapy Network, Anglo Celtic Cooperative Oncology Group","Cooperative Group, Cooperative Group","Disease-free survival, Overall survival, Quality of Life",,True,NCT00003680,57462
3126,135,"ISRCTN52623943, TrialTroveID-000135",High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for High-Risk Breast Cancer,Oncology,Oncology: Breast,Amgen,"Industry, Top 20 Pharma","Disease-free survival, Overall survival",,False,,57462
3127,166428,"01248, 2014-0946, 6986, HS410-101, J1474, NCT02010203, TrialTroveID-166428, TX138321, US-1256","A Phase I/II Placebo-Controlled, Randomized Study to Evaluate the Safety, Immune Response and Clinical Activity of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer Who Have Undergone Transurethral Resection of Bladder Tumor (TURBT)",Oncology,Oncology: Bladder,Heat Biologics,"Industry, all other pharma","Disease-free survival, Recurrence, Safety and Tolerability, Safety and Tolerability","Disease-free survival, Immune Response, Overall survival, Recurrence, Safety and Tolerability",True,NCT02010203,76450
3128,388188,"C-550-02, NCT04607200, TrialTroveID-388188","A Phase II Study Examining AGEN2034 as a Single-Agent and in Combination With AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma",Oncology,Oncology: Soft Tissue Sarcoma,Agenus {Antigenics},"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate",,True,NCT04607200,71141
3129,376893,"CTMS 19-0193, HSC20200027H, NCI-2020-05751, NCT04430036, TrialTroveID-376893",A Phase II Trial of Neoadjuvant AGEN1884 Plus AGEN2034 in Combination With Cisplatin-Gemcitabine for Muscle-Invasive Bladder Cancer Prior to Radical Cystectomy,Oncology,Oncology: Bladder,University of Texas Health Science Center at San Antonio,Academic,Complete response,"Safety and Tolerability, Safety and Tolerability",True,NCT04430036,71141
3130,353807,"19-0554, 19-0554.cc, NCI-2020-00728,, NCT04028063, TrialTroveID-353807","An Open-Label, Phase II Efficacy Trial of Doxorubicin in Combination With Dual Checkpoint Blockade Using AGEN1884 and AGEN2034 for Advanced or Metastatic Soft Tissue Sarcomas",Oncology,Oncology: (N/A); Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Agenus {Antigenics}, University of Colorado","Government, Industry, all other pharma, Academic","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival",True,NCT04028063,71141
3131,346346,"C-750-01/GOG-3028, NCI-2019-04431, NCT03894215, RaPiDS, S18-01528, TrialTroveID-346346","A Two-arm, Randomized, Non-comparative, Phase II Trial of AGEN2034 (Anti-PD-1) as a Monotherapy or Combination Therapy With AGEN1884 (Anti-CTLA4) or With Placebo in Women With Recurrent Cervical Cancer (Second Line) - RaPiDS",Oncology,Oncology: Cervical,"Gynecologic Oncology Group (GOG), Agenus {Antigenics}","Cooperative Group, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Brief Pain Inventory, Clinical benefit rate, Concentration at steady state, Disease Progression - duration, Duration of overall response, Elimination half-life, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Tmax, Volume of distribution",True,NCT03894215,71141
3132,309144,"ACTRN12617001061325, C-500-03, NCT03411473, TrialTroveID-309144","A Phase IIa Open-Label Trial of AGEN1884 in Combination With Pembrolizumab in Subjects With Chemotherapy NaÃ¯ve, PD-L1 High, Metastatic Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",Agenus {Antigenics},"Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Elimination half-life, Elimination rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Tmax, Treatment Emergent Adverse Events",True,NCT03411473,71141
3133,297818,"20181020, ACTRN12618000003279, C-550-01, EudraCT Number: 2018-000120-33, NCI-2019-02121, NCT03495882, TrialTroveID-297818","A Phase I/II Safety, Tolerability, Pharmacokinetics, Biological, and Clinical Activity of AGEN1884 in Combination With AGEN2034 in Subjects With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical)",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Esophageal; Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Soft Tissue Sarcoma","(Other Industry Sponsor), Agenus {Antigenics}","Industry, all other pharma, Industry, all other pharma","Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Area under the curve score, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression - duration, Disease Progression, Duration of overall response, Elimination half-life, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response, Tmax, Treatment Emergent Adverse Events, Volume of distribution",True,NCT03495882,71141
3134,274016,"20160238, Agenus C-500-01, C-500-01, DRUG C-500-01, NCI-2016-00339, NCT02694822, OSU-15281, TrialTroveID-274016","Phase I/II, Open-Label, Multicenter Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of an Anti-CTLA-4 Human Monoclonal Antibody (AGEN1884) in Subjects With Advanced or Refractory Cancer and in Subjects Who Have Progressed During Treatment With a PD 1/PD-L1 Inhibitor as Their Most Recent Therapy",Oncology,"Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Liver; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","Agenus {Antigenics}, Recepta Biopharma","Industry, all other pharma, Industry, all other pharma","Adverse Events, Area under the curve score, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Concentration at steady state, Creatinine kinase level, Diastolic blood pressure, Dose-limiting toxicities, Elimination half-life, Elimination rate, Platelet count, Safety and Tolerability, Safety and Tolerability, Tmax, Urine protein level, Volume of distribution","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival",True,NCT02694822,71141
3135,400356,"HIFUREGONIVO2101, NCT04819516, TrialTroveID-400356","A Single-arm, Single-center Exploratory Study of the Safety and Effectiveness of High-intensity Focused Ultrasound Therapy Combined With REGOTORI for Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Clinical benefit rate, Numeric Rating Scale, Progression-free survival, Quality of Life",True,NCT04819516,126134
3136,400265,"ChiCTR2100044790, TrialTroveID-400265",A Phase II Clinical Study of the Efficacy and Safety of Donafenib Combined with Toripalimab in the Second-line Treatment of Patients with Extensive-stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3137,400038,"ChiCTR2100044622, TrialTroveID-400038","A Single-Arm, Single-Center, Phase II Exploratory Clinical Study of PD-1 Combined with Nedaplatin and Docetaxel for Preoperative Neoadjuvant Treatment of Head and Neck Squamous Cell Carcinoma",Oncology,Oncology: (N/A); Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease-free survival, Overall response rate, Resection rate, Safety and Tolerability",False,,126134
3138,400009,"ChiCTR2100044628, TrialTroveID-400009",Observation on the Efficacy and Safety of PD-1 Inhibitor Plus Chemotherapy Plus Thalidomide in the Treatment of Unresectable Local Advanced Gastric Cancer with Failure of First-Line Chemotherapy,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival",False,,126134
3139,399585,"002, HNSCC-002, NCT04807140, TrialTroveID-399585","An Open Label, Two Arm Phase II Study of Toripalimab Versus Toripalimab in Combination With Carboplatin and Nab-paclitaxel as a Novel Neoadjuvant Pre-Surgical Therapy for HNSCC",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response","Complete response, Disease-free survival, Overall survival, Recurrence, Response evaluation criteria in solid tumors",True,NCT04807140,126134
3140,399484,"ESCC003, NCT04804696, TrialTroveID-399484",Toripalimab With Paclitaxel and Cisplatin as Neoadjuvant Treatment for Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Complete response, Disease Progression, Disease-free survival, Overall response rate, Overall survival, Partial response, Recurrence, Resection rate, Response evaluation criteria in solid tumors, Response rate",True,NCT04804696,126134
3141,398467,"ChiCTR2100043981, TrialTroveID-398467",Toripalimab Combined with Concurrent Chemoradiotherapy in Stage IV Hypopharyngeal Carcinoma without Distant Metastasis,Oncology,Oncology: Head/Neck,"Chinese Academy of Medical Sciences, Suzhou Zhonghe Biopharmaceutical","Government, Industry, all other pharma",Safety and Tolerability,,False,,126134
3142,398214,"NCT04778956, SYSUCC-CMY-2020-2302, TrialTroveID-398214","Toripalimab Plus Surgery vs Surgery Alone for Resectable Recurrent Nasopharyngeal Carcinoma: a Prospective, Parallel, Multicenter, Phase III, Randomized Clinical Trial",Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Nanfang Hospital of Southern Medical University","Academic, Academic","Disease Progression, Disease-free survival","Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Metastasis-free survival, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate",True,NCT04778956,126134
3143,397868,"LungMate-008, NCT04772287, TrialTroveID-397868","Adjuvant Toripalimab Versus Placebo Combined With Chemotherapy for EGFR/ALK Mutation Negative Stage II-IIIB(N2) Non-small-cell Lung Cancer (LungMate-008): a Randomised, Double-blind, Controlled, Phase III Trial",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Disease-free survival","Adverse Events, EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Safety and Tolerability",True,NCT04772287,126134
3144,397735,"NCT04771715, S-K1517",An Observational Real-world Study of Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Chinese Patients With Advanced Colorectal Cancer,,NA: ClinicalTrials.gov,Peking Union Medical College Hospital,ClinicalTrials.gov,,Treatment Emergent Adverse Events,True,NCT04771715,126134
3145,397084,TrialTroveID-397084,A Clinical Study of Teriprizumab Injection in Patients with Squamous Cell Carcinoma of the Head and Neck,Oncology,Oncology: Head/Neck,"Shanghai Junshi Biosciences Co., Suzhou Zhonghe Biopharmaceutical","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3146,396493,"(NICE Trial), NCT04744649, NFEC-2021-016, NICE, TrialTroveID-396493","Efficacy and Safety of Neoadjuvant Immunotherapy and Chemotherapy for Locally Advanced Esophagogastric Junction and Gastric Cancer : a Open-label, Phase II Randomised Controlled Trial (NICE Trial)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Nanfang Hospital of Southern Medical University, Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Complete response,"Adverse Events, Complete response, Disease-free survival, Overall survival, Recurrence, Resection rate, Treatment Emergent Adverse Events",True,NCT04744649,126134
3147,395728,"ChiCTR2100042794, TrialTroveID-395728",A Prospective Phase II Clinical Study of Radiotherapy Combined with Toripalimab in the Treatment of Elderly Locally Advanced Nasopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,126134
3148,395714,"ChiCTR2100042602, TrialTroveID-395714","Toripalimab Combined with IMRT for Nasopharyngeal Carcinoma with Unsatisfactory Response or Detectable EBV DNA after Induction Chemotherapy: A Prospective, Single-arm, Phase II Clinical Trial",Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Progression-free survival,"Overall survival, Safety and Tolerability",False,,126134
3149,395681,"ALT-SCLC-02, NCT04731909, TrialTroveID-395681","Clinical Study of Toripalimab Combined With Anlotinib, Etoposide and Platinum in the Treatment of Extensive-stage Small Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04731909,126134
3150,395477,"COMSTRAIN-CESC, NCT04731038, TrialTroveID-395477","Combination of Paclitaxel, Cisplatin\Carboplatin With Toripalimab and Anlotinib for First Line Treatment of Advanced Cervical Cancer",Oncology,Oncology: Cervical,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival",True,NCT04731038,126134
3151,395434,"ChiCTR2100042530, TrialTroveID-395434",Safety and Efficacy of Toripalimab Combined with Preoperative Neoadjuvant Chemoradiation for Resectable and Potentially Resectable III-IVA Esophageal Squamous Cell Carcinoma: A Phase I/II Single-arm Exploratory Clinical Study,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall response rate, Resection rate, Response rate",,False,,126134
3152,395114,"JS001-ISS-CO200, NCT04725448, TrialTroveID-395114","A Single-arm Exploratory Clinical Study on the Efficacy and Safety of Toripalimab Combined With Bevacizumab, Nab-paclitaxel and Carboplatin for Untreated Metastatic Pulmonary Sarcomatoid Carcinoma",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Disease Progression,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT04725448,126134
3153,395015,TrialTroveID-395015,"A Phase 3 Combination Clinical Trial of Toripalimab in Combination with Axitinib versus Pembrolizumab As A First-line Treatment in Patients with Unresectable, Locally Advanced or Metastatic mucosal melanoma.",Oncology,Oncology: Melanoma,Shanghai Junshi Biosciences Co.,"Industry, all other pharma",Progression-free survival,"Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",False,,126134
3154,394912,"2020-SR-496, ATNPC, NCT04718701, TrialTroveID-394912","Anlotinib Plus Toripalimab and Nab-paclitaxel in Patients With Locally Advanced or Metastatic Pancreatic Cancer: an Open-label, Non-randomized, Phase II Study",Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Adverse Events, Clinical benefit rate, Complete response, EORTC Quality of Life Questionnaire, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Quality of Life, Response rate, Stable Disease",True,NCT04718701,126134
3155,394690,"LungMate-011(FK-NEO-TSCC-001), NCT04716751, TrialTroveID-394690",Clinical Study of Neoadjuvant Anti-PD-1 Drug Toripalimab Combined With Chemotherapy in the Treatment of Primary Tracheal Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Complete response, Safety and Tolerability","Clinical benefit rate, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall survival, Progression-free survival, Quality of Life",True,NCT04716751,126134
3156,394582,"FK-NEO-MPM-001, NCT04713761, TrialTroveID-394582",Clinical Study of Neoadjuvant Anti-PD-1 Drug Toripalimab Combined With Chemotherapy in the Treatment of Locally Advanced Epithelial or Mixed Tissue Malignant Pleural Mesothelioma,Oncology,Oncology: Mesothelioma,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Quality of Life, Safety and Tolerability","Clinical benefit rate, Disease Progression, Overall response rate - duration, Overall survival, Progression-free survival",True,NCT04713761,126134
3157,394334,"B2020-059-01, NCT04711434, TrialTroveID-394334","PD-1 Antibody for the Prevention of Adenomatous Polyps and Second Primary Tumors in Patients With Lynch Syndrome: An Open-label, Multicenter, Randomized Controlled Clinical Trial",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Treatment Emergent Adverse Events",True,NCT04711434,126134
3158,394222,"NCC2509, NCT04709380, TrialTroveID-394222",Phase III Randomized Clinical Trial of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis,Oncology,Oncology: Liver,Chinese Academy of Medical Sciences,Government,Time to progression,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT04709380,126134
3159,394086,"ChiCTR2100041953, TrialTroveID-394086",A Phase II Exploratory Clinical Study On The Efficacy And Safety Of TNF-alpha Combined With Treprizumab In Advanced Solid Tumor Who Have Failed Multi-Line Treatment,Oncology,Oncology: Breast; Oncology: Ovarian; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival",False,,126134
3160,393949,TrialTroveID-393949,A Phase I Clinical Study of Toripalimab Injection for the Treatment of Patients with Extensive stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine","Shanghai Junshi Biosciences Co., Suzhou Zhonghe Biopharmaceutical","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3161,392690,"NCT04680598, SH-2, TrialTroveID-392690",Comparison of Hepatitis B Virus Reactivation Between Patients With High HBV-DNA and Low HBV-DNA Loads Undergoing Programmed Cell Death Protein-1 Inhibitor and Concurrent Antiviral Prophylaxis: a Prospective Observational Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,Overall survival,True,NCT04680598,126134
3162,392495,TrialTroveID-392495,A Clinical Trial of Gumatinib tablets to be used in combination with Treprilimab for the Treatment of Recurrent and Metastatic Non-Small cell lung cancer,Oncology,"Oncology: Lung, Non-Small Cell",Shanghai HaiHe Biopharma Co. {ShangHai HaiHe Pharmaceutical Co.},"Industry, all other pharma",,,False,,126134
3163,391970,"ChestMate-001(FK-NEO-TET-001), NCT04667793",Clinical Study of Neoadjuvant PD-1 Antibody (Toripalimab) Plus Chemotherapy for Locally Advanced Thymic Epithelial Tumor,,NA: ClinicalTrials.gov,"Shanghai Pulmonary Hospital, Shanghai, China",ClinicalTrials.gov,"Adverse Events, Safety and Tolerability","Disease-free survival, Quality of Life",True,NCT04667793,126134
3164,391925,"NCT04669496, TrialTroveID-391925, ZS--ICC-NA","A Randomized Controlled, Multicenter, Open, Seamless Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Event-free survival, Recurrence","Adverse Events, CA-125 Response, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival",True,NCT04669496,126134
3165,391437,"ChiCTR2000040620, TrialTroveID-391437",Efficacy And Safety Of Regorafenib Combined With Triplicumab In The Treatment Of Hepatocellular Carcinoma With Extrahepatic Metastasis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall response rate - duration, Overall survival, Progression-free survival",False,,126134
3166,391018,"APHRODITE, NCT04653480, TrialTroveID-391018",Surufatinib and Toripalimab Combined With Chemotherapy for Second-line Treatment of Advanced RAS/BRAF Mutant and Microsatellite Stable Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response","Overall survival, Progression-free survival",True,NCT04653480,126134
3167,390904,"B2020-229-01, NCT04651127, TrialTroveID-390904","Toripalimab, a Anti-PD-1 Antibody, and Histone Deacetylase Inhibitor Chidamide in Patients With Persistent, Recurrent, or Metastatic Cervical Cancer, a Multicenter, Open-label, Single-arm, Phase Ib/II Trial",Oncology,Oncology: Cervical,(Other Hospital/Academic/Medical Center),Academic,"Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Neutropenia, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04651127,126134
3168,390293,"GLYY-EC-NAD-01, NCT04644250, TrialTroveID-390293",Phase II of Toripalimab Chemoradiotherapy in Neoadjuvant Treatment of Locally Advanced Esophageal Squamous Cell Carcinoma: A Single-center Open Label Single-arm Exploratory Clinical Research,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Overall response rate, Overall survival, Partial response, Resection rate, Treatment Emergent Adverse Events",True,NCT04644250,126134
3169,389926,TrialTroveID-389926,"A single-centre, prospective, open-label, single-arm trial of toripalimab with nab-paclitaxel and S-1 as a neoadjuvant therapy for esophageal squamous cell carcinoma (ESCC)",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Clinical benefit rate, Complete response, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3170,389349,"GYEYJR-2, NCT04627012, TrialTroveID-389349",The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT04627012,126134
3171,389335,"GYEYJR-3, NCT04627363, TrialTroveID-389335",HAIC Synchronously Combined With Bevacizumab and Toripalimab First-line for Advanced Hepatocellular Carcinama,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04627363,126134
3172,389039,"2020-JS001-HPSCC, NCT04624308, TrialTroveID-389039","Toripalimab Plus TPF Inductive Chemotherapy and Definitive Radiotherapy for Resectable Locally Advanced Hypopharyngeal Squamous Cell Carcinoma, Efficacy and Safety: a Phase II Prospective Cohort Study",Oncology,Oncology: Head/Neck,Shanghai Junshi Biosciences Co.,"Industry, all other pharma",Complete response,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival",True,NCT04624308,126134
3173,388563,"NCT04613804, SCOG001, TrialTroveID-388563",Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy :a Single-arm Phase II Trial,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors",True,NCT04613804,126134
3174,388063,"JS001-DN-028, NCT04606303, TrialTroveID-388063","A Single-center, Prospective, Single-arm PhaseII Trial of Neoadjuvant Toripalimab Plus Platinum-doublet Chemotherapy (Chemo) in Locally Advanced NSCLC.",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability","Disease-free survival, Myocardial infarction (safety), Myocardial infarction, Progression-free survival, Recurrence, Resection rate, Response evaluation criteria in solid tumors, Stroke",True,NCT04606303,126134
3175,388002,"ChiCTR2000039371, TrialTroveID-388002","Evaluating The Efficacy And Safety Of Toripalimab  Injection (JS001) Combined With Lenvatinib As First-Line Treatment In Patients With Advanced Hepatocellular Carcinoma.A Single-Arm, Open-Label Clinical Trial",Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Overall response rate,"Clinical benefit rate, Progression-free survival",False,,126134
3176,387951,"CTR20202085, JS001D-C-103, NCT04605185, TrialTroveID-387951",Dose Escalation Study Of Donafenib and Toripalimab Combined With TACE in Patients With Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,Suzhou Zelgen Biopharmaceuticals Co.,"Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT04605185,126134
3177,387858,"JS001-033-II-GC, NCT04603040, TrialTroveID-387858","A Single-arm, Multicenter, Phase II Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in the Treatment of Recurrent or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Who Have Failed at Least Two Prior Lines of Therapy and Are Positive Specific Markers",Oncology,Oncology: Esophageal; Oncology: Gastric,Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04603040,126134
3178,387556,"ChiCTR2000039175, TrialTroveID-387556",Clinical Study of Toripalimab with Anlotinib for Patients With Recurrent Glioblastoma,Oncology,"Oncology: CNS, Glioblastoma",(Other Hospital/Academic/Medical Center),Academic,Overall survival,"EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,126134
3179,387546,"ChiCTR2000039129, TrialTroveID-387546",Efficacy and Safety of the GEMOX Regimen in Combination with or Without Treprizumab for Conversion to Initially Unresectable Biliary Tract Cancer,Oncology,Oncology: Liver,"Fudan University - Shanghai, China",Academic,,"Clinical benefit rate, Overall survival, Safety and Tolerability",False,,126134
3180,387325,"NCT04589741, TrialTroveID-387325","An Open, Single Arm, Multicenter Phase II Study of Toripalimab Combined With CAV / IE Regimen in Patients With Advanced or Unresectable Bone and Soft Tissue Sarcomas Who Failed Standard Treatment",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response",,True,NCT04589741,126134
3181,386923,"CTR20201425, JS001-033-II-GC, TrialTroveID-386923","A Single-Arm, Multi-Center Phase II Clinical Study To Evaluate The Efficacy And Safety Of Teriprizumab In The Treatment Of Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",False,,126134
3182,385698,"CTR20201856, JS001-038-III-UBC, NCT04568304, TrialTroveID-385698","A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) in Combination With Standard Chemotherapy Versus Placebo in Combination With Standard Chemotherapy as the 1st-line Therapy for Treatment-naive Subjects With PD-L1-positive Locally Advanced or Metastatic Urothelial Carcinoma",Oncology,Oncology: Bladder; Oncology: Renal,Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Serious Adverse Events",True,NCT04568304,126134
3183,385469,"NCT04563975, TrialTroveID-385469, XHZL-0236-01","Toripalimab Combined With Docetaxel in the Treatment of Advanced Gastric Cancer : a Single-arm, Phase II Clinical Trial",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival",True,NCT04563975,126134
3184,384940,"NCT04557020, NPC2020-001, TrialTroveID-384940",Adding Neoadjuvant and Adjuvant PD-1 Inhibitor to Neoadjuvant Chemotherapy Plus Concurrent Chemoradiotherapy in the Treatment of High-risk Nasopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Metastasis-free survival, Overall response rate, Overall survival, Response evaluation criteria in solid tumors",True,NCT04557020,126134
3185,384878,"2020051314, NCT04553939, TrialTroveID-384878",Phase II Study of Neoadjuvant Toripalimab in Combination With Gemcitabine Therapy in Cisplatin Ineligible Stage II-IIIB Bladder Cancer,Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",,True,NCT04553939,126134
3186,383428,"B2020-154-01, NCT04534855, TrialTroveID-383428",A Phase II Single Arm Clinical Study of Treprilimab in the Treatment of Local Recurrent/Residual Nasopharyngeal Carcinoma After Re-irradiation,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT04534855,126134
3187,382961,"ChiCTR2000037024, TrialTroveID-382961","Neoadjuvant Therapy Of Toripalimab Plus Axitinib For Von Hipple-Lindau Disease Associated Clear Cell Renal Cell Carcinoma: A Single-Arm, Single-Center, Prospective Study",Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Overall response rate, Response evaluation criteria in solid tumors",False,,126134
3188,382933,"BEVTOR, BEVTOR202008, NCT04527068, TrialTroveID-382933","QL1101A, a Biosimilar of Bevacizumab,in Combination With JS001, a Anti-PD-1 Antibody in Patients With pMMR/MSS Refractory Metastatic Colorectal Cancer: a Single-arm,Open-Label, Prospective, Single-center Study",Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Qilu Pharmaceutical Co., Shanghai Junshi Biosciences Co.","Academic, Industry, generic, Industry, all other pharma","Disease Progression, Immune-related response evaluation criteria in solid tumors, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04527068,126134
3189,382837,"ChiCTR2000036630, TrialTroveID-382837","Adjuvant Capecitabine Combined with Toripalimab or Capecitabine only in R0 resected Intrahepatic Cholangiocarcinoma: An open Rrandomised, Controlled study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,,False,,126134
3190,382687,"2020HNRT03, IMPORT, NCT04523883, TrialTroveID-382687",Randomized Phase II Trial of Postoperative Radiotherapy With Concurrent JS001(PD-1 Antibody) vs. Postoperative Radiotherapy Alone in Intermediate/High-risk Head and Neck Cancer Patients With a Contraindication to Cisplatin,Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic","Disease Progression, Disease-free survival","Common Terminology Criteria for Adverse Events, Overall survival",True,NCT04523883,126134
3191,382657,"NCT04524884, Thca-NEO-ST, TrialTroveID-382657",The Efficacy and Safety of Anti-PD-1 Antibody Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: A Phase II Study,Oncology,Oncology: Thyroid,"Fudan University - Shanghai, China",Academic,Overall response rate,"Adverse Events, Clinical benefit rate, Overall response rate - time, Overall survival, Progression-free survival, Resection rate, Time to response",True,NCT04524884,126134
3192,382332,"FDRT-2020-236-2156, NCT04518280, TrialTroveID-382332",A Prospective Phase II Trial of Immunotherapy Combined With Short-course Radiotherapy in Locally Advanced Rectal Cancer,Oncology,Oncology: Colorectal,"Fudan University - Shanghai, China",Academic,Complete response,"Adverse Events, Appetite, Disease-free survival, Overall survival, Quality of Life",True,NCT04518280,126134
3193,382189,"NCT04517214, TRANSFORM, TrialTroveID-382189",Phase II Study of Comparing Toripalimab Combined With GP Regimen Chemotherapy Versus GP Regimen Chemotherapy for Primary Metastatic Nasopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,"Fudan University - Shanghai, China, Nanfang Hospital of Southern Medical University","Academic, Academic","Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT04517214,126134
3194,382164,"ChiCTR2000035782, TrialTroveID-382164","A Prospective, One-arm, Phase I Study of High-memory Phenotypic Tumor-infiltrating T Lymphocytes (Tils) Combined with Treprizumab in the Treatment of Advanced Melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Serious Adverse Events,"Clinical benefit rate, Overall response rate",False,,126134
3195,381916,"ChiCTR2000035573, TrialTroveID-381916",The Study Of Triprilimab Therapy With Cytokine Induced Killer Cells In Advanced Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",,False,,126134
3196,381503,"NCT04506281, TrialTroveID-381503, zs-ICC-neoadjuvant","A Randomized Controlled, Multicenter, Open-label, Phase II Clinical Study of PD1 Antibody (Toripalimab) Combined With GEMOX Chemotherapy and Lenvatinib Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Event-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival",True,NCT04506281,126134
3197,381404,"JS001D-C-102, NCT04503902, TrialTroveID-381404","A Multi-center, Open, Dose Exploration and Dose Expansion Phase I/II Clinical Study of Toripalimab(JS001) Combined With Donafenib in Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,Suzhou Zelgen Biopharmaceuticals Co.,"Industry, all other pharma","Disease Progression, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors","Disease Progression, Overall survival, Progression-free survival",True,NCT04503902,126134
3198,381102,"CTR20201226, JS001-027-III-HCC, NCT04523493, TrialTroveID-381102","A Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter Phase III Study to Compare Toripalimab Combined With Lenvatinib Versus Placebo Combined With Lenvatinib as the 1st-line Therapy for Advanced HCC",Oncology,Oncology: Liver,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate - duration, Overall response rate, Partial response, Plasma concentration, Serious Adverse Events, Stable Disease, Time to progression, Vital signs",True,NCT04523493,126134
3199,380183,"NCT04483219, TRAP, TrialTroveID-380183","A Single-arm, Multicenter Phase II Clinical Study to Evaluate the Efficacy and Safety of Tyrosine Kinase Inhibitor (TKI) in Combination With Anti-PD-1 Antibody in TKI-responded Microsatellite Stability/Proficient Mismatch Repair (MSS/pMMR) Metastatic Colorectal Adenocarcinoma.",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Stable Disease, Treatment Emergent Adverse Events",True,NCT04483219,126134
3200,379676,"B2020-103-01, NCT04475016, TrialTroveID-379676",A Single Center and Single Arm Study of TIP (Paclitaxel + Ifosfamide + Cisplatin) Combined With Nimotuzumab & Triprilimab as Neoadjuvant Treatment in Locally Advanced Penile Cancer,Oncology,Oncology: Penile,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Resection rate, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04475016,126134
3201,379565,"Illuminate trial, NCT04473716, TrialTroveID-379565",Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability","Overall survival, Recurrence",True,NCT04473716,126134
3202,379436,"MTAM, NCT04472806, TrialTroveID-379436, ZLuo","A Multicenter, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab (JS001) After Chemotherapy in Combination With Endostar in Patients With Unresectable Locally Advanced or Metastatic Mucosal Melanoma",Oncology,Oncology: Melanoma,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic","Disease Progression, Progression-free survival","Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors",True,NCT04472806,126134
3203,378912,"JS001-ISS-CO148, NCT04462965, TrialTroveID-378912","A Phase II, Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Combined With Temozolomide and Cisplatin in the Postoperative Adjuvant Treatment of Completely Resected Mucosal Melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Metastasis-free survival, Overall survival, Recurrence, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04462965,126134
3204,378755,"JS001-ISS -149/JS001-ISS -CO49, NCT04459663, TrialTroveID-378755","A Single-arm, Single-center, Phase II Clinical Study to Investigate the Efficacy and Safety of JS001 Combined With Axitinib in the Treatment of Advanced Non-small Cell Lung Cancer (NSCLC) With Negative Driving Gene After First-line Chemotherapy",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT04459663,126134
3205,378327,"NCT04453813, SYSUCC-MYC-2020-2101, TrialTroveID-378327",A Multicenter Randomized Clinical Phase III Trial of Toripalimab Plus Concurrent Chemo-radiotherapy vs Concurrent Chemo-radiotherapy Alone for Unresectable Locally Recurrent Nasopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Disease-free survival, EORTC Quality of Life Questionnaire, Metastasis-free survival, Overall survival, Radiation Therapy Oncology Group Scale",True,NCT04453813,126134
3206,377979,"JS001-ISS-CO185, NCT04446663, TrialTroveID-377979","Toripalimab Combined With Chemoradiotherapy in Locoregionally-advanced Nasopharyngeal Carcinoma: an Open-label, Parallel Controlled, Phase IIa Study",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events","Complete response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Recurrence, Response evaluation criteria in solid tumors",True,NCT04446663,126134
3207,377958,"FirstGuangxiMU1, NCT04447326, TrialTroveID-377958","Randomized Controlled, Multicenter Phase II Clinical Research of Toripalimab (PD-1 Inhibitor) and Endostar Combined With Radiotherapy and Chemotherapy in the Treatment of High-risk Locally Advanced Nasopharyngeal Carcinoma",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Metastasis-free survival, Overall response rate, Overall survival, Partial response, Serious Adverse Events",True,NCT04447326,126134
3208,377746,"GC-ATJogress, NCT04443036, TrialTroveID-377746","Albumin-bound Paclitaxel Combined With Toripalimab as First-line/Second-line Treatment of Local Advanced or Metastatic Gastric or Gastroesophageal Junction Carcinoma: A Prospective, Open-label, Single-arm Phase II Clinical Study",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Appetite, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Nausea, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease, Vomiting",True,NCT04443036,126134
3209,377518,"NCT04437212, Renji-KY2019-174, TrialTroveID-377518","A Phase II Prospective, Open-label Clinical Trial of Neoadjuvant Chemoradiotherapy Combined With Perioperative Toripalimab in Patients With Locally Advanced Esophageal Squamous Cell Cancer",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Common Terminology Criteria for Adverse Events, Disease Progression, Disease-free survival, Overall survival, Treatment Emergent Adverse Events",True,NCT04437212,126134
3210,376832,"NCC2244, NCT04425824, TrialTroveID-376832","Toripalimab Combine With Rituximab for Treatment of Relapsed Refractory CD20 Positive Diffuse Large B-cell Lymphoma: An Exploratory Small Sample, Phase II, Single-center Clinical Trail",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",Chinese Academy of Medical Sciences,Government,"Disease Progression, Overall response rate, Progression-free survival",Safety and Tolerability,True,NCT04425824,126134
3211,376718,"ChiCTR2000033712, TrialTroveID-376718","An Open-label, Multicenter, Single-arm Phase Ib/II Clinical Study to Evaluate the Safety and Efficacy of PD-1 Monoclonal Antibody in Combination with Interferon Alpha 1b in the Treatment of Stage IV Melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Dose-limiting toxicities, Immune-related response evaluation criteria in solid tumors, Maximum tolerated dose, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall survival, Response evaluation criteria in solid tumors",False,,126134
3212,376577,"NCT04421469, NPC005.1, TrialTroveID-376577","A Single-arm, Open Multicenter Phase II Clinical Study of Triprilimab (JS001) and Chemotherapy Combined With Local Treatment for Multiple Metastatic NPC",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Overall response rate",True,NCT04421469,126134
3213,376496,"ChiCTR2000033668, TrialTroveID-376496",TACE and Lenvatinib Plus Programmed Cell Death Protein-1 (PD-1) Inhibitor Versus TACE Plus Lenvtinib for Advanced Unresectable Hepatocellular Carcinoma: a Single-Centre Randomised Controlled Trial.,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Clinical benefit rate, Overall response rate, Progression-free survival",,False,,126134
3214,376317,"NCT04418154, SCHBCC-NO27, TrialTroveID-376317",Dose-dense Epirubicin Hydrochloride With Cyclophosphamide Followed by Nanoparticlealbumin-bound Paclitaxel With PD-1 Regimen in Neoadjuvant Therapy for Patients With Triple-negative Breast Cancer,Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,Complete response,"Complete response, Overall response rate, Partial response",True,NCT04418154,126134
3215,376305,"2019-FXY-243, NCT04418648, TrialTroveID-376305","A Phase II, Randomised Study of Toripalimab as Consolidation Therapy in Patients With Limited-Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiotherapy",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Ability to swallow, Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, Neuropathy, Overall response rate, Overall survival, Quality of Life, Treatment Emergent Adverse Events",True,NCT04418648,126134
3216,376202,"CISLD-9, NCT04413734, TrialTroveID-376202",Combination of Anti-PD-1 Antibody and Chemotherapy for Unresectable Intrahepatic Cholangiocarcinoma: A Exploratory Clinical Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04413734,126134
3217,376030,"2020FXY-007, ChiCTR2000033506, TrialTroveID-376030",A Phase II Trial of TP and Toripalimab Neoadjuvant Chemotherapy Followed by Toripalimab Concurrent Radiotherapy for Patients with Local Advanced Laryngeal/Hypopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Overall response rate,"Overall survival, Quality of Life",False,,126134
3218,375999,TrialTroveID-375999,A Clinical Study of Toripalimab in Combination with Cetuximab for Recurrent and/or Metastatic Squamous Cell Carcinomas of the Head and Neck (R/M SCCHN),Oncology,Oncology: Head/Neck,"Merck & Co., Shanghai Junshi Biosciences Co.","Industry, Top 20 Pharma, Industry, all other pharma",Safety and Tolerability,,False,,126134
3219,375867,"ChiCTR2000033460, TrialTroveID-375867",A Phase II Clinical study of Sequential Hypofractionated IMRT Combined with Toripalimab for Unresectable Stage III Non-Small-Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Overall survival,Progression-free survival,False,,126134
3220,375859,"ChiCTR2000033462, TrialTroveID-375859",Phase IIA Clinical study of Anlotinib Combined with Toripalimab Injection plus Neoadjuvant Radiotherapy and Chemotherapy for Resectable Squamous cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability","Disease-free survival, Overall survival",False,,126134
3221,375559,"NCT04405622, SYSUCC-CMY-2020-2104, TrialTroveID-375559",Toripalimab Combined With Gemcitabine in Recurrent or Metastatic Nasopharyngeal Carcinoma,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04405622,126134
3222,375195,TrialTroveID-375195,Combination therapy with lenvatinib and anti-PD-1 antibodies for unresectable or advanced hepatocellular carcinoma: A real-world study.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,126134
3223,375103,TrialTroveID-375103,Preoperative treatment for marginally resectable metastatic melanoma: A single center experience in China,Oncology,Oncology: Melanoma,(Other Academic Cancer Center),Academic,Disease-free survival,,False,,126134
3224,375102,"NCT04398056, SYSUCC2019, TrialTroveID-375102","Chemotherapy Plus Subsequent Loco-regional Radiotherapy Combined With Toripalimab for the de Novo Metastatic Nasopharyngeal Carcinoma: a Single Center, Phase II Clinical Trial",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT04398056,126134
3225,375062,"CTR20200876, JS001-036-III-RCC, NCT04394975, TrialTroveID-375062","A Phase III, Randomized, Open-label, Active Controlled, Multicenter Study on Toripalimab Combined With Axitinib Versus Sunitinib Monotheraphy as a First-Line Treatment for Unresectable or Metastatic Renal Cell Carcinoma (RCC)",Oncology,Oncology: Renal,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04394975,126134
3226,374640,"JS001-ISS-CO24, NCT04389151, TrialTroveID-374640",Triplezumab Combined With CAPEOX Regimen Was Used in a Phase II Clinical Study of Neoadjuvant Therapy for Locally Advanced Colon Cancer With MSI-H /dMMR,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate",,True,NCT04389151,126134
3227,374451,"NCT04385654, TORAXI, TrialTroveID-374451",Toripalimab Combined With Axitinib as Neoadjuvant Therapy for Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, EQ-5D-5L, EQ-5D, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Recurrence, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events, Visual Analog Scale for Pain, Visual Analog Scale",True,NCT04385654,126134
3228,373929,"ChiCTR2000032533, TrialTroveID-373929","SBRT And Anlotinib Hydrochloride Combined With Toripalimab For The First-Line Treatment Of Patients With Locally Advanced Or Metastatic Hepatic Carcinoma: A Prospective, Single Arm, Single Center, Exploratory Clinical Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Clinical benefit rate, Objective remission rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3229,373863,"CS2020(7), NCT04376866, TrialTroveID-373863","Toripalimab in Combination With Concurrent Chemoradiotherapy for Local-regional Recurrent Nasopharyngeal Carcinoma: A Phase III, Multicentre, Randomised Controlled Trial",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT04376866,126134
3230,373398,"ChiCTR2000032293, TrialTroveID-373398","An Open-label, Single-arm, Phase Ib/II Study of Combination of Toripalimab(PD-1 antibody), Nab-paclitaxel, and Gemcitabine as the First-line Treatment for Patients with Advanced Pancreatic Ductal Adenocarcinoma",Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Safety and Tolerability","Circulating Tumor Cells, Clinical benefit rate, Complete response, Overall response rate, Progression-free survival, Resection rate",False,,126134
3231,373396,"ChiCTR2000032252, TrialTroveID-373396","Efficacy and Safety of Triplezumab Combined with Platinum-based Dural Neoadjuvant Chemotherapy in Patients with Resectable Non-small Cell Lung Cancer: A Prospective, Single-arm, Multi-center Study",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall response rate, Overall survival, Resection rate, Response rate, Time to progression","Clinical benefit rate, Complete response, Overall response rate",False,,126134
3232,373348,"JS-2295, NCT04368078, TrialTroveID-373348","Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma: a Single-center, Single-arm, Non-randomized Clinical Study",Oncology,Oncology: Liver,"Peking Union Medical College Hospital, CAMS, Beijing, China, Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Mortality, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04368078,126134
3233,373346,"M2019482, NCT04368273, TrialTroveID-373346",Phase I Study of Toripalimab Injection (Pd-1 Antibody) With Cisplatin Concurrent IMRT for Local Advanced Cervical Cancer.,Oncology,Oncology: Cervical,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability","Overall response rate, Progression-free survival",True,NCT04368273,126134
3234,373248,"B2020-040-01, NCT04365036, TrialTroveID-373248","A Multicenter, Phase III, Randomized Trial of Sequencial Chemoradiotherapy With or Without Toripalimab (PD-1 Antibody) in Newly Diagnosed Early-Stage Extranodal Natural Killer/T Cell Lymphoma, Nasal Type (ENKTL)",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival",True,NCT04365036,126134
3235,373114,"LDQ-202004, NCT04363255, TrialTroveID-373114","Efficacy and Safety of First-line Etoposide/Platinum-based Chemotherapy Followed by Toripalimab Combined With Anlotinib for Maintenance in Extensive Small Cell Lung Cancer: A Single-arm, Multicentre Phase II Study",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall survival, Progression-free survival","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04363255,126134
3236,372872,"NCT04361331, TrialTroveID-372872, zs-ICC-2020","A Randomized, Open, Two-cohort Phase II Study of Toripalimab(PD1) Combined With Lenvatnib, or Gemox Chemotherapy Combined With Lenvatinib as First-line Therapy in Patients With Advanced or Unresectable Intrahepatic Cholangiocarcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT04361331,126134
3237,372560,"Gastrim 001, NCT04354662, TrialTroveID-372560","Phase II Study of Toripalimab Combined With Fluorouracil, Leucovorin, Oxaliplatin and Docetaxel (FLOT) in Patients With Locally Advanced, Resectable Gastric Cancer or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall survival","Adverse Events, Complete response, Overall survival, Recurrence",True,NCT04354662,126134
3238,372142,"CTR20200192, JS001-035-III-HCC, NCT04723004, TrialTroveID-372142","A Randomized, Open-label, Multi-center Phase III Clinical Study to Evaluate the Safety and Efficacy of Toripalimab (JS001) Combined With Bevacizumab Versus Sorafenib as First-line Therapy for Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Safety and Tolerability, Stable Disease, Time to progression, Vital signs",True,NCT04723004,126134
3239,371519,"ChiCTR2000031730, TrialTroveID-371519","Open-label, Single-center Phase II Clinical Trial of Low-dose Decitabine Combined with Treprizumab for the Treatment of Recurrent Refractory Follicular Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall response rate - duration, Progression-free survival",False,,126134
3240,371366,"ChiCTR2000031692, TrialTroveID-371366",A Prospective Phase II Clinical Study of TACE Combined with treprizumab and Metronochemotherapy in the Treatment of Advanced Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,126134
3241,371342,"NCT04338282, TRhos-ENKTCL-5, TrialTroveID-371342","Maintenance Therapy With Anti-PD-1 Antibody for Patients With NK/T-cell Lymphoma: a Single Arm, Single Center, Open Label, Phase II Trial",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall survival, Progression-free survival",Overall survival,True,NCT04338282,126134
3242,370264,"CROC2002, NCT04316351, TrialTroveID-370264","Efficacy and Safety of Toripalimab (JS001) Combined With Pemetrexed and Anlotinib for Patients With T790M Positive Non-Small Cell Lung Cancer After Osimertinib Resistance: a Phase II, Muti-center, Single Arm Study",Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Overall response rate - duration, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT04316351,126134
3243,370175,"AVATAR 2, NCT04314297, TrialTroveID-370175",Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,,Overall survival,True,NCT04314297,126134
3244,369881,"ChiCTR2000030877, TrialTroveID-369881",Efficacy and Safety of Toripalimab Combined with First-Line Chemotherapy in Advanced Gastric or Gastroesophageal Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Safety and Tolerability","Overall survival, Progression-free survival",False,,126134
3245,369864,"CTR20200190, CTR20201822, JS001-034-II-HCC, NCT04605796, TrialTroveID-369864","A Single-arm, Open-label, Multi-center Phase II Clinical Study to Evaluate the Safety and Efficacy of Toripalimab Injection (JS001) Combined With Bevacizumab as the First-line Therapy for Advanced Hepatocellular Carcinoma (HCC)",Oncology,Oncology: Liver,Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.,"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Cmax, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Time to progression, Vital signs",True,NCT04605796,126134
3246,369564,"NCT04304248, NeoTPD01, SYSUCC B2019-116-01, TrialTroveID-369564",A Phase II Study of Neoadjuvant Toripalimab Plus Platinum-based Doublet for Potentially Resectable Stage III Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Disease-free survival, Recurrence, Resection rate",True,NCT04304248,126134
3247,369478,"B2019-177-01, NCT04301557, TrialTroveID-369478",PD1 Antibody Toripalimab and Chemoradiotherapy for dMMR/MSI-H Locally Advanced Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Recurrence, Resection rate",True,NCT04301557,126134
3248,369205,"JS001-ISS-CO159, NCT04296747, TrialTroveID-369205",A Single-arm Study Evaluating Efficacy and Safety of Toripalimab Combined With Docetaxel and Cisplatin as Induced Chemotherapy in the Treatment of Localized Hypopharyngeal Squamous Cell Carcinoma,Oncology,Oncology: Head/Neck,"Peking Union Medical College Hospital, CAMS, Beijing, China",Academic,"Overall response rate, Partial response","Complete response, Disease-free survival, Overall survival, Progression-free survival, Quality of Life",True,NCT04296747,126134
3249,369044,"ChiCTR2000030352, TrialTroveID-369044",Multi-Center Exploratory Study of Raltitrexed for Injection Combined with Toripalimab and Anlotinib in Second-Line and Above Treatment of Advanced Esophageal and Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3250,368420,"IOT-ARID1A, NCT04284202, TrialTroveID-368420",PD-1 Combined With Dasatinib for as Third-line Treatment for ARID1A Mutation Advanced NSCLC,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,Overall survival,True,NCT04284202,126134
3251,368239,"NCT04280341, RC48-C013, TrialTroveID-368239","A Phase I, Open-label, Dose Escalation Clinical Trial to Assess the Safety, Efficacy, Tolerability and Pharmacokinetics of the Recombinant Humanized Anti-PD1 Monoclonal Antiody (JS001) in Combination With Recombinant Humanized Anti-HER2 Monoclonal Antibody-MMAE Conjugate (RC48-ADC) in Treatment of HER2-Positive Advanced Malignant Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), RemeGen","Academic, Industry, all other pharma","Complete response, Overall response rate - duration, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Anti-drug antibodies, Area under the curve score, Cmax, Complete response, Overall survival, Partial response, Plasma concentration, Progression-free survival, Safety and Tolerability, Stable Disease, Tmax",True,NCT04280341,126134
3252,368229,"HCHTOG1909, NCT04280822, TrialTroveID-368229","A Phase III, Randomized Controlled Study of Neo-adjuvant Toripalimab (JS001) in Combination With Chemotherapy Versus Neo-adjuvant Chemotherapy for Resectable Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Event-free survival, Recurrence","Complete response, Disease-free survival, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Resection rate, Response evaluation criteria in solid tumors",True,NCT04280822,126134
3253,368125,"APICAL-GE, NCT04278222, TrialTroveID-368125","Anlotinib Plus Toripalimab as First-line Treatment for Patients With Advanced Gastric or Gastro-esophageal Junction Cancer (APICAL-GE): a Single Center, Single-arm Phase II Study",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease, Treatment Emergent Adverse Events",True,NCT04278222,126134
3254,367446,"ChiCTR2000029713, TrialTroveID-367446",Albumin Paclitaxel Plus Platinum And Toripalimab As First-Line Treatment For Recurrent/Metastatic Head And Neck Squamous Cell Carcinaoma: Phase II Clinical Trial,Oncology,Oncology: Head/Neck,"Chinese Academy of Medical Sciences, (Other Hospital/Academic/Medical Center)","Government, Academic",Overall response rate,"Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3255,367409,"NCT04264936, RC48-C014, TrialTroveID-367409","A Open-label, Single-arm, Phase Ib/II Study of RC48-ADC and JS001 to Evaluate the Safety and Pharmacokinetics of Subjects With Locally Advanced or Metastatic Urothelial Cancer",Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Anti-drug antibodies, Area under the curve score, Cmax, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors",True,NCT04264936,126134
3256,366759,"ChiCTR2000029500, TrialTroveID-366759","An Open Label, Single-arm Study for Effect of Neoadjuvant Toripalimab (JS001) Before Cystectomy in the treatment of Patients With Muscle-invasive Urothelial Bladder Cancer.",Oncology,Oncology: Bladder,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co./TopAlliance Biosciences","Academic, Industry, all other pharma",Adverse Events,"Overall survival, Progression-free survival",False,,126134
3257,366657,"NCT04250948, Neoadjuvant PD-1/LAGC, TrialTroveID-366657","Perioperative Chemotherapy Plus PD-1 Antibody Compared With Perioperative Chemotherapy in the Locally Advanced Gastric Cancer: a Open-label, Phase II Randomised Controlled Trial",Oncology,Oncology: Gastric; Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",,"Clinical benefit rate, Complete response, Disease-free survival, Overall response rate, Overall survival, Recurrence, Resection rate",True,NCT04250948,126134
3258,366587,"FU-Name-T001, NCT04248387, TrialTroveID-366587",A Clinical Study on the Efficacy and Safety of Toripalimab in the Neoadjuvant Treatment of BRAF V600 Wild Type Resectable Stage III / IV Malignant Melanoma,Oncology,Oncology: Melanoma,"Fudan University - Shanghai, China",Academic,Complete response,"Event-free survival, Overall response rate, Overall survival",True,NCT04248387,126134
3259,365878,"NCT04238169, TrialTroveID-365878, XQonc-014",Clinical Trial Assessing the Efficacy of Abscopal Effect Induced by SBRT and Immunotherapy in Advanced NSCLC,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall survival, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT04238169,126134
3260,365743,"JS001-PMS-CO1, NCT04234620, TrialTroveID-365743","A Prospective, Single-arm, Multicenter, Non-interventional Real-world Study of Toripalimab Injection in the Treatment of Malignant Tumors in Chinese Population.",Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Melanoma",Shanghai Junshi Biosciences Co.,"Industry, all other pharma",Adverse Events,"Adverse Events, Overall survival, Serious Adverse Events",True,NCT04234620,126134
3261,365634,"ChiCTR2000029277, TrialTroveID-365634",Neoadjuvant Toripalimab in Combination With Stereotactic Ablative Body Radiotherapy in Resectable Non-Small-Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability",Disease-free survival,False,,126134
3262,365467,"ChiCTR2000029068, TrialTroveID-365467","A Multicenter, Single-Arm Phase II Study On The Efficacy And Safety Of Toripalimab Combined With Chemoradiotherapy For Recurrent Or Metastatic Cervical Cancer",Oncology,Oncology: Cervical,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Overall survival, Safety and Tolerability",False,,126134
3263,365425,"ChiCTR2000029057, TrialTroveID-365425",A Phase II Clinical Study of Axitinib Combined with Toripalimab and Stereotactic Radiotherapy for Locally Advanced Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Quality of Life",False,,126134
3264,365304,TrialTroveID-365304,A Clinical Study of Toripalimab with STP705 in Patients with Advanced Melanoma and Squamous cell Carcinoma,Oncology,"Oncology: Melanoma; Oncology: Skin, Squamous Cell Carcinoma (cSCC)","Shanghai Junshi Biosciences Co., Sirnaomics","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3265,365266,"ChiCTR2000028979, TrialTroveID-365266","A Prospective, Single-Arm Phase II Clinical Trial of Toripalimab Combined With Chemotherapy for Neoadjuvant Treatment Followed by Toripalimab Alone for Adjuvant Treatment in Patients With Muscle-Invasive Urothelial Bladder Cancer",Oncology,Oncology: Bladder,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co./TopAlliance Biosciences","Academic, Industry, all other pharma",Complete response,"Complete response, Disease-free survival, Overall survival, Treatment Emergent Adverse Events",False,,126134
3266,365225,"ChiCTR2000028965, TrialTroveID-365225","A Prospective, Single-arm Phase II Clinical Study of Toripalimab Combined with Fruquintinib in The Treatment of pMMR /MSS Relapsed and Refractory Advanced Colorectal Cancer",Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,126134
3267,365003,"FIBTC, NCT04217954, TrialTroveID-365003","Hepatic Arterial Infusion Chemotherapy with Oxaliplatin, 5-fluorouracil and Bevacizumab Plus Intravenous Toripalimab for Advanced Biliary Tract Cancer",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall response rate, Progression-free survival","Adverse Events, Apparent diffusion coefficient, Magnetic Resonance Imaging, Overall survival",True,NCT04217954,126134
3268,364924,"CT32, CTR20192525, JS001-032-Ib/II-NSCLC, NCT04797702, TrialTroveID-364924","A Open-label, Multi-center Phase Ib/II Clinical Study of Glumetinib Combined With Toripalimab in Patients With Relapsed or Metastatic Non-small Cell Lung Cancer Who Have Failed or Are Intolerant to Standard Therapy.",Oncology,"Oncology: Lung, Non-Small Cell","Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Heart rate corrected QT interval, Heart rate, High-density lipoprotein, International normalized ratio, Low-density lipoprotein, Overall response rate, Partial thromboplastin time, Prothrombin ratio, Response evaluation criteria in solid tumors, Serious Adverse Events, Thrombin time, Vital signs","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Heart rate corrected QT interval, Heart rate, High-density lipoprotein, Immune-related response evaluation criteria in solid tumors, International normalized ratio, Low-density lipoprotein, Overall response rate - duration, Overall response rate, Overall survival, Partial thromboplastin time, Progression-free survival, Prothrombin ratio, Response evaluation criteria in solid tumors, Serious Adverse Events, Thrombin time, Vital signs",True,NCT04797702,126134
3269,364447,"ATG-008-HX-001, NCT04337463, TORCH-2, TrialTroveID-364447","An Open, Dose-escalation and Expansion Study With a Dual TORC1/2 Inhibitor of ATG-008 Combined With PD-1 Antibody of Toripalimab in Advanced Solid Tumors and Hepatocellular Carcinoma",Oncology,Oncology: Liver; Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co., Antengene Corporation Limited/Antengene Corporation Co.","Academic, Industry, all other pharma, Industry, all other pharma","Maximum tolerated dose, Overall response rate","Area under the curve score, Cmax, Plasma concentration",True,NCT04337463,126134
3270,364406,"BJCH-UC-1015, NCT04211012, TrialTroveID-364406",A Phase II Study to Evaluate the Efficacy and Safety of Toripalimab Plus Nab-Paclitaxel With or Without Cisplatin as First-line Treatment of Unresectable Locally Advanced or Metastatic Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to response",True,NCT04211012,126134
3271,364404,"JS-2171, NCT04211168, TrialTroveID-364404","Toripalimab Plus Lenvatinib as Second-line Treatment in Advanced Biliary Tract Cancers: a Single-arm, Non-randomized, Single-center Clinical Trial and Biomarker Study",Oncology,Oncology: Liver,"Peking Union Medical College Hospital, CAMS, Beijing, China, Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Adverse Events, Complete response, Overall response rate, Partial response","Clinical benefit rate, Complete response, Disease Progression, Mortality, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT04211168,126134
3272,364264,"ALTER-H003, ALTER-H-003, ChiCTR1900028295, TrialTroveID-364264","A Single-arm, Multicenter Clinical Study on the Treatment of Unresectable Hepatocellular Carcinoma With Anlotinib Hydrochloride Capsules Combined With Toripalimab Injection",Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Chia Tai Tianqing Pharmaceutical Group Co.","Academic, Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3273,364021,"ChiCTR1900028117, ChiCTR1900028413, TrialTroveID-364021",One-arm observation single-center open-label clinical study of PD-1 antibody for neoadjuvant treatment of resectable lung squamous cell carcinoma (stage IB-IIIA),Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Complete response, Disease-free survival, Overall response rate, Safety and Tolerability",False,,126134
3274,364008,"ChiCTR1900028112, TrialTroveID-364008",A Phase II Study for Exploring the Efficacy and Safety of Toripalimab with Anlotinib for Second- or third-line Treatment of EGFR-TKI-resistant Patients with Advanced Non-squamous Non-small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Chinese Academy of Medical Sciences,Government,Overall response rate,"Clinical benefit rate, Quality of Life, Safety and Tolerability",False,,126134
3275,363708,TrialTroveID-363708,Efficacy of Anti-pd1 Immunotherapy Plus Anlotinib on Metastatic Melanoma: Real-world Data from Chinese Population.,Oncology,Oncology: Melanoma,"Fudan University - Shanghai, China",Academic,"Clinical benefit rate, Progression-free survival",,False,,126134
3276,363613,"NCT04202484, TrialTroveID-363613, ZLK-XXY-1","A Prospective, Single-arm, Exploratory Clinical Research on the Efficacy and Safety of Tripletrumab Combined With Oxaliplatin and Teggio (SOX) in First-line Treatment of Unresectable Locally Advanced or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,True,NCT04202484,126134
3277,363423,"NCT04197882, OrienX010-II-12, TrialTroveID-363423","An Open-Label, Phase Ib Clinical Study to Evaluate OrienX010 in Combination With Toripalimab as Neoadjuvant Treatment in the Patients With Complete Resectable Stage III and Stage IV (M1a) Melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Safety and Tolerability, Serious Adverse Events",True,NCT04197882,126134
3278,363122,"E2019090A, NCT04193098, TrialTroveID-363122",Phase I Clinical Study of Autologous Cytotoxic T Lymphocyte (CTL) Cell Immunotherapy Combination With PD-1 Inhibitor in the Second-line Treatment of IIIB/IIIC/IV Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Partial response",,True,NCT04193098,126134
3279,363076,"ChiCTR1900027807, TrialTroveID-363076",Radiofrequency Ablation (RFA) Combined with Trepril Monoclonal Antibody (PD-1) in the Treatment of Recurrent HCC,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Circulating Tumor Cells, Overall survival",False,,126134
3280,363021,"NCT04190745, TrialTroveID-363021",Toripalimab Combined With Apatinib Mesylate for the Treatment of Gastric Adenocarcinoma in a Prospective Randomized Multicenter Phase II Clinical Study,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,True,NCT04190745,126134
3281,363010,"NCT04191343, TrialTroveID-363010","A Single-arm, Single-center, Prospective Clinical Study on the First-line Treatment of Advanced Biliary System Tumors With Tripley Monoclonal Antibody Combined With GEMOX Regimen",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,True,NCT04191343,126134
3282,362400,"JS001-ISS-132, NCT04180995, TrialTroveID-362400","A Monocentric, Single-arm, Open, Phase II Clinical Study on the Efficacy and Safety of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Localized Mucosal Melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Complete response, Disease-free survival, Overall survival, Serious Adverse Events",True,NCT04180995,126134
3283,362096,"1001, NCT04177797, TrialTroveID-362096",A Single Arm Trial of Toripalimab With Neoadjuvant Carboplatin and Paclitaxel for Locally Advanced Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Treatment Emergent Adverse Events",True,NCT04177797,126134
3284,362092,"[2019](S910), NCT04177875, T+TP, TrialTroveID-362092","A Phase II, Prospective, Open-label Clinical Trial of Pre-Operative PD-1 Antibody (Toripalimab) + Chemoradiotherapy in Patients With Locally Advanced Esophageal Cancer",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability",True,NCT04177875,126134
3285,361802,"NCT04172805, TrialTroveID-361802","A Single-arm, Open, Phase II Study of Anlotinib Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04172805,126134
3286,361718,"HCC-S068, NCT04170179, TrialTroveID-361718","Systemic Chemotherapy of Oxaliplatin, Leucovorin, 5-fluorouracil Plus Lenvatinib and Toripalimab for Hepatocellular Carcinoma with Extrahepatic Metastasis: a Prospective, Single-arm Trial.",Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT04170179,126134
3287,361577,"HCC-S1001, NCT04169399, TrialTroveID-361577","Toripalimab Plus Stereotactic Body Radiotherapy for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: a Single-arm, Prospective Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Immune-related response evaluation criteria in solid tumors, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response",True,NCT04169399,126134
3288,361383,"NCT04164238, TrialTroveID-361383, ZJU20191451",Phase II Trial of Neoadjuvant Anti-PD-1 Antibody (Toripalimab) or Combined with Chemotherapy in Head and Neck Squamous Cell Carcinoma Patients.,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Disease-free survival, Overall response rate, Progression-free survival",True,NCT04164238,126134
3289,361355,"NCT04165174, TJCC 010, TJCC010, TJCC-010, TrialTroveID-361355","A Single Arm, Observational Clinical Trial to Evaluate the Efficacy and Safety of Combination Treatment With PD-1 Monoclonal Antibody Plus Apatinib and SBRT in HCC With PVTT",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Safety and Tolerability",True,NCT04165174,126134
3290,360878,"CTR20192179, CTR20202441, JS001-029-III-NSCLC, NCT04158440, TrialTroveID-360878","A Randomized,Double-blinded, Multi-center Phase III Study of Toripalimab or Placebo Plus Chemotherapy as Treatment in Early Stage Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.,"Industry, all other pharma","Complete response, Disease Progression, Event-free survival, Recurrence, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Serious Adverse Events",True,NCT04158440,126134
3291,360741,"ChiCTR1900027236, TrialTroveID-360741","A Single-Arm Prospective Clinical Study for the Efficacy and Safety of Toripalimab in Combination with Oxaliplatin and Tegafur (SOX) for the Treatment of Unresectable Locally Advanced, Recurrent or Metastatic Gastric and Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival",False,,126134
3292,360202,"NCT04144608, TOGATHER, TrialTroveID-360202",A Phase II Study on Toripalimab Combined With Double Platinum Based Chemotherapy for as a Neoadjuvant Therapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Resection rate,Overall response rate,True,NCT04144608,126134
3293,359756,"NCT04135690, S0905, TrialTroveID-359756","Hepatic Arterial Infusion Chemotherapy Plus Toripalimab Versus Hepatic Arterial Infusion Chemotherapy Plus Sorafenib for Hepatocellular Carcinoma With Portal Vein Tumor Thrombus: A Non-comparative, Prospective, Randomized Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04135690,126134
3294,359297,"2019HNRT02, NCT04126460, RePASS, TrialTroveID-359297",High-risk Recurrent or Second Primary HNSCC With PD-1 Antibody Adjuvant After Salvage Surgery: The RePASS Study,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Disease-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Metastasis-free survival, Overall survival, Recurrence, Treatment Emergent Adverse Events",True,NCT04126460,126134
3295,358961,"2019-012-00CH1, CTR20191865, NCT04169672, TrialTroveID-358961","A Phase II, Open-label, Single-arm, Multi-center Study of the Efficacy and Safety of Surufatinib Combined With Toripalimab in Patients With Advanced Solid Tumors",Oncology,"Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",Hutchison MediPharma,"Industry, all other pharma","Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT04169672,126134
3296,358951,"ChiCTR1900026158, TrialTroveID-358951","Safety and Efficacy of Lenvaltinib Combined with Terepril Monoclonal Antibody, a PD1 Inhibitor, in the Treatment of Unresectable Intrahepatic Cholangiocarcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Duration of overall response",False,,126134
3297,358847,"ChiCTR1900026420, TrialTroveID-358847, ZLJS2019","A Prospective, Open-labelled, Phase II Clinical Trial of Neoadjuvant JS001 for Resectable Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Complete response, Overall response rate, Response rate","Adverse Events, Event-free survival, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",False,,126134
3298,358695,"AJERTNN, NCT04116918, TrialTroveID-358695",Efficacy and Safety of the Combination of Anlotinib and JS001 in EGFR-TKI Resistant T790M-Negative NSCLC,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Overall survival, Treatment Emergent Adverse Events",True,NCT04116918,126134
3299,358664,"NCT04118855, Neo-RCC, TrialTroveID-358664",Phase II Study of Toripalimab Combined With Axitinib as Neoadjuvant Therapy in Patients With Non-metastatic Locally Advanced Nonmetastatic Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Quality of Life, Safety and Tolerability",True,NCT04118855,126134
3300,358649,"JS001-ISS-CO63, NCT04119622, TrialTroveID-358649",A Phase II Study of XELOX and Toripalimab in the Neoadjuvant Treatment of Stage II/III Gastric or GE Junction Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,Chinese Academy of Medical Sciences,Government,"Complete response, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Recurrence, Resection rate, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT04119622,126134
3301,358448,"ChiCTR1900026299, TrialTroveID-358448",A Prospective Multicenter Clinical Study for Toripalimab Combined with SOX Regimen in Perioperative Treatment of Ebv (+) or Msi-h Locally Advanced Gastric Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate, Safety and Tolerability","Disease-free survival, Quality of Life",False,,126134
3302,357795,"NCC2121, NCT04099589, TrialTroveID-357795",Multicenter Phase II Study Of Gemcitabine/Cisplatin (GC) Chemotherapy Combined With PD-1 Inhibitor (Toripalimab) In The Neoadjuvant Treatment Of Upper Urinary And Muscular Invasive Bladder Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,"Chinese Academy of Medical Sciences, (Other Hospital/Academic/Medical Center)","Government, Academic",Complete response,,True,NCT04099589,126134
3303,356912,"IESO001, NCT04084158, TrialTroveID-356912","A Phase II, Randomized, Open Label, Multi-center Design Study of Toripalimab Given Before and After Concurrent Chemoradiotherapy in Patients With Locally Advanced Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma",Progression-free survival,"Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors",True,NCT04084158,126134
3304,356830,"ChiCTR1900025796, TrialTroveID-356830",Chemotherapy plus Toripalimab Augmented by Hypofractionated Radiotherapy as First Line Treatment for Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC),Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Adverse Events, Objective remission rate, Overall response rate, Progression-free survival",Overall survival,False,,126134
3305,356759,TrialTroveID-356759,A Phase I Study Of Glumetinib In Combination With Toripalimab For the Treatment Of Multiple Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Shanghai HaiHe Biopharma Co. {ShangHai HaiHe Pharmaceutical Co.}, Shanghai Junshi Biosciences Co.","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3306,356278,"NCT04073784, SYSUCC-BYK-GAT2019, TrialTroveID-356278","An Open-Label, Single Center, Nonrandomized, Phase 1 Study to Evaluate Safety and Efficacy of Gemcitabine Combined With Apatinib and Toripalimab in Recurrent or Metastatic Nasopharyngeal Carcinoma",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Cardiac Telemetry, Safety and Tolerability","Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04073784,126134
3307,356190,"LQ108, NCT04069949, STUHCCPVTT, TrialTroveID-356190",An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04069949,126134
3308,356110,"NCT04072900, TrialTroveID-356110, XYM001",A Phase I Study With a Personalized NeoAntigen Cancer Vaccine Combined With Anti-PD-1 in Metastatic Melanoma,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Complete response, Partial response",Immune Response,True,NCT04072900,126134
3309,356036,"AL3810-101, CTR20191618, TrialTroveID-356036","Lucitanib Combined With Toribipimab for the Treatment of Advanced Relapse or Metastatic Solid Tumors, Ib/II Clinical Trial",Oncology,Oncology: Unspecified Solid Tumor,"Shanghai Institute of Materia Medica, Chinese Academy of Sciences",Academic,"Dose-limiting toxicities, Safety and Tolerability","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival",False,,126134
3310,355646,"2019YJZ38, NCT04061928, TrialTroveID-355646",The Combination of Toripalimab With Preoperative Chemoradiotherapy for Locally Advanced Adenocarcinoma of Esophagogastric Junction,Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Disease-free survival",True,NCT04061928,126134
3311,355365,"NCT04058470, TREND, TrialTroveID-355365","Phase Ib/II Study of Toripalimab In Combination With R-CHOP Regimen (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone) for Elderly Naive Patients With Diffuse Large B-cell Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Safety and Tolerability","Adverse Events, Overall survival, Progression-free survival",True,NCT04058470,126134
3312,354741,"ECCT, ECCT001, NCT04046185, TrialTroveID-354741",PD-1 Inhibitor Combined With Progesterone Treatment in Early Stage Endometrial Cancer Patients Who Want to Preserve Fertility,Genitourinary; Oncology,Genitourinary: Infertility; Oncology: Endometrial,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Partial response",Pregnancy,True,NCT04046185,126134
3313,354662,"HCC-S0903, NCT04044313, TrialTroveID-354662","Hepatic Arterial Infusion Chemotherapy Plus Lenvatinib and Toripalimab for Advanced Hepatocellular Carcinoma:  A Prospective, Single-arm Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04044313,126134
3314,353751,"NCT04027764, TrialTroveID-353751, TSA-01","Toripalimab Combined With S1 and Albumin Paclitaxel as First Line in Patients With Advanced Biliary Tract Cancer: a Single-arm,One Center, Phase II Clinical Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT04027764,126134
3315,353668,"NCT04025931, SunYat-senU-chidamide, TrialTroveID-353668","A Single-arm, Open, Phase II Study of Chidamide Combined With Toripalimab in Refractory and Advanced Soft-tissue Sarcoma",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04025931,126134
3316,353372,"ChiCTR1900024480, TrialTroveID-353372","A Randomized, Controlled, Multicenter Study Comparing Endonasal Surgery, Endonasal Surgery Combined With Toripalimab Injection (JS001) And Radiation Therapy (IMRT) for Early Primary Nasopharyngeal Cancer",Oncology,Oncology: Head/Neck,"Fudan University - Shanghai, China",Academic,"Disease-free survival, Overall survival",Adverse Events,False,,126134
3317,352968,"CTR20191139, JS001-028-III-SCLC, NCT04012606, TrialTroveID-352968","A Phase III Randomized, Double-Blind, Placebo-controlled Study of Platinum(Cisplatin or Carboplatin) Plus Etoposide With or Without Toripalimab as First Line Therapy in Patients With ExtensiveStage Small Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.,"Industry, all other pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events, Time to response",True,NCT04012606,126134
3318,352884,"JS-1964, NCT04010071, TrialTroveID-352884","Axitinib Plus Toripalimab as Second-line Treatment in Hepatobiliary Malignant Tumors: a Single-arm, Non-randomized, Single-center Phase II Trial",Oncology,Oncology: Liver,"Peking Union Medical College Hospital, CAMS, Beijing, China, Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT04010071,126134
3319,352583,"NCT04005170, TORIDEFEC, TrialTroveID-352583",A Phase II Trial of Combination of Toripalimab and Definitive Chemoradiotherapy in Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,,"Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04005170,126134
3320,352558,"NCT04006041, TORINEOEC, TrialTroveID-352558",A Phase II Trial of Combination of Toripalimab and Neoadjuvant Chemoradiotherapy in Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Common Terminology Criteria for Adverse Events, Disease Progression, Disease-free survival, Mortality, Overall survival, Resection rate, Treatment Emergent Adverse Events",True,NCT04006041,126134
3321,352098,"ChiCTR1900024014, TrialTroveID-352098",Clinical study of neoadjuvant toripalimab or toripalimab plus chemotherapy as anti PD-1 treatment for resectable II-IIIA non-small cell lung cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Safety and Tolerability","Overall survival, Progression-free survival, Quality of Life, Recurrence, Resection rate",False,,126134
3322,351882,"LP-201, NCT03992911, TrialTroveID-351882",Phase II/III Trial of Simmitecan and 5-FU/LV Regimen (FOLFSIM) Plus Toripalimab Versus EP/EC in Advanced or Metastatic Neuroendocrine Carcinoma,Oncology,Oncology: Neuroendocrine,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03992911,126134
3323,351525,"HenanCH immunotherapy001, NCT03985670, TrialTroveID-351525",Neoadjuvant Teripalimab Plus Chemotherapy in Local Advanced Esophageal Squamous Cancer,Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Disease-free survival, Overall survival, Progression-free survival",True,NCT03985670,126134
3324,351520,"JSFOL, JSFOL--CC., NCT03985891, TrialTroveID-351520","A Randomized, Prospective Clinical Trial of Safety and Efficacy of JS001 Combined With Chemotherapy in Patients With Locally Advanced Colon Cancer (Perioperative Treatment)",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate","Disease-free survival, Overall survival",True,NCT03985891,126134
3325,351273,"NCT03982680, TrialTroveID-351273",Clinical Study of Toripalimab Monoclonal Antibody Combined With Gemcitabine/5--fluoropyrimidine in the Treatment of Advanced Cholangiocarcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Progression-free survival","Clinical benefit rate, Complete response, Overall response rate, Overall survival",True,NCT03982680,126134
3326,351241,"ChiCTR1900023710, TrialTroveID-351241","Toripalimab Combined With Capecitabine For Locally Persistent Nasopharyngeal Carcinoma After Radical Chemoradiotherapy: A Prospective, Single-Arm, Phase II Trial",Oncology,Oncology: Head/Neck,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Overall response rate, Response rate","Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",False,,126134
3327,350856,"NCC1835, NCT03971214, PICARES, PICCARE, TrialTroveID-350856",Pilot Study on PD-1 Inhibitors Consolidation After Standard First-line Chemotherapy and Radiotherapy in Extensive-stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Chinese Academy of Medical Sciences,Government,"Adverse Events, Complete response, Objective remission rate, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Circulating Tumor Cells, Clinical benefit rate, Complete response, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease, Time to response, Tumor control rate",True,NCT03971214,126134
3328,350544,"JS001LT, NCT03966209, TrialTroveID-350544",Evaluation of PD-1 Inhibition in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantations,Autoimmune/Inflammation; Oncology,Autoimmune/Inflammation: Transplantation/GVHD; Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Allograft rejection, Serious Adverse Events","Overall response rate, Overall survival, Patient survival, Progression-free survival",True,NCT03966209,126134
3329,349675,"Artery Toripalimab for HNC, NCT03952065, TrialTroveID-349675",A Phase III Randomized Trial of Comparison of Survival Benefit of Administration of PD1/PDL1 Inhibitor Via Neck Artery Versus Vein Infusion for Immunotherapy of HNC,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Disease Progression, Progression-free survival",True,NCT03952065,126134
3330,349616,"NCT03951597, TrialTroveID-349616, zs-ICC-2019","A Single-arm Study of Combined Therapy Using Oxaliplatin and Gemcitabine Chemotherapy, Lenvatinib and Programmed Cell Death Protein 1 Antibody (JS001) for Patients With Advanced and Unresectable Intrahepatic Cholangiocarcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT03951597,126134
3331,349487,"Artery Toripalimab for HCC, NCT03949231, TrialTroveID-349487",A Phase III Randomized Trial of Comparison of Survival Benefit of Administration of Toripalimab Via Hepatic Arterial Infusion Versus Vein for Immunotherapy of Advanced Liver Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Disease Progression, Progression-free survival",True,NCT03949231,126134
3332,349407,"JS001/Regorafenib in mCRC, NCT03946917, TrialTroveID-349407","A Multi-center, Open-label, Phase I/II Clinical Trial of Tolerability, Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection (JS001) Combined With Regorafenib in Patients With Advanced Colorectal Cancer",Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT03946917,126134
3333,349406,"FHJLU-003, NCT03946943, TrialTroveID-349406","A Single-Arm, Single-Center Prospective Study of Anlotinib Hydrochloride and Toripalimab in Subjects With Unresectable or Metastatic Undifferentiated Pleomorphic Sarcoma Patients",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT03946943,126134
3334,348989,"B2018-151-01, NCT03939975, TrialTroveID-348989",A Prospective Study of Anti-PD-1 Inhibitors Therapy in Combination With Incomplete Thermal Ablation in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Partial response, Safety and Tolerability, Stable Disease","Disease Progression, Overall survival, Progression-free survival",True,NCT03939975,126134
3335,348476,"High-risk rNPC-JS001, NCT03930498, TrialTroveID-348476","PD-1 Antibody Combined With Chemotherapy in High-risk Recurrent Nasopharyngeal Carcinoma: a Prospective, Open, Single-arm Phase II Clinical Trial",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, EQ-5D-5L, Overall survival, Progression-free survival, Quality of Life",True,NCT03930498,126134
3336,348446,"ChiCTR1900022834, TrialTroveID-348446","A Single Centre, Single Arm and Phase II trial for Treprizumab with Whole Brain Radiotherapy for Patients with Lung Cancer and Untreated Brain Metastases",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer",(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Progression-free survival","Adverse Events, Overall response rate, Overall survival, Quality of Life, Response rate, Tumor control rate",False,,126134
3337,348220,"18-223/1781, NCT03927898, TrialTroveID-348220",Phase II Study of Toripalimab (JS001) Plus Stereotactic Body Radiotherapy in Colorectal Cancer Patients With Oligometastasis,Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,"Chinese Academy of Medical Sciences, Shanghai Junshi Biosciences Co.","Government, Industry, all other pharma",Progression-free survival,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival",True,NCT03927898,126134
3338,348081,"GIHSYSU-14, NCT03926338, TrialTroveID-348081",A Pilot Study of Toripalimab With or Without Celecoxib as Neoadjuvant Therapy in Resectable Non-metastatic Colorectal Cancer Patients With Mismatch Repair-deficient or Microsatellite Instability-high,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Treatment Emergent Adverse Events","Complete response, Disease-free survival, Overall response rate, Overall survival, Resection rate, Response rate",True,NCT03926338,126134
3339,348013,"CTR20190768, JS001-CT25-III-NSCLC, NCT03924050, TrialTroveID-348013","A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of Pemetrexed + Platinum Chemotherapy With or Without Toripalimab (JS001) in Advanced Non-small Cell Lung Cancer (NSCLC) Participants With TKI-resistant EGFR-mutated Tumors",Oncology,"Oncology: Lung, Non-Small Cell","Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events, Time to response",True,NCT03924050,126134
3340,347990,"B2019-014-01, NCT03925090, TrialTroveID-347990","Randomized, Placebo-controlled, Double-blind Phase II Clinical Trial of Neoadjuvant and Adjuvant Anti-PD-1 Antibody Toripalimab Immunotherapy Combined With Concurrent Chemoradiotherapy for High-risk Nasopharyngeal Carcinoma",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Metastasis-free survival, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",True,NCT03925090,126134
3341,347758,"hcc-S052b, NCT03919383, TrialTroveID-347758",Phase II of Lenvatinib Plus Toripalimab Advanced Hepatocellular Carcinoma: a Single-arm Prospective Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03919383,126134
3342,347445,"ChiCTR1900022491, K19406-JS001-ISS-141, NCT04118933, TrialTroveID-347445",An Exploratory Study for PD-1 Antibody JS001 in Participants With Microsatellite Instability-high (MSI-H) Advanced or Recurrent Colorectal Cancer,Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co., Shanghai Tongshu Biotech Co.","Academic, Industry, all other pharma, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall survival, Progression-free survival",True,NCT04118933,126134
3343,347187,"NCT03907826, rNPC-JS001, TrialTroveID-347187","PD-1 Antibody Combined With IMRT vs. IMRT in Recurrent Nasopharyngeal Carcinoma Patients: a Multi-center, Randomized Controlled, Phase III Clinical Trial",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Common Terminology Criteria for Adverse Events, Disease Progression, EQ-5D-5L, Overall response rate, Progression-free survival, Quality of Life",True,NCT03907826,126134
3344,347139,TrialTroveID-347139,A Phase I Study of APG-1387 and Toripalimab in Patients with Solid and Hematological Tumors.,Oncology,Oncology: Unspecified Hematological Cancer; Oncology: Unspecified Solid Tumor,"Ascentage Pharma Group, Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3345,346993,"CM082-CA-II-203, NCT03904719, TrialTroveID-346993",Combination of CM082 With JS001 in Patients With Advanced Small-cell Lung Cancer (SCLC) Who Progressed on First-line Treatment: a Phase II Study,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",AnewPharma,"Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT03904719,126134
3346,346934,"ChiCTR1900022282, TrialTroveID-346934","A Open, Single-center, Phase Ib Clinical Trial for Assessing Radiotherapy and Toripalimab for Neoadjuvant Treatment of Resectable Esophageal Squamous Cell Cancer",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Complete response, Disease-free survival",False,,126134
3347,345454,"CGOG-3006/2018-012-00CH2, NCT03879057, TrialTroveID-345454","Phase I Trial Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of Surufatinib Combined With JS001 in Patients With Advanced Solid Tumors",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Maximum tolerated dose, Safety and Tolerability","Cmax, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors, Time to treatment failure",True,NCT03879057,126134
3348,344867,"CTR20190396, JS001-020-Ib-HCC, NCT03867370, TrialTroveID-344867","A Phase Ib/II, Open-Label, Multi-Center Study Evaluating the Efficacy and Safety of Neoadjuvant Toripalimab Injection (JS001) or Toripalimab in Combination With Lenvatinib for Patients With Resectable Hepatocellular Carcinoma (HCC)",Oncology,Oncology: Liver,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT03867370,126134
3349,344701,"NCT03864211, RI11330, TrialTroveID-344701",Phase I/II Study of Thermal Ablation Followed by Toripalimab in Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Immune Response, Overall response rate, Progression-free survival, Safety and Tolerability","Adverse Events, Clinical benefit rate, Complete response, Leukocyte count, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03864211,126134
3350,344268,"CHOICE-01, CTR20190147, JS001-019-III-NSCLC, NCT03856411, TrialTroveID-344268","A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Study to Evaluate the Efficacy and Safety of Toripalimab Injection (JS001) or Placebo Combined With First-line Standard Chemotherapy in Treatment-naive Advanced Non-small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Serious Adverse Events, Time to response",True,NCT03856411,126134
3351,344166,"2019-FXY-020, NCT03854838, TrialTroveID-344166","A Single Center, Single Arm Phase I/II Clinical Trial of Intensity-modulated Radiotherapy Combined With Toripalimab in the Treating of Unresectable  Locally Recurrent Nasopharyngeal Carcinoma.",Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Overall survival, Progression-free survival, Serious Adverse Events, Treatment Emergent Adverse Events",True,NCT03854838,126134
3352,344031,"B2018-158-01, NCT03851939, TrialTroveID-344031","The Efficacy of Transarterial Chemoinfusion (TAI) Combine Toripalimab in Advanced Hepatocellular Carcinoma (HCC): A Prospective, Single-armed, Stage II Clinical Trial.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Progression-free survival","Clinical benefit rate, Overall survival",True,NCT03851939,126134
3353,343926,"CM082-CA-IV-401, NCT03848611, TrialTroveID-343926",Combination of CM082 With JS001 in Patients With Advanced Non-Small Cell Lung Cancer (SCLC) Who Progressed on First-line Treatment: a Phase II Study,Oncology,"Oncology: Lung, Non-Small Cell",AnewPharma,"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Time to response",True,NCT03848611,126134
3354,341799,"CTR20182326, JS001-016-III-HCC, JUPITER 04, NCT03859128, TrialTroveID-341799","A Phase II/III, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Toripalimab (Recombinant Humanized Anti-PD-1 Monoclonal Antibody, JS001) / Placebo as Adjuvant Therapy in Patients With Local Advanced Hepatocellular Carcinoma After Curative Hepatic Resection",Oncology,Oncology: Liver,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Recurrence, Response evaluation criteria in solid tumors","Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to response, Vital signs",True,NCT03859128,126134
3355,341328,"NCT03811379, PD-1/SCCE, TrialTroveID-341328","Phase II Clinical Trial of Toripalimab (JS001), a Recombinant Humanized Anti-PD-1 Monoclonal PD1 Antibody, as Monotherapy for Patients With Small Cell Esophageal Carcinoma Who Failed Chemotherapy",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Treatment Emergent Adverse Events",True,NCT03811379,126134
3356,341128,"NCT03810339, PPM, TrialTroveID-341128","A Phase II Open Label Study of Toripalimab, a PD-1 Antibody, in Participants With POLE or POLD-1 Mutated and Non-MSI-H Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Treatment Emergent Adverse Events",True,NCT03810339,126134
3357,340371,"JS001-ZS-BC001, NCT03796429, TrialTroveID-340371","A Single-arm, Single-center, Prospective Clinical Study of the Efficacy and Safety of Chemotherapy Combined With Toripalimab in the Treatment of Advanced Biliary Tract Cancer",Oncology,Oncology: Liver,"(Other Industry Sponsor), (Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Industry, all other pharma, Academic, Industry, all other pharma","Overall survival, Progression-free survival","Adverse Events, Complete response, Overall response rate, Partial response, Safety and Tolerability, Vomiting",True,NCT03796429,126134
3358,340035,TrialTroveID-340035,A Phase Ib Study of Surufatinib In Combination with Toripalimab In Patients with Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Hutchison MediPharma, Shanghai Junshi Biosciences Co.","Industry, all other pharma, Industry, all other pharma",,,False,,126134
3359,339028,"CTR20182403, CTR20191428, JS001-026-III-TNBC, NABP201801, NCT03777579, NCT04085276, TORCHLIGHT, TrialTroveID-339028","A Phase III, Multicenter, Randomized, Placebo-Controlled Study of JS001 (Anti-PD-1 Antibody) in Combination With Nab-Paclitaxel Compared With Placebo With Nab-Paclitaxel as First-line Therapy for Patients With Primarily Diagnose or Recurrent and Metastatic Triple-Negative Breast Cancer",Oncology,Oncology: Breast,"CSPC Pharmaceutical Group Co./CSPC ZhongQi Pharmaceutical Technology Co., Shanghai Junshi Biosciences Co./TopAlliance Biosciences","Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03777579,126134
3360,338994,"CTR20182314, JS001-021-III-ESCC, Jupiter06, NCT03829969, TrialTroveID-338994","A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center Study to Compare Toripalimab Injection (JS001) Combined With Standard Chemotherapy Versus Placebo Combined With Standard Chemotherapy in Treatment of Advanced or Metastatic Esophageal Squamous Cell Cancer (ESCC) Without Previous Systemic Chemotherapy",Oncology,Oncology: Esophageal,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Time to response",True,NCT03829969,126134
3361,330106,"GASTO1038, NAJSCR, NCT03623776, TrialTroveID-330106","A Multicenter Phase II Trial of Neoadjuvant JS001, or JS001 in Combination With Chemotherapy in Resectable NSCLC",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Treatment Emergent Adverse Events",True,NCT03623776,126134
3362,329058,"CM082-CA-II-202, NCT03602547, TrialTroveID-329058",Phase II Clinical Study of CM082 Combined With JS001 in the Treatment of Advanced Mucosal Melanoma,Oncology,Oncology: Melanoma,AnewPharma,"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Time to response",True,NCT03602547,126134
3363,325834,"CTR20180789, JS001-015-III-NPC, JUPITER-02, NCT03581786, TrialTroveID-325834","A Phase III, Randomized, Placebo Controlled, Muticenter, Double Blind Study Comparing Toripalimab Injection (JS001) Combined With Chemotherapy Versus Placebo Combined With Chemotherapy for Recurrent or Metastatic Nasopharyngeal Cancer",Oncology,Oncology: Head/Neck,Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.,"Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT03581786,126134
3364,320900,"2017-0214, J1928, NCI-2018-00597, NCT03474640, TAB001-01, TrialTroveID-320900","A Phase 1, Multicenter, Open-label Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of TAB001 in Subjects With Advanced Malignancies",Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./TopAlliance Biosciences","Industry, all other pharma, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03474640,126134
3365,320529,"CTR20180275, JS001- PII-LC-001, JS001-PII-LC-001, NCT03513666, TrialTroveID-320529","Toripalimab Combined With Pemetrexed Plus Carboplatin for Treatment of Recurrent or Advanced Non-small-cell Lung Cancer With EGFR-mutation Positive and T790M Negative After Progression on EGFR-TKI Treatment:a Multi-center, Single Arm Phase II Study",Oncology,"Oncology: Lung, Non-Small Cell","Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Objective remission rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to response",True,NCT03513666,126134
3366,317910,"CTR20180025, HMO-JS001-III-MM-01, Junshi-013, NCT03430297, TrialTroveID-317910","A Randomized, Controlled, Multi-center, Phase ? Clinical Study to Investigate Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection Toripalimab (JS001) Versus Dacarbazine as the First Line Therapy for Unresectable or Metastatic Melanoma",Oncology,Oncology: Melanoma,Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.,"Industry, all other pharma",Progression-free survival,"Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03430297,126134
3367,310409,"CTR20171117, HMO-JS001-I-PK-01, Junshi-JS001-012, NCT03301688, TrialTroveID-310409",A Similar Phase I Study on the Pharmacokinetics and Safety of Single-dose and Parallel Comparisons in Patients With Advanced NSCLC Treated With Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) Before and After Process Change,Oncology,"Oncology: Lung, Non-Small Cell",Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Area under the curve score, Safety and Tolerability","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to response, Tmax, Vital signs, Volume of distribution",True,NCT03301688,126134
3368,308617,"CTR20170779, HMO-JS001-II-MM-02, TrialTroveID-308617","A Phase II Randomized, Controlled, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb In Combination with Interferon as Adjuvant therapy For Melanoma.",Oncology,Oncology: Melanoma,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma",Disease-free survival,"Disease-free survival, Overall survival, Safety and Tolerability, Safety and Tolerability",False,,126134
3369,305452,"CTR20170747, JS001-I, Junshi-JS001-011, NCT03316144, TrialTroveID-305452","A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Recurrent Malignant Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Lipid Profile, Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Area under the curve score, Cmax, Overall response rate, Response evaluation criteria in solid tumors, Tmax",True,NCT03316144,126134
3370,302956,"Junshi-JS001-010, NCT03178123, TrialTroveID-302956","A Phase II Randomized, Control, Multi-center Study of Recombinant Humanized Anti-PD-1 mAb for Injection Compared to High-Dose Interferon In Patients With Mucosal Melanoma That Has Been Removed by Surgery",Oncology,Oncology: Melanoma,Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Disease-free survival, Overall survival","Common Terminology Criteria for Adverse Events, Metastasis-free survival, Overall survival, Recurrence, Treatment Emergent Adverse Events",True,NCT03178123,126134
3371,302564,"HMO-JS001-Ib-NEC-02, NCT03167853, TrialTroveID-302564",Phase Ib Study of Safety and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Patients With Advanced Neuroendocrine Tumors Following Failure of First-Line,Oncology,Oncology: Neuroendocrine,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Duration of overall response, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03167853,126134
3372,300249,"CTR20170347, CXSL1400138, HMO-JS001-II-CRP-02, TrialTroveID-300249","A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of JS001 in Patients with Urothelial Carcinoma after Standard Treatment Failure",Oncology,Oncology: Bladder; Oncology: Renal,"Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co., Shanghai Junshi Biosciences Co./TopAlliance Biosciences","Industry, all other pharma, Industry, all other pharma",Safety and Tolerability,"Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",False,,126134
3373,299311,"Junshi-JS001-009, NCT03113266, POLARIS03, POLARIS-03, TrialTroveID-299311","A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Bladder Urothelial Carcinoma.",Oncology,Oncology: Bladder,Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT03113266,126134
3374,298018,"CTR20170109, HMO-JS001-Ib-CRP-01, Junshi-JS001-008, NCT03086174, TrialTroveID-298018","A Phase Ib, Open, Mono-center, Dose-escalation, Tolerability and Pharmacokinetic Study of Recombinant Humanized Anti-PD-1 mAb for Injection in Combination With Axitinib in Patients With Advanced Kidney Cancer and Melanoma",Oncology,Oncology: Melanoma; Oncology: Renal; Oncology: Vaginal,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Common Terminology Criteria for Adverse Events, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to response, Tmax, Volume of distribution",True,NCT03086174,126134
3375,293779,"CTR20160900, HMO-JS001-II-CRP-01, Junshi-JS001-BJZL-II, NCT03013101, TrialTroveID-293779","A Phase II, Open, Multi-center and Single Arm Study Investigating Safety and Efficacy of Recombinant Humanized Anti-PD-1 mAb for Injection in Patients With Locally Advanced or Metastatic Melanoma and Standard Treatment Failure",Oncology,Oncology: Melanoma,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03013101,126134
3376,293475,"CTR20160813, Fudan-P1-201701, HMO-JS001-I-CRP-1.5, NCT03251313, TrialTroveID-293475",Recombinant Humanized PD-1 Monoclonal Antibody (JS001) Combined With Gemcitabine and Cisplatin (GP) as First Line Treatment for Triple Negative Breast Cancer patients-a Phase I Clinical Trial,Oncology,Oncology: Breast,"Fudan University - Shanghai, China, Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Academic, Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Maximum tolerated dose, Safety and Tolerability, Vital signs","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Disease Progression, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to response, Tmax, Treatment Emergent Adverse Events",True,NCT03251313,126134
3377,293289,"CTR20160976, HMO-JS001-I-CRP-1.4, TrialTroveID-293289",Radiotherapy Combined with Recombinant Humanized Anti-PD-1 Monoclonal Antibody Injection (JS001) in the Treatment of Advanced Triple-negative Breast Cancer: Prospective Phase I Clinical Study,Oncology,Oncology: Breast,"Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Vital signs","Clinical benefit rate, Cmax, Complete response, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response, Tmax",False,,126134
3378,287420,"CTR20160740, JS001-Ib-CRP-1.0, NCT02915432, POLARIS-02, TrialTroveID-287420","A Multi-Center, Open Label Phase Ib/II Clinical Study to Evaluate JS001 in Patients With Advanced Gastric Adenocarcinoma, Esophageal Squamous Cell Carcinoma, Nasopharyngeal Carcinoma and Head and Neck Squamous Cell Carcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck,Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Safety and Tolerability, Tmax, Volume of distribution",True,NCT02915432,126134
3379,282827,"CTR20160412, HMO-JS001-I-CRP-03, Junshi-JS001-307-I, NCT02838823, TrialTroveID-282827","A Phase I,Open,Mono-center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Anti-PD-1 Monoclonal Antibody in Patients With Triple-negative Breast Cancer",Oncology,Oncology: Breast,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response, Tmax, Volume of distribution",True,NCT02838823,126134
3380,279504,"CTR20160274, JS001-I-CRP-1.3, Junshi-JS001-YKZL-I, NCT02836834, TrialTroveID-279504","A Phase I Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Soft Tissue Sarcoma",Shanghai Junshi Biosciences Co.,"Industry, all other pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Immune-related response evaluation criteria in solid tumors, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02836834,126134
3381,278534,"CTR20160187, HMO-JS001-I-CRP-01, Junshi-JS001-BJZL-I, NCT02836795, TrialTroveID-278534","A Phase I, Open Label, Single Center and Dose Escalation Study Investigating Tolerance and Pharmacokinetics of Single and Multiple Doses of Recombinant Humanized Anti-PD-1 Monoclonal Antibody for Injection in Patients With Advanced Solid Tumors",Oncology,Oncology: Bladder; Oncology: Melanoma; Oncology: Renal,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Treatment Emergent Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response, Tmax, Volume of distribution",True,NCT02836795,126134
3382,278402,"CTR20160176, JS001-I-CRP-1.0, JS001-I-CRP-1.4, Junshi-JS001-ZSZL-I, NCT02857166, TrialTroveID-278402","Phase IA Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Recombinant Humanized Anti-PD-1 Monoclonal Antibody (JS001) in Patients With Advanced Solid Tumors",Oncology,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Melanoma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,"Shanghai Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Taizhou Junshi Biosciences Co., Shanghai Junshi Biosciences Co./Suzhou Junmeng Biosciences Co.","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Anti-drug antibodies, Area under the curve score, Cmax, Cmin, Dose-limiting toxicities, Duration of overall response, Elimination half-life, Occupancy, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Tmax, Volume of distribution",True,NCT02857166,126134
3383,147396,"GO27817, MFG4991g, NCT01363024, REFMAL 250 IST, TrialTroveID-147396","An Open-Label, Multicenter, Phase I Dose-Escalation Trial Evaluating the Safety and Pharmacokinetics of MFGR1877S in Patients With Advanced Solid Tumors",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Cervical; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Prostate,Roche/Genentech,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities","Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT01363024,68731
3384,127164,"2422, 2422.00, GO01331, MFG4809g, NCT01122875, TrialTroveID-127164, UMCC 2010.057","An Open-Label, Multicenter, Phase I Trial of the Safety and Pharmacokinetics of Escalating Doses of MFGR1877S in Patients With Relapsed or Refractory t(4;14)-Positive Multiple Myeloma",Oncology,Oncology: Multiple Myeloma,Roche/Genentech,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Adverse Events, Duration of overall response, Overall response rate, Progression-free survival, Safety and Tolerability, Volume of distribution",True,NCT01122875,68731
3385,359145,TrialTroveID-359145,A Phase I Study of Varlitinib (VAR; ASLAN001) An Oral Pan-HER Tyrosine Kinase Inhibitor (TKI) Combined with mFOLFIRI Chemotherapy in Advanced Solid Tumours,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas,"(Other Hospital/Academic/Medical Center), National Medical Research Council of Singapore, Aslan Pharmaceuticals","Academic, Government, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability",,False,,30661
3386,347447,"4-2018-1011, KCT0003583, KM-13, TrialTroveID-347447",A Phase Ib/II Umbrella Study to Evaluate the Safety and Efficacy of Varlitinib in Combination with Weekly Paclitaxel in HER1/HER2 Co-Expressing Advanced or Metastatic Gastric Cancer,Oncology,Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Response evaluation criteria in solid tumors",Adverse Events,False,,30661
3387,314376,"ASLAN001-018, NCT03368846, TrialTroveID-314376","An Open Label, Single-dose, Single-period Study Designed to Assess the Mass Balance Recovery, Metabolite Profile and Metabolite Identification of [14C]-Varlitinib in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,Aslan Pharmaceuticals,"Industry, all other pharma",,"Adverse Events, Area under the curve score, Cmax, Elimination half-life, Plasma concentration, Safety and Tolerability, Safety and Tolerability",True,NCT03368846,30661
3388,312761,"ASLAN001-013, TrialTroveID-312761","A Phase II, single arm, multicenter study of varlitinib in combination with 5-FU, oxaliplatin and leucovorin (mFOLFOX6) or 5-FU, irinotecan and leucovorin (mFOLFIRI) in subjects with HER2-positive advanced or metastatic colorectal cancer",Oncology,Oncology: Colorectal,Aslan Pharmaceuticals,"Industry, all other pharma",,,False,,30661
3389,306077,"ABC-02, ASLAN001-008, CTR20171140, NCT03231176, TrialTroveID-306077","A Phase IIA, Single Arm, Multicentre, Study of Varlitinib Plus Capecitabine in Chinese Patients With Advanced or Metastatic Biliary Tract Cancer Who Progressed on at Least 1 Line of Systemic Therapy",Oncology,Oncology: Liver,"Charles River Laboratories {Inveresk Research Group}, Aslan Pharmaceuticals","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT03231176,30661
3390,300224,"ASLAN001-016, NCT03129074, TrialTroveID-300224","A Phase II, Single Arm Study of Varlitinib Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as First-line Systemic Therapy",Oncology,Oncology: Liver,Aslan Pharmaceuticals,"Industry, all other pharma","Disease Progression, Overall response rate","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Vital signs",True,NCT03129074,30661
3391,299767,"2016/01227, HC01/12/16, NCT03499626, TrialTroveID-299767",Phase Ib Open Label Dose Assessment Study of ASLAN001 (Varlitinib) in Patients With Advanced/ Metastatic Hepatocellular Carcinoma (HCC) With an Expansion Cohort in HCC Patients Expressing HER3 Who Have Progressed on First Line Sorafenib or Lenvatinib,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Aslan Pharmaceuticals","Academic, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03499626,30661
3392,298326,"2017-0481, ASLAN001-009, CT983, CTR20191749, EudraCT Number: 2017-000114-30, JapicCTI-183951, NCI-2017-01586, NCT03093870, TreeTopp, TrialTroveID-298326","A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy, , TREatmEnT OPPortunity (TreeTopp)",Oncology,Oncology: Liver,"Ion Channel Innovations, Aslan Pharmaceuticals","Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs","Adverse Events, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Elimination half-life, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Tmax, Vital signs, Volume of distribution",True,NCT03093870,30661
3393,295830,"ASLAN001-010, JapicCTI-173497, NCT03082053, TrialTroveID-295830",A Phase IB Study of Varlitinib in Japanese Subjects With Advanced or Metastatic Solid Tumours,Oncology,Oncology: Liver; Oncology: Unspecified Solid Tumor,Aslan Pharmaceuticals,"Industry, all other pharma",Dose-limiting toxicities,"Area under the curve score, Cmax, Cmin, Elimination half-life, Plasma concentration",True,NCT03082053,30661
3394,286878,"ASLAN001/006, TrialTroveID-286878","A Phase II Single Arm Trial To Assess The Efficacy Of ASLAN001 Plus Capecitabine In Previously Irradiated, Progressing Central Nervous System (CNS) Metastases For HER2 Positive Breast Cancer Patients",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Complete response, Overall survival, Partial response, Progression-free survival, Stable Disease",False,,30661
3395,286877,"ASLAN001-007, NCT02992340, Study 007, TrialTroveID-286877","A Multicentre, Phase Ib/II Study Of Varlitinib In Combination With Gemcitabine And Cisplatin For Treatment Naive Advanced Or Metastatic Biliary Tract Cancer",Oncology,Oncology: Liver,Aslan Pharmaceuticals,"Industry, all other pharma","Adverse Events, Cardiac Telemetry, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs","Adverse Events, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Elimination half-life, Mean residence time, Overall response rate, Overall survival, Plasma concentration, Safety and Tolerability, Stable Disease, Tmax, Vital signs, Volume of distribution",True,NCT02992340,30661
3396,264591,"ASLAN001-005, NCT02609958, TrialTroveID-264591","A Phase IIA, Single Arm, Multicentre, Study of ASLAN001 in Patients With Advanced or Metastatic Cholangiocarcinoma Who Progressed on at Least 1 Line of Systemic Therapy",Oncology,Oncology: Liver,"Pfizer {Array BioPharma}, Aslan Pharmaceuticals, Hyundai Pharm","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Vital signs",True,NCT02609958,30661
3397,254374,"ASLAN001-002SG, NCT02435927, Study 002SG, TrialTroveID-254374",Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination with Oxaliplatin and Capecitabine or Oxaliplatin and 5-FU with Leucovorin,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,"(Other Academic Cancer Center), National Medical Research Council of Singapore, Aslan Pharmaceuticals","Academic, Government, Industry, all other pharma",Maximum tolerated dose,"Area under the curve score, Cmax, Cmin, Overall response rate, Plasma concentration",True,NCT02435927,30661
3398,254309,"2014/01282, ASLAN001-004, NCT02396108, TrialTroveID-254309","Phase Ib Dose-confirmation Study of ASLAN001 Combined With Weekly Paclitaxel and Carboplatin in Advanced Solid Tumours, Followed by an Open-label Phase II Study in Patients With Stage I-III HER2 Positive Breast Cancer",Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Resection rate","Adverse Events, Complete response, Disease Progression, Disease-free survival, Neutropenia, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT02396108,30661
3399,250457,"2015-CT0298, ASLAN001-003, NCT02338245, PHRR150911-001084, TrialTroveID-250457",Randomized Phase IIA/IIB Study to Compare the Efficacy and Safety of ASLAN001 + Capecitabine to Lapatinib + Capecitabine in Patients With HER 2-Positive MBC That Has Failed on Prior Trastuzumab Therapy,Oncology,Oncology: Breast,"Pfizer {Array BioPharma}, Aslan Pharmaceuticals, Hyundai Pharm","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma",Progression-free survival,"Adverse Events, Cardiac Telemetry, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT02338245,30661
3400,216415,"ASLAN001-012, ASLAN001-012 35126, ASLAN001-12, EudraCT Number: 2017-001833-15, NCT03130790, NMRR-17-658-35126, TrialTroveID-216415","A Two-Part Phase II/III  Multicentre, Double-Blind, Randomized, Placebo Controlled Study of Varlitinib Plus mFOLFOX6 Verses Placebo Plus mFOLFOX6 In Subjects With HER1/ HER2 Co Expressing Advanced or Metastatic Gastric Cancer Without Prior Exposure to Systemic Therapy",Oncology,Oncology: Esophageal; Oncology: Gastric,Aslan Pharmaceuticals,"Industry, all other pharma","Overall survival, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Diastolic blood pressure, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response, Tmax, Vital signs",True,NCT03130790,30661
3401,187288,"Aslan001-002, NCT02648425, Study 002, TrialTroveID-187288",Phase I Study to Evaluate the Safety and Tolerability of ASLAN001 in Combination With Cisplatin and 5-Fluorouracil or Cisplatin and Capecitabine,Oncology,Oncology: Breast; Oncology: Gastric; Oncology: Liver; Oncology: Prostate,Aslan Pharmaceuticals,"Industry, all other pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Cmin, Overall response rate, Plasma concentration, Tmax",True,NCT02648425,30661
3402,151979,"ASLAN001-001, KCT0000348, NCT01614522, TrialTroveID-151979","Phase II Open Label Study to Evaluate the Biological Activity of ASLAN001 (ARRY 334543) in Patients With Recurrent/Metastatic Gastric, Gastro-oesophageal Junction, and Oesophageal Carcinoma Whose Tumours Are Epidermal Growth Factor Receptor-2 (HER 2) Amplified or Co-expressing Epidermal Growth Factor Receptor-1 (HER-1) and HER-2",Oncology,Oncology: Esophageal; Oncology: Gastric,"Pfizer {Array BioPharma}, Aslan Pharmaceuticals","Industry, Top 20 Pharma, Industry, all other pharma",,Overall response rate,True,NCT01614522,30661
3403,103964,"09-164, ARRAY-543-206, NCT00862524, REFMAL 160, TrialTroveID-103964",A Phase ll Study of ARRY-334543 and Gemcitabine as First Line Therapy in Patients with Pancreatic Cancer Following A Phase 1 Lead-In to Assess the Safety in Patients with Advanced Cancer.,Oncology,Oncology: Pancreas; Oncology: Unspecified Solid Tumor,Pfizer {Array BioPharma},"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00862524,30661
3404,97054,"ARRAY-543-104, COMIRB 08-1209, NCT00833326, REFMAL 150, TrialTroveID-097054",A Phase Ib Study to Assess the Safety and Pharmacokinetics of ARRY-334543 with Docetaxel in Patients with Advanced Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,Pfizer {Array BioPharma},"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability",,True,NCT00833326,30661
3405,85941,"ARRAY 543-103, ARRAY-543-103, NCT00637702, TrialTroveID-085941","A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Effect of Food on Pharmacokinetics of the ARRY-334543 Tablet Formulation Given on a Twice-Daily Oral Regimen in Patients With Advanced Solid Tumors.",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate",Pfizer {Array BioPharma},"Industry, Top 20 Pharma","Maximum tolerated dose, Plasma pharmacokinetics, Safety and Tolerability, Safety and Tolerability",,True,NCT00637702,30661
3406,78830,TrialTroveID-078830,Phase Ib/II trial of ARRY-543 in Combination with Trastuzumab as Maintenance Therapy for Patients with Metastatic Breast Cancer.,Oncology,Oncology: Breast,Pfizer {Array BioPharma},"Industry, Top 20 Pharma",,,False,,30661
3407,78828,TrialTroveID-078828,Phase 1b/2 Trial of ARRY-543 in Combination with Cetuximab in Patients with Metastatic Colorectal Cancer.,Oncology,Oncology: Colorectal,Pfizer {Array BioPharma},"Industry, Top 20 Pharma",,,False,,30661
3408,55861,"ARRAY-543-204, NCT00710736, TrialTroveID-055861",A Phase I Study to Assess the Safety of ARRY-334543 With Capecitabine in Patients With Advanced Cancer,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Liver; Oncology: Ovarian; Oncology: Unspecified Cancer,Pfizer {Array BioPharma},"Industry, Top 20 Pharma","Adverse Events, Maximum tolerated dose, Safety and Tolerability",,True,NCT00710736,30661
3409,32030,"06044, ARRY-0501, NCT00278902, P1T0501, PARRAY002, PHI 0570, PHI0570, REFMAL 151, RRC10806, TrialTroveID-032030, VICC PHI 0570, VICCPHI0570","A Phase I, Open-Label, Multiple Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of ARRY-334543 Given on a Daily Oral Regimen in Patients with Advanced Cancer.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma",Pfizer {Array BioPharma},"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","CA-125 Response, Circulating Tumor Cells",True,NCT00278902,30661
3410,370120,"BGOG-cx12, ENGOT-cx12, EudraCT Number: 2019-001655-39, GCT1015-07, GOG-3037, innovaTV 301, NCT04697628, SGNTV-003, TrialTroveID-370120","A Randomized, Open-Label, Phase III Trial of Tisotumab Vedotin vs Investigator's Choice Chemotherapy in Second- or Third-Line Recurrent or Metastatic Cervical Cancer",Oncology,Oncology: Cervical,"(Other Cooperative Group), Seagen","Cooperative Group, Industry, all other pharma",Overall survival,"Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Time to response, Visual Analog Scale",True,NCT04697628,42289
3411,339474,"125348, 19-177, BGOG-cx8, BGOG-cx-8, ENGOT-cx8, EudraCT Number: 2017-004758-40, GCT1015-05, GCT1015-05/ BGOG/ ENGOT-cx8, GCT1015-05/ENGOT-cx8, Gct1015-05/Gog-3024, GOG-3024, GOG3024 GCT1015-05/ENGOT-cx8, GOG-3024/GCT1015-05, innovaTV 205, IRAS ID 255753, METc number: 2019/265, MK3475 KN 834, NCI-2019-01361, NCT03786081, NL66166.018.18, TrialTroveID-339474",A Phase Ib/II Open-Label Trial of Tisotumab Vedotin (HuMax-TF-ADC) Monotherapy and in Combination With Other Agents in Subjects With Recurrent or Stage IVB Cervical Cancer,Oncology,Oncology: Cervical,"(Other Cooperative Group), Gynecologic Oncology Group (GOG), Seagen {Seattle Genetics}, Genmab, Merck & Co./Merck Sharp & Dohme (MSD)","Cooperative Group, Cooperative Group, Industry, all other pharma, Industry, all other pharma, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03786081,42289
3412,332015,"18-6061, 19758, AAAS1622, EudraCT Number: 2019-001219-22, innovaTV 208, NCI-2018-02323, NCT03657043, OSU-18220, SGNTV002, SGNTV-002, STUDY00143494, TrialTroveID-332015",Open Label Phase II Study of Tisotumab Vedotin for Patients With Platinum-Resistant Ovarian Cancer With a Safety Run-in of a Dose-Dense Regimen,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Seagen {Seattle Genetics}, Genmab","Industry, all other pharma, Industry, all other pharma","Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Adverse Events, Anti-drug antibodies, CA-125 Response, Clinical benefit rate, Cmax, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT03657043,42289
3413,321748,"GCT1015-06, innovaTV 206, JapicCTI-194639, NCT03913741, TrialTroveID-321748",Open Label Phase I/II Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignancies,Oncology,Oncology: Cervical; Oncology: Unspecified Solid Tumor,"Seagen {Seattle Genetics}, Genmab","Industry, all other pharma, Industry, all other pharma","Adverse Events, Anti-drug antibodies, Cmax, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Elimination half-life, Maximum tolerated dose, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax","Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Time to response",True,NCT03913741,42289
3414,321654,"2018-0293, EudraCT Number: 2017-005076-26, innovaTV 207, IRAS ID 250033, NCI-2018-00676, NCT03485209, SGNTV-001, TrialTroveID-321654",Open Label Phase II Study of Tisotumab Vedotin for Locally Advanced or Metastatic Disease in Solid Tumors,Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas","Seagen {Seattle Genetics}, Genmab","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03485209,42289
3415,310798,"0020026, 20180702, BGOG-cx6, C-334, ECLAT/AGO-OP.6, ENGOT-cx6, EudraCT Number: 2017-003413-25, GCT1015-04, Genmab 1015-04 GOG 3023, GOG-3023, innovaTV 204, innovaTV 204/GOG-3023/ENGOT-cx6, NCI-2018-01637, NCT03438396, TrialTroveID-310798","A Single Arm, Multicenter, International Trial of Tisotumab Vedotin (HuMax-TF-ADC) in Previously Treated, Recurrent or Metastatic Cervical Cancer",Oncology,Oncology: Cervical,"(Other Cooperative Group), Seagen {Seattle Genetics}, Genmab","Cooperative Group, Industry, all other pharma, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03438396,42289
3416,303358,"20170362, EudraCT Number: 2016-004743-37, GCT1015-03, IRAS ID-222308, NCI-2017-02045, NCT03245736, TrialTroveID-303358","A Multi-Center, Open-Label Trial Investigating the Efficacy and Safety of Continued Treatment with Tisotumab Vedotin in Patients with Solid Tumors Known to Express Tissue Factor",Oncology,"Oncology: Bladder; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate","Genmab, Seagen","Industry, all other pharma, Industry, all other pharma","Adverse Events, Safety and Tolerability",,True,NCT03245736,42289
3417,264611,"2015-0597, EudraCT Number: 2015-001120-29, GEN702, innovaTV 202, IRAS ID: 179637, NCI-2015-01770, NCT02552121, TrialTroveID-264611",Dose-escalating and Cohort Expansion Safety Trial of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax-TF-ADC) in Patients With Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor,Oncology,"Oncology: Bladder; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Prostate","Seagen {Seattle Genetics}, Genmab","Industry, all other pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Anti-drug antibodies, Area under the curve score, CA-125 Response, Cmax, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Maximum tolerated dose, Neuropathy, Overall response rate, Partial response, Plasma concentration, Plasma pharmacokinetics, Progression-free survival, Progressive disease rate, Safety and Tolerability, Stable Disease, Tmax, Volume of distribution",True,NCT02552121,42289
3418,190531,"2013-0699, 20151076, 201612043, C-279, EudraCT Number: 2013-001074-15, GEN701, innovaTV 201, IRAS ID: 135103, NCI-2014-01166, NCT02001623, TrialTroveID-190531","First-in-human, Dose-escalating Safety Study of Tissue Factor Specific Antibody Drug Conjugate Tisotumab Vedotin (HuMax TF ADC) in Patients with Locally Advanced and/or Metastatic Solid Tumors Known to Express Tissue Factor",Oncology,"Oncology: Bladder; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate","Seagen {Seattle Genetics}, Genmab","Industry, all other pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Anti-drug antibodies, CA-125 Response, Cmax, Duration of overall response, Elimination half-life, Maximum tolerated dose, Neuropathy, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Tmax, Volume of distribution",True,NCT02001623,42289
3419,398659,"NCT04788420, Sorafenib-Flt3 AML-2020",Influence of Co-existing Mutations on Sorafenib Maintenance Therapy After Allogeneic Hematopoietic Stem Cell Transplantation for Patients With FLT3-ITD Positive Acute Myeloid Leukemia,,NA: ClinicalTrials.gov,"First Affiliated Hospital of Zhejiang University, Institute of Hematology & Blood Diseases Hospital, Nanfang Hospital of Southern Medical University, Peking University People's Hospital, The First Affiliated Hospital of Guangzhou Medical University, The First Affiliated Hospital of Soochow University, Third Affiliated Hospital, Sun Yat-Sen University, Xiangya Hospital of Central South University, Xinqiao Hospital of Chongqing, Zhujiang Hospital, First People's Hospital of Chenzhou","ClinicalTrials.gov, Academic, Academic, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov, ClinicalTrials.gov, Academic, ClinicalTrials.gov, ClinicalTrials.gov",,Disease-free survival,True,NCT04788420,15581
3420,396811,"NCT04752527, SZ-AML01, TrialTroveID-396811",The Clinical Study of Individualized Induction Therapy for Non-elderly Patients With Acute Myeloid Leukemia and Adverse Risk Features Guided by Rapid Screening With FISH and NGS,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival","Adverse Events, Event-free survival, Overall survival",True,NCT04752527,15581
3421,394362,"ChiCTR2100041874, DOUBLE-001, TrialTroveID-394362",DOUBLE-001: A Multi-center Phase II Trial Evaluating the Effcacy and Safety of Hepatic Infusion of Camrelizumab and Oxaliplatin Plus Fluorouracil/ Leucovorin Combined with Sorafenib for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Overall survival, Progression-free survival, Quality of Life",False,,15581
3422,393063,"NCT04687163, SH-3, TrialTroveID-393063","Sorafenib or Lenvatinib Plus Hepatic Artery Infusion of 130 mg/mÂ² Oxaliplatin, Leucovorin, and Fluorouracil Versus Sorafenib or Lenvatinib Plus Hepatic Artery Infusion of 85 mg/mÂ² Oxaliplatin, Leucovorin, and 1200 mg/mÂ² Fluorouracil for Unresectable Advanced Hepatocellular Carcinoma: a Randomised Phase III Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Overall response rate, Progression-free survival, Time to response",True,NCT04687163,15581
3423,392332,"NCT04674345, Sorafenib-Non-Flt3 AL-2020, TrialTroveID-392332",Sorafenib Maintenance for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients With FLT3 Negative Acute Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous","(Other Hospital/Academic/Medical Center), Nanfang Hospital of Southern Medical University","Academic, Academic",,"Disease-free survival, Overall survival",True,NCT04674345,15581
3424,391403,"1-10-72-277-19, NCT04659343, TrialTroveID-391403",Therapeutic Drug Monitoring for Optimized Outcome in Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Rigshospitalet, (Other Hospital/Academic/Medical Center), Herlev and Gentofte Hospital {Herlev Hospital}, Odense University Hospital","Academic, Academic, Academic, Academic","Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors",,True,NCT04659343,15581
3425,389842,"COMOHCC, NCT04639284, TrialTroveID-389842",Combination Therapy with Anti-angiogenic Agents and Anti-PD-1 Antibodies for Unresectable or Advanced Hepatocellular Carcinoma: a Cohort Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response","Complete response, Duration of overall response, Overall survival, Progression-free survival",True,NCT04639284,15581
3426,389468,"EudraCT Number: 2008-002667-13, PREST, TrialTroveID-389468",A Single-Center Controlled Pilot Study To Investigate Pre- And Perioperative Therapy With Sorafenib (NexavarÂ®) In Patients Who Are Candidates For A Curative Surgery Of Renal Cell Cancer,Oncology,Oncology: Renal,University of Heidelberg,Academic,"Gene expression profiling, Progression-free survival, Safety and Tolerability, Wound healing","Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,15581
3427,387776,"MIIR-03, NCT04599777, TrialTroveID-387776","Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events, Stable Disease",True,NCT04599777,15581
3428,384884,"22/09/2020, NCT04553458",Factors Affecting Post-treatment Outcomes in Patients With Hepatocellular Carcinoma,,NA: ClinicalTrials.gov,Sohag University,ClinicalTrials.gov,,,True,NCT04553458,15581
3429,383080,"ChiCTR2000036907, TrialTroveID-383080",A Multicenter Clinical Study Of Ba Qi Ling Mao Formulation In The Treatment Of BCLC B / C Stage Of Primary Liver Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Liver function, Magnetic Resonance Imaging, Overall response rate, Quality of Life",False,,15581
3430,382742,"ChiCTR2000035749, ChiMCTR2000003577, TrialTroveID-382742",Prevention and Treatment of Recurrence and Metastasis of Hepatocellular Carcinoma after Operation with Ganyanshu Decoctions,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Adverse Events, Overall survival",False,,15581
3431,382313,"GXu, NCT04518852, TrialTroveID-382313","TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Overall survival, Partial response","Clinical benefit rate, Complete response, Duration of overall response, Partial response, Progression-free survival, Progressive disease rate, Stable Disease, Time to progression",True,NCT04518852,15581
3432,381020,TrialTroveID-381020,Efficacy of Sorafenib in Treatment of Advanced Hepatocellular Carcinoma in the Mexican Population: Evidence From a Third Level Hospital in Mexico,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Time to progression",,False,,15581
3433,381009,TrialTroveID-381009,"The combined sorafenib for the individuals with intermittent stage hepatocellular carcinoma unresponsive to transarterial, chemoembolization",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3434,380111,"ChiCTR2000034757, TrialTroveID-380111",Comparison Of The Effectiveness And Safety Of Hepatic Arterial Infusion Of Idarubicin And Oral SorafenibTreating Barcelona Clinic Liver Cancer (BCLC) Stage C Hepatocellular Carcinoma: A Multicenter Randomized Controlled Study,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",Overall survival,"Clinical benefit rate, Overall response rate, Progression-free survival, Time to progression",False,,15581
3435,379093,"CTR20200257, NUCIEN-2019-002, TrialTroveID-379093","Multi-center, Open Phase Ib/IIa Clinical Study of Sorafenib Tablets for Oral Treatment of Advanced Liver Cancer",Oncology,Oncology: Liver,Guangzhou Nanxin Pharmaceutical Co.,"Industry, generic","Adverse Events, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Complete response, Partial response, Progressive disease rate, Serious Adverse Events, Stable Disease, Tmax, Vital signs","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability, Time to progression",False,,15581
3436,378263,"ChiCTR2000034267, TrialTroveID-378263","A Prospective, One-arm, Single-center Clinical Study Of the Effect Of TACE Combined With Camrelizumab + Sorafenib On Recurrence Rate Of MVI Positive Patients After Hepatectomy",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Recurrence,"Adverse Events, Overall survival, Recurrence",False,,15581
3437,376827,TrialTroveID-376827,"IGH-Child-Turcotte-Pugh Score as a Predictor of Treatment Outcome in Child-Pugh a, Advanced Hepatocellular Carcinoma Patients Undergoing Sorafenib Thera",Oncology,Oncology: Liver,"MD Anderson Cancer Center, University of Texas, National Institutes of Health","Academic, Government","Overall survival, Progression-free survival",,False,,15581
3438,376445,TrialTroveID-376445,"Personalized multimodality therapy (ICT) with immune checkpoint inhibitors (ICI), chemotherapy (CT), and targeted treatment (TT), in advanced/refractory cancer",Oncology,"Oncology: (N/A); Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas",(Other Academic Cancer Center),Academic,,,False,,15581
3439,370780,"ChiCTR2000031437, TrialTroveID-370780",Study on the efficacy and safety of hepatic artery infusion chemotherapy (HAIC) combined with sintilimab and sorafenib in advanced HCC,Oncology,Oncology: Liver,Chinese Academy of Medical Sciences,Government,Progression-free survival,"Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Safety and Tolerability",False,,15581
3440,370637,"AflacLL1901, CHOA-AML, NCI-2019-07692, NCT04326439, TrialTroveID-370637",CHOA-AML: A Pilot Study for Newly Diagnosed Pediatric Patients With Acute Myeloid Leukemia (AML),Oncology,"Oncology: Leukemia, Acute Myelogenous",Emory University Hospital - Atlanta,Academic,Event-free survival,"Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Minimal Residual Disease, Overall survival",True,NCT04326439,15581
3441,370527,"ChiCTR2000031242, TrialTroveID-370527",A study of sintilimab combined with sorafenib for the treatment of advanced hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression, Time to response",False,,15581
3442,370387,"2019-ky121, ChiCTR2000031195, TrialTroveID-370387",The Exploration and Prediction of The Difference Of The First-line Treatment Response Of Advanced Hepatocellular Carcinoma HCC Between Sintilimab and Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3443,370326,"2019B110233002, NCT04317248, TrialTroveID-370326","Precision Study on ""Cocktail"" Therapy to Improve the Efficacy of Hepatitis B-related Hepatocellular Carcinoma",Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Nanfang Hospital of Southern Medical University","Academic, Academic",Progression-free survival,"Common Terminology Criteria for Adverse Events, Overall survival, Treatment Emergent Adverse Events",True,NCT04317248,15581
3444,369250,"ChiCTR2000030303, TrialTroveID-369250",Clinical Trial of TACE with Oxaliplatin Regimen in Continuous Hepatic Artery Chemotherapy Combined with Sorafenib in the Treatment of Intermediate and Advanced Primary Liver Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability","Overall response rate, Overall survival",False,,15581
3445,367968,"ChiCTR2000029970, TrialTroveID-367968",Accurate Target Therapy Based on PDX Drug Screening for One to One Treatment of Primary Liver Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3446,366367,"jRCT1041190082, TrialTroveID-366367",Phase II Study of Sorafenib-Regorafenib Sequential Therapy for the Patients with Advanced Hepatocellular Carcinoma Previously Treated with Lenvatinib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Time to progression, Time to treatment failure, Tumor control rate",False,,15581
3447,365611,"CISLD6, NCT04232722, TrialTroveID-365611","An Exploratory Study Evaluating the Efficacy, Safety, and Pharmacokinetics of Sorafenib Combined With Realgar-Indigo Naturalis Formula (RIF) in in Treating Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Clinical benefit rate, Overall survival, Progression-free survival",True,NCT04232722,15581
3448,365444,"DEEP, NCT04229355, TrialTroveID-365444",Drug-eluting Bead Transarterial Chemoembolization Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma: a Multicentric Prospective Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,Overall survival,True,NCT04229355,15581
3449,364539,"KC18MNDS0777, KCT0004398, TrialTroveID-364539",Implementation of Targeted Therapy During Remission Induction Chemotherapy of De Novo Pediatric Acute Myeloid Leukemia to Improve Rates of Complete Remission,Oncology,"Oncology: Leukemia, Acute Myelogenous","(Other Hospital/Academic/Medical Center), Ministry of Health &  Welfare of the Republic of Korea","Academic, Government",,Complete response,False,,15581
3450,363919,"ChiCTR1900028222, TrialTroveID-363919",Study For Novel Molecular Markers For Predicting The Targeting And Immunotherapeutic Effects Of Hepatic Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Disease-free survival, Overall response rate, Overall survival",,False,,15581
3451,363080,"ChiCTR1900027832, TrialTroveID-363080",Clinical Application Of iNKT Cell Immunotherapy In Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Progression-free survival",,False,,15581
3452,361872,TrialTroveID-361872,Mutations In Circulating Tumor DNA Predict Primary Resistance To Sorafenib In Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Circulating Tumor Cells, Progression-free survival","Overall response rate, Overall survival",False,,15581
3453,361739,TrialTroveID-361739,RNA-Sequencing Of Plasma Exosomes Reveals Novel Transcriptomic Profiles In Patients With Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
3454,361275,"GuangXiMU-HCC-PD1(2), NCT04163237, TrialTroveID-361275",Study on Combined Immunotherapy and Targeted Therapy for Advanced Liver Cancer.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,Overall survival,True,NCT04163237,15581
3455,361138,TrialTroveID-361138,Salvage Therapy In Cancer Patients With Hepatitis C Without Sustained Virologic Response After Direct-Acting Antivirals â A Prospective Study,Infectious Disease,Infectious Disease: HCV,"MD Anderson Cancer Center, University of Texas, Medical University of South Carolina","Academic, Academic","Safety and Tolerability, Sustained Virologic Response at 12 weeks",,False,,15581
3456,360631,TrialTroveID-360631,Optimal Strategy Of Switching From Transarterial Chemoembolization To Molecular Targeted Therapy For Patients With Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,,False,,15581
3457,360578,"GuangXiMU-HCC-PD1, NCT04152356, TrialTroveID-360578",Study on Combined Immunotherapy and Targeted Therapy for Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,Overall survival,True,NCT04152356,15581
3458,360334,"EudraCT Number: 2008-000225-19, getne-0801, GETNE0801, TrialTroveID-360334","Classic Phase II, Multicentric, Open, Uncontrolled Test to Evaluate the Effectiveness of the Combination of Sorafenib and Bevacizumab in the Treatment of Patients With Advanced Neuroendocrine Tumor and / or Metastasic",Oncology,Oncology: Neuroendocrine,(Other Cooperative Group),Cooperative Group,"Overall survival, Progression-free survival","Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",False,,15581
3459,360082,"FAH-20190358, NCT04143191, SOURCE, TrialTroveID-360082","Sorafenib Plus Transarterial Chemoembolization Versus Sorafenib Alone as Postoperative Adjuvant Treatment for Resectable Primary Advanced Hepatocellular Carcinoma: A Phase 3, Multicenter, Randomized Controlled Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence","Adverse Events, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Time to response",True,NCT04143191,15581
3460,358194,"20190921, NCT04103398, TREAT, TrialTroveID-358194","TRansarterial ChEmoembolization Plus SorAfenib Versus Transarterial Chemoembolization Alone for Recurrent Unresectable Hepatocellular Carcinoma: A Phase 3, Open Label, Multicenter, Randomized Controlled Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Partial response, Progression-free survival, Quality of Life, Stable Disease, Time to progression",True,NCT04103398,15581
3461,356190,"LQ108, NCT04069949, STUHCCPVTT, TrialTroveID-356190",An Exploratory Study of Sorafenib Plus Toripalimab for Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Shanghai Junshi Biosciences Co.","Academic, Industry, all other pharma","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04069949,15581
3462,355858,"ChiCTR1900025300, TrialTroveID-355858",A Randomized Controlled Trial For Transcatheter Arterial Chemoembolization (TACE) And Sorafenib In Hepatocellular Carcinoma With Portal Vein Cancer And Non-Combined Stereotactic Radiotherapy (SBRT) In The Treatment Of Hepatocellular Carcinoma With Portal Vein Cancer (TACE) And The Combination And Disassociation Of Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Complete response,,False,,15581
3463,355046,"2014_078#B2014419a, NCT04051853, SORBE, TrialTroveID-355046",Population Pharmacokinetics and Pharmacodynamics of Sorafenib in HCC Patients With Child Pugh B Liver Cirrhosis (SORBE-trial),Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Academic Medical Center Amsterdam","Academic, Academic","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT04051853,15581
3464,350857,"NCT03971201, TrialTroveID-350857, WPH20190507",A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Progression-free survival,True,NCT03971201,15581
3465,350239,"CTR20190875, HZ-2019-01-P, TrialTroveID-350239","Open, Randomized, Single-dose, Three-cycle, Three-sequence, Reference Preparation Repeated Crossover Test of Sorafenib Tosylate",Oncology,Oncology: Unspecified Cancer,Furen Pharmaceutical Group Co.,"Industry, generic",Safety and Tolerability,"Adverse Events, Safety and Tolerability, Vital signs",False,,15581
3466,350143,TrialTroveID-350143,Early treatment with sorafenib and mTOR inhibitor in recurrent hepatocellular carcinoma after liver transplantation: Safety and survival,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3467,350121,"2018-A02911-54, HELP, NCT03956940, TrialTroveID-350121",A Sorafenib-Regorafenib Sequence Treatment Monitoring Study Using Liquid Biopsy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival",True,NCT03956940,15581
3468,349465,TrialTroveID-349465,Identifying optimal candidates for combining transarterial chemoembolization and sorafenib in patients with unresectable hepatocellular carcinoma: A multicenter observational study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Time to progression",,False,,15581
3469,347965,TrialTroveID-347965,New multi inflammation indicators in advanced hepatocellular carcinoma patients receiving sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Absolute Neutrophil Count, Leukocyte count, Overall survival, Platelet count, Progression-free survival",,False,,15581
3470,346243,"JS-1391, NCT03892577, TrialTroveID-346243","Real-world Study for Targeted Therapy and Immunotherapy in Patients With Advanced Hepatobiliary Tumors: a Multi-centers, Open-assess Observational Study.",Oncology,Oncology: Liver,"(Other Industry Sponsor), Peking Union Medical College Hospital, CAMS, Beijing, China","Industry, all other pharma, Academic","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall survival, Partial response, Quality of Life, Stable Disease, Treatment Emergent Adverse Events",True,NCT03892577,15581
3471,345470,"NCI-2020-02743, NCT03878524, SMMART, STUDY00015588, TrialTroveID-345470",Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) Trial,Oncology,"Oncology: Breast; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms; Oncology: Pancreas; Oncology: Prostate","(Other Cooperative Group), National Institutes of Health/National Cancer Institute, OHSU Cancer Institute, Oregon Health and Science University","Cooperative Group, Government, Academic, Academic",,"Activities of Daily Living, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Quality of Life",True,NCT03878524,15581
3472,341458,"HCC-OXA, NCT03812770, TrialTroveID-341458","Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response",True,NCT03812770,15581
3473,341457,"HCC-S053, NCT03812783, TrialTroveID-341457","Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-Fluorouracil and Leucovorin Plus Sorafenib Versus Hepatic Arterial Infusion Chemotherapy of Irinotecan, Oxaliplatin, 5-Fluorouracil and Leucovorin Plus Sorafenib for Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03812783,15581
3474,340275,TrialTroveID-340275,Prognostic Significance of Baseline FLT3-ITD Mutant Allele Burden in Acute Myeloid Leukemia Treated with Intensive Chemotherapy with/without Sorafenib,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Disease-free survival, Overall survival",,False,,15581
3475,338962,TrialTroveID-338962,Survival and Tolerance to Sorafenib in Child-Pugh B Patients with Hepatocellular Carcinoma: a Prospective Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3476,338403,"DLY201812, NCT03768375, TrialTroveID-338403","A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With FORFIRINOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors",,True,NCT03768375,15581
3477,338104,TrialTroveID-338104,Early Prediction of Sorafenib Response in Patients with Hepatocellular Carcinoma: The Possible Role of Secretory Clusterin in Acquired Sorafenib Resistance,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progressive disease rate, Response evaluation criteria in solid tumors",,False,,15581
3478,336162,"NCT03730675, TrialTroveID-336162, ZhongdaH-PATENCY",Irradiation Stent Placement Plus Transcatheter Arterial Chemoembolization in Hepatocellular Carcinoma With Portal Vein Tumor Thrombosis: A Multicenter Randomized Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Doppler ultrasound, Partial response, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT03730675,15581
3479,335743,"1, EudraCT Number: 2010-024306-36, TrialTroveID-335743",An Exploratory Study of Sorafenib for Patients Listed for Transplantation Due to HCC,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Liver function, Mortality, Quality of Life","Circulating Tumor Cells, EORTC Quality of Life Questionnaire, Liver function, Mortality, Quality of Life, Response evaluation criteria in solid tumors",False,,15581
3480,335734,"HCC-H171011, NCT03722498, TrialTroveID-335734","Randomized Phase II Study of Second-line Treatment Comparing Hepatic Arterial Infusion Chemotherapy of Oxaliplatin, 5-fluorouracil and Leucovorin With Sorafenib in Hepatocellular Carcinoma Refractory to Transarterial Chemoembolization",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival",True,NCT03722498,15581
3481,333076,"ChiCTR1800018392, TrialTroveID-333076",A Multicenter Randomized Controlled Trial for the Effect of Maintenance Dasatanib or Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Core- Binding Factor Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Mortality, Overall survival",,False,,15581
3482,331147,"20215, NCT03644511, SORAGO-HCC, TrialTroveID-331147",Use Of Sorafenib And/Or Regorafenib In Hepatocellular Carcinoma (HCC) Subsequent To Another Systemic First-line Treatment,Oncology,Oncology: Liver,Bayer AG,"Industry, Top 20 Pharma",,"Complete response, Overall survival, Partial response, Progression-free survival, Stable Disease, Time to progression, Treatment Emergent Adverse Events",True,NCT03644511,15581
3483,330428,"19442, MCC-19442, NCI-2018-01831, NCT03630120, TrialTroveID-330428",Adaptive Tyrosine Kinase Inhibitor Therapy In Patients With Advanced Progressive Thyroid Cancer,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,H. Lee Moffitt Cancer Center and Research Institute,Academic,,"Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response rate, Stable Disease",True,NCT03630120,15581
3484,330137,"AML004, NCT03622541, TrialTroveID-330137",Using Sorafenib as a Salvage Treatment for Relapsed or Refractory Acute Myeloid Leukemia Carrying FLT3 Internal Tandem Duplication (ITD),Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,Complete response,,True,NCT03622541,15581
3485,329262,"EF-30, HEPANOVA, NCT03606590, TrialTroveID-329262","HEPANOVA: A Phase II Trial of Tumor Treating Fields (TTFields, 150kHz) Concomitant with Sorafenib for Advanced Hepatocellular Carcinoma (HCC).",Oncology,Oncology: Liver,Novocure,"Industry, diagnostics or device","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Metastasis-free survival, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03606590,15581
3486,329061,"CTRI/2018/07/014865, SMASH, TrialTroveID-329061",A Prospective Proof of Concept Dose De-escalation Open Label Clinical Study to Evaluate the Safety and Efficacy of Sorafenib with Metformin and Atorvastatin in Advanced Hepatocellular Carcinoma (Smash),Oncology,Oncology: Liver,Tata Memorial Hospital,Academic,"Adverse Events, Safety and Tolerability","Event-free survival, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",False,,15581
3487,327804,"CVM-004, NCT03582618, TrialTroveID-327804","A Phase II, Open-Label Study With Orally Administered CVM-1118 and Sorafenib in Subjects With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,TaiRx,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Heart rate, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression, Vital signs",True,NCT03582618,15581
3488,326670,"NCT03565536, TrialTroveID-326670, UTC-NEXAVAR",Prospective Study of Nexavar for Neoadjuvant Treatment of Anaplastic Thyroid Cancer,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Time to progression",True,NCT03565536,15581
3489,326338,TrialTroveID-326338,Impact of Adrenergic and Prostanoid Inhibitors Used Chronobiologically on Outcomes in Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3490,324959,"NCC201803020, NCT03535259, SIRAHCC, TrialTroveID-324959",Phase II Study of Concurrent Sorafenib and Intensity-modulated Radiotherapy (IMRT) for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,Chinese Academy of Medical Sciences,Government,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Time to progression",True,NCT03535259,15581
3491,324888,"18-452, 20180800, AHEP1531, NCI-2017-01910, NCT03533582, PHITT, TrialTroveID-324888, TX8977",Pediatric Hepatic Malignancy International Therapeutic Trial (PHITT),Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Disease Progression, Event-free survival, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Event-free survival, Overall survival, Progression-free survival, Recurrence, Resection rate, Response evaluation criteria in solid tumors",True,NCT03533582,15581
3492,322513,"2012AS0313, NCT03518502, TrialTroveID-322513",Comparison of Efficacy Between Sorafenib Monotherapy vs. Transarterial Chemoembolization -Sorafenib Sequential Therapy in Hepatocellular Carcinoma Patients With Extrahepatic Metastasis,Oncology,Oncology: Liver,"(Other Cooperative Group), Korea University Medical Center, Seoul","Cooperative Group, Academic",Overall survival,"Overall survival, Progression-free survival, Time to progression",True,NCT03518502,15581
3493,322293,TrialTroveID-322293,Sorafenib increases the percentage and cytotoxicity of circulating NK cells in hepatocellular carcinoma patients,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3494,321851,TrialTroveID-321851,Efficacy and Safety of REGORAFENIB in Real Life in the Treatment of Hepatocellular Carcinoma. Multicenter Experience,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3495,321741,TrialTroveID-321741,The Effect of Sorafenib on the Outcomes of Acute Myeloid Leukemia with FLT3-ITD Undergoing Allogeneic Hematopoietic Stem Cell Transplantation,Oncology,"Oncology: Leukemia, Acute Myelogenous","Peking Union Medical College Hospital, CAMS, Beijing, China, (Other Hospital/Academic/Medical Center)","Academic, Academic",,,False,,15581
3496,321674,TrialTroveID-321674,The Prognostic Factors Between Different Viral Etiologies Among Advanced Hepatocellular Carcinoma Patients Receiving Sorafenib Treatment,Oncology,Oncology: Liver,Kaohsiung Medical University Hospital,Academic,Overall survival,,False,,15581
3497,321004,"HCC-20180309, NCT03468231, TrialTroveID-321004","Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin, Fluorouracil/Leucovorin Versus Sorafenib Plus Hepatic Artery Infusion Chemotherapy of Oxaliplatin for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT03468231,15581
3498,320772,TrialTroveID-320772,Impact of sorafenib on quality of life in hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Quality of Life,Overall survival,False,,15581
3499,320467,TrialTroveID-320467,First Line Sorafenib Treatment For Metastatic Medullary Thyroid Cancer: Efficacy And Safety Analysis,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,Clinical benefit rate,False,,15581
3500,319341,"001, EudraCT Number: 2014-001956-52, NCT03456401, TOKIO, Tokio Study, TrialTroveID-319341",Activity and safety of third line tyrosin kinase inhibitor (TKI) after 2 tyrosin kinase inhibitors(TKIs) in patients with metastatic renal cell carcinoma (mRCC) (Tokio Study),Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival, Progressive disease rate","Adverse Events, EORTC Quality of Life Questionnaire, NCI-CTC scale, Overall survival, Quality of Life, Safety and Tolerability",True,NCT03456401,15581
3501,319049,"CTR20171556, NUCIEN-2017-001, TrialTroveID-319049","Single-Center, Open, Dose-Tolerant, PK Phase I Clinical Trial of Sorafenib in Patients with Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,Guangzhou Nanxin Pharmaceutical Co.,"Industry, generic","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Progression-free survival",False,,15581
3502,318982,"17-23590, 174523, NCI-2018-00051, NCT03439891, TrialTroveID-318982","Multicenter Pilot Study of the Safety, Efficacy, and Immune Cell Profiling in Advanced Hepatocellular Carcinoma (HCC) Patients Treated With the Combination of Sorafenib Plus Nivolumab as First-Line of Systemic Therapy",Oncology,Oncology: Liver,"Bristol-Myers Squibb, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Complete response, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tumor control rate",True,NCT03439891,15581
3503,317633,"DRKS00015849, EudraCT Number: 2018-003237-16, SoraTram, SORATRAM, TrialTroveID-317633","Cross-Institutional, Prospective, Open Label, Single Group Basket Study of Combined CRAF and MEK Inhibition in Advanced-Stage Malignancies Harboring BRAF Mutations with Impaired Kinase Activity",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,Safety and Tolerability,False,,15581
3504,317097,"MEOMG1A20170313, NCT03406364, TrialTroveID-317097",A Phase I/IIa Study to Assess the Safety and Activity of Combined MG005 and Sorafenib (NEXAVAR) Treatment in Patients With Solid Tumor,Oncology,Oncology: Liver; Oncology: Renal; Oncology: Unspecified Solid Tumor,Metagone Biotech,"Industry, all other pharma","Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors",,True,NCT03406364,15581
3505,316621,"TrialTroveID-316621, UMIN000030718",Combination Of Molecularly-Targeted Therapy With Stereotactic Body Radiotherapy In Hepatocellular Carcinoma With Major Vascular Invasion,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate",False,,15581
3506,314902,TrialTroveID-314902,"Sorafenib tosylate, Ribavirin and Sofosbuvir combination therapy for HCV virus infected patients with decompensated liver cancer",Infectious Disease,Infectious Disease: HCV,(Other Hospital/Academic/Medical Center),Academic,Sustained Virologic Response at 12 weeks,,False,,15581
3507,313476,"EudraCT Number: 2017-002470-40, MEC 17-490 METC Erasmus MC, NL62522.078.17, NTR6967, PROSORA, PROSORA-study, TrialTroveID-313476",Observational Study of the Effects of Probenecid on the Pharmacokinetics and Pharmacodynamics of Sorafenib (PROSORA-study),Oncology,Oncology: Liver; Oncology: Renal; Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,Area under the curve score,"Cmax, Cmin, Elimination half-life, Quality of Life, Volume of distribution",False,,15581
3508,312519,"16-109, NCT03340636, PharmacoCHC, TrialTroveID-312519",Relationship Between the Residual Plasma Concentration of Sorafenib and the Occurrence of Adverse Events in Patients Treated for Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Plasma concentration,,True,NCT03340636,15581
3509,311600,TrialTroveID-311600,Serum HMGB1 concentrations is a useful predictor of extreme poor prognosis for advanced hepatocellular carcinoma treated with sorafenib and hepatic arterial infusion chemotherapy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3510,311492,TrialTroveID-311492,Treatment and Prognosis of Locally Advanced HCC with Main Portal Vein Invasion,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3511,311482,TrialTroveID-311482,Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Biomarker of Hepatic Progenitor Cell/Biliary Features in Hepatocellular Carcinoma and of Prognosis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3512,311248,TrialTroveID-311248,Robust Efficacy of Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion: a Comparative Study with Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall response rate, Response rate, Safety and Tolerability",False,,15581
3513,310816,TrialTroveID-310816,The Efficacy and Safety of Sorafenib in Patients with Renal Insufficiency of Advanced Renal Cell Carcinoma: Real- World Data of Sorafenib in Japan,Oncology,Oncology: Renal,Bayer AG,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
3514,307181,"EudraCT Number: 2017-000456-26, NCT03251612, TICC1, TrialTroveID-307181, Tumorspheres Colrec, Tumorspheres_Colrec",Predictive Value of In-vitro Testing Anti-cancer Therapy Sensitivity on Tumorspheres From Patients With Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"EQ-5D-5L, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response rate",True,NCT03251612,15581
3515,306981,"2016-0592, NCI-2018-01607, NCT03247088, TrialTroveID-306981",Phase I/II Study Of Sorafenib Added To Busulfan And Fludarabine Conditioning Regimen In Patients With Relapsed/Refractory AML Undergoing Stem Cell Transplantation,Oncology,"Oncology: Leukemia, Acute Myelogenous","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Bayer AG","Academic, Government, Industry, Top 20 Pharma","Maximum tolerated dose, Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Mortality, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT03247088,15581
3516,306536,"EudraCT Number: 2006-004822-97, EU-RD-001, TrialTroveID-306536",A Phase I / II Trial to Evaluate the Combination of Infliximab and Sorafenib in the Treatment of Renal Cell Carcinoma,Oncology,Oncology: Renal,Royal Marsden NHS Trust,Government,Safety and Tolerability,"Overall response rate, Overall survival, Progression-free survival, Response rate",False,,15581
3517,306266,"DRKS00012551, EudraCT Number: 2014-005406-38, INTERSORTACE, TrialTroveID-306266",Intermittent Treatment With Sorafenib In Combination With Transarterial Chemoembolization (TACE) In Hepatocellular Carcinoma (HCC): A Randomized Open-Label Phase II Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Complete response, EQ-5D, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Partial response, Quality of Life, Response rate, Safety and Tolerability",False,,15581
3518,305316,TrialTroveID-305316,A prospective biomarker study to assess IGF-1 score ability to sub-stratify Child-Turcotte-Pugh classes and predict response to systemic therapy in hepatocellular carcinoma.,Oncology,Oncology: Liver,"MD Anderson Cancer Center, University of Texas",Academic,"Overall survival, Progression-free survival",,False,,15581
3519,304949,TrialTroveID-304949,Prognostic Role Of Circulating Tumor Cells-Ctcs In Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate",False,,15581
3520,304868,"I 35316, NCI-2017-01114, NCT03211416, TrialTroveID-304868",A Phase Ib/ II Study of Sorafenib and Pembrolizumab in Advanced Hepatocellular Cancer (HCC),Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute, Merck & Co./Merck Sharp & Dohme (MSD)","Government, Academic, Industry, Top 20 Pharma","Complete response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Percentage of Responders, Response rate",Overall survival,True,NCT03211416,15581
3521,303827,"TrialTroveID-303827, UMIN000027619, UroPRO","Effect of systemic chemotherapy, hormonal therapy and immunotherapy on onclogical outcomes and patient reported outcomes in urological cancers (UroPRO study)",Oncology,Oncology: Bladder; Oncology: Prostate; Oncology: Renal; Oncology: Testicular,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3522,303086,"chenxp007, NCT03178656, TrialTroveID-303086",RCT Research: the Treatment of Hepatic Carcinoma With Portal Vein Branch Tumor Thrombosis (Resection or Sorafenib),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Magnetic Resonance Imaging, Mortality, Time to progression",True,NCT03178656,15581
3523,302672,"AML008, NCT03170895, TrialTroveID-302672",A Phase II Single-arm Open-labeled Study Evaluating Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Absolute Neutrophil Count, Complete response, Disease-free survival, Overall survival, Partial response, Platelet count","Disease-free survival, Overall survival",True,NCT03170895,15581
3524,302196,"18-490, AML16, NCI-2017-00928, NCT03164057, PHO-STJUDE-AML16, TrialTroveID-302196, TX10534",A Phase II Trial of Epigenetic Priming in Patients With Newly Diagnosed Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",St. Jude Children's Research Hospital,Academic,Event-free survival,"Event-free survival, Minimal Residual Disease, Overall survival",True,NCT03164057,15581
3525,301618,TrialTroveID-301618,Transarterial chemoembolizaton combined with sorafenib for intermediate-stage hepatocellular carcinoma: a window of tumor burden for survival benefit,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Time to progression",,False,,15581
3526,300751,TrialTroveID-300751,The mechanism of sorafenib anti-leukaemic effect seen in AML patients relapsing post alloHSCT involves the augmentation of alloreactivity which includes infiltration of the affected marrow by CD8+ cells having PD-1 receptor which presence characterize lymphocytes with anti-tumour potential,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Academic Cancer Center),Academic,,,False,,15581
3527,300737,TrialTroveID-300737,Hand-foot-skin reaction of grade two or higher within sixty days as the best response criterion for survival prediction in hepatocellular carcinoma treated by sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival",,False,,15581
3528,300513,TrialTroveID-300513,Treatment-stage Migration Maximizes Survival Outcomes in Patients with Hepatocellular Carcinoma Treated with Sorafenib: An Observational Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3529,299142,TrialTroveID-299142,Early Changes In Perfusion-Computed Tomography Scan Parameters As A Marker Of Improved Outcomes In Patients With Hepatocellular Carcinoma Treated With Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Stable Disease",,False,,15581
3530,298573,"ESCALATOR, NCT03097848, SWHB 019, TrialTroveID-298573",Efficacy and Safety of Combination of Sorafenib as Preoperative Adjuvant and Latter Radiofrequency Ablation in the Treatment Of Recurrent Hepatocellular Carcinoma: A Prospective Multicenter Cohort Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease-free survival,"Mortality, Overall survival, Recurrence",True,NCT03097848,15581
3531,297734,TrialTroveID-297734,A Comparsion of Clinical Outcomes in Patients with Progression after Sorafenib Treated by Best Supportive Care or Other Therapy or Combination of Sorafenib and Cytotoxic Chemotherapy,Oncology,Oncology: Liver; Oncology: Supportive Care,(Other Hospital/Academic/Medical Center),Academic,"Response evaluation criteria in solid tumors, Safety and Tolerability",,False,,15581
3532,297315,TrialTroveID-297315,Metformin Effects On Clinical Outcome In Advanced HCC Patients Receiving Sorafenib: Validation Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3533,297309,TrialTroveID-297309,"Sorafenib With Or Without Transarterial Chemoembolization Plus Radiofrequency Ablation For Advanced Recurrent Hepatocellular, Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3534,297230,"HKUCTR-2033, HKU-MONC-HCC-003, NCT03578874, TrialTroveID-297230","A Combination of Sorafenib, Capecitabine and Oxaliplatin (SECOX) as Neoadjuvant Therapy in Patients with Locally Advanced Hepatocellular Carcinoma: A Phase II Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03578874,15581
3535,295538,TrialTroveID-295538,Effectiveness and safety of sorafenib for unresectable and advanced intrahepatic cholangiocarcinoma: A pilot study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,"Adverse Events, Overall survival, Progression-free survival, Time to progression",False,,15581
3536,295139,"CTMS 16-0076, HSC20160515H, NCI-2017-00157, NCT03037437, TrialTroveID-295139",Modulation of Sorafenib Induced Autophagy Using Hydroxychloroquine in Hepatocellular Cancer,Oncology,Oncology: Liver,University of Texas Health Science Center at San Antonio,Academic,"Magnetic Resonance Imaging, Response evaluation criteria in solid tumors, Time to progression","Adverse Events, Overall response rate, Overall survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03037437,15581
3537,293570,"MPVTT, NCT03009461, TrialTroveID-293570",Randomized Trial of Sorafenib Plus Hepatic Arterial Infusion With Oxaliplatin and Fluorouracil Versus Sorafenib for Hepatocellular Carcinoma With Major Portal Vein Tumor Thrombosis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall response rate, Progression-free survival, Safety and Tolerability",True,NCT03009461,15581
3538,293176,TrialTroveID-293176,Efficacy Of Low Dose Capecitabine And Sorafenib In Patients With Advanced Alfa-Fetoprotein Secreting Hepatocellular Carcinoma: A 1 Year Experience,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3539,293022,"ChiCTR-IPR-16010204, TrialTroveID-293022","Prevention of Recurrence after Liver Transplantation for Hepatocellular Carcinoma: Comparison fo Iodine[131I] Metuximab Injection, Sorafenib, Chemotherapy and Iodine[131I] Metuximab Injection combined with Sorafenib.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to response,Overall survival,False,,15581
3540,292151,TrialTroveID-292151,Effect of Sorafenib on Hepatitis C Viremia in Cirrhotic Patients with Hepatocellular Carcinoma,Infectious Disease,Infectious Disease: HCV,"MD Anderson Cancer Center, University of Texas",Academic,Degree of viremia,,False,,15581
3541,291851,"HCC-S027, NCT02981498, TrialTroveID-291851","Phase II Trial of Sorafenib Combined With Concurrent Hepatic Arterial Infusion (HAI) of Oxaliplatin, 5-fluorouracil and Leucovorin for Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Clinical benefit rate, Overall response rate, Overall survival",True,NCT02981498,15581
3542,291294,"NCT02973204, SK-HCC-NET, TrialTroveID-291294",Circulating Tumor Cells and Tumor DNA in HCC and NET - Patient-specific Biomarkers for Clinical Decision Support and Tailored Relapse Diagnostics,Oncology,Oncology: Liver; Oncology: Neuroendocrine,Aarhus University Hospital,Academic,Circulating Tumor Cells,"Circulating Tumor Cells, Response evaluation criteria in solid tumors",True,NCT02973204,15581
3543,291166,"40, NCT02971696, TrialTroveID-291166",Sorafenib Versus Best Supportive Care in Egyptian Hepatocellular Carcinoma Patients. Prospective Phase III Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Event-free survival, Overall survival",Quality of Life,True,NCT02971696,15581
3544,290565,"2016-FXY-006, NCT02961998",Preventive Effect of Celecoxib on Sorafenib-related Hand Foot Syndrome,,NA: ClinicalTrials.gov,Sun Yat-sen University,ClinicalTrials.gov,,,True,NCT02961998,15581
3545,289760,TrialTroveID-289760,"A Randomized, Prospective, Comparative Study about Effects and Safety of Sorafenib vs. Hepatic Arterial Infusion Chemotherapy for Advanced Hepatocellular Carcinoma Patients with Portal Vein Tumor Thrombosis",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3546,289132,TrialTroveID-289132,Can Sorafenib Increase Survival For Recurrent Hepatocellular Carcinoma After Liver Transplantation?,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Recurrence,,False,,15581
3547,289074,TrialTroveID-289074,A Novel Biomarker-Based Model for the Prediction of Response to Sorafenib and Overall Survival for Advanced Hepatocellular Carcinoma: A Prospective Cohort Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3548,287584,TrialTroveID-287584,Comparison Between Liver Transplantation and Sorafenib for BCLC B or C Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Time to progression,False,,15581
3549,287583,TrialTroveID-287583,A clinical evaluation of sorafenib treatment and HAIC for advanced hepatocellular carcinoma (HCC),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3550,287430,TrialTroveID-287430,A Clinical Study on Effect of Sorafenib on Liver Fibrogenesis in Patients with Cirrhosis and Hepatocellular Carcinoma,Autoimmune/Inflammation,Autoimmune/Inflammation: Hepatic Fibrosis,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3551,287380,TrialTroveID-287380,A Clinical Study on Prediction of Outcome by MELD Scores in Patients with Hepatocellular Carcinoma Treated with Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3552,287302,TrialTroveID-287302,Neutrophil-to-lymphocyte Ratio (NLR) is Predictive Factor for Survival in Patients with Advanced Hepatocellular Carcinoma Treated by Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Liver function, Overall survival",,False,,15581
3553,286780,"1601017096, NCT02908165, TrialTroveID-286780",Randomized Phase II Trial of Chemoembolization and Sorafenib: Comparison Between Continuous and Sequential Treatment Regimens,Oncology,Oncology: Liver,Yale University,Academic,"Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease",Overall survival,True,NCT02908165,15581
3554,286656,"CTR20160541, TrialTroveID-286656, YY-2016-001-HN","An Open, Balanced, Randomized, Single-Dose, Two Formulations, Two Serial, Two Period Crossover Study To Evaluate Bioequivalence Of Sorafenib Tosylate In Healthy  Volunteers",Oncology,Oncology: Liver,Shanghai Fosun Pharmaceutical (Group) Co./YaoPharma Co.,"Industry, generic","Area under the curve score, Cmax, Safety and Tolerability","Safety and Tolerability, Tmax",False,,15581
3555,284606,"NCT02867891, SIRA, TrialTroveID-284606","Multicenter, Observational Trial to Determine the Response Rate of Sorafenib and Donor Lymphocyte Infusions (DLI) Versus Best Available Treatment (BAT) in FLT3-ITD-mutant AML Relapse After Allogeneic Hematopoietic Cell Transplantation",Oncology,"Oncology: Leukemia, Acute Myelogenous",University of Freiburg,Academic,Complete response,Overall survival,True,NCT02867891,15581
3556,284419,"NCT02867280, Sorafenib-MVI, TrialTroveID-284419",A Prospective Multicenter Non-randomized Controlled Study of Sorafenib (Nexavar) Treatment in Patients With Hepatocellular Carcinoma With Microvascular Invasion After Radical Resection,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall survival","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Time to response, Treatment Emergent Adverse Events",True,NCT02867280,15581
3557,283472,"EudraCT Number: 2015-004108-44, NCT02847468, PREMETHEP, TrialTroveID-283472",Multimetabolic 18F-Fluorodeoxyglucose (FDG) and 18F-Fluorocholine (FCH) Positron Emission Tomography (PET) as an Early Predictive Factor of Overall Survival in Patients With Advanced Hepatocellular Carcinoma Treated With Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT02847468,15581
3558,282546,"ACTES, CHUBX 2014/25, NCT02834546, TrialTroveID-282546","Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Adverse Events, Magnetic Resonance Imaging, Overall survival, Progression-free survival",True,NCT02834546,15581
3559,282052,"Bisgrove, NCT00530192, SCRI-CA-001, TrialTroveID-282052",A Pilot Study Utilizing Molecular Profiling of Patients' Tumors to Find Potential Targets and Select Treatments for Their Refractory Cancers,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Ovarian",(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00530192,15581
3560,282038,"BAY43-9006/13337, EudraCT Number: 2008-006022-34, TrialTroveID-282038",Randomized Phase II Study of Sorafenib Plus Bicaluamide vs. Placebo Plus Bicalutamide in Castration-Resistant Asymptomatic or Mildly Symptomatic Metastatic Prostate Cancer Patients Who Had Orchiectomy or are Receiving a LHRH Analogue,Oncology,Oncology: Prostate,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, PSA progression, Response rate, Safety and Tolerability",False,,15581
3561,281789,"ChiCTR-IOR-16008729, DLY201507, NCT02836847, TrialTroveID-281789","A Multicentre, Open-label, Randomised, Controlled Study of Molecularly Precision Target Therapy Based on Tumor Molecular Profiling With GEMOX in Advanced or Recurrent Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02836847,15581
3562,280074,"TrialTroveID-280074, UMIN000022324",Pilot Study Of The Combination Of Sorafenib and Fractionated Irinotecan In Pediatric Relapse/Refractory Hepatic Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Dose-limiting toxicities,Adverse Events,False,,15581
3563,279928,"160121, 16-C-0121, COXEN, NCI-16-C-0121, NCI-2016-00966, NCI-2018-03327, NCT02788201, P152399, TrialTroveID-279928",A Pilot Clinical Trial of Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,,"Adverse Events, Circulating Tumor Cells, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT02788201,15581
3564,279227,"NCI-2016-00083, NCT02779283, TrialTroveID-279227",A Phase Ib Feasibility Study of Personalized Kinase Inhibitor Therapy Combined With Induction in Acute Leukemias Who Exhibit In Vitro Kinase Inhibitor Sensitivity,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, OHSU Cancer Institute","Government, Academic",,"Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Dose-limiting toxicities, Minimal Residual Disease, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT02779283,15581
3565,279108,TrialTroveID-279108,The Efficacy and Safety of Sorafenib Treatment on Iodide Refractory Metastatic differentiated Thyroid Carcinomas,Oncology,Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3566,278222,"TrialTroveID-278222, UMIN000021981",Prognostic Evaluation With Focus On Renal Function Of Molecular Target Drugs For Unresectable Or Metastatic Renal Cell Carcinoma Patients With Renal Dysfunction,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",False,,15581
3567,278221,"FINEX, TrialTroveID-278221, UMIN000021931",Pilot Study Of The Combination Of Sorafenib And Fractionated Irinotecan In Pediatric Relapse/Refractory Hepatic Cancer,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Overall survival, Progression-free survival, Serious Adverse Events",False,,15581
3568,277361,"Huashan 003, NCT02748304, TrialTroveID-277361",A Prospective Randomized Control Trial of the Effect of Sorafenib Combined With Aspirin in Preventing the Recurrence in High-risk Patients With Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Fudan University - Shanghai, China",Academic,Overall survival,Disease-free survival,True,NCT02748304,15581
3569,277232,"201605006, NCI-2016-00680, NCT02747537, TrialTroveID-277232",Phase II Clinical Trial Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With the Genomically-Targeted Agent Sorafenib in Combination With Irinotecan,Oncology,Oncology: Unspecified Solid Tumor,Washington University School of Medicine,Academic,"Complete response, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Progressive disease rate, Time to progression",True,NCT02747537,15581
3570,276912,TrialTroveID-276912,"A Clinical Study to Evaluate the Usefulness Of Carbonic Anhydrase IX Baseline, Evolutive Angiopoyetin 2 and Optimization Of Survival Prediction In Patients Under Sorafenib Treatment",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3571,276894,"INNOVATE, IRSTB051, NCT02786342, TrialTroveID-276894",Italian Multicentric Prospective Study of Validation of Angiogenesis Polymorphisms In HCC Patients Treated With Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall survival, Progression-free survival",True,NCT02786342,15581
3572,276581,TrialTroveID-276581,A Large Mixed-race Prospective Cohort Study on Integration of the Cancer-Related Pro-Inflammatory Response as a Stratifying Biomarker of Survival Benefit with Sorafenib in Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3573,276572,"KSULDRCSSMH001, NCT02733809, TrialTroveID-276572",Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",,True,NCT02733809,15581
3574,276271,"9510, NCI-2016-00286, NCT02728050, RG1016000, TrialTroveID-276271","Addition of Sorafenib to G-CSF, Cladribine, Cytarabine and Mitoxantrone (G-CLAM) in Adults With Newly-Diagnosed Acute Myeloid Leukemia (AML) Independent of FLT3-ITD Status: A Phase I/II Study",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms","National Institutes of Health/National Cancer Institute, Bayer AG, University of Washington","Government, Industry, Top 20 Pharma, Academic","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Minimal Residual Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Disease-free survival, Event-free survival, Minimal Residual Disease, Neutropenia, Overall response rate, Overall survival, Partial response, Quality of Life, Safety and Tolerability",True,NCT02728050,15581
3575,275366,"HKU-MONC-HCC-001, NCT02716766, SECOX, TrialTroveID-275366","Randomised Phase II Trial of Sorafenib, Capecitabine and Oxaliplatin (SECOX) Versus Single Agent Sorafenib in Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Sexual Desire",True,NCT02716766,15581
3576,274968,"ChiCTR-ONRC-11001849, TrialTroveID-274968",Study Of Sorafenib And Transarterial Chemoembolization (TACE) Versus TACE To Treat Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Clinical benefit rate, Overall survival, Progression-free survival",False,,15581
3577,274342,"ChiCTR-IPC-14005410, TrialTroveID-274342",Prospective Phase II Trial To Evaluate Efficacy And Safety Of Systemic Therapy In Combination With Entecavir In Advanced Or Metastatic Hepatocellular Carcinoma With Chronic Hepatitis B,Infectious Disease; Oncology,Infectious Disease: HBV; Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Overall response rate, Overall survival, Progression-free survival, Recurrence",False,,15581
3578,274131,"ChiCTR-TNRC-11001557, TrialTroveID-274131","A Multi-Center, Non-Randomized Control Clinical Trial for Gemcitabine and Oxaliplatin Combined With Sorafenib for HCC",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Time to progression",False,,15581
3579,273792,"2016-02-097, NCT02691780, TrialTroveID-273792","Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Safety and Tolerability, Time to progression",True,NCT02691780,15581
3580,273524,"ChiCTR-ONN-16007928, TrialTroveID-273524","TACE plus sorafenib VS TACE monotherapy for the treatment of Multi-nodular hepatocellular carcinoma (Stage BCLC B): A prospective, multi-center comparison study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Clinical benefit rate, Time to progression",False,,15581
3581,272520,"METSOR, NCT02672488, TrialTroveID-272520",Safety and Efficacy of Metformin Plus Sorafenib as First-line Therapy in Patients With Advanced Hepatocellular Carcinoma(BCLC-C): A Phase II Randomized Study,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic",Overall survival,"Overall response rate, Progression-free survival, Time to progression",True,NCT02672488,15581
3582,270834,"ACTRN12616001187437, MatchMel, MIA2015/174, MIA-M-15-01, NCT02645149, TrialTroveID-270834",Molecular Profiling and Matched Targeted Therapy for Patients With Metastatic Melanoma,Oncology,Oncology: Melanoma,"(Other Cooperative Group), National Health and Medical Research Council  (NHMRC)","Cooperative Group, Government",,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02645149,15581
3583,270346,"2015-08-008, NCT02638428, TrialTroveID-270346",Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Unspecified Solid Tumor","(Other Hospital/Academic/Medical Center), Ministry of Health &  Welfare of the Republic of Korea","Academic, Government","Disease Progression, Event-free survival, Treatment related mortality","Common Terminology Criteria for Adverse Events, Treatment Emergent Adverse Events",True,NCT02638428,15581
3584,270129,"2015.224, EudraCT Number: 2015-001379-37, NCT02636426, NL53039.029.15, NTR5571, SOPRANO, TrialTroveID-270129","Sorafenib Administered Using a High-dose, Pulsatile Regimen in Patients With Advanced Solid Malignancies: A Phase I Exposure Escalation Study",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, NCI-CTC scale, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Cmax, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Tmax",True,NCT02636426,15581
3585,269436,"HM20005967, MCC-14-10790, NCI-2015-02190, NCT02624700, TrialTroveID-269436",Phase II Study of Pemetrexed and Sorafenib for Treatment of Recurrent or Metastatic Triple Negative Breast Cancer,Oncology,Oncology: Breast,"Eli Lilly, (Other Cooperative Group), Bayer AG, Virginia Commonwealth University","Industry, Top 20 Pharma, Cooperative Group, Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT02624700,15581
3586,268744,TrialTroveID-268744,"A Prospective Cohort Study for Evaluating Clinical Effects and Safety of Intra-arterial Infusion Therapy of Cisplatin Suspension in Lipiodol Combined with 5-fluorouracil and Sorafenib for Advanced Hepatocellular Carcinoma with  Macroscopic Vascular Invasion, Without Extra-hepatic Spread",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,15581
3587,267835,TrialTroveID-267835,A Clinical Study on Pro-angiogenic Tie2-expressing Monocytes/TEMs as a Biomarker of the Response to Sorafenib in Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",,False,,15581
3588,267783,TrialTroveID-267783,A Clinical Study on Combination of Modified Response Evaluation Criteria in Solid Tumors and Hand-foot-skin Reaction for Hepatocellular Carcinoma Patients Treated with Sorafenib and Transarterial Chemoembolization,Oncology,Oncology: Liver,(Other government agency),Government,"Overall survival, Response evaluation criteria in solid tumors",,False,,15581
3589,267777,"EudraCT Number: 2013-001525-10, NTR4110, SORA-RIFA, TrialTroveID-267777",Studying the metabolism of sorafenib (Nexavar) by OATP1B blockage in adult cancer patients.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Plasma pharmacokinetics,,False,,15581
3590,267590,"2008-0059 Phase II, NCI-2012-01617, NCT02599090, TrialTroveID-267590",Phase II Portion of Multi Phase Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma,Oncology,"Oncology: CNS, Glioblastoma","MD Anderson Cancer Center, University of Texas, Bayer AG","Academic, Industry, Top 20 Pharma",Time to progression,,True,NCT02599090,15581
3591,267583,"150230, NCT02599337, TrialTroveID-267583","Randomized, Open-label, 3-way Reference Replicated Crossover Bioequivalence Study of Sorafenib 200 mg Tablet and Nexavar (Reference) Following a 200 mg Dose in Healthy Subjects Under Fasting Conditions",Oncology,Oncology: Unspecified Cancer,Yabao Pharmaceutical Group Co.,"Industry, all other pharma","Area under the curve score, Cmax","Adverse Events, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT02599337,15581
3592,267024,TrialTroveID-267024,Early Tumor Shrinkage Under Treatment With First-Line Tyrosine Kinase Inhibitors As A Surrogate Endpoint of Overall Survival In Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3593,265222,"GU-14-102, HSC-14-0665, NCT02560012, TrialTroveID-265222",Targeting of Renal Cell Cancer With Specific Inhibitors: A Model for Selective Adaptive Medicine Based on Molecular Alterations,Oncology,Oncology: Renal,University of Texas- Houston Medical School,Academic,"Disease Progression, Progression-free survival",,True,NCT02560012,15581
3594,265106,"NCT02559778, NMTRC012, PEDS-PLAN, TrialTroveID-265106",A Study Using Molecular Guided Therapy With Induction Chemotherapy Followed by a Randomized Controlled Trial of Standard Immunotherapy With or Without DFMO Followed by DFMO Maintenance for Subjects With Newly Diagnosed High-Risk Neuroblastoma,Oncology,Oncology: Neuroblastoma,"(Other Industry Sponsor), (Other Cooperative Group), KC Pharma","Industry, all other pharma, Cooperative Group, Industry, generic",,"Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Overall response rate, Treatment Emergent Adverse Events",True,NCT02559778,15581
3595,264768,"ChiCTR-TRC-13003243, TrialTroveID-264768",A randomized controlled study on TACE combined with three-dimensional conformal radiotherapy compared with oral sorafenib treatment for unresectable hepatocellular carcinoma with portal vein tumor thrombus,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Liver function, Overall survival, Stable Disease",,False,,15581
3596,264619,"9226, NCI-2015-01299, NCT02551718, RG1015012, TrialTroveID-264619",Individualized Treatment for Relapsed/Refractory Acute Leukemia Based on Chemosensitivity and Genomics/Gene Expression Data,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic",,"Complete response, Overall response rate - duration, Overall survival",True,NCT02551718,15581
3597,264436,"chictr-onc-11001681, TrialTroveID-264436",Targeted therapy with sunitinib or sorafenib combining with gemcitabine plus cisplatin in the treatment of metastatic collecting duct carcinoma of the kidney,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
3598,264095,"2015/91, EudraCT Number: 2014-004830-25, KIT, TrialTroveID-264095",Kidney Cancer Integrated Therapy (KIT) - Personalized integrated therapy for patients with advanced kidney cancer,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Circulating Tumor Cells, Quality of Life",False,,15581
3599,264011,"18175, EudraCT Number: 2015-002083-16, NCT02538393, TrialTroveID-264011","An Open Label, Randomized, Four-Way Crossover Study In Healthy Male Subjects To Assess The Relative Bioavailability Of Sorafenib Tablet For Oral Suspension Compared To Marketed Tablet And To Investigate The Pharmacokinetics Of Sorafenib Tablet For Oral Suspension Including Food Effect And Dose Proportionality.",Oncology,Oncology: Unspecified Cancer,Bayer AG,"Industry, Top 20 Pharma","Area under the curve score, Bioavailability, Cmax","Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT02538393,15581
3600,263896,"CH-GI-077, NCT02537158, TrialTroveID-263896",Sorafenib and TACE as Adjuvant Therapy for MVI in HCC Patients After Radical Resection:a Non-randomized Controlled Trial,Oncology,Oncology: Liver,Chinese Academy of Medical Sciences,Government,Disease-free survival,Overall survival,True,NCT02537158,15581
3601,263434,"2014-0975, NCI-2015-01523, NCT02530476, TrialTroveID-263434","Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Karyopharm Therapeutics","Academic, Government, Industry, all other pharma","Complete response, Composite complete response, Cytogenetic response, Dose-limiting toxicities, Maximum tolerated dose","Complete response, Composite complete response, Cytogenetic response, Duration of overall response, Event-free survival, Hematologic Improvement, Neutropenia, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Platelet count, Response rate, Safety and Tolerability",True,NCT02530476,15581
3602,263399,"NCT02529761, S-T 002, TrialTroveID-263399",Transarterial Chemoembolization (TACE) With or Without Sorafenib in Intermediate Stage Hepatocellular Carcinoma: a Multicenter Prospective Nonrandomized Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT02529761,15581
3603,261917,"104-1686A3, NCT02504983, TrialTroveID-261917","Randomized, Open Label, Clinical Trial for GALNT14 Genotype - Guided, Sorafenib in Combination With TACE Therapy in Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT02504983,15581
3604,259836,"NCT02474290, Sorafenib-Flt3 AML-2015, TrialTroveID-259836",Sorafenib for Prophylaxis of Leukemia Relapse in Allogeneic Hematopoietic Stem Cell Transplant Recipients with FLT3-ITD Positive Acute Myeloid Leukemia.,Oncology,"Oncology: Leukemia, Acute Myelogenous","Peking Union Medical College Hospital, CAMS, Beijing, China, (Other Hospital/Academic/Medical Center)","Academic, Academic",,"Disease-free survival, Overall survival",True,NCT02474290,15581
3605,258741,"RAI-skip, TrialTroveID-258741, UMIN000017777",The Study Evaluating The Efficacy and Safety Of Sorafenib in Patients with Differentiated Thyroid Cancer Not Amendable to Radioactive Iodine Therapy and Other Alternative Treatment.,Oncology,Oncology: Thyroid,"Bayer AG/Bayer Yakuhin, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall response rate, Response rate","Adverse Events, Clinical benefit rate, Growth velocity, Overall survival, Progression-free survival",False,,15581
3606,258508,TrialTroveID-258508,Tyrosine-kinase inhibitor sorafenib (S) in treatment of metastatic renal cell carcinoma cancer (mRCC) with lung metastases.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",,False,,15581
3607,257857,"2015-02-002, NCT02450149, TrialTroveID-257857","Single-arm Study to Evaluate the Safety and Efficacy of Sorafenib, in Subjects With BRAF Mutation Refractory Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Time to progression",True,NCT02450149,15581
3608,257544,TrialTroveID-257544,Assessment of second-line VEGF-inhibitor therapy in radioiodine-refractory (RAIR) differentiated thyroid cancer (DTC).,Oncology,Oncology: Thyroid,Memorial Sloan-Kettering Cancer Center,Academic,,,False,,15581
3609,257471,TrialTroveID-257471,Prognostic significance of early dynamics of peripheral blood counts in patients with AML/MDS undergoing induction chemotherapy.,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, Baylor College of Medicine","Academic, Academic",,,False,,15581
3610,257380,"EudraCT Number: 2014-005341-44, ICT, TrialTroveID-257380",Molecular-Biological Tumor Profiling for Drug Treatment Selection in Patients with Advanced and Refractory Carcinoma,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,15581
3611,257227,"TrialTroveID-257227, UMIN000017373",Clinical investigation of therapeutic effects of sorafenib on cutaneous angiosarcoma,Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3612,257087,"A-TACE/S-HCC, NCT02436902, TrialTroveID-257087",Adjuvant Transarterial Chemoembolization with or without Sorafenib for Patients with Hepatocellular Carcinoma and Microvascular Invasion,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Mortality, Recurrence",True,NCT02436902,15581
3613,257075,"EudraCT Number: 2014â003925â16, TrialTroveID-257075","An Open-Label, Prospective and Randomized Study on Efficacy and Safety of Combined Sequential Treatment with Radiofrequency Ablation (RFA) and Sorafenib in Patients with HCC in Intermediate Stage Ineligible for Transarterial Chemoembolization (TACE)",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Safety and Tolerability,False,,15581
3614,256337,"4-2014-0803, NCT02425605, TrialTroveID-256337",Efficacy of Localized Concurrent Chemo-radiation Therapy and Sorafenib Sequential Therapy in Advanced Hepatocellular Carcinoma: a Prospective Phase II Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02425605,15581
3615,255171,"Epigenetic, NCT02412475, TrialTroveID-255171","Epigenetic Reprogramming in Relapse AML: A Phase I Study of Decitabine and Vorinostat Followed by Fludarabine, Cytarabine and G-CSF (FLAG) in Children and Young Adults With Relapsed/Refractory AML",Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Maximum tolerated dose",Gene expression profiling,True,NCT02412475,15581
3616,254857,"14-523, NCI-2015-00915, NCT02406521, ONC-2014-092, TrialTroveID-254857",Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Bayer AG","Academic, Industry, Top 20 Pharma","Bone turnover marker, C-terminal telopeptide measurements, N-terminal telopeptide measurements","Brief Pain Inventory, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02406521,15581
3617,252906,"e:Med Tuebingen, e:Med-HCC-1, HCC Multiscale Trial-1, NCT02372162, Protocol #1, TrialTroveID-252906",Fingerprint characterization of advanced HCC to optimize treatment decisions and enable an early prediction of therapy resistance (HCC Multiscale Trial-1),Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",,,True,NCT02372162,15581
3618,249852,"17436, EudraCT Number:2014-001907-36, NCT02332031, TrialTroveID-249852",An Open-label Study in Healthy Male Subjects to Assess the Effect of Hyperthyroidism Mimicked by Oral Dosing of Levothyroxine on the Pharmacokinetics of Sorafenib,Oncology,Oncology: Unspecified Cancer,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Area under the curve score,"Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Safety and Tolerability, Safety and Tolerability, Tmax, Volume of distribution",True,NCT02332031,15581
3619,243262,TrialTroveID-243262,A Clinical Study on Outcomes in patients with Hepatocellular Carcinoma After Hepatitis C Viral Eradication by Antiviral Therapy,Infectious Disease; Oncology,Infectious Disease: HCV; Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3620,243058,"14-494, N2013-02, NANT 2013-02, NCI-2015-00984, NCT02298348, TrialTroveID-243058",NANT N2013-02 A Phase I Study of Sorafenib and Cyclophosphamide/Topotecan in Patients With Relapsed and Refractory Neuroblastoma,Oncology,Oncology: Neuroblastoma,"(Other Cooperative Group), Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, University of California, San Francisco, (Other Hospital/Academic/Medical Center), The Hospital for Sick Children, Seattle Children's Hospital","Cooperative Group, Academic, Academic, Academic, Academic, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose",,True,NCT02298348,15581
3621,241735,"Bayer IST000266, MCC-15783, NCT00964743",A Single Arm Pilot Study of Intrathecally Administered DepoCyt?? With Systemic Sorafenib in the Treatment of Neoplastic Meningitis From Solid Tumors,,NA: ClinicalTrials.gov,"H. Lee Moffitt Cancer Center and Research Institute, Bayer","Academic, ClinicalTrials.gov",Adverse Events,,True,NCT00964743,15581
3622,241559,"09-094, NCT00942682",Phase I Study of Sorafenib in Combination With RAD001 in Patients With Advanced Neuroendocrine Tumors,,NA: ClinicalTrials.gov,"Novartis, Bayer, Dana-Farber Cancer Institute","Industry, Top 20 Pharma, ClinicalTrials.gov, ClinicalTrials.gov","Dose-limiting toxicities, Maximum tolerated dose","Safety and Tolerability, Safety and Tolerability",True,NCT00942682,15581
3623,240959,"NCT00864032, STS Sorafenib",Phase I/II Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall,,NA: ClinicalTrials.gov,"Bayer, University of California, Davis","ClinicalTrials.gov, ClinicalTrials.gov",Dose-limiting toxicities,,True,NCT00864032,15581
3624,240301,"EudraCT 2008-000759-91, NCT00786110, PAXO",Sorafenib Plus Paclitaxel Metronomic Chemotherapy in Adreno-Cortical-Carcinoma Patients Progressing After 1st or 2nd Line Cytotoxic Chemotherapy,,NA: ClinicalTrials.gov,"University of Turin, Italy",ClinicalTrials.gov,Disease-free survival,,True,NCT00786110,15581
3625,238923,"14374B, Barrett's, NCT00619242",A Pilot Study of the Effect of Sorafenib on Molecular Biomarkers in Barrett's Esophagus With High Grade Dysplasia,,NA: ClinicalTrials.gov,"Bayer, University of Chicago","ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT00619242,15581
3626,238808,"NCT00605566, SORNET, SOR-NET-001, TrialTroveID-238808",Tailored-dose Sorafenib Plus Metronomic Cyclophosphamide in Advanced Neuroendocrine Tumors (NET): a Phase II Clinical Trial Based on Individual Pharmacodynamic Assessment,Oncology,Oncology: Neuroendocrine,"University Health Network, Toronto",Academic,"Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Overall survival, Progression-free survival, Progressive disease rate",True,NCT00605566,15581
3627,238017,"Bayer Protocol# 12138, DDPDRO-002, NCT00510250",A Phase I/II Study of Cisplatin and Radiation in Combination With Sorafenib in Cervical Cancer,,NA: ClinicalTrials.gov,"University Health Network, Toronto, Bayer","Academic, ClinicalTrials.gov",,Disease-free survival,True,NCT00510250,15581
3628,235963,"060083, 06-C-0083, NCT00287495",Phase I and Pharmacokinetic Study of BAY 43-9006 (Sorafenib) in Patients With Kaposi's Sarcoma,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,,True,NCT00287495,15581
3629,234452,"7046, CDR0000437792, MC044H, N01CM62205, NCI-2009-00121, NCT00131911",A Phase II Trial of Bay 43-9006 in Progressive Metastatic Neuroendocrine Tumors,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,,True,NCT00131911,15581
3630,231750,"819185, NCT02021929, SHPS, UM1HL116886",Sorafenib in Patients With Hepatopulmonary Syndrome: A Double-Blind Randomized Clinical Trial,,NA: ClinicalTrials.gov,"University of Pennsylvania, National Heart, Lung, and Blood Institute (NHLBI)","Academic, ClinicalTrials.gov",,,True,NCT02021929,15581
3631,231676,"GIHSYSU04, GITIC, NCT02013089, TrialTroveID-231676",A Pilot Study of Genomic Sequencing Guided Individualized Therapy in Gastrointestinal Cancers,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Clinical benefit rate, Overall response rate, Response rate",True,NCT02013089,15581
3632,229496,"1002006266, NCT01714609","A Multi-Center, Placebo-Controlled Randomized Pilot of the Effect of Sorafenib on Portal Pressure in Patients With Cirrhosis, Portal Hypertension and Hepatocellular Carcinoma Treated With Ablative Therapy and/or Transarterial Chemoembolization",,NA: ClinicalTrials.gov,"Yale University, Onyx Therapeutics, Inc.","Academic, ClinicalTrials.gov",,,True,NCT01714609,15581
3633,228463,"AAML12B8, CDR0000730390, COG-AAML12B8, NCI-2012-00724, NCT01576185",Development of Pediatric Acute Myeloid Leukemia Xenograft Models for the Testing of Targeted Therapeutic Agents,,NA: ClinicalTrials.gov,"Children's Oncology Group, National Cancer Institute (NCI)","ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT01576185,15581
3634,227915,"NCT01507740, Praemarker AAT 08",Profile of Soluble and Cellular Biomarkers and of Functional Imaging During Antiangiogenic Therapies in Cancer Patients,,NA: ClinicalTrials.gov,Medical University Innsbruck,ClinicalTrials.gov,,,True,NCT01507740,15581
3635,227264,"NCT01425216, Tirgan 11-05",Phase II Trial of Sorafenib in Patients With Extensive Keloids,,NA: ClinicalTrials.gov,"Tirgan, Michael H., M.D.",ClinicalTrials.gov,,Serious Adverse Events,True,NCT01425216,15581
3636,226601,"2010-019726-14, NCT01342627, SERCC",Sorafenib in Elderly Patients With Metastatic Renal Cell Carcinoma (SERCC Study) Impact of Adverse Events Management in Elderly mRCC Patients Treated With Sorafenib,,NA: ClinicalTrials.gov,Centro di Riferimento Oncologico - Aviano,Academic,,Adverse Events,True,NCT01342627,15581
3637,222663,TrialTroveID-222663,A Clinical Study on Impact of Deviation from Guidelines Recommendation in a Real Life Treatment of Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3638,222423,"2014-0902, COTSOM, COTSOM Study, NCT02311205, TrialTroveID-222423","A Phase II, Prospective, Open-label, Single Arm Study of the Efficacy and Safety of Concurrent Conventional TACE and Sorafenib in Patients with Hepatocellular Carcinoma and Extrahepatic Metastasis (COTSOM Study)",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Asan Medical Center","Industry, Top 20 Pharma, Academic",Overall survival,"Adverse Events, Clinical benefit rate, Complete response, Overall response rate, Partial response, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT02311205,15581
3639,222197,"TrialTroveID-222197, UMIN000015739","The efficacy of HAIC in combination with sorafenib: multicenter, phase II study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival, Progression-free survival, Response rate",,False,,15581
3640,221890,"17852, 20160142, 20160142, NCI-2015-02094, NCT02303444, NX1401, PHRR180618-001031, RIFTOS MKI, STU 022015-083, TrialTroveID-221890",RIFTOS MKI - Radioactive Iodine reFractory Asymptomatic Patients in Differentiated Thyroid Cancer - an Observational Study to Assess the Use of Multikinase Inhibitors,Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,"Adverse Events, Complete response, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT02303444,15581
3641,221815,TrialTroveID-221815,A Clinical Study on Circulating SCCA-Igm Complex Biomarker in the Prediction of Therapy Outcome In Hepatocellular Carcinoma (HCC) Patients,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3642,220813,"14.10.0021, 17932, MCC 17932, MCC-17932, NCI-2014-02614, NCT02292173, TrialTroveID-220813",A Phase Ia/Ib Trial of Trametinib in Combination With Sorafenib in Patients With Advanced Hepatocellular Cancer,Oncology,Oncology: Liver,H. Lee Moffitt Cancer Center and Research Institute,Academic,"Dose-limiting toxicities, Maximum tolerated dose","Clinical benefit rate, Complete response, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT02292173,15581
3643,220781,"TrialTroveID-220781, UMIN000015696",Safety and efficacy of tyrosine kinase inhibitors for the treatment of severe and progressive pulmonary hypertension,Cardiovascular,Cardiovascular: Hypertension,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability",,False,,15581
3644,220537,"1149818, 173794, 1-854066-1, 20141916, Acoba 2014 -1, NCI-2014-02378, NCT02288507, TrialTroveID-220537",Phase I Study of Sorafenib Concurrent with Yttrium-90 Transarterial Radioembolization in Patients with Advanced Hepatocellular Cancer.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT02288507,15581
3645,220034,TrialTroveID-220034,A Clinical Study on Assessment of Therapeutic Response to Sorafenib for Advanced Hepatocellular Carcinoma by Automatic Measurements of Tumor Volume and Density on Computed Tomography,Oncology,Oncology: Liver,"(Other Industry Sponsor), (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Academic","Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",,False,,15581
3646,219862,"ChiCTR-TRC-14004737, TrialTroveID-219862","The outcome of gemcitabine, sorafenib and S1 combination in the treatment of inoperable hilar cholangiocarcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3647,219526,TrialTroveID-219526,Sorafenib and locoregional deep electro-hyperthermia in advanced hepatocellular carcinoma: A phase II study.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Mortality, Overall survival, Progressive disease rate, Time to progression",False,,15581
3648,218597,TrialTroveID-218597,The Predictive Value of Bone Morphogenetic Protein 9 (BMP-9) in the Serum of HCC Patients Treated with Sorafenib.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3649,217650,"AUPSG 01/07, EudraCT Number: 2007-002370-64, TrialTroveID-217650","Multi-center, randomized, double-blind phase II study of sorafenib or placebo with best supportive care after failure of deocetaxol in metastatic hormone-refractory prostate cancer.",Oncology,Oncology: Prostate,(Other Cooperative Group),Cooperative Group,"Partial response, Stable Disease","EORTC Quality of Life Questionnaire, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",False,,15581
3650,216665,"TrialTroveID-216665, UMIN000014999",Comparison of Sorafenib and DEB-TACE in Patients With Hepatocellular Carcinoma Refractory to Conventional TACE.,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Overall survival,"Overall response rate, Progression-free survival, Response rate",False,,15581
3651,213651,"EudraCT Number: 2011-006350-87, HORUS, TrialTroveID-213651",HydrOxychloRoqUine and Sorafenib in locally advanced or Metastatic Hepatocellular Carcinoma as First line therapy: a multi-center phase II trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,15581
3652,213520,"2014-0076, NCI-2014-01702, NCT02196857, TrialTroveID-213520",Phase II Study of Sorafenib Plus 5-Azacitidine for the Initial Therapy of Patients With Acute Myeloid Leukemia and High Risk Myelodysplastic Syndrome With FLT3-ITD Mutation,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",Overall response rate,"Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale, Safety and Tolerability",True,NCT02196857,15581
3653,213120,"jRCTs031180429, TrialTroveID-213120, UMIN000014566","A Randomized, Open, Phase II Comparison of the Safety and Efficacy of a Reduced and Re-Escalated Dose of Sorafenib Versus a Reduced and Maintained Dose of Sorafenib in Patients with Advanced Hepatocellular Carcinoma.",Oncology,Oncology: Liver,"Bayer AG/Bayer Yakuhin, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Time to progression,"Overall survival, Safety and Tolerability, Time to progression",False,,15581
3654,212813,"NCT02187081, REASSESS, SWHB008, TrialTroveID-212813",Radiofrequency Ablation Accompanied With Spontaneous Sorafenib Administration in the Treatment of Early to Intermediate Stage Hepatocellular Carcinoma: a Prospective Multicenter Cohort Study (REASSESS),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Recurrence,"Clinical benefit rate, Overall survival, Recurrence, Time to progression",True,NCT02187081,15581
3655,212725,"17391, JPMS-DTC, NCT02185560, NEXAVAR-TC-01, TrialTroveID-212725",Drug Use Investigation of Sorafenib/ NEXAVAR for Unresectable Differentiated Thyroid Carcinoma (DTC),Oncology,Oncology: Thyroid,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Adverse Events, Disease Progression, Time to treatment failure",True,NCT02185560,15581
3656,211877,"00056072, 111405, 118613, 14222, 1504015718, 16-704, 20140686, AAAO4053, ARST1321, ARST1321 (SRC.6), ARST1321-RTOG1313, Clinical Trial 18937, COG ARST1321, COG-NRG ARST1321, LAPS-ARST1321, NCG 260314, NCI-2014-01340, NCT02180867, NSC# 737754, PAZNTIS, S14-02023, SRC6, TrialTroveID-211877",Pazopanib Neoadjuvant Trial in Non-Rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation Plus or Minus Pazopanib (NSC# 737754),Oncology,Oncology: (N/A); Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Complete response, Event-free survival","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease-free survival, Event-free survival, Metastasis-free survival, Overall survival, Recurrence",True,NCT02180867,15581
3657,211374,TrialTroveID-211374,"Relationships between Pharmacokinetics of Antiangiogenic Drugs, Large Arteries Properties and Cancer Progression",Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3658,210385,"ChiCTR-OCH-14004731, NCT02156297, SZ3201, TrialTroveID-210385",Sorafenib to Treat AML Patients With FLT3-ITD Mutation: a Non-interventional Cohort Study,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Adverse Events, Disease-free survival, Overall survival",True,NCT02156297,15581
3659,210307,TrialTroveID-210307,A clinical study on elevated blood eosinophil level prediction on response and longer survival in patients with metastatic renal cell carcinoma treated by sorafenib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Eosinophil levels,,False,,15581
3660,210284,"09-067, CHU Caen#OMELSORA, EudraCT Number: 2010-022527-29, NCT02517736, O-Mel-Sora, OMELSORA, ORPHA299953, RECF1744, TrialTroveID-210284",Multicenter Phase II study evaluating the efficacy and toxicity of sorafenib (Nexavar) in patients with metastatic uveal melanoma dissemination.,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Overall response rate, Overall survival, Quality of Life, Time to progression",True,NCT02517736,15581
3661,209956,"EHBHKY2013-001-08, NCT02150317, TrialTroveID-209956",A Prospective Randomized Trial Comparing Transcatheter Arterial Chemoembolization (TACE) Followed by Sorafenib Versus TACE Alone for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,True,NCT02150317,15581
3662,209628,"BfArM-No.: 4034380, DRKS00003947, EudraCT Number: 2008-001090-15, MADONNA, TrialTroveID-209628","Randomized, double-blind Phase II study of Docetaxel + Sorafenib (Nexavar) versus Docetaxel + Placebo in First-Line treatment of patients with HER2-negative, metastatic breast cancer.",Oncology,Oncology: Breast,University of Heidelberg,Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Duration of overall response, Functional Assessment of Cancer Therapy-Breast, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to progression",False,,15581
3663,209489,TrialTroveID-209489,Efficacy of Sorafenib in Patients With Pulmonary Metastatic Hepatocellular Carcinoma after Liver Transplantation.,Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3664,209379,"1457GCC, 9608, AAAQ9684, MC1315, NCI-2014-01043, NCI9608, NCT02143401, TrialTroveID-209379","A Phase I Trial of ABT-263 (Navitoclax), a Bcl-2 Inhibitor, and Sorafenib (Nexavar) in Patients With Relapsed or Refractory Solid Organ Tumors",Oncology,Oncology: Liver; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Absolute Neutrophil Count, Maximum tolerated dose, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression, Time to treatment failure",True,NCT02143401,15581
3665,209115,TrialTroveID-209115,Therapeutic effects of sorafenib combined with transcatheter arterial chemoembolization and microwave ablation on postsurgical recurrent hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3666,208798,TrialTroveID-208798,A Multicenter Study on Clinical Features and its Association With Radiological Response to Sorafenib Therapy for Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Liver function, Overall response rate, Partial response, Response evaluation criteria in solid tumors",,False,,15581
3667,208743,TrialTroveID-208743,A Clinical Study on Evaluation of Adverse Events Safety Profile of Sorafenib in Hepatocellular Carcinoma,Oncology,Oncology: Liver,University of Florida - Gainesville,Academic,Overall survival,,False,,15581
3668,207615,"EudraCT Number: 2014-000777-38, GP2, NCT02122003, SOAP, TrialTroveID-207615",Activity and Safety of Second Line Sorafenib After Pazopanib in Patients With Metastatic Renal Cell Carcinoma (SOAP Study),Oncology,Oncology: Renal,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,Progression-free survival,"Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT02122003,15581
3669,207351,"ChiCTR-TNRC-10001065, TrialTroveID-207351",Effects of Sorafenib and Radiofrequency Ablation on Hepatacellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Liver function,,False,,15581
3670,207286,"2012/478, EudraCT Number: 2012-004961-42, NCT02111889, PET_imaging_of_kinase_inhibitors, PIKTURE, TrialTroveID-207286","Measurement of Tumor Kinase Inhibitor Concentrations Using PET Imaging in Patients With Advanced Solid Malignancies, , PET imaging of kinase inhibitors",Oncology,Oncology: Unspecified Solid Tumor,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,Magnetic Resonance Imaging,True,NCT02111889,15581
3671,207174,"2012-0648, NCI-2014-01103, NCT02115295, TrialTroveID-207174","Phase II Study of Cladribine Plus Idarubicin Plus Cytarabine (ARAC) in Patients With AML, HR MDS, or Myeloid Blast Phase of CML",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government",Complete response,"Duration of overall response, Event-free survival, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT02115295,15581
3672,207054,"17073, JapicCTI-142512, NCT02114658, TrialTroveID-207054","A Multi-center, Single-arm, Open-label Phase II Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Sorafenib in Japanese Patients With Anaplastic Thyroid Carcinoma or Locally Advanced or Metastatic Medullary Thyroid Carcinoma",Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Yakuhin","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Leukocyte count, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Clinical benefit rate, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT02114658,15581
3673,206472,TrialTroveID-206472,A Clinical Study on Association of Arterial Blood Supply of Hepatocellular Carcinoma with Efficacy of Sorafenib Therapy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Magnetic Resonance Imaging,,False,,15581
3674,206423,TrialTroveID-206423,A Clinical Study on Prognostic Significance of Neutrophil-to-Lymphocyte Ratio (NLR) in Hepatocellular Carcinoma Patients Treated with Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3675,205963,TrialTroveID-205963,The Survival Outcomes of Hepatic Resection Compared with Transcatheter Arterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3676,205835,TrialTroveID-205835,A clinical study on selection standard for therapeutic strategy (HAIC or sorafenib) against intractable advanced HCC -from a view point of Child-Pugh score and hepatic volume,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Liver function, Overall survival",,False,,15581
3677,205488,TrialTroveID-205488,A Clinical Study on Efficacy and Safety of Simultaneous Combined Therapy of Sorafenib and Radiation for the Hepatocellular Carcinoma with Extrahepatic Metastasis,Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3678,205427,TrialTroveID-205427,A Clinical Study on Evaluation of Effect of Change in the Albumin Value During Sorafenib Therapy for Advance Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3679,205039,"TrialTroveID-205039, UMIN000013461",Combination Therapy With A Molecular Target Drug And Iron Chelator For The Treatment Of Intractable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Safety and Tolerability, Treatment compliance","Liver function, Overall survival",False,,15581
3680,204901,"ChiCTR-OCH-13003281, TrialTroveID-204901",Evaluation of Effects and Prognosis of Transarterial Chemoembolization Therapy for Patients With Liver Cancers by Circulating Tumor Cells Detection,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China, (Other government agency)","Academic, Academic, Government",Circulating Tumor Cells,Overall survival,False,,15581
3681,204792,"CTP NK 2012, DRKS00006375, NCT02086734, TrialTroveID-204792",Perfusion CT as a Predictor for Response to Antiangiogenic Therapy in Patients with Metastasized Renal Cell Carcinoma,Oncology,Oncology: Renal,Ludwig Maximilians University of Munich,Academic,Overall survival,Response evaluation criteria in solid tumors,True,NCT02086734,15581
3682,204652,"410-30610-258, NCT02084732, TrialTroveID-204652",Safety and Efficacy of Sorafenib in Patients With Advanced Thyroid Cancer: a Phase II Clinical Study,Oncology,Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Adverse Events, Progression-free survival",True,NCT02084732,15581
3683,204565,"TrialTroveID-204565, UMIN000008581",Comparison between coagulations of RFA with sorafenib and standard RFA in patients with HCC,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,Liver function,False,,15581
3684,204507,"MCC-12-07328, NCI-2015-00017, NCT02349867, TrialTroveID-204507","A Phase I Study of Neoadjuvant Chemotherapy With Gemcitabine Plus Nab-paclitaxel, Followed by Concurrent Chemoradiation With Gemcitabine, Sorafenib, and Vorinostat in Pancreatic Cancer",Oncology,Oncology: Pancreas,"National Institutes of Health/National Cancer Institute, Virginia Commonwealth University","Government, Academic",,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Mortality, Overall survival, Partial response, Progression-free survival, Resection rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT02349867,15581
3685,203713,"I 238913, NCI-2014-00180, NCT02072486, TrialTroveID-203713",Granzyme B Production as a Biomarker for the Immunomodulatory Activity of Sorafenib in HCC,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute","Government, Academic","Adverse Events, Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT02072486,15581
3686,203653,"2012/109, 2012/109 METC VUmc, NCT02071719, NTR3710, TrialTroveID-203653",Prediction of Response to Kinase Inhibitors Based on Protein Phosphorylation Profiles in Tumor Tissue From Advanced Renal Cell Cancer Patients.,Oncology,Oncology: Renal,"(Other Industry Sponsor), Vanderbilt University Medical Center","Industry, all other pharma, Academic","Disease Progression, Progression-free survival",Progression-free survival,True,NCT02071719,15581
3687,203090,"00054427, 14-015, A091105, A091105/14-703, Alliance A091105, CALGB A091105, NCI-2014-00264, NCIC CTG: SRC.7/A091105, NCT02066181, PA091105_A04PAMDREVW01, SRC7, TrialTroveID-203090","A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)",Oncology,Oncology: Soft Tissue Sarcoma,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Cooperative Group, Government, Cooperative Group","Adverse Events, Overall response rate, Progression-free survival","Adverse Events, Brief Pain Inventory, Duration of overall response, Gene expression profiling, Magnetic Resonance Imaging, Numeric Rating Scale, Overall response rate, Overall survival, Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life, Resection rate, Response evaluation criteria in solid tumors, Response rate",True,NCT02066181,15581
3688,202265,"KHBO 1303, KHBO1303, MISORA, TrialTroveID-202265, UMIN000013089",Maintenance Therapy of Sorafenib After Hepatic Resection for High Risk Recurrence Hepatocellular Carcinoma (MISORA),Oncology,Oncology: Liver,"(Other Cooperative Group), Kyoto University Hospital","Cooperative Group, Academic",Progression-free survival,"Overall survival, Safety and Tolerability, Time to progression",False,,15581
3689,201755,"NCI-2013-02414, NCT02050919, TrialTroveID-201755","A Phase II Study of Sorafenib With Chemotherapy, Radiation, and Surgery for High-Risk Soft Tissue Sarcomas",Oncology,Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, OHSU Cancer Institute","Government, Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Response rate","Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Resection rate, Safety and Tolerability",True,NCT02050919,15581
3690,201684,"CRO-2010-48, EudraCT Number: 2010-023602-12, sorafenib-HAART, TrialTroveID-201684",A feasibility study evaluating the efficacy and safety of sorafenib in patients with advanced hepatocellular (HCC) carcinoma and HIV infection treated with HAART regimens,Infectious Disease; Oncology,Infectious Disease: HCV; Infectious Disease: HIV; Oncology: Liver,(Other government agency),Government,"Safety and Tolerability, Time to progression","Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Quality of Life, Response rate",False,,15581
3691,200938,TrialTroveID-200938,Prognosis of advanced hepatocellular carcinoma (HCC) in patients undergoing surgery combined with peri- or postoperative treatment with sorafenib.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Time to progression",,False,,15581
3692,200638,"NCI-2013-02086, NCT02035527, OSU-13141, TrialTroveID-200638",A Phase I/II Clinical Trial of Sorafenib in Combination With Cisplatin and Docetaxel in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN),Oncology,Oncology: Head/Neck,"(Other Academic Cancer Center), Ohio State University, National Comprehensive Cancer Network","Academic, Academic, Cooperative Group","Dose-limiting toxicities, Progression-free survival","Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",True,NCT02035527,15581
3693,200294,"ET12-081, EudraCT number: 2012-004510-34, MOST, NCT02029001, ProfiLER, TrialTroveID-200294","A Two-period, Multicenter, Randomized, Open-label, Phase II Study Evaluating the Clinical Benefit of a Maintenance Treatment Targeting Tumor Molecular Alterations in Patients With Progressive Locally-advanced or Metastatic Solid Tumors.",Oncology,Oncology: Colorectal; Oncology: Unspecified Solid Tumor,(Other Academic Cancer Center),Academic,"Disease Progression, Progression-free survival","Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Quality of Life, Safety and Tolerability",True,NCT02029001,15581
3694,199501,"TrialTroveID-199501, UMIN000012636",The Efficacy of Sorafenib Administration Prior to TACE Against the Patients with Intermediate HCC Refractory to TACE,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Overall response rate, Overall survival, Time to progression",False,,15581
3695,199472,"BAY 43-9006, EudraCT Number: 2008-000066-22, TrialTroveID-199472",A Phase II Study of Sorafenib (BAY 43-9006) in Patients with Advanced Salivary Adenoid Cystic Carcinoma,Oncology,Oncology: Head/Neck,"Christie Hospital N.H.S. Trust, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Academic, Industry, Top 20 Pharma","Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate","Overall response rate, Overall survival, Time to progression",False,,15581
3696,199442,"NCT02015728, SC-9006, SEED, TrialTroveID-199442","The Feasibility of Selecting Patient-Specific Biologically Targeted Therapy with Sorafenib, Everolimus, Erlotinib or Dasatinib for Pediatric Patients with Refractory or Recurrent Brain Tumors",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other","(Other Cooperative Group), Seattle Children's Hospital","Cooperative Group, Academic",,"Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progressive disease rate, Time to progression",True,NCT02015728,15581
3697,199104,TrialTroveID-199104,A Clinical Study on Prediction of Survival in Patients with Hepatocellular Carcinoma Treated with Sorafenib by Comprehensive Serum Glycan Analysis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3698,199002,"TrialTroveID-199002, UMIN000012484",Sorafenib vs. half dose Sorafenib and UFT combined therapy in patients with Hepatocellular carcinoma refractory to TACE: Randomized Prospective Study,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Progression-free survival,"Overall response rate, Overall survival, Recurrence, Response rate, Safety and Tolerability",False,,15581
3699,198475,TrialTroveID-198475,A Clinical Study on Comparison of Efficacy of Hepatic Arterial Infusion Chemotherapy and Sorafenib in Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Time to progression","Overall response rate, Response rate",False,,15581
3700,198439,TrialTroveID-198439,A clinical study to evaluate the efficacy of continued sorafenib treatment after radiological confirmation of disease progression in patients with advanced hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Disease Progression,,False,,15581
3701,197174,"16933, NCT01982097, NX1307RU, SANE, TrialTroveID-197174","Multicenter, Prospective, Non-interventional Study ""Sorafenib as Neoadjuvant Therapy Before Cytoreductive Nephrectomy in Patients With Metastatic Renal Cell Carcinoma""",Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Response evaluation criteria in solid tumors",True,NCT01982097,15581
3702,196936,"NL38229.029.11, TrialTroveID-196936",A phase II study of sorafenib and metformin in patients with stage IV non-small cell lung cancer (NSCLC) with a KRAS mutation,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Response evaluation criteria in solid tumors","Duration of overall response, Overall survival, Progression-free survival",False,,15581
3703,194123,"ESFT13, NCI-2013-01657, NCT01946529, TrialTroveID-194123",Therapeutic Trial for Patients With Ewing Sarcoma Family of Tumor and Desmoplastic Small Round Cell Tumors,Oncology,Oncology: (N/A); Oncology: Soft Tissue Sarcoma,"(Other Cooperative Group), St. Jude Children's Research Hospital, University of Florida - Gainesville, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic, Academic, Academic","Complete response, Overall response rate, Partial response, Response rate","Disease Progression, Overall survival, Progression-free survival, Time to progression",True,NCT01946529,15581
3704,193224,"16560, CTRI/2014/12/005310, EUPAS4564, NCT01933945, NX1301, NX1301/Ver 2.1/4, OPTIMIS, TrialTroveID-193224",OPTIMIS - Outcomes of HCC Patients Treated With TACE Followed or Not Followed by Sorafenib and the Influence of Timing to Initiate Sorafenib,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, International normalized ratio, Liver function, Overall survival, Partial response, Progression-free survival, Prothrombin ratio, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Treatment Emergent Adverse Events",True,NCT01933945,15581
3705,193088,"NCT01932385, QCH20130823, TrialTroveID-193088",Phase II Study of Sorafenib in the Management of Liver Function Impaired Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Overall response rate, Response rate",True,NCT01932385,15581
3706,192983,"STAB study, TrialTroveID-192983, UMIN000011599, UMIN000014213",Phase II trial of Sorafenib combined with on-demand Transarterial Chemoembolization for Advanced Hepatocellular Carcinoma (Barcelona Clinic Liver Cancer stage C),Oncology,Oncology: Liver,"(Other Cooperative Group), Japanese Ministry of Health, Labour and Welfare","Cooperative Group, Government",,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",False,,15581
3707,191639,TrialTroveID-191639,Clinical Outcomes of Korean Patients with Hepatocellular Carcinoma Treated with Sorafenib as their First Line Therapy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3708,191591,TrialTroveID-191591,A Clinical Study to Evaluate the Role of Hand-foot Skin Reaction on Prognosis of Initial Radiological Progression in Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3709,191072,"16628, NCT01908322, SORINT, TrialTroveID-191072",SORINT - SORafenib for Treatment of Patients With INTermediate Stage Hepatocellular Carcinoma,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT01908322,15581
3710,191012,"NCT01906216, SELECT, TrialTroveID-191012, XHDD-001","Sorafenib With or Without Transarterial Chemoembolization (TACE) in Advanced Hepatocellular Carcinoma : A Multicenter, Randomized, Controlled Trial",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01906216,15581
3711,190574,"NCT01901692, START, TrialTroveID-190574",Randomized Trial Comparing Sorafenib and Transarterial Chemoembolization Plus External Beam Radiotherapy in Patients With Hepatocellular Carcinoma Showing Macroscopic Vascular Invasion,Oncology,Oncology: Liver,Asan Medical Center,Academic,"Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT01901692,15581
3712,190429,"2012-0870, NCI-2013-01667, NCT01900002, TrialTroveID-190429, Y-90","A Phase II Study of Sorafenib and Yttrium-90 Glass Microspheres for Advanced Hepatocellular Carcinoma, BCLC Stage C",Oncology,Oncology: Liver,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Adverse Events, Disease Progression, Progression-free survival, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Insulin-like growth factor-1 level, Mortality, Overall survival, Quality of Life, Safety and Tolerability, Time to progression",True,NCT01900002,15581
3713,190415,"EudraCT number: 2007-005967-82, NL20351.058.07, TrialTroveID-190415",Phase II trial of Sorafenib and Capecitabine in Advanced Renal Cell Carcinoma (RCC),Oncology,Oncology: Renal,"(Other Industry Sponsor), (Other government agency)","Industry, all other pharma, Government","Progression-free survival, Recurrence","Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,15581
3714,189899,"CHUV-CePO-code 16295, NCT01893099, SORASIRT, TrialTroveID-189899",Sorafenib and Radioembolization with Sir-Spheres for the Treatment of Metastatic Ocular Melanoma,Oncology,Oncology: Melanoma; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Safety and Tolerability, Safety and Tolerability","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01893099,15581
3715,188716,TrialTroveID-188716,Sorafenib (SFB) low dose in octogenarians with advanced or inoperable (a/i) HCC: Toxicity and efficacy evaluation.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3716,188505,"TrialTroveID-188505, UMIN000010957",Investigation Of Anti-Tumoral Effect And Safety Of Combination Therapy LD-GP (Low Dose Gemcitabine And Paclitaxel) Therapy And Sorafenib In Patients With Cisplatin-Resistant Advanced Urothelial Cancer.,Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall survival, Quality of Life, Visual Analog Scale",,False,,15581
3717,188388,TrialTroveID-188388,Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) in the treatment of patients with brain metastases (BM) from renal cell cancer (RCC).,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Academic Cancer Center),Academic,"Overall response rate, Overall survival, Partial response, Progression-free survival",,False,,15581
3718,188270,"NCI-2013-00913, NCT01871766, RMS13, TrialTroveID-188270","Risk-Adapted Focal Proton Beam Radiation and/or Surgery in Patients With Low, Intermediate and High Risk Rhabdomyosarcoma Receiving Standard or Intensified Chemotherapy",Oncology,Oncology: Soft Tissue Sarcoma,"St. Jude Children's Research Hospital, (Other Hospital/Academic/Medical Center)","Academic, Academic",Event-free survival,"Clinical benefit rate, Event-free survival, Recurrence",True,NCT01871766,15581
3719,187469,TrialTroveID-187469,TACE plus sorafenib for the treatment of advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3720,187446,"2012-716, CHU Lyon, EudraCT Number: 2012-002818-39, Evesor, NCT01932177, RECF1923, TrialTroveID-187446",EVESOR: A Phase I Trial of Everolimus and Sorafenib to assess the Impact of Doses and Administration Sequences on Pharmacokinetic and Pharmacodynamic Effects of the Combination,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid","Novartis, National Institutes of Health/National Cancer Institute, (Other Hospital/Academic/Medical Center), Hospices Civils de Lyon","Industry, Top 20 Pharma, Government, Academic, Academic","Dose-limiting toxicities, Safety and Tolerability","Circulating Tumor Cells, Overall response rate, Progressive disease rate, Response rate",True,NCT01932177,15581
3721,187271,TrialTroveID-187271,Effect of the combination therapy of sorafenib and radiofrequency ablation on the survival time of advanced HCC,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3722,187220,TrialTroveID-187220,A Prospective Study on Early Prediction of Response to Sorafenib in Patients With Advanced Hepatocellular Carcinoma: the Role of Dynamic Contrast Enhanced Ultrasound,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Area under the curve score, Overall survival, Time to progression",,False,,15581
3723,187069,"9422, NCI-2013-00999, NCT01861314, OSU 11186, OSU-11186, TrialTroveID-187069",Phase I Study of the Combination of Bortezomib and Sorafenib Followed by Decitabine in Elderly Patients with Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous",National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability","Complete response, Overall response rate",True,NCT01861314,15581
3724,186089,"12-213, NCI-2013-01103, NCT01849588, TrialTroveID-186089",A Prospective Study of HCV-RNA Kinetics During Treatment With Sorafenib in Patients With Advanced Hepatocellular Carcinoma and Chronic Hepatitis C,Infectious Disease; Oncology,Infectious Disease: HCV; Oncology: Liver,Massachusetts General Hospital,Academic,,Overall survival,True,NCT01849588,15581
3725,185824,"EudraCT Number: 2011-004289-14, NCT01844947, NUCOG III, slut_VINSOR, TrialTroveID-185824, VINSOR",An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"Nordic Urothelial Cancer Group, Bayer AG/Bayer Pharmaceuticals, Pierre Fabre","Cooperative Group, Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01844947,15581
3726,185334,"16608, NCT01839630, NX1216CN, SUCCESS, TrialTroveID-185334",Study of Unresectable HCC Treated Concomitantly With TACE and Sorafenib in Chinese Patients,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Time to progression",True,NCT01839630,15581
3727,185296,TrialTroveID-185296,A randomized phase II trial of maintenance therapy with Sorafenib in front-line ovarian carcinoma.,Oncology,Oncology: (N/A); Oncology: Ovarian,Bayer AG,"Industry, Top 20 Pharma",Progression-free survival,,False,,15581
3728,185244,"12-259, NCI-2013-00867, NCT01840592, TrialTroveID-185244",Phase II Study of Sorafenib Plus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma With Disease Progression on Sorafenib,Oncology,Oncology: Liver,"Memorial Sloan-Kettering Cancer Center, Bayer AG/Bayer Pharmaceuticals, National Comprehensive Cancer Network","Academic, Industry, Top 20 Pharma, Cooperative Group",Overall survival,"NCI-CTC scale, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT01840592,15581
3729,185217,TrialTroveID-185217,Relationship Between Plasma Concentration and Daily Dose of Sorafenib In Cirrhotic Patients with Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Plasma concentration,,False,,15581
3730,185213,TrialTroveID-185213,"A Single-center, Observational, Prospective Study on Identification of Clinical and Analytical Variables with Prognostic Value in HCC Patients Treated with Sorafenib",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Time to progression",,False,,15581
3731,185053,TrialTroveID-185053,A Clinical Study to Evaluate miR Expression Profile Of Surgically Resected Or Sorafenib Treated hepatocellular carcinoma (HCC),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Resection rate,,False,,15581
3732,184909,"NCT01833299, TrialTroveID-184909",Transcatheter Arterial Chemoembolization Combined With Sorafenib for Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,Time to progression,True,NCT01833299,15581
3733,183831,"CTC-11-011, HM14816, MCC 14816, MCC-14816, MCC-14816 (CTC-11-011), NCI-2013-00705, NCT01817751, TrialTroveID-183831","Phase II Study of Sorafenib, Valproic Acid, and Sildenafil in the Treatment of Recurrent High-Grade Glioma",Oncology,"Oncology: CNS, Glioblastoma","National Institutes of Health/National Cancer Institute, Virginia Commonwealth University","Government, Academic","Progression-free survival, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01817751,15581
3734,183762,"EudraCT Number: 2005-006024-11, HD/BN-2005-MM-R, TrialTroveID-183762",Sorafenib in patients with refractory or recurrent multiple myeloma,Oncology,Oncology: Multiple Myeloma,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Duration of overall response, Gene expression profiling, Overall response rate, Response rate, Safety and Tolerability",False,,15581
3735,183438,TrialTroveID-183438,A clinical study on tumor growth rates before and after the withdrawal of molecular targeted agents in patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Growth velocity, Progressive disease rate",,False,,15581
3736,183024,"TrialTroveID-183024, UMIN000010085",A Prospective Multicenter Study Of Patients Treated With Molecular Target Therapy For Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,,False,,15581
3737,182780,"IUCRO-0404, NCT01801163, TrialTroveID-182780",A Phase Ib Study of Stereotactic Radiotherapy (SBRT) Plus Sorafenib in Patients With Unresectable Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Disease Progression, Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT01801163,15581
3738,182025,TrialTroveID-182025,A prospective study evaluating relationship between cutaneous toxicity (rash and hand-foot skin reaction-HFSR) and survival in patients with non resectable or advanced HCC treated with sorafenib.,Oncology,Oncology: Liver,University of Rome La Sapienza,Academic,,,False,,15581
3739,181545,"TrialTroveID-181545, UMIN000010000",Prospective observational study to investigate the predictive factors on the efficacy of molecular targeting therapy for unresectable advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Cooperative Group, Academic, Government",Time to progression,Overall survival,False,,15581
3740,181319,TrialTroveID-181319,Phase II clinical trial of sorafenib plus local chemotherapy in the treatment of metastatic renal cell carcinoma with pleural effusion.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3741,181231,"TrialTroveID-181231, UMIN000009921",Transcatheter Arterial Chemo-Embolization (TACE) vs. Sorafenib in Patients with Hepatocellular Carcinoma Refractory to TACE: A Randomized Phase II Trial,Oncology,Oncology: Liver,"University School of Medicine, Tokyo",Academic,Overall survival,"Overall response rate, Progression-free survival, Safety and Tolerability",False,,15581
3742,180975,"JPRN-UMIN000009812, TrialTroveID-180975, UMIN000009812",Japan multicenter prospective study: FDG PET/CT in the assessment of advanced renal cell carcinoma treated with sorafenib,Oncology,Oncology: Renal,"(Other Cooperative Group), Bayer AG/Bayer Yakuhin","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability",False,,15581
3743,180954,"12-218, NCI-2013-00627, NCT01775501, TrialTroveID-180954",Phase II Trial of Sorafenib in Combination With Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,Massachusetts General Hospital,Academic,"Disease Progression, Progressive disease rate, Response evaluation criteria in solid tumors, Time to progression","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01775501,15581
3744,180640,"EudraCT Number: 2012-002646-20, IC 2012-04, NCT01771458, RECF1848, SHIVA, TrialTroveID-180640",A Randomized Proof-of-concept Phase II Trial Comparing Therapy Based on Tumor Molecular Profiling Versus Conventional Therapy in Patients With Refractory Cancer,Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor",(Other Cooperative Group),Cooperative Group,"Progression-free survival, Response evaluation criteria in solid tumors","Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01771458,15581
3745,180423,"ChiCTR-ONC-12002851, TrialTroveID-180423",Effects and Safety of Radiofrequency ablation combined with Sorafenib in hepatocellular carcinoma(HCC): a pilot study,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Progression-free survival, Time to progression",,False,,15581
3746,180343,"TrialTroveID-180343, UMIN000009771",A Prospective Cohort Study on the Prediction of Effectiveness of Sorafenib on the Basis of Angiogenesis-Related Cytokines,Oncology,Oncology: Liver,"Bayer AG/Bayer Yakuhin, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Time to progression,"Adverse Events, Disease Progression, Overall survival, Time to progression",False,,15581
3747,180199,"BCH-RCC-120601, NCT01762150, TrialTroveID-180199","Sorafenib Combined with Cisplatin and Gemcitabine for the Treatment of Patients with Advanced Renal Collecting Duct Carcinoma: A Pilot, Open Study.",Oncology,Oncology: Renal,"Bayer AG, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival","Adverse Events, Disease Progression, Overall response rate, Overall survival",True,NCT01762150,15581
3748,180006,"2012/76, EudraCT Number: 2011-005309-57, NCT01758575, TrialTroveID-180006",Clinical Evaluation of the Underlying Mechanisms of Targeted Therapy Related Toxicities,Oncology,Oncology: Unspecified Solid Tumor,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,,True,NCT01758575,15581
3749,179542,"16621, NCT01751763, NX1218CN, SECURE, TrialTroveID-179542",Investigations of Sorafenib for HCC Patients Who Have Residue Disease After Resection With Curative Intent,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Recurrence,"Adverse Events, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to response",True,NCT01751763,15581
3750,179530,TrialTroveID-179530,Early Response to Anti-Tumoral Treatment in Hepatocellular Carcinoma - Can Quantitative Contrast-Enhanced Ultrasound Predict Outcome?,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3751,179003,"TrialTroveID-179003, UMIN000009026","A phase II clinical study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma., , Uncontrolled exploratory clinical study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Overall survival, Safety and Tolerability, Time to progression",False,,15581
3752,178485,"DRKS00004455, EARL-2, EudraCT Number: 2011-006250-90, NCT01736878, SUMMIT, TrialTroveID-178485","Randomized Double-blind Placebo Controlled Phase II Study to Evaluate the Efficacy and Safety of Sorafenib Treatment in Patients With Advanced (Recurrent, Persistent and/or Metastasizing) Medullary Thyroid Carcinoma.",Oncology,Oncology: Thyroid,(Other Cooperative Group),Cooperative Group,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, EQ-5D, Functional Assessment of Cancer Therapy-General, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression, Vital signs",True,NCT01736878,15581
3753,178238,TrialTroveID-178238,A prospective study of SCCA-IgM as a new biomarker to predict the efficacy of HCC treatments,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3754,178150,TrialTroveID-178150,A clinical study on the effect of transarterial chemoembolization versus sorafenib: single center experience from real life outcomes of advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3755,178074,TrialTroveID-178074,"A Randomized, Pilot Study on the Short-Term Effect of Sorafenib on Suppression of Angiogenetic Cytokines for Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3756,178021,TrialTroveID-178021,A clinical study on the comparison of treatment efficacy between sorafenib monotherapy and sorafenib-based combination therapy in advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3757,177981,TrialTroveID-177981,"A Clinical Study on Tumor Markers Alpha-fetoprotein (AFP) and Des-gamma-carboxy prothrombin (DCP), and Anti tumor Response in the Patients with Advanced Hepatocellular Carcinoma (HCC) Treated with Sorafenib",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Appetite, Common Terminology Criteria for Adverse Events, Partial response, Progressive disease rate, Prothrombin ratio, Response evaluation criteria in solid tumors, Stable Disease",,False,,15581
3758,177921,"071501, 13-250, 13-295, AAAL8103, CIRB #H-32213, NCI-2012-02057, NCT01730937, RTOG #R1112, RTOG 1112, RTOG 1112 GI, RTOG-1112, TrialTroveID-177921",Randomized Phase III Study of Sorafenib Versus Stereotactic Body Radiation Therapy Followed by Sorafenib in Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Radiation Therapy Oncology Group (RTOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, EQ-5D, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Time to progression",True,NCT01730937,15581
3759,177835,"BERAT, BERAT C-II-008, C-II-008, C-II-008 / BERAT, DRKS00005606, EudraCT Number: 2011-005939-78, NCT01731158, TrialTroveID-177835","A Prospective, Open-label, Multicenter, Randomized Phase II Trial: Sequential Therapy With BEvacizumab, RAd001 (Everolimus) and Tyrosinekinase Inhibitors (TKI) in Metastatic Renal Cell Carcinoma (mRCC) (BERAT Study)",Oncology,Oncology: Renal,Central European Society for Anticancer Drug Research,Not for Profit Funding Entity,"Circulating Tumor Cells, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT01731158,15581
3760,177825,"16399, NCT01728948, NX1212CN, TrialTroveID-177825",Non-interventional Study of Effectiveness of Elderly Metastatic Renal Cell Carcinoma (mRCC) Treated With Sorafenib,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Clinical benefit rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT01728948,15581
3761,177722,TrialTroveID-177722,Combination of Sorafenib and 5-Azacytidine Has Significant Activity in Patients with Relapsed/Refractory or Untreated Acute Myeloid Leukemia and FLT3-ITD mutation.,Oncology,"Oncology: Leukemia, Acute Myelogenous","MD Anderson Cancer Center, University of Texas, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Academic, Academic",,,False,,15581
3762,177409,"12-039, 12-046, NCI-2012-02547, NCI-2015-01799, NCT01621906, NCT01724606, TrialTroveID-177409",Whole Brain Radiotherapy (WBRT) With Sorafenib for Breast Cancer Brain Metastases (BCBM): A Phase I Study,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Memorial Sloan-Kettering Cancer Center, Bayer AG/Bayer Pharmaceuticals, Susan G. Komen {Susan G. Komen Breast Cancer Research Foundation}","Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability","Magnetic Resonance Imaging, Progression-free survival",True,NCT01621906,15581
3763,177111,TrialTroveID-177111,A clinical study to evaluate sorafenib treatment effects in cirrhotic (C) and non-cirrhotic (non-C) hepatocellular carcinoma patients.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3764,176869,"EudraCT Number: 2012-000644-94, NCT01715441, NEXIRI 2, NEXIRI 2-PRODIGE 27, RECF1793, TrialTroveID-176869, VA_2012/01",A Randomized Phase II Trial Assessing Sorafenib in Combination with Irinotecan in Metastatic Colorectal Cancer Patients with KRAS Mutated Tumors After Failure of All Drugs Known to be Effective,Oncology,Oncology: Colorectal,"(Other Academic Cancer Center), Bayer AG","Academic, Industry, Top 20 Pharma","Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Cmax, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Tmax",True,NCT01715441,15581
3765,176028,"TrialTroveID-176028, UMIN000009126",Evaluation of Efficacy of Dose Escalation Strategy for Treatment With Sorafenib for Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3766,175843,"HICS 55, TrialTroveID-175843, UMIN000009094",Pilot Study of Hepatic Arterial Infusion Chemotherapy Followed by Sorafenib for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Liver function, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",False,,15581
3767,175649,TrialTroveID-175649,"Response to Sorafenib In Pdgfra-D842v Mutated Metastatic Gastrointestinal Stromal Tumor (GIST), Supported by Biomolecular Functional Analyses",Oncology,Oncology: GIST,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3768,175325,"CNIO-GI-01-2012, EudraCT Number: 2012-001307-20, NCT01703910, TrialTroveID-175325",Phase II Individualized Therapies Selection Study for Patients With Metastatic Colorectal Carcinoma According to the Genomic Expression Profile in Tumor Samples,Oncology,Oncology: Colorectal,"(Other Hospital/Academic/Medical Center), Centro Nacional de Investigaciones Oncologicas (CNIO)","Academic, Miscellaneous","Gene expression profiling, Overall survival, Progression-free survival","Gene expression profiling, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01703910,15581
3769,175299,TrialTroveID-175299,Sorafenib versus capecitabine in the Management of Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall survival, Safety and Tolerability",False,,15581
3770,174749,"TrialTroveID-174749, UMIN000008689",A Clinical Study on Safety and Efficacy of Sorafenib as Maintenance Chemotherapy after Percutaneous Isolated Hepatic Perfusion Chemotherapy (PIHP) for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Overall survival,"Disease-free survival, Overall survival, Safety and Tolerability",False,,15581
3771,174328,"20121024, 534-2012, MCC-16963, NCT01683149, ONC-2011-49, Sunshine Project 002, TrialTroveID-174328","Phase I, Traditional 3+3, Trial of PO Sorafenib and Topotecan in Refractory or Recurrent Pediatric Solid Malignancies",Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Unspecified Solid Tumor","(Other Cooperative Group), H. Lee Moffitt Cancer Center and Research Institute, Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, NCI-CTC scale, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",True,NCT01683149,15581
3772,173665,"TrialTroveID-173665, UMIN000008808",Exploratory study for biomarkers to predict efficacy and toxicity to Sorafenib in patients with advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"Bayer AG/Bayer Yakuhin, National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, (Other government agency)","Industry, Top 20 Pharma, Academic, Government",Adverse Events,,False,,15581
3773,173652,"TrialTroveID-173652, UMIN000008782",Phase I Study of Sorafenib and Hepatic Arterial Infusion Chemotherapy with Miriplatin for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,Overall survival,False,,15581
3774,172973,"TrialTroveID-172973, UMIN000008710",Randomized phase II study comparing pegylated interferon alpha-2b combined with intra-arterial 5-fluorouracil and sorafenib alone for advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Progression-free survival,,False,,15581
3775,172114,"AVEC, EudraCT Number: 2007-004135-34, RECF1783, TrialTroveID-172114",Phase II Open Study Evaluating The Safety And Efficacy Of Combining Bevacizumab And Sorafenib After Second Line Therapy In Patients With Metastatic Breast Cancer Or Locally Advanced,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",False,,15581
3776,172027,"TrialTroveID-172027, UMIN000008571",Phase II Study of Weekly Fractionated Hepatic Arterial Infusion of Sorafenib and Cisplatin for Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival",False,,15581
3777,171912,"EudraCT Number: 2007-004129-75, N07NEX, NL19076.031.07, TrialTroveID-171912",Phase I study of gemcitabine and carboplatin plus sorafenib in patients with advanced solid tumors,Oncology,Oncology: Ovarian; Oncology: Pancreas,"Netherlands Cancer Institute, Bayer AG","Government, Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Cmax, Complete response, Elimination half-life, Partial response, Response evaluation criteria in solid tumors, Stable Disease, Tmax",False,,15581
3778,171400,"GC0212, HIC 1112009424, NCT01640665, TrialTroveID-171400, Yale0051494",Pilot Study of Sorafenib and Bi-weekly Capecitabine in Patients With Advanced Breast and Gastrointestinal Tumors,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Pancreas,"Bayer AG/Bayer Pharmaceuticals, Yale University","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT01640665,15581
3779,171181,"2011/128, NCT01636908, OND1355289, TrialTroveID-171181",Pilot Study on the Determination of Intratumoral Concentrations of Kinase Inhibitors in Patients With Advanced Solid Malignancies.,Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,,,True,NCT01636908,15581
3780,169977,"11-003311, 11-01612, 20083976, 2011-2015, 201304108, 406-12, AAAK6255, JCCC-SUPPL-8-2014, NCI-2012-00911, NCT01624285, NU UCLA12I08 15766, ONC-2010-31, TrialTroveID-169977",A Phase II Randomized Multicenter Placebo-Controlled Blinded Study of Sorafenib Adjuvant Therapy in High Risk Orthotopic Liver Transplant (OLT) Recipients With Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,"Jonsson Comprehensive Cancer Center, UCLA, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Disease-free survival, Recurrence, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Wound healing",True,NCT01624285,15581
3781,169908,"TrialTroveID-169908, UMIN000008184",Study Of Sorafenib And Radiation Therapy For Advanced Hepatocellular Carcinoma With Portal Vein Thrombosis,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Safety and Tolerability",,False,,15581
3782,169741,"IIT-RT-SORAFENIB, NCT01618253, PRO00017344, TrialTroveID-169741",Phase I Study of Radiation Therapy With Concurrent Sorafenib for Hepatocellular Carcinoma Not Responding to Transarterial Chemoembolization,Oncology,Oncology: Liver,Medical College of Wisconsin Cancer Center,Academic,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale","Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Quality of Life",True,NCT01618253,15581
3783,169720,"7195, CA180-392, NCI-2012-01084, NCT01620216, TrialTroveID-169720","A Phase II Proof-of-Concept Trial to Study Kinase Inhibition in Relapsed/Refractory Acute Leukemias: Using a Comprehensive In Vitro Kinase Inhibitor Panel to Select Individualized, Targeted Therapies",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","Bristol-Myers Squibb, National Institutes of Health/National Cancer Institute, OHSU Cancer Institute, Oregon Health and Science University","Industry, Top 20 Pharma, Government, Academic, Academic",,"Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival",True,NCT01620216,15581
3784,169653,"TrialTroveID-169653, UMIN000007515",Pilot study of sorafenib for RET fusion positive non-small cell lung cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Cooperative Group),Cooperative Group,,,False,,15581
3785,169497,"BAY43, NCT02209441, TrialTroveID-169497",Phase I/II trial of sorafenib combined with FOLFOX4 in untreated patients with advanced gastric adenocarcinoma.,Oncology,Oncology: Gastric,"Chinese Academy of Medical Sciences, Bayer AG/Bayer Pharmaceuticals, (Other government agency)","Government, Industry, Top 20 Pharma, Government","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,True,NCT02209441,15581
3786,169426,"NCT01616186, TrialTroveID-169426, UCSF CC# 12521",A Randomized Non-Comparative Multicenter Phase II Study of Everolimus/Sorafenib or Sunitinib in Patients With Metastatic Renal Cell Carcinoma (RCC),Oncology,Oncology: Renal,Novartis,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Cardiac Telemetry, Clinical benefit rate, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01616186,15581
3787,169313,"16037, 16037 / AN 33/11, AN 33/11 - SWITCH-2, AUO AN 33/11, DRKS00004419, EudraCT Number: 2011-004396-36, NCT01613846, NCT02083094, NL40447.094.12, SW-2 ON 33/11, SWITCH-2 study, SWITCH-II, TrialTroveID-169313",Phase III Randomized Sequential Open-label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Pazopanib Versus Pazopanib Followed by Sorafenib in the Treatment of Advanced / Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Technische Universitaet Muenchen, Association of Urogenital Oncology (AUO)","Academic, Cooperative Group",Progression-free survival,"Adverse Events, C reactive protein, Circulating Tumor Cells, Clinical benefit rate, FACIT-Fatigue, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT01613846,15581
3788,169260,TrialTroveID-169260,Predictable clinical responses to sorafenib in stage IV uveal melanoma.,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3789,169182,TrialTroveID-169182,Sorafenib (S) for hepatocellular carcinoma (HCC) treatment: Russian experience in cirrhotic (C) and non-cirrhotic (non-C) patients.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3790,168701,TrialTroveID-168701,Sorafenib (SOR) in advanced non-small cell lung cancer (NSCLC): A phase II study of patient progress after several lines of treatment,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,15581
3791,168407,"NCT01605734, ShandongCHI-002, TrialTroveID-168407",Phase II Trial of TACE Combined With Sorafenib in Treating Patients with Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Academic Cancer Center),Academic,Time to progression,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT01605734,15581
3792,166658,"TrialTroveID-166658, UMIN000007855",Study For The Add-On Effect Of Vitamin K To Sorafenib Treatment For Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Safety and Tolerability,False,,15581
3793,166615,"16263, NCT01585974, NX1211TR, TrialTroveID-166615, TURCOS",Duration of Treatment With TKIs in the Treatment of Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,Treatment Emergent Adverse Events,True,NCT01585974,15581
3794,166549,"15977, Bayer-15977, EudraCT Number: 2011-005849-12, NCT01585870, RECF2122, TrialTroveID-166549","A Phase I, Multi-center, Non-randomized, Open Label, Dose Escalation Design Study of Sorafenib (BAY43-9006) in Combination with Eribulin in Subjects with Advanced, Metastatic or Refractory Solid Tumors",Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cmax, Heart rate, Plasma concentration, Safety and Tolerability, Safety and Tolerability",,True,NCT01585870,15581
3795,166139,TrialTroveID-166139,"An Efficacy Study on the Effect of Sorafenib on Plasma VEGF Changes in Patients with Advanced, Inoperable Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Liver function, Response evaluation criteria in solid tumors",,False,,15581
3796,165797,"1351GCC, 8992, J11116, JHOC-J11116, NCI 8992, NCI-2012-00727, NCT01578109, TrialTroveID-165797",A Pilot Study of Sorafenib in Patients With Acute Myeloid Leukemia as Peri-transplant Remission Maintenance,Oncology,"Oncology: Leukemia, Acute Myelogenous",National Institutes of Health/National Cancer Institute,Government,Safety and Tolerability,"Absolute Neutrophil Count, Disease-free survival, Minimal Residual Disease, Mortality, Overall survival",True,NCT01578109,15581
3797,165795,TrialTroveID-165795,"A Prospective, Randomized Study on the Effect of Sorafenib in Patients with Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Response evaluation criteria in solid tumors, Time to progression",,False,,15581
3798,165785,TrialTroveID-165785,A Clinical Study On The Role Of VEGF And VEGF Polymorphisms In The Prediction Of Clinical Outcome For Advanced Hepatocellular Carcinoma Receiving Sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Time to progression",,False,,15581
3799,165777,TrialTroveID-165777,A Single-center study on the Safety and Efficacy of Sorafenib in the Palliative Treatment of Hepatocellular Carcinoma (HCC) Developed in Non-Fibrotic Liver (F0-F1).,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Safety and Tolerability",,False,,15581
3800,164690,"EudraCT Number: 2010-023411-33, ONC-2009-002, TrialTroveID-164690","A phase II, randomized, double-blind, placebo controlled trial of Sorafenib as adjuvant treatment for hepatocellular carcinoma after TACE-based treatments",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Disease-free survival, Overall survival",False,,15581
3801,164350,"16268, NCT01557127, NEXST, TrialTroveID-164350",Nexavar Dose Evaluation Study in Patients With Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,Adverse Events,True,NCT01557127,15581
3802,164337,"NCT01556815, ShandongCHI-001, TrialTroveID-164337",Phase II Trial of Sorafenib Combined With Transarterial Chemoembolization in HBV-infected Patients With Intermediate Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Adverse Events, Safety and Tolerability",True,NCT01556815,15581
3803,164009,"TrialTroveID-164009, UMIN000007488",To evaluate the effect of Sorafenib with TACE for intrahepatic metastasis of hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate, Response rate, Safety and Tolerability",False,,15581
3804,163857,"i-STEP, TrialTroveID-163857, UMIN000006475",Evaluation of the safety and efficacy of sorafenib therapy after TACE for unresectable hepatocellular carcinoma (multicenter study),Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,,False,,15581
3805,163588,TrialTroveID-163588,"Phase II trial of letrozole (L), cyclophosphamide (C) and sorafenib (S) as neoadjuvant therapy in breast cancer patients (BC): Pharmacokinetic (PK) and pharmacodinamic (PD) analysis",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,Progressive disease rate,,False,,15581
3806,163265,"TrialTroveID-163265, UMIN000007427",A prospective cohort study about efficacy and safety for sorafenib treatment in patients with advanced hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3807,163084,"ESLC01, ESLC1 (SADAT study), NCT01539018, TrialTroveID-163084","A Phase II Trial of Sorafenib Plus Tegafur-uracil (UFT) vs. Sorafenib as First Line Systemic Treatment for Patients With Advanced Stage HCC, Unresectable & Not Eligible for Local Ablation &/or TACE",Oncology,Oncology: Liver,(Other Cooperative Group),Cooperative Group,"Disease Progression, Response evaluation criteria in solid tumors, Time to progression","Clinical benefit rate, Complete response, EQ-5D, NCI-CTC scale, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT01539018,15581
3808,163078,"16028, IMPACT 16028, NCT01539681, NX1110IT, STELLA, TrialTroveID-163078",Sorafenib Treatment Modalities for Hepatocellular Carcinoma Patients in Italy,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",True,NCT01539681,15581
3809,162801,"1110007281, IUCRO-0327, NCI-2012-00200, NCT01534260, SorVorBor study, TrialTroveID-162801","Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype",Oncology,"Oncology: Leukemia, Acute Myelogenous","Bayer AG/Bayer Pharmaceuticals, Takeda/Takeda Oncology {Millennium}, Indiana University Cancer Center, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Complete response, Overall response rate - duration, Partial response, Safety and Tolerability, Safety and Tolerability",True,NCT01534260,15581
3810,162168,"2011-1183, NCI-2012-00217, NCT01531361, TrialTroveID-162168","A Phase I Trial of Sorafenib (CRAF, BRAF, KIT, RET, VEGFR, PDGFR Inhibitor) or Crizotinib (MET, ALK, ROS1 Inhibitor) in Combination With Vemurafenib (BRAF Inhibitor) in Patients With Advanced Malignancies",Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Thyroid; Oncology: Unspecified Cancer","MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability",,True,NCT01531361,15581
3811,162143,TrialTroveID-162143,The effects of sorafenib on the portal hypertensive syndrome in patients with liver cirrhosis and hepatocellular carcinoma- A pilot study.,Autoimmune/Inflammation,Autoimmune/Inflammation: Hepatic Fibrosis,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3812,161695,TrialTroveID-161695,Clinical evaluation of dose escalation of sorafenib in treating advanced renal cell carcinoma after failing to routine dosage of sorafenib,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
3813,161693,TrialTroveID-161693,Efficacy of sorafenib in treating metastatic non-clear cell renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3814,161668,"TrialTroveID-161668, UMIN000007199",Phase II study of sorafenib with S-1 for advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Time to progression,"Clinical benefit rate, Overall response rate, Overall survival, Response rate",False,,15581
3815,161625,TrialTroveID-161625,Use of sorafenib in the treatment of advanced renal cell carcinoma: toxicity profile and management,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3816,161610,TrialTroveID-161610,Phase II study of sorafenib as first line treatment in patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3817,161599,TrialTroveID-161599,Sorafenib in combination with interferon-a-2b for the treatment of metastatic renal cell carcinoma:,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3818,161583,TrialTroveID-161583,Relationship between sorafenib's side effects and efficacy in treatment of advanced renal cell carcinoma patients,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3819,161576,TrialTroveID-161576,Preliminary report of dosage-escalated sorafenib in patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3820,161541,TrialTroveID-161541,Clinical study of sorafenib in the treatment of Chinese patients with metastatic renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3821,161493,TrialTroveID-161493,Sorafenib in the treatment of advanced renal clear cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3822,161487,TrialTroveID-161487,Preliminary evaluation about efficacy and safety of sorafenib therapy in elderly patients with advanced renal cell carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3823,161485,TrialTroveID-161485,Efficacy of sorafenib in treating metastatic renal cell carcinoma with sarcomatoid feature,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3824,161478,TrialTroveID-161478,Phase IV clinical trial of sorafenib in combination with interferon-alpha as the first-line treatment in patients with advanced renal cell carcinoma:interim analysis of efficacy and safety,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,,False,,15581
3825,161080,"12-C-0208, DFCI 11-420, NCI-12-C-0208, NCT01518413, SorIrin1576, TrialTroveID-161080",Phase I Dose Escalation Study of Sorafenib and Irinotecan Combination Therapy in Pediatric Patients With Relapsed or Refractory Solid Tumors,Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose","Plasma pharmacokinetics, Response evaluation criteria in solid tumors",True,NCT01518413,15581
3826,160710,TrialTroveID-160710,Efficacy of Transcatheter Arterial Chemoembolization (TACE) in Combination with Sorafenib for the Treatment of Unresectable Hepatocellular Carcinoma in Chinese Patients.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3827,160366,"110574, NCT01510756, TrialTroveID-160366, UCSD 110574",A Phase II Translational Study of Sorafenib for the Treatment of Chronic Lymphocytic Leukemia Patients,Oncology,"Oncology: Leukemia, Chronic Lymphocytic",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Leukocyte count, Minimal Residual Disease, Overall response rate","Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Safety and Tolerability, Safety and Tolerability",True,NCT01510756,15581
3828,160188,"EudraCT Number: 2011-000561-12, NCT01804374, S.E.R.I.O., SERIO, TrialTroveID-160188","A phase II, open label, non-randomized study of second or third line treatment with the combination of sorafenib and everolimus in patients affected by relapsed and non-resectable high-grade osteosarcoma, , S.E.R.I.O. (Sorafenib+Everolimus in Relapsed Inoperable Osteosarcoma)",Oncology,Oncology: Osteosarcoma,Italian Sarcoma Group,Cooperative Group,"Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Vital signs",True,NCT01804374,15581
3829,160155,"16091, DRKS00004148, NCT01508364, NEXTAR, NX1111, TrialTroveID-160155, URO 00025",NEXTAR - NEXavar as First TARgeted Treatment for Patients With Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,"Complete response, Overall survival, Partial response, Progression-free survival, Quality of Life, Stable Disease, Time to progression, Time to treatment failure, Treatment Emergent Adverse Events",True,NCT01508364,15581
3830,160067,"epatologia2, LANEX, NCT01507064, TrialTroveID-160067",Randomized Controlled Phase II Trial Of Neoadjuvant Sorafenib Therapy Prior to Thermal Ablation for Hepatocellular Carcinoma More Than 4 cm in Size,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Partial response","Adverse Events, Safety and Tolerability",True,NCT01507064,15581
3831,159815,"TrialTroveID-159815, UMIN000005731",Hepatic arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma: Prospective randomized study,Oncology,Oncology: Liver,Yamaguchi University School of Medicine,Academic,,"Progression-free survival, Safety and Tolerability",False,,15581
3832,159456,"12-139, 12-C-0098, 2012CG033, 212812, AAAJ4351, ADVL1121, COG-ADVL1121, NCI-2012-00106, NCT01502410, SOL-12017-C, STU 062012-067, TrialTroveID-159456","A Phase II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib in Children and Young Adults With Relapsed/Refractory Rhabdomyosarcoma, Wilms Tumor, Hepatocellular Carcinoma, and Papillary Thyroid Carcinoma",Oncology,Oncology: Liver; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01502410,15581
3833,159113,"CDR0000720022, N1153, NCCTG-N1153, NCI-2012-00095, NCT01497444, TH-IST-4004, TrialTroveID-159113",Study of Sorafenib + TH-302: Phase I in Advanced Renal Cell Carcinoma (RCC) and Advanced Hepatocellular Carcinoma (HCC) and Phase II in Ist Line Advanced HCC,Oncology,Oncology: Liver; Oncology: Renal,"Cancer and Leukemia Group B (CALGB), North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Molecular Templates {Threshold Pharmaceuticals}, American College of Surgeons Oncology Group (ACOSOG), Alliance for Clinical Trials in Oncology","Cooperative Group, Cooperative Group, Government, Industry, all other pharma, Cooperative Group, Cooperative Group","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT01497444,15581
3834,158521,"SCOOP-2, Scoop-II, TrialTroveID-158521, UMIN000006147",Sequential Hepatic Arterial Infusion Chemotherapy With Cisplatin Followed by Sorafenib Versus Sorafenib Alone in Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",,"Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",False,,15581
3835,158515,TrialTroveID-158515,A Clinical Study on Therapeutic Efficacy of Nexavar on Liver Cancer and its Relation to the Expression of Ki-67 and CD34.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3836,157818,"TrialTroveID-157818, UMIN000005847",Sorafenib in TACE-refractory or TACE-failure advanced hepatocellular carcinoma: Safety and effectiveness,Oncology,Oncology: Liver,Kyoto University Hospital,Academic,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression, Time to treatment failure",False,,15581
3837,157600,"NCT01480817, STAP, TrialTroveID-157600","An Open Label, Phase II Trial Comparing Sorafenib And TACE in Advanced Hepatocellular Carcinoma with Portal Vein Invasion",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Adverse Events, NCI-CTC scale, Overall response rate, Overall survival, Progression-free survival, Tumor control rate",True,NCT01480817,15581
3838,157458,"TrialTroveID-157458, UMIN000005818",An Investigation of the Safety of Continued Treatment with Sorafenib in Patients with Unresectable Hepatocellular Carcinoma after the First Disease Progression,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progressive disease rate, Safety and Tolerability","Clinical benefit rate, Overall response rate, Overall survival, Progressive disease rate, Response rate, Safety and Tolerability",False,,15581
3839,157022,TrialTroveID-157022,"An Open-label, Pilot, Single Center, Randomized, Safety and Efficacy Study of Sorafenib and Cryotherapy in Patients with Advanced Hepatocellular Carcinoma.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Adverse Events, Overall survival, Safety and Tolerability",False,,15581
3840,156974,"507-2011, NCT01471353, ONC2010-23, ONC23-2010, TrialTroveID-156974",Sorafenib Plus Capecitabine (SorCape) in Previously Treated Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"University of Florida - Gainesville, Bayer AG","Academic, Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Quality of Life, Response rate, Time to progression",True,NCT01471353,15581
3841,156926,TrialTroveID-156926,An Efficacy Study on the Effectiveness of Sorafenib and Clinical Factors in Patients with Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,15581
3842,156758,"NCT01470495, swhb005, TrialTroveID-156758",Radiofrequency Ablation Plus Sorafenib Administration in Early Recurrent Hepatocellular Carcinoma: a Prospective Multicenter Cohort Trial (Repeat) Tumors for BCLC B Stage HCC Undergone Curative Hepatectomy,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Recurrence,Overall survival,True,NCT01470495,15581
3843,156680,TrialTroveID-156680,A Prospective Study on the Effect of Sorafenib in Advanced Hepatocellular Carcinoma Patients with Extrahepatic Metastasis and Comparison of Patients without Extrahepatic Metastasis.,Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3844,156476,TrialTroveID-156476,A Prospective Clinical Study on the Efficacy and Tolerance of Sorafenib in Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Magnetic Resonance Imaging",,False,,15581
3845,156422,"TrialTroveID-156422, UMIN000005910",Safety Evaluation Of The Maintenance Treatment Of Sorafenib In Hepatocellular Carcinoma Patients With Tumor Thrombus After Palliative Surgery,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Adverse Events,"Overall survival, Progression-free survival, Time to progression",False,,15581
3846,156336,"D11004, NCT01466504, TrialTroveID-156336",A Study of the Effect of Sorafenib or Regorafenib on p63 Expression and Keratinocyte Differentiation in Human Skin,Oncology,Oncology: Colorectal; Oncology: Liver; Oncology: Renal,"National Institutes of Health/National Cancer Institute, Dartmouth-Hitchcock Medical Center","Government, Academic",,,True,NCT01466504,15581
3847,155685,TrialTroveID-155685,A Clinical Study on the Effect of Short Treatment with Sorafenib on Tumor Progression and Time to Progression in Patients with Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Time to progression",,False,,15581
3848,155667,TrialTroveID-155667,A Clincal Study to Compare the Efficacy of Overall Survival  in the View of the Duration of Stable Dsease in Patients with Advanced Hepatocellular Carcinoma Receiving Sorafenib.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression - duration, Overall survival, Response evaluation criteria in solid tumors",,False,,15581
3849,155665,TrialTroveID-155665,A Prospective Study on Long-term Effect of sorafenib Treatment in Cirrhotic Patients with Advanced-Stage Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Response evaluation criteria in solid tumors, Safety and Tolerability",,False,,15581
3850,155565,TrialTroveID-155565,Register trial of sorafenib (S) for patients (pts) with metastatic uveal melanoma (metUvMel),Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Safety and Tolerability,False,,15581
3851,154981,"HCC_Sor_CDDP_rP2, TrialTroveID-154981, UMIN000005703",Randomized phase II study of sorafenib and hepatic arterial infusion chemotherapy with cisplatin versus sorafenib for advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Japanese Ministry of Health, Labour and Welfare","Academic, Government",Overall survival,"Adverse Events, Overall response rate, Response rate, Time to progression",False,,15581
3852,154845,"MCC-13874, NCI-2011-03035, NCT01450384, ONC-2012-58, TrialTroveID-154845",Phase I Study of Pemetrexed and Sorafenib in Advanced Malignancy.,Oncology,Oncology: Breast; Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Virginia Commonwealth University","Government, Academic",Safety and Tolerability,"Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01450384,15581
3853,154533,"09-0155, HCC BRIDGE, TrialTroveID-154533",Observations of Hepatocellular Carcinoma (HCC) Management Patterns From the Multinational HCC BRIDGE Study.,Oncology,Oncology: Liver,Bristol-Myers Squibb,"Industry, Top 20 Pharma","Mortality, Overall survival","Adverse Events, Disease Progression",False,,15581
3854,154237,"TrialTroveID-154237, UMIN000005410",Effects of Sorafenib on Intrahepatic Circulations in Patients with Advanced Hepatocullar Carcinoma: A Prospective Cohort Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,15581
3855,154222,TrialTroveID-154222,Sorafenib Combined with Cryoablation to Treat Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3856,154185,"EudraCT Number: 2012-000708-14, GP1, NCT01444807, ONC-RCC-02, RESORT TRIAL, TrialTroveID-154185","A Randomized, Open Label, Multicenter Phase II Study, to Evaluate the Efficacy of Sorafenib in Patients With Advanced Renal Cell Carcinoma (RCC) After a Radical Resection of the Metastases",Oncology,Oncology: Renal,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), Bayer AG","Academic, Industry, Top 20 Pharma",Disease-free survival,"Adverse Events, Circulating Tumor Cells, Disease-free survival, Eosinophil levels, Hematocrit level, Hemoglobin level, Leukocyte count, Overall survival, Phosphate level, Platelet count, Safety and Tolerability, Uric acid level, Vital signs",True,NCT01444807,15581
3857,154148,TrialTroveID-154148,Clinical observation of the treatment with combination of transcatheter arterial chemoembolization and sorafenib for hepatocellular carcinoma with lung metastasis.,Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3858,153819,TrialTroveID-153819,Treatment of Metastatic Renal Cancer with High-dose Interleukin-2 After Targeted Therapy Can Be Given Safely and Can Produce High Rates of Response Including Complete Remissions,Oncology,Oncology: Renal,Christie Hospital N.H.S. Trust,Academic,Complete response,,False,,15581
3859,153589,TrialTroveID-153589,Clinical observation of sorafenib monotherapy in Chinese patients with advanced hepatocellular carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3860,153456,TrialTroveID-153456,Clinical observation of transarterial chemoembolization combined with sorafenib for advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"Fudan University - Shanghai, China",Academic,,,False,,15581
3861,153444,TrialTroveID-153444,Therapeutic efficacy and prognostic factors of sorafenib treatment in patients with unresectable primary hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3862,153318,"TrialTroveID-153318, UMIN000004313",A Phase I study of 5-FU and sorafenib combination therapy in patients with hepatocellular carcinoma. Non-blind dosage gradual increase study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose","Overall response rate, Response rate",False,,15581
3863,153283,TrialTroveID-153283,Chromogranine a (CG-A) Plus Vascular Endothelial Growth Factor (VEGF) as Predicting Factors (PF) of Sorafenib (SFB) Treatment of Multifocal Hepatocellular Carcinoma (M-HCC) in Elderly Patients,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3864,153183,TrialTroveID-153183,Sorafenib Dose Ramp-up Scheme for the Treatment of Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,Asan Medical Center,Academic,Safety and Tolerability,,False,,15581
3865,152981,"09-01, 160011, 16-C-0011, BTTC09-01, BTTC3312, CTO# 101834, NCI-2015-02100, NCI-2018-03750, NCT01434602, NU 12C02, P152430, STU 042014-012, TrialTroveID-152981",A Phase I-II Trial of Everolimus and Sorafenib in Patients with Recurrent High-Grade Gliomas,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","Novartis, (Other Cooperative Group), National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals","Industry, Top 20 Pharma, Cooperative Group, Government, Industry, Top 20 Pharma","Disease Progression, Disease-free survival, Maximum tolerated dose, Overall survival, Progression-free survival, Safety and Tolerability","Disease Progression, MD Anderson Symptom Inventory, Overall response rate, Overall survival, Time to progression",True,NCT01434602,15581
3866,152325,"DRKS00000591, EudraCT Number: 2010-018539-16, KKS-134, LN_SAL_2010_477, SORMAIN, TrialTroveID-152325","A double-blind, placebo-controlled, randomized, multi-center phase II trial to assess the efficacy of Sorafenib-maintenance therapy in Flt3-ITD positive AML in complete hematological remission after allogenic stem cell transplantation, , SORMAIN (sorafenib Maintenance therapy after allo-SCT)",Oncology,"Oncology: Leukemia, Acute Myelogenous","Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, (Other Hospital/Academic/Medical Center), Bayer AG/Bayer Vital GmbH","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma",Disease-free survival,"Disease-free survival, Overall survival, Response rate, Safety and Tolerability",False,,15581
3867,151230,"15037, NCT01412671, NEXAVAR-RCC-01, TrialTroveID-151230",Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma: Early Access Program),Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma","Safety and Tolerability, Serious Adverse Events","Overall response rate, Overall survival, Response rate, Stable Disease",True,NCT01412671,15581
3868,151155,"15039, NCT01411436, NEXAVAR-HCC-01, TrialTroveID-151155",Special Drug Use Investigation of Nexavar (Unresectable Hepatocellular Carcinoma),Oncology,Oncology: Liver,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",Serious Adverse Events,"Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT01411436,15581
3869,151151,"15038, NCT01411423, NEXAVAR-RCC-02, TrialTroveID-151151",Special Drug Use Investigation of Nexavar (Unresectable or Advanced Renal Cell Carcinoma),Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",Serious Adverse Events,"Overall response rate, Overall survival, Response rate, Stable Disease",True,NCT01411423,15581
3870,151138,"TrialTroveID-151138, UMIN000005090",First line Therapy by Sorafenib for Lung Metastases Patients in Renal Cell Carcinoma.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,"Overall response rate, Progression-free survival, Response rate, Safety and Tolerability",False,,15581
3871,151085,"2011PTAHCC, NCT01409499, TrialTroveID-151085",A Prospective Multicenter Non-randomized Controlled Study of Palliative Treatments for Patients With Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Progression-free survival",True,NCT01409499,15581
3872,150798,"BOOST, EudraCT Number: 2009-013870-42, NCT01405573, TrialTroveID-150798",Sorafenib in the First Line Treatment of Advanced Hepatocellular Carcinoma with Child-Pugh Liver Function Class B: Multicentre Phase III Randomized Trial,Oncology,Oncology: Liver,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), Istituto Nazionale per la Ricerca sul Cancro, Italian Ministry of Health","Academic, Academic, Government","Liver function, Overall survival","Common Terminology Criteria for Adverse Events, Progression-free survival, Quality of Life",True,NCT01405573,15581
3873,150791,"ACTRN12611001112954, ALLG AML M16, ALLG AMLM16, ALLG AMLM16, AMLM16, NC49, TrialTroveID-150791, U1111-1122-6056",A Phase II Randomised Study Investigating the FLT3 Inhibitor Sorafenib in Sequence after Intensive Chemotherapy for Untreated Adult AML Harbouring FLT3 mutations,Oncology,"Oncology: Leukemia, Acute Myelogenous","(Other Cooperative Group), Australasian Leukaemia and Lymphoma Group (ALLG)","Cooperative Group, Cooperative Group","Complete response, Event-free survival","Complete response, Composite complete response, Cytogenetic response, Disease-free survival, Event-free survival, Minimal Residual Disease, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to response",False,,15581
3874,150097,"11-114, NCT01398501, TrialTroveID-150097",Phase I Trial of Sorafenib Maintenance Therapy for Patients With FLT3-ITD AML After Allogeneic Stem Cell Transplantation,Oncology,"Oncology: Leukemia, Acute Myelogenous","Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Massachusetts General Hospital","Academic, Academic",Maximum tolerated dose,"Dose-limiting toxicities, Overall survival",True,NCT01398501,15581
3875,149997,"TrialTroveID-149997, UMIN000005335",A Phase I Study of Sorafenib/UFT Chemotherapy in Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,,False,,15581
3876,149972,TrialTroveID-149972,Sorafenib as a third line therapy in patients with epithelial ovarian cancer or primary peritoneal cancer: A Phase II study,Oncology,Oncology: (N/A); Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
3877,149333,"INT 80/09, NCT01387503, TrialTroveID-149333, XXL Trial",Controlled Expansion of Conventional Criteria for Liver Transplantation in Hepatocellular Carcinoma Through Downstaging Procedures: a Randomized Trial (XXL Trial).,Oncology,Oncology: Liver,"(Other Cooperative Group), Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy), Istituto Nazionale per la Ricerca sul Cancro, (Other government agency)","Cooperative Group, Academic, Academic, Government","Complete response, Event-free survival, Overall survival, Recurrence","Quality-adjusted life year, Response evaluation criteria in solid tumors",True,NCT01387503,15581
3878,148925,"8877, MAYO-MC1017, MC1017, NCI-2011-02595, NCT01383343, TrialTroveID-148925",Phase I Trial of FOLFIRI in Combination With Sorafenib and Bevacizumab in Patients With Advanced Gastrointestinal Malignancies,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Hemoglobin level, NCI-CTC scale, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT01383343,15581
3879,148916,"EudraCT Number: 2010-022687-12, NCT01377025, STREAM, TrialTroveID-148916","A Randomized Discontinuation, Blinded, Placebo-Controlled Phase II Study of Sorafenib in Patients With Chemonaive Metastatic Uveal Melanoma. , , Sorafenib Treatment of Metastatic Uveal Melanoma",Oncology,Oncology: Melanoma; Oncology: Metastatic Cancer,University of Duisburg-Essen {University of Essen},Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT01377025,15581
3880,148550,"TrialTroveID-148550, UMIN000004067",Phase II Clinical Study of Interferon+Sorafenib Combination Therapy in Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,Overall response rate,Safety and Tolerability,False,,15581
3881,148445,"16475, IST 000575, MCC-16475, NCT01376453, TrialTroveID-148445","Phase I Study of Pre-operative Continuous 5-FU, and Sorafenib With External Radiation Therapy in Locally Advanced Rectal Adenocarcinoma",Oncology,Oncology: Colorectal,"H. Lee Moffitt Cancer Center and Research Institute, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Complete response, Overall response rate, Response rate, Safety and Tolerability, Serious Adverse Events",True,NCT01376453,15581
3882,148441,"TrialTroveID-148441, UMIN000004215",Safety and Efficacy Study of Sorafenib in Japanese Child-Pugh A and B Patients with Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Overall response rate, Overall survival",False,,15581
3883,148028,"00031615, 111104, 11184, 13-120, 1412602364, 2011-455, 2011CG134, 20120324, 20160853, 204320, 80-0066-01031, AAAI4455, AALL10B1, AAML1031, CDR0000701850, CHOC-AAML1031, CIRB/COG AAML1031, COG AAML1031, COGAAML1031, COG-AAML1031, HEM-11103-C, HIC#: 1301011299, NCG 217112, NCI-2011-02670, NCI-CIRB-AAML1031, NCT01371981, PAAML1031, PSHCI-11-097, S12-02301, STU 082011-083, TrialTroveID-148028","A Phase III Randomized Trial for Patients With De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients With High Allelic Ratio FLT3/ITD",Oncology,"Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group {Pediatric Oncology Group}, Takeda/Takeda Oncology {Millennium}","Government, Cooperative Group, Industry, Top 20 Pharma","Event-free survival, Overall survival","Common Terminology Criteria for Adverse Events, Complete response, Cumulative Incidence of Relapse, Disease-free survival, Duration of hospitalization, Minimal Residual Disease, Overall survival, Quality of Life, Treatment related mortality",True,NCT01371981,15581
3884,147888,TrialTroveID-147888,Efficacy and toxicity of sorafenib in patients with advanced renal cell cancer in northeast China: A multicenter study.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall survival, Progression-free survival",False,,15581
3885,147717,TrialTroveID-147717,Sorafenib and locoregional treatment in patients with stage B and stage C HCC: Sardinian experience.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3886,146824,TrialTroveID-146824,Efficacy of sorafenib in combination with gemcitabine and fluorouracil in metastatic renal-cell carcinoma: Preliminary result of a multicenter phase II study.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
3887,146810,"107/2007/O/Sper, EudraCT Number: 2007-005894-77, SITMP3, SoMe Study, TrialTroveID-146810",Phase I/II study with cisplatin and pemetrexed +/- sorafenib in malignant pleural mesothelioma (SoMe study),Oncology,Oncology: Mesothelioma,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival, Safety and Tolerability","Duration of overall response, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Time to progression",False,,15581
3888,146746,"21 PRODIGY, CHUBX 2010 22, CHUBX 2010/22, EudraCT Number: 2011-000432-28, NCT01357486, PRODIGE 21, RECF1707, TrialTroveID-146746",Phase II Randomized Trial Evaluating the Administration of Sorafenib or Pravastatin or Association Sorafenib-pravastatin or Best Supportive Care for the Palliative Treatment of Hepatocellular Carcinoma in Patient with CHILD B Cirrhosis,Oncology,Oncology: Liver,"Federation Nationale des Centres de Lutte contre le Cancer, Federation Francophone de Cancerologie Digestive, French Health Ministry, (Other Hospital/Academic/Medical Center)","Cooperative Group, Miscellaneous, Government, Academic","Magnetic Resonance Imaging, Progression-free survival, Time to progression","EORTC Quality of Life Questionnaire, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Serious Adverse Events, Time to treatment failure",True,NCT01357486,15581
3889,146528,"15246, NCT01353794, NX0913IN, POWER-NEXT, TrialTroveID-146528","Prospective, Multicentric, Large Scale Observational Study to Evaluate Effectiveness and Safety of Nexavar in Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Quality of Life,Adverse Events,True,NCT01353794,15581
3890,146394,"TrialTroveID-146394, UMIN000004022","Cohort Phase II Study of Hepatic Arterial Chemotherapy With Cisplatin and 5-FU, and Sorafenib in Patients with Advanced Unresectable Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,Overall survival,False,,15581
3891,145379,"CASE2209, CC729, NCT01337492, TrialTroveID-145379",Pilot Study: Safety and Feasibility of Using Sorafenib as Neoadjuvant Treatment Prior to Orthotopic Liver Transplantation (OLT) in Patients With Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Case Western Reserve University","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Adverse Events, Safety and Tolerability","Disease Progression, Time to progression",True,NCT01337492,15581
3892,144917,TrialTroveID-144917,A Clinical Study on Assessment Of Response To Sorafenib In Hepatocellular Carcinoma using Prognostic Value Of Tumoral Density And Arterial Enhancement Measurements In Target Lesions.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3893,144590,TrialTroveID-144590,An Observational Study on Safety and Effectiveness of Treatment with Sorafenib in Older Patients with Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, NCI-CTC scale, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",,False,,15581
3894,144589,TrialTroveID-144589,A Prospective Cohort Study on Effect of Combined Therapy of Transarterial Chemoembolization with Sorafenib on Tumor Response in Korean Patients with Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",,False,,15581
3895,144504,"ISRCTN95691970, SORAFENIB2011, TrialTroveID-144504, WESTERN Trial",Sorafenib Combined With Percutaneous Radio-Frequency Ablation Of Both Hepatocellular Carcinoma Nodule And Portal Vein Tumor Thrombus Compared With Sorafenib Alone: A Western Randomized Controlled Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,,False,,15581
3896,144500,"CHANGH ANGH Study, TrialTroveID-144500",Treatment of Hepatocellular Carcinoma with Sorafenib: Results in the Real Life of CHANG Cohort,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3897,144321,TrialTroveID-144321,A Clinical Study on the Response to Targeted Therapy Between the Primary Tumor and Metastatic Lesions in Patients with Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3898,144203,"NCT01319942, NCT01328223, RT-sorafenib, TrialTroveID-144203",Phase II Study of Combined Sorafenib With Radiotherapy in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"China Medical College Hospital, Taichung, Taiwan",Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Overall survival, Progression-free survival, Quality of Life",True,NCT01319942,15581
3899,142920,"090906, 1R01CA149627-01, 8850, CINJ-090906, NCI/CTEP #8850, NCI-2011-02597, NCT01303341, TrialTroveID-142920",A Phase I Trial of Riluzole and Sorafenib in Patients with Advanced Solid Tumors and Melanoma,Oncology,Oncology: Melanoma; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Maximum tolerated dose",,True,NCT01303341,15581
3900,142624,TrialTroveID-142624,"A Pilot, Randomized Study of Lovastatin on the Cytostatic Effects of Sorafenib in Hepatic Carcinoma.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",,False,,15581
3901,142534,TrialTroveID-142534,Anti-VEGF drugs combined with gemcitabine-based chemotherapy in treatment of metastatic collecting duct carcinoma,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,,,False,,15581
3902,142211,"JPRN-UMIN000004107, TrialTroveID-142211, UMIN000004107",The effect of Sorafenib and intermittent hepatic arterial infusion chemotherapy using Cisplatin for advanced hepatocellular carcinoma with portal vein tumor thrombus: a phase I study.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Dose-limiting toxicities,"Adverse Events, Overall response rate, Response rate",False,,15581
3903,141988,"EudraCT Number: 2010-023695-91, NCT01290926, SoMore, SoMore version 2.0, TrialTroveID-141988",Sorafenib Plus Capecitabine Efficacy Assessment in Patients with Advanced Pre-treated Colorectal Cancer,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT01290926,15581
3904,141834,TrialTroveID-141834,"An Open-label, Two-period Sequential Treatment Study on the Effect of Neomycin on the Pharmacokinetics (PK) of Sorafenib (S).",Oncology,Oncology: Unspecified Cancer,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,,False,,15581
3905,140905,"NCI-2010-02407, NCT01276210, ONC-2010-18, TrialTroveID-140905, VICC RAD1060, VICCRAD1060",A Phase I Trial of Sorafenib and Stereotactic Radiosurgery for Patients With 1-4 Brain Metastases,Oncology,Oncology: Metastatic Cancer; Oncology: Unspecified Cancer,"National Institutes of Health/National Cancer Institute, Vanderbilt-Ingram Cancer Center","Government, Academic","Maximum tolerated dose, Safety and Tolerability","Overall survival, Progression-free survival",True,NCT01276210,15581
3906,140705,"EudraCT Number: 2010-020375-24, INT29/10, NCT01703455, TrialTroveID-140705",Phase II trial of sorafenib in patients with relapsed or metastatic carcinoma of the salivary glands.,Oncology,Oncology: Head/Neck,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01703455,15581
3907,140699,"ISHCC-RCT, TrialTroveID-140699, UMIN000002399",Randomized control study comparing intra-hepatic arterial chemotherapy (IHAC) with sorafenib for advanced hepatocellular carcinoma (ISHCC-RCT).,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Overall survival,"Adverse Events, Overall response rate, Progression-free survival, Response rate, Tumor control rate",False,,15581
3908,140685,"ISHCC-cohort, TrialTroveID-140685, UMIN000002416",Efficacy of intra-hepatic arterial chemotherapy (IHAC) vs. sorafenib on advanced hepatocellular carcinoma; a prospective cohort study (ISHCC-cohort).,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Overall survival,"Adverse Events, Overall response rate, Progression-free survival, Response rate, Tumor control rate",False,,15581
3909,139603,"2008-004223-27, EudraCT Number: 2008-004223-27, GEMCAD-0802, NCT01262482, TrialTroveID-139603","A Phase II Trial of Oxaliplatin and Sorafenib Combination in Patients With Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma, Relapsed After a Cisplatin Based Treatment",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Cooperative Group),Cooperative Group,"Magnetic Resonance Imaging, Progression-free survival, Response evaluation criteria in solid tumors","Magnetic Resonance Imaging, Overall response rate - duration, Overall survival, Quality of Life, Response evaluation criteria in solid tumors",True,NCT01262482,15581
3910,139581,"CROSS-J-RCC, NCT01481870, TrialTroveID-139581, UMIN000003040",Randomized comparison of Sequential therapies with Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall survival, Progression-free survival",True,NCT01481870,15581
3911,139569,"TrialTroveID-139569, UMIN000002972",Phase II study of sorafenib in patients with advanced hepatocellular carcinoma,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government",Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Response rate",False,,15581
3912,139431,"LCI-10-10-20, NCT01259193, SRFB-021, TrialTroveID-139431",Phase II Study of Sorafenib and Zoledronic Acid in Advanced HCC,Oncology,Oncology: Liver,"Fudan University - Shanghai, China",Academic,Adverse Events,"Overall survival, Time to progression",True,NCT01259193,15581
3913,139270,TrialTroveID-139270,"Clinical Activity, Pharmacokinetics, and Pharmacodynamics of Sorafenib In Pediatric Acute Myeloid Leukemia",Oncology,"Oncology: Leukemia, Acute Myelogenous",St. Jude Children's Research Hospital,Academic,,,False,,15581
3914,139143,"TrialTroveID-139143, UMIN000002418, UMIN000002590",A phase I study of TS-1 and sorafenib combination therapy in patients with advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",False,,15581
3915,139014,"2010-0511, NCI-2011-00257, NCT01254890, TrialTroveID-139014, VZ-MDS-PI-0227",Phase I/II Study of Sorafenib and 5-Azacitidine for the Treatment of Patients With Refractory or Relapsed Acute Leukemia and Myelodysplastic Syndrome (MDS) - (VZ-MDS-PI-0227),Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Bristol-Myers Squibb/Celgene, Amgen {Onyx Pharmaceuticals}","Academic, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Complete response, Partial response, Platelet count",True,NCT01254890,15581
3916,138933,"11-0207, C11001, CALGB 11001, CALGB 361006, CALGB-11001, NCI-2011-02618, NCT01253070, TrialTroveID-138933",A Phase II Study Incorporating Sorafenib ( NSC 724772) Into the Therapy of Patients > or = 60 Years of Age With FLT3 Mutated Acute Myeloid Leukemia,Oncology,"Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group",Overall survival,"Adverse Events, Complete response, Cytogenetic response, Event-free survival, Overall survival, Quality of Life, Treatment related mortality",True,NCT01253070,15581
3917,138208,TrialTroveID-138208,A clinical study evaluating the impact of early treatment interruption and biomarker profiling in patients with hepatocellular carcinoma (HCC) treated with sorafenib.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Response evaluation criteria in solid tumors, Time to progression",,False,,15581
3918,138183,TrialTroveID-138183,A Clinical Study Comparing Therapeutic Response to Sorafenib for Patients with Advanced Hepatocellular Carcinoma Through  RECIST Criteria and Modified RECIST Criteria.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Response evaluation criteria in solid tumors,,False,,15581
3919,137974,TrialTroveID-137974,Clinical Activity and Safety of the Combined Therapy with the AKT Inhibitor Perifosine and the Multikinase Inhibitor Sorafenib In Heavily Pretreated Patients with Relapsed/Refractory Lymphomas,Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Common Terminology Criteria for Adverse Events, Safety and Tolerability",,False,,15581
3920,137920,"CCMO / METC VUmc, EudraCT Number: 2009-016632-12, NL30000.029.09 / 2009/305, NTR2530, TrialTroveID-137920",A Phase II Study of Sorafenib in Patients with Locally Advanced and/or Metastatic (Stage IIIB or IV) Non-Small Lung Cancer (NSCLC) with a K-Ras Mutation,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,"Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Time to progression",False,,15581
3921,137824,TrialTroveID-137824,A prospective study on overall survival in patients with advanced hepatocellular carcinoma treated with sorafenib.,Oncology,Oncology: Liver,University of Heidelberg,Academic,,,False,,15581
3922,137800,TrialTroveID-137800,A clinical study on biological downstaging of intermediate hepatocellular carcinoma in patients treated with sorafenib.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",Progression-free survival,False,,15581
3923,137148,"662010, NCT01230697, SORHORM, TrialTroveID-137148",Perspective Evaluation of Hormones Involved in Serum Phosphate Homeostasis in Patients With Metastatic Renal Cells Carcinoma or Hepatocellular Carcinoma Treated With Sorafenib. Multicenter Cohort Study,Oncology,Oncology: Liver; Oncology: Renal,University of Turin,Academic,Phosphate level,"Bone Mineral Density, Overall survival, Phosphate level, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT01230697,15581
3924,136753,"EudraCT Number: 2008-002660-34, IEO S426/508, NCT01226056, S075SORD01, TrialTroveID-136753","Phase I/II Trial With Sorafenib in Combination with RAD001 Administered Orally in Patients with Advanced Solid Tumors, Selected on the Base of Molecular Targets",Oncology,"Oncology: GIST; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Soft Tissue Sarcoma","Novartis, Bayer AG/Bayer Pharmaceuticals, Southern Europe New Drug Organization","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Not for Profit Funding Entity","Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01226056,15581
3925,136682,"EudraCT Number: 2007-002941-20, GEST, TrialTroveID-136682",Randomized Phase II Study Of Sorafenib Plus Gemcitabine or Sorafenib Plus Erlotinib in Advanced Non Small Cell Lung Cancer (Nsclc) Elderly or Ps 2 Patients,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Overall survival","Clinical benefit rate, Overall response rate, Overall survival, Response rate",False,,15581
3926,136539,"12386, TrialTroveID-136539",A Phase Ib Pharmacological Study of Sorafenib in Combination With Gemcitabine/Cisplatin in Patients With  Refractory Solid Tumors Including Non-Small Cell Lung Cancer,Oncology,"Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
3927,136492,"EU-21077, EudraCT Number: 2010-022653-41, INT52/10, IRCCS INT 52/10, ITA-MIL-IRCCS-INT-52/10, NCT01222676, TrialTroveID-136492",A Phase II Study of Neoadjuvant Cisplatin and Gemcitabine Plus Sorafenib for Patients With Transitional-Cell Carcinoma of the Bladder,Oncology,Oncology: Bladder,"Istituto Nazionale per lo Studio e la Cura dei Tumori (National Cancer Institute, Naples, Italy)",Academic,Complete response,"Adverse Events, Complete response, NCI-CTC scale, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT01222676,15581
3928,136098,"JLOG 1001 trial, NCT01217034, TACTICS, TrialTroveID-136098, UMIN000004316",Phase II Study: Transcatheter Arterial Chemoembolization Therapy In Combination With Sorafenib (TACTICS),Oncology,Oncology: Liver,(Other Cooperative Group),Cooperative Group,"Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT01217034,15581
3929,135861,"NCT01214343, SILIUS Phase III trial, TrialTroveID-135861, UMIN000004315",Randomized Controlled Trial Comparing Efficacy of Sorafenib Versus Sorafenib In Combination With Low Dose Cisplatin /Fluorouracil Hepatic Arterial InfUSion Chemotherapy in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Japanese Ministry of Health, Labour and Welfare",Government,Overall survival,"Clinical benefit rate, Overall response rate, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT01214343,15581
3930,135314,TrialTroveID-135314,"Safety and pharmacokinetics of the dual action Raf kinase and vascular endothelial growth factor receptor inhibitor, BAY 43-9006, in patients with advanced, refractory solid tumors.",Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Maximum tolerated dose,,False,,15581
3931,135312,TrialTroveID-135312,Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose",,False,,15581
3932,135019,"NCT01203787, ONC-2010-19, TrialTroveID-135019","Multicenter, Randomized Pilot Study of the Effect of Sorafenib Dosing Schedule on Tolerability and Drug Delivery",Oncology,Oncology: Liver,University of Florida - Gainesville,Academic,,Safety and Tolerability,True,NCT01203787,15581
3933,135000,"14899, BASIL, NCT01204177, TrialTroveID-135000",A Phase II Trial of BAY86-9766 Plus Sorafenib as First Line Systemic Treatment for Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Clinical benefit rate,"Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Time to progression, Vital signs",True,NCT01204177,15581
3934,134513,"15242, NCT01195649, NX1010TW, TrialTroveID-134513","Advanced Renal Cell Carcinoma, With Failure or Unsuitable on Prior Interferon-alpha or Interleukin-2 Based Therapy",Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability",,True,NCT01195649,15581
3935,134307,"NCT01194869, TrialTroveID-134307, WCI1590-08","Phase II Neoadjuvant Trial of Sorafenib in Combination With Cisplatin Followed by Dose Dense Paclitaxel for ER-, PR-, Her2- (Triple Negative) Early-Stage Breast Cancer",Oncology,Oncology: Breast,"Bayer AG/Bayer Pharmaceuticals, Winship Cancer Institute of Emory University, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Complete response, Overall response rate, Response rate","Complete response, Overall response rate, Progressive disease rate, Recurrence, Response rate, Safety and Tolerability",True,NCT01194869,15581
3936,134158,"2010/124, ABR-32011, EudraCT Number: 2010-019982-27, NCT01190241, NL2353, NTR2460, TrialTroveID-134158, TSAP","Targeted Therapy Selection Based on Tumor Tissue Kinase Activity Profiles for Patients With Advanced Solid Malignancies, an Exploratory Study",Oncology,Oncology: Unspecified Solid Tumor,"Vrije Universiteit Medical Center, Amsterdam, Netherlands",Academic,"Clinical benefit rate, Overall response rate, Partial response, Stable Disease",Progression-free survival,True,NCT01190241,15581
3937,133706,"11277, IST000366, NCT01189370, TrialTroveID-133706",A Phase II Study of the Efficacy and Tolerability of the Dose Escalation of Sorafenib in Advanced Renal Cell Cancer,Oncology,Oncology: Renal,"University of Kansas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",,"Disease Progression, Response evaluation criteria in solid tumors",True,NCT01189370,15581
3938,133671,"AIO-HEP-0109, EudraCT Number: 2009-011904-47, NCT01272557, SoraDox, SoraDox 2009, TrialTroveID-133671",Sorafenib plus Doxorubicin versus Sorafenib alone for the treatment of Advanced Hepatocellular Carcinoma: a Randomized Phase II trial,Oncology,Oncology: Liver,Arbeitsgemeinschaft fur Internistische Onkologie,Cooperative Group,"Response evaluation criteria in solid tumors, Time to progression","Clinical benefit rate, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01272557,15581
3939,133594,"10-GI-82-MCC-BP, ONC-2009-11, TrialTroveID-133594",Phase I/II Study of Sorafenib and Everolimus with Capecitabine and Oxaliplatin (CAPOX) in First-Line Treatment of Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,University of Kentucky,Academic,"Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival",Dose-limiting toxicities,False,,15581
3940,133117,"201102036MB, AMC1002, AMC-ONCGI-1002, NCT01187212, STARGATE, TrialTroveID-133117","A Randomized Phase II Study of Capecitabine and Cisplatin (XP) + or - Sorafenib (Nexavar) in Patients With Advanced Gastric Cancer, , Sorafenib Trial in Advanced and/or Recurrent Gastric Adenocarcinoma: Treatment Evaluation (STARGATE)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Bayer AG/Bayer Pharmaceuticals, Asan Medical Center","Industry, Top 20 Pharma, Academic",Progression-free survival,"Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01187212,15581
3941,132214,"BIOSHARE, D09-1, EU-21058, EudraCT Number: 2009-018058-44, FRE-GERCOR-D09-1-BIOSHARE, NCT01182272, RECF1494, TrialTroveID-132214",Proof-of-concept Phase II Study to Evaluate the Anti-Tumor Activity of Sorafenib along with Pathological and Molecular Changes in Tumor Samples from Patients With Resectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,GERCOR,Cooperative Group,,"Resection rate, Safety and Tolerability",True,NCT01182272,15581
3942,132059,"HIC 0901004690, NCT01561833, TrialTroveID-132059, Yale5062786",A Pilot Study of Sorafenib Examining Biomarkers in Refractory or Relapsed T-Cell Lymphoma Patients,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Yale Comprehensive Cancer Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response","Disease Progression - duration, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response rate, Stable Disease",True,NCT01561833,15581
3943,132056,"07-2010-010, NCT01171482, TrialTroveID-132056","An Open Label, Phase II Trial Comparing Sorafenib and 5-fluorouracil/Mitomycin in Hepatocellular Carcinoma With Pulmonary Metastasis.",Oncology,Oncology: Liver; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Adverse Events, Overall response rate, Overall survival, Time to progression",True,NCT01171482,15581
3944,131863,"CAUHHO 2009-1, KCSG-HB09-02, NCT01170104, TrialTroveID-131863",Phase II Trial of TACE With Sorafenib in Patients With Locally Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,,True,NCT01170104,15581
3945,131541,"NCT01263951, TrialTroveID-131541, UPCC 19309",A Phase II Study of Everolimus and Sorafenib in Patients With Metastatic Differentiated Thyroid Cancer Who Have Progressed on Sorafenib Alone,Oncology,Oncology: Thyroid,"Novartis, Bayer AG/Bayer Pharmaceuticals, University of Pennsylvania","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Overall response rate, Progression-free survival, Stable Disease","Duration of overall response, Overall response rate, Overall survival, Response rate, Time to progression",True,NCT01263951,15581
3946,130898,"TrialTroveID-130898, UMIN000003831","A Phase I Study of a Combination Chemotherapy, Sorafenib and Intrahepatic Arterial Infusion of IA-call (DDP-H), for Advanced Hepatocellular Carcinoma.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Dose-limiting toxicities","Overall response rate, Overall survival, Response rate, Time to progression",False,,15581
3947,130773,"KCSG-LU10-14, NCCCTS-10-476, NCT01159327, TrialTroveID-130773",A Randomized Phase II Study of Sorafenib Maintenance in Patients With Extensive Disease Small Cell Lung Cancer (ED-SCLC) After Response to Induction Chemotherapy,Oncology,"Oncology: Lung, Small Cell","Bayer AG/Bayer Pharmaceuticals, National Cancer Center - Goyang, Korea","Industry, Top 20 Pharma, Government","Progression-free survival, Progressive disease rate","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival",True,NCT01159327,15581
3948,130752,"EU-21045, EudraCT Number: 2008-005062-31, ICORG-06-41, NCT01158287, TrialTroveID-130752",Phase II Study of Single Agent Sorafenib in the Treatment of Relapsed Esophageal/Gastric Adenocarcinoma in Platinum Pre-Treated Patients.,Oncology,Oncology: Esophageal; Oncology: Gastric,Cancer Trials Ireland {Irish Clinical Oncology Research Group},Cooperative Group,"Clinical benefit rate, Complete response, Partial response, Stable Disease","Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Time to progression",True,NCT01158287,15581
3949,129227,TrialTroveID-129227,TKI Therapy-related Proteomic Patterns in Serum from Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Bayer AG, Pfizer {Wyeth}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progressive disease rate, Response evaluation criteria in solid tumors",,False,,15581
3950,129191,TrialTroveID-129191,Feasibility and safety of administration of sorafenib in chronic hemodialysis patients with metastatic renal cell carcinoma: Clinical results and pharmacokinetics in a single Japanese center.,Oncology,Oncology: Renal,Tokyo Womens Medical University School of Medicine,Academic,Safety and Tolerability,,False,,15581
3951,129108,"5100104, NCT01141478, TrialTroveID-129108",Randomized Controlled Trial of Proton Beam Radiotherapy + Sorafenib vs. Sorafenib for Patients with Hepatocellular Carcinoma Exceeding San Francisco Criteria,Oncology,Oncology: Liver,Loma Linda University,Academic,Overall survival,"Histological Response, Response evaluation criteria in solid tumors",True,NCT01141478,15581
3952,129061,TrialTroveID-129061,Chromosomal imbalances as biomarkers for recurrence and antiangiogenic resistance in clear cell renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Recurrence,,False,,15581
3953,128570,TrialTroveID-128570,A Clinical study on Fiducial-free frameless real-time image guided single-fraction radiosurgery using the Cyberknife effectively controls spinal and cerebral metastases from renal cell carcinoma under systemic angiogenic therapy.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3954,128489,TrialTroveID-128489,A clinical study evaluating efficacy of sorafenib in treating metastatic renal cell carcinoma with sarcomatoid feature.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3955,128047,"2008-10-009, NCT01131689, TrialTroveID-128047",Phase I Trial of S-1 in Combination with Sorafenib for Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Dose-limiting toxicities, Safety and Tolerability",True,NCT01131689,15581
3956,127974,"A1210, NCT01128998, NICR-CT2008-01, TrialTroveID-127974",An Open-Label Phase I Dose-Escalation Study of Sorafenib Plus S-1 in Advanced Solid Tumors.,Oncology,Oncology: Neuroendocrine; Oncology: Unspecified Solid Tumor,"(Other Hospital/Academic/Medical Center), National Health Research Institutes, Taiwan","Academic, Government",Dose-limiting toxicities,Dose-limiting toxicities,True,NCT01128998,15581
3957,127871,TrialTroveID-127871,Usefulness of sorafenib in the management of advanced thyroid carcinoma,Oncology,Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3958,127697,"EudraCT Number: 2009-012576-27, IRAS ID:149388, NCT01126645, NL32649.018.10, RAD85, SORAMIC, TrialTroveID-127697, UKCRN ID: 17305","Evaluation of Sorafenib in Combination with Local Micro-therapy Guided by Gd-EOB-DTPA Enhanced MRI in Patients with Inoperable Hepatocellular Carcinoma, , SORAMIC (Sorafenib and Micro-therapy Guided by Primovist- Enhanced MRI in Patients with Inoperable Liver Cancer)",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, (Other Hospital/Academic/Medical Center), Sirtex Medical","Industry, Top 20 Pharma, Academic, Industry, all other pharma","Magnetic Resonance Imaging, Overall survival, Recurrence, Time to response","Magnetic Resonance Imaging, Overall survival, Quality of Life, Recurrence, Safety and Tolerability",True,NCT01126645,15581
3959,127397,"EudraCT Number: 2007-004396-19, HGosteo-BAY, NCT00889057, TrialTroveID-127397","Phase II, Open Label, Non-Randomized Study of Second or Third Line Treatment With Sorafenib (BAY 43-9006) in Patients Affected by Relapsed High-Grade Osteosarcoma.",Oncology,Oncology: Osteosarcoma,Italian Sarcoma Group,Cooperative Group,Progression-free survival,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00889057,15581
3960,127202,"2007-006306-25, IEO S385/607, TrialTroveID-127202","A study of Pegylated liposomal doxorubicin (Caelyx), cisplatin and 5-fluorouracil continuous infusion (CCF), followed by metronomic therapy with cyclophosphamide, Capecitabine and Sorafenib (CCS) as preoperative treatment of locally advanced breast cancer.",Oncology,Oncology: Breast,European Institute of Oncology,Government,,,False,,15581
3961,127151,"ASL608LIOM02, EudraCT Number: 2008-001763-11, GLIMESOR, L04P15, STUDIO GLIMESOR â ASL608LIOM02, TrialTroveID-127151","Low-Dose Metronomic Temozolomide And Sorafenib In Patients With Recurrent Glioblastoma Multiforme: A Phase II Clinical Trial With Evaluation Of Clinical, Biologic And Pharmacodynamic Effects of The Combination",Oncology,"Oncology: CNS, Glioblastoma",Gruppo Oncologico Nord-Ovest (G.O.N.O.),Cooperative Group,Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate",False,,15581
3962,125927,TrialTroveID-125927,"A prospective long term, safety and efficacy study of sorafenib in patients with hepatocellular carcinoma.",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3963,125570,TrialTroveID-125570,Phase II Study of Sorafenib in Patients with Relapsed Flt3-ITC Positive Acute Myeloid Leukemia (AML).,Oncology,"Oncology: Leukemia, Acute Myelogenous",Southwest Oncology Group,Cooperative Group,,,False,,15581
3964,125533,"S1006, TrialTroveID-125533",Phase I/II Study of Sorafenib + AMG 102 for Patients with Advanced Hepatocellular Carcinoma (HCC).,Oncology,Oncology: Liver,Southwest Oncology Group,Cooperative Group,,,False,,15581
3965,125481,"INST 0812, NCI-2011-02944, NCT01100242, TrialTroveID-125481",Velcade (Bortezomib) and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Magnetic Resonance Imaging, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate",True,NCT01100242,15581
3966,125253,TrialTroveID-125253,A pilot study on sorafenib in patients with post liver transplant recurrence of hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Magnetic Resonance Imaging, Overall survival, Recurrence, Response evaluation criteria in solid tumors, Time to progression",,False,,15581
3967,125246,"14898, HATT, NCT01098760, TrialTroveID-125246","A Phase IV, Single-arm, Open-label Study of Sorafenib (Nexavar) in Advanced Hepatocellular Carcinoma (HCC), , Hepatocellular carcinoma - Advanced stage - sorafenib Trial in Taiwanese patients (HATT)",Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Adverse Events, Clinical benefit rate, Complete response, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events, Stable Disease, Time to progression",Safety and Tolerability,True,NCT01098760,15581
3968,124612,"2009-08-102, NCT01091207, TrialTroveID-124612",A Phase II Study of Sorafenib in Patients with Metastatic or Advanced Gastrointestinal Stromal Tumors who Failed to Imatinib and Sunitinib,Oncology,Oncology: GIST,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Clinical benefit rate,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",True,NCT01091207,15581
3969,123997,TrialTroveID-123997,Efficacy of sorafenib on metastatic renal cell carcinoma in Asian patients: results from a multicenter study.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,15581
3970,123741,TrialTroveID-123741,Effect of Sorafenib on the percentage of tumor-infiltrating regulatory T cells (Tregs) in patients with renal cell carcinoma (RCC),Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3971,123649,"09-443, DFCI 09-443, NCT01078961, TrialTroveID-123649, X05297",A Phase I Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma,Oncology,Oncology: Melanoma,"Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bayer AG/Bayer Pharmaceuticals, Takeda/Takeda Oncology {Millennium}, Massachusetts General Hospital, Brigham and Womens Hospital","Academic, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Academic",Maximum tolerated dose,"Overall response rate, Progression-free survival",True,NCT01078961,15581
3972,123644,"DOSE-HEP, MWWH009, NCT01078311, TrialTroveID-123644",Phase II Study of Measurement of Trough Levels of Sorafenib in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other government agency),Government,Overall survival,"Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01078311,15581
3973,123467,"20992548, 33551, MCC-12122, NCI-2010-00185, NCT01075113, TrialTroveID-123467",A Phase I Study of Sorafenib and Vorinostat in Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Merck & Co., Massey Cancer Center, Virginia Commonwealth University","Industry, Top 20 Pharma, Academic, Academic",Maximum tolerated dose,"Adverse Events, Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01075113,15581
3974,121721,TrialTroveID-121721,Phase I/pharmacodynamic trial of sorafenib in combination with irinotecan.,Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Pancreas",(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3975,121336,"ENGOT-ov9, EudraCT Number: 2009-011922-33, NCT01047891, NOGGO â AGO â TRIAS, NOGGO / AGO-OVAR 2.18, NOGGO-AGO, NOGGO-AGO-TRIAS, TrialTroveID-121336, TRIAS, TRIAS 2009, TRIAS2009","A Randomized, Double-blind, Placebo Controlled, Multicenter Phase II Study to Assess the Efficacy and Safety of Sorafenib Added to Standard Treatment With Topotecan in Patients With Platinum-resistant Recurrent Ovarian Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Amgen, GlaxoSmithKline, Bayer AG, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Progression-free survival, Progressive disease rate","Adverse Events, Duration of overall response, Overall response rate, Overall survival, Progressive disease rate, Quality of Life, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression",True,NCT01047891,15581
3976,120969,"NCI-2009-01488, NCT01042041, TrialTroveID-120969, UPCC 08208",A Phase I Study of Sorafenib Integrated With Chemoembolization for Patients With Unresectable Hepatocellular Carcinoma,Oncology,Oncology: Liver,Abramson Cancer Center at  University of Pennsylvania Medical Center,Academic,"Adverse Events, Safety and Tolerability","Response evaluation criteria in solid tumors, Time to progression",True,NCT01042041,15581
3977,120945,"AGuo, Bay 43-9006, NCT01041482, TrialTroveID-120945","A Multi-Center, Non-Controlled Clinical Study of Sorafenib Adjuvant Therapy in Locally Advanced Renal-Cell Carcinoma After Radical Nephrectomy",Oncology,Oncology: Renal,"Chinese Academy of Medical Sciences, Peking Union Medical College Hospital, CAMS, Beijing, China, (Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Government, Academic, Academic, Academic",Disease-free survival,"Adverse Events, Overall survival, Safety and Tolerability",True,NCT01041482,15581
3978,120561,"CALGB 80904, TrialTroveID-120561",Sorafenib vs. Imatinib In Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors: A Randomized Phase II Trial.,Oncology,Oncology: GIST,Cancer and Leukemia Group B (CALGB),Cooperative Group,,,False,,15581
3979,120314,"HSC-13188, INST 0820, INST0820, NCI-2011-02945, NCT01032850, TrialTroveID-120314",Sorafenib in Combination With Capecitabine for Patients With Measurable Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, University of New Mexico Cancer Research and Treatment Center","Industry, Top 20 Pharma, Academic","Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Overall survival, Progression-free survival",True,NCT01032850,15581
3980,119815,TrialTroveID-119815,Clinical Efficacy of Sorafenib in Patients with Acute Myeloid Leukemia (AML) and Activating FLT3-Mutations,Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
3981,119765,"09-148, NCT01025453, TrialTroveID-119765",Phase II Study Evaluating the Combination of Temsirolimus and Sorafenib in the Treatment of Radioactive Iodine Refractory Thyroid Cancer,Oncology,Oncology: Thyroid,"Memorial Sloan-Kettering Cancer Center, Pfizer, National Comprehensive Cancer Network","Academic, Industry, Top 20 Pharma, Cooperative Group","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT01025453,15581
3982,119351,TrialTroveID-119351,Combined sorafenib and yttrium-90 radio-embolization in the treatment of advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,McGill University Health Centre,Academic,"Safety and Tolerability, Safety and Tolerability",,False,,15581
3983,119330,"SOFIA, TrialTroveID-119330","A post marketing surveillance study on field practice with sorafenib in advanced hepatocellular carcinoma: effectiveness confirmed, reduced tolerability compared to registration trials, , SOraFenib Italian Assessment Study (SOFIA)",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3984,119324,TrialTroveID-119324,"Safety of Sorafenib Treatment for Intermediate/Advanced Hepatocellular Carcinoma in Patients with Childâs A, B or C",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Overall response rate, Response rate, Safety and Tolerability",,False,,15581
3985,118944,"10-157B, 11-039, AAAJ9252, C80802, CALGB 80802, CALGB-80802, CTSU/C80802, CTSUGIC80802-M, ECALGB80802, EudraCT Number: 2013-002625-35, GIHEC.1, H-26756, HEC.1 GI, HEC1, ICORG 13-08, NCI-2011-01989, NCT01015833, TrialTroveID-118944, UIC 2010-0811",Phase III Randomized Study of Sorafenib Plus Doxorubicin Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC).,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Disease Progression, Overall survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT01015833,15581
3986,118830,"61-3910-4033485, CONKO-006, DRKS00000242, EudraCT Number: 2007-000718-35, TrialTroveID-118830, U1111-1114-0963","CONKO-006: Additive Therapy in R1-Resected Pancreatic Cancer with Gemcitabine plus Sorafenib vs. Gemcitabine Plus Placebo Over 12 Months - A Double Blind, Placebo-Controlled Phase IIb Trial",Oncology,Oncology: Pancreas,"Arbeitsgemeinschaft fur Internistische Onkologie, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Disease-free survival,"Disease-free survival, Overall survival, Safety and Tolerability",False,,15581
3987,118743,"14792, NCT01012011, NX0910KR, TrialTroveID-118743",Regulatory Post Marketing Surveillance Study on Nexavar.,Oncology,Oncology: Liver; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Adverse Events,,True,NCT01012011,15581
3988,118687,"LCCC0902, NCT01011010, TrialTroveID-118687, UNC-LCCC-0902",Phase Ib Clinical Trial of Sorafenib in Combination With Transarterial Chemoembolization (TACE) in Patients With Unresectable Hepatocellular Carcinoma (HCC).,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Government, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability","Overall survival, Time to progression",True,NCT01011010,15581
3989,118675,"10-0577-04, NCI-2011-02027, NCT01093222, S0941, SWOG-S0941, TrialTroveID-118675",Phase II Study of Sorafenib (NSC-724772) and Erlotinib (NSC-718781) in Patients With Advanced Gallbladder Carcinoma or Cholangiocarcinoma,Oncology,Oncology: Liver,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Progression-free survival,"Adverse Events, Complete response, Overall response rate, Overall survival, Partial response",True,NCT01093222,15581
3990,118525,TrialTroveID-118525,Preliminary Results of a Phase II Trial with the Multikinase Inhibitor Sorafenib in Heavily Pretreated Patients with Relapsed/Refractory Non-Hodgkin Lymphoma (NHL),Oncology,"Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
3991,118415,"09455, 124511, CC 09455, CC# 09455, H5535-34892, NCI-2012-02021, NCT01008917, NCT01013519, NCT01687673, NU UCSF09I1, TrialTroveID-118415, UCSF-09455, UCSF09I1",Phase I/II Trial of the Combination of Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Pfizer, Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Northwestern University, University of California, San Francisco","Government, Industry, Top 20 Pharma, Academic, Academic, Academic","Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression","Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Time to treatment failure",True,NCT01008917,15581
3992,118096,"F090910004, NCT01005875, RAD 0901, TrialTroveID-118096",RAD 0901- Stereotactic Radiation Therapy and Sorafenib in the Treatment of Hepatocellular Carcinoma,Oncology,Oncology: Liver,"University of Alabama, Birmingham, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Academic, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability","Apparent diffusion coefficient, Magnetic Resonance Imaging",True,NCT01005875,15581
3993,118066,"10-00544, CTSU E1208, E1208, ECOG1208, ECOG1208 /09-201, ECOG-E1208, NCI-2011-01981, NCT01004978, TrialTroveID-118066","A Phase III Randomized, Double-Blind Trial of Chemoembolization With or Without Sorafenib in Unresectable Hepatocellular Carcinoma (HCC) in Patients With and Without Vascular Invasion",Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, ECOG-ACRIN Cancer Research Group","Government, Cooperative Group",Progression-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01004978,15581
3994,117707,"LCR-004, NCT00999843, TrialTroveID-117707",Maintenance of Sorafenib Following Combined Therapy of Three-dimensional Conformal Radiation Therapy/Intensity-modulated Radiation Therapy and Transcatheter Arterial Chemoembolization in Patients With Locally Advanced Hepatocellular Carcinoma: a Phase I/II Study.,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, Fudan University - Shanghai, China, The Ministry of Health of the Peoples Republic of China","Industry, Top 20 Pharma, Academic, Government","Safety and Tolerability, Safety and Tolerability","Overall survival, Progression-free survival, Time to progression",True,NCT00999843,15581
3995,117428,"10-000481, 11-000591, 3L-10-3, AAAD3519, NCT00997022, TrialTroveID-117428","Phase I Open-Label, Dose-Finding Study of BAY 43-9006 (Sorafenib) in High-risk Hepatocellular Cancer Patients After Liver Transplantation",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Columbia University Medical Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Disease-free survival, Progression-free survival",True,NCT00997022,15581
3996,117275,"12602, EudraCT Number: 2007-007599-40, ISRCTN56178790, MRS, NCT00772694, PL/ 183/UR/CEBK/04/08, TrialTroveID-117275",Sorafenib (NEXAVAR) Monotherapy in Patients with Inoperable/Recurrent Germ Cell Carcinoma Refractory to Chemotherapy,Oncology,Oncology: Testicular,"(Other Cooperative Group), Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Quality of Life",True,NCT00772694,15581
3997,117109,"ETES08/90721, NCT01157013, PI09/90721, TrialTroveID-117109",The Role of Positron Emission Tomography (PET) Imaging in the Evaluation of Response to Sorafenib Treatment in Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,"Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT01157013,15581
3998,116956,TrialTroveID-116956,Phase II Study of Sorafenib in Patients With Sunitinib-Refractory Metastatic Renal Cell Cancer.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall survival, Time to progression",False,,15581
3999,116833,"BAY 43-9006 / 13967 3870, ISS-13967, NCT00990860, NMRR-09-382-3870, START, TrialTroveID-116833",START (Study in Asia of the Combination of Transcatheter Arterial Chemoembolization (TACE) With Sorafenib in Hepatocellular Carcinoma (HCC) Patients) Trial,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Taipei Veterans General Hospital","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","C reactive protein, Overall survival, Progression-free survival, Time to progression",True,NCT00990860,15581
4000,116719,"EudraCT Number: 2008-004285-53, NCT00989469, NEXIRI, RECF1185, TrialTroveID-116719",SORAFENIB (NEXAVAR) in Combination With Irinotecan in the Second Line Treatment or More of Metastatic Colorectal Cancer With K-RAS Mutation : a Multicentre Two-part Phase I/II Study.,Oncology,Oncology: Colorectal,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Maximum tolerated dose, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival",True,NCT00989469,15581
4001,116714,"EudraCT Number: 2009-018025-73, GMIHO-008/2008, NCT01320111, PASO, TrialTroveID-116714",Randomised Phase II Study of Paclitaxel Alone Versus Paclitaxel Plus Sorafenib in Second- or Third-line Treatment of Patients With Metastatic Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), Arbeitsgemeinschaft fur Internistische Onkologie","Cooperative Group, Cooperative Group","Disease Progression, Progression-free survival","Overall response rate, Overall survival, Safety and Tolerability, Time to next treatment, Time to progression",True,NCT01320111,15581
4002,116484,TrialTroveID-116484,Serial alpha-fetoprotein evaluation and survival in hepatocellular carcinoma patients treated with sorafenib,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4003,116368,TrialTroveID-116368,Phase I Clinical and Pharmacokinetic Study of Sorafenib in Combination with Carboplatin and Paclitaxel in Patients with Advanced Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4004,116367,"NCT00984425, ONC-2008-005, TrialTroveID-116367",Phase I and Pharmacokinetics Study of Lapatinib in Combination With Sorafenib in Patients With Advanced Refractory Solid Tumors.,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Gastric; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Prostate",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose","Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00984425,15581
4005,116085,"EMC 06/342, TrialTroveID-116085",Phase I Dose-Escalation Trial for the Combination of Sorafenib with Interleukin-2 Treatment in Patients with Renal Cancer.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Response evaluation criteria in solid tumors, Time to progression",False,,15581
4006,115739,"TrialTroveID-115739, UMIN000002401",A Randomized Controlled Trial of Sorafenib Versus 5-FU Arterial Infusion and Interferon Therapy (FAIT) for Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Overall survival,"Adverse Events, Overall response rate, Progression-free survival, Response rate",False,,15581
4007,115615,"TrialTroveID-115615, UMIN000002466",Multi-Center Phase II Clinical Trial on Efficacy and Safety of Interferon Alfa-n1 + Sorafenib Combination Therapy in Renal Cell Carcinoma,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,15581
4008,114920,"EudraCT Number:2008-008232-87, SOCS-B, TrialTroveID-114920",Open-label phase II study of sorafenib in patients with advanced hepatocellular carcinoma (HCC) and Child Pugh score B with special analysis of patients 65 years or older,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events","Adverse Events, Clinical benefit rate, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",False,,15581
4009,114887,"NCT00971126, TCOGP-1209, TrialTroveID-114887",A Phase I/II Study of Sorafenib With Combination of Thalidomide in Advanced or Metastatic Hepatocellular Carcinoma,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), National Health Research Institutes, Taiwan","Academic, Government","Clinical benefit rate, Complete response, Maximum tolerated dose, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease","Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00971126,15581
4010,114842,TrialTroveID-114842,Sorafenib in Pretreated Patients with Advanced Non-Small Lung Cancer Harbouring a K-ras Mutation,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4011,113910,"07130, BAYER-CRUK-TACE-2, BIOCOM-UK-CRUK-TACE-2, CRUK-13136, CRUKE/08/022, CRUK-HE3005, CRUK-TACE-2, CTA-20363/0272/001, EU-21108, EudraCT Number: 2008-005073-36, ISRCTN93375053, MREC NÂ° 09/H1102/114, NCT01324076, RRK3937, Tace-2, TACE-2, TrialTroveID-113910, UCL-07130, UKCRN ID: 5347","TACE-2: A Randomized Placebo-Controlled, Double Blinded, Phase III Trial of Sorafenib in Combination With Transarterial Chemoembolization in Hepatocellular Cancer",Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, University College London, Boston Scientific/BTG {Biocompatibles}","Government, Industry, Top 20 Pharma, Academic, Industry, all other pharma",Progression-free survival,"Complete response, Overall survival, Partial response, Quality of Life, Stable Disease, Time to progression",True,NCT01324076,15581
4012,113559,"20090256, NCT00955721, SCCC-2009003, TrialTroveID-113559, UMIAMI-20090256","A Phase I/II Study of Combination of Gemcitabine, Oxaliplatin and Sorafenib (GEMOX-Sorafenib) in Patients With Advanced Biliary Tract Cancer",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival","Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT00955721,15581
4013,113518,"A534260, CO 08511, CO08511, H-2009-0011, IST 000381, NCI-2011-00813, NCT00954278, SMPH/MEDICINE/MEDICINE*H, TrialTroveID-113518, WON CO08511","A Phase I, Intrapatient Dose-Escalation Study of Sorafenib in Advanced or Relapsed Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, University of Wisconsin","Industry, Top 20 Pharma, Academic",Dose-limiting toxicities,"Adverse Events, Safety and Tolerability, Serious Adverse Events",True,NCT00954278,15581
4014,113463,"EudraCT Number: 2007-006208-39, NCT00954135, TrialTroveID-113463","Letrozole Plus Oral Cyclophosphamide Plus/Minus Sorafenib as Primary Systemic Treatment in Post-menopausal, Estrogen Receptor Positive, Breast Cancer Patients",Oncology,Oncology: Breast,University of Turin,Academic,Progression-free survival,"Overall survival, Progression-free survival",True,NCT00954135,15581
4015,113008,"BAYER-IST000477, NCT00949182, TrialTroveID-113008, UMDNJ-20090859",Micro and Macro Ateriolar Blockade of Hepatocellular Carcinoma (HCC): Treatment With Sorafenib Before and After Hepatic Arterial Embolization (HAE) Therapy for Liver Cancer.,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Complete response, Overall survival, Progression-free survival",True,NCT00949182,15581
4016,112859,TrialTroveID-112859,Paradoxical cutaneous squamous cell proliferations in patients treated with sorafenib.,Oncology,Oncology: Liver; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4017,112573,"2008-0501, NCI-2009-01512, NCT00943943, TrialTroveID-112573",G-CSF and Plerixafor With Sorafenib for Acute Myelogenous Leukemia With FLT3 Mutations,Oncology,"Oncology: Leukemia, Acute Myelogenous","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme}, Amgen {Onyx Pharmaceuticals}, FDA Office of Orphan Products Development, (Other Hospital/Academic/Medical Center)","Academic, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,True,NCT00943943,15581
4018,112384,"15780, 8070, J1085, MCC-15780, MCC-8070, NCI 8070, NCI-2012-02847, NCI8070, NCT00939627, TrialTroveID-112384, VICCHN0899, VU-VICC-HN-0899","Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab in Patients With Refractory, Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)",Oncology,Oncology: Head/Neck,National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00939627,15581
4019,112345,"CLCC Montpellier, CSET 1478, EudraCT Number:2008-000123-26, GONEXT, GONEXT PRODIGE 10, INCA-GONEXT-PRODIGE-10, NCT00941967, PRODIG 10, PRODIG 10 GONEXT, PRODIGE 10, RECF0917, RODIGE 10/VA 2007-40, TrialTroveID-112345, VA 2007/40","Randomized Phase II Trial Assessing the Combination of Nexavar (Sorafenib), and Gemcitabine/Oxaliplatin in Patients Treated for Advanced (Unresectable/Metastatic) Hepatocellular Carcinoma.",Oncology,Oncology: Liver,"Federation Nationale des Centres de Lutte contre le Cancer, Federation Francophone de Cancerologie Digestive, (Other Hospital/Academic/Medical Center)","Cooperative Group, Miscellaneous, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00941967,15581
4020,111821,"JLOG0901, NCT00933816, SILIUS, TrialTroveID-111821",Phase I/II Study of Sorafenib In Combination With Low-Dose FP Intraarterial Infusion Chemotherapy.,Oncology,Oncology: Liver,(Other Cooperative Group),Cooperative Group,"Dose-limiting toxicities, Time to progression","Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT00933816,15581
4021,111750,"13075, EudraCT Number: 2008-005440-16, NCT00933777, SORAVE, TrialTroveID-111750",SORAVE-Sorafenib and Everolimus in Solid Tumors. A Phase I Clinical Trial to Evaluate the Safety of Combined Sorafenib and Everolimus Treatment in Patients with Relapsed Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas","(Other Cooperative Group), University of Cologne Germany","Cooperative Group, Academic",,"Area under the curve score, Cmax, Maximum tolerated dose, Safety and Tolerability",True,NCT00933777,15581
4022,110761,"081-06, 96919, NCT00496756, NCT00854620, RENAL0009, SU-02272009-1898, TrialTroveID-110761, UNMC-08106",A Phase II Study of Sorafenib in Patients with Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, University of Nebraska Medical Center, Stanford University Medical Center, Bayer AG/Bayer Pharmaceuticals","Government, Academic, Academic, Industry, Top 20 Pharma","Safety and Tolerability, Time to progression","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT00496756,15581
4023,110730,"NCT00924807, SR06-959, TrialTroveID-110730",Phase I/II Study of Sorafenib Concurrent With Androgen Deprivation and Radiotherapy in the Treatment of Intermediate- and High-Risk Localized Prostate Cancer,Oncology,Oncology: Prostate,"Beth Israel Deaconess Medical Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Disease-free survival, Overall survival",True,NCT00924807,15581
4024,110590,"CTONG0805, C-TONG0805, NCT00922584, TrialTroveID-110590",A Phase II Study of Sorafenib (BAY 43-9006) in Patients with Relapsed Advanced Non-Small Cell Lung Cancer(NSCLC) After Failure of Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitor (EGFR-TKI)Treatment,Oncology,"Oncology: Lung, Non-Small Cell",(Other Cooperative Group),Cooperative Group,Clinical benefit rate,"Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00922584,15581
4025,110416,TrialTroveID-110416,Prognostic and predictive values of carbonic anhydrase IX (CAIX) and pathologic features in patients with metastatic clear cell renal cell carcinoma receiving targeted therapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4026,110389,TrialTroveID-110389,"Durable response of the triple combination of temozolomide, sorafenib, and bevacizumab as second-line therapy for patients with stage IV acral melanoma",Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,15581
4027,110383,TrialTroveID-110383,Hypogonadism in male cancer patients treated with the tyrosine kinase inhibitors sunitinib (SUN) or sorafenib (SOR).,Oncology,Oncology: GIST; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4028,110317,TrialTroveID-110317,Correlation of sorafenib plasma concentrations and clinical toxicity: A prospective population pharmacodynamic and pharmacokinetic study.,Oncology,Oncology: Liver; Oncology: Melanoma; Oncology: Renal; Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4029,110287,"09-029, NCT00919061, TrialTroveID-110287",A Phase II Study of Gemcitabine and Cisplatin Plus Sorafenib in Patients With Advanced Biliary Tract Carcinomas Naive to Systemic Therapy.,Oncology,Oncology: Liver,"Memorial Sloan-Kettering Cancer Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Disease Progression, Overall survival, Progression-free survival","Overall response rate, Overall survival, Progression-free survival, Response rate, Time to progression",True,NCT00919061,15581
4030,110208,"COTSUN, COTSUN Korea Trial, NCT00919009, TrialTroveID-110208",A Phase II Study of the Combination of TACE and Sorafenib for Patients With Unresectable Hepatocellular Carcinoma in National Cancer Center Korea (COTSUN Korea Trial).,Oncology,Oncology: Liver,"National Cancer Center - Goyang, Korea",Government,"Adverse Events, Safety and Tolerability, Safety and Tolerability, Time to progression","Overall response rate, Progression-free survival",True,NCT00919009,15581
4031,110171,TrialTroveID-110171,Bioavailability of sorafenib tablets administered as a liquid suspension.,Oncology,Oncology: Unspecified Cancer,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Bioavailability,,False,,15581
4032,110150,"09-016, NCT00917462, TrialTroveID-110150",Phase II Trial of Sorafenib for Patients with Metastatic or Recurrent Esophageal and Gastroesophageal Junction Cancer,Oncology,Oncology: Esophageal; Oncology: Gastric,"Memorial Sloan-Kettering Cancer Center, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Complete response, Overall response rate, Partial response",True,NCT00917462,15581
4033,109783,TrialTroveID-109783,Tolerability of sorafenib in the treatment of hepatocellular carcinoma (HCC) in patients with Child A and B liver cirrhosis.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4034,109612,TrialTroveID-109612,Phase I study of Sorafenib and Radiation in Patients with Pancreatic Cancer,Oncology,Oncology: Pancreas,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4035,109609,TrialTroveID-109609,Phase I study of Sorafenib and radiation in patients with colorectal cancer.,Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4036,109531,TrialTroveID-109531,The effects of sorafenib and sunitinib on bone turnover markers in patients with bone metastases from renal cell carcinoma.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4037,109421,TrialTroveID-109421,Long-term use of sorafenib (SOR) in metastatic renal cell carcinoma (mRCC) previously treated with systemic therapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",,False,,15581
4038,109415,TrialTroveID-109415,Phase I trial of sorafenib in combination with interferon-alpha in Japanese patients with unresectable or metastatic renal cell carcinoma.,Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",,,False,,15581
4039,109409,TrialTroveID-109409,Phase II study of sorafenib combined with gemcitabine and 5-fluorouracil in patients with metastatic renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Overall survival, Progression-free survival",False,,15581
4040,109230,"NCI-2011-01252, NCT00908167, R01CA138744, RELHEM, TrialTroveID-109230","A Pilot Pharmacokinetic, Pharmacodynamic and Feasibility Study of Sorafenib in Combination With Cytarabine and Clofarabine in Patients With Refractory or Relapsed Hematologic Malignancies",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, St. Jude Children's Research Hospital, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Government, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00908167,15581
4041,109200,TrialTroveID-109200,Phase II dose escalation study of sorafenib in patients with metastatic renal cell carcinoma (mRCC) who have had prior treatment with VEGFR-TKI antiangiogenic treatment.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4042,109192,TrialTroveID-109192,Modulation of regulatory T cells and myeloid-derived suppressor cells by sorafenib and sunitinib in renal cell carcinoma patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4043,108458,"12649, 12650, 12730, 12731, 12755, 12806, 12807, 12808, 12943, 12944, 13049, 13068, 13094, 13095, 13121, 13167, 13209, 13210, 13211, 13274, 13277, 13601, 14178, 14242, 14686, NCT00895674, NX0601, PREDICT, TrialTroveID-108458",Patient Characteristics in Advanced Renal Cell Carcinoma and Daily Practice Treatment with Nexavar.,Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",,"Progression-free survival, Safety and Tolerability",True,NCT00895674,15581
4044,108278,"AML SORAML SAL, EudraCT Number: 2008-004968-40, LN_SAL_2009_313, NCT00893373, SAL-Soraml, SORAML, TrialTroveID-108278, TUD-SORAML-034","A Double-Blind, Placebo-Controlled, Randomized, Multicenter Phase-II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Patients with Newly Diagnosed AML < or = 60 Years of Age.",Oncology,"Oncology: Leukemia, Acute Myelogenous","Bayer AG/Bayer Pharmaceuticals, Dresden University of Technology","Industry, Top 20 Pharma, Academic","Complete response, Event-free survival","Adverse Events, Complete response, Disease-free survival, Event-free survival, Minimal Residual Disease, Overall survival",True,NCT00893373,15581
4045,108263,"NCT00892658, SHEP, TrialTroveID-108263, UHN REB 08-0761-C",A Phase I Study of Sorafenib and Radiation Therapy in Patients with Hepatocellular Carcinoma,Oncology,Oncology: Liver,"University Health Network, Toronto",Academic,Maximum tolerated dose,"Overall survival, Progression-free survival, Quality of Life",True,NCT00892658,15581
4046,108210,"NCT00892424, SLIM, TrialTroveID-108210, UHN REB 08-0598-C",Phase I/II Trial of Radiation Therapy and Sorafenib for Treatment of Unresectable Liver Metastases,Oncology,Oncology: Metastatic Cancer; Oncology: Unspecified Cancer,"University Health Network, Toronto",Academic,Maximum tolerated dose,"Overall survival, Quality of Life, Time to progression",True,NCT00892424,15581
4047,107666,"EudraCT Number: 2007-002365-13, IMP 12791, NCT00887107, NL17727.058.07, P07.109, TrialTroveID-107666",Sorafenib as Adjuvant to Radioiodine Therapy in Non-Medullary Thyroid Carcinoma.,Oncology,Oncology: Thyroid,Leiden University Medical Center,Academic,"Response evaluation criteria in solid tumors, Stable Disease","Disease Progression, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00887107,15581
4048,107447,"08-122, 13031, 2009DR1029, NCT00884416, TrialTroveID-107447",Phase I Dose Finding Study of Sorafenib in Combination With Radiation Therapy and Temozolomide as a First Line Treatment of Patients With High Grade Glioma,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other; Oncology: Soft Tissue Sarcoma","Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Event-free survival, Overall response rate, Overall survival, Progression-free survival, Response rate, Time to treatment failure",True,NCT00884416,15581
4049,107192,"07-04-086, BAYER-UCLA-0704086, NCT00880542, ONYX-UCLA-0704086, P30CA016042, TrialTroveID-107192, UCLA-0704086",A Phase II Study of Sorafenib and Ifosfamide as a Treatment for Patients With Sarcoma.,Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Amgen {Onyx Pharmaceuticals}, Bayer AG","Academic, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,Disease-free survival,True,NCT00880542,15581
4050,107128,TrialTroveID-107128,A clinical study on the evaluation of tumor perfusion at computed tomography as a tool to detect the effect of sorafenib treatment in patients with hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Additional Treatment Necessary, Response evaluation criteria in solid tumors",,False,,15581
4051,107125,TrialTroveID-107125,A prospective evaluation of sorafenib in patients with hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability",,False,,15581
4052,106921,"2007101, BAYER-SCCC-2007101, NCT00875615, SCCC-2007101, TrialTroveID-106921, UMIAMI-20080793",Phase II Trial of Intrahepatic Artery Chemotherapy With Nexavar in Hepatocellular Carcinoma Patients.,Oncology,Oncology: Liver,"Sylvester Cancer Center, University of Miami",Academic,"Adverse Events, Safety and Tolerability","Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00875615,15581
4053,106910,"0902-08, IUCRO-0234, NCT00875745, TrialTroveID-106910","Phase I, Open-label, Dose-escalation Study of the Combination of Sorafenib and Vorinostat in Poor-risk Acute Myelogenous Leukemia (AML) and High Risk Myelodysplastic Syndrome (MDS).",Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","Merck & Co., Bayer AG, Indiana University School of Medicine","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,Duration of overall response,True,NCT00875745,15581
4054,106718,"08-3-LUN, NCT00870532, TrialTroveID-106718",A Prospective Study of Metronomic Oral Vinorelbine in Combination With Sorafenib in Advanced Non-Small Cell Lung Cancer a) A Phase I Dose-Finding Study of the Combination of Metronomic Oral Vinorelbine and Sorafenib b) Pharmacokinetics Profiling of the Combination of Metronomic Oral Vinorelbine and Sorafenib at MTD.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Academic Cancer Center),Academic,,"Overall response rate, Response rate",True,NCT00870532,15581
4055,106358,TrialTroveID-106358,Use of Tyrosine Kinase inhibitors (TKi) in hemodialytic metastatic renal cell carcinoma patients,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,"Safety and Tolerability, Safety and Tolerability",,False,,15581
4056,106344,TrialTroveID-106344,Effectivity of radiation therapy in combination with Multi-Kinase inhibition based on Sorafenib or Sunitinib in progressive metastatic renal cancer,Oncology,Oncology: Renal,Ludwig Maximilians University of Munich,Academic,Response evaluation criteria in solid tumors,,False,,15581
4057,106117,"13266, BAY 43-9006 / 13266, CTRI/2009/091/000557, EudraCT no:2008-006914-62, JapicCTI-090779, LUN0035, LUN044, McG 0931, MISSION, NCRN073, NCT00863746, NL27293.003.09, RECF1034, SU-05272010-6183, TrialTroveID-106117, UKCRN ID:  6843","A Phase III, Multi-center, Placebo-Controlled Trial of Sorafenib (BAY43-9006) in Patients With Relapsed or Refractory Advanced Predominantly Non Squamous Non-Small Cell Lung Cancer (NSCLC) After 2 or 3 Previous Treatment Regimens for Advanced Disease, , Monotherapy administration of Sorafenib in patients with non-small cell lung cancer (MISSION)",Oncology,"Oncology: Lung, Non-Small Cell","Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall survival,"Complete response, Disease Progression, EORTC Quality of Life Questionnaire, EQ-5D, Global health status, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Stable Disease, Time to progression, Visual Analog Scale",True,NCT00863746,15581
4058,105856,"NCT01829035, STAH Korea Trial, STAH Study, TrialTroveID-105856","A Randomized, Controlled Phase III Trial of Sorafenib With or Without Conventional Transarterial Chemoembolization in Patients With Advanced Hepatocellular Carcinoma (STAH Study)",Oncology,Oncology: Liver,"Amgen {Onyx Pharmaceuticals}, National Cancer Center - Goyang, Korea","Industry, Top 20 Pharma, Government",Overall survival,"Adverse Events, Complete response, Overall response rate, Partial response, Progression-free survival, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT01829035,15581
4059,105847,"TrialTroveID-105847, UMIN000001496",A Phase I Study of the Combination Chemotherapy of Sorafenib with Cisplatin Transcatheter Arterial Infusion for Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}",Academic,"Adverse Events, Dose-limiting toxicities","Overall response rate, Overall survival, Response rate, Time to progression",False,,15581
4060,105742,"TrialTroveID-105742, UMIN000001709",Multikinase Inhibitor (Tyrosine and Serine/Threonine Kinase Inhibitor) for the Treatment of Severe Pulmonary Arterial Hypertension,Cardiovascular,Cardiovascular: Hypertension,(Other Hospital/Academic/Medical Center),Academic,"6-minute walk test, Brain Natriuretic Peptide concentration, Catheterization required",,False,,15581
4061,105137,TrialTroveID-105137,Prospective Comparison of Sorafenib and Sunitinib for Second-line Treatment of Cytokine-Refractory Kidney Cancer Patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,,False,,15581
4062,104782,"12594, MERITS, NCT00848640, TrialTroveID-104782","Multi-center,Middle East, Phase-II Study, Non-comparative, of the RAF-Kinase Inhibitor Sorafenib in Patients With Advanced Renal Cell Carcinoma to Evaluate The Efficacy and Tolerability of the Drug",Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,"Clinical benefit rate, Safety and Tolerability","Progression-free survival, Quality of Life",True,NCT00848640,15581
4063,104711,"IST000362, NCT00846131, NU08I4, STU00005761, TrialTroveID-104711","A Single-Center Proof of Concept Pilot Study to Evaluate the Safety, Efficacy, and Tolerability of Sorafenib Combined With Therasphere in Subjects With Hepatocellular Carcinoma Awaiting Liver Transplantation",Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Northwestern University, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Government, Academic, Industry, Top 20 Pharma",Adverse Events,Adverse Events,True,NCT00846131,15581
4064,104679,"6697, IR-6697, NCI-2009-01659, NCT00844168, TrialTroveID-104679, UWCC-6697",Phase I Adjuvant Trial of Sorafenib in Hepatocellular Carcinoma Patients After Liver Transplantation,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic","Adverse Events, Dose-limiting toxicities, Safety and Tolerability",,True,NCT00844168,15581
4065,104651,"NCT00844688, TrialTroveID-104651",A Phase II Feasibility Study of Sorafenib and Gemcitabine Combination Treatment in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Response evaluation criteria in solid tumors, Safety and Tolerability",Common Terminology Criteria for Adverse Events,True,NCT00844688,15581
4066,104650,"J08110, NCT00844883, TrialTroveID-104650",Phase II Trial of Sorafenib Combined With Doxorubicin Eluting Bead-Transarterial Chemoembolization (LC Bead-TACE) for Patients With Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Yale University, Boston Scientific/BTG {Biocompatibles}","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT00844883,15581
4067,104578,"09-156, EU-20908, EudraCT Number: 2008-006312-38, NCT00869570, SAKK 41/08, SWS-SAKK-41/08, TrialTroveID-104578","Neoadjuvant Radiotherapy Combined With Capecitabine and Sorafenib in Patients With Advanced, K-ras Mutated Rectal Cancer. A Multicenter Phase I/IIa Trial.",Oncology,Oncology: Colorectal,Swiss Group for Clinical Cancer Research - SAKK,Cooperative Group,"Complete response, Dose-limiting toxicities, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Disease-free survival",True,NCT00869570,15581
4068,104539,"12349, NCT00829231, TrialTroveID-104539","Open Label, Phase I to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetic of Sorafenib (BAY43-9006)",Oncology,Oncology: Unspecified Cancer,Bayer AG,"Industry, Top 20 Pharma","Adverse Events, Area under the curve score, Cmax, Elimination half-life","Cardiac Telemetry, Safety and Tolerability, Vital signs",True,NCT00829231,15581
4069,104275,"Bay43-9006-2008005, NCT00839111, TrialTroveID-104275","A Phase II Open Label, Non Randomized Study, in Which Sorafenib is Used in Combination with Irinotecan, Leucovorin and Fluorouracil in Patients with Advanced Colorectal Cancer After Failure of Oxaliplatin Treatment",Oncology,Oncology: Colorectal,"Fudan University - Shanghai, China",Academic,"Disease Progression, Progression-free survival","Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Response rate, Safety and Tolerability, Stable Disease",True,NCT00839111,15581
4070,104214,"NCT00837876, TrialTroveID-104214, VICC GI 0815, VICCGI0815, VU-VICC-GI-0815",A Phase II Trial of Sorafenib and Erlotinib in Unresectable Pancreatic Cancer,Oncology,Oncology: Pancreas,"National Institutes of Health/National Cancer Institute, Vanderbilt-Ingram Cancer Center","Government, Academic","Overall survival, Progression-free survival","NCI-CTC scale, Overall response rate, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00837876,15581
4071,104204,"14295, BAY43-9006/14295, BAYER 14295, CTR20130038, DECISION, DRKS00005542, EudraCT Number: 2009-012007-25, JapicCTI-101022, MDACC 2009-0600, NCT00984282, NL29757.058.09, RECF1272, TrialTroveID-104204, VICCHN0969","A Double-Blind Randomized Phase III Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid Cancer, , DECISION (stuDy of sorafEnib in loCally advanced or metastatIc patientS with radioactive Iodine-refractory thyrOid caNcer)",Oncology,Oncology: Thyroid,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00984282,15581
4072,104200,"08-068, NCT00837148, TrialTroveID-104200",Phase II Trial of Sorafenib and Dacarbazine in Soft Tissue Sarcoma.,Oncology,Oncology: Soft Tissue Sarcoma,"Memorial Sloan-Kettering Cancer Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Clinical benefit rate, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT00837148,15581
4073,104046,"AIO KRK 0307, EudraCT Number: 2008-000803-26, FOSCO, NCT00889343, TrialTroveID-104046",A Controlled Randomized Double-blind Multi-center Phase II Study of FOLFOX6 or FOLFIRI Combined With Sorafenib Versus Placebo in Second-line Metastatic Colorectal Carcinoma,Oncology,Oncology: Colorectal,Arbeitsgemeinschaft fur Internistische Onkologie,Cooperative Group,"Disease Progression, Progression-free survival","Clinical benefit rate, Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT00889343,15581
4074,103771,TrialTroveID-103771,"Efficacy, safety and impact on quality of life of a treatment with sorafenib in elderly cancer patients with advanced hepatocellular carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Quality of Life, SF-36",False,,15581
4075,103680,TrialTroveID-103680,Clinical outcomes of sorafenib in metastatic hepatocellular carcinoma (HCC) patients who had previously received fluoropyrimidine plus platinum-based chemotherapy.,Oncology,Oncology: Liver,"Korea University Medical Center, Seoul",Academic,,,False,,15581
4076,103619,"08103, BAYER-CHNMC-08103, CHNMC-08103, NCT00828074, P30CA033572, TrialTroveID-103619",Phase I/II Vinorelbine and Sorafenib as Salvage Therapy in Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, City of Hope Comprehensive Cancer Center","Government, Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Nausea, Neutropenia, Overall survival, Progression-free survival, Safety and Tolerability, Triglyceride, Vomiting","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to treatment failure",True,NCT00828074,15581
4077,103427,"BRE 138, BRE 138 IIT, NCT00825734, SCRI BRE 138, TrialTroveID-103427",Phase I/II Trial of Sorafenib Plus Ixabepilone in HER2-Negative Metastatic Breast Cancer (MBC),Oncology,Oncology: Breast,"Bristol-Myers Squibb, Bayer AG/Bayer Pharmaceuticals","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00825734,15581
4078,103414,"4653, BAYER-OHSU-4653, FHCRC 7195, NCT00822848, OHSU-4653, OHSU-SOL-08080-L, SOL-08080-L, TrialTroveID-103414","Antiangiogenic Potentiation of Preoperative Chemoradiotherapy for High Risk Extremity Soft Tissue Sarcomas: A Phase I Study of Sorafenib With Epirubicin, Ifosfamide, Hypofractionated Radiation, and Surgery",Oncology,Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, OHSU Cancer Institute","Government, Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Amputation rate, Complete response, Disease-free survival, Overall survival, Progression-free survival, Recurrence, Resection rate, Response evaluation criteria in solid tumors",True,NCT00822848,15581
4079,103181,"12918, BAY 43-9006 / 12918, EudraCT Number: 2008-005056-24, NCT00855218, PD 12918, RECF1033, SOL-09017-P, SPACE, SPACE 12918, TrialTroveID-103181","A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Sorafenib or Placebo in Combination With Transarterial Chemoembolization (TACE) Performed With DC Bead and Doxorubicin for Intermediate Stage Hepatocellular Carcinoma (HCC)",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Boston Scientific/BTG {Biocompatibles}","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Time to progression","Complete response, EQ-5D, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT00855218,15581
4080,102675,"EudraCT Number: 2007-007001-73, NL21093.041.07, PERI-ABLATIVE SORAFENIB, TrialTroveID-102675, UMCU 08-006/G-O","A Phase I Safety, Toxicity and Biomarker Study of Peri-operative Sorafenib Treatment in Patients Undergoing Radiofrequency Ablation (RFA) for Liver Metastases of Colorectal Cancer.",Oncology,Oncology: Colorectal; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Liver function, Neutropenia, Safety and Tolerability",Disease-free survival,False,,15581
4081,102651,"1516, NCT00815295, Pro00001516, TrialTroveID-102651",Sorafenib and Cetuximab in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN): a Phase IB/II Trial,Oncology,Oncology: Head/Neck,"Bayer AG/Bayer Pharmaceuticals, Duke University Medical Center","Industry, Top 20 Pharma, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale, Overall response rate, Partial response, Progressive disease rate, Stable Disease, Tumor control rate","Disease Progression, Functional Assessment of Cancer Therapy-Head & Neck Cancer, Likert scale, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors",True,NCT00815295,15581
4082,102466,"08-256, DFCI 08-256, IST000508, K23CA139005, NCT00813293, TrialTroveID-102466","Randomized, Double-Blind, Placebo-Controlled, Phase II Trial Of Short Course Sorafenib Therapy Prior to Radiofrequency Ablation for Intermediate Sized (3.5 to 7cm) Hepatocellular Cancer",Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, Beth Israel Deaconess Medical Center, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Brigham and Womens Hospital","Government, Academic, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",,"Magnetic Resonance Imaging, Safety and Tolerability",True,NCT00813293,15581
4083,102432,"200816532, 200816532-1, BAYER-UCDCC-213, IST000375, NCT00810394, TrialTroveID-102432, UCDCC#213, UCDCC-213",Single Agent Sorafenib in Advanced Solid Tumors: Phase II Evaluation of Dose Re-Escalation Following a Dose Reduction (IST000375).,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular; Oncology: Thyroid","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, University of California Davis","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",,"Overall response rate, Progression-free survival, Response rate, Time to progression",True,NCT00810394,15581
4084,102332,"13414, 3L-09-1, CTRI/2009/091/000810, GIDEON, NCT00812175, NX0802, TEMP UTRN 100837292-011020091288164, TrialTroveID-102332","Global Investigation of Therapeutic Decisions in Hepatocellular Carcinoma and of Its Treatment With Sorafenib, , GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and of its treatment with sorafeNib)",Oncology,Oncology: Liver,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,"Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT00812175,15581
4085,102267,"BAYER-IGR-CSET-2006/1261, CSET 2006/1261, EUDRACT-2007-00527-18, IGR#SORAF-TEM#ST1#CSET 2006/1261, IGR-CSET-2006/1261, IGR-SORAF-TEM ST1, INCA-RECF0818, NCT00811759, SCHER-IGR-CSET-2006/1261, SORAF-TEM ST1, TrialTroveID-102267","Open-Label, Single Center, Uncontrolled Phase I/II Study Evaluating the Safety and Maximum Tolerated Dose of Daily Sorafenib Administered in Combination With Prolonged Temozolomide in Patients With Metastatic Melanoma.",Oncology,Oncology: Melanoma,"Merck & Co. {Schering-Plough}, Institut Gustave Roussy, Bayer AG","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Progression-free survival, Safety and Tolerability","Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT00811759,15581
4086,101977,"2008-108, NCT00808145, TrialTroveID-101977",A Phase II Study of Sorafenib With Gemcitabine/Cisplatin in Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Time to progression,True,NCT00808145,15581
4087,101836,"BAYER-UCDCC-216, IST000449, NCT00805727, TrialTroveID-101836, UCDCC-216",Phase I/II Trial of Neoadjuvant Conformal Radiotherapy Plus Sorafenib for Patients With Soft Tissue Sarcoma of the Extremity and Body Wall.,Oncology,Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, University of California Davis","Government, Academic","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability","Clinical benefit rate, Disease-free survival, Overall response rate, Overall survival, Progression-free survival, Recurrence, Response evaluation criteria in solid tumors, Response rate",True,NCT00805727,15581
4088,101560,"F080703006, NCT00801801, TrialTroveID-101560, UAB 0750",Pilot Phase IIa Study of Metronomic Chemotherapy With Taxotere (Docetaxel) Plus Nexavar (Sorafenib) as First-Line Therapy in Performance Status-2 Patients With Advanced Non-Squamous Cell Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall survival, Progression-free survival","Complete response, Overall response rate, Partial response, Response rate, Stable Disease, Tumor control rate",True,NCT00801801,15581
4089,101477,"4-2008-0160, NCT00801385, TrialTroveID-101477, YONSEI-4-2008-0160","A Multicenter, Open-Label, Phase II Study of Sorafenib in Combination with Erlotinib in Non-Small Cell Lung Cancer (NSCLC) Refractory to One or Two Prior Chemotherapy Regimens",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00801385,15581
4090,101091,"BAY 13278, NCT00794235, TrialTroveID-101091",Monocentric Pilot Study Investigating the Metabolic Activity of Melanoma in Vivo During Sorafenib and Dacarbazine,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Gene expression profiling,,True,NCT00794235,15581
4091,101056,TrialTroveID-101056,A single center study on efficacy and tolerability of sorafenib in patients with hepatocellular carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4092,100970,"13162, EudraCT Number: 2008-005025-11, NCT00865709, RESPECT, TrialTroveID-100970, UKCRN ID#9425","Phase IIb, DB, Randomized Study Evaluating Efficacy & Safety of Sorafenib Compared With Placebo When Administered in Combination With Modified FOLFOX6 for the Treatment of Metastatic CRC Subjects Previously Untreated for Stage IV Disease",Oncology,Oncology: Colorectal,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00865709,15581
4093,100934,"EudraCT Number: 2007-005091-13, NCT00794859, SMS, TrialTroveID-100934",Trial of Sorafenib in Malignant Mesothelioma Previously Treated With Platinum-Based Chemotherapy.,Oncology,Oncology: Mesothelioma,"Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Clinical benefit rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Clinical benefit rate, Overall response rate, Overall survival, Response rate, Stable Disease",True,NCT00794859,15581
4094,100760,"13419, 13420, 14690, INSIGHT, NCT00792350, NX0801, NX0801AT, NX0801DE, TrialTroveID-100760",International Study With Nexavar About Safety and Efficacy in Carcinoma Hepatocellular Therapy (HCC),Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}},"Industry, Top 20 Pharma",,Adverse Events,True,NCT00792350,15581
4095,100745,"12007, Bayer 12007, EudraCT Number: 2008-004429-41, JapicCTI-090895, NCT00791778, NL25894.003.08, RECF0923, TrialTroveID-100745","A Double-Blind, Randomized Phase II Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo in Ovarian Epithelial Cancer or Primary Peritoneal Cancer Patients Who Have Achieved a Complete Clinical Response After Standard Platinum/Taxane Containing Chemotherapy",Oncology,Oncology: (N/A); Oncology: Ovarian,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Yakuhin","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Safety and Tolerability","Adverse Events, CA-125 Response, EQ-5D, Functional Assessment of Cancer Therapy-Ovarian Cancer, Overall survival, Recurrence, Safety and Tolerability, Visual Analog Scale",True,NCT00791778,15581
4096,100708,TrialTroveID-100708,Cardiac Toxicity of Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Medical University of Vienna,Academic,,,False,,15581
4097,100649,TrialTroveID-100649,A single center study on significance and management of adverse events associated with systemic therapy with sorafenib in patients with advanced hepatocellular carcinoma.,Oncology,Oncology: Liver,University of Duisburg-Essen {University of Essen},Academic,,,False,,15581
4098,100616,"EudraCT Number: 2007-003211-31, GEMCAD 01/07, NCT00789763, TrialTroveID-100616","Open-label, Multicentric Phase I-II Trial to Evaluate the Efficacy and Safety of the Combination of Sorafenib (BAY 43-9006), Gemcitabine and Concurrent Radiotherapy, in Locally Advanced Pancreatic Carcinoma",Oncology,Oncology: Pancreas,(Other Cooperative Group),Cooperative Group,"Maximum tolerated dose, Progression-free survival, Safety and Tolerability","Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",True,NCT00789763,15581
4099,99735,"NCT00780169, OTT 06-08, TrialTroveID-099735",A Phase I Study of Sorafenib (Nexavar) in Combination With FOLFIRI as First Line Therapy for Metastatic Colorectal Cancer.,Oncology,Oncology: Colorectal,"Bayer AG/Bayer Pharmaceuticals, Ottawa Regional Cancer Center","Industry, Top 20 Pharma, Academic","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT00780169,15581
4100,99651,"507, TrialTroveID-099651","A Phase II Randomized, Double-Blind, Multicenter Study to Optimize the Treatment Therapy in Hormone Refractory Chemotherapy-Naive Prostate Cancer Patients with Sorafenib + Docetaxel + Prednisone versus Placebo + Docetaxel + Prednisone.",Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Time to progression",,False,,15581
4101,99586,"AFMSMCRC0706, NCT00779311, TrialTroveID-099586",A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal,"(Other Cooperative Group), Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose","Progression-free survival, Quality of Life",True,NCT00779311,15581
4102,99456,"1910, Angio-Next, ANGIONEXT, Angio-Next-0710, BAYER-COL-Angio-Next, CLCC Lille#Angio-Next #2007-10, COL-2007-10, COL-Angio-Next, EudraCT Number: 2007-004651-10, INCA-RECF0636, NCT00874874, RECF0636, TrialTroveID-099456",Phase II Multicenter Stratified Study Evaluating the Efficacy and Toxicity of Sorafenib in Treating Locally Advanced or Metastatic Angiosarcomas That Are Not Accessible to Curative Surgery,Oncology,Oncology: Soft Tissue Sarcoma,"Federation Nationale des Centres de Lutte contre le Cancer, Bayer AG/Bayer Pharmaceuticals, French Sarcoma Group, (Other government agency)","Cooperative Group, Industry, Top 20 Pharma, Cooperative Group, Government","Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Response rate, Time to progression",True,NCT00874874,15581
4103,99026,"13102, NCT00771147, NX0710BE, PONDIAC, TrialTroveID-099026","Prospective Open-label Non-interventional, Non-controlled Multi Observational and Pharmaco-economic Phase IV Trial to Evaluate the Characteristics of Patients Treated for Advanced Renal Cell Carcinoma With Nexavar as Well as Effectiveness, Safety and Direct Medical Costs of Nexavar Treatment Under Daily-life Treatment Conditions",Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}},"Industry, Top 20 Pharma",Response evaluation criteria in solid tumors,,True,NCT00771147,15581
4104,98836,TrialTroveID-098836,Open-Label Phase II Study of Sorafenib + Dacarbazine in Patients with Advanced Metastatic Melanoma,Oncology,Oncology: Melanoma,(Other Hospital/Academic/Medical Center),Academic,Clinical benefit rate,,False,,15581
4105,98653,"NCT00768937, SORATACE1, TrialTroveID-098653",Sorafenib as Inhibitor of Collateral Tumor Vessel Growth During Transarterial Chemoembolisation (TACE) for Hepatocellular Carcinoma (HCC)- a Pilot Trial to Evaluate Safety and Biological Response.,Oncology,Oncology: Liver,Medical University of Vienna,Academic,"Disease Progression, Safety and Tolerability, Time to progression",,True,NCT00768937,15581
4106,98375,"McG 0713, NCT00764972, TrialTroveID-098375",A Phase IB/II Trial of Combination of Vinorelbine With Sorafenib (BAY 43-9006) as First-Line Treatment in Patients With Metastatic Breast Cancer,Oncology,Oncology: Breast,McGill University Health Centre,Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Progression-free survival, Safety and Tolerability",True,NCT00764972,15581
4107,98369,"0717, BAYER-UNC-LCCC-0717, IST000379, LCCC 0717, LCCC0717, NCT00767468, TrialTroveID-098369, UNC-LCCC-0717",A Phase IB Study of Sorafenib for Patient With Locally Advanced or Metastatic Hepatocellular Carcinoma and Child's B Cirrhosis,Oncology,Oncology: Liver,"National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center, Bayer AG/Bayer Pharmaceuticals","Government, Academic, Industry, Top 20 Pharma",,"Dose-limiting toxicities, Magnetic Resonance Imaging, Overall survival, Safety and Tolerability",True,NCT00767468,15581
4108,98065,TrialTroveID-098065,Safety and Efficacy of Sorafenib in Patients with Castrate Resistant Prostate Cancer: A Phase II Study,Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
4109,97977,"LUN 175, LUN 175 IIT, LUN 175 TIER IIT, NCT00759928, SCRI LUN 175, TrialTroveID-097977",Pharmacokinetic Trial of Sorafenib and Erlotinib in Patients With Refractory Solid Tumors,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor","Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT00759928,15581
4110,97944,"2007-001781-32, EudraCT Number: 2007-001781-32, GISCAD, MAPS, NCT00758381, STUDIO MAPS, TrialTroveID-097944",A Randomized Phase II Study of Gemcitabine/Cisplatin with or without Sorafenib to Evaluate the Efficacy and Safety in Patients with Locally Advanced or Metastatic Pancreatic Cancer. MAPS Trial,Oncology,Oncology: Pancreas,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Progression-free survival,"Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to treatment failure",True,NCT00758381,15581
4111,97782,"BAYER-OSU-08017, NCI-2011-03192, NCT00754923, OSU-08017, OSU-2008C0079, TrialTroveID-097782",A Phase II Study of Single Agent Sorafenib in Non-Small Cell Lung Cancer Patients Who Never Smoked or Were Former Light Smokers,Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival",True,NCT00754923,15581
4112,97390,"HKCTR-664, HKU-SRG-P001, NCT00752063, SECOX, TrialTroveID-097390",A Phase IIa Trial of Sorafenib With Capecitabine and Oxaliplatin in Patients With Locally Advanced or Metastatic Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Time to progression","Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",True,NCT00752063,15581
4113,96938,"BAY43-9006-2008003, NCT00747799, TrialTroveID-096938",Phase II Study of Combination of Sorafenib With Cisplatin and 5-fluorouracil as First-line Treatment of Recurrence After Radiotherapy Patients Who Are Failure of Radiotherapy in Recurrent or Metastatic Nasopharyngeal Carcinoma (NPC),Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Clinical benefit rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00747799,15581
4114,96738,"31/05-RUTT AB 204, AB 31/05, AB 31/05 â RUTT 204, AB 31/05 - RUTT 204 - SUSE, AB 31/05 RUTT 204, AUO AB 31/05, AUO-AB 31/05, EudraCT Number: 2005-006098-29, NCT01215266, SUSE, TrialTroveID-096738","Prospective, Randomized, Double-Blind, Multicenter phase II trial comparing the efficacy of chemotherapy with cisplatin and gemcitabine plus sorafenib (BAY 43-9006) versus gemcitabine plus cisplatin, and placebo in the treatment of locally advanced or Metastatic urothelial cancer AB 31/05 - RUTTE 204 - SUSE",Oncology,Oncology: Bladder,"University of Duisburg-Essen {University of Essen}, Association of Urogenital Oncology (AUO)","Academic, Cooperative Group",Progression-free survival,"Duration of overall response, Overall response rate, Overall survival, Quality of Life, Response rate, Time to progression",True,NCT01215266,15581
4115,95764,"2008-0059, NCI-2012-01617, NCT00734526, TrialTroveID-095764",A Phase I Study of Sorafenib With Radiation and Temozolomide in Newly Diagnosed Glioblastoma or Gliosarcoma.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma","MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Progression-free survival",Time to progression,True,NCT00734526,15581
4116,95705,"100375, NCT00941863, TrialTroveID-095705","Phase I Study to Determine the Safety, Maximum Tolerated Dose, PK of BAY 43-9006 in Repeated Cycles of 18 Days On/3 Days Off in Combination With Paclitaxel and Carboplatin Chemotherapy in Patients With Advanced, Refractory Solid Tumors",Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Liver function, Maximum tolerated dose, NCI-CTC scale, Neutropenia, Safety and Tolerability","Adverse Events, Area under the curve score, Cmax, Complete response, Overall response rate, Partial response, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events, Stable Disease, Tmax",True,NCT00941863,15581
4117,95607,"09072008-13772, 520, DRKS00003884, EudraCT Number: 2008-005011-18, NCT00732914, RCC SWITCH study, SWITCH, TrialTroveID-095607",A Phase III Randomized Sequential Open-Label Study to Evaluate the Efficacy and Safety of Sorafenib Followed by Sunitinib Versus Sunitinib Followed by Sorafenib in the Treatment of First-Line Advanced / Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"(Other Cooperative Group), Bayer AG","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Brain Natriuretic Peptide concentration, Clinical benefit rate, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00732914,15581
4118,95241,"BAYER-NU-07U1, NCT00727532, NU 07U1, NU-07U1, TrialTroveID-095241",Correlation of Pathologic Findings After Neo-Adjuvant Sorafenib With Results of Diffusion-Weighted Magnetic Resonance Imaging in Patients With Locally Advanced or Metastatic Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Northwestern University, Bayer AG/Bayer Pharmaceuticals","Government, Academic, Industry, Top 20 Pharma","Apparent diffusion coefficient, Magnetic Resonance Imaging, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",,True,NCT00727532,15581
4119,95142,"13863, AAAE6304, CASE 8507, CASE8507, CASE-8507, CASE-8507-CC486, NCT00726986, SR06-937, TrialTroveID-095142",Phase II Trial of Sorafenib in Conjunction With Chemotherapy and as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Small Cell",National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",Safety and Tolerability,True,NCT00726986,15581
4120,94992,"AHCC protocol 05, AHCC05, AHCC05 2875, NCT00712790, NMRC - AHCC05, NMRR-08-1369-2875, TrialTroveID-094992",Phase I/II Study of SIR-Spheres Plus Sorafenib (Chemo-Radiotherapy) as First Line Treatment in Patients With Non-Resectable Primary Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}, (Other Hospital/Academic/Medical Center), National Medical Research Council of Singapore, Sirtex Medical","Industry, Top 20 Pharma, Academic, Government, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Recurrence, Resection rate, Stable Disease",True,NCT00712790,15581
4121,94848,"07/203, EudraCT Number: 2007-004625-14, NCT00722969, NL19335.029.07, TrialTroveID-094848",A Phase II Study of Erlotinib and Sorafenib in Patients with Locally Advanced and/or Metastatic (Stage IIIb or IV) Non Small Cell Lung Cancer who Have Not Received Prior Chemotherapy.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Time to response",True,NCT00722969,15581
4122,94752,"BAYER-OHSU-4318, CDR0000601002, NCT00722072, OHSU-4318, SOL-08020-LM, TrialTroveID-094752",A Phase II Open-Label Study of Sorafenib Plus Fulvestrant as Salvage Therapy for Hormone Receptor Positive Metastatic Breast Cancer Failing Prior Aromatase Inhibitor Treatment,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Oregon Health and Science University","Government, Industry, Top 20 Pharma, Academic","Complete response, Overall survival, Partial response, Progression-free survival, Stable Disease","Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00722072,15581
4123,93976,"07-168, NCT00714948, TrialTroveID-093976",Phase II Study of Gemcitabine and Split-dose Cisplatin (GC) Plus Sorafenib in Chemotherapy-naive Patients With Locally Advanced or Metastatic Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,"Memorial Sloan-Kettering Cancer Center, Bayer AG","Academic, Industry, Top 20 Pharma","Overall response rate, Overall survival, Progression-free survival, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00714948,15581
4124,92776,"12849, NCT00703365, TrialTroveID-092776","A Multicenter, Open Label, Single Arm, Phase II Study to Investigate the Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Patients With Advanced Hepatocellular Carcinoma (HCC).",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Mahidol University, Bangkok, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic, Academic",Progression-free survival,"Clinical benefit rate, Overall response rate, Response evaluation criteria in solid tumors, Time to progression",True,NCT00703365,15581
4125,92750,"0712M22703, 2007LS086, BAYER-UMN-2007LS086, NCT00703638, TrialTroveID-092750, UMN-2007LS086","Phase I Study of Sorafenib, Pemetrexed, and Cisplatin for the Treatment of Advanced Solid Tumors.",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma","University of Minnesota Cancer Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Area under the curve score, Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00703638,15581
4126,92445,TrialTroveID-092445,Thyroid dysfunction in patients (pts) with metastatic renal cell cancer (RCC) treated with sorafenib.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4127,92308,"FCCC 07-038, IRB07038 /07-038, NCT00694291, TrialTroveID-092308, UPCC 07808",Phase II Double Blind Randomized Placebo Controlled Study of Sorafenib in Hormone NaÃ¯ve Biochemical Recurrence of Prostate Cancer.,Oncology,Oncology: Prostate,"Fox Chase Cancer Center, Bayer AG","Academic, Industry, Top 20 Pharma",Recurrence,"Overall response rate, PSA progression, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00694291,15581
4128,92238,TrialTroveID-092238,Carbonic anhydrase IX (CA IX) and pathologic features as predictors of outcome in patients (pts) with metastatic renal cell carcinoma (mRCC) receiving VEGF-targeted therapy.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4129,91944,"EudraCT Number: 2006-004644-24, SorOvar_07, TrialTroveID-091944","Prospective, Open, Multicenter Phase II Study with Neoadjuvant Chemotherapy in Combination with Sorafenib (oral), in Patients with Primary Advanced Ovarian Cancer (FIGO IIIC + IV) and Ascites (> 500 ml).",Oncology,Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Complete response, Duration of overall response, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Safety and Tolerability, Time to treatment failure",False,,15581
4130,91205,"07-006234, MAYO-07-006234, MAYO-MC078A, MC078A, NCT00687674, TrialTroveID-091205","Phase I/II Study of Sorafenib, Lenalidomide, and Dexamethasone in Relapsed/Refractory Multiple Myeloma",Oncology,Oncology: Multiple Myeloma,"National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Maximum tolerated dose, Partial response","Adverse Events, Gene expression profiling, Overall survival, Time to progression",True,NCT00687674,15581
4131,91074,"EudraCT Number: 2008-002269-29, HeiLivCa, ISRCTN24081794, NCT-2007-11-01-1011, TrialTroveID-091074","A prospective, randomized, double-blind, multicenter, phase III clinical study on transarterial chemoembolisation (TACE) combined with sorafenib vs TACE plus placebo in patients with hepatocellular cancer (HCC) before liver transplantation (LTx) - Heidelberg Liver Cancer Study (HeiLivCa Study).",Oncology,Oncology: Liver,"University of Heidelberg, Bayer AG/Bayer Vital GmbH","Academic, Industry, Top 20 Pharma",Time to progression,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Mortality, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Safety and Tolerability",False,,15581
4132,90804,"So.LAR., SoLar, TrialTroveID-090804",Sorafenib plus long-acting octreotide in advanced hepatocellular carcinoma. a multicenter study.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4133,90755,TrialTroveID-090755,Early prediction of response to sorafenib treatment in patients with hepatocellular carcinoma (HCC) with 18F- fluorodeoxyglucose-positron emission tomography (18F-FDG-PET).,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4134,90676,TrialTroveID-090676,"A Phase II placebo-controlled, multi-center, cross-over study of sorafenib in patients with stable disease on pre-existing prostacyclin-based therapy",Cardiovascular,Cardiovascular: Hypertension,University of Chicago Medical Center,Academic,,,False,,15581
4135,90656,TrialTroveID-090656,Efficacy and tolerability of single agent sorafenib in poor risk advanced hepatocellular carcinoma patients.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Overall response rate, Progression-free survival, Response rate",False,,15581
4136,90653,"EudraCT Number: 2006-001014-32, TrialTroveID-090653",A phase II trial of sorafenib (SOR) in patients (pts) with advanced cholangiocarcinoma (CC).,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Clinical benefit rate, Response evaluation criteria in solid tumors","Overall survival, Time to progression",False,,15581
4137,90622,TrialTroveID-090622,Progression free survival in patients with metastatic and recurrent renal cancer treated with sorafenib--Single center experience.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4138,90611,TrialTroveID-090611,Sorafenib as a second-line and sequential therapy for patients with metastatic renal cell carcinoma (mRCC): Analysis for safety and activity on sunitinib progressive patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4139,90591,TrialTroveID-090591,Sorafenib in the treatment of Chinese patients with advanced renal cell cancer.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,15581
4140,90581,TrialTroveID-090581,High-resolution electrocardiography (HRECG) in detection of preclinical cardiotoxicity of sunitinib and sorafenib in renal cell carcinoma (RCC) patients.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4141,90569,TrialTroveID-090569,Clinical benefits of long-term use of sorafenib in Japanese patients with unresectable renal cell carcinoma (RCC).,Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",,,False,,15581
4142,90435,"06-882, NCT00696696, NYU 06-882, PA-7604, SR06-937, TrialTroveID-090435",A Phase II Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer.,Oncology,Oncology: Pancreas,"Astellas Pharma {OSI Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, New York University, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00696696,15581
4143,90316,"12782, CONCERT, EudraCT Number: 2007-005083-28, NCT00678288, RECF0682, TrialTroveID-090316","A Phase II, Randomized, Open-Label, Multicenter, Study Evaluating the Efficacy of Sorafenib Alone and Sorafenib in Combination With Low Dose Interferon Alpha-2a as Second-Line Treatment of Sunitinib Failure in Patients With Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,Bayer AG,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT00678288,15581
4144,90258,"9361, 9361 (SR05-888), NCT00673361, SR05-888, TrialTroveID-090258","Phase II Pilot Trial of ""Chemo-Switch"" Regimen of Biochemotherapy Followed by Daily Low-Dose Temozolomide Plus Sorafenib in Advanced Melanoma.",Oncology,Oncology: Melanoma,"Bayer AG/Bayer Pharmaceuticals, Duke University Medical Center","Industry, Top 20 Pharma, Academic",Progression-free survival,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00673361,15581
4145,89736,"NCT00672178, Pro00001398, SBRT RCC, TrialTroveID-089736","Phase I/II Trial Evaluating Toxicity and Efficacy of Adding Stereotactic Body Radiotherapy to Sorafenib in Patients With Metastatic, Recurrent, or Unresectable Renal Cell Cancer.",Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Duke University Medical Center","Industry, Top 20 Pharma, Academic","Overall response rate, Partial response",,True,NCT00672178,15581
4146,89617,"Alliance, N0745, NCCTG N0745, NCCTG-N0745, NCT00867321, Trial N0745, TrialTroveID-089617",Phase I/II Randomized Trial of Sorafenib and Bevacizumab as First-Line Therapy in Patients with Locally Advanced or Metastatic Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"North Central Cancer Treatment Group (NCCTG), Bayer AG/Bayer Pharmaceuticals, Alliance for Clinical Trials in Oncology","Cooperative Group, Industry, Top 20 Pharma, Cooperative Group","Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Time to progression","Adverse Events, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate, Safety and Tolerability",True,NCT00867321,15581
4147,88576,"12931, NCT00663741, TrialTroveID-088576","Phase I Study to Investigate Safety, Pharmacokinetics and Preliminary Efficacy Profile of Sorafenib (BAY 43-9006) in Combination With S-1 Plus CDDP in Asian Patients With Unresectable / Recurrent Gastric Cancer.",Oncology,Oncology: Gastric,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma",Safety and Tolerability,"Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00663741,15581
4148,88471,"CC-GEMSO-2007, EudraCT Number: 2007-005796-34, GEMSO, GEMSO-CCC-2007, NCT00661830, TrialTroveID-088471","A Randomized, Double-Blind, Multicenter Phase II Trial With Gemcitabine Plus Sorafenib Versus Gemcitabine Plus Placebo in Patients With Chemo-Naive Advanced or Metastatic Adenocarcinoma of the Biliary Tract",Oncology,Oncology: Liver,"Arbeitsgemeinschaft fur Internistische Onkologie, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Disease Progression, Progression-free survival","Complete response, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT00661830,15581
4149,87939,"10922, NCT00657254, TrialTroveID-087939",Extension Program for Bay 43-9006,Oncology,Oncology: Unspecified Cancer,Bayer AG,"Industry, Top 20 Pharma",,"Complete response, Disease Progression, Overall response rate - duration, Overall response rate - time, Overall response rate, Response rate, Safety and Tolerability, Time to progression",True,NCT00657254,15581
4150,87920,TrialTroveID-087920,Phase II Study for the Evaluation of Sequential Interleukin 2 and Interferon alpha followed by Subcutaneous Sorafenib (BAY 43-9006) in Patients with Renal Cell Carcinoma (RCC).,Oncology,Oncology: Renal,Spanish Oncology GenitoUrinary Group,Cooperative Group,Progression-free survival,,False,,15581
4151,86708,"ANGIO1, NCT00665990, TrialTroveID-086708",Phase I Study of Bevacizumab and Sorafenib Combined With Low Dose Cyclophosphamide in Patients With Refractory Solid Tumors and Leukemia,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","Pfizer, St. Jude Children's Research Hospital","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00665990,15581
4152,86293,"07C.381, 07P.381, 2006-58, IRB Control # 07C.381 (2006-58), NCT00639262, TrialTroveID-086293",Phase I Study of the Combination of Sorafenib and Radiation Therapy - or + Temozolomide for the Treatment of Patients With Brain Metastases and Primary Brain Tumors,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Metastatic Cancer","Bayer AG/Bayer Pharmaceuticals, Kimmel Cancer Center-Thomas Jefferson University - Philadelphia, PA","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Overall response rate, Recurrence, Response rate, Safety and Tolerability",True,NCT00639262,15581
4153,86153,"2007-0248, A534260, CO07204, NCI-2011-00475, NCT00634751, SMPH\MEDICINE\HEM-ONC, TrialTroveID-086153","A Phase I/II Study of Oxaliplatin, Oral Capecitabine and Sorafenib in Patients With Advanced Pancreatic and Biliary Carcinoma.",Oncology,Oncology: Liver; Oncology: Pancreas,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, University of Wisconsin, Sanofi {Sanofi-Aventis}","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma","Complete response, Dose-limiting toxicities, Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability","Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression",True,NCT00634751,15581
4154,85768,"07-0537, 07-0537.cc, NCI-2013-00413, NCT00635791, TrialTroveID-085768","A Phase I Safety and Tolerability Study of Vorinostat in Combination With Sorafenib in Patients With Advanced Solid Tumors, With Exploration of Two Tumor-type Specific Expanded Cohorts at the Recommended Phase 2 Dose",Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","Merck & Co., Bayer AG/Bayer Pharmaceuticals, University of Colorado","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00635791,15581
4155,85025,"0220070284, 040706, CFEM345AUS56, CINJOG 040706, NCI-2012-00525, NCT00634634, NJ 1107, NJ 1107 [CINJOG], SR06-974, TrialTroveID-085025",Phase I/II Trial of Letrozole (Femara) and Sorafenib (Nexavar) in Postmenopausal Women With Hormone-Receptor Positive Locally Advanced or Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Novartis, National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Cancer Institute of New Jersey, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Government, Industry, Top 20 Pharma, Academic, Academic","Clinical benefit rate, Safety and Tolerability","Circulating Tumor Cells, Overall survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00634634,15581
4156,85024,"NCT00627835, OZM-003, TrialTroveID-085024","A Phase I Dose Escalation Trial of Neoadjuvant Sorafenib and Concurrent Sorafenib, Cisplatin and Radiation in Locally Advanced Squamous Cell Carcinomas of the Head and Neck (SCCHN).",Oncology,Oncology: Head/Neck,British Columbia Cancer Agency,Government,Safety and Tolerability,Maximum tolerated dose,True,NCT00627835,15581
4157,84999,"112007-035, NCI-2011-02791, NCT00622466, ONYX-SCCC-112007-035, SCCC-02107, SCCC-112007-035, STU 082010-161, TrialTroveID-084999",Phase II Trial of Sorafenib and Paclitaxel for Measurable Metastatic HER2-Negative Breast Cancer,Oncology,Oncology: Breast,University of Texas Southwest Medical Center,Academic,"Response evaluation criteria in solid tumors, Time to progression","Clinical benefit rate, Duration of overall response, Overall response rate, Progression-free survival, Response rate, Stable Disease, Time to progression, Time to treatment failure",True,NCT00622466,15581
4158,84856,"00625378, 12311, 15/08, ADHB #3933, BAY 43-9006 / 12311, Bayer 12311 (STEP), CTR20131621, EudraCT Number: 2007-002604-17, HIC 0809004248, McG 0522LTF, NCI-2012-01207, NCT00625378, STEP, TrialTroveID-084856, U136, V#5.2, 5/07/07: IB V#7",Sorafenib Long Term Extension Program,Oncology,Oncology: Liver; Oncology: Melanoma; Oncology: Renal; Oncology: Unspecified Cancer,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall survival, Safety and Tolerability",Safety and Tolerability,True,NCT00625378,15581
4159,84759,"DeCOG SoraPeg 2007, DeCOG-MM-PAL-9, EudraCT 2007-001918-16, NCT00623402, Sora-2007, SoraPeg, Sora-Peg 2007, TrialTroveID-084759","Combined Treatment of Sorafenib and Pegylated Interferon alpha 2b in Stage IV Metastatic Melanoma: a Prospective Non-Randomized, Multicenter Phase II Study.",Oncology,Oncology: Melanoma,"(Other Hospital/Academic/Medical Center), Dermatologic Cooperative Oncology Group","Academic, Cooperative Group","Clinical benefit rate, Tumor control rate","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00623402,15581
4160,84740,"EudraCT Number: 2007-000730-40, NCT00618384, SOCRATES, SOCRATES-072, TrialTroveID-084740",Phase II Study Evaluating Transarterial Chemoembolization (TACE) in Combination With Sorafenib for the Treatment of Advanced Hepatocellular Carcinoma (HCC).,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Time to progression,"Adverse Events, Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00618384,15581
4161,84702,"12345, NCT00622479, TrialTroveID-084702",Mechanistic Evaluations on Sorafenib Induced Hypophosphatemia in Patients with Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Phosphate level,Brain Natriuretic Peptide concentration,True,NCT00622479,15581
4162,84670,"N0776, NCCTG N0776, NCCTG-N0776, NCI-2009-00832, NCT00621686, TrialTroveID-084670",Phase II Trial of Bevacizumab in Combination With Sorafenib in Recurrent Glioblastoma Multiforme,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Cooperative Group, Government, Cooperative Group","Magnetic Resonance Imaging, Progression-free survival, Safety and Tolerability","Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Time to progression",True,NCT00621686,15581
4163,84424,"GAO1, GAOUNO, NCT00619996, PISAUNO, TrialTroveID-084424",Phase II Study of Sorafenib (Bay 43-9006) and Docetaxel in Metastatic Prostate Cancer.,Oncology,Oncology: Prostate,(Other Cooperative Group),Cooperative Group,,"Duration of overall response, Gene expression profiling, Overall response rate, Overall survival, Time to progression",True,NCT00619996,15581
4164,84401,"12913, EudraCT 2007-004875-21, NCT00618982, RECF0734, TrialTroveID-084401","A Phase II, Multi-Center, Open-Label Study to Assess the Efficacy, Safety, Tolerability and Pharmacokinetics of Intrapatient Dose Escalation of Sorafenib as First Line Treatment for Metastatic Renal Cell Carcinoma",Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Complete response, Nausea, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Vomiting","Area under the curve score, Cmax, Complete response, Disease Progression, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Tmax",True,NCT00618982,15581
4165,84369,"NCT00619541, P2, PISADUE, TrialTroveID-084369",Phase II Study of Sorafenib (Bay 43-9006) and Infusional 5-Fluorouracil in Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Cooperative Group),Cooperative Group,"Clinical benefit rate, Partial response, Stable Disease","Gene expression profiling, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT00619541,15581
4166,84215,TrialTroveID-084215,Sorafenib is superior to combination therapy with gemcitabine plus doxorubicin for patients with sarcomatoid renal cell carcinoma.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Safety and Tolerability",False,,15581
4167,84167,"05-167, BAYER-CASE-11805, CASE-11805, NCT00866320, TrialTroveID-084167",A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma (RCC) Refractory to SU11248 or Bevacizumab Therapy,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, (Other Hospital/Academic/Medical Center)","Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Progression-free survival, Progressive disease rate","Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00866320,15581
4168,83817,"NCT00613145, SCRI REFMAL 122, TrialTroveID-083817",A Phase I Pharmacokinetic and Safety Study of Sorafenib + Capecitabine in Advanced Solid Tumors.,Oncology,Oncology: Colorectal; Oncology: Pancreas; Oncology: Prostate,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,True,NCT00613145,15581
4169,83690,"07-0097-C, NCT00610246, TAP, TrialTroveID-083690","A Phase I Dose Escalation Study of Concurrent Low Dose Radiation With Sorafenib in Three Anatomically-based Independent Cohorts (Thorax, Abdomen, Pelvis)",Oncology,"Oncology: Bladder; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Testicular","University Health Network, Toronto",Academic,"Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT00610246,15581
4170,83654,"BRE 162, LUN 162, LUN 162 IIT, NCT00609804, SCRI LUN 162, TrialTroveID-083654",Randomized Phase II Trial of Sorafenib and Erlotinib or Sorafenib Alone in Patients With Advanced Non-Small Cell Lung Cancer Progressing on Erlotinib,Oncology,"Oncology: Lung, Non-Small Cell","Astellas Pharma {OSI Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals","Industry, all other pharma, Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT00609804,15581
4171,83603,"EudraCT Number: 2006-003137-32, ITMO 002, NCT00609401, ROSORC, TrialTroveID-083603",A Randomized Open Label Multicenter Phase II Study of First Line Therapy With Sorafenib in Association With IL-2 vs Sorafenib Alone in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,(Other Cooperative Group),Cooperative Group,Progression-free survival,"Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT00609401,15581
4172,83567,"DDPDRO-004, DDP-DRO4, NCT00609934, TrialTroveID-083567, UHN REB 07-0357-C",A Phase I/II Study of Sorafenib and Palliative Radiotherapy in Patients With Advanced Renal Cell Carcinoma and Symptomatic Bony Metastases.,CNS; Oncology,CNS: Pain (nociceptive); Oncology: Renal,"University Health Network, Toronto",Academic,Brief Pain Inventory,"Brief Pain Inventory, Disease-free survival",True,NCT00609934,15581
4173,83176,"NCT00602862, NL14551.091.07, TrialTroveID-083176",The Effect of Sorafenib (Nexavar) on 111-Indium Labeled Chimeric Monoclonal Antibody G250 or 111-Indium Labeled Bevacizumab (Avastin) Uptake in Patients With Clear Cell RCC (ccRCC).,Oncology,Oncology: Renal,"(Other Hospital/Academic/Medical Center), Dutch Cancer Society","Academic, Not for Profit Funding Entity",,,True,NCT00602862,15581
4174,82890,TrialTroveID-082890,A Study in Patients with Metastatic Papillary RCC (PRCC) and Chromophobe RCC (ChRCC) Who Received Either Sunitinib or Sorafenib As Their Initial TKI Treatment,Oncology,Oncology: Renal,Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute,Academic,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",,False,,15581
4175,82725,TrialTroveID-082725,Safety of sorafenib alone or in combination with locoregional therapy in patients with advanced hepatocellular carcinoma (HCC) and decompensated cirrhosis.,Oncology,Oncology: Liver,University of Florida - Gainesville,Academic,"Safety and Tolerability, Safety and Tolerability",,False,,15581
4176,82488,TrialTroveID-082488,A Phase I Study of Concurrent Sorafenib (BAY 43-9006) and Palliative Radiation Therapy in Adult Patients with Advanced Solid Tumors.,Oncology,Oncology: Breast; Oncology: Prostate,Nevada Cancer Center,Academic,,,False,,15581
4177,82409,"00000464, 07217, NCT00597493, Pro00000464, TrialTroveID-082409",Phase II Study of Sorafenib Plus Protracted Temozolomide in Recurrent Glioblastoma Multiforme,Oncology,"Oncology: CNS, Glioblastoma","Merck & Co. {Schering-Plough}, Bayer AG/Bayer Pharmaceuticals, Duke University Medical Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Overall survival, Progression-free survival","Cmax, Overall survival, Plasma concentration, Safety and Tolerability, Tmax",True,NCT00597493,15581
4178,82386,"NCT00595985, Sorafenib-MGC, TrialTroveID-082386",Phase II Trial of Sorafenib as Second Line Therapy in Patients with Advanced or Metastatic Gastric Cancer.,Oncology,Oncology: Gastric,"Fudan University - Shanghai, China",Academic,Time to progression,,True,NCT00595985,15581
4179,82221,"EudraCT N. 2007-001416-23, FMB0701, FM-B07-01, ISRCTN72153214, SOR, TrialTroveID-082221","A Multinational Double-Blind, Randomised Phase IIb Cooperative Group Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Chemotherapy and/or Endocrine Therapy in Patients with Locally Recurrent or Metastatic Breast Cancer",Oncology,Oncology: Breast,"(Other Cooperative Group), Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Duration of overall response, Overall response rate, Overall survival, Safety and Tolerability, Time to progression",False,,15581
4180,82219,"LUN 160, NCT00600015, SCRI LUN 160, SR06-1015, TrialTroveID-082219",A Randomized Double-Blind Placebo-Controlled Phase II Trial of Sorafenib and Erlotinib or Erlotinib Alone in Previously Treated Advanced Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Progression-free survival","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival",True,NCT00600015,15581
4181,82081,"NCT00589550, OSU 06113, OSU-06113, OSU-2007C0088, TrialTroveID-082081",A Phase I Study Of Peginterferon Alfa-2b (PEG-INTRON) With Sorafenib (Nexavar) In Patients With Unresectable Or Metastatic Clear Cell Renal Carcinoma (RCC).,Oncology,Oncology: Renal,"Merck & Co. {Schering-Plough}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00589550,15581
4182,82054,"11559, NCT00586105, TrialTroveID-082054",A Multicenter Uncontrolled Study of Sorafenib in Patients with Unresectable and/or Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Cmin, Safety and Tolerability, Tmax","Complete response, Disease Progression, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT00586105,15581
4183,81956,"12056, NCT00586495, TrialTroveID-081956",Extension Study for BAY43-9006 in Japanese Patients With Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Complete response, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT00586495,15581
4184,81783,"NCT00589420, SANOFI-AVENTIS-UPCC-03806, TrialTroveID-081783, UPCC#03806, UPCC-03806",A Phase II Study of Sorafenib in Combination With Docetaxel in Patients with Androgen-Independent Prostate Cancer,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, University of Pennsylvania, Sanofi {Sanofi-Aventis}","Government, Academic, Industry, Top 20 Pharma","Disease Progression, Overall response rate, PSA progression, Response rate","Adverse Events, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response rate, Stable Disease, Time to progression",True,NCT00589420,15581
4185,81533,"EudraCT Number: 2006-000231-95, IST 10140, TAGUSG6, TrialTroveID-081533",A Phase II Study of BAY 43-9006 in Combination with Weekly Gemcitabine for the Treatment of Metastatic Renal Cell Cancer (RCC) either Unsuitable for or Refractory to Prior Treatment with Cytokines.,Oncology,Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate - duration, Overall survival, Progression-free survival, Quality of Life, Time to response",False,,15581
4186,81418,"AVF3980s, BRE06-109, HOG BRE06-109, NCT00632541, SR06-947, TrialTroveID-081418",A Phase II Study of Combined VEGF Inhibitor (Bevacizumab + Sorafenib) in Patients With Metastatic Breast Cancer: Hoosier Oncology Group BRE06-109,Oncology,Oncology: Breast,"Roche/Genentech {Genentech}, Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Overall response rate, Partial response, Safety and Tolerability, Stable Disease",True,NCT00632541,15581
4187,81184,"07-047, NCT00576056, TrialTroveID-081184, UPMC-07-047","Phase II Trial of Transcatheter Arterial Chemoembolization (TACE) Plus Oral Sorafenib (BAY 43-9006, Nexavar) for Unresectable Hepatocellular Carcinoma (HCC).",Oncology,Oncology: Liver,"Bayer AG, University of Pittsburgh","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors",Overall survival,True,NCT00576056,15581
4188,81094,"H3E-US-I021, LCCC0613, NCT00573690, SRO6-954, TrialTroveID-081094, UNC-LCC-07-0971, UNC-LCCC 0613, UNC-LCCC-0613",A Two Arm Phase I Trial of Sorafenib in Combination With Cisplatin/Etoposide or Carboplatin/ Pemetrexed in Patients With Solid Tumors.,Oncology,"Oncology: CNS, Other; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell","National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Government, Academic",Maximum tolerated dose,"CA-125 Response, Response evaluation criteria in solid tumors",True,NCT00573690,15581
4189,80969,"06025 ION, I06-025, I-06-025, ION 06-025, ION 1-06-025, NCT00607438, TrialTroveID-080969",A Phase II Study of Abraxane and Nexavar in the First-Line Treatment of Locally Advanced or Metastatic Breast Cancer,Oncology,Oncology: Breast,"Bayer AG/Bayer Pharmaceuticals, Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Duration of overall response, Progression-free survival","Overall response rate, Overall survival, Response rate",True,NCT00607438,15581
4190,80953,"0706-05, IUCRO-0171, NCT00572078, TrialTroveID-080953",Phase I Dose-Escalation Drug-Interaction Study of Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors.,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian; Oncology: Prostate,"Roche/Genentech {Genentech}, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Indiana University School of Medicine","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00572078,15581
4191,80478,"DUMC-Pro00001344, MSKCC-08-052, NCT00565968, Pro00001344, TrialTroveID-080478",A Phase I Dose Escalation Trial to Evaluate Safety and Efficacy of Oral Sorafenib (Nexavar) With Regional Melphalan Via Normothermic Isolated Limb Infusion (ILI) in Patients With Intransit Extremity Melanoma.,Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, Duke Comprehensive Cancer Center","Government, Academic","Dose-limiting toxicities, Maximum tolerated dose","Duration of overall response, Overall response rate, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00565968,15581
4192,80407,"AMC-ONCOGI-0701, NCT00565370, TrialTroveID-080407",A Phase I-II Study of Sorafenib (Nexavar) in Combination With Capecitabine and Cisplatin (XP) in Patients With Advanced Gastric Cancer,Oncology,Oncology: Gastric,"(Other Cooperative Group), Asan Medical Center","Cooperative Group, Academic","Dose-limiting toxicities, Progression-free survival","Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00565370,15581
4193,80341,"12347, NCT00562913, TrialTroveID-080341","Phase I Open-Label, Non-Randomized, Non-Placebo Controlled Study to Determine the Safety, Pharmacokinetics, and Tumor Response Profile of Sorafenib as Continuous Dosing in Combination With Cyclophosphamide and Doxorubicin in Patients With Advanced, Refractory Solid Tumors.",Oncology,Oncology: Unspecified Solid Tumor,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00562913,15581
4194,80177,"12438, MCC-15208, NCT00562523, PBAYER004, TrialTroveID-080177",A Phase I Dose Escalation Study With Sorafenib Administered Continuously in Combination With Docetaxel Administered Once Every Three Weeks in Patients With Advanced Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,True,NCT00562523,15581
4195,79776,"12621, NCT00558636, TrialTroveID-079776",A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Lung Cancer, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Stable Disease",True,NCT00558636,15581
4196,79620,"AVJARCC0702, NCT00557830, TrialTroveID-079620",Randomized Phase IIb Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma (RCC),Oncology,Oncology: Renal,"(Other Cooperative Group), Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT00557830,15581
4197,78433,"EudraCT- 2007-000124-41, GBG 45, GBG45 Sofia, NCT00548899, SOFIA, Sofia / GBG 45, TrialTroveID-078433","Phase II Study of Neoadjuvant Epirubicin, Cyclophosphamide (EC) + Sorafenib Followed by Paclitaxel (P) + Sorafenib in Women with Previously Untreated Breast Cancer.",Oncology,Oncology: Breast,"Bayer AG/Bayer Pharmaceuticals, German Breast Group","Industry, Top 20 Pharma, Cooperative Group",Complete response,"Complete response, Overall response rate, Overall survival, Safety and Tolerability",True,NCT00548899,15581
4198,78420,"NCT00647426, TrialTroveID-078420, UPCC 12506",A Phase II Study of Sorafenib in Combination with Carboplatin and Docetaxel in the First Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Abramson Cancer Center at  University of Pennsylvania Medical Center,Academic,"Complete response, Disease Progression, Overall response rate, Partial response, Progressive disease rate, Response rate","Adverse Events, Disease Progression, Emergency room visits, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Serious Adverse Events, Time to progression",True,NCT00647426,15581
4199,78339,"052007-068, BAYER-SCCC-052007-068, NCT00547443, SCCC-03507, SCCC-052007-068, TrialTroveID-078339",A Randomized Phase I/II Study of Sorafenib in Combination with High Dose Chemoradiation in Patients with Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, Simmons Cancer Center, University of Texas Southwest Medical Center","Industry, Top 20 Pharma, Academic, Academic",,"Overall response rate, Progression-free survival, Quality of Life, Safety and Tolerability, Treatment compliance",True,NCT00547443,15581
4200,78103,"NCT00544609, SOGUG 07-01, SOGUG-07-01, TrialTroveID-078103",Phase I Trial of Sorafenib in Combination With Radiotherapy in the Treatment of Invasive Bladder Cancer With Conservative Intent.,Oncology,Oncology: Bladder,Spanish Oncology GenitoUrinary Group,Cooperative Group,"Maximum tolerated dose, Safety and Tolerability",,True,NCT00544609,15581
4201,78049,"2006-0977, NCT00542971, TrialTroveID-078049","Phase I-II Study of Idarubicin, Cytarabine, and Sorafenib (BAY43-9006), an Oral Vascular Endothelial Growth Factor (VEGF), Rapidly Accelerated Fibrosarcoma (RAF) and FMS-like Tyrosine Kinase 3 (FLT3), in Patients With High-risk MDS and AML",Oncology,"Oncology: Leukemia, Acute Myelogenous","MD Anderson Cancer Center, University of Texas, Bayer AG","Academic, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale","Complete response, Disease Progression",True,NCT00542971,15581
4202,78026,"2006-0638, NCI-2012-01552, NCT00543504, TrialTroveID-078026","A Phase I Study of Bevacizumab in Combination With 1) Sunitinib, 2) Sorafenib, 3) Erlotinib and Cetuximab, 4) Trastuzumab and Lapatinib.",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",Safety and Tolerability,True,NCT00543504,15581
4203,77751,"EudraCT: 2007-002176-34, GEIS 14 (2007), GEIS01-07, NCT00541840, TrialTroveID-077751","Phase I-II, Not-Randomized, Multicenter Clinical Trial to Evaluate Safety and Efficacy of Sorafenib (BAY-43-9006) in Combination With Ifosfamide in Soft Tissue Sarcoma.",Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,(Other Cooperative Group),Cooperative Group,"Dose-limiting toxicities, Maximum tolerated dose, Progression-free survival, Safety and Tolerability","Area under the curve score, Cmax, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Tmax",True,NCT00541840,15581
4204,77722,"2007-0352, MDACC 2007-0352, NCT00543335, NCT01636921, TrialTroveID-077722",Phase I/II Trial of Sorafenib With Concurrent Thoracic Radiotherapy for Poor Prognosis Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Complete response, Dose-limiting toxicities, Maximum tolerated dose, Partial response, Progression-free survival, Safety and Tolerability",,True,NCT00543335,15581
4205,77544,"BAYPAN, Brittany # PACA, CPI # 2005-006 BAYPAN, EudraCT: 2006-000240-11, INCA-BAYPAN, INCA-IPC-2005-006, INCA-RECF0426, IPC-2005-006, IPC-BAYPAN, NCT00541021, RECF0426, TrialTroveID-077544","Phase III Randomized, Double-Blind Study Comparing Gemcitabine and Sorafenib or a Placebo in Patients with Locally Advanced or Metastatic Cancer of the Pancreas.",Oncology,Oncology: Pancreas,"(Other Academic Cancer Center), National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals","Academic, Government, Industry, Top 20 Pharma",Progression-free survival,"EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Quality of Life, Response rate",True,NCT00541021,15581
4206,77200,"BRE 112, NCT00544167, SCRI BRE 112, TrialTroveID-077200",A Pilot Study of Adjuvant Doxorubicin and Cyclophosphamide Followed by Paclitaxel Plus Sorafenib in Women With Node Positive or High-Risk Early Stage Breast Cancer.,Oncology,Oncology: Breast,Bayer AG,"Industry, Top 20 Pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability",Overall survival,True,NCT00544167,15581
4207,77121,TrialTroveID-077121,Phase II Study of Sorafenib and Erlotinib in Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell",University of Chicago Medical Center,Academic,,,False,,15581
4208,77069,"MM 14, NCT00536575, SCRI MM 14, TrialTroveID-077069",Phase I/II Trial of Sorafenib and Weekly Bortezomib in the Treatment of Patients With Relapsed or Refractory Multiple Myeloma,Oncology,Oncology: Multiple Myeloma,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Overall response rate, Progression-free survival",,True,NCT00536575,15581
4209,76945,"06-03, NCT00538005, POHA-0603, TrialTroveID-076945","A Phase I/II Trial of Nexavar, Avastin and Eloxatin in Patients With Metastatic Malignant Melanoma",Oncology,Oncology: Melanoma,(Other Cooperative Group),Cooperative Group,"Maximum tolerated dose, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",,True,NCT00538005,15581
4210,76631,"2006-0921, NCT00532064, TrialTroveID-076631",Early Detection of Cardiotoxicity During Sunitinib or Sorafenib Chemotherapy Using Cardiac Biomarkers,Oncology,Oncology: Unspecified Cancer,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government",Brain Natriuretic Peptide concentration,MD Anderson Symptom Inventory,True,NCT00532064,15581
4211,76581,"NCT00532025, SIRN, SIRN-TOM1 KKS 2006-010, TrialTroveID-076581",A Phase II Study to Investigate the Efficacy and Safety of Sorafenib as Adjuvant Treatment Following Resection of Non-Small Cell Lung Carcinoma (NSCLC) in Patients Not Eligible for Cisplatin-Based Adjuvant Chemotherapy.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Progression-free survival, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00532025,15581
4212,75870,"GYN06-111, HOG GYN06-111, HOG GYN-111, NCT00526799, TrialTroveID-075870",A Phase I/II Study of Sorafenib in Combination with Topotecan for the Treatment of Platinum-Resistant Recurrent Ovarian Cancer or Primary Peritoneal Carcinomatosis: Hoosier Oncology Group GYN06-111.,Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Hoosier Cancer Research Network {Hoosier Oncology Group}, Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Industry, Top 20 Pharma","Complete response, Disease Progression, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease","CA-125 Response, Disease Progression - duration, Overall response rate, Progression-free survival, Stable Disease",True,NCT00526799,15581
4213,75748,"04-BRE-41-BP, 07-BRE-41-BP, IRB# 07-0402-F6A, NCT00525161, SR-06-1036, TrialTroveID-075748",A Phase II Study of Adding the Multikinase Inhibitor Sorafenib (Nexavar) to Existing Endocrine Therapy in Patients With Advanced Breast Cancer.,Oncology,Oncology: Breast,"Amgen {Onyx Pharmaceuticals}, Bayer AG, University of Kentucky","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Complete response, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00525161,15581
4214,75526,"MAYO-RC0731, MCCRC RC0731, N063G, NCCTG-N063G, NCT00573755, RC0731, TrialTroveID-075526",Phase II Randomized Study of Sorafenib Compared to Placebo When Administered in Combination With Aromatase Inhibitors for Postmenopausal Women With Metastatic Breast Cancer,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Disease Progression, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Response rate, Time to treatment failure",True,NCT00573755,15581
4215,75442,"07-080, BAYER-MSKCC-07-080, MSKCC-07080, MSKCC-07-080, NCT00522301, TrialTroveID-075442","A Phase II Trial of Oral Sorafenib (Bay43-9006) In Women With Epithelial Ovarian, Fallopian Tube Or Peritoneal Carcinoma In Second Or Greater Remission.",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Bayer AG","Academic, Government, Industry, Top 20 Pharma",Progression-free survival,"Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT00522301,15581
4216,75399,"N054C, NCCTG N054C, NCCTG-N054C, NCI-2009-01177, NCT00826540, TrialTroveID-075399",Phase II Study of Sorafenib/Bevacizumab as Salvage Therapy in Patients with Metastatic Colorectal Cancer.,Oncology,Oncology: Colorectal,"National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Government, Cooperative Group","Overall survival, Progression-free survival","Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT00826540,15581
4217,74824,"03042012, 12444, 64493, BAY 43-9006 / 12444, BAY 43-9006/12444, CTR20132870, EudraCT Number: 2010-018501-10, EudraCT Number: 2012-002053-29, JapicCTI-111537, LBA8, NCRN260, NCT01234337, RESILIENCE, TrialTroveID-074824, UKCRN ID: 10159","A Phase III Randomized, Double Blind, Placebo-controlled Trial Comparing Capecitabine Plus Sorafenib Versus Capecitabine Plus Placebo in the Treatment of Locally Advanced or Metastatic HER2-Negative Breast Cancer (The RESILIENCE Trial).",Oncology,Oncology: Breast,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Karolinska Hospital and Institutet","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-Breast, Hemoglobin level, International normalized ratio, Liver function, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to progression, Visual Analog Scale",True,NCT01234337,15581
4218,74801,"ACTRN12606000140550, AUS1, TrialTroveID-074801","An Open-Label, Non-Comparative Expanded Access Study of the Raf-Kinase Inhibitor Sorafenib as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma",Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, (Other government agency)","Industry, Top 20 Pharma, Government",,,False,,15581
4219,74667,"11988, HIC 0609001825, NCT00606125, TrialTroveID-074667",Phase I Study With Sorafenib in Combination With Carboplatin and Paclitaxel to Evaluate the Safety and Pharmacokinetics of This Combination in Patients With Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,"Yale Comprehensive Cancer Center, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",Safety and Tolerability,Safety and Tolerability,True,NCT00606125,15581
4220,74147,"07026, 8662, NCT00510289, Pro00008151, TrialTroveID-074147",Phase II Trial of Sorafenib in Patients with Myelodysplastic Syndrome.,Oncology,Oncology: Myelodysplastic Syndrome,"Bayer AG/Bayer Pharmaceuticals, Duke University Medical Center","Industry, Top 20 Pharma, Academic","Absolute Neutrophil Count, Complete response, Hematologic Improvement, Hemoglobin level, Partial response, Platelet count","Overall survival, Time to progression",True,NCT00510289,15581
4221,74057,TrialTroveID-074057,A confirmatory study of ascending doses of sorafenib in previously treated renal cancer patients.,Oncology,Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,,,False,,15581
4222,74040,"2006-006454-10, NCT00509613, NL15796.091.06, ONCO 2006-1, TrialTroveID-074040, UMCNONCO 2006_01",Phase l Dose Escalation Study With Sorafenib in Combination With Sirolimus in Patients With Solid Tumor.,Oncology,"Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma","(Other Academic Cancer Center), Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma",Maximum tolerated dose,"Area under the curve score, Cmax, Maximum tolerated dose, Overall response rate, Response rate, Safety and Tolerability, Stable Disease",True,NCT00509613,15581
4223,72979,"NCT00499525, NU 07B1, NU07B1, NU-07B1, NU-STU00000776, ONYX-NU-07B1, STU00000776, TrialTroveID-072979","A Double-Blind, Randomized Phase IIB Study Evaluating the Efficacy and Safety of Sorafenib Compared to Placebo when Administered in Combination with Paclitaxel in Patients with Locally Recurrent or Metastatic Breast Cancer",Oncology,Oncology: Breast,"Amgen, National Institutes of Health/National Cancer Institute, Robert H. Lurie Comprehensive Cancer Center at Northwestern University","Industry, Top 20 Pharma, Government, Academic","Disease Progression, Progression-free survival","Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Time to progression, Treatment Emergent Adverse Events",True,NCT00499525,15581
4224,72712,"EudraCT Number: 2006-003429-95, NCT00496301, SOGUG-02-06, TrialTroveID-072712","Phase II Clinical Trial, Non-Randomized, Multicentre, on the Combination of Gemcitabine, Capecitabine and Sorafenib (Bay 43-9006) in Treatment of Patients With Unresectable and/or Metastatic Renal Cell Carcinoma (RCC)",Oncology,Oncology: Renal,Spanish Oncology GenitoUrinary Group,Cooperative Group,Progression-free survival,"Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT00496301,15581
4225,72501,"2007-0170, 27763, NCT00495872, TrialTroveID-072501",A Multi-Arm Complete Phase I Trial of Valproic Acid-Based 2-Agent Oral Regimens for Patients With Advanced Solid Tumor,Oncology,Oncology: Ovarian; Oncology: Unspecified Solid Tumor,"MD Anderson Cancer Center, University of Texas",Academic,"Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00495872,15581
4226,72212,"2006-0940, NCI-2010-00623, NCT00494182, TrialTroveID-072212",A Phase II Study of Sorafenib in Combination With Carboplatin and Paclitaxel in Metastatic or Recurrent Head and Neck Squamous Cell Cancer,Oncology,Oncology: Head/Neck,"MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Overall response rate, Progression-free survival, Time to progression","Overall response rate, Overall survival, Response rate, Safety and Tolerability",True,NCT00494182,15581
4227,72077,"06-02, NCT00492505, POHA-0602, TrialTroveID-072077","A Phase II Pilot Trial of Sorafenib, Tamoxifen and Cisplatin as Adjuvant Therapy for Patients With Stage III Malignant Melanoma.",Oncology,Oncology: Melanoma,(Other Cooperative Group),Cooperative Group,"Disease-free survival, Overall survival",,True,NCT00492505,15581
4228,72061,"CNS 09, NCT00544817, SC CNS 09, SCRI CNS 09, TrialTroveID-072061",A Phase II Trial of Concurrent Radiation Therapy and Temozolomide Followed by Temozolomide Plus Sorafenib in the First-Line Treatment of Patients With Glioblastoma Multiforme,Oncology,"Oncology: CNS, Glioblastoma",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Progression-free survival,"Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progressive disease rate, Stable Disease",True,NCT00544817,15581
4229,72049,"12414, 2008034, 20080410, 20080597, 2008IS061, 3L-08-2, BAY 43-9006 / 12414, BAY 43-9006/12414, Bay43-9006/12414, Bayer 12414, CTR20131653, DFCI ID: 08-238, EudraCT: 2008-001087-36, JapicCTI-080614, KMUHIRB-97-05-02/1510, NCT00692770, RECF0837, STORM, TrialTroveID-072049","A Phase III Randomized, Double-blind, Placebo-controlled Study of Sorafenib as Adjuvant Treatment for Hepatocellular Carcinoma After Surgical Resection or Local Ablation.",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease-free survival, Recurrence, Resection rate, Response evaluation criteria in solid tumors","Area under the curve score, Disease-free survival, EQ-5D, Functional Assessment of Cancer Therapy-General, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall survival, Quality of Life, Recurrence, Time to response, Visual Analog Scale",True,NCT00692770,15581
4230,71939,"EUDRACT 2007-000758-30, NCT00490685, ONC-2006-004, TrialTroveID-071939","Randomized Continuation, Dose Escalation Trial of Sorafenib in Patients With Advanced HCC With Radiological Progression on Prior Sorafenib Treatment (Phase II Study)",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Progression-free survival,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",True,NCT00490685,15581
4231,71670,TrialTroveID-071670,Circulating endothelial cells and progenitor cells in metastatic renal cell cancer: Predictive value during anti-angiogenic therapy?,Oncology,Oncology: Renal,Institut Gustave Roussy,Academic,Disease-free survival,,False,,15581
4232,71255,"0681, EudraCT Number: 2005-005770-72, GOIRC- 0681, GOIRC Study 0681, RAPSODY, TrialTroveID-071255",Randomized prospective phase II trial of two schedules of sorafenib daily and interferon-a2a (IFN) in metastatic renal cell carcinoma (RAPSODY): GOIRC Study 0681,Oncology,Oncology: Renal,Gruppo Oncologico Italiano di Ricerca Clinica (GOIRC) {Italian Oncology Group for Cancer Research},Cooperative Group,"Overall survival, Progression-free survival, Safety and Tolerability",Overall survival,False,,15581
4233,71135,"Mel 0205, MEL0205, NCT00483301, TrialTroveID-071135","A Phase II Trial of Carboplatin, ABI-007 (Abraxane) And Sorafenib (BAY 43-9006) in Metastatic Melanoma.",Oncology,Oncology: Melanoma,"Mount Sinai Medical Center, NY, Bristol-Myers Squibb/Celgene {Abraxis BioScience {American BioScience/American Pharmaceutical Partners}}, Bayer AG","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Response rate","Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00483301,15581
4234,70982,TrialTroveID-070982,Phase I trial of sorafenib (S) in combination with dacarbazine (DTIC) in patients with advanced metastatic melanoma or other solid tumors.,Oncology,Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Soft Tissue Sarcoma,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4235,70968,"SOGUG 06-01, TrialTroveID-070968",First-line phase II trial of sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma unsuitable for cytokine treatment.,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}},"Industry, Top 20 Pharma",Progression-free survival,"Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate",False,,15581
4236,70940,"NCT00606866, TrialTroveID-070940, UCIRB 12977A","Dynamic contrast enhanced MRI (DCE-MRI) pharmacodynamic (PD) study of sorafenib in metastatic renal cell carcinoma (RCC): A randomized, phase II trial.",Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, University of Chicago Medical Center","Industry, Top 20 Pharma, Academic",Magnetic Resonance Imaging,,True,NCT00606866,15581
4237,70879,"802861, NCT00601783, NCT00654238, TrialTroveID-070879, UPCC 03305, UPCC#03305, UPCC-03305, UPCC-802861",Phase II Study of Sorafenib Tosylate in Patients with Metastatic Thyroid Cancer.,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, University of Pennsylvania","Government, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression","Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00601783,15581
4238,70812,TrialTroveID-070812,Sequential therapy with sorafenib and sunitinib in renal cell carcinoma.,Oncology,Oncology: Renal,University of Minnesota,Academic,,,False,,15581
4239,70806,TrialTroveID-070806,Safety and activity of sorafenib in advanced renal cell cancer: A single institution experience.,Oncology,Oncology: Renal,(Other Academic Cancer Center),Academic,Safety and Tolerability,,False,,15581
4240,70782,TrialTroveID-070782,Effect of sorafenib in symptomatic metastatic medullary thyroid cancer.,Oncology,Oncology: Thyroid,(Other Hospital/Academic/Medical Center),Academic,,,False,,15581
4241,70319,"950914, NCT00464919, TrialTroveID-070319",A Phase II Study of Sorafenib Plus Tegafur/Uracil for the Treatment of Advanced or Metastatic Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"National Taiwan University Hospital, TTY Biopharm","Academic, Industry, all other pharma",Progression-free survival,"Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT00464919,15581
4242,70316,"06-0655-C, NCT00480389, TrialTroveID-070316",Pre-Operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Cytoreductive Nephrectomy.,Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, University Health Network, Toronto","Industry, Top 20 Pharma, Academic","Complete response, Safety and Tolerability, Time to progression",Gene expression profiling,True,NCT00480389,15581
4243,70057,"JFD-12581, NCT00478374, SAK/SASL 25, SASL 25, S-TACE, TrialTroveID-070057",Transarterial Chemoembolization with Doxorubicin in Combination with Systemic Administration of Sorafenib for Patients with Hepatocellular Carcinoma.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability",,True,NCT00478374,15581
4244,70034,"12750, NCT00478114, TrialTroveID-070034","An Open-label, Non-comparative, Treatment Protocol for the Use of BAY 43-9006 (Sorafenib) in Patients with Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Mahidol University, Bangkok","Industry, Top 20 Pharma, Academic","Progression-free survival, Time to progression","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability",True,NCT00478114,15581
4245,69748,"200805760, LS0689, MAYO-07-000710, MAYO-LS0689, NCT00474929, PRMC#: 05-08-01-34, TrialTroveID-069748","A Phase I/II Study of the Raf Kinase/VEGFR Inhibitor Sorafenib in Combination With the mTOR Inhibitor RAD001 (Everolimus) in Patients With Relapsed Non-Hodgkin Lymphoma, Hodgkin Lymphoma, or Multiple Myeloma",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma","University of Iowa, Mayo Clinic","Academic, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Leukocyte count, Maximum tolerated dose, Partial response","Disease Progression, Progression-free survival, Time to progression",True,NCT00474929,15581
4246,69501,"EudraCT Number: 2008-006777-33, GOIM 2705, TrialTroveID-069501",Sorafenib + Cisplatin + Gemcitabine in the Treatment of Advanced hepatocellular Carcinoma: A multicenter Phase I/II Study of the Southern Italy Oncology Group (GOIM),Oncology,Oncology: Liver,Southern Italy Cooperative Oncology Group,Cooperative Group,Time to progression,Safety and Tolerability,False,,15581
4247,69448,"EudraCT Number: 2006-005970-26, KKS / INNERE_A / NSCLC2006, NCT00473486, PECASO, TrialTroveID-069448","A Randomized (PhaseII), Double-Blind, Multicenter Phase I/II Trial of Pemetrexed, Carboplatin Plus or Minus Sorafenib in the First-Line Treatment of Patients With Stage IIIb or IV Non-Small Cell Lung Cancer.",Oncology,"Oncology: Lung, Non-Small Cell","Eli Lilly, Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Progression-free survival, Time to progression","Clinical benefit rate, Dose-limiting toxicities, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Time to progression, Time to response",True,NCT00473486,15581
4248,68932,"EudraCT Number: 2006-006615-80, Matisse study, N0258191009, TrialTroveID-068932",Matisse Study: A Pilot Study in Metastatic Advanced Thyroid Cancer Evaluating the Safety and Efficacy of Sorafenib.,Oncology,Oncology: Thyroid,"Royal Marsden NHS Trust, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Government, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",False,,15581
4249,68926,"6307, FHCRC-6307, NCI-2010-00604, NCT00466752, TrialTroveID-068926, UWCC-06-2996-H/B, UWCC-UW-6307",A Phase II Study of Sorafenib (Nexavar) Prior to Radical Prostatectomy in Patients With High-Risk Localized Prostate Cancer.,Oncology,Oncology: Prostate,"National Institutes of Health/National Cancer Institute, University of Washington","Government, Academic",Complete response,Complete response,True,NCT00466752,15581
4250,68579,"CAN-NCIC-IND186, I186, IND.186, IND186, NCIC CTG IND.186, NCT00516828, TrialTroveID-068579",A Phase I/II Study of Sorafenib (BAY 43-9006) in Combination With Low Dose ARA-C (CYTARABINE) in Elderly Patients With AML or High-Risk MDS.,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome",Canadian Cancer Trials Group {NCIC Clinical Trials Group},Cooperative Group,"Complete response, Dose-limiting toxicities","Overall response rate, Overall survival, Partial response, Time to progression",True,NCT00516828,15581
4251,68348,"3557-07-C, NCT00466232, TrialTroveID-068348",Phase I Study of Weekly Topotecan in Combination With Sorafenib in Treatment of Relapsed Small Cell Lung cancer,Oncology,"Oncology: Lung, Small Cell","Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Stable Disease, Time to progression",True,NCT00466232,15581
4252,67833,"0609001823, CINJ 080804, HIC 0609001823, NCT00461851, TrialTroveID-067833","A Phase II, Multicenter Trial Of Gemcitabine, Carboplatin, And Sorafenib In Chemotherapy-naive Patients With Advanced/Metastatic Bladder Carcinoma",Oncology,Oncology: Bladder,"Bayer AG/Bayer Pharmaceuticals, Yale University","Industry, Top 20 Pharma, Academic","Mortality, Progression-free survival, Time to progression","Partial response, Safety and Tolerability, Safety and Tolerability",True,NCT00461851,15581
4253,67217,"CRC 0639, NCT00456716, TrialTroveID-067217",A Phase II Trial of Sorafenib in BAC or Never-Smokers With Any Lung Adenocarcinoma.,Oncology,"Oncology: Lung, Non-Small Cell","Amgen {Onyx Pharmaceuticals}, Bayer AG, Swedish Cancer Institute","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Overall response rate, Response rate",Progression-free survival,True,NCT00456716,15581
4254,66974,"11497, TrialTroveID-066974",A Phase 1 dose-ranging study of Sorafenib in patients with solid tumors.,Oncology,Oncology: Unspecified Solid Tumor,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4255,66849,"N0626, NCCTG N0626, NCCTG-N0626, NCT00454194, TrialTroveID-066849",Phase II Randomized Study of Pemetrexed With Sorafenib Versus Pemetrexed Alone as Second-Line Therapy in Patients With Advanced Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Cooperative Group, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Time to treatment failure",True,NCT00454194,15581
4256,66650,"ACORN AVAHRPC0607, AVAHRPC0607, NCT00452387, TrialTroveID-066650","Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC).",Oncology,Oncology: Prostate,"(Other Cooperative Group), Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Industry, Top 20 Pharma",Time to progression,"Complete response, Overall survival, Partial response, PSA progression, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00452387,15581
4257,66626,"14636A, NCT00452218, TrialTroveID-066626",Sorafenib Study: Dosing in Patients With Pulmonary Arterial Hypertension (PAH),Cardiovascular,Cardiovascular: Hypertension,"Bayer AG, University of Chicago Medical Center","Industry, Top 20 Pharma, Academic",,Catheterization required,True,NCT00452218,15581
4258,66444,"14908B, NCT00449280, TrialTroveID-066444",A Drug Interaction Study of Sorafenib (BAY 43-9006 Tosylate) and Rapamycin in Patients With Advanced Malignancies.,Oncology,Oncology: Unspecified Solid Tumor,"Bayer AG, University of Chicago Medical Center","Industry, Top 20 Pharma, Academic",,"Overall response rate, Response rate",True,NCT00449280,15581
4259,66335,"12006, Bayer 12006, EudraCT 2006-002688-26, NCT00449033, NExUS, NL14907.003.06, RECF0545, TrialTroveID-066335","A Phase III Randomized, Double-Blind, Placebo Controlled Trial Comparing the Efficacy of Gemcitabine, Cisplatin and Sorafenib to Gemcitabine, Cisplatin and Placebo in First-Line Treatment of Patients With Stage IIIb With Effusion and Stage IV Non-Small Cell Lung Cancer (NSCLC)., , NSCLC research Experience Utilizing Sorafenib (NExUS).",Oncology,"Oncology: Lung, Non-Small Cell","Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall survival, Progression-free survival","Clinical benefit rate, Complete response, Disease Progression - duration, Disease Progression, Duration of overall response, EQ-5D, Functional Assessment of Cancer Therapy-General, Functional Assessment of Cancer Therapy-Lung Cancer, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Visual Analog Scale",True,NCT00449033,15581
4260,65922,TrialTroveID-065922,"Phase I trial to evaluate safety, pharmacokinetics, and efficacy of sorafenib combined with docetaxel in patients with advanced, refractory solid tumors.",Oncology,Oncology: Breast; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate,Bayer AG,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4261,65569,"COMIRB 06-0294, PRMC 06-42, SR05-903, TrialTroveID-065569",Phase II study of sorafenib and pemetrexed after 1st line platinum chemotherapy in advanced stage IIIB malignant effusion or IV non small cell lung cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell",Bayer AG,"Industry, Top 20 Pharma",,,False,,15581
4262,65181,"15002A, 7768, NCI-2009-00221, NCT00436579, TrialTroveID-065181, UCCRC-15002A","A Dose Escalation Study of Sorafenib (BAY 43-9006, NSC 724772) in Normotensive Patients With Advanced Malignancies",Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals","Government, Industry, Top 20 Pharma",,"Parathyroid hormone level, Phosphate level",True,NCT00436579,15581
4263,63960,"NCT00430235, OZM-001, TrialTroveID-063960",A Phase II Study of BAY 43-9006 in Combination With Bicalutamide in Patients With Chemo-Naive Hormone Refractory Prostate Cancer.,Oncology,Oncology: Prostate,British Columbia Cancer Agency,Government,"PSA progression, Stable Disease","Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate - duration, Overall response rate, Overall survival, PSA progression, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to treatment failure",True,NCT00430235,15581
4264,63312,"CST1571BUS260 (0617), NCT00424385, TrialTroveID-063312",Phase I Study Investigating the Safety and Feasibility of Combining Imatinib Mesylate (Gleevec) With Sorafenib in Patients With Androgen-Independent Chemotherapy-Failure Prostate Cancer.,Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose","Complete response, Disease Progression, Partial response, Progressive disease rate, PSA progression, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT00424385,15581
4265,63050,"EudraCT 2007-000290-32, SOLTI0701, SOLTI-0701, TrialTroveID-063050","Phase II randomized, double-blind, placebo-controlled study of nexavar plus capecitabine when compared to capecitabine treatment alone in patients with locally advanced or metastatic breast cancer.",Oncology,Oncology: Breast,"(Other Cooperative Group), Amgen {Onyx Pharmaceuticals}","Cooperative Group, Industry, Top 20 Pharma",Progression-free survival,"Duration of overall response, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Time to progression",False,,15581
4266,63049,"AC01B007, ACORN AC01B07, M10-757, NCT00493636, TrialTroveID-063049, VICCBRE0749","A Double-Blind, Randomized Phase IIb Study of Sorafenib Compared to Placebo When Administered in Combination With Chemotherapy for Patients With Locally Advanced or MBC That Has Progressed During or After Bevacizumab Therapy.",Oncology,Oncology: Breast,"(Other Cooperative Group), Amgen {Onyx Pharmaceuticals}","Cooperative Group, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT00493636,15581
4267,62881,"070058, 07-C-0058, 07-C-0058 N, 100173, 10-C-0173, 7358, NCI-07-C-0058, NCI-P6840, NCT00436215, NCT01176500, TrialTroveID-062881","A Phase II Study of Sorafenib and Bevacizumab in Epithelial Ovarian, Fallopian, and Peritoneal Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Adverse Events, Magnetic Resonance Imaging, Progression-free survival",True,NCT00436215,15581
4268,62463,"CPRL002AUS07, NCI-2011-03199, NCT00418496, OSU-06006, R05- 890, TrialTroveID-062463",A Phase I Study of Bolus High Dose Interleukin-2 With Sorafenib (BAY 43-9006) in Patients With Unresectable or Metastatic Clear Cell Renal Carcinoma (RCC) and Metastatic Melanoma,Oncology,Oncology: Melanoma; Oncology: Renal,"Novartis, Bayer AG/Bayer Pharmaceuticals, Ohio State University","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,"Overall response rate, Progression-free survival, Response rate",True,NCT00418496,15581
4269,62311,"HOG LUN06-107, LUN06-107, NCT00417248, TrialTroveID-062311",A Phase II Trial of Concurrent Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Sorafenib in Patients With Inoperable Stage III Non-Small Cell Lung Cancer (NSCLC): Hoosier Oncology Group LUN06-107,Oncology,"Oncology: Lung, Non-Small Cell","Hoosier Cancer Research Network {Hoosier Oncology Group}, Amgen {Onyx Pharmaceuticals}, Bayer AG, Walther Cancer Institute","Cooperative Group, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Not for Profit Funding Entity","Maximum tolerated dose, Time to progression",Overall survival,True,NCT00417248,15581
4270,62019,"0603, NCT00414388, TrialTroveID-062019",Phase I/II Study to Evaluate the Ability of Sorafenib in Overcoming Resistance to Systemic Chemotherapy in Androgen-Independent Prostate Cancer (AIPC).,Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,"Complete response, Disease Progression, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression",True,NCT00414388,15581
4271,61478,"2005-0823, 2005-0827, BATTLE Program, NCI-2018-01767, NCT00409968, NCT00411671, TrialTroveID-061478",A Phase II Study of Sorafenib (BAY 43-9006) in Chemorefractory Patients With Advanced Non-small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals, US Department of Defense","Academic, Industry, Top 20 Pharma, Government","Overall survival, Progression-free survival","Overall response rate, Overall survival, Time to progression",True,NCT00409968,15581
4272,61095,"2006/31MAY/117, BAY 43-9006/12180, NCT00405210, TrialTroveID-061095, UCL-ONCO 06-001","Open-label, Multicenter,PhaseI Trial in Order To Determine the Safety and Pharmacokinetics of BAY43-9006 in Combination With Docetaxel as First-line Treatment in Metastatic Hormone Refractory Prostate Cancer Patients",Oncology,Oncology: Prostate,(Other Hospital/Academic/Medical Center),Academic,,"Overall response rate - duration, Overall response rate, Progression-free survival, PSA progression, Response rate, Safety and Tolerability",True,NCT00405210,15581
4273,61039,TrialTroveID-061039,Phase II study of Nexavar in combination with aromatase inhibitors for patients with breast cancer.,Oncology,Oncology: Breast,Amgen {Onyx Pharmaceuticals},"Industry, Top 20 Pharma",Progression-free survival,,False,,15581
4274,60996,"EudraCT Number: 2006-004437-15, NCT00406601, ONC-2006-002, TrialTroveID-060996","Phase II Prospective Study With BAY-43-9006 in Advanced, Metastatic Soft Tissue Sarcomas, After Anthracycline-Based Therapy.",Oncology,Oncology: Soft Tissue Sarcoma,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00406601,15581
4275,60870,"LCCC 0603, NCT00405366, PETS funds, SR05-900, TrialTroveID-060870, UNC-LCCC-0603",A Pilot Neoadjuvant Clinical Trial With Evaluation of Molecular Effects With Sorafenib Tosylate for Patients With Stage II or Greater Renal Cell Carcinoma,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Government, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT00405366,15581
4276,59941,TrialTroveID-059941,Study of sorafenib in combination with radiation therapy in head and neck cancer patients.,Oncology,Oncology: Head/Neck,Bayer AG,"Industry, Top 20 Pharma",,,False,,15581
4277,59820,TrialTroveID-059820,"A Phase I study of sorafenib in combination with capecitabine in patients with advanced, solid tumors.",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4278,59749,TrialTroveID-059749,Phase I study of sorafenib in Japanese patients with hepatocellular carcinoma,Oncology,Oncology: Liver,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability",,False,,15581
4279,58781,"11515, NCT00661375, TrialTroveID-058781",Phase II Study of BAY 43-9006 in Japanese Patients With Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Functional Assessment of Cancer Therapy-General, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Plasma concentration, Quality of Life, Response rate, Safety and Tolerability, Time to progression",True,NCT00661375,15581
4280,58739,"CRAD001C2480, GU 44, GU 44 IIT, GU 44 SCRI, GU 44 SCRI IIT, NCT00392821, SCRI GU 44, TrialTroveID-058739",Phase I/II Trial of Sorafenib (Nexavar) and RAD001 (Everolimus)in the Treatment of Patients With Advanced Clear Cell Renal Cell Carcinoma,Oncology,Oncology: Renal,"Novartis, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bayer AG/Bayer Pharmaceuticals","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma",Overall response rate,"Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00392821,15581
4281,58409,"GYN 19, GYN 19 SCRI IIT, NCT00390611, SCRI GYN 19, SR05-918, TrialTroveID-058409",A Randomized Phase II Study of Paclitaxel/Carboplatin With or Without Sorafenib in the First-Line Treatment of Patients With Stage III/IV Epithelial Ovarian Cancer,Oncology,Oncology: Ovarian,"Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00390611,15581
4282,58391,"IRB 2006C0050, NCI-2009-00196, NCI-7609, NCT00390325, NCT01645631, OSU-06054, TrialTroveID-058391",Phase II Study of Sorafenib (BAY 43-9006) in Patients With Metastatic Medullary Thyroid Carcinoma.,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, Richard J. Solove Research Institute, Arthur G. James Cancer Hospital","Government, Academic, Academic","Magnetic Resonance Imaging, Overall response rate","Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging",True,NCT00390325,15581
4283,57792,"7200, CTRC-05-25, CTRC-056-5011-233, NCI-7200, NCT00387751, TrialTroveID-057792","A Phase II, Pharmacokinetic (PK), Pharmacodynamic (PD) and Biological Correlative Study of the Efficacy and Safety of Dual Antiangiogenic Inhibition Using Bevacizumab and Sorafenib in Patients With Advanced Malignant Melanoma",Oncology,Oncology: Melanoma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Partial response, Progressive disease rate, Stable Disease","Common Terminology Criteria for Adverse Events, Overall survival, Plasma concentration, Progression-free survival, Progressive disease rate, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00387751,15581
4284,56877,"1_20071106_118, ACRIN 6676, ACRIN Protocol 6676, BEST, CDR0000499788, CTSU E2804, CTSU/E2804, CTSU/ECOG E2804, E2804, E2804/ACRIN 6676, ECOG E2804, ECOG2804 /08-201, ECOG-E2804, ECOGUROE2804, NCI-2009-00533, NCT00378703, TrialTroveID-056877, UIC 2008-0149","The BeST Trial: A Randomized Phase II Study of VEGF, RAF Kinase, and mTOR Combination Targeted Therapy (CTT) With Bevacizumab, Sorafenib and Temsirolimus in Advanced Renal Cell Carcinoma",Oncology,Oncology: Renal,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Disease Progression, Progression-free survival","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease",True,NCT00378703,15581
4285,56406,"0607-09, IUCRO-0155, NCT00375310, TrialTroveID-056406",Phase I Study of Gemcitabine With Novel RAF Kinase-Vascular Endothelial Growth Factor Receptor Inhibitor Sorafenib (BAY 43-9006) and Radiotherapy in Patients With Locally Advanced Unresectable Pancreatic Adenocarcinoma.,Oncology,Oncology: Pancreas,"Amgen {Onyx Pharmaceuticals}, Indiana University School of Medicine","Industry, Top 20 Pharma, Academic","Safety and Tolerability, Safety and Tolerability","Maximum tolerated dose, Overall response rate, Overall survival, Response rate, Time to progression",True,NCT00375310,15581
4286,55950,"03-0194-05, 4988, e4988, NCT00445042, SorafenibRCC-01, Sorafenib-RCC-01, SU-01082008-966, TrialTroveID-055950",A Phase II Study of Sorafenib in Patients With Metastatic Renal Cell Carcinoma,Oncology,Oncology: Renal,"Amgen {Onyx Pharmaceuticals}, Bayer AG, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Response evaluation criteria in solid tumors,"Overall response rate, Overall survival, Time to progression",True,NCT00445042,15581
4287,55197,"11804, NCT00119639, TrialTroveID-055197","A Study to Evaluate the Effect of Renal Function on the Single-Dose Pharmacokinetics of Sorafenib (BAY 43-9006, Nexavar).",Oncology,Oncology: Unspecified Cancer,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,Safety and Tolerability,True,NCT00119639,15581
4288,53456,"05061, 13572A, 5U-05-2, B.05.010, NCI-2009-00068, NCI-6569, NCT00238121, PHII-72, PHL 043, PHL.043, PHL-043, TrialTroveID-053456, UCCRC-13572A, UOC 13572",A Phase II Study of BAY 43-9006 in Advanced/Recurrent Uterine Carcinoma/Carcinosarcoma.,Oncology,Oncology: Soft Tissue Sarcoma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Complete response, Duration of overall response, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00238121,15581
4289,53214,"12178, BAY43-9006/12178, NCT00352859, PROGRESS, TrialTroveID-053214",A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients with Advanced Renal Cell Carcinoma,Oncology,Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Progression-free survival,"Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to response",True,NCT00352859,15581
4290,53124,"11956, 2005-0818, NCT00533585, NCT01069328, TrialTroveID-053124","Phase I Dose-Escalating, Open-Label, Non-Placebo Controlled Study of BAY 43-9006 (Sorafenib) in Combination With Carboplatin, Paclitaxel and Bevacizumab in Previously Untreated Patients With Stage IIIB (With Malignant Pleural Effusions) or Stage IV Non-Small Cell Lung Cancer (NSCLC).",Oncology,"Oncology: Lung, Non-Small Cell","MD Anderson Cancer Center, University of Texas, Bayer AG/Bayer Pharmaceuticals","Academic, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,True,NCT00533585,15581
4291,51846,"060233, 06-C-0233, 16-225, 2006CG033, 69896, 97147, AAAC0593, ADVL 0413, ADVL0413, CDR0000483040, COG ADVL0413, COG-ADVL0413, DFCI ID: 06-166, HICCC AAAC0593, HUM00008401, NCI-06-C-0233, NCT00343694, NCT01445080, NCT01648413, SOL-06122-C, SU-06222010-6386, TrialTroveID-051846","A Phase I/II Study of the Raf Kinase and Receptor Tyrosine Kinase Inhibitor Sorafenib (BAY 43-9006, NSC# 724772) in Children With Refractory Solid Tumors or Refractory Leukemias",Oncology,"Oncology: (N/A); Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Liver; Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Area under the curve score, Cmax, Dose-limiting toxicities, Elimination half-life, Maximum tolerated dose, Treatment Emergent Adverse Events, Volume of distribution","Complete response, Magnetic Resonance Imaging, Maximum tolerated dose, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT00343694,15581
4292,51382,"06604, 802514, NCT00602576, SPRI-UPCC-06604, TrialTroveID-051382",Randomized Phase II Study Comparing Two Schedules of Temozolomide in Combination with BAY 43-9006 in Patients with Advanced Melanoma.,Oncology,Oncology: Melanoma,"Merck & Co. {Schering-Plough}, National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, University of Pennsylvania","Industry, Top 20 Pharma, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Progression-free survival, Stable Disease, Time to progression","Overall response rate - duration, Overall response rate, Overall survival, Response rate",True,NCT00602576,15581
4293,50799,"AML-Sorafenib-Study, EudraCT Number: 2005-005966-35, KKS/INNERE_A/AML2006, LN_SAL_2006_211, NCT00373373, ORPHA86786, Study 240, TrialTroveID-050799","A Double-Blind, Placebo-Controlled, Randomized, Multi-Center Phase II Trial to Assess the Efficacy of Sorafenib Added to Standard Primary Therapy in Elderly Patients With Newly Diagnosed AML.",Oncology,"Oncology: Leukemia, Acute Myelogenous","Bayer AG/Bayer Pharmaceuticals, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic",Event-free survival,"Complete response, Event-free survival, Minimal Residual Disease, Overall survival",True,NCT00373373,15581
4294,50732,"11721, BAY43-9006/11721, JapicCTI-132062, JapicCTI-R130321, NCT00494299, TrialTroveID-050732",Phase III Study of BAY43-9006 in Patients With Advanced Hepatocellular Carcinoma (HCC) Treated After Transcatheter Arterial Chemoembolization (TACE),Oncology,Oncology: Liver,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Yakuhin","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progression-free survival, Recurrence, Time to progression",Overall survival,True,NCT00494299,15581
4295,50682,"TrialTroveID-050682, UCIRB-13016","A Pharmacokinetic, Pharmacodynamic and Pharmacogenetic Study of Sorafenib (BAY-43-9006 Tosylate) and Blood Pressure Elevation in Patients with Advanced Malignancies",Oncology,Oncology: Renal; Oncology: Unspecified Solid Tumor,(Other Academic Cancer Center),Academic,"Plasma concentration, Progressive disease rate",,False,,15581
4296,50208,"MCC 15044, NABTT 0502, NABTT-0502, NCT00445588, TrialTroveID-050208",A Phase II Trial of Erlotinib (OSI-774) and Sorafenib (BAY 43-9006) for Patients with Progression or Recurrent Glioblastoma Multiforme.,Oncology,"Oncology: CNS, Glioblastoma","National Institutes of Health/National Cancer Institute, Adult Brain Tumor Consortium {New Approaches to Brain Tumor Therapy}","Government, Cooperative Group",Overall survival,"Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT00445588,15581
4297,50108,"05-033, 6948, DFCI-05033, NCI Protocol 6948, NCI-6948, NCT00330421, TrialTroveID-050108","A Phase II Clinical and Correlative Study of BAY43-9006 (Sorafenib) IND 69,896 in Sarcoma",Oncology,Oncology: Osteosarcoma; Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute","Government, Academic","Adverse Events, Leukocyte count, Response evaluation criteria in solid tumors",,True,NCT00330421,15581
4298,50047,"1720, MA-14, MSKCC 07-124, N0572, NCCTG-N0572, NCI-2009-00652, NCT00329719, OP-06-0724, TrialTroveID-050047",A Phase I/II Trial of Sorafenib and CCI-779 in Patients With Recurrent Glioblastoma.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Soft Tissue Sarcoma","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute, Alliance for Clinical Trials in Oncology","Cooperative Group, Government, Cooperative Group","Maximum tolerated dose, Progression-free survival, Safety and Tolerability","Disease Progression, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00329719,15581
4299,49656,"060164, 06-C-0164, 7416, NCI-06-C-0164, NCI-7416, NCI-P6821, NCT00326495, NCT00343772, TrialTroveID-049656",A Phase II Study of BAY 43-9006 (Sorafenib) in Combination With Cetuximab (Erbitux ) in EGFR Expressing Metastatic Colorectal Cancer (CRC),Oncology,Oncology: Colorectal,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease","Adverse Events, Magnetic Resonance Imaging, Progression-free survival",True,NCT00326495,15581
4300,49634,"BAY-EC1, TrialTroveID-049634",A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).,Oncology,Oncology: Head/Neck,"University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Bayer AG","Academic, Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4301,49398,TrialTroveID-049398,A Phase II study of Sorafenib (BAY 43-9006) in patients with recurrent and/or metastatic head and neck squamous cell carcinoma (HNSCC) and nasopharyngeal cancer (NPC).,Oncology,Oncology: Head/Neck,Bayer AG,"Industry, Top 20 Pharma","Adverse Events, Safety and Tolerability, Stable Disease, Time to progression",,False,,15581
4302,48411,"2005-0215, 7149, CDR0000480157, MDA-2005-0215, NCI-7149, NCT00349206, NCT01851408, TrialTroveID-048411",A Phase I/II Study of the Combination of BAY43-9006 (Sorafenib) and CCI-779 (Temsirolimus) in Patients With Metastatic Melanoma.,Oncology,Oncology: Melanoma,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Cmax, Overall survival, Plasma concentration, Progression-free survival, Safety and Tolerability, Tmax",True,NCT00349206,15581
4303,47574,"HUM00006937, NCT00329641, S0512, SWOG S0512, SWOG-S0512, TrialTroveID-047574",Phase II Trial of BAY 43-9006 (SORAFENIB; NSC-724772) in Combination With Carboplatin and Paclitaxel in Patients With Metastatic Uveal Melanoma,Oncology,Oncology: Melanoma,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Partial response, Response rate","Adverse Events, Disease Progression, Overall survival, Progression-free survival",True,NCT00329641,15581
4304,46219,"14194B, GCC 0619, NCI-7071, NCT00303966, TrialTroveID-046219, UCCRC-14194B",A Phase II Study of BAY 43-9006 in Relapsed Chronic Lymphocytic Leukemia,Oncology,"Oncology: Leukemia, Chronic Lymphocytic","National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Time to progression",,True,NCT00303966,15581
4305,46061,"NCI-7296, NCT00301847, TrialTroveID-046061, UCCRC-14227",A Phase II Study of Sorafenib (BAY 43-9006) in Metastatic Renal Cell Cancer to the Brain.,Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"National Institutes of Health/National Cancer Institute, University of Chicago Medical Center","Government, Academic","Overall response rate, Response evaluation criteria in solid tumors, Response rate","NCI-CTC scale, Safety and Tolerability",True,NCT00301847,15581
4306,45835,"ISRCTN62522358, NTR577, TrialTroveID-045835",A single center open-label uncontrolled study to investigate the prostate specific antigen (PSA) and tumor vascularization response rate of neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable prostate cancer.,Oncology,Oncology: Prostate,Academic Medical Center Amsterdam,Academic,"Magnetic Resonance Imaging, Overall response rate, Response rate","Adverse Events, Serious Adverse Events",False,,15581
4307,44971,"ISRCTN46317673, TrialTroveID-044971",A single center open-label uncontrolled study to investigate tumor response and vascularization changes in neoadjuvant therapy with BAY 43-9006 single agent therapy in patients with operable renal cell cancer.,Oncology,Oncology: Renal,Academic Medical Center Amsterdam,Academic,,"Adverse Events, Serious Adverse Events",False,,15581
4308,44083,"05-004028, 7082, MAYO-IRB-05-004028, MAYO-MC0511, MC0511, MC0511, NCI-2009-00124, NCI-7082, NCT00303797, TrialTroveID-044083",A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Multiple Myeloma; Oncology: Pancreas; Oncology: Renal; Oncology: Unspecified Hematological Cancer",National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Magnetic Resonance Imaging, Maximum tolerated dose, Overall response rate","Disease Progression - duration, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall response rate - duration, Overall response rate, Response evaluation criteria in solid tumors",True,NCT00303797,15581
4309,43690,"0508 GCC, GCC 0508, MSGCC-0508, MSGCC-H27040-0508, NCI-7058, NCT00278382, TrialTroveID-043690",A Phase II Study of BAY 43-9006 (IND 69896) in Chemosensitive Relapsed Aggressive Non-Hodgkinâs Lymphomas.,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","National Institutes of Health/National Cancer Institute, University of Maryland Greenebaum Cancer Center","Government, Academic","Overall response rate, Partial response","Overall survival, Time to progression",True,NCT00278382,15581
4310,43433,"ACRIN 6675, COH-06037, HCI 25699, NCT00281957, S0438, SWOG-S0438, TrialTroveID-043433",A Randomized Phase II Trial of BAY 43-9006 (SORAFENIB; NSC-724772) With Either CCI-779 (TEMSIROLIMUS; NSC-683864) or R115777 (TIPIFARNIB: NSC-702818) in Metastatic Melanoma,Oncology,Oncology: Melanoma,"Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Cooperative Group, Government","Overall response rate, Overall survival, Progression-free survival, Response rate","Adverse Events, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT00281957,15581
4311,41133,"13780A, 7028, MSKCC-06-028, NCI-2009-00116, NCI-7028, NCT00265798, PHII-66, TrialTroveID-041133, UCCRC-13780A, UCIRB 13780",A Phase II Study of BAY 43-9006 for Imatinib- and Sunitinib-Resistant Malignant Gastrointestinal Stromal Tumor,Oncology,Oncology: GIST,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00265798,15581
4312,41063,"11961, BAY43-9006/11961, ESCAPE, EudraCT 2005-005245-19, HCI 18468, NCT00300885, TrialTroveID-041063","A Randomized Controlled Trial Comparing Safety and Efficacy of Carboplatin and Paclitaxel Plus or Minus Sorafenib (BAY 43-9006) in Chemonaive Patients With Stage IIIB-IV Non-Small Cell Lung Cancer (NSCLC). , , Evaluation of Sorafenib, Carboplatin And Paclitaxel Efficacy in NSCLC (ESCAPE).",Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall survival,"Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Lung Cancer, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Stable Disease",True,NCT00300885,15581
4313,41059,"ACTRN12609000048280, CRUK/06/004, CTA 00316/0222/001-0001, EORTC 30072, EU-20734, EU-20867, EudaCT Number: 2006-006079-19, ISRCTN38934710, MRC-RE05-SORCE, MRC-RE05-TRANSORCE, MREC NÂ°07/MRE01/10, N0264192974, NCT00492258, NCT00900536, NL24110.091.08, PAS in SORCE, RE05, RE-05, RE05/SORCE, RECF1325, SORCE, SORCE BHOC 535, TRANSORCE, TrialTroveID-041059, UKCRN-1753",SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse,Oncology,Oncology: Renal,"(Other Cooperative Group), Medical Research Council, National Institutes of Health/National Cancer Institute, Cancer Research UK, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, (Other Hospital/Academic/Medical Center)","Cooperative Group, Government, Government, Not for Profit Funding Entity, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic",Disease-free survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Cost effectiveness, Metastasis-free survival, Overall survival",True,NCT00492258,15581
4314,41057,"12848, 97243, ASSURE, CALGB-E2805, CAN-NCIC-E2805, CTSU E2805, CTSU/E2805, E2805, ECOG 2805, ECOG-ACRIN 2805, ECOG-ACRIN E2805, ECOGE2805, ECOG-E2805, ECOGUROE2805, HCI 19793, NCI-2009-00534, NCT00326898, REC2, SU-07232007-560, SWOG-E2805, TrialTroveID-041057",ASSURE: Adjuvant Sorafenib or Sunitinib for Unfavorable Renal Carcinoma,Oncology,Oncology: Renal,"Cancer and Leukemia Group B (CALGB), Canadian Cancer Trials Group {NCIC Clinical Trials Group}, Southwest Oncology Group, National Institutes of Health/National Cancer Institute, Pfizer, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, Alliance for Clinical Trials in Oncology, ECOG-ACRIN Cancer Research Group","Cooperative Group, Cooperative Group, Cooperative Group, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Disease-free survival, FACIT-Fatigue, Overall survival, Recurrence","Common Terminology Criteria for Adverse Events, Congestive heart failure, Disease-free survival, FACIT-Fatigue, Overall survival, Patient-Reported Outcomes Measurement Information System, Quality of Life, Recurrence, Safety and Tolerability",True,NCT00326898,15581
4315,40727,"05172, 100561, NCT00259129, TrialTroveID-040727",Effect of BAY 43-9006 (Sorafenib) on Cardiovascular Safety Parameters in Cancer Patients.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Mesothelioma; Oncology: Osteosarcoma; Oncology: Prostate; Oncology: Renal; Oncology: Thyroid","Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Cardiac Telemetry, Heart rate, Safety and Tolerability","Adverse Events, Cardiac Telemetry, Heart rate, Safety and Tolerability",True,NCT00259129,15581
4316,40065,"E1804, ECOG-E1804, ECOGUROE1804, NCT00112905, SU-11082007-849, TrialTroveID-040065",Phase II Trial of Sorafenib (BAY43-9006) (IND 69896; NSC 724772) in Patients With Advanced Urothelial Cancer.,Oncology,Oncology: Bladder; Oncology: Renal,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Overall survival, Progression-free survival, Response rate","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Time to progression",True,NCT00112905,15581
4317,39821,"7146, CTRC-IDD-0512, NCI-7146, NCT00255658, TrialTroveID-039821","Phase I, Pharmacokinetic and Pharmacodynamic Study of BAY 43-9006 (Sorafenib) in Combination With CCI-779 (Temsirolimus) in Advanced Solid Malignancies.",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, Cancer Therapy & Research Center San Antonio, Texas","Government, Academic","Maximum tolerated dose, Safety and Tolerability",,True,NCT00255658,15581
4318,39763,TrialTroveID-039763,Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma.,Oncology,Oncology: Melanoma; Oncology: Renal,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Duration of overall response, Overall survival, Progression-free survival",False,,15581
4319,39520,"IRB# H-25647, NCT00253578, S0434, SWOG S0434, SWOG-S0434, TrialTroveID-039520",A Phase II Trial of BAY 43-9006 (Sorafenib) (NSC-724772) in Patients With Relapsing or Resistant Multiple Myeloma,Oncology,Oncology: Multiple Myeloma,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Overall survival, Progression-free survival",,True,NCT00253578,15581
4320,39432,"DMH.06.030, E5203, ECOG E5203, ECOG-E5203, NCI-2012-02951, NCT00253370, TrialTroveID-039432",A Phase II Study to Evaluate Overall Response Rate of BAY 43-9006 (Sorafenib) Combined With Docetaxel and Cisplatin or Oxaliplatin in the Treatment of Metastatic or Advanced Unresectable Gastric and Gastroesophageal Junction (GEJ) Adenocarcinoma,Oncology,Oncology: Esophageal; Oncology: Gastric,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Disease Progression, Overall survival, Progression-free survival",True,NCT00253370,15581
4321,38287,"05-0181A(2), 05-081, 100943, 2006-040, CTEP-7060, HUM00001243, MSKCC 1705, MSKCC Protocol 05-081, MSKCC-05081, NCI-2012-01469, NCI-7060, NCT00245102, TrialTroveID-038287, UCCRC-14266, UMCC 2005.090",A Multicenter Phase II Study of Sorafenib (BAY43-9006) in Non-GIST Sarcomas.,Oncology,Oncology: Soft Tissue Sarcoma,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Overall survival, Progression-free survival, Stable Disease",True,NCT00245102,15581
4322,37616,"NCT00238212, S0514, SWOG-S0514, TrialTroveID-037616",Phase II Study of BAY 43-9006 as Single Agent in Unresectable or Metastatic Gallbladder Carcinoma and Cholangiocarcinoma,Oncology,Oncology: Liver,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Partial response","Overall survival, Progression-free survival, Time to progression, Time to treatment failure",True,NCT00238212,15581
4323,37081,"7037, CASE5304, CASE-5304, NCI 7037, NCI-2009-00118, NCI-7037, NCT00126568, TrialTroveID-037081",Phase II Trial of BAY 43-9006 in Patients With Advanced Anaplastic Carcinoma of the Thyroid,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, Case Western Reserve University","Government, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Adverse Events, Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00126568,15581
4324,36720,"2004-0702, MDA-2004-0702, NCI-6742, NCT00217646, Ph I BAY-43-9006, TrialTroveID-036720","Phase I Study of BAY 43-9006 (NSC 724772) in Patients With Acute Leukemias, Myelodysplastic Syndromes and Chronic Myeloid Leukemia in Blast Phase.",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Dose-limiting toxicities, Maximum tolerated dose",,True,NCT00217646,15581
4325,36598,"CTSU S0505, NCT00217620, S0505, SWOG S0505, SWOGS0505, SWOG-S0505, TrialTroveID-036598",Phase II Trial of BAY-9006 (NSC #724772) in Advanced Soft Tissue Sarcomas.,Oncology,Oncology: Soft Tissue Sarcoma,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Partial response, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival",True,NCT00217620,15581
4326,36412,"04-251, GUMC-2004-251, HIC 0708002990, NCI-6584, NCT00217399, TrialTroveID-036412",A Phase I/II Trial of BAY-43-9006 (Sorafenib) in Combination With Anastrozole in Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, Lombardi Cancer Center at Georgetown University Medical Center","Government, Academic","Clinical benefit rate, Complete response, Magnetic Resonance Imaging, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events",True,NCT00217399,15581
4327,35893,"NCT00199160, TrialTroveID-035893",Phase II trial evaluating the efficacy and the biological activity of BAY 43-9006 in patients with recurrent and/or metastatic head and neck cancer.,Oncology,Oncology: Head/Neck,(Other Academic Cancer Center),Academic,"Overall response rate, Response rate",,True,NCT00199160,15581
4328,35834,"NCT00182689, S0435, SWOGS0435, SWOG-S0435, TrialTroveID-035834",A Phase II Trial of BAY 43-9006 (NSC-724772) in Patients With Platinum-Treated Extensive Stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell","Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Overall survival",True,NCT00182689,15581
4329,34878,"11849, BAY43-9006/11849, NCT00492752, TrialTroveID-034878","A Randomized, Double-Blinded, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Overall survival,"Area under the curve score, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Tmax",True,NCT00492752,15581
4330,34026,"05/MRE04/75, 11941, ARCCS, BAY43-9006/11941, EU ARCCS, EudraCT 2005-002524-34, N0258171354, NCT00492986, TrialTroveID-034026","An Open-Label, Non-Comparative, Phase III Study of the Raf-Kinase Inhibitor BAY 43-9006 as a Subsequent to First-Line Therapy in Patients with Advanced Renal Cell Carcinoma., , European Advanced Renal Cell Carcinoma Sorafenib (EU-ARCCS).",Oncology,Oncology: Renal,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals {Bayer HealthCare {Bayer Schering Pharma {Schering AG}}}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Safety and Tolerability,,True,NCT00492986,15581
4331,32883,"07-0571, 6996, J04104, JHOC-05012408, JHOC-J04104, NCI-6996, NCT00134069, TrialTroveID-032883, UCHSC-07-0571","Phase I/II Clinical, Pharmacological, and Biological Study of BAY 43-9006 in Combination with Cetuximab and Irinotecan in Patients with Advanced Colorectal Cancer.",Oncology,Oncology: Colorectal,"National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}, University of Colorado","Government, Academic, Academic","Common Terminology Criteria for Adverse Events, Response evaluation criteria in solid tumors",,True,NCT00134069,15581
4332,32682,"05-02-23-01, 6745, J0509, JHOC-J-0509, NCI-6745, NCT00131989, P30CA006973, TrialTroveID-032682, U01CA070095",Phase I Dose Escalation Trial of the Raf Kinase Inhibitor BAY 43-9006 (NSC #724772) as Single Agent for Adults With Relapsed and Refractory Acute Leukemias and Chronic Myeloid Leukemia in Blast Crisis.,Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Myelogenous","National Institutes of Health/National Cancer Institute, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins {Johns Hopkins Oncology Center}","Government, Academic",Maximum tolerated dose,Adverse Events,True,NCT00131989,15581
4333,32674,"DMH.06-022, ECOG-E1404, NCI-2014-00658, NCT00131937, TrialTroveID-032674",A Phase II Study of Sorafenib (BAY 43-9006) in Recurrent Aggressive Non-Hodgkin's Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival",True,NCT00131937,15581
4334,31845,"04MRE04/92, 11538, BAY43-9006/11538, EudraCT Number: 2004-000725-30, N0258156394, NCT00492297, TrialTroveID-031845","A Phase II, Multi-center, Open-label, Uncontrolled Study to Evaluate the Efficacy and Safety of BAY 43-9006 Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma.",Oncology,Oncology: Melanoma,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response-duration, Complete response, Disease Progression - duration, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to progression, Time to response",True,NCT00492297,15581
4335,31746,"NCI-7178, NCT00126620, PHL.042, PMH-PHL-042, TrialTroveID-031746",A Phase I Study of BAY 43-9006 (Sorafenib) in Combination With OSI-774 (Erlotinib; Tarceva) in Advanced Solid Tumors.,Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Ovarian; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}, Bayer AG/Bayer Pharmaceuticals, University Health Network, Toronto","Government, Academic, Industry, Top 20 Pharma, Academic",Maximum tolerated dose,Safety and Tolerability,True,NCT00126620,15581
4336,31740,"2004-0526, 6629, MDA-2004-0526, NCI-2012-02910, NCI-6629, NCT00126594, TrialTroveID-031740",A Phase II Clinical Trial to Evaluate the Efficacy of BAY 43-9006 With or Without Low Dose Interferon in Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Complete response, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall survival, Progression-free survival, Stable Disease",True,NCT00126594,15581
4337,31724,"2004-0516, 6630, MDA-2004-0516, NCI-6630, NCT00126659, TrialTroveID-031724",A Phase II Neoadjuvant Clinical Trial to Evaluate the Efficacy of BAY 43-9006 (Sorafenib) in Metastatic Renal Cell Carcinoma.,Oncology,Oncology: Renal,"MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease","Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall survival, Partial response, Time to progression",True,NCT00126659,15581
4338,31703,"6555, DFCI-04393, NCI-6555, NCT00126503, TrialTroveID-031703, U01CA099177, VICCURO0470, VICC-URO-0470",A Phase I/II Trial of BAY 43-9006 in Combination with Bevacizumab in Patients with Advanced Renal Cancer.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Vanderbilt-Ingram Cancer Center, Amgen {Onyx Pharmaceuticals}, Bayer AG","Government, Academic, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Absolute Neutrophil Count, Complete response, Dose-limiting toxicities, Maximum tolerated dose, NCI-CTC scale, Overall response rate - duration, Overall response rate, Partial response, Platelet count, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Time to progression","Magnetic Resonance Imaging, Overall survival, Plasma concentration, Progression-free survival",True,NCT00126503,15581
4339,31689,"2004CG075, CALGB 30307, CALGB-30307, NCT00107432, TrialTroveID-031689","A Phase II Study of BAY 43-9006 (NSC #724772, IND #69896) in Patients With Malignant Mesothelioma.",Oncology,Oncology: Mesothelioma,"Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Partial response, Response rate","Overall survival, Progression-free survival",True,NCT00107432,15581
4340,31246,"6972, GCC 0458, NCI-6972, NCT00121264, TrialTroveID-031246, WSU-C-2890","A Phase I Dose-Escalation Study of Intravenous 17-Allylaminogeldanamycin (17-AAG) [NSC 330507, IND 57, 966] and Oral Bay 43-9006 [NSC 724772, IND # 69,896] Administered in Patients With Pretreated Advanced Solid Tumors.",Oncology,Oncology: (N/A); Oncology: Colorectal; Oncology: Head/Neck; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal; Oncology: Thyroid,"Barbara Ann Karmanos Cancer Institute, National Institutes of Health/National Cancer Institute","Academic, Government","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","CA-125 Response, Magnetic Resonance Imaging, Response evaluation criteria in solid tumors",True,NCT00121264,15581
4341,31245,"0501007709, 6981, AAAC0224, AECM-0501007709, NCI 6981, NCI-2009-00108, NCI-6981, NCT00121251, NYWCCC-0501007709, TrialTroveID-031245",A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma.,Oncology,Oncology: Renal,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response evaluation criteria in solid tumors, Response rate","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00121251,15581
4342,30966,"6617, NCI-6617, NCT00119249, NYU 04-38, NYWCCC-NYU-0438, TrialTroveID-030966",A Phase II Study of BAY 43-9006 (NSC 724772) in Unresectable Stage III and Stage IV Melanoma,Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, Weill Cornell Cancer Center at Cornell University","Government, Academic","Complete response, Overall response rate, Response evaluation criteria in solid tumors, Response rate",Time to progression,True,NCT00119249,15581
4343,30826,"C60301, CALGB-60301, MSKCC 05-056, NCT00118170, TrialTroveID-030826, UCIRB 13567","Pharmacokinetic and Phase I Study of Sorafenib (BAY 43-9006, NSC 724772, IND 69896) for Solid Tumors and Hematologic Malignancies in Patients With Hepatic or Renal Dysfunction",Oncology,"Oncology: Lymphoma, Non-Hodgkin's; Oncology: Multiple Myeloma; Oncology: Unspecified Solid Tumor","Cancer and Leukemia Group B (CALGB), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Area under the curve score, Common Terminology Criteria for Adverse Events, Creatinine kinase level, Dose-limiting toxicities, Maximum tolerated dose, Renal dysfunction, Safety and Tolerability",,True,NCT00118170,15581
4344,30756,"11848, BAY43-9006/11848, EudraCT Number: 2005-000544-86, N0258161829, NCT00117637, TrialTroveID-030756","A Randomised, Open-label, Multi-centre Phase II Study of BAY43-9006 (Sorafenib) Versus Standard Treatment With Interferon Alpha-2a in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Amgen {Onyx Pharmaceuticals}, Bayer AG/Bayer Vital GmbH","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to progression, Time to response, Treatment Satisfaction Questionnaire for Medication",True,NCT00117637,15581
4345,30696,"05069, 11547, BAY43-9006/11547, NCT00110344, TrialTroveID-030696",A Phase II Study of BAY 43-9006 Prior to and Following Nephrectomy in Patients with Metastatic Renal Cell Carcinoma. In the neoadjuvant setting.,Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Gene expression profiling, Magnetic Resonance Imaging, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Safety and Tolerability, Stable Disease, Time to response",True,NCT00110344,15581
4346,30368,"C-II-001/2, TrialTroveID-030368",Phase II Study of First Line Sorafenib (BAY 43-9006) in Patients with Locally Advanced and/or Metastatic Pancreatic Cancer - A Study of the Central European Society for Anticancer Drug Research - EWIV (CESAR).,Oncology,Oncology: Pancreas,"Central European Society for Anticancer Drug Research, Bayer AG/Bayer Vital GmbH","Not for Profit Funding Entity, Industry, Top 20 Pharma",Time to progression,"NCI-CTC scale, Overall survival, Safety and Tolerability",False,,15581
4347,29841,"3P-04-2, 6576, CCC-PHII-50, NCI-6576, NCT00114244, PHII-50 NCI#6576, TrialTroveID-029841",A Randomized Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Metastatic Pancreatic Carcinoma,Oncology,Oncology: Pancreas,"National Institutes of Health/National Cancer Institute, California Cancer Consortium","Government, Academic","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00114244,15581
4348,29235,"7062, NCI-2012-03095, NCI-7062, NCT00112671, PHL-036, PMH-PHL-036, TrialTroveID-029235","A Phase II Study of BAY 43-9006 in Advanced or Metastatic Urothelial Cancer (Transitional Cell Cancer of the Bladder, Ureter and Renal Pelvis)",Oncology,Oncology: Bladder; Oncology: Renal,"National Institutes of Health/National Cancer Institute, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}","Government, Academic","Complete response, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression - duration, Progression-free survival, Time to progression",True,NCT00112671,15581
4349,28862,TrialTroveID-028862,"Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal",Bayer AG,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,False,,15581
4350,28617,TrialTroveID-028617,"Phase I study of BAY 43-9006 (sorafenib), a Raf kinase and VEGFR inhibitor, combined with irinotecan (CPT-11) in advanced solid tumors",Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: Ovarian; Oncology: Pancreas,Bayer AG,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4351,28585,TrialTroveID-028585,"Phase I/II, pharmacokinetic and pharmacodynamic trial of BAY 43-9006 alone in patients with metastatic melanoma.",Oncology,Oncology: Melanoma,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Magnetic Resonance Imaging,,False,,15581
4352,28580,TrialTroveID-028580,Pharmacodynamic study of BAY 43-9006 in patients with metastatic renal cell carcinoma.,Oncology,Oncology: Renal,Bayer AG,"Industry, Top 20 Pharma",Magnetic Resonance Imaging,,False,,15581
4353,28573,TrialTroveID-028573,"Phase I and Pharmacokinetic Study of Sorafenib, an Oral Multikinase Inhibitor, in Japanese Patients with Advanced Refractory Solid Tumors.",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal",Bayer AG/Bayer Yakuhin,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Elimination half-life, Nausea, Platelet count, Response evaluation criteria in solid tumors, Tmax, Vomiting","Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",False,,15581
4354,28548,"11868, ARCCS, BAY43-9006/11868, DHMC F0527, IRB# 05-030, NCT00111020, TrialTroveID-028548, UCSC 051212, Yale 0506000138","Open Label, Non-Comparative Treatment Protocol for the use of Sorafenib in Patients with Advanced Renal Cell Carcinoma.",Oncology,Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Response evaluation criteria in solid tumors, Safety and Tolerability",,True,NCT00111020,15581
4355,28540,"04-153, 11715, BAY43-9006/11715, NCT00110994, Onyx 11715, TrialTroveID-028540",Phase II Randomized Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination with Dacarbazine (DTIC) in Subjects with Unresectable Stage III or Stage IV Melanoma,Oncology,Oncology: Melanoma,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Complete response, Disease Progression, Duration of overall response, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression, Visual Analog Scale",True,NCT00110994,15581
4356,28336,"05/MRE02/31, 05-112, 11718, 343-05, ACTRN12605000684628, BAY43-9006/11718, BAYER-UVACC-ONYX-11718, Brown 343-05, EudraCT Number: 2005-000941-12, N0123176488, N0258166456, NCT00111007, NCT00262912, PRISM, SLEH 2594, TrialTroveID-028336, UHL9879, UHL9879 Onyx Melanoma, UVACC-HIC-11860, UVACC-ONYX-11718, VICCMEL0519","Phase III Randomized, Placebo Controlled Study of Sorafenib in Repeated Cycles of 21 Days in Combination With Paclitaxel/Carboplatin Chemotherapy in Subjects With Unresectable Stage III or Stage IV Melanoma",Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, University of Virginia","Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Complete response, Disease Progression, Duration of overall response, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression",True,NCT00111007,15581
4357,27991,"05173, CTSU E2603, CTSU ECOG 2603, CTSU/E2603, E2603, E2603T1, ECOGE2603, ECOG-E2603, ECOG-E2603T1, ECOGMELE2603, HUM00000836, NCI-2012-02978, NCT00110019, NCT01209299, SU-11092007-862, SWOG-E2603, TrialTroveID-027991","A Double-Blind, Randomized, Placebo-Controlled Phase III Trial of Carboplatin, Paclitaxel and Sorafenib Versus Carboplatin, Paclitaxel and Placebo in Patients With Unresectable Locally Advanced or Stage IV Melanoma",Oncology,Oncology: Melanoma,"Eastern Cooperative Oncology Group (ECOG), Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Cooperative Group, Government","Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT00110019,15581
4358,27194,"05-115, 11546, 20050158, 2005IS021, BAY43-9006/11546, EudraCT 2004-001770-40, NCT00108953, TrialTroveID-027194",A Randomized Controlled Study of BAY43-9006 in Combination With Doxorubicin Versus Doxorubicin in Patients With Advanced Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Time to progression","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to response",True,NCT00108953,15581
4359,25725,TrialTroveID-025725,"An open-label, non-randomized, one-way crossover study of ketoconazole, a potent CYP3A inhibitor,effect on BAY 43-9006 pharmacokinetics",Oncology,Oncology: Unspecified Cancer,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",,,False,,15581
4360,25673,TrialTroveID-025673,A phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer.,Oncology,Oncology: Liver,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4361,25636,TrialTroveID-025636,a phase I combination trial of BAY 43-9006 with oxaliplatin in patients with colorectal cancer,Oncology,Oncology: Colorectal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4362,25459,TrialTroveID-025459,Phase I trial of BAY 43-9006 in combination with 5-fluorouracil (5-FU) and leucovorin (LCV) in patients with advanced refractory solid tumors.,Oncology,Oncology: Colorectal; Oncology: Pancreas,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4363,25133,"100554, ACTRN12605000644662, BAY43-9006/100554, CRC 04100CRC, EudraCT Number: 2004-001773-26, HCC 100554, NCT00105443, SHARP, TrialTroveID-025133","A Phase III Randomized, Placebo-Controlled Study of Sorafenib in Patients With Advanced Hepatocellular Carcinoma. , , Sorafenib HCC Assessment Randomized Protocol (SHARP) trial.",Oncology,Oncology: Liver,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall survival, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Functional Assessment of Cancer Therapy-Hepatobiliary Cancer, Gene expression profiling, Overall response rate - duration, Overall response rate - time, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to progression, Time to response",True,NCT00105443,15581
4364,24781,"NCI-6608, NCT00095693, OSU-0441, OSU-2004C0068, TrialTroveID-024781",Phase II Study of BAY 43-9006 in Patients With Metastatic Thyroid Carcinoma.,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, Richard J. Solove Research Institute, Arthur G. James Cancer Hospital","Government, Academic, Academic",Overall response rate,Magnetic Resonance Imaging,True,NCT00095693,15581
4365,24779,"100557, BAY43-9006/100557, NCT00101413, TrialTroveID-024779",A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Patients With Relapsed or Refractory Advanced Non-small Cell Lung Carcinoma,Oncology,"Oncology: Lung, Non-Small Cell","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Clinical benefit rate, Disease Progression - duration, Duration of overall response, Functional Assessment of Cancer Therapy-Lung Cancer, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Stable Disease, Time to progression, Time to response",True,NCT00101413,15581
4366,22842,TrialTroveID-022842,A phase I study of BAY 43-9006 in combination with dacarbazine for metastatic melanoma.,Oncology,Oncology: Melanoma,"Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Maximum tolerated dose, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability",,False,,15581
4367,22409,"100555, BAY43-9006/100555, NCT00101400, TrialTroveID-022409",A Phase II Multicenter Uncontrolled Trial of BAY43-9006 in Subjects With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate - time, Overall response rate, Stable Disease, Time to progression, Time to response",True,NCT00101400,15581
4368,22354,"NCT00101114, S0412, SWOG-S0412, TrialTroveID-022354","A Phase II Study of the RAF-Kinase Inhibitor BAY 43-9006 (NSC0724772, IND 69,896) in Combination With Interferon-a2B in Patients With Advanced Renal Cancer.",Oncology,Oncology: Renal,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Response evaluation criteria in solid tumors, Response rate",,True,NCT00101114,15581
4369,20711,"N0326, NCCTG-N0326, NCT00098540, TrialTroveID-020711",Phase II Study of the Raf Kinase Inhibitor BAY43-9006 in Patients With Advanced Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Response rate","Overall survival, Progression-free survival, Time to progression",True,NCT00098540,15581
4370,20696,"050049, 05-C-0049, 6654, NCI-05-C-0049, NCI-6654, NCI-P6272, NCT00098254, NCT00100763, TrialTroveID-020696",Phase II Study of Bay 43-9006 (Sorafenib) With Evaluation of RAS Signal Pathway in Patients With Relapsed Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Stable Disease","Clinical benefit rate, Complete response, Magnetic Resonance Imaging, Overall survival, Partial response, Progression-free survival, Stable Disease, Time to progression",True,NCT00098254,15581
4371,20691,"DUMC 04140, DUMC-6258-04-9R0, NCI-6553, NCT00098618, TrialTroveID-020691",A Phase II Study Of BAY 43-9006 In Combination With Interferon Alfa-2b In Metastatic Renal Cell Cancer.,Oncology,Oncology: Renal,"National Institutes of Health/National Cancer Institute, Duke Comprehensive Cancer Center","Government, Academic","Complete response, Overall response rate, Partial response, Response rate","Duration of overall response, Overall survival, Progression-free survival",True,NCT00098618,15581
4372,19548,"6557, CASE 2804, CASE2804, CASE-2804, CASE-CWRU-2804, CWRU-CASE-2804, MCC#14889, NCI-2009-00067, NCI-6557, NCT00096200, TrialTroveID-019548","A Phase II Trial Of BAY 43-9006, A Novel Raf Kinase Inhibitor Plus Paclitaxel/Carboplatin In Women With Recurrent Platinum Sensitive Epithelial Ovarian, Peritoneal Or Fallopian Tube Cancer",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to progression","Overall survival, Progression-free survival",True,NCT00096200,15581
4373,19454,"13169, NCI-6567, NCT00095966, PA-7092, TrialTroveID-019454, UCCRC-13169B",A Phase II Study of BAY 43-9006/Gemcitabine for Advanced Pancreatic Cancer.,Oncology,Oncology: Pancreas,"National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate","Overall survival, Progression-free survival, Time to progression",True,NCT00095966,15581
4374,19428,"6565, NCI-6565, NCT00096395, PHL-025, PMH-PHL-025, TrialTroveID-019428",A Phase II Study of BAY 43-9006 in Combination With Gemcitabine in Recurrent Epithelial Ovarian Cancer.,Oncology,Oncology: (N/A); Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, University Health Network, Toronto/Princess Margaret Cancer Centre {Princess Margaret Hospital}","Government, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","CA-125 Response, Overall response rate - duration, Overall survival, Stable Disease, Time to progression",True,NCT00096395,15581
4375,19396,"N0336, NCCTG-N0336, NCT00096434, TrialTroveID-019396",Phase II Trial of Raf Kinase Inhibitor BAY 43-9006 as Single Agent in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and/or Taxane.,Oncology,Oncology: Breast,"North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Partial response,,True,NCT00096434,15581
4376,19389,"NCT00096512, S0420, SWOG-S0420, TrialTroveID-019389",Phase II Evaluation of BAY 43-9006 (NSC-724772) in Patients With Recurrent or Metastatic Head and Neck Cancer,Oncology,Oncology: Head/Neck,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate",,True,NCT00096512,15581
4377,16899,"050022, 05-C-0022, 6750, NCI-05-C-0022, NCI-6750, NCT00095459, NCT00098592, TrialTroveID-016899",A Phase I Trial of BAY 43-9006 (Sorafenib) and Bevacizumab in Refractory Solid Tumors with Biologic and Proteomic Analysis.,Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","National Institutes of Health/National Cancer Institute, Center for Cancer Research, Warren G Magnuson Clinical Center, National Institutes of Health","Government, Academic, Government, Government","Maximum tolerated dose, Safety and Tolerability",Magnetic Resonance Imaging,True,NCT00095459,15581
4378,15957,"CAN-NCIC-IND.167, I167, NCT00093457, TrialTroveID-015957","A Phase II Study Of BAY 43-9006 (NSC 724772; CTEP IND# 69,896) In Patients With Hormone Refractory Prostate Cancer.",Oncology,Oncology: Prostate,"Canadian Cancer Trials Group {NCIC Clinical Trials Group}, National Institutes of Health/National Cancer Institute, National Cancer Institute of Canada","Cooperative Group, Government, Government","Disease Progression, PSA progression","Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Time to treatment failure",True,NCT00093457,15581
4379,15313,"14106, CCF IRB 7749, Emory IRB 0040-2005, JHOC-NABTT-0401, N0401, NABTT 0401, NCT00093613, TrialTroveID-015313",A Phase I Trial of BAY 43-9006 for Patients With Recurrent or Progressive Malignant Glioma.,Oncology,"Oncology: CNS, Glioblastoma; Oncology: CNS, Other","National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Adult Brain Tumor Consortium {New Approaches to Brain Tumor Therapy}","Government, Industry, Top 20 Pharma, Cooperative Group","Maximum tolerated dose, Overall survival",,True,NCT00093613,15581
4380,15298,"102347, GOG 0170F, GOG-0170F, NCT00093626, TrialTroveID-015298","A Phase II Evaluation of BAY 43-9006 (NCI-Supplied Agent, NSC #724722, IND #69,896) in the Treatment of Persistent or Recurrent Epithelial Ovarian or Primary Peritoneal Carcinoma.",Oncology,Oncology: (N/A); Oncology: Ovarian,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Adverse Events, Common Terminology Criteria for Adverse Events, Progression-free survival","Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival",True,NCT00093626,15581
4381,14550,"C-II-001/1, TrialTroveID-014550",Phase II study of Sorafenib (BAY 43-9006) in hormone-refractory patients with prostate cancer: A study of the Central European Society for Anticancer Drug Research--EWIV (CESAR).,Oncology,Oncology: Prostate,"Amgen {Onyx Pharmaceuticals}, Bayer AG, Central European Society for Anticancer Drug Research","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Not for Profit Funding Entity",Progression-free survival,"Common Terminology Criteria for Adverse Events, NCI-CTC scale, Safety and Tolerability",False,,15581
4382,14276,TrialTroveID-014276,Phase I pharmacokinetic and pharmacodynamic study of the raf kinase inhibitor BAY 43-9006 in patients with solid tumors,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell",Bayer AG,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose",,False,,15581
4383,14044,"040262, 04-C-0262, NCI-04-C-0262, NCI-6594, NCT00090545, NCT00093431, TrialTroveID-014044","A Phase II Study of BAY 43-9006 (Sorafenib) in Metastatic, Androgen-Independent Prostate Cancer.",Oncology,Oncology: Prostate,National Institutes of Health/National Cancer Institute,Government,Progression-free survival,"Adverse Events, Overall survival, Time to progression",True,NCT00090545,15581
4384,13411,TrialTroveID-013411,A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC).,Oncology,"Oncology: Lung, Non-Small Cell","Amgen {Onyx Pharmaceuticals}, Bayer AG","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability",,False,,15581
4385,10221,TrialTroveID-010221,A phase I/II trial of BAY 43-9006 and gemcitabine in advanced solid tumors and in advanced pancreatic cancer.,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability","Overall response rate, Response rate",False,,15581
4386,10220,TrialTroveID-010220,Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors.,Oncology,Oncology: Colorectal; Oncology: Gastric; Oncology: Melanoma; Oncology: Renal,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4387,10219,TrialTroveID-010219,Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with refractory solid tumors.,Oncology,"Oncology: (N/A); Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Renal",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4388,10215,TrialTroveID-010215,"Phase I/II trial of BAY 43-9006, carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma.",Oncology,Oncology: Melanoma,Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma",Safety and Tolerability,,False,,15581
4389,10214,TrialTroveID-010214,Pharmacodynamic study of the raf kinase inhibitor BAY 43-9006: Mechanisms of hypertension.,Oncology,Oncology: Unspecified Cancer,University of Pennsylvania,Academic,,,False,,15581
4390,9739,"10941, BAYER-10941, NCT00085007, NCT00661180, ORACLE, TrialTroveID-009739, UCLA-0312018-01",Open Label Multi-Centric Phase II Study of the Raf Kinase Inhibitor BAY 43-9006 in Chronic Myelogenous Leukemia (CML) Patients Resistant to Gleevec (Imatinib),Oncology,"Oncology: Leukemia, Chronic Myelogenous","Jonsson Comprehensive Cancer Center, UCLA, National Institutes of Health/National Cancer Institute, Bayer AG","Academic, Government, Industry, Top 20 Pharma","Complete response, Overall response rate, Response rate, Safety and Tolerability","Complete response, Cytogenetic response, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT00085007,15581
4391,9090,"I141, NCIC IND.141, TrialTroveID-009090",Phase I trial of BAY 43-9006 in acute myelogenous leukemia (AML) and myelodysplastic syndrome (MDS).,Oncology,"Oncology: Leukemia, Acute Myelogenous; Oncology: Myelodysplastic Syndrome","Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}, National Cancer Institute of Canada","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government","Maximum tolerated dose, Overall response rate",,False,,15581
4392,5909,TrialTroveID-005909,Phase I study of the Raf-1 kinase inhibitor BAY 43-9006 in patients with advanced refractory solid tumors.,Oncology,Oncology: (N/A); Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Head/Neck; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Maximum tolerated dose, Safety and Tolerability",,False,,15581
4393,5908,TrialTroveID-005908,Sorafenib combined with carboplatin/paclitaxel for advanced non-small cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",Bayer AG/Bayer Pharmaceuticals,"Industry, Top 20 Pharma","Adverse Events, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression",,False,,15581
4394,5705,"100874, 10874, BAY 43-9006/10874-HOPE, BAY43-9006/10874, BAYER-10874, MSKCC-02105, NCT00044512, NCT00048919, NCT00058383, TrialTroveID-005705",A Phase II Multicenter Uncontrolled Trial of Sorafenib (BAY43-9006) in Patients With Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Academic, Government, Industry, Top 20 Pharma, Industry, Top 20 Pharma","Complete response, Partial response","Disease Progression - duration, Duration of overall response, Overall survival, Progressive disease rate, Time to progression, Time to response",True,NCT00044512,15581
4395,4160,"000834, 11213, ACTRN12605000643673, BAY43-9006/11213, N0258171420, NCT00073307, TARGET, TrialTroveID-004160","A Phase III Randomized Study of BAY43-9006 in Patients With Unresectable and/or Metastatic Renal Cell Cancer., , Treatment Approaches in Renal cancer Global Evaluation Trial (TARGETs).",Oncology,Oncology: Metastatic Cancer; Oncology: Renal,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Functional Assessment of Cancer Therapy-General, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease",True,NCT00073307,15581
4396,2262,"E-2501, ECOG-E2501, ECOG-E2501T2, ECOGTHOE2501, NCT00064350, NCT01124669, TrialTroveID-002262",A Double Blind Phase II Study of BAY 43-9006 in Patients With Non-Small Cell Lung Cancer Who Have Failed at Least Two Prior Chemotherapy Regimens.,Oncology,"Oncology: Lung, Non-Small Cell","Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute, Bayer AG/Bayer Pharmaceuticals","Cooperative Group, Government, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Disease Progression, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00064350,15581
4397,1186,"100391, BAY43-9006/100391, NCT00044499, NCT00079612, TrialTroveID-001186",Randomized Discontinuation Study of BAY 43-9006 in Patients With Advanced Refractory Cancer.,Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: GIST; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid,"Bayer AG/Bayer Pharmaceuticals, Amgen {Onyx Pharmaceuticals}","Industry, Top 20 Pharma, Industry, Top 20 Pharma",Stable Disease,"Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Stable Disease, Time to progression",True,NCT00044499,15581
4398,398118,TrialTroveID-398118,A Phase I Study of Ampligen in Combination with Checkpoint Inhibitors for the Treatment of Pancreatic Cancer,Oncology,Oncology: Pancreas,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4399,396134,"AMP-COV-100, CHDR2049, TrialTroveID-396134","A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Activity of Repeated Intranasal Administration of Ampligen (Poly I:Poly C12U) in Healthy Subjects.",Infectious Disease,"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19)",AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",Safety and Tolerability,,False,,924
4400,386394,"AMP-511, TrialTroveID-386394",An Expanded Access Program to evalaute Ampligen for Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and SARS-CoV-2 Patients,Infectious Disease,"Infectious Disease: (N/A); Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19)",AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4401,374547,TrialTroveID-374547,A Clinical Trial to Evaluate Ampligen for the Treatment of COVID-19 infection,Infectious Disease,"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19)",(Other government agency),Government,,,False,,924
4402,373956,"I 659920, NCI-2020-02317, NCT04379518, TrialTroveID-373956",Phase 1/2A Study of Rintatolimod and IFN-Alpha Regimen in Cancer Patients With Mild or Moderate COVID-19 Infection,Infectious Disease,"Infectious Disease: Novel coronavirus (2019-nCoV, COVID-19)","National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute, AIM ImmunoTech {Hemispherx Biopharma}","Government, Academic, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability","C reactive protein, Hospitalization rate, Mortality",True,NCT04379518,924
4403,348140,TrialTroveID-348140,A Phase II Study of Ampligen in Combination with Checkpoint Inhibitors in Patients with Advanced Pancreatic Cancer,Oncology,Oncology: Pancreas,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4404,348037,TrialTroveID-348037,A Study of Ampligen in Combination with Pembrolizumab as First-line Therapy for Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4405,336401,"HCC 18-087, NCT03734692, TrialTroveID-336401",Systemic Immune Checkpoint Blockade and Intraperitoneal Chemo-Immunotherapy in Recurrent Ovarian Cancer,Oncology,Oncology: Ovarian,"AIM ImmunoTech {Hemispherx Biopharma}, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, all other pharma, Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03734692,924
4406,325448,TrialTroveID-325448,"A Phase I/II Study of Ampligen in Combination with Checkpoint Inhibitors in Patients with Advanced Urothelial Carcinoma, Renal Cell Carcinoma and Melanoma",Oncology,Oncology: Bladder; Oncology: Melanoma; Oncology: Renal,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4407,294356,TrialTroveID-294356,An Early Access Program of Rintatolimod in Patients with Chronic Fatigue Syndrome and Pancreatic Cancer,Oncology,Oncology: (N/A); Oncology: Pancreas,"AIM ImmunoTech {Hemispherx Biopharma}, (Other government agency)","Industry, all other pharma, Government",Disease Progression,,False,,924
4408,268871,"15-023, NCI-2016-00923, NCT02615574, TrialTroveID-268871, UPCI 15-023","A Phase II Study of Type-1 Polarized Dendritic Cell (alpha DC1) Vaccine in Combination With Tumor-Selective Chemokine Modulation (Interferon-alpha 2b, Rintatolimod, and Celecoxib) in Subjects With Chemo-Refractory Metastatic Colorectal Cance",Oncology,Oncology: Colorectal,University of Pittsburgh,Academic,Overall survival,"Overall response rate, Progression-free survival",True,NCT02615574,924
4409,256838,"11-128, NCI-2015-00800, NCT02432378, TrialTroveID-256838, UPCI 11-128","A Phase I/II Neoadjuvant Dose Finding, Safety, and Immunologic Efficacy Trial of Intensive Locoregional Chemoimmunotherapy for Recurrent Ovarian Cancer and Tumor-Specific Intranodal Autologous Alpha-DC1 Vaccines",Oncology,Oncology: Ovarian,"National Institutes of Health/National Cancer Institute, Roswell Park Cancer Institute, AIM ImmunoTech {Hemispherx Biopharma}, University of Pittsburgh","Government, Academic, Industry, all other pharma, Academic","Adverse Events, Immune Response, Maximum tolerated dose, Safety and Tolerability","CA-125 Response, Immune Response, Overall survival, Progression-free survival",True,NCT02432378,924
4410,235291,"AMP 516, NCT00215800","A Multi-center, Double-blind, Randomized, Placebo-controlled Study of the Safety and Efficacy of Poly I:Poly C12U (Ampligen??) 400 mg IV Twice Weekly Versus Placebo in Patients With Severely Debilitating Chronic Fatigue Syndrome (CFS)/Myalgic Encephalomyelitis (ME)",,NA: ClinicalTrials.gov,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",Safety and Tolerability,,True,NCT00215800,924
4411,223793,"073A, AMP-700, NCT00002269","A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen",,NA: ClinicalTrials.gov,HEM Research,ClinicalTrials.gov,,,True,NCT00002269,924
4412,223298,"11030, ACTG 056, NCT00001000",Immunologic Effect After Single Dose Atvogen in Healthy Volunteers and Asymptomatic HIV-Infected Patients,,NA: ClinicalTrials.gov,National Institute of Allergy and Infectious Diseases (NIAID),ClinicalTrials.gov,Mortality,,True,NCT00001000,924
4413,223112,"11028, ACTG 054, NCT00000735",A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC,,NA: ClinicalTrials.gov,National Institute of Allergy and Infectious Diseases (NIAID),ClinicalTrials.gov,"Appetite, Nausea, Safety and Tolerability",,True,NCT00000735,924
4414,223091,"11014, ACTG 038, NCT00000713","A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects",,NA: ClinicalTrials.gov,National Institute of Allergy and Infectious Diseases (NIAID),ClinicalTrials.gov,"Appetite, Nausea, Safety and Tolerability",,True,NCT00000713,924
4415,150128,"AMP-600, NCT01591473, TrialTroveID-150128","A Phase I/II, Two-Staged, Single-Center, Randomized, Double-Blind, Antibody Titer Study to Assess Immunogenicity and Safety of FluMist Intranasal Influenza Vaccine Administered With and Without a TLR-3 Agonist, Ampligen",Infectious Disease; Vaccines (Infectious Disease),Infectious Disease: Respiratory Infections; Vaccines (Infectious Disease): Influenza Vaccines,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma","Adverse Events, Immunogenicity at 28 days, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Immunogenicity (other timeframe), Immunogenicity at 28 days",True,NCT01591473,924
4416,146636,"133, 7425, 7425/133, NCI-2011-00658, NCT01355393, TrialTroveID-146636",Phase I-II Study of HER2 Vaccination With Poly(I)* Poly(C12U) (Ampligen) as an Adjuvant in Optimally Treated Breast Cancer Patients,Oncology,Oncology: Breast,"National Institutes of Health/National Cancer Institute, University of Washington, AIM ImmunoTech {Hemispherx Biopharma}","Government, Academic, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Immune Response, Safety and Tolerability","Disease-free survival, Overall survival",True,NCT01355393,924
4417,127217,TrialTroveID-127217,A phase II study of Ampligen in the treatment of seriously ill hospitalized influenza patients.,Infectious Disease,Infectious Disease: Respiratory Infections,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4418,125256,TrialTroveID-125256,A Proof-Of-Concept Study Of Oregovomab In Combination With A TLR-3 Agonist In The Maintenance Setting For The Treatment Of Advanced Ovarian Cancer Patients Following Front-Line Chemotherapy.,Oncology,Oncology: Ovarian,"AIM ImmunoTech {Hemispherx Biopharma}, Quest Pharmatech {Altachem Pharma}","Industry, all other pharma, Industry, all other pharma",Immune Response,,False,,924
4419,81178,TrialTroveID-081178,Phase II trial of Ampligen and a seasonal influenza vaccine.,Infectious Disease; Vaccines (Infectious Disease),Infectious Disease: Respiratory Infections; Vaccines (Infectious Disease): Influenza Vaccines,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4420,49446,"ACTRN12609000083291, TrialTroveID-049446","A Randomized, Double-blind, Placebo-controlled Study of the Dosaging of an Immunostimulant in Conjunction with Influenza Vaccination (Stage I), with a Nine Month (Stage II) Observation Period Evaluating the Duration of the Immunologic Response",Infectious Disease; Vaccines (Infectious Disease),Infectious Disease: Respiratory Infections; Vaccines (Infectious Disease): Influenza Vaccines,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma","Adverse Events, Immunogenicity (other timeframe), Safety and Tolerability, Seroconversion","Adverse Events, Cardiac Telemetry, Safety and Tolerability",False,,924
4421,47367,TrialTroveID-047367,Phase II study of Ampligen to treat patients with metastatic renal cell carcinoma.,Oncology,Oncology: Renal,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4422,47366,TrialTroveID-047366,Phase II study of Ampligen to treat patients with metastatic melanoma.,Oncology,Oncology: Melanoma,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4423,44769,"EXOSOMES2, M0054185429, N0678172323, TrialTroveID-044769",EXOSOMES2 - vaccination with autologous ovarian cancer ascites derived exosomes in combination with systemic adjuvant treatment with poly I: poly C12U (AMPLIGEN): A phase I/II clinical study in patients with advanced ovarian cancer.,Oncology,Oncology: Ovarian,Velindre NHS Trust,Government,Immune Response,Progression-free survival,False,,924
4424,21960,TrialTroveID-021960,A phase II pilot study of Ampligen in HIV-1 patients with or without HCV co-infection.,Infectious Disease,Infectious Disease: HIV,"AIM ImmunoTech {Hemispherx Biopharma}, Esteve","Industry, all other pharma, Industry, all other pharma",,,False,,924
4425,16809,TrialTroveID-016809,A phase II clinical trial of Ampligen for the treatment of Hepatitis B.,Infectious Disease,Infectious Disease: HBV,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4426,13148,TrialTroveID-013148,A Phase III study of Ampligen to treat HIV in China.,Infectious Disease,Infectious Disease: HIV,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,,False,,924
4427,12636,"AMP 720, AMP720, NCT00035893, TrialTroveID-012636","The Role of Ampligen in Strategic Therapeutic Intervention (STI) of Highly Active Anti-Retroviral Therapy (HAART) : A Multi-Center, Randomized, Controlled Study of Ampligen Potentiation of the HAART-Free Interval",Infectious Disease,Infectious Disease: HIV,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,"Quality of Life, Safety and Tolerability",True,NCT00035893,924
4428,12272,"AMP 719, AMP719, NCT00035581, TrialTroveID-012272","A multicenter, randomized control study of the Biological Actions of Ampligen as an Adjunct to HAART in HIV Disease.",Infectious Disease,Infectious Disease: HIV,AIM ImmunoTech {Hemispherx Biopharma},"Industry, all other pharma",,"Quality of Life, Safety and Tolerability",True,NCT00035581,924
4429,312332,"TrialTroveID-312332, VINTREX",A Phase I Exploratory Trial Of Combined Treatment With Pemetrexed And Vinflunine in Patients With Metastatic Urothelial Cell Carcinoma After Prior Platinum-Containing Chemotherapy,Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability",,False,,19074
4430,283355,"DRKS00011168, EudraCT Number: 2016-000081-33, JaNEO, JaNEO-001, NCT02845050, TrialTroveID-283355",Phase Ib/II Study Assessing the Neo-adjuvant Combination Therapy of Vinflunine With Cisplatin Followed by Radical Cystectomy in Patients With Muscle-invasive Bladder Cancer (JaNEO),Oncology,Oncology: Bladder,(Other Industry Sponsor),"Industry, all other pharma","Complete response, Safety and Tolerability","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of hospitalization, EORTC Quality of Life Questionnaire, Hospital readmission, Overall response rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT02845050,19074
4431,265022,"EudraCT Number: 2014-005396-82, IRAS ID:193989, Jasint-2, L00070 IN312 P1, L00070IN312P1, TrialTroveID-265022",Randomized Phase III Study Comparing Vinflunine-Gemcitabine And Gemcitabine-Carboplatin Combinations In Patients Ineligible To Cisplatin With Advanced Or Metastatic Urothelial Carcinoma.(Jasint-2),Oncology,Oncology: Bladder,Pierre Fabre,"Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Stable Disease, Time to treatment failure",False,,19074
4432,257535,TrialTroveID-257535,Phase I dose-finding and pharmacokinetic study of IV vinflunine in combination with methotrexate in patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) previously treated with platinum-based chemotherapy.,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,,,False,,19074
4433,250913,TrialTroveID-250913,The First Slovak Experience with Second line Vinflunine in Advanced Urothelial Carcinomas,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,19074
4434,232048,"13/LO/0822, CCR3858, CRUK/12/021, EudraCT Number: 2012-002592-34, ICR-CTSU/2012/10036, NCT02057913, TrialTroveID-232048, VinCaP",A Phase II Trial of Vinflunine Chemotherapy in Locally-advanced and Metastatic Carcinoma of the Penis,Oncology,Oncology: Penile,"Institute of Cancer Research - UK, (Other Hospital/Academic/Medical Center)","Academic, Academic","Overall response rate, Stable Disease","Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Serious Adverse Events, Treatment compliance",True,NCT02057913,19074
4435,209910,"15-ENG-2, EudraCT Number: 2011-005081-38, L00070 IN 309 F0, L00070IN309F0, L0070, NCT02347332, RECF2343, TrialTroveID-209910",Phase III Study of IV Vinflunine in Combination With Methotrexate Versus Methotrexate Alone in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck Previously Treated With Platinum-based Chemotherapy,Oncology,Oncology: Head/Neck,Pierre Fabre,"Industry, all other pharma",Overall survival,"Clinical benefit rate, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Progression-free survival, Quality of Life, Safety and Tolerability",True,NCT02347332,19074
4436,198558,"31749, EudraCT number: 2013-002417-35, NCT02665039, NUCOG - I, NUCOG 1 / VINGEM, NUCOG I, NUCOG I-VINGEM, TrialTroveID-198558, VINGEM","A Multicenter, Randomized Phase II Trial of Vinflunine/Gemcitabine vs Carboplatin/Gemcitabine as First Line Treatment in Patients With Metastatic Urothelial Carcinoma Unfit for Cisplatin Based Chemotherapy Due to Impaired Renal Function.",Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"Nordic Urothelial Cancer Group, (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic","Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT02665039,19074
4437,193809,"CTR20131443, CTR20131444, CTR20131445, CTR20131773, L00070 IN 311 B0, NCT01953003, TrialTroveID-193809","A Multicenter, Randomized, Phase III Study of Vinflunine Plus Capecitabine Versus Capecitabine Alone in Patients With Advanced Breast Cancer Previously",Oncology,Oncology: Breast,"Pierre Fabre, Orient Europharma","Industry, all other pharma, Industry, all other pharma",Progression-free survival,"Adverse Events, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to response",True,NCT01953003,19074
4438,185824,"EudraCT Number: 2011-004289-14, NCT01844947, NUCOG III, slut_VINSOR, TrialTroveID-185824, VINSOR",An Exploratory Phase I Study With Sorafenib in Addition to Vinflunine in Progressive Locally Advanced or Metastatic Transitional Cell Carcinoma of the Urothelial Tract,Oncology,Oncology: (N/A); Oncology: Bladder; Oncology: Renal,"Nordic Urothelial Cancer Group, Bayer AG/Bayer Pharmaceuticals, Pierre Fabre","Cooperative Group, Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT01844947,19074
4439,180327,TrialTroveID-180327,Phase I dose-escalation study of oral vinflunine administered once daily for 6 weeks every 8 weeks in patients with advanced/metastatic solid tumours,Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,,Safety and Tolerability,False,,19074
4440,167948,"EudraCT Number: 2011-000272-34, JASiMA, Jasima (L00070 IN 214 P1), JASIMA-JAVLOR, L00070 IN 214 P1, L00070IN214P1, L00070-IN-214-P1, TrialTroveID-167948","Phase II study assessing the maintenance treatment with vinflunine after first-line therapy with gemcitabine and cisplatin in patients with advanced or metastatic transitional cell carcinoma of the urothelial tract , , JASiMA - Javlor Switch in Maintenance",Oncology,Oncology: Bladder,Pierre Fabre,"Industry, all other pharma","Overall survival, Progression-free survival","Clinical benefit rate, Disease Progression - duration, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Time to treatment failure",False,,19074
4441,147813,TrialTroveID-147813,Influence of renal dysfunction on the pharmacokinetic of intravenous vinflunine: Results of a phase I trial in patients with cancer,Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal",(Other Hospital/Academic/Medical Center),Academic,,,False,,19074
4442,145339,"EudraCT Number: 2011-001271-39, MAJA study, NCT01529411, SOGUG 2011/02, SOGUG2011/02, TrialTroveID-145339",Randomized Phase II Study of Vinflunine as Maintenance Monotherapy in Patients With Advanced or Metastatic Urothelial Cancer That Obtains Clinical Benefit of the First Line With Cisplatin-gemcitabine Combination,Oncology,Oncology: Bladder; Oncology: Renal,"Spanish Oncology GenitoUrinary Group, Pierre Fabre","Cooperative Group, Industry, all other pharma","Overall response rate, Progression-free survival","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response",True,NCT01529411,19074
4443,145223,"0003112/2011, 10378, AUO No: 38/11 AB, DRKS00007582, EudraCT Number: 2010-020620-22, Jasint, JASINT 1, JASINT1, L00070 IN 213 P1, L00070IN213P1, NCT01599013, NL34225.094.11, RECF1561, TrialTroveID-145223",Randomized Phase II Study Assessing the Combination of Vinflunine With Gemcitabine and Vinflunine With Carboplatin in Patients Ineligible to Cisplatin With Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium,Oncology,Oncology: Bladder; Oncology: Renal,Pierre Fabre,"Industry, all other pharma","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to treatment failure","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Serious Adverse Events, Time to response, Time to treatment failure",True,NCT01599013,19074
4444,137111,TrialTroveID-137111,Influence of Age on the Pharmacokinetic of I.V. Vinflunine: Results of a Phase I trial in Elderly Cancer Patients,Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,19074
4445,136365,TrialTroveID-136365,Vinflunine After Failure of A First-Line Vinorelbine Based Chemotherapy in Advanced Breast Cancer: Results of A Phase II Multicentre Study,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,19074
4446,130309,"NCRN050, TrialTroveID-130309, UKCRN ID: 5944",Phase II-III double-blind study of oral vinflunine plus best supportive care versus placebo plus best supportive care in patients with malignant pleural mesothelioma previously treated with systemic chemotherapy.,Oncology,Oncology: Mesothelioma,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4447,125758,"DRKS00003890, JONAS-1, JONAS-1 NIS, NCT01103544, Stud-10-45, TrialTroveID-125758",Usage of Vinflunine i.v. (JAVLOR) for the Treatment of Advanced or Metastatic Transitional Cell Carcinoma of the Urothelium in Adult Patients After Failure of a Cisplatinum-containing Therapy,Oncology,Oncology: Bladder; Oncology: Renal,Pierre Fabre,"Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events","Overall response rate, Quality of Life, Treatment compliance",True,NCT01103544,19074
4448,124665,"2009/748, EudraCT Number: 2009-011118-47, IRAS ID 16232, L00070 IN 3 08 B0, L00070 IN 308 B0, L00070 in 308 BO Javlor, L00070IN308B0, NCRN099, NCT01091168, TrialTroveID-124665, UKCRN 7366","A phase III trial of IV vinflunine versus an alkylating agent in patients with metastatic breast cancer previously treated with or resistant to an anthracycline, a taxane, an antimetabolite and a vinca-alkaloid",Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma","Disease Progression, Overall survival","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to response",True,NCT01091168,19074
4449,124213,TrialTroveID-124213,Phase I/II and pharmacokinetic study of intravenous vinflunine in combination with cisplatin for the treatment of chemonaive patients with advanced non-small-cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response rate",,False,,19074
4450,114937,TrialTroveID-114937,Phase I Dose-Escalation Study of Oral Vinflunine in Combination with Capecitabine in Patients with Metastatic Breast Cancer.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4451,111412,"09-022, 10282, CSET 1532, CTRI/2009/091/000607, EudraCT Number: 2008-004171-21, IRAS ID 3753, L00070 IN 305 B0, L00070IN305B0, NCRN070, NCT01095003, PER-079-10, TrialTroveID-111412, UKCRN 6225",A Phase III study of Vinflunine plus Capecitabine versus Capecitabine alone in patients with Advanced Breast Cancer Previously Treated with or Resistant to Anthracycline and who are Taxane Resistant.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma","Complete response, Magnetic Resonance Imaging, Progression-free survival","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Time to response",True,NCT01095003,19074
4452,109500,"2008-001852-31, L00070 GE 106 J1, TrialTroveID-109500",Phase I dose-escalation study of oral vinflunine in combination with erlotinib in patients with locally advanced or metastatic non-small cell lung cancer.,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,"Quality of Life, Safety and Tolerability",False,,19074
4453,94446,"L00070 GE 102Q0, TrialTroveID-094446",Phase I Dose-Escalation Study of Oral Vinflunine Given Twice a Day for 2 Consecutive Days Every Week in Patients with Solid Tumours,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Thyroid",Pierre Fabre,"Industry, all other pharma",Maximum tolerated dose,,False,,19074
4454,87779,TrialTroveID-087779,"Phase I study of i.v. vinflunine (VFL), a novel microtubule inhibitor, given every three weeks in Japanese patients with solid tumors",Oncology,"Oncology: Bladder; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas",(Other Hospital/Academic/Medical Center),Academic,Maximum tolerated dose,,False,,19074
4455,82311,TrialTroveID-082311,A Dose-Finding and Pharmacokinetic Study of  i.v. Vinflunine in Combination with Epirubicin As First Line Treatment of Metastatic Breast Cancer.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",,Safety and Tolerability,False,,19074
4456,79650,TrialTroveID-079650,"Absolute bioavailability of an oral form of vinflunine, a first phase I trial.",Oncology,Oncology: Unspecified Solid Tumor,(Other Hospital/Academic/Medical Center),Academic,Bioavailability,,False,,19074
4457,76905,"L00070 GE 103 Q0, TrialTroveID-076905, ZOOM VINFLUMINE ORALE",Phase I Dose-escalation Study of Vinflunine Hard Capsules Administered Once a Cay from D1 to D5 and from D8 to D12 Every 3 Weeks in Patients with Advanced/metastatic Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Pierre Fabre,"Industry, all other pharma",Maximum tolerated dose,,False,,19074
4458,76847,"CA183-033, NCT00534807, TrialTroveID-076847",Effect of Rifampin on the Pharmacokinetics of Intravenous (IV) Vinflunine in Subjects With Advanced Cancer.,Oncology,Oncology: Unspecified Cancer,Bristol-Myers Squibb,"Industry, Top 20 Pharma",,"Safety and Tolerability, Safety and Tolerability",True,NCT00534807,19074
4459,76232,"GU 35, NCT00545766, SCRI GU 35, SCRI/GU 35, TrialTroveID-076232",A Phase II Trial of Vinflunine as Salvage Chemotherapy in Hormone Refractory Prostate Cancer (HRPC),Oncology,Oncology: Prostate,"Bristol-Myers Squibb, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Academic","Overall response rate, PSA progression, Response rate","Overall response rate, Overall survival, PSA progression, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT00545766,19074
4460,73681,TrialTroveID-073681,Phase II study of IV vinflunine in patients with chemotherapy naive metastatic malignant melanoma,Oncology,Oncology: Melanoma,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4461,73017,TrialTroveID-073017,Phase I and pharmacokinetic (PK) dose-adjusted study of IV vinflunine (VFL) in cancer patients with liver dysfunction (LD): Pharmacokinetic results,Oncology,Oncology: Unspecified Cancer,(Other Hospital/Academic/Medical Center),Academic,,,False,,19074
4462,71569,TrialTroveID-071569,A phase I study of Vinflunine in combination with trastuzumab for treatment of HER2-positive metastatic breast cancer,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4463,66470,"N0632, NCCTG-N0632, NCT00450515, TrialTroveID-066470",Phase II Trial of Vinfluinine and Capecitabine in Previously Treated Metastatic Breast Cancer.,Oncology,Oncology: Breast,"North Central Cancer Treatment Group (NCCTG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government",,"Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Quality of Life, Time to treatment failure",True,NCT00450515,19074
4464,65913,"L00070 IN 111 B0, TrialTroveID-065913, VIDOX, VIDOX (L00070 IN 111 B0), ZOOM VIDOX",A Phase I/II Study to Evaluate I.V. Vinflunine in Combination with Doxorubicin as First Line Treatment of Metastatic Breast Cancer,Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors",Safety and Tolerability,False,,19074
4465,65157,TrialTroveID-065157,A Multicenter Randomized Open Label Phase III Study in the First Line Treatment of Advanced/Metastatic HER2-Positive Breast Cancer Patients Comparing Trastuzumab Plus Vinflunine (TV) versus Trastuzumab plus Paclitaxel (TP).,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4466,64049,"057-07, 200706 S06L, B128, EudraCT Number: 2006-001139-23, JAVLOR study, L00070 303 B0, L00070 IN 303 B0, NCT02054338, PIERFAB_III_2006_001, TrialTroveID-064049, VICTORIA","Phase III Study of Vinflunine Plus Gemcitabine Versus Paclitaxel Plus Gemcitabine in Patients With Unresectable, Locally Recurrent or Metastatic Breast Cancer After Prior Anthracycline-based Adjuvant Chemotherapy",Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate - time, Overall response rate, Overall survival, Partial response, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease, Time to treatment failure",True,NCT02054338,19074
4467,62096,TrialTroveID-062096,Phase II study of i.v. Vinflunine (VFL) as Third-Line Treatment of Metastatic Breast Carcinoma after Failure of Anthracycline-/Taxane-Based Chemotherapy.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma","Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability",False,,19074
4468,58228,"10116, 20061855, BLDR0007, BMS CA183002, BMS-002, CA183002, CA183-002, CA183-002 (07060806), EudraCT Number: 2005-003733-40, IRB# 97831, NCT00389155, Project 848, SU-11062007-806, TrialTroveID-058228, VINCENT, VINCENT CA183002","A Multicenter, Randomized Double-Blind Phase II/III Study in the First-Line Treatment of Advanced Transitional Cell Carcinoma (TCC) of the Urothelium Comparing Vinflunine/Gemcitabine to Placebo/Gemcitabine in Patients Who Are Ineligible to Receive Cisplatin-Based Therapy",Oncology,Oncology: Bladder,Bristol-Myers Squibb,"Industry, Top 20 Pharma","Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to response",True,NCT00389155,19074
4469,54638,"CA183-008, NCT00362830, SCCC 2006111, TrialTroveID-054638",A Study of the Alternating Administration of Ixabepilone and Vinflunine Every Three Weeks in Patients With Advanced Cancer.,Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Soft Tissue Sarcoma",Bristol-Myers Squibb,"Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose",Safety and Tolerability,True,NCT00362830,19074
4470,54163,"CA183-023, NCT00359476, TrialTroveID-054163","A Multicenter, Single-Arm, Phase II Study of Single-Agent Vinflunine in the Second-Line Treatment of Patients With Gastric Cancer.",Oncology,Oncology: Esophageal; Oncology: Gastric,Bristol-Myers Squibb,"Industry, Top 20 Pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to response",True,NCT00359476,19074
4471,52497,"BMS CA 183009, CA183-009, NCT00388557, REFMAL 75, TrialTroveID-052497",Effect of Ketoconazole on the Pharmacokinetics of Intravenous (IV) Vinflunine in Patients With Advanced Cancer.,Oncology,Oncology: Unspecified Solid Tumor,Bristol-Myers Squibb,"Industry, Top 20 Pharma",,Safety and Tolerability,True,NCT00388557,19074
4472,50046,"LCCC 0503, LCCC0503, NCT00330031, NCT00519831, TrialTroveID-050046, UNC LCCC 0503",Phase II Study of Vinflunine and Cetuximab in the Second Line Treatment of Stage IIIB/IV Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Industry, Top 20 Pharma, Government, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00330031,19074
4473,48681,"H3E-US-1015, LCC 0506, LCCC0509, NCT00320073, OSI3719s, TrialTroveID-048681, UNC-LCCC-0509",A Two Arm Phase I Dose Escalation Trial of Vinflunine With Erlotinib or Pemetrexed in Refractory Solid Tumors.,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Soft Tissue Sarcoma","Bristol-Myers Squibb, Eli Lilly, Roche/Genentech {Genentech}, National Institutes of Health/National Cancer Institute, UNC Lineberger Comprehensive Cancer Center","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Government, Academic",Maximum tolerated dose,"Overall response rate, Response rate, Safety and Tolerability",True,NCT00320073,19074
4474,43763,"BRE 89, NCT00284180, SCRI BRE 89, TrialTroveID-043763",Phase II Trial of Vinflunine Plus Trastuzumab in Human Epidermal Growth Factor Receptor 2 (HER2neu) Over-Expressing Metastatic Breast Cancer,Oncology,Oncology: Breast,"Bristol-Myers Squibb, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression - duration, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT00284180,19074
4475,43759,"CA183017, LUN 122, NCT00284154, SCRI LUN 122, TrialTroveID-043759",A Phase II Trial of VInflunine in the Treatment of Patients With Relapsed Extensive Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Small Cell","Bristol-Myers Squibb, Sarah Cannon Research Institute {Sarah Cannon-Minnie Pearl Cancer Center}","Industry, Top 20 Pharma, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival",True,NCT00284154,19074
4476,39135,"CA183-011, I-05-009, ION 05-009, NCT00251446, TrialTroveID-039135",A Phase II Single Arm Trial of Single-Agent Vinflunine as Second-Line Treatment of Advanced Non-Small Cell Lung Cancer.,Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, International Oncology Network","Industry, Top 20 Pharma, Miscellaneous",Overall survival,"Disease Progression - duration, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Time to response",True,NCT00251446,19074
4477,30965,TrialTroveID-030965,Phase I and pharmacokinetic study of vinflunine (VFL) in combination with carboplatin (CBDCA) for treatment of advanced non-small cell lung cancer (NSCLC) in chemonaive patients (pts),Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,Dose-limiting toxicities,,False,,19074
4478,30575,TrialTroveID-030575,Interim results of the phase II study of vinflunine in malignant pleural mesothelioma.,Oncology,Oncology: Mesothelioma,"Cancer Research UK, Pierre Fabre","Not for Profit Funding Entity, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",,False,,19074
4479,22650,"02592005, 05-04-022, 05-04-022, 050533, 10128, 2005-0359, 321-05, 62385, BMS (-001), BMS CA183001, BMS-CA183001, CA183001, CA183-001, EudraCT Number: 2005-001463-64, GCC 0515, HIC 27510, J04106, McG 0626, NCT00101608, NCT00268424, TrialTroveID-022650, UCIRB#13628, UCSD-050533, UPCC-07804, UPCI-05-053",A Phase II Study of Intravenous (IV) Vinflunine in Patients With Locally Advanced or Metastatic Transitional Cell Carcinoma (TCC) of the Urothelium.,Oncology,Oncology: Bladder; Oncology: Renal,"Bristol-Myers Squibb, Pierre Fabre","Industry, Top 20 Pharma, Industry, all other pharma","Overall response rate, Overall survival","Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response rate, Safety and Tolerability, Time to response",True,NCT00101608,19074
4480,12735,"L00070 IN 109 B0, TrialTroveID-012735",Dose-finding and Pharmacokinetic Study of IV Vinflunine in Combination with Capecitabine in Metastatic Breast Cancer.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",Maximum tolerated dose,Safety and Tolerability,False,,19074
4481,12724,"2810, L00070 IN 106 J1, TrialTroveID-012724",Phase I Study of I.V. Vinflunine in Combination with Gemcitabine for Treatment of Advanced Non-Small-Cell Lung Cancer in Chemonaive Patients.,Oncology,"Oncology: Lung, Non-Small Cell","Istituto Nazionale per la Ricerca sul Cancro, Pierre Fabre","Academic, Industry, all other pharma",Dose-limiting toxicities,,False,,19074
4482,8871,TrialTroveID-008871,Phase II study of intravenous vinflunine as second line therapy in patients with metastatic breast cancer after anhracycline-taxane based regimen failure.,Oncology,Oncology: Breast,Pierre Fabre,"Industry, all other pharma",Overall response rate,"Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Progressive disease rate, Safety and Tolerability",False,,19074
4483,6838,TrialTroveID-006838,Phase I study of intravenous vinflunine given weekly in previously untreated patients with advanced solid umors.,Oncology,Oncology: Gastric; Oncology: Melanoma; Oncology: Pancreas; Oncology: Renal,Pierre Fabre,"Industry, all other pharma","Dose-limiting toxicities, Safety and Tolerability",,False,,19074
4484,6837,TrialTroveID-006837,Phase II study testing intravenous vinflunine as salvage treatment in relapsed (12 months) ovarian cancer,Oncology,Oncology: Ovarian,"Bristol-Myers Squibb, Pierre Fabre","Industry, Top 20 Pharma, Industry, all other pharma",Safety and Tolerability,,False,,19074
4485,6836,"CCR1855, TrialTroveID-006836",Phase II Study of I.V. Vinflunine in Patients with Metastatic Renal Cell Carcinoma Previously Untreated (SCB/2000),Oncology,Oncology: Renal,Pierre Fabre,"Industry, all other pharma","Overall response rate, Response rate",,False,,19074
4486,6835,"9 L0070 99 IN 102, CCR1692, TrialTroveID-006835",A phase I study and pharmacokinetic analysis of Vinflunine (VFL) given as a 10 minute infusion of days 1 and 8 every three weeks,Oncology,Oncology: Unspecified Solid Tumor,Pierre Fabre,"Industry, all other pharma",Maximum tolerated dose,,False,,19074
4487,6834,TrialTroveID-006834,Vinflunine metabolism and disposition in cancer patients.,Oncology,Oncology: Unspecified Cancer,Pierre Fabre,"Industry, all other pharma",,,False,,19074
4488,6833,"CCR1854, TrialTroveID-006833",Phase II Study of IV Vinflunine in Patients with Chemotherapy Naive Metastatic Malignant Melanoma.,Oncology,Oncology: Melanoma,Pierre Fabre,"Industry, all other pharma","Overall response rate, Response rate",,False,,19074
4489,6832,"CCR1862, PFM (-202), TrialTroveID-006832",Intravenous vinflunine as second line therapy in advanced transitional cell cancer of the bladder,Oncology,Oncology: Bladder,Pierre Fabre,"Industry, all other pharma","Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival",False,,19074
4490,6831,"CCR2027, N0258107471, TrialTroveID-006831",Phase II Study of IV Vinflunine as Second Line Treatment of Patients with Advanced Non-Small Cell Lung Cancer Previously Treated with a Platinum Based Regimen.,Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, Pierre Fabre","Industry, Top 20 Pharma, Industry, all other pharma","Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival",False,,19074
4491,6830,"302 P1-2301, CA183004, CA183-004, CA183-004-009, IdRPF L00070 IN 302 P1, L00070 IN 302 P1-2301, LOOO70 IN 302 P1, McG 0516, MREC03/01/101, N0143148076, NCT00315237, PFM (-302) (-004), TrialTroveID-006830, VINF/BSC","Prospective, Randomized Phase III Trial of I.V. Vinflunine Plus Best Supportive Care as Second Line Therapy Versus Best Supportive Care After a Platinum-containing Regimen, in Patients With Advanced Transitional Cell Carcinoma of Urothelial Tract",Oncology,Oncology: Bladder; Oncology: Renal,"Bristol-Myers Squibb, Pierre Fabre","Industry, Top 20 Pharma, Industry, all other pharma",Overall survival,"Overall response rate - duration, Overall response rate, Progression-free survival, Quality of Life, Response rate, Safety and Tolerability, Time to response",True,NCT00315237,19074
4492,6829,"FA711Z0058, TrialTroveID-006829",Prospective Randomised Clinical Phase III Trial of Vinflunine versus Docetaxel in Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer Previously Treated with One Platinum Containing Regimen.,Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb, Pierre Fabre","Industry, Top 20 Pharma, Industry, all other pharma",Progression-free survival,"Overall response rate - duration, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability",False,,19074
4493,387315,"D1346C00011, NCT04590235","A Phase 1 Open Label Study to Assess the Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of Selumetinib, a Selective Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor, in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)",,NA: ClinicalTrials.gov,"AstraZeneca, Merck Sharp & Dohme Corp.","Industry, Top 20 Pharma, ClinicalTrials.gov","Adverse Events, Area under the curve score, Cmax, Elimination half-life","FLACC, Numeric Rating Scale, Patient-Reported Outcomes Measurement Information System, Quality of Life",True,NCT04590235,29657
4494,386256,"ACNS1931, NCI-2020-07549, NCT04576117, U10CA180886","A Phase 3 Study of Selumetinib (NSC# 748727) or Selumetinib in Combination With Vinblastine for Non-NF1, Non-TSC Patients With Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations",,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,"Event-free survival, Maximum tolerated dose","Adverse Events, Event-free survival, Quality of Life",True,NCT04576117,29657
4495,371931,"D19-02, EudraCT Number: 2019-004366-18, MAZEPPA D19-02, MAZEPPA D19-02 PRODIGE 72, MAZEPPA_D19-02, NCT04348045, PRODIGY 72 - MAZEPPA, TrialTroveID-371931",MAZEPPA: Phase II PRODIGE-GERCOR Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients,Oncology,Oncology: Pancreas,"AstraZeneca, GERCOR","Industry, Top 20 Pharma, Cooperative Group","Immune-related response evaluation criteria in solid tumors, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Clinical benefit rate, Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04348045,29657
4496,361505,"ACNS1833, NCI-2019-07600, NCT04166409, U10CA180886",A Phase 3 Randomized Non-Inferiority Study of Carboplatin and Vincristine Versus Selumetinib (NSC# 748727) in Newly Diagnosed or Previously Untreated Low-Grade Glioma (LGG) Not Associated With BRAFV600E Mutations or Systemic Neurofibromatosis Type 1 (NF1),,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,Event-free survival,Quality of Life,True,NCT04166409,29657
4497,345097,"ACNS1831, NCI-2019-01396, NCT03871257, U10CA180886",A Phase 3 Randomized Study of Selumetinib Versus Carboplatin/Vincristine in Newly Diagnosed or Previously Untreated Neurofibromatosis Type 1 (NF1) Associated Low-Grade Glioma (LGG),,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,Event-free survival,Quality of Life,True,NCT03871257,29657
4498,342550,"5618-001, MK-5618-001, NCT03833427, TrialTroveID-342550",A Phase 1b Multi-center Clinical Study of Selumetinib (MK-5618) in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic Solid Tumors.,Oncology,Oncology: Unspecified Solid Tumor,Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities","Area under the curve score, Cmax, Cmin, Plasma concentration",True,NCT03833427,29657
4499,337066,"8353-014, BASEC2018-0199, MK-8353-014, NCT03745989, SNCTP000003193, TrialTroveID-337066",Phase Ib Open-label Study of MK-8353 in Combination With Selumetinib (MK-5618) in Participants With Advanced/Metastatic Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,Merck & Co./Merck Sharp & Dohme (MSD),"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities","Area under the curve score, Cmax, Cmin, Plasma concentration",True,NCT03745989,29657
4500,336827,"BEGONIA, D933LC00001, EudraCT Number: 2018-000764-29, NCI-2019-05878, NCT03742102, TrialTroveID-336827","A Phase IB/II, 2-stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) + Paclitaxel and Durvalumab (MEDI4736) in Combination With Novel Oncology Therapies With or Without Paclitaxel for First-line Metastatic Triple Negative Breast Cancer",Oncology,Oncology: Breast,AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT03742102,29657
4501,331500,"D1532C00089, NCT03649165, TrialTroveID-331500","A Phase I, Open-label, Single-center Relative Bioavailability and Food Effect Randomized Crossover Study of New Granule and Capsule Formulations of Selumetinib (AZD6244) in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Area under the curve score, BCVA, Cardiac Telemetry, Cmax, Creatinine kinase level, Drug clearance, Elimination half-life, Elimination rate, Eosinophil levels, Hemoglobin level, Liver function, Ophthalmic examination, Phosphate level, Plasma concentration, Platelet count, Safety and Tolerability, Safety and Tolerability, Tmax, Urine protein level, Vital signs, Volume of distribution",True,NCT03649165,29657
4502,327719,"2017-0888, NCI-2018-01098, NCT03581487, TrialTroveID-327719",Phase I/II Trial Immunotherapy With Durvalumab and Tremelimumab With Continuous or Intermittent MEK Inhibitor Selumetinib in NSCLC,Oncology,"Oncology: Lung, Non-Small Cell","MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute","Academic, Government","Maximum tolerated dose, Progression-free survival","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT03581487,29657
4503,325230,"17/YH/0123, CPMS ID: 33990, EudraCT Number: 2016-003904-29, IRAS ID: 203556, ISRCTN92323261, ITCC-063 SELUDEX, NCT03705507, NL64779.041.19, RG_16-186, SeluDex, TrialTroveID-325230",International Phase I/II Expansion Trial of the MEK Inhibitor Selumetinib in Combination with Dexamethasone for the Treatment of Relapsed/refractory RAS-pathway Mutated Paediatric and Adult Acute Lymphoblastic Leukaemia,Oncology,"Oncology: Leukemia, Acute Lymphocytic","AstraZeneca, Cancer Research UK, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic","Complete response, Dose-limiting toxicities, Minimal Residual Disease, Partial response","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Dose-limiting toxicities, Elimination half-life, Minimal Residual Disease, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT03705507,29657
4504,318595,"CDMRP-NF150092, NCI-2019-06514, NCT03433183, SARC031, TrialTroveID-318595",SARC031: A Phase II Trial of the MEK Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Combination With the mTOR Inhibitor Sirolimus for Patients With Unresectable or Metastatic Malignant Peripheral Nerve Sheath Tumors,Oncology,Oncology: Soft Tissue Sarcoma,"AstraZeneca, US Department of Defense, Sarcoma Alliance for Research through Collaboration","Industry, Top 20 Pharma, Government, Cooperative Group","Clinical benefit rate, Complete response, Overall response rate, Partial response, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Likert scale, Numeric Rating Scale, Overall survival, Patient-Reported Outcomes Measurement Information System, Progression-free survival, Progressive disease rate, Quality of Life",True,NCT03433183,29657
4505,315981,"17-540, NCI-2018-00300, NCT03392246, TrialTroveID-315981",A Phase II Study of Osimertinib in Combination With Selumetinib in EGFR Inhibitor naive Advanced EGFR Mutant Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute, National Comprehensive Cancer Network","Academic, Cooperative Group","Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Progression-free survival",True,NCT03392246,29657
4506,313095,"15Hi53, INSPECT, NCT03326388",A Paediatric Phase I/II Study Of Intermittent Dosing Of The Mek-1 Inhibitor Selumetinib In Children With Neurofibromatosis Type-1 And Inoperable Plexiform Neurofibroma And/Or Progressive Optic Pathway Glioma,,NA: ClinicalTrials.gov,"AstraZeneca, Great Ormond Street Hospital for Children NHS Foundation Trust","Industry, Top 20 Pharma, ClinicalTrials.gov",Maximum tolerated dose,"Heart rate corrected QT interval, Quality of Life, Treatment Emergent Adverse Events",True,NCT03326388,29657
4507,311799,"NCI-2018-00008, NCT03326310, TrialTroveID-311799","Phase I Study of MEK Inhibitor Selumetinib in Combination With Azacitidine in Patients With Higher Risk Chronic Myeloid Neoplasia: MDS, MDS/MPNs, and Myelofibrosis",Oncology,"Oncology: Leukemia, Chronic Myelogenous; Oncology: Myelodysplastic Syndrome; Oncology: Myeloproliferative Neoplasms",University of Chicago Cancer Research Center,Academic,"Adverse Events, Maximum tolerated dose","Complete response, Disease Progression, Hematologic Improvement, Overall response rate, Overall survival, Partial response, Progression-free survival, Response rate",True,NCT03326310,29657
4508,307749,"D1346R00002, NCT03259633","An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1 With Inoperable, Progressive/Symptomatic Plexiform Neurofibromas (PN)",,NA: ClinicalTrials.gov,AstraZeneca,"Industry, Top 20 Pharma",Ability to swallow,,True,NCT03259633,29657
4509,305019,"APEC 1621 E, APEC 1621-E, APEC1621 E, APEC1621E, APEC1621E (primary), COG APEC1621E, NCI-2017-01250, NCT03213691, OCR16979, Pediatric MATCH, S17-01739, TrialTroveID-305019",NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase II Subprotocol of Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Tumors Harboring Activating MAPK Pathway Mutations,Oncology,"Oncology: CNS, Glioblastoma; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroblastoma; Oncology: Unspecified Solid Tumor","National Institutes of Health/National Cancer Institute, Childrenâs Oncology Group","Government, Cooperative Group","Complete response, Overall response rate, Partial response, Response rate","Common Terminology Criteria for Adverse Events, Disease Progression, Progression-free survival, Recurrence, Treatment Emergent Adverse Events",True,NCT03213691,29657
4510,302111,"2016-1129, NCI-2018-01205, NCT03162627, TrialTroveID-302111","Evaluation of the Combination of Selumetinib and Olaparib in Endometrial, Ovarian and Other Solid Tumors With Ras Pathway Alterations, and Ovarian Tumors With PARP Resistance",Oncology,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Thyroid; Oncology: Unspecified Solid Tumor,"AstraZeneca, MD Anderson Cancer Center, University of Texas","Industry, Top 20 Pharma, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Clinical benefit rate, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03162627,29657
4511,301676,"17-729, 2017-0625, 20170841, APEC1621SC, COGAPEC1621, COGAPEC1621SC, N 55017 SC, NCI-2017-01251, NCI-COG Pediatric MATCH, NCT03155620, Pediatric MATCH, TrialTroveID-301676",NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) Screening Protocol,Oncology,"Oncology: (N/A); Oncology: CNS, Glioblastoma; Oncology: CNS, Medulloblastoma; Oncology: CNS, Other; Oncology: Liver; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Neuroblastoma; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Testicular; Oncology: Unspecified Solid Tumor",National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Drug clearance, Overall response rate, Progression-free survival, Recurrence, Response rate",True,NCT03155620,29657
4512,299232,"170084, 17-C-0084, NCI-2016-01094, NCT03109301, TrialTroveID-299232",A Phase II Trial of the Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Patients With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST),Oncology,Oncology: GIST,National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response evaluation criteria in solid tumors, Response rate",,True,NCT03109301,29657
4513,298905,"9990, NCT03105258, X161202002",Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (cNF),,NA: ClinicalTrials.gov,"National Cancer Institute (NCI), University of Alabama at Birmingham","ClinicalTrials.gov, ClinicalTrials.gov",,,True,NCT03105258,29657
4514,298413,"2016-8833, NCT03095248, SEL-TH-1601",Phase 2 Trial of Selumetinib in Patients With Neurofibromatosis Type II Related Tumors,,NA: ClinicalTrials.gov,"AstraZeneca, Children's Hospital Medical Center, Cincinnati","Industry, Top 20 Pharma, ClinicalTrials.gov",,Quality of Life,True,NCT03095248,29657
4515,295250,"10050, 17C0144, 17-C-0144, 18-710, NCI-17-C-0144, NCI-2017-00118, NCT03040986, OSU-17376, TrialTroveID-295250",A Phase II Study of Selumetinib (AZD6244) for the Treatment of Advanced Pancreas Cancer Harboring KRAS G12R Mutations,Oncology,Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Progression-free survival, Safety and Tolerability, Serious Adverse Events",True,NCT03040986,29657
4516,293264,"2016-0060, NCT03004105, TrialTroveID-293264",Phase II Trial of Immunotherapy With Durvalumab (MEDI4736) With Continuous or Intermittent MEK Inhibitor Selumetinib in KRAS Mutant Non-Small Cell Lung Cancer (NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","MD Anderson Cancer Center, University of Texas, AstraZeneca {MedImmune}","Academic, Industry, Top 20 Pharma","Progression-free survival, Safety and Tolerability","Overall response rate, Response evaluation criteria in solid tumors, Response rate",True,NCT03004105,29657
4517,284970,"8810, MC1012, NCI-2011-01083, NCI-2012-02906, NCT02876068, TrialTroveID-284970","Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies",Oncology,Oncology: Melanoma; Oncology: Unspecified Solid Tumor,"National Institutes of Health/National Cancer Institute, Mayo Clinic","Government, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, NCI-CTC scale, Neutropenia, Partial response, Response evaluation criteria in solid tumors",True,NCT02876068,29657
4518,282935,"9990, NCI-2016-01087, NCT02839720, P30CA013148",Pilot Study of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) for Adults With Neurofibromatosis Type 1 (NF1) and Cutaneous Neurofibromas (CNF),,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,,True,NCT02839720,29657
4519,278657,"16-1611, 2016-0569, AAAQ6999, NCI-2016-01205, NCT02768766, TrialTroveID-278657","Multi-Center Phase Ib Study of Intermittent Dosing of the MEK Inhibitor, Selumetinib, in Patients With Advanced Uveal Melanoma Not Previously Treated With a MEK Inhibitor",Oncology,Oncology: Melanoma,"AstraZeneca, (Other Cooperative Group)","Industry, Top 20 Pharma, Cooperative Group","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Adverse Events, Dose-limiting toxicities, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT02768766,29657
4520,277108,"19937, CRUK/14/041, EudraCT Number: 2015-002269-47, IRAS ID: 183600, ISRCTN17468602, SEL-I-METRY, STH18441, TrialTroveID-277108",Investigating The Potential Clinical Benefit of Selumetinib In Resensitising Advanced Iodine Refractory Differentiated Thyroid Cancer to Radioiodine Therapy,Oncology,Oncology: Thyroid,"AstraZeneca, (Other Cooperative Group), Cancer Research UK, Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme}, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Cooperative Group, Not for Profit Funding Entity, Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival","Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, EQ-5D, Overall response rate, Overall survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,29657
4521,273429,"ESR-14-10735, NCT02685657, TrialTroveID-273429",A Phase II Randomized Multicenter Open Label Prospective Study of Neoadjuvant Chemotherapy Docetaxel With or Without MEK Inhibitor SELUMETINIB in Patients With Early and Locally Advanced Triple Negative Breast Cancer,Oncology,Oncology: Breast,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Complete response,"Adverse Events, Complete response, Overall response rate",True,NCT02685657,29657
4522,270858,"160043, 16-C-0043, NCT02644512",Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,"Magnetic Resonance Imaging, Quality of Life",True,NCT02644512,29657
4523,266997,"051515, D1345C00003, EudraCT Number: 2016-003780-19, i2409, NCI-2016-00915, NCT02586987, SELECT-4, TrialTroveID-266997","A Phase I, Open-Label, Multi-Centre Study to Assess the Safety, Tolerability and Preliminary Anti-tumour Activity of Ascending Doses of Selumetinib (AZD6244 Hyd-sulfate) in Combination With MEDI4736 and Selumetinib in Combination With MEDI4736 and Tremelimumab in Patients With Advanced Solid Tumours",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Pancreas",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, BCVA, Cardiac Telemetry, Disease Progression, Ophthalmic examination, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT02586987,29657
4524,265019,"009896QM, CPMS ID: 18725, CRUKDE/14/010, EudraCT Number: 2014-002613-31, IRAS ID 172356, NCT02583542, Torcmek, TrialTroveID-265019, UKCRN ID:18725",A Phase Ib/IIa Study of AZD2014 in Combination With Selumetinib in Patients With Advanced Cancers,Oncology,"Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Basal Cell Carcinoma; Oncology: Thyroid","AstraZeneca, Cancer Research UK, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic","Clinical benefit rate, Dose-limiting toxicities, Nausea, Neutropenia, Partial response, Response evaluation criteria in solid tumors, Stable Disease, Vomiting","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax, Vital signs",True,NCT02583542,29657
4525,264527,"16-1579, AAAQ4008, AZ-D2615C00001-GU118, BISCAY, CANC 5232, CR1722AZ, D2615C00001, EudraCT Number: 2015-002228-25, GU 118, GUTBISCAY, IRAS ID: 184374, J1604, NCI-2016-01122, NCT02546661, S15-00877, TrialTroveID-264527","An Open-Label, Randomised, Multi-Drug, Biomarker-Directed, Multi-Centre, Multi-arm Phase Ib Study in Patients With Muscle Invasive Bladder Cancer (MIBC) Who Have Progressed on Prior Treatment (BISCAY)",Oncology,Oncology: Bladder; Oncology: Renal,AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Cardiac Telemetry, Dose-limiting toxicities, Lipid Profile, Safety and Tolerability, Safety and Tolerability, Vital signs","Anti-drug antibodies, Area under the curve score, Circulating Tumor Cells, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Gene expression profiling, Neutralizing antibody response, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02546661,29657
4526,261854,"11,462, NCI-2015-01018, NCT02503358, SOL-15008-L, TrialTroveID-261854","A Randomized, Open-Label, Phase I Trial of Continuous, Intermittent, and Pulsatile Selumetinib (AZD6244) Plus Paclitaxel as Second-Line Treatment for Stage IIIB or IV Non-small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, National Institutes of Health/National Cancer Institute, OHSU Cancer Institute, Oregon Health and Science University","Industry, Top 20 Pharma, Government, Academic, Academic","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease",True,NCT02503358,29657
4527,260558,"169996, 19090, EudraCT Number: 2014-004437-22, IRAS ID 169996, ISRCTN29621851, MEL041, SelPac, SelPac Version 1, TrialTroveID-260558, UKCRN ID: 19090, UoL001077","A Randomised three-arm, open label, Phase II study of continuous Selumetinib versus continuous or interrupted Selumetinib in combination with weekly Paclitaxel in metastatic Uveal Melanoma",Oncology,Oncology: Melanoma,"AstraZeneca, University of Liverpool","Industry, Top 20 Pharma, Academic",Progression-free survival,"Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",False,,29657
4528,257645,"2014-04-126-010, NCT02448290, TrialTroveID-257645, VIKTORY","Phase II, Single-arm Study of Selumetinib in Combination With Docetaxel, in Advanced Gastric Adenocarcinoma Patients With Low/High MEK Signature, RAS Mutation or RAS Amplification as a Second-line Chemotherapy",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate","Cardiac Telemetry, Circulating Tumor Cells, Clinical benefit rate, Duration of overall response, Heart rate, Heart rhythm, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT02448290,29657
4529,254903,"160043, 16-C-0043, NCT02407405",Phase II Trial of the MEK1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,,"Magnetic Resonance Imaging, Quality of Life",True,NCT02407405,29657
4530,253990,"14-008494, 15-097, 2015-0003, Mod14-008494-03, NCI-2015-00277, NCT02393690, RU241306I, TrialTroveID-253990",Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers,Oncology,Oncology: Thyroid,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Complete response, Overall response rate, Response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT02393690,29657
4531,251759,"EudraCT Number: 2014-001855-22, M14AFS, NCT02450656, NL49983.031.14, TrialTroveID-251759",Phase I/II Study With the Combination of Afatinib and Selumetinib in Advanced KRAS Mutant Positive and PIK3CA Wildtype Non-small Cell Lung Cancer,Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Pancreas","AstraZeneca, Netherlands Cancer Institute, Boehringer Ingelheim","Industry, Top 20 Pharma, Government, Industry, Top 20 Pharma","Dose-limiting toxicities, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT02450656,29657
4532,250384,"CCTG IND219, I219, IND.219, LUIND219, NCIC GEC IND.219, NCIC IND.219, NCT02337530, TrialTroveID-250384",A Randomized Phase II Trial of Selumetinib in Patients Receiving Standard Pemetrexed and Platinum-based Chemotherapy for the Treatment of Advanced or Metastatic KRAS Wildtype or Unknown Non-Squamous Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group",Overall response rate,"Adverse Events, Overall survival, Progression-free survival",True,NCT02337530,29657
4533,249176,"D1532C00078, NCT02322749, TrialTroveID-249176","A Phase I, Single Centre, Randomised, Open Label, Crossover Study to Assess the Bioequivalence or Relative Bioavailability of Variants of Selumetinib (AZD6244, Hyd-Sulfate) Blue Capsules in Healthy Male Volunteers Aged 18 to 45 Years",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Area under the curve score, Bioavailability, Cardiac Telemetry, Cmax, Drug clearance, Elimination half-life, Mean residence time, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs, Volume of distribution",True,NCT02322749,29657
4534,242687,"CDR667932, NCI-2012-03173, NCT01089101, PBTC-029, PBTC-029B, U01CA081457, UM1CA081457",A Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,"Dose-limiting toxicities, Maximum tolerated dose",,True,NCT01089101,29657
4535,226953,"110191, 11-C-0191, NCT01386450",Phase 1 and Phase II and Re-Treatment Study of AZD6244 for Recurrent or Refractory Pediatric Low Grade Glioma,,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,"Maximum tolerated dose, Safety and Tolerability",Magnetic Resonance Imaging,True,NCT01386450,29657
4536,226767,"110161, 11-C-0161, NCT01362803",A Phase I/II Study of the Mitogen Activated Protein Kinase Kinase (MEK) 1 Inhibitor Selumetinib (AZD6244; HYD Sulfate) in Children With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN),,NA: ClinicalTrials.gov,National Cancer Institute (NCI),ClinicalTrials.gov,Maximum tolerated dose,"Bone Mineral Density, Growth velocity, Quality of Life, Safety and Tolerability",True,NCT01362803,29657
4537,221349,"(UCBG- 0105/1304), CSET 2099, EudraCT Number: 2013-001652-36, NCT02299999, RECF3026, SAFIR02, SAFIR02 BREAST, SAFIR02_Breast, TrialTroveID-221349, UC-0105/1304, UCBG UC-0105/1304",PERSONALIZED MEDICINE GROUP / UCBG UC-0105/1304: SAFIR02_Breast - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast Cancer.,Oncology,Oncology: Breast,"AstraZeneca, (Other Cooperative Group), Federation Nationale des Centres de Lutte contre le Cancer","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT02299999,29657
4538,216742,"D1532C00080, NCT02238782, TrialTroveID-216742",A Study to Assess the Absolute Bioavailability of a Single Oral Dose of Selumetinib With Respect to an Intravenous Microdose of [14C] Selumetinib in Healthy Male Volunteers,Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Bioavailability","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Drug clearance, Elimination half-life, Mean residence time, Ophthalmic examination, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs, Volume of distribution",True,NCT02238782,29657
4539,213886,TrialTroveID-213886,Pivotal Trial of Selumetinib in First Line KRASm NSCLC,Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma",,,False,,29657
4540,212843,"051406, 13-2628, 201409113, 9571, NCI # 9571/COMIRB # 13-2628, NCI/CTEP #9571, NCI-2014-01484, NCI9571, NCI-9571-CIRB, NCT02188264, P9571_A01PAMDREVW01, TrialTroveID-212843",A Phase IB Study of the Combination of AZD6244 Hydrogen Sulfate (Selumetinib) and Cyclosporin A (CsA) in Patients With Advanced Solid Tumors With an Expansion Cohort in Metastatic Colorectal Cancer,Oncology,Oncology: Colorectal; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT02188264,29657
4541,212196,"201408131, 2014-0872, D4191C00011, NCT02179671, TrialTroveID-212196","A Phase IIa, Open-Label, Multi-Center, Multi-Cohort, Immune-Modulated Study of Selected Small Molecules (Gefitinib, AZD9291, or Selumetinib + Docetaxel) or a 1st Immune-Mediated Therapy (IMT; Tremelimumab) With a Sequential Switch to a 2nd IMT (MEDI4736) in Patients With Locally Advanced or Metastatic Non-Small-Cell Lung Cancer (Stage IIIB-IV)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma",Complete response,"Adverse Events, Clinical benefit rate, Overall response rate, Safety and Tolerability, Safety and Tolerability",True,NCT02179671,29657
4542,210007,"BILMEK, BIL-MEK, NCT02151084, TrialTroveID-210007",A Randomized Phase II Trial of MEK Inhibitor Selumetinib (AZD6244) Combined Continuously or Sequentially with Cisplatin/Gemcitabine (CIS/GEM) Versus CIS/GEM Alone in Patients with Advanced Biliary Cancer,Oncology,Oncology: Liver,"University Health Network, Toronto",Academic,Response evaluation criteria in solid tumors,"Adverse Events, Clinical benefit rate, Disease Progression, Overall response rate, Overall survival, Progression-free survival, Stable Disease",True,NCT02151084,29657
4543,207256,"EudraCT Number: 2013-001653-27, IFCT-1301 SAFIR02 Lung, NCT02117167, SAFIR 02 Lung, SAFIR02 Lung ITTC-1301, SAFIR02 LUNG-IMMUNO, SAFIR02_Lung, SAFIR02-Lung / IFCT-1301, TrialTroveID-207256, UC 0105-1305 / IFCT 1301, UC_0105-1305_/_IFCT_1301",Intergroup Trial UNICANCER UC 0105-1305/ IFCT 1301: SAFIR02_Lung - Evaluation of the Efficacy of High Throughput Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Non-small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, (Other Cooperative Group), Federation Nationale des Centres de Lutte contre le Cancer","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT02117167,29657
4544,207251,"EudraCT Number: 2014-000814-73, IRAS ID: 151280, ISRCTN38344105, MREC NÂ°: 14/SC/1346, National Lung Matrix trial, NCT02664935, RG_14-072, TrialTroveID-207251, UKCRN ID: 17746","National Lung Matrix Trial: Multi-drug, Genetic Marker-directed, Non-comparative, Multi-centre, Multi-arm Phase II Trial in Non-small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, (Other Academic Cancer Center), Pfizer, Cancer Research UK, Mirati Therapeutics {MethylGene}, (Other Hospital/Academic/Medical Center), University of Cambridge","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma, Not for Profit Funding Entity, Industry, all other pharma, Academic, Academic","Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Time to progression",True,NCT02664935,29657
4545,205298,"D1532C00083, NCT02093728, TrialTroveID-205298","A Phase I, Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inhibitor Itraconazole and the CYP2C19 Inhibitor Fluconazole on the Pharmacokinetics of a 25 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142866) ( Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Plasma concentration","Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Mean residence time, Metabolite to parent ratio, Plasma concentration, Safety and Tolerability, Tmax, Vital signs",True,NCT02093728,29657
4546,202861,"D1532C00082, NCT02063230, TrialTroveID-202861","An Open-label, Comparative Study to Assess the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) (Hyd-Sulfate) Following Single Oral Dosing to Healthy Subjects and to Subjects With Mild, Moderate, and Severe Hepatic Impairment",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax","Area under the curve score, Cmax",True,NCT02063230,29657
4547,202797,"D1532C00081, NCT02063204, TrialTroveID-202797","An Open Label Comparative Study of the Pharmacokinetics, Safety and Tolerability of Selumetinib (AZD6244, ARRY 142886) (Hyd Sulfate) Following a Single Oral Dose in Subjects With Renal Impairment and Healthy Subjects",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax","Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Mean residence time, Plasma concentration, Safety and Tolerability, Tmax, Vital signs, Volume of distribution",True,NCT02063204,29657
4548,202252,"5005, D1532C00071, NCT02056392, TrialTroveID-202252","A Phase I, Double-blind (Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), Placebo-controlled, Open-Label (Moxifloxacin) Positive-controlled, Randomized, Three-period Crossover Study to Assess the Effects of Single Oral Dose of Selumetinib (75 mg) on QTc Interval Compared to Placebo, Using AVELOX (Moxifloxacin) as a Positive Control, in Healthy Male Volunteers Aged 18 to 45 Years",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma",,,True,NCT02056392,29657
4549,201574,"D1532C00085, NCT02046850, TrialTroveID-201574","A Phase I Open-label, Single-center Study to Assess the Effect of the CYP3A4 Inducer Rifampicin on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Volunteers Aged 18 to 45 Years",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Plasma concentration","Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Mean residence time, Metabolite to parent ratio, Plasma concentration, Safety and Tolerability, Tmax, Vital signs",True,NCT02046850,29657
4550,200019,"201312070MIP, 201312070MIPC, NCT02025114, TrialTroveID-200019","A Phase IB/II, Open Label, Multicenter Study of Selumetinib Administered Orally in Combination With Gefitinib in Patients With EGFR-mutated Non-small Cell Lung Cancer Who Have Developed Acquired Resistance of EGFR Inhibitor Treatment",Oncology,"Oncology: Lung, Non-Small Cell",National Taiwan University Hospital,Academic,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Disease Progression, Overall response rate",True,NCT02025114,29657
4551,196548,"D1532C00069, NCT01974349, TrialTroveID-196548","A Phase I, Randomized, Open-label, Single-center, Crossover Study to Assess the Effect of Food on the Pharmacokinetics of a 75 mg Single Oral Dose of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Healthy Male Volunteers Aged 18 to 45 Years",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma",Cmax,"Adverse Events, Area under the curve score, Cmax, Drug clearance, Elimination half-life, Mean residence time, Metabolite to parent ratio, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs",True,NCT01974349,29657
4552,196499,"D1344C00001, EudraCT Number: 2013-003545-41, NCRN - 2951 SUMIT, NCT01974752, NL47183.058.14, ORPHA391969, ORPHA405798, ORPHA409714, REec-2014-1095, SUMIT, TrialTroveID-196499, UKCRN ID 16066","A Randomised, Double-Blind Study to Assess the Efficacy of Selumetinib (AZD6244: ARRY-142886) (Hyd-Sulfate) in Combination with Dacarbazine Compared with Placebo in Combination with Dacarbazine as First Systemic Therapy in Patients with Metastatic Uveal Melanoma (SUMIT) , , Selumetinib in Uveal Melanoma Investigator Trial (SUMIT)",Oncology,Oncology: Melanoma,AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of hospitalization, Duration of overall response, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT01974752,29657
4553,195299,"D1532C00086, NCT01960374, TrialTroveID-195299","A Phase I, Single-centre, Open-label, Dose-escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of Selumetinib Given Orally in Japanese and Non-Japanese Asian Healthy Male Volunteers",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax, Plasma concentration","Adverse Events, Area under the curve score, BCVA, Bioavailability, Cardiac Telemetry, Cmax, Common Terminology Criteria for Adverse Events, Drug clearance, Elimination half-life, Ophthalmic examination, Plasma concentration, Safety and Tolerability, Safety and Tolerability, Tmax, Vital signs, Volume of distribution",True,NCT01960374,29657
4554,194446,"D1532C00075, JapicCTI-132399, NCT01949870, TrialTroveID-194446","A Phase I, Open-Label, Multi-Center Study to Assess the Safety and Tolerability of Selumetinib (AZD6244, ARRY-142886) in Combination With Cisplatin/Gemcitabine in Japanese Patients With Inoperable Locally Advanced or Metastatic Biliary Tract Cancer (BTC)",Oncology,Oncology: Liver,AstraZeneca,"Industry, Top 20 Pharma",Dose-limiting toxicities,"Cmax, Overall response rate, Plasma concentration, Tmax",True,NCT01949870,29657
4555,193023,"D1532C00077, EudraCT Number: 2013-003242-16, IRAS ID: 136295, NCT01931761, TrialTroveID-193023","A Phase I, Single-centre, Non-randomised, Open-label, Pharmacokinetic and Mass Balance Study of Orally Administered [14C]-Selumetinib in Healthy Male Volunteers",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma",,"Adverse Events, Area under the curve score, Cmax, Drug clearance, Plasma concentration, Safety and Tolerability, Tmax, Vital signs",True,NCT01931761,29657
4556,186897,"NCI-2013-01014, NCT01859182, OSU 12181, TrialTroveID-186897",A Multicenter Phase II Study of the Combination of AZD6244 Hydrogen Sulfate and MK-2206 in Patients With Refractory Advanced Biliary Cancers,Oncology,Oncology: Liver,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Functional Assessment of Cancer Therapy-General, Overall response rate, Overall survival, Progression-free survival, Quality of Life",True,NCT01859182,29657
4557,183262,"120448, 28746, D1532C00070, EudraCT number: 2012-005202-22, NCT01809210, SELECT-3, TrialTroveID-183262","A Phase I, Open-Label, Multicentre Study to Assess the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of Selumetinib (AZD6244; ARRY-142886) in Combination With First Line Chemotherapy Regimens in Patients With Non-Small Cell Lung Cancer (NSCLC)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Dose-limiting toxicities, Safety and Tolerability","Area under the curve score, Cmax, Complete response, Concentration at steady state, Drug clearance, Magnetic Resonance Imaging, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT01809210,29657
4558,181830,"00044927, 13/09, 13-133, 13-327, 14-0094, ASTRA, Astra-studie 65, D1532C00065, DRKS00005563, EudraCT Number: 2013-000423-14, NCT01843062, TrialTroveID-181830, VICCTHN1318","A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer",Oncology,Oncology: Neuroendocrine; Oncology: Thyroid,AstraZeneca,"Industry, Top 20 Pharma",Complete response,"Adverse Events, Area under the curve score, Common Terminology Criteria for Adverse Events, Complete response, Plasma concentration, Safety and Tolerability, Safety and Tolerability",True,NCT01843062,29657
4559,181347,"00048490, 14-057, AAAM0650, CTBE2014000251, D1532C00079, EudraCT Number: 2013-001676-38, IRAS ID: 136253, McG 1336, NCI-2014-00422, NCRN - 2652, NCT01933932, NL45179.031.13, PER-071-13, RECF2424, REec-2014-0815, SELECT-1, TrialTroveID-181347, VICCTHN1379","A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Plasma concentration, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01933932,29657
4560,179373,"12-547, AstraZeneca#SELECT-2, AZD-D1532C00064, CSET 1958, D1532C00064, EudraCT number: 2012-003622-25, NCT01750281, NL44811.031.13, RECF2425, SELECT-2, TrialTroveID-179373","A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, Compared With Placebo in Combination With Docetaxel, in Patients Receiving Second Line Treatment for Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Quality of Life, Safety and Tolerability, Safety and Tolerability",True,NCT01750281,29657
4561,179022,"I215, IND.215, IND215, LUIND215, NCT01783197, TrialTroveID-179022",A Phase Ib Study Of Selumetinib In Patients With Previously Treated Or Untreated Advanced/Metastatic NSCLC Who Are Receiving Standard Chemotherapy Regimens,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Canadian Cancer Trials Group {NCIC Clinical Trials Group}","Industry, Top 20 Pharma, Cooperative Group",Safety and Tolerability,,True,NCT01783197,29657
4562,171454,"AZD6244Formula, D1532C00066, NCT01635023, TrialTroveID-171454","A Phase I, Single-center, Randomized, Open-label, Crossover Study to Compare the White (Current Phase II) and Blue (Planned Phase III) Capsule Formulations of AZD6244 Hyd-Sulfate in Healthy Male Subjects",Oncology,Oncology: Unspecified Cancer,AstraZeneca,"Industry, Top 20 Pharma","Area under the curve score, Cmax","Adverse Events, Area under the curve score, Cmax",True,NCT01635023,29657
4563,169729,"EudraCT Number: 2011-003099-35, ISRCTN24921472, NCT01752569, SA1001, SCART, STH16059, TrialTroveID-169729, UKCRN ID: 11876",Phase I/II study of oral MEK inhibitor Selumetinib (AZD6244 Hyd-Sulphate) in Combination with Highly Active Anti-Retroviral Therapy (HAART) in AIDS-associated Kaposiâs sarcoma (KS),Infectious Disease,Infectious Disease: HIV,"(Other Industry Sponsor), AstraZeneca, (Other Cooperative Group), Cancer Research UK, University of Sheffield, (Other Hospital/Academic/Medical Center)","Industry, all other pharma, Industry, Top 20 Pharma, Cooperative Group, Not for Profit Funding Entity, Academic, Academic","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Safety and Tolerability",,True,NCT01752569,29657
4564,169027,"120130, 12-C-0130, NCT01610544, TrialTroveID-169027",A Pilot Study of 18F FLT PET/CT in Evaluating Early Response to Anti-Proliferative Therapies in Non Small Cell Lung Cancer and Thymic Tumors,Oncology,"Oncology: (N/A); Oncology: Lung, Non-Small Cell",National Institutes of Health/National Cancer Institute,Government,Progression-free survival,,True,NCT01610544,29657
4565,168410,"D1532C00067, JapicCTI-121881, NCT01605916, TrialTroveID-168410","A Phase I, Open-Label Study to Investigate the Safety and Tolerability of AZD6244 (Selumetinib) When Given as a Monotherapy in Japanese Patients With Advanced Solid Malignancies, and When Given in Combination With Docetaxel as 2nd Line Therapy in Japanese Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIB-IV)",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",AstraZeneca,"Industry, Top 20 Pharma","Cmax, Plasma concentration, Tmax","Cmax, Plasma concentration, Tmax",True,NCT01605916,29657
4566,160356,"8867, MCC-16950, MCC-VICCMEL1120, NCI 8867, NCI-2012-00238, NCT01510444, NCT01519427, TrialTroveID-160356, VICCMEL1120","A Phase II Trial of MAP Kinase Inhibition With AZD6244 Hydrogen Sulfate in Combination With MK-2206 (Akt Inhibitor) in Patients With BRAF V600-Mutant Advanced Melanoma Whose Disease Has Progressed on Prior Therapy With a Selective BRAF Inhibitor (i.e., Vemurafenib, Dabrafenib, LGX818)",Oncology,Oncology: Melanoma,"National Institutes of Health/National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute","Government, Academic","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Stable Disease","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01510444,29657
4567,156307,"11219, CRUKD/11/001, EudraCT Number:2011-000627-33, IRAS ID: 87422, ISRCTN69481429, MREC NÂ°:11/SC/0409, NCT01586624, TrialTroveID-156307, UKCRN ID:11219, VanSel1, VanSel-1","A Cancer Research UK Phase I Dose Escalation Trial of Oral VEGFR and EGFR Inhibitor, Vandetanib in Combination With the Oral MEK Inhibitor, Selumetinib (VanSel-1) in Solid Tumours (Dose Escalation) and NSCLC (Expansion Cohort).",Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell; Oncology: Mesothelioma; Oncology: Pancreas; Oncology: Unspecified Solid Tumor","AstraZeneca, Cancer Research UK, Pfizer {Array BioPharma}","Industry, Top 20 Pharma, Not for Profit Funding Entity, Industry, Top 20 Pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability","Maximum tolerated dose, Overall survival, Plasma pharmacokinetics, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01586624,29657
4568,147431,"8810, MAYO-MC1012, MC1012, NCI-2011-01083, NCI-2012-02906, NCT01364051, TrialTroveID-147431","Phase I Study of the Combination of the VEGFR Inhibitor, AZD2171, and MEK Inhibitor, AZD6244, in the Treatment of Solid Malignancies",Oncology,Oncology: Melanoma; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, NCI-CTC scale, Neutropenia, Partial response, Response evaluation criteria in solid tumors",True,NCT01364051,29657
4569,146179,"12.09.008, CALGB S1115, NCI-2012-01993, NCT01658943, S1115, SWOG S1115, SWOG-S1115, TrialTroveID-146179",Randomized Phase II Clinical Trial of AZD6244 Hydrogen Sulfate (NSC-748727) and MK-2206 (NSC-749607) vs mFOLFOX in Patients with Metastatic Pancreatic Cancer after Prior Chemotherapy,Oncology,Oncology: Pancreas,"Southwest Oncology Group, National Institutes of Health/National Cancer Institute","Cooperative Group, Government",Overall survival,"Adverse Events, Overall response rate, Partial response, Progression-free survival",True,NCT01658943,29657
4570,145040,"110117, 11-C-0117, NCI-11-C-0117, NCT01333475, TrialTroveID-145040","Pilot Study of the Combination of MK-2206, an AKT Inhibitor, and AZD6244, a MEK Inhibitor, in Patients With Advanced Colorectal Carcinoma.",Oncology,Oncology: Colorectal,National Institutes of Health/National Cancer Institute,Government,,Adverse Events,True,NCT01333475,29657
4571,143556,"20100252, EPROST-20100252, NCT01313039, TrialTroveID-143556, UMIAMI-20100252",Evaluation of the Use of AZD6244 to Induce Increased ER Expression and Anti-Estrogen Response in ER-Negative/Low Breast Cancer,Oncology,Oncology: Breast,"Sylvester Cancer Center, University of Miami",Academic,"Overall response rate, Response rate",,True,NCT01313039,29657
4572,143177,"110096, 11-C-0096, CUSTOM, NCI-11-C-0096, NCT01306045, TrialTroveID-143177","Pilot Trial of Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies.",Oncology,"Oncology: (N/A); Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell",National Institutes of Health/National Cancer Institute,Government,"Overall response rate, Response rate","Duration of overall response, Overall survival, Progression-free survival",True,NCT01306045,29657
4573,141077,"12-0110, 2013-0366, 8611, NCI-10H03, NCI-2011-02558, NCT01278615, NU-10H03, TrialTroveID-141077",A Single-Arm Phase II Clinical Trial With the Novel MEK Inhibitor AZD-6244 for the Treatment of MCT-1 Related Relapsed or Refractory Diffuse Large B-cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",National Institutes of Health/National Cancer Institute,Government,"Clinical benefit rate, Complete response, Overall response rate, Partial response, Response rate, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to treatment failure",True,NCT01278615,29657
4574,138455,"2009-0360, BATTLE-2, NCI-2011-01104, NCT01248247, TrialTroveID-138455",BATTLE-2 Program: A Biomarker-Integrated Targeted Therapy Study in Previously Treated Patients with Advanced Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, GlaxoSmithKline, Novartis, MD Anderson Cancer Center, University of Texas, National Institutes of Health/National Cancer Institute, Astellas Pharma {OSI Pharmaceuticals}, Bayer AG/Bayer Pharmaceuticals, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic, Government, Industry, all other pharma, Industry, Top 20 Pharma, Industry, Top 20 Pharma",Clinical benefit rate,"Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Time to progression",True,NCT01248247,29657
4575,137964,"ABC-04, CRUKE/10/036, EudraCT: 2010-018522-39, MREC No 11/SC/0128, NCT01242605, TrialTroveID-137964, UCL/10/0254, UKCRN 10110","ABC-04 a Phase IB Study of Cisplatin, Gemcitabine and Selumetinib in Patients With Advanced Biliary Tract Cancer",Oncology,Oncology: Liver; Oncology: Pancreas,"AstraZeneca, Cancer Research UK, University College London","Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic","Dose-limiting toxicities, Safety and Tolerability, Safety and Tolerability","Overall response rate, Response rate",True,NCT01242605,29657
4576,137251,"CRUKE/10/026, DOC-MEK, EudraCT Number: 2009-018153-23, ISRCTN 89118367, MEL033, MREC NÂ° H10/0604/59, NCT01256359, OCTO_015, TrialTroveID-137251, UKCRN ID 8672",A Double Blind Randomised Phase II Trial of Docetaxel With or Without AZD6244 in wt BRAF Advanced Melanoma.,Oncology,Oncology: Melanoma,"AstraZeneca, University of Oxford","Industry, Top 20 Pharma, Academic","Disease Progression, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT01256359,29657
4577,137023,"100218, 10-C-0218, 11-0005, 8444, NCI-10-C-0218, NCI-8444, NCT01229150, NCT01239290, PHII-120, TrialTroveID-137023",Randomized Phase II Study of AZD6244 MEK-Inhibitor With Erlotinib in KRAS Wild Type and KRAS Mutant Advanced Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell","National Institutes of Health/National Cancer Institute, Beckman Research Institute, University of Southern California, City of Hope Comprehensive Cancer Center, (Other Hospital/Academic/Medical Center), University of California Davis","Government, Academic, Academic, Academic, Academic, Academic","Complete response, Disease Progression, Overall response rate, Partial response, Progression-free survival","Adverse Events, Clinical benefit rate, Complete response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT01229150,29657
4578,136607,"10454, 8598, NCI-2011-01266, NCT01222689, TrialTroveID-136607, USCF-10454",A Phase II Study of AZD6244 Plus Erlotinib for the Second-Line Treatment of Advanced Pancreatic Adenocarcinoma,Oncology,Oncology: Pancreas,National Institutes of Health/National Cancer Institute,Government,Overall survival,"Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT01222689,29657
4579,136108,"110075, 11-C-0075, 8627, CO10901, NCT01217450, NCT01287130, TrialTroveID-136108, WCCC-CO-10901",A Phase I Study of AZD6244 in Combination With Cetuximab in Refractory Solid Tumors.,Oncology,"Oncology: Colorectal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell",National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors","NCI-CTC scale, Safety and Tolerability, Safety and Tolerability",True,NCT01217450,29657
4580,135203,"10082, 11S-10-1, 8412, CHNMC-PHII-95, NCCN-T06, NCI #8412, NCI-2011-02532, NCT01206140, PHII-95, TrialTroveID-135203","Randomized, Phase II Trial of AZD6244 Alone and AZD6244 Plus Temsirolimus for Soft-Tissue Sarcomas",Oncology,Oncology: GIST; Oncology: Soft Tissue Sarcoma,"National Institutes of Health/National Cancer Institute, National Comprehensive Cancer Network","Government, Cooperative Group","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate",True,NCT01206140,29657
4581,131488,"16066, MCC-16066, NCI-2012-02846, NCI-P-8436, NCT01166126, TrialTroveID-131488",Phase II Trial of mTOR Inhibitor Temsirolimus Combined With MEK Inhibitor AZD 6244 in Patients With BRAF Mutant Stage IV Melanoma,Oncology,Oncology: Melanoma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Disease Progression, Magnetic Resonance Imaging, NCI-CTC scale, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Serious Adverse Events",True,NCT01166126,29657
4582,131063,"09_DOG03_184, CRUKD/10/013, DREAM, DREAMtherapy, EudraCT 2009-016524-31, MREC NÂ°09/H1008/136, NCT01160926, TrialTroveID-131063, UKCRN 8671","Dual Phase I Studies to Determine the Dose of Cediranib (AZD2171) or AZD6244 to Use With Conventional Rectal Chemoradiotherapy. , , DREAM: Dual REctal Angiogenesis or MEK inhibition radioTHERAPY trial",Oncology,Oncology: Colorectal,"AstraZeneca, Cancer Research UK, Christie Hospital N.H.S. Trust","Industry, Top 20 Pharma, Not for Profit Funding Entity, Academic",Maximum tolerated dose,"Complete response, Magnetic Resonance Imaging, Resection rate, Treatment compliance",True,NCT01160926,29657
4583,130896,"EU-21046, EUDRACT-2010-019965-27, NCT01160718, SAKK 21/08, SAKK-21/08, SWS-SAKK-21/08, TrialTroveID-130896","Fulvestrant With or Without AZD6244, a Mitogen-Activated Protein Kinase Kinase (MEK) Â½ Inhibitor, in  Advanced Stage Breast Cancer Progressing After Aromatase Inhibitor: A Randomized  Placebo-Controlled Double-Blind Phase II Trial",Oncology,Oncology: Breast,"AstraZeneca, (Other Cooperative Group), Swiss Group for Clinical Cancer Research - SAKK","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group","Complete response, Partial response, Response evaluation criteria in solid tumors, Stable Disease","Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to treatment failure",True,NCT01160718,29657
4584,129690,"09/H1010/73, 09_DOG07_104, 10005 MEKRT, Eudract Number: 2009-013922-18, MEKRT, NCT01146756, TrialTroveID-129690","Phase I Trial of the MEK Inhibitor AZD6244 in Combination With Thoracic Radiotherapy in Non-small Cell Lung Cancer , , MEK Inhibitor and Thoracic Radiotherapy Trial (MEKRT)",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, (Other Hospital/Academic/Medical Center)","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Safety and Tolerability",Safety and Tolerability,True,NCT01146756,29657
4585,129102,"10-053, 203466042011, 8443, CONSORT, MSKCC-10053, NCI-2011-01411, NCI8443, NCT01143402, P2C 8443, TrialTroveID-129102, VICCMEL1053",Randomized Phase II Trial of Temozolomide Versus Hyd-sulfate AZD6244 [NSC 748727] in Patients with Metastatic Uveal Melanoma,Oncology,Oncology: Melanoma,National Institutes of Health/National Cancer Institute,Government,"Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, NCI-CTC scale, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT01143402,29657
4586,128302,"100132, 10-C-0132, NCI-10-C-0132, NCT01134601, TrialTroveID-128302",A Phase I Study of AZD6244 in Combination With Capecitabine and Radiotherapy in Locally Advanced Adenocarcinoma of the Rectum,Oncology,Oncology: Colorectal,National Institutes of Health/National Cancer Institute,Government,"Dose-limiting toxicities, Safety and Tolerability","Complete response, Maximum tolerated dose, Overall response rate, Response rate",True,NCT01134601,29657
4587,126867,"09CRC02, AGICC 09CRC02, AGICC003 /10-016, D9010C00009, NCT01116271, TrialTroveID-126867","A Dose Finding and Phase II Study of Selumetinib (AZD6244) (Hyd-Sulfate) in Combination With Irinotecan, in 2nd Line Patients With K-ras or B-raf Mutation Positive Advanced or Metastatic Colorectal Cancer",Oncology,Oncology: Colorectal,AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Response rate","Adverse Events, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events",True,NCT01116271,29657
4588,124092,"10-C-0079, 16137, 24918/1, 8631, GCC 1004, MCC#16137, MCC-16137, NCI-10-C-0079, NCI-2012-02929, NCI-8631, NCT01085214, TrialTroveID-124092",A Phase II Study of AZD6244 in Multiple Myeloma.,Oncology,Oncology: Multiple Myeloma,National Institutes of Health/National Cancer Institute,Government,"Complete response, Overall response rate, Partial response, Response rate","Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Progression-free survival, Progressive disease rate",True,NCT01085214,29657
4589,122285,"8269, J0961, NA_00028512, NCI-2012-02912, NCT01061749, TrialTroveID-122285","A Phase I, Single-institution Open Label, Dose-escalation Trial With an Expansion Trial Cohort Evaluating the Safety and Tolerability of AZD6244 and IMCA12 in Subjects With Advanced Solid Malignancies",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Osteosarcoma; Oncology: Pancreas; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","AstraZeneca, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Government","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Area under the curve score, Cmax, Cmin, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT01061749,29657
4590,120034,"09-20-HEP, NCT01029418, TrialTroveID-120034",A Phase I/II Study of AZD6244 in Combination With Sorafenib in Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,"AstraZeneca, (Other Academic Cancer Center)","Industry, Top 20 Pharma, Academic","Dose-limiting toxicities, Maximum tolerated dose",Time to progression,True,NCT01029418,29657
4591,118635,"09-342-B, CC824, GOG 0229H, GOG-0229H, NCI-2011-01958, NCT01011933, TrialTroveID-118635","A Phase II Evaluation of AZD6244 (NSC #748727, IND #77782) in the Treatment of Recurrent or Persistent Endometrial Carcinoma",Oncology,Oncology: Endometrial,"AstraZeneca, Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Cooperative Group, Government","CA-125 Response, Common Terminology Criteria for Adverse Events, Complete response, Event-free survival, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT01011933,29657
4592,114780,"09-048, NCT00970359, TrialTroveID-114780",Reacquisition of RAI Uptake of RAI-Refractory Metastatic Thyroid Cancers by Pretreatment with the Selective MEK Inhibitor AZD6244: A Pilot Study,Oncology,Oncology: Metastatic Cancer; Oncology: Thyroid,"AstraZeneca, Memorial Sloan-Kettering Cancer Center, Sanofi {Sanofi-Aventis}/Sanofi Genzyme {Genzyme}","Industry, Top 20 Pharma, Academic, Industry, Top 20 Pharma",Response evaluation criteria in solid tumors,,True,NCT00970359,29657
4593,111762,"AstraZeneca BV D1532C00006, CSET 1525, D1532C00006, EudraCT Number: 2008-006344-19, MDACC 2009-0214, NCRN063, NCT00936221, RECF1110, TrialTroveID-111762, UKCRN 6059","A Phase II, Double-blind, Randomized Study to Assess the Efficacy of AZD6244 in Combination With Dacarbazine Compared With Dacarbazine Alone in First Line Patients With BRAF Mutation Positive Advanced Cutaneous or Unknown Primary Melanoma",Oncology,Oncology: Melanoma,AstraZeneca,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Complete response, Disease Progression, Magnetic Resonance Imaging, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT00936221,29657
4594,109659,"010-02, 2009_698, 2009-0878, 2206-010, MK-2206-010 AM6, MK2206-010-01, NCT01021748, TrialTroveID-109659",A Phase I Study of Oral MK2206 in Combination With Oral AZD6244 in Patients With Locally Advanced or Metastatic Solid Tumors.,Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","AstraZeneca, Merck & Co./Merck Sharp & Dohme (MSD)","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Disease Progression, Overall response rate, Plasma concentration, Response evaluation criteria in solid tumors",True,NCT01021748,29657
4595,107957,"10283, D1532C00016, EudraCT Number: 2008-006323-31, NCT00890825, RECF1032, Study 16, TrialTroveID-107957","A Phase II, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy of AZD6244 (Hyd-Sulfate) in Combination with Docetaxel, Compared With Docetaxel Alone, in 2nd Line Patients with KRAS Mutation Positive Locally Advanced Metastatic Non Small Cell Lung Cancer (Stage IIIB- IV)",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma","Overall survival, Progression-free survival","Adverse Events, Disease Progression, Duration of overall response, Overall response rate, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00890825,29657
4596,99760,"2007-0574, NCI-2012-01671, NCT00780676, TrialTroveID-099760",Personalized Treatment Selection for Metastatic Breast Cancer,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"AstraZeneca, Bristol-Myers Squibb, MD Anderson Cancer Center, University of Texas","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Academic","Clinical benefit rate, Complete response, Disease Progression, Overall response rate, Partial response, Progressive disease rate, Stable Disease",Safety and Tolerability,True,NCT00780676,29657
4597,93628,"D1532C00020, EudraCT Number: 2007-004456-37, M08AZD, NCT00710515, SA127, TrialTroveID-093628","A Phase I, Open-Label Study to Assess the Effect of Dosing AZD6244 HydSulfate in the Presence and Absence of Food in Patients With Advanced Solid Malignancies",Oncology,Oncology: Unspecified Solid Tumor,AstraZeneca,"Industry, Top 20 Pharma",,"Safety and Tolerability, Safety and Tolerability",True,NCT00710515,29657
4598,90334,"09-005, DFCI 09-005, MSKCC 10-010, NCI # 8281, NCI-2013-00576, NCT00888134, TrialTroveID-090334",Phase II Clinical Trial of the MEK 1/2 Inhibitor AZD6244 in Cancers With BRAF Mutations Identified by Prospective Genotypic Analysis,Oncology,"Oncology: Colorectal; Oncology: Lung, Non-Small Cell","AstraZeneca, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Government","Complete response, Overall response rate, Partial response","Circulating Tumor Cells, Complete response, Overall response rate, Partial response, Progression-free survival",True,NCT00888134,29657
4599,90333,"09-003, 8252, NCI #8252, NCI-2009-01164, NCT00866177, TrialTroveID-090333",Phase II Trial of Hyd-sulfate AZD6244 [NSC 748727] in Patients With BRAF or NRAS Mutated Melanomas,Oncology,Oncology: Melanoma,"AstraZeneca, National Institutes of Health/National Cancer Institute","Industry, Top 20 Pharma, Government",Response evaluation criteria in solid tumors,"Overall response rate, Response rate",True,NCT00866177,29657
4600,82829,"D1532C00004, MDACC-2008-0499, NCT00600496, REFMAL 129, RM 129, TrialTroveID-082829","A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886) When Given in Combination With Standard Doses of Selected Chemotherapies to Patients With Advanced Solid Tumors",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Renal",AstraZeneca,"Industry, Top 20 Pharma","Adverse Events, Brain Natriuretic Peptide concentration, Cardiac Telemetry, Common Terminology Criteria for Adverse Events, Liver function, Safety and Tolerability, Safety and Tolerability, Vital signs","Cmax, Gene expression profiling, Overall response rate, Plasma concentration, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT00600496,29657
4601,81647,"15455B, 7925, COH 07196, NCI #7925, NCI-2009-00250, NCT00588809, PHII-86, TrialTroveID-081647, UCCRC-15455B, UOC 15455B",A Phase II Study of AZD6244 in Relapsed or Refractory AML.,Oncology,"Oncology: Leukemia, Acute Myelogenous","National Institutes of Health/National Cancer Institute, University of Chicago Cancer Research Center","Government, Academic","Complete response, Overall response rate, Partial response, Response rate",Safety and Tolerability,True,NCT00588809,29657
4602,79986,"7918, HN 0763, LOI 7918, MCC#15305, MCC-LOI-7918, NCI7918, NCT00559949, NCT00589940, PHL-066, TrialTroveID-079986",Phase II Study of AZD6244 Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements,Oncology,Oncology: Thyroid,"National Institutes of Health/National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute","Government, Academic","Complete response, Overall response rate, Partial response","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT00559949,29657
4603,79064,"07056, 2007c0050, 7932, NCI-2009-00251, NCT00553332, NCT01645644, OSU-07056, TrialTroveID-079064, VICCGI0811",A Phase II Study of AZD6244 in Biliary Cancers,Oncology,Oncology: Liver,"AstraZeneca, National Institutes of Health/National Cancer Institute, Richard J. Solove Research Institute, Arthur G. James Cancer Hospital","Industry, Top 20 Pharma, Government, Academic, Academic","Complete response, Magnetic Resonance Imaging, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT00553332,29657
4604,78668,"09-007, BROW002718HE, GOG 239, GOG0239, GOG-0239, GOG-0239, NCI-2009-00604, NCT00551070, SU-05192008-1165, TrialTroveID-078668","A Phase II Trial of AZD6244 (NSC #741078, IND #77782) in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary or Peritoneum",Oncology,Oncology: (N/A); Oncology: Ovarian,"Gynecologic Oncology Group (GOG), National Institutes of Health/National Cancer Institute, NRG Oncology","Cooperative Group, Government, Cooperative Group","Adverse Events, Area under the curve score, Cmax, Common Terminology Criteria for Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Response rate","Common Terminology Criteria for Adverse Events, Overall survival, Progression-free survival",True,NCT00551070,29657
4605,78622,"07-0973, 77782, 7909, GCRC-2625-ORC, MCC-07-0973, MCC-15260, NCI#7909, NCI-2009-00247, NCI7909, NCT00550719, NCT00604721, NCT01656291, TrialTroveID-078622, VICCGI0726, VU-VICC-GI-0726",A Phase II Study of AZD6244 in Advanced or Metastatic Hepatocellular Carcinoma.,Oncology,Oncology: Liver,"AstraZeneca, National Institutes of Health/National Cancer Institute, H. Lee Moffitt Cancer Center and Research Institute","Industry, Top 20 Pharma, Government, Academic","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Disease Progression, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT00550719,29657
4606,68042,"D1532C00005, NCT00463814, TrialTroveID-068042","A Phase I, Open Label, Multi-Centre Study to Assess the Safety, Tolerability and Pharmacokinetics of a Solid Oral Dosage Formulation (Capsule) of AZD6244 in Patients With Advanced Solid Malignancies.",Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma","AstraZeneca, Pfizer {Array BioPharma}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Safety and Tolerability, Safety and Tolerability","Bioavailability, Safety and Tolerability, Safety and Tolerability",True,NCT00463814,29657
4607,56126,"AZ-D1532C00012, D1532C00012, HSR-06-0692, NCT00372788, SJMHS IRB #2, TrialTroveID-056126","A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 Versus Pemetrexed (Alimta) in Patients With Non-Small Cell Lung Cancer, Who Have Failed One or Two Prior Chemotherapy Regimen.",Oncology,"Oncology: Lung, Non-Small Cell",AstraZeneca,"Industry, Top 20 Pharma",Disease Progression,"Adverse Events, Safety and Tolerability, Safety and Tolerability",True,NCT00372788,29657
4608,56076,"AZ-D1532C00008, CRC 0658, D1532C00008, EudraCT Number: 2006-005746-36, NCT00372944, TrialTroveID-056076","A Phase II, Open, Randomised Study to Assess the Efficacy and Safety of AZD6244 vs. Capecitabine (Xeloda) in Patients With Advanced or Metastatic Pancreatic Cancer, Who Have Failed First Line Gemcitabine Therapy.",Oncology,Oncology: Pancreas,AstraZeneca,"Industry, Top 20 Pharma",Overall survival,"Adverse Events, Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00372944,29657
4609,50868,"06/MRE10/43, D1532C00003, EudraCT Number: 2006-001456-12, N0258179495, NCT00338130, TrialTroveID-050868, VICCMEL0619","A Phase II, Multi-Centre, Open-Label, Parallel Group, Randomised Study To Compare the Efficacy of AZD6244 vs Temozolomide in Patients With Unresectable AJCC Stage 3 or 4 Malignant Melanoma.",Oncology,Oncology: Melanoma,AstraZeneca,"Industry, Top 20 Pharma","Duration of overall response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Duration of overall response, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT00338130,29657
4610,50169,"D1532C00011, E3-studien CR, EudraCT Number: 2006-001457-10, NCT00514761, TrialTroveID-050169","A Phase II, Open, Randomized Study to Assess the Efficacy and Safety of AZD6244 vs Capecitabine (Xeloda) in Patients With Colorectal Cancer Who Have Failed One or Two Prior Chemotherapeutic Regimens.",Oncology,Oncology: Colorectal,"AstraZeneca, Pfizer {Array BioPharma}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Safety and Tolerability, Safety and Tolerability",True,NCT00514761,29657
4611,9258,"ARRY-0401, NCT00085787, PARRAY001, TrialTroveID-009258","A Phase I, Open-Label, Multiple Dose Study to Assess the Tolerability, Pharmacokinetics and Pharmacodynamics of ARRY-142886 Given on a Daily Oral Regime in Subjects with Advanced Solid Malignancies",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Thyroid","AstraZeneca, Pfizer {Array BioPharma}","Industry, Top 20 Pharma, Industry, Top 20 Pharma","CA-125 Response, Dose-limiting toxicities, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",,True,NCT00085787,29657
4612,268202,"2015-0480, EudraCT Number: 2015-002947-33, J1689, NCI-2015-02144, NCT02608125, PRN1371, PRN1371-001, TrialTroveID-268202","A Phase I Open-Label, Multicenter, Dose-Escalation Study of PRN1371, a FGFR 1-4 Kinase Inhibitor, in Adult Patients With Advanced Solid Tumors, Followed by an Expansion Cohort in Patients With Metastatic Urothelial Carcinoma With FGFR I, II, III, or IV Genetic Alterations",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Renal; Oncology: Unspecified Solid Tumor",Sanofi/Principia Biopharma,"Industry, Top 20 Pharma","Adverse Events, Dose-limiting toxicities, Duration of overall response, Maximum tolerated dose, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vital signs","Area under the curve score, Bioavailability, Duration of overall response, Overall response rate, Phosphate level, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT02608125,87604
4613,169170,"A9301/A9302, EN3329-A9301/A9302, NCT01316874, TrialTroveID-169170",Intravesical AD 32 (Valrubicin) in Patients With Carcinoma in Situ (CIS) of the Bladder Who Have Failed or Have Recurrence Following Treatment With Bacillus Calmette-Guerin (BCG),Oncology,Oncology: Bladder,Endo International {Endo Pharmaceuticals},"Industry, all other pharma",Recurrence,,True,NCT01316874,18983
4614,168499,"16722, MCC-16722, NCT01606345, TrialTroveID-168499",Phase I Dose Escalation and Landmark Study of Percutaneous Valrubicin for Upper Tract Urothelial Carcinoma (UTUC) Following Endoscopic Resection,Oncology,Oncology: Bladder; Oncology: Renal,"H. Lee Moffitt Cancer Center and Research Institute, Endo International {Endo Pharmaceuticals}","Academic, Industry, all other pharma","Maximum tolerated dose, Safety and Tolerability","Disease-free survival, Progression-free survival, Recurrence",True,NCT01606345,18983
4615,168496,"9607 03, A9303, ANTHRA-A9303, NCI-V95-0696, TrialTroveID-168496",Phase II/III Study of Intravesical AD 32 (a Doxorubicin Analogue) for in Situ Transitional Cell Carcinoma of the Bladder with or without Prior BCG,Oncology,Oncology: Bladder,Anthra Pharmaceuticals,"Industry, all other pharma",,,False,,18983
4616,143636,"EN3329-402, NCT01314664, TrialTroveID-143636",A Prospective Registry to Assess the Effectiveness and Local Tolerability of Intravesical Valrubicin in Subjects with Non-Muscle Invasive Bladder Cancer (NMIBC),Oncology,Oncology: Bladder,Endo International {Endo Pharmaceuticals},"Industry, all other pharma",,,True,NCT01314664,18983
4617,143519,"EN3329-301, NCT01310803, TrialTroveID-143519","A Phase IIIb, Randomized, Open-Label, Multi-Center Study to Evaluate the Efficacy and Safety of Maintenance Therapy with Valrubicin versus no Maintenance, in Subjects Treated with Valrubicin Induction for Carcinoma in Situ (CIS) of the Bladder",Oncology,Oncology: Bladder,Endo International {Endo Pharmaceuticals},"Industry, all other pharma",Recurrence,"Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT01310803,18983
4618,2959,"ANTHRA-A9601, NCT00003725, TrialTroveID-002959",Phase III Randomized Study of AD 32 Following Transurethral Resection in Patients with Newly Diagnosed or Recurrent Superficial Transitional Cell Carcinoma of the Bladder,Oncology,Oncology: Bladder,Anthra Pharmaceuticals,"Industry, all other pharma",,,True,NCT00003725,18983
4619,2718,"ANTHRA-A9503, TrialTroveID-002718","Phase III Randomized Study of Intraperitoneal AD 32 Versus Oral Altretamine in Patients with Refractory or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Who Have Failed Platinum and Paclitaxel Chemotherapy",Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,Anthra Pharmaceuticals,"Industry, all other pharma","CA-125 Response, Quality of Life, Time to progression",,False,,18983
4620,441,"E3897, E-3897, ECOG-3897, FCCC-98209, NCT00003129, TrialTroveID-000441",Phase II Study of Intravesical Therapy With AD-32 in Patients With Papillary Urothelial Carcinoma or Carcinoma in Situ (CIS) Refractory to Prior Therapy With Bacillus Calmette-Guerin,Oncology,Oncology: Bladder,"Eastern Cooperative Oncology Group (ECOG), National Institutes of Health/National Cancer Institute","Cooperative Group, Government","Disease-free survival, Recurrence, Safety and Tolerability",,True,NCT00003129,18983
4621,433,"ANTHRA-A9701/ID97-038, MDA-ID-97038, NCT00003759, TrialTroveID-000433",Phase II Randomized Study of Peri-Operative Intravesical AD 32 Alone or Supplemented with BCG in Patients With Newly Diagnosed or Recurrent Superficial Bladder Cancer,Oncology,Oncology: Bladder,Anthra Pharmaceuticals,"Industry, all other pharma",Recurrence,,True,NCT00003759,18983
4622,188292,TrialTroveID-188292,A Compassionate Use Program of Site Specific Immunomodulators (SSis) for the Treatment of Advanced Cancer and Autoimmune Disease,Autoimmune/Inflammation; Oncology,"Autoimmune/Inflammation: Crohn's Disease; Autoimmune/Inflammation: Rheumatoid Arthritis; Autoimmune/Inflammation: Ulcerative Colitis; Oncology: Breast; Oncology: Colorectal; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Prostate; Oncology: Skin, Basal Cell Carcinoma",Qu Biologics,"Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability",,False,,79614
4623,392922,TrialTroveID-392922,A Clinical Trial of TT-00434 for the Treatment of Bladder Cancer and Cholangiocarcinoma,Oncology,Oncology: Bladder; Oncology: Liver,TransThera Biosciences Co.,"Industry, all other pharma",,,False,,167463
4624,204499,"SUCCESS, TrialTroveID-204499, UMIN000008611","A single-center open-label parallel-group study on the efficacy and the safety of survivin-2B peptide vaccine therapy for patients with advanced or recurrent digestive organ cancer, for which there is no effective treatment",Oncology,Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government","Safety and Tolerability, Vital signs",Magnetic Resonance Imaging,False,,38288
4625,196537,"SUCCESS-II, TrialTroveID-196537, UMIN000012146","A Multi-Center Double-Blind Parallel-Group Placebo-Control Phase II Study on the Efficacy of Survivin-2B Peptide Vaccine Therapy for Patients with Advanced or Recurrent Pancreatic Cancer, and for Which there is no Effective Treatment",Oncology,Oncology: Pancreas,"(Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare","Academic, Government","Disease Progression, Progression-free survival, Time to progression","Common Terminology Criteria for Adverse Events, Immune Response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,38288
4626,156728,"TrialTroveID-156728, UMIN000005859",Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Combined with IFA and IFN-alpha for Patients with Urothelial Cancer (Phase I clinical study),Oncology,Oncology: Bladder; Oncology: Renal,"Ministry of Education, Science and Culture, Japan, (Other Hospital/Academic/Medical Center)","Government, Academic",,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4627,95257,"TrialTroveID-095257, UMIN000000905","Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA, IFA and IFN-alpha, IFA and IL-2, or IFA and GM-CSF for Patients with Digestive Cancer and Endocrine Organic Cancer (Phase I clinical study).",Oncology,Oncology: Pancreas,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center), Japanese Ministry of Health, Labour and Welfare, (Other government agency)","Cooperative Group, Academic, Government, Government",Safety and Tolerability,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4628,94034,"TrialTroveID-094034, UMIN000000976",Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Oral Cancer.,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4629,93663,"TrialTroveID-093663, UMIN000000999",Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide Mixed with IFA and IFN-alpha for Patients with Oral Cancer (Phase I clinical study),Oncology,Oncology: Head/Neck,"Ministry of Education, Science and Culture, Japan, (Other Hospital/Academic/Medical Center)","Government, Academic",,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4630,84498,"TrialTroveID-084498, UMIN000000902",Immunotherapy Using HLA-A24-restricted Survivin-derived Peptide for Patients with Colorectal Cancer and Breast Cancer,Oncology,Oncology: Breast; Oncology: Colorectal,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Safety and Tolerability,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4631,70039,"TrialTroveID-070039, UMIN000001499","Phase I Clinical Study of Anti-Apoptosis Protein, Survivin-Derived Peptide Vaccine Therapy for Patients with Advanced or Recurrent Urothelial Cancer.",Oncology,Oncology: Bladder; Oncology: Renal,(Other Academic Cancer Center),Academic,,"Immune Response, Response evaluation criteria in solid tumors",False,,38288
4632,61274,TrialTroveID-061274,"Induction of Survivin-Specific, HLA-A24 Restricted Cytotoxic T Lymphocytes Using an Immunodominant Peptide; a Clinical Trial of Survivin Peptide Vaccination",Oncology,"Oncology: Lymphoma, Hodgkin's; Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,,False,,38288
4633,387879,"ISPY-P1.01, NCT04602117, TrialTroveID-387879",Evaluating the Safety of Weekly Paclitaxel With Trastuzumab Duocarmazine (SYD985) in Patients With Metastatic Cancer: A Phase I/Ib Trial,Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Ovarian,(Other Cooperative Group),Cooperative Group,"Adverse Events, Common Terminology Criteria for Adverse Events, NCI-CTC scale",,True,NCT04602117,35802
4634,365737,"NCT04235101, SYD985.004, TrialTroveID-365737","A Two-part Phase I Study With the Antibody-drug Conjugate SYD985 in Combination With Niraparib to Evaluate Safety, Pharmacokinetics and Efficacy in Patients With HER2-expressing Locally Advanced or Metastatic Solid Tumors.",Oncology,Oncology: Breast; Oncology: Endometrial; Oncology: Ovarian; Oncology: Unspecified Solid Tumor,Byondis {Synthon},"Industry, all other pharma",Dose-limiting toxicities,"Adverse Events, Area under the curve score, Overall response rate, Plasma concentration",True,NCT04235101,35802
4635,363841,"NCT04205630, SYD985.003, TrialTroveID-363841",A Single-arm Phase II Trial to Evaluate the Safety and Efficacy of the Antibody-Drug Conjugate (ADC) SYD985 in Patients With Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Endometrial Carcinoma Who Previously Progressed on or After First Line Platinum-based Chemotherapy,Oncology,Oncology: Endometrial,Byondis {Synthon},"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04205630,35802
4636,307767,"17027, EudraCT Number: 2017-001994-18, IRAS ID:230951, NCI-2018-01394, NCT03262935, SYD985, SYD985.002, TrialTroveID-307767, TULIP, TULIP SYD985.002","A Multi-centre, Open-label, Randomized Clinical Trial Comparing the Efficacy and Safety of the Antibody-drug Conjugate SYD985 to Physician's Choice in Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer",Oncology,Oncology: Breast,Byondis {Synthon},"Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03262935,35802
4637,201742,"EudraCT Number: 2014-001798-15, IRAS ID 159824, MOMULT05, NCT02277717, NL50221.091.14, SYD985.001, TrialTroveID-201742","A Two Part First-in-human Phase I Study (With Expanded Cohorts) With the Antibody-drug Conjugate SYD985 to Evaluate the Safety, Pharmacokinetics and Efficacy in Patients With Locally Advanced or Metastatic Solid Tumors",Oncology,Oncology: Bladder; Oncology: Breast; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Renal; Oncology: Unspecified Solid Tumor,Byondis {Synthon},"Industry, all other pharma","Complete response, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Area under the curve score, Cmax, Duration of overall response, Elimination half-life, Overall response rate, Plasma concentration, Progression-free survival, Safety and Tolerability, Vital signs",True,NCT02277717,35802
4638,120942,"01042379, 097517, 17268, 2010-0145, 202755051910, 7518, ACRIN 6698 (Substudy), ACRIN-6698, Clinical Trial 17268, CRC 10016, I-SPY 2, I-SPY 2 Trial, I-SPY2, NCI-2014-00596, NCI-2015-00014, NCT01042379, NCT01564368, NCT02830282, STU 052011-089, TrialTroveID-120942, UPCC 16113",I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2),Oncology,Oncology: Breast,"(Other Cooperative Group), National Institutes of Health/National Cancer Institute, American College of Radiology Imaging Network (ACRIN)","Cooperative Group, Government, Cooperative Group","Complete response, Quality of Life","Adverse Events, Complete response, Disease-free survival, Event-free survival, Magnetic Resonance Imaging, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability, Serious Adverse Events",True,NCT01042379,35802
4639,396821,"NCT04752059, TrialTroveID-396821, TUXEDO-1",Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients With Newly Diagnosed or Progressing Brain Metastases,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Medical University of Vienna, Daiichi Sankyo","Academic, Industry, all other pharma","Overall response rate, Response rate","Adverse Events, Overall survival, Progression-free survival, Safety and Tolerability",True,NCT04752059,117921
4640,396211,"D9673C00007, DESTINY-B12, DESTINY-Breast12, NCT04739761, TrialTroveID-396211","An Open-Label, Multinational, Multicenter, Phase IIIb/IV Study of Trastuzumab Deruxtecan in Patients With or Without Baseline Brain Metastasis With Previously Treated Advanced/Metastatic HER2-Positive Breast Cancer (DESTINY-Breast12)",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Duration of overall response, EORTC Quality of Life Questionnaire, MD Anderson Symptom Inventory, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to progression, Treatment Emergent Adverse Events",True,NCT04739761,117921
4641,394056,"10358, DASH Trial, NCI-2020-13883, NCT04704661, TrialTroveID-394056",Phase I/I B Study of DS-8201a in Combination With ATR Inhibition (AZD6738) in Advanced Solid Tumors With HER2 Expression (DASH Trial),Oncology,Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Metastatic Cancer; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Progressive disease rate, Safety and Tolerability","Clinical benefit rate, Complete response, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors",True,NCT04704661,117921
4642,392844,TrialTroveID-392844,A Phase II Study of DS-8201 in Patients with HER2 Expressing Ovarian Cancer,Oncology,Oncology: Ovarian,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4643,392843,"DESTINY-PanTumor01, TrialTroveID-392843","Phase II, Multicenter, Open-Label Clinical Trial to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) as a Treatment for Unresectable and/or Metastasized Solid Cancer with HER2 Activating Mutation Regardless of Tumor Histology (DESTINY PanTumor01)",Oncology,Oncology: Unspecified Cancer,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Safety and Tolerability,,False,,117921
4644,392842,TrialTroveID-392842,A Phase III Study of DS-8201 as Combination in Patients with HER2 Expressing Metastatic Colorectal Cancer (CRC),Oncology,Oncology: Colorectal,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4645,392841,TrialTroveID-392841,A Phase III Study of DS-8201 as Combination in Patients with HER2 Expressing Metastatic Colorectal Cancer (CRC),Oncology,Oncology: Colorectal,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4646,392840,"DESTINY-CRC02, DS8201-A-U207, EudraCT Number: 2020-004782-39, jRCT2051200124, NCT04744831, TrialTroveID-392840","A Phase II, Multicenter, Randomized, Study of Trastuzumab Deruxtecan in Participants With HER2-overexpressing Locally Advanced, Unresectable or Metastatic Colorectal Cancer (DESTINY-CRC02)",Oncology,Oncology: Colorectal,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Abdominal pain, Anti-drug antibodies, Appetite, Bloat, Bowel Movement Frequency, Clinical benefit rate, Clinical Global Impression, Complete response, Duration of hospitalization, Duration of overall response, Dyspareunia, Dysuria, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Global health status, Nausea, Neutralizing antibody response, Overall response rate, Overall survival, Partial response, Patient Global Impression of Change, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Sexual Desire, Stable Disease, Treatment Emergent Adverse Events, Urinary incontinence, Vomiting",True,NCT04744831,117921
4647,392839,TrialTroveID-392839,A Phase III Study of DS-8201 as Combination in Patients with Early Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4648,392838,TrialTroveID-392838,A Phase III Study of DS-8201 in Patients with Advanced or Metastatic HER2 Mutated Non-Small Lung Cell Cancer,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4649,392837,"245497, D967YC00001, DESTINY-Lung03, DL03, NCT04686305, TrialTroveID-392837","A Phase Ib Multicenter, Open-label Dose-escalation Study to Evaluate the Safety and Tolerability of Trastuzumab Deruxtecan (T-DXd) and Durvalumab in Combination With Cisplatin, Carboplatin or Pemetrexed in First-line Treatment of Patients With Advanced or Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) and Human Epidermal Growth Factor Receptor 2 Overexpression (HER2+) (DESTINY-Lung03)",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04686305,117921
4650,392836,TrialTroveID-392836,"A Phase III Study of DS-8201 in Patients with HER2 Positive, Advanced or Metastatic Gastric Cancer",Oncology,Oncology: Gastric,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4651,392835,TrialTroveID-392835,"A Phase III Study of DS-8201 in Patients with HER2 Low, HR+ Metastaic Breast Cancer",Oncology,Oncology: Breast,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4652,392834,TrialTroveID-392834,"A Phase III Study of DS-8201 in Patients with HER2 Low, HR- Breast Cancer",Oncology,Oncology: Breast,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4653,392833,TrialTroveID-392833,"A Phase III Study of DS-8201 in Patients HER2 Low, HR+/HR- Breast Cancer",Oncology,Oncology: Breast,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4654,392832,TrialTroveID-392832,A Phase III Study of Adjuvant Treatment with DS-8201 in Patients with HEr2 Positive Breast Cancer,Oncology,Oncology: Breast,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4655,392831,TrialTroveID-392831,A Phase III Study of Neoadjuvant Treatment of DS-8201 in Patients with HER2 Positive Breast Cancer,Oncology,Oncology: Breast,Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4656,392830,"D967UC00001, DESTINY-Breast09, NCT04784715, TrialTroveID-392830","Phase III Study of Trastuzumab Deruxtecan (T-DXd) With or Without Pertuzumab Versus Taxane, Trastuzumab and Pertuzumab in HER2-positive, First-line Metastatic Breast Cancer (DESTINY-Breast09)",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT04784715,117921
4657,390294,"(DESTINY-LUNG02), DESTINY-LUNG02, DS8201-A-U206, jRCT2061200038, NCT04644237, TrialTroveID-390294","A Phase II, Multicenter, Randomized Study of Trastuzumab Deruxtecan in Subjects With HER2-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) (DESTINY-LUNG02)",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Anti-drug antibodies, Appetite, Area under the curve score, Clinical benefit rate, Cmax, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Nausea, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease, Time to progression, Treatment Emergent Adverse Events, Vomiting",True,NCT04644237,117921
4658,389845,"D967MC00001, DPT01, EudraCT Number: 2020-002368-30, NCT04639219, TrialTroveID-389845","A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd) for the Treatment of Unresectable and/or Metastatic Solid Tumors Harboring HER2 Activating Mutations Regardless of Tumor Histology",Oncology,Oncology: Unspecified Solid Tumor,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT04639219,117921
4659,388735,"21-2749, NCI-2020-08428, NCT04616560, PEPN1924, TrialTroveID-388735","A Phase II Study of DS-8201a (NSC# 807708) in Adolescents, or Young Adults With Recurrent HER2+ Osteosarcoma",Oncology,Oncology: Osteosarcoma,National Institutes of Health/National Cancer Institute,Government,Event-free survival,"Adverse Events, Circulating Tumor Cells, Event-free survival, Overall response rate, Overall survival, Response rate, Safety and Tolerability, Time to progression",True,NCT04616560,117921
4660,388425,"DESTINY-Breast05, DS8201-A-U305, EudraCT Number: 2020-003982-20, GBG-103, jRCT2061200033, NCT04622319, NSABP B-60, SOLTI-2001, TrialTroveID-388425","A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in Participants With High-Risk HER2-Positive Primary Breast Cancer Who Have Residual Invasive Disease in Breast or Axillary Lymph Nodes Following Neoadjuvant Therapy (DESTINY-Breast05)",Oncology,Oncology: Breast,"AstraZeneca, National Surgical Adjuvant Breast and Bowel Project (NSABP), Spanish Breast Cancer Research Group, German Breast Group, Daiichi Sankyo","Industry, Top 20 Pharma, Cooperative Group, Cooperative Group, Cooperative Group, Industry, all other pharma","Disease-free survival, Recurrence","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Disease-free survival, Overall survival, Recurrence, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events, Vital signs",True,NCT04622319,117921
4661,387075,"10355, NCI-2020-07841, NCT04585958, TrialTroveID-387075",A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies,Oncology,Oncology: Endometrial; Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,"Adverse Events, Common Terminology Criteria for Adverse Events, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Plasma pharmacokinetics, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04585958,117921
4662,385552,"EudraCT Number: 2020-000981-41, TrialTroveID-385552, TUXEDO-1",Phase II Study of Trastuzumab-Deruxtecan (T-DX; DS-8201a) in HER2-positive Breast Cancer Patients with newly diagnosed or progressing Brain Metastases,Oncology,Oncology: Breast; Oncology: Metastatic Cancer,(Other Hospital/Academic/Medical Center),Academic,Progressive disease rate,"Clinical benefit rate, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",False,,117921
4663,385306,TrialTroveID-385306,A Phase III clinical Trial of DS-8201 in Patients With Advanced or Metastatic Non Small Cell Lung Cancer Having HER2 Mutations,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4664,385305,TrialTroveID-385305,A Phase III clinical Trial of DS-8201 in Patients With Advanced or Metastatic Non Small Cell Lung Cancer Having HER2 Mutations,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4665,385304,TrialTroveID-385304,A Phase III clinical Trial of DS-8201 in Patients With First Line Non Small Cell Lung Cancer Having Her2 Mutations,Oncology,"Oncology: Lung, Non-Small Cell",Daiichi Sankyo,"Industry, all other pharma",,,False,,117921
4666,384947,"D967JC00002, DB-08, DESTINY Breast08, DESTINY-Breast08, NCT04556773, TrialTroveID-384947","A Phase Ib Multicentre, Open-Label, Modular, Dose-Finding And Dose-Expansion Study To Explore The Safety, Tolerability, Pharmacokinetics And Anti-Tumour Activity Of Trastuzumab Deruxtecan (T-Dxd) In Combination With Other Anti-Cancer Agents In Patients With Metastatic HER2-Low Breast Cancer (DESTINY-Breast08)",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04556773,117921
4667,384832,"20-001275, NCI-2020-06086, NCT04553770, TrialTroveID-384832","A Phase II, Multicenter, Open-Label Trial to Evaluate the Safety and Efficacy of Trastuzumab Deruxtecan (DS-8201a) With or Without Anastrozole for HER2 Low Hormone Receptor Positive (HR+) Breast Cancer in the Neoadjuvant Setting",Oncology,Oncology: Breast,"Eli Lilly, Jonsson Comprehensive Cancer Center, UCLA, Organisation for Oncology and Translational Research, Daiichi Sankyo","Industry, Top 20 Pharma, Academic, Not for Profit Funding Entity, Industry, all other pharma",Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Overall response rate, Quality of Life, Serious Adverse Events",True,NCT04553770,117921
4668,383969,"HER2CLIMB-04, NCT04539938, SGNTUC-025, TrialTroveID-383969","A Single Arm, Open Label Phase II Study of Tucatinib in Combination With Trastuzumab Deruxtecan in Subjects With Previously Treated Unresectable Locally-Advanced or Metastatic HER2+ Breast Cancer",Oncology,Oncology: Breast,Seagen {Seattle Genetics},"Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04539938,117921
4669,383749,"BRE 363, D967JC00001, DB-07, DESTINY-Breast07, EudraCT Number: 2019-004531-22, NCT04538742, TrialTroveID-383749","A Phase Ib/II Multicentre, Open-label, Modular, Dose-finding and Dose-expansion Study to Explore the Safety, Tolerability, and Anti-tumour Activity of Trastuzumab Deruxtecan (T-DXd) in Combination With Other Anti-cancer Agents in Patients With HER2-positive Metastatic Breast Cancer (DESTINY-Breast07)",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Disease Progression, Duration of overall response, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04538742,117921
4670,381169,"TrialTroveID-381169, UMIN000041004","To Establish Of Optimal Antiemetic Therapy For Trastuzumab Deruxtecan Therapy-Induced Nausea And Vomiting In Patients With Breast Cancer:An Open-Label, Randomized Pilot Study",Oncology,Oncology: Breast; Oncology: Supportive Care,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Emesis control",,False,,117921
4671,380865,"CTR20202365, CTRI/2020/09/028041, D9670C00001, DB-06, DESTINY Breast06, DESTINY-Breast06, EudraCT Number: 2019-004493-26, jRCT2061200028, NCT04494425, TrialTroveID-380865","A Phase III, Randomized, Multi-center, Open-label Study of Trastuzumab Deruxtecan (T-DXd) Versus Investigator's Choice Chemotherapy in HER2-Low, Hormone Receptor Positive Breast Cancer Patients Whose Disease Has Progressed on Endocrine Therapy in the Metastatic Setting (DESTINY-Breast06)",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression",True,NCT04494425,117921
4672,380046,"(DESTINY-PanTumor02), D967VC00001, DESTINY-PanTumour02, DPT02, EudraCT Number:2020-001574-29, NCI-2020-11363, NCT04482309, TrialTroveID-380046","A Phase II, Multicenter, Open-label Study to Evaluate the Efficacy and Safety of Trastuzumab Deruxtecan (T-DXd, DS-8201a) for the Treatment of Selected HER2 Expressing Tumors (DESTINY-PanTumor02)",Oncology,Oncology: Bladder; Oncology: Cervical; Oncology: Endometrial; Oncology: Liver; Oncology: Ovarian; Oncology: Pancreas; Oncology: Unspecified Solid Tumor,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT04482309,117921
4673,376599,"DEBBRAH, EudraCT Number: 2019-001739-29, MEDOPP243, NCT04420598, TrialTroveID-376599","A Multicenter, Open-Label, Single-Arm, Multicohort Phase II Clinical Trial of Trastuzumab Deruxtecan (DS-8201a) in Human Epidermal Growth Factor Receptor 2 (HER2)- Positive Advanced Breast Cancer With Brain Metastases and/or Leptomeningeal Carcinomatosis - The DEBBRAH Study""",Oncology,Oncology: Breast; Oncology: Metastatic Cancer,"Daiichi Sankyo, MedSIR","Industry, all other pharma, Miscellaneous","Complete response, Disease Progression, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, EORTC Quality of Life Questionnaire, Global health status, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to progression, Time to response",True,NCT04420598,117921
4674,373955,"D967LC00001, DESTINY-Gastric03, DG-03, EudraCT Number: 2019-004483-22, jRCT2031200203, NCT04379596, TrialTroveID-373955","A Phase Ib/II Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of Trastuzumab Deruxtecan (T-DXd) Monotherapy and Combinations in Adult Participants With HER2 Overexpressing Gastric Cancer (DESTINY-Gastric03)",Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease",True,NCT04379596,117921
4675,371674,"DS8201-C-J4001, JapicCTI-205234, TrialTroveID-371674","An Open-Label, Multi-Center, Expanded Access Study Of Trastuzumab Deruxtecan In Japanese Subjects With Her2-Positive Advanced Gastric Or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Adverse Events,,False,,117921
4676,369122,"10346, NCI-2020-01206, NCT04294628, TrialTroveID-369122",Pilot Study of DS-8201a Pharmacodynamics in Patients With HER2-Expressing Advanced Solid Tumors,Oncology,Oncology: Unspecified Solid Tumor,National Institutes of Health/National Cancer Institute,Government,Disease Progression,"Adverse Events, Anti-drug antibodies, Area under the curve score, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Safety and Tolerability",True,NCT04294628,117921
4677,361002,"EudraCT Number: 2019-002991-15, HER2-PREDICT, NCT04257162, SOLTI-1804, TrialTroveID-361002",HER2-PREDICT: Translational Study of Tumor Samples From Patients Treated With Trastuzumab Deruxtecan (T-DXd; DS-8201a),Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Daiichi Sankyo","Academic, Industry, all other pharma","Circulating Tumor Cells, Overall response rate, Overall survival, Progression-free survival","Circulating Tumor Cells, Overall response rate, Overall survival, Progression-free survival",True,NCT04257162,117921
4678,359605,"DAISY, EudraCT Number:2018-004868-57, NCT04132960, TrialTroveID-359605, UC-0105/1815","Phase II, Open Label Study of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC) for Advanced Breast Cancer Patients, With Biomarkers Analysis to Characterize Response/Resistance to Therapy",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), Daiichi Sankyo","Academic, Industry, all other pharma","Complete response, Overall response rate",,True,NCT04132960,117921
4679,353079,"19-377, 2019-0582, DESTINY-Gastric02, DS8201-A-U205, EudraCT Number: 2019-001512-34, IRAS ID: 265510, NCI-2019-04828, NCT04014075, TrialTroveID-353079","A Phase II, Open-label, Single-arm Trial of Trastuzumab Deruxtecan (DS 8201a) in HER2-positive, Unresectable or Metastatic Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-containing Regimen (DESTINY-Gastric02)",Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Anti-drug antibodies, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, General HEOR measures, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04014075,117921
4680,351976,"31-0271, HERB trial, JMA-IIA00423, NCCH1805, TrialTroveID-351976",A Phase II Trial of DS-8201a For HER2 Positive Biliary Tract Cancer,Oncology,Oncology: Liver,"(Other Cooperative Group), National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Daiichi Sankyo","Cooperative Group, Academic, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",False,,117921
4681,348056,"EPOC1806, HERALD, HERALD TR study, JapicCTI-194707, JapicCTI-194758, TrialTroveID-348056","A Basket Trial of DS-8201a, A Novel HER2-targeted Antibody-drug Conjugate, For HER2 Amplified Solid Tumors Identified by ctDNA Analysis",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Daiichi Sankyo, (Other government agency)","Academic, Industry, all other pharma, Government",Overall response rate,"Clinical benefit rate, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to treatment failure",False,,117921
4682,336555,TrialTroveID-336555,"A Phase Ib Study to Evaluate Maximum Tolerated Dose, Safety and Efficacy DS-8201 in Combination with Avelumab in Patients with HER2 Expressing Solid Tumor.",Oncology,Oncology: Unspecified Solid Tumor,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Maximum tolerated dose, Overall response rate","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Time to response",False,,117921
4683,336411,"184223, 19-100, 20252, CTR20191730, DESTINY 04 DS8201-A-U303, DESTINY-B04, DESTINY-Breast04, DS8201-A-U303, EudraCT Number: 2018-003069-33, JapicCTI-184223, NCI-2019-00010, NCT03734029, TrialTroveID-336411","A Phase III, Multicenter, Randomized, Open-label, Active Controlled Trial of DS-8201a, an Anti-HER2-antibody Drug Conjugate (ADC), Versus Treatment of Physician's Choice for HER2-low, Unresectable and/or Metastatic Breast Cancer Subjects",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EQ-5D-5L, General HEOR measures, Infusion-related reactions, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Time to response, Treatment Emergent Adverse Events, Vital signs",True,NCT03734029,117921
4684,333318,"DS8201-A-U106, EudraCT Number: 2018-002489-38, NCI-2020-01136, NCT04042701, TrialTroveID-333318","A Phase Ib, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan (DS-8201a), An Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), In Combination With Pembrolizumab, An Anti-PD-1 Antibody, In Subjects With Locally Advanced/Metastatic Breast Or Non-Small Cell Lung Cancer (NSCLC).",Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell","AstraZeneca, Merck & Co./Merck Sharp & Dohme (MSD), Daiichi Sankyo","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma","Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response",True,NCT04042701,117921
4685,317623,TrialTroveID-317623,A Phase I/II Clinical Trial of DS-8201 in Combination With Immunotherapy Drug in Patients With HER2+ Metastatic Breast and Non-small Cell Lung Cancer,Oncology,"Oncology: Breast; Oncology: Lung, Non-Small Cell","AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",,,False,,117921
4686,315085,"18-257, 18-528, 19743, 20182077, DESTINY-Lung01, DS8201-A-U204, EudraCT Number: 2017-004781-94, JapicCTI-183916, NCI-2018-02097, NCT03505710, NL65483.031.18, TrialTroveID-315085","A Phase II, Multicenter, Open-Label, 2-Cohort Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2 Antibody Drug Conjugate (ADC), for HER2-Over-Expressing or -Mutated, Unresectable and/or Metastatic Non Small Cell Lung Cancer (NSCLC) (DESTINY-Lung01)",Oncology,"Oncology: Lung, Non-Small Cell","AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Stable Disease, Time to response",True,NCT03505710,117921
4687,315082,"DESTINY-Gastric04, DS8201-A-U306, EudraCT Number: 2020-004559-34, jRCT2031200369, NCT04704934, TrialTroveID-315082","A Phase III, Multicenter, 2-Arm Randomized, Open-Label Study of Trastuzumab Deruxtecan in Subjects With HER2-Positive Metastatic and/or Unresectable Gastric or Gastro-Esophageal Junction (GEJ) Adenocarcinoma Subjects Who Have Progressed on or After a Trastuzumab-Containing Regimen (DESTINY-Gastric04)",Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Overall survival,"Adverse Events, Anti-drug antibodies, Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Treatment Emergent Adverse Events",True,NCT04704934,117921
4688,315079,"2018-0612, CTR20190378, DESTINY-B03, DESTINY-Breast03, DS8201-A-U302, EudraCT Number: 2018-000222-61, JapicCTI-183976, NCI-2018-02956, NCT03529110, TrialTroveID-315079","A Phase III, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane",Oncology,Oncology: Breast,"AstraZeneca, Baxter International/Baxter Oncology {ASTA Medica Oncology}, Daiichi Sankyo, Fisher Clinical Services","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma, Miscellaneous","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, General HEOR measures, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability",True,NCT03529110,117921
4689,315017,"18-500, DESTINY 02, DESTINY-B02, DESTINY-Breast02, DS8201-A-U301, EudraCT Number: 2018-000221-31, JapicCTI-184017, NCI-2018-03422, NCT03523585, TrialTroveID-315017","A Phase III, Multicenter, Randomized, Open-label, Active-controlled Study of Trastuzumab Deruxtecan (DS-8201a), an Anti-HER2-antibody Drug Conjugate, Versus Treatment of Investigator's Choice for HER2-positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, General HEOR measures, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Stable Disease",True,NCT03523585,117921
4690,315016,"17494, 2017-0988, 3C-18-1, DESTINY-C01, DESTINY-CRC01, DS8201-A-J203, EudraCT Number: 2017-003466-28, JapicCTI-173808, NCI-2018-00817, NCT03384940, TrialTroveID-315016","A Phase II, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-Expressing Advanced Colorectal Cancer.",Oncology,Oncology: Colorectal,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response, Tmax",True,NCT03384940,117921
4691,314387,"DS8201-A-A103, NCT03368196, TrialTroveID-314387","Phase I, Multicenter, Open Label Study of DS-8201a to Assess Safety and Pharmacokinetics in Subjects With HER2 Positive Advanced and/or Refractory Gastric, Gastroesophageal Junction Adenocarcinoma, or Breast Cancer",Oncology,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Anti-drug antibodies, Clinical benefit rate, Cmax, Cmin, Complete response, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Tmax",True,NCT03368196,117921
4692,314345,"DS8201-A-A104, JapicCTI-173790, NCT03383692, TrialTroveID-314345","A Phase I, Multicenter, Open-Label, Single Sequence Crossover Study to Evaluate Drug-Drug Interaction Potential of OATP1B/CYP3A Inhibitor on The Pharmacokinetics of DS-8201a in Subjects with HER2-Expressing Advanced Solid Malignant Tumors",Oncology,Oncology: Breast; Oncology: Gastric; Oncology: Unspecified Solid Tumor,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma",Cmax,"Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Complete response, Disease Progression - duration, Duration of overall response, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease, Time to response, Treatment Emergent Adverse Events, Vital signs",True,NCT03383692,117921
4693,314264,"DS8201-A-J102, JapicCTI-173791, NCT03366428, TrialTroveID-314264","Phase I, Multicenter, Open-label, Multiple-dose Study of DS-8201a to Assess the Effect on the QT Interval and Pharmacokinetics in Subjects With HER2-expressing Metastatic and/or Unresectable Breast Cancer",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Area under the curve score, Cmax, Elimination half-life, Heart rate corrected QT interval, Heart rate, Tmax, Volume of distribution","Clinical benefit rate, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Stable Disease",True,NCT03366428,117921
4694,311169,"NCCH1615, STATICE, TrialTroveID-311169, UMIN000029506",A clinical trial of DS-8201a in HER2 positive(HER2 > or =1) metastatic/recurrent uterine carcinosarcoma patients,Oncology,Oncology: Soft Tissue Sarcoma,"National Cancer Center Hospital East {National Cancer Center Hospital - Tokyo, Japan}, Daiichi Sankyo, (Other government agency)","Academic, Industry, all other pharma, Government",Overall response rate,"Adverse Events, Overall response rate, Overall survival, Progression-free survival",False,,117921
4695,307937,"DS8201-A-U105, EudraCT Number: 2018-000371-32, NCI-2018-02026, NCT03523572, TrialTroveID-307937","A Phase Ib, Multicenter, Two-Part, Open-Label Study of Trastuzumab Deruxtecan, an Anti-Human Epidermal Growth Factor Receptor-2 (HER2)-Antibody Drug Conjugate (ADC), in Combination With Nivolumab, an Anti-PD-1 Antibody, for Subjects With HER2-expressing Advanced Breast and Urothelial Cancer",Oncology,Oncology: Bladder; Oncology: Breast,"AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Disease Progression, Dose-limiting toxicities, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events","Clinical benefit rate, Cmax, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Time to response, Treatment Emergent Adverse Events",True,NCT03523572,117921
4696,304651,"DESTINY-G01, DESTINY-Gastric01, DS8201-A-J202, JapicCTI-173727, NCT03329690, TrialTroveID-304651","A Phase II, Multicenter, Open-label Study of DS-8201a in Subjects With HER2-expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Stable Disease","Adverse Events, Anti-drug antibodies, Area under the curve score, Cardiac Telemetry, Clinical benefit rate, Cmax, Complete response, Disease Progression, Duration of overall response, Elimination half-life, EQ-5D-5L, General HEOR measures, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to response, Time to treatment failure, Tmax, Treatment Emergent Adverse Events, Vital signs",True,NCT03329690,117921
4697,303276,"17-516, 17-539, 20170626, 2017-0820, DESTINY - Breast 01, DESTINY-B01, DESTINY-Breast 01, DESTINY-Breast01, DS8201-A-U201, EudraCT Number: 2016-004986-18, JapicCTI-173693, NCI-2017-02077, NCT03248492, TrialTroveID-303276","A Phase II, Multicenter, Open-Label Study of DS-8201a, an Anti-HER2-Antibody Drug Conjugate (ADC) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With T-DM1",Oncology,Oncology: Breast,"AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Overall response rate, Response evaluation criteria in solid tumors","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT03248492,117921
4698,265575,"152978, 16-1598, 16-520, 2016-0583, DS8201-A-J101, JapicCTI-152978, NCI-2016-01280, NCT02564900, TrialTroveID-265575","Phase I, Two-Part, Multicenter, Non-randomized, Open-label, Multiple Dose First-In-Human Study Of DS-8201A, In Subjects With Advanced Solid Malignant Tumors.",Oncology,"Oncology: Breast; Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor","AstraZeneca, Daiichi Sankyo","Industry, Top 20 Pharma, Industry, all other pharma","Adverse Events, Maximum tolerated dose, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Anti-drug antibodies, Area under the curve score, Cmax, Tmax",True,NCT02564900,117921
4699,108523,"06-163, MSKCC-06163, NCT00897702, TrialTroveID-108523",Molecular Mechanisms of Clinical Resistance to Targeted Therapy Among Patients With Breast Cancer,Oncology,Oncology: Breast,"Memorial Sloan-Kettering Cancer Center, National Institutes of Health/National Cancer Institute","Academic, Government",Disease Progression,Disease Progression,True,NCT00897702,117921
4700,400459,"NCC2749, NCT04821765, TrialTroveID-400459",A Phase II Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,Chinese Academy of Medical Sciences,Government,Clinical benefit rate,"Complete response, Magnetic Resonance Imaging, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Response rate",True,NCT04821765,91363
4701,400383,"ACTRN12621000273886, ADELE, ANZGOG 1910/2020, CTC0299, TrialTroveID-400383",The Effect Of Adjuvant Tislelizumab Plus Chemotherapy on Failure Free Survival After Post-Operative Pelvic Chemoradiation in High Risk Endometrial Cancer - ADELE: a Randomised Phase II Trial,Oncology,Oncology: Endometrial,"(Other Hospital/Academic/Medical Center), (Other government agency)","Academic, Government",Progression-free survival,"Common Terminology Criteria for Adverse Events, EORTC Quality of Life Questionnaire, EQ-5D-5L, Neuropathy, Overall survival, Progression-free survival, Quality of Life, Treatment Emergent Adverse Events",False,,91363
4702,400342,"NCT04819971, TIS-HER2GC-PERIOPERATIVE-IIT, TrialTroveID-400342","Efficacy and Safety of Perioperative Chemotherapy Combined With Tirelizumab and Trastuzumab in Patients With HER2-positive Resectable Gastric or Gastr-oesophageal Junction Carcinoma (GC/EGJ) -- a Prospective, Single-arm, Phase II Study",Oncology,Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Disease-free survival, Overall survival",True,NCT04819971,91363
4703,400085,"NCT04815408, TrialTroveID-400085, Z2HOC-01",A Phase II Study of PD-1 Antibody Plus Neoadjuvant Chemotherapy for Advanced-stage Ovarian Cancer (Z2HOC-01),Oncology,Oncology: (N/A); Oncology: Fallopian Tube; Oncology: Ovarian,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Overall survival, Partial response, Response evaluation criteria in solid tumors, Response rate, Treatment Emergent Adverse Events",True,NCT04815408,91363
4704,399963,"2021HNRT01, NCT04814069, The POTENTIAL Study, TrialTroveID-399963",A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma:The POTENTIAL Study,Oncology,Oncology: Head/Neck,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Disease-free survival","Common Terminology Criteria for Adverse Events, Overall survival",True,NCT04814069,91363
4705,399646,"ChiCTR2100044313, TrialTroveID-399646","A Single-arm, Prospective, Multi-center Phase Ii Clinical Study of Tislelizumab Injection Combined with R-CHOP in the Treatment of Primary Mediastinal Large B-cell Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Hospital/Academic/Medical Center), BeiGene/BeiGene (Shanghai) Co.","Academic, Industry, all other pharma",Overall response rate,"Objective remission rate, Overall survival, Progression-free survival, Safety and Tolerability",False,,91363
4706,399255,"NCT04799314, NHL-PD1-2, TrialTroveID-399255","PD-1 Inhibitor Tislelizumab Maintenance Therapy in Relapsed/Refractory DLBCL Patients After ASCT: A Multicenter, Randomized Controlled Clinical Study on Efficacy and Safety.",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Complete response, Disease Progression, Overall survival",True,NCT04799314,91363
4707,399138,"NCT04796857, TALEND, TrialTroveID-399138","Tislelizumab in Combination With Lenalidomide in in Patients With Relapsed or Refractory Elderly Patients With Non-GCB Diffuse Large B Cell Lymphoma: a Prospective Phase Ib/II, Multicentre, Open-label, Single-arm Trial",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Safety and Tolerability","Adverse Events, Duration of overall response, Overall survival, Progression-free survival, Progressive disease rate, Time to progression",True,NCT04796857,91363
4708,398628,"NCT04789434, NHL-PD1-1, TrialTroveID-398628","PD-1 Inhibitor Tislelizumab Maintenance Therapy in Newly Diagnosed DLBCL Patients After ASCT: A Multicenter, Randomized Controlled Clinical Study on Efficacy and Safety",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Progression-free survival","Complete response, Disease Progression, Overall survival",True,NCT04789434,91363
4709,398287,"HUASHAN006, NCT04782804, TrialTroveID-398287",PD-1 Antibody(Tislelizumab) Combined With Capecitabine as Adjuvant Therapy to Prevent the Recurrence in High-risk Patients With Cholangiocarcinoma After Curative Resection,Oncology,Oncology: Liver,"Fudan University - Shanghai, China",Academic,"Disease-free survival, Recurrence",Overall survival,True,NCT04782804,91363
4710,398241,"ChiCTR2100043836, TrialTroveID-398241","Anlotinib Hydrochloride Combined with Tislelizumab, Paclitaxel Liposome and Nedaplatin in a Single-Arm, Single-Center, Phase II Exploratory Clinical Study of Preoperative Neoadjuvant Therapy for Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,"(Other Hospital/Academic/Medical Center), Chia Tai Tianqing Pharmaceutical Group Co., BeiGene/BeiGene (Beijing) Co.","Academic, Industry, all other pharma, Industry, all other pharma",Overall response rate,,False,,91363
4711,398099,"NCT04777162, TrialTroveID-398099",Efficacy and Safety of Tislelizumab Plus Anlotinib in PD-1/PD-L1 Resistant Metastatic Gastric or Colorectal Cancer: a Single Arm Phase II Clinical Trial,Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric,(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response evaluation criteria in solid tumors","Overall survival, Progression-free survival",True,NCT04777162,91363
4712,398047,"ChiCTR2100043772, TrialTroveID-398047",Phase II Clinical Study Of Tislelizumab Combined With Neoadjuvant Chemotherapy in the Treatment Of Locally Advanced Esophageal Squamous Cell Carcinoma,Oncology,Oncology: Esophageal,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Complete response,"Complete response, Event-free survival, Objective remission rate, Overall survival",False,,91363
4713,397947,"CRISEC, ESC001, NCT04776590, TrialTroveID-397947","Neoadjuvant Chemoradiotherapy Plus Tislelizumab Followed by Surgery for Thoracic Esophageal Squamous Cell Cancer: A Prospective, Single Arm, Pilot Study",Oncology,Oncology: Esophageal,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Complete response,"Disease-free survival, Overall survival",True,NCT04776590,91363
4714,397735,"NCT04771715, S-K1517",An Observational Real-world Study of Regorafenib Plus Programmed Cell Death-1 (PD-1) Inhibitors in Chinese Patients With Advanced Colorectal Cancer,,NA: ClinicalTrials.gov,Peking Union Medical College Hospital,ClinicalTrials.gov,,Treatment Emergent Adverse Events,True,NCT04771715,91363
4715,397507,"ChiCTR2100043615, TrialTroveID-397507","Efficacy and Safety of Tislelizumab combined with Albumin Paclitaxel in the treatment of Relapsed and Refractory Extranodal NK/T Cell Lymphoma, Nasal Type: A Multi-Center, Prospective, Single-Arm, Phase II Clinical Study",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Response rate",,False,,91363
4716,396408,"ChiCTR2100043195, TrialTroveID-396408",Phase II Trial of Neoadjuvant Tislelizumab combined with chemotherapy in Muscle-Invasive Bladder Cancer(MIBC) Patients,Oncology,Oncology: Bladder,"(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Complete response,"Safety and Tolerability, Safety and Tolerability",False,,91363
4717,395794,"BGB-900-2001-IIT, NCT04734262, TrialTroveID-395794","A Phase II Study to Explore the Safety, Tolerability, and Preliminary Antitumor Activity of Sitravatinib and Tislelizumab in Patients With Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)",Oncology,Oncology: Breast,"Fudan University - Shanghai, China",Academic,"Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Serious Adverse Events, Stable Disease",True,NCT04734262,91363
4718,395664,"BGB-A317-A1217-203, CTR20210243, EudraCT Number: 2020-004658-32, NCT04732494, TrialTroveID-395664","A Phase II, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Plus Anti-TIGIT Monoclonal Antibody BGB-A1217 Versus Tislelizumab Plus Placebo as Second-Line Treatment in Patients With PD-L1 vCPS >or= 10% Unresectable, Locally Advanced, Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,BeiGene,"Industry, all other pharma","Complete response, Overall response rate, Overall survival, Partial response, Response evaluation criteria in solid tumors","Ability to swallow, Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Reflux, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease",True,NCT04732494,91363
4719,395505,"NCT04730219, TrialTroveID-395505, Truce-01","An Open Label, Single-arm, Phase II Study of Neoadjuvant Tislelizumab Combined With Nab-Paclitaxel Before Cystectomy or Complete TURBT for Patients With Muscle-invasive Urothelial Bladder Cancer.",Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Event-free survival, Overall response rate, Overall survival, Patient-Reported Outcomes Measurement Information System, Recurrence, Safety and Tolerability",True,NCT04730219,91363
4720,395504,"NCT04730232, TrialTroveID-395504, Truce-02","An Open Label, Single-arm, Phase II Study of Tislelizumab Combined With Nab-Paclitaxel for Patients With High-Risk Non-Muscle-Invasive Urothelial Bladder Carcinoma Which is Not Completely Resectable",Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Duration of overall response, Overall response rate - duration, Patient-Reported Outcomes Measurement Information System, Safety and Tolerability",True,NCT04730232,91363
4721,395235,"BTC-BGB, H-2005-156-1126, KCT0005512, NCT04727996, TrialTroveID-395235",Phase II Study of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Biliary Tract Cancer Who Have Failed to At Least 1 Prior Systemic Treatment,Oncology,Oncology: Liver,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Clinical benefit rate,"Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability",True,NCT04727996,91363
4722,394040,"NCT04705129, RJ-PMBCL-1, TrialTroveID-394040",A Phase II Study on the Safety and Efficacy of Zanubrutinib Combined With Tislelizumab in the Treatment of Relapsed/Refractory Primary Mediastinal Large B-cell Lymphoma and Epstein-Barr Virus-positive Diffuse Large B-cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Complete response,"Adverse Events, Common Terminology Criteria for Adverse Events, Disease Progression, Overall survival, Progression-free survival, Treatment Emergent Adverse Events",True,NCT04705129,91363
4723,393584,"ChiCTR2100041675, TrialTroveID-393584",Multicenter Clinical Study of Tislelizumab Combined with Nab-Paclitaxel and Carboplatin in Neoadjuvant Therapy Followed by Adjuvant Therapy with Tislelizumab in Triple Negative Breast Cancer (TNBC),Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Complete response,"Complete response, Event-free survival, Overall survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",False,,91363
4724,393450,"BGB-A317-A1217-202, EudraCT Number: 2020-004657-77, NCT04693234, TrialTroveID-393450",Phase II Study Investigating Efficacy and Safety of Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody BGB-A1217 in Patients With Previously Treated Recurrent or Metastatic Cervical Cancer,Oncology,Oncology: Cervical,"Novartis, BeiGene","Industry, Top 20 Pharma, Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Serious Adverse Events, Stable Disease, Time to response",True,NCT04693234,91363
4725,392881,"ChiCTR2000041542, TrialTroveID-392881",Phase II study of Chidamide and Tislelizumab in Advanced Non-Small Cell Lung Cancer,Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,,Progression-free survival,False,,91363
4726,392877,"ChiCTR2000041541, TrialTroveID-392877",Phase II Study Of Chidamide And Tislelizumab In Advanced Urothelial Carcinoma,Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Overall survival,Progression-free survival,False,,91363
4727,392101,"NCT04672317, TrialTroveID-392101, UTUC-NEOCI","A Prospective, Open Clinical Study to Examine the Efficacy and Safety of Neoadjuvant Tislelizumab Combined With Cisplatin-based Chemotherapy in Patients With Locally Advanced Upper Urinary Tract Urothelial Carcinoma",Oncology,Oncology: Bladder,(Other Hospital/Academic/Medical Center),Academic,Complete response,"Complete response, Overall response rate, Response rate",True,NCT04672317,91363
4728,392100,"NCT04672330, NEO-IO, TrialTroveID-392100","A Prospective, Open, Single-center Clinical Study to Examine the Efficacy and Safety of Neoadjuvant Tislelizumab in Patients With Locally Advanced Upper Urinary Tract Urothelial Carcinoma",Oncology,Oncology: Bladder; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Overall response rate, Response rate",True,NCT04672330,91363
4729,391490,"B2020-195-01, NCT04663035, TrialTroveID-391490",CT-guided Thermal Ablation Plus Tislelizumab Versus Ablation Alone for Intrahepatic Recurrent Early Stage Hepatocellular Carcinoma: a Randomized Controlled Phase II Clinical Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease-free survival, Recurrence","Adverse Events, Disease-free survival, EORTC Quality of Life Questionnaire, Overall survival, Quality of Life, Recurrence, Safety and Tolerability, Serious Adverse Events, Time to response",True,NCT04663035,91363
4730,390872,"B2020-197-01, NCT04652440, TrialTroveID-390872",Phase II Study of Ablation Combined With PD-1 Antibody in Patients With Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Common Terminology Criteria for Adverse Events, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Complete response, Disease-free survival, Overall survival, Recurrence",True,NCT04652440,91363
4731,390870,"BGB-A317-2004-IIT, NCT04652492, TrialTroveID-390870","A Multicentric, Open-Label Study to Evaluate Tislelizumab in Combination With Transarterial Chemoembolization as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Immune-related response evaluation criteria in solid tumors, Time to progression","Clinical benefit rate, Disease Progression, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Safety and Tolerability, Time to progression",True,NCT04652492,91363
4732,390761,"BGB-A317-15025-101, NCT04649385, TrialTroveID-390761","A Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,BeiGene,"Industry, all other pharma","Adverse Events, Maximum tolerated dose, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Cmin, Drug clearance, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Plasma concentration, Tmax, Volume of distribution",True,NCT04649385,91363
4733,390575,"ChiCTR2000040487, TrialTroveID-390575",An Observational Study On The Efficacy And Safety Of Tislelizumab Combined With Albumin Paclitaxel In Neoadjuvant Treatment Of MIBC,Oncology,Oncology: Bladder,"(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Complete response,"Adverse Events, Event-free survival, Overall survival, Safety and Tolerability, Serious Adverse Events",False,,91363
4734,390237,"ChiCTR2000040139, TrialTroveID-390237",A Prospective Study of the Efficacy and Safety of Tislelizumab Combined with Regorafenib in Patients with Unresectable or Recurring Cholangiocarcinoma After Resection.,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival","Clinical benefit rate, Overall response rate, Overall survival, Time to progression",False,,91363
4735,389349,"GYEYJR-2, NCT04627012, TrialTroveID-389349",The Effectiveness and Safety of Lenvatinib Combined Anti-programmed Death Immunotherapy for the Advanced Hepatocellular Carcinoma,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Stable Disease",True,NCT04627012,91363
4736,388966,"NCC-04254, NCT04620837, TrialTroveID-388966","A Prospective, Open Label, Single-arm, Phase II Study of Tislelizumab in Combination With Anlotinib as Maintenance Therapy in Subject With Extensive Stage Small Cell Lung Cancer (ES-SCLC) as Maintenance Therapy After First Line Chemotherapy",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",Chinese Academy of Medical Sciences,Government,Progression-free survival,Overall survival,True,NCT04620837,91363
4737,388629,"NCT04615143, RHCC2020, TrialTroveID-388629",Tislelizumab Neo-adjuvant Treatment for Resectable Recurrent Hepatocellular Carcinoma: A Single-arm Phase II Clinical Trial,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Adverse Events, Complete response, Disease-free survival, Overall response rate, Partial response, Recurrence, Response evaluation criteria in solid tumors",True,NCT04615143,91363
4738,388386,"ChiCTR2000039464, TrialTroveID-388386","A Phase II, Prospective Study of Tlislelizumab Plus Chidamide as Sequential Therapy in Patients with Locally Advanced, Unresectable Non-Small Cell Lung Cancer (Stage III) Who Have Not Progressed Following Definitive, Platinum-based, Concurrent Chemoradiation Therapy",Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma",Safety and Tolerability,Progression-free survival,False,,91363
4739,387932,"ChiCTR2000039372, TrialTroveID-387932","A Prospective, Single-Arm Clinical Trial of Tislelizumab Combined Gemcitabine and Oxaliplatin in the First-Line Treatment of Patients with Peripheral T Cell Lymphoma",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Cooperative Group), (Other Hospital/Academic/Medical Center)","Cooperative Group, Academic",Overall response rate,"Adverse Events, Duration of overall response, Overall survival, Progression-free survival",False,,91363
4740,387926,"ChiCTR2000039389, TrialTroveID-387926","Neoadjuvant Chemotherapy And Tilelizumab In Stage III(Ctnm-IIIA.IIIB)Non-Small-Cell Lung Cancer : An Open-Label, Single-Arm, Phase II Trial",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,,,False,,91363
4741,387776,"MIIR-03, NCT04599777, TrialTroveID-387776","Transcatheter Arterial Chemoembolization Combined With Sintilimab and Bevacizumab for Advanced Hepatocellular Carcinoma: An Open-label, Single-arm, Single-center, Prospective Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Serious Adverse Events, Stable Disease",True,NCT04599777,91363
4742,386934,"ChiCTR2000039022, TrialTroveID-386934","Advanced Primary Hepatocellular Carcinoma Treated by Radiotherapy Combined with Tislelizumab - Single Arm, Single Center Clinical Study",Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,Overall survival,"Magnetic Resonance Imaging, Objective remission rate",False,,91363
4743,386496,"2020-012-GLOB1, NCT04579757, TrialTroveID-386496",An Open-Label Phase Ib/II Study of Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors,Oncology,"Oncology: (N/A); Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Soft Tissue Sarcoma; Oncology: Unspecified Solid Tumor","BeiGene, Hutchison MediPharma/Hutchison MediPharma (Suzhou)","Industry, all other pharma, Industry, all other pharma","Dose-limiting toxicities, Overall response rate","Adverse Events, Clinical benefit rate, Cmax, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, Partial response, Progression-free survival, Progressive disease rate, Recurrence, Safety and Tolerability, Stable Disease, Time to response",True,NCT04579757,91363
4744,386373,"2020-013-00US3, NCT04577963, TrialTroveID-386373","An Open-Label, Phase Ib/II Study to Evaluate the Safety and Efficacy of Fruquintinib in Combination With Tislelizumab in Patients With Advanced Triple Negative Breast Cancer",Oncology,Oncology: Breast,"Hutchison MediPharma, BeiGene","Industry, all other pharma, Industry, all other pharma","Adverse Events, Overall response rate, Safety and Tolerability, Safety and Tolerability",,True,NCT04577963,91363
4745,385341,"B2020-192-01, NCT04562311, TrialTroveID-385341","The Efficacy and Safety of Chidamide Combined With Immunotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Who Had Previously Received Platinum-based Chemotherapy:An Open, One-arm, Phase II Study",Oncology,Oncology: Bladder; Oncology: Neuroendocrine; Oncology: Renal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT04562311,91363
4746,384109,"NCT04541277, PDCXG-RR&ELDER, TrialTroveID-384109","A Phase II, Single Arm Study of Tislelizumab Combined With DNA Demethylation Agent +/- CAG Regimen in the Treatment of Patients With High-risk AML or AML Patients Older Than 60 Years of Age Who Are Unfit for Intensive Chemotherapy",Oncology,"Oncology: Leukemia, Acute Myelogenous",(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate","Adverse Events, Common Terminology Criteria for Adverse Events, Minimal Residual Disease, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT04541277,91363
4747,384074,"LungMate-006(FK-LYIB-001), NCT04542369, TrialTroveID-384074",Clinical Study Of PD-1 Antibody (BGB-A317) Plus Chemotherapy (Cisplatin And Etoposide) For Limited Stage Small Cell Lung Cancer,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Safety and Tolerability","Complete response, Disease Progression, Disease-free survival, EORTC Quality of Life Questionnaire, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life",True,NCT04542369,91363
4748,383983,"CCPD-1 in lymphoma, NCT04539444, TrialTroveID-383983",A Study Evaluated Efficacy and Safety of CD19/22 Chimeric Antigen Receptor T Cells Combined With PD-1 Inhibitor in Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's","(Other Hospital/Academic/Medical Center), Shanghai Unicar-Therapy Bio-medicine Technology Co.","Academic, Industry, all other pharma","Complete response, Overall response rate, Partial response, Progression-free survival","Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall survival, Treatment Emergent Adverse Events",True,NCT04539444,91363
4749,383799,"ChiCTR2000037759, NCT04799548, TrialTroveID-383799, ZSGC-ITPD1-2020",A Phase II Study of Neoadjuvant Transcatheter Arterial Chemoembolization(TACE)Plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma,Oncology,Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic","Complete response, Overall response rate, Overall survival, Progression-free survival","Complete response, Overall response rate, Overall survival, Progression-free survival, Response rate",True,NCT04799548,91363
4750,382996,"ChiCTR2000036385, TrialTroveID-382996",Neoadjuvant PD-1 plus Radiotherapy in Patients with Locally Advanced Hepatocellular Carcinoma: A Single Arm Study,Oncology,Oncology: Liver,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Disease-free survival, Safety and Tolerability",False,,91363
4751,382563,"ChiCTR2000035684, TrialTroveID-382563","An Exploratory Study on the Efficacy, Predictive Markers and Resistance Mechanisms of Tislelizumab (Anti-PD-1 Antibody) Combined With Chemotherapy in the Treatment of Non-Squamous Non-Small Cell Lung Cancer Patients With EGFR-Sensitive Mutations and Previous EGFR-TKI Treatment Failure",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall survival, Progression-free survival",,False,,91363
4752,382260,"ChiCTR2000035665, TrialTroveID-382260","A Phase III, Prospective, Multicenter, Randomized, Controlled Trial of Neoadjuvant Transcatheter Arterial Chemoembolization (TACE) plus PD-1 Antibody (Tislelizumab) in the Locally Advanced Stomach Adenocarcinoma",Oncology,Oncology: Gastric,"(Other Hospital/Academic/Medical Center), Fudan University - Shanghai, China","Academic, Academic",Complete response,"Overall response rate, Overall survival, Progression-free survival",False,,91363
4753,381821,"ChiCTR2000035262, TREND, TrialTroveID-381821","A prospective, single-arm clinical study on Tislelizumab in combination with albumin-bound paclitaxel followed by epirubicin and cyclophosphamide in the neoadjuvant treatment of triple negative breast cancer (TREND)",Oncology,Oncology: Breast,"(Other Hospital/Academic/Medical Center), BeiGene/BeiGene (Beijing) Co.","Academic, Industry, all other pharma",Complete response,"Overall response rate, Safety and Tolerability",False,,91363
4754,381668,"BGB-A317-2003-IIT, NCT04507217, TrialTroveID-381668","A Phase II, Open-Label, Multicenter, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Pemetrexed/ Carboplatin in Patients With Brain Metastases of Non-squamous Non-small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Metastatic Cancer","(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Treatment Emergent Adverse Events",True,NCT04507217,91363
4755,381443,"ChiCTR2000035275, TrialTroveID-381443",Phase II clinical study of Tislelizumab Combined With Radiotherapy In The Treatment of Non Muscle Invasive Bladder Cancer After BCG Treatment Failure,Oncology,Oncology: Bladder,"(Other Hospital/Academic/Medical Center), BeiGene/BeiGene (Beijing) Co.","Academic, Industry, all other pharma",Disease-free survival,"Adverse Events, Quality of Life",False,,91363
4756,381312,"Apollo, NCT04501523, SunYatsenU2H-LQ3, TrialTroveID-381312","A Prospective, Phase II Trial Using Circulating Tumor DNA to Initiate Post-operation Boost Therapy After Neoadjuvant Chemotherapy in Triple-negative Breast Cancer",Oncology,Oncology: Breast,(Other Hospital/Academic/Medical Center),Academic,"Circulating Tumor Cells, Disease-free survival","Adverse Events, Circulating Tumor Cells, Complete response, Disease-free survival, Overall response rate, Overall survival, Safety and Tolerability, Safety and Tolerability",True,NCT04501523,91363
4757,381209,"NCC2474, NCT04498793, TrialTroveID-381209",Study of Tislelizumab Plus Chemotherapy vs Chemotherapy Alone as Perioperative Treatment in Participants With HER2 Negative Breast Cancer,Oncology,Oncology: Breast,"Chinese Academy of Medical Sciences, (Other Hospital/Academic/Medical Center)","Government, Academic",Complete response,,True,NCT04498793,91363
4758,380265,"BGB-A317-314, CTR20201517, NCT04486391, TrialTroveID-380265","A Multicenter, Open-Label, Randomized Controlled Phase III Study of Tislelizumab Monotherapy Versus Salvage Chemotherapy in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's",BeiGene,"Industry, all other pharma","Progression-free survival, Progressive disease rate","Adverse Events, Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progressive disease rate, Serious Adverse Events, Time to response",True,NCT04486391,91363
4759,379717,"ChiCTR2000034748, TrialTroveID-379717","Tislelizumab Combined with Chemoradiotherapy in The Treatment of Recurrent Cervical Cancer: a Single Arm, Phase II and Observational Clinical Study",Oncology,Oncology: Cervical,"Fudan University - Shanghai, China",Academic,Progression-free survival,Overall survival,False,,91363
4760,377761,"CARTOnG-2001, NCT04443543, TrialTroveID-377761","Watch and Wait Strategy in Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiotherapy: A Multi-centre, Adaptive-design, Phase II Prospective Cohort Study",Oncology,Oncology: Colorectal,(Other Hospital/Academic/Medical Center),Academic,,"Disease-free survival, Overall survival, Quality of Life, Recurrence",True,NCT04443543,91363
4761,377094,"ChiCTR2000033793, TrialTroveID-377094",A Single-arm Exploratory Clinical study of Tislelizumab combined with Anlotinib in the Treatment of Refractory Small Cell Lung Cancer after First-line Platinum-based Chemotherapy,Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Overall survival, Progression-free survival, Safety and Tolerability",False,,91363
4762,376694,"ChiCTR2000033625, TrialTroveID-376694","PD-1 Monoclonal Antibody (tislelizumab) Monotherapy or Combination Regimen for the Treatment of Extranodal NK/T Cell Lymphoma in Children: A Prospective, Open-label Real-world Study",Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Safety and Tolerability,Safety and Tolerability,False,,91363
4763,376464,"ChiCTR2000033599, TrialTroveID-376464","PD-1 Monoclonal Antibody (Tislelizumab) Alternative Radiotherapy for Children with Classic Hodgkin's Lymphoma: A Prospective, One-arm, Open-label Real-world Study",Oncology,"Oncology: Lymphoma, Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,,Safety and Tolerability,False,,91363
4764,375866,"ChiCTR2000033416, TrialTroveID-375866","A Prospective, Single-Arm Clinical Study On The Safety And Efficacy Of Tislelizumab In Combination With Liposome Paclitaxel + Cisplatin In The Neoadjuvant Therapy Of Potentially Resectable Local Advanced Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,(Other Hospital/Academic/Medical Center),Academic,"Complete response, Overall response rate, Response rate","Disease-free survival, Overall response rate, Overall survival",False,,91363
4765,375861,"ChiCTR2000033441, TrialTroveID-375861","Tislelizumab Plus Gemox in Relapsed or Refractory Patients with cHL: a Multicentre, Single-Am, Phase II Trial",Oncology,"Oncology: Lymphoma, Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Response rate,"Overall response rate, Progression-free survival",False,,91363
4766,375558,"A317-2001-IIT, NCT04405674, TrialTroveID-375558","A Phase II, Open-Label, Multicenter, Single-Arm, Prospective Clinical Study to Investigate the Efficacy and Safety of Tislelizumab Combined With Chemotherapy in Non-squamous NSCLC With EGFR Sensitizing Mutation Who Failed EGFR TKI Therapy",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease",True,NCT04405674,91363
4767,375511,"BGB-A317-fruquintinib-201, NCT04716634, TrialTroveID-375511","A Multiple-Cohort, Safety, Tolerability and Efficacy Study of Combination of Surufatinib with Tislelizumab or Fruquintinib with Tislelizumab in Patients with Multiple Solid Tumor Cancer Indications",Oncology,Oncology: Colorectal; Oncology: Esophageal; Oncology: Gastric; Oncology: Unspecified Solid Tumor,"Novartis, Hutchison MediPharma, BeiGene","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04716634,91363
4768,375497,"ChiCTR2000033177, TrialTroveID-375497",The Real World Study of Tislilizumab in the Treatment of Locally Advanced or Metastatic Urothelial Carcinoma,Oncology,Oncology: Bladder; Oncology: Renal,"(Other Hospital/Academic/Medical Center), BeiGene/BeiGene (Beijing) Co.","Academic, Industry, all other pharma",Overall response rate,"Clinical benefit rate, Overall response rate - duration, Progression-free survival",False,,91363
4769,375398,"ChiCTR2000033239, TrialTroveID-375398",Safety and Efficacy of Tiranizumab combined with Chemotherapy in Advanced NSCLC Patients,Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), BeiGene","Academic, Industry, all other pharma","Clinical benefit rate, Overall response rate - duration, Overall response rate, Progression-free survival, Time to treatment failure, Treatment Emergent Adverse Events",,False,,91363
4770,375345,"BGB-A317-211, CTR20200972, NCT04401800, TrialTroveID-375345","A Phase II Study to Investigate the Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib in Patients With Unresectable Locally Advanced or Metastatic Hepatocellular Carcinoma",Oncology,Oncology: Liver,BeiGene,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability","Adverse Events, Clinical benefit rate, Duration of overall response, Immune-related response evaluation criteria in solid tumors, Overall response rate - duration, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04401800,91363
4771,374368,"ChiCTR2000032825, TrialTroveID-374368",Clinical Trial of Ondo Combined With DP Combined With Tirelizumab In The Treatment Of Stage IIIB-IV Lung Squamous Cell Carcinoma,Oncology,"Oncology: Lung, Non-Small Cell","(Other Hospital/Academic/Medical Center), BeiGene/BeiGene (Beijing) Co.","Academic, Industry, all other pharma",Overall response rate,"Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival",False,,91363
4772,374242,"CICPD, IR2020001132, NCT04381741, TrialTroveID-374242",CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma,Oncology,"Oncology: Lymphoma, Non-Hodgkin's",(Other Hospital/Academic/Medical Center),Academic,Overall response rate,"Duration of overall response, Overall response rate - duration, Overall survival, Progression-free survival",True,NCT04381741,91363
4773,373954,"BGB-A317-315, CTR20200821, NCT04379635, TrialTroveID-373954","A Randomized, Double-Blind, Placebo-Controlled, Phase III Study to Compare the Efficacy and Safety of Neoadjuvant Treatment With Tislelizumab (BGB-A317, Anti-PD-1 Antibody) or Placebo Plus Platinum-Based Doublet Chemotherapy Followed By Adjuvant Tislelizumab or Placebo in Resectable Stage II or IIIA Non-Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell",BeiGene,"Industry, all other pharma","Complete response, Event-free survival","Complete response, Disease-free survival, Event-free survival, Overall response rate, Overall survival, Quality of Life, Response rate, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT04379635,91363
4774,373657,"ChiCTR2000032509, TrialTroveID-373657","Efficacy and Safety of Tislelizumab (BGB-A317) plus Nab-paclitaxel With or Without Platinum as First-line Treatment in Elderly (aged > or = 70 years) Advanced Non-Small Cell Lung Cancer Patients: a Single arm, Prospective Clinical Study",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Overall response rate, Safety and Tolerability","Clinical benefit rate, Disease-free survival, Overall response rate - duration, Progression-free survival, Quality of Life",False,,91363
4775,370311,"BGB-A317-210, BGB-A317-210/TIRHOL, EudraCT Number: 2019-002105-22, NCT04318080, TIRHOL, TrialTroveID-370311","A Phase II, Multicenter, Open-Label Study of Tislelizumab (BGB-A317) in Participants With Relapsed or Refractory Classical Hodgkin Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's","(Other Cooperative Group), BeiGene","Cooperative Group, Industry, all other pharma","Complete response, Overall response rate, Partial response","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to response, Vital signs",True,NCT04318080,91363
4776,369947,"CROC2003, NCT04310943, TrialTroveID-369947","Tislelizumab Combined With Bevacizumab and Albumin Paclitaxel in the Treatment of Advanced Lung Adenocarcinoma: a Single-arm, Phase II Clinical Trial",Oncology,"Oncology: Lung, Non-Small Cell",(Other Hospital/Academic/Medical Center),Academic,"Adverse Events, Progression-free survival, Safety and Tolerability","Overall response rate, Overall survival",True,NCT04310943,91363
4777,368347,"BGB-A317-3111-10188-101, NCT04282018, TrialTroveID-368347","A Phase I/II, Dose Escalation and Expansion Study of BGB-10188, a Phosphatidylinositol 3-Kinase Delta (PI3Kd) Inhibitor, Combined With Zanubrutinib in Patients With Mature B-Cell Malignancies and Combined With Tislelizumab in Patients With Solid Tumors",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Lymphoma, Non-Hodgkin's; Oncology: Melanoma; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Renal; Oncology: Unspecified Solid Tumor",BeiGene,"Industry, all other pharma","Adverse Events, Maximum tolerated dose, Treatment Emergent Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Partial response, Plasma concentration",True,NCT04282018,91363
4778,368156,"BGB-A317-ZW25-101, CTR20210237, NCT04276493, TrialTroveID-368156","A Phase Ib/2 Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activity of Anti-HER2 Bispecific Antibody ZW25 in Combination With Chemotherapy With/Without Tislelizumab in Patients With Advanced HER2-positive Breast Cancer or Gastric/Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Breast; Oncology: Esophageal; Oncology: Gastric,"Patheon, BeiGene","Industry, Technology provider, Industry, all other pharma","Adverse Events, Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Clinical benefit rate, Cmax, Complete response, Duration of overall response, Elimination half-life, Neutralizing antibody response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease, Time to response",True,NCT04276493,91363
4779,367800,"5751, CLL-RT1, EudraCT Number: 2018-002492-17, NCT04271956, TrialTroveID-367800","A Prospective, Open-label, Multicenter Phase-II Trial to Evaluate the Efficacy and Safety of Zanubrutinib (BGB-3111), a BTK Inhibitor, Plus Tislelizumab (BGB-A317), a PD1 Inhibitor, for Treatment of Patients With Richter Transformation",Oncology,"Oncology: Leukemia, Chronic Lymphocytic",German CLL Study Group - GCLLSG,Cooperative Group,"Complete response, Overall response rate, Partial response","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Time to next treatment",True,NCT04271956,91363
4780,364836,TrialTroveID-364836,Clinical Study to Evaluate the Combination of DKN-01 with Tislelizumab and Chemotherapy in Patients with First-Line Gastric Cancer (GC) / Gastroesophageal Junction Cancer (GEJ),Oncology,Oncology: Esophageal; Oncology: Gastric,"Leap Therapeutics {HealthCare Pharmaceuticals {Dekkun}}, BeiGene","Industry, all other pharma, Industry, all other pharma",,,False,,91363
4781,364831,"DEK-DKK1-P205, DisTinGuish, NCI-2020-05263, NCT04363801, TrialTroveID-364831","A Phase IIa, Multicenter, Open-Label Study of DKN-01 in Combination With Tislelizumab Â± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients With Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)",Oncology,Oncology: Esophageal; Oncology: Gastric,"Leap Therapeutics {HealthCare Pharmaceuticals {Dekkun}}, BeiGene","Industry, all other pharma, Industry, all other pharma","Common Terminology Criteria for Adverse Events, Safety and Tolerability, Safety and Tolerability","Area under the curve score, Clinical benefit rate, Cmax, Complete response-duration, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability",True,NCT04363801,91363
4782,364668,"BGB-A317-A445-101, NCT04215978, TrialTroveID-364668","Phase I Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of the Anti OX40 Agonist Monoclonal Antibody BGB-A445 in Combination With the Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,BeiGene,"Industry, all other pharma","Adverse Events, Complete response, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Partial response, Serious Adverse Events","Adverse Events, Area under the curve score, Clinical benefit rate, Cmax, Cmin, Duration of overall response, Overall response rate - duration, Overall response rate, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Serious Adverse Events, Tmax",True,NCT04215978,91363
4783,362609,"201911021MIFB, NCT04183088, TrialTroveID-362609",Regorafenib Plus Tislelizumab as First-line Systemic Therapy for Patients With Advanced Hepatocellular Carcinoma (HCC),Oncology,Oncology: Liver,National Taiwan University Hospital,Academic,"Common Terminology Criteria for Adverse Events, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events, Treatment Emergent Adverse Events","Common Terminology Criteria for Adverse Events, Overall response rate, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment compliance",True,NCT04183088,91363
4784,361385,"BGB-A317-290, BGB-A317-290-LTE1, EudraCT Number: 2019-002554-23, NCT04164199, TrialTroveID-361385","An open Label, Multicentre, Long-Term Extension Study of Tislelizumab- Containing Treatment and/or Pamiparib-Containing Treatment in Patients With Advanced Malignancies.",Oncology,"Oncology: CNS, Glioblastoma; Oncology: Unspecified Solid Tumor",BeiGene,"Industry, all other pharma","Adverse Events, Safety and Tolerability, Serious Adverse Events",Overall survival,True,NCT04164199,91363
4785,354844,"BGB-900-105, CTR20202608, NCT04047862, TrialTroveID-354844","Phase I/Ib Study Investigating Safety, Tolerability, PK and Antitumor Activity of Anti-TIGIT Monoclonal Antibody BGB-A1217 in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Unspecified Solid Tumor",BeiGene,"Industry, all other pharma","Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Clinical benefit rate, Duration of overall response, Overall response rate - duration, Progression-free survival, Response evaluation criteria in solid tumors",True,NCT04047862,91363
4786,350391,"BGB-A317-312, CTR20190511, NCT04005716, TrialTroveID-350391","A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Platinum Plus Etoposide With or Without Tislelizumab (BGB-A317) in Patients With Untreated Extensive-Stage Small Cell Lung Cancer",Oncology,"Oncology: Lung, Small Cell; Oncology: Neuroendocrine",BeiGene/BeiGene (Shanghai) Co.,"Industry, all other pharma","Overall survival, Progression-free survival, Safety and Tolerability","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability, Time to progression, Treatment Emergent Adverse Events",True,NCT04005716,91363
4787,349995,"BGB-A317-311, CTR20190198, NCT03957590, TrialTroveID-349995","A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Patients With Localized Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,BeiGene,"Industry, all other pharma","Progression-free survival, Response evaluation criteria in solid tumors","Ability to swallow, Adverse Events, Appetite, Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Heartburn, Nausea, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Reflux, Safety and Tolerability, Safety and Tolerability, Sense of smell, Treatment Emergent Adverse Events, Vomiting",True,NCT03957590,91363
4788,349783,"BGB-A317-310, CTR20190543, NCT03967977, TrialTroveID-349783","A Phase III, Multi-center, Randomized, Double-Blind, Placebo-Controlled Study of Either Cisplatin or Carboplatin +Gemcitabine + Tislelizumab Compared With Either Cisplatin or Carboplatin + Gemcitabine + Placebo as First-line Treatment for Patients With Locally Advanced or Metastatic Urothelial Carcinoma",Oncology,Oncology: Bladder,BeiGene/BeiGene (Shanghai) Co.,"Industry, all other pharma",Overall survival,"Adverse Events, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, EQ-5D-5L, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Progressive disease rate, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03967977,91363
4789,346947,"BGB-A317-309, CTR20182534, NCT03924986, TrialTroveID-346947","Phase III, Double-Blind, Randomized Study to Compare the Efficacy and Safety of Tislelizumab Combined With Chemotherapy Versus Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer",Oncology,Oncology: Head/Neck,"BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Disease Progression, Duration of overall response, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Response rate, Safety and Tolerability",True,NCT03924986,91363
4790,339970,"BGB-900-104, CTR20182149, CTR20182363, NCT03941873, TrialTroveID-339970","A Phase I/II Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib as Monotherapy and in Combination With Tislelizumab in Patients With Unresectable Locally Advanced or Metastatic HCC or GC/GEJC",Oncology,Oncology: Esophageal; Oncology: Gastric; Oncology: Liver,"(Other Industry Sponsor), BeiGene/BeiGene (Beijing) Co., BeiGene","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Overall response rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Drug clearance, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Tmax",True,NCT03941873,91363
4791,339025,"18-1070, BGB-A317-305, CTR20181841, EudraCT Number: 2018-000312-24, IRAS ID:260693, JapicCTI-194799, NCI-2018-03719, NCT03777657, RATIONALE 305, TrialTroveID-339025","A Randomized, Double-Blind, Placebo-Controlled, Phase III Clinical Study Comparing the Efficacy and Safety of Tislelizumab (BGB-A317) Plus Platinum and Fluoropyrimidine Versus Placebo Plus Platinum and Fluoropyrimidine as First-Line Treatment in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,"Novartis, BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Clinical benefit rate, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Stable Disease, Time to response",True,NCT03777657,91363
4792,337030,"BGB-A317-NSCL-001, EudraCT Number: 2018-001132-22, IRAS ID:249945, JapicCTI-194692, NCT03745222, RATIONALE 001, RATIONALE001, TrialTroveID-337030, U1111-1216-4294","A Phase III, Randomized, Blinded, Placebo-controlled Study of Tislelizumab (BGB-A317) Plus Chemoradiotherapy Followed by Tislelizumab Monotherapy in Newly Diagnosed, Stage III Subjects With Locally Advanced, Unresectable Non-small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb/Celgene, BeiGene","Industry, Top 20 Pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Appetite, Chest discomfort, Common Terminology Criteria for Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs",True,NCT03745222,91363
4793,333487,"BGB-A317-306, CTR20181013, EudraCT Number: 2018-000587-28, JapicCTI-194741, NCI-2019-02346, NCT03783442, Pro00086110, TrialTroveID-333487","A Randomized, Placebo-Controlled, Double-Blind Phase III Study to Evaluate the Efficacy and Safety of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First-Line Treatment in Patients With Unresectable, Locally Advanced Recurrent or Metastatic Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,"BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Disease Progression, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors","Adverse Events, Complete response, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Overall response rate - duration, Overall response rate, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT03783442,91363
4794,332113,"BGB-A317-209, CTR20180867, NCT03736889, TrialTroveID-332113","A Single-Arm, Multi-Center, Open-Label, Phase II Study to Evaluate Efficacy and Safety of Tislelizumab (BGB-A317), an Anti-PD-1 Monoclonal Antibody, as Monotherapy in Patients With Previously-Treated Locally Advanced Unresectable or Metastatic Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Solid Tumors",Oncology,Oncology: Unspecified Solid Tumor,BeiGene,"Industry, all other pharma","Overall response rate, Response evaluation criteria in solid tumors","Clinical benefit rate, Common Terminology Criteria for Adverse Events, Duration of overall response, Objective remission rate, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to response",True,NCT03736889,91363
4795,330727,"BGB-900-103, CTR20181404, CTR20181947, NCT03666143, TrialTroveID-330727","A Phase Ib Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Sitravatinib in Combination With Tislelizumab in Patients With Advanced Solid Tumors",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Ovarian; Oncology: Renal","(Other Industry Sponsor), BeiGene/BeiGene (Beijing) Co., BeiGene","Industry, all other pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Cardiac Telemetry, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Area under the curve score, Clinical benefit rate, Cmax, Drug clearance, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Tmax",True,NCT03666143,91363
4796,328636,"BGB-A317-304, CTR20180032, NCT03663205, RATIONALE 304, TrialTroveID-328636",Phase III Open Label First Line Therapy Study of Tislelizumab With Chemotherapy Versus Chemotherapy in Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer(NSCLC),Oncology,"Oncology: Lung, Non-Small Cell","BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Ability to swallow, Adverse Events, Appetite, Duration of overall response, EORTC Quality of Life Questionnaire, Global health status, Nausea, Neuropathy, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events, Vomiting",True,NCT03663205,91363
4797,328552,"BGB-A317-307, CTR20180292, CTR20181746, NCT03594747, TrialTroveID-328552","A Phase III, Multicenter, Randomized Open-Label Study to Compare the Efficacy and Safety of Tislelizumab (BGB A317, Anti-PD1 Antibody) Combined With Paclitaxel Plus Carboplatin or Nab Paclitaxel Plus Carboplatin Versus Paclitaxel Plus Carboplatin Alone as First-Line Treatment for Untreated Advanced Squamous Non Small Cell Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb/Celgene, Fresenius Kabi, BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, Top 20 Pharma, Industry, diagnostics or device, Industry, all other pharma, Industry, all other pharma","Disease Progression, Progression-free survival, Response evaluation criteria in solid tumors","Complete response, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT03594747,91363
4798,318015,"BGB-A317-207, CTR20171387, EudraCT Number: 2017-003700-44, HKUCTR-2388, NCI-2018-03488, NCT03493451, PXL236036, TrialTroveID-318015","A Phase II, Open-Label Study of BGB-A317 in Patients With Relapsed or Refractory Mature T- and NK- Neoplasms",Oncology,"Oncology: Lymphoma, Non-Hodgkin's","BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Complete response, Disease Progression, Overall response rate, Partial response, Safety and Tolerability","Adverse Events, Anti-drug antibodies, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Time to response, Vital signs",True,NCT03493451,91363
4799,317857,"BGB-A317-208, CTR20171257, EudraCT Number: 2017-003983-10, IRAS ID: 240385, NCI-2018-01960, NCT03419897, RATIONALE-208, TrialTroveID-317857","A Phase II, Open-label, Multicenter Study to Investigate the Efficacy, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Patients With Previously Treated Hepatocellular Unresectable Carcinoma",Oncology,Oncology: Liver,"Bristol-Myers Squibb/Celgene, BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Cardiac Telemetry, Clinical benefit rate, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Overall response rate - duration, Overall response rate, Overall survival, Plasma concentration, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs",True,NCT03419897,91363
4800,317703,"BGB-A317-302, CTR20171026, EudraCT Number: 2017-003699-30, IRAS ID : 242092, NCI-2018-01544, NCT03430843, RATIONALE 302, TrialTroveID-317703","A Randomized, Controlled, Open-label, Global Phase III Study Comparing the Efficacy of the Anti-PD-1 Antibody Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Patients With Advanced Unresectable/Metastatic Esophageal Squamous Cell Carcinoma",Oncology,Oncology: Esophageal,"Bristol-Myers Squibb/Celgene, BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma",Overall survival,"Adverse Events, Complete response, Disease Progression, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, EQ-5D, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT03430843,91363
4801,315816,"18-237, BGB-A317-301, CSET 2722, CTMS# 17-0105, CTR20170882, EudraCT Number: 2017-002423-19, JapicCTI-194569, NCI-2018-00593, NCT03412773, RATIONALE-301, RECF3537, TrialTroveID-315816, UCI-17-89","A Randomized, Open-label, Multicenter Phase III Study to Compare the Efficacy and Safety of BGB-A317 Versus Sorafenib as First-Line Treatment in Patients With Unresectable Hepatocellular Carcinoma",Oncology,Oncology: Liver,"Bristol-Myers Squibb/Celgene, BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma","Adverse Events, Area under the curve score, Cardiac Telemetry, Cmax, Cmin, Dose-limiting toxicities, Overall response rate, Overall survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Vital signs","Adverse Events, Cardiac Telemetry, Clinical benefit rate, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Time to progression, Vital signs",True,NCT03412773,91363
4802,309493,"MYPHISMO, NCT03287427, The MYPHISMO study, TrialTroveID-309493",First-in-human Phase I Clinical Trial of a Combined Immune Modulatory Approach Using TetMYB Vaccine and Anti-PD1 Antibody in Patients With Advanced Solid Cancer Including Colorectal or Adenoid Cystic Carcinoma.,Oncology,Oncology: Colorectal; Oncology: Head/Neck,"Peter MacCallum Cancer Centre, Australia",Academic,"Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability","Adverse Events, Circulating Tumor Cells, Common Terminology Criteria for Adverse Events, Disease Progression, Immune Response, Immune-related response evaluation criteria in solid tumors, Overall response rate, Overall survival, Partial response, Progression-free survival, Stable Disease",True,NCT03287427,91363
4803,306946,"BGB-A317-206, CTR20170361, NCT03432598, TrialTroveID-306946","A Phase II, Open-Label, Multi-Cohort Study to Investigate the Preliminary Antitumor Activity, Safety, and Pharmacokinetics of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Chinese Subjects With Locally Advanced or Metastatic Lung Cancer",Oncology,"Oncology: Lung, Non-Small Cell; Oncology: Lung, Small Cell; Oncology: Neuroendocrine","BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response evaluation criteria in solid tumors","Adverse Events, Anti-drug antibodies, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Disease Progression, Duration of overall response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability",True,NCT03432598,91363
4804,305396,"BGB-A317-205, CTR20170515, NCT03469557, TrialTroveID-305396","A Phase II, Multi-Cohort Study to Investigate the Safety, Pharmacokinetics and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB A317 in Combination With Chemotherapy as First-Line Treatment in Adults With Inoperable, Locally Advanced or Metastatic Esophageal, Gastric, or Gastroesophageal Junction Carcinoma",Oncology,Oncology: Esophageal; Oncology: Gastric,"BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Anti-drug antibodies, Clinical benefit rate, Duration of overall response, Overall response rate, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events, Vital signs","Clinical benefit rate, Overall response rate, Progression-free survival, Safety and Tolerability",True,NCT03469557,91363
4805,304898,"135200, BGB-A317-303, CTR20171112, EudraCT Number: 2018-000245-39, NCT03358875, RATIONALE 303, TrialTroveID-304898","A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of BGB-A317 (Anti-PD1 Antibody) Compared With Docetaxel in Patients With Non-Small Cell Lung Cancer Who Have Progressed on a Prior Platinum-Containing Regimen",Oncology,"Oncology: Lung, Non-Small Cell","Bristol-Myers Squibb/Celgene, BeiGene, BeiGene/BeiGene (Shanghai) Co., BeiGene/BeiGene USA","Industry, Top 20 Pharma, Industry, all other pharma, Industry, all other pharma, Industry, all other pharma",Overall survival,"Common Terminology Criteria for Adverse Events, Duration of overall response, EORTC Quality of Life Questionnaire, EQ-5D-5L, Overall response rate - duration, Overall response rate, Progression-free survival, Quality of Life, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events",True,NCT03358875,91363
4806,300660,"BGB-A317-203, CTR20170119, NCT03209973, TrialTroveID-300660","A Single Arm, Multicenter, Phase II Study of BGB-A317 as Monotherapy in Relapsed or Refractory Classical Hodgkin Lymphoma",Oncology,"Oncology: Lymphoma, Hodgkin's","BeiGene, BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Complete response, Overall response rate, Partial response, Response rate","Duration of overall response, Overall response rate - duration, Progression-free survival, Progressive disease rate, Response rate, Safety and Tolerability, Time to response",True,NCT03209973,91363
4807,300651,"BGB-A317-204, CTR20170071, NCT04004221, TrialTroveID-300651","A Single-Arm, Multicenter, Phase II Study of BGB-A317 in Treatment of Patients with PD-L1 Positive Locally Advanced or Metastatic Bladder Urothelial Carcinoma",Oncology,Oncology: Bladder; Oncology: Renal,BeiGene/BeiGene (Shanghai) Co.,"Industry, all other pharma","Clinical benefit rate, Complete response, Disease Progression, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Partial response, Progression-free survival, Response evaluation criteria in solid tumors, Stable Disease","Clinical benefit rate, Duration of overall response, Overall survival, Progression-free survival, Safety and Tolerability, Safety and Tolerability",True,NCT04004221,91363
4808,294211,"BGB-A317-102, CTR20160872, NCT04068519, TrialTroveID-294211","Phase I/II Study Investigating Safety, Tolerability, Pharmacokinetics and Preliminary Antitumor Activities of Anti-PD-1 Monoclonal Antibody BGB-A317 in Chinese Patients With Advanced Solid Tumors",Oncology,"Oncology: Colorectal; Oncology: Esophageal; Oncology: Head/Neck; Oncology: Lung, Non-Small Cell; Oncology: Unspecified Solid Tumor",BeiGene/BeiGene (Shanghai) Co.,"Industry, all other pharma","Adverse Events, Area under the curve score, Cmax, Maximum tolerated dose, Objective remission rate, Overall response rate, Overall survival, Plasma concentration, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events","Adverse Events, Anti-drug antibodies, Common Terminology Criteria for Adverse Events, Complete response, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Serious Adverse Events",True,NCT04068519,91363
4809,280339,"BGB-3111_BGB-A317_Study_001, CT798, CTR20180193, CTR20181690, NCT02795182, TrialTroveID-280339","A Phase Ib, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Assess Safety, Tolerability and Antitumor Activities of the Combination of BGB-3111 with BGB-A317 in Subjects With B-Cell Lymphoid Malignancies",Oncology,"Oncology: Leukemia, Acute Lymphocytic; Oncology: Leukemia, Acute Myelogenous; Oncology: Leukemia, Chronic Lymphocytic; Oncology: Leukemia, Chronic Myelogenous; Oncology: Lymphoma, Non-Hodgkin's","BeiGene/BeiGene (Beijing) Co., BeiGene/BeiGene (Shanghai) Co.","Industry, all other pharma, Industry, all other pharma","Adverse Events, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Maximum tolerated dose, Safety and Tolerability, Safety and Tolerability","Anti-drug antibodies, Area under the curve score, Cmax, Complete response, Disease Progression, Duration of overall response, Elimination half-life, Overall response rate - duration, Overall response rate, Partial response, Plasma concentration, Progression-free survival, Progressive disease rate, Safety and Tolerability",True,NCT02795182,91363
4810,271778,"16-183, 18-009, A317/290, BGB-A317/BGB-290, BGB-A317/BGB-290_Study_001, CT783, EudraCT Number: 2017-003580-35, NCI-2018-00791, NCT02660034, P 55217, TrialTroveID-271778, VICCPHI1814","A Phase I/Ib, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activity of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Combination With the PARP Inhibitor BGB-290 in Participants With Advanced Solid Tumors",Oncology,"Oncology: (N/A); Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Fallopian Tube; Oncology: Gastric; Oncology: Lung, Small Cell; Oncology: Neuroendocrine; Oncology: Ovarian; Oncology: Pancreas; Oncology: Prostate; Oncology: Renal; Oncology: Unspecified Solid Tumor","Myrexis {Myriad Pharmaceuticals {Myriad Genetics}}, BeiGene","Industry, all other pharma, Industry, all other pharma","Adverse Events, Clinical benefit rate, Common Terminology Criteria for Adverse Events, Dose-limiting toxicities, Duration of overall response, Maximum tolerated dose, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Treatment Emergent Adverse Events","Adverse Events, Clinical benefit rate, Cmax, Duration of overall response, Overall response rate - duration, Overall response rate, Overall survival, Progression-free survival, Progressive disease rate, Response evaluation criteria in solid tumors, Safety and Tolerability, Safety and Tolerability, Tmax",True,NCT02660034,91363
4811,254915,"BGB-A317_Study_001, CT745, NCI-2016-01917, NCT02407990, TrialTroveID-254915","A Phase IA/IB, Open Label, Multiple Dose, Dose Escalation and Expansion Study to Investigate the Safety, Pharmacokinetics and Antitumor Activities of the Anti-PD-1 Monoclonal Antibody BGB-A317 in Subjects With Advanced Tumors",Oncology,"Oncology: Bladder; Oncology: Breast; Oncology: Cervical; Oncology: CNS, Glioblastoma; Oncology: Colorectal; Oncology: Endometrial; Oncology: Esophageal; Oncology: Gastric; Oncology: Head/Neck; Oncology: Liver; Oncology: Lung, Non-Small Cell; Oncology: Melanoma; Oncology: Mesothelioma; Oncology: Neuroendocrine; Oncology: Osteosarcoma; Oncology: Ovarian; Oncology: Pancreas; Oncology: Renal; Oncology: Skin, Squamous Cell Carcinoma (cSCC); Oncology: Soft Tissue Sarcoma; Oncology: Thyroid; Oncology: Unspecified Solid Tumor",BeiGene,"Industry, all other pharma","Adverse Events, Response evaluation criteria in solid tumors","Adverse Events, Area under the curve score, Cmax, Elimination half-life, Plasma concentration, Tmax",True,NCT02407990,91363
